Compounds > gefitinib
Page last updated: 2024-11-07

gefitinib

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID123631
CHEMBL ID939
CHEBI ID49668
SCHEMBL ID7866
MeSH IDM0444984

Synonyms (139)

Synonym
AC-1556
4-quinazolinamine, n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-4-morpholin)propoxy)-
4-quinazolinamine, n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-
ccris 9011
zd 1839
gefitinib [usan]
cid_123631
bdbm5447
n-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine
zd1839
iressa ,
n-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
chembl939 ,
HY-50895
AB01273954-01
AB01273954-03
AB01273954-02
184475-35-2
g-4408
gefitinib ,
n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
nsc715055
zd-1839
n-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
NCHEMBIO866-COMP14
4-quinazolinamine, n-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-
gefitini; iressa
K00240
3-chloro-4-fluoro-n-[(4z)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4(1h)-ylidene]aniline
IRE ,
BCB03_000781
n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
NCGC00159455-02
NCGC00159455-03
DB00317
iressa (astrazeneca)
nsc-715055
gefitinib (jan/usan/inn)
D01977
iressa (tn)
KBIOSS_002241
CU-00000000396-1 ,
6-(3-morpholinopropoxy)-n-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
irressat
CHEBI:49668 ,
gefitinibum
HMS2089B19
AKOS000280752
iressa(tm)
n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
n-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
nsc-759856
EC-000.2409
KINOME_3321
KINOME_3322
STK621310
NCGC00159455-06
NCGC00159455-04
NCGC00159455-05
cas-184475-35-2
tox21_111683
dtxcid6021034
dtxsid8041034 ,
A812870
nsc759856
pharmakon1600-01502274
GEFITINIB - IRESSA
c22h24clfn4o3
BCP9000718
gefitinib [usan:inn:ban]
s65743jhbs ,
nsc 759856
unii-s65743jhbs
HMS3244N21
HMS3244M22
HMS3244M21
BCPP000221
smr002204119
MLS003899193
gefitinib,zd-1839,iressa
FT-0602325
NCGC00159455-08
AB20814
gefitinib [orange book]
gefitinib [inn]
gefitinib [jan]
gefitinib [ema epar]
gefitinib [who-dd]
gefitinib [mi]
gefitinib [ep monograph]
gefitinib [vandf]
gefitinib [mart.]
CS-0124
S1025
gtpl4941
CCG-220642
AM20090619
SCHEMBL7866
NCGC00159455-09
tox21_111683_1
KS-1204
4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)-quinazoline
Q-201149
gefitinib (zd1839)
AB01273954_04
mfcd04307832
gefitinib (iressa) ,
(3-chloro-4-fluoro-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine
SR-00000000262-2
sr-00000000262
HMS3654A07
gefitinib for system suitability, europepharmacopoeia (ep) reference standard
gefitinib, europepharmacopoeia (ep) reference standard
gefitinib, >=98% (hplc)
SR-00000000262-3
NCGC00159455-14
HMS3714A05
4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-(3-morpholinopropoxy)quinazoline
SY002154
SW199108-4
Q417824
Z1546610485
HMS3677H08
BCP01365
HMS3413H08
HMS3295A21
HMS3748E17
nsc-800105
nsc800105
CS-0622782
HY-50895G
gefitinib (gmp)
EN300-123024
BG164498
gefitinib (mart.)
gefitinib (ep monograph)
l01xe02
G0546

Research Excerpts

Overview

Gefitinib is an inhibitor of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) commonly used to suppress tumour growth. It is a widely used therapeutic drug for non-small cell lung cancer (NSCLC)

ExcerptReferenceRelevance
"Gefitinib is a tyrosine kinase inhibitor that is intended for oral administration yet suffers poor bioavailability along with undesirable side effects. "( Solid Dispersions of Gefitinib Prepared by Spray Drying with Improved Mucoadhesive and Drug Dissolution Properties.
Alany, RG; Fletcher, J; Khoder, M; Mustafa, WW, 2022)		2.48
"Gefitinib is an inhibitor of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) commonly used to suppress tumour growth."( Black phosphorus nanoparticles for dual therapy of non-small cell lung cancer.
Chen, S; Deng, Q; Fang, Q; Huang, X; Li, X; Lin, Z; Liu, X; Miao, Y; Wang, J; Yang, L; Yu, XY, 2022)		1.44
"Gefitinib is a tyrosine kinase inhibitor (TKI) that selectively inhibits the epidermal growth factor receptor (EGFR), hampering cell growth and proliferation. "( A Transcriptomic Approach to Elucidate the Mechanisms of Gefitinib-Induced Toxicity in Healthy Human Intestinal Organoids.
Chung, SW; Coyle, L; de Kok, TM; Ferreira, S; Fisher, C; Herpers, B; Jennen, DGJ; Jo, H; Kleinjans, JCS; Rodrigues, D, 2022)		2.41
"Gefitinib (G) is a recommended molecular-targeted agent for elderly patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). "( A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01).
Ando, M; Asami, K; Atagi, S; Kawahara, M; Minato, K; Mori, M; Nishimura, T; Ogushi, F; Tamura, A; Yamamoto, A; Yokoi, T; Yoshioka, H, 2022)		2.38
"Gefitinib (GF) is a RTKI (receptor tyrosine kinase inhibitor) first-choice drug for EGFR mutated advanced lung cancer."( Daidzein Synergizes with Gefitinib to Induce ROS/JNK/c-Jun Activation and Inhibit EGFR-STAT/AKT/ERK Pathways to enhance Lung Adenocarcinoma cells chemosensitivity.
Chang, YC; Chen, MC; Chen, RJ; Huang, CY; Kuo, CH; Kuo, WW; Mhone, TG; Shih, TC; Wang, TF; Yeh, CM, 2022)		1.75
"Gefitinib (GEF) is an anti-tumor oral solid formulation with a superior advantage for lung tumors. "( Gefitinib-resveratrol Cocrystal with Optimized Performance in Dissolution and Stability.
Dong, H; Guo, L; Yu, J; Zhai, L; Zhang, G; Zhang, Z, 2022)		3.61
"Gefitinib is a widely used therapeutic drug for non-small cell lung cancer (NSCLC), and its acquired resistance has become one of the barriers to the successful use of the drugs to treat NSCLC patients. "( E2F1-induced long non-coding RNA MCF2L-AS1 modulates Cyclin D1 mRNA stability through ELAVL1 to induce Gefitinib resistance in non-small cell lung cancer.
Deng, YJ; Du, ZQ; Shan, KZ; Yang, SF; Yue, PY, 2022)		2.38
"Gefitinib is a first-line TK inhibitor used against metastatic non-small cell lung cancer (NSCLC)."( Gefitinib derivatives and drug-resistance: A perspective from molecular dynamics simulations.
Ahmadi, A; Mohammadnejadi, E; Razzaghi-Asl, N, 2023)		3.07
"Gefitinib is an important drug approved for the treatment of cancer. "( Amelioration of the therapeutic potential of gefitinib against breast cancer using nanostructured lipid carriers.
Aggarwal, G; Ahsan, W; Javed, S; Kumar, P; Mangla, B, 2023)		2.61
"Gefitinib is a potent and selective orally active growth factor receptor (EGFR)-tyrosine kinase inhibitor that is commonly used to treat advanced non-small cell lung cancer patients with activating EGFR mutations. "( Sensorineural hearing loss induced by gefitinib: A CARE-compliant case report and literature reviews.
Gong, Y; Hua, GD; Huang, M; Lei, ZZ; Liang, Y; Sun, XD; Wang, JG; Wang, Y; Xue, CM; Yang, WH; Zhang, SS; Zhu, BC, 2023)		2.62
"Gefitinib (Gef) is a clinical drug for cancer patients."( Gefitinib and curcumin-loaded nanoparticles enhance cell apoptosis in human oral cancer SAS cells in vitro and inhibit SAS cell xenografted tumor in vivo.
Cheng, ZY; Chueh, FS; Chung, JG; Hsiao, YT; Lai, KC; Lien, JC; Liu, KC; Peng, SF, 2019)		2.68
"Gefitinib is a widely used targeted therapeutic drug in East Asian non-small cell lung cancer (NSCLC) patients. "( Polymorphisms of NF-κB pathway genes influence adverse drug reactions of gefitinib in NSCLC patients.
Huang, M; Huang, Y; Ma, Y; Wang, C; Wang, X; Xin, S; Xu, X; Zhang, L; Zhao, Y; Zhuang, W, 2020)		2.23
"Gefitinib (Ge) is an EGFR tyrosine kinase inhibitor (TKI), and Golgi phosphoprotein 3 (GOLPH3) expression is associated with worse glioma prognosis."( Co-delivery of GOLPH3 siRNA and gefitinib by cationic lipid-PLGA nanoparticles improves EGFR-targeted therapy for glioma.
Liu, H; Lu, J; Pan, B; Shen, J; Xu, H; Ye, C; Yu, R; Zhao, Z, 2019)		1.52
"Gefitinib is a first tyrosine kinase inhibitor (TKI) designed with an EGFR tyrosine kinase for lung cancer targeted therapy. "( Fucoidan increased the sensitivity to gefitinib in lung cancer cells correlates with reduction of TGFβ-mediated Slug expression.
Hsu, HY; Hsu, WH; Hua, WJ; Lin, TY; Lin, ZH; Qiu, WL; Tseng, AJ, 2020)		2.27
"Gefitinib is an ATP-competitive inhibitor of receptor tyrosine kinases known to repress the progression of various types of cancers. "( Gefitinib modulates stress fibers and tubular-like structure formation and attenuates angiogenesis in an in vivo chicken model of chorioallantoic membrane angiogenesis.
Lin, TC, 2020)		3.44
"Gefitinib is an oral, reversible, epidermal growth factor receptor inhibitor used in advance non-small cell lung cancer."( Gefitinib induced severe hyponatremia: A case report.
Bohra, GK; Kumar, D; Meena, DS; Midha, N, 2021)		2.79
"Gefitinib is an orally potent and selective ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase and is commonly used to treat locally advanced or metastatic non-small-cell lung cancer (NSCLC) with sensitive EGFR mutations. "( Tentative identification of gefitinib metabolites in non-small-cell lung cancer patient plasma using ultra-performance liquid chromatography coupled with triple quadrupole time-of-flight mass spectrometry.
Han, F; Ling, J; Ling, R; Wang, C; Yu, L; Zhang, J; Zhou, S, 2020)		2.29
"Gefitinib is an important drug used to treat Non-Small Cell Lung Cancer (NSCLC) with EGFR activating mutations, but drug resistance restricts its clinical application. "( Combined Treatment with JFKD and Gefitinib Overcomes Drug Resistance in Non-Small Cell Lung Cancer.
Huang, X; Sun, J, 2021)		2.35
"Gefitinib is a first-line treatment option for epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma. "( Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial-mesenchymal transition through targeting major vault protein (MVP).
Li, Y; Lou, L; Lv, F; Shen, H; Wang, G; Wang, J; Xing, L; Zhang, X, 2021)		2.33
"Gefitinib (Iressa), is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), used in the targeted treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). "( Gefitinib-Induced Cutaneous Toxicities in Brown Norway Rats Are Associated with Macrophage Infiltration.
Chen, Z; Gu, R; He, F; Hua, Q; Jiang, M; Liu, T; Song, C; Tan, Y; Tang, Y; Wan, L; Wang, X; Wang, Y; Wei, P; Yang, K; Zhang, C; Zhang, Y, 2020)		3.44
"Gefitinib is a tyrosine kinase inhibitor of EGFR (epidermal growth factor receptor) and represents the first-line treatment for EGFR mutation patients with NSCLC (non-small-cell lung cancer) therapeutics. "( Trifolium Flavonoids Overcome Gefitinib Resistance of Non-Small-Cell Lung Cancer Cell by Suppressing ERK and STAT3 Signaling Pathways.
Chen, M; He, Q; Hu, Z; Wu, Z; Xu, B; Yu, Z; Zhou, S; Zhu, L, 2020)		2.29
"Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for first-line treatment of non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations. "( Repurposing loperamide to overcome gefitinib resistance by triggering apoptosis independent of autophagy induction in KRAS mutant NSCLC cells.
Cho, WCS; To, KKW; Tong, CWS; Wu, MMX; Yan, VW, 2020)		2.28
"Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic or advanced non-small cell lung cancer (NSCLC) whose tumors have specific EGFR mutations. "( Crosstalk between alveolar macrophages and alveolar epithelial cells/fibroblasts contributes to the pulmonary toxicity of gefitinib.
Du, J; He, Q; Jiang, L; Li, G; Luo, P; Xu, Z; Yan, H; Yang, X; Zhang, X; Zhou, Z, 2021)		2.27
"Gefitinib is a first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). "( Efficacy and safety of domestic and imported gefitinib in patients with advanced non-small cell lung cancer.
Cheng, H; Du, Q; Liu, H; Liu, Y; Shao, J; Shi, J; Sun, Y; Wang, Y; Wei, Q; Wu, N; Xu, S; Yang, F; Yu, B; Zhai, Q; Zhang, B; Zhang, H; Zhang, X, 2021)		2.32
"Gefitinib is a first-line anti-cancer drug for the treatment of advanced non-small cell lung cancer (NSCLC). "( Gefitinib reduces oocyte quality by disturbing meiotic progression.
Li, J; Meng, TG; Ouyang, YC; Qian, WP; Schatten, H; Sun, QY; Yue, W; Zhang, CH; Zhang, HY, 2021)		3.51
"Gefitinib is a first-line palliative chemotherapy drug used to treat advanced non-small-cell lung cancer (NSCLC) in patients who have an epidermal growth factor receptor (EGFR) mutation. "( Long-term progression-free survival in a patient with advanced non-small-cell lung cancer treated with low-dose gefitinib and traditional herbal medicine: A case report.
Choi, CW; Kim, JY; Kim, KI; Lee, BJ; Lee, JH, 2021)		2.28
"Gefitinib is a selective tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) used for the treatment of malignant neoplasms. "( Erosive pustular dermatosis of the scalp induced by gefitinib: case and review of the literature.
Bortoluzzi, P; Giacalone, S; Marzano, AV; Nazzaro, G; Veraldi, S, 2021)		2.31
"Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), clinically used to treat patients with non-small cell lung cancer driven by EGFR mutations. "( MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
He, J; Li, Q; Wang, Y, 2021)		2.3
"Gefitinib is a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and has been approved for the treatment of non-small cell lung cancers (NSCLCs) with EGFR mutations. "( Gefitinib Enhances Mitochondrial Biological Functions in NSCLCs with
Fujii, I; Hagiwara, M; Katayama, M; Kobayashi, SS; Nakase, I; Sugiyama, A; Takatani-Nakase, T; Takenaka, T, 2017)		3.34
"Gefitinib is a drug used for the treatment of non-small cell lung cancer (NSCLC) patients. "( Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity.
Cho, S; Gwak, HS; Jeong Rhie, S; Kim, JY; Yee, J, 2018)		2.19
"Gefitinib is a selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase and is used for the treatment of non-small-cell lung cancer (NSCLC) with activating EGFR mutations. "( Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers.
Al-Huniti, N; Chen, Y; Masson, E; Tang, W; Zhou, D; Zhou, W, 2018)		2.15
"Gefitinib is an oral tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) for non-small-cell lung cancer with EGFR mutations. "( Factors affecting time to reach and recover from gefitinib-induced hepatotoxicity.
Cho, S; Gwak, HS; Kim, JY; Park, YH; Rhie, SJ; Yee, J, 2018)		2.18
"Gefitinib is a novel drug targeting VEGF."( Gefitinib inhibits malignant melanoma cells through the VEGF/AKT signaling pathway.
Hou, W; Wan, X; Zhang, L; Zhu, Y, 2018)		2.64
"Gefitinib is an orally active selective inhibitor epidermal growth factor receptor (EGFR). "( Gefitinib.
Rawluk, J; Waller, CF, )		3.02
"Gefitinib is a tyrosine kinase inhibitor, indicated in advanced non-small cell lung cancer in all lines of treatment for patients harboring EGFR mutations. "( Gefitinib in non-small cell lung carcinoma: a case report of an unusual side effect and complete response in advanced disease.
Brangi, M; Cartenì, G; Chiurazzi, B; Laterza, MM; Riccardi, F, )		3.02
"Gefitinib is an essential drug for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations. "( Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
Hayakawa, H; Honda, Y; Hotta, K; Ichihara, E; Kato, Y; Kiura, K; Kudo, K; Minami, D; Sato, A; Tabata, M; Takigawa, N; Tanimoto, M, 2013)		2.13
"Gefitinib is a P-gp substrate and has limited active BBB penetration. "( Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis.
Chen, Y; Wang, M; Zhao, J; Zhong, W, 2013)		2.09
"Gefitinib is a tyrosine kinase inhibitor that targets and inhibits epidermal growth factor receptors. "( Gefitinib-associated vitiligo: report in a man with parotid squamous cell carcinoma and review of drug-induced hypopigmentation.
Cohen, PR; Jalalat, SZ, 2013)		3.28
"Gefitinib is a selective inhibitor of the EGFR and lapatinib is a dual inhibitor of both the EGFR and HER2 (human EGFR type 2 receptor)."( Apoptosis-related molecular differences for response to tyrosin kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells.
He, Z; Li, J; Li, X; Lv, B; Zhou, K, )		0.85
"Gefitinib is a common first-line treatment, but most patients develop resistance."( Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Horai, T; Horiike, A; Kudo, K; Murakami, H; Naito, T; Nishio, M; Ohyanagi, F; Ono, A; Tanaka, H; Yamamoto, N; Yanagitani, N, 2014)		1.37
"Gefitinib (Iressa®) is a selective inhibitor of epidermal growth factor, a growth factor that plays a pivotal role in the control of cell growth, apoptosis, and angiogenesis. "( Gefitinib.
Kassem, MG; Korashy, HM; Rahman, AF, 2014)		3.29
"Gefitinib (GF) is a US Food and Drug Administration-approved epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for treating the lung cancers. "( Colloidal gold nanoparticle conjugates of gefitinib.
Cho, KH; Choo, J; Ganbold, EO; Joo, SW; Kim, D; Lam, AT; Lee, K; Lee, SY; Singh, DK; Yoon, J, 2014)		2.11
"Gefitinib is a reversible and highly selective tyrosine kinase inhibitor that competitively blocks the binding of adenosine triphosphate to its binding site in the tyrosine kinase domain of the EGFR."( Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells.
Ahn, SH; Jeong, EH; Kim, CH; Kim, HR; Kim, SY; Lee, TG, 2014)		2.57
"Gefitinib is a selective inhibitor of the epidermal growth factor receptor (EGFR) which represents a potential pharmacological target for PCO prevention."( EGFR inhibitor Gefitinib attenuates posterior capsule opacification in vitro and in the ex vivo human capsular bag model.
Eibl-Lindner, K; Kampik, A; Klingenstein, A; Kook, D; Mayer, WJ; Siedlecki, J; Wertheimer, C; Wolf, A, 2015)		1.49
"Gefitinib (Iressa®) is a selective inhibitor of the EGFR and lapatinib is a dual inhibitor of both the EGFR and HER2 (human EGFR type 2 receptor)."( Biomarkers for predicting response to tyrosine kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells.
He, Z; Li, J; Li, X; Lin, B; Tang, X; Zhou, K, 2015)		1.14
"Gefitinib (Iressa®) is a selective small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR TKI) indicated for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR tyrosine kinase. "( Gefitinib: a review of its use in adults with advanced non-small cell lung cancer.
Dhillon, S, 2015)		3.3
"Gefitinib is an effective first-line chemotherapy for advanced non-small cell lung cancer (NSCLC) patients harboring sensitive EGFR mutations. "( Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Hisada, T; Imai, H; Ishihara, S; Kaira, K; Kuwako, T; Masuda, T; Minato, K; Miura, Y; Mogi, A; Saito, R; Shimizu, K; Sunaga, N; Takise, A; Tomizawa, Y; Yamada, M; Yoshino, R, 2015)		2.1
"Gefitinib (Gef) is an orally active inhibitor targeting the adenosine tri phosphate-binding domain of EGFR, and cucurbitacin B (CuB) is a selective inhibitor of JAK/STAT signaling with potent antitumor activity via suppression of STAT3 phosphorylation, but the underlying mechanism is not clear."( Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines.
Alp, E; Elmazoglu, Z; Menevse, S; Yar Saglam, AS, 2016)		1.4
"Gefitinib is an essential drug for NSCLC patients harboring EGFR sensitive mutations. "( The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations.
Chen, L; Guo, Y; Hu, Z; Huang, M; Huang, Y; Li, H; Li, J; Ma, Y; Wang, X; Xin, S; Zhang, J; Zhang, L; Zhao, Y, 2015)		2.18
"Gefitinib is an orally active, selective EGFR tyrosine kinase inhibitor used in the treatment of patients with advanced non small cell lung cancer (NSCLC) carrying activating EGFR mutations."( Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
Alfieri, RR; Andreoli, R; Ardizzoni, A; Bonelli, M; Caffarra, C; Cavazzoni, A; Cretella, D; Fumarola, C; Galetti, M; La Monica, S; Mutti, A; Petronini, PG; Saccani, F; Tiseo, M, 2015)		1.38
"Gefitinib (Iressa) is a selective and potent EGFR tyrosine kinase inhibitor. "( A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans.
An, G; Bi, Y; Deng, J; Murry, DJ, 2016)		2.12
"Gefitinib is an orally active antitumor agent which inhibits uncontrolled cell proliferation by interrupting epidermal growth factor receptor (EGFR) signaling pathways. "( Overexpression of BRCA1 attenuates the sensitivity of PC9 cells to gefitinib.
Deng, Y; Feng, W; Liang, J; Wu, J; Xian, H; Yang, S; Zhang, H, 2015)		2.1
"Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor. "( Total regression of brain metastases in non-small cell lung cancer patients harboring EGFR mutations treated with gefitinib without radiotherapy: two case reports.
Chonan, M; Narita, N; Tominaga, T, 2016)		2.09
"Gefitinib is a potent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor and is a key drug for patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). "( Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.
Fujita, K; Hirose, T; Ishida, H; Kusumoto, S; Murata, Y; Nakashima, M; Ohmori, T; Oki, Y; Okuda, K; Sasaki, Y; Shirai, T; Sugiyama, T; Yamaoka, T, 2016)		2.1
"Gefitinib is a selective tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) used to treat adults with EGFR mutation-positive non-small-cell lung cancer (NSCLC). "( Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Hong, D; Liang, X; Zhang, G; Zhang, X, 2016)		2.18
"Gefitinib (GEF) is a multi-targeted tyrosine kinase inhibitor with anti-cancer properties, yet few cases of cardiotoxicity has been reported as a significant side effect associated with GEF treatment. "( Molecular mechanisms of cardiotoxicity of gefitinib in vivo and in vitro rat cardiomyocyte: Role of apoptosis and oxidative stress.
Ahmad, SF; Al-Alallah, IA; Alhaider, AA; Anazi, FE; Ansari, MA; Assiri, MA; Attafi, IM; Belali, OM; Korashy, HM, 2016)		2.14
"Gefitinib is a well-tolerated treatment for advanced NSCLC. "( Safety of gefitinib in non-small cell lung cancer treatment.
Hsiue, EH; Lee, JH; Lin, CC; Yang, JC, 2016)		2.28
"Gefitinib is an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and used as an anticancer drug; however, gefitinib treatment may sometimes lead cancer cells gradually into a gefitinib-tolerance."( Neighbors' death is required for surviving human adenocarcinoma PC-9 cells in an early stage of gefitinib treatment.
Fukuoka, M; Hohjoh, H; Takahashi, M; Yoshioka, K, 2016)		1.37
"Gefitinib is a first line anti-tumor drug used for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. "( MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway.
Feng, X; Jiang, J; Wu, Y; Yang, Y; Zhou, W, 2016)		2.2
"Gefitinib is an oral EGFR tyrosine kinase inhibitors which may act as a radiosensitizer."( A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer.
Adam, J; Artignan, X; Bardet, E; Lacas, B; Lacroix, L; Le Péchoux, C; Levy, A; Pignon, JP; Verrelle, P, 2017)		2.16
"Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor which has been proven effective for cancer treatment. "( Gefitinib enhances radiotherapeutic effects of
Peng, H; Xia, L; Xiaoli, Z; Zhiqiang, L, 2017)		3.34
"Gefitinib is a molecular targeting agent and more effective in patients with characteristics of oriental ethnicity, female gender, adenocarcinoma and non-smokers. "( [Efficacy of gefitinib according to smoking status in non-small cell lung cancer patients].
Hirama, M; Ishiwata, T; Miura, K; Miyaji, A; Seyama, K; Shukuya, T; Takahashi, K; Yae, T, 2008)		2.16
"Gefitinib is an orally bioavailable, EGF receptor tyrosine kinase inhibitor and was the first targeted drug to be approved for non-small-cell lung cancer (NSCLC). "( Gefitinib for the treatment of non-small-cell lung cancer.
Hida, T; Horio, Y; Ogawa, S; Park, JC; Park, JY; Shimizu, J; Yoshida, K, 2009)		3.24
"Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). "( Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice.
Katayama, H; Kishino, D; Kiura, K; Kuyama, S; Ohashi, K; Okada, T; Sato, K; Takigawa, N; Tanimoto, M, 2009)		2.2
"Gefitinib (Iressa) is a specific and effective epidermal growth factor receptor inhibitor. "( Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer.
Coombes, RC; Francis, RE; Guest, SK; Krol, J; Kwok, JM; Lam, EW; McGovern, UB; Myatt, SS; Peck, B; Polychronis, A; Wang, J, 2009)		3.24
"Gefitinib (Iressa) is a selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. "( In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib.
Fukumura, T; Hatori, A; Irie, T; Kanno, I; Kawamura, K; Konno, F; Kumata, K; Suzuki, K; Yamasaki, T; Yui, J; Zhang, MR, 2009)		2.01
"Gefitinib is a valid second-line therapy for previously treated non-small cell lung cancer (NSCLC) patients. "( Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer.
Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ, 2010)		2.04
"Gefitinib (Iressa) is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for human non-small cell lung cancer (NSCLC)."( Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation.
Chen, RS; Cheng, CM; Chuang, SM; Ciou, SC; Jhan, JY; Ko, JC; Lee, WT; Lin, ST; Lin, YW; Su, YJ, 2009)		1.42
"Gefitinib is an orally active and selective EGFR-TKI (EGFR-tyrosine kinase inhibitor) that blocks signal transduction pathways responsible for the proliferation and survival of cancer cells, and other host-dependent processes promoting cancer growth."( Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest.
Chen, F; Han, X; Lin, H; Sun, Y; Yong, W; Zheng, M; Zhou, X; Zhu, Y, 2009)		2.52
"Gefitinib is an orally active, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is widely used in the treatment of advanced non-small-cell lung cancer (NSCLC). "( [Comparative evaluation of adverse reactions between gefitinib and erlotinib treatments in the same patients].
Murakami, H; Ohashi, Y; Sakurai, M; Shino, M; Suzuki, K; Takahashi, T; Yamamoto, N, 2009)		2.05
"Gefitinib is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and it shows favorable antitumor activity against chemorefractory non-small cell lung cancer (NSCLC), especially with EGFR gene mutations. "( [A case of lung adenocarcinoma successfully treated with dose-reescalated gefitinib after resistance was acquired].
Hirano, S; Kobayashi, N; Kudo, K; Morii, S; Morita, A; Sano, K; Sugiyama, H; Takeda, Y; Uruga, K, 2009)		2.03
"Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase and has been approved for the treatment of nonsmall cell lung cancer refractory to established cancer treatments. "( Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities.
Cameron, MD; Kamenecka, TM; Li, X, 2009)		2.03
"Gefitinib (Iressa) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that offers treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), in particular in those who are harbouring EGFR mutations. "( Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer.
Sanford, M; Scott, LJ, 2009)		3.24
"Gefitinib is an anti-cancer drug that selectively inhibits epithelial growth factor receptor (EGFR) tyrosine kinase activity and induces apoptosis in many cancer cells. "( Gefitinib induces apoptosis and decreases telomerase activity in MDA-MB-231 human breast cancer cells.
Choi, YH; Heo, MS; Kim, GY; Kim, MO; Lee, JD; Moon, DO, 2009)		3.24
"Gefitinib is an orally active, selective epidermal growth factor receptor-tyrosine kinase inhibitor. "( Tumor-specific cytotoxicity and type of cell death induced by gefitinib in oral squamous cell carcinoma cell lines.
Amano, O; Chu, Q; Kanda, Y; Kunii, S; Sakagami, H; Wang, Q, 2009)		2.04
"Gefitinib is a tyrosine kinase inhibitor that targets epidermal growth factor receptor (EGFR)."( MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer.
Chen, L; Ma, X; Sun, C; Zhong, M, 2010)		1.31
"Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that has dramatic effects in selective patients with non-small cell lung cancer (NSCLC). "( Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Doi, S; Fukuda, M; Hayashi, T; Kohno, S; Nagashima, S; Nakamura, Y; Nakano, H; Nakatomi, K; Soda, H; Takasu, M; Takatani, H; Tomonaga, N; Tsukamoto, K; Yamaguchi, H, 2011)		2.04
"Gefitinib is an orally active inhibitor of the epidermal growth factor receptor approved for use in patients with locally advanced or metastatic non-small cell lung cancer. "( Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.
Agarwal, S; Elmquist, WF; Gallardo, JL; Ohlfest, JR; Sane, R, 2010)		2.15
"Gefitinib is an EGFR-TK inhibitor that is clinically used to treat NSCLC; however, this drug frequently causes adverse effects, including skin eruptions."( Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes.
Muro, Y; Shimoyama, Y; Sugiura, K; Tomita, Y; Yamaki, M, 2010)		1.08
"Gefitinib (ZD1839) is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with a significant antitumour effect on various cancers. "( Gefitinib-induced epidermal growth factor receptor-independent keratinocyte apoptosis is mediated by the JNK activation pathway.
Chang, CH; Chang, KC; Chu, CY; Kuo, TC; Lu, PH, 2011)		3.25
"Gefitinib is an orally active, highly selective, reversible inhibitor of the tyrosine kinase domain associated with the epidermal growth factor receptor (EGFR). "( Geftinib.
Gupta, A; Raina, V, )		1.57
"Gefitinib is an epidermal growth factor tyrosine kinase inhibitor used as a targeted chemotherapeutic agent in the treatment of lung cancer and other solid malignancies. "( Recurrent myocardial infarction associated with gefitinib therapy.
Kickler, TS; Lynch, DR; Rade, JJ, 2011)		2.07
"Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR). "( Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Cappuzzo, F; Cortinovis, D; De Marinis, F; Di Maio, M; Gridelli, C; Mok, T, 2011)		3.25
"Gefitinib is a highly effective and well-tolerated agent for Chinese women with pretreated advanced NSCLC."( Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer.
Chen, J; Chu, BB; Deng, J; Fang, HM; Fang, WJ; Mou, HB; Qian, J; Teng, LS; Wu, DP; Xu, N; Zhang, XC, 2012)		1.43
"Gefitinib is an oral tyrosine kinase inhibitor against the epidermal growth factor receptor (EGFR). "( Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.
de Lima Lopes, G; Haaland, BA; Ku, GY, 2011)		3.25
"Gefitinib is an oral, reversible, tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) that plays a key role in the biology of non small cell lung cancer (NSCLC). "( Gefitinib in non small cell lung cancer.
Bryce, J; Carillio, G; Costanzo, R; Daniele, G; De Feo, G; Di Maio, M; Giordano, P; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C, 2011)		3.25
"Gefitinib is an inhibitor of the epidermal growth factor receptor, which is frequently expressed on both choroidal and nonchoroidal melanoma cells. "( A phase II study of gefitinib in patients with metastatic melanoma.
Bar-Eli, M; Bassett, RL; Bedikian, AY; Bronstein, Y; Dobroff, A; Hwu, P; Hwu, WJ; Kim, KB; Papadopoulos, NE; Patel, SP; Prieto, VG; Vardeleon, AG; Zigler, M, 2011)		2.14
"Gefitinib is an EGFR tyrosine kinase inhibitor (EGFR-TKI) that demonstrated efficacy in patients with advanced non-small cell lung cancer (NSCLC) across therapy lines. "( Gefitinib for non-small-cell lung cancer treatment.
Cappuzzo, F; D'Incecco, A, 2011)		3.25
"Gefitinib (Iressa) is an inhibitor of the epidermal growth factor receptor (EGFR) that has shown promising activity in the treatment of patients with non-small cell lung cancer (NSCLC). "( Neonatal lethality in knockout mice expressing the kinase-dead form of the gefitinib target GAK is caused by pulmonary dysfunction.
Ito, A; Katsuma, A; Naito, Y; Nojima, H; Ohno, S; Sakurai, MA; Shimizu, H; Tabara, H; Yabuta, N, 2011)		2.04
"Gefitinib is a tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) especially effective in tumors with activating EGFR gene mutations while EGFR wild-type non small cell lung cancer (NSCLC) patients at present do not benefit from this treatment.The primary site of gefitinib metabolism is the liver, nevertheless tumor cell metabolism can significantly affect treatment effectiveness."( Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines.
Alfieri, RR; Andreoli, R; Ardizzoni, A; Bonelli, M; Cavazzoni, A; De Palma, G; Fumarola, C; Galetti, M; Galvani, E; La Monica, S; Mari, E; Mor, M; Mozzoni, P; Mutti, A; Petronini, PG; Tiseo, M; Tramonti, S, 2011)		2.07
"Gefitinib is an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that has been widely used for the treatment of non-small cell lung cancer (NSCLC). "( [Clinical response to gefitinib retreatment of lung adenocarcinoma patients who benefited from an initial gefitinib therapy: a retrospective analysis].
Hao, X; Li, J; Shi, Y; Wang, Y; Zhang, X, 2012)		2.14
"  Gefitinib is a dominant cost saving strategy compared with docetaxel for the second-line treatment of advanced NSCLC from the Thai payer perspective."( Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
Permsuwan, U; Thongprasert, S; Tinmanee, S, 2012)		1.36
"Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) of potential use in patients with breast cancer. "( A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells.
Boerner, JL; Bollig-Fischer, A; Giordano, CR; Krentz, KA; Mueller, KL; Terlecky, LJ; Terlecky, SR, 2012)		1.82
"Gefitinib is a promising agent for the treatment of non-small cell lung cancer. "( Novel liposomal gefitinib (L-GEF) formulations.
Hu, X; Huang, Y; Lee, RJ; Li, H; Xiang, G; Yung, B; Zhou, X, 2012)		2.17
"Gefitinib is a well known therapy for non-small-cell lung cancer (NSCLC). "( Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients.
Biaoxue, R; Shuanying, Y; Wei, L; Wei, Z; Zongjuan, M, 2012)		2.13
"Gefitinib is an effective treatment for patients with non-small cell lung cancer who harbor activating epidermal growth factor receptor (EGFR) mutations. "( Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations.
Asami, K; Atagi, S; Hirashima, T; Kawaguchi, T; Kawahara, M; Okishio, K; Okuma, T; Omachi, N; Takeuchi, N, 2013)		2.14
"Gefitinib is an anticancer drug developed to inhibit the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). "( Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease.
Matsuo, K; Takada, Y, 2012)		3.26
"Gefitinib is an Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor, approved for patients with non-small cell lung cancer (NSCLC). "( p300/CBP dependent hyperacetylation of histone potentiates anticancer activity of gefitinib nanoparticles.
Kaur, J; Tikoo, K, 2013)		2.06
"Gefitinib (ZD1839) is an orally active selective inhibitor of epidermal growth factor receptor tyrosine kinase, an enzyme that regulates intracellular signalling pathways implicated in the proliferation and survival of cancer cells. "( Gefitinib.
Culy, CR; Faulds, D, 2002)		3.2
"Gefitinib is an oral selective inhibitor of the epidermal growth factor receptor tyrosine kinase that is an effective treatment for patients with advanced non-small cell lung cancer who do not respond to platinum-based chemotherapy. "( Severe acute interstitial pneumonia and gefitinib.
Ebina, M; Gomi, K; Inoue, A; Kikuchi, T; Kimura, Y; Maemondo, M; Moriya, T; Nukiwa, T; Saijo, Y; Tokue, Y, 2003)		2.03
"Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC [corrected]"( Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
Averbuch, S; Baselga, J; Dong, RP; Douillard, JY; Eek, R; Feyereislova, A; Fukuoka, M; Giaccone, G; Horai, T; Kudoh, S; Macleod, A; Nakagawa, K; Nishiwaki, Y; Noda, K; Rischin, D; Smit, E; Takata, I; Tamura, T; Vansteenkiste, J; Yano, S, 2003)		1.29
"Gefitinib is an oral agent that inhibits the tyrosine kinase of the epidermal growth factor receptor. "( Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
Carbone, D; Heelan, RT; Johnson, DH; Kris, MG; Krozely, P; Krug, LM; Miller, VA; Ochs, J; Perez, W; Pizzo, B; Sandler, A; Smith, R; Tyson, L, 2003)		1.99
"Gefitinib (Iressa) is a synthetic anilinoquinazoline capable of inhibiting the epidermal growth factor receptor tyrosine kinase in vitro at nanomolar concentrations. "( Gefitinib (Iressa) trials in non-small cell lung cancer.
Johnson, DH, 2003)		3.2
"Gefitinib is a potent drug used in the treatment of nonsmall-cell lung cancer (NSCLC). "( Acute lung injury as a possible adverse drug reaction related to gefitinib.
Ieki, R; Saitoh, E; Shibuya, M, 2003)		2
"Gefitinib is an epidermal growth factor receptor (EGFR) inhibitor that is reported to be well tolerated and active in patients with chemotherapy-resistant non small cell lung cancer. "( [Iressa (gefitinib)].
Gemma, A; Kudoh, S; Yoshimura, A, 2003)		2.18
"Gefitinib is a low-molecular-weight epidermal growth factor receptor tyrosine kinase inhibitor. "( Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine.
Herchenhorn, D; Rabinowits, G; Rabinowits, M; Torres, W; Weatge, D, 2003)		2.01
"Gefitinib is a newly developed molecular-target drug with selective inhibitory activity for tyrosine kinase of the epidermal growth factor receptor and has an encouraging effect on non-small cell lung cancer in an advanced stage. "( [Radiation recall pneumonitis induced by Gefitinib (Iressa): a case report].
Goya, T; Koshiishi, Y; Miya, T; Ono, Y; Tanaka, H, 2003)		2.03
"Gefitinib is a selective EGFR tyrosine kinase inhibitor."( Gefitinib therapy for advanced non-small-cell lung cancer.
Liu, CY; Seen, S, 2003)		2.48
"Gefitinib is a potent and selective inhibitor of EGFR tyrosine kinase (EGFRTK)."( EGFR tyrosine kinase inhibitor "gefitinib (Iressa)" for cancer therapy.
Dong, RP; Yamaguchi, M; Yano, S, 2003)		1.32
"Gefitinib is a small-molecule agent specifically targeted to inhibit the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). "( Pharmacokinetic evaluation of gefitinib when administered with chemotherapy.
Hammond, LA, 2003)		2.05
"Gefitinib is an orally available small-molecule tyrosine kinase inhibitor that targets the intracellular domain of the EGFR."( Pharmacy practice issues with targeted therapy for lung cancer.
Jones, S, 2003)		1.04
"Gefitinib (Iressa) is an orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor in advanced clinical development, and the first agent of its kind to receive approval."( Gefitinib (Iressa): a novel treatment for non-small cell lung cancer.
Vansteenkiste, J, 2004)		2.49
"Gefitinib is an anilinoquinazoline compound with the chemical name 4-quinazolinamine,N-(3-chloro-4-flurophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]."( United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.
Abraham, S; Baird, A; Chen, G; Cohen, MH; Liang, C; Lostritto, R; McGuinn, WD; Morse, D; Pazdur, R; Rahman, A; Sridhara, R; Williams, GA, 2004)		1.28
"Gefitinib is an orally active epidermal growth factor receptor tyrosine kinase inhibitor that blocks signal-transduction pathways implicated in the proliferation and survival of cancer cells."( Gefitinib: phase II and III results in advanced non-small cell lung cancer.
Averbuch, S; Kelly, K, 2004)		2.49
"Gefitinib is an orally active agent that blocks signal transduction pathways implicated in the proliferation and survival of cancer cells and host-dependent processes that promote tumor growth."( Long-term effect of gefitinib (ZD1839) on squamous cell carcinoma of the lung.
Bessho, A; Date, H; Hamazaki, S; Kiura, K; Kozuki, T; Tabata, M; Tanimoto, M; Ueoka, H, )		1.18
"Gefitinib is an oral, highly tolerable, specific inhibitor of epidermal growth factor receptor-associated tyrosine kinase, which has shown activity in chemotherapy pre-treated NSCLC."( Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial.
Bartolini, S; Cappuzzo, F; Ceresoli, GL; Crinò, L; Gregorc, V; Villa, E, 2004)		2.49
"Gefitinib (Iressa) is a novel targeted therapy that inhibits the tyrosine kinase activity of the epidermal growth factor receptor by competitively blocking the ATP binding site. "( The role of gefitinib in lung cancer treatment.
Giaccone, G, 2004)		2.15
"Gefitinib is an orally active epidermal growth factor receptor tyrosine kinase inhibitor that blocks the signal transduction pathways implicated in cancer cell growth and survival."( Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer.
Faulkner, K; Forsythe, B, 2004)		1.33
"Gefitinib ('Iressa') is an orally active tyrosine kinase inhibitor (TKI) targeted to the ATP-binding domain of EGFR (HER1; erbB1)."( The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P, 2004)		1.36
"Gefitinib ("Iressa") is an selective EGFR tyrosine kinase inhibitor (TKI) that blocks signal transduction pathways."( Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.
Koh, Y; Koizumi, F; Nishio, K; Saijo, N; Taguchi, F; Tamura, T, 2004)		1.27
"Gefitinib ("Iressa") is a selective EGFR tyrosine kinase inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation."( Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.
Arao, T; Fukumoto, H; Nishio, K; Saijo, N; Takeda, M; Tamura, T, 2004)		1.04
"Gefitinib (Iressa) is a novel drug approved in 28 countries (as of June 2004), including Japan, the US, Canada and Australia as second- and third-line monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer refractory to prior chemotherapy. "( Gefitinib: current status in the treatment of non-small cell lung cancer.
Alfaro, V; Tanović, A, 2004)		3.21
"Gefitinib is a small molecule that specifically inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) type 1 by interfering with the adenosine triphosphate (ATP) binding site. "( Gefitinib therapy for non-small cell lung cancer.
Birnbaum, A; Ready, N, 2005)		3.21
"Gefitinib is a meaningful active therapy in NSCLC with a favorable toxicity profile. "( [French experience of gefitinib in non-small cell bronchial carcinoma].
Blandin, S; Gérinière, L; Girard, N; Perrot, E; Souquet, PJ, 2004)		2.08
"Gefitinib is an oral, selective epidermal growth factor receptor (EGFR) inhibitor that has activity in non-small cell lung cancer (NSCLC)."( Gefitinib in advanced non-small cell lung cancer.
Boyer, M; Clarke, S; Millward, M; Sharma, R, 2005)		3.21
"Gefitinib ("Iressa") is a novel epidermal growth factor receptor tyrosine kinase inhibitor that targets cell signaling involved in tumor growth and differentiation."( Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer.
Gatzemeier, U; Reck, M, 2005)		2.49
"Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. "( Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel.
Kris, MG; Lobo, J; Rosen, N; Scher, HI; She, Y; Sirotnak, FM; Solit, DB, 2005)		2
"Gefitinib is an oral selective inhibitor of the epidermal growth factor receptor tyrosine kinase which is effective for patients with advanced non-small cell lung cancer. "( Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy.
Aoe, K; Eda, R; Hiraki, A; Katayama, H; Maeda, T; Murakami, T; Takeyama, H; Umemori, Y, )		1.82
"Gefitinib is an oral agent that inhibits the tyrosine kinase of epidermal growth factor receptor (EGFR), which had antitumor activity in patients with previously treated non-small cell lung cancer (NSCLC). "( Analysis of the response and toxicity to gefitinib of non-small cell lung cancer.
Asahina, H; Dosaka-Akita, H; Hattori, T; Imura, M; Ishida, T; Isobe, H; Kikuchi, E; Kikuchi, J; Kinoshita, I; Konishi, J; Munakata, M; Nakadate, M; Nishikawa, S; Nishimura, M; Ogura, S; Sekine, S; Shinagawa, N; Takashima, R; Yamazaki, K; Yokouchi, H, )		1.84
"Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor that induces an early and dramatic response in 10% of patients with advanced nonsmall cell lung carcinoma (NSCLC). "( High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
Abrey, LE; Franceschi, E; Kris, MG; Miller, VA; Milton, DT; Omuro, AM; Shah, N, 2005)		1.98
"Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor effective in patients with lung cancer with mutations in exons 19 and 21 of the EGFR tyrosine kinase domain. "( EGFR tyrosine kinase domain mutations in human gliomas.
Carpentier, AF; Delattre, JY; Hoang-Xuan, K; Marie, Y; Omuro, AM; Sanson, M; Thillet, J, 2005)		1.77
"Gefitinib is a selective inhibitor of the epidermal growth factor (EGFR) tyrosine kinase, which is overexpressed in many cancers, including non-small-cell lung cancer (NSCLC). "( Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
Bartolini, S; Bemis, L; Bunn, PA; Cappuzzo, F; Ceresoli, GL; Crino, L; Danenberg, K; Doglioni, C; Domenichini, I; Franklin, WA; Gregorc, V; Haney, J; Hirsch, FR; Ludovini, V; Magrini, E; Rossi, E; Sidoni, A; Tonato, M; Varella-Garcia, M; Witta, S, 2005)		2.02
"Gefitinib is an orally active epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor."( Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
Astoul, P; Barlési, F; Doddoli, C; Greillier, L; Kleisbauer, JP; Tchouhadjian, C; Thomas, P; Villani, P, 2005)		2.49
"Gefitinib is an inhibitor of epidermal growth factor receptor tyrosine kinase, which has a tumour reducing effect in non-small cell lung cancer (NSCLC). "( Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer.
Ichinose, Y; Ikeda, J; Maruyama, R; Miyake, T; Nakamura, T; Okamoto, T; Shoji, F; Wataya, H, 2005)		2
"Gefitinib (Iressa) is a selective epidermal growth factor receptor tyrosine kinase inhibitor and is used for the treatment of lung cancer. "( Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.
Doi, S; Kitazaki, T; Kohno, S; Nakamura, Y; Oka, M; Soda, H; Takemura, M; Tsurutani, J; Yabuuchi, H; Yasunaga, M, 2005)		3.21
"Gefitinib is a synthetic, oral anilinoquinazoline specifically designed to inhibit the epidermal growth factor receptor tyrosine kinase, and is the first targeted drug to demonstrate reproducible activity in non-small cell lung cancer patients who do not respond to platinum-based chemotherapy. "( Drug interaction between gefitinib and warfarin.
Abe, T; Hagiri, S; Ishii, K; Katagiri, M; Kato, E; Kobayashi, H; Kuboto, M; Masuda, N; Mitsufuji, H; Onoda, S; Ryuge, S; Takada, N; Tanaka, N; Wada, M; Yamamoto, M; Yanaihara, T; Yanase, N; Yokoba, M, 2005)		2.07
"Gefitinib is a new drug that was approved by the US Food and Drug Administration in May 2003 for non-small cell cancer of the lung refractory to first- and second-line therapy. "( Myocarditis temporally related to the use of gefitinib (Iressa).
Figlin, R; Fishbein, MC; Truell, JS, 2005)		2.03
"Gefitinib is a small-molecule inhibitor that competes for the ATP-binding site on EGF receptor (EGFR) and has been approved for patients with advanced lung cancers."( Epithelial membrane protein-1 is a biomarker of gefitinib resistance.
Afar, DE; Agus, DB; Aronson, N; Curran, J; Galkin, A; Hunter, JB; Jain, A; Laux, I; Natale, RB; Shak, S; Tindell, CA, 2005)		1.31
"Gefitinib is an inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and has been introduced in the treatment of advanced lung cancers."( Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.
Fukuyama, S; Hagiwara, K; Kanazawa, M; Kato, M; Kobayashi, K; Miyazawa, H; Nagai, Y; Tanaka, T; Udagawa, K; Yokote, A, 2005)		1.05
"Gefitinib is a selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinases, and shows favorable antitumor activity against chemorefractory non-small cell lung cancer (NSCLC). "( Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases.
Edakuni, N; Inayama, M; Kakiuchi, S; Muguruma, H; Nakataki, E; Nishikubo, N; Ohtsuka, S; Sone, S; Tomimoto, H; Yano, S, 2005)		2.03
"Gefitinib (Iressa) is an anticancer drug that selectively inhibits tyrosine kinases of epidermal growth factor receptor. "( Gefitinib (Iressa) inhibits the CYP3A4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin but activates that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin from irinotecan.
Ando, Y; Araki, K; Endo, H; Fujita, K; Kodama, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Yamamoto, W, 2005)		3.21
"Gefitinib (Iressa() is an orally active, selective EGFR tyrosine kinase inhibitor that blocks signal transduction pathways. "( Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.
Kasahara, K; Kimura, H; Nishio, K; Sekijima, M; Tamura, T, 2005)		1.97
"Gefitinib is a safe oral agent that may benefit these patients."( Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
Bradof, JE; Brierre, JE; Burkett, ER; Burris, HA; Dickson, NR; Greco, FA; Hainsworth, JD; Jones, SF; Rubinsak, JR; Scullin, DC; Spigel, DR; Thomas, M; Yardley, DA, 2005)		1.42
"Gefitinib is a small molecule inhibitor that specifically binds and inhibits the EGFR tyrosine kinase and has been shown to inhibit the growth, proliferation, survival and invasion of a range of tumour cells overexpressing EGFR."( Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII.
Ottesen, LH; Pedersen, MW; Pedersen, N; Poulsen, HS, 2005)		1.35
"Gefitinib is an orally active, EGFR-tyrosine kinase inhibitor that blocks signal transduction pathways implicated in the proliferation and survival of cancer cells and other host-dependent processes promoting cancer cell growth."( Gefitinib: current and future status in cancer therapy.
Herbst, RS; Kies, MS, 2003)		2.48
"Gefitinib is an oral agent with a mild toxicity profile, and thus, may be an optimal addition to chemotherapeutic regimens for some solid tumors."( Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy.
Allen, D; Bohlin, C; Penne, K; Schneider, S, )		2.3
"Gefitinib is an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that blocks signal transduction pathways involved in cell proliferation. "( Clinical experience with gefitinib: an update.
Bartolini, S; Cancellieri, A; Cappuzzo, F; Castaldini, L; Crino, L; Finocchiaro, G; Magrini, E; Metro, G; Tallini, G; Trisolini, R, 2006)		2.08
"Gefitinib, which is an orally active epidermal growth factor receptor tyrosine kinase inhibitor, has demonstrated activity against hormone-refractory prostate cancer (HRPC) in preclinical studies. "( Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
Das-Gupta, A; Small, E; Soulie, P; Trump, D; Wilding, G, 2006)		2.05
"Gefitinib is an active agent in advanced stage BAC. "( Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.
Chansky, K; Crowley, JJ; Franklin, WA; Gandara, DR; Gumerlock, PH; Lau, DH; McCoy, J; Vance, R; West, HL, 2006)		3.22
"Gefitinib (Iressa) is a new antineoplastic agent that acts by selectively inhibiting epidermal growth factor receptor tyrosine kinase (EGFR-TK). "( [Gefitinib-induced perforating dermatosis].
Aldanondo, I; Fernández-Guarino, M; Garrido, P; González-García, C; Jaén, P; Marquet, A; Pérez-García, B, 2006)		2.69
"Gefitinib is an orally active epidermal growth factor receptor tyrosine kinase inhibitor with activity in previously treated patients with advanced-stage non-small-cell lung cancer (NSCLC). "( Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer.
Buchholz, E; Gatzemeier, U; Krutzfeldt, K; Manegold, C; Reck, M; Romer, KS, 2006)		3.22
"Gefitinib is an inhibitor of epidermal growth factor receptor tyrosine kinase, and induces radiographic regression and symptomatic improvement in patients with non-small cell lung cancer (NSCLC). "( Smoking history and prior surgical resection predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
Hirata, K; Iwao, H; Kimura, T; Kudoh, S; Matsuura, K; Mitsuoka, S; Yoshikawa, J; Yoshimura, N, 2006)		2.01
"Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor and is approved for use in the treatment of non-small cell lung cancer."( Effect of gefitinib on brain metastases from non-small cell lung cancer.
Fujimoto, K; Kawai, S; Masui, K; Nishi, N; Yonezawa, T, 2006)		1.46
"Gefitinib is an orally active inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) with activity in non-small-cell lung cancer. "( CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.
Baker, SD; Brahmer, J; Hidalgo, M; Karlsson, MO; Li, J; Spitz, A; Zhao, M, 2006)		1.78
"Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase with activity in non-small-cell lung cancer. "( Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.
Baker, SD; Cusatis, G; Gregorc, V; Hidalgo, M; Ingersoll, RG; Li, J; Ludovini, V; Sparreboom, A; Spreafico, A; Verweij, J; Villa, E, 2006)		2.03
"Gefitinib is a selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, and has been used in treating advanced non-small cell lung cancer (NSCLC). "( [Efficacy of gefitinib on advanced non-small cell lung cancer in expanded access program (EAP)].
Guan, ZZ; Pan, ZK; Wang, ZQ; Xu, F; Xu, GC; Zhang, L; Zhang, Y; Zhao, HY, 2006)		2.15
"Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor. "( Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J, 2006)		3.22
"Gefitinib is an orally active epidermal growth factor receptor tyrosine kinase inhibitor, and it shows favorable antitumor activity against chemorefractory nonsmall cell lung cancer (NSCLC). "( Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib.
Inuzuka, K; Kasahara, K; Kawashima, A; Kita, T; Yoshimoto, A, 2007)		2.1
"Gefitinib (500 mg/d) is an active and generally well-tolerated treatment for ACE. "( A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response.
Anderson, M; Atherfold, P; Beddard, K; Ferry, DR; Harrison, R; Jankowski, J; Obszynska, J; Tomlinson, S, 2007)		2.11
"Gefitinib is a specific inhibitor of the epidermal growth factor receptor (EGFR) that causes growth delay in cancer cell lines and human tumor xenografts expressing high levels of EGFR. "( The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells.
Albergaria, A; Coombes, RC; Francis, RE; Krol, J; Lam, EW; Polychronis, A; Sunters, A, 2007)		2.02
"Gefitinib (Iressa) is an EGFR inhibitor."( Maintenance therapy with gefitinib after first-line chemotherapy in patients affected by advanced non-small cell lung cancer.
Bergaglio, M; Faravelli, B; Galbusera, V; Grosso, M; Ivaldi, GP; Mencoboni, M; Racchi, O; Rebella, L; Serra, M; Tredici, S, )		1.16
"Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor, which blocks signal transduction pathways implicated in proliferation and survival of cancer cells. "( Late fatal recurrence in gefitinib-treated NSCLC patients.
Ano, T; Miyazaki, K; Nakazawa, K; Ohtsuka, M; Satoh, H, 2007)		2.09
"Gefitinib is a inhibitor of epidermal growth factor receptor and can be used for the treatment of advanced non-small cell lung cancer (NSCLC)."( [Gefitinib in the treatment of advanced non-small cell lung cancer with brain metastasis].
Li, LY; Wang, HZ; Wang, MZ; Wang, SL; Wu, C; Zhang, L; Zhang, XT; Zhong, W, 2007)		1.97

Effects

Gefitinib has an anti-migratory effect on MDA-MB231 that results in anAnti-proliferative effect. Has a modest activity in previously treated patients with advanced non-small cell lung cancer (NSCLC)

Gefitinib has been shown to inhibit cell survival and growth signaling pathways such as the extracellular signal-regulated kinase 1/2 pathway and the Akt pathway, as a consequence of the inactivation of EGFR. The drug has been approved for the treatment of patients with non-small cell lung cancer.

ExcerptReferenceRelevance
"Gefitinib has an anti-migratory effect on MDA-MB231 that results in an anti-proliferative effect. "( PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839).
Aoe, M; Doihara, H; Hara, H; Ishibe, Y; Shien, T; Shimizu, N; Taira, N; Takahashi, H; Teramoto, J; Yoshitomi, S, 2004)		1.99
"Gefitinib has a modest activity in previously treated patients with advanced non-small cell lung cancer (NSCLC). "( Gefitinib for previously untreated patients with non-small cell lung cancer (NSCLC)--a retrospective study of 12 patients treated in one institution.
Hirashima, T; Kawahara, K; Kawase, I; Kobayashi, M; Matsui, K; Nakamura, Y; Nitta, T; Sasada, S; Takimoto, T, 2005)		3.21
"Gefitinib has a modest activity in second-line treatment of advanced esophageal cancer. "( Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.
Gallegos-Ruiz, MI; Giaccone, G; Janmaat, ML; Meijer, GA; Richel, DJ; Rodriguez, JA; Van Groeningen, C; Vervenne, WL, 2006)		2.02
"Gefitinib has shown good efficacy in patients with "( Role of allogeneic natural killer T cells in the treatment of a patient with gefitinib-sensitive lung adenocarcinoma.
Chen, D; Li, J; Mao, C; Xia, S; Ye, F; Yu, W; Yuan, X; Zhang, M, 2022)		2.39
"Gefitinib has been widely used in the first-line treatment of advanced EGFR-mutated non-small-cell lung cancer (NSCLC). "( Krüppel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer.
Feng, W; Ji, Y; Jin, L; Li, C; Liu, S; Wang, C; Xie, Q, 2018)		2.17
"Gefitinib has been approved only for EGFR mutation bearing patients regardless the line of treatment, while erlotinib is also indicated in patients without EGFR mutation who undergo second- or third-line treatment."( Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.
Bronte, G; Castiglia, M; Cicero, G; Fiorentino, E; Giovannetti, E; Passiglia, F; Pauwels, P; Rizzo, S; Rolfo, C; Russo, A; Van Meerbeeck, J; Vullo, FL, 2014)		1.46
"Gefitinib treatment has offered some promising results in estrogen receptor + breast cancer."( Emerging EGFR antagonists for breast cancer.
Eroles, P; Lluch, A; Perez-Fidalgo, JA, 2014)		1.12
"Gefitinib (Iressa) has demonstrated clinical efficacy in NSCLC patients harboring EGFR mutations or refractory to chemotherapy."( Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR.
Ding, HR; Han, SY; Li, PP; Teng, F; Zhao, W, 2014)		1.48
"Gefitinib has been evaluated as a first-line treatment in selected patients, and it has shown favorable efficacy especially in NSCLC, but it is not effective for everyone."( Fibroblasts weaken the anti-tumor effect of gefitinib on co-cultured non-small cell lung cancer cells.
Han, Y; Jiang, T; Li, Q; Shang, Y; Wang, P; Yong, X; Yu, W; Zhang, P, 2014)		1.38
"Gefitinib has lower anti-tumor activity on A549 lung cancer cells when co-cultured with HFL-1 fibroblasts."( Fibroblasts weaken the anti-tumor effect of gefitinib on co-cultured non-small cell lung cancer cells.
Han, Y; Jiang, T; Li, Q; Shang, Y; Wang, P; Yong, X; Yu, W; Zhang, P, 2014)		2.11
"Gefitinib has similar activity and toxicity compared with erlotinib and offers a valuable alternative to patients with NSCLC. "( Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
Burotto, M; Fojo, T; Manasanch, EE; Wilkerson, J, 2015)		3.3
"Gefitinib has potential to become a standard treatment for pulmonary MEC patients, including pediatric patients. "( Pathological complete response to gefitinib in a 10-year-old boy with EGFR-negative pulmonary mucoepidermoid carcinoma: a case report and literature review.
Chang, Y; Gao, Y; He, Z; Li, S; Liu, K; Ma, J; Ma, W; Ma, Z; Tang, H; Wang, Q; Wei, B; Zhang, Z, 2017)		2.18
"Gefitinib resistance has been shown to complicate cancer therapy. "( Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
Chang, VH; Chen, CC; Jiang, X; Lin, HY; Liu, YR; Wang, J; Yang, SH; Yen, Y; Zhang, K, 2015)		2.18
"Gefitinib treatment has come to be recognized as the standard therapy for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. "( Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations.
Igawa, S; Ishihara, M; Katagiri, M; Masuda, N; Otani, S; Sasaki, J; Takakura, A, 2015)		2.12
"Gefitinib has been used as an anti-cancer drug in lung cancer patients; however, some patients eventually become gefitinib resistant."( Bufalin inhibits gefitinib resistant NCI-H460 human lung cancer cell migration and invasion in vitro.
Cheng, YD; Chung, JG; Hsia, TC; Hsiao, YT; Huang, AC; Kuo, CL; Lin, TS; Ma, YS; Peng, SF; Yang, MD, 2016)		1.5
"Gefitinib has shown modest activity in patients with recurrent non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. "( A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Akamine, SJ; Ebi, N; Kuraki, T; Nakanishi, Y; Okamoto, I; Semba, H; Takayama, K; Tokunaga, SJ; Wataya, H; Yamamoto, H, 2008)		2.11
"Gefitinib has potential as a first-line therapeutic option in elderly patients with advanced NSCLC."( A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Akamine, SJ; Ebi, N; Kuraki, T; Nakanishi, Y; Okamoto, I; Semba, H; Takayama, K; Tokunaga, SJ; Wataya, H; Yamamoto, H, 2008)		1.39
"Gefitinib has been approved for the treatment of patients with non-small cell lung cancer. "( Combined treatment with TNF-alpha/gefitinib alleviates the resistance to gefitinib in PC-9 cells.
Ji, Y; Lu, YJ; Ma, SL; Tang, JJ; Wu, YM; Zhang, YP, 2009)		2.07
"Gefitinib has been shown to inhibit cell survival and growth signaling pathways such as the extracellular signal-regulated kinase 1/2 pathway and the Akt pathway, as a consequence of the inactivation of EGFR."( EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors.
Ito, F; Takeuchi, K, 2010)		1.08
"Gefitinib has been generally considered to be a relatively safe agent."( Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature.
Liao, XB; Liu, JQ; Sun, XL; Wang, YX; Yan, DF; Yan, SX; Yang, JS, 2010)		1.32
"Gefitinib has different efficacy according to the type of complex EGFR mutations."( Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer.
Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Nishiyama, A; Tomii, K; Yoshioka, H, 2010)		1.08
"Gefitinib has shown evidence of antitumor activity in advanced non-small cell lung cancer (NSCLC)."( Restoration of gefitinib efficacy following chemotherapy in a patient with metastatic non-small cell lung cancer.
Geng, YT; Li, XD; Shen, H; Shu, YQ; Sun, J; Wu, CP; Yin, YM, 2010)		2.16
"Gefitinib has shown its efficacy in term of response and survival in first line treatment of NSCLC arboring EGFR mutations."( [Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments].
Giroux Leprieur, E; Planchard, D, 2011)		1.09
"Gefitinib has shown high response rate and improved progression-free survival (PFS) in never-smokers with lung adenocarcinoma (NSLAs). "( First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
Ahn, JS; Ahn, MJ; Han, JH; Han, JY; Jo, SJ; Kim, HT; Kim, HY; Kim, SW; Lee, DH; Lee, JS; Lee, JW; Park, K; Suh, C; Yoon, SJ; Yun, T, 2012)		1.82
"Gefitinib has activity in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) and skin toxicity has been postulated to be a predictor of response and improved outcome."( Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck.
Agulnik, M; Blair, EA; Cohen, EE; Dekker, A; Grushko, TA; Olopade, OI; Perez, CA; Raez, LE; Seiwert, TY; Song, H; Stenson, K; Vokes, EE, 2012)		2.16
"Gefitinib has clinical activity as monotherapy in SCCHN. "( Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck.
Agulnik, M; Blair, EA; Cohen, EE; Dekker, A; Grushko, TA; Olopade, OI; Perez, CA; Raez, LE; Seiwert, TY; Song, H; Stenson, K; Vokes, EE, 2012)		2.16
"Gefitinib has promising activity with a good toxicity profile in patients with progressive NSCLC who have received one or two prior chemotherapy regimens. "( Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer.
Alloisio, M; Campagnoli, E; Cavina, R; Ferrari, B; Ginanni, V; Latteri, F; Morenghi, E; Pedicini, V; Ravasi, G; Roncalli, M; Santoro, A; Soto Parra, HJ; Zucali, PA, 2004)		2.05
"Gefitinib has also shown promising efficacy in other solid tumors that rely on EGFR-related mechanisms for growth and survival."( Gefitinib (Iressa): a novel treatment for non-small cell lung cancer.
Vansteenkiste, J, 2004)		2.49
"Gefitinib has demonstrated encouraging efficacy in advanced NSCLC in phase II trials in pretreated patients, and a phase I trial of gefitinib in combination with gemcitabine and cisplatin showed favorable tolerability."( Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Averbuch, SD; Fandi, A; Gatzemeier, U; Giaccone, G; Grous, J; Herbst, RS; Johnson, DH; Manegold, C; Miller, V; Natale, RB; Ochs, JS; Pluzanska, A; Rennie, P; Rosell, R; Scagliotti, G; Schiller, JH; Von Pawel, J; Wolf, MK, 2004)		2.49
"Gefitinib 250 mg/day has been approved for use in advanced, previously treated NSCLC in several countries including the USA, Japan and Australia."( Gefitinib, a novel, orally administered agent for the treatment of cancer.
Ranson, M; Wardell, S, 2004)		2.49
"Gefitinib has anti-tumor activity, in a heterogeneous population of NSCLC patients treated on the EAP study. "( Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Fidias, P; Gurubhagavatula, S; Jänne, PA; Johnson, BE; Lucca, J; Lynch, TJ; Ostler, P; Skarin, AT; Yeap, BY, 2004)		2
"Gefitinib has been shown to improve pulmonary symptoms and quality of life in patients who did not have an objective response to treatment."( Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer.
Cersosimo, RJ, 2004)		2.49
"Gefitinib has modest activity with an overall response rate of 11-18% in patients with metastatic non-small cell lung cancer (NSCLC) who have had progressive disease following platinum containing chemotherapy. "( Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience.
Behnken, D; Coplin, MA; Gao, F; Govindan, R; Kommareddy, A; Read, W; Romvari, E, 2004)		2.14
"Gefitinib has shown meaningful antitumor activity with tolerable toxicity in chemotherapy-refractory NSCLC in previous studies. "( Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer.
Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Kim, DW; Kim, NK; Kim, TY; Kim, YT, 2005)		1.99
"Gefitinib has been approved for the treatment of advanced NSCLC in Japan, the USA, and other countries."( Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Von Pawel, J, 2004)		2.49
"Gefitinib has an anti-migratory effect on MDA-MB231 that results in an anti-proliferative effect. "( PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839).
Aoe, M; Doihara, H; Hara, H; Ishibe, Y; Shien, T; Shimizu, N; Taira, N; Takahashi, H; Teramoto, J; Yoshitomi, S, 2004)		1.99
"Gefitinib has favorable pharmacokinetic and pharmacodynamic properties and low toxicity."( Gefitinib: current status in the treatment of non-small cell lung cancer.
Alfaro, V; Tanović, A, 2004)		2.49
"Gefitinib has minimal single-agent activity in HRPC."( Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Baetz, T; Berry, S; Brundage, M; Canil, CM; Chi, KN; Douglas, L; Ernst, DS; Fisher, B; McKenna, A; Moore, MJ; Pollak, M; Seymour, L; Winquist, E, 2005)		1.31
"Gefitinib has been the first of these drugs to be licensed for third-line treatment of advanced NSCLC patients."( Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Ciardiello, F; Di Maio, M; Gridelli, C; Normanno, N; Perrone, F, 2005)		1.05
"As gefitinib has demonstrated antitumour activity and an acceptable tolerability profile not typically associated with cytotoxic adverse events, such as hematological toxicities, combinations with cytotoxic drugs have been evaluated."( Gefitinib in non-small cell lung cancer.
Fukuoka, M; Tamura, K, 2005)		2.29
"Gefitinib has recently been approved for treatment of disease in the third line."( Second-line chemotherapy and beyond for non-small-cell lung cancer.
Edelman, MJ, 2004)		1.04
"Gefitinib has a modest activity in previously treated patients with advanced non-small cell lung cancer (NSCLC). "( Gefitinib for previously untreated patients with non-small cell lung cancer (NSCLC)--a retrospective study of 12 patients treated in one institution.
Hirashima, T; Kawahara, K; Kawase, I; Kobayashi, M; Matsui, K; Nakamura, Y; Nitta, T; Sasada, S; Takimoto, T, 2005)		3.21
"Gefitinib has demonstrated significant efficacy in non-small-cell lung cancer (NSCLC), leading to FDA approval for treatment of this refractory disease."( Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy.
Allen, D; Bohlin, C; Penne, K; Schneider, S, )		2.3
"Gefitinib has shown activity in the treatment of non-small-cell lung cancer (NSCLC) patients who failed previous platinum-based combination chemotherapy and/or taxane treatment. "( Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: a prospective phase II study.
Chen, YM; Perng, RP; Tsai, CM, 2005)		3.21
"Gefitinib has demonstrated activity in patients with non-small cell lung cancer (NSCLC). "( Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial.
Axelson, J; Breen, TE; Einhorn, LH; Estes, D; Govindan, R; Hanna, NH; Moore, AM; Vinson, J; Yu, M, 2006)		3.22
"Gefitinib has a modest activity in second-line treatment of advanced esophageal cancer. "( Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.
Gallegos-Ruiz, MI; Giaccone, G; Janmaat, ML; Meijer, GA; Richel, DJ; Rodriguez, JA; Van Groeningen, C; Vervenne, WL, 2006)		2.02
"Gefitinib monotherapy has some efficacy in chemotherapy-naive patients with advanced-stage or metastatic NSCLC. "( Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer.
Buchholz, E; Gatzemeier, U; Krutzfeldt, K; Manegold, C; Reck, M; Romer, KS, 2006)		3.22
"Gefitinib has fairly effective anti-tumour activity in patients with tumours harboring EGFR gene mutations."( Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation.
Bashar, AH; Funai, K; Kazui, T; Mori, H; Sugimura, H; Suzuki, K; Takamochi, K, 2007)		1.36
"Gefitinib has no single-agent activity in non-metastatic HRPC, as assessed by decreases in serum PSA level. "( A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.
DiPaola, RS; Fontana, J; Iacona, RB; Kabbinavar, FF; Rubin, M; Small, EJ; Tannir, N; Wilding, G, 2007)		2.11
"Gefitinib has been reported to be more effective in patients with non-small-cell lung cancer (NSCLC) who had low or never-smoking history than for heavier smokers. "( Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer.
Fujiwara, Y; Hotta, K; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H, 2008)		2.07

Actions

Gefitinib has lower anti-tumor activity on A549 lung cancer cells when co-cultured with HFL-1 fibroblasts. Gefit inib can inhibit ABCG2-mediated PpIX efflux from malignant brain tumor cells to increase the intracellular Ppix.

ExcerptReferenceRelevance
"Gefitinib can inhibit CC proliferation and tumor growth by SEC61G."( SEC61G Promotes Cervical Cancer Proliferation by Activating MAPK Signaling Pathway.
Fan, Y; Li, Q; Liu, F; Wang, H; Wang, Y, 2022)		1.44
"Gefitinib (GEF) may increase the risk of corrected QT prolongation (QTc). "( Gefitinib Increases the Incidence of QT Prolongation in Patients with Non-Small Cell Lung Cancer.
Abulimiti, B; Dong, X; Fu, Z; Jin, M; Maimaitituersun, G, 2023)		3.8
"Gefitinib could inhibit proliferation, migration and invasion and promote cell apoptosis. "( A novel risk model of three gefitinib-related genes FBP1, SBK1 and AURKA is related to the immune microenvironment and is predicting prognosis of lung adenocarcinoma patients.
Guo, Q; Jiang, N; Li, K; Rao, XR; Wu, CY; Zhou, R, 2023)		2.65
"Gefitinib can inhibit EGFR signaling and block the autophosphorylation of critical tyrosine residues on EGFR."( Co-delivery of GOLPH3 siRNA and gefitinib by cationic lipid-PLGA nanoparticles improves EGFR-targeted therapy for glioma.
Liu, H; Lu, J; Pan, B; Shen, J; Xu, H; Ye, C; Yu, R; Zhao, Z, 2019)		1.52
"Gefitinib did not inhibit ADAM17 expression in both the gefitinib-sensitive PC-9 and gefitinib-resistant RPC-9 cells (P > 0.05)."( Lentivirus-mediated disintegrin and metalloproteinase 17 RNA interference reversed the acquired resistance to gefitinib in lung adenocarcinoma cells in vitro.
Jing, YT; Li, YQ; Liu, YS; Wang, Z; Wu, SC; Yan, JP; Yang, Y; Ying, XW; Zhou, HB, 2018)		1.41
"Gefitinib can inhibit ABCG2-mediated PpIX efflux from malignant brain tumor cells to increase the intracellular PpIX and thereby enhance the PDT effect."( Gefitinib enhances the efficacy of photodynamic therapy using 5-aminolevulinic acid in malignant brain tumor cells.
Inoue, H; Ishikawa, T; Kajimoto, Y; Kuroiwa, T; Miyatake, S; Sun, W, 2013)		3.28
"Gefitinib has lower anti-tumor activity on A549 lung cancer cells when co-cultured with HFL-1 fibroblasts."( Fibroblasts weaken the anti-tumor effect of gefitinib on co-cultured non-small cell lung cancer cells.
Han, Y; Jiang, T; Li, Q; Shang, Y; Wang, P; Yong, X; Yu, W; Zhang, P, 2014)		2.11
"Gefitinib can enhance the radiosensitivity of nasopharyngeal carcinoma CNE2 cells in vitro possibly by inhibiting cell proliferation, inducing cell apoptosis, and causing changes in the cell cycle distribution."( [Gefitinib enhances the radiosensitivity of nasopharyngeal carcinoma cell line CNE2 in vitro].
He, BF; Huang, BY; Luo, RC; Sun, AM; Wang, WJ; Zheng, XK, 2011)		2.72
"Gefitinib could enhance AMTA effects through mechanisms not restricted to Pgp blockage."( Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation.
Chang, KT; Chen, JT; Chen, YM; Chiu, CH; Hsiao, SY; Lai, CL; Tsai, CM, 2012)		2.54
"Gefitinib is known to suppress the activation of EGFR signaling, which is required for cell survival and proliferation in non-small cell lung cancer (NSCLC) cell lines. "( Silencing of SNX1 by siRNA stimulates the ligand-induced endocytosis of EGFR and increases EGFR phosphorylation in gefitinib-resistant human lung cancer cell lines.
Itoh, K; Nakabeppu, Y; Nishimura, Y; Takiguchi, S; Yoshioka, K, 2012)		2.03
"Gefitinib may produce dramatic clinical responses when administered to patients with poor performance status who had received heavy platinum/docetaxel-based prior chemotherapy."( [Gefitinib for advanced bronchioloalveolar carcinoma].
Li, LY; Wang, SL; Zhang, XT, 2004)		1.96
"Gefitinib could inhibit the growth of NPC CNE2 xenografts. "( [Effect of epidermal growth factor receptor-selective tyrosine kinase inhibitor gefitinib on nasopharyngeal carcinoma xenografts].
Guan, ZZ; Jiang, WQ; Lin, TY; Wang, SS; Xiang, YQ; Zhang, L, 2004)		1.99
"Gefitinib, developed to inhibit the tyrosine kinase of the epidermal growth factor receptor (EGFR), represents the first new treatment modality for NSCLC to emerge from the last decade."( Gefitinib is also active for carcinomatous meningitis in NSCLC.
Choi, JH; Hyun, MS; Kim, MK; Lee, JK; Lee, KH, 2005)		2.49
"Gefitinib was shown to inhibit proliferation in all five JPA cell-cultures tested, with IC-50's between 1.6 and 9.6 microM. "( Gefitinib is effective against juvenile pilocytic astrocytoma in vitro.
Donson, AM; Foreman, NK; Gore, L; Heideman, R; Straessle, J; Wells, D, 2006)		3.22
"Gefitinib failed to inhibit the MAPK pathway in resistant cell lines."( Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer.
Amador, ML; Grunwald, V; Hidalgo, M; Iacobuzio-Donahue, C; Jimeno, A; Maitra, A; Rubio-Viqueira, B, 2007)		1.06

Treatment

The gefitinib + anlotinib treatment exerted a synergistic antitumor effect by downregulating the activation of VEGFR2 and downstream effectors, Akt and ERK. Gefit inib treatment for bone metastases in patients harboring EGFR mutation resulted in a beneficial osteosclerotic change in most patients.

ExcerptReferenceRelevance
"The gefitinib + anlotinib treatment exerted a synergistic antitumor effect by downregulating the activation of VEGFR2 and downstream effectors, Akt and ERK."( Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.
Cao, H; Cui, Y; Gao, W; Guo, R; Huang, C; Jin, S; Zhang, C, 2021)		1.1
"Gefitinib treatment for bone metastases in patients harboring EGFR mutation resulted in a beneficial osteosclerotic change in most patients. "( Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis.
Harada, H; Katagiri, H; Miyagi, M; Mori, K; Murakami, H; Murata, H; Takahashi, M; Takahashi, T; Wasa, J, 2022)		2.42
"Gefitinib and zerumbone treatment significantly promoted the apoptosis of tumor cells."( Zerumbone combined with gefitinib alleviates lung cancer cell growth through the AKT/STAT3/SLC7A11 axis.
Fan, R; Li, DL; Wang, JG; Yan, MJ, 2023)		1.94
"Gefitinib treatment induced EGFR arrest in the early endosome, and YC-1 treatment promoted delayed EGFR transport into the late endosome as well as receptor degradation."( YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells.
Hu, H; Hu, MN; Li, JY; Miao, XK; Mou, LY; Xu, JJ; Yang, WL; Zhang, JY; Zhang, XW; Zhou, TX, 2020)		1.54
"Gefitinib treatment strongly blocked epithelial-like cSCC-PDX growth in the absence of"( FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma.
Bermejo, JO; Bernat-Peguera, A; Bosio, M; Capella-Gutierrez, S; da Silva-Diz, V; González-Suárez, E; Lorenzo-Sanz, L; Mesia, R; Muñoz, P; Navarro-Ventura, J; Palomero, L; Penin, RM; Pérez Sidelnikova, D; Piulats, JM; Taberna, M; Vilariño, N; Villanueva, A; Viñals, F; Viñals, JM, 2021)		1.34
"Gefitinib and lapatinib treatments reduced mammosphere formation in the sensitive cells, but not in the therapy resistant variants, indicating enhanced mesenchymal and cancer stem cell-like characteristics in therapy resistant cells. "( Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer.
Borrero-García, LD; Del Mar Maldonado, M; Dharmawardhane, S; Grafals-Ruiz, N; Medina-Velázquez, J; Troche-Torres, AL; Velazquez, L, 2021)		2.06
"Gefitinib treatment was able to restore fluorescence after EGF stimulation in U87MG cells but not in BS153 cells, overexpressing EGFR/EGFRvIII."( Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence.
Burgio, F; Faia-Torres, AB; Fontana, AO; Marchi, F; Paganetti, P; Pieles, U; Piffaretti, D; Pinton, S; Reinert, M, 2017)		1.18
"Gefitinib/MK‑2206 treatment synergistically decreased the mTOR signaling target substrates along with the downregulation of ribosomal protein S6 (RPS6), a marker of cell proliferation and target substrate of the AKT-mTOR signaling pathway."( Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
Kwak, SJ; Seong, YS; Yi, YW; You, KS, 2018)		1.2
"Gefitinib-treated patients displayed a relative slower disc degenerating progression, in contrast to control subjects."( Therapeutic effects of gefitinib-encapsulated thermosensitive injectable hydrogel in intervertebral disc degeneration.
Bunpetch, V; Fu, Q; Heng, BC; Hu, W; Li, J; Ouyang, H; Pan, Z; Shen, W; Sun, H; Wang, Y; Wang, Z; Wu, Y; Xia, D; Xie, B; Xu, Y; Yang, Y; Yu, D; Zhang, S; Zhang, X, 2018)		1.51
"Gefitinib treatment negatively regulated miR-138 in PC9 cells."( HOXA4-regulated miR-138 suppresses proliferation and gefitinib resistance in non-small cell lung cancer.
He, N; Jiang, J; Tan, J; Tang, X; Zhu, J, 2019)		1.48
"Gefitinib treatment decreases securin levels at the protein level by inducing protein instability but did not affect on the securin gene expression."( Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells.
Chang, CC; Chao, JI; Liu, HF; Tsai, CM; Wang, SP; Yu, SY, 2013)		1.37
"Gefitinib treatment results in considerably better progression-free survival compared with that of platinum doublets in the first line treatment of nonsmall-cell lung cancer (NSCLC) carrying an activating epidermal growth factor receptor (EGFR) mutation. "( A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment.
Imamura, F; Kijima, T; Komuta, K; Kumagai, T; Kumanogoh, A; Minami, S; Mori, M; Morita, S; Nakazawa, Y; Namba, Y; Nishino, K; Okuyama, T; Tachibana, I; Takahashi, R; Uchida, J; Yamamoto, S; Yano, Y, 2013)		2.06
"Gefitinib-treated EGFR-TKI-sensitive NSCLC cells showed a wide spectrum of chemo-refractoriness, suggesting that concomitantly combined EGFR-TKI-chemotherapy might not be a good treatment strategy for NSCLC harboring SEM."( Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.
Chang, KT; Chen, JT; Chiu, CH; Hsiao, SY; Lai, CL; Tsai, CM, 2013)		2.02
"Gefitinib treatment increases clonogenic cell killing by radiation but only in cell lines sensitive to gefitinib alone. "( Short-course treatment with gefitinib enhances curative potential of radiation therapy in a mouse model of human non-small cell lung cancer.
Bokobza, SM; Devery, AM; Jiang, Y; Ryan, AJ; Weber, AM, 2014)		2.14
"Gefitinib treatment has offered some promising results in estrogen receptor + breast cancer."( Emerging EGFR antagonists for breast cancer.
Eroles, P; Lluch, A; Perez-Fidalgo, JA, 2014)		1.12
"Gefitinib retreatment was introduced in February 2013 and resulted in partial remission with excellent clinical status."( [Gefitinib treatment in lung cancer -- rebiopsy, retreatment, remission].
Balázs, G; Kovalszky, I; Losonczy, G; Moldvay, J; Pápay, J; Puskás, R, 2014)		2.03
"Gefitinib treatment also inhibited hyperuricemia-induced activation of the TGF-β1 and NF-κB signaling pathways and expression of multiple profibrogenic cytokines/chemokines in the kidney."( EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy.
Bao, W; Cheng, SB; Chin, YE; Liu, N; Qiu, A; Shi, Y; Wang, L; Xiong, C; Xu, L; Yan, H; Yang, T; Zhuang, S, 2015)		1.14
"Gefitinib treatment has come to be recognized as the standard therapy for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. "( Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations.
Igawa, S; Ishihara, M; Katagiri, M; Masuda, N; Otani, S; Sasaki, J; Takakura, A, 2015)		2.12
"Gefitinib treatment significantly decreased mucin 3 expression and beta-glucuronidase activity."( Effects of epidermal growth factor receptor inhibitor on proliferative cholangitis in hepatolithiasis.
Cheng, NS; Li, FY; Ma, WJ; Mao, H; Shrestha, A; Yang, Q; Zhang, W; Zhou, Y, 2015)		1.14
"Gefitinib treatment abrogated the increased phosphorylation of EGFR, Smad3, signal transducer and activator of transcription 3, and NF-κB during peritoneal fibrosis; it also inhibited the accompanying overproduction of TGF-β1 and proinflammatory cytokines and the infiltration of macrophages to the injured peritoneum."( Inhibition of EGF Receptor Blocks the Development and Progression of Peritoneal Fibrosis.
Liu, N; Mao, H; Qiu, A; Shi, Y; Wang, L; Xiong, C; Xu, L; Zang, X; Zhuang, S, 2016)		1.16
"Gefitinib treatment attenuated subtotal nephrectomy-induced cardiac hypertrophy."( Midkine Deteriorates Cardiac Remodeling via Epidermal Growth Factor Receptor Signaling in Chronic Kidney Disease.
Arimoto, T; Honda, Y; Kadomatsu, K; Kadowaki, S; Kinoshita, D; Kishida, S; Kubota, I; Miyamoto, T; Narumi, T; Netsu, S; Nishiyama, S; Shishido, T; Takahashi, H; Takahashi, T; Takeishi, Y; Watanabe, T, 2016)		1.16
"Gefitinib and S3I-201 treatment significantly reduced the expression of CEBPD and enhanced the sensitivity of CDDP-resistant UCUB cells to CDDP and paclitaxel."( Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.
Chang, WC; Chu, YY; Hour, TC; Li, CF; Wang, JM; Wang, WJ; Wang, YH; Yen, CJ, 2017)		1.18
"Gefitinib treatment suppressed surfactant protein (SP)-A expression in H441 human lung adenocarcinoma cells expressing SP-A, -B, -C and -D by inhibiting epidermal growth factor signal."( Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation.
Fukuhara, T; Inoue, A; Kanehira, M; Kikuchi, T; Kuroki, Y; Maemondo, M; Nukiwa, T; Saijo, Y; Suzuki, T; Xin, H, 2008)		1.07
"gefitinib; group 3, treated with 50 mg/kg p.o."( Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice.
Katayama, H; Kishino, D; Kiura, K; Kuyama, S; Ohashi, K; Okada, T; Sato, K; Takigawa, N; Tanimoto, M, 2009)		1.48
"Gefitinib treatment was of significantly greater benefit in patients with adenocarcinoma than in those with non-adenocarcinoma (test for interaction p< 0.001)."( Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras.
Ahn, JS; Ahn, MJ; Jun, HJ; Kim, HS; Kim, S; Lee, J; Lee, S; Park, K; Park, YH; Yi, SY, 2009)		1.29
"Gefitinib treatment resulted in significant tumor growth inhibition (pulsed: 439 +/- 93; daily: 404 +/- 53; control: 891 +/- 174 mm(3), P < 0.050) and lower cell density (pulsed: 0.15 +/- 0.01, daily: 0.17 +/- 0.01, control: 0.24 +/- 0.01, P < 0.050) after 9 days. "( MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model.
Aliu, SO; Hann, BC; Hylton, NM; Li, KL; Moasser, MM; Wang, D; Wilmes, LJ, 2009)		1.8
"Gefitinib-treatment decreased both CCD-independent and FGF-2- or VEGF-A-promoted Fes activity with a maximal decrease at 1 microM."( Inhibition of endothelial cell chemotaxis toward FGF-2 by gefitinib associates with downregulation of Fes activity.
Kanda, S; Miyata, Y; Naba, A, 2009)		1.32
"Gefitinib treatment increased EGFR Bmax, possibly through membrane stabilization of inactive receptor dimers that we show to be induced by the drug also in the absence of EGF."( Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation.
Bajetto, A; Barbieri, F; Corte, G; Favoni, RE; Florio, T; Gatti, M; Gaudino, G; Lo Casto, M; Mutti, L; Paleari, L; Pattarozzi, A; Porcile, C, 2010)		2.52
"Gefitinib treatment and toxicity data from five paediatric clinical trials were combined. "( Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib.
Allen, JW; Daw, NC; Furman, WL; Geyer, JR; McGregor, LM; McKibbin, T; Stewart, CF; Tagen, M; Zhao, W, 2010)		2.02
"Gefitinib pretreatment induced multinucleated cells after IR exposure in NCI-H460 and VMRC-LCD, but not in A549 cells."( Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated.
Kim, YM; Park, SY; Pyo, H, 2010)		2.52
"Gefitinib treatment after naphthalene prolonged neutrophil sequestration and worsened acute lung injury. "( EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium.
Hamada, N; Harada, C; Kawaguchi, T; Kuwano, K; Maeyama, T; Nakanishi, Y; Ogata-Suetsugu, S; Souzaki, R; Taguchi, T; Tajiri, T; Yamada, M, 2011)		1.81
"For gefitinib treatment, longer median PFS is likely to be obtained in patients with > 70 years old, earlier clinical stage (IIIb), non-bone metastasis."( [Analysis of prognostic factors of 80 advanced NSCLC patients treated with gefitinib for more than 6 months].
Chen, X; Dai, L; Fang, J; Han, J; Han, S; Hu, W; Liu, X; Nie, J; Tian, G, 2010)		1.15
"Gefitinib (Gef) treatment was recommended if the patients had EGFR mutation (mEGFR)."( Prospective study of second-line chemotherapy for non-small cell lung cancer selected according to EGFR gene status.
Honda, T; Kameda, Y; Kondo, T; Miyagi, Y; Murakami, S; Noda, K; Obata, M; Oshita, F; Saito, H; Sakuma, Y; Yamada, K; Yokose, T, 2010)		1.08
"Gefitinib plus UFT treatment had better PFS than gefitinib alone treatment. "( A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy.
Chen, YM; Chou, KT; Chou, TY; Fan, WC; Lee, YC; Liu, SH; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J; Wu, CH, 2011)		2.1
"Gefitinib-treated mice showed increased Fosl1 and Ccl2 expression and developed interstitial lung disease in response to LPS, endogenous TLR ligands and chemotherapy."( Interstitial lung disease induced by gefitinib and toll-like receptor ligands is mediated by Fra-1.
Asano, K; Bozec, A; Gresh, L; Ikeda, E; Kamiya, K; Kobayashi, K; Matsuo, K; Takada, Y; Toyama, Y; Wagner, EF; Watanabe, M, 2011)		1.36
"Gefitinib treatment was started and his levels of plasma D-dimer immediately decreased."( [A case of adenocarcinoma of the lung with a pulmonary thromboembolism which improved with gefitinib].
Horai, T; Horiike, A; Kudo, K; Nishio, M; Ohyanagi, F; Yanagitani, N, 2011)		1.31
"Gefitinib treatment did not alter the number of EGFR or HER2 expressed in tumor cell lines A431, U343, SKOV3 and SKBR3."( Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF.
Andersson, K; Barta, P; Björkelund, H; Gedda, L; Malmqvist, M, 2011)		2.53
"Gefitinib treatment of primary GBM cells resulted in a robust apoptotic response, partially conveyed by mitogen-activated protein kinase (MAPK) signaling attenuation and accompanied by BIM(EL) expression."( Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
Acquaviva, J; Boskovitz, A; Bronson, RT; Charest, A; Donovan, M; Housman, DE; Jun, HJ; Lessard, J; Pfannl, R; Raval, A; Ruiz, R; Whittaker, CA; Woolfenden, S; Zhu, H, 2011)		1.09
"Gefitinib treatment decreased both tumor size and corticosterone levels; it also reversed signs of hypercortisolemia, including elevated glucose levels and excess omental fat."( EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.
Ben-Shlomo, A; Bruyette, D; Cooper, O; Fukuoka, H; Mamelak, A; Melmed, S; Ren, SG, 2011)		1.09
"Post-gefitinib treated EGFR TKD mutant tumors demonstrated lower tumor cellularity and proliferative index compared to wild type ADC and non-ADC cases, features correlating with clinical response."( Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer.
Chung, CT; Hwang, DM; Lara-Guerra, H; Leighl, NB; Pintilie, M; Schwock, J; Tsao, MS; Waddell, TK, 2012)		1.05
"Gefitinib treatment-related UP was prolonged with increasing age: 8.2 months, 14.2 months and 18.2 months in the age groups of < or = 49-years, 50-69-years and > or = 70-years, respectively (log-rank P = 0.002)."( Differential efficacy of gefitinib across age groups in treatment of advanced lung adenocarcinoma.
Fan, Q; Li, P; Ma, Z; Qi, G; Wang, H; Wang, Q; Yan, X; Zhang, G; Zhu, H, 2012)		1.4
"Gefitinib treatment increased the infiltration of inflammatory cells, which produced more pro-inflammatory cytokines (IL-6, IL-1β), in the lungs of the irradiated rats on days 15 and 57, while gefitinib treatment reduced collagen content of the lungs in irradiated rats and decreased proliferation and EGFR expression in the lung fibroblasts from irradiated rats on day 57."( Epidermal growth factor receptor-tyrosine kinase inhibitor (gefitinib) augments pneumonitis, but attenuates lung fibrosis in response to radiation injury in rats.
Aono, Y; Hanibuchi, M; Kakiuchi, S; Kishi, J; Miyake, K; Nishioka, Y; Sone, S; Suzuka, C; Tani, K; Tezuka, T; Toyoda, Y; Yuasa, S, 2012)		2.06
"Gefitinib-treated patients with sufficient archived tissue were included. "( Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer.
Basu, S; Batus, M; Bonomi, P; Buckingham, L; Coon, J; Fidler, MJ; McCormack, S; Walters, K, 2012)		2.06
"Gefitinib treatment affords no significant clinical benefit on DFS in an unselected population of patients with head and neck cancer. "( Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02).
Bensadoun, RJ; Bertucci, F; Cayre, A; Dassonville, O; De Raucourt, D; Etienne-Grimaldi, MC; Finetti, P; Geoffrois, L; Giraud, P; Grall, D; Milano, G; Morinière, S; Penault-Llorca, F; Racadot, S; Sudaka, A; Thariat, J; Van Obberghen-Schilling, E, 2012)		2.13
"Gefitinib treatment increased the cyclin-dependent kinase inhibitor p27, and this was not abrogated by IGF1R activation."( Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cells.
Beckler, AD; Carlson, HT; Francom, CR; Jameson, MJ; Khalil, AA; Mendez, RE; Stuart, MM; Taniguchi, LE; Thomas, CY; VanKoevering, KK, 2013)		1.11
"Gefitinib treatment at high concentration inhibited the proliferation of the CCC cell lines."( Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
Horiguchi, N; Kakizaki, S; Mori, M; Nakajima, Y; Sato, K; Sunaga, N; Takagi, H, 2012)		2.54
"Gefitinib treatment resulted in objective radiographic regressions of tumor and symptom improvement in patients with advanced, heavily pretreated NSCLC in clinical trials and in the Expanded Access Program."( Antitumor activity and tolerability of gefitinib in patients with non-small-cell lung cancer treated in an expanded access program.
Miller, VA; Shah, NT, 2003)		1.31
"Gefitinib pretreatment blocked receptor cross-talk, reestablished corepressor complexes with tamoxifen-bound ER on target gene promoters, eliminated tamoxifen's agonist effects, and restored its antitumor activity both in vitro and in vivo in MCF-7/HER2-18 cells."( Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Ali, S; Massarweh, S; Osborne, CK; Schiff, R; Shou, J; Wakeling, AE; Weiss, H, 2004)		1.04
"Gefitinib treatment (1 micromol/L) leads to significant apoptosis accompanied by increased poly(ADP-ribose) polymerase cleavage only in the H3255 cell line, leads to G(1)-S arrest in H1666, and has no effects in the A549 and H441 cell lines."( Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
Hansen, M; Jänne, PA; Johnson, BE; Meyerson, M; Mukohara, T; Tracy, S, 2004)		2.49
"Gefitinib-treatment induced both mitochondria-dependent and -independent apoptosis."( Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
Höpfner, M; Huether, A; Scherübl, H; Schuppan, D; Sutter, AP; Zeitz, M, 2004)		1.3
"Gefitinib treatment resulted in tumor shrinkage and/or CEA decrease to less than half of the baseline level in 26 patients, tumor growth and/or CEA elevation in 24 patients, and gefitinib effect was not assessable in nine patients."( Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
Endoh, H; Hatooka, S; Hida, T; Horio, Y; Kosaka, T; Mitsudomi, T; Mori, S; Shinoda, M; Takahashi, T; Yatabe, Y, 2005)		1.27
"Gefitinib treatment significantly suppressed androgen levels, especially in women who had no smoking history."( Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients.
Horai, T; Horiike, A; Ishikawa, Y; Nakagawa, K; Nishio, K; Nishio, M; Ohyanagi, F; Okumura, S; Satoh, Y, 2005)		2.49
"Gefitinib treatment decreased EGFR, ERK1/2, and Akt phosphorylation in EGFR mutant cell lines whereas cetuximab had relatively little effect."( Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
Cantley, LC; Engelman, JA; Halmos, B; Hanna, NH; Jänne, PA; Johnson, BE; Kobayashi, S; Lindeman, N; Mukohara, T; Pearlberg, J; Tenen, DG; Tsuchihashi, Z; Yeap, BY, 2005)		1.36
"Gefitinib-treated NSCLC patients whose serum amphiregulin or TGF-alpha was positive showed a poorer tumor-specific survival (P = 0.037 and 0.002, respectively, by univariate analysis) compared with those whose serum amphiregulin or TGF-alpha concentrations were negative."( Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers.
Daigo, Y; Hayama, S; Inai, K; Ishikawa, N; Kato, T; Kohno, N; Murakami, H; Nakamura, Y; Nishimura, H; Takano, A; Takeshima, Y; Taniwaki, M; Tsuchiya, E, 2005)		1.26
"Gefitinib treatment reduced DNA-PK activity in MCF-7 and AR42J but not MDA-453 cells."( Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment.
Ashworth, A; Caplin, M; Friedmann, BJ; Hartley, JA; Hochhauser, D; Lord, CJ; Savic, B; Shah, T, 2006)		1.27
"Upon gefitinib treatment, EGFR activation and subsequent downstream activation through Erk and Akt were significantly inhibited in HAG-1 cells."( Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Ariyama, H; Baba, E; Harada, M; Kusaba, H; Nakano, S; Qin, B; Tanaka, R, 2006)		1.08
"Gefitinib treatment was begun in September, 2002 at her request."( [A case of complete response in a primary lesion treated by gefitinib for two years after surgery of brain metastasis from lung cancer].
Fujii, Y; Kuga, T; Matsuoka, T; Morikage, N; Nakayama, T, 2006)		1.3
"Gefitinib treatment was proposed because of the persistence of meningitic symptoms despite cranial irradiation."( [Gefitinib treatment for carcinomatous meningitis in non-small cell lung cancer].
Breau, JL; Brechot, JM; Chouahnia, K; Des-Guetz, G; Morere, JF; Saintigny, P, 2006)		1.97
"Gefitinib treatment was well tolerated; skin toxicities occurred in 71% of patients, including severe skin toxicities in 2 patients, and mild to moderate diarrhea occurred in 50% of patients."( Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer.
Buchholz, E; Gatzemeier, U; Krutzfeldt, K; Manegold, C; Reck, M; Romer, KS, 2006)		2.5
"In gefitinib-treated patients, the presence of EGFR mutation was associated with a higher response rate to gefitinib and a longer overall survival, but the increased EGFR gene copy number was not."( Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.
Endo, K; Fujii, Y; Haneda, H; Kawano, O; Kobayashi, Y; Sasaki, H; Suzuki, E; Yano, M; Yukiue, H, 2006)		1.06
"Gefitinib treatment was continued until disease progression, development of unacceptable toxicity, or withdrawal of patients consent."( Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial.
Agelaki, S; Argiraki, A; Christofillakis, Ch; Georgoulias, V; Kalykaki, A; Kotsakis, A; Mavroudis, D; Pallis, AG; Souglakos, J; Tselepatiotis, E; Vamvakas, L; Vardakis, N, 2007)		1.3
"Gefitinib treatment inhibited EGFR, Akt, and Erk phosphorylation in the skin."( A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors.
Bernardi, RJ; Black, JD; Brattain, MG; Creaven, PJ; Fakih, MG; French, R; Hutson, A; Johnson, CS; Muindi, JR; Schwartz, J; Trump, DL, 2007)		1.28
"In gefitinib-treated NSCLC patients, correlation was good between 4-week TMR and IBR. "( Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib.
Chen, YM; Chiu, CH; Liou, JL; Perng, RP; Shih, YN; Tsai, CM, 2007)		1.17
"Gefitinib treatment of hypercalcaemic mice with RWGT2 and HARA xenografts resulted in a significant reduction of plasma total calcium concentrations by 78 h."( Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice.
Foley, J; Gilmore, JL; Gonterman, RM; Koltz, PF; Konger, RL; Laughner, R; Lewis, DA; Lorch, G; Nadella, KS; Rosol, TJ; Toribio, RE, 2007)		1.06
"Gefitinib treatment diminished phosphorylation of the ErbB-3 > EGFR > HER2/neu and signal transducers and activators of transcriptions in a dose-dependent fashion."( Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Dibbley, SK; Lonardo, F; Piechocki, MP; Yoo, GH, 2007)		1.3
"Gefitinib treatment did not result in any objective measurable response or responses in prostate-specific antigen."( Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity.
Curigliano, G; De Braud, F; De Cobelli, O; De Pas, T; Matei, V; Noberasco, C; Nolè, F; Renne, G; Rocco, B; Scardino, E; Spitaleri, G; Teresa Sandri, M; Verweij, F; Zorzino, L, 2007)		2.5
"Gefitinib treatment inhibited not only the EGF-dependent proliferation and ERK1/2 activation but also the effects of SDF-1 and E2, suggesting that these activities were mediated by EGFR transactivation."( 17beta-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment.
Bajetto, A; Barbieri, F; Favoni, R; Ferrari, A; Florio, T; Gatti, M; Lunardi, G; Pattarozzi, A; Porcile, C; Ratto, A; Würth, R, 2008)		1.26
"Gefitinib and B[a]P co-treatment decreased Rad51 protein stability by triggering degradation via a 26S proteasome-dependent pathway."( The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancer.
Hong, JH; Ko, JC; Lin, YW; Wang, LH, 2008)		1.27
"For gefitinib treatment for non-small cell lung cancer (NSCLC), KRAS mutations reportedly behave as a resistance marker, and the epidermal growth factor receptor (EGFR) as a responsive marker. "( EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.
Guo, AL; Wang, Z; Wu, YL; Xu, CR; Zhang, GC; Zhou, Q, 2008)		1.21
"Gefitinib treatment should be considered for patients with carcinomatous meningitis and lung adenocarcinoma harboring a mutated EGF gene."( Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene.
Fukuhara, T; Inoue, A; Kanamori, M; Morikawa, N; Nakashima, I; Nukiwa, T; Saijo, Y; Sakakibara, T, 2008)		1.32
"Gefitinib treatment strongly reduced the phosphorylation level of EGFR, and subsequent endocytosis of EGFR was significantly suppressed in PC9 cells."( Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line.
Bereczky, B; Itoh, K; Nishimura, Y; Yoshioka, K, 2008)		1.27
"Treatment with Gefitinib was continued until disease progression, intolerable adverse effects were developed, or consent was withdrawn."( Efficacy and safety of EGFR inhibitor gefitinib in recurrent or metastatic cervical cancer: a preliminary report.
Athiyamaan, MS; Banerjee, S; Jawahar, V; Krishna, A; Lobo, D; Makkapatti, BS; Mukesh, S; Sathya, M; Srinivas, C; Sunny, J, 2023)		1.52
"Treatment with gefitinib prevented tumor-supportive alterations in macrophage phenotype and resulted in reduced metastasis."( Pharmacological prevention of surgery-accelerated metastasis in an animal model of osteosarcoma.
Blank, B; Kallis, MP; Maloney, C; Soffer, SZ; Steinberg, BM; Symons, M, 2020)		0.9
"The treatment of gefitinib-resistant cells with efatutazone reduced the growth of gefitinib-resistant cells in a dose- and time-dependent manner, and facilitated the anti-proliferative effects of gefitinib."( PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
Cao, H; Ding, L; Dong, S; Du, Y; Fan, F; Feng, J; Li, H; Liu, S; Lou, R; Ma, R; Ni, J; Wang, Z; Wu, J; Zhao, X; Zhou, LL, 2017)		1.07
"Treatment with gefitinib (250 mg/day) resulted in clinical and radiological improvements scored as partial response that lasted 12 months."( Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report.
Karpov, I; Kovalenko, S; Kozlov, V; Shamanin, V, 2017)		1.01
"Treatment with gefitinib of lung adenocarcinoma that carries mutation EGFR 19ins can result in durable response."( Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report.
Karpov, I; Kovalenko, S; Kozlov, V; Shamanin, V, 2017)		1.02
"Treatment with gefitinib alone resulted in a significantly lower cell inhibition rate in resistant H1650 cells than in the parental H1650 cells (P<0.05) and HCC827 cells (P<0.01)."( [Activation of nuclear factor-κB subunit p50/p65 enhances gefitinib resistance of lung adenocarcinoma H1650 cell line].
DU, JX; Gong, WX; Huang, SC; Liang, CW; Pan, Y; Peng, DX; Quan, W; Wang, X; Xie, Y; Zhang, N; Zheng, LP, 2018)		1.06
"Treatment with gefitinib specifically targeted high-burst cell subpopulations only in EGFR-amplified tumors, decreasing bursting frequency and amplitude."( Intratumoral heterogeneity of endogenous tumor cell invasive behavior in human glioblastoma.
Canoll, P; Foshay, K; Kleinschmidt-DeMasters, BK; Niswander, L; Parker, JJ; Waziri, A, 2018)		0.82
"Treatment with gefitinib induced cytotoxicity in various human cancer cell types, including RKO (colon cancer), A549 (lung cancer), BFTC905 (bladder cancer), MCF7 (breast cancer) and A375 (skin cancer)."( Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells.
Chang, CC; Chao, JI; Liu, HF; Tsai, CM; Wang, SP; Yu, SY, 2013)		0.99
"Treatment with gefitinib had a clear effect on PFS and ORR, and it might contribute considerably to the OS. "( Chemotherapy with or without gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of 6,844 patients.
Diao, P; Wang, LY; Wei, Y; Xie, H; Yao, WX; Zeng, C; Zhao, X; Zhou, H; Zhou, J, 2013)		1.03
"Treatment with gefitinib resulted in the upregulation of p27Kip1 expression and induction of G1 cell cycle arrest, concomitantly associated with inactivation of PI3K/Akt signaling in COLM-5 cells and marked inhibition of xenografted tumors in nude mice, but not evident in COLM-2 cells."( Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
Fujita, M; Hara, M; Ito, Y; Kanemitsu, Y; Kondo, E; Nakanishi, H; Nakata, S; Tanaka, H; Yatabe, Y, 2014)		0.97
"The treatment of gefitinib for 6 hr, 12 h, and 24 hr significantly increased the cellular expression of phosphorylated γH2AX."( Overexpression of BRCA1 attenuates the sensitivity of PC9 cells to gefitinib.
Deng, Y; Feng, W; Liang, J; Wu, J; Xian, H; Yang, S; Zhang, H, 2015)		0.98
"Treatment of a gefitinib-resistant cell line derived from PC9 cell (PC9-DR) with the gefitinib-loaded cetuximab-capped MP-SiO2 NP showed a significant inhibition of cell growth."( Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance.
Huang, HY; Ji, H; Wang, Y; Yang, L; Zhang, Z, 2016)		0.77
"Mice treated with gefitinib exhibited decreased tumor tissue ERK1/2 phosphorylation and down-regulated tumor PRL and Pttg1 mRNA abundance."( Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands.
Donangelo, I; Gutman, S; Melmed, S; Ren, SG; Siegel, E; Vlotides, G, 2008)		0.67
"Treatment with gefitinib was continued until she died because of the complete relief of bone pain."( [Potent and continuous relief of spinal bone pain due to metastasis of non-small cell lung cancer by treatment with gefitinib--a case report].
Fujimoto, T; Ito, T; Kanda, S; Mori, S, 2009)		0.9
"Pretreatment with gefitinib inhibits EGF-induced stimulation of both EGFR and downstream Akt and MAPK more efficiently in MCF-7/CAV1 than in MCF-7 cells."( Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition.
Agelaki, S; Georgoulias, V; Kallergi, G; Markomanolaki, H; Mavroudis, D; Spiliotaki, M; Stournaras, C, 2009)		0.9
"Cotreatment with gefitinib plus tamoxifen decreased the proliferation and increased the apoptosis of A549 and H1650 adencarcinoma cell lines, when compared with either drug alone."( Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects.
Gao, W; Shen, H; Shu, YQ; Sun, J; Yuan, Y, 2010)		1
"The treatment with Gefitinib induced cell cycle arrest in both cell lines, while apoptosis was observed only for high concentrations and prolonged drug exposure."( Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation.
Bajetto, A; Barbieri, F; Corte, G; Favoni, RE; Florio, T; Gatti, M; Gaudino, G; Lo Casto, M; Mutti, L; Paleari, L; Pattarozzi, A; Porcile, C, 2010)		2.12
"Treatment with gefitinib is usually well tolerated."( Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.
Cappuzzo, F; Cortinovis, D; De Marinis, F; Di Maio, M; Gridelli, C; Mok, T, 2011)		2.15
"Treatment with gefitinib was continued for 6 months."( Cryoablation combined with molecular target therapy improves the curative effect in patients with advanced non-small cell lung cancer.
Fang, W; Gu, XY; Jiang, Z, 2011)		0.71
"Treatment with gefitinib also led to improvements in disease-related symptoms in approximately 40% of cases."( Antitumor activity and tolerability of gefitinib in patients with non-small-cell lung cancer treated in an expanded access program.
Miller, VA; Shah, NT, 2003)		0.93
"Treatment with gefitinib in this population is associated with a longer survival in women, those with good performance status and in patients with adenocarcinomas."( Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Fidias, P; Gurubhagavatula, S; Jänne, PA; Johnson, BE; Lucca, J; Lynch, TJ; Ostler, P; Skarin, AT; Yeap, BY, 2004)		0.89
"Treatment with gefitinib or erlotinib, but not cetuximab, also could further inhibit the activation of downstream effectors of EGFR signaling in cetuximab-resistant cells, including MAPK and AKT."( Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Armstrong, EA; Benavente, S; Chinnaiyan, P; Harari, PM; Huang, S, 2004)		0.66
"Treatment with gefitinib has resulted in clinical benefit in patients, and, recently, heterozygous somatic mutations within the EGFR catalytic domain have been identified as a clinical correlate to objective response to gefitinib."( Epithelial membrane protein-1 is a biomarker of gefitinib resistance.
Afar, DE; Agus, DB; Aronson, N; Curran, J; Galkin, A; Hunter, JB; Jain, A; Laux, I; Natale, RB; Shak, S; Tindell, CA, 2005)		0.92
"Treatment of gefitinib at a dose of 1 microM resulted in a significant growth inhibition, and the cell number irreversibly declined after 72-h incubation, with a progressive expansion of apoptotic cell population over 120-h."( Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells.
Ariyama, H; Baba, E; Harada, M; Mitsugi, K; Nakano, S; Qin, B; Tanaka, R, 2006)		2.13
"Treatment with gefitinib was not associated with significant improvement in survival in either coprimary population. "( Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
Archer, V; Carroll, K; Chang, A; Ciuleanu, T; Parikh, P; Pemberton, K; Rodrigues Pereira, J; Tan, EH; Thatcher, N; Thongprasert, S; von Pawel, J, )		1.93
"Treatment with gefitinib modulates association of EGFR and DNA-PK(CS)."( Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment.
Ashworth, A; Caplin, M; Friedmann, BJ; Hartley, JA; Hochhauser, D; Lord, CJ; Savic, B; Shah, T, 2006)		0.89
"Treatment with gefitinib resulted in a median time to progression of > 3 months and a median survival time of > 6 months in most studies."( A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.
Goto, K; Park, K, 2006)		0.94
"Treatment with gefitinib alone for chemotherapy-naïve NSCLC patients with EGFR mutations could achieve a high efficacy with acceptable toxicity. "( Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
Fukuhara, T; Inoue, A; Kimura, Y; Maemondo, M; Morikawa, N; Nukiwa, T; Saijo, Y; Suzuki, T; Watanabe, H, 2006)		0.98
"Treatment with gefitinib alone effectively inhibited EGFR activation but failed to block ERK1/2 phosphorylation and tumor growth."( Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.
Altiok, S; Amador, ML; Chan, A; Hidalgo, M; Jimeno, A; Maitra, A; Mezzadra, H; Nielsen, ME; Patel, P, 2006)		1.03
"Treatment with gefitinib or ZD6474 also inhibited the expression of EGFR downstream signal molecules, p-Erk1/2 and p-Akt, although the magnitude of these effects varied between treatments and cell lines."( Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects.
Azzariti, A; Paradiso, A; Porcelli, L; Simone, GM; Xu, JM, 2006)		0.89
"Treatment with gefitinib, a specific inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK), has resulted in dramatic responses in some patients with non-small cell lung cancer (NSCLC). "( p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer.
Choi, YJ; Kim, CH; Lee, JC; Na, II; Rho, JK; Ryoo, BY; Yang, SH, 2007)		1.06
"Treatment with gefitinib was associated with a significant improvement in survival in a subgroup of patients of Asian origin with previously treated refractory advanced NSCLC."( Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study.
Botwood, N; Chang, A; Ganzon, D; Parikh, P; Perng, RP; Tan, EH; Thatcher, N; Thongprasert, S; Tsao, CJ; Watkins, C; Yang, CH, 2006)		2.13
"Treatment with gefitinib, but not cetuximab, induced EGFR:IGF-IR heterodimerization and activation of IGF-IR and its downstream signaling mediators, resulting in increased survivin expression in NSCLC cell lines with high levels of IGF-IR expression."( Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
Ciardiello, F; Hong, WK; Kim, ES; Kim, WY; Lee, HY; Morgillo, F, 2007)		0.88
"Pretreatment with gefitinib reduced the inflammatory cell counts and released cytokine concentrations (IL-4 and IL-13) in BALF, as well as eosinophil recruitment in the lungs and AHR, in a dose-dependent manner."( Potential use of an anticancer drug gefinitib, an EGFR inhibitor, on allergic airway inflammation.
Hur, GY; In, KH; Jung, JY; Jung, KH; Kang, EH; Kang, KH; Kim, JH; Kim, SJ; Lee, EJ; Lee, KJ; Lee, SH; Lee, SY; Shim, JJ; Shin, C; Yoo, SH, 2007)		0.66
"Treatment with gefitinib alters the dynamics of this system, promoting IGF-IR signalling, the dominant gefitinib-resistant growth regulatory pathway in Tam-R cells, thus, potentially limiting its efficacy."( Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
Barrow, D; Gee, JM; Hutcheson, IR; Jones, HE; Knowlden, JM; Nicholson, RI, 2008)		0.89
"Co-treatment with gefitinib and B[a]P can further inhibit cell growth significantly after depletion of endogenous Rad51 by siRad51 RNA transfection."( The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancer.
Hong, JH; Ko, JC; Lin, YW; Wang, LH, 2008)		0.87

Toxicity

Gefitinib (GEF) is a multi-targeted tyrosine kinase inhibitor with anti-cancer properties. Few cases of cardiotoxicity has been reported as a significant side effect associated with GEF treatment.

ExcerptReferenceRelevance
" The most frequent drug-related adverse events (AEs) were acne-like rash (64%) and diarrhea (47%), which were generally mild (grade 1/2) and reversible on cessation of treatment."( Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Albanell, J; Averbuch, SD; Baselga, J; Bjork, T; Calvert, H; Feyereislova, A; Gianni, L; Harris, A; Kaye, SB; Kieback, DG; Ranson, M; Raymond, E; Rischin, D; Rojo, F; Swaisland, H, 2002)		0.31
" The most commonly reported adverse events were diarrhea, acne-like skin rash, nausea, vomiting and asthenia."( Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine.
Herchenhorn, D; Rabinowits, G; Rabinowits, M; Torres, W; Weatge, D, 2003)		0.57
" The most common cutaneous adverse effect was the development of an acneiform eruption on the face, anterior trunk and back (39%)."( Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor.
Choi, JH; Kim, SW; Koh, JK; Lee, HW; Lee, MW; Moon, KC; Seo, CW; Yang, HJ, 2004)		0.32
" In this report, we investigated the efficacy and adverse events during treatment with gefitinib."( Acute lung injury as an adverse event of gefitinib.
Abe, S; Inomata, S; Nagata, M; Saitoh, T; Sato, T; Satoh, M; Shiratori, M; Takahashi, H; Tanaka, H; Yamada, G, 2004)		0.81
" Adverse events (AEs) were generally mild (grade 1 and 2) and reversible."( Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
Li, LY; Mu, XL; Wang, MZ; Wang, SL; Zhang, XT, 2004)		0.6
" Three volunteers experienced adverse events (AEs) that were considered possibly related to gefitinib (pruritus and dry skin), and 6 volunteers experienced procedure-related AEs (cannula-site reaction and rhinorrhea); these AEs were mild or moderate."( Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.
Bailey, C; Cantarini, MV; Marshall, AL; McFarquhar, T; Smith, RP, 2004)		0.8
" Most drug-related adverse events were mild."( Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity.
Chen, YM; Chiang, SC; Chiu, CH; Liou, JL; Perng, RP; Tsai, CM, 2005)		1.77
" We examined the correlations between the plasma levels of several cytokines and the risk of development of adverse events, especially skin toxicity, induced by the administration of gefitinib as first-line monotherapy in non-small cell lung cancer (NSCLC) patients."( Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.
Kasahara, K; Kimura, H; Nishio, K; Sekijima, M; Tamura, T, 2005)		0.72
" Safety data for 38 recruited patients (18 gefitinib and 20 placebo) showed no unexpected adverse drug reactions (ADRs), with the most common being grade 1/2 gastrointestinal and skin disorders in 12 and 16 patients receiving gefitinib and in five and six patients receiving placebo, respectively."( Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer.
Fukuoka, M; Ichinose, Y; Jiang, H; Kato, H; Nagai, K; Tada, H; Tsuboi, M; Tsuchiya, R; Wada, H, 2005)		2.03
" In the elderly group, adverse events were generally mild to moderate and grade 3-4 adverse events were observed in 8 (9%) patients."( Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience.
Bessho, A; Gemba, K; Harita, S; Hotta, K; Kiura, K; Maeda, T; Ogino, A; Tabata, M; Tanimoto, M; Ueoka, H; Umemura, S; Yonei, T, 2005)		0.64
"Skin toxicity, a common drug-related adverse event observed in cancer patients treated with epidermal growth factor receptor (EGFR)-directed therapies is rarely seen with therapies targeting HER2."( Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies.
Agus, DB; Jain, A; Laux, I; Singh, S, 2006)		0.33
" However, the relationship between EGFR mutation and adverse events of gefitinib is still unknown."( Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
Aoe, M; Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Matsuo, K; Tabata, M; Takigawa, N; Tanimoto, M; Tokumo, M; Toyooka, S, 2006)		0.78
" We retrospectively reviewed the clinical records and compared EGFR mutation status with adverse events during gefitinib treatment."( Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
Aoe, M; Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Matsuo, K; Tabata, M; Takigawa, N; Tanimoto, M; Tokumo, M; Toyooka, S, 2006)		0.76
" The principal adverse event was skin rash (89%), diarrhea (39%), and liver injury (39%)."( Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
Aoe, M; Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Matsuo, K; Tabata, M; Takigawa, N; Tanimoto, M; Tokumo, M; Toyooka, S, 2006)		0.55
"Our study did not demonstrate the presence of close relationships between EGFR mutation status and adverse events during gefitinib treatment."( Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
Aoe, M; Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Matsuo, K; Tabata, M; Takigawa, N; Tanimoto, M; Tokumo, M; Toyooka, S, 2006)		0.75
"We measured serum levels of soluble (s) P-selectin and thromboxane B2 (TxB2) in patients with lung cancer treated with gefitinib, and investigated the effect of low-dose aspirin on some adverse effects of gefitinib."( Aspirin reduces adverse effects of gefitinib.
Kanazawa, S; Kinoshita, Y; Komiyama, Y; Muramatsu, M; Nomura, S; Yamaguchi, K, 2006)		0.82
" The most common adverse effects are rash, diarrhoea, acne, dry skin, nausea and vomiting."( Gefitinib: an adverse effects profile.
Cersosimo, RJ, 2006)		1.78
"The most common side effect of anti-EGFR therapy is skin toxicity, which is generally mild to moderate, but may be severe in up to 18% of patients."( Common side effects of anti-EGFR therapy: acneform rash.
Sipples, R, 2006)		0.33
" However, some nondermatologic adverse events can also be common."( Nondermatologic adverse events associated with anti-EGFR therapy.
Sandler, AB, 2006)		0.33
" The most common adverse events were diarrhea (31."( Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program.
Belani, CP; Govindan, R; Hensing, T; Herbst, R; Kelly, K; Krebs, A; Natale, R; Ochs, J; Reiling, R; Wade, J; Wozniak, A, 2006)		0.64
" Our aim was to describe key clinical features of common dermatologic adverse reactions among EGFR inhibitors, focusing mainly on skin toxicity, as well as to discuss the pathology, possible causes, and suggested treatments for these reactions."( Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.
Agero, AL; Benvenuto-Andrade, C; Busam, KJ; Dusza, SW; Halpern, AC; Myskowski, P, 2006)		0.33
"Factors predicting gefitinib sensitivity and adverse events in non-small cell lung cancer (NSCLC) remain controversial."( The characterization of gefitinib sensitivity and adverse events in patients with non-small cell lung cancer.
Hagiwara, K; Inase, N; Jinn, Y; Kanazawa, M; Koyama, N; Miyake, S; Takabe, K; Usui, Y; Yoshizawa, M; Yoshizawa, Y, )		0.77
"Correlations among clinicopathological characteristics, gefitinib sensitivity and adverse events were studied in 154 patients with NSCLC, whereas epidermal growth factor receptor (EGFR) mutations were analyzed in 44 patients."( The characterization of gefitinib sensitivity and adverse events in patients with non-small cell lung cancer.
Hagiwara, K; Inase, N; Jinn, Y; Kanazawa, M; Koyama, N; Miyake, S; Takabe, K; Usui, Y; Yoshizawa, M; Yoshizawa, Y, )		0.68
"Certain clinicopathological characteristics and EGFR mutations can be either predictive of gefitinib sensitivity or adverse events."( The characterization of gefitinib sensitivity and adverse events in patients with non-small cell lung cancer.
Hagiwara, K; Inase, N; Jinn, Y; Kanazawa, M; Koyama, N; Miyake, S; Takabe, K; Usui, Y; Yoshizawa, M; Yoshizawa, Y, )		0.66
" At least one of these adverse events would be observed in 40."( [Safety and efficacy of gefitinib for treatment of advanced non-small cell lung cancer].
Han, Y; Li, YM; Liu, XQ; Song, ST; Xu, JM; Yang, WW; Zhang, Y, 2007)		0.65
" Severe hematological adverse events related to gefitinib treatment were not observed in any of the included trials."( The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis.
Chan, KA; Chang, CH; Chen, KY; Kurth, T; Orav, EJ; Yang, PC; Young-Xu, Y, 2008)		0.9
" Adverse events were generally mild (grade 1 and 2) and reversible."( [Evaluation of efficacy and safety of ZD1839 as monotherapy in Chinese patients with advanced non-small cell lung cancer].
Li, JR; Li, LY; Wang, MZ; Wang, SL; Zhang, L; Zhang, XT; Zhong, W, 2008)		0.35
" Adverse drug reactions were frequently observed in the skin, gastrointestinal tract, and liver, but they were generally mild in severity and reversible."( Bilateral subdural hemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancer.
Ahn, BM; Choi, DR; Choi, JS; Jung, JY; Kim, HJ; Kim, HS; Kim, HY; Kim, JH; Kwon, JH; Lee, KM; Park, S; Shin, YC; Song, HH; Zang, DY, 2009)		0.59
"Common adverse events included grade 1 skin rash (63%), grade 1 to 2 gastrointestinal symptoms including anorexia, nausea, vomiting, and diarrhea occurred in 63% of patients, grade 3 nausea occurred in 45% of patients."( Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to the
Chen, H; Chen, Y; Eckhardt, SG; Kane, M; Leong, S; Mack, P; McCarter, MD; Olsen, CC; Raben, D; Schefter, TE; Stiegmann, G, 2009)		0.57
" Adverse events included skin rash, dry skin, diarrhea and elevation of serum glutamate pyruvate transaminase (SGPT), and were usually mild."( [Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)].
Guan, ZZ; Huang, H; Wang, ZQ; Xu, F; Xu, GC; Zhang, L; Zhang, Y; Zhao, HY, 2009)		0.62
" The patients with controlled disease may achieve a long survival, and the adverse reactions are mild and tolerable."( [Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)].
Guan, ZZ; Huang, H; Wang, ZQ; Xu, F; Xu, GC; Zhang, L; Zhang, Y; Zhao, HY, 2009)		0.62
" Their cutaneous toxicity is a specific and frequent side effect that has shown to be correlated to the antitumoral effect."( [Cutaneous side effects of EGF receptor inhibitors].
Aractingi, S; Nassar, D; Soutou, B, 2009)		0.35
"Q141K substitution, is more prevalent in Asian populations, the putative relationship between gefitinib-induced adverse effects and this functional polymorphism was investigated in Japanese patients."( Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.
Abe, K; Akasaka, K; Imai, Y; Imura, J; Kaburagi, T; Nagao, K; Ohmori, K; Sagara, H; Ueda, Y; Yasuda, S, 2010)		0.82
"ABCG2 gene polymorphisms were evaluated in 75 patients with non-small-cell lung cancer treated with gefitinib 250 mg/day orally, and results were correlated with treatment-related adverse effects."( Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.
Abe, K; Akasaka, K; Imai, Y; Imura, J; Kaburagi, T; Nagao, K; Ohmori, K; Sagara, H; Ueda, Y; Yasuda, S, 2010)		0.81
" No significant group difference was observed in frequency of gefitinib-related diarrhea or other adverse effects."( Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.
Abe, K; Akasaka, K; Imai, Y; Imura, J; Kaburagi, T; Nagao, K; Ohmori, K; Sagara, H; Ueda, Y; Yasuda, S, 2010)		0.84
"421C > A, and susceptibility to gefitinib-induced adverse effects."( Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.
Abe, K; Akasaka, K; Imai, Y; Imura, J; Kaburagi, T; Nagao, K; Ohmori, K; Sagara, H; Ueda, Y; Yasuda, S, 2010)		0.88
" Grade 3/4 adverse events (AEs) were reported by 6 patients and treatment-related Grade 3 AEs by 3 patients."( A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
Heo, DS; Kang, JH; Kim, DW; Kim, HK; Kim, SY; Lee, JS; Lee, MA; Lee, SH; Shin, SW, 2011)		0.6
" The severe hematological adverse events related to EGFR TKIs treatment were rare."( The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status.
Chen, B; Liu, S; Wang, D; Wang, Y; Wu, J; Zhao, W, 2011)		0.37
" Significantly different adverse events have been associated with gefitinib and erlotinib."( Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.
Fujita, S; Fukuhara, A; Hatachi, Y; Kim, YH; Masago, K; Mio, T; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y, 2011)		0.86
"A retrospective investigation examining the adverse events and tolerances of 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer (NSCLC) was performed."( Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.
Fujita, S; Fukuhara, A; Hatachi, Y; Kim, YH; Masago, K; Mio, T; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y, 2011)		0.84
"More adverse events including skin disorders, diarrhea, oral mucositis, asthenic conditions, anorexia, nausea, vomiting, and gastrointestinal bleeding were observed in the erlotinib group."( Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.
Fujita, S; Fukuhara, A; Hatachi, Y; Kim, YH; Masago, K; Mio, T; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y, 2011)		0.62
" Although agents such as gefitinib, erlotinib, cetuximab, lapatinib, and panitumumab have less systemic side-effects than traditional cytotoxic chemotherapy, dermatologic adverse events from EGFRIs are significantly more common."( Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Anadkat, MJ; Balagula, Y; Lacouture, ME; Wu, PA, 2011)		0.67
"This review provides a symptom-based treatment approach to the common dermatologic adverse effects seen with the epidermal growth factor receptor antagonists: papulopustular rash, xerosis, pruritus as well as hair, nail, and mucosal changes."( Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Anadkat, MJ; Balagula, Y; Lacouture, ME; Wu, PA, 2011)		0.37
"Although the field continues to evolve, this review presents the most up-to-date information on managing dermatologic adverse effects of EGFRIs."( Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Anadkat, MJ; Balagula, Y; Lacouture, ME; Wu, PA, 2011)		0.37
"Historically, skin toxicity has been assessed in prospective clinical trials using the clinician-reported National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE)."( Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993).
Atherton, PJ; Burger, KN; Jatoi, A; Loprinzi, CL; Miller, RC; Neben Wittich, MA; Sloan, JA, 2012)		0.38
" Statistical procedures, including Pearson correlations, were utilized to determine relationships between adverse event (AE) grades and Skindex-16 scores."( Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993).
Atherton, PJ; Burger, KN; Jatoi, A; Loprinzi, CL; Miller, RC; Neben Wittich, MA; Sloan, JA, 2012)		0.38
" The most common gefitinib-related adverse events were nausea and diarrhea, vomiting, and rash."( Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study.
Agus, DB; Gross, ME; Leichman, L; Lowe, ES; Swaisland, A, 2012)		0.98
"Rash, liver dysfunction, and diarrhea are known as adverse events of erlotinib and gefitinib."( Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.
Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Mitsuoka, S; Nagata, M; Suzumura, T; Tanaka, H; Umekawa, K; Yoshimura, N, 2012)		0.85
"The frequency of each adverse event was evaluated in a case-control study on Japanese patients who were treated with gefitinib or erlotinib."( Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.
Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Mitsuoka, S; Nagata, M; Suzumura, T; Tanaka, H; Umekawa, K; Yoshimura, N, 2012)		0.83
" Reduced function of CYP2D6 was not associated with an increased risk of any adverse events in both gefitinib and erlotinib cohorts."( Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.
Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Mitsuoka, S; Nagata, M; Suzumura, T; Tanaka, H; Umekawa, K; Yoshimura, N, 2012)		0.84
" However, the efficacy of these agents against EGFR wild-type (-wt) NSCLC remains unclear, and the frequency of adverse events (AEs) appears to differ between them at each approved dose."( Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis.
Abe, H; Azuma, K; Hattori, S; Hoshino, T; Kage, M; Kawahara, A; Yamada, K; Yamashita, F; Yoshida, T; Zaizen, Y, 2013)		0.64
" It has a favorable toxicity profile but may induce unexpected adverse effects, such as an infiammatory reaction in the bladder."( Gefitinib in non-small cell lung carcinoma: a case report of an unusual side effect and complete response in advanced disease.
Brangi, M; Cartenì, G; Chiurazzi, B; Laterza, MM; Riccardi, F, )		1.57
"The dermatologic side effects are the most common adverse effects associated with Epidermal Growth Factor Receptor tyrosine kinase inhibitors."( IL-33/IL-31 axis: a new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicity.
Adamo, V; David, A; Franchina, T; Gangemi, S; Kennez, I; Minciullo, PL; Profita, M; Zanghì, M, 2013)		0.39
" Serious adverse event was defined as grade 3/4 hematological and non-hematological toxicities."( Concurrent chemoradiation with weekly cisplatin, docetaxel and gefitinib: A study to assess feasibility, toxicity and immediate response.
Azmi, KS; Eswaran, P, )		0.37
"All patients (three in dose level 1 [5 mg/m(2)], level 2 [10 mg/m(2)] and level 3 [15 mg/m(2)]) did not experience any hematological serious adverse events."( Concurrent chemoradiation with weekly cisplatin, docetaxel and gefitinib: A study to assess feasibility, toxicity and immediate response.
Azmi, KS; Eswaran, P, )		0.37
"Gefitinib, a selective inhibitor of the epidermal growth factor receptor-tyrosine kinase, it's one of the most frequent drug-related adverse effects (AEs) reported in literature is dermatologic AEs."( A severe dermatologic adverse effect related with gefitinib: case report and review of the literature.
Li, YQ; Sun, H; Xue, D, 2013)		2.09
" From a literature review and this observation, arguments have been provided to justify erlotinib as a safe and well-tolered alternative for patients who have to stop gefitinib after a severe hepatotoxicity."( [Treatment with erlotinib after gefitinib induced hepatotoxicity: literature review and case report].
Durand, M; Fonrose, X; Logerot, S; Schir, E, )		0.61
" Common treatment-related adverse events were dermatitis acneiform, diarrhea, and paronychia; there were no treatment-related grade 4 or 5 adverse events."( Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
Ahn, MJ; Campbell, AK; Cho, BC; Gernhardt, D; Giri, N; Heo, DS; Kim, DW; Lee, SY; Letrent, SP; O'Connell, J; Park, K; Taylor, I; Zhang, H, 2014)		0.6
" We compared the frequencies of severe adverse events (AEs) among EGFR mutation-positive NSCLC patients treated with these three EGFR-TKIs."( Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Nakagawa, K; Okamoto, I; Takeda, M, 2015)		0.42
"Previous reports regarding the cutaneous adverse events of epidermal growth factor receptor inhibitors are mostly limited to small case reports and case series, mainly involving Caucasian patients."( Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases.
Chanprapaph, K; Pongcharoen, P; Vachiramon, V, )		0.13
"We describe the trends in the clinical presentation of Asian patients who had cutaneous adverse events induced by epidermal growth factor receptor inhibitors and to explore the relationship between skin adverse events and tumor response."( Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases.
Chanprapaph, K; Pongcharoen, P; Vachiramon, V, )		0.13
" Cutaneous adverse events occurred in 43 (57."( Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases.
Chanprapaph, K; Pongcharoen, P; Vachiramon, V, )		0.13
"The limitations of study include its retrospective nature, and the initial screening of cutaneous adverse events was done by non-dermatologists."( Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases.
Chanprapaph, K; Pongcharoen, P; Vachiramon, V, )		0.13
"Cutaneous adverse events due to epidermal growth factor receptor inhibitors are not uncommon in the Asian population."( Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases.
Chanprapaph, K; Pongcharoen, P; Vachiramon, V, )		0.13
" TKIs plus radiotherapy significantly prolong the CNS-TTP and MOS of patients without enhancing overall severe adverse events."( Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases.
Chen, L; Chen, X; Luo, S; Xie, X, 2015)		0.42
" Our study showed that long-term gefitinib-induced hepatotoxicity was a common adverse event, especially for the cohort with a duration of longer than 14 months."( Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer.
Dong, M; He, X; Li, J; Wang, J; Wang, Y; Wang, Z; Wu, Y, 2016)		0.97
" The common adverse events were skin toxicity (68% of patients), diarrhea (46%), and liver injury (63%)."( Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.
Fujita, K; Hirose, T; Ishida, H; Kusumoto, S; Murata, Y; Nakashima, M; Ohmori, T; Oki, Y; Okuda, K; Sasaki, Y; Shirai, T; Sugiyama, T; Yamaoka, T, 2016)		0.66
"Gefitinib (GEF) is a multi-targeted tyrosine kinase inhibitor with anti-cancer properties, yet few cases of cardiotoxicity has been reported as a significant side effect associated with GEF treatment."( Molecular mechanisms of cardiotoxicity of gefitinib in vivo and in vitro rat cardiomyocyte: Role of apoptosis and oxidative stress.
Ahmad, SF; Al-Alallah, IA; Alhaider, AA; Anazi, FE; Ansari, MA; Assiri, MA; Attafi, IM; Belali, OM; Korashy, HM, 2016)		2.14
" The most common adverse events are skin reaction and diarrhea, both of which are generally mild, noncumulative, and manageable."( Safety of gefitinib in non-small cell lung cancer treatment.
Hsiue, EH; Lee, JH; Lin, CC; Yang, JC, 2016)		0.84
" The elimination half-life was not a significant factor for PFS, but it was significantly correlated with high-grade adverse events."( Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
Fukuda, M; Ikeda, T; Ikegami, Y; Izumikawa, K; Mizoguchi, K; Motoshima, K; Mukae, H; Nakamura, Y; Nakatomi, K; Ogawara, D; Sano, K; Sato, S; Senju, H; Sugasaki, N; Takemoto, S; Yamaguchi, H, 2016)		0.72
" On the other hand, long elimination half-life was related to high-grade adverse events in these patients."( Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
Fukuda, M; Ikeda, T; Ikegami, Y; Izumikawa, K; Mizoguchi, K; Motoshima, K; Mukae, H; Nakamura, Y; Nakatomi, K; Ogawara, D; Sano, K; Sato, S; Senju, H; Sugasaki, N; Takemoto, S; Yamaguchi, H, 2016)		0.72
"Patients with advanced NSCLC (N = 191) who entered the IRESSA Clinical Access Program (ICAP) (June 2011 to January 2013) and had previously obtained a clinical benefit from gefitinib therapy (including patients who had received gefitinib since 2001) were analyzed for adverse events (AEs)."( Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
Bunn, PA; Croft, EF; DeVincenzo, D; Freivogel, K; Gore, I; Hirsch, FR; Mooradian, M; Munley, J; Sequist, LV; Sifakis, F; Simon, G; Stein, D, 2018)		0.95
" Antitumor effectiveness (overall survival [OS], progression-free survival [PFS], objective response rate [ORR] and disease control rate [DCR]) and adverse effects [AEs]) were assessed."( Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis.
Peng, J; Wei, Y; Xu, J; Yu, D; Zhang, W, 2018)		1.92
" Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse effects (AEs) were analyzed as primary endpoints."( Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis.
Peng, J; Wei, Y; Xu, J; Yu, D; Zhang, W, 2018)		1.92
" The network meta-analysis is applied to compare the efficacies and adverse events of five targeted agents (erlotinib, gefitinib, vandetanib, dacomitinib, and icotinib) for advanced or metastatic NSCLC."( Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
Li, XF; Liu, GF; Miao, YY; Yu, SN; Zhang, SH, 2019)		0.72
" The common adverse events were skin toxicities(50."( [Efficacy and Safety of Gefitinib as First-Line Chemotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer(NSCLC)].
Kawai, S; Kitazono, M; Murata, K; Ohashi, K; Takahashi, Y; Takamori, M; Wada, A; Yamamoto, M, 2019)		0.82
" We extracted data from these studies to evaluate the relative risk (RR) of overall response rate (ORR) and grade 3/4 treatment-related adverse events (AEs), the hazard ratios (HRs) of overall survival (OS), and progression-free survival (PFS)."( Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients: Pooled analysis and subgroup analysis of efficacy and safety.
Ju, Q; Shao, H; Shi, H; Xu, R; Zhu, J, 2019)		0.51
"Clinical trials with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) reported severe adverse events (SAEs) in 6%-49% of patients with EGFR-mutated non-small cell lung cancer."( The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
DerSarkissian, M; Duh, MS; Fernandes, AW; Laliberté, F; Pavilack, M; Subramanian, J, 2019)		0.51
"In a subgroup of Japanese patients in the ARCHER 1050 randomized phase 3 trial, we evaluated the efficacy and safety and determined the effects of dose modifications on adverse events (AE) and therapy management of first-line oral dacomitinib 45 mg compared with oral gefitinib 250 mg, each once daily in 28-d cycles, in patients with EGFR-activating mutation-positive (EGFR-positive; exon 19 deletion or exon 21 L858R substitution mutations) advanced non-small cell lung cancer (NSCLC)."( Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.
Fujita, Y; Isozaki, M; Kaneda, H; Kato, T; Nakagawa, K; Niho, S; Nishio, M; Nogami, N; Takahashi, T; Tsuji, F; Wada, S; Wilner, K; Yamamoto, N; Yoshida, M, 2020)		0.74
" We conducted a disproportionality analysis of the adverse events (AEs) of EGFR-TKIs (gefitinib, erlotinib, afatinib, osimertinib) by data mining using the FDA adverse event reporting system (AERS) database, and by calculating the reporting odds ratios (ROR) with 95% confidence intervals."( Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System.
Chen, H; Huang, J; Luo, Z; Meng, L; Sun, S; Yang, B, 2020)		0.78
" However, one of the major adverse effects associated with this therapy is skin toxicity, which impacts the patient's quality of life."( Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: An observational study.
Chen, KH; Tseng, LC; Wang, CL; Weng, LC, 2020)		0.56
"Search the online electronic databases on comparison the effectiveness and adverse effects of pemetrexed versus gefitinib in therapy outcomes of pre-treated NSCLC to September 2019."( A meta-analysis of the safety and effectiveness of pemetrexed compared with gefitinib for pre-treated advanced or metastatic NSCLC.
Chen, W; Li, F; Li, S; Li, Y; Lu, X; Zheng, D, 2020)		1
" Pulmonary toxicity is one of the fatal adverse effects of gefitinib and the underlying mechanism remains unclear."( Crosstalk between alveolar macrophages and alveolar epithelial cells/fibroblasts contributes to the pulmonary toxicity of gefitinib.
Du, J; He, Q; Jiang, L; Li, G; Luo, P; Xu, Z; Yan, H; Yang, X; Zhang, X; Zhou, Z, 2021)		1.07
" Because gefitinib resistance usually occurs within 8-10 months of gefitinib administration, the patients were followed up for one year to observe their conditions and compare the occurrence of adverse reactions between the two groups."( Efficacy and safety of domestic and imported gefitinib in patients with advanced non-small cell lung cancer.
Cheng, H; Du, Q; Liu, H; Liu, Y; Shao, J; Shi, J; Sun, Y; Wang, Y; Wei, Q; Wu, N; Xu, S; Yang, F; Yu, B; Zhai, Q; Zhang, B; Zhang, H; Zhang, X, 2021)		1.3
" The incidence of adverse reactions in these two groups were not significantly different."( Efficacy and safety of domestic and imported gefitinib in patients with advanced non-small cell lung cancer.
Cheng, H; Du, Q; Liu, H; Liu, Y; Shao, J; Shi, J; Sun, Y; Wang, Y; Wei, Q; Wu, N; Xu, S; Yang, F; Yu, B; Zhai, Q; Zhang, B; Zhang, H; Zhang, X, 2021)		0.88
" In this study, zebrafish (Danio rerio) were used as model animals to compare the hepatotoxicity and their toxic mechanism."( Mechanism of hepatotoxicity of first-line tyrosine kinase inhibitors: Gefitinib and afatinib.
Cai, Y; He, MF; Jiang, LL; Li, CY; Wei, P; Zhang, SR; Zhang, Y, 2021)		0.86
" The safety of the trail is being assessed based on adverse events (AEs)."( A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer.
An, H; Chen, D; Dai, C; Fan, X; Guo, Z; Li, J; Li, X; Ma, Y; Mao, C; Qian, F; Wang, D; Xia, S; Ye, F; Yu, W; Yuan, X; Zhang, M; Zhou, Y, 2021)		0.85
"The toxic effects of gefitinib were confirmed by the increased liver index, decreased body weight and survival rate, injured liver function and histopathology followed 16 days of oral administration."( Study on the hepatotoxicity and potential mechanism of gefitinib based on CYP450 in mice and AML12 cells.
Bai, M; Li, C; Li, M; Li, Y; Liu, H; Lu, S; Ma, S; Su, P; Yin, X; Zhang, C, 2023)		1.48
" Treatment with Gefitinib was continued until disease progression, intolerable adverse effects were developed, or consent was withdrawn."( Efficacy and safety of EGFR inhibitor gefitinib in recurrent or metastatic cervical cancer: a preliminary report.
Athiyamaan, MS; Banerjee, S; Jawahar, V; Krishna, A; Lobo, D; Makkapatti, BS; Mukesh, S; Sathya, M; Srinivas, C; Sunny, J, 2023)		1.53

Pharmacokinetics

We studied the combination of bexarotene and gefitinib in the third-line treatment of advanced non-small-cell lung cancer to examine pharmacokinetic interactions and establish the maximum tolerated dose. The potential for drug interactions between gef itinib and cytotoxic agents was evaluated through pharmacokinetics assessments.

ExcerptReferenceRelevance
" Cmax and area under the concentration-time curve (AUC) were dose-proportional from 10 to 100mg."( Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers.
Dane, A; Jones, H; Laight, A; Morris, C; Stafford, L; Swaisland, H; Yates, R, 2001)		0.31
" The elimination half-life suggests that once daily oral administration is appropriate."( Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers.
Dane, A; Jones, H; Laight, A; Morris, C; Stafford, L; Swaisland, H; Yates, R, 2001)		0.31
" In various tumor types, such as head and neck squamous carcinoma and gastric and breast adenocarcinoma, a relationship between EGFR and downstream markers (such as phosphorylated MAPK) has been characterized, further supporting the potential of these molecules for pharmacodynamic studies."( Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.
Albanell, J; Baselga, J; Rojo, F, 2001)		0.31
" We studied the pharmacodynamic effects of ZD1839 on EGFR in the skin, an EGFR-dependent tissue, in cancer patients participating in ZD1839 phase I clinical trials."( Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.
Albanell, J; Averbuch, S; Baselga, J; Feyereislova, A; Gee, J; Herbst, R; LoRusso, P; Mascaro, JM; Nicholson, RI; Rischin, D; Rojo, F; Sauleda, S, 2002)		0.31
" These effects were profound at doses well below the one producing unacceptable toxicity, a finding that strongly supports pharmacodynamic assessments to select optimal doses instead of a maximum-tolerated dose for definitive efficacy and safety trials."( Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.
Albanell, J; Averbuch, S; Baselga, J; Feyereislova, A; Gee, J; Herbst, R; LoRusso, P; Mascaro, JM; Nicholson, RI; Rischin, D; Rojo, F; Sauleda, S, 2002)		0.31
"To establish the safety and tolerability of ZD1839 (Iressa), a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and to explore its pharmacokinetic and pharmacodynamic effects in patients with selected solid tumor types."( Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Albanell, J; Averbuch, SD; Baselga, J; Bjork, T; Calvert, H; Feyereislova, A; Gianni, L; Harris, A; Kaye, SB; Kieback, DG; Ranson, M; Raymond, E; Rischin, D; Rojo, F; Swaisland, H, 2002)		0.31
" Pharmacodynamic changes in skin confirmed inhibition of EGFR signaling, which was predicted from the mode of action of ZD1839."( Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Albanell, J; Averbuch, SD; Baselga, J; Bjork, T; Calvert, H; Feyereislova, A; Gianni, L; Harris, A; Kaye, SB; Kieback, DG; Ranson, M; Raymond, E; Rischin, D; Rojo, F; Swaisland, H, 2002)		0.31
" Mean terminal half-life following multiple dosing was 50."( Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.
Dong, RP; Fukuoka, M; Hirose, M; Kudoh, S; Nakagawa, K; Nakatani, I; Negoro, S; Swaisland, H; Takeda, K; Tamura, T; Yamamoto, N, 2003)		0.53
" The safety profile, pharmacokinetic parameters and antitumor activity observed in our study are comparable to those observed in patients from the USA and Europe."( Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.
Dong, RP; Fukuoka, M; Hirose, M; Kudoh, S; Nakagawa, K; Nakatani, I; Negoro, S; Swaisland, H; Takeda, K; Tamura, T; Yamamoto, N, 2003)		0.53
" The potential for drug interactions between gefitinib and cytotoxic agents was evaluated through pharmacokinetic assessments."( Pharmacokinetic evaluation of gefitinib when administered with chemotherapy.
Hammond, LA, 2003)		0.87
" Specifically, we compare the pharmacokinetic and pharmacodynamic properties of these EGFR inhibitors examined in preclinical and clinical studies."( Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation.
Grandis, JR; Thomas, SM, 2004)		0.32
" Following intravenous dosing (5 mg kg(-1), gefitinib plasma half-life was 3-6h in rats and dogs, although studies using a more sensitive HPLC-MS assay produced longer estimates of half-life (7-14h)."( Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog.
Bardsley, J; Hutchison, M; McKillop, D; Parry, AC; Partridge, EA; Rhead, SA; Swaisland, HC; Woodman, HM, 2004)		0.91
"In this phase II multicenter trial, the primary objective was assessment of the tumor response rate with gefitinib; secondary objectives included analysis of the pharmacodynamic and biologic profiles in healthy and tumor tissue."( Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.
Albanell, J; Baselga, J; Gascón, P; González, S; Guillém, V; Koehler, MT; Lluch, A; Marimón, I; Rojo, F; Ruiz, A; Sauleda, S; Tabernero, JM, 2005)		0.8
" Pharmacokinetic and safety assessments were conducted throughout the trial."( A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers.
Bailey, CJ; Cantarini, MV; Macpherson, MP; Marshall, AL; Robinson, AV, 2005)		0.54
" The presence of tamoxifen did not have a clinically significant effect on the primary variables AUC and Cmax of gefitinib, nor on the secondary variables AUC(0-t), tmax, t1/2, and lambdaz."( A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers.
Bailey, CJ; Cantarini, MV; Macpherson, MP; Marshall, AL; Robinson, AV, 2005)		0.75
" Pharmacokinetic studies were performed during course one (day 1 through 28)."( Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study.
Adamson, PC; Bernstein, ML; Blaney, SM; Croop, JM; Dancey, JE; Daw, NC; Furman, WL; Iacono, LC; Krailo, M; Reaman, GH; Speights, RA; Stewart, CF, 2005)		0.6
" The median apparent clearance and median half-life were 14."( Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study.
Adamson, PC; Bernstein, ML; Blaney, SM; Croop, JM; Dancey, JE; Daw, NC; Furman, WL; Iacono, LC; Krailo, M; Reaman, GH; Speights, RA; Stewart, CF, 2005)		0.6
" Based on these findings, three clinical studies were carried out to investigate pharmacokinetic drug interactions in vivo with gefitinib."( Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Laight, A; Leadbetter, J; McKillop, D; Ranson, M; Smith, RP; Swaisland, HC; Wild, MJ, 2005)		0.81
" Appropriate pharmacokinetic parameters were determined by noncompartmental methods."( Single-dose clinical pharmacokinetic studies of gefitinib.
Duvauchelle, T; Kerr, DJ; Laight, A; Ranson, M; Smith, RP; Swaisland, HC; Wilder-Smith, CH, 2005)		0.58
" Absorption was again moderately slow, with gmean Cmax of 159 ng/mL (range 48."( Single-dose clinical pharmacokinetic studies of gefitinib.
Duvauchelle, T; Kerr, DJ; Laight, A; Ranson, M; Smith, RP; Swaisland, HC; Wilder-Smith, CH, 2005)		0.58
" Gefitinib undergoes rapid plasma clearance and has an extensive volume of distribution, resulting in a pharmacokinetic profile supportive of a once-daily dosage regimen."( Single-dose clinical pharmacokinetic studies of gefitinib.
Duvauchelle, T; Kerr, DJ; Laight, A; Ranson, M; Smith, RP; Swaisland, HC; Wilder-Smith, CH, 2005)		1.49
" In an attempt to explain this variability, three pharmacokinetic studies were carried out in healthy volunteers to investigate the relationship between exposure to gefitinib and cytochrome P450 (CYP) 3A phenotype (study 1), CYP3A5 genotype (study 2) and CYP2D6 genotype (study 3)."( Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
Cantarini, MV; Fuhr, R; Holt, A; Swaisland, HC, 2006)		0.76
" In study 2, 73 healthy volunteers with previously defined single-dose gefitinib pharmacokinetic profiles were genotyped for CYP3A5."( Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
Cantarini, MV; Fuhr, R; Holt, A; Swaisland, HC, 2006)		0.8
" Strategies to lower volume of distribution and shorten half-life through structure and pKa modulation are discussed."( Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
Ballard, P; Bradbury, RH; Harris, CS; Hennequin, LF; Hickinson, M; Kendrew, J; Kettle, JG; Klinowska, T; Ogilvie, DJ; Pearson, SE; Williams, EJ; Wilson, I, 2006)		0.33
" Pharmacokinetic studies were done for calcitriol and gefitinib."( A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors.
Bernardi, RJ; Black, JD; Brattain, MG; Creaven, PJ; Fakih, MG; French, R; Hutson, A; Johnson, CS; Muindi, JR; Schwartz, J; Trump, DL, 2007)		0.8
"To investigate whether differences in plasma pharmacokinetic profiles of gefitinib between healthy subjects having normal (N; t(1/2)>20h) and altered (A; t(1/2)<20h) pharmacokinetic (PK) profiles might be explained by inter-individual variability in gastric emptying and/or precipitation/dissolution of gefitinib in the proximal small intestine."( Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors.
Bergman, E; Cantarini, MV; Dickinson, P; Farmer, MR; Forsell, P; Knutson, L; Lennernäs, H; Persson, EM; Smith, R; Swaisland, H, 2007)		0.89
"Epidermal growth factor receptor (EGFR) inhibitors, such as gefitinib, are examples of targeted anticancer drugs whose drug sensitivity is related to gene mutations that adds a pharmacogenetic (PG) dimension to any pharmacokinetic (PK) and pharmacodynamic (PD) analysis."( Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models.
Gallo, JM; Guo, P; Wang, S; Wang, X; Zhou, Q, 2008)		0.84
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008)		0.35
"The goals of this investigation were to illustrate the use of pharmacokinetic (PK)/pharmacodynamic (PD) modeling strategies in drug development based on a multiple-dose study of gefitinib in a preclinical tumor model."( Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib.
Gallo, JM; Wang, S; Zhou, Q, 2009)		0.76
" Post marketing study commitments have been made upon (accelerated) approval such as additional pharmacokinetic studies in patients with renal- or hepatic impairment, in children, additional interactions studies and studies on the relative or absolute bioavailability."( Clinical pharmacokinetics of tyrosine kinase inhibitors.
Gelderblom, H; Guchelaar, HJ; van Erp, NP, 2009)		0.35
" Four patients with locally advanced esophageal adenocarcinoma were treated with gefitinib (250 mg/day) for 14 days and pharmacokinetic (PK) studies were conducted to monitor plasma drug concentrations."( A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer.
Abdallah, N; Altiok, S; Berman, D; Forastiere, A; Gibson, MK; Jagannath, S; Mezzadra, H; Rudek, MA; Tsottles, N, 2010)		0.8
" In Study 2, the geometric mean gefitinib steady-state AUC during the 24-h dosing interval was slightly, but not significantly, higher in patients with moderate hepatic impairment; there were, however, no significant differences between groups in gefitinib and metabolite pharmacokinetic parameters."( The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib.
Cantarini, M; Carmichael, J; Harris, AL; Holt, A; Horak, J; Macpherson, M; Swaisland, A; Swaisland, H; Twelves, C; Verrill, M; White, J, 2011)		0.88
" Pharmacokinetic data demonstrated no consistent increase in exposure to gefitinib with increasing dose across cohorts."( Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study.
Agus, DB; Gross, ME; Leichman, L; Lowe, ES; Swaisland, A, 2012)		0.88
"Heterogeneity in brain tumors can result in variable drug distribution and possibly drug response; however, there are no readily accessible means to obtain regional pharmacokinetic (PK)/pharmacodynamic (PD) information in preclinical tumor models that typically rely on average drug concentration measurements."( Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model.
Gallo, JM; Lv, H; Sharma, J, 2012)		0.6
" The correlations between these pharmacokinetic variables and the objective responses, including progression-free survival(PFS)and overall survival(OS), were retrospectively analyzed."( The pharmacokinetics and long-term therapeutic effects of gefitinib in patients with lung adenocarcinoma harboring the epidermal growth factor receptor(EGFR)mutation.
Hirano, S; Hojo, M; Iikura, M; Ishii, S; Izumi, S; Kobayashi, N; Kudo, K; Naka, G; Sano, K; Sugiyama, H; Takeda, Y, 2012)		0.62
"The Cmax of gefitinib in patients with a partial response(PR)was significantly lower than that of patients with stable disease(SD)(median Cmax: 278 vs 588 ng/mL, p<0."( The pharmacokinetics and long-term therapeutic effects of gefitinib in patients with lung adenocarcinoma harboring the epidermal growth factor receptor(EGFR)mutation.
Hirano, S; Hojo, M; Iikura, M; Ishii, S; Izumi, S; Kobayashi, N; Kudo, K; Naka, G; Sano, K; Sugiyama, H; Takeda, Y, 2012)		1
" No pharmacokinetic interaction between S-1 and gefitinib was detected."( Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung.
Azuma, K; Daga, H; Hayashi, H; Kiyota, H; Miyazaki, M; Murakami, H; Naito, T; Nakagawa, K; Okada, H; Okamoto, I; Takeda, K; Takeda, M; Tanaka, K; Terashima, M; Yamamoto, N, 2013)		0.92
" We studied the combination of bexarotene and gefitinib in the third-line treatment of advanced non-small-cell lung cancer to examine pharmacokinetic interactions and establish the maximum tolerated dose."( Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report.
Chhatwani, L; Jacobs, CD; Lopez-Anaya, A; Padda, SK; Wakelee, HA; Zhou, L, 2013)		0.88
"Like many solid tumors, glioblastomas are characterized by intratumoral biologic heterogeneity that may contribute to a variable distribution of drugs and their associated pharmacodynamic responses, such that the standard pharmacokinetic approaches based on analysis of whole-tumor homogenates may be inaccurate."( Intratumoral modeling of gefitinib pharmacokinetics and pharmacodynamics in an orthotopic mouse model of glioblastoma.
Gallo, JM; Lv, H; Sharma, J, 2013)		0.69
" In vivo pharmacokinetic and pharmacodynamic evaluation was performed in both normal nude mice and a BM model established by intra-carotid artery (ICA) injection of PC-9 cells."( Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis.
Chen, Y; Wang, M; Zhao, J; Zhong, W, 2013)		0.65
"Structural optimization of a series of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl compounds, potential new irreversible EGFR inhibitors, was performed to improve pharmacokinetic properties of the compounds."( Design, synthesis, and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties.
Ding, K; Liu, Y; Lu, X; Luo, J; Ren, X; Tu, Z; Xu, S; Xu, T; Zhang, L; Zhang, Z, 2013)		0.39
" In this paper, the pharmacokinetic characteristics (absorption, distribution, metabolism and excretion) and drug-drug interactions of the approved TKIs are reviewed."( [Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Ding, JF; Zhong, DF, 2013)		0.39
" This Perspective discusses the use of (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET) for pharmacodynamic evaluation in a very early phase of treatment to predict clinical outcomes in patients with advanced non-small-cell lung cancer."( Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction.
Ando, M; Asami, K; Atagi, S; Ishii, M; Kanazu, M; Kawaguchi, T; Kubo, A; Kusunoki, Y; Maruyama, K; Matsuda, Y; Minomo, S; Ogawa, Y; Takada, M; Uehira, K, 2014)		0.4
"Sixteen of 19 patients were evaluable, with serial pharmacokinetic studies in ten patients."( Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.
Brennan, RC; Furman, W; Mao, S; McGregor, LM; Santana, V; Stewart, CF; Turner, DC; Wu, J, 2014)		0.65
" Pharmacokinetic analysis confirms that co-administration of gefitinib increases irinotecan bioavailability leading to an increased SN-38 lactone systemic exposure."( Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.
Brennan, RC; Furman, W; Mao, S; McGregor, LM; Santana, V; Stewart, CF; Turner, DC; Wu, J, 2014)		0.89
" Incorporation of these olefins into the quinazoline templates produced potent EGFR inhibitors with improved safety and pharmacokinetic properties."( A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.
Chen, W; Deng, H; Han, J; Huang, W; Li, B; Li, P; Li, Y; Liu, Y; Ma, C; Miao, H; Qi, W; Shao, J; Shen, J; Sun, X; Xia, G; Xiang, Z; Xu, J; Yu, Y; Zhang, J; Zhang, L; Zhang, Y, 2014)		0.4
" This phase I dose-finding study was designed to assess the tolerability and drug-drug interactions in this combination using full pharmacokinetic (PK) samplings."( Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
Ando-Makihara, R; Hayashi, Y; Makino, Y; Motonaga, M; Ohe, Y; Takano, M; Yamamoto, N, 2015)		0.66
" A comprehensive whole-body physiologically based pharmacokinetic (PBPK) model of gefitinib in mice was developed, which adequately captured gefitinib concentration-time profiles in plasma and various tissues."( A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans.
An, G; Bi, Y; Deng, J; Murry, DJ, 2016)		0.9
" This simple and reproducible high-throughput method was successfully applied to the pharmacokinetic study of gefitinib and its major metabolites in mouse."( Simultaneous determination of gefitinib and its major metabolites in mouse plasma by HPLC-MS/MS and its application to a pharmacokinetics study.
Han, SY; He, XR; Jiang, ST; Li, PP; Xu, GB; Zhao, C; Zheng, N, 2016)		0.93
" However, the AUC and Cmax were highest and the trough value on day 8 was the second highest in one patient who died of drug-induced ILD."( Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.
Fujita, K; Hirose, T; Ishida, H; Kusumoto, S; Murata, Y; Nakashima, M; Ohmori, T; Oki, Y; Okuda, K; Sasaki, Y; Shirai, T; Sugiyama, T; Yamaoka, T, 2016)		0.66
" Plasma concentrations of gefitinib were also measured 10 h after the first administration in 21 of these patients to calculate the elimination half-life of gefitinib."( Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
Fukuda, M; Ikeda, T; Ikegami, Y; Izumikawa, K; Mizoguchi, K; Motoshima, K; Mukae, H; Nakamura, Y; Nakatomi, K; Ogawara, D; Sano, K; Sato, S; Senju, H; Sugasaki, N; Takemoto, S; Yamaguchi, H, 2016)		1.02
"709, and the median elimination half-life was 15."( Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
Fukuda, M; Ikeda, T; Ikegami, Y; Izumikawa, K; Mizoguchi, K; Motoshima, K; Mukae, H; Nakamura, Y; Nakatomi, K; Ogawara, D; Sano, K; Sato, S; Senju, H; Sugasaki, N; Takemoto, S; Yamaguchi, H, 2016)		0.72
" On the other hand, long elimination half-life was related to high-grade adverse events in these patients."( Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
Fukuda, M; Ikeda, T; Ikegami, Y; Izumikawa, K; Mizoguchi, K; Motoshima, K; Mukae, H; Nakamura, Y; Nakatomi, K; Ogawara, D; Sano, K; Sato, S; Senju, H; Sugasaki, N; Takemoto, S; Yamaguchi, H, 2016)		0.72
" In this review, we have comprehensively summarized the pharmacokinetic characteristics of gefitinib: absorption, distribution, metabolism and excretion (ADME)."( Pharmacokinetics of Gefitinib: Roles of Drug Metabolizing Enzymes and Transporters.
Han, SY; Li, PP; Zhao, C, 2017)		1
" Our objective was to simulate DDIs between the antineoplastics erlotinib and gefitinib with key antiretroviral drugs and to predict dose adjustments using a physiologically based pharmacokinetic (PBPK) model."( Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.
Back, D; Clotet, B; Miranda, C; Moltó, J; Owen, A; Rajoli, R; Siccardi, M; Valle, M, 2017)		0.68
"In vitro data describing chemical properties and pharmacokinetic processes of each drug and their effect on cytochrome P450 isoforms were obtained from the literature."( Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.
Back, D; Clotet, B; Miranda, C; Moltó, J; Owen, A; Rajoli, R; Siccardi, M; Valle, M, 2017)		0.46
" This method was successfully applied to a pharmacokinetic study of volitinib and gefitinib after the administration of an intravenous or oral dose, indicating that the developed assay can be used to simultaneously determine the concentrations of volitinib and gefitinib in rat plasma."( Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC-MS/MS for application to a pharmacokinetic study in rats.
Chung, SJ; Kim, MS; Lee, JH; Maeng, HJ; Noh, CK, 2017)		0.94
" Physiologically based pharmacokinetic (PBPK) modeling was conducted using a population-based simulator."( Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers.
Al-Huniti, N; Chen, Y; Masson, E; Tang, W; Zhou, D; Zhou, W, 2018)		0.71
"To evaluate the potential pharmacokinetic interactions of the anticancer agent gefitinib (Iressa®) and the oriental medications Guipi Decoction (, GPD, Guibi-tang in Korean) and Bawu Decoction (, BWD, Palmul-tang in Korean)."( Alterations of Gefitinib Pharmacokinetics by Co-administration of Herbal Medications in Rats.
Jeong, SW; Joo, SH; Kim, MG; Kim, TH; Ma, E; Shin, BS; Shin, S; Weon, KY; Yoo, SD; Youn, YS, 2018)		1.06
" In this approach, we further carried out systematic pharmacokinetic and pharmacodynamic study of MBRI-001 in vitro and in vivo."( In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.
Cheng, H; Deng, M; Ding, Z; Dou, G; Hou, Y; Li, F; Li, W; Ma, M; Zhao, J, 2018)		0.48
" Such changes in Ctrough,ss warrant further investigation and highlight the ability of pharmacokinetic modelling to investigate populations that may be difficult to recruit for traditional clinical studies."( The Pharmacokinetics of Gefitinib in a Chinese Cancer Population Group: A Virtual Clinical Trials Population Study.
Singh Badhan, RK; Yu, H, 2021)		0.93

Compound-Compound Interactions

Osimertinib, rather than gefitinib combined with anti-PD-L1 treatment could lead to lung injury in an EGFR mutated tumor-bearing mouse model.

ExcerptReferenceRelevance
" Preclinical studies have shown additive to synergistic effects when ZD1839 is combined with radiation or chemotherapy in colon, head and neck, and non-small cell lung cancers."( ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.
Bunn, PA; Chan, D; Helfrich, BA; Johnson, G; Raben, D, 2002)		0.31
" In this study, we evaluated the ability of CU201 to produce additive or synergistic growth inhibition in combination with various antitumor agents used in lung cancer therapy."( Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
Bunn, PA; Chan, DC; Chan, KK; Covey, JM; Feng, WY; Gera, L; Helfrich, B; Stewart, JM; Zhao, TL, 2002)		0.31
"Clinical trials of gefitinib (Iressa, ZD1839) in combination with cytotoxic agents have been carried out or are ongoing in several varieties of tumor."( The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines.
Azzariti, A; Colucci, G; Paradiso, A; Xu, JM, 2003)		1.01
" Based on the expectation that this drug combined with immunotherapy would be highly effective, we recently conducted an experiment in tumor-bearing mice."( [Significance of gefitinib combined with immunotherapy in tumor-bearing mice].
Maruyama, S; Sukegawa, Y; Yagita, A, 2003)		0.66
" In preclinical studies, gefitinib has shown additive and even supra-additive antitumor effects when combined with different cytotoxic agents."( Pharmacokinetic evaluation of gefitinib when administered with chemotherapy.
Hammond, LA, 2003)		0.91
" Gefitinib has demonstrated encouraging efficacy in advanced NSCLC in phase II trials in pretreated patients, and a phase I trial of gefitinib in combination with gemcitabine and cisplatin showed favorable tolerability."( Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Averbuch, SD; Fandi, A; Gatzemeier, U; Giaccone, G; Grous, J; Herbst, RS; Johnson, DH; Manegold, C; Miller, V; Natale, RB; Ochs, JS; Pluzanska, A; Rennie, P; Rosell, R; Scagliotti, G; Schiller, JH; Von Pawel, J; Wolf, MK, 2004)		2.68
"Gefitinib in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced NSCLC did not have improved efficacy over gemcitabine and cisplatin alone."( Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Averbuch, SD; Fandi, A; Gatzemeier, U; Giaccone, G; Grous, J; Herbst, RS; Johnson, DH; Manegold, C; Miller, V; Natale, RB; Ochs, JS; Pluzanska, A; Rennie, P; Rosell, R; Scagliotti, G; Schiller, JH; Von Pawel, J; Wolf, MK, 2004)		3.21
"Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, may enhance antitumor efficacy of cytotoxics, and combination with paclitaxel and carboplatin had acceptable tolerability in a phase I trial."( Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Averbuch, SD; Fandi, A; Giaccone, G; Grous, J; Herbst, RS; Johnson, DH; Krebs, AD; Manegold, C; Miller, V; Natale, RB; Ochs, JS; Oliff, I; Reeves, JA; Rosell, R; Scagliotti, G; Schiller, JH; Wolf, MK, 2004)		2.05
" Expected dose-related diarrhea and skin toxicity were observed in gefitinib-treated patients, with no new significant/unexpected safety findings from combination with chemotherapy."( Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Averbuch, SD; Fandi, A; Giaccone, G; Grous, J; Herbst, RS; Johnson, DH; Krebs, AD; Manegold, C; Miller, V; Natale, RB; Ochs, JS; Oliff, I; Reeves, JA; Rosell, R; Scagliotti, G; Schiller, JH; Wolf, MK, 2004)		2
"Although in vivo efficacy studies in two HER-2/neu overexpressing breast xenograft models showed that the combination of trastuzumab and gefitinib was effective, analyses of various cellular parameters failed to reveal beneficial effects and argue that this drug combination may not be favorable."( Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction
Bally, MB; Chia, S; Denyssevych, T; Dragowska, WH; Gelmon, K; Masin, D; Wallis, AE; Warburton, C; Yan, H, 2004)		0.74
" The different drug combination schedules were tested in various concentrations by using equiactive concentrations of the two drugs."( The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
Azzariti, A; Paradiso, A; Porcelli, L; Xu, JM, 2004)		0.53
" ZD6126 caused marked vessel destruction through loss of endothelial cells and thrombosis, substantially increasing the level of necrosis seen when combined with radiation therapy."( Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft
Bianco, AR; Bianco, C; Bianco, R; Bunn, P; Ciardiello, F; Cionini, L; D'Armiento, FP; Damiano, V; Melisi, D; Mignogna, C; Raben, D; Tortora, G, 2004)		0.32
"In this study we have used a standardised ATP-based tumour chemosensitivity assay (ATP-TCA) to measure the activity of gefitinib alone or in combination with different cytotoxic drugs (cisplatin, gemcitabine, oxaliplatin and treosulfan) against a variety of solid tumours (n = 86), including breast, colorectal, oesophageal and ovarian cancer, carcinoma of unknown primary site, cutaneous and uveal melanoma, non-small cell lung cancer (NSCLC) and sarcoma."( The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P, 2004)		0.84
" Interestingly, gefitinib had both positive and negative effects when used in combination with different cytotoxics."( The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P, 2004)		0.98
"To investigate the inhibitory effect of gefitinib combined with cytotoxic agent cisplatin (CDDP) on hepatocellular carcinoma (HCC)."( Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma.
Li, X; Li, Y; Lu, QY; Yuan, SJ; Zhao, QC; Zhu, BD, 2005)		0.92
"2 mg/kg BW; d1-5, or d6-10), Gefitinib (d1-5, or d6-10, or d1-10), and Gefitinib combined with CDDP groups."( Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma.
Li, X; Li, Y; Lu, QY; Yuan, SJ; Zhao, QC; Zhu, BD, 2005)		0.94
" The highest inhibitory effect (IR: 56%) on HCC growth was observed in Gefitinib (d1-10) combined with CDDP (d1-5) group."( Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma.
Li, X; Li, Y; Lu, QY; Yuan, SJ; Zhao, QC; Zhu, BD, 2005)		0.89
"The aim of this study was to determine the effect of ZD1839 on growth and apoptosis in SCC-15 (a human head and neck cancer cell line) lone, or in combination with cisplatin."( The effect of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC-15 cells.
Al-Hazzaa, A; Birchall, MA; Bowen, ID; Randerson, P, 2005)		0.33
" This open-label pilot trial investigated the safety, pharmacokinetics, and efficacy of 2 doses of gefitinib (250 and 500 mg per day) combined with docetaxel (75 mg/m2) in patients with locally advanced or metastatic NSCLC as first- and second-line chemotherapy."( A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.
Buchholz, E; Fandi, A; Gatzemeier, U; Manegold, C; Smith, RP, 2005)		0.88
"The recommended dose of epirubicin for phase II studies is 30 mg/m2 in combination with gefitinib at the daily dose of 250 mg."( Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate.
Amici, S; Gasparini, G; Gattuso, D; Gion, M; Longo, R; Sarmiento, R; Zancan, M, 2005)		1.99
"Preclinical studies have suggested antitumor activity of an epidermal growth factor (EGF)-receptor targeted therapy with selective tyrosine kinase inhibitors alone or in combination with conventional cytostatic drugs."( Preclinical evaluation of ZD1839 alone or in combination with oxaliplatin in a panel of human tumor cell lines -- implications for clinical use.
Arnold, D; Mueller, T; Pfeiffer, C; Pickan, V; Simon, H; Voigt, W, 2005)		0.33
"In the present study, the activity of ZD1839 alone or in combination with oxaliplatin (Eloxatin) was evaluated in 12 human cancer cell lines including colon, testicular, anaplastic thyroid and epidermoid carcinoma cells."( Preclinical evaluation of ZD1839 alone or in combination with oxaliplatin in a panel of human tumor cell lines -- implications for clinical use.
Arnold, D; Mueller, T; Pfeiffer, C; Pickan, V; Simon, H; Voigt, W, 2005)		0.33
"Up to now, there have been no established predictive markers for response to epidermal growth factor receptor (EGFR/HER1/erbB1) inhibitors alone and in combination with chemotherapy in colorectal cancer."( Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
Galligan, L; Johnston, P; Karaiskou-McCaul, A; Kelly, D; Longley, D; Van Cutsem, E; Van Schaeybroeck, S, 2005)		0.55
" In contrast to oxaliplatin, 5-FU treatment increased EGFR phosphorylation in all cell lines and this correlated with synergistic decreases in cell viability when 5-FU was combined with gefitinib."( Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
Galligan, L; Johnston, P; Karaiskou-McCaul, A; Kelly, D; Longley, D; Van Cutsem, E; Van Schaeybroeck, S, 2005)		0.74
" We evaluated the antitumor activity of ZD1839 in combination with HSP90 antagonist, 17-AAG in malignant human glioma cell lines."( Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth.
Arnold, B; Pollack, IF; Premkumar, DR, 2006)		0.33
" In this pilot Phase I trial, the authors evaluated the tolerability, efficacy, and pharmacokinetics of gefitinib combined with estramustine and docetaxel in patients with HRPC."( Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
Das-Gupta, A; Small, E; Soulie, P; Trump, D; Wilding, G, 2006)		0.82
"The results of the current study demonstrated that gefitinib combined with estramustine and docetaxel had acceptable and predictable tolerability."( Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
Das-Gupta, A; Small, E; Soulie, P; Trump, D; Wilding, G, 2006)		0.86
"We have evaluated the activity and safety of gefitinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in combination with docetaxel as first-line treatment of women with metastatic breast cancer (MBC)."( Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.
Bianco, AR; Caputo, F; Catalano, G; Ciardiello, F; Colantuoni, G; De Laurentiis, M; De Placido, S; De Vita, F; Diadema, MR; Gridelli, C; Orditura, M; Palmieri, G; Tortora, G; Troiani, T, 2006)		0.93
"Intravenous (iv) vinorelbine and interperitoneal (ip) cisplatin were administered intermittently (q4d x 3) in combination with sorafenib administered orally (po) once daily for 9 days starting on the same day as the standard agent."( Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
Brink, C; Carter, CA; Chen, C; Gilbert, KS; Maxuitenko, YY; Vincent, P; Waud, WR; Zhang, X, 2007)		0.34
" This phase I/II dose-finding study evaluated gefitinib in combination with a 5-fluorouracil (5-FU)/folinic acid (FA)/irinotecan (FOLFIRI-AIO) regimen in patients with metastatic colorectal cancer."( Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J, 2006)		2.03
"To assess the optimal regimen and its mechanism of ZD1839 in combination with SN38, the active metabolite of irinotecan (CPT-11), in the colon cancer cell lines HT-29 and LoVo."( [Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].
Azzariti, A; Han, Y; Li, YM; Li, ZQ; Paradiso, A; Wang, Y; Xu, JM; Yang, WW; Yuan, SJ; Zhao, CH, 2006)		0.33
" calcitriol can be administered safely in combination with gefitinib."( A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors.
Bernardi, RJ; Black, JD; Brattain, MG; Creaven, PJ; Fakih, MG; French, R; Hutson, A; Johnson, CS; Muindi, JR; Schwartz, J; Trump, DL, 2007)		0.8
" Vandetanib has demonstrated enhanced efficacy in combination with radiation therapy (RT) in human tumor models."( Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
Frederick, B; Gustafson, DL; Merz, AL; Raben, D, 2008)		0.35
" Potential drug-drug interactions and the relationship between pharmacokinetics and toxicity were also assessed."( Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
Adjei, AA; Croghan, G; Hanson, LJ; Jett, JR; Lathia, C; Mandrekar, SJ; Marks, R; Molina, JR; Reid, JR; Simantov, R; Xia, C, 2007)		0.6
"Sorafenib combined with gefitinib is well tolerated, with promising efficacy in patients with advanced non-small cell lung cancer."( Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
Adjei, AA; Croghan, G; Hanson, LJ; Jett, JR; Lathia, C; Mandrekar, SJ; Marks, R; Molina, JR; Reid, JR; Simantov, R; Xia, C, 2007)		0.9
"Gefitinib, an orally active inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, combined with chemotherapy, has shown efficacy as second-line treatment for advanced colorectal cancer (CRC)."( First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer.
Boselli, S; de Braud, F; Lorizzo, K; Magni, E; Martignetti, A; Massacesi, C; Santoro, L; Zampino, MG; Zaniboni, A; Zorzino, L, 2007)		1.78
"Patients with metastatic EGFR-positive CRC received gefitinib at a dose of 250 mg/day combined with simplified FOLFOX6."( First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer.
Boselli, S; de Braud, F; Lorizzo, K; Magni, E; Martignetti, A; Massacesi, C; Santoro, L; Zampino, MG; Zaniboni, A; Zorzino, L, 2007)		0.59
" In vitro, gefitinib, an orally administered tyrosine kinase inhibitor, has shown a significant increase in antitumor activity when combined with chemotherapy."( An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer.
Borner, M; Knuth, A; Morant, R; Pedrazzini, A; Rochlitz, C; Roggero, E; Salzberg, M; Schönenberger, A; Thalmann, G, 2007)		0.94
"In this phase II study, the safety and efficacy of gefitinib in combination with docetaxel, a chemotherapeutic agent commonly used for prostate cancer, was investigated in patients with hormone-refractory prostate cancer (HRPC)."( An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer.
Borner, M; Knuth, A; Morant, R; Pedrazzini, A; Rochlitz, C; Roggero, E; Salzberg, M; Schönenberger, A; Thalmann, G, 2007)		0.8
" Our results do not support the efficacy of gefitinib in combination with endocrine treatment for hormone-refractory prostate cancer."( Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity.
Curigliano, G; De Braud, F; De Cobelli, O; De Pas, T; Matei, V; Noberasco, C; Nolè, F; Renne, G; Rocco, B; Scardino, E; Spitaleri, G; Teresa Sandri, M; Verweij, F; Zorzino, L, 2007)		2.04
" This study also demonstrates the importance of timing of gefitinib administration when this agent is combined with irradiation."( Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro.
Andersson, U; Behnam-Motlagh, P; Johansson, D; Johansson, M; Malmer, B, 2007)		0.85
" This study was to assess the effects of ZD1839 in combination with oxaliplatin on lung adenocarcinoma cell line A549, and to provide pre-clinical evidence for optimizing the schedule of oxaliplatin combined with ZD1839."( [Cytotoxic effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with oxaliplatin on lung cancer cell line A549].
Ge, FJ; Luo, WD; Wang, Y; Xu, JM; Yuan, SJ; Zhao, CH, 2007)		0.34
" The effects of oxaliplatin combined with ZD1839 on the proliferation of A549 cells in nude mice were also evaluated."( [Cytotoxic effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with oxaliplatin on lung cancer cell line A549].
Ge, FJ; Luo, WD; Wang, Y; Xu, JM; Yuan, SJ; Zhao, CH, 2007)		0.34
" We carried out the in vitro study using selective COX-2 inhibitor celecoxib combined with EGFR-tyrosine kinase inhibitor (EGFR-TKI) ZD1839 on NSCLC cell lines to investigate the anti proliferation effect and the cell molecular mechanism."( Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.
Chen, L; He, Y; Huang, H; Liao, H; Wei, W, 2008)		0.35
"EGFR blockade combined with conventional chemotherapy results in anti-human STS activity in vitro and in vivo, suggesting the possibility that combining these synergistic treatments will improve anti-STS therapy."( Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo.
Dicker, A; Heymach, J; Korchin, B; Lazar, A; Lev, D; Pollock, RE; Ren, W; Wei, C; Zhu, QS, 2008)		0.35
"Gefitinib at a dose of 250 mg daily in combination with weekly 5-fluorouracil at 2,000 mg/m(2) or gefitinib at a dose of 500 mg daily with 5-fluorouracil at 1,600 mg/m(2) plus oxaliplatin has an acceptable safety profile."( Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).
Bokemeyer, C; Hartmann, JT; Höhler, T; Holtmann, M; Kröning, H; Pintoffl, JP, 2008)		3.23
"Two large, randomized, placebo-controlled trials (IRESSA NSCLC Trial Assessing Combination Therapy; INTACT 1 and 2) in non-small-cell lung cancer (NSCLC) failed to show survival benefit for gefitinib (IRESSA) in combination with first-line platinum-based chemotherapy."( Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy.
Fandi, A; Giaccone, G; Herbst, RS; Iacona, RB; Janas, M; Johnson, DH; Ochs, JS, 2009)		0.75
"Women with measurable MBC pretreated with anthracycline- and taxane-based chemotherapy received oral gefitinib (250 mg/day) continuously combined with intravenous gemcitabine 1000 mg/m2 and vinorelbine 25 mg/m2 on day 1, every 2 weeks."( Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial.
Amarantidis, K; Georgoulias, V; Gioulbasanis, I; Ignatiadis, M; Kakolyris, S; Kalbakis, K; Kalykaki, A; Mavroudis, D; Saridaki, Z; Vamvakas, L, )		1.79
") calcitriol administered in combination with a fixed oral dose of dexamethasone and gefitinib in patients with refractory solid tumors."( A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors.
Christy, R; Engler, KL; Fakih, MG; Johnson, CS; Muindi, JR; Trump, DL, 2009)		0.79
" Lung cancer combined with pregnancy is a very rare situation, so we report this case with some references."( [A case of lung cancer combined with pregnancy; dramatically deteriorating condition after caesarian section].
Fujita, S; Harada, Y; Hata, A; Imai, Y; Ishihara, K; Katakami, N; Nishimura, T; Seo, R; Takeshim, Y; Tomii, K, 2009)		0.35
"Activity and toxiciy of gefitinib in combination with topotecan and cyclophosphamide (CPA) were evaluated in a case-series of relapsed neuroblastoma (NB) patients."( Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.
Castellano, A; Cialfi, S; De Ioris, MA; De Laurentis, C; De Pasquale, MD; Dominici, C; Donfrancesco, A; Ilari, I; Jenkner, A; McDowell, HP, 2010)		2.11
" Antitumor activity of gefitinib as single agent and in combination with either topotecan or CPA was assessed in a panel of NB cell lines."( Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.
Castellano, A; Cialfi, S; De Ioris, MA; De Laurentis, C; De Pasquale, MD; Dominici, C; Donfrancesco, A; Ilari, I; Jenkner, A; McDowell, HP, 2010)		2.11
"We aimed to investigate and compare the effects of erlotinib and gefitinib on UDP-glucuronosyltransferase (UGT) activities and to quantitatively evaluate their drug-drug interaction (DDI) potential due to UGT inhibition."( Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.
House, L; Liu, Y; Ramírez, J; Ratain, MJ, 2010)		0.83
" Cediranib pharmacokinetic parameters were not substantially different when given alone or in combination with gefitinib."( Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
Giaccone, G; Hoekman, K; Jürgensmeier, JM; Meijerink, MR; Puchalski, TA; Punt, CJ; Robertson, J; Saunders, O; van Cruijsen, H; van Herpen, CM; Voest, EE; Witteveen, PO, 2010)		0.79
"This phase II investigated efficacy and tolerability of gefitinib in combination with paclitaxel (P) and carboplatin (C) for second-line treatment of patients (pts) with ovarian, tubal or peritoneal adenocarcinoma."( Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
Bougnoux, P; Carrasco, AT; Fumoleau, P; Joly, F; Kerbrat, P; Lhommé, C; Pautier, P; Petit, T; Ringeisen, F; Rixe, O, 2010)		0.94
"Gefitinib, administered in combination with paclitaxel and carboplatin, provides a good clinical response but associated with an increased risk of hematologic disorders."( Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
Bougnoux, P; Carrasco, AT; Fumoleau, P; Joly, F; Kerbrat, P; Lhommé, C; Pautier, P; Petit, T; Ringeisen, F; Rixe, O, 2010)		2.14
"This phase II randomized trial evaluated the efficacy and tolerability of anastrozole combined with gefitinib or anastrozole with placebo in women with hormone receptor-positive metastatic breast cancer (MBC)."( Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Anderson, E; Arena, FP; Bacus, S; Cora, EM; Cristofanilli, M; Curcio, E; Kroener, JF; Magill, PJ; Mangalik, A; Rabinowitz, I; Royce, M; Valero, V; Watkins, C, 2010)		0.82
"This small randomized study showed that anastrozole in combination with gefitinib is associated with a marked advantage in PFS compared with anastrozole plus placebo, and that the combination was tolerated in postmenopausal women with hormone receptor-positive MBC."( Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Anderson, E; Arena, FP; Bacus, S; Cora, EM; Cristofanilli, M; Curcio, E; Kroener, JF; Magill, PJ; Mangalik, A; Rabinowitz, I; Royce, M; Valero, V; Watkins, C, 2010)		0.83
"This phase I/II study was conducted to assess the maximal tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of gefitinib in combination with capecitabine in patients with advanced colorectal cancer (aCRC)."( Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Frieling, T; Graeven, U; Hegewisch-Becker, S; Lehnert, L; Reinacher-Schick, A; Schmiegel, W; Trarbach, T; Vanhoefer, U, 2010)		2.01
"After failure of a 1st-line therapy, patients with aCRC received escalating doses of gefitinib once daily in combination with capecitabine twice daily: dose level (DL) 1: gefitinib 250 mg and capecitabine 1,000 mg/m(2), DL 2: gefitinib 250 mg and capecitabine 1,250 mg/m(2), DL 3: gefitinib 500 mg and capecitabine 850 mg/m(2)."( Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Frieling, T; Graeven, U; Hegewisch-Becker, S; Lehnert, L; Reinacher-Schick, A; Schmiegel, W; Trarbach, T; Vanhoefer, U, 2010)		2.03
"Gefitinib (250 mg daily) in combination with RT and CDDP in patients with Stage III NSCLC is feasible, but CDDP likely enhances toxicity."( Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial.
Aebersold, DM; Bernier, J; Bucher, SE; Ciernik, IF; Glanzmann, C; Lippuner, T; Lombrieser, N; Lütolf, UM; Ries, G; Rothschild, S; Zouhair, A, 2011)		3.25
"Thus, we showed that L858R receptor mutation in combination with expression of its negative regulator, Mig6, alters signaling outcomes and results in variable drug sensitivity."( Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity.
Nagashima, T; Naka, T; Nakakuki, T; Naruo, Y; Okada-Hatakeyama, M; Saeki, Y; Tanaka, H; Tsai, SF; Ushikoshi-Nakayama, R, 2011)		0.59
"We have investigated in vitro effects of anticancer therapy with the histone deacetylase inhibitor (HDACi) 4-phenylbutyrate (4-PB) combined with receptor tyrosine kinase inhibitors (RTKi) gefitinib or vandetanib on the survival of glioblastoma (U343MGa) and medulloblastoma (D324Med) cells."( Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models.
Baryawno, N; Ekström, TJ; Johnsen, JI; Larsson, C; Marino, AM; Sofiadis, A; Vukojević, V, 2011)		0.56
"This study investigated the curative effect of cryoablation combined with molecular target therapy for advanced non-small cell lung cancer (NSCLC)."( Cryoablation combined with molecular target therapy improves the curative effect in patients with advanced non-small cell lung cancer.
Fang, W; Gu, XY; Jiang, Z, 2011)		0.37
"From September 2008 to October 2011, a total of 31 patients of NSCLC with multiple brain metastases (≥3) received selected incranial, bronchial and corresponding target arterial infusion chemotherapy combined with EGFR-TKIs."( [Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase].
Guo, Z; Li, J, 2012)		0.38
" The current study evaluated the tolerability and efficacy of stereotactic body radiation therapy (SBRT) in combined with gefitinib as a second-line or third-line treatment in patients with advanced NSCLC."( Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer.
Hou, B; Jiang, WR; Kong, QT; Li, B; Li, J; Liu, ZB; Shen, TZ; Wang, Y; Wang, Z; Wu, XH; Zhu, XX, 2014)		2.05
"The SBRT combined with gefitinib is a promising treatment strategy for advanced (stage IIIb or IV) NSCLC after the failure of previously chemotherapy."( Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer.
Hou, B; Jiang, WR; Kong, QT; Li, B; Li, J; Liu, ZB; Shen, TZ; Wang, Y; Wang, Z; Wu, XH; Zhu, XX, 2014)		2.16
" In xenograft models, while gefitinib induced marked regression via apoptosis of tumors without the BIM polymorphism, its combination with vorinostat was needed to induce marked regression of tumors with the BIM polymorphism in the same manner."( EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
Ebi, H; Hasegawa, Y; Ishikawa, D; Nakagawa, T; Nanjo, S; Sano, T; Sato, M; Sekido, Y; Takeuchi, S; Yamada, T; Yano, S, 2013)		0.68
" Metformin is a widely used antidiabetic drug and also displays significant growth-inhibitory and proapoptotic effects in several cancer models, alone or in combination with chemotherapeutic drugs."( Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Ciardiello, F; D'Aiuto, E; De Palma, R; De Vita, F; Della Corte, CM; Martinelli, E; Morgillo, F; Orditura, M; Sasso, FC; Troiani, T; Vitagliano, D, 2013)		0.63
" However, further studies are required to investigate better the effect of metformin action on the RAS/RAF/MAPK pathway and the best context in which to use metformin in combination with molecular targeted agents."( Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Ciardiello, F; D'Aiuto, E; De Palma, R; De Vita, F; Della Corte, CM; Martinelli, E; Morgillo, F; Orditura, M; Sasso, FC; Troiani, T; Vitagliano, D, 2013)		0.63
" In addition, we aimed to explore differences in drug-drug interactions across multiple GBM-derived cell cultures and predict such differences by use of transcriptional biomarkers."( Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions.
Baskaran, S; Forsberg Nilsson, K; Gerlee, P; Häggblad, M; Hansson, C; Karlsson-Lindahl, L; Kling, T; Lundgren, B; Martens, U; Monsefi, N; Nelander, S; Olsson, M; Schmidt, L; Uhrbom, L; Westermark, B, 2013)		0.39
"We performed a screen in which we quantified drug-drug interactions for 465 drug pairs in each of the 5 GBM cell lines U87MG, U343MG, U373MG, A172, and T98G."( Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions.
Baskaran, S; Forsberg Nilsson, K; Gerlee, P; Häggblad, M; Hansson, C; Karlsson-Lindahl, L; Kling, T; Lundgren, B; Martens, U; Monsefi, N; Nelander, S; Olsson, M; Schmidt, L; Uhrbom, L; Westermark, B, 2013)		0.39
"Clinical data of 45 patients with advanced NSCLC who received local radiotherapy combined with EGFR-TKI after solitary progression were reviewed and analyzed."( [Local treatment combined with EGFR-TKIs for advanced non-small cell lung cancer with solitary progression during EGFR-TKI treatment].
Chen, S; Hao, X; Li, J; Lin, L; Shi, Y; Wang, B; Zhang, X, 2013)		0.39
"Local therapies combined with EGFR-TKIs can prolong the PFS of patients with NSCLC who exhibited solitary progression during EGFR-TKI treatment."( [Local treatment combined with EGFR-TKIs for advanced non-small cell lung cancer with solitary progression during EGFR-TKI treatment].
Chen, S; Hao, X; Li, J; Lin, L; Shi, Y; Wang, B; Zhang, X, 2013)		0.39
" This combination was highly active with a treatment response lasting for 9 months supporting the hypothesis that EGFR monoclonal antibodies in combination with chemotherapy may play a role in reversing EGFR-TKI resistance in EGFR mutation-positive NSCLC."( Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.
Fiegl, M; Hilbe, W; Manzl, C; Pircher, A; Pirker, R; Popper, H, 2014)		0.4
" A stronger inhibitory effect was observed when CUS was combined with gefitinib."( PANC-1 pancreatic cancer cell growth inhibited by cucurmosin alone and in combination with an epidermal growth factor receptor-targeted drug.
Chen, M; Huang, H; Wang, C; Xie, J; Yang, A; Yin, Q; Zhang, B, 2014)		0.64
" Erlotinib combined with pemetrexed/cisplatin may be effective in the treatment of LM in EGFR mutation patients after gefitinib failure."( Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure.
Deng, Q; He, J; Liu, X; Xu, X; Yang, H; Yang, X; Zhang, Y; Zhao, M, 2015)		0.82
"The purpose of this study is to compare the efficacy and safety of Gefitinib versus VMP in combination with three-dimensional conformal radiotherapy (3D-CRT) for multiple brain metastases from non-small cell lung cancer (NSCLC)."( Comparison of Gefitinib versus VMP in the combination with radiotherapy for multiple brain metastases from non-small cell lung cancer.
Chen, S; Hao, Y; Li, B; Li, L; Liu, C; Ning, F; Wang, F; Yu, Z, 2015)		1.01
"To analyze the efficacy and survival associated factors of gefitinib combined with cisplatin and gemcitabine for advanced non-small cell lung cancer."( Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
Fang, H; Lin, RY; Sun, MX; Tian, Y; Wang, Q; Wang, XY; Yu, JL; Zhao, YL, 2014)		0.9
"A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression."( Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
Fang, H; Lin, RY; Sun, MX; Tian, Y; Wang, Q; Wang, XY; Yu, JL; Zhao, YL, 2014)		0.86
"Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb~IV NSCLC who received multiple cycles of chemotherapy."( Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
Fang, H; Lin, RY; Sun, MX; Tian, Y; Wang, Q; Wang, XY; Yu, JL; Zhao, YL, 2014)		2.1
" Ad-p53 combined with gefitinib was used in vivo to explore their effect on tumor xenograft in nude mice."( [Effect of recombinant human p53 adenovirus (Ad-p53) combined with EGFR inhibitor gefitinib on the sensitivity of breast cancer MDA-MB-468 cells].
Guan, X; Liu, Q; Wang, L; Wang, X; Xie, L; Yu, Z, 2014)		0.94
" We conducted a phase II trial to investigate the efficacy and safety of gefitinib when combined with bevacizumab as first-line therapy in patients with advanced NSCLC harboring EGFR gene mutations."( Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
Aoe, K; Bessho, A; Chikamori, K; Fujii, M; Harada, D; Hisamoto-Sato, A; Hosokawa, S; Hotta, K; Ichihara, E; Kishino, D; Kiura, K; Kozuki, T; Kubo, T; Kuyama, S; Nogami, N; Oze, I; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H, 2015)		0.98
"Gefitinib in combination with bevacizumab as first-line therapy seems to be a favorable and well-tolerated treatment for patients with advanced NSCLC with activating EGFR gene mutations, especially those with EGFR exon 19 deletion mutations, although the primary end point was not met because the lower limit of the CI was less than 40%."( Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
Aoe, K; Bessho, A; Chikamori, K; Fujii, M; Harada, D; Hisamoto-Sato, A; Hosokawa, S; Hotta, K; Ichihara, E; Kishino, D; Kiura, K; Kozuki, T; Kubo, T; Kuyama, S; Nogami, N; Oze, I; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H, 2015)		2.19
" The purpose of the present trial is to determine whether CHM (Fuzheng Kang'ai decoction (FZKA), a CHM formula) combined with gefitinib results in longer progression-free survival with less toxicity than gefitinib alone."( Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Cai, JZ; Deng, H; He, WF; Li, QP; Liao, GY; Long, SQ; Pan, ZQ; Wu, WY; Xiao, SJ; Yang, XB; Zhou, YS, 2015)		0.89
" This trial is designed to determine if CHM (FZKA) combined with gefitinib results in longer progression-free survival with less toxicity than gefitinib alone."( Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Cai, JZ; Deng, H; He, WF; Li, QP; Liao, GY; Long, SQ; Pan, ZQ; Wu, WY; Xiao, SJ; Yang, XB; Zhou, YS, 2015)		0.92
" This study will provide objective evidence to evaluate the efficiency of CHM combined with gefitinib in NSCLC patients with EGFR mutations, and may provide a novel regimen for patients with NSCLC."( Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Cai, JZ; Deng, H; He, WF; Li, QP; Liao, GY; Long, SQ; Pan, ZQ; Wu, WY; Xiao, SJ; Yang, XB; Zhou, YS, 2015)		0.9
" We aimed to investigate the apoptotic and antiproliferative effects of CuB as a single agent and in combination with Gef on both HT-29 and HCT-116 cell lines."( Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines.
Alp, E; Elmazoglu, Z; Menevse, S; Yar Saglam, AS, 2016)		0.68
" Both drugs are mainly metabolized by CYP3A4, and drug-drug interactions are a major concern."( Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
Ando-Makihara, R; Hayashi, Y; Makino, Y; Motonaga, M; Ohe, Y; Takano, M; Yamamoto, N, 2015)		0.66
"The tolerability of 60 mg/m(2) docetaxel with 250 mg/day gefitinib was confirmed, and we observed no drug-drug interaction in this combination."( Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
Ando-Makihara, R; Hayashi, Y; Makino, Y; Motonaga, M; Ohe, Y; Takano, M; Yamamoto, N, 2015)		0.9
"PET-CT imaging with [(18)F]-gefitinib is a powerful tool to non-invasively assess potential ABCB1- and ABCG2-mediated drug-drug interactions (DDIs) in vivo."( PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
DeGroot, J; Jansen, HT; Kivits, S; Läppchen, T; Sio, CF; Steinbach, OC; van de Steeg, E; van der Hoorn, JW; van Driel, A; Vlaming, ML, 2015)		1.01
" This study aimed to evaluate the effect of metformin in combination with EGFR-TKI on the prognosis of non-small cell lung cancer (NSCLC) patients with diabetes mellitus type 2 (DM2)."( Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
Cao, M; Chen, H; Chu, Q; Han, R; He, Y; Sun, J; Wang, D; Wang, Y; Yao, W, 2015)		0.42
" The drug-drug molecular salt may have some bearing on the treatment of patient suffering from anticancer and hypertension."( Drug-Drug Molecular Salt Hydrate of an Anticancer Drug Gefitinib and a Loop Diuretic Drug Furosemide: An Alternative for Multidrug Treatment.
Badiger, MV; Gonnade, RG; Patwadkar, MV; Sahu, SK; Thorat, SH, 2015)		0.66
" Using NSCLC cell lines with differential EGFR status, we examined the potency of PA-MSHA (Pseudomonas aeruginosa-mannose-sensitive hemagglutinin) in combination with Gefitinib on proliferation, apoptosis, cell cycle arrest, EGFR signaling and tumor growth."( PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells.
Cai, XW; Chang, JH; Fu, XL; Huang, QL; Liu, Q; Liu, ZB; Lu, YN; Pan, SY; Wang, JL; Wu, XH; Zhao, XM, 2016)		0.63
" Methods The study comprised a 3 + 3 dose-escalation part for LY2875358 monotherapy in patients with advanced malignancies (Part A) followed by an assessment of LY2875358 in combination with erlotinib or gefitinib in patients with non-small cell lung cancer (Part B)."( A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.
Doi, T; Enatsu, S; Kojima, T; Nakamura, T; Ohmatsu, H; Takahashi, H; Turner, K; Uenaka, K; Wacheck, V; Yoh, K; Zenke, Y, 2016)		0.83
" We assessed the clinical relevance of this potential drug-drug interaction (DDI) in a retrospective cohort of EGFR-mutant NSCLC patients."( EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.
Asmat, A; Kumarakulasinghe, NB; Loy, EY; Pang, B; Soo, RA; Soon, YY; Syn, N; Zheng, H, 2016)		0.43
"Co-administration of antineoplastics with ART is challenging due to potential drug-drug interactions (DDIs)."( Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.
Back, D; Clotet, B; Miranda, C; Moltó, J; Owen, A; Rajoli, R; Siccardi, M; Valle, M, 2017)		0.46
" Despite a clear potential in inhibiting these proteins in ovarian cancer, as a single agent or in combination with a carboplatin treatment, we need to target kinases in tandem because of their capacity to trigger compensatory pathways that synergize to promote drug resistance."( Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Jean-Claude, B; Thibault, B, 2017)		0.83
"Here we target EGFR, c-Src and Met individually or in combination with carboplatin, using Gefitinib, Dasatinib and Crizotinib respectively, in a panel of carboplatin-sensitive (OVCAR-3, IGROV-1 and A2780) and carboplatin-resistant cells (SKOV-3 and EFO-21)."( Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Jean-Claude, B; Thibault, B, 2017)		1.06
"Crizotinib, Dasatinib and Gefitinib, alone or in combination with carboplatin, showed a cell-specific cytotoxic synergy in ovarian cancer cells."( Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Jean-Claude, B; Thibault, B, 2017)		1.13
" In MDA-MB-468 and HCC1806 orthotopic TNBC xenograft tumors in nude mice, the drug combination inhibited tumor growth and prolonged mouse survival, although this effect was not significant for the gefitinib-resistant cell line HCC70."( Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
Baxter, RC; Boyle, FM; de Silva, HC; Julovi, SM; Lin, MZ; Martin, JL, 2017)		0.64
" Here we examined whether the metformin analogue phenformin, either used alone or in combination with gefitinib, could inhibit growth of bladder cancer cells."( Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways.
Darko, KO; Deng, J; He, C; Huang, Y; Peng, M; Su, Q; Tao, T; Yang, X; Zhou, S, 2018)		0.98
"Phenformin shows potential as an effective drug against bladder cancer, either alone or in combination with gefitinib."( Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways.
Darko, KO; Deng, J; He, C; Huang, Y; Peng, M; Su, Q; Tao, T; Yang, X; Zhou, S, 2018)		0.97
"In gefitinib-resistant cell line PC9/AB2, gefitinib combined with EZH2 inhibitor GSK343 can significantly inhibit cell viability, reduce cell migration and increase cell apoptosis."( [Role of EZH2 Inhibitor Combined with Gefitinib in EGFR-TKIs Resistant Lung Cancer Cells].
Chen, J; Cui, L; Gong, H; Li, W; Li, Y; Liu, C; Liu, H; Shi, R; Wang, P; Yuan, Y; Zhang, H, 2019)		1.41
" Here, we have evaluated the efficacy of the pan-Aurora inhibitor (CCT137690) alone and in combination with different chemotherapeutic and targeted drugs to identify its synergistic partners in oral cancer cell lines (ORL-48 and ORL-115)."( Identification and evaluation of novel drug combinations of Aurora kinase inhibitor CCT137690 for enhanced efficacy in oral cancer cells.
Ashfaq, Z; Bilal, A; Faisal, A; Furqan, M; Huma, Z; Hussain, I; Iqbal, M; Khalid, MH; Nasir, A; Ullah, R, 2019)		0.51
" Our findings indicate that osimertinib, rather than gefitinib combined with anti-PD-L1 treatment could lead to lung injury in an EGFR mutated tumor-bearing mouse model."( Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice.
Han, R; Jia, Y; Jiang, T; Li, X; Liu, S; Liu, Y; Qiao, M; Ren, S; Su, C; Zhao, C; Zhao, S; Zhou, C, 2019)		0.76
" The primary aim is to assess progression-free survival after EGFR-TKIs treatment combined with apatinib 250 mg once daily."( Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185).
Chen, J; Li, X; Liu, H; Liu, M; Zhang, H, 2020)		0.56
"The objectives of this study were to determine the objective effective response rate, survival, and safety of radiotherapy combined with gefitinib in patients with locally advanced non-small cell lung cancer (NSCLC) who were unfit for surgery or concurrent chemoradiotherapy."( Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial.
Bi, N; Chen, D; Deng, L; Fu, Z; Liang, J; Wang, L; Wang, W; Wang, X; Yang, X; Zhang, T; Zhou, Z, 2020)		1.06
"The patients with the locally advanced NSCLC who were unfit to receive surgery or concurrent chemoradiotherapy, received thoracic intensity-modulated radiotherapy (IMRT) combined with gefitinib 250 mg daily."( Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial.
Bi, N; Chen, D; Deng, L; Fu, Z; Liang, J; Wang, L; Wang, W; Wang, X; Yang, X; Zhang, T; Zhou, Z, 2020)		1.05
"For patients with locally advanced NSCLC who are not eligible for surgery or concurrent chemoradiotherapy, IMRT combined with gefitinib can improve the objective effective rate and is generally well-tolerated."( Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial.
Bi, N; Chen, D; Deng, L; Fu, Z; Liang, J; Wang, L; Wang, W; Wang, X; Yang, X; Zhang, T; Zhou, Z, 2020)		1.06
" This study aimed to summarize the currently available evidence and compare the efficacy and safety of gefitinib combined with chemotherapy versus chemotherapy alone for treating advanced NSCLC."( A meta-analysis of the therapeutic effect of gefitinib combined with chemotherapy and chemotherapy alone in treating non-small cell lung cancer.
Cai, L; Lei, X; Sun, K; Zhao, Q, 2020)		1.03
"Literature on comparing the effects of gefitinib combined with chemotherapy and chemotherapy alone in treating NSCLC was retrieved from the PubMed, EMBASE and Cochrane Database."( A meta-analysis of the therapeutic effect of gefitinib combined with chemotherapy and chemotherapy alone in treating non-small cell lung cancer.
Cai, L; Lei, X; Sun, K; Zhao, Q, 2020)		1.09
"001) after treatment with gefitinib combined with chemotherapy when compared with chemotherapy alone."( A meta-analysis of the therapeutic effect of gefitinib combined with chemotherapy and chemotherapy alone in treating non-small cell lung cancer.
Cai, L; Lei, X; Sun, K; Zhao, Q, 2020)		1.12
"Gefitinib combined with chemotherapy is superior to chemotherapy alone in PFS, sequential administration prolongs the patients' PFS, however, a survival advantage is not shown in OS or ORR."( A meta-analysis of the therapeutic effect of gefitinib combined with chemotherapy and chemotherapy alone in treating non-small cell lung cancer.
Cai, L; Lei, X; Sun, K; Zhao, Q, 2020)		2.26
" We conducted a retrospective cohort study using data from the claims database of Taipei Veterans General Hospital to perform direct comparisons of these three EGFR-TKIs (gefitinib, erlotinib, and afatinib) combined with co-medications (metformin, statins, antacids, and steroids)."( The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer.
Chang, YL; Chen, YM; Chou, YC; He, CH; Hsu, CC; Huang, TY; Su, VY; Yang, KY; Yen, JC, 2020)		0.75
" Inhibition of CYP1A1 may increase the concentration of ningetinib in target tissues, and the long-term safety and efficacy of ningetinib combined with gefitinib should be evaluated."( Drug interaction of ningetinib and gefitinib involving CYP1A1 and efflux transporters in non-small cell lung cancer patients.
Chen, X; Guo, Z; Hou, X; Li, J; Li, M; Liu, L; Sun, M; Wang, Q; Xi, N; Xie, C; Xie, N, 2021)		1.1
" Targeted therapy with gefitinib combined with crizotinib was administered as treatment."( Patient with EGFR-mutant lung cancer harboring de novo MET amplification successfully treated with gefitinib combined with crizotinib.
Fang, M; Gu, ZB; Huang, L; Liao, LM; Yao, GJ, 2021)		1.15
" The aim of this trial was to explore the efficacy and safety of CD8 + CD56+ NKT cell immunotherapy combined with gefitinib in patients with advanced EGFR-mutated NSCLC."( A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer.
An, H; Chen, D; Dai, C; Fan, X; Guo, Z; Li, J; Li, X; Ma, Y; Mao, C; Qian, F; Wang, D; Xia, S; Ye, F; Yu, W; Yuan, X; Zhang, M; Zhou, Y, 2021)		1.06
" Assessing the safety and therapeutic potential of allogeneic CD8 + CD56+ NKT killer cells in combination with EGFR-TKIs in NSCLC will be of great interest."( A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer.
An, H; Chen, D; Dai, C; Fan, X; Guo, Z; Li, J; Li, X; Ma, Y; Mao, C; Qian, F; Wang, D; Xia, S; Ye, F; Yu, W; Yuan, X; Zhang, M; Zhou, Y, 2021)		0.85
"This trial (Phase I/II Trails of NKT Cell in Combination With Gefitinib For Non Small Cell Lung Cancer) was registered on 21 November 2017 with www."( A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer.
An, H; Chen, D; Dai, C; Fan, X; Guo, Z; Li, J; Li, X; Ma, Y; Mao, C; Qian, F; Wang, D; Xia, S; Ye, F; Yu, W; Yuan, X; Zhang, M; Zhou, Y, 2021)		1.09
" EGFR fusion mutations combined with EGFR amplification are even rarer in NSCLC."( Gefitinib Combined with Cetuximab for the Treatment of Lung Adenocarcinoma Harboring the EGFR-Intergenic Region (SEC61G) Fusion and EGFR Amplification.
Li, J; Li, X; Wang, X; Xia, P; Yuan, L; Zhang, G; Zhao, S, 2021)		2.06
" For cancer patients suffering from other diseases such as hypertension and hyperlipidemia, it is necessary to pay special attention to the drug-drug interactions and metabolic pathways among drug combinations."( Severe adverse cutaneous reactions induced by gefitinib combined with antihypertensive and antihyperlipidemic drugs in lung cancer: a case report.
Fan, G; Li, Q; Liu, G; Liu, X; Lu, J; Shen, X; Wang, F; Wang, S; Zhu, H; Zhu, Y, 2022)		0.98
" This study aimed to compare the anti-cancer efficacy of EGFR inhibitors (gefitinib and erlotinib) alone and in combination with nutritional supplements of Se/FO in treating lung cancer."( Targeting EGFR in Combination with Nutritional Supplements on Antitumor Efficacy in a Lung Cancer Mouse Model.
Chen, PC; Guo, CH; Hsia, S; Lee, SY; Li, WC; Peng, CL, 2022)		0.95
" Our research aimed to investigate the effect of zerumbone combined with gefitinib in lung cancer."( Zerumbone combined with gefitinib alleviates lung cancer cell growth through the AKT/STAT3/SLC7A11 axis.
Fan, R; Li, DL; Wang, JG; Yan, MJ, 2023)		1.45
"Apatinib combined with gefitinib was proven to benefit advanced EGFR-mutant NSCLC patients in first-line treatment."( Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study.
Chen, Q; Fang, W; Hou, Z; Huang, Y; Li, S; Liu, Q; Ma, Y; Wang, J; Xue, J; Yang, Y; Zhang, L; Zhang, Y; Zhao, H; Zhao, Y, 2023)		1.44
"In this phase 1b, multi-center, open-label, fixed-sequence study, the drug-drug interaction of gefitinib and apatinib was evaluated when coadministered in EGFR-mutated NSCLC patients."( Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study.
Chen, Q; Fang, W; Hou, Z; Huang, Y; Li, S; Liu, Q; Ma, Y; Wang, J; Xue, J; Yang, Y; Zhang, L; Zhang, Y; Zhao, H; Zhao, Y, 2023)		1.35
" Second, the sample size of the chemotherapy combined with targeted therapy group was not large enough, and the cost data obtained would need confirmation in future studies."( Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China.
Hua, S; Li, SC; Wei, W; Yang, C; Yang, K; Zhu, X, )		0.37

Bioavailability

Gefitinib (Iressa, ZD 1839) is an orally bioavailable small molecule that selectively inhibits epidermal growth factor receptor(EGFR) tyrosine kinase activity. Resveratrol and Gefit inib are adjunct therapies for various cancers. Both have been limited by low solubility, low cellular uptake, and bioavailability issues.

ExcerptReferenceRelevance
" The third study investigated the effect of food on the bioavailability of a single 50mg dose of ZD1839."( Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers.
Dane, A; Jones, H; Laight, A; Morris, C; Stafford, L; Swaisland, H; Yates, R, 2001)		0.31
" Results from Phase I trials, in healthy volunteers and in patients with advanced disease, have shown that ZD1839 has excellent bioavailability and an acceptable tolerability profile."( ZD1839: targeting the epidermal growth factor receptor in cancer therapy.
Herbst, RS, 2002)		0.31
" Gefitinib is orally bioavailable and is cleared via the cytochrome P450 3A4 pathway."( Gefitinib.
Culy, CR; Faulds, D, 2002)		2.67
"Clinical development of ZD1839 (Iressa; AstraZeneca Pharmaceuticals LP, Wilmington, DE) was initiated based on strong preclinical studies that showed antitumor responses in a variety of solid tumor types and established its oral bioavailability and tolerability."( Phase I studies of ZD1839 in patients with common solid tumors.
Lorusso, PM, 2003)		0.32
" However, gefitinib treatment dramatically increased the oral bioavailability of irinotecan after simultaneous oral administration."( Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
Cheshire, PJ; Daw, N; Germain, GS; Gilbertson, R; Harwood, FC; Houghton, PJ; Jenkins, JJ; Leggas, M; Panetta, JC; Peterson, J; Schuetz, JD; Stewart, CF, 2004)		2.17
"The aim of the present study was to determine the relative bioavailability and safety profile of a single dose of gefitinib, an orally active inhibitor of epidermal growth factor receptor tyrosine kinase, when administered as a whole 250-mg tablet or as a dispersion preparation via drink or nasogastric tube in healthy male volunteers."( Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.
Bailey, C; Cantarini, MV; Marshall, AL; McFarquhar, T; Smith, RP, 2004)		0.79
" The pharmacokinetic parameters of interest included AUC, C(max), and the relative bioavailability of the dispersion via drink or nasogastric tube compared with the standard tablet."( Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.
Bailey, C; Cantarini, MV; Marshall, AL; McFarquhar, T; Smith, RP, 2004)		0.58
" The gefitinib dispersion preparation administered by drink had a mean bioavailability of 103."( Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.
Bailey, C; Cantarini, MV; Marshall, AL; McFarquhar, T; Smith, RP, 2004)		1.09
"Study 1: Oral bioavailability of a gefitinib 250 mg dose was 57% in healthy volunteers."( Single-dose clinical pharmacokinetic studies of gefitinib.
Duvauchelle, T; Kerr, DJ; Laight, A; Ranson, M; Smith, RP; Swaisland, HC; Wilder-Smith, CH, 2005)		0.86
"The gefitinib 250 mg tablet is orally bioavailable in both healthy volunteers and cancer patients; bioavailability is independent of dose and unaffected by food to any clinically significant extent."( Single-dose clinical pharmacokinetic studies of gefitinib.
Duvauchelle, T; Kerr, DJ; Laight, A; Ranson, M; Smith, RP; Swaisland, HC; Wilder-Smith, CH, 2005)		1.14
"Gefitinib (Iressa, ZD 1839) is an orally bioavailable small molecule that selectively inhibits epidermal growth factor receptor(EGFR) tyrosine kinase activity."( [Molecular targeted therapy--non-small-cell lung cancer and gefitinib].
Horio, Y; Mitsudomi, T; Shimizu, J, 2005)		2.01
"Our results show that YM-359445 is more potent than orally bioavailable VEGFR2 tyrosine kinase inhibitors, which leads to great expectations for clinical applicability."( YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino, N; Hisamichi, H; Ideyama, Y; Kudoh, M; Kuromitsu, S; Matsuhisa, A; Samizu, K; Shibasaki, M; Shirasuna, K; Tajinda, K; Yamano, M, 2006)		0.33
" Oral administration of 4-AQ molecules, such as gefitinib, inhibits ATP-binding cassette (ABC) transporter-mediated drug efflux and strongly increases the apparent bioavailability of coadministered drug molecules that are transporter substrates."( Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.
Bai, F; Houghton, PJ; Johnston, B; Leggas, M; Panetta, JC; Schuetz, JD; Sorrentino, B; Stewart, CF; Zhou, S; Zhuang, Y, 2006)		2.03
" When administered orally, sulfasalazine is poorly absorbed with an estimated bioavailability of 3-12%."( Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.
Brayman, TG; Khan, AA; Palandra, J; Ware, JA; Yu, L; Zaher, H, )		0.13
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007)		0.34
"The aims of this study were to determine the relative bioavailability of a single dose of gefitinib when administered as 250 mg of a new granular formulation compared with the standard 250 mg tablet, and to assess the intra-subject variability of the granular formulation, in healthy subjects."( The relative bioavailability of gefitinib administered by granular formulation.
Bailey, CJ; Cantarini, MV; Collins, B; Smith, RP, 2008)		0.85
" To assess the effect of gefitinib on the pharmacokinetics of IV irinotecan and on the bioavailability of a single oral dose of irinotecan."( Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.
Crews, KR; Daw, NC; Furman, WL; Gajjar, AJ; Houghton, PJ; McCarville, MB; McGregor, LM; Navid, F; Panetta, JC; Rodriguez-Galindo, C; Santana, VM; Spunt, SL; Stewart, CF; Wu, J, 2009)		0.66
" Gefitinib significantly enhances the bioavailability of oral irinotecan."( Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.
Crews, KR; Daw, NC; Furman, WL; Gajjar, AJ; Houghton, PJ; McCarville, MB; McGregor, LM; Navid, F; Panetta, JC; Rodriguez-Galindo, C; Santana, VM; Spunt, SL; Stewart, CF; Wu, J, 2009)		1.26
" They are characterized by a moderate rate of absorption after oral administration with peak plasma concentrations at several hours post-dose."( Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.
Di Gion, P; Doroshyenko, O; Fuhr, U; Scheffler, M; Wolf, J, 2011)		0.37
" SKLB1206 also showed a very good oral bioavailability (50."( SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo.
Cao, Z; Chen, X; Feng, S; Ji, P; Liu, J; Luo, S; Pan, Y; Wang, BL; Wang, L; Wang, X; Wang, Z; Wei, YQ; Xu, Y; Yang, HY; Yang, J; Yang, SY; Yu, Y; Zhang, S; Zheng, R; Zhong, L, 2012)		0.38
" Pharmacokinetically, after oral administration, gefitinib is slowly absorbed with bioavailability of approximately 60% in human."( Gefitinib.
Kassem, MG; Korashy, HM; Rahman, AF, 2014)		2.1
" Pharmacokinetic analysis confirms that co-administration of gefitinib increases irinotecan bioavailability leading to an increased SN-38 lactone systemic exposure."( Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.
Brennan, RC; Furman, W; Mao, S; McGregor, LM; Santana, V; Stewart, CF; Turner, DC; Wu, J, 2014)		0.89
" Also, 5a exhibited improved oral bioavailability and safety as well as favorable tissue distribution properties and enhanced brain uptake."( A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.
Chen, W; Deng, H; Han, J; Huang, W; Li, B; Li, P; Li, Y; Liu, Y; Ma, C; Miao, H; Qi, W; Shao, J; Shen, J; Sun, X; Xia, G; Xiang, Z; Xu, J; Yu, Y; Zhang, J; Zhang, L; Zhang, Y, 2014)		0.4
" Despite limitations in its physical properties, 5 is orally bioavailable in mice and demonstrates pronounced antitumor activity in in vivo models of mutant EGFR-driven cancers."( Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation.
Ashton, S; Chuaqui, C; Colclough, N; Cross, DA; Debreczeni, JÉ; Eberlein, C; Gingipalli, L; Hennessy, EJ; Klinowska, TC; Orme, JP; Sha, L; Wu, X, 2016)		0.43
"This open-label, randomized, phase 1 crossover study investigated the effect of elevated gastric pH level (>5) on the relative bioavailability and pharmacokinetic profile of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib."( Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure.
Masson, E; Tang, W; Tomkinson, H, 2017)		0.89
" However, STAT3 inhibitors with good selectivity and bioavailability are rare."( Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
Chen, Y; Kong, L; Li, C; Li, S; Lin, JY; Liu, M; Luo, J; Sun, H; Xia, Y; Yang, L; Yu, K; Yu, W; Zhang, W, 2017)		0.46
" It is an accepted opinion that modifying GEF strong hydrophobicity and poor bioavailability would not only enhance its antitumor effects, but also reduce its side effects."( In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer.
Chen, LX; Chen, Y; Fu, SZ; Liu, J; Ni, XL; Wu, JB; Wu, M; Xu, S; Yang, B; Yang, LL; Zhang, H, 2017)		0.72
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
"75-fold increase in the bioavailability of GEF delivered from GEF/ZnO-FCL@GPMs as compared to its trademarked drug (Iressa®)."( Novel β-1,3-d-glucan porous microcapsule enveloped folate-functionalized liposomes as a Trojan horse for facilitated oral tumor-targeted co-delivery of chemotherapeutic drugs and quantum dots.
Li, X; Liu, Z; Wang, J; Xu, Y; Yang, Y; Zhang, Y; Zhao, Z, 2020)		0.56
" Gefitinib (GEF) is one of them, but its poor solubility in gastric fluids weakens its bioavailability and therapeutic activity."( p28-functionalized PLGA nanoparticles loaded with gefitinib reduce tumor burden and metastases formation on lung cancer.
Almeida, A; Barrias, CC; Bernardes, N; Castro, F; Dias, TP; Fernardes, F; Fialho, AM; Garizo, AR; Martins, C; Sarmento, B, 2021)		1.78
"Gefitinib is a tyrosine kinase inhibitor that is intended for oral administration yet suffers poor bioavailability along with undesirable side effects."( Solid Dispersions of Gefitinib Prepared by Spray Drying with Improved Mucoadhesive and Drug Dissolution Properties.
Alany, RG; Fletcher, J; Khoder, M; Mustafa, WW, 2022)		2.48
" Multiple-target inhibitors of efflux transporter can be overcome the resistance and improve the oral bioavailability of chemotherapy drugs."( Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
Cai, Z; Ghaleb, H; Huang, W; Jiang, Y; Liu, Y; Qian, H; Qiu, Q; Shi, W; Yin, Z; Zhang, P; Zhou, J; Zou, F, 2022)		0.72
" This variability can be explained, at least in part, by their oral route of administration, which leads to a large inter- and intra-patient variation in bioavailability based on differences in absorption."( Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer.
Assaraf, YG; Bins, S; de With, M; Dingemans, AC; Heersche, N; Jansman, FGA; Mathijssen, RHJ; van Schaik, RHN; Veerman, GDM, 2022)		0.72
"The poor water solubility and inadequate oral bioavailability of gefitinib (Gef) remain a critical issue to achieve the therapeutic outcomes."( Poly(maleic anhydride-alt-1-octadecene)-based bioadhesive nanovehicles improve oral bioavailability of poor water-soluble gefitinib.
Li, J; Li, Y; Qian, X; Shan, Y; Wang, G; Xie, Y; Zhang, M; Zhang, X; Zhang, Z, 2022)		1.17
"Resveratrol and Gefitinib are adjunct therapies for various cancers; however, both have been limited by low solubility, low cellular uptake, and bioavailability issues."( A novel RP-HPLC method development and validation for simultaneous quantification of gefitinib and resveratrol in polymeric hybrid lipid nanoparticles and glioma cells.
Ghazwani, M; Gowda, DV; Gurupadayya, BM; Hani, U; Hemanth Vikram, PR; Osmani, RAM; Sathishbabu, P; Shakeela, C, 2022)		1.29
" Furthermore, the in-vivo study showed that TPGS-NLC was able to enhance GEF bioavailability (1."( TPGS decorated NLC shift gefitinib from portal absorption into lymphatic delivery: Intracellular trafficking, biodistribution and bioavailability studies.
Alanazi, FK; Ali, EA; Alqahtani, AS; Attia, SM; Harisa, GI; Nasr, FA; Omran, GA; Sherif, AY, 2023)		1.21
" It was observed that the prepared formulation not only improved bioavailability but also improved the targeting as more gefitinib entered the cancer cells when present in the formulation, decreasing the toxicity of gefitinib on other organs."( Amelioration of the therapeutic potential of gefitinib against breast cancer using nanostructured lipid carriers.
Aggarwal, G; Ahsan, W; Javed, S; Kumar, P; Mangla, B, 2023)		1.38

Dosage Studied

Gefitinib and sirolimus were administered on a continuous daily dosing schedule. At 200 days suppressed small intestinal tumourigenesis more effectively than either treatment alone (median small intestinal adenoma volume (47 mm(3) (comb) vs 248’mm( 3) (AZ12253801), P=0.5).

ExcerptRelevanceReference
" dosing might be a suitable therapeutic regimen."( ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
Ashton, SE; Barker, AJ; Curry, BJ; Gibson, KH; Guy, SP; Wakeling, AE; Woodburn, JR, 2002)		0.31
" Intermittent and continuous dosing schedules with ZD1839 were well tolerated by these patients for up to 6 months or more."( Phase I studies of ZD1839 in patients with common solid tumors.
Lorusso, PM, 2003)		0.32
" Mean terminal half-life following multiple dosing was 50."( Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.
Dong, RP; Fukuoka, M; Hirose, M; Kudoh, S; Nakagawa, K; Nakatani, I; Negoro, S; Swaisland, H; Takeda, K; Tamura, T; Yamamoto, N, 2003)		0.53
" However, since the tumor in this animal model was EGFR positive and because tumor growth tended to be suppressed in mice with higher immune activity, it seems likely that additional studies of this therapy will contribute to identifying the optimum drugs to be combined with gefitinib and the optimum method of dosing that will lead to satisfactory efficacy and safety of gefitinib combined with immunotherapy."( [Significance of gefitinib combined with immunotherapy in tumor-bearing mice].
Maruyama, S; Sukegawa, Y; Yagita, A, 2003)		0.84
" Dosing erlotinib at the maximum tolerated dose, which is associated with more frequent and more severe rash, may improve response rates and survival durations."( Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
Pérez-Soler, R, 2003)		0.32
" Gefitinib was investigated clinically by a single dose ascending study and 3-day multiple dosing study in male volunteers in the UK initially."( [Development of novel molecular targeted drug, "Iressa", for the treatment of malignant diseases--its basic and clinical studies].
Mikami, O; Tsukagoshi, S, 2003)		1.23
" Patient characteristics, lack of patient selection, dosing schedule, and trial design may all have played roles."( HER1/EGFR targeting: refining the strategy.
Pérez-Soler, R, 2004)		0.32
" Gefitinib, which can be given at doses below the maximum tolerated dose, is associated with slightly lower rates of adverse events than erlotinib, which is dosed at the maximum tolerated dose."( Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer.
Caponigro, F, 2004)		1.23
" Gefitinib is administered orally at a dosage of 250 mg/day."( Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer.
Cersosimo, RJ, 2004)		2.68
" Gefitinib represents a significant advance in the treatment of this population; a once-daily, oral dosage of 250 mg/day was well tolerated, produced objective tumour responses and disease stabilisation, and improved disease-related symptoms and quality of life."( Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer.
Easthope, SE; Frampton, JE, 2004)		2.68
" Gefitinib was found to be generally well tolerated at the approved dosage of 250 mg/day; the most commonly reported adverse drug reactions (ADRs) were mild to moderate skin rash and diarrhoea, which were manageable and non-cumulative."( Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer.
Faulkner, K; Forsythe, B, 2004)		1.52
" Plasma samples obtained before dosing to 240 hours after dosing were analyzed for gefitinib using reverse-phase high-performance liquid chromatography with tandem mass-spectrometric detection."( Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.
Bailey, C; Cantarini, MV; Marshall, AL; McFarquhar, T; Smith, RP, 2004)		0.81
" No dosage adjustment is required for patient age, body weight, gender, ethnicity or moderate to severe hepatic impairment due to liver metastases."( Gefitinib: current status in the treatment of non-small cell lung cancer.
Alfaro, V; Tanović, A, 2004)		1.77
" The anti-EGFR mAbs and TKIs have partially overlapping toxicity profiles, but distinct routes of administration, serum half-lives and therefore dosing schedules."( Epidermal growth factor receptor inhibition strategies in oncology.
Harari, PM, 2004)		0.32
" PK demonstrated steady state within the first 2 weeks of dosing and dose dependent exposure."( A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Batist, G; Douglas, L; Friedmann, J; Goss, G; Hanna, P; Hirte, H; Lorimer, IA; Mathews, S; Miller, WH; Parolin, DA; Seymour, LK; Stafford, S; Stewart, D; Walsh, W, 2005)		0.33
" Eleven patients required dosing modification (hold or reduction), while 3 patients discontinued therapy because of toxicity."( A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer.
Batist, G; Douglas, L; Glenwood, G; Goel, R; Hirte, HW; Jean, M; Lorimer, IA; Mackenzie, MJ; Major, PP; Matthews, S; Miller, WH; Panasci, L; Seymour, L, 2005)		0.33
" Furthermore, we hypothesized that intermittent dosing would allow for dose escalation and greater inhibition of EGFR-dependent antiapoptotic pathways."( Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel.
Kris, MG; Lobo, J; Rosen, N; Scher, HI; She, Y; Sirotnak, FM; Solit, DB, 2005)		0.56
"To test these assertions, we compared combinations of paclitaxel and gefitinib using either intermittent or continuous dosing schedules in mice."( Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel.
Kris, MG; Lobo, J; Rosen, N; Scher, HI; She, Y; Sirotnak, FM; Solit, DB, 2005)		0.79
" Following intravenous dosing (5 mg kg(-1), gefitinib plasma half-life was 3-6h in rats and dogs, although studies using a more sensitive HPLC-MS assay produced longer estimates of half-life (7-14h)."( Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog.
Bardsley, J; Hutchison, M; McKillop, D; Parry, AC; Partridge, EA; Rhead, SA; Swaisland, HC; Woodman, HM, 2004)		0.91
" Gefitinib represents a significant advance in the treatment of this population; a once-daily oral dosage of 250 mg/day was well tolerated, produced objective tumour responses and disease stabilization, and improved disease-related symptoms and quality of life."( Spotlight on gefitinib in non-small-cell lung cancer.
Easthope, SE; Frampton, JE, 2005)		1.61
" The major challenges on the clinical development of targeted therapy include the proper selection of patients, the identification of the optimal dosage and schedule of administration, the combinations with conventional treatments and the more appropriate therapeutic strategy."( Therapy of breast cancer with molecular targeting agents.
Gasparini, G; Longo, R; Morabito, A; Torino, F, 2005)		0.33
" Because of the potentially serious consequences of this interaction, close monitoring of the International Normalized Ratio and warfarin dosage adjustment are recommended for patients receiving warfarin together with gefitinib."( Drug interaction between gefitinib and warfarin.
Abe, T; Hagiri, S; Ishii, K; Katagiri, M; Kato, E; Kobayashi, H; Kuboto, M; Masuda, N; Mitsufuji, H; Onoda, S; Ryuge, S; Takada, N; Tanaka, N; Wada, M; Yamamoto, M; Yanaihara, T; Yanase, N; Yokoba, M, 2005)		0.82
" Cell growth was analyzed by the MTS assay, with differences between dose-response curves analyzed nonparametrically."( Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
Cantley, LC; Engelman, JA; Halmos, B; Hanna, NH; Jänne, PA; Johnson, BE; Kobayashi, S; Lindeman, N; Mukohara, T; Pearlberg, J; Tenen, DG; Tsuchihashi, Z; Yeap, BY, 2005)		0.64
" Exposure to gefitinib is increased by coadministration with CYP3A4 inhibitors, but since gefitinib is known to have a good tolerability profile, a dosage reduction is not recommended."( Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Laight, A; Leadbetter, J; McKillop, D; Ranson, M; Smith, RP; Swaisland, HC; Wild, MJ, 2005)		0.97
" Gefitinib undergoes rapid plasma clearance and has an extensive volume of distribution, resulting in a pharmacokinetic profile supportive of a once-daily dosage regimen."( Single-dose clinical pharmacokinetic studies of gefitinib.
Duvauchelle, T; Kerr, DJ; Laight, A; Ranson, M; Smith, RP; Swaisland, HC; Wilder-Smith, CH, 2005)		1.49
" A dose-response relationship may exist for this agent in SCCHN and grade of cutaneous toxicity attributable to gefitinib is a clinical predictor of better outcome."( Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Brockstein, BE; Cohen, EE; Dekker, A; Huo, D; Kane, MA; List, MA; Mauer, AM; Mehrotra, B; Pierce, C; Vokes, EE, 2005)		0.87
"Gefitinib and sirolimus were administered on a continuous daily dosing schedule at dose levels that were escalated in successive cohorts of malignant glioma patients at any recurrence who were stratified based on concurrent use of CYP3A-inducing anticonvulsants [enzyme-inducing antiepileptic drugs, (EIAED)]."( Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
Bigner, DD; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Lyons, P; McLendon, RE; Ochs, JS; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Sathornsumetee, S; Smith, RP; Swaisland, AJ; Tourt-Uhlig, S; Vredenburgh, JJ, 2006)		2.12
"We show that gefitinib plus sirolimus can be safely coadministered on a continuous, daily dosing schedule, and established the recommended dose level of these agents in combination for future phase 2 clinical trials."( Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
Bigner, DD; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Lyons, P; McLendon, RE; Ochs, JS; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Sathornsumetee, S; Smith, RP; Swaisland, AJ; Tourt-Uhlig, S; Vredenburgh, JJ, 2006)		1.04
"Epidermal growth factor receptor (EGFR) mRNA expression and EGFR gene dosage by quantitative PCR in tumor samples obtained from patients with gefitinib-treated non-small cell lung cancer were analyzed in order to determine the association with treatment outcome, clinical, and biological features [EGFR copy number by fluorescent in situ hybridization (FISH), EGFR tyrosine kinase mutations, and EGFR protein expression]."( Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.
Barón, AE; Bunn, PA; Cappuzzo, F; Crino, L; Danenberg, KD; Danenberg, PV; Dziadziuszko, R; Franklin, WA; Hirsch, FR; Park, S; Tanaka, K; Varella-Garcia, M; Witta, SE, 2006)		0.76
"EGFR mRNA expression was measured by real-time quantitative reverse transcription-PCR in 64 patients, and EGFR gene dosage was analyzed by real-time quantitative PCR in 82 patients from paraffin-embedded specimens."( Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.
Barón, AE; Bunn, PA; Cappuzzo, F; Crino, L; Danenberg, KD; Danenberg, PV; Dziadziuszko, R; Franklin, WA; Hirsch, FR; Park, S; Tanaka, K; Varella-Garcia, M; Witta, SE, 2006)		0.56
" EGFR gene dosage is neither predictive for response nor progression-free nor overall survival."( Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.
Barón, AE; Bunn, PA; Cappuzzo, F; Crino, L; Danenberg, KD; Danenberg, PV; Dziadziuszko, R; Franklin, WA; Hirsch, FR; Park, S; Tanaka, K; Varella-Garcia, M; Witta, SE, 2006)		0.56
" Although higher exposure to gefitinib occurs in individuals who are poor CYP2D6 metabolisers, genotyping prior to initiation of therapy and dosage adjustment are not warranted."( Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
Cantarini, MV; Fuhr, R; Holt, A; Swaisland, HC, 2006)		0.85
" This study aimed to evaluate the schedule-dependent interaction of clinically relevant dosing of vandetanib with RT in human head and neck cancer models that had been characterized as EGFR positive (EGFR+) or negative (EGFR-) in order to begin differentiating vandetanib and RT interactions at the level of antitumor (EGFR) or antivascular (VEGFR2) activities."( Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
Frederick, B; Gustafson, DL; Merz, AL; Raben, D, 2008)		0.35
" Vandetanib was dosed at 30 mg kg(-1) day(-1) based on pharmacokinetic studies in nude mice showing that this dose results in drug exposure similar to that seen in humans at clinical doses."( Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
Frederick, B; Gustafson, DL; Merz, AL; Raben, D, 2008)		0.35
" Due to difficulties in crystalline identification in the jejunal fluid samples, only the same crystalline form as the dosed form was identified."( Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors.
Bergman, E; Cantarini, MV; Dickinson, P; Farmer, MR; Forsell, P; Knutson, L; Lennernäs, H; Persson, EM; Smith, R; Swaisland, H, 2007)		0.66
" When various dosing schedules were applied, MP-412 showed significant effects with daily and every-other-day schedules, but not with a once-weekly schedule, suggesting that frequent dosing is preferable for this compound."( Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.
Abe, D; Amano, Y; Fujii, A; Kitano, Y; Nakamura, H; Ohya, J; Suzuki, T, 2007)		0.34
" Healthy male subjects (n = 18) received either a single gefitinib 250 mg tablet (once), or a 250 mg granular formulation of gefitinib (on two separate occasions) over the three dosing periods, in randomized order."( The relative bioavailability of gefitinib administered by granular formulation.
Bailey, CJ; Cantarini, MV; Collins, B; Smith, RP, 2008)		0.87
" This case suggests that, in some patients with NSCLC, even short-term administration of gefitinib may bring about clinical benefits and disease response comparable to the standard long-term daily dosing schedule."( Short-term gefitinib treatment brought about a long-term regression of bronchioloalveolar carcinoma without EGFR gene alterations: a case report.
Goya, S; Kawase, I; Kijima, T; Kumagai, T; Matsuoka, H; Minami, S; Osaki, T; Suzuki, M; Tachibana, I; Takeda, Y; Ueda, K; Yokota, S; Yoshida, M, 2007)		0.95
" The goal of this investigation was to cast the combined PG/PK/PD variables into models that could be used to design equivalent PK/PD dosing regimens for gefitinib in genetically distinct tumor models."( Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models.
Gallo, JM; Guo, P; Wang, S; Wang, X; Zhou, Q, 2008)		0.79
"Our present results imply that (1) mutation analyses of EGFR and KRAS provide valuable information about whether or not to apply treatments targeting against EGFR and the selection of dosage for such treatments, and (2) siRNA-mediated knockdown is effective in lung adenocarcinomas with EGFR mutation, probably in those with resistance to gefitinib by acquired mutation in EGFR."( siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma.
Fujisaki, R; Gu, Z; Horii, A; Inomata, K; Inoue, A; Kondo, T; Nukiwa, T; Sakurada, A; Sato, M; Yamanaka, S, 2008)		0.52
" Our findings suggest that HKI-272 treatment at maximally tolerated dosing may lead to the emergence of T790M-mediated resistance, whereas treatment with a more potent irreversible inhibitor could yield a resistance mutation at EGFR C797."( The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
Brannigan, BW; Godin-Heymann, N; Haber, DA; Lamb, J; Maheswaran, S; McDermott, U; Settleman, J; Ulkus, L, 2008)		0.35
" Treatment arms with gefitinib 250mg/day and platinum-based doublets chemotherapy irrespective of dosage and schedule were combined to calculate the pooled estimates for efficacy and safety outcomes of interest."( The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis.
Chan, KA; Chang, CH; Chen, KY; Kurth, T; Orav, EJ; Yang, PC; Young-Xu, Y, 2008)		0.96
" Gefitinib was administrated orally at a dosage of 250mg/day during the radiation course and was continued for each 28-day treatment cycle until progression of the disease, unacceptable toxicity, or withdrawal of consent."( Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population.
Deng, Q; Ma, S; Xu, Y; Yu, X, 2009)		1.48
" x 15 days, respectively, as dictated by the equivalent PK/PD dosing strategy."( Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib.
Gallo, JM; Wang, S; Zhou, Q, 2009)		0.57
" Medical information, including the indication for warfarin use, warfarin dosing and dosing changes, and exposure to gefitinib were collected from computerized databases and medical records."( Effect of gefitinib on warfarin antithrombotic activity.
Arai, S; Fukui, T; Hataishi, R; Iwasaki, M; Katagiri, M; Katono, K; Kobayashi, H; Kubota, M; Masuda, N; Mitsufuji, H; Nishii, Y; Onoda, S; Otani, S; Ryuge, S; Takakura, A; Wada, M; Yamamoto, M; Yanaihara, T; Yanase, N; Yokoba, M, 2009)		0.96
" The proposed method is applied to time course microarray data of lung cells treated by stimulating EGF receptors and dosing an anticancer drug, Gefitinib."( A state space representation of VAR models with sparse learning for dynamic gene networks.
Gotoh, N; Higuchi, T; Imoto, S; Kojima, K; Miyano, S; Nagasaki, M; Shimamura, T; Ueno, K; Yamaguchi, R; Yamauchi, M; Yoshida, R, 2010)		0.56
" Blood samples were collected before dosing and on days 7, 14, 21, and 28."( The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib.
Guo, Y; Jiang, W; Li, S; Liao, H; Shi, YX; Xue, C; Zhang, L; Zhang, Y; Zhao, HY; Zhao, YY, 2011)		0.58
" The initial gefitinib dosage was 100mg/m(2)/d commencing with radiation therapy and the dose-finding period extended until 2 weeks post-radiation."( A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas.
Banerjee, A; Blaney, SM; Boyett, JM; Broniscer, A; Douglas, JG; Geyer, JR; Gilbertson, RJ; Gururangan, S; Kieran, MW; Kocak, M; Kun, LE; Packer, RJ; Phillips, P; Stewart, CF, 2010)		1.02
" PEG-IFNα was dosed subcutaneously once weekly (initially 6 μg/kg/week, later reduced to 4 μg/kg/week) for 12 weeks."( A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma.
Frankel, P; Gandara, DR; Lara, PN; Longmate, J; Margolin, KA; Pan, CX; Quinn, DI; Shek, D; Twardowski, P, 2011)		0.69
" In Study 2, the geometric mean gefitinib steady-state AUC during the 24-h dosing interval was slightly, but not significantly, higher in patients with moderate hepatic impairment; there were, however, no significant differences between groups in gefitinib and metabolite pharmacokinetic parameters."( The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib.
Cantarini, M; Carmichael, J; Harris, AL; Holt, A; Horak, J; Macpherson, M; Swaisland, A; Swaisland, H; Twelves, C; Verrill, M; White, J, 2011)		0.88
" We applied ImageRail to collect and analyze drug dose-response landscapes in human cell lines at single-cell resolution."( Adaptive informatics for multifactorial and high-content biological data.
Menden, MP; Millard, BL; Muhlich, JL; Niepel, M; Sorger, PK, 2011)		0.37
" Because both drugs were developed to target wild-type EGFR, we hypothesized that current dosing schedules were not optimized for mutant EGFR or to prevent resistance."( Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.
Amato, KR; Arcila, M; Chmielecki, J; de Stanchina, E; Foo, J; Ginsberg, MS; Hutchinson, K; Inoue, A; Kris, MG; Ladanyi, M; Michor, F; Miller, VA; Ohashi, K; Oxnard, GR; Pao, W; Socci, ND; Somwar, R; Sos, ML; Thomas, RK; Viale, A; Wang, L, 2011)		0.37
" Combined dosing with gefitinib and AZ12253801 similarly delayed the onset of symptoms, and at 200 days suppressed small intestinal tumourigenesis more effectively than either treatment alone (median small intestinal adenoma volume (47 mm(3) (comb) vs 248 mm(3) (AZ12253801), P=0."( Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse.
Clarke, AR; Maughan, TS; Shaw, PH, 2011)		0.68
" Irinotecan dosing started at 50 mg m(-2) and was escalated in patients by 25 mg m(-2) increments up to a maximum dose of 150 mg m(-2)."( Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.
Horai, T; Horiike, A; Kasahara, K; Kudo, K; Miyauchi, E; Nishio, M; Ohyanagi, F, 2011)		0.65
"MET gene dosage of the tumor tissues from 208 NSCLC patients was investigated by real time quantitative polymerase chain reaction and compared with molecular and clinical features, including EGFR mutations, KRAS mutations, EGFR gene copy numbers, and patient survivals."( Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment.
Chang, JW; Chen, YR; Chen, YT; Chiu, YT; Hsieh, JJ; Huang, SF; Liu, HP; Wu, HD; Yu, TF, 2011)		0.37
"The proportion of high MET gene dosage was 10."( Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment.
Chang, JW; Chen, YR; Chen, YT; Chiu, YT; Hsieh, JJ; Huang, SF; Liu, HP; Wu, HD; Yu, TF, 2011)		0.37
"High MET gene dosage was not related to primary TKI resistance and the incidence was increased after chemotherapy, suggesting high MET gene dosage may also be related to chemotherapy resistance."( Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment.
Chang, JW; Chen, YR; Chen, YT; Chiu, YT; Hsieh, JJ; Huang, SF; Liu, HP; Wu, HD; Yu, TF, 2011)		0.37
"From May 2005 to August 2006, 15 patients received a 250 mg/day dosage of gefitinib after having disease progression while taking erlotinib at a dose of 150 mg/day."( The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.
Barletta, G; Boldrini, L; Brianti, A; Cosso, M; Dal Bello, MG; Defferrari, C; Fontanini, G; Genova, C; Grossi, F; Murolo, C; Pronzato, P; Rijavec, E; Truini, M, 2012)		0.92
" For a real data application, our proposed approach is applied to time series data from normal Human lung cells and Human lung cells treated by stimulating EGF-receptors and dosing an anticancer drug termed Gefitinib."( Identifying regulational alterations in gene regulatory networks by state space representation of vector autoregressive models and variational annealing.
Fujita, A; Gotoh, N; Imoto, S; Kojima, K; Miyano, S; Yamaguchi, R; Yamauchi, M, 2012)		0.57
" Double dosage of gefitinib (500 mg per day) together with pemetrexed were given as the second-line therapy after the patient developed new brain lesions and leptomeningeal metastasis during the maintenance therapy of gefitinib."( Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.
Fang, X; Hu, Y; Li, M; Ma, S; Shen, H; Tan, C; Yuan, Y, 2012)		0.99
" On detection of epidermal growth factor receptor(EGFR)mutations, we administered gefitinib, an EGFR tyrosine kinase inhibitor, at a dosage of 250 mg daily."( [Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
Hokkoku, K; Igarashi, S; Kitade, H; Mori, M; Nakai, M; Sagawa, M; Shintaku, K; Yamada, T; Yano, S, 2013)		0.88
" The optimum dosing combination of these two agents has yet to be determined however, and in many patients it is likely that greater overall survival will be achieved by using them in successive lines rather than in combination."( New oxaliplatin-based combinations in the treatment of colorectal cancer.
Cassidy, J; Hochster, H, 2003)		0.32
" The approved dosage is 250 mg/body/day without adjustment for physical size such as body surface area (BSA), and the impact of physical size on the efficacy of gefitinib has not been evaluated."( Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
Hayakawa, H; Honda, Y; Hotta, K; Ichihara, E; Kato, Y; Kiura, K; Kudo, K; Minami, D; Sato, A; Tabata, M; Takigawa, N; Tanimoto, M, 2013)		0.88
"Cigarette smoking dosage of ≥ 30 pack-years is an independent negative predictive factor of EGFR-TKI treatment outcome in lung adenocarcinoma patients with activating EGFR mutations."( Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Bae, MK; Cho, BC; Kang, DR; Kim, EY; Kim, HR; Kim, JH; Kim, MH; Lee, CY; Lee, JS, 2014)		0.4
" Inhibitory concentrations on cell proliferation were calculated by non-linear regression analysis using sigmoidal fitting of dose-response curves."( Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells.
Díaz, L; Esparza-López, J; García-Becerra, R; García-Quiroz, J; González-González, ME; Ibarra-Sánchez, MJ; Larrea, F; Martínez-Reza, I; Prado-Garcia, H; Segovia-Mendoza, M, 2015)		0.65
"This phase I open-label trial of a novel gefitinib dosing schedule employed a 3+3 design."( A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer.
Cioffredi, LA; Jackman, DM; Jacobs, L; Johnson, BE; Kesari, S; Lucca, J; Lynch, TJ; Marcoux, PJ; Morse, LK; Plotkin, SR; Rabin, MS; Sharmeen, F, 2015)		0.97
" Eligible patients were randomized to one of the following treatment arms: PCG, P 175 mg/m(2), and C AUC 5 administered intravenously on day 1 intercalated with G 250 mg orally on days 2 through 15 every 3 weeks for four cycles followed by G 250 mg orally until progressive disease; or PC, same dosing schedule for four cycles only."( Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcino
Ahn, JH; Choi, CM; Choi, YJ; Kim, SW; Lee, DH; Lee, JS; Lee, SJ, 2015)		0.65
" The therapeutic window of erlotinib is narrow, and the recommended dosage is close to the maximum tolerable dosage."( Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer.
Ni, J; Zhang, L, 2016)		0.43
"Purpose The approval history, pharmacology, pharmacokinetics, clinical trials, efficacy, dosing recommendations, drug interactions, safety, place in therapy, and economic considerations of gefitinib are reviewed."( Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer.
Bogdanowicz, BS; Hartranft, ME; Hoch, MA, 2017)		0.97
" We confirmed the diagnosis by evaluating the total radiation dosage and by excluding target therapy-induced maculopathy based on a review of the medical literature."( Rapid onset of radiation maculopathy after whole-brain radiation therapy: A case report.
Chang, YH; Chien, KH; Hsu, CR; Tai, MC, 2016)		0.43
" Based on our predictions, dose-adjustment strategies may consist of once-daily dosing erlotinib at 25 mg and gefitinib at 125 mg with darunavir/ritonavir; or erlotinib at 200 mg and gefitinib at 375 mg with etravirine."( Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.
Back, D; Clotet, B; Miranda, C; Moltó, J; Owen, A; Rajoli, R; Siccardi, M; Valle, M, 2017)		0.67
" The average dosage of EGFR-TKI was 56±22% of the standard dosage."( Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC.
Hamaguchi, R; Hasegawa, M; Okamoto, T; Sato, M; Wada, H, 2017)		0.46
" weekly dosing with EGFR inhibitors (gefitinib and lapatinib) and an AKT inhibitor (MK2206) were compared in two rodent breast cancer models."( Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.
Bode, A; Grubbs, CJ; Juliana, MM; Lubet, RA; Moeinpour, F; Steele, VE, 2018)		1.01
" These drawbacks foresight the need to have an alternate dosage form, preferably a sustained release formulation."( Design of Experiments (DoE) Approach to Optimize the Sustained Release Microparticles of Gefitinib.
Gupta, MK; Soni, G; Yadav, KS, 2019)		0.74
" Inhibitory concentrations were determined by non-linear regression analysis using dose-response curves."( ASTEMIZOLE, AN INHIBITOR OF ETHER-À-GO-GO-1 POTASSIUM CHANNEL, INCREASES THE ACTIVITY OF THE TYROSINE KINASE INHIBITOR GEFITINIB IN BREAST CANCER CELLS.
Díaz, L; García-Becerra, R; García-Quiroz, J; González-González, ME; Larrea, F; Ordaz-Rosado, D; Prado-García, H; Segovia-Mendoza, M, 2019)		0.72
" In the present study, we developed a dry powder inhaler dosage form containing gefitinib loaded glucosamine targeted solid lipid nanopaticles (Gef-G-SLNs) to locally transfer anticancer agent to the lung tumor."( Preparation and evaluation of inhalable dry powder containing glucosamine-conjugated gefitinib SLNs for lung cancer therapy.
Mirian, M; Rostami, M; Satari, N; Taymouri, S; Varshosaz, J, 2020)		1.01
" An ad hoc updated analysis of OS was conducted at the protocol-defined cut-off of 48 months from first dosing of the last enrolled patient (13 May 2019)."( Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Chawla, A; Cheng, Y; Corral, J; Lee, KH; Migliorino, MR; Mok, TS; Nakagawa, K; Niho, S; Noonan, K; Pastel, M; Pluzanski, A; Rosell, R; Tang, Y; Wilner, KD; Wu, YL; Zhou, X, 2021)		0.85
" When employed for the analysis of mouse urine, derived from the oral dosing of mice with the EGFR inhibitor gefitinib, we observed more symmetrical LC peaks."( Hybrid organic/inorganic hybrid surface technology for increasing the performance of LC/MS(MS)-based drug metabolite identification studies: Application to gefitinib and metabolites in mouse plasma and urine.
Gethings, LA; King, A; Maker, G; Mullin, LG; Plumb, RS; Trengove, R; Wilson, ID, 2021)		1.03
" The Gef-PY NCs have good water-solubility, non-toxicity (correspond to 1/10 dosage of effective gefitinib (hydrochloride) (Gef·HCl) (normal drug administration and slow-release) and high stability (120 days, 80% drug retention at 4 or 25 °C)."( Constructing a passive targeting and long retention therapeutic nanoplatform based on water-soluble, non-toxic and highly-stable core-shell poly(amino acid) nanocomplexes.
Chen, Y; Deng, B; Hu, J; Li, A; Wang, X; Wu, Q; Yu, M; Zeng, T, 2021)		0.84
" These drug concentrations were selected using physiologically-based pharmacokinetic simulation considering patient dosing regimens."( A Transcriptomic Approach to Elucidate the Mechanisms of Gefitinib-Induced Toxicity in Healthy Human Intestinal Organoids.
Chung, SW; Coyle, L; de Kok, TM; Ferreira, S; Fisher, C; Herpers, B; Jennen, DGJ; Jo, H; Kleinjans, JCS; Rodrigues, D, 2022)		0.97
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
epidermal growth factor receptor antagonistAn antagonist at the epidermal growth factor receptor.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
quinazolinesAny organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.
morpholinesAny compound containing morpholine as part of its structure.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
monofluorobenzenesAny member of the class of fluorobenzenes containing a mono- or poly-substituted benzene ring carrying a single fluorine substitutent.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Gefitinib Action Pathway11
EGFR tyrosine kinase inhibitor resistance03

Protein Targets (539)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency36.78650.002541.796015,848.9004AID1347395; AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency12.35720.006038.004119,952.5996AID1159521; AID1159523
Fumarate hydrataseHomo sapiens (human)Potency29.65350.00308.794948.0869AID1347053
TDP1 proteinHomo sapiens (human)Potency5.30910.000811.382244.6684AID686979
GLI family zinc finger 3Homo sapiens (human)Potency14.14670.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency32.46480.180013.557439.8107AID1460; AID1468
AR proteinHomo sapiens (human)Potency26.58540.000221.22318,912.5098AID1259243; AID1259247; AID743042; AID743054
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency7.49780.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency3.71970.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency27.31160.000417.946075.1148AID1346784; AID1346795
EWS/FLI fusion proteinHomo sapiens (human)Potency30.54010.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency22.85060.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency5.68040.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency16.77800.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency26.60110.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency28.18380.005428.02631,258.9301AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency25.68440.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743078; AID743079; AID743091
cytochrome P450 2D6Homo sapiens (human)Potency4.89750.00108.379861.1304AID1645840
polyproteinZika virusPotency29.65350.00308.794948.0869AID1347053
caspase-3Homo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
aryl hydrocarbon receptorHomo sapiens (human)Potency11.08780.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.53080.001723.839378.1014AID743083
Caspase-7Cricetulus griseus (Chinese hamster)Potency33.49150.006723.496068.5896AID1346980
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency35.48130.01789.637444.6684AID588834
caspase-3Cricetulus griseus (Chinese hamster)Potency33.49150.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency9.34340.000323.4451159.6830AID743065; AID743067
epidermal growth factor receptor isoform a precursorHomo sapiens (human)Potency0.37610.00080.48193.5481AID1727; AID1729; AID1731
tyrosine-protein kinase YesHomo sapiens (human)Potency1.55120.00005.018279.2586AID686947
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency4.73040.000627.21521,122.0200AID743219
gemininHomo sapiens (human)Potency21.59570.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency36.12540.005612.367736.1254AID624032
lamin isoform A-delta10Homo sapiens (human)Potency0.00080.891312.067628.1838AID1487
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency19.95260.316212.765731.6228AID881
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency33.49150.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency26.60320.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency33.49150.001551.739315,848.9004AID1259244
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency19.95260.00638.235039.8107AID881
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency12.58930.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
epidermal growth factor receptor isoform a precursorHomo sapiens (human)IC50 (µMol)0.00400.001016.8616100.0000AID1742
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)IC50 (µMol)50.00000.00010.33717.3000AID507074
Cyclin-G-associated kinaseHomo sapiens (human)IC50 (µMol)0.42000.00100.29721.1000AID1595621
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)4.60000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)10.90000.11007.190310.0000AID1443980; AID1443989; AID1473738
Tyrosine-protein kinase ABL1Homo sapiens (human)IC50 (µMol)1.20000.00010.712810.0000AID507079
Epidermal growth factor receptorHomo sapiens (human)IC50 (µMol)1.32920.00000.536910.0000AID1068982; AID1068983; AID1128932; AID1129567; AID1129568; AID1129569; AID1140573; AID1171419; AID1171420; AID1174871; AID1175520; AID1201369; AID1241286; AID1241287; AID1241288; AID1244850; AID1250365; AID1250380; AID1252466; AID1264286; AID1264287; AID1264288; AID1264289; AID1266267; AID1266268; AID1278392; AID1278393; AID1283992; AID1283993; AID1301349; AID1301350; AID1306574; AID1306576; AID1306577; AID1306580; AID1306581; AID1309512; AID1309514; AID1312557; AID1312564; AID1312565; AID1315978; AID1315982; AID1330924; AID1330931; AID1341757; AID1341758; AID1353459; AID1353460; AID1353461; AID1353462; AID1359917; AID1365576; AID1365577; AID1365578; AID1365583; AID1368035; AID1368036; AID1378273; AID1381744; AID1389969; AID1389971; AID1396811; AID1402963; AID1407099; AID1407100; AID1407101; AID1424192; AID1424193; AID1428362; AID1432775; AID1432776; AID1439619; AID1441910; AID1441911; AID1441912; AID1443455; AID1445468; AID1445469; AID1445470; AID1458976; AID1458977; AID1458978; AID1463973; AID1470863; AID1470864; AID1470939; AID1470940; AID1499606; AID1511366; AID1532891; AID1532893; AID1535423; AID1545469; AID1574929; AID1574930; AID1585919; AID1585920; AID1585964; AID1585970; AID1586911; AID1589887; AID1595620; AID1616555; AID1616556; AID1617466; AID1617467; AID1617468; AID1632290; AID1632301; AID1656985; AID1659246; AID1667574; AID1667575; AID1689697; AID1690749; AID1702615; AID1702616; AID1708302; AID1715796; AID1719558; AID1719559; AID1724046; AID1756967; AID1756968; AID1762240; AID1768123; AID1771675; AID1771676; AID1795774; AID1801080; AID1802936; AID1845392; AID1855769; AID1876161; AID1876269; AID1894146; AID1896772; AID1896773; AID1896774; AID1896775; AID1904122; AID1915705; AID1916784; AID260895; AID260898; AID264807; AID264808; AID271124; AID271125; AID295762; AID295765; AID310063; AID345876; AID371183; AID410943; AID449028; AID456588; AID456904; AID463638; AID489609; AID492109; AID492110; AID507084; AID528338; AID528340; AID580190; AID589577; AID611842; AID634930; AID638084; AID644746; AID66608; AID670513; AID674789; AID69416; AID69892; AID739693; AID740935; AID748091; AID748093; AID748094; AID761601; AID761602; AID761603; AID770081; AID770082; AID770083; AID770794; AID771341; AID771342; AID771345; AID777422; AID777423; AID780347
Epidermal growth factor receptorHomo sapiens (human)Ki0.00040.00000.29533.5000AID512580
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)IC50 (µMol)0.56990.00010.545310.0000AID1068981; AID1171421; AID1250365; AID1266268; AID1306577; AID1312556; AID1312565; AID1315979; AID1330932; AID1428363; AID1574931; AID1632302; AID1656984; AID1667576; AID1676531; AID1795774; AID260896; AID260903; AID410944; AID463639; AID580189; AID638068; AID68106; AID770082; AID91107
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)0.15100.00011.774010.0000AID1574931
Cytochrome P450 2E1Homo sapiens (human)IC50 (µMol)0.46000.01401.68726.2000AID1574930
Insulin receptorHomo sapiens (human)IC50 (µMol)50.00000.00170.847910.0000AID507423
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)IC50 (µMol)1.70000.00010.34843.5970AID507422
ATP-dependent translocase ABCB1Homo sapiens (human)IC50 (µMol)19.97000.00022.318510.0000AID1904130
Tyrosine-protein kinase HCKHomo sapiens (human)IC50 (µMol)0.11000.00011.22267.7000AID507080
Quinolone resistance protein NorAStaphylococcus aureusIC50 (µMol)9.70007.00008.50009.7000AID1460599
Cytochrome P450 2C8Homo sapiens (human)IC50 (µMol)0.15100.00081.88487.9000AID1574931
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)IC50 (µMol)1.10000.00020.533510.0000AID507081
Serine/threonine-protein kinase B-rafHomo sapiens (human)IC50 (µMol)2.00000.00010.28007.5890AID1128931
Receptor tyrosine-protein kinase erbB-3Homo sapiens (human)IC50 (µMol)0.00800.00010.07801.0240AID1250365; AID1266268; AID1306577; AID1312565; AID770082
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)IC50 (µMol)0.28100.00070.97749.7000AID1632302
CruzipainTrypanosoma cruziIC50 (µMol)118.00000.00022.04508.0000AID484274; AID484275
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)0.15100.00002.398310.0000AID1574931
Type-1 angiotensin II receptorOryctolagus cuniculus (rabbit)IC50 (µMol)0.00730.00010.09130.5000AID644746
Vascular endothelial growth factor receptor 2Homo sapiens (human)IC50 (µMol)7.92480.00000.48308.8000AID1389970; AID1802937; AID295769; AID295771; AID507083; AID589578
Mitogen-activated protein kinase kinase kinase 8Homo sapiens (human)IC50 (µMol)1.00000.00163.17869.9500AID1315989
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)IC50 (µMol)50.00000.00000.734010.0000AID507072
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)IC50 (µMol)50.00000.00020.595310.0000AID507073
Serine/threonine-protein kinase mTORHomo sapiens (human)IC50 (µMol)50.00000.00000.857510.0000AID507076
Casein kinase I isoform alphaHomo sapiens (human)IC50 (µMol)50.00000.00102.249910.0000AID507421
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)IC50 (µMol)50.00000.00030.660710.0000AID507075
Tyrosine-protein kinase JAK3Homo sapiens (human)IC50 (µMol)1.00000.00010.41937.9200AID1315989
Ephrin type-B receptor 4Homo sapiens (human)IC50 (µMol)1.00000.00021.07365.1000AID507085
Beta-secretase 1Homo sapiens (human)IC50 (µMol)20.00000.00061.619410.0000AID1307964
DNA-dependent protein kinase catalytic subunitHomo sapiens (human)IC50 (µMol)50.00000.00051.350010.0000AID507077
Synaptic vesicular amine transporterRattus norvegicus (Norway rat)IC50 (µMol)0.00100.00100.01460.1000AID1632301
Transcription factor p65Homo sapiens (human)IC50 (µMol)0.05500.00011.89818.8000AID1689696
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)IC50 (µMol)0.08600.00010.17362.5900AID1250365; AID1266268; AID1306577; AID1312565; AID1315980; AID770082
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC50 (µMol)1.29000.00401.966610.0000AID1057953; AID1873220; AID451987; AID451988; AID678801
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Leukotriene C4 synthaseCavia porcellus (domestic guinea pig)Kd10.00000.93002.54785.7000AID625128
Bone morphogenetic protein receptor type-1BHomo sapiens (human)Kd20.00000.00091.14133.7000AID1424922; AID624825
Cell division cycle 7-related protein kinaseHomo sapiens (human)Kd30.00000.51100.51100.5110AID1424936
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)Kd10.00000.00331.51757.6000AID624974
Serine/threonine-protein kinase PLK4Homo sapiens (human)Kd16.66670.00081.51449.0000AID1425121; AID436044; AID625076
Serine/threonine-protein kinase 25Homo sapiens (human)Kd10.00000.01202.57349.2000AID435329; AID625059
ATP-dependent RNA helicase DDX3XHomo sapiens (human)Kd30.00000.43500.43500.4350AID1424975
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)Kd10.00000.00051.01525.2000AID624877
Pyridoxal kinaseHomo sapiens (human)Kd30.00000.28605.076516.4040AID1425106
Citron Rho-interacting kinaseHomo sapiens (human)Kd10.86670.03303.064648.8760AID1424954; AID435523; AID625065
Serine/threonine-protein kinase RIO3Homo sapiens (human)Kd10.00000.00771.40999.7000AID435191; AID624926
Dual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)Kd10.00000.02701.44715.3000AID624722
Serine/threonine-protein kinase Chk1Homo sapiens (human)Kd16.66670.00281.47448.7000AID1424953; AID435396; AID624831
Inhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)Kd10.00000.01201.58276.3000AID624836
Peripheral plasma membrane protein CASKHomo sapiens (human)Kd10.00000.01900.93302.8000AID624749
Aurora kinase AHomo sapiens (human)Kd16.66670.00010.73429.3000AID1424917; AID435518; AID624919
Cyclin-G-associated kinaseHomo sapiens (human)Kd0.11660.00030.908628.6510AID1205944; AID1425009; AID1595619; AID1638772; AID1673304; AID1876266; AID256612; AID435821; AID625012
Serine/threonine-protein kinase DCLK1Homo sapiens (human)Kd10.00000.00491.83608.1000AID435284; AID624966
Inhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)Kd10.00000.00581.50585.9000AID624832
Muscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)Kd10.00000.00310.61284.1000AID435678; AID625022
Ephrin type-B receptor 6Homo sapiens (human)Kd16.60000.00001.07689.0000AID1424995; AID624957
Peroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)Kd30.00000.02601.31402.6020AID1424896
Mitogen-activated protein kinase 13Homo sapiens (human)Kd10.00000.00011.46676.6000AID624892
3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)Kd10.00000.00171.34323.5000AID435189; AID624876
Mitogen-activated protein kinase kinase kinase 13Homo sapiens (human)Kd10.00000.01600.93165.3000AID624965
Death-associated protein kinase 3Homo sapiens (human)Kd7.13330.00101.82419.9000AID435155; AID435398; AID624834
Mitogen-activated protein kinase kinase kinase 7Homo sapiens (human)Kd10.00000.00151.66608.5000AID624724
Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)Kd0.69070.00201.621211.4330AID1425155; AID256611; AID435935; AID624925
Mitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)Kd30.00000.09401.39103.5070AID1424926
NUAK family SNF1-like kinase 1Homo sapiens (human)Kd10.00000.00370.52145.9000AID435150; AID625088
Dynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)Kd30.00000.01700.36100.7050AID1425097
Phosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)Kd10.00000.01802.48906.7000AID624751
Tyrosine-protein kinase JAK2Homo sapiens (human)Kd16.66670.00000.88517.0000AID1425031; AID435658; AID624973
Rho-associated protein kinase 2Homo sapiens (human)Kd20.00000.00022.710556.0660AID1425158; AID624969
Serine/threonine-protein kinase ULK1Homo sapiens (human)Kd20.00000.00081.841023.2730AID1425208; AID624916
Serine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)Kd20.00000.00572.009512.2010AID1424997; AID624835
Ribosomal protein S6 kinase alpha-5Homo sapiens (human)Kd16.66670.01701.973729.9570AID1425162; AID435831; AID436051; AID624736; AID624967
U5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)Kd30.00001.38201.38201.3820AID1425174
Ribosomal protein S6 kinase alpha-4Homo sapiens (human)Kd12.24000.01201.63967.2000AID1425161; AID435325; AID435441; AID624806; AID624927
Serine/threonine-protein kinase 16Homo sapiens (human)Kd16.66670.00171.24839.9690AID1425179; AID435692; AID624775
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)Kd10.00000.00321.00247.5000AID624958
Serine/threonine-protein kinase PAK 3Homo sapiens (human)Kd10.00000.00051.44835.7000AID435823; AID624873
Cyclin-dependent kinase-like 5Homo sapiens (human)Kd10.00000.00171.47887.3000AID624905
Serine/threonine-protein kinase 17BHomo sapiens (human)Kd4.70000.00482.19829.4000AID256605; AID435401; AID624942
Serine/threonine-protein kinase 10Homo sapiens (human)Kd1.76150.00002.923457.4530AID1425177; AID256604; AID435677; AID625030
Serine/threonine-protein kinase D3Homo sapiens (human)Kd16.66670.00892.273823.3410AID1425137; AID435554; AID625024
Cyclin-dependent kinase 14Homo sapiens (human)Kd10.00000.01600.99203.6000AID435689; AID625070
Structural maintenance of chromosomes protein 2Homo sapiens (human)Kd30.00000.20900.65751.1060AID1425173
Mitogen-activated protein kinase kinase kinase 6Homo sapiens (human)Kd20.00000.17001.57818.0000AID1425050; AID624962
Serine/threonine-protein kinase OSR1Homo sapiens (human)Kd10.00000.04802.34988.0000AID624977
Mitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)Kd16.66670.00822.364562.7720AID1425054; AID435910; AID624756
Serine/threonine-protein kinase LATS1Homo sapiens (human)Kd16.66670.01401.839310.7330AID1425033; AID435529; AID624963
Serine/threonine-protein kinase PAK 4Homo sapiens (human)Kd16.66670.00272.569430.3710AID1425100; AID435929; AID624811
Serine/threonine-protein kinase Chk2Homo sapiens (human)Kd0.80000.00711.27297.7000AID624803
Tyrosine-protein kinase ABL1Homo sapiens (human)Kd6.28740.00001.041113.4530AID1424890; AID435146; AID435514; AID435515; AID435644; AID435775; AID435776; AID435897; AID624978; AID624979; AID624980; AID624981; AID624982; AID624983; AID624984; AID624985; AID624986; AID624987; AID624988; AID624989; AID624990; AID624991; AID624992
Epidermal growth factor receptorHomo sapiens (human)EC50 (µMol)6.44750.00200.99027.9300AID1441913; AID1441914
Epidermal growth factor receptorHomo sapiens (human)Kd0.03600.00011.351420.8270AID1424983; AID1582368; AID1595618; AID1673305; AID1798633; AID1798634; AID1817372; AID256664; AID394660; AID394661; AID394664; AID435156; AID435157; AID435402; AID435525; AID435652; AID435653; AID435791; AID435792; AID435906; AID435907; AID624996; AID624997; AID624998; AID624999; AID625000; AID625001; AID625002; AID625003; AID625004; AID625005; AID625006; AID625007
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)Kd10.00000.00661.14674.4000AID435556; AID624897
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)Kd2.70000.00081.29315.1000AID256662; AID435796; AID624804
High affinity nerve growth factor receptorHomo sapiens (human)Kd10.00000.00201.34849.2000AID435201; AID624808
Guanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)Kd30.00000.18400.18400.1840AID1425011
ADP/ATP translocase 2Homo sapiens (human)Kd30.00000.45100.45100.4510AID1425169
Protein kinase C beta typeHomo sapiens (human)Kd30.00000.00132.708126.3240AID1425130
Insulin receptorHomo sapiens (human)Kd16.66670.00171.08237.9060AID1425026; AID435408; AID624784
Tyrosine-protein kinase LckHomo sapiens (human)Kd8.09000.00021.117424.2210AID1425034; AID256657; AID435676; AID625013
Tyrosine-protein kinase FynHomo sapiens (human)Kd16.66670.00081.42388.4000AID1425008; AID435800; AID624727
Cyclin-dependent kinase 1Homo sapiens (human)Kd30.00000.28801.49523.0490AID1424937
Glycogen phosphorylase, liver formHomo sapiens (human)Kd30.00002.12102.12102.1210AID1425146
Tyrosine-protein kinase Fes/FpsHomo sapiens (human)Kd16.66670.00481.09867.4000AID1425003; AID435161; AID624852
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)Kd10.00000.00060.69938.1000AID435280; AID624995
Adenine phosphoribosyltransferaseHomo sapiens (human)Kd30.00000.02900.02900.0290AID1424914
Tyrosine-protein kinase YesHomo sapiens (human)Kd16.66670.00031.370817.1520AID1425212; AID435328; AID625018
Tyrosine-protein kinase LynHomo sapiens (human)Kd10.66000.00061.04855.7000AID1425037; AID435804; AID624862
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)Kd12.85710.00070.864227.5420AID1425154; AID435323; AID435434; AID625121; AID625122; AID625123; AID625124
Insulin-like growth factor 1 receptorHomo sapiens (human)Kd16.66670.00101.921119.2170AID1425022; AID435164; AID624800
ATP-dependent translocase ABCB1Homo sapiens (human)EC50 (µMol)1.00000.01600.67863.1000AID1904123
Signal recognition particle receptor subunit alphaHomo sapiens (human)Kd30.00000.00800.00800.0080AID1425176
Cytochrome c1, heme protein, mitochondrialHomo sapiens (human)Kd30.00000.20200.20200.2020AID1424969
Hepatocyte growth factor receptorHomo sapiens (human)Kd7.57440.00021.62978.5000AID1425076; AID435312; AID624794; AID624795; AID624796
Tyrosine-protein kinase HCKHomo sapiens (human)Kd12.93330.00032.034315.9930AID1425017; AID435311; AID624857
Proto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)Kd10.00000.00051.17415.8000AID435192; AID624899
Platelet-derived growth factor receptor betaHomo sapiens (human)Kd16.66670.00011.005011.1070AID1425104; AID435926; AID624875
Tyrosine-protein kinase FgrHomo sapiens (human)Kd14.20000.00051.07217.8000AID1425005; AID435798; AID625011
Wee1-like protein kinase 2Homo sapiens (human)Kd10.00000.00392.18749.4000AID624746
Uncharacterized serine/threonine-protein kinase SBK3Homo sapiens (human)Kd10.00000.02501.47395.8000AID624747
Serine/threonine-protein kinase A-RafHomo sapiens (human)Kd30.00000.04709.683233.6550AID1424915
Mast/stem cell growth factor receptor KitHomo sapiens (human)Kd9.38750.00020.81599.8000AID1425032; AID435167; AID435410; AID435411; AID435675; AID435802; AID599957; AID599959; AID624786; AID624787; AID624788; AID624789; AID624790; AID624791; AID624792; AID624793
Glycogen phosphorylase, brain formHomo sapiens (human)Kd30.00003.56903.56903.5690AID1425145
Breakpoint cluster region proteinHomo sapiens (human)Kd30.00000.00301.219617.3640AID1424919
Serine/threonine-protein kinase pim-1Homo sapiens (human)Kd16.66670.00101.139319.3160AID1425111; AID435931; AID624878
Fibroblast growth factor receptor 1Homo sapiens (human)Kd16.66670.00031.55816.2000AID1425004; AID435526; AID625132
DNA topoisomerase 2-alphaHomo sapiens (human)Kd30.00000.06400.27500.4860AID1425202
Myosin light chain kinase, smooth muscleGallus gallus (chicken)Kd10.00000.00200.32031.7000AID435413
Cyclin-dependent kinase 4Homo sapiens (human)Kd16.66670.00331.60508.6000AID1424946; AID624780; AID624781
ADP/ATP translocase 3Homo sapiens (human)Kd30.00000.00600.25050.4950AID1425170
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)Kd10.65000.00021.50779.6000AID1425175; AID256676; AID435195; AID625016
cAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)Kd30.00000.05201.75353.4550AID1425128
Insulin receptor-related proteinHomo sapiens (human)Kd10.00000.00621.38144.6000AID435430; AID625075
Serine/threonine-protein kinase B-rafHomo sapiens (human)Kd14.00000.00021.625826.0180AID1424924; AID435901; AID435902; AID624946; AID624947
Phosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)Kd12.27500.00012.05699.5000AID1425110; AID256618; AID435930; AID624797
Ribosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)Kd30.00000.00406.755688.9030AID1425093
Platelet-derived growth factor receptor alphaHomo sapiens (human)Kd10.00000.00040.70908.8000AID435827; AID625034
Tyrosine-protein kinase FerHomo sapiens (human)Kd16.66670.00141.36048.8000AID1425002; AID435160; AID625010
Protein kinase C alpha typeHomo sapiens (human)Kd30.00000.00031.792221.3520AID1425129
cAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)Kd16.66670.00392.947923.2450AID1425123; AID435932; AID624881
Vascular endothelial growth factor receptor 1 Homo sapiens (human)Kd10.00000.00070.95859.9000AID435429; AID624853
General transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)Kd30.00000.00201.690612.0220AID1424996
Interferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)Kd10.00000.12002.32387.4000AID435555; AID624896
Casein kinase II subunit alpha'Homo sapiens (human)Kd16.66670.00102.530928.8720AID1424968; AID435789; AID624849
Ras-related protein Rab-6AHomo sapiens (human)Kd30.00000.03300.03300.0330AID1425150
Serine/threonine-protein kinase MAKHomo sapiens (human)Kd10.00000.02801.34612.6000AID625025
Cyclin-dependent kinase 11BHomo sapiens (human)Kd10.00000.00840.86792.1000AID435395; AID624708
Ephrin type-A receptor 1Homo sapiens (human)Kd12.66670.00411.80009.8000AID1424987; AID435793; AID625008
Fibroblast growth factor receptor 2Homo sapiens (human)Kd10.00000.03101.15795.5000AID435290; AID625131
Receptor tyrosine-protein kinase erbB-3Homo sapiens (human)Kd0.79000.00082.25459.2000AID624851
Multifunctional protein ADE2Homo sapiens (human)Kd30.00005.48105.48105.4810AID1425098
Fibroblast growth factor receptor 4Homo sapiens (human)Kd10.00000.11002.67737.2000AID435656; AID625130
Fibroblast growth factor receptor 3Homo sapiens (human)Kd10.00000.02301.26526.9000AID435291; AID435527; AID624782; AID624783
cAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)Kd30.00000.00208.557749.2780AID1425125
cAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)Kd20.00000.01300.74084.1000AID1425124; AID435182; AID624882
Ferrochelatase, mitochondrialHomo sapiens (human)Kd3.84100.24306.434367.9140AID1425001; AID1801713
Ribosomal protein S6 kinase beta-1Homo sapiens (human)Kd20.00000.00131.18054.8000AID1425164; AID624906
Tyrosine-protein kinase JAK1Homo sapiens (human)Kd15.00000.00161.21667.8000AID1425030; AID435165; AID624858; AID624859
Protein kinase C eta typeHomo sapiens (human)Kd10.00000.00040.28811.8000AID436034; AID625049
Cyclin-dependent kinase 2Homo sapiens (human)Kd16.66670.00701.517910.4870AID1424944; AID435785; AID624844
Beta-adrenergic receptor kinase 1Homo sapiens (human)Kd30.00000.17005.579122.4940AID1424908
Probable ATP-dependent RNA helicase DDX6Homo sapiens (human)Kd30.00004.10304.10304.1030AID1424977
Activin receptor type-2AHomo sapiens (human)Kd10.00000.01002.07898.9000AID436004; AID624838
Mitogen-activated protein kinase 3 Homo sapiens (human)Kd16.66670.43005.27439.8000AID1425061; AID436016; AID624885
MAP/microtubule affinity-regulating kinase 3Homo sapiens (human)Kd16.66670.00303.968958.2400AID1425069; AID435659; AID624863
Deoxycytidine kinaseHomo sapiens (human)Kd30.00000.01201.08752.1630AID1424970
Mitogen-activated protein kinase 1Homo sapiens (human)Kd16.66670.00012.74417.3000AID1425056; AID435654; AID624713
Ephrin type-A receptor 2Homo sapiens (human)Kd16.66670.00091.07528.1980AID1424988; AID435908; AID624951
Ephrin type-A receptor 3Homo sapiens (human)Kd7.75000.00012.15218.6000AID435794; AID625009
Ephrin type-A receptor 8Homo sapiens (human)Kd1.80000.00021.28757.7000AID435287; AID625120
Ephrin type-B receptor 2Homo sapiens (human)Kd16.66670.00043.153653.1980AID1424992; AID435288; AID625105
Leukocyte tyrosine kinase receptorHomo sapiens (human)Kd7.75000.00102.06317.5000AID435168; AID624743
Non-receptor tyrosine-protein kinase TYK2Homo sapiens (human)Kd15.00000.00091.55758.7000AID1425207; AID435444; AID624912; AID624913
UMP-CMP kinase Homo sapiens (human)Kd30.00000.00300.00450.0060AID1424959
Phosphatidylethanolamine-binding protein 1Homo sapiens (human)Kd30.00000.00300.00300.0030AID1425107
Wee1-like protein kinaseHomo sapiens (human)Kd16.66670.00143.538965.1580AID1425210; AID435204; AID624914
Heme oxygenase 2Homo sapiens (human)Kd30.00000.11900.11900.1190AID1425018
Tyrosine-protein kinase receptor UFOHomo sapiens (human)Kd5.90000.00011.28916.3000AID436007; AID624840
Mitogen-activated protein kinase 4Homo sapiens (human)Kd3.10001.10003.05565.4000AID436017; AID624886
DnaJ homolog subfamily A member 1Homo sapiens (human)Kd30.00000.96200.96200.9620AID1424980
RAC-alpha serine/threonine-protein kinaseHomo sapiens (human)Kd16.66670.00061.06214.4000AID1424910; AID435899; AID624994
RAC-beta serine/threonine-protein kinaseHomo sapiens (human)Kd16.66670.00211.61968.7000AID1424911; AID435517; AID624839
G protein-coupled receptor kinase 4Homo sapiens (human)Kd10.00000.01201.68527.3000AID624739
Dual specificity protein kinase TTKHomo sapiens (human)Kd16.66670.00651.62698.5000AID1425205; AID435203; AID624910
DNA replication licensing factor MCM4Homo sapiens (human)Kd30.00000.62900.62900.6290AID1425072
Prostaglandin G/H synthase 2Homo sapiens (human)Kd10.00000.00901.87258.4000AID625141
Tyrosine-protein kinase receptor Tie-1Homo sapiens (human)Kd10.00000.00031.06455.7000AID435198; AID625017
Vascular endothelial growth factor receptor 3Homo sapiens (human)Kd10.00000.00150.94507.2000AID436018; AID624854
Vascular endothelial growth factor receptor 2Homo sapiens (human)Kd10.00000.00020.80635.7000AID435327; AID624860
Dual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)Kd16.66670.00391.64299.6000AID1425039; AID435169; AID625137
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)Kd5.75380.00020.95599.9000AID1425006; AID435162; AID435310; AID435406; AID435407; AID435799; AID624934; AID624935; AID624936; AID624937; AID624938; AID624939; AID624940
Bone morphogenetic protein receptor type-1AHomo sapiens (human)Kd16.66670.06001.50107.0000AID1424921; AID435276; AID624945
Activin receptor type-1BHomo sapiens (human)Kd16.66670.00401.511015.2580AID1424901; AID435898; AID624943
TGF-beta receptor type-1Homo sapiens (human)Kd16.66670.00502.27859.6000AID1425196; AID435938; AID624961
Serine/threonine-protein kinase receptor R3Homo sapiens (human)Kd10.00000.00291.99369.5000AID435645; AID624778
TGF-beta receptor type-2Homo sapiens (human)Kd16.66670.08001.83516.9000AID1425197; AID435693; AID624909
Electron transfer flavoprotein subunit betaHomo sapiens (human)Kd30.00000.01200.01200.0120AID1424999
Tyrosine-protein kinase CSKHomo sapiens (human)Kd16.66670.00103.457839.5530AID1424960; AID435904; AID624948
Glycine--tRNA ligaseHomo sapiens (human)Kd30.00000.04000.04000.0400AID1425010
Protein kinase C iota typeHomo sapiens (human)Kd20.00000.02609.331651.0180AID1425133; AID624883
Exosome RNA helicase MTR4Homo sapiens (human)Kd30.00002.60702.60702.6070AID1425168
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)Kd10.00000.00060.84627.4000AID435552; AID436033; AID625036; AID625037; AID625038; AID625039; AID625040; AID625041; AID625042; AID625043; AID625044; AID625045
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)Kd10.00000.00170.83166.7000AID625046
Serine/threonine-protein kinase mTORHomo sapiens (human)Kd10.00000.00010.59939.2000AID624972
Megakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)Kd10.00000.26003.07007.7000AID624864
Tyrosine-protein kinase TecHomo sapiens (human)Kd16.66670.00101.00958.7000AID1425193; AID435197; AID624908
Tyrosine-protein kinase TXKHomo sapiens (human)Kd6.00000.00061.91966.0000AID435443; AID624911
Tyrosine-protein kinase ABL2Homo sapiens (human)Kd17.90000.00021.124914.9240AID1424891; AID435777; AID624993
Tyrosine-protein kinase FRKHomo sapiens (human)Kd11.33330.00031.242410.8370AID1425007; AID436019; AID624855
G protein-coupled receptor kinase 6Homo sapiens (human)Kd30.00001.18901.40201.6150AID1425012
Tyrosine-protein kinase ZAP-70Homo sapiens (human)Kd10.00000.01601.68444.2000AID435445; AID624744
Tyrosine-protein kinase SYKHomo sapiens (human)Kd16.66670.00702.00529.2260AID1425188; AID435442; AID624907
26S proteasome regulatory subunit 6BHomo sapiens (human)Kd30.00000.00500.00500.0050AID1425141
Mitogen-activated protein kinase 8Homo sapiens (human)Kd16.66670.01102.096526.0590AID1425063; AID435166; AID624889
Mitogen-activated protein kinase 9Homo sapiens (human)Kd10.77500.00201.45968.1000AID1425064; AID256637; AID435409; AID624717
Dual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)Kd16.66670.00381.62649.9000AID1425041; AID435822; AID624902
Dual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)Kd16.66670.00502.04626.6000AID1425040; AID436022; AID624894
Phosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)Kd30.00000.20803.61257.0170AID1425113
Casein kinase I isoform alphaHomo sapiens (human)Kd20.00000.00102.575619.3520AID1424961; AID624846
Casein kinase I isoform deltaHomo sapiens (human)Kd14.40000.01502.227018.3960AID1424962; AID435524; AID624716
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)Kd10.00000.00261.46028.4000AID624879
MAP kinase-activated protein kinase 2Homo sapiens (human)Kd16.66670.00032.027414.7420AID1425065; AID435180; AID624703
Cyclin-dependent kinase 8Homo sapiens (human)Kd10.00000.00141.29088.0000AID435903; AID624829
Elongation factor Tu, mitochondrialHomo sapiens (human)Kd30.00000.46400.46400.4640AID1425206
Cysteine--tRNA ligase, cytoplasmicHomo sapiens (human)Kd30.00000.01200.33200.6520AID1424932
Casein kinase I isoform epsilonHomo sapiens (human)Kd8.21500.01301.408612.4090AID1424963; AID256644; AID435650; AID624847
Very long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)Kd30.00001.68901.68901.6890AID1424894
Dual specificity protein kinase CLK1Homo sapiens (human)Kd16.66670.00201.879129.8810AID1424955; AID435786; AID624764
Dual specificity protein kinase CLK2Homo sapiens (human)Kd16.66670.00701.13846.5000AID1424956; AID435787; AID624932
Dual specificity protein kinase CLK3Homo sapiens (human)Kd10.00000.01002.44999.0000AID436011; AID624931
Glycogen synthase kinase-3 alphaHomo sapiens (human)Kd16.66670.00602.475422.5430AID1425013; AID435801; AID625114
Glycogen synthase kinase-3 betaHomo sapiens (human)Kd16.66670.00701.00576.1680AID1425014; AID435163; AID624856
Cyclin-dependent kinase 7Homo sapiens (human)Kd13.53670.00251.67837.7000AID1424949; AID435278; AID624845
Cyclin-dependent kinase 9Homo sapiens (human)Kd16.66670.00101.61669.9010AID1424950; AID435279; AID624830
Ras-related protein Rab-27AHomo sapiens (human)Kd30.00004.49304.49304.4930AID1425149
Tyrosine-protein kinase BlkHomo sapiens (human)Kd1.20000.00020.82287.9000AID435646; AID624841
Interleukin-1 receptor-associated kinase 1Homo sapiens (human)Kd15.03450.00611.52528.5000AID1425027; AID624837
Ribosomal protein S6 kinase alpha-3Homo sapiens (human)Kd16.66670.01702.889637.6050AID1425160; AID435558; AID624960
Cytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)Kd10.00000.00141.54897.4000AID435781; AID624842
cAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)Kd10.00000.00721.30665.8000AID436047; AID624976
Serine/threonine-protein kinase Nek2Homo sapiens (human)Kd16.66670.11001.56496.5000AID1425086; AID435665; AID624869
Serine/threonine-protein kinase Nek3Homo sapiens (human)Kd20.00000.17005.936838.0880AID1425087; AID624870
Serine/threonine-protein kinase Nek4Homo sapiens (human)Kd10.00000.46001.53202.7000AID624904
Tyrosine-protein kinase JAK3Homo sapiens (human)Kd10.00000.00021.06888.7000AID435674; AID624785
Dual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)Kd16.66670.00342.39436.5000AID1425043; AID435911; AID624895
Serine/threonine-protein kinase PLK1Homo sapiens (human)Kd16.66670.00010.57115.0000AID1425120; AID435934; AID624975
Death-associated protein kinase 1Homo sapiens (human)Kd10.00000.00141.25424.7000AID435283; AID624971
LIM domain kinase 1Homo sapiens (human)Kd16.66670.02601.784021.0890AID1425035; AID435803; AID624861
LIM domain kinase 2Homo sapiens (human)Kd16.66670.05704.971752.0560AID1425036; AID435294; AID625021
Mitogen-activated protein kinase 12Homo sapiens (human)Kd10.00000.00012.21389.9000AID435438; AID624766
Mitogen-activated protein kinase 10Homo sapiens (human)Kd9.67500.00101.63545.9000AID1425057; AID256636; AID435293; AID624891
Tyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)Kd30.00003.31603.31603.3160AID1425211
5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)Kd30.00000.00601.468110.2120AID1425126
5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)Kd10.00000.01200.77985.0000AID435149; AID625047
Ephrin type-B receptor 3Homo sapiens (human)Kd16.66670.00692.17136.4100AID1424993; AID435159; AID624955
Ephrin type-A receptor 5Homo sapiens (human)Kd13.83330.00021.21005.9000AID1424990; AID435158; AID624737
Ephrin type-B receptor 4Homo sapiens (human)Kd14.16670.00032.167826.3990AID1424994; AID435404; AID624956
Ephrin type-B receptor 1Homo sapiens (human)Kd6.20000.00041.72167.3000AID256590; AID435403; AID624954
Ephrin type-A receptor 4Homo sapiens (human)Kd16.66670.00123.152543.9420AID1424989; AID435795; AID624952
Adenylate kinase 2, mitochondrialHomo sapiens (human)Kd30.00001.03601.03601.0360AID1424909
Adenosine kinaseHomo sapiens (human)Kd30.00000.01301.83683.4930AID1424907
Hormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)Kd10.00000.00372.51399.8000AID625084
Serine/threonine-protein kinase SIK1Homo sapiens (human)Kd10.00000.00221.15303.2000AID435560; AID624733
Receptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)Kd10.00000.01301.55069.8000AID624763
Ras-related protein Rab-10Homo sapiens (human)Kd30.00001.34801.34801.3480AID1425148
Cell division control protein 2 homologPlasmodium falciparum 3D7Kd10.00000.80003.23335.6000AID624760
Actin-related protein 3Homo sapiens (human)Kd30.00000.03602.77355.5110AID1424899
Actin-related protein 2Homo sapiens (human)Kd30.00000.00400.00400.0040AID1424898
Calcium-dependent protein kinase 1Plasmodium falciparum 3D7Kd10.00000.00030.85383.3000AID624759
GTP-binding nuclear protein RanHomo sapiens (human)Kd30.00000.75900.75900.7590AID1425153
Tubulin alpha-1A chainRattus norvegicus (Norway rat)Kd0.41000.02100.89824.9000AID435797
Casein kinase II subunit alphaHomo sapiens (human)Kd10.00000.00061.76357.5000AID436012; AID624848
Phosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)Kd10.00000.01700.86557.8000AID435828; AID624915
SRSF protein kinase 2Homo sapiens (human)Kd10.00000.01500.28031.1000AID435196; AID624768
Casein kinase I isoform gamma-2Homo sapiens (human)Kd16.66670.04601.45066.6000AID1424965; AID435282; AID624833
Mitogen-activated protein kinase kinase kinase 9Homo sapiens (human)Kd10.00000.00352.20939.9000AID435297; AID624706
Serine/threonine-protein kinase PknBMycobacterium tuberculosis H37RvKd10.00000.00321.27245.5000AID624753
Cyclin-dependent kinase 3Homo sapiens (human)Kd16.66670.00803.060263.6140AID1424945; AID435277; AID624828
Cyclin-dependent kinase-like 1Homo sapiens (human)Kd10.00000.01300.73322.1000AID624941
Cyclin-dependent kinase 6Homo sapiens (human)Kd30.00000.03201.20073.3560AID1424948
Cyclin-dependent-like kinase 5 Homo sapiens (human)Kd16.66670.04301.37578.3000AID1424947; AID436010; AID624970
Cyclin-dependent kinase 16Homo sapiens (human)Kd16.66670.00111.585510.0000AID1424941; AID435925; AID625033
Cyclin-dependent kinase 17Homo sapiens (human)Kd16.66670.00100.82335.6000AID1424942; AID435688; AID624776
ATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)Kd30.00000.98300.98300.9830AID1425108
Protein kinase C epsilon typeHomo sapiens (human)Kd10.00000.00020.58498.1000AID435320; AID625014
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)Kd16.66670.00021.13868.7730AID1425038; AID435808; AID624893
Angiopoietin-1 receptorHomo sapiens (human)Kd10.00000.00311.34646.7000AID435939; AID624799
Mitogen-activated protein kinase kinase kinase 10Homo sapiens (human)Kd10.00000.00382.10746.9000AID435432; AID624867
DNA topoisomerase 2-betaHomo sapiens (human)Kd30.00000.14801.22702.5970AID1425203
Protein kinase C theta typeHomo sapiens (human)Kd16.66670.00071.61407.2000AID1425134; AID435321; AID625051
Activin receptor type-1Homo sapiens (human)Kd16.66670.00401.485316.1210AID1424900; AID435274; AID624819
Macrophage-stimulating protein receptorHomo sapiens (human)Kd20.00000.00302.07188.4000AID1425078; AID624868
Focal adhesion kinase 1Homo sapiens (human)Kd16.66670.00051.225513.0390AID1425142; AID435184; AID624729
Protein kinase C delta typeHomo sapiens (human)Kd16.66670.00021.12619.2060AID1425131; AID435553; AID625048
Tyrosine-protein kinase BTKHomo sapiens (human)Kd16.66670.00061.529910.1530AID1424925; AID436008; AID624779
Tyrosine-protein kinase receptor TYRO3Homo sapiens (human)Kd10.00000.00202.20669.3000AID435326; AID625057
Cyclin-dependent kinase 18Homo sapiens (human)Kd10.00000.01401.49418.4000AID435826; AID624874
Activated CDC42 kinase 1Homo sapiens (human)Kd16.66670.00201.71389.6000AID1425201; AID435694; AID624807
Epithelial discoidin domain-containing receptor 1Homo sapiens (human)Kd16.66670.00021.631471.4840AID1424972; AID435400; AID624850
Tyrosine-protein kinase ITK/TSKHomo sapiens (human)Kd10.00000.01300.86005.6000AID435292; AID625020
Myotonin-protein kinaseHomo sapiens (human)Kd6.90000.00352.05287.0000AID435285; AID624950
Mitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)Kd20.00000.00311.468114.0430AID1425052; AID624959
Mitogen-activated protein kinase kinase kinase 12Homo sapiens (human)Kd10.00000.02201.05546.3000AID624762
Tyrosine-protein kinase MerHomo sapiens (human)Kd10.00000.00031.70556.8000AID436023; AID624767
Serine/threonine-protein kinase 4Homo sapiens (human)Kd16.66670.00021.712025.9020AID1425185; AID435433; AID625055
5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)Kd16.66670.00371.891315.3890AID1425122; AID435148; AID624773
Serine/threonine-protein kinase PAK 1Homo sapiens (human)Kd10.00000.00061.62064.4000AID435318; AID624871
Dual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)Kd20.20000.00022.659065.6770AID1425042; AID624721
Mitogen-activated protein kinase 7Homo sapiens (human)Kd16.66670.04202.00739.9000AID1425062; AID435655; AID624888
Serine/threonine-protein kinase PAK 2Homo sapiens (human)Kd20.00000.00312.30456.0000AID1425099; AID435439; AID624872
Serine/threonine-protein kinase 3Homo sapiens (human)Kd16.66670.00021.860217.5260AID1425182; AID435662; AID625054
Mitogen-activated protein kinase kinase kinase 1Homo sapiens (human)Kd20.00000.09702.599512.4730AID1425044; AID625026
cGMP-dependent protein kinase 2Homo sapiens (human)Kd10.00000.00310.83103.6000AID435322; AID625053
Integrin-linked protein kinaseHomo sapiens (human)Kd30.00000.02000.46031.3290AID1425024
Rho-associated protein kinase 1Homo sapiens (human)Kd20.00000.00031.755513.4620AID1425157; AID625015
Non-receptor tyrosine-protein kinase TNK1Homo sapiens (human)Kd16.66670.00181.006411.2690AID1425200; AID435833; AID624930
Serine/threonine-protein kinase PRP4 homologHomo sapiens (human)Kd10.00000.00841.18997.6000AID624750
Receptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)Kd10.00000.02001.14875.4000AID435557; AID624924
Calcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)Kd10.00000.00131.72216.8000AID435394; AID624827
Calcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)Kd16.66670.00051.02097.8000AID1424929; AID435784; AID624731
Calcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)Kd16.66670.00031.504420.3010AID1424928; AID435647; AID624770
Dual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)Kd20.00000.00012.101640.2910AID1424981; AID624712
Activin receptor type-2BHomo sapiens (human)Kd16.66670.00762.73289.9000AID1424902; AID435147; AID624820
Bone morphogenetic protein receptor type-2Homo sapiens (human)Kd16.66670.01902.591714.3770AID1424923; AID435780; AID624826
Protein-tyrosine kinase 6Homo sapiens (human)Kd16.66670.00431.74309.0000AID1425144; AID436049; AID625029
cGMP-dependent protein kinase 1 Homo sapiens (human)Kd16.66670.00160.70723.8000AID1425138; AID435546; AID625052
Cyclin-dependent kinase 13Homo sapiens (human)Kd20.00000.00091.25714.5180AID1424940; AID624761
Calcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)Kd10.00000.02702.29257.0000AID436009; AID624922
Inhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)Kd16.66670.00511.10938.3000AID1425023; AID435657; AID625074
Protein-tyrosine kinase 2-betaHomo sapiens (human)Kd16.66670.00111.945030.4140AID1425143; AID436048; AID624732
Maternal embryonic leucine zipper kinaseHomo sapiens (human)Kd16.66670.00492.283529.9330AID1425074; AID435660; AID625087
Structural maintenance of chromosomes protein 1AHomo sapiens (human)Kd30.00000.36500.36500.3650AID1425172
Chromodomain-helicase-DNA-binding protein 4Homo sapiens (human)Kd30.00000.00300.00300.0030AID1424952
Peroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)Kd30.00000.01400.14250.2710AID1424895
Serine/threonine-protein kinase D1Homo sapiens (human)Kd6.75000.01401.41168.4000AID436045; AID624884
Serine/threonine-protein kinase 38Homo sapiens (human)Kd10.00000.05601.56519.4000AID625067
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)Kd0.41000.00091.25487.0000AID624815
Ribosomal protein S6 kinase alpha-2Homo sapiens (human)Kd10.00000.00892.04219.6000AID435830; AID436050; AID624805; AID625127
Ephrin type-A receptor 7Homo sapiens (human)Kd16.66670.00251.44456.5000AID1424991; AID435286; AID624953
Delta(24)-sterol reductaseHomo sapiens (human)Kd30.00000.43200.43200.4320AID1424978
Ribosomal protein S6 kinase alpha-1Homo sapiens (human)Kd14.00000.02802.528622.7260AID1425159; AID435690; AID435829; AID624900; AID624901
Dual specificity testis-specific protein kinase 1Homo sapiens (human)Kd16.66670.03301.75685.6000AID1425194; AID435937; AID625056
Myosin light chain kinase, smooth muscleHomo sapiens (human)Kd16.66670.00301.20887.9000AID1425081; AID435664; AID624709
Mitogen-activated protein kinase 11Homo sapiens (human)Kd16.66670.00010.46103.7430AID1425058; AID435551; AID624890
Serine/threonine-protein kinase STK11Homo sapiens (human)Kd16.66670.00300.99495.9000AID1425178; AID435909; AID624798
Rhodopsin kinase GRK1Homo sapiens (human)Kd10.00000.00100.68642.2000AID624898
NT-3 growth factor receptorHomo sapiens (human)Kd10.00000.00341.20208.6000AID435202; AID624765
Serine/threonine-protein kinase N1Homo sapiens (human)Kd16.66670.00133.172949.8130AID1425117; AID435319; AID624745
Serine/threonine-protein kinase N2Homo sapiens (human)Kd16.66670.00181.75279.9000AID1425118; AID435933; AID625050
Mitogen-activated protein kinase 14Homo sapiens (human)Kd16.66670.00000.50368.5000AID1425059; AID435181; AID624714
Calcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)Kd16.66670.03001.92155.4600AID1424930; AID435152; AID624843
Mitogen-activated protein kinase kinase kinase 11Homo sapiens (human)Kd16.66670.01101.563917.9840AID1425045; AID435414; AID624866
BDNF/NT-3 growth factors receptorHomo sapiens (human)Kd10.00000.00380.78757.2000AID435564; AID625032
Mitogen-activated protein kinase 6Homo sapiens (human)Kd1.60000.17001.91675.5000AID435289; AID624887
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)Kd3.70000.00041.55897.1000AID436042; AID625035
Discoidin domain-containing receptor 2Homo sapiens (human)Kd16.66670.00301.988842.2800AID1424973; AID435154; AID624777
AP2-associated protein kinase 1Homo sapiens (human)Kd13.25000.00121.370713.7110AID1424889; AID1876267; AID435896; AID625089
Myosin light chain kinase 3Homo sapiens (human)Kd10.00000.00201.618410.4240AID624738
Uncharacterized aarF domain-containing protein kinase 5Homo sapiens (human)Kd30.00000.20200.49900.7960AID1424906
Serine/threonine-protein kinase ULK3Mus musculus (house mouse)Kd1.40000.00301.10383.8000AID256563
Serine/threonine-protein kinase SBK1Homo sapiens (human)Kd0.56000.00320.90484.8000AID624812
Mitogen-activated protein kinase kinase kinase 19Homo sapiens (human)Kd0.24000.00050.84206.4000AID625136
Putative heat shock protein HSP 90-beta 2Homo sapiens (human)Kd30.00002.56602.56602.5660AID1425019
Serine/threonine-protein kinase TNNI3KHomo sapiens (human)Kd10.00000.01101.73457.2000AID435200; AID625097
Leucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)Kd10.00000.00041.20429.7000AID624740; AID624741
Serine/threonine-protein kinase MRCK alphaHomo sapiens (human)Kd20.00000.05704.554714.0200AID1424933; AID436024; AID624920
Serine/threonine-protein kinase MRCK gammaHomo sapiens (human)Kd16.66670.03701.96259.5000AID1424935; AID436013; AID625107
Acyl-CoA dehydrogenase family member 10Homo sapiens (human)Kd33.79500.07801.69973.9570AID1424892
Serine/threonine-protein kinase Nek5Homo sapiens (human)Kd10.00000.01302.41147.3000AID435534; AID624742
Serine/threonine-protein kinase N3Homo sapiens (human)Kd30.00000.09900.73651.3740AID1425119
Serine/threonine-protein kinase ULK3Homo sapiens (human)Kd20.00000.00121.33509.9000AID1425209; AID624818
Dual serine/threonine and tyrosine protein kinaseHomo sapiens (human)Kd10.00000.00531.73376.4000AID624758
Mitogen-activated protein kinase kinase kinase 15Homo sapiens (human)Kd10.00000.00250.99092.8000AID624801
Uncharacterized protein FLJ45252Homo sapiens (human)Kd30.00000.00301.22929.3110AID1425147
Acyl-CoA dehydrogenase family member 11Homo sapiens (human)Kd30.00001.91603.07304.1470AID1424893
Serine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)Kd30.00000.11600.76041.5000AID1424998
Serine/threonine-protein kinase MARK2Homo sapiens (human)Kd16.66670.00011.842511.1030AID1425068; AID435296; AID625106
Serine/threonine-protein kinase TAO1Homo sapiens (human)Kd20.00000.00042.161218.7570AID1425189; AID625126
STE20-related kinase adapter protein alphaHomo sapiens (human)Kd30.00000.31601.72083.6720AID1425186
AarF domain-containing protein kinase 1Homo sapiens (human)Kd30.00000.02303.113722.7470AID1424904
Serine/threonine-protein kinase tousled-like 2Homo sapiens (human)Kd10.00000.01600.90122.6000AID436054; AID624771
Serine/threonine-protein kinase 32CHomo sapiens (human)Kd10.00000.05502.16888.0000AID435834; AID624734
Serine/threonine-protein kinase pim-3Homo sapiens (human)Kd5.80000.00051.34285.8000AID435679; AID624802
Serine/threonine-protein kinase VRK2Homo sapiens (human)Kd10.00000.06301.99334.0000AID625058
Myosin light chain kinase family member 4Homo sapiens (human)Kd10.00000.01500.66593.4000AID435691; AID624809
Homeodomain-interacting protein kinase 1Homo sapiens (human)Kd10.00000.05501.66266.8000AID624726
Calcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)Kd10.00000.00111.85475.9000AID435393; AID625118
Mitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)Kd16.66670.00511.641315.4350AID1425053; AID435295; AID624921
Cyclin-dependent kinase-like 3Homo sapiens (human)Kd10.00000.00391.45495.1000AID624822
MAP kinase-activated protein kinase 5Homo sapiens (human)Kd16.66670.00801.12413.1180AID1425067; AID435806; AID624923
Serine/threonine-protein kinase BRSK2Homo sapiens (human)Kd10.00000.00351.98638.9000AID435783; AID624929
Serine/threonine-protein kinase NIM1Homo sapiens (human)Kd10.00000.14002.61888.7000AID624728
Eukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)Kd30.00000.00300.00300.0030AID1425015
Serine/threonine-protein kinase ULK2Homo sapiens (human)Kd10.00000.00081.08849.9000AID625085
Misshapen-like kinase 1Homo sapiens (human)Kd1.80000.00101.14258.9000AID624813
Serine/threonine-protein kinase DCLK2Homo sapiens (human)Kd10.00000.01601.69074.5000AID435651; AID624814
Calcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)Kd10.00000.00001.14115.1000AID435521; AID625143
Casein kinase I isoform alpha-likeHomo sapiens (human)Kd10.00000.25002.20567.1000AID435281; AID624723
Homeodomain-interacting protein kinase 4Homo sapiens (human)Kd0.31000.00051.33398.1000AID624720
Myosin-IIIaHomo sapiens (human)Kd10.00000.04101.66266.3000AID435170; AID625104
Ankyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)Kd10.00000.03201.65349.4000AID436005; AID624735
Serine/threonine-protein kinase Nek11Homo sapiens (human)Kd10.00000.17001.23503.1000AID624725
Atypical kinase COQ8A, mitochondrialHomo sapiens (human)Kd20.00000.09405.167365.3020AID1424905; AID435516; AID625116
Phosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)Kd18.75000.00302.75228.8000AID1425115; AID625134
Mitogen-activated protein kinase 15Homo sapiens (human)Kd20.00000.00490.68804.5000AID1425060; AID435405; AID624715
Serine/threonine-protein kinase Nek9Homo sapiens (human)Kd20.00000.01602.742819.6170AID1425089; AID435171; AID624704
Serine/threonine-protein kinase BRSK1Homo sapiens (human)Kd10.00000.01402.39248.4000AID435782; AID624702
Serine/threonine-protein kinase 35Homo sapiens (human)Kd10.00000.00200.97065.4000AID624711
Serine/threonine-protein kinase Nek7Homo sapiens (human)Kd16.66670.00303.67198.7000AID1425088; AID435666; AID624754
Rhodopsin kinase GRK7Homo sapiens (human)Kd10.00000.00091.27937.5000AID624719
Serine/threonine-protein kinase 32AHomo sapiens (human)Kd10.00000.01302.20435.5000AID624821
Myosin-IIIbHomo sapiens (human)Kd10.00000.08102.41557.1000AID436032; AID624817
ATP-dependent RNA helicase DDX1Homo sapiens (human)Kd30.00000.08600.08600.0860AID1424974
Dual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)Kd10.00000.02202.36937.6000AID624918
Cyclin-dependent kinase-like 2Homo sapiens (human)Kd10.00000.00051.35195.9000AID624928
Mitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)Kd16.66670.00100.93785.5000AID1425051; AID435431; AID624816
Serine/threonine-protein kinase Sgk3Homo sapiens (human)Kd10.00000.00341.35617.2000AID625073
Atypical kinase COQ8B, mitochondrialHomo sapiens (human)Kd10.00000.02702.32136.1000AID435778; AID625135
Aurora kinase BHomo sapiens (human)Kd16.66670.00201.061422.8520AID1424918; AID435519; AID624772
MAP/microtubule affinity-regulating kinase 4Homo sapiens (human)Kd16.66670.00541.10294.9000AID1425070; AID435924; AID625140
Calcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)Kd10.00000.00101.91486.8000AID435151; AID625119
Serine/threonine-protein kinase Nek1Homo sapiens (human)Kd16.66670.17002.42948.3000AID1425085; AID435533; AID625068
Cyclin-dependent kinase 15Homo sapiens (human)Kd10.00000.03201.88868.6000AID624718
PAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)Kd30.00001.06701.06701.0670AID1425102
Calcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)Kd16.66670.00003.233152.8470AID1424931; AID435648; AID625060
EKC/KEOPS complex subunit TP53RKHomo sapiens (human)Kd30.00000.31101.95193.8400AID1425204
SRSF protein kinase 1Homo sapiens (human)Kd10.00000.00551.08915.2000AID435936; AID624903
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)Kd16.66670.04400.92852.9000AID1425116; AID436043; AID624757
Mitogen-activated protein kinase kinase kinase 5Homo sapiens (human)Kd16.66670.07006.564750.5360AID1425049; AID435412; AID625028
Phosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)Kd10.00000.03601.83819.7000AID435190; AID624824
Mitogen-activated protein kinase kinase kinase 3Homo sapiens (human)Kd16.05000.00601.53319.9000AID1425047; AID624865
Eukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)Kd20.00000.05801.92244.8360AID1424984; AID625080
Serine/threonine-protein kinase RIO1Homo sapiens (human)Kd10.00000.00901.31958.4000AID435324; AID625141
MAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)Kd0.29000.02601.97347.3000AID435661; AID624823
Serine/threonine-protein kinase RIO2Homo sapiens (human)Kd10.00000.04901.76679.1000AID625111
Cyclin-dependent kinase 19Homo sapiens (human)Kd10.00000.00151.92047.2000AID435522; AID625094
Transient receptor potential cation channel subfamily M member 6Homo sapiens (human)Kd10.00000.00790.00790.0079AID625110
Testis-specific serine/threonine-protein kinase 1Homo sapiens (human)Kd10.00000.02402.85776.3000AID435940; AID625142
Serine/threonine-protein kinase 33Homo sapiens (human)Kd10.00000.00181.35424.9000AID436053; AID625138
Nucleolar GTP-binding protein 1Homo sapiens (human)Kd30.00000.00904.10358.1980AID1425016
Serine/threonine-protein kinase D2Homo sapiens (human)Kd16.66670.00812.372325.0190AID1425136; AID436046; AID625102
Serine/threonine-protein kinase DCLK3Homo sapiens (human)Kd6.45000.00451.40116.5000AID435399; AID624707
NUAK family SNF1-like kinase 2Homo sapiens (human)Kd14.86670.00010.67744.6000AID1425095; AID435559; AID625139
RNA cytidine acetyltransferaseHomo sapiens (human)Kd30.00001.24001.24001.2400AID1425083
Serine/threonine-protein kinase SIK2Homo sapiens (human)Kd11.40000.00111.816541.7950AID1425166; AID436052; AID625095
Myosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)Kd1.90000.04301.13125.4000AID435415; AID624705
STE20-like serine/threonine-protein kinase Homo sapiens (human)Kd8.23500.00003.857399.2320AID1425171; AID256578; AID435832; AID625086
Serine/threonine-protein kinase TAO3Homo sapiens (human)Kd20.00000.00022.713114.1960AID1425191; AID625101
Homeodomain-interacting protein kinase 2Homo sapiens (human)Kd10.00000.00731.37395.0000AID625129
Tyrosine-protein kinase SrmsHomo sapiens (human)Kd10.00000.01302.60079.8000AID435561; AID624710
Homeodomain-interacting protein kinase 3Homo sapiens (human)Kd10.00000.00401.70469.7000AID625023
Serine/threonine-protein kinase PLK3Homo sapiens (human)Kd10.00000.00402.90568.5000AID435183; AID624933
dCTP pyrophosphatase 1Homo sapiens (human)Kd30.00000.57301.74033.0540AID1424971
Dual specificity protein kinase CLK4Homo sapiens (human)Kd10.00000.00201.41228.3000AID435788; AID625125
MAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)Kd0.92000.00141.41315.7000AID256576; AID435531; AID625108
Serine/threonine-protein kinase Nek6Homo sapiens (human)Kd10.00000.00631.33854.4000AID435545; AID625079
Casein kinase I isoform gamma-1Homo sapiens (human)Kd16.66670.05302.06225.7000AID1424964; AID435397; AID625128
Serine/threonine-protein kinase PAK 6Homo sapiens (human)Kd16.66670.00041.91949.7000AID1425101; AID435188; AID625115
SNF-related serine/threonine-protein kinaseHomo sapiens (human)Kd10.00000.09000.55201.5000AID624752
Serine/threonine-protein kinase LATS2Homo sapiens (human)Kd10.00000.00101.68798.0000AID436021; AID625083
Serine/threonine-protein kinase 36Homo sapiens (human)Kd7.85000.18002.76518.3000AID435562; AID625096
Phenylalanine--tRNA ligase beta subunitHomo sapiens (human)Kd30.00000.00300.00450.0060AID1425000
Isoleucine--tRNA ligase, mitochondrialHomo sapiens (human)Kd30.00000.01100.01100.0110AID1425020
BMP-2-inducible protein kinaseHomo sapiens (human)Kd16.66670.00222.409756.0320AID1424920; AID435275; AID625109
Obg-like ATPase 1Homo sapiens (human)Kd30.00000.00300.00500.0070AID1425096
Interleukin-1 receptor-associated kinase 4Homo sapiens (human)Kd15.27000.00173.471934.1450AID1425029; AID625098
Serine/threonine-protein kinase 32BHomo sapiens (human)Kd10.00000.02402.70406.4000AID436055; AID625112
Mitogen-activated protein kinase kinase kinase 20Homo sapiens (human)Kd16.66670.00231.703413.6380AID1425213; AID435941; AID624755
Cyclin-dependent kinase 12Homo sapiens (human)Kd30.00000.03201.80325.6350AID1424939
Serine/threonine-protein kinase PLK2Homo sapiens (human)Kd10.00000.00081.80838.3000AID625063
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)Kd30.00003.92003.92003.9200AID1425084
Serine/threonine-protein kinase MARK1Homo sapiens (human)Kd10.00000.00401.26154.9000AID435807; AID625113
Serine/threonine-protein kinase pim-2Homo sapiens (human)Kd16.66670.00190.84155.0000AID1425112; AID435440; AID625064
Serine/threonine-protein kinase PAK 5Homo sapiens (human)Kd10.00000.00120.88013.3000AID435687; AID625117
Serine/threonine-protein kinase 26Homo sapiens (human)Kd16.66670.00741.73808.3000AID1425181; AID435663; AID625103
eIF-2-alpha kinase GCN2Homo sapiens (human)Kd10.00000.00331.18284.4000AID436020; AID624810
Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)Kd30.00000.00700.00700.0070AID1425187
Serine/threonine-protein kinase NLKHomo sapiens (human)Kd14.73330.00601.02264.4000AID1425090; AID435667; AID625100
Phosphatidylinositol 4-kinase betaHomo sapiens (human)Kd10.00000.03901.19823.5000AID624880
Serine/threonine-protein kinase 17AHomo sapiens (human)Kd2.30000.00101.72189.0000AID256568; AID435790; AID624968
STE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)Kd10.00000.13000.98793.7000AID625071
Ephrin type-A receptor 6Homo sapiens (human)Kd0.86000.00111.02559.1000AID256567; AID436015; AID624748
5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)Kd30.00000.00501.15819.1280AID1425127
Serine/threonine-protein kinase TBK1Homo sapiens (human)Kd20.00000.00091.767449.6010AID1425192; AID625072
Septin-9Homo sapiens (human)Kd30.00000.01000.24300.6350AID1425165
Death-associated protein kinase 2Homo sapiens (human)Kd10.00000.00161.12619.1000AID435153; AID625077
Ribosomal protein S6 kinase alpha-6Homo sapiens (human)Kd14.00000.00402.415323.7620AID1425163; AID435193; AID435194; AID625081; AID625082
TRAF2 and NCK-interacting protein kinaseHomo sapiens (human)Kd15.63330.00471.393510.0000AID1425199; AID435563; AID625093
Serine/threonine-protein kinase tousled-like 1Homo sapiens (human)Kd10.00000.02701.05134.0000AID435199; AID625069
Serine/threonine-protein kinase TAO2Homo sapiens (human)Kd20.00000.01002.017612.9420AID1425190; AID625099
Long-chain-fatty-acid--CoA ligase 5Homo sapiens (human)Kd30.00000.00800.63531.6900AID1424897
ALK tyrosine kinase receptorHomo sapiens (human)Kd10.00000.00051.35077.7000AID435779; AID624944
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)EC50 (µMol)0.30000.00540.42203.2000AID1904124
SRSF protein kinase 3Homo sapiens (human)Kd10.00000.01202.11549.3000AID625078
Serine/threonine-protein kinase ICKHomo sapiens (human)Kd20.00000.00071.47179.3000AID1425021; AID625090
Cyclin-dependent kinase 11AHomo sapiens (human)Kd10.00000.00520.66171.3000AID435649; AID625133
Aurora kinase CHomo sapiens (human)Kd10.00000.00131.08488.7000AID436006; AID624769
Calcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)Kd10.00000.00011.69969.6000AID435520; AID624730
RAC-gamma serine/threonine-protein kinaseHomo sapiens (human)Kd16.66670.00251.76466.2000AID1424912; AID435900; AID625019
Serine/threonine-protein kinase 38-likeHomo sapiens (human)Kd10.00000.02801.46926.9000AID436025; AID625092
Microtubule-associated serine/threonine-protein kinase 1Homo sapiens (human)Kd10.00000.01901.54206.2000AID625091
Serine/threonine-protein kinase SIK3Homo sapiens (human)Kd20.00000.00051.508610.3180AID1425167; AID624774
Mitogen-activated protein kinase kinase kinase 2Homo sapiens (human)Kd16.65000.00241.32986.9000AID1425046; AID625062
Thyroid hormone receptor-associated protein 3Homo sapiens (human)Kd30.00002.74602.74602.7460AID1425198
Dual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)Kd10.00000.02801.81299.5000AID436014; AID624964
Mitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)Kd16.66670.00051.949450.2140AID1425055; AID435805; AID625061
Receptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)Kd2.66400.01101.47976.7000AID1425156
Serine/threonine-protein kinase MRCK betaHomo sapiens (human)Kd16.66670.03403.625250.0050AID1424934; AID435912; AID625031
Interleukin-1 receptor-associated kinase 3Homo sapiens (human)Kd11.00000.00701.713725.5810AID1425028; AID435528; AID625066
Serine/threonine-protein kinase 24Homo sapiens (human)Kd16.66670.00650.89204.0840AID1425180; AID435532; AID624917
Casein kinase I isoform gamma-3Homo sapiens (human)Kd16.66670.09702.39788.7000AID1424966; AID435905; AID624949
Mitogen-activated protein kinase kinase kinase 4Homo sapiens (human)Kd16.66670.03902.39708.4000AID1425048; AID435530; AID625027
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3168)

Processvia Protein(s)Taxonomy
positive regulation of gene expressionBone morphogenetic protein receptor type-1BHomo sapiens (human)
cartilage condensationBone morphogenetic protein receptor type-1BHomo sapiens (human)
ovarian cumulus expansionBone morphogenetic protein receptor type-1BHomo sapiens (human)
osteoblast differentiationBone morphogenetic protein receptor type-1BHomo sapiens (human)
eye developmentBone morphogenetic protein receptor type-1BHomo sapiens (human)
chondrocyte developmentBone morphogenetic protein receptor type-1BHomo sapiens (human)
inflammatory responseBone morphogenetic protein receptor type-1BHomo sapiens (human)
central nervous system neuron differentiationBone morphogenetic protein receptor type-1BHomo sapiens (human)
proteoglycan biosynthetic processBone morphogenetic protein receptor type-1BHomo sapiens (human)
positive regulation of bone mineralizationBone morphogenetic protein receptor type-1BHomo sapiens (human)
BMP signaling pathwayBone morphogenetic protein receptor type-1BHomo sapiens (human)
retinal ganglion cell axon guidanceBone morphogenetic protein receptor type-1BHomo sapiens (human)
positive regulation of chondrocyte differentiationBone morphogenetic protein receptor type-1BHomo sapiens (human)
ovulation cycleBone morphogenetic protein receptor type-1BHomo sapiens (human)
positive regulation of osteoblast differentiationBone morphogenetic protein receptor type-1BHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBone morphogenetic protein receptor type-1BHomo sapiens (human)
retina development in camera-type eyeBone morphogenetic protein receptor type-1BHomo sapiens (human)
endochondral bone morphogenesisBone morphogenetic protein receptor type-1BHomo sapiens (human)
positive regulation of cartilage developmentBone morphogenetic protein receptor type-1BHomo sapiens (human)
cellular response to BMP stimulusBone morphogenetic protein receptor type-1BHomo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway via death domain receptorsBone morphogenetic protein receptor type-1BHomo sapiens (human)
negative regulation of chondrocyte proliferationBone morphogenetic protein receptor type-1BHomo sapiens (human)
dorsal/ventral pattern formationBone morphogenetic protein receptor type-1BHomo sapiens (human)
protein phosphorylationBone morphogenetic protein receptor type-1BHomo sapiens (human)
cellular response to growth factor stimulusBone morphogenetic protein receptor type-1BHomo sapiens (human)
G1/S transition of mitotic cell cycleCell division cycle 7-related protein kinaseHomo sapiens (human)
positive regulation of cell population proliferationCell division cycle 7-related protein kinaseHomo sapiens (human)
positive regulation of nuclear cell cycle DNA replicationCell division cycle 7-related protein kinaseHomo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleCell division cycle 7-related protein kinaseHomo sapiens (human)
cell cycle phase transitionCell division cycle 7-related protein kinaseHomo sapiens (human)
cell divisionCell division cycle 7-related protein kinaseHomo sapiens (human)
peptidyl-serine phosphorylationCell division cycle 7-related protein kinaseHomo sapiens (human)
double-strand break repair via break-induced replicationCell division cycle 7-related protein kinaseHomo sapiens (human)
signal transductionCell division cycle 7-related protein kinaseHomo sapiens (human)
phosphorylationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
natural killer cell differentiationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of cytokine productionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of endothelial cell proliferationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
adaptive immune responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
mast cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
respiratory burst involved in defense responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
protein phosphorylationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
inflammatory responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
immune responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of endothelial cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of gene expressionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
T cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
natural killer cell activationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
B cell differentiationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
T cell differentiationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
neutrophil chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of neutrophil apoptotic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
natural killer cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
B cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
vascular endothelial growth factor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
T cell activationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
B cell activationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
mast cell degranulationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
innate immune responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of angiogenesisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
T cell receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
B cell receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
mast cell differentiationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
neutrophil extravasationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of epithelial tube formationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of centriole replicationSerine/threonine-protein kinase PLK4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PLK4Homo sapiens (human)
centriole replicationSerine/threonine-protein kinase PLK4Homo sapiens (human)
positive regulation of centriole replicationSerine/threonine-protein kinase PLK4Homo sapiens (human)
cilium assemblySerine/threonine-protein kinase PLK4Homo sapiens (human)
trophoblast giant cell differentiationSerine/threonine-protein kinase PLK4Homo sapiens (human)
de novo centriole assembly involved in multi-ciliated epithelial cell differentiationSerine/threonine-protein kinase PLK4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 25Homo sapiens (human)
response to oxidative stressSerine/threonine-protein kinase 25Homo sapiens (human)
establishment or maintenance of cell polaritySerine/threonine-protein kinase 25Homo sapiens (human)
signal transductionSerine/threonine-protein kinase 25Homo sapiens (human)
axonogenesisSerine/threonine-protein kinase 25Homo sapiens (human)
positive regulation of stress-activated MAPK cascadeSerine/threonine-protein kinase 25Homo sapiens (human)
cellular response to oxidative stressSerine/threonine-protein kinase 25Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hydrogen peroxideSerine/threonine-protein kinase 25Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 25Homo sapiens (human)
positive regulation of axonogenesisSerine/threonine-protein kinase 25Homo sapiens (human)
Golgi localizationSerine/threonine-protein kinase 25Homo sapiens (human)
establishment of Golgi localizationSerine/threonine-protein kinase 25Homo sapiens (human)
Golgi reassemblySerine/threonine-protein kinase 25Homo sapiens (human)
translational initiationATP-dependent RNA helicase DDX3XHomo sapiens (human)
chromosome segregationATP-dependent RNA helicase DDX3XHomo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsATP-dependent RNA helicase DDX3XHomo sapiens (human)
response to virusATP-dependent RNA helicase DDX3XHomo sapiens (human)
RNA secondary structure unwindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of gene expressionATP-dependent RNA helicase DDX3XHomo sapiens (human)
Wnt signaling pathwayATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of translationATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of cell growthATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of cell growthATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of protein-containing complex assemblyATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of protein autophosphorylationATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of type I interferon productionATP-dependent RNA helicase DDX3XHomo sapiens (human)
DNA duplex unwindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of interferon-alpha productionATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of interferon-beta productionATP-dependent RNA helicase DDX3XHomo sapiens (human)
stress granule assemblyATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of toll-like receptor 7 signaling pathwayATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of toll-like receptor 8 signaling pathwayATP-dependent RNA helicase DDX3XHomo sapiens (human)
intracellular signal transductionATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of translation in response to endoplasmic reticulum stressATP-dependent RNA helicase DDX3XHomo sapiens (human)
cytosolic ribosome assemblyATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of apoptotic processATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of apoptotic processATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of viral genome replicationATP-dependent RNA helicase DDX3XHomo sapiens (human)
innate immune responseATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of translationATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of translational initiationATP-dependent RNA helicase DDX3XHomo sapiens (human)
lipid homeostasisATP-dependent RNA helicase DDX3XHomo sapiens (human)
cellular response to arsenic-containing substanceATP-dependent RNA helicase DDX3XHomo sapiens (human)
cellular response to osmotic stressATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of chemokine (C-C motif) ligand 5 productionATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayATP-dependent RNA helicase DDX3XHomo sapiens (human)
intrinsic apoptotic signaling pathwayATP-dependent RNA helicase DDX3XHomo sapiens (human)
cellular response to virusATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblyATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of protein acetylationATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of protein K63-linked ubiquitinationATP-dependent RNA helicase DDX3XHomo sapiens (human)
protein localization to cytoplasmic stress granuleATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of gene expressionATP-dependent RNA helicase DDX3XHomo sapiens (human)
gamete generationATP-dependent RNA helicase DDX3XHomo sapiens (human)
cell differentiationATP-dependent RNA helicase DDX3XHomo sapiens (human)
biological_processPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
cellular response to starvationPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
autophagosome organizationPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
cell migrationPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
pyridoxal 5'-phosphate salvagePyridoxal kinaseHomo sapiens (human)
pyridoxal metabolic processPyridoxal kinaseHomo sapiens (human)
pyridoxamine metabolic processPyridoxal kinaseHomo sapiens (human)
mitotic cell cycleCitron Rho-interacting kinaseHomo sapiens (human)
mitotic cytokinesisCitron Rho-interacting kinaseHomo sapiens (human)
positive regulation of cytokinesisCitron Rho-interacting kinaseHomo sapiens (human)
negative regulation of hippo signalingCitron Rho-interacting kinaseHomo sapiens (human)
generation of neuronsCitron Rho-interacting kinaseHomo sapiens (human)
neuron apoptotic processCitron Rho-interacting kinaseHomo sapiens (human)
chromosome segregationSerine/threonine-protein kinase RIO3Homo sapiens (human)
maturation of SSU-rRNASerine/threonine-protein kinase RIO3Homo sapiens (human)
negative regulation of protein-containing complex assemblySerine/threonine-protein kinase RIO3Homo sapiens (human)
positive regulation of interferon-beta productionSerine/threonine-protein kinase RIO3Homo sapiens (human)
negative regulation of MDA-5 signaling pathwaySerine/threonine-protein kinase RIO3Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase RIO3Homo sapiens (human)
innate immune responseSerine/threonine-protein kinase RIO3Homo sapiens (human)
positive regulation of innate immune responseSerine/threonine-protein kinase RIO3Homo sapiens (human)
defense response to virusSerine/threonine-protein kinase RIO3Homo sapiens (human)
cellular response to dsRNASerine/threonine-protein kinase RIO3Homo sapiens (human)
cellular response to virusSerine/threonine-protein kinase RIO3Homo sapiens (human)
cellular response to dsDNASerine/threonine-protein kinase RIO3Homo sapiens (human)
apoptotic processDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
response to osmotic stressDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
JNK cascadeDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
response to heatDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
response to UVDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
response to woundingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
response to tumor necrosis factorDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
Fc-epsilon receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of JUN kinase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of JNK cascadeDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
stress-activated MAPK cascadeDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of telomerase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
cellular response to lipopolysaccharideDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
cellular response to interleukin-1Dual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
cellular senescenceDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of telomere cappingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
regulation of motor neuron apoptotic processDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
DNA damage checkpoint signalingSerine/threonine-protein kinase Chk1Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase Chk1Homo sapiens (human)
inner cell mass cell proliferationSerine/threonine-protein kinase Chk1Homo sapiens (human)
DNA replicationSerine/threonine-protein kinase Chk1Homo sapiens (human)
DNA repairSerine/threonine-protein kinase Chk1Homo sapiens (human)
chromatin remodelingSerine/threonine-protein kinase Chk1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Chk1Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase Chk1Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase Chk1Homo sapiens (human)
nucleus organizationSerine/threonine-protein kinase Chk1Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine/threonine-protein kinase Chk1Homo sapiens (human)
regulation of double-strand break repair via homologous recombinationSerine/threonine-protein kinase Chk1Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase Chk1Homo sapiens (human)
regulation of cell population proliferationSerine/threonine-protein kinase Chk1Homo sapiens (human)
signal transduction in response to DNA damageSerine/threonine-protein kinase Chk1Homo sapiens (human)
mitotic G2/M transition checkpointSerine/threonine-protein kinase Chk1Homo sapiens (human)
positive regulation of cell cycleSerine/threonine-protein kinase Chk1Homo sapiens (human)
negative regulation of gene expression, epigeneticSerine/threonine-protein kinase Chk1Homo sapiens (human)
negative regulation of mitotic nuclear divisionSerine/threonine-protein kinase Chk1Homo sapiens (human)
regulation of mitotic centrosome separationSerine/threonine-protein kinase Chk1Homo sapiens (human)
negative regulation of G0 to G1 transitionSerine/threonine-protein kinase Chk1Homo sapiens (human)
cellular response to mechanical stimulusSerine/threonine-protein kinase Chk1Homo sapiens (human)
cellular response to caffeineSerine/threonine-protein kinase Chk1Homo sapiens (human)
replicative senescenceSerine/threonine-protein kinase Chk1Homo sapiens (human)
regulation of signal transduction by p53 class mediatorSerine/threonine-protein kinase Chk1Homo sapiens (human)
apoptotic process involved in developmentSerine/threonine-protein kinase Chk1Homo sapiens (human)
negative regulation of DNA biosynthetic processSerine/threonine-protein kinase Chk1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependentInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
inflammatory responseInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
response to virusInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
peptidyl-serine phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cortical actin cytoskeleton organizationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
toll-like receptor 3 signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
TRIF-dependent toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
Fc-epsilon receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
innate immune responseInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
T cell receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
stress-activated MAPK cascadeInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein maturationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
interleukin-1-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cellular response to tumor necrosis factorInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein localization to plasma membraneInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of establishment of endothelial barrierInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
negative regulation of bicellular tight junction assemblyInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
negative regulation of cell-matrix adhesionPeripheral plasma membrane protein CASKHomo sapiens (human)
cell adhesionPeripheral plasma membrane protein CASKHomo sapiens (human)
negative regulation of keratinocyte proliferationPeripheral plasma membrane protein CASKHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeripheral plasma membrane protein CASKHomo sapiens (human)
GMP metabolic processPeripheral plasma membrane protein CASKHomo sapiens (human)
GDP metabolic processPeripheral plasma membrane protein CASKHomo sapiens (human)
establishment of localization in cellPeripheral plasma membrane protein CASKHomo sapiens (human)
negative regulation of wound healingPeripheral plasma membrane protein CASKHomo sapiens (human)
calcium ion importPeripheral plasma membrane protein CASKHomo sapiens (human)
positive regulation of calcium ion importPeripheral plasma membrane protein CASKHomo sapiens (human)
negative regulation of cellular response to growth factor stimulusPeripheral plasma membrane protein CASKHomo sapiens (human)
regulation of synaptic vesicle exocytosisPeripheral plasma membrane protein CASKHomo sapiens (human)
protein localizationPeripheral plasma membrane protein CASKHomo sapiens (human)
regulation of neurotransmitter secretionPeripheral plasma membrane protein CASKHomo sapiens (human)
protein phosphorylationAurora kinase AHomo sapiens (human)
response to woundingAurora kinase AHomo sapiens (human)
liver regenerationAurora kinase AHomo sapiens (human)
G2/M transition of mitotic cell cycleAurora kinase AHomo sapiens (human)
mitotic cell cycleAurora kinase AHomo sapiens (human)
chromatin remodelingAurora kinase AHomo sapiens (human)
protein phosphorylationAurora kinase AHomo sapiens (human)
apoptotic processAurora kinase AHomo sapiens (human)
spindle organizationAurora kinase AHomo sapiens (human)
spindle assembly involved in female meiosis IAurora kinase AHomo sapiens (human)
mitotic centrosome separationAurora kinase AHomo sapiens (human)
anterior/posterior axis specificationAurora kinase AHomo sapiens (human)
regulation of G2/M transition of mitotic cell cycleAurora kinase AHomo sapiens (human)
negative regulation of gene expressionAurora kinase AHomo sapiens (human)
peptidyl-serine phosphorylationAurora kinase AHomo sapiens (human)
regulation of protein stabilityAurora kinase AHomo sapiens (human)
negative regulation of protein bindingAurora kinase AHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processAurora kinase AHomo sapiens (human)
negative regulation of apoptotic processAurora kinase AHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processAurora kinase AHomo sapiens (human)
positive regulation of mitotic nuclear divisionAurora kinase AHomo sapiens (human)
positive regulation of mitotic cell cycleAurora kinase AHomo sapiens (human)
regulation of centrosome cycleAurora kinase AHomo sapiens (human)
protein autophosphorylationAurora kinase AHomo sapiens (human)
cell divisionAurora kinase AHomo sapiens (human)
centrosome localizationAurora kinase AHomo sapiens (human)
cilium disassemblyAurora kinase AHomo sapiens (human)
protein localization to centrosomeAurora kinase AHomo sapiens (human)
positive regulation of mitochondrial fissionAurora kinase AHomo sapiens (human)
positive regulation of oocyte maturationAurora kinase AHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase AHomo sapiens (human)
neuron projection extensionAurora kinase AHomo sapiens (human)
mitotic spindle organizationAurora kinase AHomo sapiens (human)
regulation of cytokinesisAurora kinase AHomo sapiens (human)
receptor-mediated endocytosisCyclin-G-associated kinaseHomo sapiens (human)
endoplasmic reticulum organizationCyclin-G-associated kinaseHomo sapiens (human)
Golgi organizationCyclin-G-associated kinaseHomo sapiens (human)
negative regulation of neuron projection developmentCyclin-G-associated kinaseHomo sapiens (human)
synaptic vesicle uncoatingCyclin-G-associated kinaseHomo sapiens (human)
protein localization to Golgi apparatusCyclin-G-associated kinaseHomo sapiens (human)
intracellular transportCyclin-G-associated kinaseHomo sapiens (human)
clathrin coat assemblyCyclin-G-associated kinaseHomo sapiens (human)
chaperone cofactor-dependent protein refoldingCyclin-G-associated kinaseHomo sapiens (human)
clathrin coat disassemblyCyclin-G-associated kinaseHomo sapiens (human)
clathrin-dependent endocytosisCyclin-G-associated kinaseHomo sapiens (human)
protein localization to plasma membraneCyclin-G-associated kinaseHomo sapiens (human)
Golgi to lysosome transportCyclin-G-associated kinaseHomo sapiens (human)
regulation of clathrin coat assemblyCyclin-G-associated kinaseHomo sapiens (human)
neuron migrationSerine/threonine-protein kinase DCLK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase DCLK1Homo sapiens (human)
nervous system developmentSerine/threonine-protein kinase DCLK1Homo sapiens (human)
central nervous system developmentSerine/threonine-protein kinase DCLK1Homo sapiens (human)
response to virusSerine/threonine-protein kinase DCLK1Homo sapiens (human)
endosomal transportSerine/threonine-protein kinase DCLK1Homo sapiens (human)
central nervous system projection neuron axonogenesisSerine/threonine-protein kinase DCLK1Homo sapiens (human)
forebrain developmentSerine/threonine-protein kinase DCLK1Homo sapiens (human)
protein localization to nucleusSerine/threonine-protein kinase DCLK1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase DCLK1Homo sapiens (human)
axon extensionSerine/threonine-protein kinase DCLK1Homo sapiens (human)
dendrite morphogenesisSerine/threonine-protein kinase DCLK1Homo sapiens (human)
negative regulation of protein localization to nucleusSerine/threonine-protein kinase DCLK1Homo sapiens (human)
neuron projection morphogenesisSerine/threonine-protein kinase DCLK1Homo sapiens (human)
skeletal muscle contractionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein phosphorylationInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
inflammatory responseInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
immune responseInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
I-kappaB phosphorylationInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
Rho protein signal transductionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to xenobiotic stimulusInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to virusInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to toxic substanceInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
anatomical structure morphogenesisInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to acetateInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
negative regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to lipopolysaccharideInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of interferon-alpha productionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to hydroperoxideInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
toll-like receptor 4 signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cellular response to reactive oxygen speciesInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
non-canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to amino acidInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
innate immune responseInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
striated muscle cell differentiationInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to cholecystokininInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cellular response to cadmium ionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cellular response to tumor necrosis factorInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cellular response to virusInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
peptidyl-serine phosphorylationInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of protein phosphorylationMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
neuromuscular junction developmentMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
memoryMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
regulation of synaptic assembly at neuromuscular junctionMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
positive regulation of gene expressionMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
cell differentiationMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
protein autophosphorylationMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
skeletal muscle acetylcholine-gated channel clusteringMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
positive regulation of protein geranylgeranylationMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
multicellular organism developmentMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
positive regulation of kinase activityMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
positive regulation of neuron projection developmentMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
protein phosphorylationEphrin type-B receptor 6Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-B receptor 6Homo sapiens (human)
axon guidanceEphrin type-B receptor 6Homo sapiens (human)
fatty acid beta-oxidation using acyl-CoA oxidasePeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
lipid homeostasisPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
response to osmotic stressMitogen-activated protein kinase 13Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 13Homo sapiens (human)
positive regulation of interleukin-6 productionMitogen-activated protein kinase 13Homo sapiens (human)
cellular response to UVMitogen-activated protein kinase 13Homo sapiens (human)
positive regulation of inflammatory responseMitogen-activated protein kinase 13Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 13Homo sapiens (human)
cellular response to hydrogen peroxideMitogen-activated protein kinase 13Homo sapiens (human)
cellular response to interleukin-1Mitogen-activated protein kinase 13Homo sapiens (human)
cellular response to sorbitolMitogen-activated protein kinase 13Homo sapiens (human)
cellular response to anisomycinMitogen-activated protein kinase 13Homo sapiens (human)
cellular response to sodium arseniteMitogen-activated protein kinase 13Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 13Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
intracellular signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
type B pancreatic cell development3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein phosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of protein kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
hyperosmotic response3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
epidermal growth factor receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
insulin receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of phospholipase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of cardiac muscle cell apoptotic process3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cell migration3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
calcium-mediated signaling3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
actin cytoskeleton organization3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
T cell costimulation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
activation of protein kinase B activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cellular response to insulin stimulus3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of toll-like receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
regulation of canonical NF-kappaB signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
regulation of mast cell degranulation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of angiogenesis3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein autophosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
insulin-like growth factor receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cellular response to epidermal growth factor stimulus3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
extrinsic apoptotic signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of protein localization to plasma membrane3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of sprouting angiogenesis3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of vascular endothelial cell proliferation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of endothelial cell apoptotic process3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
intracellular signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
positive regulation of neuron maturationMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
positive regulation of axon extensionMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
positive regulation of neuron projection arborizationMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
positive regulation of branching morphogenesis of a nerveMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
chromatin organizationDeath-associated protein kinase 3Homo sapiens (human)
regulation of DNA-templated transcriptionDeath-associated protein kinase 3Homo sapiens (human)
protein phosphorylationDeath-associated protein kinase 3Homo sapiens (human)
apoptotic processDeath-associated protein kinase 3Homo sapiens (human)
regulation of smooth muscle contractionDeath-associated protein kinase 3Homo sapiens (human)
regulation of mitotic nuclear divisionDeath-associated protein kinase 3Homo sapiens (human)
regulation of mitotic cell cycleDeath-associated protein kinase 3Homo sapiens (human)
regulation of cell shapeDeath-associated protein kinase 3Homo sapiens (human)
regulation of autophagyDeath-associated protein kinase 3Homo sapiens (human)
negative regulation of translationDeath-associated protein kinase 3Homo sapiens (human)
positive regulation of cell migrationDeath-associated protein kinase 3Homo sapiens (human)
regulation of actin cytoskeleton organizationDeath-associated protein kinase 3Homo sapiens (human)
intracellular signal transductionDeath-associated protein kinase 3Homo sapiens (human)
regulation of apoptotic processDeath-associated protein kinase 3Homo sapiens (human)
positive regulation of apoptotic processDeath-associated protein kinase 3Homo sapiens (human)
regulation of myosin II filament organizationDeath-associated protein kinase 3Homo sapiens (human)
protein autophosphorylationDeath-associated protein kinase 3Homo sapiens (human)
regulation of focal adhesion assemblyDeath-associated protein kinase 3Homo sapiens (human)
cellular response to type II interferonDeath-associated protein kinase 3Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayDeath-associated protein kinase 3Homo sapiens (human)
apoptotic signaling pathwayDeath-associated protein kinase 3Homo sapiens (human)
regulation of cell motilityDeath-associated protein kinase 3Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of T cell cytokine productionMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
cytoplasmic pattern recognition receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
chromatin remodelingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
inflammatory responseMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
canonical NF-kappaB signal transductionMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
I-kappaB phosphorylationMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
negative regulation of gene expressionMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of macroautophagyMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of interleukin-2 productionMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
toll-like receptor 3 signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
toll-like receptor 4 signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
TRIF-dependent toll-like receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
interleukin-33-mediated signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
interleukin-17A-mediated signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
defense response to bacteriumMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
anoikisMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of cell cycleMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of cell sizeMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
T cell receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
interleukin-1-mediated signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
cellular response to hypoxiaMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
cellular response to angiotensinMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell migrationMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
immune responseMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
toll-like receptor 2 signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of cytokine-mediated signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
adaptive immune responseReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of T-helper 1 type immune responseReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
apoptotic processReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
inflammatory responseReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
signal transductionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
JNK cascadeReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cytokine-mediated signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein ubiquitinationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of chemokine productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of interferon-alpha productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of interferon-beta productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of type II interferon productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of interleukin-1 beta productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of interleukin-12 productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of interleukin-2 productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of interleukin-6 productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of stress-activated MAPK cascadeReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
immature T cell proliferation in thymusReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of immature T cell proliferation in thymusReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
toll-like receptor 4 signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
CD4-positive, alpha-beta T cell proliferationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
defense response to bacteriumReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of apoptotic processReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
response to exogenous dsRNAReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
innate immune responseReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of T-helper 1 cell differentiationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of JNK cascadeReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
defense response to Gram-positive bacteriumReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
T cell receptor signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein homooligomerizationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
stress-activated MAPK cascadeReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of macrophage cytokine productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
ERK1 and ERK2 cascadeReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
nucleotide-binding oligomerization domain containing 1 signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
response to interleukin-1Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
response to interleukin-12Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
response to interleukin-18Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to lipoteichoic acidReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to peptidoglycanReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to muramyl dipeptideReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
activation of cysteine-type endopeptidase activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
xenophagyReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein K63-linked ubiquitinationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of xenophagyReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of CD4-positive, alpha-beta T cell proliferationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
chromatin remodelingMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
apoptotic processMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
chromosome segregationMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
regulation of sister chromatid cohesionMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
mitotic spindle assembly checkpoint signalingMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
cell divisionMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
regulation of chromosome segregationMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
positive regulation of maintenance of mitotic sister chromatid cohesion, centromericMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
meiotic sister chromatid cohesion, centromericMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
protein phosphorylationNUAK family SNF1-like kinase 1Homo sapiens (human)
DNA damage responseNUAK family SNF1-like kinase 1Homo sapiens (human)
cell adhesionNUAK family SNF1-like kinase 1Homo sapiens (human)
regulation of cell adhesionNUAK family SNF1-like kinase 1Homo sapiens (human)
regulation of myosin-light-chain-phosphatase activityNUAK family SNF1-like kinase 1Homo sapiens (human)
regulation of cell population proliferationNUAK family SNF1-like kinase 1Homo sapiens (human)
regulation of signal transduction by p53 class mediatorNUAK family SNF1-like kinase 1Homo sapiens (human)
regulation of cellular senescenceNUAK family SNF1-like kinase 1Homo sapiens (human)
mitochondrion organizationDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial genome maintenanceDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial fissionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
neural tube closureDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
apoptotic processDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrion organizationDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
inner mitochondrial membrane organizationDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
visual perceptionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial fusionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
axonal transport of mitochondrionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-17 productionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
cristae formationDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
negative regulation of apoptotic processDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
GTP metabolic processDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
protein complex oligomerizationDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
membrane fusionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
negative regulation of release of cytochrome c from mitochondriaDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
cellular senescenceDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
membrane tubulationDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane fusionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
positive regulation of T-helper 17 cell lineage commitmentDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
phosphatidylinositol biosynthetic processPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
phagocytosisPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
synaptic vesicle exocytosisPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
actin cytoskeleton organizationPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
neutrophil chemotaxisPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
adherens junction assemblyPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
synaptic vesicle endocytosisPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
membrane organizationPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
clathrin-dependent endocytosisPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
cell-cell adhesionPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
positive regulation of platelet aggregationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of platelet activationTyrosine-protein kinase JAK2Homo sapiens (human)
response to antibioticTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of SMAD protein signal transductionTyrosine-protein kinase JAK2Homo sapiens (human)
microglial cell activationTyrosine-protein kinase JAK2Homo sapiens (human)
adaptive immune responseTyrosine-protein kinase JAK2Homo sapiens (human)
chromatin remodelingTyrosine-protein kinase JAK2Homo sapiens (human)
transcription by RNA polymerase IITyrosine-protein kinase JAK2Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase JAK2Homo sapiens (human)
apoptotic processTyrosine-protein kinase JAK2Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTyrosine-protein kinase JAK2Homo sapiens (human)
immune responseTyrosine-protein kinase JAK2Homo sapiens (human)
signal transductionTyrosine-protein kinase JAK2Homo sapiens (human)
enzyme-linked receptor protein signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
G protein-coupled receptor signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationTyrosine-protein kinase JAK2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK2Homo sapiens (human)
tyrosine phosphorylation of STAT proteinTyrosine-protein kinase JAK2Homo sapiens (human)
mesoderm developmentTyrosine-protein kinase JAK2Homo sapiens (human)
negative regulation of cell population proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressTyrosine-protein kinase JAK2Homo sapiens (human)
negative regulation of cardiac muscle cell apoptotic processTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of cell-substrate adhesionTyrosine-protein kinase JAK2Homo sapiens (human)
response to amineTyrosine-protein kinase JAK2Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase JAK2Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
negative regulation of cell-cell adhesionTyrosine-protein kinase JAK2Homo sapiens (human)
actin filament polymerizationTyrosine-protein kinase JAK2Homo sapiens (human)
cell differentiationTyrosine-protein kinase JAK2Homo sapiens (human)
erythrocyte differentiationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of cell migrationTyrosine-protein kinase JAK2Homo sapiens (human)
axon regenerationTyrosine-protein kinase JAK2Homo sapiens (human)
intracellular mineralocorticoid receptor signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of insulin secretionTyrosine-protein kinase JAK2Homo sapiens (human)
response to lipopolysaccharideTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of type II interferon productionTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of interleukin-1 beta productionTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of interleukin-17 productionTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of tumor necrosis factor productionTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of natural killer cell proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
response to hydroperoxideTyrosine-protein kinase JAK2Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
symbiont-induced defense-related programmed cell deathTyrosine-protein kinase JAK2Homo sapiens (human)
response to tumor necrosis factorTyrosine-protein kinase JAK2Homo sapiens (human)
post-embryonic hemopoiesisTyrosine-protein kinase JAK2Homo sapiens (human)
intracellular signal transductionTyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-12-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
cellular response to interleukin-3Tyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-5-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
collagen-activated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-3-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
granulocyte-macrophage colony-stimulating factor signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of T cell proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of protein import into nucleusTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein kinase JAK2Homo sapiens (human)
activation of Janus kinase activityTyrosine-protein kinase JAK2Homo sapiens (human)
negative regulation of DNA bindingTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of MAPK cascadeTyrosine-protein kinase JAK2Homo sapiens (human)
negative regulation of neuron apoptotic processTyrosine-protein kinase JAK2Homo sapiens (human)
post-translational protein modificationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of MHC class II biosynthetic processTyrosine-protein kinase JAK2Homo sapiens (human)
regulation of nitric oxide biosynthetic processTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of cell differentiationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITyrosine-protein kinase JAK2Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK2Homo sapiens (human)
protein autophosphorylationTyrosine-protein kinase JAK2Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
regulation of inflammatory responseTyrosine-protein kinase JAK2Homo sapiens (human)
modulation of chemical synaptic transmissionTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of NK T cell proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase JAK2Homo sapiens (human)
type II interferon-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
growth hormone receptor signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of growth hormone receptor signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
mammary gland epithelium developmentTyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-6-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of leukocyte proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
response to interleukin-12Tyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-35-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
cellular response to lipopolysaccharideTyrosine-protein kinase JAK2Homo sapiens (human)
cellular response to dexamethasone stimulusTyrosine-protein kinase JAK2Homo sapiens (human)
extrinsic apoptotic signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
cellular response to virusTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of cold-induced thermogenesisTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of growth factor dependent skeletal muscle satellite cell proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of epithelial cell apoptotic processTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
regulation of postsynapse to nucleus signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of signaling receptor activityTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of T-helper 17 type immune responseTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of apoptotic signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
regulation of apoptotic processTyrosine-protein kinase JAK2Homo sapiens (human)
epithelial to mesenchymal transitionRho-associated protein kinase 2Homo sapiens (human)
positive regulation of protein phosphorylationRho-associated protein kinase 2Homo sapiens (human)
response to ischemiaRho-associated protein kinase 2Homo sapiens (human)
aortic valve morphogenesisRho-associated protein kinase 2Homo sapiens (human)
protein phosphorylationRho-associated protein kinase 2Homo sapiens (human)
smooth muscle contractionRho-associated protein kinase 2Homo sapiens (human)
canonical NF-kappaB signal transductionRho-associated protein kinase 2Homo sapiens (human)
positive regulation of endothelial cell migrationRho-associated protein kinase 2Homo sapiens (human)
positive regulation of cardiac muscle hypertrophyRho-associated protein kinase 2Homo sapiens (human)
positive regulation of gene expressionRho-associated protein kinase 2Homo sapiens (human)
negative regulation of gene expressionRho-associated protein kinase 2Homo sapiens (human)
positive regulation of centrosome duplicationRho-associated protein kinase 2Homo sapiens (human)
negative regulation of angiogenesisRho-associated protein kinase 2Homo sapiens (human)
actin cytoskeleton organizationRho-associated protein kinase 2Homo sapiens (human)
regulation of cell adhesionRho-associated protein kinase 2Homo sapiens (human)
positive regulation of cell migrationRho-associated protein kinase 2Homo sapiens (human)
cortical actin cytoskeleton organizationRho-associated protein kinase 2Homo sapiens (human)
regulation of nervous system processRho-associated protein kinase 2Homo sapiens (human)
positive regulation of connective tissue growth factor productionRho-associated protein kinase 2Homo sapiens (human)
regulation of actin cytoskeleton organizationRho-associated protein kinase 2Homo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activityRho-associated protein kinase 2Homo sapiens (human)
regulation of circadian rhythmRho-associated protein kinase 2Homo sapiens (human)
positive regulation of MAPK cascadeRho-associated protein kinase 2Homo sapiens (human)
modulation by host of viral processRho-associated protein kinase 2Homo sapiens (human)
negative regulation of nitric oxide biosynthetic processRho-associated protein kinase 2Homo sapiens (human)
regulation of keratinocyte differentiationRho-associated protein kinase 2Homo sapiens (human)
rhythmic processRho-associated protein kinase 2Homo sapiens (human)
centrosome duplicationRho-associated protein kinase 2Homo sapiens (human)
regulation of stress fiber assemblyRho-associated protein kinase 2Homo sapiens (human)
positive regulation of stress fiber assemblyRho-associated protein kinase 2Homo sapiens (human)
regulation of focal adhesion assemblyRho-associated protein kinase 2Homo sapiens (human)
mRNA destabilizationRho-associated protein kinase 2Homo sapiens (human)
negative regulation of biomineral tissue developmentRho-associated protein kinase 2Homo sapiens (human)
cellular response to testosterone stimulusRho-associated protein kinase 2Homo sapiens (human)
response to transforming growth factor betaRho-associated protein kinase 2Homo sapiens (human)
protein localization to plasma membraneRho-associated protein kinase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionRho-associated protein kinase 2Homo sapiens (human)
blood vessel diameter maintenanceRho-associated protein kinase 2Homo sapiens (human)
regulation of angiotensin-activated signaling pathwayRho-associated protein kinase 2Homo sapiens (human)
negative regulation of protein localization to lysosomeRho-associated protein kinase 2Homo sapiens (human)
regulation of cellular response to hypoxiaRho-associated protein kinase 2Homo sapiens (human)
positive regulation of amyloid-beta formationRho-associated protein kinase 2Homo sapiens (human)
positive regulation of protein localization to early endosomeRho-associated protein kinase 2Homo sapiens (human)
positive regulation of amyloid precursor protein catabolic processRho-associated protein kinase 2Homo sapiens (human)
regulation of establishment of endothelial barrierRho-associated protein kinase 2Homo sapiens (human)
negative regulation of bicellular tight junction assemblyRho-associated protein kinase 2Homo sapiens (human)
cellular response to acetylcholineRho-associated protein kinase 2Homo sapiens (human)
positive regulation of connective tissue replacementRho-associated protein kinase 2Homo sapiens (human)
response to angiotensinRho-associated protein kinase 2Homo sapiens (human)
regulation of establishment of cell polarityRho-associated protein kinase 2Homo sapiens (human)
regulation of cell motilityRho-associated protein kinase 2Homo sapiens (human)
actomyosin structure organizationRho-associated protein kinase 2Homo sapiens (human)
peptidyl-threonine phosphorylationRho-associated protein kinase 2Homo sapiens (human)
mitotic cytokinesisRho-associated protein kinase 2Homo sapiens (human)
embryonic morphogenesisRho-associated protein kinase 2Homo sapiens (human)
regulation of cell junction assemblyRho-associated protein kinase 2Homo sapiens (human)
Rho protein signal transductionRho-associated protein kinase 2Homo sapiens (human)
autophagosome assemblySerine/threonine-protein kinase ULK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagySerine/threonine-protein kinase ULK1Homo sapiens (human)
signal transductionSerine/threonine-protein kinase ULK1Homo sapiens (human)
protein localizationSerine/threonine-protein kinase ULK1Homo sapiens (human)
negative regulation of cell population proliferationSerine/threonine-protein kinase ULK1Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase ULK1Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwaySerine/threonine-protein kinase ULK1Homo sapiens (human)
macroautophagySerine/threonine-protein kinase ULK1Homo sapiens (human)
regulation of macroautophagySerine/threonine-protein kinase ULK1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase ULK1Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase ULK1Homo sapiens (human)
neuron projection regenerationSerine/threonine-protein kinase ULK1Homo sapiens (human)
neuron projection developmentSerine/threonine-protein kinase ULK1Homo sapiens (human)
negative regulation of protein-containing complex assemblySerine/threonine-protein kinase ULK1Homo sapiens (human)
cellular response to nutrient levelsSerine/threonine-protein kinase ULK1Homo sapiens (human)
response to starvationSerine/threonine-protein kinase ULK1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase ULK1Homo sapiens (human)
regulation of protein lipidationSerine/threonine-protein kinase ULK1Homo sapiens (human)
positive regulation of autophagosome assemblySerine/threonine-protein kinase ULK1Homo sapiens (human)
axon extensionSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagy of mitochondrionSerine/threonine-protein kinase ULK1Homo sapiens (human)
reticulophagySerine/threonine-protein kinase ULK1Homo sapiens (human)
piecemeal microautophagy of the nucleusSerine/threonine-protein kinase ULK1Homo sapiens (human)
negative regulation of collateral sproutingSerine/threonine-protein kinase ULK1Homo sapiens (human)
endothelial cell proliferationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
mRNA catabolic processSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
regulation of macroautophagySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
positive regulation of RNA splicingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cellular response to unfolded proteinSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
response to endoplasmic reticulum stressSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
peptidyl-serine autophosphorylationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
IRE1-mediated unfolded protein responseSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
positive regulation of JUN kinase activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
mRNA splicing, via endonucleolytic cleavage and ligationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cellular response to hydrogen peroxideSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cellular response to glucose stimulusSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
positive regulation of endoplasmic reticulum unfolded protein responseSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
insulin metabolic processSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
peptidyl-serine trans-autophosphorylationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
negative regulation of cytokine productionRibosomal protein S6 kinase alpha-5Homo sapiens (human)
chromatin remodelingRibosomal protein S6 kinase alpha-5Homo sapiens (human)
regulation of DNA-templated transcriptionRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein phosphorylationRibosomal protein S6 kinase alpha-5Homo sapiens (human)
inflammatory responseRibosomal protein S6 kinase alpha-5Homo sapiens (human)
axon guidanceRibosomal protein S6 kinase alpha-5Homo sapiens (human)
positive regulation of CREB transcription factor activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
intracellular signal transductionRibosomal protein S6 kinase alpha-5Homo sapiens (human)
post-translational protein modificationRibosomal protein S6 kinase alpha-5Homo sapiens (human)
negative regulation of DNA-templated transcriptionRibosomal protein S6 kinase alpha-5Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRibosomal protein S6 kinase alpha-5Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
interleukin-1-mediated signaling pathwayRibosomal protein S6 kinase alpha-5Homo sapiens (human)
regulation of postsynapse organizationRibosomal protein S6 kinase alpha-5Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-5Homo sapiens (human)
cis assembly of pre-catalytic spliceosomeU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
spliceosome conformational change to release U4 (or U4atac) and U1 (or U11)U5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
mRNA splicing, via spliceosomeU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
osteoblast differentiationU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
negative regulation of cytokine productionRibosomal protein S6 kinase alpha-4Homo sapiens (human)
chromatin remodelingRibosomal protein S6 kinase alpha-4Homo sapiens (human)
regulation of DNA-templated transcriptionRibosomal protein S6 kinase alpha-4Homo sapiens (human)
protein phosphorylationRibosomal protein S6 kinase alpha-4Homo sapiens (human)
inflammatory responseRibosomal protein S6 kinase alpha-4Homo sapiens (human)
positive regulation of CREB transcription factor activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
intracellular signal transductionRibosomal protein S6 kinase alpha-4Homo sapiens (human)
post-translational protein modificationRibosomal protein S6 kinase alpha-4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRibosomal protein S6 kinase alpha-4Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
interleukin-1-mediated signaling pathwayRibosomal protein S6 kinase alpha-4Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine/threonine-protein kinase 16Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 16Homo sapiens (human)
cellular response to transforming growth factor beta stimulusSerine/threonine-protein kinase 16Homo sapiens (human)
chemotaxisPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
modulation by host of viral processPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
cell migrationPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
MAPK cascadeSerine/threonine-protein kinase PAK 3Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathwaySerine/threonine-protein kinase PAK 3Homo sapiens (human)
axonogenesisSerine/threonine-protein kinase PAK 3Homo sapiens (human)
dendrite developmentSerine/threonine-protein kinase PAK 3Homo sapiens (human)
regulation of actin filament polymerizationSerine/threonine-protein kinase PAK 3Homo sapiens (human)
ephrin receptor signaling pathwaySerine/threonine-protein kinase PAK 3Homo sapiens (human)
synapse organizationSerine/threonine-protein kinase PAK 3Homo sapiens (human)
dendritic spine morphogenesisSerine/threonine-protein kinase PAK 3Homo sapiens (human)
cellular response to organic cyclic compoundSerine/threonine-protein kinase PAK 3Homo sapiens (human)
regulation of postsynapse organizationSerine/threonine-protein kinase PAK 3Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase PAK 3Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase PAK 3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 3Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase PAK 3Homo sapiens (human)
regulation of actin cytoskeleton organizationSerine/threonine-protein kinase PAK 3Homo sapiens (human)
neuron migrationCyclin-dependent kinase-like 5Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase-like 5Homo sapiens (human)
positive regulation of GTPase activityCyclin-dependent kinase-like 5Homo sapiens (human)
positive regulation of axon extensionCyclin-dependent kinase-like 5Homo sapiens (human)
protein autophosphorylationCyclin-dependent kinase-like 5Homo sapiens (human)
regulation of dendrite developmentCyclin-dependent kinase-like 5Homo sapiens (human)
positive regulation of dendrite morphogenesisCyclin-dependent kinase-like 5Homo sapiens (human)
modulation of chemical synaptic transmissionCyclin-dependent kinase-like 5Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase-like 5Homo sapiens (human)
positive regulation of dendritic spine developmentCyclin-dependent kinase-like 5Homo sapiens (human)
regulation of postsynapse organizationCyclin-dependent kinase-like 5Homo sapiens (human)
regulation of cilium assemblyCyclin-dependent kinase-like 5Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 17BHomo sapiens (human)
apoptotic processSerine/threonine-protein kinase 17BHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 17BHomo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 17BHomo sapiens (human)
positive regulation of fibroblast apoptotic processSerine/threonine-protein kinase 17BHomo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase 17BHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 10Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 10Homo sapiens (human)
lymphocyte aggregationSerine/threonine-protein kinase 10Homo sapiens (human)
regulation of lymphocyte migrationSerine/threonine-protein kinase 10Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase D3Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwaySerine/threonine-protein kinase D3Homo sapiens (human)
sphingolipid biosynthetic processSerine/threonine-protein kinase D3Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase D3Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySerine/threonine-protein kinase D3Homo sapiens (human)
G2/M transition of mitotic cell cycleCyclin-dependent kinase 14Homo sapiens (human)
Wnt signaling pathwayCyclin-dependent kinase 14Homo sapiens (human)
cell divisionCyclin-dependent kinase 14Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 14Homo sapiens (human)
regulation of canonical Wnt signaling pathwayCyclin-dependent kinase 14Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 14Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
mitotic chromosome condensationStructural maintenance of chromosomes protein 2Homo sapiens (human)
meiotic chromosome condensationStructural maintenance of chromosomes protein 2Homo sapiens (human)
meiotic chromosome segregationStructural maintenance of chromosomes protein 2Homo sapiens (human)
cell divisionStructural maintenance of chromosomes protein 2Homo sapiens (human)
kinetochore organizationStructural maintenance of chromosomes protein 2Homo sapiens (human)
positive regulation of chromosome segregationStructural maintenance of chromosomes protein 2Homo sapiens (human)
positive regulation of chromosome separationStructural maintenance of chromosomes protein 2Homo sapiens (human)
positive regulation of chromosome condensationStructural maintenance of chromosomes protein 2Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
signal transductionMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
cellular response to stressMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase OSR1Homo sapiens (human)
cell volume homeostasisSerine/threonine-protein kinase OSR1Homo sapiens (human)
response to oxidative stressSerine/threonine-protein kinase OSR1Homo sapiens (human)
signal transductionSerine/threonine-protein kinase OSR1Homo sapiens (human)
osmosensory signaling pathwaySerine/threonine-protein kinase OSR1Homo sapiens (human)
response to xenobiotic stimulusSerine/threonine-protein kinase OSR1Homo sapiens (human)
positive regulation of T cell chemotaxisSerine/threonine-protein kinase OSR1Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase OSR1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase OSR1Homo sapiens (human)
chemokine (C-C motif) ligand 21 signaling pathwaySerine/threonine-protein kinase OSR1Homo sapiens (human)
chemokine (C-X-C motif) ligand 12 signaling pathwaySerine/threonine-protein kinase OSR1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase OSR1Homo sapiens (human)
renal sodium ion absorptionSerine/threonine-protein kinase OSR1Homo sapiens (human)
cellular hyperosmotic responseSerine/threonine-protein kinase OSR1Homo sapiens (human)
cellular hypotonic responseSerine/threonine-protein kinase OSR1Homo sapiens (human)
negative regulation of potassium ion transmembrane transportSerine/threonine-protein kinase OSR1Homo sapiens (human)
cellular response to chemokineSerine/threonine-protein kinase OSR1Homo sapiens (human)
negative regulation of potassium ion transmembrane transporter activitySerine/threonine-protein kinase OSR1Homo sapiens (human)
microvillus assemblyMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
negative regulation of cell-matrix adhesionMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of cell migrationMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of ARF protein signal transductionMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of hippo signalingMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
negative regulation of apoptotic processMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of GTPase activityMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
regulation of JNK cascadeMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of keratinocyte migrationMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of focal adhesion assemblyMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of focal adhesion disassemblyMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
regulation of MAPK cascadeMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
neuron projection morphogenesisMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase LATS1Homo sapiens (human)
sister chromatid segregationSerine/threonine-protein kinase LATS1Homo sapiens (human)
inner cell mass cell fate commitmentSerine/threonine-protein kinase LATS1Homo sapiens (human)
inner cell mass cellular morphogenesisSerine/threonine-protein kinase LATS1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase LATS1Homo sapiens (human)
hormone-mediated signaling pathwaySerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of transforming growth factor beta receptor signaling pathwaySerine/threonine-protein kinase LATS1Homo sapiens (human)
keratinocyte differentiationSerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of actin filament polymerizationSerine/threonine-protein kinase LATS1Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of intracellular estrogen receptor signaling pathwaySerine/threonine-protein kinase LATS1Homo sapiens (human)
hippo signalingSerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of protein-containing complex assemblySerine/threonine-protein kinase LATS1Homo sapiens (human)
negative regulation of cyclin-dependent protein serine/threonine kinase activitySerine/threonine-protein kinase LATS1Homo sapiens (human)
cytoplasmic sequestering of proteinSerine/threonine-protein kinase LATS1Homo sapiens (human)
cell divisionSerine/threonine-protein kinase LATS1Homo sapiens (human)
mammary gland epithelial cell differentiationSerine/threonine-protein kinase LATS1Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwaySerine/threonine-protein kinase LATS1Homo sapiens (human)
negative regulation of protein localization to nucleusSerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of ubiquitin-dependent protein catabolic processSerine/threonine-protein kinase LATS1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase LATS1Homo sapiens (human)
G1/S transition of mitotic cell cycleSerine/threonine-protein kinase LATS1Homo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of organ growthSerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of cell growthSerine/threonine-protein kinase PAK 4Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cytoskeleton organizationSerine/threonine-protein kinase PAK 4Homo sapiens (human)
signal transductionSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cell migrationSerine/threonine-protein kinase PAK 4Homo sapiens (human)
positive regulation of angiogenesisSerine/threonine-protein kinase PAK 4Homo sapiens (human)
dendritic spine developmentSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cellular response to organic cyclic compoundSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cell-cell adhesionSerine/threonine-protein kinase PAK 4Homo sapiens (human)
negative regulation of endothelial cell apoptotic processSerine/threonine-protein kinase PAK 4Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase PAK 4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 4Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase PAK 4Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase Chk2Homo sapiens (human)
signal transduction in response to DNA damageSerine/threonine-protein kinase Chk2Homo sapiens (human)
DNA damage checkpoint signalingSerine/threonine-protein kinase Chk2Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase Chk2Homo sapiens (human)
double-strand break repairSerine/threonine-protein kinase Chk2Homo sapiens (human)
regulation of DNA-templated transcriptionSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Chk2Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase Chk2Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestSerine/threonine-protein kinase Chk2Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorSerine/threonine-protein kinase Chk2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein catabolic processSerine/threonine-protein kinase Chk2Homo sapiens (human)
mitotic intra-S DNA damage checkpoint signalingSerine/threonine-protein kinase Chk2Homo sapiens (human)
regulation of protein catabolic processSerine/threonine-protein kinase Chk2Homo sapiens (human)
signal transduction in response to DNA damageSerine/threonine-protein kinase Chk2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorSerine/threonine-protein kinase Chk2Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase Chk2Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Chk2Homo sapiens (human)
thymocyte apoptotic processSerine/threonine-protein kinase Chk2Homo sapiens (human)
cellular response to gamma radiationSerine/threonine-protein kinase Chk2Homo sapiens (human)
mitotic spindle assemblySerine/threonine-protein kinase Chk2Homo sapiens (human)
replicative senescenceSerine/threonine-protein kinase Chk2Homo sapiens (human)
regulation of signal transduction by p53 class mediatorSerine/threonine-protein kinase Chk2Homo sapiens (human)
regulation of autophagosome assemblySerine/threonine-protein kinase Chk2Homo sapiens (human)
mitotic DNA damage checkpoint signalingSerine/threonine-protein kinase Chk2Homo sapiens (human)
response to oxidative stressTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of ubiquitin-protein transferase activityTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of phospholipase C activityTyrosine-protein kinase ABL1Homo sapiens (human)
mitotic cell cycleTyrosine-protein kinase ABL1Homo sapiens (human)
neural tube closureTyrosine-protein kinase ABL1Homo sapiens (human)
B-1 B cell homeostasisTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of protein phosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
B cell proliferation involved in immune responseTyrosine-protein kinase ABL1Homo sapiens (human)
transitional one stage B cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
mismatch repairTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of DNA-templated transcriptionTyrosine-protein kinase ABL1Homo sapiens (human)
autophagyTyrosine-protein kinase ABL1Homo sapiens (human)
DNA damage responseTyrosine-protein kinase ABL1Homo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
canonical NF-kappaB signal transductionTyrosine-protein kinase ABL1Homo sapiens (human)
associative learningTyrosine-protein kinase ABL1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageTyrosine-protein kinase ABL1Homo sapiens (human)
response to xenobiotic stimulusTyrosine-protein kinase ABL1Homo sapiens (human)
post-embryonic developmentTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of autophagyTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of endothelial cell migrationTyrosine-protein kinase ABL1Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
cerebellum morphogenesisTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of cell-cell adhesionTyrosine-protein kinase ABL1Homo sapiens (human)
microspike assemblyTyrosine-protein kinase ABL1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein kinase ABL1Homo sapiens (human)
actin filament polymerizationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of endocytosisTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of cell adhesionTyrosine-protein kinase ABL1Homo sapiens (human)
neuron differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
BMP signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of BMP signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of axon extensionTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of microtubule polymerizationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of Cdc42 protein signal transductionTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of type II interferon productionTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of interleukin-2 productionTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of actin cytoskeleton organizationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of osteoblast proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
substrate adhesion-dependent cell spreadingTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to oxidative stressTyrosine-protein kinase ABL1Homo sapiens (human)
response to endoplasmic reticulum stressTyrosine-protein kinase ABL1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
protein modification processTyrosine-protein kinase ABL1Homo sapiens (human)
peptidyl-tyrosine autophosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase ABL1Homo sapiens (human)
neuropilin signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
signal transduction in response to DNA damageTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of neuron apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
endothelial cell migrationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of T cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of vasoconstrictionTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of mitotic cell cycleTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of mitotic cell cycleTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITyrosine-protein kinase ABL1Homo sapiens (human)
alpha-beta T cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
protein autophosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of fibroblast proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
spleen developmentTyrosine-protein kinase ABL1Homo sapiens (human)
thymus developmentTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
activated T cell proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
neuromuscular process controlling balanceTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of oxidoreductase activityTyrosine-protein kinase ABL1Homo sapiens (human)
neuron apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of ubiquitin-protein transferase activityTyrosine-protein kinase ABL1Homo sapiens (human)
myoblast proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of stress fiber assemblyTyrosine-protein kinase ABL1Homo sapiens (human)
establishment of localization in cellTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of cell cycleTyrosine-protein kinase ABL1Homo sapiens (human)
mitochondrial depolarizationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of focal adhesion assemblyTyrosine-protein kinase ABL1Homo sapiens (human)
Bergmann glial cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
cardiac muscle cell proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
neuroepithelial cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to hydrogen peroxideTyrosine-protein kinase ABL1Homo sapiens (human)
ERK1 and ERK2 cascadeTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase ABL1Homo sapiens (human)
DNA conformation changeTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to lipopolysaccharideTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to transforming growth factor beta stimulusTyrosine-protein kinase ABL1Homo sapiens (human)
response to epinephrineTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of protein serine/threonine kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisTyrosine-protein kinase ABL1Homo sapiens (human)
cellular senescenceTyrosine-protein kinase ABL1Homo sapiens (human)
cell-cell adhesionTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of dendrite developmentTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of long-term synaptic potentiationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of hematopoietic stem cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of extracellular matrix organizationTyrosine-protein kinase ABL1Homo sapiens (human)
podocyte apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to dopamineTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of establishment of T cell polarityTyrosine-protein kinase ABL1Homo sapiens (human)
DN4 thymocyte differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
protein localization to cytoplasmic microtubule plus-endTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of microtubule bindingTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of actin filament bindingTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of modification of synaptic structureTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of blood vessel branchingTyrosine-protein kinase ABL1Homo sapiens (human)
activation of protein kinase C activityTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of double-strand break repair via homologous recombinationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of Wnt signaling pathway, planar cell polarity pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of cell motilityTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of endothelial cell apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of T cell migrationTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of cellular senescenceTyrosine-protein kinase ABL1Homo sapiens (human)
epidermal growth factor receptor signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
cell surface receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
MAPK cascadeEpidermal growth factor receptorHomo sapiens (human)
ossificationEpidermal growth factor receptorHomo sapiens (human)
embryonic placenta developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationEpidermal growth factor receptorHomo sapiens (human)
hair follicle developmentEpidermal growth factor receptorHomo sapiens (human)
translationEpidermal growth factor receptorHomo sapiens (human)
signal transductionEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
activation of phospholipase C activityEpidermal growth factor receptorHomo sapiens (human)
salivary gland morphogenesisEpidermal growth factor receptorHomo sapiens (human)
midgut developmentEpidermal growth factor receptorHomo sapiens (human)
learning or memoryEpidermal growth factor receptorHomo sapiens (human)
circadian rhythmEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
diterpenoid metabolic processEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
cerebral cortex cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell growthEpidermal growth factor receptorHomo sapiens (human)
lung developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of superoxide anion generationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
response to cobalaminEpidermal growth factor receptorHomo sapiens (human)
response to hydroxyisoflavoneEpidermal growth factor receptorHomo sapiens (human)
cellular response to reactive oxygen speciesEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
ERBB2-EGFR signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of protein catabolic processEpidermal growth factor receptorHomo sapiens (human)
vasodilationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphorylationEpidermal growth factor receptorHomo sapiens (human)
ovulation cycleEpidermal growth factor receptorHomo sapiens (human)
hydrogen peroxide metabolic processEpidermal growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processEpidermal growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityEpidermal growth factor receptorHomo sapiens (human)
tongue developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA repairEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA replicationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of bone resorptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of vasoconstrictionEpidermal growth factor receptorHomo sapiens (human)
negative regulation of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEpidermal growth factor receptorHomo sapiens (human)
regulation of JNK cascadeEpidermal growth factor receptorHomo sapiens (human)
symbiont entry into host cellEpidermal growth factor receptorHomo sapiens (human)
protein autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
astrocyte activationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEpidermal growth factor receptorHomo sapiens (human)
digestive tract morphogenesisEpidermal growth factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationEpidermal growth factor receptorHomo sapiens (human)
neuron projection morphogenesisEpidermal growth factor receptorHomo sapiens (human)
epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
protein insertion into membraneEpidermal growth factor receptorHomo sapiens (human)
response to calcium ionEpidermal growth factor receptorHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicEpidermal growth factor receptorHomo sapiens (human)
positive regulation of glial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
morphogenesis of an epithelial foldEpidermal growth factor receptorHomo sapiens (human)
eyelid development in camera-type eyeEpidermal growth factor receptorHomo sapiens (human)
response to UV-AEpidermal growth factor receptorHomo sapiens (human)
positive regulation of mucus secretionEpidermal growth factor receptorHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
cellular response to amino acid stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to mechanical stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to cadmium ionEpidermal growth factor receptorHomo sapiens (human)
cellular response to epidermal growth factor stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to estradiol stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to xenobiotic stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to dexamethasone stimulusEpidermal growth factor receptorHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
liver regenerationEpidermal growth factor receptorHomo sapiens (human)
cell-cell adhesionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein kinase C activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of prolactin secretionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of miRNA transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein localization to plasma membraneEpidermal growth factor receptorHomo sapiens (human)
negative regulation of cardiocyte differentiationEpidermal growth factor receptorHomo sapiens (human)
neurogenesisEpidermal growth factor receptorHomo sapiens (human)
multicellular organism developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of kinase activityEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
apoptotic processRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
protein phosphorylationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
signal transductionRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
activation of adenylate cyclase activityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of cell population proliferationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
insulin receptor signaling pathwayRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
Schwann cell developmentRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
thyroid gland developmentRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of protein-containing complex assemblyRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
somatic stem cell population maintenanceRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
regulation of Rho protein signal transductionRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
insulin secretion involved in cellular response to glucose stimulusRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
response to muscle stretchRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
ERBB2-ERBB3 signaling pathwayRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
wound healingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
myelinationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
regulation of apoptotic processRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of apoptotic processRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of MAPK cascadeRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
type B pancreatic cell proliferationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
intermediate filament cytoskeleton organizationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
regulation of cell differentiationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
neurotrophin TRK receptor signaling pathwayRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
thymus developmentRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
face developmentRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
type II interferon-mediated signaling pathwayRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
death-inducing signaling complex assemblyRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
regulation of cell motilityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
MAPK cascadeRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
cell surface receptor signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of protein phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
enzyme-linked receptor protein signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
heart developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuromuscular junction developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
motor neuron axon guidanceReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
Schwann cell developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
peptidyl-tyrosine phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell growthReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of microtubule-based processReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
immature T cell proliferation in thymusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
negative regulation of immature T cell proliferation in thymusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of Rho protein signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
intracellular signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-EGFR signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
wound healingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
myelinationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of MAP kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of translationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of angiogenesisReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell adhesionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
oligodendrocyte differentiationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of epithelial cell proliferationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cellular response to growth factor stimulusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cellular response to epidermal growth factor stimulusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
semaphorin-plexin signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of protein targeting to membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neurogenesisReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of MAPK cascadeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
negative regulation of apoptotic processReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
multicellular organism developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuron differentiationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cellular response to amyloid-betaHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationHigh affinity nerve growth factor receptorHomo sapiens (human)
protein phosphorylationHigh affinity nerve growth factor receptorHomo sapiens (human)
axon guidanceHigh affinity nerve growth factor receptorHomo sapiens (human)
learning or memoryHigh affinity nerve growth factor receptorHomo sapiens (human)
circadian rhythmHigh affinity nerve growth factor receptorHomo sapiens (human)
negative regulation of cell population proliferationHigh affinity nerve growth factor receptorHomo sapiens (human)
response to xenobiotic stimulusHigh affinity nerve growth factor receptorHomo sapiens (human)
programmed cell death involved in cell developmentHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of neuron projection developmentHigh affinity nerve growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationHigh affinity nerve growth factor receptorHomo sapiens (human)
olfactory nerve developmentHigh affinity nerve growth factor receptorHomo sapiens (human)
B cell differentiationHigh affinity nerve growth factor receptorHomo sapiens (human)
response to nutrient levelsHigh affinity nerve growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationHigh affinity nerve growth factor receptorHomo sapiens (human)
nerve growth factor signaling pathwayHigh affinity nerve growth factor receptorHomo sapiens (human)
mechanoreceptor differentiationHigh affinity nerve growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of programmed cell deathHigh affinity nerve growth factor receptorHomo sapiens (human)
negative regulation of neuron apoptotic processHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of GTPase activityHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of Ras protein signal transductionHigh affinity nerve growth factor receptorHomo sapiens (human)
protein autophosphorylationHigh affinity nerve growth factor receptorHomo sapiens (human)
neurotrophin TRK receptor signaling pathwayHigh affinity nerve growth factor receptorHomo sapiens (human)
ephrin receptor signaling pathwayHigh affinity nerve growth factor receptorHomo sapiens (human)
sympathetic nervous system developmentHigh affinity nerve growth factor receptorHomo sapiens (human)
response to axon injuryHigh affinity nerve growth factor receptorHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of painHigh affinity nerve growth factor receptorHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityHigh affinity nerve growth factor receptorHomo sapiens (human)
neuron apoptotic processHigh affinity nerve growth factor receptorHomo sapiens (human)
response to hydrostatic pressureHigh affinity nerve growth factor receptorHomo sapiens (human)
response to electrical stimulusHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of synapse assemblyHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicHigh affinity nerve growth factor receptorHomo sapiens (human)
Sertoli cell developmentHigh affinity nerve growth factor receptorHomo sapiens (human)
axonogenesis involved in innervationHigh affinity nerve growth factor receptorHomo sapiens (human)
behavioral response to formalin induced painHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeHigh affinity nerve growth factor receptorHomo sapiens (human)
cellular response to nicotineHigh affinity nerve growth factor receptorHomo sapiens (human)
cellular response to nerve growth factor stimulusHigh affinity nerve growth factor receptorHomo sapiens (human)
multicellular organism developmentHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of kinase activityHigh affinity nerve growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionHigh affinity nerve growth factor receptorHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
signal transductionGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
negative regulation of adenylate cyclase activityGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
response to nutrientGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
cell population proliferationGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of cell population proliferationGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of cell migrationGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of superoxide anion generationGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of urine volumeGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
negative regulation of calcium ion-dependent exocytosisGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of insulin receptor signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
negative regulation of synaptic transmissionGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
cell divisionGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
regulation of calcium ion transportGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathway involved in heart processGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of neural precursor cell proliferationGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
negative regulation of apoptotic signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
chromosome segregationADP/ATP translocase 2Homo sapiens (human)
positive regulation of cell population proliferationADP/ATP translocase 2Homo sapiens (human)
adenine transportADP/ATP translocase 2Homo sapiens (human)
B cell differentiationADP/ATP translocase 2Homo sapiens (human)
erythrocyte differentiationADP/ATP translocase 2Homo sapiens (human)
regulation of mitochondrial membrane permeabilityADP/ATP translocase 2Homo sapiens (human)
adenine nucleotide transportADP/ATP translocase 2Homo sapiens (human)
mitochondrial ADP transmembrane transportADP/ATP translocase 2Homo sapiens (human)
negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayADP/ATP translocase 2Homo sapiens (human)
positive regulation of mitophagyADP/ATP translocase 2Homo sapiens (human)
proton transmembrane transportADP/ATP translocase 2Homo sapiens (human)
mitochondrial ATP transmembrane transportADP/ATP translocase 2Homo sapiens (human)
cellular response to leukemia inhibitory factorADP/ATP translocase 2Homo sapiens (human)
adaptive thermogenesisADP/ATP translocase 2Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2E1Homo sapiens (human)
lipid hydroxylationCytochrome P450 2E1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2E1Homo sapiens (human)
steroid metabolic processCytochrome P450 2E1Homo sapiens (human)
response to bacteriumCytochrome P450 2E1Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2E1Homo sapiens (human)
carbon tetrachloride metabolic processCytochrome P450 2E1Homo sapiens (human)
benzene metabolic processCytochrome P450 2E1Homo sapiens (human)
4-nitrophenol metabolic processCytochrome P450 2E1Homo sapiens (human)
halogenated hydrocarbon metabolic processCytochrome P450 2E1Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2E1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2E1Homo sapiens (human)
adaptive immune responseProtein kinase C beta typeHomo sapiens (human)
chromatin remodelingProtein kinase C beta typeHomo sapiens (human)
regulation of transcription by RNA polymerase IIProtein kinase C beta typeHomo sapiens (human)
protein phosphorylationProtein kinase C beta typeHomo sapiens (human)
calcium ion transportProtein kinase C beta typeHomo sapiens (human)
intracellular calcium ion homeostasisProtein kinase C beta typeHomo sapiens (human)
apoptotic processProtein kinase C beta typeHomo sapiens (human)
mitotic nuclear membrane disassemblyProtein kinase C beta typeHomo sapiens (human)
signal transductionProtein kinase C beta typeHomo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
response to xenobiotic stimulusProtein kinase C beta typeHomo sapiens (human)
response to glucoseProtein kinase C beta typeHomo sapiens (human)
regulation of glucose transmembrane transportProtein kinase C beta typeHomo sapiens (human)
negative regulation of glucose transmembrane transportProtein kinase C beta typeHomo sapiens (human)
regulation of dopamine secretionProtein kinase C beta typeHomo sapiens (human)
dibenzo-p-dioxin metabolic processProtein kinase C beta typeHomo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
positive regulation of insulin secretionProtein kinase C beta typeHomo sapiens (human)
response to vitamin DProtein kinase C beta typeHomo sapiens (human)
regulation of growthProtein kinase C beta typeHomo sapiens (human)
B cell activationProtein kinase C beta typeHomo sapiens (human)
positive regulation of odontogenesis of dentin-containing toothProtein kinase C beta typeHomo sapiens (human)
lipoprotein transportProtein kinase C beta typeHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionProtein kinase C beta typeHomo sapiens (human)
post-translational protein modificationProtein kinase C beta typeHomo sapiens (human)
response to ethanolProtein kinase C beta typeHomo sapiens (human)
positive regulation of angiogenesisProtein kinase C beta typeHomo sapiens (human)
positive regulation of DNA-templated transcriptionProtein kinase C beta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
B cell receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
positive regulation of B cell receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
cellular response to carbohydrate stimulusProtein kinase C beta typeHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionProtein kinase C beta typeHomo sapiens (human)
regulation of synaptic vesicle exocytosisProtein kinase C beta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C beta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C beta typeHomo sapiens (human)
positive regulation of MAP kinase activityInsulin receptorHomo sapiens (human)
positive regulation of protein phosphorylationInsulin receptorHomo sapiens (human)
positive regulation of receptor internalizationInsulin receptorHomo sapiens (human)
heart morphogenesisInsulin receptorHomo sapiens (human)
regulation of DNA-templated transcriptionInsulin receptorHomo sapiens (human)
protein phosphorylationInsulin receptorHomo sapiens (human)
receptor-mediated endocytosisInsulin receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayInsulin receptorHomo sapiens (human)
learningInsulin receptorHomo sapiens (human)
memoryInsulin receptorHomo sapiens (human)
positive regulation of cell population proliferationInsulin receptorHomo sapiens (human)
insulin receptor signaling pathwayInsulin receptorHomo sapiens (human)
epidermis developmentInsulin receptorHomo sapiens (human)
male gonad developmentInsulin receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationInsulin receptorHomo sapiens (human)
male sex determinationInsulin receptorHomo sapiens (human)
adrenal gland developmentInsulin receptorHomo sapiens (human)
positive regulation of cell migrationInsulin receptorHomo sapiens (human)
exocrine pancreas developmentInsulin receptorHomo sapiens (human)
receptor internalizationInsulin receptorHomo sapiens (human)
activation of protein kinase activityInsulin receptorHomo sapiens (human)
activation of protein kinase B activityInsulin receptorHomo sapiens (human)
cellular response to insulin stimulusInsulin receptorHomo sapiens (human)
glucose homeostasisInsulin receptorHomo sapiens (human)
positive regulation of protein-containing complex disassemblyInsulin receptorHomo sapiens (human)
positive regulation of MAPK cascadeInsulin receptorHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processInsulin receptorHomo sapiens (human)
positive regulation of glycogen biosynthetic processInsulin receptorHomo sapiens (human)
positive regulation of glycolytic processInsulin receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionInsulin receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionInsulin receptorHomo sapiens (human)
regulation of embryonic developmentInsulin receptorHomo sapiens (human)
positive regulation of glucose importInsulin receptorHomo sapiens (human)
symbiont entry into host cellInsulin receptorHomo sapiens (human)
protein autophosphorylationInsulin receptorHomo sapiens (human)
positive regulation of developmental growthInsulin receptorHomo sapiens (human)
positive regulation of meiotic cell cycleInsulin receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionInsulin receptorHomo sapiens (human)
positive regulation of respiratory burstInsulin receptorHomo sapiens (human)
cellular response to growth factor stimulusInsulin receptorHomo sapiens (human)
dendritic spine maintenanceInsulin receptorHomo sapiens (human)
amyloid-beta clearanceInsulin receptorHomo sapiens (human)
transport across blood-brain barrierInsulin receptorHomo sapiens (human)
neuron projection maintenanceInsulin receptorHomo sapiens (human)
regulation of female gonad developmentInsulin receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayInsulin receptorHomo sapiens (human)
multicellular organism developmentInsulin receptorHomo sapiens (human)
positive regulation of kinase activityInsulin receptorHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase LckHomo sapiens (human)
intracellular zinc ion homeostasisTyrosine-protein kinase LckHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTyrosine-protein kinase LckHomo sapiens (human)
response to xenobiotic stimulusTyrosine-protein kinase LckHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase LckHomo sapiens (human)
hemopoiesisTyrosine-protein kinase LckHomo sapiens (human)
platelet activationTyrosine-protein kinase LckHomo sapiens (human)
T cell differentiationTyrosine-protein kinase LckHomo sapiens (human)
T cell costimulationTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of heterotypic cell-cell adhesionTyrosine-protein kinase LckHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase LckHomo sapiens (human)
peptidyl-tyrosine autophosphorylationTyrosine-protein kinase LckHomo sapiens (human)
Fc-gamma receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of T cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of T cell activationTyrosine-protein kinase LckHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase LckHomo sapiens (human)
release of sequestered calcium ion into cytosolTyrosine-protein kinase LckHomo sapiens (human)
regulation of lymphocyte activationTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of leukocyte cell-cell adhesionTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
innate immune responseTyrosine-protein kinase LckHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
response to singlet oxygenTyrosine-protein kinase FynHomo sapiens (human)
neuron migrationTyrosine-protein kinase FynHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase FynHomo sapiens (human)
heart processTyrosine-protein kinase FynHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
calcium ion transportTyrosine-protein kinase FynHomo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
axon guidanceTyrosine-protein kinase FynHomo sapiens (human)
learningTyrosine-protein kinase FynHomo sapiens (human)
feeding behaviorTyrosine-protein kinase FynHomo sapiens (human)
regulation of cell shapeTyrosine-protein kinase FynHomo sapiens (human)
gene expressionTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of gene expressionTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of hydrogen peroxide biosynthetic processTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of neuron projection developmentTyrosine-protein kinase FynHomo sapiens (human)
protein ubiquitinationTyrosine-protein kinase FynHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
protein catabolic processTyrosine-protein kinase FynHomo sapiens (human)
forebrain developmentTyrosine-protein kinase FynHomo sapiens (human)
T cell costimulationTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of protein ubiquitinationTyrosine-protein kinase FynHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase FynHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusTyrosine-protein kinase FynHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of protein catabolic processTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein kinase FynHomo sapiens (human)
response to ethanolTyrosine-protein kinase FynHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
dendrite morphogenesisTyrosine-protein kinase FynHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
activated T cell proliferationTyrosine-protein kinase FynHomo sapiens (human)
modulation of chemical synaptic transmissionTyrosine-protein kinase FynHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase FynHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTyrosine-protein kinase FynHomo sapiens (human)
cellular response to hydrogen peroxideTyrosine-protein kinase FynHomo sapiens (human)
cellular response to transforming growth factor beta stimulusTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein targeting to membraneTyrosine-protein kinase FynHomo sapiens (human)
dendritic spine maintenanceTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein localization to nucleusTyrosine-protein kinase FynHomo sapiens (human)
regulation of glutamate receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of dendritic spine maintenanceTyrosine-protein kinase FynHomo sapiens (human)
response to amyloid-betaTyrosine-protein kinase FynHomo sapiens (human)
cellular response to amyloid-betaTyrosine-protein kinase FynHomo sapiens (human)
cellular response to L-glutamateTyrosine-protein kinase FynHomo sapiens (human)
cellular response to glycineTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein localization to membraneTyrosine-protein kinase FynHomo sapiens (human)
regulation of calcium ion import across plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activityTyrosine-protein kinase FynHomo sapiens (human)
innate immune responseTyrosine-protein kinase FynHomo sapiens (human)
cell differentiationTyrosine-protein kinase FynHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 1Homo sapiens (human)
G2/M transition of mitotic cell cycleCyclin-dependent kinase 1Homo sapiens (human)
microtubule cytoskeleton organizationCyclin-dependent kinase 1Homo sapiens (human)
DNA replicationCyclin-dependent kinase 1Homo sapiens (human)
DNA repairCyclin-dependent kinase 1Homo sapiens (human)
chromatin remodelingCyclin-dependent kinase 1Homo sapiens (human)
regulation of transcription by RNA polymerase IICyclin-dependent kinase 1Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 1Homo sapiens (human)
apoptotic processCyclin-dependent kinase 1Homo sapiens (human)
DNA damage responseCyclin-dependent kinase 1Homo sapiens (human)
mitotic nuclear membrane disassemblyCyclin-dependent kinase 1Homo sapiens (human)
centrosome cycleCyclin-dependent kinase 1Homo sapiens (human)
pronuclear fusionCyclin-dependent kinase 1Homo sapiens (human)
response to xenobiotic stimulusCyclin-dependent kinase 1Homo sapiens (human)
response to toxic substanceCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of gene expressionCyclin-dependent kinase 1Homo sapiens (human)
negative regulation of gene expressionCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 1Homo sapiens (human)
regulation of Schwann cell differentiationCyclin-dependent kinase 1Homo sapiens (human)
response to amineCyclin-dependent kinase 1Homo sapiens (human)
response to activityCyclin-dependent kinase 1Homo sapiens (human)
cell migrationCyclin-dependent kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylationCyclin-dependent kinase 1Homo sapiens (human)
chromosome condensationCyclin-dependent kinase 1Homo sapiens (human)
epithelial cell differentiationCyclin-dependent kinase 1Homo sapiens (human)
animal organ regenerationCyclin-dependent kinase 1Homo sapiens (human)
protein localization to kinetochoreCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of protein import into nucleusCyclin-dependent kinase 1Homo sapiens (human)
regulation of circadian rhythmCyclin-dependent kinase 1Homo sapiens (human)
negative regulation of apoptotic processCyclin-dependent kinase 1Homo sapiens (human)
response to ethanolCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of DNA replicationCyclin-dependent kinase 1Homo sapiens (human)
regulation of embryonic developmentCyclin-dependent kinase 1Homo sapiens (human)
response to cadmium ionCyclin-dependent kinase 1Homo sapiens (human)
response to copper ionCyclin-dependent kinase 1Homo sapiens (human)
symbiont entry into host cellCyclin-dependent kinase 1Homo sapiens (human)
fibroblast proliferationCyclin-dependent kinase 1Homo sapiens (human)
rhythmic processCyclin-dependent kinase 1Homo sapiens (human)
response to axon injuryCyclin-dependent kinase 1Homo sapiens (human)
cell divisionCyclin-dependent kinase 1Homo sapiens (human)
ventricular cardiac muscle cell developmentCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of mitotic sister chromatid segregationCyclin-dependent kinase 1Homo sapiens (human)
protein-containing complex assemblyCyclin-dependent kinase 1Homo sapiens (human)
cellular response to hydrogen peroxideCyclin-dependent kinase 1Homo sapiens (human)
ERK1 and ERK2 cascadeCyclin-dependent kinase 1Homo sapiens (human)
cellular response to organic cyclic compoundCyclin-dependent kinase 1Homo sapiens (human)
Golgi disassemblyCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of protein localization to nucleusCyclin-dependent kinase 1Homo sapiens (human)
regulation of attachment of mitotic spindle microtubules to kinetochoreCyclin-dependent kinase 1Homo sapiens (human)
microtubule cytoskeleton organization involved in mitosisCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of mitochondrial ATP synthesis coupled electron transportCyclin-dependent kinase 1Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingCyclin-dependent kinase 1Homo sapiens (human)
protein deubiquitinationCyclin-dependent kinase 1Homo sapiens (human)
glycogen metabolic processGlycogen phosphorylase, liver formHomo sapiens (human)
5-phosphoribose 1-diphosphate biosynthetic processGlycogen phosphorylase, liver formHomo sapiens (human)
response to bacteriumGlycogen phosphorylase, liver formHomo sapiens (human)
glucose homeostasisGlycogen phosphorylase, liver formHomo sapiens (human)
necroptotic processGlycogen phosphorylase, liver formHomo sapiens (human)
glycogen catabolic processGlycogen phosphorylase, liver formHomo sapiens (human)
microtubule bundle formationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
centrosome cycleTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell shapeTyrosine-protein kinase Fes/FpsHomo sapiens (human)
positive regulation of neuron projection developmentTyrosine-protein kinase Fes/FpsHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell adhesionTyrosine-protein kinase Fes/FpsHomo sapiens (human)
positive regulation of microtubule polymerizationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell population proliferationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of mast cell degranulationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell differentiationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
positive regulation of myeloid cell differentiationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
positive regulation of monocyte differentiationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
protein autophosphorylationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
myoblast proliferationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cardiac muscle cell proliferationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of vesicle-mediated transportTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cellular response to vitamin DTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell motilityTyrosine-protein kinase Fes/FpsHomo sapiens (human)
chemotaxisTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cell adhesionTyrosine-protein kinase Fes/FpsHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
positive regulation of macrophage chemotaxisMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of macrophage proliferationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of protein phosphorylationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
response to ischemiaMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
inflammatory responseMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
signal transductionMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
axon guidanceMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cell population proliferationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of cell population proliferationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
negative regulation of cell population proliferationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
regulation of cell shapeMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cytokine-mediated signaling pathwayMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
olfactory bulb developmentMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
forebrain neuron differentiationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
hemopoiesisMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
monocyte differentiationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
macrophage differentiationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
osteoclast differentiationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
ruffle organizationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of chemokine productionMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
regulation of actin cytoskeleton organizationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cellular response to macrophage colony-stimulating factor stimulusMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
macrophage colony-stimulating factor signaling pathwayMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
negative regulation of apoptotic processMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation by host of viral processMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
innate immune responseMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
regulation of bone resorptionMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cell-cell junction maintenanceMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
protein autophosphorylationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
mammary gland duct morphogenesisMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of protein tyrosine kinase activityMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
microglial cell proliferationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cellular response to cytokine stimulusMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
regulation of macrophage migrationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of cell motilityMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of cell migrationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
regulation of MAPK cascadeMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of kinase activityMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
multicellular organism developmentMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
purine ribonucleoside salvageAdenine phosphoribosyltransferaseHomo sapiens (human)
grooming behaviorAdenine phosphoribosyltransferaseHomo sapiens (human)
GMP salvageAdenine phosphoribosyltransferaseHomo sapiens (human)
IMP salvageAdenine phosphoribosyltransferaseHomo sapiens (human)
AMP salvageAdenine phosphoribosyltransferaseHomo sapiens (human)
adenine salvageAdenine phosphoribosyltransferaseHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase YesHomo sapiens (human)
regulation of glucose transmembrane transportTyrosine-protein kinase YesHomo sapiens (human)
T cell costimulationTyrosine-protein kinase YesHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusTyrosine-protein kinase YesHomo sapiens (human)
protein modification processTyrosine-protein kinase YesHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase YesHomo sapiens (human)
regulation of vascular permeabilityTyrosine-protein kinase YesHomo sapiens (human)
positive regulation of transcription by RNA polymerase IITyrosine-protein kinase YesHomo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein kinase YesHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase YesHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase YesHomo sapiens (human)
cellular response to retinoic acidTyrosine-protein kinase YesHomo sapiens (human)
cellular response to transforming growth factor beta stimulusTyrosine-protein kinase YesHomo sapiens (human)
innate immune responseTyrosine-protein kinase YesHomo sapiens (human)
cell differentiationTyrosine-protein kinase YesHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase YesHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase YesHomo sapiens (human)
DNA damage checkpoint signalingTyrosine-protein kinase LynHomo sapiens (human)
B cell homeostasisTyrosine-protein kinase LynHomo sapiens (human)
regulation of cytokine productionTyrosine-protein kinase LynHomo sapiens (human)
regulation of protein phosphorylationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of protein phosphorylationTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of protein phosphorylationTyrosine-protein kinase LynHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
hematopoietic progenitor cell differentiationTyrosine-protein kinase LynHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase LynHomo sapiens (human)
Fc receptor mediated stimulatory signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
tolerance induction to self antigenTyrosine-protein kinase LynHomo sapiens (human)
histamine secretion by mast cellTyrosine-protein kinase LynHomo sapiens (human)
platelet degranulationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of myeloid leukocyte differentiationTyrosine-protein kinase LynHomo sapiens (human)
immune response-regulating cell surface receptor signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
Fc receptor mediated inhibitory signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase LynHomo sapiens (human)
regulation of B cell apoptotic processTyrosine-protein kinase LynHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase LynHomo sapiens (human)
DNA damage responseTyrosine-protein kinase LynHomo sapiens (human)
response to sterol depletionTyrosine-protein kinase LynHomo sapiens (human)
signal transductionTyrosine-protein kinase LynHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of cell population proliferationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of cell population proliferationTyrosine-protein kinase LynHomo sapiens (human)
response to xenobiotic stimulusTyrosine-protein kinase LynHomo sapiens (human)
response to toxic substanceTyrosine-protein kinase LynHomo sapiens (human)
response to hormoneTyrosine-protein kinase LynHomo sapiens (human)
response to carbohydrateTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of neuron projection developmentTyrosine-protein kinase LynHomo sapiens (human)
oligodendrocyte developmentTyrosine-protein kinase LynHomo sapiens (human)
response to organic cyclic compoundTyrosine-protein kinase LynHomo sapiens (human)
fatty acid transportTyrosine-protein kinase LynHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase LynHomo sapiens (human)
erythrocyte differentiationTyrosine-protein kinase LynHomo sapiens (human)
eosinophil differentiationTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of cell migrationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of B cell proliferationTyrosine-protein kinase LynHomo sapiens (human)
T cell costimulationTyrosine-protein kinase LynHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
response to insulinTyrosine-protein kinase LynHomo sapiens (human)
regulation of mast cell activationTyrosine-protein kinase LynHomo sapiens (human)
regulation of cell adhesion mediated by integrinTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of toll-like receptor 2 signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
toll-like receptor 4 signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of toll-like receptor 4 signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
cellular response to heatTyrosine-protein kinase LynHomo sapiens (human)
interleukin-5-mediated signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
Fc-epsilon receptor signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase LynHomo sapiens (human)
C-X-C chemokine receptor CXCR4 signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein kinase LynHomo sapiens (human)
response to amino acidTyrosine-protein kinase LynHomo sapiens (human)
regulation of mast cell degranulationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of MAPK cascadeTyrosine-protein kinase LynHomo sapiens (human)
regulation of erythrocyte differentiationTyrosine-protein kinase LynHomo sapiens (human)
protein autophosphorylationTyrosine-protein kinase LynHomo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
response to axon injuryTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of immune responseTyrosine-protein kinase LynHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
regulation of B cell receptor signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase LynHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosolTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of glial cell proliferationTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of Fc receptor mediated stimulatory signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein kinase LynHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of oligodendrocyte progenitor proliferationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of mast cell proliferationTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of mast cell proliferationTyrosine-protein kinase LynHomo sapiens (human)
cellular response to retinoic acidTyrosine-protein kinase LynHomo sapiens (human)
regulation of monocyte chemotaxisTyrosine-protein kinase LynHomo sapiens (human)
regulation of platelet aggregationTyrosine-protein kinase LynHomo sapiens (human)
dendritic cell differentiationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of intracellular signal transductionTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic processTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of dendritic cell apoptotic processTyrosine-protein kinase LynHomo sapiens (human)
neuron projection developmentTyrosine-protein kinase LynHomo sapiens (human)
innate immune responseTyrosine-protein kinase LynHomo sapiens (human)
MAPK cascadeProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
ureteric bud developmentProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
neural crest cell migrationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
embryonic epithelial tube formationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
protein phosphorylationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
homophilic cell adhesion via plasma membrane adhesion moleculesProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
neuron cell-cell adhesionProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
signal transductionProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
axon guidanceProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
posterior midgut developmentProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
response to xenobiotic stimulusProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of gene expressionProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of neuron projection developmentProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of neuron maturationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
regulation of cell adhesionProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of cell migrationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
membrane protein proteolysisProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of cell adhesion mediated by integrinProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
ureter maturationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
glial cell-derived neurotrophic factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
neuron maturationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of MAPK cascadeProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of cell sizeProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of DNA-templated transcriptionProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
response to painProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
enteric nervous system developmentProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
regulation of axonogenesisProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
retina development in camera-type eyeProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
innervationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
Peyer's patch morphogenesisProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
cellular response to retinoic acidProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of metanephric glomerulus developmentProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
lymphocyte migration into lymphoid organsProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
GDF15-GFRAL signaling pathwayProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway in absence of ligandProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of kinase activityProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
multicellular organism developmentProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
peptidyl-tyrosine autophosphorylationInsulin-like growth factor 1 receptorHomo sapiens (human)
cardiac atrium developmentInsulin-like growth factor 1 receptorHomo sapiens (human)
immune responseInsulin-like growth factor 1 receptorHomo sapiens (human)
signal transductionInsulin-like growth factor 1 receptorHomo sapiens (human)
axonogenesisInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of cell population proliferationInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor signaling pathwayInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of muscle cell apoptotic processInsulin-like growth factor 1 receptorHomo sapiens (human)
cerebellum developmentInsulin-like growth factor 1 receptorHomo sapiens (human)
hippocampus developmentInsulin-like growth factor 1 receptorHomo sapiens (human)
establishment of cell polarityInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of cell migrationInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of cytokinesisInsulin-like growth factor 1 receptorHomo sapiens (human)
response to vitamin EInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of osteoblast proliferationInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to zinc ion starvationInsulin-like growth factor 1 receptorHomo sapiens (human)
response to nicotineInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of apoptotic processInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of protein-containing complex disassemblyInsulin-like growth factor 1 receptorHomo sapiens (human)
response to alkaloidInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of MAPK cascadeInsulin-like growth factor 1 receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionInsulin-like growth factor 1 receptorHomo sapiens (human)
estrous cycleInsulin-like growth factor 1 receptorHomo sapiens (human)
transcytosisInsulin-like growth factor 1 receptorHomo sapiens (human)
response to ethanolInsulin-like growth factor 1 receptorHomo sapiens (human)
regulation of JNK cascadeInsulin-like growth factor 1 receptorHomo sapiens (human)
protein autophosphorylationInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of axon regenerationInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of DNA metabolic processInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to mechanical stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to estradiol stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to progesterone stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to testosterone stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to dexamethasone stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to transforming growth factor beta stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of steroid hormone biosynthetic processInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular senescenceInsulin-like growth factor 1 receptorHomo sapiens (human)
dendritic spine maintenanceInsulin-like growth factor 1 receptorHomo sapiens (human)
amyloid-beta clearanceInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisInsulin-like growth factor 1 receptorHomo sapiens (human)
response to L-glutamateInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of hepatocyte apoptotic processInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to aldosteroneInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of cholangiocyte apoptotic processInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to angiotensinInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to amyloid-betaInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to insulin-like growth factor stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
multicellular organism developmentInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of kinase activityInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to glucose stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of MAPK cascadeInsulin-like growth factor 1 receptorHomo sapiens (human)
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
cotranslational protein targeting to membraneSignal recognition particle receptor subunit alphaHomo sapiens (human)
SRP-dependent cotranslational protein targeting to membrane, signal sequence recognitionSignal recognition particle receptor subunit alphaHomo sapiens (human)
intracellular protein transportSignal recognition particle receptor subunit alphaHomo sapiens (human)
protein targeting to ERSignal recognition particle receptor subunit alphaHomo sapiens (human)
mitochondrial electron transport, ubiquinol to cytochrome cCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
response to glucagonCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
cellular respirationCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
proton transmembrane transportCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
endothelial cell morphogenesisHepatocyte growth factor receptorHomo sapiens (human)
signal transductionHepatocyte growth factor receptorHomo sapiens (human)
cell surface receptor signaling pathwayHepatocyte growth factor receptorHomo sapiens (human)
negative regulation of autophagyHepatocyte growth factor receptorHomo sapiens (human)
positive regulation of microtubule polymerizationHepatocyte growth factor receptorHomo sapiens (human)
negative regulation of Rho protein signal transductionHepatocyte growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHepatocyte growth factor receptorHomo sapiens (human)
hepatocyte growth factor receptor signaling pathwayHepatocyte growth factor receptorHomo sapiens (human)
branching morphogenesis of an epithelial tubeHepatocyte growth factor receptorHomo sapiens (human)
positive chemotaxisHepatocyte growth factor receptorHomo sapiens (human)
negative regulation of stress fiber assemblyHepatocyte growth factor receptorHomo sapiens (human)
excitatory postsynaptic potentialHepatocyte growth factor receptorHomo sapiens (human)
establishment of skin barrierHepatocyte growth factor receptorHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayHepatocyte growth factor receptorHomo sapiens (human)
semaphorin-plexin signaling pathwayHepatocyte growth factor receptorHomo sapiens (human)
negative regulation of hydrogen peroxide-mediated programmed cell deathHepatocyte growth factor receptorHomo sapiens (human)
negative regulation of guanyl-nucleotide exchange factor activityHepatocyte growth factor receptorHomo sapiens (human)
positive regulation of endothelial cell chemotaxisHepatocyte growth factor receptorHomo sapiens (human)
liver developmentHepatocyte growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayHepatocyte growth factor receptorHomo sapiens (human)
phagocytosisHepatocyte growth factor receptorHomo sapiens (human)
multicellular organism developmentHepatocyte growth factor receptorHomo sapiens (human)
neuron differentiationHepatocyte growth factor receptorHomo sapiens (human)
positive regulation of kinase activityHepatocyte growth factor receptorHomo sapiens (human)
cell migrationHepatocyte growth factor receptorHomo sapiens (human)
pancreas developmentHepatocyte growth factor receptorHomo sapiens (human)
nervous system developmentHepatocyte growth factor receptorHomo sapiens (human)
leukocyte migration involved in immune responseTyrosine-protein kinase HCKHomo sapiens (human)
innate immune response-activating signaling pathwayTyrosine-protein kinase HCKHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase HCKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase HCKHomo sapiens (human)
inflammatory responseTyrosine-protein kinase HCKHomo sapiens (human)
cell adhesionTyrosine-protein kinase HCKHomo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein kinase HCKHomo sapiens (human)
mesoderm developmentTyrosine-protein kinase HCKHomo sapiens (human)
positive regulation of cell population proliferationTyrosine-protein kinase HCKHomo sapiens (human)
regulation of cell shapeTyrosine-protein kinase HCKHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase HCKHomo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein kinase HCKHomo sapiens (human)
positive regulation of actin filament polymerizationTyrosine-protein kinase HCKHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayTyrosine-protein kinase HCKHomo sapiens (human)
regulation of actin cytoskeleton organizationTyrosine-protein kinase HCKHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase HCKHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase HCKHomo sapiens (human)
negative regulation of apoptotic processTyrosine-protein kinase HCKHomo sapiens (human)
leukocyte degranulationTyrosine-protein kinase HCKHomo sapiens (human)
respiratory burst after phagocytosisTyrosine-protein kinase HCKHomo sapiens (human)
protein autophosphorylationTyrosine-protein kinase HCKHomo sapiens (human)
regulation of inflammatory responseTyrosine-protein kinase HCKHomo sapiens (human)
regulation of phagocytosisTyrosine-protein kinase HCKHomo sapiens (human)
regulation of DNA-binding transcription factor activityTyrosine-protein kinase HCKHomo sapiens (human)
type II interferon-mediated signaling pathwayTyrosine-protein kinase HCKHomo sapiens (human)
regulation of podosome assemblyTyrosine-protein kinase HCKHomo sapiens (human)
cell differentiationTyrosine-protein kinase HCKHomo sapiens (human)
innate immune responseTyrosine-protein kinase HCKHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase HCKHomo sapiens (human)
regulation of cell growthProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
columnar/cuboidal epithelial cell developmentProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
protein phosphorylationProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
spermatogenesisProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
cell differentiationProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
regulation of TOR signalingProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
positive regulation of kinase activityProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
multicellular organism developmentProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
signal transductionPlatelet-derived growth factor receptor betaHomo sapiens (human)
G protein-coupled receptor signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of cell population proliferationPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of phospholipase C activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of smooth muscle cell migrationPlatelet-derived growth factor receptor betaHomo sapiens (human)
peptidyl-tyrosine phosphorylationPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of cell migrationPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of phosphoprotein phosphatase activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
regulation of actin cytoskeleton organizationPlatelet-derived growth factor receptor betaHomo sapiens (human)
cell migration involved in vasculogenesisPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
aorta morphogenesisPlatelet-derived growth factor receptor betaHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of MAP kinase activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of mitotic nuclear divisionPlatelet-derived growth factor receptor betaHomo sapiens (human)
phosphatidylinositol metabolic processPlatelet-derived growth factor receptor betaHomo sapiens (human)
protein autophosphorylationPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of smooth muscle cell proliferationPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of calcium-mediated signalingPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of chemotaxisPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPlatelet-derived growth factor receptor betaHomo sapiens (human)
cardiac myofibril assemblyPlatelet-derived growth factor receptor betaHomo sapiens (human)
cell chemotaxisPlatelet-derived growth factor receptor betaHomo sapiens (human)
cell migration involved in coronary angiogenesisPlatelet-derived growth factor receptor betaHomo sapiens (human)
retina vasculature development in camera-type eyePlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadePlatelet-derived growth factor receptor betaHomo sapiens (human)
smooth muscle cell chemotaxisPlatelet-derived growth factor receptor betaHomo sapiens (human)
metanephric glomerular mesangial cell proliferation involved in metanephros developmentPlatelet-derived growth factor receptor betaHomo sapiens (human)
metanephric glomerular capillary formationPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of calcium ion importPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of DNA biosynthetic processPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of kinase activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
angiogenesisPlatelet-derived growth factor receptor betaHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
multicellular organism developmentPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of cytokine productionTyrosine-protein kinase FgrHomo sapiens (human)
immune response-regulating cell surface receptor signaling pathwayTyrosine-protein kinase FgrHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase FgrHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase FgrHomo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein kinase FgrHomo sapiens (human)
regulation of cell shapeTyrosine-protein kinase FgrHomo sapiens (human)
response to virusTyrosine-protein kinase FgrHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase FgrHomo sapiens (human)
bone mineralizationTyrosine-protein kinase FgrHomo sapiens (human)
positive regulation of cell migrationTyrosine-protein kinase FgrHomo sapiens (human)
negative regulation of natural killer cell activationTyrosine-protein kinase FgrHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase FgrHomo sapiens (human)
positive regulation of mast cell degranulationTyrosine-protein kinase FgrHomo sapiens (human)
regulation of innate immune responseTyrosine-protein kinase FgrHomo sapiens (human)
regulation of protein kinase activityTyrosine-protein kinase FgrHomo sapiens (human)
protein autophosphorylationTyrosine-protein kinase FgrHomo sapiens (human)
skeletal system morphogenesisTyrosine-protein kinase FgrHomo sapiens (human)
regulation of phagocytosisTyrosine-protein kinase FgrHomo sapiens (human)
defense response to Gram-positive bacteriumTyrosine-protein kinase FgrHomo sapiens (human)
myoblast proliferationTyrosine-protein kinase FgrHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase FgrHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase FgrHomo sapiens (human)
cell differentiationTyrosine-protein kinase FgrHomo sapiens (human)
innate immune responseTyrosine-protein kinase FgrHomo sapiens (human)
mitotic cell cycleWee1-like protein kinase 2Homo sapiens (human)
female meiotic nuclear divisionWee1-like protein kinase 2Homo sapiens (human)
female pronucleus assemblyWee1-like protein kinase 2Homo sapiens (human)
positive regulation of phosphorylationWee1-like protein kinase 2Homo sapiens (human)
regulation of meiosis IWee1-like protein kinase 2Homo sapiens (human)
regulation of fertilizationWee1-like protein kinase 2Homo sapiens (human)
negative regulation of oocyte maturationWee1-like protein kinase 2Homo sapiens (human)
protein phosphorylationWee1-like protein kinase 2Homo sapiens (human)
regulation of TOR signalingSerine/threonine-protein kinase A-RafHomo sapiens (human)
regulation of proteasomal ubiquitin-dependent protein catabolic processSerine/threonine-protein kinase A-RafHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase A-RafHomo sapiens (human)
protein modification processSerine/threonine-protein kinase A-RafHomo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase A-RafHomo sapiens (human)
MAPK cascadeSerine/threonine-protein kinase A-RafHomo sapiens (human)
lipid hydroxylationCytochrome P450 2C8Homo sapiens (human)
organic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C8Homo sapiens (human)
steroid metabolic processCytochrome P450 2C8Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C8Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C8Homo sapiens (human)
retinol metabolic processCytochrome P450 2C8Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
oxidative demethylationCytochrome P450 2C8Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
ovarian follicle developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
myeloid progenitor cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
lymphoid progenitor cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
immature B cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
mast cell chemotaxisMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of dendritic cell cytokine productionMast/stem cell growth factor receptor KitHomo sapiens (human)
glycosphingolipid metabolic processMast/stem cell growth factor receptor KitHomo sapiens (human)
inflammatory responseMast/stem cell growth factor receptor KitHomo sapiens (human)
signal transductionMast/stem cell growth factor receptor KitHomo sapiens (human)
spermatogenesisMast/stem cell growth factor receptor KitHomo sapiens (human)
spermatid developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
germ cell migrationMast/stem cell growth factor receptor KitHomo sapiens (human)
regulation of cell shapeMast/stem cell growth factor receptor KitHomo sapiens (human)
visual learningMast/stem cell growth factor receptor KitHomo sapiens (human)
male gonad developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of phospholipase C activityMast/stem cell growth factor receptor KitHomo sapiens (human)
cytokine-mediated signaling pathwayMast/stem cell growth factor receptor KitHomo sapiens (human)
stem cell population maintenanceMast/stem cell growth factor receptor KitHomo sapiens (human)
lamellipodium assemblyMast/stem cell growth factor receptor KitHomo sapiens (human)
actin cytoskeleton organizationMast/stem cell growth factor receptor KitHomo sapiens (human)
hemopoiesisMast/stem cell growth factor receptor KitHomo sapiens (human)
T cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
erythrocyte differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
melanocyte differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of pseudopodium assemblyMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of mast cell cytokine productionMast/stem cell growth factor receptor KitHomo sapiens (human)
somatic stem cell population maintenanceMast/stem cell growth factor receptor KitHomo sapiens (human)
embryonic hemopoiesisMast/stem cell growth factor receptor KitHomo sapiens (human)
ectopic germ cell programmed cell deathMast/stem cell growth factor receptor KitHomo sapiens (human)
intracellular signal transductionMast/stem cell growth factor receptor KitHomo sapiens (human)
hematopoietic stem cell migrationMast/stem cell growth factor receptor KitHomo sapiens (human)
megakaryocyte developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
Fc receptor signaling pathwayMast/stem cell growth factor receptor KitHomo sapiens (human)
Kit signaling pathwayMast/stem cell growth factor receptor KitHomo sapiens (human)
erythropoietin-mediated signaling pathwayMast/stem cell growth factor receptor KitHomo sapiens (human)
regulation of cell population proliferationMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinMast/stem cell growth factor receptor KitHomo sapiens (human)
negative regulation of programmed cell deathMast/stem cell growth factor receptor KitHomo sapiens (human)
mast cell degranulationMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of MAPK cascadeMast/stem cell growth factor receptor KitHomo sapiens (human)
pigmentationMast/stem cell growth factor receptor KitHomo sapiens (human)
tongue developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of Notch signaling pathwayMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATMast/stem cell growth factor receptor KitHomo sapiens (human)
response to cadmium ionMast/stem cell growth factor receptor KitHomo sapiens (human)
protein autophosphorylationMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of long-term neuronal synaptic plasticityMast/stem cell growth factor receptor KitHomo sapiens (human)
digestive tract developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
stem cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
epithelial cell proliferationMast/stem cell growth factor receptor KitHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of soundMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityMast/stem cell growth factor receptor KitHomo sapiens (human)
negative regulation of developmental processMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionMast/stem cell growth factor receptor KitHomo sapiens (human)
cell chemotaxisMast/stem cell growth factor receptor KitHomo sapiens (human)
mast cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
mast cell proliferationMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of mast cell proliferationMast/stem cell growth factor receptor KitHomo sapiens (human)
melanocyte migrationMast/stem cell growth factor receptor KitHomo sapiens (human)
melanocyte adhesionMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of pyloric antrum smooth muscle contractionMast/stem cell growth factor receptor KitHomo sapiens (human)
regulation of bile acid metabolic processMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of colon smooth muscle contractionMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of small intestine smooth muscle contractionMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
negative regulation of reproductive processMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of cell migrationMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of MAP kinase activityMast/stem cell growth factor receptor KitHomo sapiens (human)
multicellular organism developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
B cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
hematopoietic progenitor cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
glycogen catabolic processGlycogen phosphorylase, brain formHomo sapiens (human)
negative regulation of cellular extravasationBreakpoint cluster region proteinHomo sapiens (human)
renal system processBreakpoint cluster region proteinHomo sapiens (human)
protein phosphorylationBreakpoint cluster region proteinHomo sapiens (human)
phagocytosisBreakpoint cluster region proteinHomo sapiens (human)
signal transductionBreakpoint cluster region proteinHomo sapiens (human)
small GTPase-mediated signal transductionBreakpoint cluster region proteinHomo sapiens (human)
brain developmentBreakpoint cluster region proteinHomo sapiens (human)
actin cytoskeleton organizationBreakpoint cluster region proteinHomo sapiens (human)
keratinocyte differentiationBreakpoint cluster region proteinHomo sapiens (human)
regulation of Rho protein signal transductionBreakpoint cluster region proteinHomo sapiens (human)
inner ear morphogenesisBreakpoint cluster region proteinHomo sapiens (human)
regulation of vascular permeabilityBreakpoint cluster region proteinHomo sapiens (human)
neutrophil degranulationBreakpoint cluster region proteinHomo sapiens (human)
negative regulation of neutrophil degranulationBreakpoint cluster region proteinHomo sapiens (human)
focal adhesion assemblyBreakpoint cluster region proteinHomo sapiens (human)
homeostasis of number of cellsBreakpoint cluster region proteinHomo sapiens (human)
negative regulation of inflammatory responseBreakpoint cluster region proteinHomo sapiens (human)
positive regulation of phagocytosisBreakpoint cluster region proteinHomo sapiens (human)
modulation of chemical synaptic transmissionBreakpoint cluster region proteinHomo sapiens (human)
neuromuscular process controlling balanceBreakpoint cluster region proteinHomo sapiens (human)
regulation of small GTPase mediated signal transductionBreakpoint cluster region proteinHomo sapiens (human)
regulation of cell cycleBreakpoint cluster region proteinHomo sapiens (human)
definitive hemopoiesisBreakpoint cluster region proteinHomo sapiens (human)
negative regulation of respiratory burstBreakpoint cluster region proteinHomo sapiens (human)
negative regulation of blood vessel remodelingBreakpoint cluster region proteinHomo sapiens (human)
intracellular protein transmembrane transportBreakpoint cluster region proteinHomo sapiens (human)
cellular response to lipopolysaccharideBreakpoint cluster region proteinHomo sapiens (human)
activation of GTPase activityBreakpoint cluster region proteinHomo sapiens (human)
macrophage migrationBreakpoint cluster region proteinHomo sapiens (human)
negative regulation of macrophage migrationBreakpoint cluster region proteinHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processBreakpoint cluster region proteinHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase pim-1Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase pim-1Homo sapiens (human)
regulation of transmembrane transporter activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of DNA-binding transcription factor activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of innate immune responseSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
vitamin D receptor signaling pathwaySerine/threonine-protein kinase pim-1Homo sapiens (human)
cellular response to type II interferonSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of brown fat cell differentiationSerine/threonine-protein kinase pim-1Homo sapiens (human)
regulation of hematopoietic stem cell proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of TORC1 signalingSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of cardioblast proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
cellular detoxificationSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIFibroblast growth factor receptor 1Homo sapiens (human)
MAPK cascadeFibroblast growth factor receptor 1Homo sapiens (human)
skeletal system developmentFibroblast growth factor receptor 1Homo sapiens (human)
angiogenesisFibroblast growth factor receptor 1Homo sapiens (human)
ureteric bud developmentFibroblast growth factor receptor 1Homo sapiens (human)
in utero embryonic developmentFibroblast growth factor receptor 1Homo sapiens (human)
organ inductionFibroblast growth factor receptor 1Homo sapiens (human)
neuron migrationFibroblast growth factor receptor 1Homo sapiens (human)
epithelial to mesenchymal transitionFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of mesenchymal cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
chondrocyte differentiationFibroblast growth factor receptor 1Homo sapiens (human)
protein phosphorylationFibroblast growth factor receptor 1Homo sapiens (human)
sensory perception of soundFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 1Homo sapiens (human)
mesenchymal cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
gene expressionFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of phospholipase activityFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of phospholipase C activityFibroblast growth factor receptor 1Homo sapiens (human)
regulation of phosphate transportFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of neuron projection developmentFibroblast growth factor receptor 1Homo sapiens (human)
cell migrationFibroblast growth factor receptor 1Homo sapiens (human)
peptidyl-tyrosine phosphorylationFibroblast growth factor receptor 1Homo sapiens (human)
ventricular zone neuroblast divisionFibroblast growth factor receptor 1Homo sapiens (human)
cell projection assemblyFibroblast growth factor receptor 1Homo sapiens (human)
embryonic limb morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
midbrain developmentFibroblast growth factor receptor 1Homo sapiens (human)
neuron projection developmentFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex developmentFibroblast growth factor receptor 1Homo sapiens (human)
inner ear morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
outer ear morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
middle ear morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
chordate embryonic developmentFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of MAP kinase activityFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of MAPK cascadeFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationFibroblast growth factor receptor 1Homo sapiens (human)
cellular response to fibroblast growth factor stimulusFibroblast growth factor receptor 1Homo sapiens (human)
regulation of cell differentiationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of neuron differentiationFibroblast growth factor receptor 1Homo sapiens (human)
protein autophosphorylationFibroblast growth factor receptor 1Homo sapiens (human)
phosphatidylinositol-mediated signalingFibroblast growth factor receptor 1Homo sapiens (human)
paraxial mesoderm developmentFibroblast growth factor receptor 1Homo sapiens (human)
regulation of lateral mesodermal cell fate specificationFibroblast growth factor receptor 1Homo sapiens (human)
cell maturationFibroblast growth factor receptor 1Homo sapiens (human)
skeletal system morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
stem cell differentiationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionFibroblast growth factor receptor 1Homo sapiens (human)
calcium ion homeostasisFibroblast growth factor receptor 1Homo sapiens (human)
cardiac muscle cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
auditory receptor cell developmentFibroblast growth factor receptor 1Homo sapiens (human)
branching involved in salivary gland morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
lung-associated mesenchyme developmentFibroblast growth factor receptor 1Homo sapiens (human)
regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signalingFibroblast growth factor receptor 1Homo sapiens (human)
vitamin D3 metabolic processFibroblast growth factor receptor 1Homo sapiens (human)
diphosphate metabolic processFibroblast growth factor receptor 1Homo sapiens (human)
cementum mineralizationFibroblast growth factor receptor 1Homo sapiens (human)
stem cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 1Homo sapiens (human)
negative regulation of fibroblast growth factor productionFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of mitotic cell cycle DNA replicationFibroblast growth factor receptor 1Homo sapiens (human)
response to sodium phosphateFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of stem cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of parathyroid hormone secretionFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of endothelial cell chemotaxisFibroblast growth factor receptor 1Homo sapiens (human)
regulation of extrinsic apoptotic signaling pathway in absence of ligandFibroblast growth factor receptor 1Homo sapiens (human)
multicellular organism developmentFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of cell differentiationFibroblast growth factor receptor 1Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of kinase activityFibroblast growth factor receptor 1Homo sapiens (human)
hematopoietic progenitor cell differentiationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-alphaHomo sapiens (human)
DNA ligationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA damage responseDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome segregationDNA topoisomerase 2-alphaHomo sapiens (human)
female meiotic nuclear divisionDNA topoisomerase 2-alphaHomo sapiens (human)
apoptotic chromosome condensationDNA topoisomerase 2-alphaHomo sapiens (human)
embryonic cleavageDNA topoisomerase 2-alphaHomo sapiens (human)
regulation of circadian rhythmDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of apoptotic processDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA topoisomerase 2-alphaHomo sapiens (human)
rhythmic processDNA topoisomerase 2-alphaHomo sapiens (human)
negative regulation of DNA duplex unwindingDNA topoisomerase 2-alphaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-alphaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-alphaHomo sapiens (human)
muscle structure developmentMyosin light chain kinase, smooth muscleGallus gallus (chicken)
tonic smooth muscle contractionMyosin light chain kinase, smooth muscleGallus gallus (chicken)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 4Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 4Homo sapiens (human)
positive regulation of cell population proliferationCyclin-dependent kinase 4Homo sapiens (human)
response to xenobiotic stimulusCyclin-dependent kinase 4Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 4Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 4Homo sapiens (human)
positive regulation of fibroblast proliferationCyclin-dependent kinase 4Homo sapiens (human)
cell divisionCyclin-dependent kinase 4Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 4Homo sapiens (human)
regulation of transcription initiation by RNA polymerase IICyclin-dependent kinase 4Homo sapiens (human)
regulation of type B pancreatic cell proliferationCyclin-dependent kinase 4Homo sapiens (human)
cellular response to lipopolysaccharideCyclin-dependent kinase 4Homo sapiens (human)
cellular response to interleukin-4Cyclin-dependent kinase 4Homo sapiens (human)
cellular response to phorbol 13-acetate 12-myristateCyclin-dependent kinase 4Homo sapiens (human)
cellular response to ionomycinCyclin-dependent kinase 4Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 4Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 4Homo sapiens (human)
signal transductionCyclin-dependent kinase 4Homo sapiens (human)
apoptotic processADP/ATP translocase 3Homo sapiens (human)
mitochondrial ADP transmembrane transportADP/ATP translocase 3Homo sapiens (human)
mitochondrial ATP transmembrane transportADP/ATP translocase 3Homo sapiens (human)
negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayADP/ATP translocase 3Homo sapiens (human)
GMP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
GTP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
circadian rhythmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
lymphocyte proliferationInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cellular response to interleukin-4Inosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
'de novo' XMP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
primary ovarian follicle growthProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of cytokine productionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signal complex assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
epidermal growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transforming growth factor beta receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
integrin-mediated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
spermatogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
learning or memoryProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to xenobiotic stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to mechanical stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to acidic pHProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of gene expressionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of epithelial cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of epithelial cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of glucose metabolic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein processingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
skeletal muscle cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of smooth muscle cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
macroautophagyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of cell-cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
platelet activationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
forebrain developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
T cell costimulationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of protein-containing complex assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein destabilizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to nutrient levelsProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of telomere maintenance via telomeraseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to insulin stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of intracellular estrogen receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of integrin activationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of toll-like receptor 3 signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
adherens junction organizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
substrate adhesion-dependent cell spreadingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of dephosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of hippo signalingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
intracellular signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
entry of bacterium into host cellProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
osteoclast developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ERBB2 signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
angiotensin-activated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
odontogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of vascular permeabilityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
stress fiber assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transcytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of Notch signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of Ras protein signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein autophosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
neurotrophin TRK receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ephrin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
focal adhesion assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
oogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
progesterone receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
leukocyte migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of small GTPase mediated signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein transportProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to mineralocorticoidProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
myoblast proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to electrical stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of focal adhesion assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of mitochondrial depolarizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of telomerase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
uterus developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
branching involved in mammary gland duct morphogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of cell projection assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
intestinal epithelial cell developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
interleukin-6-mediated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to hydrogen peroxideProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to interleukin-1Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to lipopolysaccharideProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to peptide hormone stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to progesterone stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to fatty acidProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to hypoxiaProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to fluid shear stressProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of podosome assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
DNA biosynthetic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of heart rate by cardiac conductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell-cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein localization to nucleusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of non-membrane spanning protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of TORC1 signalingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to prolactinProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of male germ cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of ovarian follicle developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of lamellipodium morphogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor-beta signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of early endosome to late endosome transportProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of anoikisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of caveolin-mediated endocytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell differentiationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
innate immune responseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
symbiont entry into host cellProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of protein phosphorylationcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
intracellular signal transductioncAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
negative regulation of cAMP/PKA signal transductioncAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
negative regulation of cAMP-dependent protein kinase activitycAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayInsulin receptor-related proteinHomo sapiens (human)
insulin receptor signaling pathwayInsulin receptor-related proteinHomo sapiens (human)
actin cytoskeleton organizationInsulin receptor-related proteinHomo sapiens (human)
male sex determinationInsulin receptor-related proteinHomo sapiens (human)
protein autophosphorylationInsulin receptor-related proteinHomo sapiens (human)
cellular response to alkaline pHInsulin receptor-related proteinHomo sapiens (human)
positive regulation of kinase activityInsulin receptor-related proteinHomo sapiens (human)
multicellular organism developmentInsulin receptor-related proteinHomo sapiens (human)
MAPK cascadeSerine/threonine-protein kinase B-rafHomo sapiens (human)
myeloid progenitor cell differentiationSerine/threonine-protein kinase B-rafHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase B-rafHomo sapiens (human)
epidermal growth factor receptor signaling pathwaySerine/threonine-protein kinase B-rafHomo sapiens (human)
visual learningSerine/threonine-protein kinase B-rafHomo sapiens (human)
animal organ morphogenesisSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of gene expressionSerine/threonine-protein kinase B-rafHomo sapiens (human)
negative regulation of fibroblast migrationSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of glucose transmembrane transportSerine/threonine-protein kinase B-rafHomo sapiens (human)
synaptic vesicle exocytosisSerine/threonine-protein kinase B-rafHomo sapiens (human)
thyroid gland developmentSerine/threonine-protein kinase B-rafHomo sapiens (human)
T cell differentiation in thymusSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase B-rafHomo sapiens (human)
substrate adhesion-dependent cell spreadingSerine/threonine-protein kinase B-rafHomo sapiens (human)
somatic stem cell population maintenanceSerine/threonine-protein kinase B-rafHomo sapiens (human)
regulation of cell population proliferationSerine/threonine-protein kinase B-rafHomo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase B-rafHomo sapiens (human)
stress fiber assemblySerine/threonine-protein kinase B-rafHomo sapiens (human)
CD4-positive, alpha-beta T cell differentiationSerine/threonine-protein kinase B-rafHomo sapiens (human)
CD4-positive or CD8-positive, alpha-beta T cell lineage commitmentSerine/threonine-protein kinase B-rafHomo sapiens (human)
response to peptide hormoneSerine/threonine-protein kinase B-rafHomo sapiens (human)
negative regulation of neuron apoptotic processSerine/threonine-protein kinase B-rafHomo sapiens (human)
regulation of T cell differentiationSerine/threonine-protein kinase B-rafHomo sapiens (human)
thymus developmentSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of axon regenerationSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of axonogenesisSerine/threonine-protein kinase B-rafHomo sapiens (human)
T cell receptor signaling pathwaySerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of stress fiber assemblySerine/threonine-protein kinase B-rafHomo sapiens (human)
response to cAMPSerine/threonine-protein kinase B-rafHomo sapiens (human)
long-term synaptic potentiationSerine/threonine-protein kinase B-rafHomo sapiens (human)
head morphogenesisSerine/threonine-protein kinase B-rafHomo sapiens (human)
face developmentSerine/threonine-protein kinase B-rafHomo sapiens (human)
ERK1 and ERK2 cascadeSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeSerine/threonine-protein kinase B-rafHomo sapiens (human)
cellular response to calcium ionSerine/threonine-protein kinase B-rafHomo sapiens (human)
cellular response to xenobiotic stimulusSerine/threonine-protein kinase B-rafHomo sapiens (human)
endothelial cell apoptotic processSerine/threonine-protein kinase B-rafHomo sapiens (human)
establishment of protein localization to membraneSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingSerine/threonine-protein kinase B-rafHomo sapiens (human)
cellular response to nerve growth factor stimulusSerine/threonine-protein kinase B-rafHomo sapiens (human)
negative regulation of synaptic vesicle exocytosisSerine/threonine-protein kinase B-rafHomo sapiens (human)
negative regulation of endothelial cell apoptotic processSerine/threonine-protein kinase B-rafHomo sapiens (human)
glycogen metabolic processPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
glycogen biosynthetic processPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
glycogen catabolic processPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
generation of precursor metabolites and energyPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
protein phosphorylationPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
positive regulation of glycogen catabolic processPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
quinone catabolic processRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cellular response to reactive oxygen speciesPlatelet-derived growth factor receptor alphaHomo sapiens (human)
luteinizationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
in utero embryonic developmentPlatelet-derived growth factor receptor alphaHomo sapiens (human)
cell activationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
hematopoietic progenitor cell differentiationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
estrogen metabolic processPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of cell population proliferationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
negative regulation of platelet activationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of phospholipase C activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
peptidyl-tyrosine phosphorylationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
signal transduction involved in regulation of gene expressionPlatelet-derived growth factor receptor alphaHomo sapiens (human)
extracellular matrix organizationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
lung developmentPlatelet-derived growth factor receptor alphaHomo sapiens (human)
adrenal gland developmentPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of cell migrationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
male genitalia developmentPlatelet-derived growth factor receptor alphaHomo sapiens (human)
regulation of actin cytoskeleton organizationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
Leydig cell differentiationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
platelet-derived growth factor receptor-alpha signaling pathwayPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathwayPlatelet-derived growth factor receptor alphaHomo sapiens (human)
wound healingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
odontogenesis of dentin-containing toothPlatelet-derived growth factor receptor alphaHomo sapiens (human)
protein autophosphorylationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of fibroblast proliferationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
embryonic digestive tract morphogenesisPlatelet-derived growth factor receptor alphaHomo sapiens (human)
embryonic cranial skeleton morphogenesisPlatelet-derived growth factor receptor alphaHomo sapiens (human)
embryonic skeletal system morphogenesisPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of calcium-mediated signalingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
white fat cell differentiationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of chemotaxisPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPlatelet-derived growth factor receptor alphaHomo sapiens (human)
cardiac myofibril assemblyPlatelet-derived growth factor receptor alphaHomo sapiens (human)
roof of mouth developmentPlatelet-derived growth factor receptor alphaHomo sapiens (human)
face morphogenesisPlatelet-derived growth factor receptor alphaHomo sapiens (human)
cell chemotaxisPlatelet-derived growth factor receptor alphaHomo sapiens (human)
retina vasculature development in camera-type eyePlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadePlatelet-derived growth factor receptor alphaHomo sapiens (human)
platelet aggregationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
cellular response to amino acid stimulusPlatelet-derived growth factor receptor alphaHomo sapiens (human)
metanephric glomerular capillary formationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
regulation of mesenchymal stem cell differentiationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of kinase activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
multicellular organism developmentPlatelet-derived growth factor receptor alphaHomo sapiens (human)
microtubule cytoskeleton organizationTyrosine-protein kinase FerHomo sapiens (human)
regulation of protein phosphorylationTyrosine-protein kinase FerHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase FerHomo sapiens (human)
tyrosine phosphorylation of STAT proteinTyrosine-protein kinase FerHomo sapiens (human)
germ cell developmentTyrosine-protein kinase FerHomo sapiens (human)
positive regulation of cell population proliferationTyrosine-protein kinase FerHomo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
regulation of lamellipodium assemblyTyrosine-protein kinase FerHomo sapiens (human)
regulation of fibroblast migrationTyrosine-protein kinase FerHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase FerHomo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
actin cytoskeleton organizationTyrosine-protein kinase FerHomo sapiens (human)
positive regulation of cell migrationTyrosine-protein kinase FerHomo sapiens (human)
positive regulation of actin filament polymerizationTyrosine-protein kinase FerHomo sapiens (human)
response to lipopolysaccharideTyrosine-protein kinase FerHomo sapiens (human)
negative regulation of mast cell activation involved in immune responseTyrosine-protein kinase FerHomo sapiens (human)
adherens junction assemblyTyrosine-protein kinase FerHomo sapiens (human)
substrate adhesion-dependent cell spreadingTyrosine-protein kinase FerHomo sapiens (human)
cellular response to reactive oxygen speciesTyrosine-protein kinase FerHomo sapiens (human)
extracellular matrix-cell signalingTyrosine-protein kinase FerHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase FerHomo sapiens (human)
cellular response to macrophage colony-stimulating factor stimulusTyrosine-protein kinase FerHomo sapiens (human)
response to platelet-derived growth factorTyrosine-protein kinase FerHomo sapiens (human)
Fc-epsilon receptor signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
Kit signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
regulation of epidermal growth factor receptor signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
cell-cell adhesion mediated by cadherinTyrosine-protein kinase FerHomo sapiens (human)
protein autophosphorylationTyrosine-protein kinase FerHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
diapedesisTyrosine-protein kinase FerHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTyrosine-protein kinase FerHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase FerHomo sapiens (human)
Sertoli cell developmentTyrosine-protein kinase FerHomo sapiens (human)
interleukin-6-mediated signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
seminiferous tubule developmentTyrosine-protein kinase FerHomo sapiens (human)
adherens junction disassemblyTyrosine-protein kinase FerHomo sapiens (human)
cell adhesionTyrosine-protein kinase FerHomo sapiens (human)
chemotaxisTyrosine-protein kinase FerHomo sapiens (human)
angiogenesisProtein kinase C alpha typeHomo sapiens (human)
positive regulation of endothelial cell proliferationProtein kinase C alpha typeHomo sapiens (human)
desmosome assemblyProtein kinase C alpha typeHomo sapiens (human)
chromatin remodelingProtein kinase C alpha typeHomo sapiens (human)
protein phosphorylationProtein kinase C alpha typeHomo sapiens (human)
mitotic nuclear membrane disassemblyProtein kinase C alpha typeHomo sapiens (human)
cell adhesionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of endothelial cell migrationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyProtein kinase C alpha typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C alpha typeHomo sapiens (human)
peptidyl-threonine phosphorylationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cell migrationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C alpha typeHomo sapiens (human)
regulation of mRNA stabilityProtein kinase C alpha typeHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationProtein kinase C alpha typeHomo sapiens (human)
post-translational protein modificationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of macrophage differentiationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of angiogenesisProtein kinase C alpha typeHomo sapiens (human)
positive regulation of bone resorptionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cell adhesionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of mitotic cell cycleProtein kinase C alpha typeHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProtein kinase C alpha typeHomo sapiens (human)
response to interleukin-1Protein kinase C alpha typeHomo sapiens (human)
regulation of platelet aggregationProtein kinase C alpha typeHomo sapiens (human)
apoptotic signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of angiotensin-activated signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of dense core granule biogenesisProtein kinase C alpha typeHomo sapiens (human)
intracellular signal transductionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of insulin secretionProtein kinase C alpha typeHomo sapiens (human)
mesoderm formationcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
neural tube closurecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of heart ratecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
renal water homeostasiscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
mRNA processingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein phosphorylationcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein export from nucleuscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of macroautophagycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
peptidyl-serine phosphorylationcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cytokine-mediated signaling pathwaycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
positive regulation of insulin secretioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
negative regulation of interleukin-2 productioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
high-density lipoprotein particle assemblycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cellular response to heatcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
mitochondrial protein catabolic processcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of osteoblast differentiationcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
positive regulation of gluconeogenesiscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
negative regulation of smoothened signaling pathwaycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
positive regulation of protein export from nucleuscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
sperm capacitationcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
positive regulation of calcium-mediated signalingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of cell cyclecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of cardiac muscle contractioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of proteasomal protein catabolic processcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cellular response to coldcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of protein processingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cellular response to glucose stimuluscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cellular response to parathyroid hormone stimuluscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cellular response to glucagon stimuluscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cellular response to epinephrine stimuluscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of cardiac conductioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
negative regulation of TORC1 signalingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
negative regulation of glycolytic process through fructose-6-phosphatecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein localization to lipid dropletcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of bicellular tight junction assemblycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein kinase A signalingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
angiogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
monocyte chemotaxisVascular endothelial growth factor receptor 1 Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of cell population proliferationVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of phospholipase C activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
cell migrationVascular endothelial growth factor receptor 1 Homo sapiens (human)
peptidyl-tyrosine phosphorylationVascular endothelial growth factor receptor 1 Homo sapiens (human)
cell differentiationVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of cell migrationVascular endothelial growth factor receptor 1 Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor receptor-1 signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of MAP kinase activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of MAPK cascadeVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of angiogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
protein autophosphorylationVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
blood vessel morphogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
embryonic morphogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionVascular endothelial growth factor receptor 1 Homo sapiens (human)
negative regulation of vascular endothelial cell proliferationVascular endothelial growth factor receptor 1 Homo sapiens (human)
hyaloid vascular plexus regressionVascular endothelial growth factor receptor 1 Homo sapiens (human)
multicellular organism developmentVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of kinase activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)General transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
response to hypoxiaGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
in utero embryonic developmentGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription-coupled nucleotide-excision repairGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
nucleotide-excision repairGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
regulation of transcription by RNA polymerase IIGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription elongation by RNA polymerase IGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription by RNA polymerase IIGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription initiation at RNA polymerase II promoterGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
apoptotic processGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
response to oxidative stressGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
chromosome segregationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
determination of adult lifespanGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
UV protectionGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
post-embryonic developmentGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
spinal cord developmentGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
extracellular matrix organizationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
bone mineralizationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
central nervous system myelin formationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
DNA duplex unwindingGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
multicellular organism growthGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
hair cell differentiationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
embryonic cleavageGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
erythrocyte maturationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
embryonic organ developmentGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
hair follicle maturationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
hematopoietic stem cell differentiationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
hematopoietic stem cell proliferationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
regulation of mitotic cell cycle phase transitionGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
positive regulation of mitotic recombinationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
positive regulation of cytokine productionInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
translationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein phosphorylationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of cell population proliferationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
response to virusInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of translationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
endoplasmic reticulum unfolded protein responseInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of chemokine productionInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of stress-activated MAPK cascadeInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of osteoblast proliferationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
cellular response to amino acid starvationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
response to interferon-alphaInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of apoptotic processInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of MAPK cascadeInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of viral genome replicationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein autophosphorylationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
defense response to virusInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
antiviral innate immune responseInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
regulation of NLRP3 inflammasome complex assemblyInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
regulation of hematopoietic progenitor cell differentiationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
regulation of hematopoietic stem cell proliferationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
regulation of hematopoietic stem cell differentiationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
eiF2alpha phosphorylation in response to endoplasmic reticulum stressInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
double-strand break repairCasein kinase II subunit alpha'Homo sapiens (human)
apoptotic processCasein kinase II subunit alpha'Homo sapiens (human)
spermatogenesisCasein kinase II subunit alpha'Homo sapiens (human)
Wnt signaling pathwayCasein kinase II subunit alpha'Homo sapiens (human)
cerebral cortex developmentCasein kinase II subunit alpha'Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase II subunit alpha'Homo sapiens (human)
liver regenerationCasein kinase II subunit alpha'Homo sapiens (human)
regulation of mitophagyCasein kinase II subunit alpha'Homo sapiens (human)
positive regulation of protein targeting to mitochondrionCasein kinase II subunit alpha'Homo sapiens (human)
regulation of chromosome separationCasein kinase II subunit alpha'Homo sapiens (human)
negative regulation of apoptotic signaling pathwayCasein kinase II subunit alpha'Homo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit alpha'Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase II subunit alpha'Homo sapiens (human)
peptidyl-cysteine methylationRas-related protein Rab-6AHomo sapiens (human)
retrograde vesicle-mediated transport, Golgi to endoplasmic reticulumRas-related protein Rab-6AHomo sapiens (human)
antigen processing and presentationRas-related protein Rab-6AHomo sapiens (human)
neuron projection developmentRas-related protein Rab-6AHomo sapiens (human)
protein localization to Golgi apparatusRas-related protein Rab-6AHomo sapiens (human)
early endosome to Golgi transportRas-related protein Rab-6AHomo sapiens (human)
minus-end-directed organelle transport along microtubuleRas-related protein Rab-6AHomo sapiens (human)
protein localization to Golgi membraneRas-related protein Rab-6AHomo sapiens (human)
intracellular protein transportRas-related protein Rab-6AHomo sapiens (human)
intra-Golgi vesicle-mediated transportRas-related protein Rab-6AHomo sapiens (human)
retrograde transport, endosome to GolgiRas-related protein Rab-6AHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase MAKHomo sapiens (human)
spermatogenesisSerine/threonine-protein kinase MAKHomo sapiens (human)
cell differentiationSerine/threonine-protein kinase MAKHomo sapiens (human)
photoreceptor cell maintenanceSerine/threonine-protein kinase MAKHomo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase MAKHomo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase MAKHomo sapiens (human)
negative regulation of non-motile cilium assemblySerine/threonine-protein kinase MAKHomo sapiens (human)
non-motile cilium assemblySerine/threonine-protein kinase MAKHomo sapiens (human)
intraciliary transportSerine/threonine-protein kinase MAKHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase MAKHomo sapiens (human)
cilium assemblySerine/threonine-protein kinase MAKHomo sapiens (human)
mitotic cell cycleCyclin-dependent kinase 11BHomo sapiens (human)
regulation of cell growthCyclin-dependent kinase 11BHomo sapiens (human)
regulation of DNA-templated transcriptionCyclin-dependent kinase 11BHomo sapiens (human)
protein phosphorylationCyclin-dependent kinase 11BHomo sapiens (human)
apoptotic processCyclin-dependent kinase 11BHomo sapiens (human)
regulation of mRNA processingCyclin-dependent kinase 11BHomo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 11BHomo sapiens (human)
positive regulation of cell-matrix adhesionEphrin type-A receptor 1Homo sapiens (human)
negative regulation of protein kinase activityEphrin type-A receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayEphrin type-A receptor 1Homo sapiens (human)
positive regulation of cell population proliferationEphrin type-A receptor 1Homo sapiens (human)
peptidyl-tyrosine phosphorylationEphrin type-A receptor 1Homo sapiens (human)
positive regulation of cell migrationEphrin type-A receptor 1Homo sapiens (human)
negative regulation of cell migrationEphrin type-A receptor 1Homo sapiens (human)
substrate adhesion-dependent cell spreadingEphrin type-A receptor 1Homo sapiens (human)
regulation of GTPase activityEphrin type-A receptor 1Homo sapiens (human)
positive regulation of angiogenesisEphrin type-A receptor 1Homo sapiens (human)
protein autophosphorylationEphrin type-A receptor 1Homo sapiens (human)
positive regulation of stress fiber assemblyEphrin type-A receptor 1Homo sapiens (human)
activation of GTPase activityEphrin type-A receptor 1Homo sapiens (human)
positive regulation of kinase activityEphrin type-A receptor 1Homo sapiens (human)
multicellular organism developmentEphrin type-A receptor 1Homo sapiens (human)
angiogenesisEphrin type-A receptor 1Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 1Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIFibroblast growth factor receptor 2Homo sapiens (human)
angiogenesisFibroblast growth factor receptor 2Homo sapiens (human)
ureteric bud developmentFibroblast growth factor receptor 2Homo sapiens (human)
in utero embryonic developmentFibroblast growth factor receptor 2Homo sapiens (human)
epithelial to mesenchymal transitionFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of mesenchymal cell proliferationFibroblast growth factor receptor 2Homo sapiens (human)
outflow tract septum morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
membranous septum morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
endochondral bone growthFibroblast growth factor receptor 2Homo sapiens (human)
apoptotic processFibroblast growth factor receptor 2Homo sapiens (human)
cell-cell signalingFibroblast growth factor receptor 2Homo sapiens (human)
axonogenesisFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
regulation of smoothened signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
post-embryonic developmentFibroblast growth factor receptor 2Homo sapiens (human)
embryonic pattern specificationFibroblast growth factor receptor 2Homo sapiens (human)
animal organ morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of phospholipase activityFibroblast growth factor receptor 2Homo sapiens (human)
negative regulation of keratinocyte proliferationFibroblast growth factor receptor 2Homo sapiens (human)
morphogenesis of embryonic epitheliumFibroblast growth factor receptor 2Homo sapiens (human)
peptidyl-tyrosine phosphorylationFibroblast growth factor receptor 2Homo sapiens (human)
orbitofrontal cortex developmentFibroblast growth factor receptor 2Homo sapiens (human)
ventricular zone neuroblast divisionFibroblast growth factor receptor 2Homo sapiens (human)
pyramidal neuron developmentFibroblast growth factor receptor 2Homo sapiens (human)
gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of Wnt signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
bone mineralizationFibroblast growth factor receptor 2Homo sapiens (human)
lung developmentFibroblast growth factor receptor 2Homo sapiens (human)
epithelial cell differentiationFibroblast growth factor receptor 2Homo sapiens (human)
midbrain developmentFibroblast growth factor receptor 2Homo sapiens (human)
otic vesicle formationFibroblast growth factor receptor 2Homo sapiens (human)
hair follicle morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
response to lipopolysaccharideFibroblast growth factor receptor 2Homo sapiens (human)
lacrimal gland developmentFibroblast growth factor receptor 2Homo sapiens (human)
regulation of osteoblast proliferationFibroblast growth factor receptor 2Homo sapiens (human)
organ growthFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow cellFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in hemopoiesisFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrowFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex developmentFibroblast growth factor receptor 2Homo sapiens (human)
inner ear morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
odontogenesisFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of MAPK cascadeFibroblast growth factor receptor 2Homo sapiens (human)
cell fate commitmentFibroblast growth factor receptor 2Homo sapiens (human)
response to ethanolFibroblast growth factor receptor 2Homo sapiens (human)
regulation of osteoblast differentiationFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of cell cycleFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIFibroblast growth factor receptor 2Homo sapiens (human)
protein autophosphorylationFibroblast growth factor receptor 2Homo sapiens (human)
lung alveolus developmentFibroblast growth factor receptor 2Homo sapiens (human)
mesodermal cell differentiationFibroblast growth factor receptor 2Homo sapiens (human)
embryonic digestive tract morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
embryonic organ morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
digestive tract developmentFibroblast growth factor receptor 2Homo sapiens (human)
embryonic organ developmentFibroblast growth factor receptor 2Homo sapiens (human)
reproductive structure developmentFibroblast growth factor receptor 2Homo sapiens (human)
embryonic cranial skeleton morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
skeletal system morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
epidermis morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
branching morphogenesis of a nerveFibroblast growth factor receptor 2Homo sapiens (human)
mesenchymal cell differentiationFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of epithelial cell proliferationFibroblast growth factor receptor 2Homo sapiens (human)
regulation of smooth muscle cell differentiationFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of cell divisionFibroblast growth factor receptor 2Homo sapiens (human)
ventricular cardiac muscle tissue morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationFibroblast growth factor receptor 2Homo sapiens (human)
limb bud formationFibroblast growth factor receptor 2Homo sapiens (human)
bone developmentFibroblast growth factor receptor 2Homo sapiens (human)
bone morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
branching involved in prostate gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
branching involved in salivary gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
bud elongation involved in lung branchingFibroblast growth factor receptor 2Homo sapiens (human)
lung lobe morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
lung-associated mesenchyme developmentFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of epithelial cell proliferation involved in lung morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
prostate gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
prostate epithelial cord elongationFibroblast growth factor receptor 2Homo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
squamous basal epithelial stem cell differentiation involved in prostate gland acinus developmentFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in mammary gland specificationFibroblast growth factor receptor 2Homo sapiens (human)
lateral sprouting from an epitheliumFibroblast growth factor receptor 2Homo sapiens (human)
mammary gland bud formationFibroblast growth factor receptor 2Homo sapiens (human)
epithelial cell proliferation involved in salivary gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
branch elongation involved in salivary gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
branching involved in labyrinthine layer morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
regulation of morphogenesis of a branching structureFibroblast growth factor receptor 2Homo sapiens (human)
mesenchymal cell differentiation involved in lung developmentFibroblast growth factor receptor 2Homo sapiens (human)
mesenchymal cell proliferation involved in lung developmentFibroblast growth factor receptor 2Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeFibroblast growth factor receptor 2Homo sapiens (human)
cellular response to retinoic acidFibroblast growth factor receptor 2Homo sapiens (human)
cellular response to hypoxiaFibroblast growth factor receptor 2Homo sapiens (human)
cellular response to transforming growth factor beta stimulusFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationFibroblast growth factor receptor 2Homo sapiens (human)
multicellular organism developmentFibroblast growth factor receptor 2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of kinase activityFibroblast growth factor receptor 2Homo sapiens (human)
endocardial cushion developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of cell adhesionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
signal transductionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
peripheral nervous system developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
heart developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of signal transductionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of gene expressionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
Schwann cell differentiationReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
Schwann cell developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
cranial nerve developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
wound healingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
myelinationReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of neuron apoptotic processReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of secretionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
neuron apoptotic processReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of cardiac muscle tissue developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of calcineurin-NFAT signaling cascadeReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
motor neuron apoptotic processReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of motor neuron apoptotic processReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of apoptotic processReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
neurogenesisReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of kinase activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
multicellular organism developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
GMP biosynthetic processMultifunctional protein ADE2Homo sapiens (human)
'de novo' IMP biosynthetic processMultifunctional protein ADE2Homo sapiens (human)
purine nucleobase biosynthetic processMultifunctional protein ADE2Homo sapiens (human)
'de novo' AMP biosynthetic processMultifunctional protein ADE2Homo sapiens (human)
'de novo' XMP biosynthetic processMultifunctional protein ADE2Homo sapiens (human)
response to bile acidFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 4Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 4Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of gene expressionFibroblast growth factor receptor 4Homo sapiens (human)
regulation of extracellular matrix disassemblyFibroblast growth factor receptor 4Homo sapiens (human)
cell migrationFibroblast growth factor receptor 4Homo sapiens (human)
peptidyl-tyrosine phosphorylationFibroblast growth factor receptor 4Homo sapiens (human)
regulation of lipid metabolic processFibroblast growth factor receptor 4Homo sapiens (human)
glucose homeostasisFibroblast growth factor receptor 4Homo sapiens (human)
cholesterol homeostasisFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of catalytic activityFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of proteolysisFibroblast growth factor receptor 4Homo sapiens (human)
protein autophosphorylationFibroblast growth factor receptor 4Homo sapiens (human)
phosphate ion homeostasisFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeFibroblast growth factor receptor 4Homo sapiens (human)
regulation of bile acid biosynthetic processFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of DNA biosynthetic processFibroblast growth factor receptor 4Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayFibroblast growth factor receptor 4Homo sapiens (human)
multicellular organism developmentFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of kinase activityFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 3Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 3Homo sapiens (human)
MAPK cascadeFibroblast growth factor receptor 3Homo sapiens (human)
skeletal system developmentFibroblast growth factor receptor 3Homo sapiens (human)
endochondral ossificationFibroblast growth factor receptor 3Homo sapiens (human)
chondrocyte differentiationFibroblast growth factor receptor 3Homo sapiens (human)
endochondral bone growthFibroblast growth factor receptor 3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATFibroblast growth factor receptor 3Homo sapiens (human)
cell-cell signalingFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 3Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of phospholipase activityFibroblast growth factor receptor 3Homo sapiens (human)
bone mineralizationFibroblast growth factor receptor 3Homo sapiens (human)
chondrocyte proliferationFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of MAPK cascadeFibroblast growth factor receptor 3Homo sapiens (human)
negative regulation of developmental growthFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionFibroblast growth factor receptor 3Homo sapiens (human)
bone morphogenesisFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeFibroblast growth factor receptor 3Homo sapiens (human)
bone maturationFibroblast growth factor receptor 3Homo sapiens (human)
fibroblast growth factor receptor apoptotic signaling pathwayFibroblast growth factor receptor 3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayFibroblast growth factor receptor 3Homo sapiens (human)
multicellular organism developmentFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of kinase activityFibroblast growth factor receptor 3Homo sapiens (human)
renal water homeostasiscAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
spermatogenesiscAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
male gonad developmentcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
high-density lipoprotein particle assemblycAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
protein kinase A signalingcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
neural tube closurecAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
renal water homeostasiscAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
protein phosphorylationcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
signal transductioncAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwaycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
high-density lipoprotein particle assemblycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
negative regulation of smoothened signaling pathwaycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
regulation of protein processingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
negative regulation of TORC1 signalingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
protein kinase A signalingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
generation of precursor metabolites and energyFerrochelatase, mitochondrialHomo sapiens (human)
heme biosynthetic processFerrochelatase, mitochondrialHomo sapiens (human)
heme A biosynthetic processFerrochelatase, mitochondrialHomo sapiens (human)
heme B biosynthetic processFerrochelatase, mitochondrialHomo sapiens (human)
cholesterol metabolic processFerrochelatase, mitochondrialHomo sapiens (human)
response to xenobiotic stimulusFerrochelatase, mitochondrialHomo sapiens (human)
response to light stimulusFerrochelatase, mitochondrialHomo sapiens (human)
detection of UVFerrochelatase, mitochondrialHomo sapiens (human)
response to lead ionFerrochelatase, mitochondrialHomo sapiens (human)
regulation of eIF2 alpha phosphorylation by hemeFerrochelatase, mitochondrialHomo sapiens (human)
response to insecticideFerrochelatase, mitochondrialHomo sapiens (human)
erythrocyte differentiationFerrochelatase, mitochondrialHomo sapiens (human)
very-low-density lipoprotein particle assemblyFerrochelatase, mitochondrialHomo sapiens (human)
response to ethanolFerrochelatase, mitochondrialHomo sapiens (human)
protoporphyrinogen IX metabolic processFerrochelatase, mitochondrialHomo sapiens (human)
response to arsenic-containing substanceFerrochelatase, mitochondrialHomo sapiens (human)
regulation of hemoglobin biosynthetic processFerrochelatase, mitochondrialHomo sapiens (human)
heme O biosynthetic processFerrochelatase, mitochondrialHomo sapiens (human)
response to methylmercuryFerrochelatase, mitochondrialHomo sapiens (human)
multicellular organismal-level iron ion homeostasisFerrochelatase, mitochondrialHomo sapiens (human)
response to platinum ionFerrochelatase, mitochondrialHomo sapiens (human)
cellular response to dexamethasone stimulusFerrochelatase, mitochondrialHomo sapiens (human)
G1/S transition of mitotic cell cycleRibosomal protein S6 kinase beta-1Homo sapiens (human)
behavioral fear responseRibosomal protein S6 kinase beta-1Homo sapiens (human)
skeletal muscle contractionRibosomal protein S6 kinase beta-1Homo sapiens (human)
apoptotic processRibosomal protein S6 kinase beta-1Homo sapiens (human)
signal transductionRibosomal protein S6 kinase beta-1Homo sapiens (human)
germ cell developmentRibosomal protein S6 kinase beta-1Homo sapiens (human)
long-term memoryRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to xenobiotic stimulusRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to mechanical stimulusRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to toxic substanceRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to glucoseRibosomal protein S6 kinase beta-1Homo sapiens (human)
skeletal muscle atrophyRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to electrical stimulus involved in regulation of muscle adaptationRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of smooth muscle cell migrationRibosomal protein S6 kinase beta-1Homo sapiens (human)
cell migrationRibosomal protein S6 kinase beta-1Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to nutrient levelsRibosomal protein S6 kinase beta-1Homo sapiens (human)
cellular response to nutrientRibosomal protein S6 kinase beta-1Homo sapiens (human)
TOR signalingRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to lipopolysaccharideRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to testosteroneRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to glucagonRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to tumor necrosis factorRibosomal protein S6 kinase beta-1Homo sapiens (human)
negative regulation of apoptotic processRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to L-leucineRibosomal protein S6 kinase beta-1Homo sapiens (human)
long-chain fatty acid import into cellRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to ethanolRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of translationRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of mitotic cell cycleRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of translational initiationRibosomal protein S6 kinase beta-1Homo sapiens (human)
regulation of glucose importRibosomal protein S6 kinase beta-1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayRibosomal protein S6 kinase beta-1Homo sapiens (human)
phosphatidylinositol-mediated signalingRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of skeletal muscle tissue growthRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of smooth muscle cell proliferationRibosomal protein S6 kinase beta-1Homo sapiens (human)
modulation of chemical synaptic transmissionRibosomal protein S6 kinase beta-1Homo sapiens (human)
cellular response to type II interferonRibosomal protein S6 kinase beta-1Homo sapiens (human)
cellular response to growth factor stimulusRibosomal protein S6 kinase beta-1Homo sapiens (human)
cellular response to dexamethasone stimulusRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of TORC1 signalingRibosomal protein S6 kinase beta-1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayRibosomal protein S6 kinase beta-1Homo sapiens (human)
cellular response to insulin stimulusRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to antibioticTyrosine-protein kinase JAK1Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase JAK1Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK1Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
positive regulation of homotypic cell-cell adhesionTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-15-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-4-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-2-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-9-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-11-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
type III interferon-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
type II interferon-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
type I interferon-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-6-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
T-helper 17 cell lineage commitmentTyrosine-protein kinase JAK1Homo sapiens (human)
cellular response to virusTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-10-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
protein localization to cell-cell junctionTyrosine-protein kinase JAK1Homo sapiens (human)
positive regulation of protein localization to nucleusTyrosine-protein kinase JAK1Homo sapiens (human)
positive regulation of sprouting angiogenesisTyrosine-protein kinase JAK1Homo sapiens (human)
intracellular signal transductionTyrosine-protein kinase JAK1Homo sapiens (human)
tyrosine phosphorylation of STAT proteinTyrosine-protein kinase JAK1Homo sapiens (human)
cell differentiationTyrosine-protein kinase JAK1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK1Homo sapiens (human)
protein phosphorylationProtein kinase C eta typeHomo sapiens (human)
signal transductionProtein kinase C eta typeHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationProtein kinase C eta typeHomo sapiens (human)
cell differentiationProtein kinase C eta typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C eta typeHomo sapiens (human)
positive regulation of keratinocyte differentiationProtein kinase C eta typeHomo sapiens (human)
positive regulation of B cell receptor signaling pathwayProtein kinase C eta typeHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProtein kinase C eta typeHomo sapiens (human)
positive regulation of glial cell proliferationProtein kinase C eta typeHomo sapiens (human)
protein kinase C signalingProtein kinase C eta typeHomo sapiens (human)
positive regulation of protein localization to plasma membraneProtein kinase C eta typeHomo sapiens (human)
regulation of bicellular tight junction assemblyProtein kinase C eta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C eta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C eta typeHomo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICyclin-dependent kinase 2Homo sapiens (human)
DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
DNA repairCyclin-dependent kinase 2Homo sapiens (human)
chromatin remodelingCyclin-dependent kinase 2Homo sapiens (human)
DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
potassium ion transportCyclin-dependent kinase 2Homo sapiens (human)
centriole replicationCyclin-dependent kinase 2Homo sapiens (human)
Ras protein signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of cell population proliferationCyclin-dependent kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of heterochromatin formationCyclin-dependent kinase 2Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated DNA replication initiationCyclin-dependent kinase 2Homo sapiens (human)
telomere maintenance in response to DNA damageCyclin-dependent kinase 2Homo sapiens (human)
post-translational protein modificationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
centrosome duplicationCyclin-dependent kinase 2Homo sapiens (human)
cell divisionCyclin-dependent kinase 2Homo sapiens (human)
meiotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
cellular response to nitric oxideCyclin-dependent kinase 2Homo sapiens (human)
cellular senescenceCyclin-dependent kinase 2Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic processCyclin-dependent kinase 2Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 2Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 2Homo sapiens (human)
desensitization of G protein-coupled receptor signaling pathwayBeta-adrenergic receptor kinase 1Homo sapiens (human)
negative regulation of the force of heart contraction by chemical signalBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayBeta-adrenergic receptor kinase 1Homo sapiens (human)
tachykinin receptor signaling pathwayBeta-adrenergic receptor kinase 1Homo sapiens (human)
heart developmentBeta-adrenergic receptor kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationBeta-adrenergic receptor kinase 1Homo sapiens (human)
viral genome replicationBeta-adrenergic receptor kinase 1Homo sapiens (human)
receptor internalizationBeta-adrenergic receptor kinase 1Homo sapiens (human)
positive regulation of catecholamine secretionBeta-adrenergic receptor kinase 1Homo sapiens (human)
negative regulation of striated muscle contractionBeta-adrenergic receptor kinase 1Homo sapiens (human)
symbiont entry into host cellBeta-adrenergic receptor kinase 1Homo sapiens (human)
cardiac muscle contractionBeta-adrenergic receptor kinase 1Homo sapiens (human)
negative regulation of relaxation of smooth muscleBeta-adrenergic receptor kinase 1Homo sapiens (human)
regulation of the force of heart contractionBeta-adrenergic receptor kinase 1Homo sapiens (human)
protein phosphorylationBeta-adrenergic receptor kinase 1Homo sapiens (human)
P-body assemblyProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
miRNA-mediated gene silencing by inhibition of translationProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
negative regulation of translationProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
viral RNA genome packagingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
stem cell population maintenanceProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
neuron differentiationProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
P-body assemblyProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
negative regulation of neuron differentiationProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
stress granule assemblyProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
positive regulation of protein phosphorylationActivin receptor type-2AHomo sapiens (human)
BMP signaling pathwayActivin receptor type-2AHomo sapiens (human)
gastrulation with mouth forming secondActivin receptor type-2AHomo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayActivin receptor type-2AHomo sapiens (human)
spermatogenesisActivin receptor type-2AHomo sapiens (human)
determination of left/right symmetryActivin receptor type-2AHomo sapiens (human)
mesoderm developmentActivin receptor type-2AHomo sapiens (human)
anterior/posterior pattern specificationActivin receptor type-2AHomo sapiens (human)
positive regulation of bone mineralizationActivin receptor type-2AHomo sapiens (human)
BMP signaling pathwayActivin receptor type-2AHomo sapiens (human)
activin receptor signaling pathwayActivin receptor type-2AHomo sapiens (human)
positive regulation of activin receptor signaling pathwayActivin receptor type-2AHomo sapiens (human)
odontogenesis of dentin-containing toothActivin receptor type-2AHomo sapiens (human)
sperm ejaculationActivin receptor type-2AHomo sapiens (human)
penile erectionActivin receptor type-2AHomo sapiens (human)
regulation of nitric oxide biosynthetic processActivin receptor type-2AHomo sapiens (human)
positive regulation of erythrocyte differentiationActivin receptor type-2AHomo sapiens (human)
positive regulation of osteoblast differentiationActivin receptor type-2AHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIActivin receptor type-2AHomo sapiens (human)
embryonic skeletal system developmentActivin receptor type-2AHomo sapiens (human)
Sertoli cell proliferationActivin receptor type-2AHomo sapiens (human)
positive regulation of SMAD protein signal transductionActivin receptor type-2AHomo sapiens (human)
cellular response to BMP stimulusActivin receptor type-2AHomo sapiens (human)
protein phosphorylationActivin receptor type-2AHomo sapiens (human)
cellular response to growth factor stimulusActivin receptor type-2AHomo sapiens (human)
positive regulation of macrophage chemotaxisMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of macrophage proliferationMitogen-activated protein kinase 3 Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
DNA-templated transcriptionMitogen-activated protein kinase 3 Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 3 Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 3 Homo sapiens (human)
insulin receptor signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
Schwann cell developmentMitogen-activated protein kinase 3 Homo sapiens (human)
phosphorylationMitogen-activated protein kinase 3 Homo sapiens (human)
sensory perception of painMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 3 Homo sapiens (human)
BMP signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of cellular pHMitogen-activated protein kinase 3 Homo sapiens (human)
thyroid gland developmentMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 3 Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of stress-activated MAPK cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to amino acid starvationMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to reactive oxygen speciesMitogen-activated protein kinase 3 Homo sapiens (human)
peptidyl-tyrosine autophosphorylationMitogen-activated protein kinase 3 Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
outer ear morphogenesisMitogen-activated protein kinase 3 Homo sapiens (human)
myelinationMitogen-activated protein kinase 3 Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 3 Homo sapiens (human)
response to exogenous dsRNAMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 3 Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
thymus developmentMitogen-activated protein kinase 3 Homo sapiens (human)
modulation of chemical synaptic transmissionMitogen-activated protein kinase 3 Homo sapiens (human)
cartilage developmentMitogen-activated protein kinase 3 Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of cytoskeleton organizationMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of telomerase activityMitogen-activated protein kinase 3 Homo sapiens (human)
Bergmann glial cell differentiationMitogen-activated protein kinase 3 Homo sapiens (human)
face developmentMitogen-activated protein kinase 3 Homo sapiens (human)
lung morphogenesisMitogen-activated protein kinase 3 Homo sapiens (human)
trachea formationMitogen-activated protein kinase 3 Homo sapiens (human)
cardiac neural crest cell development involved in heart developmentMitogen-activated protein kinase 3 Homo sapiens (human)
ERK1 and ERK2 cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
interleukin-1-mediated signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
response to epidermal growth factorMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to mechanical stimulusMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to cadmium ionMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 3 Homo sapiens (human)
caveolin-mediated endocytosisMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of Golgi inheritanceMitogen-activated protein kinase 3 Homo sapiens (human)
xenophagyMitogen-activated protein kinase 3 Homo sapiens (human)
negative regulation of TORC1 signalingMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of telomere cappingMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of xenophagyMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of early endosome to late endosome transportMitogen-activated protein kinase 3 Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 3 Homo sapiens (human)
protein phosphorylationMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
peptidyl-serine phosphorylationMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
positive regulation of protein bindingMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
negative regulation of hippo signalingMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
peptidyl-serine autophosphorylationMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
negative regulation of protein localization to nucleusMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
intracellular signal transductionMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
pyrimidine nucleotide metabolic processDeoxycytidine kinaseHomo sapiens (human)
CMP biosynthetic processDeoxycytidine kinaseHomo sapiens (human)
dAMP salvageDeoxycytidine kinaseHomo sapiens (human)
nucleoside phosphate biosynthetic processDeoxycytidine kinaseHomo sapiens (human)
positive regulation of macrophage chemotaxisMitogen-activated protein kinase 1Homo sapiens (human)
positive regulation of macrophage proliferationMitogen-activated protein kinase 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 1Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 1Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 1Homo sapiens (human)
chemotaxisMitogen-activated protein kinase 1Homo sapiens (human)
DNA damage responseMitogen-activated protein kinase 1Homo sapiens (human)
signal transductionMitogen-activated protein kinase 1Homo sapiens (human)
chemical synaptic transmissionMitogen-activated protein kinase 1Homo sapiens (human)
learning or memoryMitogen-activated protein kinase 1Homo sapiens (human)
insulin receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationMitogen-activated protein kinase 1Homo sapiens (human)
Schwann cell developmentMitogen-activated protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylationMitogen-activated protein kinase 1Homo sapiens (human)
cytosine metabolic processMitogen-activated protein kinase 1Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 1Homo sapiens (human)
androgen receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
regulation of cellular pHMitogen-activated protein kinase 1Homo sapiens (human)
thyroid gland developmentMitogen-activated protein kinase 1Homo sapiens (human)
regulation of protein stabilityMitogen-activated protein kinase 1Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseMitogen-activated protein kinase 1Homo sapiens (human)
regulation of stress-activated MAPK cascadeMitogen-activated protein kinase 1Homo sapiens (human)
mammary gland epithelial cell proliferationMitogen-activated protein kinase 1Homo sapiens (human)
cellular response to amino acid starvationMitogen-activated protein kinase 1Homo sapiens (human)
cellular response to reactive oxygen speciesMitogen-activated protein kinase 1Homo sapiens (human)
response to nicotineMitogen-activated protein kinase 1Homo sapiens (human)
ERBB signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
outer ear morphogenesisMitogen-activated protein kinase 1Homo sapiens (human)
myelinationMitogen-activated protein kinase 1Homo sapiens (human)
response to exogenous dsRNAMitogen-activated protein kinase 1Homo sapiens (human)
steroid hormone mediated signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
negative regulation of cell differentiationMitogen-activated protein kinase 1Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
thymus developmentMitogen-activated protein kinase 1Homo sapiens (human)
progesterone receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
T cell receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
B cell receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 1Homo sapiens (human)
regulation of cytoskeleton organizationMitogen-activated protein kinase 1Homo sapiens (human)
positive regulation of telomerase activityMitogen-activated protein kinase 1Homo sapiens (human)
Bergmann glial cell differentiationMitogen-activated protein kinase 1Homo sapiens (human)
long-term synaptic potentiationMitogen-activated protein kinase 1Homo sapiens (human)
face developmentMitogen-activated protein kinase 1Homo sapiens (human)
lung morphogenesisMitogen-activated protein kinase 1Homo sapiens (human)
trachea formationMitogen-activated protein kinase 1Homo sapiens (human)
labyrinthine layer blood vessel developmentMitogen-activated protein kinase 1Homo sapiens (human)
cardiac neural crest cell development involved in heart developmentMitogen-activated protein kinase 1Homo sapiens (human)
ERK1 and ERK2 cascadeMitogen-activated protein kinase 1Homo sapiens (human)
response to epidermal growth factorMitogen-activated protein kinase 1Homo sapiens (human)
cellular response to cadmium ionMitogen-activated protein kinase 1Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 1Homo sapiens (human)
caveolin-mediated endocytosisMitogen-activated protein kinase 1Homo sapiens (human)
regulation of Golgi inheritanceMitogen-activated protein kinase 1Homo sapiens (human)
positive regulation of telomere cappingMitogen-activated protein kinase 1Homo sapiens (human)
regulation of early endosome to late endosome transportMitogen-activated protein kinase 1Homo sapiens (human)
cell surface receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 1Homo sapiens (human)
skeletal system developmentEphrin type-A receptor 2Homo sapiens (human)
vasculogenesisEphrin type-A receptor 2Homo sapiens (human)
osteoblast differentiationEphrin type-A receptor 2Homo sapiens (human)
blood vessel endothelial cell proliferation involved in sprouting angiogenesisEphrin type-A receptor 2Homo sapiens (human)
inflammatory responseEphrin type-A receptor 2Homo sapiens (human)
cell adhesionEphrin type-A receptor 2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageEphrin type-A receptor 2Homo sapiens (human)
regulation of lamellipodium assemblyEphrin type-A receptor 2Homo sapiens (human)
notochord formationEphrin type-A receptor 2Homo sapiens (human)
cell migrationEphrin type-A receptor 2Homo sapiens (human)
negative regulation of angiogenesisEphrin type-A receptor 2Homo sapiens (human)
neural tube developmentEphrin type-A receptor 2Homo sapiens (human)
neuron differentiationEphrin type-A receptor 2Homo sapiens (human)
keratinocyte differentiationEphrin type-A receptor 2Homo sapiens (human)
osteoclast differentiationEphrin type-A receptor 2Homo sapiens (human)
positive regulation of cell migrationEphrin type-A receptor 2Homo sapiens (human)
negative regulation of chemokine productionEphrin type-A receptor 2Homo sapiens (human)
mammary gland epithelial cell proliferationEphrin type-A receptor 2Homo sapiens (human)
regulation of cell adhesion mediated by integrinEphrin type-A receptor 2Homo sapiens (human)
post-anal tail morphogenesisEphrin type-A receptor 2Homo sapiens (human)
regulation of blood vessel endothelial cell migrationEphrin type-A receptor 2Homo sapiens (human)
regulation of angiogenesisEphrin type-A receptor 2Homo sapiens (human)
cAMP metabolic processEphrin type-A receptor 2Homo sapiens (human)
symbiont entry into host cellEphrin type-A receptor 2Homo sapiens (human)
bone remodelingEphrin type-A receptor 2Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 2Homo sapiens (human)
axial mesoderm formationEphrin type-A receptor 2Homo sapiens (human)
cell motilityEphrin type-A receptor 2Homo sapiens (human)
defense response to Gram-positive bacteriumEphrin type-A receptor 2Homo sapiens (human)
notochord cell developmentEphrin type-A receptor 2Homo sapiens (human)
cell chemotaxisEphrin type-A receptor 2Homo sapiens (human)
branching involved in mammary gland duct morphogenesisEphrin type-A receptor 2Homo sapiens (human)
lens fiber cell morphogenesisEphrin type-A receptor 2Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeEphrin type-A receptor 2Homo sapiens (human)
response to growth factorEphrin type-A receptor 2Homo sapiens (human)
protein localization to plasma membraneEphrin type-A receptor 2Homo sapiens (human)
activation of GTPase activityEphrin type-A receptor 2Homo sapiens (human)
negative regulation of lymphangiogenesisEphrin type-A receptor 2Homo sapiens (human)
positive regulation of protein localization to plasma membraneEphrin type-A receptor 2Homo sapiens (human)
positive regulation of bicellular tight junction assemblyEphrin type-A receptor 2Homo sapiens (human)
pericyte cell differentiationEphrin type-A receptor 2Homo sapiens (human)
positive regulation of kinase activityEphrin type-A receptor 2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEphrin type-A receptor 2Homo sapiens (human)
multicellular organism developmentEphrin type-A receptor 2Homo sapiens (human)
cell adhesionEphrin type-A receptor 3Homo sapiens (human)
regulation of epithelial to mesenchymal transitionEphrin type-A receptor 3Homo sapiens (human)
positive regulation of neuron projection developmentEphrin type-A receptor 3Homo sapiens (human)
cell migrationEphrin type-A receptor 3Homo sapiens (human)
peptidyl-tyrosine phosphorylationEphrin type-A receptor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationEphrin type-A receptor 3Homo sapiens (human)
regulation of GTPase activityEphrin type-A receptor 3Homo sapiens (human)
negative regulation of endocytosisEphrin type-A receptor 3Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 3Homo sapiens (human)
regulation of focal adhesion assemblyEphrin type-A receptor 3Homo sapiens (human)
regulation of microtubule cytoskeleton organizationEphrin type-A receptor 3Homo sapiens (human)
cellular response to retinoic acidEphrin type-A receptor 3Homo sapiens (human)
fasciculation of sensory neuron axonEphrin type-A receptor 3Homo sapiens (human)
fasciculation of motor neuron axonEphrin type-A receptor 3Homo sapiens (human)
positive regulation of protein localization to plasma membraneEphrin type-A receptor 3Homo sapiens (human)
protein phosphorylationEphrin type-A receptor 3Homo sapiens (human)
axon guidanceEphrin type-A receptor 3Homo sapiens (human)
substrate-dependent cell migrationEphrin type-A receptor 8Homo sapiens (human)
cell adhesionEphrin type-A receptor 8Homo sapiens (human)
axon guidanceEphrin type-A receptor 8Homo sapiens (human)
neuron remodelingEphrin type-A receptor 8Homo sapiens (human)
regulation of cell adhesionEphrin type-A receptor 8Homo sapiens (human)
neuron projection developmentEphrin type-A receptor 8Homo sapiens (human)
regulation of cell adhesion mediated by integrinEphrin type-A receptor 8Homo sapiens (human)
positive regulation of MAPK cascadeEphrin type-A receptor 8Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 8Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEphrin type-A receptor 8Homo sapiens (human)
cellular response to follicle-stimulating hormone stimulusEphrin type-A receptor 8Homo sapiens (human)
protein phosphorylationEphrin type-A receptor 8Homo sapiens (human)
negative regulation of protein kinase activityEphrin type-B receptor 2Homo sapiens (human)
regulation of autophagosome assemblyEphrin type-B receptor 2Homo sapiens (human)
angiogenesisEphrin type-B receptor 2Homo sapiens (human)
urogenital system developmentEphrin type-B receptor 2Homo sapiens (human)
negative regulation of protein phosphorylationEphrin type-B receptor 2Homo sapiens (human)
positive regulation of immunoglobulin productionEphrin type-B receptor 2Homo sapiens (human)
negative regulation of cell adhesionEphrin type-B receptor 2Homo sapiens (human)
nervous system developmentEphrin type-B receptor 2Homo sapiens (human)
axon guidanceEphrin type-B receptor 2Homo sapiens (human)
axonal fasciculationEphrin type-B receptor 2Homo sapiens (human)
learning or memoryEphrin type-B receptor 2Homo sapiens (human)
learningEphrin type-B receptor 2Homo sapiens (human)
positive regulation of gene expressionEphrin type-B receptor 2Homo sapiens (human)
phosphorylationEphrin type-B receptor 2Homo sapiens (human)
peptidyl-tyrosine phosphorylationEphrin type-B receptor 2Homo sapiens (human)
optic nerve morphogenesisEphrin type-B receptor 2Homo sapiens (human)
hindbrain tangential cell migrationEphrin type-B receptor 2Homo sapiens (human)
central nervous system projection neuron axonogenesisEphrin type-B receptor 2Homo sapiens (human)
corpus callosum developmentEphrin type-B receptor 2Homo sapiens (human)
regulation of blood coagulationEphrin type-B receptor 2Homo sapiens (human)
positive regulation of cell migrationEphrin type-B receptor 2Homo sapiens (human)
positive regulation of B cell proliferationEphrin type-B receptor 2Homo sapiens (human)
retinal ganglion cell axon guidanceEphrin type-B receptor 2Homo sapiens (human)
positive regulation of synaptic plasticityEphrin type-B receptor 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionEphrin type-B receptor 2Homo sapiens (human)
B cell activationEphrin type-B receptor 2Homo sapiens (human)
inner ear morphogenesisEphrin type-B receptor 2Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STATEphrin type-B receptor 2Homo sapiens (human)
negative regulation of Ras protein signal transductionEphrin type-B receptor 2Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-B receptor 2Homo sapiens (human)
regulation of neuronal synaptic plasticityEphrin type-B receptor 2Homo sapiens (human)
positive regulation of long-term neuronal synaptic plasticityEphrin type-B receptor 2Homo sapiens (human)
camera-type eye morphogenesisEphrin type-B receptor 2Homo sapiens (human)
negative regulation of axonogenesisEphrin type-B receptor 2Homo sapiens (human)
regulation of body fluid levelsEphrin type-B receptor 2Homo sapiens (human)
regulation of filopodium assemblyEphrin type-B receptor 2Homo sapiens (human)
positive regulation of synapse assemblyEphrin type-B receptor 2Homo sapiens (human)
roof of mouth developmentEphrin type-B receptor 2Homo sapiens (human)
dendritic spine developmentEphrin type-B receptor 2Homo sapiens (human)
dendritic spine morphogenesisEphrin type-B receptor 2Homo sapiens (human)
positive regulation of dendritic spine morphogenesisEphrin type-B receptor 2Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeEphrin type-B receptor 2Homo sapiens (human)
cellular response to lipopolysaccharideEphrin type-B receptor 2Homo sapiens (human)
commissural neuron axon guidanceEphrin type-B receptor 2Homo sapiens (human)
postsynaptic membrane assemblyEphrin type-B receptor 2Homo sapiens (human)
trans-synaptic signaling by trans-synaptic complex, modulating synaptic transmissionEphrin type-B receptor 2Homo sapiens (human)
neuron projection retractionEphrin type-B receptor 2Homo sapiens (human)
vesicle-mediated intercellular transportEphrin type-B receptor 2Homo sapiens (human)
tight junction assemblyEphrin type-B receptor 2Homo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseEphrin type-B receptor 2Homo sapiens (human)
positive regulation of long-term synaptic potentiationEphrin type-B receptor 2Homo sapiens (human)
positive regulation of protein localization to plasma membraneEphrin type-B receptor 2Homo sapiens (human)
cellular response to amyloid-betaEphrin type-B receptor 2Homo sapiens (human)
negative regulation of NMDA glutamate receptor activityEphrin type-B receptor 2Homo sapiens (human)
positive regulation of NMDA glutamate receptor activityEphrin type-B receptor 2Homo sapiens (human)
positive regulation of protein localization to cell surfaceEphrin type-B receptor 2Homo sapiens (human)
regulation of T-helper 17 type immune responseEphrin type-B receptor 2Homo sapiens (human)
regulation of behavioral fear responseEphrin type-B receptor 2Homo sapiens (human)
protein phosphorylationEphrin type-B receptor 2Homo sapiens (human)
protein phosphorylationLeukocyte tyrosine kinase receptorHomo sapiens (human)
signal transductionLeukocyte tyrosine kinase receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayLeukocyte tyrosine kinase receptorHomo sapiens (human)
cell population proliferationLeukocyte tyrosine kinase receptorHomo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processLeukocyte tyrosine kinase receptorHomo sapiens (human)
positive regulation of neuron projection developmentLeukocyte tyrosine kinase receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationLeukocyte tyrosine kinase receptorHomo sapiens (human)
negative regulation of apoptotic processLeukocyte tyrosine kinase receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionLeukocyte tyrosine kinase receptorHomo sapiens (human)
cellular response to retinoic acidLeukocyte tyrosine kinase receptorHomo sapiens (human)
regulation of cell population proliferationLeukocyte tyrosine kinase receptorHomo sapiens (human)
positive regulation of kinase activityLeukocyte tyrosine kinase receptorHomo sapiens (human)
regulation of neuron differentiationLeukocyte tyrosine kinase receptorHomo sapiens (human)
multicellular organism developmentLeukocyte tyrosine kinase receptorHomo sapiens (human)
protein phosphorylationNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
immune responseNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytokine-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of type II interferon productionNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of interleukin-17 productionNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of natural killer cell proliferationNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
interleukin-12-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
type III interferon-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of T cell proliferationNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of NK T cell proliferationNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
type II interferon-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
type I interferon-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cellular response to virusNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
interleukin-10-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of protein localization to nucleusNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of T-helper 17 type immune responseNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
intracellular signal transductionNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cell differentiationNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
'de novo' pyrimidine nucleobase biosynthetic processUMP-CMP kinase Homo sapiens (human)
UMP biosynthetic processUMP-CMP kinase Homo sapiens (human)
UDP biosynthetic processUMP-CMP kinase Homo sapiens (human)
pyrimidine ribonucleotide biosynthetic processUMP-CMP kinase Homo sapiens (human)
nucleobase-containing small molecule interconversionUMP-CMP kinase Homo sapiens (human)
nucleoside monophosphate phosphorylationUMP-CMP kinase Homo sapiens (human)
CDP biosynthetic processUMP-CMP kinase Homo sapiens (human)
negative regulation of MAPK cascadePhosphatidylethanolamine-binding protein 1Homo sapiens (human)
G2/M transition of mitotic cell cycleWee1-like protein kinaseHomo sapiens (human)
microtubule cytoskeleton organizationWee1-like protein kinaseHomo sapiens (human)
negative regulation of G2/M transition of mitotic cell cycleWee1-like protein kinaseHomo sapiens (human)
establishment of cell polarityWee1-like protein kinaseHomo sapiens (human)
positive regulation of DNA replicationWee1-like protein kinaseHomo sapiens (human)
neuron projection morphogenesisWee1-like protein kinaseHomo sapiens (human)
cell divisionWee1-like protein kinaseHomo sapiens (human)
negative regulation of G1/S transition of mitotic cell cycleWee1-like protein kinaseHomo sapiens (human)
protein phosphorylationWee1-like protein kinaseHomo sapiens (human)
response to hypoxiaHeme oxygenase 2Homo sapiens (human)
response to oxidative stressHeme oxygenase 2Homo sapiens (human)
heme catabolic processHeme oxygenase 2Homo sapiens (human)
heme oxidationHeme oxygenase 2Homo sapiens (human)
neuron migrationTyrosine-protein kinase receptor UFOHomo sapiens (human)
positive regulation of cytokine-mediated signaling pathwayTyrosine-protein kinase receptor UFOHomo sapiens (human)
blood vessel remodelingTyrosine-protein kinase receptor UFOHomo sapiens (human)
phagocytosisTyrosine-protein kinase receptor UFOHomo sapiens (human)
inflammatory responseTyrosine-protein kinase receptor UFOHomo sapiens (human)
signal transductionTyrosine-protein kinase receptor UFOHomo sapiens (human)
spermatogenesisTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of macrophage cytokine productionTyrosine-protein kinase receptor UFOHomo sapiens (human)
forebrain cell migrationTyrosine-protein kinase receptor UFOHomo sapiens (human)
animal organ regenerationTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of type II interferon productionTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of tumor necrosis factor productionTyrosine-protein kinase receptor UFOHomo sapiens (human)
positive regulation of natural killer cell differentiationTyrosine-protein kinase receptor UFOHomo sapiens (human)
secretion by cellTyrosine-protein kinase receptor UFOHomo sapiens (human)
erythrocyte homeostasisTyrosine-protein kinase receptor UFOHomo sapiens (human)
substrate adhesion-dependent cell spreadingTyrosine-protein kinase receptor UFOHomo sapiens (human)
cellular response to interferon-alphaTyrosine-protein kinase receptor UFOHomo sapiens (human)
ovulation cycleTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of neuron apoptotic processTyrosine-protein kinase receptor UFOHomo sapiens (human)
innate immune responseTyrosine-protein kinase receptor UFOHomo sapiens (human)
symbiont entry into host cellTyrosine-protein kinase receptor UFOHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayTyrosine-protein kinase receptor UFOHomo sapiens (human)
cell maturationTyrosine-protein kinase receptor UFOHomo sapiens (human)
positive regulation of pinocytosisTyrosine-protein kinase receptor UFOHomo sapiens (human)
response to axon injuryTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of lymphocyte activationTyrosine-protein kinase receptor UFOHomo sapiens (human)
neuron apoptotic processTyrosine-protein kinase receptor UFOHomo sapiens (human)
establishment of localization in cellTyrosine-protein kinase receptor UFOHomo sapiens (human)
vagina developmentTyrosine-protein kinase receptor UFOHomo sapiens (human)
cellular response to hydrogen peroxideTyrosine-protein kinase receptor UFOHomo sapiens (human)
cellular response to lipopolysaccharideTyrosine-protein kinase receptor UFOHomo sapiens (human)
dendritic cell differentiationTyrosine-protein kinase receptor UFOHomo sapiens (human)
neutrophil clearanceTyrosine-protein kinase receptor UFOHomo sapiens (human)
positive regulation of viral life cycleTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of dendritic cell apoptotic processTyrosine-protein kinase receptor UFOHomo sapiens (human)
platelet activationTyrosine-protein kinase receptor UFOHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase receptor UFOHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase receptor UFOHomo sapiens (human)
natural killer cell differentiationTyrosine-protein kinase receptor UFOHomo sapiens (human)
cell migrationTyrosine-protein kinase receptor UFOHomo sapiens (human)
positive regulation of kinase activityTyrosine-protein kinase receptor UFOHomo sapiens (human)
nervous system developmentTyrosine-protein kinase receptor UFOHomo sapiens (human)
multicellular organism developmentTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of apoptotic processTyrosine-protein kinase receptor UFOHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 4Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 4Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 4Homo sapiens (human)
S-adenosylmethionine biosynthetic processS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
one-carbon metabolic processS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
protein hexamerizationS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
protein heterooligomerizationS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
cellular response to methionineS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
positive regulation of TORC1 signalingS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
cellular response to leukemia inhibitory factorS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
protein foldingDnaJ homolog subfamily A member 1Homo sapiens (human)
response to unfolded proteinDnaJ homolog subfamily A member 1Homo sapiens (human)
spermatogenesisDnaJ homolog subfamily A member 1Homo sapiens (human)
response to heatDnaJ homolog subfamily A member 1Homo sapiens (human)
flagellated sperm motilityDnaJ homolog subfamily A member 1Homo sapiens (human)
androgen receptor signaling pathwayDnaJ homolog subfamily A member 1Homo sapiens (human)
negative regulation of protein ubiquitinationDnaJ homolog subfamily A member 1Homo sapiens (human)
positive regulation of apoptotic processDnaJ homolog subfamily A member 1Homo sapiens (human)
negative regulation of apoptotic processDnaJ homolog subfamily A member 1Homo sapiens (human)
negative regulation of JUN kinase activityDnaJ homolog subfamily A member 1Homo sapiens (human)
regulation of protein transportDnaJ homolog subfamily A member 1Homo sapiens (human)
protein localization to mitochondrionDnaJ homolog subfamily A member 1Homo sapiens (human)
negative regulation of establishment of protein localization to mitochondrionDnaJ homolog subfamily A member 1Homo sapiens (human)
negative regulation of nitrosative stress-induced intrinsic apoptotic signaling pathwayDnaJ homolog subfamily A member 1Homo sapiens (human)
protein refoldingDnaJ homolog subfamily A member 1Homo sapiens (human)
protein phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
activation-induced cell death of T cellsRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
intracellular signal transductionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
osteoblast differentiationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
maternal placenta developmentRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of endothelial cell proliferationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cell migration involved in sprouting angiogenesisRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
glycogen biosynthetic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of glycogen biosynthetic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
glucose metabolic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of translationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of protein kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein import into nucleusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
nitric oxide biosynthetic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
inflammatory responseRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to oxidative stressRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
signal transductionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
epidermal growth factor receptor signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
G protein-coupled receptor signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
canonical NF-kappaB signal transductionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cell population proliferationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
insulin receptor signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
apoptotic mitochondrial changesRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to heatRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
gene expressionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of autophagyRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of endothelial cell migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of gene expressionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of gene expressionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of long-chain fatty acid import across plasma membraneRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
fibroblast migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of fibroblast migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of sodium ion transportRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of glucose metabolic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of endopeptidase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of neuron projection developmentRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of macroautophagyRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein ubiquitinationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
peptidyl-serine phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
peptidyl-threonine phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
virus-mediated perturbation of host defense responseRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cytokine-mediated signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
mammalian oogenesis stageRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cell differentiationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cell growthRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of cell migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cell migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
T cell costimulationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of protein ubiquitinationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of myelinationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
TOR signalingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of fatty acid beta-oxidationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of endodeoxyribonuclease activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of protein bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to foodRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
peripheral nervous system myelin maintenanceRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to insulin stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to fluid shear stressRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to reactive oxygen speciesRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
interleukin-18-mediated signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to vascular endothelial growth factor stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to decreased oxygen levelsRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
non-canonical NF-kappaB signal transductionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
glucose homeostasisRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of apoptotic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of apoptotic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
anoikisRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of mRNA stabilityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of fat cell differentiationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of glycogen biosynthetic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of Notch signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of proteolysisRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of DNA-templated transcriptionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of glucose importRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of organ growthRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein autophosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of lipid biosynthetic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
behavioral response to painRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of smooth muscle cell proliferationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
striated muscle cell differentiationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein metabolic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
excitatory postsynaptic potentialRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to growth hormoneRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
mammary gland epithelial cell differentiationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
labyrinthine layer blood vessel developmentRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to UV-ARAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to growth factorRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to cadmium ionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to tumor necrosis factorRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to epidermal growth factor stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to prostaglandin E stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of protein serine/threonine kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
establishment of protein localization to mitochondrionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
maintenance of protein location in mitochondrionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of release of cytochrome c from mitochondriaRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to granulocyte macrophage colony-stimulating factor stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
execution phase of apoptosisRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of postsynapse organizationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of tRNA methylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to oxidised low-density lipoprotein particle stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of protein localization to lysosomeRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein localization to nucleusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to peptideRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of signal transduction by p53 class mediatorRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of cilium assemblyRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of leukocyte cell-cell adhesionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein localization to plasma membraneRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of I-kappaB phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of TORC1 signalingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein localization to endoplasmic reticulumRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to nerve growth factor stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to insulin-like growth factor stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein localization to cell surfaceRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of type B pancreatic cell developmentRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of lymphocyte migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
intracellular signal transductionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
glycogen biosynthetic processRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
glucose metabolic processRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
regulation of translationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
signal transductionRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
insulin receptor signaling pathwayRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of long-chain fatty acid import across plasma membraneRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of glucose metabolic processRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
regulation of cell migrationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cell migrationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of fatty acid beta-oxidationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
peripheral nervous system myelin maintenanceRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
cellular response to insulin stimulusRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
protein modification processRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
fat cell differentiationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of glycogen biosynthetic processRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of glucose importRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
regulation of cell cycleRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
mammary gland epithelial cell differentiationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
cellular response to high light intensityRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
organic substance transportRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
protein localization to plasma membraneRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein targeting to membraneRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
retinal rod cell apoptotic processRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cell motilityRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
intracellular signal transductionRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
peptidyl-serine phosphorylationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
signal transductionG protein-coupled receptor kinase 4Homo sapiens (human)
regulation of G protein-coupled receptor signaling pathwayG protein-coupled receptor kinase 4Homo sapiens (human)
regulation of opsin-mediated signaling pathwayG protein-coupled receptor kinase 4Homo sapiens (human)
receptor internalizationG protein-coupled receptor kinase 4Homo sapiens (human)
protein phosphorylationG protein-coupled receptor kinase 4Homo sapiens (human)
regulation of signal transductionG protein-coupled receptor kinase 4Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
spindle organizationDual specificity protein kinase TTKHomo sapiens (human)
mitotic spindle organizationDual specificity protein kinase TTKHomo sapiens (human)
positive regulation of cell population proliferationDual specificity protein kinase TTKHomo sapiens (human)
female meiosis chromosome segregationDual specificity protein kinase TTKHomo sapiens (human)
protein localization to meiotic spindle midzoneDual specificity protein kinase TTKHomo sapiens (human)
chromosome segregationDual specificity protein kinase TTKHomo sapiens (human)
peptidyl-serine phosphorylationDual specificity protein kinase TTKHomo sapiens (human)
protein localization to kinetochoreDual specificity protein kinase TTKHomo sapiens (human)
mitotic spindle assembly checkpoint signalingDual specificity protein kinase TTKHomo sapiens (human)
meiotic spindle assembly checkpoint signalingDual specificity protein kinase TTKHomo sapiens (human)
DNA replicationDNA replication licensing factor MCM4Homo sapiens (human)
DNA unwinding involved in DNA replicationDNA replication licensing factor MCM4Homo sapiens (human)
regulation of DNA-templated DNA replication initiationDNA replication licensing factor MCM4Homo sapiens (human)
double-strand break repair via break-induced replicationDNA replication licensing factor MCM4Homo sapiens (human)
DNA strand elongation involved in DNA replicationDNA replication licensing factor MCM4Homo sapiens (human)
mitotic DNA replication initiationDNA replication licensing factor MCM4Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
regulation of extracellular matrix assemblyTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
regulation of endothelial cell proliferationTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
lymphatic endothelial cell differentiationTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
angiogenesisTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
vasculogenesisTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
in utero embryonic developmentTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
aortic valve morphogenesisTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
signal transductionTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
mesoderm developmentTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
negative regulation of angiogenesisTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
negative regulation of cell migrationTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
response to retinoic acidTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
plasma membrane fusionTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
tissue remodelingTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
branching involved in lymph vessel morphogenesisTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
positive regulation of angiogenesisTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
positive regulation of kinase activityTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
multicellular organism developmentTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of protein phosphorylationVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of endothelial cell proliferationVascular endothelial growth factor receptor 3Homo sapiens (human)
vasculature developmentVascular endothelial growth factor receptor 3Homo sapiens (human)
lymph vessel developmentVascular endothelial growth factor receptor 3Homo sapiens (human)
lymphangiogenesisVascular endothelial growth factor receptor 3Homo sapiens (human)
sprouting angiogenesisVascular endothelial growth factor receptor 3Homo sapiens (human)
respiratory system processVascular endothelial growth factor receptor 3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of cell population proliferationVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of endothelial cell migrationVascular endothelial growth factor receptor 3Homo sapiens (human)
peptidyl-tyrosine phosphorylationVascular endothelial growth factor receptor 3Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusVascular endothelial growth factor receptor 3Homo sapiens (human)
vascular endothelial growth factor signaling pathwayVascular endothelial growth factor receptor 3Homo sapiens (human)
negative regulation of apoptotic processVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of MAPK cascadeVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of JNK cascadeVascular endothelial growth factor receptor 3Homo sapiens (human)
protein autophosphorylationVascular endothelial growth factor receptor 3Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 3Homo sapiens (human)
lung alveolus developmentVascular endothelial growth factor receptor 3Homo sapiens (human)
blood vessel morphogenesisVascular endothelial growth factor receptor 3Homo sapiens (human)
regulation of blood vessel remodelingVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of protein kinase C signalingVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of cell migrationVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of kinase activityVascular endothelial growth factor receptor 3Homo sapiens (human)
multicellular organism developmentVascular endothelial growth factor receptor 3Homo sapiens (human)
regulation of MAPK cascadeVascular endothelial growth factor receptor 3Homo sapiens (human)
angiogenesisVascular endothelial growth factor receptor 3Homo sapiens (human)
branching involved in blood vessel morphogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of macroautophagyVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of mitochondrial depolarizationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of mitochondrial fissionVascular endothelial growth factor receptor 2Homo sapiens (human)
angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
ovarian follicle developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
vasculogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of protein phosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of endothelial cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
lymph vessel developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cell migration involved in sprouting angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of mesenchymal cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
epithelial cell maturationVascular endothelial growth factor receptor 2Homo sapiens (human)
endocardium developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
endothelium developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of cell population proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of cell shapeVascular endothelial growth factor receptor 2Homo sapiens (human)
mesenchymal cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of endothelial cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
negative regulation of gene expressionVascular endothelial growth factor receptor 2Homo sapiens (human)
peptidyl-tyrosine phosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of BMP signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
embryonic hemopoiesisVascular endothelial growth factor receptor 2Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor receptor-2 signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
peptidyl-tyrosine autophosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
surfactant homeostasisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of MAPK cascadeVascular endothelial growth factor receptor 2Homo sapiens (human)
negative regulation of neuron apoptotic processVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
cell fate commitmentVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
protein autophosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
lung alveolus developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
post-embryonic camera-type eye morphogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
epithelial cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of positive chemotaxisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of focal adhesion assemblyVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionVascular endothelial growth factor receptor 2Homo sapiens (human)
calcium ion homeostasisVascular endothelial growth factor receptor 2Homo sapiens (human)
blood vessel endothelial cell differentiationVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular wound healingVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeVascular endothelial growth factor receptor 2Homo sapiens (human)
semaphorin-plexin signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
stem cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of hematopoietic progenitor cell differentiationVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of bone developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cellular response to hydrogen sulfideVascular endothelial growth factor receptor 2Homo sapiens (human)
negative regulation of endothelial cell apoptotic processVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of stem cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of endothelial cell chemotaxisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of vasculogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of MAPK cascadeVascular endothelial growth factor receptor 2Homo sapiens (human)
multicellular organism developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
endothelial cell differentiationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of kinase activityVascular endothelial growth factor receptor 2Homo sapiens (human)
heart developmentDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
positive regulation of gene expressionDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
Schwann cell developmentDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
thyroid gland developmentDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
regulation of stress-activated MAPK cascadeDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
peptidyl-serine autophosphorylationDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
myelinationDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
thymus developmentDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
regulation of axon regenerationDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
positive regulation of axonogenesisDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
face developmentDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
trachea formationDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
epithelial cell proliferation involved in lung morphogenesisDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
ERK1 and ERK2 cascadeDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
positive regulation of protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
regulation of Golgi inheritanceDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
positive regulation of cell motilityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
regulation of early endosome to late endosome transportDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
hemopoiesisReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
leukocyte homeostasisReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
myeloid progenitor cell differentiationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
pro-B cell differentiationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of cell population proliferationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
response to organonitrogen compoundReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
peptidyl-tyrosine phosphorylationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cytokine-mediated signaling pathwayReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
B cell differentiationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
animal organ regenerationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
common myeloid progenitor cell proliferationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
vascular endothelial growth factor signaling pathwayReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
regulation of apoptotic processReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of MAP kinase activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of MAPK cascadeReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
lymphocyte proliferationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
protein autophosphorylationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cellular response to cytokine stimulusReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cellular response to glucocorticoid stimulusReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
dendritic cell differentiationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of kinase activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
multicellular organism developmentReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
regulation of cardiac muscle cell apoptotic processBone morphogenetic protein receptor type-1AHomo sapiens (human)
regulation of neural crest cell differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of gene expressionBone morphogenetic protein receptor type-1AHomo sapiens (human)
negative regulation of gene expressionBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of transforming growth factor beta2 productionBone morphogenetic protein receptor type-1AHomo sapiens (human)
angiogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
osteoblast differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
in utero embryonic developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
mesoderm formationBone morphogenetic protein receptor type-1AHomo sapiens (human)
somitogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
Mullerian duct regressionBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of mesenchymal cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
chondrocyte differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
outflow tract septum morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
outflow tract morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
cardiac conduction system developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
atrioventricular valve developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
mitral valve morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
tricuspid valve morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
endocardial cushion morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
cardiac right ventricle morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
ventricular trabecula myocardium morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
ventricular compact myocardium morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
endocardial cushion formationBone morphogenetic protein receptor type-1AHomo sapiens (human)
immune responseBone morphogenetic protein receptor type-1AHomo sapiens (human)
transforming growth factor beta receptor signaling pathwayBone morphogenetic protein receptor type-1AHomo sapiens (human)
ectoderm developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
dorsal/ventral axis specificationBone morphogenetic protein receptor type-1AHomo sapiens (human)
neural crest cell developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
negative regulation of smooth muscle cell migrationBone morphogenetic protein receptor type-1AHomo sapiens (human)
central nervous system neuron differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
pituitary gland developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
neural plate mediolateral regionalizationBone morphogenetic protein receptor type-1AHomo sapiens (human)
lung developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of bone mineralizationBone morphogenetic protein receptor type-1AHomo sapiens (human)
BMP signaling pathwayBone morphogenetic protein receptor type-1AHomo sapiens (human)
somatic stem cell population maintenanceBone morphogenetic protein receptor type-1AHomo sapiens (human)
hindlimb morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
dorsal aorta morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
odontogenesis of dentin-containing toothBone morphogenetic protein receptor type-1AHomo sapiens (human)
embryonic digit morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of osteoblast differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBone morphogenetic protein receptor type-1AHomo sapiens (human)
paraxial mesoderm structural organizationBone morphogenetic protein receptor type-1AHomo sapiens (human)
lateral mesoderm developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
regulation of lateral mesodermal cell fate specificationBone morphogenetic protein receptor type-1AHomo sapiens (human)
mesendoderm developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
embryonic organ developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
developmental growthBone morphogenetic protein receptor type-1AHomo sapiens (human)
epithelial cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of epithelial cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
negative regulation of neurogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
negative regulation of muscle cell differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
roof of mouth developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
regulation of cardiac muscle cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of cardiac muscle cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of SMAD protein signal transductionBone morphogenetic protein receptor type-1AHomo sapiens (human)
ventricular septum morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
heart formationBone morphogenetic protein receptor type-1AHomo sapiens (human)
atrioventricular node cell developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
pharyngeal arch artery morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
cellular response to BMP stimulusBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of miRNA transcriptionBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of cardiac ventricle developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
fibrous ring of heart morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
regulation of cellular senescenceBone morphogenetic protein receptor type-1AHomo sapiens (human)
protein phosphorylationBone morphogenetic protein receptor type-1AHomo sapiens (human)
dorsal/ventral pattern formationBone morphogenetic protein receptor type-1AHomo sapiens (human)
cellular response to growth factor stimulusBone morphogenetic protein receptor type-1AHomo sapiens (human)
G1/S transition of mitotic cell cycleActivin receptor type-1BHomo sapiens (human)
in utero embryonic developmentActivin receptor type-1BHomo sapiens (human)
hair follicle developmentActivin receptor type-1BHomo sapiens (human)
regulation of DNA-templated transcriptionActivin receptor type-1BHomo sapiens (human)
signal transductionActivin receptor type-1BHomo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayActivin receptor type-1BHomo sapiens (human)
positive regulation of gene expressionActivin receptor type-1BHomo sapiens (human)
negative regulation of gene expressionActivin receptor type-1BHomo sapiens (human)
peptidyl-threonine phosphorylationActivin receptor type-1BHomo sapiens (human)
negative regulation of cell growthActivin receptor type-1BHomo sapiens (human)
activin receptor signaling pathwayActivin receptor type-1BHomo sapiens (human)
positive regulation of activin receptor signaling pathwayActivin receptor type-1BHomo sapiens (human)
nodal signaling pathwayActivin receptor type-1BHomo sapiens (human)
positive regulation of erythrocyte differentiationActivin receptor type-1BHomo sapiens (human)
protein autophosphorylationActivin receptor type-1BHomo sapiens (human)
extrinsic apoptotic signaling pathwayActivin receptor type-1BHomo sapiens (human)
positive regulation of trophoblast cell migrationActivin receptor type-1BHomo sapiens (human)
cellular response to growth factor stimulusActivin receptor type-1BHomo sapiens (human)
protein phosphorylationActivin receptor type-1BHomo sapiens (human)
nervous system developmentActivin receptor type-1BHomo sapiens (human)
proepicardium developmentTGF-beta receptor type-1Homo sapiens (human)
negative regulation of cell migrationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of extracellular matrix assemblyTGF-beta receptor type-1Homo sapiens (human)
skeletal system developmentTGF-beta receptor type-1Homo sapiens (human)
in utero embryonic developmentTGF-beta receptor type-1Homo sapiens (human)
kidney developmentTGF-beta receptor type-1Homo sapiens (human)
blastocyst developmentTGF-beta receptor type-1Homo sapiens (human)
epithelial to mesenchymal transitionTGF-beta receptor type-1Homo sapiens (human)
endothelial cell proliferationTGF-beta receptor type-1Homo sapiens (human)
negative regulation of endothelial cell proliferationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of endothelial cell proliferationTGF-beta receptor type-1Homo sapiens (human)
lens development in camera-type eyeTGF-beta receptor type-1Homo sapiens (human)
ventricular trabecula myocardium morphogenesisTGF-beta receptor type-1Homo sapiens (human)
ventricular compact myocardium morphogenesisTGF-beta receptor type-1Homo sapiens (human)
regulation of DNA-templated transcriptionTGF-beta receptor type-1Homo sapiens (human)
apoptotic processTGF-beta receptor type-1Homo sapiens (human)
signal transductionTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayTGF-beta receptor type-1Homo sapiens (human)
heart developmentTGF-beta receptor type-1Homo sapiens (human)
positive regulation of cell population proliferationTGF-beta receptor type-1Homo sapiens (human)
germ cell migrationTGF-beta receptor type-1Homo sapiens (human)
male gonad developmentTGF-beta receptor type-1Homo sapiens (human)
post-embryonic developmentTGF-beta receptor type-1Homo sapiens (human)
anterior/posterior pattern specificationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of gene expressionTGF-beta receptor type-1Homo sapiens (human)
regulation of epithelial to mesenchymal transitionTGF-beta receptor type-1Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionTGF-beta receptor type-1Homo sapiens (human)
peptidyl-serine phosphorylationTGF-beta receptor type-1Homo sapiens (human)
collagen fibril organizationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of cell growthTGF-beta receptor type-1Homo sapiens (human)
positive regulation of cell migrationTGF-beta receptor type-1Homo sapiens (human)
regulation of protein ubiquitinationTGF-beta receptor type-1Homo sapiens (human)
negative regulation of chondrocyte differentiationTGF-beta receptor type-1Homo sapiens (human)
activin receptor signaling pathwayTGF-beta receptor type-1Homo sapiens (human)
intracellular signal transductionTGF-beta receptor type-1Homo sapiens (human)
myofibroblast differentiationTGF-beta receptor type-1Homo sapiens (human)
wound healingTGF-beta receptor type-1Homo sapiens (human)
endothelial cell activationTGF-beta receptor type-1Homo sapiens (human)
extracellular structure organizationTGF-beta receptor type-1Homo sapiens (human)
endothelial cell migrationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionTGF-beta receptor type-1Homo sapiens (human)
filopodium assemblyTGF-beta receptor type-1Homo sapiens (human)
thymus developmentTGF-beta receptor type-1Homo sapiens (human)
neuron fate commitmentTGF-beta receptor type-1Homo sapiens (human)
embryonic cranial skeleton morphogenesisTGF-beta receptor type-1Homo sapiens (human)
skeletal system morphogenesisTGF-beta receptor type-1Homo sapiens (human)
mesenchymal cell differentiationTGF-beta receptor type-1Homo sapiens (human)
artery morphogenesisTGF-beta receptor type-1Homo sapiens (human)
cell motilityTGF-beta receptor type-1Homo sapiens (human)
positive regulation of filopodium assemblyTGF-beta receptor type-1Homo sapiens (human)
positive regulation of stress fiber assemblyTGF-beta receptor type-1Homo sapiens (human)
regulation of cell cycleTGF-beta receptor type-1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTGF-beta receptor type-1Homo sapiens (human)
parathyroid gland developmentTGF-beta receptor type-1Homo sapiens (human)
roof of mouth developmentTGF-beta receptor type-1Homo sapiens (human)
pharyngeal system developmentTGF-beta receptor type-1Homo sapiens (human)
regulation of cardiac muscle cell proliferationTGF-beta receptor type-1Homo sapiens (human)
cardiac epithelial to mesenchymal transitionTGF-beta receptor type-1Homo sapiens (human)
positive regulation of SMAD protein signal transductionTGF-beta receptor type-1Homo sapiens (human)
ventricular septum morphogenesisTGF-beta receptor type-1Homo sapiens (human)
angiogenesis involved in coronary vascular morphogenesisTGF-beta receptor type-1Homo sapiens (human)
coronary artery morphogenesisTGF-beta receptor type-1Homo sapiens (human)
response to cholesterolTGF-beta receptor type-1Homo sapiens (human)
cellular response to transforming growth factor beta stimulusTGF-beta receptor type-1Homo sapiens (human)
positive regulation of mesenchymal stem cell proliferationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of vasculature developmentTGF-beta receptor type-1Homo sapiens (human)
positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of tight junction disassemblyTGF-beta receptor type-1Homo sapiens (human)
epicardium morphogenesisTGF-beta receptor type-1Homo sapiens (human)
positive regulation of apoptotic signaling pathwayTGF-beta receptor type-1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayTGF-beta receptor type-1Homo sapiens (human)
protein phosphorylationTGF-beta receptor type-1Homo sapiens (human)
cellular response to growth factor stimulusTGF-beta receptor type-1Homo sapiens (human)
nervous system developmentTGF-beta receptor type-1Homo sapiens (human)
endocardial cushion to mesenchymal transitionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of epithelial cell differentiationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of Notch signaling pathwaySerine/threonine-protein kinase receptor R3Homo sapiens (human)
angiogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
response to hypoxiaSerine/threonine-protein kinase receptor R3Homo sapiens (human)
in utero embryonic developmentSerine/threonine-protein kinase receptor R3Homo sapiens (human)
regulation of endothelial cell proliferationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of endothelial cell proliferationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of endothelial cell proliferationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
lymphangiogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
blood vessel maturationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
blood vessel remodelingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
blood vessel endothelial cell proliferation involved in sprouting angiogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
endocardial cushion morphogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
regulation of DNA replicationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
regulation of DNA-templated transcriptionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of cell adhesionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
signal transductionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
transforming growth factor beta receptor signaling pathwaySerine/threonine-protein kinase receptor R3Homo sapiens (human)
blood circulationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
regulation of blood pressureSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of cell population proliferationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of endothelial cell migrationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of gene expressionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of cell growthSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of cell migrationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
BMP signaling pathwaySerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of BMP signaling pathwaySerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of chondrocyte differentiationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
activin receptor signaling pathwaySerine/threonine-protein kinase receptor R3Homo sapiens (human)
wound healing, spreading of epidermal cellsSerine/threonine-protein kinase receptor R3Homo sapiens (human)
dorsal aorta morphogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
regulation of blood vessel endothelial cell migrationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of blood vessel endothelial cell migrationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of endothelial cell differentiationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of endothelial cell differentiationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of angiogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of focal adhesion assemblySerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of SMAD protein signal transductionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
lymphatic endothelial cell differentiationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
artery developmentSerine/threonine-protein kinase receptor R3Homo sapiens (human)
venous blood vessel developmentSerine/threonine-protein kinase receptor R3Homo sapiens (human)
endothelial tube morphogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
retina vasculature development in camera-type eyeSerine/threonine-protein kinase receptor R3Homo sapiens (human)
cellular response to transforming growth factor beta stimulusSerine/threonine-protein kinase receptor R3Homo sapiens (human)
cellular response to BMP stimulusSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of bicellular tight junction assemblySerine/threonine-protein kinase receptor R3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
dorsal/ventral pattern formationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
heart developmentSerine/threonine-protein kinase receptor R3Homo sapiens (human)
cellular response to growth factor stimulusSerine/threonine-protein kinase receptor R3Homo sapiens (human)
cell proliferation involved in endocardial cushion morphogenesisTGF-beta receptor type-2Homo sapiens (human)
superior endocardial cushion morphogenesisTGF-beta receptor type-2Homo sapiens (human)
blood vessel developmentTGF-beta receptor type-2Homo sapiens (human)
branching involved in blood vessel morphogenesisTGF-beta receptor type-2Homo sapiens (human)
vasculogenesisTGF-beta receptor type-2Homo sapiens (human)
in utero embryonic developmentTGF-beta receptor type-2Homo sapiens (human)
epithelial to mesenchymal transitionTGF-beta receptor type-2Homo sapiens (human)
heart loopingTGF-beta receptor type-2Homo sapiens (human)
positive regulation of mesenchymal cell proliferationTGF-beta receptor type-2Homo sapiens (human)
lens development in camera-type eyeTGF-beta receptor type-2Homo sapiens (human)
positive regulation of tolerance induction to self antigenTGF-beta receptor type-2Homo sapiens (human)
positive regulation of B cell tolerance inductionTGF-beta receptor type-2Homo sapiens (human)
positive regulation of T cell tolerance inductionTGF-beta receptor type-2Homo sapiens (human)
outflow tract septum morphogenesisTGF-beta receptor type-2Homo sapiens (human)
membranous septum morphogenesisTGF-beta receptor type-2Homo sapiens (human)
outflow tract morphogenesisTGF-beta receptor type-2Homo sapiens (human)
aortic valve morphogenesisTGF-beta receptor type-2Homo sapiens (human)
atrioventricular valve morphogenesisTGF-beta receptor type-2Homo sapiens (human)
tricuspid valve morphogenesisTGF-beta receptor type-2Homo sapiens (human)
cardiac left ventricle morphogenesisTGF-beta receptor type-2Homo sapiens (human)
endocardial cushion fusionTGF-beta receptor type-2Homo sapiens (human)
growth plate cartilage chondrocyte growthTGF-beta receptor type-2Homo sapiens (human)
apoptotic processTGF-beta receptor type-2Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayTGF-beta receptor type-2Homo sapiens (human)
Notch signaling pathwayTGF-beta receptor type-2Homo sapiens (human)
smoothened signaling pathwayTGF-beta receptor type-2Homo sapiens (human)
gastrulationTGF-beta receptor type-2Homo sapiens (human)
brain developmentTGF-beta receptor type-2Homo sapiens (human)
heart developmentTGF-beta receptor type-2Homo sapiens (human)
positive regulation of cell population proliferationTGF-beta receptor type-2Homo sapiens (human)
response to xenobiotic stimulusTGF-beta receptor type-2Homo sapiens (human)
regulation of gene expressionTGF-beta receptor type-2Homo sapiens (human)
positive regulation of epithelial cell migrationTGF-beta receptor type-2Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionTGF-beta receptor type-2Homo sapiens (human)
activation of protein kinase activityTGF-beta receptor type-2Homo sapiens (human)
activin receptor signaling pathwayTGF-beta receptor type-2Homo sapiens (human)
embryonic hemopoiesisTGF-beta receptor type-2Homo sapiens (human)
aorta morphogenesisTGF-beta receptor type-2Homo sapiens (human)
regulation of cell population proliferationTGF-beta receptor type-2Homo sapiens (human)
myeloid dendritic cell differentiationTGF-beta receptor type-2Homo sapiens (human)
positive regulation of angiogenesisTGF-beta receptor type-2Homo sapiens (human)
embryonic cranial skeleton morphogenesisTGF-beta receptor type-2Homo sapiens (human)
artery morphogenesisTGF-beta receptor type-2Homo sapiens (human)
positive regulation of NK T cell differentiationTGF-beta receptor type-2Homo sapiens (human)
roof of mouth developmentTGF-beta receptor type-2Homo sapiens (human)
positive regulation of SMAD protein signal transductionTGF-beta receptor type-2Homo sapiens (human)
SMAD protein signal transductionTGF-beta receptor type-2Homo sapiens (human)
ventricular septum morphogenesisTGF-beta receptor type-2Homo sapiens (human)
bronchus morphogenesisTGF-beta receptor type-2Homo sapiens (human)
trachea formationTGF-beta receptor type-2Homo sapiens (human)
mammary gland morphogenesisTGF-beta receptor type-2Homo sapiens (human)
lung lobe morphogenesisTGF-beta receptor type-2Homo sapiens (human)
Langerhans cell differentiationTGF-beta receptor type-2Homo sapiens (human)
secondary palate developmentTGF-beta receptor type-2Homo sapiens (human)
response to cholesterolTGF-beta receptor type-2Homo sapiens (human)
regulation of stem cell proliferationTGF-beta receptor type-2Homo sapiens (human)
positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formationTGF-beta receptor type-2Homo sapiens (human)
inferior endocardial cushion morphogenesisTGF-beta receptor type-2Homo sapiens (human)
lens fiber cell apoptotic processTGF-beta receptor type-2Homo sapiens (human)
miRNA transportTGF-beta receptor type-2Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processTGF-beta receptor type-2Homo sapiens (human)
positive regulation of CD4-positive, alpha-beta T cell proliferationTGF-beta receptor type-2Homo sapiens (human)
regulation of stem cell differentiationTGF-beta receptor type-2Homo sapiens (human)
cellular response to growth factor stimulusTGF-beta receptor type-2Homo sapiens (human)
protein phosphorylationTGF-beta receptor type-2Homo sapiens (human)
amino acid catabolic processElectron transfer flavoprotein subunit betaHomo sapiens (human)
respiratory electron transport chainElectron transfer flavoprotein subunit betaHomo sapiens (human)
fatty acid beta-oxidation using acyl-CoA dehydrogenaseElectron transfer flavoprotein subunit betaHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase CSKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of cell population proliferationTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of low-density lipoprotein particle clearanceTyrosine-protein kinase CSKHomo sapiens (human)
T cell costimulationTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of interleukin-6 productionTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of Golgi to plasma membrane protein transportTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of bone resorptionTyrosine-protein kinase CSKHomo sapiens (human)
oligodendrocyte differentiationTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of phagocytosisTyrosine-protein kinase CSKHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase CSKHomo sapiens (human)
cellular response to peptide hormone stimulusTyrosine-protein kinase CSKHomo sapiens (human)
regulation of Fc receptor mediated stimulatory signaling pathwayTyrosine-protein kinase CSKHomo sapiens (human)
adherens junction organizationTyrosine-protein kinase CSKHomo sapiens (human)
tRNA aminoacylation for protein translationGlycine--tRNA ligaseHomo sapiens (human)
diadenosine tetraphosphate biosynthetic processGlycine--tRNA ligaseHomo sapiens (human)
mitochondrial glycyl-tRNA aminoacylationGlycine--tRNA ligaseHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 8Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 8Homo sapiens (human)
T cell costimulationMitogen-activated protein kinase kinase kinase 8Homo sapiens (human)
protein phosphorylationProtein kinase C iota typeHomo sapiens (human)
protein targeting to membraneProtein kinase C iota typeHomo sapiens (human)
cytoskeleton organizationProtein kinase C iota typeHomo sapiens (human)
actin filament organizationProtein kinase C iota typeHomo sapiens (human)
positive regulation of neuron projection developmentProtein kinase C iota typeHomo sapiens (human)
vesicle-mediated transportProtein kinase C iota typeHomo sapiens (human)
cell migrationProtein kinase C iota typeHomo sapiens (human)
cellular response to insulin stimulusProtein kinase C iota typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C iota typeHomo sapiens (human)
establishment of apical/basal cell polarityProtein kinase C iota typeHomo sapiens (human)
eye photoreceptor cell developmentProtein kinase C iota typeHomo sapiens (human)
negative regulation of apoptotic processProtein kinase C iota typeHomo sapiens (human)
negative regulation of neuron apoptotic processProtein kinase C iota typeHomo sapiens (human)
establishment or maintenance of epithelial cell apical/basal polarityProtein kinase C iota typeHomo sapiens (human)
cell-cell junction organizationProtein kinase C iota typeHomo sapiens (human)
positive regulation of Notch signaling pathwayProtein kinase C iota typeHomo sapiens (human)
positive regulation of glucose importProtein kinase C iota typeHomo sapiens (human)
secretionProtein kinase C iota typeHomo sapiens (human)
Golgi vesicle buddingProtein kinase C iota typeHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProtein kinase C iota typeHomo sapiens (human)
positive regulation of glial cell proliferationProtein kinase C iota typeHomo sapiens (human)
membrane organizationProtein kinase C iota typeHomo sapiens (human)
cellular response to chemical stressProtein kinase C iota typeHomo sapiens (human)
response to interleukin-1Protein kinase C iota typeHomo sapiens (human)
regulation of postsynaptic membrane neurotransmitter receptor levelsProtein kinase C iota typeHomo sapiens (human)
positive regulation of protein localization to plasma membraneProtein kinase C iota typeHomo sapiens (human)
positive regulation of endothelial cell apoptotic processProtein kinase C iota typeHomo sapiens (human)
intracellular signal transductionProtein kinase C iota typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C iota typeHomo sapiens (human)
mRNA splicing, via spliceosomeExosome RNA helicase MTR4Homo sapiens (human)
maturation of 5.8S rRNAExosome RNA helicase MTR4Homo sapiens (human)
rRNA processingExosome RNA helicase MTR4Homo sapiens (human)
RNA catabolic processExosome RNA helicase MTR4Homo sapiens (human)
DNA damage responseExosome RNA helicase MTR4Homo sapiens (human)
snRNA catabolic processExosome RNA helicase MTR4Homo sapiens (human)
phosphorylationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
angiogenesisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
liver developmentPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
regulation of protein phosphorylationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
vasculature developmentPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
glucose metabolic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phagocytosisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
epidermal growth factor receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
insulin receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
positive regulation of lamellipodium assemblyPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of gene expressionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
response to activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
response to muscle inactivityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of macroautophagyPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
actin cytoskeleton organizationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
platelet activationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of actin filament depolymerizationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
T cell costimulationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
positive regulation of TOR signalingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cellular response to insulin stimulusPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
response to muscle stretchPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
vascular endothelial growth factor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
regulation of multicellular organism growthPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
response to L-leucinePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
anoikisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
regulation of cellular respirationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of neuron apoptotic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
endothelial cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
positive regulation of smooth muscle cell proliferationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
T cell receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
relaxation of cardiac musclePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cardiac muscle contractionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
adipose tissue developmentPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cellular response to glucose stimulusPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cellular response to hydrostatic pressurePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
response to dexamethasonePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cardiac muscle cell contractionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
energy homeostasisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
regulation of actin filament organizationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
autosome genomic imprintingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
response to butyratePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
positive regulation of protein localization to membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of fibroblast apoptotic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of anoikisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
regulation of cell-matrix adhesionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
positive regulation of gene expressionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphorylationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
endothelial cell proliferationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
response to ischemiaPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
intracellular calcium ion homeostasisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
endocytosisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
autophagyPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
homophilic cell adhesion via plasma membrane adhesion moleculesPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
G protein-coupled receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
positive regulation of autophagyPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
positive regulation of endothelial cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
platelet activationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
positive regulation of neutrophil apoptotic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
positive regulation of Rac protein signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
embryonic cleavagePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
negative regulation of MAPK cascadePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
angiogenesis involved in wound healingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
platelet aggregationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
negative regulation of vascular endothelial growth factor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
negative regulation of hypoxia-induced intrinsic apoptotic signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
negative regulation of sprouting angiogenesisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
regulation of clathrin-dependent endocytosisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
protein destabilizationSerine/threonine-protein kinase mTORHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of macroautophagySerine/threonine-protein kinase mTORHomo sapiens (human)
phosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of cell growthSerine/threonine-protein kinase mTORHomo sapiens (human)
T-helper 1 cell lineage commitmentSerine/threonine-protein kinase mTORHomo sapiens (human)
heart morphogenesisSerine/threonine-protein kinase mTORHomo sapiens (human)
heart valve morphogenesisSerine/threonine-protein kinase mTORHomo sapiens (human)
energy reserve metabolic processSerine/threonine-protein kinase mTORHomo sapiens (human)
'de novo' pyrimidine nucleobase biosynthetic processSerine/threonine-protein kinase mTORHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
inflammatory responseSerine/threonine-protein kinase mTORHomo sapiens (human)
DNA damage responseSerine/threonine-protein kinase mTORHomo sapiens (human)
cytoskeleton organizationSerine/threonine-protein kinase mTORHomo sapiens (human)
lysosome organizationSerine/threonine-protein kinase mTORHomo sapiens (human)
germ cell developmentSerine/threonine-protein kinase mTORHomo sapiens (human)
response to nutrientSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of cell sizeSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to starvationSerine/threonine-protein kinase mTORHomo sapiens (human)
response to heatSerine/threonine-protein kinase mTORHomo sapiens (human)
post-embryonic developmentSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of autophagySerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of lamellipodium assemblySerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of gene expressionSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of epithelial to mesenchymal transitionSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of myotube differentiationSerine/threonine-protein kinase mTORHomo sapiens (human)
macroautophagySerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of macroautophagySerine/threonine-protein kinase mTORHomo sapiens (human)
phosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
neuronal action potentialSerine/threonine-protein kinase mTORHomo sapiens (human)
protein catabolic processSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of cell growthSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of actin filament polymerizationSerine/threonine-protein kinase mTORHomo sapiens (human)
T cell costimulationSerine/threonine-protein kinase mTORHomo sapiens (human)
ruffle organizationSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of myelinationSerine/threonine-protein kinase mTORHomo sapiens (human)
response to nutrient levelsSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to nutrient levelsSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to nutrientSerine/threonine-protein kinase mTORHomo sapiens (human)
TOR signalingSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of phosphoprotein phosphatase activitySerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to insulin stimulusSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of actin cytoskeleton organizationSerine/threonine-protein kinase mTORHomo sapiens (human)
calcineurin-NFAT signaling cascadeSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to amino acid starvationSerine/threonine-protein kinase mTORHomo sapiens (human)
multicellular organism growthSerine/threonine-protein kinase mTORHomo sapiens (human)
TORC1 signalingSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of circadian rhythmSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase mTORHomo sapiens (human)
response to amino acidSerine/threonine-protein kinase mTORHomo sapiens (human)
anoikisSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of osteoclast differentiationSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of translationSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of cell sizeSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of glycolytic processSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIISerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of translational initiationSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of lipid biosynthetic processSerine/threonine-protein kinase mTORHomo sapiens (human)
behavioral response to painSerine/threonine-protein kinase mTORHomo sapiens (human)
rhythmic processSerine/threonine-protein kinase mTORHomo sapiens (human)
oligodendrocyte differentiationSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of oligodendrocyte differentiationSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
voluntary musculoskeletal movementSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of stress fiber assemblySerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of keratinocyte migrationSerine/threonine-protein kinase mTORHomo sapiens (human)
nucleus localizationSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein kinase mTORHomo sapiens (human)
cardiac muscle cell developmentSerine/threonine-protein kinase mTORHomo sapiens (human)
cardiac muscle contractionSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to methionineSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascadeSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to amino acid stimulusSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to L-leucineSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to hypoxiaSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to osmotic stressSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of membrane permeabilitySerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of cellular response to heatSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of protein localization to nucleusSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of signal transduction by p53 class mediatorSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of transcription of nucleolar large rRNA by RNA polymerase ISerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of wound healing, spreading of epidermal cellsSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of locomotor rhythmSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of cytoplasmic translational initiationSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of lysosome organizationSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of pentose-phosphate shuntSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to leucine starvationSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of autophagosome assemblySerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of macroautophagySerine/threonine-protein kinase mTORHomo sapiens (human)
protein phosphorylationMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
positive regulation of cell population proliferationMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase TecHomo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein kinase TecHomo sapiens (human)
regulation of platelet activationTyrosine-protein kinase TecHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase TecHomo sapiens (human)
tissue regenerationTyrosine-protein kinase TecHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase TecHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase TecHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase TecHomo sapiens (human)
positive regulation of cytokine productionTyrosine-protein kinase TXKHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase TXKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase TXKHomo sapiens (human)
activation of phospholipase C activityTyrosine-protein kinase TXKHomo sapiens (human)
regulation of gene expressionTyrosine-protein kinase TXKHomo sapiens (human)
positive regulation of type II interferon productionTyrosine-protein kinase TXKHomo sapiens (human)
positive regulation of transcription by RNA polymerase IITyrosine-protein kinase TXKHomo sapiens (human)
protein autophosphorylationTyrosine-protein kinase TXKHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase TXKHomo sapiens (human)
positive regulation of type II interferon-mediated signaling pathwayTyrosine-protein kinase TXKHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationTyrosine-protein kinase ABL2Homo sapiens (human)
positive regulation of phospholipase C activityTyrosine-protein kinase ABL2Homo sapiens (human)
negative regulation of Rho protein signal transductionTyrosine-protein kinase ABL2Homo sapiens (human)
exploration behaviorTyrosine-protein kinase ABL2Homo sapiens (human)
cell adhesionTyrosine-protein kinase ABL2Homo sapiens (human)
signal transductionTyrosine-protein kinase ABL2Homo sapiens (human)
regulation of autophagyTyrosine-protein kinase ABL2Homo sapiens (human)
positive regulation of neuron projection developmentTyrosine-protein kinase ABL2Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase ABL2Homo sapiens (human)
regulation of endocytosisTyrosine-protein kinase ABL2Homo sapiens (human)
regulation of cell adhesionTyrosine-protein kinase ABL2Homo sapiens (human)
regulation of actin cytoskeleton organizationTyrosine-protein kinase ABL2Homo sapiens (human)
protein modification processTyrosine-protein kinase ABL2Homo sapiens (human)
positive regulation of oxidoreductase activityTyrosine-protein kinase ABL2Homo sapiens (human)
cellular response to retinoic acidTyrosine-protein kinase ABL2Homo sapiens (human)
positive regulation of establishment of T cell polarityTyrosine-protein kinase ABL2Homo sapiens (human)
regulation of cell motilityTyrosine-protein kinase ABL2Homo sapiens (human)
positive regulation of T cell migrationTyrosine-protein kinase ABL2Homo sapiens (human)
epidermal growth factor receptor signaling pathwayTyrosine-protein kinase ABL2Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase ABL2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IITyrosine-protein kinase FRKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase FRKHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase FRKHomo sapiens (human)
cell differentiationTyrosine-protein kinase FRKHomo sapiens (human)
innate immune responseTyrosine-protein kinase FRKHomo sapiens (human)
G protein-coupled receptor signaling pathwayG protein-coupled receptor kinase 6Homo sapiens (human)
regulation of G protein-coupled receptor signaling pathwayG protein-coupled receptor kinase 6Homo sapiens (human)
Wnt signaling pathwayG protein-coupled receptor kinase 6Homo sapiens (human)
regulation of signal transductionG protein-coupled receptor kinase 6Homo sapiens (human)
protein phosphorylationG protein-coupled receptor kinase 6Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase ZAP-70Homo sapiens (human)
positive thymic T cell selectionTyrosine-protein kinase ZAP-70Homo sapiens (human)
positive regulation of T cell differentiationTyrosine-protein kinase ZAP-70Homo sapiens (human)
adaptive immune responseTyrosine-protein kinase ZAP-70Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase ZAP-70Homo sapiens (human)
immune responseTyrosine-protein kinase ZAP-70Homo sapiens (human)
calcium-mediated signalingTyrosine-protein kinase ZAP-70Homo sapiens (human)
T cell differentiationTyrosine-protein kinase ZAP-70Homo sapiens (human)
intracellular signal transductionTyrosine-protein kinase ZAP-70Homo sapiens (human)
T cell activationTyrosine-protein kinase ZAP-70Homo sapiens (human)
B cell activationTyrosine-protein kinase ZAP-70Homo sapiens (human)
beta selectionTyrosine-protein kinase ZAP-70Homo sapiens (human)
negative thymic T cell selectionTyrosine-protein kinase ZAP-70Homo sapiens (human)
positive regulation of alpha-beta T cell differentiationTyrosine-protein kinase ZAP-70Homo sapiens (human)
positive regulation of alpha-beta T cell proliferationTyrosine-protein kinase ZAP-70Homo sapiens (human)
positive regulation of calcium-mediated signalingTyrosine-protein kinase ZAP-70Homo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase ZAP-70Homo sapiens (human)
T cell aggregationTyrosine-protein kinase ZAP-70Homo sapiens (human)
T cell migrationTyrosine-protein kinase ZAP-70Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase ZAP-70Homo sapiens (human)
cell differentiationTyrosine-protein kinase ZAP-70Homo sapiens (human)
innate immune responseTyrosine-protein kinase ZAP-70Homo sapiens (human)
protein import into nucleusTyrosine-protein kinase SYKHomo sapiens (human)
regulation of DNA-binding transcription factor activityTyrosine-protein kinase SYKHomo sapiens (human)
angiogenesisTyrosine-protein kinase SYKHomo sapiens (human)
cell activationTyrosine-protein kinase SYKHomo sapiens (human)
lymph vessel developmentTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of receptor internalizationTyrosine-protein kinase SYKHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase SYKHomo sapiens (human)
macrophage activation involved in immune responseTyrosine-protein kinase SYKHomo sapiens (human)
neutrophil activation involved in immune responseTyrosine-protein kinase SYKHomo sapiens (human)
leukocyte activation involved in immune responseTyrosine-protein kinase SYKHomo sapiens (human)
serotonin secretion by plateletTyrosine-protein kinase SYKHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase SYKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase SYKHomo sapiens (human)
leukocyte cell-cell adhesionTyrosine-protein kinase SYKHomo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
animal organ morphogenesisTyrosine-protein kinase SYKHomo sapiens (human)
regulation of platelet activationTyrosine-protein kinase SYKHomo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase SYKHomo sapiens (human)
leukotriene biosynthetic processTyrosine-protein kinase SYKHomo sapiens (human)
calcium-mediated signalingTyrosine-protein kinase SYKHomo sapiens (human)
platelet activationTyrosine-protein kinase SYKHomo sapiens (human)
B cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
neutrophil chemotaxisTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of protein-containing complex assemblyTyrosine-protein kinase SYKHomo sapiens (human)
receptor internalizationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of type I interferon productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of granulocyte macrophage colony-stimulating factor productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-10 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-12 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-3 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-4 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-6 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-8 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of tumor necrosis factor productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of mast cell cytokine productionTyrosine-protein kinase SYKHomo sapiens (human)
regulation of superoxide anion generationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of superoxide anion generationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of cell adhesion mediated by integrinTyrosine-protein kinase SYKHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase SYKHomo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
Fc-epsilon receptor signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase SYKHomo sapiens (human)
interleukin-3-mediated signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
gamma-delta T cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
defense response to bacteriumTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processTyrosine-protein kinase SYKHomo sapiens (human)
mast cell degranulationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of mast cell degranulationTyrosine-protein kinase SYKHomo sapiens (human)
regulation of neutrophil degranulationTyrosine-protein kinase SYKHomo sapiens (human)
beta selectionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of MAPK cascadeTyrosine-protein kinase SYKHomo sapiens (human)
innate immune responseTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of B cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of gamma-delta T cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of bone resorptionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of alpha-beta T cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of alpha-beta T cell proliferationTyrosine-protein kinase SYKHomo sapiens (human)
blood vessel morphogenesisTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase SYKHomo sapiens (human)
regulation of phagocytosisTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of calcium-mediated signalingTyrosine-protein kinase SYKHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of killing of cells of another organismTyrosine-protein kinase SYKHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase SYKHomo sapiens (human)
cellular response to molecule of fungal originTyrosine-protein kinase SYKHomo sapiens (human)
cellular response to lipidTyrosine-protein kinase SYKHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of monocyte chemotactic protein-1 productionTyrosine-protein kinase SYKHomo sapiens (human)
regulation of arachidonic acid secretionTyrosine-protein kinase SYKHomo sapiens (human)
regulation of platelet aggregationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of cold-induced thermogenesisTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of TORC1 signalingTyrosine-protein kinase SYKHomo sapiens (human)
cellular response to lectinTyrosine-protein kinase SYKHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
blastocyst development26S proteasome regulatory subunit 6BHomo sapiens (human)
proteolysis26S proteasome regulatory subunit 6BHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome regulatory subunit 6BHomo sapiens (human)
positive regulation of proteasomal protein catabolic process26S proteasome regulatory subunit 6BHomo sapiens (human)
JUN phosphorylationMitogen-activated protein kinase 8Homo sapiens (human)
response to UVMitogen-activated protein kinase 8Homo sapiens (human)
negative regulation of apoptotic processMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to lipopolysaccharideMitogen-activated protein kinase 8Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 8Homo sapiens (human)
response to oxidative stressMitogen-activated protein kinase 8Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase 8Homo sapiens (human)
JUN phosphorylationMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 8Homo sapiens (human)
regulation of macroautophagyMitogen-activated protein kinase 8Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 8Homo sapiens (human)
peptidyl-threonine phosphorylationMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of cell killingMitogen-activated protein kinase 8Homo sapiens (human)
negative regulation of protein bindingMitogen-activated protein kinase 8Homo sapiens (human)
regulation of protein localizationMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to amino acid starvationMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to oxidative stressMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to reactive oxygen speciesMitogen-activated protein kinase 8Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase 8Homo sapiens (human)
regulation of circadian rhythmMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of apoptotic processMitogen-activated protein kinase 8Homo sapiens (human)
negative regulation of apoptotic processMitogen-activated protein kinase 8Homo sapiens (human)
rhythmic processMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of protein metabolic processMitogen-activated protein kinase 8Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to mechanical stimulusMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to cadmium ionMitogen-activated protein kinase 8Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 8Homo sapiens (human)
energy homeostasisMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblyMitogen-activated protein kinase 8Homo sapiens (human)
response to mechanical stimulusMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of establishment of protein localization to mitochondrionMitogen-activated protein kinase 8Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 9Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiationMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of protein ubiquitinationMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processMitogen-activated protein kinase 9Homo sapiens (human)
cellular response to reactive oxygen speciesMitogen-activated protein kinase 9Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase 9Homo sapiens (human)
regulation of circadian rhythmMitogen-activated protein kinase 9Homo sapiens (human)
rhythmic processMitogen-activated protein kinase 9Homo sapiens (human)
modulation of chemical synaptic transmissionMitogen-activated protein kinase 9Homo sapiens (human)
protein localization to tricellular tight junctionMitogen-activated protein kinase 9Homo sapiens (human)
cellular response to cadmium ionMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of podosome assemblyMitogen-activated protein kinase 9Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 9Homo sapiens (human)
inflammatory response to woundingMitogen-activated protein kinase 9Homo sapiens (human)
apoptotic signaling pathwayMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of apoptotic signaling pathwayMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of protein phosphorylationDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
JNK cascadeDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
response to woundingDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
smooth muscle cell apoptotic processDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hydrogen peroxideDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
Fc-epsilon receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
positive regulation of neuron apoptotic processDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
positive regulation of DNA replicationDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
positive regulation of JNK cascadeDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
cell growth involved in cardiac muscle cell developmentDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
cellular response to mechanical stimulusDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
cellular response to sorbitolDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
cellular senescenceDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
negative regulation of motor neuron apoptotic processDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
regulation of cytokine productionDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
response to ischemiaDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
inflammatory responseDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
heart developmentDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
stress-activated protein kinase signaling cascadeDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
negative regulation of hippo signalingDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
p38MAPK cascadeDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
positive regulation of MAPK cascadeDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
positive regulation of protein kinase activityDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cardiac muscle contractionDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cellular response to lipopolysaccharideDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cellular response to sorbitolDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cellular senescenceDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
regulation of autophagyPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
megakaryocyte developmentPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
autophagosome-lysosome fusionPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
vesicle-mediated cholesterol transportPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic processPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
positive regulation of autophagosome assemblyPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
protein phosphorylationCasein kinase I isoform alphaHomo sapiens (human)
Golgi organizationCasein kinase I isoform alphaHomo sapiens (human)
cell surface receptor signaling pathwayCasein kinase I isoform alphaHomo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform alphaHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform alphaHomo sapiens (human)
viral protein processingCasein kinase I isoform alphaHomo sapiens (human)
cellular response to nutrientCasein kinase I isoform alphaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase I isoform alphaHomo sapiens (human)
positive regulation of Rho protein signal transductionCasein kinase I isoform alphaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processCasein kinase I isoform alphaHomo sapiens (human)
intermediate filament cytoskeleton organizationCasein kinase I isoform alphaHomo sapiens (human)
cell divisionCasein kinase I isoform alphaHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayCasein kinase I isoform alphaHomo sapiens (human)
negative regulation of NLRP3 inflammasome complex assemblyCasein kinase I isoform alphaHomo sapiens (human)
positive regulation of TORC1 signalingCasein kinase I isoform alphaHomo sapiens (human)
signal transductionCasein kinase I isoform alphaHomo sapiens (human)
microtubule nucleationCasein kinase I isoform deltaHomo sapiens (human)
Golgi organizationCasein kinase I isoform deltaHomo sapiens (human)
protein localization to Golgi apparatusCasein kinase I isoform deltaHomo sapiens (human)
protein localization to ciliumCasein kinase I isoform deltaHomo sapiens (human)
protein localization to centrosomeCasein kinase I isoform deltaHomo sapiens (human)
non-motile cilium assemblyCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of protein phosphorylationCasein kinase I isoform deltaHomo sapiens (human)
protein phosphorylationCasein kinase I isoform deltaHomo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase I isoform deltaHomo sapiens (human)
circadian regulation of gene expressionCasein kinase I isoform deltaHomo sapiens (human)
regulation of circadian rhythmCasein kinase I isoform deltaHomo sapiens (human)
COPII vesicle coatingCasein kinase I isoform deltaHomo sapiens (human)
spindle assemblyCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform deltaHomo sapiens (human)
midbrain dopaminergic neuron differentiationCasein kinase I isoform deltaHomo sapiens (human)
cellular response to nerve growth factor stimulusCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of non-canonical Wnt signaling pathwayCasein kinase I isoform deltaHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform deltaHomo sapiens (human)
signal transductionCasein kinase I isoform deltaHomo sapiens (human)
non-motile cilium assemblyCasein kinase I isoform deltaHomo sapiens (human)
endocytosisCasein kinase I isoform deltaHomo sapiens (human)
phosphorylationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
angiogenesisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of cytokine productionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
adaptive immune responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
dendritic cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of acute inflammatory responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
respiratory burst involved in defense responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
endocytosisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
inflammatory responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
immune responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
G protein-coupled receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of endothelial cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
T cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
negative regulation of triglyceride catabolic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
neutrophil chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
secretory granule localizationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
regulation of cell adhesion mediated by integrinPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of Rac protein signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
natural killer cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
T cell proliferationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
T cell activationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
mast cell degranulationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of MAP kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
innate immune responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
regulation of angiogenesisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
negative regulation of cardiac muscle contractionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
platelet aggregationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
cellular response to cAMPPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
neutrophil extravasationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
hepatocyte apoptotic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
regulation of calcium ion transmembrane transportPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
negative regulation of fibroblast apoptotic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
MAPK cascadeMAP kinase-activated protein kinase 2Homo sapiens (human)
toll-like receptor signaling pathwayMAP kinase-activated protein kinase 2Homo sapiens (human)
protein phosphorylationMAP kinase-activated protein kinase 2Homo sapiens (human)
leukotriene metabolic processMAP kinase-activated protein kinase 2Homo sapiens (human)
inflammatory responseMAP kinase-activated protein kinase 2Homo sapiens (human)
DNA damage responseMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwayMAP kinase-activated protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationMAP kinase-activated protein kinase 2Homo sapiens (human)
response to lipopolysaccharideMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of interleukin-6 productionMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of tumor necrosis factor productionMAP kinase-activated protein kinase 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionMAP kinase-activated protein kinase 2Homo sapiens (human)
response to cytokineMAP kinase-activated protein kinase 2Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusMAP kinase-activated protein kinase 2Homo sapiens (human)
p38MAPK cascadeMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of mRNA stabilityMAP kinase-activated protein kinase 2Homo sapiens (human)
macropinocytosisMAP kinase-activated protein kinase 2Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayMAP kinase-activated protein kinase 2Homo sapiens (human)
inner ear developmentMAP kinase-activated protein kinase 2Homo sapiens (human)
positive regulation of macrophage cytokine productionMAP kinase-activated protein kinase 2Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of cellular response to heatMAP kinase-activated protein kinase 2Homo sapiens (human)
protein autophosphorylationMAP kinase-activated protein kinase 2Homo sapiens (human)
intracellular signal transductionMAP kinase-activated protein kinase 2Homo sapiens (human)
protein ubiquitinationCyclin-dependent kinase 8Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICyclin-dependent kinase 8Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 8Homo sapiens (human)
negative regulation of triglyceride metabolic processCyclin-dependent kinase 8Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 8Homo sapiens (human)
translational elongationElongation factor Tu, mitochondrialHomo sapiens (human)
response to ethanolElongation factor Tu, mitochondrialHomo sapiens (human)
mitochondrial translational elongationElongation factor Tu, mitochondrialHomo sapiens (human)
cysteinyl-tRNA aminoacylationCysteine--tRNA ligase, cytoplasmicHomo sapiens (human)
DNA repairCasein kinase I isoform epsilonHomo sapiens (human)
protein phosphorylationCasein kinase I isoform epsilonHomo sapiens (human)
protein localizationCasein kinase I isoform epsilonHomo sapiens (human)
negative regulation of Wnt signaling pathwayCasein kinase I isoform epsilonHomo sapiens (human)
negative regulation of protein bindingCasein kinase I isoform epsilonHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase I isoform epsilonHomo sapiens (human)
regulation of protein localizationCasein kinase I isoform epsilonHomo sapiens (human)
circadian regulation of gene expressionCasein kinase I isoform epsilonHomo sapiens (human)
regulation of circadian rhythmCasein kinase I isoform epsilonHomo sapiens (human)
circadian behaviorCasein kinase I isoform epsilonHomo sapiens (human)
canonical Wnt signaling pathwayCasein kinase I isoform epsilonHomo sapiens (human)
positive regulation of amyloid-beta formationCasein kinase I isoform epsilonHomo sapiens (human)
cellular response to nerve growth factor stimulusCasein kinase I isoform epsilonHomo sapiens (human)
positive regulation of non-canonical Wnt signaling pathwayCasein kinase I isoform epsilonHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform epsilonHomo sapiens (human)
endocytosisCasein kinase I isoform epsilonHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform epsilonHomo sapiens (human)
signal transductionCasein kinase I isoform epsilonHomo sapiens (human)
temperature homeostasisVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
response to coldVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
energy derivation by oxidation of organic compoundsVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
epithelial cell differentiationVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
fatty acid beta-oxidation using acyl-CoA dehydrogenaseVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
negative regulation of fatty acid biosynthetic processVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
negative regulation of fatty acid oxidationVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
regulation of cholesterol metabolic processVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
regulation of RNA splicingDual specificity protein kinase CLK1Homo sapiens (human)
peptidyl-tyrosine phosphorylationDual specificity protein kinase CLK1Homo sapiens (human)
protein phosphorylationDual specificity protein kinase CLK2Homo sapiens (human)
response to ionizing radiationDual specificity protein kinase CLK2Homo sapiens (human)
regulation of RNA splicingDual specificity protein kinase CLK2Homo sapiens (human)
negative regulation of gluconeogenesisDual specificity protein kinase CLK2Homo sapiens (human)
protein autophosphorylationDual specificity protein kinase CLK2Homo sapiens (human)
peptidyl-tyrosine phosphorylationDual specificity protein kinase CLK2Homo sapiens (human)
protein phosphorylationDual specificity protein kinase CLK3Homo sapiens (human)
regulation of RNA splicingDual specificity protein kinase CLK3Homo sapiens (human)
regulation of systemic arterial blood pressureGlycogen synthase kinase-3 alphaHomo sapiens (human)
cardiac left ventricle morphogenesisGlycogen synthase kinase-3 alphaHomo sapiens (human)
glycogen metabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
dopamine receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
nervous system developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
insulin receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of autophagyGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of UDP-glucose catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
Wnt signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
cell migrationGlycogen synthase kinase-3 alphaHomo sapiens (human)
peptidyl-threonine phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
viral protein processingGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of protein ubiquitinationGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of TOR signalingGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to insulin stimulusGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to interleukin-3Glycogen synthase kinase-3 alphaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glycogen biosynthetic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of protein catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of heart contractionGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glucose importGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
excitatory postsynaptic potentialGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to lithium ionGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to glucocorticoid stimulusGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of adenylate cyclase-activating adrenergic receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
extrinsic apoptotic signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
autosome genomic imprintingGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
regulation of mitophagyGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of amyloid-beta formationGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of protein targeting to mitochondrionGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glycogen synthase activity, transferring glucose-1-phosphateGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of type B pancreatic cell developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glycogen (starch) synthase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of glycogen (starch) synthase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
cell differentiationGlycogen synthase kinase-3 alphaHomo sapiens (human)
regulation of microtubule cytoskeleton organizationGlycogen synthase kinase-3 alphaHomo sapiens (human)
regulation of neuron projection developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
ER overload responseGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-serine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
intracellular signal transductionGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of apoptotic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein export from nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
epithelial to mesenchymal transitionGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cell-matrix adhesionGlycogen synthase kinase-3 betaHomo sapiens (human)
glycogen metabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
protein phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
mitochondrion organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
dopamine receptor signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
circadian rhythmGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of autophagyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-serine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-threonine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
viral protein processingGlycogen synthase kinase-3 betaHomo sapiens (human)
hippocampus developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
establishment of cell polarityGlycogen synthase kinase-3 betaHomo sapiens (human)
maintenance of cell polarityGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of cell migrationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of axon extensionGlycogen synthase kinase-3 betaHomo sapiens (human)
neuron projection developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein-containing complex assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein-containing complex assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein ubiquitinationGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of phosphoprotein phosphatase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule-based processGlycogen synthase kinase-3 betaHomo sapiens (human)
intracellular signal transductionGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to interleukin-3Glycogen synthase kinase-3 betaHomo sapiens (human)
regulation of circadian rhythmGlycogen synthase kinase-3 betaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of GTPase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of osteoblast differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of glycogen biosynthetic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cilium assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
protein autophosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of protein export from nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of dendrite morphogenesisGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of axonogenesisGlycogen synthase kinase-3 betaHomo sapiens (human)
canonical Wnt signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
excitatory postsynaptic potentialGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule cytoskeleton organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascadeGlycogen synthase kinase-3 betaHomo sapiens (human)
superior temporal gyrus developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to retinoic acidGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
extrinsic apoptotic signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandGlycogen synthase kinase-3 betaHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionGlycogen synthase kinase-3 betaHomo sapiens (human)
neuron projection organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule anchoring at centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of cellular response to heatGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein localization to nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of long-term synaptic potentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein acetylationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein localization to ciliumGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of dopaminergic neuron differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to amyloid-betaGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein localization to centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin destruction complex disassemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of type B pancreatic cell developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of glycogen (starch) synthase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of mesenchymal stem cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of TOR signalingGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of neuron projection developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
insulin receptor signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
DNA repairCyclin-dependent kinase 7Homo sapiens (human)
transcription by RNA polymerase IICyclin-dependent kinase 7Homo sapiens (human)
transcription initiation at RNA polymerase II promoterCyclin-dependent kinase 7Homo sapiens (human)
snRNA transcription by RNA polymerase IICyclin-dependent kinase 7Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICyclin-dependent kinase 7Homo sapiens (human)
protein stabilizationCyclin-dependent kinase 7Homo sapiens (human)
cell divisionCyclin-dependent kinase 7Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 7Homo sapiens (human)
regulation of G1/S transition of mitotic cell cycleCyclin-dependent kinase 7Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 7Homo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 9Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 9Homo sapiens (human)
DNA repairCyclin-dependent kinase 9Homo sapiens (human)
regulation of DNA repairCyclin-dependent kinase 9Homo sapiens (human)
transcription by RNA polymerase IICyclin-dependent kinase 9Homo sapiens (human)
transcription initiation at RNA polymerase II promoterCyclin-dependent kinase 9Homo sapiens (human)
transcription elongation by RNA polymerase IICyclin-dependent kinase 9Homo sapiens (human)
cell population proliferationCyclin-dependent kinase 9Homo sapiens (human)
replication fork processingCyclin-dependent kinase 9Homo sapiens (human)
regulation of mRNA 3'-end processingCyclin-dependent kinase 9Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IICyclin-dependent kinase 9Homo sapiens (human)
positive regulation by host of viral transcriptionCyclin-dependent kinase 9Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICyclin-dependent kinase 9Homo sapiens (human)
regulation of muscle cell differentiationCyclin-dependent kinase 9Homo sapiens (human)
nucleus localizationCyclin-dependent kinase 9Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 9Homo sapiens (human)
cellular response to cytokine stimulusCyclin-dependent kinase 9Homo sapiens (human)
negative regulation of protein localization to chromatinCyclin-dependent kinase 9Homo sapiens (human)
positive regulation of protein localization to chromatinCyclin-dependent kinase 9Homo sapiens (human)
transcription elongation-coupled chromatin remodelingCyclin-dependent kinase 9Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 9Homo sapiens (human)
exocytosisRas-related protein Rab-27AHomo sapiens (human)
blood coagulationRas-related protein Rab-27AHomo sapiens (human)
protein secretionRas-related protein Rab-27AHomo sapiens (human)
positive regulation of gene expressionRas-related protein Rab-27AHomo sapiens (human)
antigen processing and presentationRas-related protein Rab-27AHomo sapiens (human)
melanocyte differentiationRas-related protein Rab-27AHomo sapiens (human)
melanosome localizationRas-related protein Rab-27AHomo sapiens (human)
melanosome transportRas-related protein Rab-27AHomo sapiens (human)
multivesicular body organizationRas-related protein Rab-27AHomo sapiens (human)
cytotoxic T cell degranulationRas-related protein Rab-27AHomo sapiens (human)
natural killer cell degranulationRas-related protein Rab-27AHomo sapiens (human)
positive regulation of exocytosisRas-related protein Rab-27AHomo sapiens (human)
synaptic vesicle transportRas-related protein Rab-27AHomo sapiens (human)
positive regulation of phagocytosisRas-related protein Rab-27AHomo sapiens (human)
multivesicular body sorting pathwayRas-related protein Rab-27AHomo sapiens (human)
complement-dependent cytotoxicityRas-related protein Rab-27AHomo sapiens (human)
positive regulation of regulated secretory pathwayRas-related protein Rab-27AHomo sapiens (human)
positive regulation of reactive oxygen species biosynthetic processRas-related protein Rab-27AHomo sapiens (human)
positive regulation of constitutive secretory pathwayRas-related protein Rab-27AHomo sapiens (human)
exosomal secretionRas-related protein Rab-27AHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase BlkHomo sapiens (human)
positive regulation of insulin secretionTyrosine-protein kinase BlkHomo sapiens (human)
positive regulation of protein bindingTyrosine-protein kinase BlkHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase BlkHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase BlkHomo sapiens (human)
innate immune responseTyrosine-protein kinase BlkHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase BlkHomo sapiens (human)
cell differentiationTyrosine-protein kinase BlkHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase BlkHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein autophosphorylationInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
regulation of cytokine-mediated signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
toll-like receptor signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
canonical NF-kappaB signal transductionInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
JNK cascadeInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
positive regulation of type I interferon productionInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
response to lipopolysaccharideInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
toll-like receptor 2 signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
toll-like receptor 9 signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
cellular response to heatInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
interleukin-33-mediated signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein autophosphorylationInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
positive regulation of smooth muscle cell proliferationInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
type I interferon-mediated signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
interleukin-1-mediated signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
response to interleukin-1Interleukin-1 receptor-associated kinase 1Homo sapiens (human)
cellular response to hypoxiaInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
toll-like receptor 4 signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
positive regulation of MAP kinase activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
cellular response to lipopolysaccharideInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
intracellular signal transductionInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
Toll signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
innate immune responseInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
skeletal system developmentRibosomal protein S6 kinase alpha-3Homo sapiens (human)
toll-like receptor signaling pathwayRibosomal protein S6 kinase alpha-3Homo sapiens (human)
signal transductionRibosomal protein S6 kinase alpha-3Homo sapiens (human)
chemical synaptic transmissionRibosomal protein S6 kinase alpha-3Homo sapiens (human)
central nervous system developmentRibosomal protein S6 kinase alpha-3Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-3Homo sapiens (human)
positive regulation of cell growthRibosomal protein S6 kinase alpha-3Homo sapiens (human)
response to lipopolysaccharideRibosomal protein S6 kinase alpha-3Homo sapiens (human)
intracellular signal transductionRibosomal protein S6 kinase alpha-3Homo sapiens (human)
negative regulation of apoptotic processRibosomal protein S6 kinase alpha-3Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processRibosomal protein S6 kinase alpha-3Homo sapiens (human)
regulation of translation in response to stressRibosomal protein S6 kinase alpha-3Homo sapiens (human)
positive regulation of cell differentiationRibosomal protein S6 kinase alpha-3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein phosphorylationCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
phosphatidylinositol biosynthetic processCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
apoptotic processCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
cell adhesionCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
signal transductionCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
mesoderm developmentCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
intracellular signal transductionCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
protein autophosphorylationCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
B cell receptor signaling pathwayCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
adaptive immune responseCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
angiogenesiscAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
endothelial cell proliferationcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
cell adhesioncAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
peptidyl-serine phosphorylationcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
myeloid cell differentiationcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
regulation of cell adhesioncAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
regulation of cell migrationcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
cell-substrate adhesioncAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
endothelial cell migrationcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
protein autophosphorylationcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
epithelial tube morphogenesiscAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
kidney morphogenesiscAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
regulation of epithelial cell differentiation involved in kidney developmentcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
protein kinase A signalingcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
mitotic cell cycleSerine/threonine-protein kinase Nek2Homo sapiens (human)
blastocyst developmentSerine/threonine-protein kinase Nek2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek2Homo sapiens (human)
chromosome segregationSerine/threonine-protein kinase Nek2Homo sapiens (human)
regulation of mitotic nuclear divisionSerine/threonine-protein kinase Nek2Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseSerine/threonine-protein kinase Nek2Homo sapiens (human)
regulation of mitotic centrosome separationSerine/threonine-protein kinase Nek2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase Nek2Homo sapiens (human)
spindle assemblySerine/threonine-protein kinase Nek2Homo sapiens (human)
centrosome separationSerine/threonine-protein kinase Nek2Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Nek2Homo sapiens (human)
meiotic cell cycleSerine/threonine-protein kinase Nek2Homo sapiens (human)
positive regulation of telomerase activitySerine/threonine-protein kinase Nek2Homo sapiens (human)
regulation of attachment of spindle microtubules to kinetochoreSerine/threonine-protein kinase Nek2Homo sapiens (human)
mitotic spindle assemblySerine/threonine-protein kinase Nek2Homo sapiens (human)
negative regulation of centriole-centriole cohesionSerine/threonine-protein kinase Nek2Homo sapiens (human)
positive regulation of telomere cappingSerine/threonine-protein kinase Nek2Homo sapiens (human)
mitotic cell cycleSerine/threonine-protein kinase Nek3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek3Homo sapiens (human)
establishment of cell polaritySerine/threonine-protein kinase Nek3Homo sapiens (human)
neuron projection morphogenesisSerine/threonine-protein kinase Nek3Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Nek3Homo sapiens (human)
regulation of tubulin deacetylationSerine/threonine-protein kinase Nek3Homo sapiens (human)
mitotic cell cycleSerine/threonine-protein kinase Nek4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek4Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase Nek4Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase Nek4Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Nek4Homo sapiens (human)
regulation of cellular senescenceSerine/threonine-protein kinase Nek4Homo sapiens (human)
adaptive immune responseTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of dendritic cell cytokine productionTyrosine-protein kinase JAK3Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase JAK3Homo sapiens (human)
enzyme-linked receptor protein signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
tyrosine phosphorylation of STAT proteinTyrosine-protein kinase JAK3Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase JAK3Homo sapiens (human)
B cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of interleukin-10 productionTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of interleukin-12 productionTyrosine-protein kinase JAK3Homo sapiens (human)
intracellular signal transductionTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-15-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-4-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-2-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-9-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
T cell homeostasisTyrosine-protein kinase JAK3Homo sapiens (human)
innate immune responseTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of FasL productionTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of T-helper 1 cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of T cell activationTyrosine-protein kinase JAK3Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
regulation of T cell apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of thymocyte apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-2Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-4Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-15Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-9Tyrosine-protein kinase JAK3Homo sapiens (human)
regulation of apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
osteoblast differentiationDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
positive regulation of protein phosphorylationDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
response to ischemiaDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
apoptotic processDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
response to xenobiotic stimulusDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
ovulation cycle processDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
stress-activated protein kinase signaling cascadeDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
positive regulation of prostaglandin secretionDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
p38MAPK cascadeDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
signal transduction in response to DNA damageDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
positive regulation of apoptotic processDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
positive regulation of MAPK cascadeDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
stress-activated MAPK cascadeDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
regulation of cell cycleDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cardiac muscle contractionDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
bone developmentDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cellular response to sorbitolDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cellular senescenceDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
negative regulation of cold-induced thermogenesisDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
regulation of signal transduction by p53 class mediatorDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
establishment of protein localizationSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic sister chromatid segregationSerine/threonine-protein kinase PLK1Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase PLK1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IISerine/threonine-protein kinase PLK1Homo sapiens (human)
establishment of mitotic spindle orientationSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic cell cycleSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic cytokinesisSerine/threonine-protein kinase PLK1Homo sapiens (human)
microtubule bundle formationSerine/threonine-protein kinase PLK1Homo sapiens (human)
double-strand break repairSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic spindle organizationSerine/threonine-protein kinase PLK1Homo sapiens (human)
sister chromatid cohesionSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic chromosome condensationSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic nuclear membrane disassemblySerine/threonine-protein kinase PLK1Homo sapiens (human)
metaphase/anaphase transition of mitotic cell cycleSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic spindle assembly checkpoint signalingSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine/threonine-protein kinase PLK1Homo sapiens (human)
centrosome cycleSerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase PLK1Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationSerine/threonine-protein kinase PLK1Homo sapiens (human)
female meiosis chromosome segregationSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein ubiquitinationSerine/threonine-protein kinase PLK1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of mitotic metaphase/anaphase transitionSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein destabilizationSerine/threonine-protein kinase PLK1Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processSerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of cytokinesisSerine/threonine-protein kinase PLK1Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of protein bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
homologous chromosome segregationSerine/threonine-protein kinase PLK1Homo sapiens (human)
negative regulation of cyclin-dependent protein serine/threonine kinase activitySerine/threonine-protein kinase PLK1Homo sapiens (human)
positive regulation of proteolysisSerine/threonine-protein kinase PLK1Homo sapiens (human)
Golgi inheritanceSerine/threonine-protein kinase PLK1Homo sapiens (human)
nuclear membrane disassemblySerine/threonine-protein kinase PLK1Homo sapiens (human)
positive regulation of ubiquitin-protein transferase activitySerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of cell cycleSerine/threonine-protein kinase PLK1Homo sapiens (human)
synaptonemal complex disassemblySerine/threonine-protein kinase PLK1Homo sapiens (human)
protein localization to chromatinSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein localization to nuclear envelopeSerine/threonine-protein kinase PLK1Homo sapiens (human)
double-strand break repair via alternative nonhomologous end joiningSerine/threonine-protein kinase PLK1Homo sapiens (human)
positive regulation of protein localization to nucleusSerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of mitotic spindle assemblySerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of mitotic cell cycle phase transitionSerine/threonine-protein kinase PLK1Homo sapiens (human)
positive regulation of ubiquitin protein ligase activitySerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of protein localization to cell cortexSerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic processSerine/threonine-protein kinase PLK1Homo sapiens (human)
negative regulation of double-strand break repair via homologous recombinationSerine/threonine-protein kinase PLK1Homo sapiens (human)
apoptotic processDeath-associated protein kinase 1Homo sapiens (human)
defense response to tumor cellDeath-associated protein kinase 1Homo sapiens (human)
regulation of response to tumor cellDeath-associated protein kinase 1Homo sapiens (human)
protein phosphorylationDeath-associated protein kinase 1Homo sapiens (human)
apoptotic processDeath-associated protein kinase 1Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsDeath-associated protein kinase 1Homo sapiens (human)
regulation of autophagyDeath-associated protein kinase 1Homo sapiens (human)
positive regulation of autophagyDeath-associated protein kinase 1Homo sapiens (human)
negative regulation of translationDeath-associated protein kinase 1Homo sapiens (human)
intracellular signal transductionDeath-associated protein kinase 1Homo sapiens (human)
regulation of apoptotic processDeath-associated protein kinase 1Homo sapiens (human)
positive regulation of apoptotic processDeath-associated protein kinase 1Homo sapiens (human)
negative regulation of apoptotic processDeath-associated protein kinase 1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processDeath-associated protein kinase 1Homo sapiens (human)
protein autophosphorylationDeath-associated protein kinase 1Homo sapiens (human)
cellular response to type II interferonDeath-associated protein kinase 1Homo sapiens (human)
cellular response to hydroperoxideDeath-associated protein kinase 1Homo sapiens (human)
apoptotic signaling pathwayDeath-associated protein kinase 1Homo sapiens (human)
positive regulation of autophagic cell deathDeath-associated protein kinase 1Homo sapiens (human)
regulation of NMDA receptor activityDeath-associated protein kinase 1Homo sapiens (human)
protein phosphorylationLIM domain kinase 1Homo sapiens (human)
signal transductionLIM domain kinase 1Homo sapiens (human)
Rho protein signal transductionLIM domain kinase 1Homo sapiens (human)
nervous system developmentLIM domain kinase 1Homo sapiens (human)
positive regulation of actin filament bundle assemblyLIM domain kinase 1Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisLIM domain kinase 1Homo sapiens (human)
stress fiber assemblyLIM domain kinase 1Homo sapiens (human)
positive regulation of axon extensionLIM domain kinase 1Homo sapiens (human)
axon extensionLIM domain kinase 1Homo sapiens (human)
negative regulation of ubiquitin-protein transferase activityLIM domain kinase 1Homo sapiens (human)
positive regulation of stress fiber assemblyLIM domain kinase 1Homo sapiens (human)
actin cytoskeleton organizationLIM domain kinase 1Homo sapiens (human)
positive regulation of protein phosphorylationLIM domain kinase 2Homo sapiens (human)
protein phosphorylationLIM domain kinase 2Homo sapiens (human)
spermatogenesisLIM domain kinase 2Homo sapiens (human)
phosphorylationLIM domain kinase 2Homo sapiens (human)
astral microtubule organizationLIM domain kinase 2Homo sapiens (human)
establishment of vesicle localizationLIM domain kinase 2Homo sapiens (human)
head developmentLIM domain kinase 2Homo sapiens (human)
cornea development in camera-type eyeLIM domain kinase 2Homo sapiens (human)
positive regulation of protein localization to nucleusLIM domain kinase 2Homo sapiens (human)
negative regulation of cilium assemblyLIM domain kinase 2Homo sapiens (human)
actin cytoskeleton organizationLIM domain kinase 2Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 12Homo sapiens (human)
signal transductionMitogen-activated protein kinase 12Homo sapiens (human)
muscle organ developmentMitogen-activated protein kinase 12Homo sapiens (human)
positive regulation of peptidase activityMitogen-activated protein kinase 12Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 12Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 12Homo sapiens (human)
myoblast differentiationMitogen-activated protein kinase 12Homo sapiens (human)
negative regulation of cell cycleMitogen-activated protein kinase 12Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 12Homo sapiens (human)
regulation of cell cycleMitogen-activated protein kinase 12Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 12Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 10Homo sapiens (human)
signal transductionMitogen-activated protein kinase 10Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase 10Homo sapiens (human)
response to light stimulusMitogen-activated protein kinase 10Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase 10Homo sapiens (human)
regulation of circadian rhythmMitogen-activated protein kinase 10Homo sapiens (human)
rhythmic processMitogen-activated protein kinase 10Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 10Homo sapiens (human)
tyrosyl-tRNA aminoacylationTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
apoptotic processTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
response to starvationTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
regulation of glycolytic process5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
signal transduction5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
spermatogenesis5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
positive regulation of gene expression5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
positive regulation of protein kinase activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
import into nucleus5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
regulation of catalytic activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
lipid droplet disassembly5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
chromatin remodeling5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cholesterol biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
autophagy5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
signal transduction5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
lipid biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of autophagy5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of gene expression5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
response to muscle activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
Wnt signaling pathway5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of macroautophagy5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
regulation of macroautophagy5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of TOR signaling5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to oxidative stress5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to glucose starvation5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
glucose homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
regulation of circadian rhythm5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of apoptotic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of glycolytic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
rhythmic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
fatty acid homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
regulation of stress granule assembly5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
regulation of microtubule cytoskeleton organization5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to calcium ion5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to glucose stimulus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to prostaglandin E stimulus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to xenobiotic stimulus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
energy homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of protein localization5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of hepatocyte apoptotic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of TORC1 signaling5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of tubulin deacetylation5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein localization to lipid droplet5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of peptidyl-lysine acetylation5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
angiogenesisEphrin type-B receptor 3Homo sapiens (human)
urogenital system developmentEphrin type-B receptor 3Homo sapiens (human)
axon guidanceEphrin type-B receptor 3Homo sapiens (human)
axonal fasciculationEphrin type-B receptor 3Homo sapiens (human)
cell migrationEphrin type-B receptor 3Homo sapiens (human)
central nervous system projection neuron axonogenesisEphrin type-B receptor 3Homo sapiens (human)
corpus callosum developmentEphrin type-B receptor 3Homo sapiens (human)
regulation of cell-cell adhesionEphrin type-B receptor 3Homo sapiens (human)
retinal ganglion cell axon guidanceEphrin type-B receptor 3Homo sapiens (human)
substrate adhesion-dependent cell spreadingEphrin type-B receptor 3Homo sapiens (human)
regulation of GTPase activityEphrin type-B receptor 3Homo sapiens (human)
protein autophosphorylationEphrin type-B receptor 3Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-B receptor 3Homo sapiens (human)
thymus developmentEphrin type-B receptor 3Homo sapiens (human)
digestive tract morphogenesisEphrin type-B receptor 3Homo sapiens (human)
regulation of axonogenesisEphrin type-B receptor 3Homo sapiens (human)
positive regulation of synapse assemblyEphrin type-B receptor 3Homo sapiens (human)
roof of mouth developmentEphrin type-B receptor 3Homo sapiens (human)
dendritic spine developmentEphrin type-B receptor 3Homo sapiens (human)
dendritic spine morphogenesisEphrin type-B receptor 3Homo sapiens (human)
protein phosphorylationEphrin type-B receptor 3Homo sapiens (human)
axon guidanceEphrin type-A receptor 5Homo sapiens (human)
cAMP-mediated signalingEphrin type-A receptor 5Homo sapiens (human)
hippocampus developmentEphrin type-A receptor 5Homo sapiens (human)
positive regulation of CREB transcription factor activityEphrin type-A receptor 5Homo sapiens (human)
regulation of actin cytoskeleton organizationEphrin type-A receptor 5Homo sapiens (human)
regulation of GTPase activityEphrin type-A receptor 5Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 5Homo sapiens (human)
neuron developmentEphrin type-A receptor 5Homo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusEphrin type-A receptor 5Homo sapiens (human)
protein phosphorylationEphrin type-A receptor 5Homo sapiens (human)
angiogenesisEphrin type-B receptor 4Homo sapiens (human)
cell migration involved in sprouting angiogenesisEphrin type-B receptor 4Homo sapiens (human)
heart morphogenesisEphrin type-B receptor 4Homo sapiens (human)
cell adhesionEphrin type-B receptor 4Homo sapiens (human)
protein autophosphorylationEphrin type-B receptor 4Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-B receptor 4Homo sapiens (human)
multicellular organism developmentEphrin type-B receptor 4Homo sapiens (human)
positive regulation of kinase activityEphrin type-B receptor 4Homo sapiens (human)
angiogenesisEphrin type-B receptor 1Homo sapiens (human)
immunological synapse formationEphrin type-B receptor 1Homo sapiens (human)
axon guidanceEphrin type-B receptor 1Homo sapiens (human)
skeletal muscle satellite cell activationEphrin type-B receptor 1Homo sapiens (human)
optic nerve morphogenesisEphrin type-B receptor 1Homo sapiens (human)
hindbrain tangential cell migrationEphrin type-B receptor 1Homo sapiens (human)
central nervous system projection neuron axonogenesisEphrin type-B receptor 1Homo sapiens (human)
neurogenesisEphrin type-B receptor 1Homo sapiens (human)
establishment of cell polarityEphrin type-B receptor 1Homo sapiens (human)
retinal ganglion cell axon guidanceEphrin type-B receptor 1Homo sapiens (human)
cell-substrate adhesionEphrin type-B receptor 1Homo sapiens (human)
regulation of JNK cascadeEphrin type-B receptor 1Homo sapiens (human)
protein autophosphorylationEphrin type-B receptor 1Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-B receptor 1Homo sapiens (human)
camera-type eye morphogenesisEphrin type-B receptor 1Homo sapiens (human)
modulation of chemical synaptic transmissionEphrin type-B receptor 1Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painEphrin type-B receptor 1Homo sapiens (human)
positive regulation of synapse assemblyEphrin type-B receptor 1Homo sapiens (human)
cell chemotaxisEphrin type-B receptor 1Homo sapiens (human)
dendritic spine developmentEphrin type-B receptor 1Homo sapiens (human)
dendritic spine morphogenesisEphrin type-B receptor 1Homo sapiens (human)
neural precursor cell proliferationEphrin type-B receptor 1Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeEphrin type-B receptor 1Homo sapiens (human)
negative regulation of skeletal muscle satellite cell proliferationEphrin type-B receptor 1Homo sapiens (human)
negative regulation of satellite cell differentiationEphrin type-B receptor 1Homo sapiens (human)
protein phosphorylationEphrin type-B receptor 1Homo sapiens (human)
negative regulation of cellular response to hypoxiaEphrin type-A receptor 4Homo sapiens (human)
cell adhesionEphrin type-A receptor 4Homo sapiens (human)
negative regulation of cell adhesionEphrin type-A receptor 4Homo sapiens (human)
adult walking behaviorEphrin type-A receptor 4Homo sapiens (human)
motor neuron axon guidanceEphrin type-A receptor 4Homo sapiens (human)
positive regulation of cell population proliferationEphrin type-A receptor 4Homo sapiens (human)
glial cell migrationEphrin type-A receptor 4Homo sapiens (human)
negative regulation of epithelial to mesenchymal transitionEphrin type-A receptor 4Homo sapiens (human)
negative regulation of neuron projection developmentEphrin type-A receptor 4Homo sapiens (human)
negative regulation of translationEphrin type-A receptor 4Homo sapiens (human)
peptidyl-tyrosine phosphorylationEphrin type-A receptor 4Homo sapiens (human)
corticospinal tract morphogenesisEphrin type-A receptor 4Homo sapiens (human)
positive regulation of cell migrationEphrin type-A receptor 4Homo sapiens (human)
negative regulation of cell migrationEphrin type-A receptor 4Homo sapiens (human)
adherens junction organizationEphrin type-A receptor 4Homo sapiens (human)
regulation of GTPase activityEphrin type-A receptor 4Homo sapiens (human)
positive regulation of cell adhesionEphrin type-A receptor 4Homo sapiens (human)
protein autophosphorylationEphrin type-A receptor 4Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 4Homo sapiens (human)
negative regulation of axon regenerationEphrin type-A receptor 4Homo sapiens (human)
regulation of astrocyte differentiationEphrin type-A receptor 4Homo sapiens (human)
regulation of axonogenesisEphrin type-A receptor 4Homo sapiens (human)
positive regulation of dendrite morphogenesisEphrin type-A receptor 4Homo sapiens (human)
protein stabilizationEphrin type-A receptor 4Homo sapiens (human)
regulation of dendritic spine morphogenesisEphrin type-A receptor 4Homo sapiens (human)
positive regulation of protein tyrosine kinase activityEphrin type-A receptor 4Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeEphrin type-A receptor 4Homo sapiens (human)
nephric duct morphogenesisEphrin type-A receptor 4Homo sapiens (human)
cochlea developmentEphrin type-A receptor 4Homo sapiens (human)
fasciculation of sensory neuron axonEphrin type-A receptor 4Homo sapiens (human)
fasciculation of motor neuron axonEphrin type-A receptor 4Homo sapiens (human)
neuron projection guidanceEphrin type-A receptor 4Homo sapiens (human)
synapse pruningEphrin type-A receptor 4Homo sapiens (human)
neuron projection fasciculationEphrin type-A receptor 4Homo sapiens (human)
negative regulation of long-term synaptic potentiationEphrin type-A receptor 4Homo sapiens (human)
positive regulation of amyloid-beta formationEphrin type-A receptor 4Homo sapiens (human)
positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic processEphrin type-A receptor 4Homo sapiens (human)
negative regulation of proteolysis involved in protein catabolic processEphrin type-A receptor 4Homo sapiens (human)
cellular response to amyloid-betaEphrin type-A receptor 4Homo sapiens (human)
regulation of modification of synaptic structureEphrin type-A receptor 4Homo sapiens (human)
regulation of synapse pruningEphrin type-A receptor 4Homo sapiens (human)
positive regulation of Rho guanyl-nucleotide exchange factor activityEphrin type-A receptor 4Homo sapiens (human)
protein phosphorylationEphrin type-A receptor 4Homo sapiens (human)
axon guidanceEphrin type-A receptor 4Homo sapiens (human)
ADP biosynthetic processAdenylate kinase 2, mitochondrialHomo sapiens (human)
nucleobase-containing small molecule interconversionAdenylate kinase 2, mitochondrialHomo sapiens (human)
AMP metabolic processAdenylate kinase 2, mitochondrialHomo sapiens (human)
ATP metabolic processAdenylate kinase 2, mitochondrialHomo sapiens (human)
nucleoside monophosphate phosphorylationAdenylate kinase 2, mitochondrialHomo sapiens (human)
purine ribonucleoside salvageAdenosine kinaseHomo sapiens (human)
dATP biosynthetic processAdenosine kinaseHomo sapiens (human)
ribonucleoside monophosphate biosynthetic processAdenosine kinaseHomo sapiens (human)
GMP salvageAdenosine kinaseHomo sapiens (human)
AMP salvageAdenosine kinaseHomo sapiens (human)
dAMP salvageAdenosine kinaseHomo sapiens (human)
purine nucleobase metabolic processAdenosine kinaseHomo sapiens (human)
proteolysisBeta-secretase 1Homo sapiens (human)
membrane protein ectodomain proteolysisBeta-secretase 1Homo sapiens (human)
response to lead ionBeta-secretase 1Homo sapiens (human)
protein processingBeta-secretase 1Homo sapiens (human)
amyloid-beta formationBeta-secretase 1Homo sapiens (human)
amyloid precursor protein catabolic processBeta-secretase 1Homo sapiens (human)
positive regulation of neuron apoptotic processBeta-secretase 1Homo sapiens (human)
amyloid-beta metabolic processBeta-secretase 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painBeta-secretase 1Homo sapiens (human)
prepulse inhibitionBeta-secretase 1Homo sapiens (human)
cellular response to copper ionBeta-secretase 1Homo sapiens (human)
cellular response to manganese ionBeta-secretase 1Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionBeta-secretase 1Homo sapiens (human)
signaling receptor ligand precursor processingBeta-secretase 1Homo sapiens (human)
cellular response to amyloid-betaBeta-secretase 1Homo sapiens (human)
amyloid fibril formationBeta-secretase 1Homo sapiens (human)
signal transductionHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
intracellular signal transductionHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
regulation of sodium ion transportSerine/threonine-protein kinase SIK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase SIK1Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase SIK1Homo sapiens (human)
regulation of myotube differentiationSerine/threonine-protein kinase SIK1Homo sapiens (human)
negative regulation of triglyceride biosynthetic processSerine/threonine-protein kinase SIK1Homo sapiens (human)
negative regulation of CREB transcription factor activitySerine/threonine-protein kinase SIK1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase SIK1Homo sapiens (human)
entrainment of circadian clock by photoperiodSerine/threonine-protein kinase SIK1Homo sapiens (human)
anoikisSerine/threonine-protein kinase SIK1Homo sapiens (human)
regulation of cell differentiationSerine/threonine-protein kinase SIK1Homo sapiens (human)
negative regulation of gluconeogenesisSerine/threonine-protein kinase SIK1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase SIK1Homo sapiens (human)
rhythmic processSerine/threonine-protein kinase SIK1Homo sapiens (human)
cardiac muscle cell differentiationSerine/threonine-protein kinase SIK1Homo sapiens (human)
positive regulation of anoikisSerine/threonine-protein kinase SIK1Homo sapiens (human)
morphogenesis of an epitheliumReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
Golgi to plasma membrane transportRas-related protein Rab-10Homo sapiens (human)
axonogenesisRas-related protein Rab-10Homo sapiens (human)
vesicle-mediated transportRas-related protein Rab-10Homo sapiens (human)
endosomal transportRas-related protein Rab-10Homo sapiens (human)
antigen processing and presentationRas-related protein Rab-10Homo sapiens (human)
polarized epithelial cell differentiationRas-related protein Rab-10Homo sapiens (human)
cellular response to insulin stimulusRas-related protein Rab-10Homo sapiens (human)
Golgi to plasma membrane protein transportRas-related protein Rab-10Homo sapiens (human)
regulated exocytosisRas-related protein Rab-10Homo sapiens (human)
establishment of neuroblast polarityRas-related protein Rab-10Homo sapiens (human)
endoplasmic reticulum tubular network organizationRas-related protein Rab-10Homo sapiens (human)
protein localization to plasma membraneRas-related protein Rab-10Homo sapiens (human)
establishment of protein localization to membraneRas-related protein Rab-10Homo sapiens (human)
establishment of protein localization to endoplasmic reticulum membraneRas-related protein Rab-10Homo sapiens (human)
cell-cell adhesionRas-related protein Rab-10Homo sapiens (human)
protein localization to basolateral plasma membraneRas-related protein Rab-10Homo sapiens (human)
exocytosisRas-related protein Rab-10Homo sapiens (human)
protein secretionRas-related protein Rab-10Homo sapiens (human)
establishment or maintenance of cell polarityActin-related protein 3Homo sapiens (human)
asymmetric cell divisionActin-related protein 3Homo sapiens (human)
positive regulation of lamellipodium assemblyActin-related protein 3Homo sapiens (human)
meiotic chromosome movement towards spindle poleActin-related protein 3Homo sapiens (human)
meiotic cytokinesisActin-related protein 3Homo sapiens (human)
Arp2/3 complex-mediated actin nucleationActin-related protein 3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIActin-related protein 3Homo sapiens (human)
spindle localizationActin-related protein 3Homo sapiens (human)
cilium assemblyActin-related protein 3Homo sapiens (human)
actin polymerization-dependent cell motilityActin-related protein 3Homo sapiens (human)
cellular response to type II interferonActin-related protein 3Homo sapiens (human)
regulation of double-strand break repair via nonhomologous end joiningActin-related protein 2Homo sapiens (human)
cilium assemblyActin-related protein 2Homo sapiens (human)
establishment or maintenance of cell polarityActin-related protein 2Homo sapiens (human)
asymmetric cell divisionActin-related protein 2Homo sapiens (human)
positive regulation of lamellipodium assemblyActin-related protein 2Homo sapiens (human)
meiotic chromosome movement towards spindle poleActin-related protein 2Homo sapiens (human)
cytosolic transportActin-related protein 2Homo sapiens (human)
meiotic cytokinesisActin-related protein 2Homo sapiens (human)
Arp2/3 complex-mediated actin nucleationActin-related protein 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIActin-related protein 2Homo sapiens (human)
spindle localizationActin-related protein 2Homo sapiens (human)
cellular response to type II interferonActin-related protein 2Homo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationActin-related protein 2Homo sapiens (human)
ribosomal large subunit export from nucleusGTP-binding nuclear protein RanHomo sapiens (human)
ribosomal small subunit export from nucleusGTP-binding nuclear protein RanHomo sapiens (human)
mitotic sister chromatid segregationGTP-binding nuclear protein RanHomo sapiens (human)
mitotic cell cycleGTP-binding nuclear protein RanHomo sapiens (human)
DNA metabolic processGTP-binding nuclear protein RanHomo sapiens (human)
protein import into nucleusGTP-binding nuclear protein RanHomo sapiens (human)
protein export from nucleusGTP-binding nuclear protein RanHomo sapiens (human)
mitotic spindle organizationGTP-binding nuclear protein RanHomo sapiens (human)
spermatid developmentGTP-binding nuclear protein RanHomo sapiens (human)
viral processGTP-binding nuclear protein RanHomo sapiens (human)
hippocampus developmentGTP-binding nuclear protein RanHomo sapiens (human)
actin cytoskeleton organizationGTP-binding nuclear protein RanHomo sapiens (human)
positive regulation of protein bindingGTP-binding nuclear protein RanHomo sapiens (human)
pre-miRNA export from nucleusGTP-binding nuclear protein RanHomo sapiens (human)
positive regulation of protein import into nucleusGTP-binding nuclear protein RanHomo sapiens (human)
GTP metabolic processGTP-binding nuclear protein RanHomo sapiens (human)
cell divisionGTP-binding nuclear protein RanHomo sapiens (human)
snRNA import into nucleusGTP-binding nuclear protein RanHomo sapiens (human)
cellular response to mineralocorticoid stimulusGTP-binding nuclear protein RanHomo sapiens (human)
protein localization to nucleolusGTP-binding nuclear protein RanHomo sapiens (human)
ribosomal subunit export from nucleusGTP-binding nuclear protein RanHomo sapiens (human)
double-strand break repairCasein kinase II subunit alphaHomo sapiens (human)
protein phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
apoptotic processCasein kinase II subunit alphaHomo sapiens (human)
DNA damage responseCasein kinase II subunit alphaHomo sapiens (human)
signal transductionCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of cell population proliferationCasein kinase II subunit alphaHomo sapiens (human)
Wnt signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of translationCasein kinase II subunit alphaHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of Wnt signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of cell growthCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of protein catabolic processCasein kinase II subunit alphaHomo sapiens (human)
rhythmic processCasein kinase II subunit alphaHomo sapiens (human)
protein stabilizationCasein kinase II subunit alphaHomo sapiens (human)
chaperone-mediated protein foldingCasein kinase II subunit alphaHomo sapiens (human)
symbiont-mediated disruption of host cell PML bodyCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of aggrephagyCasein kinase II subunit alphaHomo sapiens (human)
regulation of chromosome separationCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of double-strand break repair via homologous recombinationCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of apoptotic signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
regulation of cell cycleCasein kinase II subunit alphaHomo sapiens (human)
cell surface receptor signaling pathwayPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
regulation of autophagyPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
autophagosome-lysosome fusionPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic processPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
positive regulation of autophagosome assemblyPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
spliceosomal complex assemblySRSF protein kinase 2Homo sapiens (human)
angiogenesisSRSF protein kinase 2Homo sapiens (human)
protein phosphorylationSRSF protein kinase 2Homo sapiens (human)
positive regulation of cell population proliferationSRSF protein kinase 2Homo sapiens (human)
RNA splicingSRSF protein kinase 2Homo sapiens (human)
positive regulation of gene expressionSRSF protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationSRSF protein kinase 2Homo sapiens (human)
cell differentiationSRSF protein kinase 2Homo sapiens (human)
nuclear speck organizationSRSF protein kinase 2Homo sapiens (human)
intracellular signal transductionSRSF protein kinase 2Homo sapiens (human)
positive regulation of neuron apoptotic processSRSF protein kinase 2Homo sapiens (human)
positive regulation of viral genome replicationSRSF protein kinase 2Homo sapiens (human)
negative regulation of viral genome replicationSRSF protein kinase 2Homo sapiens (human)
innate immune responseSRSF protein kinase 2Homo sapiens (human)
positive regulation of cell cycleSRSF protein kinase 2Homo sapiens (human)
regulation of mRNA splicing, via spliceosomeSRSF protein kinase 2Homo sapiens (human)
R-loop processingSRSF protein kinase 2Homo sapiens (human)
regulation of mRNA processingSRSF protein kinase 2Homo sapiens (human)
protein phosphorylationCasein kinase I isoform gamma-2Homo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform gamma-2Homo sapiens (human)
sphingolipid biosynthetic processCasein kinase I isoform gamma-2Homo sapiens (human)
signal transductionCasein kinase I isoform gamma-2Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform gamma-2Homo sapiens (human)
endocytosisCasein kinase I isoform gamma-2Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform gamma-2Homo sapiens (human)
peptidyl-serine phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
maturation of 5.8S rRNADNA-dependent protein kinase catalytic subunitHomo sapiens (human)
somitogenesisDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
negative regulation of protein phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
activation of innate immune responseDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
B cell lineage commitmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
immature B cell differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
pro-B cell differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
T cell lineage commitmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
double-strand break repairDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
double-strand break repair via nonhomologous end joiningDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
chromatin remodelingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA damage responseDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
brain developmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
heart developmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
response to gamma radiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
telomere cappingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
peptidyl-serine phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
peptidyl-threonine phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
mitotic G1 DNA damage checkpoint signalingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein destabilizationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
cellular response to insulin stimulusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
T cell differentiation in thymusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
T cell receptor V(D)J recombinationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
small-subunit processome assemblyDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
ectopic germ cell programmed cell deathDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein modification processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of circadian rhythmDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of apoptotic processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
negative regulation of apoptotic processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
innate immune responseDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of lymphocyte differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of erythrocyte differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of translationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
rhythmic processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of smooth muscle cell proliferationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of epithelial cell proliferationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
double-strand break repair via alternative nonhomologous end joiningDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of hematopoietic stem cell differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of platelet formationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of double-strand break repair via nonhomologous end joiningDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
immunoglobulin V(D)J recombinationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
telomere maintenanceDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
apoptotic processMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
positive regulation of apoptotic processMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
DNA damage responseCyclin-dependent kinase 3Homo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 3Homo sapiens (human)
cell population proliferationCyclin-dependent kinase 3Homo sapiens (human)
G0 to G1 transitionCyclin-dependent kinase 3Homo sapiens (human)
negative regulation of Notch signaling pathwayCyclin-dependent kinase 3Homo sapiens (human)
cell divisionCyclin-dependent kinase 3Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 3Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 3Homo sapiens (human)
signal transductionCyclin-dependent kinase 3Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 3Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 3Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase-like 1Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase-like 1Homo sapiens (human)
regulation of cilium assemblyCyclin-dependent kinase-like 1Homo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICyclin-dependent kinase 6Homo sapiens (human)
positive regulation of cell-matrix adhesionCyclin-dependent kinase 6Homo sapiens (human)
type B pancreatic cell developmentCyclin-dependent kinase 6Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 6Homo sapiens (human)
Notch signaling pathwayCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of cell population proliferationCyclin-dependent kinase 6Homo sapiens (human)
response to virusCyclin-dependent kinase 6Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 6Homo sapiens (human)
positive regulation of gene expressionCyclin-dependent kinase 6Homo sapiens (human)
astrocyte developmentCyclin-dependent kinase 6Homo sapiens (human)
dentate gyrus developmentCyclin-dependent kinase 6Homo sapiens (human)
lateral ventricle developmentCyclin-dependent kinase 6Homo sapiens (human)
T cell differentiation in thymusCyclin-dependent kinase 6Homo sapiens (human)
gliogenesisCyclin-dependent kinase 6Homo sapiens (human)
cell dedifferentiationCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of cell differentiationCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of myeloid cell differentiationCyclin-dependent kinase 6Homo sapiens (human)
regulation of erythrocyte differentiationCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of monocyte differentiationCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of osteoblast differentiationCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of cell cycleCyclin-dependent kinase 6Homo sapiens (human)
positive regulation of fibroblast proliferationCyclin-dependent kinase 6Homo sapiens (human)
generation of neuronsCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of epithelial cell proliferationCyclin-dependent kinase 6Homo sapiens (human)
cell divisionCyclin-dependent kinase 6Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 6Homo sapiens (human)
hematopoietic stem cell differentiationCyclin-dependent kinase 6Homo sapiens (human)
regulation of hematopoietic stem cell differentiationCyclin-dependent kinase 6Homo sapiens (human)
regulation of cell motilityCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of cellular senescenceCyclin-dependent kinase 6Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 6Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 6Homo sapiens (human)
signal transductionCyclin-dependent kinase 6Homo sapiens (human)
microtubule cytoskeleton organizationCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron migrationCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic transmission, dopaminergicCyclin-dependent-like kinase 5 Homo sapiens (human)
protein phosphorylationCyclin-dependent-like kinase 5 Homo sapiens (human)
intracellular protein transportCyclin-dependent-like kinase 5 Homo sapiens (human)
cell-matrix adhesionCyclin-dependent-like kinase 5 Homo sapiens (human)
chemical synaptic transmissionCyclin-dependent-like kinase 5 Homo sapiens (human)
synapse assemblyCyclin-dependent-like kinase 5 Homo sapiens (human)
skeletal muscle tissue developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
motor neuron axon guidanceCyclin-dependent-like kinase 5 Homo sapiens (human)
visual learningCyclin-dependent-like kinase 5 Homo sapiens (human)
Schwann cell developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic vesicle exocytosisCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of macroautophagyCyclin-dependent-like kinase 5 Homo sapiens (human)
phosphorylationCyclin-dependent-like kinase 5 Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent-like kinase 5 Homo sapiens (human)
peptidyl-threonine phosphorylationCyclin-dependent-like kinase 5 Homo sapiens (human)
sensory perception of painCyclin-dependent-like kinase 5 Homo sapiens (human)
cerebellar cortex formationCyclin-dependent-like kinase 5 Homo sapiens (human)
hippocampus developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
layer formation in cerebral cortexCyclin-dependent-like kinase 5 Homo sapiens (human)
central nervous system neuron developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
corpus callosum developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron differentiationCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of cell migrationCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of axon extensionCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron projection developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of protein ubiquitinationCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of synaptic plasticityCyclin-dependent-like kinase 5 Homo sapiens (human)
receptor catabolic processCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic transmission, glutamatergicCyclin-dependent-like kinase 5 Homo sapiens (human)
protein localization to synapseCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of apoptotic processCyclin-dependent-like kinase 5 Homo sapiens (human)
receptor clusteringCyclin-dependent-like kinase 5 Homo sapiens (human)
positive regulation of neuron apoptotic processCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of cell cycleCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of proteolysisCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of DNA-templated transcriptionCyclin-dependent-like kinase 5 Homo sapiens (human)
positive regulation of calcium ion-dependent exocytosisCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of protein export from nucleusCyclin-dependent-like kinase 5 Homo sapiens (human)
behavioral response to cocaineCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of synaptic plasticityCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic vesicle endocytosisCyclin-dependent-like kinase 5 Homo sapiens (human)
rhythmic processCyclin-dependent-like kinase 5 Homo sapiens (human)
axon extensionCyclin-dependent-like kinase 5 Homo sapiens (human)
oligodendrocyte differentiationCyclin-dependent-like kinase 5 Homo sapiens (human)
dendrite morphogenesisCyclin-dependent-like kinase 5 Homo sapiens (human)
cell divisionCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron apoptotic processCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of cell cycleCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of synaptic transmission, glutamatergicCyclin-dependent-like kinase 5 Homo sapiens (human)
excitatory postsynaptic potentialCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of dendritic spine morphogenesisCyclin-dependent-like kinase 5 Homo sapiens (human)
calcium ion importCyclin-dependent-like kinase 5 Homo sapiens (human)
positive regulation of protein targeting to membraneCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of protein localization to plasma membraneCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of synaptic vesicle recyclingCyclin-dependent-like kinase 5 Homo sapiens (human)
cellular response to amyloid-betaCyclin-dependent-like kinase 5 Homo sapiens (human)
axonogenesisCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic vesicle transportCyclin-dependent-like kinase 5 Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 16Homo sapiens (human)
exocytosisCyclin-dependent kinase 16Homo sapiens (human)
spermatogenesisCyclin-dependent kinase 16Homo sapiens (human)
positive regulation of autophagyCyclin-dependent kinase 16Homo sapiens (human)
growth hormone secretionCyclin-dependent kinase 16Homo sapiens (human)
neuron projection developmentCyclin-dependent kinase 16Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 16Homo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusCyclin-dependent kinase 16Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 17Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 17Homo sapiens (human)
cellular response to leukemia inhibitory factorATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
canonical glycolysisATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
fructose 1,6-bisphosphate metabolic processATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
fructose 6-phosphate metabolic processATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
MAPK cascadeProtein kinase C epsilon typeHomo sapiens (human)
macrophage activation involved in immune responseProtein kinase C epsilon typeHomo sapiens (human)
protein phosphorylationProtein kinase C epsilon typeHomo sapiens (human)
apoptotic processProtein kinase C epsilon typeHomo sapiens (human)
signal transductionProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of epithelial cell migrationProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of fibroblast migrationProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of cell-substrate adhesionProtein kinase C epsilon typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C epsilon typeHomo sapiens (human)
insulin secretionProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of actin filament polymerizationProtein kinase C epsilon typeHomo sapiens (human)
negative regulation of protein ubiquitinationProtein kinase C epsilon typeHomo sapiens (human)
cell-substrate adhesionProtein kinase C epsilon typeHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of insulin secretionProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of cytokinesisProtein kinase C epsilon typeHomo sapiens (human)
locomotory exploration behaviorProtein kinase C epsilon typeHomo sapiens (human)
TRAM-dependent toll-like receptor 4 signaling pathwayProtein kinase C epsilon typeHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionProtein kinase C epsilon typeHomo sapiens (human)
response to morphineProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of MAPK cascadeProtein kinase C epsilon typeHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of lipid catabolic processProtein kinase C epsilon typeHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosolProtein kinase C epsilon typeHomo sapiens (human)
cell divisionProtein kinase C epsilon typeHomo sapiens (human)
establishment of localization in cellProtein kinase C epsilon typeHomo sapiens (human)
synaptic transmission, GABAergicProtein kinase C epsilon typeHomo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusProtein kinase C epsilon typeHomo sapiens (human)
mucus secretionProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of mucus secretionProtein kinase C epsilon typeHomo sapiens (human)
cellular response to ethanolProtein kinase C epsilon typeHomo sapiens (human)
cellular response to prostaglandin E stimulusProtein kinase C epsilon typeHomo sapiens (human)
cellular response to hypoxiaProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of wound healingProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of protein localization to plasma membraneProtein kinase C epsilon typeHomo sapiens (human)
negative regulation of sodium ion transmembrane transporter activityProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of cellular glucuronidationProtein kinase C epsilon typeHomo sapiens (human)
intracellular signal transductionProtein kinase C epsilon typeHomo sapiens (human)
chemotaxisDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
heart developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
negative regulation of cell population proliferationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of gene expressionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
Schwann cell developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
cerebellar cortex formationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
keratinocyte differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
thyroid gland developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of stress-activated MAPK cascadeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
endodermal cell differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
myelinationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
type B pancreatic cell proliferationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
thymus developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of axon regenerationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
cell motilityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of axonogenesisDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
Bergmann glial cell differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
face developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
trachea formationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
epithelial cell proliferation involved in lung morphogenesisDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
placenta blood vessel developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
labyrinthine layer developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
ERK1 and ERK2 cascadeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of Golgi inheritanceDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
cellular senescenceDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of endodermal cell differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of early endosome to late endosome transportDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
neuron differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAngiopoietin-1 receptorHomo sapiens (human)
angiogenesisAngiopoietin-1 receptorHomo sapiens (human)
response to hypoxiaAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of protein phosphorylationAngiopoietin-1 receptorHomo sapiens (human)
endothelial cell proliferationAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of endothelial cell proliferationAngiopoietin-1 receptorHomo sapiens (human)
endochondral ossificationAngiopoietin-1 receptorHomo sapiens (human)
sprouting angiogenesisAngiopoietin-1 receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayAngiopoietin-1 receptorHomo sapiens (human)
cell-cell signalingAngiopoietin-1 receptorHomo sapiens (human)
heart developmentAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of endothelial cell migrationAngiopoietin-1 receptorHomo sapiens (human)
negative regulation of angiogenesisAngiopoietin-1 receptorHomo sapiens (human)
regulation of establishment or maintenance of cell polarityAngiopoietin-1 receptorHomo sapiens (human)
substrate adhesion-dependent cell spreadingAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of Rac protein signal transductionAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of Rho protein signal transductionAngiopoietin-1 receptorHomo sapiens (human)
negative regulation of apoptotic processAngiopoietin-1 receptorHomo sapiens (human)
regulation of vascular permeabilityAngiopoietin-1 receptorHomo sapiens (human)
response to peptide hormoneAngiopoietin-1 receptorHomo sapiens (human)
response to estrogenAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of angiogenesisAngiopoietin-1 receptorHomo sapiens (human)
Tie signaling pathwayAngiopoietin-1 receptorHomo sapiens (human)
negative regulation of inflammatory responseAngiopoietin-1 receptorHomo sapiens (human)
response to cAMPAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of focal adhesion assemblyAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionAngiopoietin-1 receptorHomo sapiens (human)
definitive hemopoiesisAngiopoietin-1 receptorHomo sapiens (human)
heart trabecula formationAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAngiopoietin-1 receptorHomo sapiens (human)
glomerulus vasculature developmentAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of intracellular signal transductionAngiopoietin-1 receptorHomo sapiens (human)
regulation of endothelial cell apoptotic processAngiopoietin-1 receptorHomo sapiens (human)
negative regulation of endothelial cell apoptotic processAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of MAPK cascadeAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of kinase activityAngiopoietin-1 receptorHomo sapiens (human)
multicellular organism developmentAngiopoietin-1 receptorHomo sapiens (human)
apoptotic processMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
signal transductionMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
smoothened signaling pathwayMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
peptidyl-threonine phosphorylationMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
negative regulation of DNA-templated transcriptionMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
positive regulation of JNK cascadeMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
positive regulation of apoptotic processMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
neuron migrationDNA topoisomerase 2-betaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-betaHomo sapiens (human)
axonogenesisDNA topoisomerase 2-betaHomo sapiens (human)
B cell differentiationDNA topoisomerase 2-betaHomo sapiens (human)
forebrain developmentDNA topoisomerase 2-betaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-betaHomo sapiens (human)
cellular response to hydrogen peroxideDNA topoisomerase 2-betaHomo sapiens (human)
cellular response to ATPDNA topoisomerase 2-betaHomo sapiens (human)
cellular senescenceDNA topoisomerase 2-betaHomo sapiens (human)
positive regulation of double-strand break repair via nonhomologous end joiningDNA topoisomerase 2-betaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-betaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-betaHomo sapiens (human)
positive regulation of interleukin-1 beta productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
positive regulation of amyloid-beta formationTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
liver developmentTranscription factor p65Homo sapiens (human)
hair follicle developmentTranscription factor p65Homo sapiens (human)
defense response to tumor cellTranscription factor p65Homo sapiens (human)
response to ischemiaTranscription factor p65Homo sapiens (human)
acetaldehyde metabolic processTranscription factor p65Homo sapiens (human)
chromatin organizationTranscription factor p65Homo sapiens (human)
DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
inflammatory responseTranscription factor p65Homo sapiens (human)
cellular defense responseTranscription factor p65Homo sapiens (human)
neuropeptide signaling pathwayTranscription factor p65Homo sapiens (human)
canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of cell population proliferationTranscription factor p65Homo sapiens (human)
response to xenobiotic stimulusTranscription factor p65Homo sapiens (human)
animal organ morphogenesisTranscription factor p65Homo sapiens (human)
response to UV-BTranscription factor p65Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionTranscription factor p65Homo sapiens (human)
positive regulation of gene expressionTranscription factor p65Homo sapiens (human)
positive regulation of Schwann cell differentiationTranscription factor p65Homo sapiens (human)
negative regulation of angiogenesisTranscription factor p65Homo sapiens (human)
cytokine-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
protein catabolic processTranscription factor p65Homo sapiens (human)
response to muramyl dipeptideTranscription factor p65Homo sapiens (human)
response to progesteroneTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-12 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
response to insulinTranscription factor p65Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein sumoylationTranscription factor p65Homo sapiens (human)
response to cobalaminTranscription factor p65Homo sapiens (human)
toll-like receptor 4 signaling pathwayTranscription factor p65Homo sapiens (human)
intracellular signal transductionTranscription factor p65Homo sapiens (human)
cellular response to hepatocyte growth factor stimulusTranscription factor p65Homo sapiens (human)
response to muscle stretchTranscription factor p65Homo sapiens (human)
non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
vascular endothelial growth factor signaling pathwayTranscription factor p65Homo sapiens (human)
prolactin signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein catabolic processTranscription factor p65Homo sapiens (human)
negative regulation of apoptotic processTranscription factor p65Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
response to amino acidTranscription factor p65Homo sapiens (human)
negative regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTranscription factor p65Homo sapiens (human)
regulation of inflammatory responseTranscription factor p65Homo sapiens (human)
positive regulation of T cell receptor signaling pathwayTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
response to cAMPTranscription factor p65Homo sapiens (human)
defense response to virusTranscription factor p65Homo sapiens (human)
cellular response to hydrogen peroxideTranscription factor p65Homo sapiens (human)
interleukin-1-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to lipopolysaccharideTranscription factor p65Homo sapiens (human)
cellular response to lipoteichoic acidTranscription factor p65Homo sapiens (human)
cellular response to peptidoglycanTranscription factor p65Homo sapiens (human)
cellular response to nicotineTranscription factor p65Homo sapiens (human)
cellular response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to interleukin-6Transcription factor p65Homo sapiens (human)
cellular response to tumor necrosis factorTranscription factor p65Homo sapiens (human)
postsynapse to nucleus signaling pathwayTranscription factor p65Homo sapiens (human)
antiviral innate immune responseTranscription factor p65Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
negative regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
cellular response to angiotensinTranscription factor p65Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellTranscription factor p65Homo sapiens (human)
positive regulation of miRNA metabolic processTranscription factor p65Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayTranscription factor p65Homo sapiens (human)
cellular response to stressTranscription factor p65Homo sapiens (human)
response to cytokineTranscription factor p65Homo sapiens (human)
innate immune responseTranscription factor p65Homo sapiens (human)
regulation of cell growthProtein kinase C theta typeHomo sapiens (human)
regulation of DNA-templated transcriptionProtein kinase C theta typeHomo sapiens (human)
protein phosphorylationProtein kinase C theta typeHomo sapiens (human)
membrane protein ectodomain proteolysisProtein kinase C theta typeHomo sapiens (human)
inflammatory responseProtein kinase C theta typeHomo sapiens (human)
axon guidanceProtein kinase C theta typeHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseProtein kinase C theta typeHomo sapiens (human)
positive regulation of interleukin-17 productionProtein kinase C theta typeHomo sapiens (human)
positive regulation of interleukin-2 productionProtein kinase C theta typeHomo sapiens (human)
positive regulation of interleukin-4 productionProtein kinase C theta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C theta typeHomo sapiens (human)
CD4-positive, alpha-beta T cell proliferationProtein kinase C theta typeHomo sapiens (human)
Fc-epsilon receptor signaling pathwayProtein kinase C theta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C theta typeHomo sapiens (human)
positive regulation of T cell activationProtein kinase C theta typeHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProtein kinase C theta typeHomo sapiens (human)
positive regulation of telomerase activityProtein kinase C theta typeHomo sapiens (human)
cell chemotaxisProtein kinase C theta typeHomo sapiens (human)
negative regulation of T cell apoptotic processProtein kinase C theta typeHomo sapiens (human)
regulation of platelet aggregationProtein kinase C theta typeHomo sapiens (human)
positive regulation of telomere cappingProtein kinase C theta typeHomo sapiens (human)
positive regulation of T-helper 17 type immune responseProtein kinase C theta typeHomo sapiens (human)
positive regulation of CD4-positive, alpha-beta T cell proliferationProtein kinase C theta typeHomo sapiens (human)
positive regulation of T-helper 2 cell activationProtein kinase C theta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C theta typeHomo sapiens (human)
outflow tract septum morphogenesisActivin receptor type-1Homo sapiens (human)
branching involved in blood vessel morphogenesisActivin receptor type-1Homo sapiens (human)
in utero embryonic developmentActivin receptor type-1Homo sapiens (human)
gastrulation with mouth forming secondActivin receptor type-1Homo sapiens (human)
mesoderm formationActivin receptor type-1Homo sapiens (human)
neural crest cell migrationActivin receptor type-1Homo sapiens (human)
acute inflammatory responseActivin receptor type-1Homo sapiens (human)
embryonic heart tube morphogenesisActivin receptor type-1Homo sapiens (human)
atrioventricular valve morphogenesisActivin receptor type-1Homo sapiens (human)
mitral valve morphogenesisActivin receptor type-1Homo sapiens (human)
endocardial cushion formationActivin receptor type-1Homo sapiens (human)
endocardial cushion fusionActivin receptor type-1Homo sapiens (human)
atrial septum primum morphogenesisActivin receptor type-1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayActivin receptor type-1Homo sapiens (human)
germ cell developmentActivin receptor type-1Homo sapiens (human)
determination of left/right symmetryActivin receptor type-1Homo sapiens (human)
negative regulation of signal transductionActivin receptor type-1Homo sapiens (human)
regulation of ossificationActivin receptor type-1Homo sapiens (human)
positive regulation of cell migrationActivin receptor type-1Homo sapiens (human)
positive regulation of bone mineralizationActivin receptor type-1Homo sapiens (human)
BMP signaling pathwayActivin receptor type-1Homo sapiens (human)
activin receptor signaling pathwayActivin receptor type-1Homo sapiens (human)
negative regulation of activin receptor signaling pathwayActivin receptor type-1Homo sapiens (human)
positive regulation of osteoblast differentiationActivin receptor type-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionActivin receptor type-1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIActivin receptor type-1Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationActivin receptor type-1Homo sapiens (human)
smooth muscle cell differentiationActivin receptor type-1Homo sapiens (human)
pharyngeal system developmentActivin receptor type-1Homo sapiens (human)
positive regulation of SMAD protein signal transductionActivin receptor type-1Homo sapiens (human)
ventricular septum morphogenesisActivin receptor type-1Homo sapiens (human)
cardiac muscle cell fate commitmentActivin receptor type-1Homo sapiens (human)
endocardial cushion cell fate commitmentActivin receptor type-1Homo sapiens (human)
positive regulation of cardiac epithelial to mesenchymal transitionActivin receptor type-1Homo sapiens (human)
cellular response to BMP stimulusActivin receptor type-1Homo sapiens (human)
positive regulation of determination of dorsal identityActivin receptor type-1Homo sapiens (human)
negative regulation of G1/S transition of mitotic cell cycleActivin receptor type-1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayActivin receptor type-1Homo sapiens (human)
dorsal/ventral pattern formationActivin receptor type-1Homo sapiens (human)
heart developmentActivin receptor type-1Homo sapiens (human)
protein phosphorylationActivin receptor type-1Homo sapiens (human)
cellular response to growth factor stimulusActivin receptor type-1Homo sapiens (human)
defense responseMacrophage-stimulating protein receptorHomo sapiens (human)
signal transductionMacrophage-stimulating protein receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayMacrophage-stimulating protein receptorHomo sapiens (human)
single fertilizationMacrophage-stimulating protein receptorHomo sapiens (human)
positive regulation of cell population proliferationMacrophage-stimulating protein receptorHomo sapiens (human)
response to virusMacrophage-stimulating protein receptorHomo sapiens (human)
macrophage colony-stimulating factor signaling pathwayMacrophage-stimulating protein receptorHomo sapiens (human)
positive regulation of MAP kinase activityMacrophage-stimulating protein receptorHomo sapiens (human)
innate immune responseMacrophage-stimulating protein receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionMacrophage-stimulating protein receptorHomo sapiens (human)
nervous system developmentMacrophage-stimulating protein receptorHomo sapiens (human)
cell migrationMacrophage-stimulating protein receptorHomo sapiens (human)
phagocytosisMacrophage-stimulating protein receptorHomo sapiens (human)
positive regulation of kinase activityMacrophage-stimulating protein receptorHomo sapiens (human)
multicellular organism developmentMacrophage-stimulating protein receptorHomo sapiens (human)
positive regulation of macrophage chemotaxisFocal adhesion kinase 1Homo sapiens (human)
positive regulation of macrophage proliferationFocal adhesion kinase 1Homo sapiens (human)
angiogenesisFocal adhesion kinase 1Homo sapiens (human)
placenta developmentFocal adhesion kinase 1Homo sapiens (human)
regulation of protein phosphorylationFocal adhesion kinase 1Homo sapiens (human)
positive regulation of protein phosphorylationFocal adhesion kinase 1Homo sapiens (human)
heart morphogenesisFocal adhesion kinase 1Homo sapiens (human)
signal complex assemblyFocal adhesion kinase 1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
integrin-mediated signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
axon guidanceFocal adhesion kinase 1Homo sapiens (human)
positive regulation of cell population proliferationFocal adhesion kinase 1Homo sapiens (human)
regulation of cell shapeFocal adhesion kinase 1Homo sapiens (human)
regulation of endothelial cell migrationFocal adhesion kinase 1Homo sapiens (human)
regulation of epithelial cell migrationFocal adhesion kinase 1Homo sapiens (human)
positive regulation of epithelial cell migrationFocal adhesion kinase 1Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionFocal adhesion kinase 1Homo sapiens (human)
positive regulation of fibroblast migrationFocal adhesion kinase 1Homo sapiens (human)
cell migrationFocal adhesion kinase 1Homo sapiens (human)
peptidyl-tyrosine phosphorylationFocal adhesion kinase 1Homo sapiens (human)
negative regulation of cell-cell adhesionFocal adhesion kinase 1Homo sapiens (human)
establishment of cell polarityFocal adhesion kinase 1Homo sapiens (human)
positive regulation of cell migrationFocal adhesion kinase 1Homo sapiens (human)
regulation of cell adhesion mediated by integrinFocal adhesion kinase 1Homo sapiens (human)
detection of muscle stretchFocal adhesion kinase 1Homo sapiens (human)
netrin-activated signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisFocal adhesion kinase 1Homo sapiens (human)
regulation of cell population proliferationFocal adhesion kinase 1Homo sapiens (human)
negative regulation of apoptotic processFocal adhesion kinase 1Homo sapiens (human)
regulation of GTPase activityFocal adhesion kinase 1Homo sapiens (human)
regulation of osteoblast differentiationFocal adhesion kinase 1Homo sapiens (human)
positive regulation of protein kinase activityFocal adhesion kinase 1Homo sapiens (human)
protein autophosphorylationFocal adhesion kinase 1Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
ephrin receptor signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
cell motilityFocal adhesion kinase 1Homo sapiens (human)
regulation of cytoskeleton organizationFocal adhesion kinase 1Homo sapiens (human)
regulation of focal adhesion assemblyFocal adhesion kinase 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionFocal adhesion kinase 1Homo sapiens (human)
growth hormone receptor signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
positive regulation of wound healingFocal adhesion kinase 1Homo sapiens (human)
regulation of substrate adhesion-dependent cell spreadingFocal adhesion kinase 1Homo sapiens (human)
positive regulation of ubiquitin-dependent protein catabolic processFocal adhesion kinase 1Homo sapiens (human)
negative regulation of anoikisFocal adhesion kinase 1Homo sapiens (human)
protein phosphorylationFocal adhesion kinase 1Homo sapiens (human)
epidermal growth factor receptor signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
regulation of cell adhesionFocal adhesion kinase 1Homo sapiens (human)
microtubule cytoskeleton organizationProtein kinase C zeta typeHomo sapiens (human)
positive regulation of cell-matrix adhesionProtein kinase C zeta typeHomo sapiens (human)
protein phosphorylationProtein kinase C zeta typeHomo sapiens (human)
inflammatory responseProtein kinase C zeta typeHomo sapiens (human)
signal transductionProtein kinase C zeta typeHomo sapiens (human)
cell surface receptor signaling pathwayProtein kinase C zeta typeHomo sapiens (human)
long-term memoryProtein kinase C zeta typeHomo sapiens (human)
positive regulation of cell population proliferationProtein kinase C zeta typeHomo sapiens (human)
cell migrationProtein kinase C zeta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C zeta typeHomo sapiens (human)
establishment of cell polarityProtein kinase C zeta typeHomo sapiens (human)
negative regulation of protein-containing complex assemblyProtein kinase C zeta typeHomo sapiens (human)
positive regulation of interleukin-10 productionProtein kinase C zeta typeHomo sapiens (human)
positive regulation of interleukin-13 productionProtein kinase C zeta typeHomo sapiens (human)
positive regulation of interleukin-4 productionProtein kinase C zeta typeHomo sapiens (human)
positive regulation of interleukin-5 productionProtein kinase C zeta typeHomo sapiens (human)
cellular response to insulin stimulusProtein kinase C zeta typeHomo sapiens (human)
negative regulation of apoptotic processProtein kinase C zeta typeHomo sapiens (human)
establishment or maintenance of epithelial cell apical/basal polarityProtein kinase C zeta typeHomo sapiens (human)
positive regulation of T-helper 2 cell differentiationProtein kinase C zeta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C zeta typeHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayProtein kinase C zeta typeHomo sapiens (human)
vesicle transport along microtubuleProtein kinase C zeta typeHomo sapiens (human)
negative regulation of peptidyl-tyrosine phosphorylationProtein kinase C zeta typeHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProtein kinase C zeta typeHomo sapiens (human)
positive regulation of protein transportProtein kinase C zeta typeHomo sapiens (human)
membrane depolarizationProtein kinase C zeta typeHomo sapiens (human)
membrane hyperpolarizationProtein kinase C zeta typeHomo sapiens (human)
long-term synaptic potentiationProtein kinase C zeta typeHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProtein kinase C zeta typeHomo sapiens (human)
protein kinase C signalingProtein kinase C zeta typeHomo sapiens (human)
protein localization to plasma membraneProtein kinase C zeta typeHomo sapiens (human)
regulation of neurotransmitter receptor localization to postsynaptic specialization membraneProtein kinase C zeta typeHomo sapiens (human)
neuron projection extensionProtein kinase C zeta typeHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialProtein kinase C zeta typeHomo sapiens (human)
positive regulation of T-helper 2 cell cytokine productionProtein kinase C zeta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C zeta typeHomo sapiens (human)
protein phosphorylationProtein kinase C delta typeHomo sapiens (human)
apoptotic processProtein kinase C delta typeHomo sapiens (human)
DNA damage responseProtein kinase C delta typeHomo sapiens (human)
signal transductionProtein kinase C delta typeHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressProtein kinase C delta typeHomo sapiens (human)
regulation of signaling receptor activityProtein kinase C delta typeHomo sapiens (human)
immunoglobulin mediated immune responseProtein kinase C delta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C delta typeHomo sapiens (human)
peptidyl-threonine phosphorylationProtein kinase C delta typeHomo sapiens (human)
termination of signal transductionProtein kinase C delta typeHomo sapiens (human)
negative regulation of actin filament polymerizationProtein kinase C delta typeHomo sapiens (human)
positive regulation of endodeoxyribonuclease activityProtein kinase C delta typeHomo sapiens (human)
negative regulation of protein bindingProtein kinase C delta typeHomo sapiens (human)
activation of protein kinase activityProtein kinase C delta typeHomo sapiens (human)
positive regulation of superoxide anion generationProtein kinase C delta typeHomo sapiens (human)
regulation of actin cytoskeleton organizationProtein kinase C delta typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C delta typeHomo sapiens (human)
cellular response to UVProtein kinase C delta typeHomo sapiens (human)
positive regulation of protein dephosphorylationProtein kinase C delta typeHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisProtein kinase C delta typeHomo sapiens (human)
B cell proliferationProtein kinase C delta typeHomo sapiens (human)
neutrophil activationProtein kinase C delta typeHomo sapiens (human)
positive regulation of protein import into nucleusProtein kinase C delta typeHomo sapiens (human)
defense response to bacteriumProtein kinase C delta typeHomo sapiens (human)
negative regulation of MAP kinase activityProtein kinase C delta typeHomo sapiens (human)
regulation of mRNA stabilityProtein kinase C delta typeHomo sapiens (human)
post-translational protein modificationProtein kinase C delta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C delta typeHomo sapiens (human)
negative regulation of inflammatory responseProtein kinase C delta typeHomo sapiens (human)
negative regulation of peptidyl-tyrosine phosphorylationProtein kinase C delta typeHomo sapiens (human)
protein stabilizationProtein kinase C delta typeHomo sapiens (human)
negative regulation of filopodium assemblyProtein kinase C delta typeHomo sapiens (human)
cell chemotaxisProtein kinase C delta typeHomo sapiens (human)
cellular response to hydrogen peroxideProtein kinase C delta typeHomo sapiens (human)
cellular response to hydroperoxideProtein kinase C delta typeHomo sapiens (human)
negative regulation of platelet aggregationProtein kinase C delta typeHomo sapiens (human)
cellular senescenceProtein kinase C delta typeHomo sapiens (human)
positive regulation of phospholipid scramblase activityProtein kinase C delta typeHomo sapiens (human)
cellular response to angiotensinProtein kinase C delta typeHomo sapiens (human)
regulation of ceramide biosynthetic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of ceramide biosynthetic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of glucosylceramide catabolic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of sphingomyelin catabolic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProtein kinase C delta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C delta typeHomo sapiens (human)
neutrophil homeostasisTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of type III hypersensitivityTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of type I hypersensitivityTyrosine-protein kinase BTKHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase BTKHomo sapiens (human)
B cell affinity maturationTyrosine-protein kinase BTKHomo sapiens (human)
histamine secretion by mast cellTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of immunoglobulin productionTyrosine-protein kinase BTKHomo sapiens (human)
regulation of B cell cytokine productionTyrosine-protein kinase BTKHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayTyrosine-protein kinase BTKHomo sapiens (human)
regulation of B cell apoptotic processTyrosine-protein kinase BTKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase BTKHomo sapiens (human)
mesoderm developmentTyrosine-protein kinase BTKHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase BTKHomo sapiens (human)
calcium-mediated signalingTyrosine-protein kinase BTKHomo sapiens (human)
proteoglycan catabolic processTyrosine-protein kinase BTKHomo sapiens (human)
negative regulation of B cell proliferationTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of B cell proliferationTyrosine-protein kinase BTKHomo sapiens (human)
response to lipopolysaccharideTyrosine-protein kinase BTKHomo sapiens (human)
negative regulation of interleukin-10 productionTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of interleukin-6 productionTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of tumor necrosis factor productionTyrosine-protein kinase BTKHomo sapiens (human)
cellular response to reactive oxygen speciesTyrosine-protein kinase BTKHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase BTKHomo sapiens (human)
Fc-epsilon receptor signaling pathwayTyrosine-protein kinase BTKHomo sapiens (human)
B cell activationTyrosine-protein kinase BTKHomo sapiens (human)
innate immune responseTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of B cell differentiationTyrosine-protein kinase BTKHomo sapiens (human)
cell maturationTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of phagocytosisTyrosine-protein kinase BTKHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTyrosine-protein kinase BTKHomo sapiens (human)
monocyte proliferationTyrosine-protein kinase BTKHomo sapiens (human)
cellular response to molecule of fungal originTyrosine-protein kinase BTKHomo sapiens (human)
apoptotic signaling pathwayTyrosine-protein kinase BTKHomo sapiens (human)
cellular response to interleukin-7Tyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of interleukin-17A productionTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblyTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of synoviocyte proliferationTyrosine-protein kinase BTKHomo sapiens (human)
eosinophil homeostasisTyrosine-protein kinase BTKHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase BTKHomo sapiens (human)
neuron migrationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
natural killer cell differentiationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
cell adhesionTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
signal transductionTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
neuropeptide signaling pathwayTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
spermatogenesisTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
forebrain cell migrationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
platelet activationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
secretion by cellTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
negative regulation of toll-like receptor signaling pathwayTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
substrate adhesion-dependent cell spreadingTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
ovulation cycleTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
apoptotic cell clearanceTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
negative regulation of neuron apoptotic processTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
negative regulation of innate immune responseTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
symbiont entry into host cellTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
protein autophosphorylationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
negative regulation of inflammatory responseTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
negative regulation of lymphocyte activationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
neuron apoptotic processTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
establishment of localization in cellTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
vagina developmentTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
neuron cellular homeostasisTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
platelet aggregationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
positive regulation of viral life cycleTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
nervous system developmentTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
phagocytosisTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
multicellular organism developmentTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
positive regulation of kinase activityTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
cell migrationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
positive regulation of myelinationCyclin-dependent kinase 18Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 18Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 18Homo sapiens (human)
endocytosisActivated CDC42 kinase 1Homo sapiens (human)
cell surface receptor signaling pathwayActivated CDC42 kinase 1Homo sapiens (human)
small GTPase-mediated signal transductionActivated CDC42 kinase 1Homo sapiens (human)
phosphorylationActivated CDC42 kinase 1Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationActivated CDC42 kinase 1Homo sapiens (human)
regulation of clathrin-dependent endocytosisActivated CDC42 kinase 1Homo sapiens (human)
protein phosphorylationActivated CDC42 kinase 1Homo sapiens (human)
regulation of cell growthEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
regulation of cell-matrix adhesionEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
cell adhesionEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
embryo implantationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
lactationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
cell population proliferationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
negative regulation of cell population proliferationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
regulation of extracellular matrix disassemblyEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
smooth muscle cell migrationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathwayEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
peptidyl-tyrosine autophosphorylationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
ear developmentEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
wound healing, spreading of cellsEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
protein autophosphorylationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
branching involved in mammary gland duct morphogenesisEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
mammary gland alveolus developmentEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
smooth muscle cell-matrix adhesionEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
axon developmentEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
neuron projection extensionEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
multicellular organism developmentEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
positive regulation of kinase activityEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
positive regulation of neuron projection developmentEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
positive regulation of cytokine productionTyrosine-protein kinase ITK/TSKHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase ITK/TSKHomo sapiens (human)
cellular defense responseTyrosine-protein kinase ITK/TSKHomo sapiens (human)
signal transductionTyrosine-protein kinase ITK/TSKHomo sapiens (human)
activation of phospholipase C activityTyrosine-protein kinase ITK/TSKHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase ITK/TSKHomo sapiens (human)
T cell activationTyrosine-protein kinase ITK/TSKHomo sapiens (human)
gamma-delta T cell activationTyrosine-protein kinase ITK/TSKHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase ITK/TSKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase ITK/TSKHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase ITK/TSKHomo sapiens (human)
NK T cell differentiationTyrosine-protein kinase ITK/TSKHomo sapiens (human)
regulation of sodium ion transportMyotonin-protein kinaseHomo sapiens (human)
protein phosphorylationMyotonin-protein kinaseHomo sapiens (human)
intracellular calcium ion homeostasisMyotonin-protein kinaseHomo sapiens (human)
nuclear envelope organizationMyotonin-protein kinaseHomo sapiens (human)
regulation of heart contractionMyotonin-protein kinaseHomo sapiens (human)
muscle cell apoptotic processMyotonin-protein kinaseHomo sapiens (human)
regulation of myotube differentiationMyotonin-protein kinaseHomo sapiens (human)
regulation of excitatory postsynaptic membrane potential involved in skeletal muscle contractionMyotonin-protein kinaseHomo sapiens (human)
regulation of synapse structural plasticityMyotonin-protein kinaseHomo sapiens (human)
peptidyl-serine phosphorylationMyotonin-protein kinaseHomo sapiens (human)
regulation of skeletal muscle contraction by calcium ion signalingMyotonin-protein kinaseHomo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
vesicle targetingMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
immune responseMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
innate immune responseMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
positive regulation of JNK cascadeMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
post-translational protein modificationMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
positive regulation of protein kinase activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
positive regulation of DNA-templated transcriptionMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
negative regulation of motor neuron apoptotic processMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
natural killer cell differentiationTyrosine-protein kinase MerHomo sapiens (human)
negative regulation of cytokine productionTyrosine-protein kinase MerHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase MerHomo sapiens (human)
phagocytosisTyrosine-protein kinase MerHomo sapiens (human)
cell surface receptor signaling pathwayTyrosine-protein kinase MerHomo sapiens (human)
cell-cell signalingTyrosine-protein kinase MerHomo sapiens (human)
spermatogenesisTyrosine-protein kinase MerHomo sapiens (human)
platelet activationTyrosine-protein kinase MerHomo sapiens (human)
secretion by cellTyrosine-protein kinase MerHomo sapiens (human)
substrate adhesion-dependent cell spreadingTyrosine-protein kinase MerHomo sapiens (human)
positive regulation of phagocytosisTyrosine-protein kinase MerHomo sapiens (human)
negative regulation of lymphocyte activationTyrosine-protein kinase MerHomo sapiens (human)
establishment of localization in cellTyrosine-protein kinase MerHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase MerHomo sapiens (human)
retina development in camera-type eyeTyrosine-protein kinase MerHomo sapiens (human)
vagina developmentTyrosine-protein kinase MerHomo sapiens (human)
neutrophil clearanceTyrosine-protein kinase MerHomo sapiens (human)
negative regulation of leukocyte apoptotic processTyrosine-protein kinase MerHomo sapiens (human)
nervous system developmentTyrosine-protein kinase MerHomo sapiens (human)
positive regulation of kinase activityTyrosine-protein kinase MerHomo sapiens (human)
cell migrationTyrosine-protein kinase MerHomo sapiens (human)
multicellular organism developmentTyrosine-protein kinase MerHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase MerHomo sapiens (human)
cell morphogenesisSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of protein phosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of protein bindingSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase 4Homo sapiens (human)
branching involved in blood vessel morphogenesisSerine/threonine-protein kinase 4Homo sapiens (human)
neural tube formationSerine/threonine-protein kinase 4Homo sapiens (human)
endocardium developmentSerine/threonine-protein kinase 4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
protein import into nucleusSerine/threonine-protein kinase 4Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase 4Homo sapiens (human)
signal transductionSerine/threonine-protein kinase 4Homo sapiens (human)
central nervous system developmentSerine/threonine-protein kinase 4Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsSerine/threonine-protein kinase 4Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
keratinocyte differentiationSerine/threonine-protein kinase 4Homo sapiens (human)
organ growthSerine/threonine-protein kinase 4Homo sapiens (human)
hippo signalingSerine/threonine-protein kinase 4Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of fat cell differentiationSerine/threonine-protein kinase 4Homo sapiens (human)
negative regulation of organ growthSerine/threonine-protein kinase 4Homo sapiens (human)
epithelial cell proliferationSerine/threonine-protein kinase 4Homo sapiens (human)
negative regulation of epithelial cell proliferationSerine/threonine-protein kinase 4Homo sapiens (human)
protein tetramerizationSerine/threonine-protein kinase 4Homo sapiens (human)
canonical Wnt signaling pathwaySerine/threonine-protein kinase 4Homo sapiens (human)
primitive hemopoiesisSerine/threonine-protein kinase 4Homo sapiens (human)
cell differentiation involved in embryonic placenta developmentSerine/threonine-protein kinase 4Homo sapiens (human)
regulation of cell differentiation involved in embryonic placenta developmentSerine/threonine-protein kinase 4Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwaySerine/threonine-protein kinase 4Homo sapiens (human)
hepatocyte apoptotic processSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway via death domain receptorsSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of hepatocyte apoptotic processSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of substrate-dependent cell migration, cell attachment to substrateSerine/threonine-protein kinase 4Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase 4Homo sapiens (human)
lipid droplet disassembly5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to hypoxia5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
glucose metabolic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
chromatin remodeling5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cholesterol biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
autophagy5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
signal transduction5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of cell population proliferation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
lipid biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to UV5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cold acclimation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to gamma radiation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of autophagy5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of gene expression5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of gene expression5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
bile acid and bile salt transport5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
Wnt signaling pathway5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
fatty acid oxidation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to caffeine5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of TOR signaling5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of peptidyl-serine phosphorylation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to oxidative stress5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
bile acid signaling pathway5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to glucose starvation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
glucose homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of circadian rhythm5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of apoptotic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to estrogen5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of cholesterol biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of glycolytic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of DNA-templated transcription5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of glucosylceramide biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of insulin receptor signaling pathway5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
rhythmic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of skeletal muscle tissue development5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of lipid catabolic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
fatty acid homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of vesicle-mediated transport5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
motor behavior5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
CAMKK-AMPK signaling cascade5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of stress granule assembly5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
neuron cellular homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to hydrogen peroxide5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of microtubule cytoskeleton organization5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to calcium ion5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to glucose stimulus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to ethanol5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to prostaglandin E stimulus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to organonitrogen compound5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to hypoxia5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to xenobiotic stimulus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
energy homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of bile acid secretion5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of mitochondrial transcription5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of protein localization5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of hepatocyte apoptotic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of protein targeting to mitochondrion5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of adipose tissue development5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of TORC1 signaling5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of tubulin deacetylation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein localization to lipid droplet5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of peptidyl-lysine acetylation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
MAPK cascadeSerine/threonine-protein kinase PAK 1Homo sapiens (human)
cell migrationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of protein phosphorylationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathwaySerine/threonine-protein kinase PAK 1Homo sapiens (human)
chromatin remodelingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
exocytosisSerine/threonine-protein kinase PAK 1Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase PAK 1Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of cell population proliferationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
phosphorylationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of cell migrationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of microtubule polymerizationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwaySerine/threonine-protein kinase PAK 1Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisSerine/threonine-protein kinase PAK 1Homo sapiens (human)
wound healingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of JUN kinase activitySerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
hepatocyte growth factor receptor signaling pathwaySerine/threonine-protein kinase PAK 1Homo sapiens (human)
ephrin receptor signaling pathwaySerine/threonine-protein kinase PAK 1Homo sapiens (human)
branching morphogenesis of an epithelial tubeSerine/threonine-protein kinase PAK 1Homo sapiens (human)
neuron projection morphogenesisSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of stress fiber assemblySerine/threonine-protein kinase PAK 1Homo sapiens (human)
negative regulation of cell proliferation involved in contact inhibitionSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of microtubule nucleationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein localization to cytoplasmic stress granuleSerine/threonine-protein kinase PAK 1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase PAK 1Homo sapiens (human)
regulation of actin cytoskeleton organizationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase PAK 1Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase PAK 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
heart developmentDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
positive regulation of cell growthDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of interleukin-8 productionDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of heterotypic cell-cell adhesionDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of smooth muscle cell apoptotic processDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
positive regulation of MAP kinase activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
positive regulation of epithelial cell proliferationDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
positive regulation of protein metabolic processDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of response to cytokine stimulusDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
ERK5 cascadeDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
cellular response to growth factor stimulusDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
cellular response to laminar fluid shear stressDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of cell migration involved in sprouting angiogenesisDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of chemokine (C-X-C motif) ligand 2 productionDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 7Homo sapiens (human)
signal transductionMitogen-activated protein kinase 7Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayMitogen-activated protein kinase 7Homo sapiens (human)
cell differentiationMitogen-activated protein kinase 7Homo sapiens (human)
calcineurin-NFAT signaling cascadeMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of heterotypic cell-cell adhesionMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of smooth muscle cell apoptotic processMitogen-activated protein kinase 7Homo sapiens (human)
regulation of angiogenesisMitogen-activated protein kinase 7Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of inflammatory responseMitogen-activated protein kinase 7Homo sapiens (human)
positive regulation of protein metabolic processMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of response to cytokine stimulusMitogen-activated protein kinase 7Homo sapiens (human)
cellular response to hydrogen peroxideMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascadeMitogen-activated protein kinase 7Homo sapiens (human)
cellular response to growth factor stimulusMitogen-activated protein kinase 7Homo sapiens (human)
cellular response to laminar fluid shear stressMitogen-activated protein kinase 7Homo sapiens (human)
cellular response to transforming growth factor beta stimulusMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of endothelial cell apoptotic processMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandMitogen-activated protein kinase 7Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 7Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathwaySerine/threonine-protein kinase PAK 2Homo sapiens (human)
cardiac muscle hypertrophySerine/threonine-protein kinase PAK 2Homo sapiens (human)
negative regulation of protein kinase activitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase PAK 2Homo sapiens (human)
signal transductionSerine/threonine-protein kinase PAK 2Homo sapiens (human)
phosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
adherens junction assemblySerine/threonine-protein kinase PAK 2Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase PAK 2Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwaySerine/threonine-protein kinase PAK 2Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
regulation of cytoskeleton organizationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
negative regulation of stress fiber assemblySerine/threonine-protein kinase PAK 2Homo sapiens (human)
dendritic spine developmentSerine/threonine-protein kinase PAK 2Homo sapiens (human)
bicellular tight junction assemblySerine/threonine-protein kinase PAK 2Homo sapiens (human)
cellular response to organic cyclic compoundSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cellular response to transforming growth factor beta stimulusSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein localization to cell-cell junctionSerine/threonine-protein kinase PAK 2Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathwaySerine/threonine-protein kinase PAK 2Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in execution phase of apoptosisSerine/threonine-protein kinase PAK 2Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase PAK 2Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase PAK 2Homo sapiens (human)
positive regulation of protein bindingSerine/threonine-protein kinase 3Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of DNA-binding transcription factor activitySerine/threonine-protein kinase 3Homo sapiens (human)
neural tube formationSerine/threonine-protein kinase 3Homo sapiens (human)
endocardium developmentSerine/threonine-protein kinase 3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 3Homo sapiens (human)
protein import into nucleusSerine/threonine-protein kinase 3Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase 3Homo sapiens (human)
JNK cascadeSerine/threonine-protein kinase 3Homo sapiens (human)
central nervous system developmentSerine/threonine-protein kinase 3Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsSerine/threonine-protein kinase 3Homo sapiens (human)
organ growthSerine/threonine-protein kinase 3Homo sapiens (human)
hippo signalingSerine/threonine-protein kinase 3Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase 3Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of fat cell differentiationSerine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of JNK cascadeSerine/threonine-protein kinase 3Homo sapiens (human)
negative regulation of organ growthSerine/threonine-protein kinase 3Homo sapiens (human)
epithelial cell proliferationSerine/threonine-protein kinase 3Homo sapiens (human)
negative regulation of epithelial cell proliferationSerine/threonine-protein kinase 3Homo sapiens (human)
protein tetramerizationSerine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein kinase 3Homo sapiens (human)
canonical Wnt signaling pathwaySerine/threonine-protein kinase 3Homo sapiens (human)
primitive hemopoiesisSerine/threonine-protein kinase 3Homo sapiens (human)
cell differentiation involved in embryonic placenta developmentSerine/threonine-protein kinase 3Homo sapiens (human)
regulation of cell differentiation involved in embryonic placenta developmentSerine/threonine-protein kinase 3Homo sapiens (human)
protein localization to centrosomeSerine/threonine-protein kinase 3Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwaySerine/threonine-protein kinase 3Homo sapiens (human)
hepatocyte apoptotic processSerine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway via death domain receptorsSerine/threonine-protein kinase 3Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase 3Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
cellular response to mechanical stimulusMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein phosphorylationcGMP-dependent protein kinase 2Homo sapiens (human)
signal transductioncGMP-dependent protein kinase 2Homo sapiens (human)
positive regulation of chondrocyte differentiationcGMP-dependent protein kinase 2Homo sapiens (human)
tetrahydrobiopterin metabolic processcGMP-dependent protein kinase 2Homo sapiens (human)
protein localization to plasma membranecGMP-dependent protein kinase 2Homo sapiens (human)
positive regulation of protein localizationcGMP-dependent protein kinase 2Homo sapiens (human)
negative regulation of chloride transportcGMP-dependent protein kinase 2Homo sapiens (human)
protein kinase A signalingcGMP-dependent protein kinase 2Homo sapiens (human)
cell morphogenesisIntegrin-linked protein kinaseHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin-linked protein kinaseHomo sapiens (human)
branching involved in ureteric bud morphogenesisIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of protein phosphorylationIntegrin-linked protein kinaseHomo sapiens (human)
outflow tract morphogenesisIntegrin-linked protein kinaseHomo sapiens (human)
protein phosphorylationIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of cell population proliferationIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of signal transductionIntegrin-linked protein kinaseHomo sapiens (human)
fibroblast migrationIntegrin-linked protein kinaseHomo sapiens (human)
nerve developmentIntegrin-linked protein kinaseHomo sapiens (human)
myelination in peripheral nervous systemIntegrin-linked protein kinaseHomo sapiens (human)
cell projection organizationIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of BMP signaling pathwayIntegrin-linked protein kinaseHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayIntegrin-linked protein kinaseHomo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of phosphorylationIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionIntegrin-linked protein kinaseHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionIntegrin-linked protein kinaseHomo sapiens (human)
establishment or maintenance of epithelial cell apical/basal polarityIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of osteoblast differentiationIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of DNA-templated transcriptionIntegrin-linked protein kinaseHomo sapiens (human)
neural precursor cell proliferationIntegrin-linked protein kinaseHomo sapiens (human)
platelet aggregationIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin-linked protein kinaseHomo sapiens (human)
negative regulation of neural precursor cell proliferationIntegrin-linked protein kinaseHomo sapiens (human)
cell-matrix adhesionIntegrin-linked protein kinaseHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin-linked protein kinaseHomo sapiens (human)
epithelial to mesenchymal transitionRho-associated protein kinase 1Homo sapiens (human)
aortic valve morphogenesisRho-associated protein kinase 1Homo sapiens (human)
apical constrictionRho-associated protein kinase 1Homo sapiens (human)
protein phosphorylationRho-associated protein kinase 1Homo sapiens (human)
smooth muscle contractionRho-associated protein kinase 1Homo sapiens (human)
leukocyte cell-cell adhesionRho-associated protein kinase 1Homo sapiens (human)
signal transductionRho-associated protein kinase 1Homo sapiens (human)
canonical NF-kappaB signal transductionRho-associated protein kinase 1Homo sapiens (human)
Rho protein signal transductionRho-associated protein kinase 1Homo sapiens (human)
positive regulation of autophagyRho-associated protein kinase 1Homo sapiens (human)
positive regulation of cardiac muscle hypertrophyRho-associated protein kinase 1Homo sapiens (human)
positive regulation of gene expressionRho-associated protein kinase 1Homo sapiens (human)
positive regulation of phosphatase activityRho-associated protein kinase 1Homo sapiens (human)
negative regulation of angiogenesisRho-associated protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationRho-associated protein kinase 1Homo sapiens (human)
membrane to membrane dockingRho-associated protein kinase 1Homo sapiens (human)
actin cytoskeleton organizationRho-associated protein kinase 1Homo sapiens (human)
regulation of cell adhesionRho-associated protein kinase 1Homo sapiens (human)
regulation of cell migrationRho-associated protein kinase 1Homo sapiens (human)
cortical actin cytoskeleton organizationRho-associated protein kinase 1Homo sapiens (human)
neuron projection developmentRho-associated protein kinase 1Homo sapiens (human)
bleb assemblyRho-associated protein kinase 1Homo sapiens (human)
negative regulation of protein bindingRho-associated protein kinase 1Homo sapiens (human)
regulation of actin cytoskeleton organizationRho-associated protein kinase 1Homo sapiens (human)
positive regulation of dephosphorylationRho-associated protein kinase 1Homo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activityRho-associated protein kinase 1Homo sapiens (human)
negative regulation of phosphorylationRho-associated protein kinase 1Homo sapiens (human)
positive regulation of MAPK cascadeRho-associated protein kinase 1Homo sapiens (human)
regulation of keratinocyte differentiationRho-associated protein kinase 1Homo sapiens (human)
regulation of neuron differentiationRho-associated protein kinase 1Homo sapiens (human)
leukocyte migrationRho-associated protein kinase 1Homo sapiens (human)
leukocyte tethering or rollingRho-associated protein kinase 1Homo sapiens (human)
negative regulation of membrane protein ectodomain proteolysisRho-associated protein kinase 1Homo sapiens (human)
myoblast migrationRho-associated protein kinase 1Homo sapiens (human)
regulation of stress fiber assemblyRho-associated protein kinase 1Homo sapiens (human)
regulation of focal adhesion assemblyRho-associated protein kinase 1Homo sapiens (human)
positive regulation of focal adhesion assemblyRho-associated protein kinase 1Homo sapiens (human)
mRNA destabilizationRho-associated protein kinase 1Homo sapiens (human)
negative regulation of biomineral tissue developmentRho-associated protein kinase 1Homo sapiens (human)
regulation of microtubule cytoskeleton organizationRho-associated protein kinase 1Homo sapiens (human)
response to transforming growth factor betaRho-associated protein kinase 1Homo sapiens (human)
protein localization to plasma membraneRho-associated protein kinase 1Homo sapiens (human)
regulation of synapse maturationRho-associated protein kinase 1Homo sapiens (human)
podocyte cell migrationRho-associated protein kinase 1Homo sapiens (human)
motor neuron apoptotic processRho-associated protein kinase 1Homo sapiens (human)
blood vessel diameter maintenanceRho-associated protein kinase 1Homo sapiens (human)
regulation of angiotensin-activated signaling pathwayRho-associated protein kinase 1Homo sapiens (human)
neuron projection arborizationRho-associated protein kinase 1Homo sapiens (human)
positive regulation of amyloid-beta clearanceRho-associated protein kinase 1Homo sapiens (human)
regulation of synaptic vesicle endocytosisRho-associated protein kinase 1Homo sapiens (human)
negative regulation of amyloid-beta formationRho-associated protein kinase 1Homo sapiens (human)
negative regulation of amyloid precursor protein catabolic processRho-associated protein kinase 1Homo sapiens (human)
regulation of establishment of endothelial barrierRho-associated protein kinase 1Homo sapiens (human)
negative regulation of bicellular tight junction assemblyRho-associated protein kinase 1Homo sapiens (human)
positive regulation of connective tissue replacementRho-associated protein kinase 1Homo sapiens (human)
response to angiotensinRho-associated protein kinase 1Homo sapiens (human)
regulation of establishment of cell polarityRho-associated protein kinase 1Homo sapiens (human)
regulation of cell motilityRho-associated protein kinase 1Homo sapiens (human)
negative regulation of motor neuron apoptotic processRho-associated protein kinase 1Homo sapiens (human)
regulation of cell junction assemblyRho-associated protein kinase 1Homo sapiens (human)
mitotic cytokinesisRho-associated protein kinase 1Homo sapiens (human)
embryonic morphogenesisRho-associated protein kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylationRho-associated protein kinase 1Homo sapiens (human)
actomyosin structure organizationRho-associated protein kinase 1Homo sapiens (human)
protein phosphorylationNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
protein autophosphorylationNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
spliceosomal tri-snRNP complex assemblySerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
spliceosomal snRNP assemblySerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
mRNA splicing, via spliceosomeSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
positive regulation of hippo signalingSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
mRNA cis splicing, via spliceosomeSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
positive regulation of protein export from nucleusSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
regulation of mitotic cell cycle spindle assembly checkpointSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
positive regulation of miRNA processingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
MAPK cascadeReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of protein phosphorylationReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
apoptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
inflammatory responseReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
response to oxidative stressReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of gene expressionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein catabolic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of interleukin-8 productionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of tumor necrosis factor productionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
response to tumor necrosis factorReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
intracellular signal transductionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
peptidyl-serine autophosphorylationReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of apoptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
negative regulation of apoptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of programmed cell deathReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of neuron apoptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of macrophage differentiationReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of JNK cascadeReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein autophosphorylationReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of inflammatory responseReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of necroptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
negative regulation of necroptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of programmed necrotic cell deathReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of interleukin-6-mediated signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
T cell apoptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
necroptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cellular response to hydrogen peroxideReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
regulation of ATP:ADP antiporter activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cellular response to tumor necrosis factorReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cellular response to growth factor stimulusReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
extrinsic apoptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
programmed necrotic cell deathReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
ripoptosome assemblyReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
necroptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of execution phase of apoptosisReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
ripoptosome assembly involved in necroptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
amyloid fibril formationReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein phosphorylationCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
signal transductionCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
nervous system developmentCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
positive regulation of neuron projection developmentCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
regulation of skeletal muscle adaptationCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
cell differentiationCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
protein autophosphorylationCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
regulation of synapse structural plasticityCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
regulation of calcium ion transportCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
regulation of dendritic spine developmentCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
positive regulation of dendritic spine morphogenesisCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
positive regulation of synapse maturationCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
regulation of neuron migrationCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
nervous system developmentCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
regulation of neuron projection developmentCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
regulation of skeletal muscle adaptationCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
insulin secretionCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
cell differentiationCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
regulation of calcium ion transportCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
regulation of cell growthCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of the force of heart contractionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of membrane depolarizationCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of transcription by RNA polymerase IICalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
protein phosphorylationCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of heart contractionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of cell communication by electrical couplingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulumCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
peptidyl-threonine phosphorylationCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
endoplasmic reticulum calcium ion homeostasisCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
protein autophosphorylationCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
relaxation of cardiac muscleCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of ryanodine-sensitive calcium-release channel activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of cellular localizationCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
cellular response to calcium ionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
cardiac muscle cell contractionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of heart rate by cardiac conductionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of cardiac muscle cell action potentialCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of cardiac muscle cell action potential involved in regulation of contractionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conductionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of relaxation of cardiac muscleCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
negative regulation of sodium ion transmembrane transportCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
negative regulation of sodium ion transmembrane transporter activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
peptidyl-tyrosine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
chromatin remodelingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
regulation of transcription by RNA polymerase IIDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nervous system developmentDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
circadian rhythmDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
peptidyl-serine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
peptidyl-threonine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
peptidyl-tyrosine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
negative regulation of microtubule polymerizationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
positive regulation of RNA splicingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
amyloid-beta formationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
peptidyl-serine autophosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
peptidyl-tyrosine autophosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein autophosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
negative regulation of mRNA splicing, via spliceosomeDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
negative regulation of DNA methylation-dependent heterochromatin formationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
positive regulation of protein deacetylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIActivin receptor type-2BHomo sapiens (human)
gastrulation with mouth forming secondActivin receptor type-2BHomo sapiens (human)
kidney developmentActivin receptor type-2BHomo sapiens (human)
lymphangiogenesisActivin receptor type-2BHomo sapiens (human)
blood vessel remodelingActivin receptor type-2BHomo sapiens (human)
regulation of DNA-templated transcriptionActivin receptor type-2BHomo sapiens (human)
signal transductionActivin receptor type-2BHomo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayActivin receptor type-2BHomo sapiens (human)
determination of left/right symmetryActivin receptor type-2BHomo sapiens (human)
mesoderm developmentActivin receptor type-2BHomo sapiens (human)
heart developmentActivin receptor type-2BHomo sapiens (human)
response to glucoseActivin receptor type-2BHomo sapiens (human)
post-embryonic developmentActivin receptor type-2BHomo sapiens (human)
anterior/posterior pattern specificationActivin receptor type-2BHomo sapiens (human)
insulin secretionActivin receptor type-2BHomo sapiens (human)
lung developmentActivin receptor type-2BHomo sapiens (human)
positive regulation of bone mineralizationActivin receptor type-2BHomo sapiens (human)
BMP signaling pathwayActivin receptor type-2BHomo sapiens (human)
pancreas developmentActivin receptor type-2BHomo sapiens (human)
activin receptor signaling pathwayActivin receptor type-2BHomo sapiens (human)
positive regulation of activin receptor signaling pathwayActivin receptor type-2BHomo sapiens (human)
organ growthActivin receptor type-2BHomo sapiens (human)
odontogenesis of dentin-containing toothActivin receptor type-2BHomo sapiens (human)
positive regulation of osteoblast differentiationActivin receptor type-2BHomo sapiens (human)
embryonic foregut morphogenesisActivin receptor type-2BHomo sapiens (human)
skeletal system morphogenesisActivin receptor type-2BHomo sapiens (human)
roof of mouth developmentActivin receptor type-2BHomo sapiens (human)
lymphatic endothelial cell differentiationActivin receptor type-2BHomo sapiens (human)
artery developmentActivin receptor type-2BHomo sapiens (human)
venous blood vessel developmentActivin receptor type-2BHomo sapiens (human)
retina vasculature development in camera-type eyeActivin receptor type-2BHomo sapiens (human)
negative regulation of cold-induced thermogenesisActivin receptor type-2BHomo sapiens (human)
cellular response to growth factor stimulusActivin receptor type-2BHomo sapiens (human)
protein phosphorylationActivin receptor type-2BHomo sapiens (human)
outflow tract septum morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
atrioventricular valve morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
cardiac muscle tissue developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
pharyngeal arch artery morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of gene expressionBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of SMAD protein signal transductionBone morphogenetic protein receptor type-2Homo sapiens (human)
osteoblast differentiationBone morphogenetic protein receptor type-2Homo sapiens (human)
mesoderm formationBone morphogenetic protein receptor type-2Homo sapiens (human)
maternal placenta developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
endothelial cell proliferationBone morphogenetic protein receptor type-2Homo sapiens (human)
lymphangiogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
blood vessel remodelingBone morphogenetic protein receptor type-2Homo sapiens (human)
chondrocyte developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of systemic arterial blood pressureBone morphogenetic protein receptor type-2Homo sapiens (human)
outflow tract morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
aortic valve developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
pulmonary valve developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
mitral valve morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
tricuspid valve morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
endocardial cushion developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of cell proliferation involved in heart valve morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayBone morphogenetic protein receptor type-2Homo sapiens (human)
cellular response to starvationBone morphogenetic protein receptor type-2Homo sapiens (human)
anterior/posterior pattern specificationBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of epithelial cell migrationBone morphogenetic protein receptor type-2Homo sapiens (human)
regulation of lung blood pressureBone morphogenetic protein receptor type-2Homo sapiens (human)
proteoglycan biosynthetic processBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of cell growthBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of bone mineralizationBone morphogenetic protein receptor type-2Homo sapiens (human)
BMP signaling pathwayBone morphogenetic protein receptor type-2Homo sapiens (human)
activin receptor signaling pathwayBone morphogenetic protein receptor type-2Homo sapiens (human)
regulation of cell population proliferationBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of osteoblast differentiationBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of ossificationBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of vasoconstrictionBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIBone morphogenetic protein receptor type-2Homo sapiens (human)
lung alveolus developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of smooth muscle cell proliferationBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of axon extension involved in axon guidanceBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of muscle cell differentiationBone morphogenetic protein receptor type-2Homo sapiens (human)
limb developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
endochondral bone morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of SMAD protein signal transductionBone morphogenetic protein receptor type-2Homo sapiens (human)
ventricular septum morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
atrial septum morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
lung vasculature developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
lymphatic endothelial cell differentiationBone morphogenetic protein receptor type-2Homo sapiens (human)
artery developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
venous blood vessel developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of cartilage developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
retina vasculature development in camera-type eyeBone morphogenetic protein receptor type-2Homo sapiens (human)
cellular response to BMP stimulusBone morphogenetic protein receptor type-2Homo sapiens (human)
endothelial cell apoptotic processBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of chondrocyte proliferationBone morphogenetic protein receptor type-2Homo sapiens (human)
semi-lunar valve developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
cellular response to growth factor stimulusBone morphogenetic protein receptor type-2Homo sapiens (human)
blood vessel developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
protein phosphorylationBone morphogenetic protein receptor type-2Homo sapiens (human)
protein phosphorylationProtein-tyrosine kinase 6Homo sapiens (human)
tyrosine phosphorylation of STAT proteinProtein-tyrosine kinase 6Homo sapiens (human)
positive regulation of neuron projection developmentProtein-tyrosine kinase 6Homo sapiens (human)
cell migrationProtein-tyrosine kinase 6Homo sapiens (human)
ERBB2 signaling pathwayProtein-tyrosine kinase 6Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinProtein-tyrosine kinase 6Homo sapiens (human)
positive regulation of DNA replicationProtein-tyrosine kinase 6Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayProtein-tyrosine kinase 6Homo sapiens (human)
positive regulation of cell cycleProtein-tyrosine kinase 6Homo sapiens (human)
negative regulation of growthProtein-tyrosine kinase 6Homo sapiens (human)
protein autophosphorylationProtein-tyrosine kinase 6Homo sapiens (human)
intestinal epithelial cell differentiationProtein-tyrosine kinase 6Homo sapiens (human)
negative regulation of protein tyrosine kinase activityProtein-tyrosine kinase 6Homo sapiens (human)
cellular response to retinoic acidProtein-tyrosine kinase 6Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayProtein-tyrosine kinase 6Homo sapiens (human)
innate immune responseProtein-tyrosine kinase 6Homo sapiens (human)
cell differentiationProtein-tyrosine kinase 6Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATProtein-tyrosine kinase 6Homo sapiens (human)
protein phosphorylationcGMP-dependent protein kinase 1 Homo sapiens (human)
neuron migrationcGMP-dependent protein kinase 1 Homo sapiens (human)
signal transductioncGMP-dependent protein kinase 1 Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationcGMP-dependent protein kinase 1 Homo sapiens (human)
spermatid developmentcGMP-dependent protein kinase 1 Homo sapiens (human)
negative regulation of inositol phosphate biosynthetic processcGMP-dependent protein kinase 1 Homo sapiens (human)
negative regulation of glutamate secretioncGMP-dependent protein kinase 1 Homo sapiens (human)
dendrite developmentcGMP-dependent protein kinase 1 Homo sapiens (human)
cGMP-mediated signalingcGMP-dependent protein kinase 1 Homo sapiens (human)
cerebellum developmentcGMP-dependent protein kinase 1 Homo sapiens (human)
actin cytoskeleton organizationcGMP-dependent protein kinase 1 Homo sapiens (human)
forebrain developmentcGMP-dependent protein kinase 1 Homo sapiens (human)
positive regulation of circadian rhythmcGMP-dependent protein kinase 1 Homo sapiens (human)
regulation of GTPase activitycGMP-dependent protein kinase 1 Homo sapiens (human)
collateral sproutingcGMP-dependent protein kinase 1 Homo sapiens (human)
relaxation of vascular associated smooth musclecGMP-dependent protein kinase 1 Homo sapiens (human)
cell growth involved in cardiac muscle cell developmentcGMP-dependent protein kinase 1 Homo sapiens (human)
negative regulation of platelet aggregationcGMP-dependent protein kinase 1 Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferationcGMP-dependent protein kinase 1 Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell migrationcGMP-dependent protein kinase 1 Homo sapiens (human)
regulation of testosterone biosynthetic processcGMP-dependent protein kinase 1 Homo sapiens (human)
protein kinase A signalingcGMP-dependent protein kinase 1 Homo sapiens (human)
alternative mRNA splicing, via spliceosomeCyclin-dependent kinase 13Homo sapiens (human)
regulation of signal transductionCyclin-dependent kinase 13Homo sapiens (human)
hemopoiesisCyclin-dependent kinase 13Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IICyclin-dependent kinase 13Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICyclin-dependent kinase 13Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 13Homo sapiens (human)
negative regulation of stem cell differentiationCyclin-dependent kinase 13Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 13Homo sapiens (human)
protein phosphorylationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
nucleocytoplasmic transportCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
signal transductionCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
nervous system developmentCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of neuron projection developmentCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
cell differentiationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
negative regulation of protein bindingCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
regulation of protein localizationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
intracellular signal transductionCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
regulation of protein bindingCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of protein export from nucleusCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
regulation of muscle cell differentiationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of muscle cell differentiationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of synapse structural plasticityCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of dendritic spine developmentCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of protein serine/threonine kinase activityCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
immune responseInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
gene expressionInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
positive regulation of lipid storageInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
positive regulation of type I interferon productionInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
response to interferon-betaInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
regulation of protein-containing complex assemblyInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
mRNA stabilizationInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
defense response to virusInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
type I interferon-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
positive regulation of type I interferon-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
interleukin-17-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
cellular response to virusInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
peptidyl-serine phosphorylationInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProtein-tyrosine kinase 2-betaHomo sapiens (human)
MAPK cascadeProtein-tyrosine kinase 2-betaHomo sapiens (human)
oocyte maturationProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to hypoxiaProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of cell-matrix adhesionProtein-tyrosine kinase 2-betaHomo sapiens (human)
sprouting angiogenesisProtein-tyrosine kinase 2-betaHomo sapiens (human)
adaptive immune responseProtein-tyrosine kinase 2-betaHomo sapiens (human)
marginal zone B cell differentiationProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to ischemiaProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein phosphorylationProtein-tyrosine kinase 2-betaHomo sapiens (human)
apoptotic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
cellular defense responseProtein-tyrosine kinase 2-betaHomo sapiens (human)
signal transductionProtein-tyrosine kinase 2-betaHomo sapiens (human)
cell surface receptor signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
signal complex assemblyProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProtein-tyrosine kinase 2-betaHomo sapiens (human)
integrin-mediated signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of cell population proliferationProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of cell population proliferationProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of cell shapeProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to xenobiotic stimulusProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to mechanical stimulusProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to hormoneProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to glucoseProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of endothelial cell migrationProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of muscle cell apoptotic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of macrophage chemotaxisProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of neuron projection developmentProtein-tyrosine kinase 2-betaHomo sapiens (human)
glial cell proliferationProtein-tyrosine kinase 2-betaHomo sapiens (human)
peptidyl-tyrosine phosphorylationProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of cell adhesionProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of cell growthProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of cell migrationProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of bone mineralizationProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of actin filament polymerizationProtein-tyrosine kinase 2-betaHomo sapiens (human)
cortical cytoskeleton organizationProtein-tyrosine kinase 2-betaHomo sapiens (human)
neuron projection developmentProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of actin cytoskeleton organizationProtein-tyrosine kinase 2-betaHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to immobilization stressProtein-tyrosine kinase 2-betaHomo sapiens (human)
peptidyl-tyrosine autophosphorylationProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to cocaineProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to hydrogen peroxideProtein-tyrosine kinase 2-betaHomo sapiens (human)
activation of Janus kinase activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of apoptotic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
stress fiber assemblyProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to cation stressProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of potassium ion transportProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of neuron apoptotic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
blood vessel endothelial cell migrationProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
bone resorptionProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to ethanolProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of myeloid cell differentiationProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of translationProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of angiogenesisProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of protein kinase activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of JNK cascadeProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein autophosphorylationProtein-tyrosine kinase 2-betaHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
focal adhesion assemblyProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of synaptic plasticityProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosolProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to cAMPProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to calcium ionProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProtein-tyrosine kinase 2-betaHomo sapiens (human)
long-term synaptic potentiationProtein-tyrosine kinase 2-betaHomo sapiens (human)
long-term synaptic depressionProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein-containing complex assemblyProtein-tyrosine kinase 2-betaHomo sapiens (human)
chemokine-mediated signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProtein-tyrosine kinase 2-betaHomo sapiens (human)
cellular response to retinoic acidProtein-tyrosine kinase 2-betaHomo sapiens (human)
cellular response to fluid shear stressProtein-tyrosine kinase 2-betaHomo sapiens (human)
endothelin receptor signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of postsynaptic density assemblyProtein-tyrosine kinase 2-betaHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of ubiquitin-dependent protein catabolic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of ubiquitin-dependent protein catabolic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of B cell chemotaxisProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of DNA biosynthetic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
epidermal growth factor receptor signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
G2/M transition of mitotic cell cycleMaternal embryonic leucine zipper kinaseHomo sapiens (human)
apoptotic processMaternal embryonic leucine zipper kinaseHomo sapiens (human)
cell population proliferationMaternal embryonic leucine zipper kinaseHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressMaternal embryonic leucine zipper kinaseHomo sapiens (human)
hemopoiesisMaternal embryonic leucine zipper kinaseHomo sapiens (human)
positive regulation of apoptotic processMaternal embryonic leucine zipper kinaseHomo sapiens (human)
protein autophosphorylationMaternal embryonic leucine zipper kinaseHomo sapiens (human)
neural precursor cell proliferationMaternal embryonic leucine zipper kinaseHomo sapiens (human)
protein phosphorylationMaternal embryonic leucine zipper kinaseHomo sapiens (human)
mitotic sister chromatid segregationStructural maintenance of chromosomes protein 1AHomo sapiens (human)
DNA repairStructural maintenance of chromosomes protein 1AHomo sapiens (human)
sister chromatid cohesionStructural maintenance of chromosomes protein 1AHomo sapiens (human)
mitotic sister chromatid cohesionStructural maintenance of chromosomes protein 1AHomo sapiens (human)
response to radiationStructural maintenance of chromosomes protein 1AHomo sapiens (human)
establishment of mitotic sister chromatid cohesionStructural maintenance of chromosomes protein 1AHomo sapiens (human)
establishment of meiotic sister chromatid cohesionStructural maintenance of chromosomes protein 1AHomo sapiens (human)
somatic stem cell population maintenanceStructural maintenance of chromosomes protein 1AHomo sapiens (human)
cell divisionStructural maintenance of chromosomes protein 1AHomo sapiens (human)
meiotic cell cycleStructural maintenance of chromosomes protein 1AHomo sapiens (human)
response to DNA damage checkpoint signalingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
mitotic spindle assemblyStructural maintenance of chromosomes protein 1AHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
double-strand break repair via homologous recombinationChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
chromatin remodelingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
negative regulation of gene expressionChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
regulation of cell fate specificationChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
negative regulation of DNA-templated transcriptionChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
positive regulation of DNA-templated transcriptionChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
regulation of synapse assemblyChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
terminal button organizationChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
regulation of stem cell differentiationChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
very long-chain fatty acid metabolic processPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
generation of precursor metabolites and energyPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
lipid metabolic processPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
prostaglandin metabolic processPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
spermatogenesisPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
fatty acid catabolic processPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
fatty acid oxidationPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
fatty acid beta-oxidation using acyl-CoA oxidasePeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
hydrogen peroxide biosynthetic processPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
very long-chain fatty acid beta-oxidationPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
lipid homeostasisPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase D1Homo sapiens (human)
angiogenesisSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of endothelial cell proliferationSerine/threonine-protein kinase D1Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase D1Homo sapiens (human)
inflammatory responseSerine/threonine-protein kinase D1Homo sapiens (human)
Golgi organizationSerine/threonine-protein kinase D1Homo sapiens (human)
signal transductionSerine/threonine-protein kinase D1Homo sapiens (human)
integrin-mediated signaling pathwaySerine/threonine-protein kinase D1Homo sapiens (human)
nervous system developmentSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of endothelial cell migrationSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of gene expressionSerine/threonine-protein kinase D1Homo sapiens (human)
regulation of keratinocyte proliferationSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of neuron projection developmentSerine/threonine-protein kinase D1Homo sapiens (human)
regulation of skeletal muscle contraction by modulation of calcium ion sensitivity of myofibrilSerine/threonine-protein kinase D1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase D1Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase D1Homo sapiens (human)
sphingolipid biosynthetic processSerine/threonine-protein kinase D1Homo sapiens (human)
cell differentiationSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to amino acid starvationSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to oxidative stressSerine/threonine-protein kinase D1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of protein import into nucleusSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationSerine/threonine-protein kinase D1Homo sapiens (human)
innate immune responseSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of osteoblast differentiationSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of angiogenesisSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of cell sizeSerine/threonine-protein kinase D1Homo sapiens (human)
negative regulation of endocytosisSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine/threonine-protein kinase D1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of protein export from nucleusSerine/threonine-protein kinase D1Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwaySerine/threonine-protein kinase D1Homo sapiens (human)
Golgi vesicle transportSerine/threonine-protein kinase D1Homo sapiens (human)
defense response to Gram-negative bacteriumSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activitySerine/threonine-protein kinase D1Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of sarcomere organizationSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to hydroperoxideSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to norepinephrine stimulusSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of peptide hormone secretionSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblySerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to angiotensinSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to phorbol 13-acetate 12-myristateSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to endothelinSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of endothelial cell chemotaxisSerine/threonine-protein kinase D1Homo sapiens (human)
regulation of integrin-mediated signaling pathwaySerine/threonine-protein kinase D1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySerine/threonine-protein kinase D1Homo sapiens (human)
DNA damage checkpoint signalingSerine/threonine-protein kinase 38Homo sapiens (human)
chromatin organizationSerine/threonine-protein kinase 38Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 38Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase 38Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 38Homo sapiens (human)
protein modification processSerine/threonine-protein kinase 38Homo sapiens (human)
negative regulation of MAP kinase activitySerine/threonine-protein kinase 38Homo sapiens (human)
postsynapse organizationSerine/threonine-protein kinase 38Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase 38Homo sapiens (human)
neural crest cell migrationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of protein phosphorylationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
signal transductionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
epidermal growth factor receptor signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nervous system developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
synapse assemblyReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
heart developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
lactationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
negative regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
embryonic pattern specificationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell migrationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
peptidyl-tyrosine phosphorylationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
central nervous system morphogenesisReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
olfactory bulb interneuron differentiationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
regulation of cell migrationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ERBB2-ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ERBB4-ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mitochondrial fragmentation involved in apoptotic processReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell fate commitmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of DNA-templated transcriptionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein autophosphorylationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mammary gland epithelial cell differentiationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mammary gland alveolus developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cardiac muscle tissue regenerationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cellular response to epidermal growth factor stimulusReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
establishment of planar polarity involved in nephron morphogenesisReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of protein localization to cell surfaceReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
negative regulation of apoptotic processReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of kinase activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
multicellular organism developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neurogenesisReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
signal transductionRibosomal protein S6 kinase alpha-2Homo sapiens (human)
chemical synaptic transmissionRibosomal protein S6 kinase alpha-2Homo sapiens (human)
negative regulation of cell population proliferationRibosomal protein S6 kinase alpha-2Homo sapiens (human)
intracellular signal transductionRibosomal protein S6 kinase alpha-2Homo sapiens (human)
positive regulation of apoptotic processRibosomal protein S6 kinase alpha-2Homo sapiens (human)
negative regulation of cell cycleRibosomal protein S6 kinase alpha-2Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-2Homo sapiens (human)
positive regulation of protein phosphorylationEphrin type-A receptor 7Homo sapiens (human)
brain developmentEphrin type-A receptor 7Homo sapiens (human)
phosphorylationEphrin type-A receptor 7Homo sapiens (human)
regulation of cell-cell adhesionEphrin type-A receptor 7Homo sapiens (human)
retinal ganglion cell axon guidanceEphrin type-A receptor 7Homo sapiens (human)
regulation of protein autophosphorylationEphrin type-A receptor 7Homo sapiens (human)
regulation of cysteine-type endopeptidase activity involved in apoptotic processEphrin type-A receptor 7Homo sapiens (human)
positive regulation of neuron apoptotic processEphrin type-A receptor 7Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 7Homo sapiens (human)
negative regulation of collateral sproutingEphrin type-A receptor 7Homo sapiens (human)
branching morphogenesis of a nerveEphrin type-A receptor 7Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEphrin type-A receptor 7Homo sapiens (human)
modulation of chemical synaptic transmissionEphrin type-A receptor 7Homo sapiens (human)
negative chemotaxisEphrin type-A receptor 7Homo sapiens (human)
neuron apoptotic processEphrin type-A receptor 7Homo sapiens (human)
negative regulation of synapse assemblyEphrin type-A receptor 7Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeEphrin type-A receptor 7Homo sapiens (human)
nephric duct morphogenesisEphrin type-A receptor 7Homo sapiens (human)
regulation of postsynapse organizationEphrin type-A receptor 7Homo sapiens (human)
axon guidanceEphrin type-A receptor 7Homo sapiens (human)
protein phosphorylationEphrin type-A receptor 7Homo sapiens (human)
cholesterol biosynthetic processDelta(24)-sterol reductaseHomo sapiens (human)
cholesterol biosynthetic processDelta(24)-sterol reductaseHomo sapiens (human)
Ras protein signal transductionDelta(24)-sterol reductaseHomo sapiens (human)
protein localizationDelta(24)-sterol reductaseHomo sapiens (human)
negative regulation of cell population proliferationDelta(24)-sterol reductaseHomo sapiens (human)
response to hormoneDelta(24)-sterol reductaseHomo sapiens (human)
tissue developmentDelta(24)-sterol reductaseHomo sapiens (human)
male genitalia developmentDelta(24)-sterol reductaseHomo sapiens (human)
plasminogen activationDelta(24)-sterol reductaseHomo sapiens (human)
cholesterol biosynthetic process via desmosterolDelta(24)-sterol reductaseHomo sapiens (human)
cholesterol biosynthetic process via lathosterolDelta(24)-sterol reductaseHomo sapiens (human)
amyloid precursor protein catabolic processDelta(24)-sterol reductaseHomo sapiens (human)
skin developmentDelta(24)-sterol reductaseHomo sapiens (human)
membrane organizationDelta(24)-sterol reductaseHomo sapiens (human)
steroid metabolic processDelta(24)-sterol reductaseHomo sapiens (human)
protein phosphorylationRibosomal protein S6 kinase alpha-1Homo sapiens (human)
signal transductionRibosomal protein S6 kinase alpha-1Homo sapiens (human)
chemical synaptic transmissionRibosomal protein S6 kinase alpha-1Homo sapiens (human)
positive regulation of cell growthRibosomal protein S6 kinase alpha-1Homo sapiens (human)
negative regulation of TOR signalingRibosomal protein S6 kinase alpha-1Homo sapiens (human)
intracellular signal transductionRibosomal protein S6 kinase alpha-1Homo sapiens (human)
negative regulation of apoptotic processRibosomal protein S6 kinase alpha-1Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processRibosomal protein S6 kinase alpha-1Homo sapiens (human)
regulation of translation in response to stressRibosomal protein S6 kinase alpha-1Homo sapiens (human)
positive regulation of cell differentiationRibosomal protein S6 kinase alpha-1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRibosomal protein S6 kinase alpha-1Homo sapiens (human)
hepatocyte proliferationRibosomal protein S6 kinase alpha-1Homo sapiens (human)
positive regulation of hepatic stellate cell activationRibosomal protein S6 kinase alpha-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionRibosomal protein S6 kinase alpha-1Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-1Homo sapiens (human)
positive regulation of protein phosphorylationDual specificity testis-specific protein kinase 1Homo sapiens (human)
spermatogenesisDual specificity testis-specific protein kinase 1Homo sapiens (human)
negative regulation of protein autophosphorylationDual specificity testis-specific protein kinase 1Homo sapiens (human)
regulation of protein localizationDual specificity testis-specific protein kinase 1Homo sapiens (human)
regulation of actin cytoskeleton organizationDual specificity testis-specific protein kinase 1Homo sapiens (human)
negative regulation of phosphorylationDual specificity testis-specific protein kinase 1Homo sapiens (human)
positive regulation of stress fiber assemblyDual specificity testis-specific protein kinase 1Homo sapiens (human)
establishment of vesicle localizationDual specificity testis-specific protein kinase 1Homo sapiens (human)
negative regulation of protein serine/threonine kinase activityDual specificity testis-specific protein kinase 1Homo sapiens (human)
podocyte cell migrationDual specificity testis-specific protein kinase 1Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingDual specificity testis-specific protein kinase 1Homo sapiens (human)
positive regulation of protein localization to nucleusDual specificity testis-specific protein kinase 1Homo sapiens (human)
negative regulation of cilium assemblyDual specificity testis-specific protein kinase 1Homo sapiens (human)
actin cytoskeleton organizationDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein phosphorylationMyosin light chain kinase, smooth muscleHomo sapiens (human)
smooth muscle contractionMyosin light chain kinase, smooth muscleHomo sapiens (human)
tonic smooth muscle contractionMyosin light chain kinase, smooth muscleHomo sapiens (human)
positive regulation of cell migrationMyosin light chain kinase, smooth muscleHomo sapiens (human)
bleb assemblyMyosin light chain kinase, smooth muscleHomo sapiens (human)
positive regulation of calcium ion transportMyosin light chain kinase, smooth muscleHomo sapiens (human)
aorta smooth muscle tissue morphogenesisMyosin light chain kinase, smooth muscleHomo sapiens (human)
cellular hypotonic responseMyosin light chain kinase, smooth muscleHomo sapiens (human)
positive regulation of wound healingMyosin light chain kinase, smooth muscleHomo sapiens (human)
positive regulation of erythrocyte differentiationMitogen-activated protein kinase 11Homo sapiens (human)
osteoblast differentiationMitogen-activated protein kinase 11Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 11Homo sapiens (human)
stress-activated protein kinase signaling cascadeMitogen-activated protein kinase 11Homo sapiens (human)
positive regulation of interleukin-12 productionMitogen-activated protein kinase 11Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase 11Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 11Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 11Homo sapiens (human)
cardiac muscle cell proliferationMitogen-activated protein kinase 11Homo sapiens (human)
negative regulation of cardiac muscle cell proliferationMitogen-activated protein kinase 11Homo sapiens (human)
bone developmentMitogen-activated protein kinase 11Homo sapiens (human)
cellular response to interleukin-1Mitogen-activated protein kinase 11Homo sapiens (human)
cellular response to UV-BMitogen-activated protein kinase 11Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 11Homo sapiens (human)
cellular response to virusMitogen-activated protein kinase 11Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 11Homo sapiens (human)
G1 to G0 transitionSerine/threonine-protein kinase STK11Homo sapiens (human)
regulation of cell growthSerine/threonine-protein kinase STK11Homo sapiens (human)
tissue homeostasisSerine/threonine-protein kinase STK11Homo sapiens (human)
vasculature developmentSerine/threonine-protein kinase STK11Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase STK11Homo sapiens (human)
protein dephosphorylationSerine/threonine-protein kinase STK11Homo sapiens (human)
autophagySerine/threonine-protein kinase STK11Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase STK11Homo sapiens (human)
spermatogenesisSerine/threonine-protein kinase STK11Homo sapiens (human)
axonogenesisSerine/threonine-protein kinase STK11Homo sapiens (human)
negative regulation of cell population proliferationSerine/threonine-protein kinase STK11Homo sapiens (human)
response to ionizing radiationSerine/threonine-protein kinase STK11Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase STK11Homo sapiens (human)
response to activitySerine/threonine-protein kinase STK11Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase STK11Homo sapiens (human)
establishment of cell polaritySerine/threonine-protein kinase STK11Homo sapiens (human)
negative regulation of cell growthSerine/threonine-protein kinase STK11Homo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwaySerine/threonine-protein kinase STK11Homo sapiens (human)
activation of protein kinase activitySerine/threonine-protein kinase STK11Homo sapiens (human)
response to glucagonSerine/threonine-protein kinase STK11Homo sapiens (human)
response to lipidSerine/threonine-protein kinase STK11Homo sapiens (human)
protein localization to nucleusSerine/threonine-protein kinase STK11Homo sapiens (human)
glucose homeostasisSerine/threonine-protein kinase STK11Homo sapiens (human)
anoikisSerine/threonine-protein kinase STK11Homo sapiens (human)
positive thymic T cell selectionSerine/threonine-protein kinase STK11Homo sapiens (human)
positive regulation of gluconeogenesisSerine/threonine-protein kinase STK11Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase STK11Homo sapiens (human)
regulation of dendrite morphogenesisSerine/threonine-protein kinase STK11Homo sapiens (human)
positive regulation of axonogenesisSerine/threonine-protein kinase STK11Homo sapiens (human)
T cell receptor signaling pathwaySerine/threonine-protein kinase STK11Homo sapiens (human)
Golgi localizationSerine/threonine-protein kinase STK11Homo sapiens (human)
regulation of cell cycleSerine/threonine-protein kinase STK11Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein kinase STK11Homo sapiens (human)
epithelial cell proliferation involved in prostate gland developmentSerine/threonine-protein kinase STK11Homo sapiens (human)
negative regulation of epithelial cell proliferation involved in prostate gland developmentSerine/threonine-protein kinase STK11Homo sapiens (human)
cellular response to UV-BSerine/threonine-protein kinase STK11Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorSerine/threonine-protein kinase STK11Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwaySerine/threonine-protein kinase STK11Homo sapiens (human)
response to thyroid hormoneSerine/threonine-protein kinase STK11Homo sapiens (human)
dendrite extensionSerine/threonine-protein kinase STK11Homo sapiens (human)
negative regulation of cold-induced thermogenesisSerine/threonine-protein kinase STK11Homo sapiens (human)
positive regulation of protein localization to nucleusSerine/threonine-protein kinase STK11Homo sapiens (human)
positive regulation of vesicle transport along microtubuleSerine/threonine-protein kinase STK11Homo sapiens (human)
regulation of signal transduction by p53 class mediatorSerine/threonine-protein kinase STK11Homo sapiens (human)
negative regulation of TORC1 signalingSerine/threonine-protein kinase STK11Homo sapiens (human)
signal transductionSerine/threonine-protein kinase STK11Homo sapiens (human)
regulation of Wnt signaling pathwaySerine/threonine-protein kinase STK11Homo sapiens (human)
visual perceptionRhodopsin kinase GRK1Homo sapiens (human)
regulation of G protein-coupled receptor signaling pathwayRhodopsin kinase GRK1Homo sapiens (human)
rhodopsin mediated signaling pathwayRhodopsin kinase GRK1Homo sapiens (human)
regulation of opsin-mediated signaling pathwayRhodopsin kinase GRK1Homo sapiens (human)
protein autophosphorylationRhodopsin kinase GRK1Homo sapiens (human)
protein phosphorylationRhodopsin kinase GRK1Homo sapiens (human)
regulation of signal transductionRhodopsin kinase GRK1Homo sapiens (human)
activation of protein kinase B activityNT-3 growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityNT-3 growth factor receptorHomo sapiens (human)
negative regulation of protein phosphorylationNT-3 growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationNT-3 growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayNT-3 growth factor receptorHomo sapiens (human)
nervous system developmentNT-3 growth factor receptorHomo sapiens (human)
heart developmentNT-3 growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationNT-3 growth factor receptorHomo sapiens (human)
positive regulation of gene expressionNT-3 growth factor receptorHomo sapiens (human)
cell differentiationNT-3 growth factor receptorHomo sapiens (human)
positive regulation of cell migrationNT-3 growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationNT-3 growth factor receptorHomo sapiens (human)
neurotrophin signaling pathwayNT-3 growth factor receptorHomo sapiens (human)
positive regulation of positive chemotaxisNT-3 growth factor receptorHomo sapiens (human)
activation of GTPase activityNT-3 growth factor receptorHomo sapiens (human)
positive regulation of neuron projection developmentNT-3 growth factor receptorHomo sapiens (human)
positive regulation of kinase activityNT-3 growth factor receptorHomo sapiens (human)
cellular response to nerve growth factor stimulusNT-3 growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeNT-3 growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNT-3 growth factor receptorHomo sapiens (human)
multicellular organism developmentNT-3 growth factor receptorHomo sapiens (human)
B cell homeostasisSerine/threonine-protein kinase N1Homo sapiens (human)
B cell apoptotic processSerine/threonine-protein kinase N1Homo sapiens (human)
negative regulation of protein phosphorylationSerine/threonine-protein kinase N1Homo sapiens (human)
regulation of germinal center formationSerine/threonine-protein kinase N1Homo sapiens (human)
regulation of immunoglobulin productionSerine/threonine-protein kinase N1Homo sapiens (human)
renal system processSerine/threonine-protein kinase N1Homo sapiens (human)
chromatin remodelingSerine/threonine-protein kinase N1Homo sapiens (human)
regulation of transcription by RNA polymerase IISerine/threonine-protein kinase N1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase N1Homo sapiens (human)
hyperosmotic responseSerine/threonine-protein kinase N1Homo sapiens (human)
signal transductionSerine/threonine-protein kinase N1Homo sapiens (human)
epithelial cell migrationSerine/threonine-protein kinase N1Homo sapiens (human)
negative regulation of B cell proliferationSerine/threonine-protein kinase N1Homo sapiens (human)
post-translational protein modificationSerine/threonine-protein kinase N1Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase N1Homo sapiens (human)
spleen developmentSerine/threonine-protein kinase N1Homo sapiens (human)
regulation of androgen receptor signaling pathwaySerine/threonine-protein kinase N1Homo sapiens (human)
regulation of cell motilitySerine/threonine-protein kinase N1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase N1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase N1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase N2Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase N2Homo sapiens (human)
cell adhesionSerine/threonine-protein kinase N2Homo sapiens (human)
signal transductionSerine/threonine-protein kinase N2Homo sapiens (human)
epithelial cell migrationSerine/threonine-protein kinase N2Homo sapiens (human)
cell projection organizationSerine/threonine-protein kinase N2Homo sapiens (human)
positive regulation of cytokinesisSerine/threonine-protein kinase N2Homo sapiens (human)
apical junction assemblySerine/threonine-protein kinase N2Homo sapiens (human)
positive regulation of viral genome replicationSerine/threonine-protein kinase N2Homo sapiens (human)
positive regulation of mitotic cell cycleSerine/threonine-protein kinase N2Homo sapiens (human)
cell divisionSerine/threonine-protein kinase N2Homo sapiens (human)
regulation of cell motilitySerine/threonine-protein kinase N2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase N2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase N2Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipopolysaccharideMitogen-activated protein kinase 14Homo sapiens (human)
DNA damage checkpoint signalingMitogen-activated protein kinase 14Homo sapiens (human)
cell morphogenesisMitogen-activated protein kinase 14Homo sapiens (human)
cartilage condensationMitogen-activated protein kinase 14Homo sapiens (human)
angiogenesisMitogen-activated protein kinase 14Homo sapiens (human)
osteoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
placenta developmentMitogen-activated protein kinase 14Homo sapiens (human)
response to dietary excessMitogen-activated protein kinase 14Homo sapiens (human)
chondrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusMitogen-activated protein kinase 14Homo sapiens (human)
glucose metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 14Homo sapiens (human)
chemotaxisMitogen-activated protein kinase 14Homo sapiens (human)
signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
skeletal muscle tissue developmentMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myotube differentiationMitogen-activated protein kinase 14Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 14Homo sapiens (human)
fatty acid oxidationMitogen-activated protein kinase 14Homo sapiens (human)
platelet activationMitogen-activated protein kinase 14Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 14Homo sapiens (human)
osteoclast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated protein kinase signaling cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 14Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
response to muramyl dipeptideMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of interleukin-12 productionMitogen-activated protein kinase 14Homo sapiens (human)
response to insulinMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of hippo signalingMitogen-activated protein kinase 14Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusMitogen-activated protein kinase 14Homo sapiens (human)
response to muscle stretchMitogen-activated protein kinase 14Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of protein import into nucleusMitogen-activated protein kinase 14Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of erythrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
glucose importMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of glucose importMitogen-activated protein kinase 14Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
stem cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
striated muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationMitogen-activated protein kinase 14Homo sapiens (human)
bone developmentMitogen-activated protein kinase 14Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipoteichoic acidMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to ionizing radiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to UV-BMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of brown fat cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 14Homo sapiens (human)
stress-induced premature senescenceMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to virusMitogen-activated protein kinase 14Homo sapiens (human)
regulation of synaptic membrane adhesionMitogen-activated protein kinase 14Homo sapiens (human)
regulation of cytokine production involved in inflammatory responseMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast fusionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myeloid dendritic cell cytokine productionCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
adaptive immune responseCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
protein phosphorylationCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
inflammatory responseCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
signal transductionCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
long-term memoryCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
regulation of T cell differentiation in thymusCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
myeloid dendritic cell differentiationCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
regulation of osteoclast differentiationCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
positive regulation of DNA-templated transcriptionCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
protein autophosphorylationCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
intracellular signal transductionCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
microtubule-based processMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
positive regulation of neuron apoptotic processMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
cell cycle G1/S phase transitionMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
positive regulation of JNK cascadeMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
positive regulation of apoptotic processMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
negative regulation of amyloid-beta formationBDNF/NT-3 growth factors receptorHomo sapiens (human)
vasculogenesisBDNF/NT-3 growth factors receptorHomo sapiens (human)
neuron migrationBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of protein phosphorylationBDNF/NT-3 growth factors receptorHomo sapiens (human)
learningBDNF/NT-3 growth factors receptorHomo sapiens (human)
circadian rhythmBDNF/NT-3 growth factors receptorHomo sapiens (human)
feeding behaviorBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of cell population proliferationBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of gene expressionBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of neuron projection developmentBDNF/NT-3 growth factors receptorHomo sapiens (human)
glutamate secretionBDNF/NT-3 growth factors receptorHomo sapiens (human)
neuronal action potential propagationBDNF/NT-3 growth factors receptorHomo sapiens (human)
central nervous system neuron developmentBDNF/NT-3 growth factors receptorHomo sapiens (human)
cerebral cortex developmentBDNF/NT-3 growth factors receptorHomo sapiens (human)
myelination in peripheral nervous systemBDNF/NT-3 growth factors receptorHomo sapiens (human)
neuron differentiationBDNF/NT-3 growth factors receptorHomo sapiens (human)
brain-derived neurotrophic factor receptor signaling pathwayBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationBDNF/NT-3 growth factors receptorHomo sapiens (human)
neurotrophin signaling pathwayBDNF/NT-3 growth factors receptorHomo sapiens (human)
mechanoreceptor differentiationBDNF/NT-3 growth factors receptorHomo sapiens (human)
regulation of GTPase activityBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of MAPK cascadeBDNF/NT-3 growth factors receptorHomo sapiens (human)
negative regulation of neuron apoptotic processBDNF/NT-3 growth factors receptorHomo sapiens (human)
retinal rod cell developmentBDNF/NT-3 growth factors receptorHomo sapiens (human)
protein autophosphorylationBDNF/NT-3 growth factors receptorHomo sapiens (human)
oligodendrocyte differentiationBDNF/NT-3 growth factors receptorHomo sapiens (human)
peripheral nervous system neuron developmentBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of axonogenesisBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of synapse assemblyBDNF/NT-3 growth factors receptorHomo sapiens (human)
long-term synaptic potentiationBDNF/NT-3 growth factors receptorHomo sapiens (human)
cellular response to amino acid stimulusBDNF/NT-3 growth factors receptorHomo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmissionBDNF/NT-3 growth factors receptorHomo sapiens (human)
negative regulation of anoikisBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of kinase activityBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeBDNF/NT-3 growth factors receptorHomo sapiens (human)
multicellular organism developmentBDNF/NT-3 growth factors receptorHomo sapiens (human)
cellular response to brain-derived neurotrophic factor stimulusBDNF/NT-3 growth factors receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayBDNF/NT-3 growth factors receptorHomo sapiens (human)
trans-synaptic signaling by neuropeptide, modulating synaptic transmissionBDNF/NT-3 growth factors receptorHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 6Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 6Homo sapiens (human)
signal transductionMitogen-activated protein kinase 6Homo sapiens (human)
positive regulation of dendritic spine developmentMitogen-activated protein kinase 6Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 6Homo sapiens (human)
carbohydrate metabolic processPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
glycogen biosynthetic processPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
ossificationDiscoidin domain-containing receptor 2Homo sapiens (human)
endochondral bone growthDiscoidin domain-containing receptor 2Homo sapiens (human)
cell adhesionDiscoidin domain-containing receptor 2Homo sapiens (human)
signal transductionDiscoidin domain-containing receptor 2Homo sapiens (human)
regulation of extracellular matrix disassemblyDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of fibroblast migrationDiscoidin domain-containing receptor 2Homo sapiens (human)
peptidyl-tyrosine phosphorylationDiscoidin domain-containing receptor 2Homo sapiens (human)
collagen fibril organizationDiscoidin domain-containing receptor 2Homo sapiens (human)
regulation of bone mineralizationDiscoidin domain-containing receptor 2Homo sapiens (human)
biomineral tissue developmentDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of collagen biosynthetic processDiscoidin domain-containing receptor 2Homo sapiens (human)
regulation of tissue remodelingDiscoidin domain-containing receptor 2Homo sapiens (human)
chondrocyte proliferationDiscoidin domain-containing receptor 2Homo sapiens (human)
response to muscle stretchDiscoidin domain-containing receptor 2Homo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathwayDiscoidin domain-containing receptor 2Homo sapiens (human)
negative regulation of apoptotic processDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of osteoblast differentiationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of protein kinase activityDiscoidin domain-containing receptor 2Homo sapiens (human)
protein autophosphorylationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of fibroblast proliferationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityDiscoidin domain-containing receptor 2Homo sapiens (human)
cellular response to hypoxiaDiscoidin domain-containing receptor 2Homo sapiens (human)
cellular response to transforming growth factor beta stimulusDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of extracellular matrix disassemblyDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of wound healingDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDiscoidin domain-containing receptor 2Homo sapiens (human)
negative regulation of hydrogen peroxide-mediated programmed cell deathDiscoidin domain-containing receptor 2Homo sapiens (human)
cellular response to angiotensinDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell migrationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of hepatic stellate cell proliferationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of hepatic stellate cell activationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of neuron projection developmentDiscoidin domain-containing receptor 2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionDiscoidin domain-containing receptor 2Homo sapiens (human)
multicellular organism developmentDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of kinase activityDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeDiscoidin domain-containing receptor 2Homo sapiens (human)
protein phosphorylationAP2-associated protein kinase 1Homo sapiens (human)
regulation of protein localizationAP2-associated protein kinase 1Homo sapiens (human)
positive regulation of Notch signaling pathwayAP2-associated protein kinase 1Homo sapiens (human)
protein stabilizationAP2-associated protein kinase 1Homo sapiens (human)
membrane organizationAP2-associated protein kinase 1Homo sapiens (human)
presynaptic endocytosisAP2-associated protein kinase 1Homo sapiens (human)
regulation of clathrin-dependent endocytosisAP2-associated protein kinase 1Homo sapiens (human)
regulation of vascular permeability involved in acute inflammatory responseMyosin light chain kinase 3Homo sapiens (human)
protein phosphorylationMyosin light chain kinase 3Homo sapiens (human)
sarcomere organizationMyosin light chain kinase 3Homo sapiens (human)
sarcomerogenesisMyosin light chain kinase 3Homo sapiens (human)
cardiac myofibril assemblyMyosin light chain kinase 3Homo sapiens (human)
positive regulation of sarcomere organizationMyosin light chain kinase 3Homo sapiens (human)
cellular response to interleukin-1Myosin light chain kinase 3Homo sapiens (human)
biological_processPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
cellular response to heatPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
protein stabilizationPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
protein foldingPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
regulation of heart rateSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
regulation of cardiac muscle contractionSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
bundle of His cell to Purkinje myocyte communicationSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
regulation of cardiac conductionSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
negative regulation of GTPase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
MAPK cascadeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of protein phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein import into nucleusLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
endocytosisLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
autophagyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
response to oxidative stressLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrion organizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
endoplasmic reticulum organizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
Golgi organizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
lysosome organizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
JNK cascadeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
Rho protein signal transductionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
spermatogenesisLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
neuromuscular junction developmentLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein localizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
determination of adult lifespanLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to starvationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of autophagyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of autophagyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of protein kinase A signalingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of protein processingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of neuron projection developmentLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of neuron maturationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of macroautophagyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
peptidyl-threonine phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
calcium-mediated signalingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
striatum developmentLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
olfactory bulb developmentLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
tangential migration from the subventricular zone to the olfactory bulbLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein ubiquitinationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of protein stabilityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of protein bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to oxidative stressLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to reactive oxygen speciesLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
intracellular signal transductionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of kidney sizeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
exploration behaviorLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
locomotory exploration behaviorLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of lysosomal lumen pHLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of locomotionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of membrane potentialLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of programmed cell deathLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of MAP kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
GTP metabolic processLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein autophosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
intracellular distribution of mitochondriaLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
neuron projection morphogenesisLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrion localizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of mitochondrial depolarizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of synaptic transmission, glutamatergicLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
canonical Wnt signaling pathwayLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
excitatory postsynaptic potentialLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of dopamine receptor signaling pathwayLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of dopamine receptor signaling pathwayLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of ER to Golgi vesicle-mediated transportLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of canonical Wnt signaling pathwayLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of dendritic spine morphogenesisLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein localization to mitochondrionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein localization to endoplasmic reticulum exit siteLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to manganese ionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of mitochondrial fissionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of excitatory postsynaptic potentialLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
neuron projection arborizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of synaptic vesicle endocytosisLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein autoubiquitinationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of neuroblast proliferationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of synaptic vesicle transportLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of late endosome to lysosome transportLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of autophagosome assemblyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of thioredoxin peroxidase activity by peptidyl-threonine phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of protein targeting to mitochondrionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of protein processing involved in protein targeting to mitochondrionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to dopamineLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of microglial cell activationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
Wnt signalosome assemblyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of retrograde transport, endosome to GolgiLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of CAMKK-AMPK signaling cascadeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of branching morphogenesis of a nerveLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of synaptic vesicle exocytosisLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of reactive oxygen species metabolic processLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
signal transductionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
cell migrationSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
actomyosin structure organizationSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
actomyosin structure organizationSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
fatty acid beta-oxidationAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
fatty acid beta-oxidation using acyl-CoA dehydrogenaseAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase N3Homo sapiens (human)
signal transductionSerine/threonine-protein kinase N3Homo sapiens (human)
epithelial cell migrationSerine/threonine-protein kinase N3Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase N3Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase N3Homo sapiens (human)
autophagySerine/threonine-protein kinase ULK3Homo sapiens (human)
smoothened signaling pathwaySerine/threonine-protein kinase ULK3Homo sapiens (human)
negative regulation of smoothened signaling pathwaySerine/threonine-protein kinase ULK3Homo sapiens (human)
positive regulation of smoothened signaling pathwaySerine/threonine-protein kinase ULK3Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase ULK3Homo sapiens (human)
fibroblast activationSerine/threonine-protein kinase ULK3Homo sapiens (human)
cellular senescenceSerine/threonine-protein kinase ULK3Homo sapiens (human)
reticulophagySerine/threonine-protein kinase ULK3Homo sapiens (human)
piecemeal microautophagy of the nucleusSerine/threonine-protein kinase ULK3Homo sapiens (human)
response to starvationSerine/threonine-protein kinase ULK3Homo sapiens (human)
autophagosome assemblySerine/threonine-protein kinase ULK3Homo sapiens (human)
autophagy of mitochondrionSerine/threonine-protein kinase ULK3Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase ULK3Homo sapiens (human)
regulation of autophagySerine/threonine-protein kinase ULK3Homo sapiens (human)
positive regulation of kinase activityDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
negative regulation of apoptotic processDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
cellular response to fibroblast growth factor stimulusDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
positive regulation of fibroblast growth factor receptor signaling pathwayDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 15Homo sapiens (human)
cellular response to stressMitogen-activated protein kinase kinase kinase 15Homo sapiens (human)
fatty acid beta-oxidationAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
fatty acid beta-oxidation using acyl-CoA dehydrogenaseAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
mRNA processingSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
rRNA catabolic processSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
apoptotic chromosome condensationSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
response to endoplasmic reticulum stressSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
negative regulation of DNA-templated transcriptionSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
IRE1-mediated unfolded protein responseSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
autophagy of mitochondrionSerine/threonine-protein kinase MARK2Homo sapiens (human)
neuron migrationSerine/threonine-protein kinase MARK2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase MARK2Homo sapiens (human)
positive regulation of neuron projection developmentSerine/threonine-protein kinase MARK2Homo sapiens (human)
Wnt signaling pathwaySerine/threonine-protein kinase MARK2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase MARK2Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase MARK2Homo sapiens (human)
establishment of cell polaritySerine/threonine-protein kinase MARK2Homo sapiens (human)
activation of protein kinase activitySerine/threonine-protein kinase MARK2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase MARK2Homo sapiens (human)
establishment or maintenance of epithelial cell apical/basal polaritySerine/threonine-protein kinase MARK2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase MARK2Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase MARK2Homo sapiens (human)
regulation of cytoskeleton organizationSerine/threonine-protein kinase MARK2Homo sapiens (human)
mitochondrion localizationSerine/threonine-protein kinase MARK2Homo sapiens (human)
axon developmentSerine/threonine-protein kinase MARK2Homo sapiens (human)
regulation of microtubule cytoskeleton organizationSerine/threonine-protein kinase MARK2Homo sapiens (human)
establishment or maintenance of cell polarity regulating cell shapeSerine/threonine-protein kinase MARK2Homo sapiens (human)
regulation of microtubule bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
microtubule cytoskeleton organizationSerine/threonine-protein kinase MARK2Homo sapiens (human)
microtubule cytoskeleton organizationSerine/threonine-protein kinase TAO1Homo sapiens (human)
DNA repairSerine/threonine-protein kinase TAO1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase TAO1Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase TAO1Homo sapiens (human)
negative regulation of microtubule depolymerizationSerine/threonine-protein kinase TAO1Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine/threonine-protein kinase TAO1Homo sapiens (human)
phosphorylationSerine/threonine-protein kinase TAO1Homo sapiens (human)
central nervous system neuron developmentSerine/threonine-protein kinase TAO1Homo sapiens (human)
positive regulation of stress-activated MAPK cascadeSerine/threonine-protein kinase TAO1Homo sapiens (human)
regulation of actin cytoskeleton organizationSerine/threonine-protein kinase TAO1Homo sapiens (human)
positive regulation of JNK cascadeSerine/threonine-protein kinase TAO1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase TAO1Homo sapiens (human)
regulation of cytoskeleton organizationSerine/threonine-protein kinase TAO1Homo sapiens (human)
neuron cellular homeostasisSerine/threonine-protein kinase TAO1Homo sapiens (human)
regulation of microtubule cytoskeleton organizationSerine/threonine-protein kinase TAO1Homo sapiens (human)
execution phase of apoptosisSerine/threonine-protein kinase TAO1Homo sapiens (human)
positive regulation of protein acetylationSerine/threonine-protein kinase TAO1Homo sapiens (human)
protein phosphorylationSTE20-related kinase adapter protein alphaHomo sapiens (human)
G1 to G0 transitionSTE20-related kinase adapter protein alphaHomo sapiens (human)
protein export from nucleusSTE20-related kinase adapter protein alphaHomo sapiens (human)
activation of protein kinase activitySTE20-related kinase adapter protein alphaHomo sapiens (human)
skeletal muscle contractionMyosin-14Homo sapiens (human)
mitochondrion organizationMyosin-14Homo sapiens (human)
skeletal muscle tissue developmentMyosin-14Homo sapiens (human)
sensory perception of soundMyosin-14Homo sapiens (human)
regulation of cell shapeMyosin-14Homo sapiens (human)
neuronal action potentialMyosin-14Homo sapiens (human)
actin filament-based movementMyosin-14Homo sapiens (human)
actomyosin structure organizationMyosin-14Homo sapiens (human)
vocalization behaviorMyosin-14Homo sapiens (human)
negative regulation of mitochondrial fusionAarF domain-containing protein kinase 1Homo sapiens (human)
positive regulation of cristae formationAarF domain-containing protein kinase 1Homo sapiens (human)
mitochondrion organizationAarF domain-containing protein kinase 1Homo sapiens (human)
lipid homeostasisAarF domain-containing protein kinase 1Homo sapiens (human)
chromatin organizationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
chromosome segregationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
negative regulation of autophagySerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
nucleus localizationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
cellular response to gamma radiationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
regulation of chromatin organizationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 32CHomo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase 32CHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase pim-3Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase pim-3Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase pim-3Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase pim-3Homo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusSerine/threonine-protein kinase pim-3Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase pim-3Homo sapiens (human)
protein localizationATP-dependent RNA helicase DDX42Homo sapiens (human)
regulation of apoptotic processATP-dependent RNA helicase DDX42Homo sapiens (human)
U2-type prespliceosome assemblyATP-dependent RNA helicase DDX42Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase VRK2Homo sapiens (human)
cellular response to oxidative stressSerine/threonine-protein kinase VRK2Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase VRK2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase VRK2Homo sapiens (human)
regulation of interleukin-1-mediated signaling pathwaySerine/threonine-protein kinase VRK2Homo sapiens (human)
signal transductionSerine/threonine-protein kinase VRK2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase VRK2Homo sapiens (human)
eye developmentHomeodomain-interacting protein kinase 1Homo sapiens (human)
protein phosphorylationHomeodomain-interacting protein kinase 1Homo sapiens (human)
cell population proliferationHomeodomain-interacting protein kinase 1Homo sapiens (human)
positive regulation of cell population proliferationHomeodomain-interacting protein kinase 1Homo sapiens (human)
anterior/posterior pattern specificationHomeodomain-interacting protein kinase 1Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwayHomeodomain-interacting protein kinase 1Homo sapiens (human)
retina layer formationHomeodomain-interacting protein kinase 1Homo sapiens (human)
neuron differentiationHomeodomain-interacting protein kinase 1Homo sapiens (human)
adherens junction assemblyHomeodomain-interacting protein kinase 1Homo sapiens (human)
positive regulation of angiogenesisHomeodomain-interacting protein kinase 1Homo sapiens (human)
embryonic camera-type eye morphogenesisHomeodomain-interacting protein kinase 1Homo sapiens (human)
embryonic retina morphogenesis in camera-type eyeHomeodomain-interacting protein kinase 1Homo sapiens (human)
definitive hemopoiesisHomeodomain-interacting protein kinase 1Homo sapiens (human)
lens induction in camera-type eyeHomeodomain-interacting protein kinase 1Homo sapiens (human)
iris morphogenesisHomeodomain-interacting protein kinase 1Homo sapiens (human)
endothelial cell apoptotic processHomeodomain-interacting protein kinase 1Homo sapiens (human)
extrinsic apoptotic signaling pathwayHomeodomain-interacting protein kinase 1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorHomeodomain-interacting protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationHomeodomain-interacting protein kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylationHomeodomain-interacting protein kinase 1Homo sapiens (human)
smoothened signaling pathwayHomeodomain-interacting protein kinase 1Homo sapiens (human)
inflammatory responseCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
nervous system developmentCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of neuron projection developmentCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of CREB transcription factor activityCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of apoptotic processCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
negative regulation of apoptotic processCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of phagocytosisCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
regulation of dendrite developmentCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of respiratory burstCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
regulation of granulocyte chemotaxisCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of neutrophil chemotaxisCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
response to UVMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
response to tumor necrosis factorMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
protein modification processCyclin-dependent kinase-like 3Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase-like 3Homo sapiens (human)
negative regulation of axon extensionCyclin-dependent kinase-like 3Homo sapiens (human)
positive regulation of dendrite morphogenesisCyclin-dependent kinase-like 3Homo sapiens (human)
dendrite extensionCyclin-dependent kinase-like 3Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase-like 3Homo sapiens (human)
MAPK cascadeMAP kinase-activated protein kinase 5Homo sapiens (human)
regulation of translationMAP kinase-activated protein kinase 5Homo sapiens (human)
signal transductionMAP kinase-activated protein kinase 5Homo sapiens (human)
Ras protein signal transductionMAP kinase-activated protein kinase 5Homo sapiens (human)
negative regulation of TOR signalingMAP kinase-activated protein kinase 5Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseMAP kinase-activated protein kinase 5Homo sapiens (human)
protein autophosphorylationMAP kinase-activated protein kinase 5Homo sapiens (human)
positive regulation of telomerase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
positive regulation of dendritic spine developmentMAP kinase-activated protein kinase 5Homo sapiens (human)
cellular senescenceMAP kinase-activated protein kinase 5Homo sapiens (human)
stress-induced premature senescenceMAP kinase-activated protein kinase 5Homo sapiens (human)
regulation of signal transduction by p53 class mediatorMAP kinase-activated protein kinase 5Homo sapiens (human)
positive regulation of telomere cappingMAP kinase-activated protein kinase 5Homo sapiens (human)
peptidyl-serine phosphorylationMAP kinase-activated protein kinase 5Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase BRSK2Homo sapiens (human)
exocytosisSerine/threonine-protein kinase BRSK2Homo sapiens (human)
axonogenesisSerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of neuron projection developmentSerine/threonine-protein kinase BRSK2Homo sapiens (human)
establishment of cell polaritySerine/threonine-protein kinase BRSK2Homo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase BRSK2Homo sapiens (human)
neuron differentiationSerine/threonine-protein kinase BRSK2Homo sapiens (human)
ERAD pathwaySerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of ATP-dependent activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase BRSK2Homo sapiens (human)
cell divisionSerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusSerine/threonine-protein kinase BRSK2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressSerine/threonine-protein kinase BRSK2Homo sapiens (human)
microtubule cytoskeleton organization involved in establishment of planar polaritySerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of retrograde protein transport, ER to cytosolSerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of synaptic vesicle clusteringSerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase NIM1Homo sapiens (human)
nuclear-transcribed mRNA catabolic process, nonsense-mediated decayEukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)
translational terminationEukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)
translationEukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)
autophagySerine/threonine-protein kinase ULK2Homo sapiens (human)
signal transductionSerine/threonine-protein kinase ULK2Homo sapiens (human)
response to starvationSerine/threonine-protein kinase ULK2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase ULK2Homo sapiens (human)
collateral sproutingSerine/threonine-protein kinase ULK2Homo sapiens (human)
autophagy of mitochondrionSerine/threonine-protein kinase ULK2Homo sapiens (human)
axon extensionSerine/threonine-protein kinase ULK2Homo sapiens (human)
reticulophagySerine/threonine-protein kinase ULK2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase ULK2Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase ULK2Homo sapiens (human)
piecemeal microautophagy of the nucleusSerine/threonine-protein kinase ULK2Homo sapiens (human)
negative regulation of collateral sproutingSerine/threonine-protein kinase ULK2Homo sapiens (human)
autophagosome assemblySerine/threonine-protein kinase ULK2Homo sapiens (human)
microvillus assemblyMisshapen-like kinase 1Homo sapiens (human)
regulation of cell-matrix adhesionMisshapen-like kinase 1Homo sapiens (human)
protein phosphorylationMisshapen-like kinase 1Homo sapiens (human)
JNK cascadeMisshapen-like kinase 1Homo sapiens (human)
chemical synaptic transmissionMisshapen-like kinase 1Homo sapiens (human)
brain developmentMisshapen-like kinase 1Homo sapiens (human)
regulation of cell-cell adhesionMisshapen-like kinase 1Homo sapiens (human)
actin cytoskeleton organizationMisshapen-like kinase 1Homo sapiens (human)
regulation of cell migrationMisshapen-like kinase 1Homo sapiens (human)
positive regulation of JNK cascadeMisshapen-like kinase 1Homo sapiens (human)
protein autophosphorylationMisshapen-like kinase 1Homo sapiens (human)
dendrite morphogenesisMisshapen-like kinase 1Homo sapiens (human)
positive regulation of p38MAPK cascadeMisshapen-like kinase 1Homo sapiens (human)
regulation of AMPA receptor activityMisshapen-like kinase 1Homo sapiens (human)
MAPK cascadeMisshapen-like kinase 1Homo sapiens (human)
neuron projection morphogenesisMisshapen-like kinase 1Homo sapiens (human)
regulation of MAPK cascadeMisshapen-like kinase 1Homo sapiens (human)
hippocampus developmentSerine/threonine-protein kinase DCLK2Homo sapiens (human)
pyramidal neuron developmentSerine/threonine-protein kinase DCLK2Homo sapiens (human)
protein localization to nucleusSerine/threonine-protein kinase DCLK2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase DCLK2Homo sapiens (human)
negative regulation of protein localization to nucleusSerine/threonine-protein kinase DCLK2Homo sapiens (human)
microtubule cytoskeleton organizationSerine/threonine-protein kinase DCLK2Homo sapiens (human)
intracellular signal transductionCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform alpha-likeHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform alpha-likeHomo sapiens (human)
signal transductionCasein kinase I isoform alpha-likeHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayCasein kinase I isoform alpha-likeHomo sapiens (human)
chromatin remodelingHomeodomain-interacting protein kinase 4Homo sapiens (human)
regulation of signal transduction by p53 class mediatorHomeodomain-interacting protein kinase 4Homo sapiens (human)
peptidyl-threonine phosphorylationHomeodomain-interacting protein kinase 4Homo sapiens (human)
peptidyl-serine phosphorylationHomeodomain-interacting protein kinase 4Homo sapiens (human)
visual perceptionMyosin-IIIaHomo sapiens (human)
sensory perception of soundMyosin-IIIaHomo sapiens (human)
protein autophosphorylationMyosin-IIIaHomo sapiens (human)
cochlea morphogenesisMyosin-IIIaHomo sapiens (human)
regulation of actin filament lengthMyosin-IIIaHomo sapiens (human)
positive regulation of filopodium assemblyMyosin-IIIaHomo sapiens (human)
peptidyl-serine phosphorylationMyosin-IIIaHomo sapiens (human)
regulation of cell cycle processAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
regulation of cell cycle processAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek11Homo sapiens (human)
mitotic intra-S DNA damage checkpoint signalingSerine/threonine-protein kinase Nek11Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase Nek11Homo sapiens (human)
regulation of mitotic cell cycle phase transitionSerine/threonine-protein kinase Nek11Homo sapiens (human)
protein phosphorylationAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
ubiquinone biosynthetic processAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
phosphorylationAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
regulation of autophagyPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic processPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
positive regulation of autophagosome assemblyPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 15Homo sapiens (human)
regulation of COPII vesicle coatingMitogen-activated protein kinase 15Homo sapiens (human)
DNA damage responseMitogen-activated protein kinase 15Homo sapiens (human)
endoplasmic reticulum organizationMitogen-activated protein kinase 15Homo sapiens (human)
positive regulation of cell population proliferationMitogen-activated protein kinase 15Homo sapiens (human)
regulation of autophagyMitogen-activated protein kinase 15Homo sapiens (human)
negative regulation of cell migrationMitogen-activated protein kinase 15Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseMitogen-activated protein kinase 15Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase 15Homo sapiens (human)
positive regulation of telomerase activityMitogen-activated protein kinase 15Homo sapiens (human)
dopamine uptakeMitogen-activated protein kinase 15Homo sapiens (human)
regulation of cilium assemblyMitogen-activated protein kinase 15Homo sapiens (human)
positive regulation of telomere cappingMitogen-activated protein kinase 15Homo sapiens (human)
protein localization to ciliary transition zoneMitogen-activated protein kinase 15Homo sapiens (human)
positive regulation of metaphase/anaphase transition of meiosis IMitogen-activated protein kinase 15Homo sapiens (human)
positive regulation of spindle assemblyMitogen-activated protein kinase 15Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 15Homo sapiens (human)
mitotic cell cycleSerine/threonine-protein kinase Nek9Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase Nek9Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Nek9Homo sapiens (human)
response to ionizing radiationSerine/threonine-protein kinase BRSK1Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase BRSK1Homo sapiens (human)
response to UVSerine/threonine-protein kinase BRSK1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase BRSK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase BRSK1Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase BRSK1Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine/threonine-protein kinase BRSK1Homo sapiens (human)
neurotransmitter secretionSerine/threonine-protein kinase BRSK1Homo sapiens (human)
axonogenesisSerine/threonine-protein kinase BRSK1Homo sapiens (human)
associative learningSerine/threonine-protein kinase BRSK1Homo sapiens (human)
response to UVSerine/threonine-protein kinase BRSK1Homo sapiens (human)
regulation of neuron projection developmentSerine/threonine-protein kinase BRSK1Homo sapiens (human)
establishment of cell polaritySerine/threonine-protein kinase BRSK1Homo sapiens (human)
neuron differentiationSerine/threonine-protein kinase BRSK1Homo sapiens (human)
regulation of synaptic plasticitySerine/threonine-protein kinase BRSK1Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase BRSK1Homo sapiens (human)
centrosome duplicationSerine/threonine-protein kinase BRSK1Homo sapiens (human)
microtubule cytoskeleton organization involved in establishment of planar polaritySerine/threonine-protein kinase BRSK1Homo sapiens (human)
synaptic vesicle cycleSerine/threonine-protein kinase BRSK1Homo sapiens (human)
regulation of synaptic vesicle clusteringSerine/threonine-protein kinase BRSK1Homo sapiens (human)
regulation of translational initiation by eIF2 alpha phosphorylationSerine/threonine-protein kinase 35Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek7Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase Nek7Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseSerine/threonine-protein kinase Nek7Homo sapiens (human)
cellular response to potassium ionSerine/threonine-protein kinase Nek7Homo sapiens (human)
spindle assemblySerine/threonine-protein kinase Nek7Homo sapiens (human)
positive regulation of telomerase activitySerine/threonine-protein kinase Nek7Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblySerine/threonine-protein kinase Nek7Homo sapiens (human)
positive regulation of telomere cappingSerine/threonine-protein kinase Nek7Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase Nek7Homo sapiens (human)
signal transductionRhodopsin kinase GRK7Homo sapiens (human)
visual perceptionRhodopsin kinase GRK7Homo sapiens (human)
regulation of opsin-mediated signaling pathwayRhodopsin kinase GRK7Homo sapiens (human)
protein autophosphorylationRhodopsin kinase GRK7Homo sapiens (human)
regulation of signal transductionRhodopsin kinase GRK7Homo sapiens (human)
protein phosphorylationRhodopsin kinase GRK7Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 32AHomo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase 32AHomo sapiens (human)
visual perceptionMyosin-IIIbHomo sapiens (human)
sensory perception of soundMyosin-IIIbHomo sapiens (human)
cochlea morphogenesisMyosin-IIIbHomo sapiens (human)
regulation of actin filament lengthMyosin-IIIbHomo sapiens (human)
peptidyl-serine phosphorylationMyosin-IIIbHomo sapiens (human)
positive regulation of filopodium assemblyMyosin-IIIbHomo sapiens (human)
spliceosomal complex assemblyATP-dependent RNA helicase DDX1Homo sapiens (human)
positive regulation of myeloid dendritic cell cytokine productionATP-dependent RNA helicase DDX1Homo sapiens (human)
double-strand break repairATP-dependent RNA helicase DDX1Homo sapiens (human)
tRNA splicing, via endonucleolytic cleavage and ligationATP-dependent RNA helicase DDX1Homo sapiens (human)
regulation of translational initiationATP-dependent RNA helicase DDX1Homo sapiens (human)
DNA duplex unwindingATP-dependent RNA helicase DDX1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionATP-dependent RNA helicase DDX1Homo sapiens (human)
response to exogenous dsRNAATP-dependent RNA helicase DDX1Homo sapiens (human)
innate immune responseATP-dependent RNA helicase DDX1Homo sapiens (human)
defense response to virusATP-dependent RNA helicase DDX1Homo sapiens (human)
nucleic acid metabolic processATP-dependent RNA helicase DDX1Homo sapiens (human)
protein localization to cytoplasmic stress granuleATP-dependent RNA helicase DDX1Homo sapiens (human)
protein phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
DNA damage responseDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
smoothened signaling pathwayDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
positive regulation of glycogen biosynthetic processDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascadeDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
regulation of signal transduction by p53 class mediatorDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
peptidyl-threonine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
signal transductionCyclin-dependent kinase-like 2Homo sapiens (human)
sex differentiationCyclin-dependent kinase-like 2Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase-like 2Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase-like 2Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
cell population proliferationMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
positive regulation of MAPK cascadeMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
cellular response to phorbol 13-acetate 12-myristateMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
regulation of cell growthSerine/threonine-protein kinase Sgk3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Sgk3Homo sapiens (human)
regulation of cell migrationSerine/threonine-protein kinase Sgk3Homo sapiens (human)
regulation of cell population proliferationSerine/threonine-protein kinase Sgk3Homo sapiens (human)
regulation of DNA-binding transcription factor activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandSerine/threonine-protein kinase Sgk3Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase Sgk3Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase Sgk3Homo sapiens (human)
protein phosphorylationAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
ubiquinone biosynthetic processAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
cerebellar Purkinje cell layer morphogenesisAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAurora kinase BHomo sapiens (human)
mitotic cell cycleAurora kinase BHomo sapiens (human)
mitotic cytokinesisAurora kinase BHomo sapiens (human)
negative regulation of B cell apoptotic processAurora kinase BHomo sapiens (human)
protein phosphorylationAurora kinase BHomo sapiens (human)
spindle organizationAurora kinase BHomo sapiens (human)
attachment of spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
abscissionAurora kinase BHomo sapiens (human)
negative regulation of protein bindingAurora kinase BHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseAurora kinase BHomo sapiens (human)
negative regulation of cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of cytokinesisAurora kinase BHomo sapiens (human)
protein localization to kinetochoreAurora kinase BHomo sapiens (human)
cellular response to UVAurora kinase BHomo sapiens (human)
cleavage furrow formationAurora kinase BHomo sapiens (human)
post-translational protein modificationAurora kinase BHomo sapiens (human)
cell cycle G2/M phase transitionAurora kinase BHomo sapiens (human)
mitotic cytokinesis checkpoint signalingAurora kinase BHomo sapiens (human)
negative regulation of innate immune responseAurora kinase BHomo sapiens (human)
protein autophosphorylationAurora kinase BHomo sapiens (human)
mitotic spindle midzone assemblyAurora kinase BHomo sapiens (human)
positive regulation of telomerase activityAurora kinase BHomo sapiens (human)
regulation of chromosome segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic cell cycle spindle assembly checkpointAurora kinase BHomo sapiens (human)
mitotic spindle assemblyAurora kinase BHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayAurora kinase BHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid separationAurora kinase BHomo sapiens (human)
positive regulation of attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
positive regulation of mitotic cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of telomere cappingAurora kinase BHomo sapiens (human)
positive regulation of lateral attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
mitotic spindle organizationAurora kinase BHomo sapiens (human)
regulation of cytokinesisAurora kinase BHomo sapiens (human)
microtubule cytoskeleton organizationMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
positive regulation of cell cycleMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
microtubule cytoskeleton organizationMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
microtubule bundle formationMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
protein phosphorylationMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
nervous system developmentMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
positive regulation of programmed cell deathMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
cilium organizationMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
positive regulation of cilium assemblyMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
regulation of centrosome cycleMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
cell divisionMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblyMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
positive regulation of protein localization to centrosomeMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
intracellular signal transductionMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek1Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Nek1Homo sapiens (human)
cilium assemblySerine/threonine-protein kinase Nek1Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 15Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 15Homo sapiens (human)
protein phosphorylationPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
regulation of respiratory gaseous exchangePAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of glycogen biosynthetic processPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of translationPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
protein autophosphorylationPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
regulation of glucagon secretionPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
energy homeostasisPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
intracellular signal transductionPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
MAPK cascadeCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
positive regulation of protein phosphorylationCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein phosphorylationCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
calcium-mediated signalingCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
cellular response to reactive oxygen speciesCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
regulation of protein kinase activityCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein autophosphorylationCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
CAMKK-AMPK signaling cascadeCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
positive regulation of autophagy of mitochondrionCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein phosphorylationEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
tRNA processingEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
regulation of signal transduction by p53 class mediatorEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
tRNA threonylcarbamoyladenosine metabolic processEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
protein phosphorylationSRSF protein kinase 1Homo sapiens (human)
chromosome segregationSRSF protein kinase 1Homo sapiens (human)
RNA splicingSRSF protein kinase 1Homo sapiens (human)
sperm DNA condensationSRSF protein kinase 1Homo sapiens (human)
intracellular signal transductionSRSF protein kinase 1Homo sapiens (human)
positive regulation of viral genome replicationSRSF protein kinase 1Homo sapiens (human)
negative regulation of viral genome replicationSRSF protein kinase 1Homo sapiens (human)
innate immune responseSRSF protein kinase 1Homo sapiens (human)
regulation of mRNA splicing, via spliceosomeSRSF protein kinase 1Homo sapiens (human)
regulation of mRNA processingSRSF protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationSRSF protein kinase 1Homo sapiens (human)
spliceosomal complex assemblySRSF protein kinase 1Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
G2/M transition of mitotic cell cycleMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
mitotic cell cycleMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
regulation of mitotic nuclear divisionMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
negative regulation of G2/M transition of mitotic cell cycleMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
protein phosphorylationMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
negative regulation of G2/MI transition of meiotic cell cycleMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
meiotic cell cycleMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
response to ischemiaMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cellular response to amino acid starvationMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
response to endoplasmic reticulum stressMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
neuron intrinsic apoptotic signaling pathway in response to oxidative stressMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of apoptotic processMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
innate immune responseMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of myoblast differentiationMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of protein kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of DNA-templated transcriptionMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of JNK cascadeMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
neuron apoptotic processMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cellular response to hydrogen peroxideMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
endothelial cell apoptotic processMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
apoptotic signaling pathwayMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
programmed necrotic cell deathMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of p38MAPK cascadeMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cellular response to reactive nitrogen speciesMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cellular response to stressMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
glycerophospholipid metabolic processPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
phosphatidylinositol biosynthetic processPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
phagocytosisPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
signal transductionPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
phospholipid biosynthetic processPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
fibroblast migrationPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
cell migrationPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
actin cytoskeleton organizationPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
keratinocyte differentiationPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
focal adhesion assemblyPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
cell chemotaxisPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
protein localization to plasma membranePhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
activation of GTPase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
ruffle assemblyPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
blood vessel developmentMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
positive regulation of cell proliferation in bone marrowMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
positive regulation of p38MAPK cascadeMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
negative regulation of cellular senescenceMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
acute inflammatory responseEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
phagocytosisEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
negative regulation of cell population proliferationEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
regulation of eIF2 alpha phosphorylation by hemeEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
macrophage differentiationEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
negative regulation of translational initiation by ironEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
protoporphyrinogen IX metabolic processEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
protein autophosphorylationEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
negative regulation of hemoglobin biosynthetic processEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
establishment of localization in cellEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
multicellular organismal-level iron ion homeostasisEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
integrated stress response signalingEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
HRI-mediated signalingEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
positive regulation of mitophagyEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
response to iron ion starvationEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
regulation of translational initiation by eIF2 alpha phosphorylationEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
maturation of SSU-rRNASerine/threonine-protein kinase RIO1Homo sapiens (human)
ribosomal small subunit biogenesisSerine/threonine-protein kinase RIO1Homo sapiens (human)
positive regulation of rRNA processingSerine/threonine-protein kinase RIO1Homo sapiens (human)
regulation of translationMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein phosphorylationMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
intracellular signal transductionMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein autophosphorylationMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
regulation of mitotic metaphase/anaphase transitionSerine/threonine-protein kinase RIO2Homo sapiens (human)
maturation of SSU-rRNASerine/threonine-protein kinase RIO2Homo sapiens (human)
ribosomal small subunit biogenesisSerine/threonine-protein kinase RIO2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase RIO2Homo sapiens (human)
positive regulation of ribosomal small subunit export from nucleusSerine/threonine-protein kinase RIO2Homo sapiens (human)
positive regulation of rRNA processingSerine/threonine-protein kinase RIO2Homo sapiens (human)
positive regulation of apoptotic processCyclin-dependent kinase 19Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 19Homo sapiens (human)
cellular response to lipopolysaccharideCyclin-dependent kinase 19Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 19Homo sapiens (human)
response to toxic substanceTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
protein tetramerizationTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
metal ion transportTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
monoatomic cation transmembrane transportTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
protein phosphorylationTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
spermatid developmentTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 33Homo sapiens (human)
mitotic DNA damage checkpoint signalingSerine/threonine-protein kinase 33Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityNucleolar GTP-binding protein 1Homo sapiens (human)
maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)Nucleolar GTP-binding protein 1Homo sapiens (human)
osteoblast differentiationNucleolar GTP-binding protein 1Homo sapiens (human)
negative regulation of DNA replicationNucleolar GTP-binding protein 1Homo sapiens (human)
negative regulation of cell population proliferationNucleolar GTP-binding protein 1Homo sapiens (human)
negative regulation of cell-cell adhesionNucleolar GTP-binding protein 1Homo sapiens (human)
negative regulation of cell migrationNucleolar GTP-binding protein 1Homo sapiens (human)
negative regulation of protein ubiquitinationNucleolar GTP-binding protein 1Homo sapiens (human)
negative regulation of collagen bindingNucleolar GTP-binding protein 1Homo sapiens (human)
ribosomal large subunit biogenesisNucleolar GTP-binding protein 1Homo sapiens (human)
protein stabilizationNucleolar GTP-binding protein 1Homo sapiens (human)
angiogenesisSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of endothelial cell proliferationSerine/threonine-protein kinase D2Homo sapiens (human)
adaptive immune responseSerine/threonine-protein kinase D2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase D2Homo sapiens (human)
cell adhesionSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of endothelial cell migrationSerine/threonine-protein kinase D2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase D2Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase D2Homo sapiens (human)
sphingolipid biosynthetic processSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwaySerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of interleukin-2 productionSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of interleukin-8 productionSerine/threonine-protein kinase D2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase D2Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of fibroblast growth factor receptor signaling pathwaySerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of angiogenesisSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of cell adhesionSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine/threonine-protein kinase D2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase D2Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwaySerine/threonine-protein kinase D2Homo sapiens (human)
T cell receptor signaling pathwaySerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of T cell receptor signaling pathwaySerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of DNA-binding transcription factor activitySerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activitySerine/threonine-protein kinase D2Homo sapiens (human)
endothelial tube morphogenesisSerine/threonine-protein kinase D2Homo sapiens (human)
regulation of T cell apoptotic processSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of DNA biosynthetic processSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of endothelial cell chemotaxisSerine/threonine-protein kinase D2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySerine/threonine-protein kinase D2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase DCLK3Homo sapiens (human)
protein phosphorylationNUAK family SNF1-like kinase 2Homo sapiens (human)
apoptotic processNUAK family SNF1-like kinase 2Homo sapiens (human)
actin cytoskeleton organizationNUAK family SNF1-like kinase 2Homo sapiens (human)
protein localization to nucleusNUAK family SNF1-like kinase 2Homo sapiens (human)
regulation of hippo signalingNUAK family SNF1-like kinase 2Homo sapiens (human)
cellular response to glucose starvationNUAK family SNF1-like kinase 2Homo sapiens (human)
negative regulation of apoptotic processNUAK family SNF1-like kinase 2Homo sapiens (human)
rRNA modificationRNA cytidine acetyltransferaseHomo sapiens (human)
regulation of translationRNA cytidine acetyltransferaseHomo sapiens (human)
protein acetylationRNA cytidine acetyltransferaseHomo sapiens (human)
regulation of centrosome duplicationRNA cytidine acetyltransferaseHomo sapiens (human)
negative regulation of telomere maintenance via telomeraseRNA cytidine acetyltransferaseHomo sapiens (human)
ribosomal small subunit biogenesisRNA cytidine acetyltransferaseHomo sapiens (human)
positive regulation of translationRNA cytidine acetyltransferaseHomo sapiens (human)
tRNA acetylationRNA cytidine acetyltransferaseHomo sapiens (human)
rRNA acetylation involved in maturation of SSU-rRNARNA cytidine acetyltransferaseHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase SIK2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase SIK2Homo sapiens (human)
regulation of insulin receptor signaling pathwaySerine/threonine-protein kinase SIK2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase SIK2Homo sapiens (human)
striated muscle contractionMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
neuromuscular synaptic transmissionMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
positive regulation of gene expressionMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
skeletal muscle satellite cell differentiationMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
peptidyl-threonine phosphorylationMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
regulation of muscle filament slidingMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
skeletal muscle cell differentiationMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
protein autophosphorylationMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
cardiac muscle tissue morphogenesisMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
cardiac muscle contractionMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
apoptotic processSTE20-like serine/threonine-protein kinase Homo sapiens (human)
regulation of cell migrationSTE20-like serine/threonine-protein kinase Homo sapiens (human)
cytoplasmic microtubule organizationSTE20-like serine/threonine-protein kinase Homo sapiens (human)
regulation of apoptotic processSTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein autophosphorylationSTE20-like serine/threonine-protein kinase Homo sapiens (human)
regulation of focal adhesion assemblySTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein phosphorylationSTE20-like serine/threonine-protein kinase Homo sapiens (human)
MAPK cascadeSerine/threonine-protein kinase TAO3Homo sapiens (human)
DNA repairSerine/threonine-protein kinase TAO3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase TAO3Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase TAO3Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine/threonine-protein kinase TAO3Homo sapiens (human)
positive regulation of stress-activated MAPK cascadeSerine/threonine-protein kinase TAO3Homo sapiens (human)
positive regulation of JUN kinase activitySerine/threonine-protein kinase TAO3Homo sapiens (human)
negative regulation of JNK cascadeSerine/threonine-protein kinase TAO3Homo sapiens (human)
positive regulation of JNK cascadeSerine/threonine-protein kinase TAO3Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase TAO3Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase TAO3Homo sapiens (human)
neuron projection morphogenesisSerine/threonine-protein kinase TAO3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHomeodomain-interacting protein kinase 2Homo sapiens (human)
eye developmentHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of protein phosphorylationHomeodomain-interacting protein kinase 2Homo sapiens (human)
respiratory system processHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein phosphorylationHomeodomain-interacting protein kinase 2Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayHomeodomain-interacting protein kinase 2Homo sapiens (human)
adult walking behaviorHomeodomain-interacting protein kinase 2Homo sapiens (human)
cell population proliferationHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of cell population proliferationHomeodomain-interacting protein kinase 2Homo sapiens (human)
anterior/posterior pattern specificationHomeodomain-interacting protein kinase 2Homo sapiens (human)
gene expressionHomeodomain-interacting protein kinase 2Homo sapiens (human)
retina layer formationHomeodomain-interacting protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationHomeodomain-interacting protein kinase 2Homo sapiens (human)
peptidyl-threonine phosphorylationHomeodomain-interacting protein kinase 2Homo sapiens (human)
neuron differentiationHomeodomain-interacting protein kinase 2Homo sapiens (human)
erythrocyte differentiationHomeodomain-interacting protein kinase 2Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwayHomeodomain-interacting protein kinase 2Homo sapiens (human)
negative regulation of BMP signaling pathwayHomeodomain-interacting protein kinase 2Homo sapiens (human)
PML body organizationHomeodomain-interacting protein kinase 2Homo sapiens (human)
thyroid gland developmentHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of protein bindingHomeodomain-interacting protein kinase 2Homo sapiens (human)
epigenetic regulation of gene expressionHomeodomain-interacting protein kinase 2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorHomeodomain-interacting protein kinase 2Homo sapiens (human)
negative regulation of neuron apoptotic processHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of angiogenesisHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of JNK cascadeHomeodomain-interacting protein kinase 2Homo sapiens (human)
embryonic camera-type eye morphogenesisHomeodomain-interacting protein kinase 2Homo sapiens (human)
voluntary musculoskeletal movementHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
neuron apoptotic processHomeodomain-interacting protein kinase 2Homo sapiens (human)
regulation of cell cycleHomeodomain-interacting protein kinase 2Homo sapiens (human)
embryonic retina morphogenesis in camera-type eyeHomeodomain-interacting protein kinase 2Homo sapiens (human)
lens induction in camera-type eyeHomeodomain-interacting protein kinase 2Homo sapiens (human)
SMAD protein signal transductionHomeodomain-interacting protein kinase 2Homo sapiens (human)
lung morphogenesisHomeodomain-interacting protein kinase 2Homo sapiens (human)
iris morphogenesisHomeodomain-interacting protein kinase 2Homo sapiens (human)
cellular response to hypoxiaHomeodomain-interacting protein kinase 2Homo sapiens (human)
intrinsic apoptotic signaling pathwayHomeodomain-interacting protein kinase 2Homo sapiens (human)
regulation of signal transduction by p53 class mediatorHomeodomain-interacting protein kinase 2Homo sapiens (human)
negative regulation of ubiquitin-dependent protein catabolic processHomeodomain-interacting protein kinase 2Homo sapiens (human)
smoothened signaling pathwayHomeodomain-interacting protein kinase 2Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein kinase SrmsHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase SrmsHomo sapiens (human)
peptidyl-tyrosine autophosphorylationTyrosine-protein kinase SrmsHomo sapiens (human)
positive regulation of TORC1 signalingTyrosine-protein kinase SrmsHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase SrmsHomo sapiens (human)
cell differentiationTyrosine-protein kinase SrmsHomo sapiens (human)
innate immune responseTyrosine-protein kinase SrmsHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase SrmsHomo sapiens (human)
protein phosphorylationHomeodomain-interacting protein kinase 3Homo sapiens (human)
apoptotic processHomeodomain-interacting protein kinase 3Homo sapiens (human)
mRNA transcriptionHomeodomain-interacting protein kinase 3Homo sapiens (human)
peptidyl-serine phosphorylationHomeodomain-interacting protein kinase 3Homo sapiens (human)
peptidyl-threonine phosphorylationHomeodomain-interacting protein kinase 3Homo sapiens (human)
negative regulation of apoptotic processHomeodomain-interacting protein kinase 3Homo sapiens (human)
negative regulation of JUN kinase activityHomeodomain-interacting protein kinase 3Homo sapiens (human)
G1/S transition of mitotic cell cycleSerine/threonine-protein kinase PLK3Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase PLK3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IISerine/threonine-protein kinase PLK3Homo sapiens (human)
response to reactive oxygen speciesSerine/threonine-protein kinase PLK3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PLK3Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase PLK3Homo sapiens (human)
response to osmotic stressSerine/threonine-protein kinase PLK3Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase PLK3Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestSerine/threonine-protein kinase PLK3Homo sapiens (human)
endomitotic cell cycleSerine/threonine-protein kinase PLK3Homo sapiens (human)
response to radiationSerine/threonine-protein kinase PLK3Homo sapiens (human)
cytoplasmic microtubule organizationSerine/threonine-protein kinase PLK3Homo sapiens (human)
regulation of cytokinesisSerine/threonine-protein kinase PLK3Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase PLK3Homo sapiens (human)
mitotic G1/S transition checkpoint signalingSerine/threonine-protein kinase PLK3Homo sapiens (human)
regulation of cell divisionSerine/threonine-protein kinase PLK3Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein kinase PLK3Homo sapiens (human)
Golgi disassemblySerine/threonine-protein kinase PLK3Homo sapiens (human)
positive regulation of intracellular protein transportSerine/threonine-protein kinase PLK3Homo sapiens (human)
regulation of signal transduction by p53 class mediatorSerine/threonine-protein kinase PLK3Homo sapiens (human)
positive regulation of chaperone-mediated autophagySerine/threonine-protein kinase PLK3Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process involved in cellular response to hypoxiaSerine/threonine-protein kinase PLK3Homo sapiens (human)
mitotic spindle organizationSerine/threonine-protein kinase PLK3Homo sapiens (human)
dTTP catabolic processdCTP pyrophosphatase 1Homo sapiens (human)
dCTP catabolic processdCTP pyrophosphatase 1Homo sapiens (human)
nucleoside triphosphate catabolic processdCTP pyrophosphatase 1Homo sapiens (human)
DNA protectiondCTP pyrophosphatase 1Homo sapiens (human)
regulation of RNA splicingDual specificity protein kinase CLK4Homo sapiens (human)
peptidyl-tyrosine phosphorylationDual specificity protein kinase CLK4Homo sapiens (human)
regulation of translationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein phosphorylationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cell surface receptor signaling pathwayMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
hemopoiesisMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
intracellular signal transductionMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to arsenic-containing substanceMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein autophosphorylationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek6Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase Nek6Homo sapiens (human)
mitotic spindle organizationSerine/threonine-protein kinase Nek6Homo sapiens (human)
chromosome segregationSerine/threonine-protein kinase Nek6Homo sapiens (human)
mitotic nuclear membrane disassemblySerine/threonine-protein kinase Nek6Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase Nek6Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase Nek6Homo sapiens (human)
regulation of mitotic metaphase/anaphase transitionSerine/threonine-protein kinase Nek6Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase Nek6Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase Nek6Homo sapiens (human)
spindle assemblySerine/threonine-protein kinase Nek6Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Nek6Homo sapiens (human)
regulation of cellular senescenceSerine/threonine-protein kinase Nek6Homo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform gamma-1Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform gamma-1Homo sapiens (human)
signal transductionCasein kinase I isoform gamma-1Homo sapiens (human)
endocytosisCasein kinase I isoform gamma-1Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform gamma-1Homo sapiens (human)
regulation of DNA-templated transcriptionSerine/threonine-protein kinase PAK 6Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase PAK 6Homo sapiens (human)
cytoskeleton organizationSerine/threonine-protein kinase PAK 6Homo sapiens (human)
learningSerine/threonine-protein kinase PAK 6Homo sapiens (human)
memorySerine/threonine-protein kinase PAK 6Homo sapiens (human)
locomotory behaviorSerine/threonine-protein kinase PAK 6Homo sapiens (human)
neuron projection arborizationSerine/threonine-protein kinase PAK 6Homo sapiens (human)
neuron projection extensionSerine/threonine-protein kinase PAK 6Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase PAK 6Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 6Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase PAK 6Homo sapiens (human)
protein phosphorylationSNF-related serine/threonine-protein kinaseHomo sapiens (human)
myeloid cell differentiationSNF-related serine/threonine-protein kinaseHomo sapiens (human)
G1/S transition of mitotic cell cycleSerine/threonine-protein kinase LATS2Homo sapiens (human)
inner cell mass cell fate commitmentSerine/threonine-protein kinase LATS2Homo sapiens (human)
inner cell mass cellular morphogenesisSerine/threonine-protein kinase LATS2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase LATS2Homo sapiens (human)
protein localizationSerine/threonine-protein kinase LATS2Homo sapiens (human)
hormone-mediated signaling pathwaySerine/threonine-protein kinase LATS2Homo sapiens (human)
regulation of transforming growth factor beta receptor signaling pathwaySerine/threonine-protein kinase LATS2Homo sapiens (human)
keratinocyte differentiationSerine/threonine-protein kinase LATS2Homo sapiens (human)
hippo signalingSerine/threonine-protein kinase LATS2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase LATS2Homo sapiens (human)
negative regulation of cyclin-dependent protein serine/threonine kinase activitySerine/threonine-protein kinase LATS2Homo sapiens (human)
cell divisionSerine/threonine-protein kinase LATS2Homo sapiens (human)
canonical Wnt signaling pathwaySerine/threonine-protein kinase LATS2Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwaySerine/threonine-protein kinase LATS2Homo sapiens (human)
negative regulation of protein localization to nucleusSerine/threonine-protein kinase LATS2Homo sapiens (human)
regulation of organ growthSerine/threonine-protein kinase LATS2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase LATS2Homo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase LATS2Homo sapiens (human)
epithelial cilium movement involved in extracellular fluid movementSerine/threonine-protein kinase 36Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 36Homo sapiens (human)
smoothened signaling pathwaySerine/threonine-protein kinase 36Homo sapiens (human)
brain developmentSerine/threonine-protein kinase 36Homo sapiens (human)
post-embryonic developmentSerine/threonine-protein kinase 36Homo sapiens (human)
axoneme assemblySerine/threonine-protein kinase 36Homo sapiens (human)
positive regulation of smoothened signaling pathwaySerine/threonine-protein kinase 36Homo sapiens (human)
regulation of DNA-binding transcription factor activitySerine/threonine-protein kinase 36Homo sapiens (human)
cilium assemblySerine/threonine-protein kinase 36Homo sapiens (human)
translationPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
phenylalanyl-tRNA aminoacylationPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
protein heterotetramerizationPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
tRNA aminoacylation for protein translationIsoleucine--tRNA ligase, mitochondrialHomo sapiens (human)
aminoacyl-tRNA metabolism involved in translational fidelityIsoleucine--tRNA ligase, mitochondrialHomo sapiens (human)
isoleucyl-tRNA aminoacylationIsoleucine--tRNA ligase, mitochondrialHomo sapiens (human)
mitochondrial translationIsoleucine--tRNA ligase, mitochondrialHomo sapiens (human)
positive regulation of Notch signaling pathwayBMP-2-inducible protein kinaseHomo sapiens (human)
regulation of clathrin-dependent endocytosisBMP-2-inducible protein kinaseHomo sapiens (human)
regulation of bone mineralizationBMP-2-inducible protein kinaseHomo sapiens (human)
ATP metabolic processObg-like ATPase 1Homo sapiens (human)
ribosomal large subunit assemblyMidasinHomo sapiens (human)
ribosomal large subunit export from nucleusMidasinHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
toll-like receptor signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
neutrophil mediated immunityInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
JNK cascadeInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
toll-like receptor 4 signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
toll-like receptor 9 signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
interleukin-33-mediated signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
innate immune responseInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
positive regulation of smooth muscle cell proliferationInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
interleukin-1-mediated signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
neutrophil migrationInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
cytokine-mediated signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
Toll signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
cellular response to lipopolysaccharideInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
intracellular signal transductionInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 32BHomo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase 32BHomo sapiens (human)
positive regulation of programmed cell deathMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
GCN2-mediated signalingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
pyroptosisMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
DNA damage checkpoint signalingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
inflammatory responseMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cytoskeleton organizationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cell deathMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cell differentiationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
stress-activated protein kinase signaling cascadeMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
embryonic digit morphogenesisMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
positive regulation of apoptotic processMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
limb developmentMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cellular response to gamma radiationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cellular response to UV-BMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
positive regulation of mitotic DNA damage checkpointMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
regulation of mitotic metaphase/anaphase transitionMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
chromosome segregationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
transcription by RNA polymerase IICyclin-dependent kinase 12Homo sapiens (human)
mRNA processingCyclin-dependent kinase 12Homo sapiens (human)
RNA splicingCyclin-dependent kinase 12Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IICyclin-dependent kinase 12Homo sapiens (human)
regulation of MAP kinase activityCyclin-dependent kinase 12Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICyclin-dependent kinase 12Homo sapiens (human)
protein autophosphorylationCyclin-dependent kinase 12Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 12Homo sapiens (human)
negative regulation of stem cell differentiationCyclin-dependent kinase 12Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 12Homo sapiens (human)
G1/S transition of mitotic cell cycleSerine/threonine-protein kinase PLK2Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusSerine/threonine-protein kinase PLK2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PLK2Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestSerine/threonine-protein kinase PLK2Homo sapiens (human)
mitotic spindle organizationSerine/threonine-protein kinase PLK2Homo sapiens (human)
Ras protein signal transductionSerine/threonine-protein kinase PLK2Homo sapiens (human)
memorySerine/threonine-protein kinase PLK2Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase PLK2Homo sapiens (human)
negative regulation of angiogenesisSerine/threonine-protein kinase PLK2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase PLK2Homo sapiens (human)
Rap protein signal transductionSerine/threonine-protein kinase PLK2Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase PLK2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase PLK2Homo sapiens (human)
positive regulation of protein catabolic processSerine/threonine-protein kinase PLK2Homo sapiens (human)
regulation of centriole replicationSerine/threonine-protein kinase PLK2Homo sapiens (human)
regulation of synaptic plasticitySerine/threonine-protein kinase PLK2Homo sapiens (human)
long-term synaptic potentiationSerine/threonine-protein kinase PLK2Homo sapiens (human)
long-term synaptic depressionSerine/threonine-protein kinase PLK2Homo sapiens (human)
negative regulation of apoptotic process in bone marrow cellSerine/threonine-protein kinase PLK2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisSerine/threonine-protein kinase PLK2Homo sapiens (human)
negative regulation of cellular senescenceSerine/threonine-protein kinase PLK2Homo sapiens (human)
aerobic respirationNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
negative regulation of cell growthNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
mitochondrial respiratory chain complex I assemblyNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
cellular response to interferon-betaNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
proton motive force-driven mitochondrial ATP synthesisNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
protein insertion into mitochondrial inner membraneNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
positive regulation of protein catabolic processNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
negative regulation of DNA-templated transcriptionNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
cellular response to retinoic acidNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
reactive oxygen species metabolic processNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
apoptotic signaling pathwayNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
extrinsic apoptotic signaling pathwayNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
positive regulation of execution phase of apoptosisNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
positive regulation of gene expressionSerine/threonine-protein kinase MARK1Homo sapiens (human)
negative regulation of gene expressionSerine/threonine-protein kinase MARK1Homo sapiens (human)
microtubule cytoskeleton organizationSerine/threonine-protein kinase MARK1Homo sapiens (human)
neuron migrationSerine/threonine-protein kinase MARK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase MARK1Homo sapiens (human)
cytoskeleton organizationSerine/threonine-protein kinase MARK1Homo sapiens (human)
negative regulation of epithelial to mesenchymal transitionSerine/threonine-protein kinase MARK1Homo sapiens (human)
regulation of neuron projection developmentSerine/threonine-protein kinase MARK1Homo sapiens (human)
Wnt signaling pathwaySerine/threonine-protein kinase MARK1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase MARK1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase MARK1Homo sapiens (human)
regulation of dendrite developmentSerine/threonine-protein kinase MARK1Homo sapiens (human)
establishment of mitochondrion localizationSerine/threonine-protein kinase MARK1Homo sapiens (human)
G1/S transition of mitotic cell cycleSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase pim-2Homo sapiens (human)
negative regulation of cell population proliferationSerine/threonine-protein kinase pim-2Homo sapiens (human)
apoptotic mitochondrial changesSerine/threonine-protein kinase pim-2Homo sapiens (human)
response to virusSerine/threonine-protein kinase pim-2Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase pim-2Homo sapiens (human)
macroautophagySerine/threonine-protein kinase pim-2Homo sapiens (human)
positive regulation of macroautophagySerine/threonine-protein kinase pim-2Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase pim-2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase pim-2Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase pim-2Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase pim-2Homo sapiens (human)
regulation of cell growthSerine/threonine-protein kinase PAK 5Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase PAK 5Homo sapiens (human)
cytoskeleton organizationSerine/threonine-protein kinase PAK 5Homo sapiens (human)
signal transductionSerine/threonine-protein kinase PAK 5Homo sapiens (human)
learningSerine/threonine-protein kinase PAK 5Homo sapiens (human)
memorySerine/threonine-protein kinase PAK 5Homo sapiens (human)
locomotory behaviorSerine/threonine-protein kinase PAK 5Homo sapiens (human)
cell population proliferationSerine/threonine-protein kinase PAK 5Homo sapiens (human)
cell migrationSerine/threonine-protein kinase PAK 5Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwaySerine/threonine-protein kinase PAK 5Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase PAK 5Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase PAK 5Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 5Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 26Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase 26Homo sapiens (human)
cellular response to starvationSerine/threonine-protein kinase 26Homo sapiens (human)
microvillus assemblySerine/threonine-protein kinase 26Homo sapiens (human)
negative regulation of cell migrationSerine/threonine-protein kinase 26Homo sapiens (human)
cellular response to oxidative stressSerine/threonine-protein kinase 26Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 26Homo sapiens (human)
regulation of apoptotic processSerine/threonine-protein kinase 26Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 26Homo sapiens (human)
DNA damage checkpoint signalingeIF-2-alpha kinase GCN2Homo sapiens (human)
positive regulation of defense response to virus by hosteIF-2-alpha kinase GCN2Homo sapiens (human)
adaptive immune responseeIF-2-alpha kinase GCN2Homo sapiens (human)
T cell activation involved in immune responseeIF-2-alpha kinase GCN2Homo sapiens (human)
positive regulation of adaptive immune responseeIF-2-alpha kinase GCN2Homo sapiens (human)
regulation of translational initiationeIF-2-alpha kinase GCN2Homo sapiens (human)
protein phosphorylationeIF-2-alpha kinase GCN2Homo sapiens (human)
learningeIF-2-alpha kinase GCN2Homo sapiens (human)
long-term memoryeIF-2-alpha kinase GCN2Homo sapiens (human)
regulation of translational initiation by eIF2 alpha phosphorylationeIF-2-alpha kinase GCN2Homo sapiens (human)
viral translationeIF-2-alpha kinase GCN2Homo sapiens (human)
negative regulation of translational initiation in response to stresseIF-2-alpha kinase GCN2Homo sapiens (human)
negative regulation of CREB transcription factor activityeIF-2-alpha kinase GCN2Homo sapiens (human)
cellular response to amino acid starvationeIF-2-alpha kinase GCN2Homo sapiens (human)
cellular response to UVeIF-2-alpha kinase GCN2Homo sapiens (human)
eiF2alpha phosphorylation in response to endoplasmic reticulum stresseIF-2-alpha kinase GCN2Homo sapiens (human)
negative regulation by host of viral genome replicationeIF-2-alpha kinase GCN2Homo sapiens (human)
negative regulation of neuron differentiationeIF-2-alpha kinase GCN2Homo sapiens (human)
negative regulation of translational initiationeIF-2-alpha kinase GCN2Homo sapiens (human)
protein autophosphorylationeIF-2-alpha kinase GCN2Homo sapiens (human)
defense response to viruseIF-2-alpha kinase GCN2Homo sapiens (human)
regulation of feeding behavioreIF-2-alpha kinase GCN2Homo sapiens (human)
cellular response to coldeIF-2-alpha kinase GCN2Homo sapiens (human)
positive regulation of translational initiation in response to starvationeIF-2-alpha kinase GCN2Homo sapiens (human)
GCN2-mediated signalingeIF-2-alpha kinase GCN2Homo sapiens (human)
positive regulation of long-term synaptic potentiationeIF-2-alpha kinase GCN2Homo sapiens (human)
neuron projection extensioneIF-2-alpha kinase GCN2Homo sapiens (human)
negative regulation of cytoplasmic translational initiation in response to stresseIF-2-alpha kinase GCN2Homo sapiens (human)
tricarboxylic acid cycleSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
succinate metabolic processSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
succinyl-CoA pathwaySuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
succinyl-CoA catabolic processSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
succinyl-CoA metabolic processSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
MAPK cascadeSerine/threonine-protein kinase NLKHomo sapiens (human)
regulation of DNA-templated transcriptionSerine/threonine-protein kinase NLKHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase NLKHomo sapiens (human)
transforming growth factor beta receptor signaling pathwaySerine/threonine-protein kinase NLKHomo sapiens (human)
Wnt signaling pathway, calcium modulating pathwaySerine/threonine-protein kinase NLKHomo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase NLKHomo sapiens (human)
negative regulation of Wnt signaling pathwaySerine/threonine-protein kinase NLKHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase NLKHomo sapiens (human)
protein stabilizationSerine/threonine-protein kinase NLKHomo sapiens (human)
cellular response to osmotic stressSerine/threonine-protein kinase NLKHomo sapiens (human)
negative regulation of TORC1 signalingSerine/threonine-protein kinase NLKHomo sapiens (human)
positive regulation of receptor signaling pathway via STATSerine/threonine-protein kinase NLKHomo sapiens (human)
lysosome organizationPhosphatidylinositol 4-kinase betaHomo sapiens (human)
phosphatidylinositol biosynthetic processPhosphatidylinositol 4-kinase betaHomo sapiens (human)
receptor-mediated endocytosisPhosphatidylinositol 4-kinase betaHomo sapiens (human)
signal transductionPhosphatidylinositol 4-kinase betaHomo sapiens (human)
inner ear developmentPhosphatidylinositol 4-kinase betaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4-kinase betaHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4-kinase betaHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 17AHomo sapiens (human)
apoptotic processSerine/threonine-protein kinase 17AHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 17AHomo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase 17AHomo sapiens (human)
positive regulation of fibroblast apoptotic processSerine/threonine-protein kinase 17AHomo sapiens (human)
regulation of reactive oxygen species metabolic processSerine/threonine-protein kinase 17AHomo sapiens (human)
response to dietary excessSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
protein phosphorylationSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cell volume homeostasisSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
inflammatory responseSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
signal transductionSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
regulation of blood pressureSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
positive regulation of T cell chemotaxisSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
peptidyl-serine phosphorylationSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
peptidyl-threonine phosphorylationSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
intracellular chloride ion homeostasisSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
positive regulation of ion transmembrane transporter activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
intracellular signal transductionSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
sodium ion transmembrane transportSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cellular response to potassium ionSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
maintenance of lens transparencySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
chemokine (C-X-C motif) ligand 12 signaling pathwaySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
macrophage activationSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
positive regulation of potassium ion transportSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
protein autophosphorylationSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
regulation of inflammatory responseSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
renal sodium ion absorptionSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cellular hyperosmotic responseSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cellular hypotonic responseSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
negative regulation of pancreatic juice secretionSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
positive regulation of p38MAPK cascadeSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
negative regulation of potassium ion transmembrane transporter activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
negative regulation of potassium ion transmembrane transportSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
response to aldosteroneSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
negative regulation of creatine transmembrane transporter activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cellular response to chemokineSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
negative regulation of sodium ion transmembrane transporter activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
biological_processEphrin type-A receptor 6Homo sapiens (human)
axon guidanceEphrin type-A receptor 6Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 6Homo sapiens (human)
protein phosphorylationEphrin type-A receptor 6Homo sapiens (human)
glycogen metabolic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
regulation of glycolytic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
negative regulation of protein kinase activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
ATP biosynthetic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
sterol biosynthetic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
regulation of fatty acid metabolic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
intracellular signal transduction5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
positive regulation of protein kinase activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
regulation of fatty acid oxidation5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
regulation of glucose import5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
regulation of catalytic activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
activation of innate immune responseSerine/threonine-protein kinase TBK1Homo sapiens (human)
cytoplasmic pattern recognition receptor signaling pathwaySerine/threonine-protein kinase TBK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase TBK1Homo sapiens (human)
inflammatory responseSerine/threonine-protein kinase TBK1Homo sapiens (human)
canonical NF-kappaB signal transductionSerine/threonine-protein kinase TBK1Homo sapiens (human)
response to virusSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase TBK1Homo sapiens (human)
negative regulation of gene expressionSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of macroautophagySerine/threonine-protein kinase TBK1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase TBK1Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase TBK1Homo sapiens (human)
regulation of type I interferon productionSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of type I interferon productionSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of interferon-alpha productionSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of interferon-beta productionSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase TBK1Homo sapiens (human)
toll-like receptor 4 signaling pathwaySerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase TBK1Homo sapiens (human)
dendritic cell proliferationSerine/threonine-protein kinase TBK1Homo sapiens (human)
innate immune responseSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine/threonine-protein kinase TBK1Homo sapiens (human)
defense response to Gram-positive bacteriumSerine/threonine-protein kinase TBK1Homo sapiens (human)
defense response to virusSerine/threonine-protein kinase TBK1Homo sapiens (human)
type I interferon-mediated signaling pathwaySerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of type I interferon-mediated signaling pathwaySerine/threonine-protein kinase TBK1Homo sapiens (human)
antiviral innate immune responseSerine/threonine-protein kinase TBK1Homo sapiens (human)
cGAS/STING signaling pathwaySerine/threonine-protein kinase TBK1Homo sapiens (human)
negative regulation of TORC1 signalingSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of TORC1 signalingSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of xenophagySerine/threonine-protein kinase TBK1Homo sapiens (human)
macroautophagySerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of non-motile cilium assemblySeptin-9Homo sapiens (human)
protein localizationSeptin-9Homo sapiens (human)
cytoskeleton-dependent cytokinesisSeptin-9Homo sapiens (human)
protein phosphorylationDeath-associated protein kinase 2Homo sapiens (human)
apoptotic processDeath-associated protein kinase 2Homo sapiens (human)
regulation of autophagyDeath-associated protein kinase 2Homo sapiens (human)
intracellular signal transductionDeath-associated protein kinase 2Homo sapiens (human)
regulation of apoptotic processDeath-associated protein kinase 2Homo sapiens (human)
anoikisDeath-associated protein kinase 2Homo sapiens (human)
protein autophosphorylationDeath-associated protein kinase 2Homo sapiens (human)
positive regulation of neutrophil chemotaxisDeath-associated protein kinase 2Homo sapiens (human)
positive regulation of eosinophil chemotaxisDeath-associated protein kinase 2Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathwayDeath-associated protein kinase 2Homo sapiens (human)
positive regulation of apoptotic processDeath-associated protein kinase 2Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorRibosomal protein S6 kinase alpha-6Homo sapiens (human)
signal transductionRibosomal protein S6 kinase alpha-6Homo sapiens (human)
central nervous system developmentRibosomal protein S6 kinase alpha-6Homo sapiens (human)
negative regulation of embryonic developmentRibosomal protein S6 kinase alpha-6Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeRibosomal protein S6 kinase alpha-6Homo sapiens (human)
negative regulation of mesoderm developmentRibosomal protein S6 kinase alpha-6Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-6Homo sapiens (human)
positive regulation of protein phosphorylationTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein phosphorylationTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
cytoskeleton organizationTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
response to organonitrogen compoundTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
Wnt signaling pathwayTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
microvillus assemblyTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
actin cytoskeleton organizationTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
intracellular signal transductionTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
positive regulation of JNK cascadeTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein autophosphorylationTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
regulation of dendrite morphogenesisTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein localization to plasma membraneTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
neuron projection morphogenesisTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
regulation of MAPK cascadeTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
MAPK cascadeTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
chromatin organizationSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
intracellular protein transportSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
regulation of chromatin organizationSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
chromosome segregationSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
regulation of cell growthSerine/threonine-protein kinase TAO2Homo sapiens (human)
protein targeting to membraneSerine/threonine-protein kinase TAO2Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase TAO2Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase TAO2Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine/threonine-protein kinase TAO2Homo sapiens (human)
axonogenesisSerine/threonine-protein kinase TAO2Homo sapiens (human)
regulation of cell shapeSerine/threonine-protein kinase TAO2Homo sapiens (human)
cell migrationSerine/threonine-protein kinase TAO2Homo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase TAO2Homo sapiens (human)
positive regulation of protein autophosphorylationSerine/threonine-protein kinase TAO2Homo sapiens (human)
activation of protein kinase activitySerine/threonine-protein kinase TAO2Homo sapiens (human)
positive regulation of stress-activated MAPK cascadeSerine/threonine-protein kinase TAO2Homo sapiens (human)
regulation of actin cytoskeleton organizationSerine/threonine-protein kinase TAO2Homo sapiens (human)
positive regulation of MAPK cascadeSerine/threonine-protein kinase TAO2Homo sapiens (human)
positive regulation of JNK cascadeSerine/threonine-protein kinase TAO2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase TAO2Homo sapiens (human)
focal adhesion assemblySerine/threonine-protein kinase TAO2Homo sapiens (human)
stress-activated MAPK cascadeSerine/threonine-protein kinase TAO2Homo sapiens (human)
basal dendrite morphogenesisSerine/threonine-protein kinase TAO2Homo sapiens (human)
basal dendrite arborizationSerine/threonine-protein kinase TAO2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase TAO2Homo sapiens (human)
long-chain fatty acid metabolic processLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
long-chain fatty-acyl-CoA biosynthetic processLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
positive regulation of long-chain fatty acid import across plasma membraneLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
protein autophosphorylationALK tyrosine kinase receptorHomo sapiens (human)
signal transductionALK tyrosine kinase receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayALK tyrosine kinase receptorHomo sapiens (human)
phosphorylationALK tyrosine kinase receptorHomo sapiens (human)
hippocampus developmentALK tyrosine kinase receptorHomo sapiens (human)
adult behaviorALK tyrosine kinase receptorHomo sapiens (human)
swimming behaviorALK tyrosine kinase receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationALK tyrosine kinase receptorHomo sapiens (human)
regulation of apoptotic processALK tyrosine kinase receptorHomo sapiens (human)
protein autophosphorylationALK tyrosine kinase receptorHomo sapiens (human)
neuron developmentALK tyrosine kinase receptorHomo sapiens (human)
negative regulation of lipid catabolic processALK tyrosine kinase receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityALK tyrosine kinase receptorHomo sapiens (human)
regulation of dopamine receptor signaling pathwayALK tyrosine kinase receptorHomo sapiens (human)
response to environmental enrichmentALK tyrosine kinase receptorHomo sapiens (human)
energy homeostasisALK tyrosine kinase receptorHomo sapiens (human)
positive regulation of dendrite developmentALK tyrosine kinase receptorHomo sapiens (human)
regulation of neuron differentiationALK tyrosine kinase receptorHomo sapiens (human)
regulation of cell population proliferationALK tyrosine kinase receptorHomo sapiens (human)
multicellular organism developmentALK tyrosine kinase receptorHomo sapiens (human)
positive regulation of kinase activityALK tyrosine kinase receptorHomo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
skeletal muscle tissue developmentSRSF protein kinase 3Homo sapiens (human)
cell differentiationSRSF protein kinase 3Homo sapiens (human)
muscle tissue developmentSRSF protein kinase 3Homo sapiens (human)
peptidyl-serine phosphorylationSRSF protein kinase 3Homo sapiens (human)
spliceosomal complex assemblySRSF protein kinase 3Homo sapiens (human)
intracellular signal transductionSRSF protein kinase 3Homo sapiens (human)
regulation of mRNA processingSRSF protein kinase 3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase ICKHomo sapiens (human)
signal transductionSerine/threonine-protein kinase ICKHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase ICKHomo sapiens (human)
intraciliary anterograde transportSerine/threonine-protein kinase ICKHomo sapiens (human)
intraciliary retrograde transportSerine/threonine-protein kinase ICKHomo sapiens (human)
intraciliary transportSerine/threonine-protein kinase ICKHomo sapiens (human)
cilium assemblySerine/threonine-protein kinase ICKHomo sapiens (human)
mitotic cell cycleCyclin-dependent kinase 11AHomo sapiens (human)
regulation of cell growthCyclin-dependent kinase 11AHomo sapiens (human)
regulation of DNA-templated transcriptionCyclin-dependent kinase 11AHomo sapiens (human)
protein phosphorylationCyclin-dependent kinase 11AHomo sapiens (human)
apoptotic processCyclin-dependent kinase 11AHomo sapiens (human)
regulation of mRNA processingCyclin-dependent kinase 11AHomo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 11AHomo sapiens (human)
protein phosphorylationAurora kinase CHomo sapiens (human)
attachment of spindle microtubules to kinetochoreAurora kinase CHomo sapiens (human)
positive regulation of cytokinesisAurora kinase CHomo sapiens (human)
mitotic spindle midzone assemblyAurora kinase CHomo sapiens (human)
cell divisionAurora kinase CHomo sapiens (human)
meiotic cell cycleAurora kinase CHomo sapiens (human)
regulation of cytokinesisAurora kinase CHomo sapiens (human)
mitotic spindle organizationAurora kinase CHomo sapiens (human)
G1/S transition of mitotic cell cycleCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
response to ischemiaCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
protein phosphorylationCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
calcium ion transportCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
cellular response to interferon-betaCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
angiotensin-activated signaling pathwayCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
protein autophosphorylationCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
regulation of neurotransmitter secretionCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
regulation of neuronal synaptic plasticityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
negative regulation of hydrolase activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
positive regulation of calcium ion transportCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
dendritic spine developmentCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
cellular response to type II interferonCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
peptidyl-threonine autophosphorylationCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
regulation of endocannabinoid signaling pathwayCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
regulation of neuron migrationCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
mitochondrial genome maintenanceRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of endothelial cell proliferationRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
protein phosphorylationRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
signal transductionRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of TOR signalingRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of angiogenesisRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cell sizeRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
brain morphogenesisRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
homeostasis of number of cells within a tissueRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of vascular endothelial cell proliferationRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of artery morphogenesisRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of cellular senescenceRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
intracellular signal transductionRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
peptidyl-serine phosphorylationRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 38-likeHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 38-likeHomo sapiens (human)
negative regulation of autophagySerine/threonine-protein kinase 38-likeHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 38-likeHomo sapiens (human)
regulation of cellular component organizationSerine/threonine-protein kinase 38-likeHomo sapiens (human)
postsynapse organizationSerine/threonine-protein kinase 38-likeHomo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase 38-likeHomo sapiens (human)
protein phosphorylationMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
cytoskeleton organizationMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
brain developmentMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
intracellular signal transductionMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase SIK3Homo sapiens (human)
positive regulation of TORC1 signalingSerine/threonine-protein kinase SIK3Homo sapiens (human)
positive regulation of TORC2 signalingSerine/threonine-protein kinase SIK3Homo sapiens (human)
microtubule cytoskeleton organizationSerine/threonine-protein kinase SIK3Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase SIK3Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
cellular response to mechanical stimulusMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIThyroid hormone receptor-associated protein 3Homo sapiens (human)
regulation of alternative mRNA splicing, via spliceosomeThyroid hormone receptor-associated protein 3Homo sapiens (human)
nuclear-transcribed mRNA catabolic processThyroid hormone receptor-associated protein 3Homo sapiens (human)
mRNA processingThyroid hormone receptor-associated protein 3Homo sapiens (human)
circadian rhythmThyroid hormone receptor-associated protein 3Homo sapiens (human)
RNA splicingThyroid hormone receptor-associated protein 3Homo sapiens (human)
positive regulation of circadian rhythmThyroid hormone receptor-associated protein 3Homo sapiens (human)
positive regulation of DNA-templated transcriptionThyroid hormone receptor-associated protein 3Homo sapiens (human)
positive regulation of mRNA splicing, via spliceosomeThyroid hormone receptor-associated protein 3Homo sapiens (human)
mRNA stabilizationThyroid hormone receptor-associated protein 3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIThyroid hormone receptor-associated protein 3Homo sapiens (human)
DNA repairDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
myoblast fusionDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
adipose tissue developmentDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
peptidyl-serine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
peptidyl-threonine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
regulation of T cell mediated cytotoxicityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
regulation of adaptive immune responseReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of phosphatase activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
activation of protein kinase activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
regulation of type II interferon productionReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
T cell differentiation in thymusReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein modification processReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
non-canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
regulation of apoptotic processReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
T cell homeostasisReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of DNA-templated transcriptionReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
regulation of activated T cell proliferationReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein autophosphorylationReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
lymph node developmentReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
spleen developmentReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
thymus developmentReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
defense response to virusReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of necroptotic processReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
regulation of activation-induced cell death of T cellsReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
necroptotic processReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
cellular response to hydrogen peroxideReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
reactive oxygen species metabolic processReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
apoptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
programmed necrotic cell deathReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
necroptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
execution phase of necroptosisReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
amyloid fibril formationReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
regulation of CD8-positive, alpha-beta cytotoxic T cell extravasationReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
signal transductionReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
cytoskeleton organizationSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
establishment or maintenance of cell polaritySerine/threonine-protein kinase MRCK betaHomo sapiens (human)
signal transductionSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
cell migrationSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
actomyosin structure organizationSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
positive regulation of cytokine productionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of cytokine-mediated signaling pathwayInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein phosphorylationInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
response to virusInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
positive regulation of macrophage tolerance inductionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of macrophage cytokine productionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
cytokine-mediated signaling pathwayInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
response to peptidoglycanInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
response to lipopolysaccharideInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of interleukin-12 productionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of interleukin-6 productionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of tumor necrosis factor productionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of toll-like receptor signaling pathwayInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of protein catabolic processInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of protein-containing complex disassemblyInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
regulation of protein-containing complex disassemblyInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
response to exogenous dsRNAInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of MAP kinase activityInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of innate immune responseInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
interleukin-1-mediated signaling pathwayInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
response to interleukin-1Interleukin-1 receptor-associated kinase 3Homo sapiens (human)
Toll signaling pathwayInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
cellular response to lipopolysaccharideInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
intracellular signal transductionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 24Homo sapiens (human)
signal transductionSerine/threonine-protein kinase 24Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressSerine/threonine-protein kinase 24Homo sapiens (human)
cellular response to starvationSerine/threonine-protein kinase 24Homo sapiens (human)
negative regulation of cell migrationSerine/threonine-protein kinase 24Homo sapiens (human)
cellular response to oxidative stressSerine/threonine-protein kinase 24Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 24Homo sapiens (human)
regulation of axon regenerationSerine/threonine-protein kinase 24Homo sapiens (human)
positive regulation of axon regenerationSerine/threonine-protein kinase 24Homo sapiens (human)
execution phase of apoptosisSerine/threonine-protein kinase 24Homo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform gamma-3Homo sapiens (human)
protein modification processCasein kinase I isoform gamma-3Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform gamma-3Homo sapiens (human)
signal transductionCasein kinase I isoform gamma-3Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform gamma-3Homo sapiens (human)
endocytosisCasein kinase I isoform gamma-3Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
placenta developmentMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
response to UV-CMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
regulation of gene expressionMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
male germ-line sex determinationMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
positive regulation of telomerase activityMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
chorionic trophoblast cell differentiationMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
positive regulation of p38MAPK cascadeMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
positive regulation of telomere cappingMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (626)

Processvia Protein(s)Taxonomy
protein serine/threonine kinase activityBone morphogenetic protein receptor type-1BHomo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityBone morphogenetic protein receptor type-1BHomo sapiens (human)
transmembrane signaling receptor activityBone morphogenetic protein receptor type-1BHomo sapiens (human)
protein bindingBone morphogenetic protein receptor type-1BHomo sapiens (human)
ATP bindingBone morphogenetic protein receptor type-1BHomo sapiens (human)
BMP bindingBone morphogenetic protein receptor type-1BHomo sapiens (human)
SMAD bindingBone morphogenetic protein receptor type-1BHomo sapiens (human)
metal ion bindingBone morphogenetic protein receptor type-1BHomo sapiens (human)
BMP receptor activityBone morphogenetic protein receptor type-1BHomo sapiens (human)
transforming growth factor beta receptor activity, type IBone morphogenetic protein receptor type-1BHomo sapiens (human)
protein kinase activityCell division cycle 7-related protein kinaseHomo sapiens (human)
protein bindingCell division cycle 7-related protein kinaseHomo sapiens (human)
ATP bindingCell division cycle 7-related protein kinaseHomo sapiens (human)
kinase activityCell division cycle 7-related protein kinaseHomo sapiens (human)
metal ion bindingCell division cycle 7-related protein kinaseHomo sapiens (human)
protein serine kinase activityCell division cycle 7-related protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityCell division cycle 7-related protein kinaseHomo sapiens (human)
protein bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
ATP bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
1-phosphatidylinositol-3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PLK4Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PLK4Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PLK4Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase PLK4Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PLK4Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase 25Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 25Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 25Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase 25Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase 25Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 25Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 25Homo sapiens (human)
DNA bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
DNA helicase activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
RNA bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
RNA helicase activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
mRNA bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
GTPase activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
protein bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
ATP bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
transcription factor bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
poly(A) bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
eukaryotic initiation factor 4E bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
ATP hydrolysis activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
ribonucleoside triphosphate phosphatase activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
translation initiation factor bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
RNA strand annealing activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
signaling adaptor activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
RNA stem-loop bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
gamma-tubulin bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
ribosomal small subunit bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
CTPase activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
protein serine/threonine kinase activator activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
cadherin bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
mRNA 5'-UTR bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
protein bindingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
ATP bindingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
1-phosphatidylinositol-3-kinase activityPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activityPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
phosphatidylinositol bindingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
magnesium ion bindingPyridoxal kinaseHomo sapiens (human)
ATP bindingPyridoxal kinaseHomo sapiens (human)
zinc ion bindingPyridoxal kinaseHomo sapiens (human)
pyridoxal kinase activityPyridoxal kinaseHomo sapiens (human)
pyridoxal phosphate bindingPyridoxal kinaseHomo sapiens (human)
potassium ion bindingPyridoxal kinaseHomo sapiens (human)
sodium ion bindingPyridoxal kinaseHomo sapiens (human)
lithium ion bindingPyridoxal kinaseHomo sapiens (human)
protein homodimerization activityPyridoxal kinaseHomo sapiens (human)
transcription coactivator bindingCitron Rho-interacting kinaseHomo sapiens (human)
protein serine/threonine kinase activityCitron Rho-interacting kinaseHomo sapiens (human)
protein bindingCitron Rho-interacting kinaseHomo sapiens (human)
ATP bindingCitron Rho-interacting kinaseHomo sapiens (human)
SH3 domain bindingCitron Rho-interacting kinaseHomo sapiens (human)
protein kinase bindingCitron Rho-interacting kinaseHomo sapiens (human)
PDZ domain bindingCitron Rho-interacting kinaseHomo sapiens (human)
protein serine/threonine kinase inhibitor activityCitron Rho-interacting kinaseHomo sapiens (human)
metal ion bindingCitron Rho-interacting kinaseHomo sapiens (human)
scaffold protein bindingCitron Rho-interacting kinaseHomo sapiens (human)
protein serine kinase activityCitron Rho-interacting kinaseHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase RIO3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase RIO3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase RIO3Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase RIO3Homo sapiens (human)
caspase bindingSerine/threonine-protein kinase RIO3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase RIO3Homo sapiens (human)
magnesium ion bindingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
MAP kinase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
JUN kinase kinase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
enzyme bindingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
protein kinase bindingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
protein phosphatase bindingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
molecular function activator activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase Chk1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Chk1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Chk1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Chk1Homo sapiens (human)
protein domain specific bindingSerine/threonine-protein kinase Chk1Homo sapiens (human)
histone H3T11 kinase activitySerine/threonine-protein kinase Chk1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Chk1Homo sapiens (human)
protein kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein serine/threonine kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
ATP bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
IkappaB kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein kinase bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
identical protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein homodimerization activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein heterodimerization activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
scaffold protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein serine kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
transferrin receptor bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
guanylate kinase activityPeripheral plasma membrane protein CASKHomo sapiens (human)
protein serine/threonine kinase activityPeripheral plasma membrane protein CASKHomo sapiens (human)
protein bindingPeripheral plasma membrane protein CASKHomo sapiens (human)
calmodulin bindingPeripheral plasma membrane protein CASKHomo sapiens (human)
ATP bindingPeripheral plasma membrane protein CASKHomo sapiens (human)
neurexin family protein bindingPeripheral plasma membrane protein CASKHomo sapiens (human)
protein serine kinase activityPeripheral plasma membrane protein CASKHomo sapiens (human)
signaling receptor bindingPeripheral plasma membrane protein CASKHomo sapiens (human)
protein kinase activityAurora kinase AHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase AHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase AHomo sapiens (human)
protein bindingAurora kinase AHomo sapiens (human)
ATP bindingAurora kinase AHomo sapiens (human)
protein kinase bindingAurora kinase AHomo sapiens (human)
ubiquitin protein ligase bindingAurora kinase AHomo sapiens (human)
histone H3S10 kinase activityAurora kinase AHomo sapiens (human)
protein heterodimerization activityAurora kinase AHomo sapiens (human)
protein serine kinase activityAurora kinase AHomo sapiens (human)
molecular function activator activityAurora kinase AHomo sapiens (human)
protein serine/threonine kinase activityCyclin-G-associated kinaseHomo sapiens (human)
protein bindingCyclin-G-associated kinaseHomo sapiens (human)
ATP bindingCyclin-G-associated kinaseHomo sapiens (human)
cyclin bindingCyclin-G-associated kinaseHomo sapiens (human)
protein-folding chaperone bindingCyclin-G-associated kinaseHomo sapiens (human)
protein serine kinase activityCyclin-G-associated kinaseHomo sapiens (human)
clathrin bindingCyclin-G-associated kinaseHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase DCLK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase DCLK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase DCLK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase DCLK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase DCLK1Homo sapiens (human)
protein kinase activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein serine/threonine kinase activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein bindingInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
ATP bindingInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
IkappaB kinase activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein homodimerization activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein-containing complex bindingInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein heterodimerization activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
scaffold protein bindingInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
transferrin receptor bindingInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein tyrosine kinase activityMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
protein bindingMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
ATP bindingMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
metal ion bindingMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
Wnt-protein bindingMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
ephrin receptor activityEphrin type-B receptor 6Homo sapiens (human)
protein bindingEphrin type-B receptor 6Homo sapiens (human)
ATP bindingEphrin type-B receptor 6Homo sapiens (human)
signaling receptor activityEphrin type-B receptor 6Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-B receptor 6Homo sapiens (human)
FAD bindingPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
flavin adenine dinucleotide bindingPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
pristanoyl-CoA oxidase activityPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
fatty acid bindingPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 13Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 13Homo sapiens (human)
protein bindingMitogen-activated protein kinase 13Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 13Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 13Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein serine/threonine kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
3-phosphoinositide-dependent protein kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein binding3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
ATP binding3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
phospholipase activator activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
phospholipase binding3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein serine kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
enzyme bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein serine/threonine kinase activator activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
metal ion bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
IkappaB kinase complex bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein serine/threonine kinase activityDeath-associated protein kinase 3Homo sapiens (human)
protein bindingDeath-associated protein kinase 3Homo sapiens (human)
ATP bindingDeath-associated protein kinase 3Homo sapiens (human)
cAMP response element binding protein bindingDeath-associated protein kinase 3Homo sapiens (human)
small GTPase bindingDeath-associated protein kinase 3Homo sapiens (human)
identical protein bindingDeath-associated protein kinase 3Homo sapiens (human)
protein homodimerization activityDeath-associated protein kinase 3Homo sapiens (human)
leucine zipper domain bindingDeath-associated protein kinase 3Homo sapiens (human)
protein serine kinase activityDeath-associated protein kinase 3Homo sapiens (human)
magnesium ion bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
transcription coactivator bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
type II transforming growth factor beta receptor bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
MAP kinase kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
receptor tyrosine kinase bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
ubiquitin protein ligase bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
histone kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
scaffold protein bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
protein serine/threonine kinase bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
DNA-binding transcription factor bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
linear polyubiquitin bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
protein serine/threonine kinase activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
signaling receptor bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
ATP bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
LIM domain bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
signaling adaptor activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
identical protein bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein homodimerization activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
CARD domain bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
caspase bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein serine kinase activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
JUN kinase kinase kinase activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein kinase activityMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
protein serine/threonine kinase activityMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
protein bindingMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
ATP bindingMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
protein serine kinase activityMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
histone H2A kinase activityMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
p53 bindingNUAK family SNF1-like kinase 1Homo sapiens (human)
protein serine/threonine kinase activityNUAK family SNF1-like kinase 1Homo sapiens (human)
protein bindingNUAK family SNF1-like kinase 1Homo sapiens (human)
ATP bindingNUAK family SNF1-like kinase 1Homo sapiens (human)
metal ion bindingNUAK family SNF1-like kinase 1Homo sapiens (human)
protein serine kinase activityNUAK family SNF1-like kinase 1Homo sapiens (human)
magnesium ion bindingDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
GTPase activityDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
protein bindingDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
GTP bindingDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
phosphatidic acid bindingDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
GTPase-dependent fusogenic activityDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
membrane bending activityDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
cardiolipin bindingDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
microtubule bindingDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
protein bindingPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
ATP bindingPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 5-kinase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
phosphatidylinositol kinase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
protein kinase activityTyrosine-protein kinase JAK2Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase JAK2Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase JAK2Homo sapiens (human)
signaling receptor bindingTyrosine-protein kinase JAK2Homo sapiens (human)
growth hormone receptor bindingTyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-12 receptor bindingTyrosine-protein kinase JAK2Homo sapiens (human)
protein bindingTyrosine-protein kinase JAK2Homo sapiens (human)
ATP bindingTyrosine-protein kinase JAK2Homo sapiens (human)
protein kinase bindingTyrosine-protein kinase JAK2Homo sapiens (human)
heme bindingTyrosine-protein kinase JAK2Homo sapiens (human)
type 1 angiotensin receptor bindingTyrosine-protein kinase JAK2Homo sapiens (human)
acetylcholine receptor bindingTyrosine-protein kinase JAK2Homo sapiens (human)
histone H3Y41 kinase activityTyrosine-protein kinase JAK2Homo sapiens (human)
SH2 domain bindingTyrosine-protein kinase JAK2Homo sapiens (human)
histone bindingTyrosine-protein kinase JAK2Homo sapiens (human)
identical protein bindingTyrosine-protein kinase JAK2Homo sapiens (human)
phosphatidylinositol 3-kinase bindingTyrosine-protein kinase JAK2Homo sapiens (human)
insulin receptor substrate bindingTyrosine-protein kinase JAK2Homo sapiens (human)
metal ion bindingTyrosine-protein kinase JAK2Homo sapiens (human)
peptide hormone receptor bindingTyrosine-protein kinase JAK2Homo sapiens (human)
protease bindingRho-associated protein kinase 2Homo sapiens (human)
RNA bindingRho-associated protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityRho-associated protein kinase 2Homo sapiens (human)
structural molecule activityRho-associated protein kinase 2Homo sapiens (human)
protein bindingRho-associated protein kinase 2Homo sapiens (human)
ATP bindingRho-associated protein kinase 2Homo sapiens (human)
small GTPase bindingRho-associated protein kinase 2Homo sapiens (human)
metal ion bindingRho-associated protein kinase 2Homo sapiens (human)
tau protein bindingRho-associated protein kinase 2Homo sapiens (human)
tau-protein kinase activityRho-associated protein kinase 2Homo sapiens (human)
endopeptidase activator activityRho-associated protein kinase 2Homo sapiens (human)
Rho-dependent protein serine/threonine kinase activityRho-associated protein kinase 2Homo sapiens (human)
protein serine kinase activityRho-associated protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase ULK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
protein-containing complex bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
GTPase bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase ULK1Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
RNA endonuclease activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
platelet-derived growth factor receptor bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
enzyme bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
Hsp70 protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
ADP bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
Hsp90 protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
unfolded protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein tyrosine kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-5Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-5Homo sapiens (human)
histone H3S10 kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
histone H3S28 kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
histone H2AS1 kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
RNA bindingU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
RNA helicase activityU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
helicase activityU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
protein bindingU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
ATP bindingU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
ATP hydrolysis activityU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
identical protein bindingU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-4Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
ribosomal protein S6 kinase activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-4Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-4Homo sapiens (human)
histone H3S10 kinase activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
histone H3S28 kinase activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingSerine/threonine-protein kinase 16Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activitySerine/threonine-protein kinase 16Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 16Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 16Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 16Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 16Homo sapiens (human)
ATP bindingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
1-phosphatidylinositol-3-kinase activityPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activityPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
phosphatidylinositol bindingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
phosphatidylinositol kinase activityPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PAK 3Homo sapiens (human)
MAP kinase kinase activitySerine/threonine-protein kinase PAK 3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PAK 3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PAK 3Homo sapiens (human)
SH3 domain bindingSerine/threonine-protein kinase PAK 3Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase PAK 3Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase PAK 3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PAK 3Homo sapiens (human)
protein kinase activityCyclin-dependent kinase-like 5Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase-like 5Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase-like 5Homo sapiens (human)
protein bindingCyclin-dependent kinase-like 5Homo sapiens (human)
ATP bindingCyclin-dependent kinase-like 5Homo sapiens (human)
kinase activityCyclin-dependent kinase-like 5Homo sapiens (human)
small GTPase bindingCyclin-dependent kinase-like 5Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase-like 5Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase 17BHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 17BHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase 17BHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 17BHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 10Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 10Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 10Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase 10Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase 10Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 10Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activitySerine/threonine-protein kinase D3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase D3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase D3Homo sapiens (human)
kinase activitySerine/threonine-protein kinase D3Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase D3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase D3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase D3Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 14Homo sapiens (human)
protein bindingCyclin-dependent kinase 14Homo sapiens (human)
ATP bindingCyclin-dependent kinase 14Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 14Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 14Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
single-stranded DNA bindingStructural maintenance of chromosomes protein 2Homo sapiens (human)
protein bindingStructural maintenance of chromosomes protein 2Homo sapiens (human)
ATP bindingStructural maintenance of chromosomes protein 2Homo sapiens (human)
ATP hydrolysis activityStructural maintenance of chromosomes protein 2Homo sapiens (human)
chromatin bindingStructural maintenance of chromosomes protein 2Homo sapiens (human)
magnesium ion bindingMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase OSR1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase OSR1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase OSR1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase OSR1Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase OSR1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase OSR1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase OSR1Homo sapiens (human)
creatine kinase activityMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
microtubule bindingMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
MAP kinase kinase kinase kinase activityMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase LATS1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase LATS1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase LATS1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase LATS1Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase LATS1Homo sapiens (human)
nuclear estrogen receptor bindingSerine/threonine-protein kinase LATS1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase LATS1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase PAK 4Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PAK 4Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PAK 4Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cadherin binding involved in cell-cell adhesionSerine/threonine-protein kinase PAK 4Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PAK 4Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Chk2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Chk2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase Chk2Homo sapiens (human)
ubiquitin protein ligase bindingSerine/threonine-protein kinase Chk2Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase Chk2Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Chk2Homo sapiens (human)
supercoiled DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
magnesium ion bindingTyrosine-protein kinase ABL1Homo sapiens (human)
four-way junction DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
bubble DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase ABL1Homo sapiens (human)
DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
transcription coactivator activityTyrosine-protein kinase ABL1Homo sapiens (human)
actin monomer bindingTyrosine-protein kinase ABL1Homo sapiens (human)
nicotinate-nucleotide adenylyltransferase activityTyrosine-protein kinase ABL1Homo sapiens (human)
protein kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
protein kinase C bindingTyrosine-protein kinase ABL1Homo sapiens (human)
protein bindingTyrosine-protein kinase ABL1Homo sapiens (human)
ATP bindingTyrosine-protein kinase ABL1Homo sapiens (human)
kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
SH3 domain bindingTyrosine-protein kinase ABL1Homo sapiens (human)
syntaxin bindingTyrosine-protein kinase ABL1Homo sapiens (human)
manganese ion bindingTyrosine-protein kinase ABL1Homo sapiens (human)
neuropilin bindingTyrosine-protein kinase ABL1Homo sapiens (human)
SH2 domain bindingTyrosine-protein kinase ABL1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein kinase ABL1Homo sapiens (human)
actin filament bindingTyrosine-protein kinase ABL1Homo sapiens (human)
mitogen-activated protein kinase bindingTyrosine-protein kinase ABL1Homo sapiens (human)
proline-rich region bindingTyrosine-protein kinase ABL1Homo sapiens (human)
delta-catenin bindingTyrosine-protein kinase ABL1Homo sapiens (human)
sequence-specific double-stranded DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
virus receptor activityEpidermal growth factor receptorHomo sapiens (human)
chromatin bindingEpidermal growth factor receptorHomo sapiens (human)
double-stranded DNA bindingEpidermal growth factor receptorHomo sapiens (human)
MAP kinase kinase kinase activityEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane signaling receptor activityEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
integrin bindingEpidermal growth factor receptorHomo sapiens (human)
protein bindingEpidermal growth factor receptorHomo sapiens (human)
calmodulin bindingEpidermal growth factor receptorHomo sapiens (human)
ATP bindingEpidermal growth factor receptorHomo sapiens (human)
enzyme bindingEpidermal growth factor receptorHomo sapiens (human)
kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein phosphatase bindingEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
ubiquitin protein ligase bindingEpidermal growth factor receptorHomo sapiens (human)
identical protein bindingEpidermal growth factor receptorHomo sapiens (human)
cadherin bindingEpidermal growth factor receptorHomo sapiens (human)
actin filament bindingEpidermal growth factor receptorHomo sapiens (human)
ATPase bindingEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor bindingEpidermal growth factor receptorHomo sapiens (human)
small GTPase bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
protein kinase activityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
protein bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
enzyme bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
identical protein bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
metal ion bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
protein serine kinase activityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
MAP kinase kinase kinase activityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
growth factor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
RNA polymerase I core bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
transmembrane signaling receptor activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
signaling receptor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ATP bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
coreceptor activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
receptor tyrosine kinase bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
identical protein bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ErbB-3 class receptor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein heterodimerization activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein tyrosine kinase activityHigh affinity nerve growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityHigh affinity nerve growth factor receptorHomo sapiens (human)
GPI-linked ephrin receptor activityHigh affinity nerve growth factor receptorHomo sapiens (human)
neurotrophin p75 receptor bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
protein bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
ATP bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
nerve growth factor receptor activityHigh affinity nerve growth factor receptorHomo sapiens (human)
kinase bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
identical protein bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
protein homodimerization activityHigh affinity nerve growth factor receptorHomo sapiens (human)
nerve growth factor bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
neurotrophin bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
neurotrophin receptor activityHigh affinity nerve growth factor receptorHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
GTP bindingGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
metal ion bindingGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
G-protein beta/gamma-subunit complex bindingGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
G protein-coupled receptor bindingGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
GTPase activityGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
adenine nucleotide transmembrane transporter activityADP/ATP translocase 2Homo sapiens (human)
RNA bindingADP/ATP translocase 2Homo sapiens (human)
ATP:ADP antiporter activityADP/ATP translocase 2Homo sapiens (human)
protein bindingADP/ATP translocase 2Homo sapiens (human)
proton transmembrane transporter activityADP/ATP translocase 2Homo sapiens (human)
adenine transmembrane transporter activityADP/ATP translocase 2Homo sapiens (human)
oxidative phosphorylation uncoupler activityADP/ATP translocase 2Homo sapiens (human)
ubiquitin protein ligase bindingADP/ATP translocase 2Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 2E1Homo sapiens (human)
iron ion bindingCytochrome P450 2E1Homo sapiens (human)
oxidoreductase activityCytochrome P450 2E1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 2E1Homo sapiens (human)
4-nitrophenol 2-monooxygenase activityCytochrome P450 2E1Homo sapiens (human)
oxygen bindingCytochrome P450 2E1Homo sapiens (human)
enzyme bindingCytochrome P450 2E1Homo sapiens (human)
heme bindingCytochrome P450 2E1Homo sapiens (human)
Hsp70 protein bindingCytochrome P450 2E1Homo sapiens (human)
Hsp90 protein bindingCytochrome P450 2E1Homo sapiens (human)
aromatase activityCytochrome P450 2E1Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2E1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2E1Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2E1Homo sapiens (human)
chromatin bindingProtein kinase C beta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C beta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C beta typeHomo sapiens (human)
protein kinase C bindingProtein kinase C beta typeHomo sapiens (human)
calcium channel regulator activityProtein kinase C beta typeHomo sapiens (human)
protein bindingProtein kinase C beta typeHomo sapiens (human)
ATP bindingProtein kinase C beta typeHomo sapiens (human)
zinc ion bindingProtein kinase C beta typeHomo sapiens (human)
nuclear receptor coactivator activityProtein kinase C beta typeHomo sapiens (human)
histone H3T6 kinase activityProtein kinase C beta typeHomo sapiens (human)
histone bindingProtein kinase C beta typeHomo sapiens (human)
nuclear androgen receptor bindingProtein kinase C beta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C beta typeHomo sapiens (human)
amyloid-beta bindingInsulin receptorHomo sapiens (human)
protein tyrosine kinase activityInsulin receptorHomo sapiens (human)
insulin receptor activityInsulin receptorHomo sapiens (human)
insulin-like growth factor receptor bindingInsulin receptorHomo sapiens (human)
protein bindingInsulin receptorHomo sapiens (human)
ATP bindingInsulin receptorHomo sapiens (human)
GTP bindingInsulin receptorHomo sapiens (human)
protein domain specific bindingInsulin receptorHomo sapiens (human)
insulin-like growth factor I bindingInsulin receptorHomo sapiens (human)
insulin-like growth factor II bindingInsulin receptorHomo sapiens (human)
cargo receptor activityInsulin receptorHomo sapiens (human)
phosphatidylinositol 3-kinase bindingInsulin receptorHomo sapiens (human)
insulin bindingInsulin receptorHomo sapiens (human)
insulin receptor substrate bindingInsulin receptorHomo sapiens (human)
protein-containing complex bindingInsulin receptorHomo sapiens (human)
PTB domain bindingInsulin receptorHomo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase LckHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase LckHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase LckHomo sapiens (human)
protein serine/threonine phosphatase activityTyrosine-protein kinase LckHomo sapiens (human)
protein bindingTyrosine-protein kinase LckHomo sapiens (human)
ATP bindingTyrosine-protein kinase LckHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase LckHomo sapiens (human)
protein kinase bindingTyrosine-protein kinase LckHomo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase LckHomo sapiens (human)
SH2 domain bindingTyrosine-protein kinase LckHomo sapiens (human)
T cell receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
CD4 receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
CD8 receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
identical protein bindingTyrosine-protein kinase LckHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase LckHomo sapiens (human)
phosphatidylinositol 3-kinase bindingTyrosine-protein kinase LckHomo sapiens (human)
ATPase bindingTyrosine-protein kinase LckHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase FynHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase FynHomo sapiens (human)
protein bindingTyrosine-protein kinase FynHomo sapiens (human)
ATP bindingTyrosine-protein kinase FynHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase FynHomo sapiens (human)
enzyme bindingTyrosine-protein kinase FynHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
identical protein bindingTyrosine-protein kinase FynHomo sapiens (human)
alpha-tubulin bindingTyrosine-protein kinase FynHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase FynHomo sapiens (human)
transmembrane transporter bindingTyrosine-protein kinase FynHomo sapiens (human)
metal ion bindingTyrosine-protein kinase FynHomo sapiens (human)
ephrin receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
tau protein bindingTyrosine-protein kinase FynHomo sapiens (human)
tau-protein kinase activityTyrosine-protein kinase FynHomo sapiens (human)
growth factor receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
scaffold protein bindingTyrosine-protein kinase FynHomo sapiens (human)
disordered domain specific bindingTyrosine-protein kinase FynHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
virus receptor activityCyclin-dependent kinase 1Homo sapiens (human)
chromatin bindingCyclin-dependent kinase 1Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 1Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 1Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 1Homo sapiens (human)
protein bindingCyclin-dependent kinase 1Homo sapiens (human)
ATP bindingCyclin-dependent kinase 1Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityCyclin-dependent kinase 1Homo sapiens (human)
kinase activityCyclin-dependent kinase 1Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 1Homo sapiens (human)
Hsp70 protein bindingCyclin-dependent kinase 1Homo sapiens (human)
histone kinase activityCyclin-dependent kinase 1Homo sapiens (human)
cyclin-dependent protein kinase activityCyclin-dependent kinase 1Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 1Homo sapiens (human)
purine nucleobase bindingGlycogen phosphorylase, liver formHomo sapiens (human)
protein bindingGlycogen phosphorylase, liver formHomo sapiens (human)
ATP bindingGlycogen phosphorylase, liver formHomo sapiens (human)
glucose bindingGlycogen phosphorylase, liver formHomo sapiens (human)
glycogen phosphorylase activityGlycogen phosphorylase, liver formHomo sapiens (human)
AMP bindingGlycogen phosphorylase, liver formHomo sapiens (human)
vitamin bindingGlycogen phosphorylase, liver formHomo sapiens (human)
bile acid bindingGlycogen phosphorylase, liver formHomo sapiens (human)
identical protein bindingGlycogen phosphorylase, liver formHomo sapiens (human)
linear malto-oligosaccharide phosphorylase activityGlycogen phosphorylase, liver formHomo sapiens (human)
SHG alpha-glucan phosphorylase activityGlycogen phosphorylase, liver formHomo sapiens (human)
pyridoxal phosphate bindingGlycogen phosphorylase, liver formHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase Fes/FpsHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase Fes/FpsHomo sapiens (human)
protein bindingTyrosine-protein kinase Fes/FpsHomo sapiens (human)
ATP bindingTyrosine-protein kinase Fes/FpsHomo sapiens (human)
microtubule bindingTyrosine-protein kinase Fes/FpsHomo sapiens (human)
immunoglobulin receptor bindingTyrosine-protein kinase Fes/FpsHomo sapiens (human)
phosphatidylinositol bindingTyrosine-protein kinase Fes/FpsHomo sapiens (human)
protein tyrosine kinase activityMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
macrophage colony-stimulating factor receptor activityMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
protein bindingMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
ATP bindingMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
protein phosphatase bindingMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cytokine bindingMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
protein homodimerization activityMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
growth factor bindingMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
adenine phosphoribosyltransferase activityAdenine phosphoribosyltransferaseHomo sapiens (human)
protein bindingAdenine phosphoribosyltransferaseHomo sapiens (human)
AMP bindingAdenine phosphoribosyltransferaseHomo sapiens (human)
adenine bindingAdenine phosphoribosyltransferaseHomo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase YesHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase YesHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase YesHomo sapiens (human)
protein bindingTyrosine-protein kinase YesHomo sapiens (human)
ATP bindingTyrosine-protein kinase YesHomo sapiens (human)
enzyme bindingTyrosine-protein kinase YesHomo sapiens (human)
transmembrane transporter bindingTyrosine-protein kinase YesHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase YesHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase LynHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase LynHomo sapiens (human)
platelet-derived growth factor receptor bindingTyrosine-protein kinase LynHomo sapiens (human)
integrin bindingTyrosine-protein kinase LynHomo sapiens (human)
protein bindingTyrosine-protein kinase LynHomo sapiens (human)
ATP bindingTyrosine-protein kinase LynHomo sapiens (human)
kinase activityTyrosine-protein kinase LynHomo sapiens (human)
SH3 domain bindingTyrosine-protein kinase LynHomo sapiens (human)
ubiquitin protein ligase bindingTyrosine-protein kinase LynHomo sapiens (human)
gamma-tubulin bindingTyrosine-protein kinase LynHomo sapiens (human)
glycosphingolipid bindingTyrosine-protein kinase LynHomo sapiens (human)
transmembrane transporter bindingTyrosine-protein kinase LynHomo sapiens (human)
ephrin receptor bindingTyrosine-protein kinase LynHomo sapiens (human)
phosphoprotein bindingTyrosine-protein kinase LynHomo sapiens (human)
scaffold protein bindingTyrosine-protein kinase LynHomo sapiens (human)
phosphorylation-dependent protein bindingTyrosine-protein kinase LynHomo sapiens (human)
phosphatidylinositol 3-kinase activator activityTyrosine-protein kinase LynHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase LynHomo sapiens (human)
protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
calcium ion bindingProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
protein bindingProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
ATP bindingProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
signaling receptor activityProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
G-protein alpha-subunit bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
protein tyrosine kinase activityInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin-like growth factor receptor activityInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
protein bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin-like growth factor bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
ATP bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin-like growth factor I bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
identical protein bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
phosphatidylinositol 3-kinase bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor substrate bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
protein-containing complex bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
protein transporter activityInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor activityInsulin-like growth factor 1 receptorHomo sapiens (human)
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
RNA bindingSignal recognition particle receptor subunit alphaHomo sapiens (human)
GTP bindingSignal recognition particle receptor subunit alphaHomo sapiens (human)
ATP hydrolysis activitySignal recognition particle receptor subunit alphaHomo sapiens (human)
signal recognition particle bindingSignal recognition particle receptor subunit alphaHomo sapiens (human)
GTPase activitySignal recognition particle receptor subunit alphaHomo sapiens (human)
protein bindingCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
ubiquinol-cytochrome-c reductase activityCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
heme bindingCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
metal ion bindingCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
protein tyrosine kinase activityHepatocyte growth factor receptorHomo sapiens (human)
protein bindingHepatocyte growth factor receptorHomo sapiens (human)
ATP bindingHepatocyte growth factor receptorHomo sapiens (human)
semaphorin receptor activityHepatocyte growth factor receptorHomo sapiens (human)
protein phosphatase bindingHepatocyte growth factor receptorHomo sapiens (human)
identical protein bindingHepatocyte growth factor receptorHomo sapiens (human)
molecular function activator activityHepatocyte growth factor receptorHomo sapiens (human)
hepatocyte growth factor receptor activityHepatocyte growth factor receptorHomo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase HCKHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase HCKHomo sapiens (human)
protein bindingTyrosine-protein kinase HCKHomo sapiens (human)
ATP bindingTyrosine-protein kinase HCKHomo sapiens (human)
lipid bindingTyrosine-protein kinase HCKHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase HCKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase HCKHomo sapiens (human)
protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
protein bindingProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
ATP bindingProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
protein phosphatase bindingProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
protein kinase activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
protein tyrosine kinase activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet activating factor receptor activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor receptor activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor beta-receptor activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
signaling receptor bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor receptor bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
protein bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
ATP bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
enzyme bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
protein kinase bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
vascular endothelial growth factor bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase FgrHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase FgrHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase FgrHomo sapiens (human)
protein bindingTyrosine-protein kinase FgrHomo sapiens (human)
ATP bindingTyrosine-protein kinase FgrHomo sapiens (human)
protein kinase bindingTyrosine-protein kinase FgrHomo sapiens (human)
immunoglobulin receptor bindingTyrosine-protein kinase FgrHomo sapiens (human)
Fc-gamma receptor I complex bindingTyrosine-protein kinase FgrHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase FgrHomo sapiens (human)
magnesium ion bindingWee1-like protein kinase 2Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityWee1-like protein kinase 2Homo sapiens (human)
ATP bindingWee1-like protein kinase 2Homo sapiens (human)
protein tyrosine kinase activityWee1-like protein kinase 2Homo sapiens (human)
protein bindingUncharacterized serine/threonine-protein kinase SBK3Homo sapiens (human)
ATP bindingUncharacterized serine/threonine-protein kinase SBK3Homo sapiens (human)
protein serine kinase activityUncharacterized serine/threonine-protein kinase SBK3Homo sapiens (human)
protein serine/threonine kinase activityUncharacterized serine/threonine-protein kinase SBK3Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase A-RafHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase A-RafHomo sapiens (human)
protein bindingSerine/threonine-protein kinase A-RafHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase A-RafHomo sapiens (human)
metal ion bindingSerine/threonine-protein kinase A-RafHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase A-RafHomo sapiens (human)
MAP kinase kinase kinase activitySerine/threonine-protein kinase A-RafHomo sapiens (human)
monooxygenase activityCytochrome P450 2C8Homo sapiens (human)
iron ion bindingCytochrome P450 2C8Homo sapiens (human)
protein bindingCytochrome P450 2C8Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C8Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C8Homo sapiens (human)
aromatase activityCytochrome P450 2C8Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
heme bindingCytochrome P450 2C8Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C8Homo sapiens (human)
protease bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
protein tyrosine kinase activityMast/stem cell growth factor receptor KitHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityMast/stem cell growth factor receptor KitHomo sapiens (human)
stem cell factor receptor activityMast/stem cell growth factor receptor KitHomo sapiens (human)
protein bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
ATP bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
cytokine bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
SH2 domain bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
protein homodimerization activityMast/stem cell growth factor receptor KitHomo sapiens (human)
metal ion bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
growth factor bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
protein bindingGlycogen phosphorylase, brain formHomo sapiens (human)
glycogen phosphorylase activityGlycogen phosphorylase, brain formHomo sapiens (human)
linear malto-oligosaccharide phosphorylase activityGlycogen phosphorylase, brain formHomo sapiens (human)
SHG alpha-glucan phosphorylase activityGlycogen phosphorylase, brain formHomo sapiens (human)
pyridoxal phosphate bindingGlycogen phosphorylase, brain formHomo sapiens (human)
protein serine/threonine kinase activityBreakpoint cluster region proteinHomo sapiens (human)
protein tyrosine kinase activityBreakpoint cluster region proteinHomo sapiens (human)
guanyl-nucleotide exchange factor activityBreakpoint cluster region proteinHomo sapiens (human)
GTPase activator activityBreakpoint cluster region proteinHomo sapiens (human)
protein bindingBreakpoint cluster region proteinHomo sapiens (human)
ATP bindingBreakpoint cluster region proteinHomo sapiens (human)
protein serine kinase activityBreakpoint cluster region proteinHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
transcription factor bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
manganese ion bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
ribosomal small subunit bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
protein tyrosine kinase activityFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor receptor activityFibroblast growth factor receptor 1Homo sapiens (human)
protein bindingFibroblast growth factor receptor 1Homo sapiens (human)
ATP bindingFibroblast growth factor receptor 1Homo sapiens (human)
heparin bindingFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor bindingFibroblast growth factor receptor 1Homo sapiens (human)
SH2 domain bindingFibroblast growth factor receptor 1Homo sapiens (human)
identical protein bindingFibroblast growth factor receptor 1Homo sapiens (human)
protein homodimerization activityFibroblast growth factor receptor 1Homo sapiens (human)
receptor-receptor interactionFibroblast growth factor receptor 1Homo sapiens (human)
magnesium ion bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
RNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-alphaHomo sapiens (human)
protein kinase C bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP-dependent activity, acting on DNADNA topoisomerase 2-alphaHomo sapiens (human)
DNA binding, bendingDNA topoisomerase 2-alphaHomo sapiens (human)
protein homodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
ubiquitin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein heterodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
calmodulin bindingMyosin light chain kinase, smooth muscleGallus gallus (chicken)
ATP bindingMyosin light chain kinase, smooth muscleGallus gallus (chicken)
metal ion bindingMyosin light chain kinase, smooth muscleGallus gallus (chicken)
myosin light chain kinase activityMyosin light chain kinase, smooth muscleGallus gallus (chicken)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 4Homo sapiens (human)
protein bindingCyclin-dependent kinase 4Homo sapiens (human)
ATP bindingCyclin-dependent kinase 4Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activityCyclin-dependent kinase 4Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 4Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 4Homo sapiens (human)
ATP:ADP antiporter activityADP/ATP translocase 3Homo sapiens (human)
protein bindingADP/ATP translocase 3Homo sapiens (human)
nucleotide bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
DNA bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
RNA bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
IMP dehydrogenase activityInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
protein bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
metal ion bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
protein kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein kinase C bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signaling receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
insulin receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
integrin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ATP bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phospholipase activator activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
enzyme bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
heme bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
nuclear estrogen receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
SH2 domain bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phospholipase bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transmembrane transporter bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cadherin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ephrin receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ATPase bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phosphoprotein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
BMP receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
connexin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
scaffold protein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cAMP-dependent protein kinase inhibitor activitycAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
protein bindingcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cAMP-dependent protein kinase regulator activitycAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
protein domain specific bindingcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
ubiquitin protein ligase bindingcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
protein kinase A catalytic subunit bindingcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cAMP bindingcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityInsulin receptor-related proteinHomo sapiens (human)
protein bindingInsulin receptor-related proteinHomo sapiens (human)
ATP bindingInsulin receptor-related proteinHomo sapiens (human)
phosphatidylinositol 3-kinase bindingInsulin receptor-related proteinHomo sapiens (human)
insulin receptor substrate bindingInsulin receptor-related proteinHomo sapiens (human)
insulin receptor activityInsulin receptor-related proteinHomo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase B-rafHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase B-rafHomo sapiens (human)
MAP kinase kinase activitySerine/threonine-protein kinase B-rafHomo sapiens (human)
calcium ion bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
protein bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
mitogen-activated protein kinase kinase bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
identical protein bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
protein-containing complex bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
scaffold protein bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase B-rafHomo sapiens (human)
MAP kinase kinase kinase activitySerine/threonine-protein kinase B-rafHomo sapiens (human)
protein serine/threonine kinase activityPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
phosphorylase kinase activityPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
protein bindingPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
calmodulin bindingPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
ATP bindingPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
enzyme bindingPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
tau-protein kinase activityPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
dihydronicotinamide riboside quinone reductase activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
zinc ion bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
electron transfer activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
oxidoreductase activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
oxidoreductase activity, acting on other nitrogenous compounds as donorsRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
chloride ion bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein homodimerization activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
FAD bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
melatonin bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
resveratrol bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
NAD(P)H dehydrogenase (quinone) activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein kinase activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
platelet-derived growth factor alpha-receptor activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
vascular endothelial growth factor receptor activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
platelet-derived growth factor receptor bindingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
protein bindingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
ATP bindingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
vascular endothelial growth factor bindingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
protein homodimerization activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
protein-containing complex bindingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
platelet-derived growth factor bindingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase FerHomo sapiens (human)
epidermal growth factor receptor bindingTyrosine-protein kinase FerHomo sapiens (human)
protein bindingTyrosine-protein kinase FerHomo sapiens (human)
ATP bindingTyrosine-protein kinase FerHomo sapiens (human)
protein phosphatase 1 bindingTyrosine-protein kinase FerHomo sapiens (human)
lipid bindingTyrosine-protein kinase FerHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase FerHomo sapiens (human)
protein kinase activityProtein kinase C alpha typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
calcium,diacylglycerol-dependent serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
integrin bindingProtein kinase C alpha typeHomo sapiens (human)
protein bindingProtein kinase C alpha typeHomo sapiens (human)
ATP bindingProtein kinase C alpha typeHomo sapiens (human)
zinc ion bindingProtein kinase C alpha typeHomo sapiens (human)
enzyme bindingProtein kinase C alpha typeHomo sapiens (human)
histone H3T6 kinase activityProtein kinase C alpha typeHomo sapiens (human)
protein serine kinase activityProtein kinase C alpha typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
diacylglycerol bindingProtein kinase C alpha typeHomo sapiens (human)
magnesium ion bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein kinase activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein serine/threonine kinase activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
AMP-activated protein kinase activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cAMP-dependent protein kinase activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein serine/threonine/tyrosine kinase activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
ATP bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein kinase bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein domain specific bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
manganese ion bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
ubiquitin protein ligase bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein kinase A regulatory subunit bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
channel activator activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein serine kinase activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor receptor activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
protein bindingVascular endothelial growth factor receptor 1 Homo sapiens (human)
ATP bindingVascular endothelial growth factor receptor 1 Homo sapiens (human)
growth factor bindingVascular endothelial growth factor receptor 1 Homo sapiens (human)
placental growth factor receptor activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
protein bindingGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
ATP bindingGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
ATP hydrolysis activityGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
protein-macromolecule adaptor activityGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
5'-3' DNA helicase activityGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
metal ion bindingGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
4 iron, 4 sulfur cluster bindingGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
DNA helicase activityGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
damaged DNA bindingGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
RNA bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
double-stranded RNA bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
eukaryotic translation initiation factor 2alpha kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
ATP bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein phosphatase regulator activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
identical protein bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein serine kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit alpha'Homo sapiens (human)
protein bindingCasein kinase II subunit alpha'Homo sapiens (human)
ATP bindingCasein kinase II subunit alpha'Homo sapiens (human)
protein serine kinase activityCasein kinase II subunit alpha'Homo sapiens (human)
GTPase activityRas-related protein Rab-6AHomo sapiens (human)
protein bindingRas-related protein Rab-6AHomo sapiens (human)
GTP bindingRas-related protein Rab-6AHomo sapiens (human)
protein domain specific bindingRas-related protein Rab-6AHomo sapiens (human)
myosin V bindingRas-related protein Rab-6AHomo sapiens (human)
transcription coactivator activitySerine/threonine-protein kinase MAKHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase MAKHomo sapiens (human)
protein bindingSerine/threonine-protein kinase MAKHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase MAKHomo sapiens (human)
metal ion bindingSerine/threonine-protein kinase MAKHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase MAKHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase MAKHomo sapiens (human)
RNA bindingCyclin-dependent kinase 11BHomo sapiens (human)
protein kinase activityCyclin-dependent kinase 11BHomo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 11BHomo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 11BHomo sapiens (human)
protein bindingCyclin-dependent kinase 11BHomo sapiens (human)
ATP bindingCyclin-dependent kinase 11BHomo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 11BHomo sapiens (human)
fibronectin bindingEphrin type-A receptor 1Homo sapiens (human)
protein kinase activityEphrin type-A receptor 1Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 1Homo sapiens (human)
ATP bindingEphrin type-A receptor 1Homo sapiens (human)
protein kinase bindingEphrin type-A receptor 1Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEphrin type-A receptor 1Homo sapiens (human)
protein tyrosine kinase activityFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor activityFibroblast growth factor receptor 2Homo sapiens (human)
protein bindingFibroblast growth factor receptor 2Homo sapiens (human)
ATP bindingFibroblast growth factor receptor 2Homo sapiens (human)
heparin bindingFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor bindingFibroblast growth factor receptor 2Homo sapiens (human)
protein homodimerization activityFibroblast growth factor receptor 2Homo sapiens (human)
protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
transmembrane signaling receptor activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
protein bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
ATP bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
growth factor bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
protein tyrosine kinase activator activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
ubiquitin protein ligase bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
neuregulin bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
identical protein bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
ErbB-3 class receptor bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
protein heterodimerization activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
neuregulin receptor activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
phosphoribosylaminoimidazole carboxylase activityMultifunctional protein ADE2Homo sapiens (human)
phosphoribosylaminoimidazolesuccinocarboxamide synthase activityMultifunctional protein ADE2Homo sapiens (human)
protein bindingMultifunctional protein ADE2Homo sapiens (human)
ATP bindingMultifunctional protein ADE2Homo sapiens (human)
identical protein bindingMultifunctional protein ADE2Homo sapiens (human)
5-amino-4-imidazole carboxylate lyase activityMultifunctional protein ADE2Homo sapiens (human)
cadherin bindingMultifunctional protein ADE2Homo sapiens (human)
fibroblast growth factor receptor activityFibroblast growth factor receptor 4Homo sapiens (human)
protein bindingFibroblast growth factor receptor 4Homo sapiens (human)
ATP bindingFibroblast growth factor receptor 4Homo sapiens (human)
heparin bindingFibroblast growth factor receptor 4Homo sapiens (human)
fibroblast growth factor bindingFibroblast growth factor receptor 4Homo sapiens (human)
protein tyrosine kinase activityFibroblast growth factor receptor 3Homo sapiens (human)
fibroblast growth factor receptor activityFibroblast growth factor receptor 3Homo sapiens (human)
protein bindingFibroblast growth factor receptor 3Homo sapiens (human)
ATP bindingFibroblast growth factor receptor 3Homo sapiens (human)
fibroblast growth factor bindingFibroblast growth factor receptor 3Homo sapiens (human)
identical protein bindingFibroblast growth factor receptor 3Homo sapiens (human)
protein serine/threonine kinase activitycAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
AMP-activated protein kinase activitycAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
cAMP-dependent protein kinase activitycAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
protein bindingcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
ATP bindingcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
protein serine kinase activitycAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
protein kinase A regulatory subunit bindingcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
magnesium ion bindingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
protein serine/threonine kinase activitycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
AMP-activated protein kinase activitycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
cAMP-dependent protein kinase activitycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
protein bindingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
ATP bindingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
ubiquitin protein ligase bindingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
protein serine kinase activitycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
ferrochelatase activityFerrochelatase, mitochondrialHomo sapiens (human)
protein bindingFerrochelatase, mitochondrialHomo sapiens (human)
ferrous iron bindingFerrochelatase, mitochondrialHomo sapiens (human)
heme bindingFerrochelatase, mitochondrialHomo sapiens (human)
iron-responsive element bindingFerrochelatase, mitochondrialHomo sapiens (human)
identical protein bindingFerrochelatase, mitochondrialHomo sapiens (human)
protein homodimerization activityFerrochelatase, mitochondrialHomo sapiens (human)
2 iron, 2 sulfur cluster bindingFerrochelatase, mitochondrialHomo sapiens (human)
protein kinase activityRibosomal protein S6 kinase beta-1Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase beta-1Homo sapiens (human)
ribosomal protein S6 kinase activityRibosomal protein S6 kinase beta-1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityRibosomal protein S6 kinase beta-1Homo sapiens (human)
protein bindingRibosomal protein S6 kinase beta-1Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase beta-1Homo sapiens (human)
PDZ domain bindingRibosomal protein S6 kinase beta-1Homo sapiens (human)
peptide bindingRibosomal protein S6 kinase beta-1Homo sapiens (human)
identical protein bindingRibosomal protein S6 kinase beta-1Homo sapiens (human)
protein phosphatase 2A bindingRibosomal protein S6 kinase beta-1Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase beta-1Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase JAK1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase JAK1Homo sapiens (human)
growth hormone receptor bindingTyrosine-protein kinase JAK1Homo sapiens (human)
protein bindingTyrosine-protein kinase JAK1Homo sapiens (human)
ATP bindingTyrosine-protein kinase JAK1Homo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase JAK1Homo sapiens (human)
ubiquitin protein ligase bindingTyrosine-protein kinase JAK1Homo sapiens (human)
CCR5 chemokine receptor bindingTyrosine-protein kinase JAK1Homo sapiens (human)
metal ion bindingTyrosine-protein kinase JAK1Homo sapiens (human)
protein kinase activityProtein kinase C eta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C eta typeHomo sapiens (human)
diacylglycerol-dependent, calcium-independent serine/threonine kinase activityProtein kinase C eta typeHomo sapiens (human)
protein bindingProtein kinase C eta typeHomo sapiens (human)
ATP bindingProtein kinase C eta typeHomo sapiens (human)
enzyme bindingProtein kinase C eta typeHomo sapiens (human)
small GTPase bindingProtein kinase C eta typeHomo sapiens (human)
metal ion bindingProtein kinase C eta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C eta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C eta typeHomo sapiens (human)
histone kinase activityCyclin-dependent kinase 2Homo sapiens (human)
magnesium ion bindingCyclin-dependent kinase 2Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein bindingCyclin-dependent kinase 2Homo sapiens (human)
ATP bindingCyclin-dependent kinase 2Homo sapiens (human)
protein domain specific bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein kinase activityBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled receptor kinase activityBeta-adrenergic receptor kinase 1Homo sapiens (human)
protein bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
ATP bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
Edg-2 lysophosphatidic acid receptor bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
beta-adrenergic receptor kinase activityBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled receptor bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
RNA bindingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
RNA helicase activityProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
helicase activityProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
protein bindingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
ATP bindingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
ATP hydrolysis activityProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
protein domain specific bindingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cadherin bindingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
mRNA bindingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
protein bindingActivin receptor type-2AHomo sapiens (human)
activin receptor activityActivin receptor type-2AHomo sapiens (human)
activin bindingActivin receptor type-2AHomo sapiens (human)
protein serine/threonine kinase activityActivin receptor type-2AHomo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityActivin receptor type-2AHomo sapiens (human)
protein bindingActivin receptor type-2AHomo sapiens (human)
ATP bindingActivin receptor type-2AHomo sapiens (human)
coreceptor activityActivin receptor type-2AHomo sapiens (human)
activin receptor activityActivin receptor type-2AHomo sapiens (human)
growth factor bindingActivin receptor type-2AHomo sapiens (human)
PDZ domain bindingActivin receptor type-2AHomo sapiens (human)
inhibin bindingActivin receptor type-2AHomo sapiens (human)
metal ion bindingActivin receptor type-2AHomo sapiens (human)
BMP receptor activityActivin receptor type-2AHomo sapiens (human)
phosphotyrosine residue bindingMitogen-activated protein kinase 3 Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 3 Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 3 Homo sapiens (human)
protein bindingMitogen-activated protein kinase 3 Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 3 Homo sapiens (human)
phosphatase bindingMitogen-activated protein kinase 3 Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase 3 Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 3 Homo sapiens (human)
DNA-binding transcription factor bindingMitogen-activated protein kinase 3 Homo sapiens (human)
protein serine/threonine kinase activityMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
protein bindingMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
ATP bindingMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
tau protein bindingMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
tau-protein kinase activityMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
protein serine kinase activityMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
deoxyadenosine kinase activityDeoxycytidine kinaseHomo sapiens (human)
deoxycytidine kinase activityDeoxycytidine kinaseHomo sapiens (human)
deoxyguanosine kinase activityDeoxycytidine kinaseHomo sapiens (human)
ATP bindingDeoxycytidine kinaseHomo sapiens (human)
protein homodimerization activityDeoxycytidine kinaseHomo sapiens (human)
cytidine kinase activityDeoxycytidine kinaseHomo sapiens (human)
phosphotyrosine residue bindingMitogen-activated protein kinase 1Homo sapiens (human)
DNA bindingMitogen-activated protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 1Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 1Homo sapiens (human)
protein bindingMitogen-activated protein kinase 1Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 1Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityMitogen-activated protein kinase 1Homo sapiens (human)
phosphatase bindingMitogen-activated protein kinase 1Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase 1Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 1Homo sapiens (human)
virus receptor activityEphrin type-A receptor 2Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEphrin type-A receptor 2Homo sapiens (human)
ephrin receptor activityEphrin type-A receptor 2Homo sapiens (human)
protein bindingEphrin type-A receptor 2Homo sapiens (human)
ATP bindingEphrin type-A receptor 2Homo sapiens (human)
growth factor bindingEphrin type-A receptor 2Homo sapiens (human)
cadherin bindingEphrin type-A receptor 2Homo sapiens (human)
molecular function activator activityEphrin type-A receptor 2Homo sapiens (human)
ephrin receptor activityEphrin type-A receptor 3Homo sapiens (human)
GPI-linked ephrin receptor activityEphrin type-A receptor 3Homo sapiens (human)
protein bindingEphrin type-A receptor 3Homo sapiens (human)
ATP bindingEphrin type-A receptor 3Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 3Homo sapiens (human)
ephrin receptor activityEphrin type-A receptor 8Homo sapiens (human)
GPI-linked ephrin receptor activityEphrin type-A receptor 8Homo sapiens (human)
ATP bindingEphrin type-A receptor 8Homo sapiens (human)
growth factor bindingEphrin type-A receptor 8Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 8Homo sapiens (human)
amyloid-beta bindingEphrin type-B receptor 2Homo sapiens (human)
protein tyrosine kinase activityEphrin type-B receptor 2Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-B receptor 2Homo sapiens (human)
signaling receptor bindingEphrin type-B receptor 2Homo sapiens (human)
protein bindingEphrin type-B receptor 2Homo sapiens (human)
ATP bindingEphrin type-B receptor 2Homo sapiens (human)
axon guidance receptor activityEphrin type-B receptor 2Homo sapiens (human)
identical protein bindingEphrin type-B receptor 2Homo sapiens (human)
protein-containing complex bindingEphrin type-B receptor 2Homo sapiens (human)
protein kinase activityLeukocyte tyrosine kinase receptorHomo sapiens (human)
protein tyrosine kinase activityLeukocyte tyrosine kinase receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityLeukocyte tyrosine kinase receptorHomo sapiens (human)
protein bindingLeukocyte tyrosine kinase receptorHomo sapiens (human)
ATP bindingLeukocyte tyrosine kinase receptorHomo sapiens (human)
receptor signaling protein tyrosine kinase activator activityLeukocyte tyrosine kinase receptorHomo sapiens (human)
protein tyrosine kinase activityNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
growth hormone receptor bindingNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
protein bindingNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
ATP bindingNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
type 1 angiotensin receptor bindingNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
nucleoside diphosphate kinase activityUMP-CMP kinase Homo sapiens (human)
uridine kinase activityUMP-CMP kinase Homo sapiens (human)
ATP bindingUMP-CMP kinase Homo sapiens (human)
UMP kinase activityUMP-CMP kinase Homo sapiens (human)
CMP kinase activityUMP-CMP kinase Homo sapiens (human)
dCMP kinase activityUMP-CMP kinase Homo sapiens (human)
nucleoside monophosphate kinase activityUMP-CMP kinase Homo sapiens (human)
cytidylate kinase activityUMP-CMP kinase Homo sapiens (human)
RNA bindingPhosphatidylethanolamine-binding protein 1Homo sapiens (human)
serine-type endopeptidase inhibitor activityPhosphatidylethanolamine-binding protein 1Homo sapiens (human)
protein bindingPhosphatidylethanolamine-binding protein 1Homo sapiens (human)
ATP bindingPhosphatidylethanolamine-binding protein 1Homo sapiens (human)
phosphatidylethanolamine bindingPhosphatidylethanolamine-binding protein 1Homo sapiens (human)
enzyme bindingPhosphatidylethanolamine-binding protein 1Homo sapiens (human)
protein kinase bindingPhosphatidylethanolamine-binding protein 1Homo sapiens (human)
magnesium ion bindingWee1-like protein kinaseHomo sapiens (human)
protein tyrosine kinase activityWee1-like protein kinaseHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityWee1-like protein kinaseHomo sapiens (human)
protein bindingWee1-like protein kinaseHomo sapiens (human)
ATP bindingWee1-like protein kinaseHomo sapiens (human)
heme oxygenase (decyclizing) activityHeme oxygenase 2Homo sapiens (human)
protein bindingHeme oxygenase 2Homo sapiens (human)
metal ion bindingHeme oxygenase 2Homo sapiens (human)
heme bindingHeme oxygenase 2Homo sapiens (human)
virus receptor activityTyrosine-protein kinase receptor UFOHomo sapiens (human)
phosphatidylserine bindingTyrosine-protein kinase receptor UFOHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase receptor UFOHomo sapiens (human)
protein bindingTyrosine-protein kinase receptor UFOHomo sapiens (human)
ATP bindingTyrosine-protein kinase receptor UFOHomo sapiens (human)
myosin heavy chain bindingTyrosine-protein kinase receptor UFOHomo sapiens (human)
phosphatidylinositol 3-kinase bindingTyrosine-protein kinase receptor UFOHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityTyrosine-protein kinase receptor UFOHomo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 4Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 4Homo sapiens (human)
protein bindingMitogen-activated protein kinase 4Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 4Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase 4Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase 4Homo sapiens (human)
protein heterodimerization activityMitogen-activated protein kinase 4Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 4Homo sapiens (human)
methionine adenosyltransferase activityS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
protein bindingS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
ATP bindingS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
small molecule bindingS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
identical protein bindingS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
metal ion bindingS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
G protein-coupled receptor bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
ATPase activator activityDnaJ homolog subfamily A member 1Homo sapiens (human)
protein bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
ATP bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
Hsp70 protein bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
Tat protein bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
ubiquitin protein ligase bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
metal ion bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
low-density lipoprotein particle receptor bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
unfolded protein bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
protein-folding chaperone bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
C3HC4-type RING finger domain bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
protein kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
calmodulin bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
phosphatidylinositol-3,4,5-trisphosphate bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
enzyme bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein kinase bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
nitric-oxide synthase regulator activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase inhibitor activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
identical protein bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein homodimerization activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
phosphatidylinositol-3,4-bisphosphate bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
14-3-3 protein bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
potassium channel activator activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein serine kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
protein bindingRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
metal ion bindingRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
protein serine kinase activityRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
molecular function activator activityRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingG protein-coupled receptor kinase 4Homo sapiens (human)
rhodopsin kinase activityG protein-coupled receptor kinase 4Homo sapiens (human)
protein kinase activityG protein-coupled receptor kinase 4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
protein tyrosine kinase activityDual specificity protein kinase TTKHomo sapiens (human)
protein bindingDual specificity protein kinase TTKHomo sapiens (human)
ATP bindingDual specificity protein kinase TTKHomo sapiens (human)
identical protein bindingDual specificity protein kinase TTKHomo sapiens (human)
kinetochore bindingDual specificity protein kinase TTKHomo sapiens (human)
protein serine kinase activityDual specificity protein kinase TTKHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity protein kinase TTKHomo sapiens (human)
protein serine/threonine kinase activityDual specificity protein kinase TTKHomo sapiens (human)
DNA helicase activityDNA replication licensing factor MCM4Homo sapiens (human)
single-stranded DNA bindingDNA replication licensing factor MCM4Homo sapiens (human)
protein bindingDNA replication licensing factor MCM4Homo sapiens (human)
ATP bindingDNA replication licensing factor MCM4Homo sapiens (human)
ATP hydrolysis activityDNA replication licensing factor MCM4Homo sapiens (human)
single-stranded DNA helicase activityDNA replication licensing factor MCM4Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
ATP bindingTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityVascular endothelial growth factor receptor 3Homo sapiens (human)
vascular endothelial growth factor receptor activityVascular endothelial growth factor receptor 3Homo sapiens (human)
protein bindingVascular endothelial growth factor receptor 3Homo sapiens (human)
ATP bindingVascular endothelial growth factor receptor 3Homo sapiens (human)
growth factor bindingVascular endothelial growth factor receptor 3Homo sapiens (human)
protein phosphatase bindingVascular endothelial growth factor receptor 3Homo sapiens (human)
protein homodimerization activityVascular endothelial growth factor receptor 3Homo sapiens (human)
protein tyrosine kinase activityVascular endothelial growth factor receptor 2Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor receptor activityVascular endothelial growth factor receptor 2Homo sapiens (human)
integrin bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
protein bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
ATP bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
coreceptor activityVascular endothelial growth factor receptor 2Homo sapiens (human)
growth factor bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
identical protein bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
cadherin bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
Hsp90 protein bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
MAP-kinase scaffold activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
PDZ domain bindingDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
protein serine/threonine kinase activator activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
metal ion bindingDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
scaffold protein bindingDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
protein tyrosine kinase activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cytokine receptor activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
vascular endothelial growth factor receptor activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
protein bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
ATP bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
nuclear glucocorticoid receptor bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
protein-containing complex bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
phosphatidylinositol 3-kinase activator activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
growth factor bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
protein serine/threonine kinase activityBone morphogenetic protein receptor type-1AHomo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityBone morphogenetic protein receptor type-1AHomo sapiens (human)
transforming growth factor beta receptor activity, type IBone morphogenetic protein receptor type-1AHomo sapiens (human)
protein bindingBone morphogenetic protein receptor type-1AHomo sapiens (human)
ATP bindingBone morphogenetic protein receptor type-1AHomo sapiens (human)
BMP bindingBone morphogenetic protein receptor type-1AHomo sapiens (human)
protein homodimerization activityBone morphogenetic protein receptor type-1AHomo sapiens (human)
SMAD bindingBone morphogenetic protein receptor type-1AHomo sapiens (human)
metal ion bindingBone morphogenetic protein receptor type-1AHomo sapiens (human)
BMP receptor activityBone morphogenetic protein receptor type-1AHomo sapiens (human)
activin receptor activityActivin receptor type-1BHomo sapiens (human)
growth factor bindingActivin receptor type-1BHomo sapiens (human)
activin bindingActivin receptor type-1BHomo sapiens (human)
protein serine/threonine kinase activityActivin receptor type-1BHomo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityActivin receptor type-1BHomo sapiens (human)
protein bindingActivin receptor type-1BHomo sapiens (human)
ATP bindingActivin receptor type-1BHomo sapiens (human)
activin receptor activity, type IActivin receptor type-1BHomo sapiens (human)
activin receptor activityActivin receptor type-1BHomo sapiens (human)
ubiquitin protein ligase bindingActivin receptor type-1BHomo sapiens (human)
inhibin bindingActivin receptor type-1BHomo sapiens (human)
SMAD bindingActivin receptor type-1BHomo sapiens (human)
metal ion bindingActivin receptor type-1BHomo sapiens (human)
I-SMAD bindingActivin receptor type-1BHomo sapiens (human)
transforming growth factor beta receptor activityTGF-beta receptor type-1Homo sapiens (human)
growth factor bindingTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta bindingTGF-beta receptor type-1Homo sapiens (human)
protein kinase activityTGF-beta receptor type-1Homo sapiens (human)
protein serine/threonine kinase activityTGF-beta receptor type-1Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta receptor activityTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta receptor activity, type ITGF-beta receptor type-1Homo sapiens (human)
type II transforming growth factor beta receptor bindingTGF-beta receptor type-1Homo sapiens (human)
protein bindingTGF-beta receptor type-1Homo sapiens (human)
ATP bindingTGF-beta receptor type-1Homo sapiens (human)
ubiquitin protein ligase bindingTGF-beta receptor type-1Homo sapiens (human)
SMAD bindingTGF-beta receptor type-1Homo sapiens (human)
metal ion bindingTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta bindingTGF-beta receptor type-1Homo sapiens (human)
I-SMAD bindingTGF-beta receptor type-1Homo sapiens (human)
activin receptor activity, type ITGF-beta receptor type-1Homo sapiens (human)
activin bindingTGF-beta receptor type-1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase receptor R3Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activitySerine/threonine-protein kinase receptor R3Homo sapiens (human)
transforming growth factor beta receptor activitySerine/threonine-protein kinase receptor R3Homo sapiens (human)
transforming growth factor beta receptor activity, type ISerine/threonine-protein kinase receptor R3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
activin receptor activity, type ISerine/threonine-protein kinase receptor R3Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
SMAD bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
activin bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
transforming growth factor beta bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
BMP receptor activitySerine/threonine-protein kinase receptor R3Homo sapiens (human)
transforming growth factor beta bindingTGF-beta receptor type-2Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityTGF-beta receptor type-2Homo sapiens (human)
transforming growth factor beta receptor activityTGF-beta receptor type-2Homo sapiens (human)
transforming growth factor beta receptor activity, type IITGF-beta receptor type-2Homo sapiens (human)
protein bindingTGF-beta receptor type-2Homo sapiens (human)
ATP bindingTGF-beta receptor type-2Homo sapiens (human)
glycosaminoglycan bindingTGF-beta receptor type-2Homo sapiens (human)
kinase activator activityTGF-beta receptor type-2Homo sapiens (human)
type I transforming growth factor beta receptor bindingTGF-beta receptor type-2Homo sapiens (human)
SMAD bindingTGF-beta receptor type-2Homo sapiens (human)
metal ion bindingTGF-beta receptor type-2Homo sapiens (human)
transforming growth factor beta bindingTGF-beta receptor type-2Homo sapiens (human)
molecular adaptor activityTGF-beta receptor type-2Homo sapiens (human)
activin receptor activityTGF-beta receptor type-2Homo sapiens (human)
activin bindingTGF-beta receptor type-2Homo sapiens (human)
protein serine/threonine kinase activityTGF-beta receptor type-2Homo sapiens (human)
protein bindingElectron transfer flavoprotein subunit betaHomo sapiens (human)
electron transfer activityElectron transfer flavoprotein subunit betaHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase CSKHomo sapiens (human)
protein bindingTyrosine-protein kinase CSKHomo sapiens (human)
ATP bindingTyrosine-protein kinase CSKHomo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase CSKHomo sapiens (human)
protein kinase A catalytic subunit bindingTyrosine-protein kinase CSKHomo sapiens (human)
identical protein bindingTyrosine-protein kinase CSKHomo sapiens (human)
metal ion bindingTyrosine-protein kinase CSKHomo sapiens (human)
proline-rich region bindingTyrosine-protein kinase CSKHomo sapiens (human)
protein tyrosine kinase bindingTyrosine-protein kinase CSKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase CSKHomo sapiens (human)
bis(5'-nucleosyl)-tetraphosphatase (asymmetrical) activityGlycine--tRNA ligaseHomo sapiens (human)
glycine-tRNA ligase activityGlycine--tRNA ligaseHomo sapiens (human)
protein bindingGlycine--tRNA ligaseHomo sapiens (human)
ATP bindingGlycine--tRNA ligaseHomo sapiens (human)
transferase activityGlycine--tRNA ligaseHomo sapiens (human)
identical protein bindingGlycine--tRNA ligaseHomo sapiens (human)
protein dimerization activityGlycine--tRNA ligaseHomo sapiens (human)
magnesium ion bindingMitogen-activated protein kinase kinase kinase 8Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 8Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 8Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 8Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 8Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 8Homo sapiens (human)
protein kinase activityProtein kinase C iota typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C iota typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C iota typeHomo sapiens (human)
protein bindingProtein kinase C iota typeHomo sapiens (human)
ATP bindingProtein kinase C iota typeHomo sapiens (human)
phospholipid bindingProtein kinase C iota typeHomo sapiens (human)
metal ion bindingProtein kinase C iota typeHomo sapiens (human)
protein serine kinase activityProtein kinase C iota typeHomo sapiens (human)
RNA bindingExosome RNA helicase MTR4Homo sapiens (human)
RNA helicase activityExosome RNA helicase MTR4Homo sapiens (human)
protein bindingExosome RNA helicase MTR4Homo sapiens (human)
ATP bindingExosome RNA helicase MTR4Homo sapiens (human)
ATP hydrolysis activityExosome RNA helicase MTR4Homo sapiens (human)
protein serine/threonine kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
protein bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
ATP bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
1-phosphatidylinositol-3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
protein kinase activator activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
insulin receptor substrate bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
protein serine kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
protein bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
ATP bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
1-phosphatidylinositol-3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
insulin receptor substrate bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
protein serine kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
RNA polymerase III type 1 promoter sequence-specific DNA bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
RNA polymerase III type 2 promoter sequence-specific DNA bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
RNA polymerase III type 3 promoter sequence-specific DNA bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
TFIIIC-class transcription factor complex bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase mTORHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase mTORHomo sapiens (human)
protein bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
kinase activitySerine/threonine-protein kinase mTORHomo sapiens (human)
identical protein bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
ribosome bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
phosphoprotein bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase mTORHomo sapiens (human)
protein tyrosine kinase activityMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
protein bindingMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
ATP bindingMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase TecHomo sapiens (human)
protein bindingTyrosine-protein kinase TecHomo sapiens (human)
ATP bindingTyrosine-protein kinase TecHomo sapiens (human)
phospholipid bindingTyrosine-protein kinase TecHomo sapiens (human)
metal ion bindingTyrosine-protein kinase TecHomo sapiens (human)
protein bindingTyrosine-protein kinase TXKHomo sapiens (human)
ATP bindingTyrosine-protein kinase TXKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase TXKHomo sapiens (human)
magnesium ion bindingTyrosine-protein kinase ABL2Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase ABL2Homo sapiens (human)
actin monomer bindingTyrosine-protein kinase ABL2Homo sapiens (human)
protein kinase activityTyrosine-protein kinase ABL2Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase ABL2Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase ABL2Homo sapiens (human)
protein bindingTyrosine-protein kinase ABL2Homo sapiens (human)
ATP bindingTyrosine-protein kinase ABL2Homo sapiens (human)
manganese ion bindingTyrosine-protein kinase ABL2Homo sapiens (human)
actin filament bindingTyrosine-protein kinase ABL2Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase FRKHomo sapiens (human)
protein bindingTyrosine-protein kinase FRKHomo sapiens (human)
ATP bindingTyrosine-protein kinase FRKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase FRKHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase FRKHomo sapiens (human)
protein bindingG protein-coupled receptor kinase 6Homo sapiens (human)
ATP bindingG protein-coupled receptor kinase 6Homo sapiens (human)
beta-adrenergic receptor kinase activityG protein-coupled receptor kinase 6Homo sapiens (human)
G protein-coupled receptor kinase activityG protein-coupled receptor kinase 6Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase ZAP-70Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase ZAP-70Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase ZAP-70Homo sapiens (human)
protein bindingTyrosine-protein kinase ZAP-70Homo sapiens (human)
ATP bindingTyrosine-protein kinase ZAP-70Homo sapiens (human)
signaling receptor bindingTyrosine-protein kinase ZAP-70Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase SYKHomo sapiens (human)
protein kinase activityTyrosine-protein kinase SYKHomo sapiens (human)
protein serine/threonine kinase activityTyrosine-protein kinase SYKHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase SYKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase SYKHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase SYKHomo sapiens (human)
integrin bindingTyrosine-protein kinase SYKHomo sapiens (human)
protein bindingTyrosine-protein kinase SYKHomo sapiens (human)
ATP bindingTyrosine-protein kinase SYKHomo sapiens (human)
interleukin-15 receptor bindingTyrosine-protein kinase SYKHomo sapiens (human)
kinase activityTyrosine-protein kinase SYKHomo sapiens (human)
protein kinase bindingTyrosine-protein kinase SYKHomo sapiens (human)
phosphatase bindingTyrosine-protein kinase SYKHomo sapiens (human)
Toll-like receptor bindingTyrosine-protein kinase SYKHomo sapiens (human)
SH2 domain bindingTyrosine-protein kinase SYKHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase SYKHomo sapiens (human)
scaffold protein bindingTyrosine-protein kinase SYKHomo sapiens (human)
protein binding26S proteasome regulatory subunit 6BHomo sapiens (human)
ATP binding26S proteasome regulatory subunit 6BHomo sapiens (human)
ATP hydrolysis activity26S proteasome regulatory subunit 6BHomo sapiens (human)
proteasome-activating activity26S proteasome regulatory subunit 6BHomo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 8Homo sapiens (human)
JUN kinase activityMitogen-activated protein kinase 8Homo sapiens (human)
protein bindingMitogen-activated protein kinase 8Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 8Homo sapiens (human)
enzyme bindingMitogen-activated protein kinase 8Homo sapiens (human)
protein phosphatase bindingMitogen-activated protein kinase 8Homo sapiens (human)
histone deacetylase regulator activityMitogen-activated protein kinase 8Homo sapiens (human)
histone deacetylase bindingMitogen-activated protein kinase 8Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 8Homo sapiens (human)
protein serine/threonine kinase bindingMitogen-activated protein kinase 8Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 9Homo sapiens (human)
JUN kinase activityMitogen-activated protein kinase 9Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityMitogen-activated protein kinase 9Homo sapiens (human)
protein bindingMitogen-activated protein kinase 9Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 9Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 9Homo sapiens (human)
protein kinase activityDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
JUN kinase kinase activityDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
molecular adaptor activityDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
protein kinase bindingDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
protein bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
ATP bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 5-kinase activityPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
1-phosphatidylinositol-5-phosphate 4-kinase activityPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
protein homodimerization activityPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
protein kinase activityCasein kinase I isoform alphaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform alphaHomo sapiens (human)
protein bindingCasein kinase I isoform alphaHomo sapiens (human)
ATP bindingCasein kinase I isoform alphaHomo sapiens (human)
protein serine kinase activityCasein kinase I isoform alphaHomo sapiens (human)
protein kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein bindingCasein kinase I isoform deltaHomo sapiens (human)
ATP bindingCasein kinase I isoform deltaHomo sapiens (human)
cadherin bindingCasein kinase I isoform deltaHomo sapiens (human)
tau-protein kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein serine kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
protein serine/threonine kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
protein bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
ATP bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
1-phosphatidylinositol-3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
identical protein bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
ephrin receptor bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
protein serine kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
protein kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
protein bindingMAP kinase-activated protein kinase 2Homo sapiens (human)
ATP bindingMAP kinase-activated protein kinase 2Homo sapiens (human)
protein serine kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
calmodulin bindingMAP kinase-activated protein kinase 2Homo sapiens (human)
calmodulin-dependent protein kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
mitogen-activated protein kinase bindingMAP kinase-activated protein kinase 2Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 8Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 8Homo sapiens (human)
protein bindingCyclin-dependent kinase 8Homo sapiens (human)
ATP bindingCyclin-dependent kinase 8Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityCyclin-dependent kinase 8Homo sapiens (human)
ubiquitin protein ligase activityCyclin-dependent kinase 8Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 8Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 8Homo sapiens (human)
RNA bindingElongation factor Tu, mitochondrialHomo sapiens (human)
translation elongation factor activityElongation factor Tu, mitochondrialHomo sapiens (human)
GTPase activityElongation factor Tu, mitochondrialHomo sapiens (human)
protein bindingElongation factor Tu, mitochondrialHomo sapiens (human)
GTP bindingElongation factor Tu, mitochondrialHomo sapiens (human)
tRNA bindingCysteine--tRNA ligase, cytoplasmicHomo sapiens (human)
cysteine-tRNA ligase activityCysteine--tRNA ligase, cytoplasmicHomo sapiens (human)
protein bindingCysteine--tRNA ligase, cytoplasmicHomo sapiens (human)
ATP bindingCysteine--tRNA ligase, cytoplasmicHomo sapiens (human)
identical protein bindingCysteine--tRNA ligase, cytoplasmicHomo sapiens (human)
metal ion bindingCysteine--tRNA ligase, cytoplasmicHomo sapiens (human)
RNA bindingCasein kinase I isoform epsilonHomo sapiens (human)
protein kinase activityCasein kinase I isoform epsilonHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform epsilonHomo sapiens (human)
protein bindingCasein kinase I isoform epsilonHomo sapiens (human)
ATP bindingCasein kinase I isoform epsilonHomo sapiens (human)
protein serine kinase activityCasein kinase I isoform epsilonHomo sapiens (human)
acyl-CoA dehydrogenase activityVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
long-chain fatty acyl-CoA dehydrogenase activityVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
protein bindingVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
very-long-chain fatty acyl-CoA dehydrogenase activityVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
identical protein bindingVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
flavin adenine dinucleotide bindingVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
fatty-acyl-CoA bindingVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
protein serine/threonine kinase activityDual specificity protein kinase CLK1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity protein kinase CLK1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityDual specificity protein kinase CLK1Homo sapiens (human)
protein bindingDual specificity protein kinase CLK1Homo sapiens (human)
ATP bindingDual specificity protein kinase CLK1Homo sapiens (human)
protein serine kinase activityDual specificity protein kinase CLK1Homo sapiens (human)
protein tyrosine kinase activityDual specificity protein kinase CLK1Homo sapiens (human)
protein serine/threonine kinase activityDual specificity protein kinase CLK2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity protein kinase CLK2Homo sapiens (human)
protein bindingDual specificity protein kinase CLK2Homo sapiens (human)
ATP bindingDual specificity protein kinase CLK2Homo sapiens (human)
identical protein bindingDual specificity protein kinase CLK2Homo sapiens (human)
protein serine kinase activityDual specificity protein kinase CLK2Homo sapiens (human)
protein tyrosine kinase activityDual specificity protein kinase CLK2Homo sapiens (human)
RNA bindingDual specificity protein kinase CLK3Homo sapiens (human)
protein serine/threonine kinase activityDual specificity protein kinase CLK3Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity protein kinase CLK3Homo sapiens (human)
protein tyrosine kinase activityDual specificity protein kinase CLK3Homo sapiens (human)
protein bindingDual specificity protein kinase CLK3Homo sapiens (human)
ATP bindingDual specificity protein kinase CLK3Homo sapiens (human)
identical protein bindingDual specificity protein kinase CLK3Homo sapiens (human)
protein serine kinase activityDual specificity protein kinase CLK3Homo sapiens (human)
protein serine/threonine kinase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
signaling receptor bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
ATP bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein kinase A catalytic subunit bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
tau protein bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
tau-protein kinase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein serine kinase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
protease bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
p53 bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein serine/threonine kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
ATP bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
ubiquitin protein ligase bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase A catalytic subunit bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
dynactin bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
tau protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
tau-protein kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
NF-kappaB bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein serine kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase activityCyclin-dependent kinase 7Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 7Homo sapiens (human)
protein bindingCyclin-dependent kinase 7Homo sapiens (human)
ATP bindingCyclin-dependent kinase 7Homo sapiens (human)
ATP-dependent activity, acting on DNACyclin-dependent kinase 7Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityCyclin-dependent kinase 7Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 7Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 7Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCyclin-dependent kinase 9Homo sapiens (human)
transcription coactivator bindingCyclin-dependent kinase 9Homo sapiens (human)
DNA bindingCyclin-dependent kinase 9Homo sapiens (human)
chromatin bindingCyclin-dependent kinase 9Homo sapiens (human)
transcription elongation factor activityCyclin-dependent kinase 9Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 9Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 9Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 9Homo sapiens (human)
protein bindingCyclin-dependent kinase 9Homo sapiens (human)
ATP bindingCyclin-dependent kinase 9Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityCyclin-dependent kinase 9Homo sapiens (human)
kinase activityCyclin-dependent kinase 9Homo sapiens (human)
protein kinase bindingCyclin-dependent kinase 9Homo sapiens (human)
7SK snRNA bindingCyclin-dependent kinase 9Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 9Homo sapiens (human)
GTPase activityRas-related protein Rab-27AHomo sapiens (human)
G protein activityRas-related protein Rab-27AHomo sapiens (human)
protein bindingRas-related protein Rab-27AHomo sapiens (human)
GTP bindingRas-related protein Rab-27AHomo sapiens (human)
GDP bindingRas-related protein Rab-27AHomo sapiens (human)
protein domain specific bindingRas-related protein Rab-27AHomo sapiens (human)
myosin V bindingRas-related protein Rab-27AHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase BlkHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase BlkHomo sapiens (human)
protein bindingTyrosine-protein kinase BlkHomo sapiens (human)
ATP bindingTyrosine-protein kinase BlkHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase BlkHomo sapiens (human)
protein kinase activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein serine/threonine kinase activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein bindingInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
ATP bindingInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
kinase activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein kinase bindingInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
heat shock protein bindingInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
identical protein bindingInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein homodimerization activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein heterodimerization activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein serine kinase activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein kinase activityRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-3Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein kinase bindingRibosomal protein S6 kinase alpha-3Homo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-3Homo sapiens (human)
ribosomal protein S6 kinase activityRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein tyrosine kinase activityCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
protein bindingCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
ATP bindingCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
metal ion bindingCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
cAMP-dependent protein kinase activitycAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
protein bindingcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
ATP bindingcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
protein serine kinase activitycAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase Nek2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek2Homo sapiens (human)
protein phosphatase bindingSerine/threonine-protein kinase Nek2Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek3Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek4Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek4Homo sapiens (human)
manganese ion bindingSerine/threonine-protein kinase Nek4Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek4Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase JAK3Homo sapiens (human)
protein bindingTyrosine-protein kinase JAK3Homo sapiens (human)
ATP bindingTyrosine-protein kinase JAK3Homo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase JAK3Homo sapiens (human)
growth hormone receptor bindingTyrosine-protein kinase JAK3Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase JAK3Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
protein kinase bindingDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase PLK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PLK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
microtubule bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
anaphase-promoting complex bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PLK1Homo sapiens (human)
protein kinase activityDeath-associated protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityDeath-associated protein kinase 1Homo sapiens (human)
calmodulin-dependent protein kinase activityDeath-associated protein kinase 1Homo sapiens (human)
protein bindingDeath-associated protein kinase 1Homo sapiens (human)
calmodulin bindingDeath-associated protein kinase 1Homo sapiens (human)
ATP bindingDeath-associated protein kinase 1Homo sapiens (human)
GTP bindingDeath-associated protein kinase 1Homo sapiens (human)
syntaxin-1 bindingDeath-associated protein kinase 1Homo sapiens (human)
identical protein bindingDeath-associated protein kinase 1Homo sapiens (human)
protein serine kinase activityDeath-associated protein kinase 1Homo sapiens (human)
protein kinase activityLIM domain kinase 1Homo sapiens (human)
protein serine/threonine kinase activityLIM domain kinase 1Homo sapiens (human)
protein bindingLIM domain kinase 1Homo sapiens (human)
ATP bindingLIM domain kinase 1Homo sapiens (human)
heat shock protein bindingLIM domain kinase 1Homo sapiens (human)
metal ion bindingLIM domain kinase 1Homo sapiens (human)
protein serine kinase activityLIM domain kinase 1Homo sapiens (human)
protein serine/threonine kinase activityLIM domain kinase 2Homo sapiens (human)
protein bindingLIM domain kinase 2Homo sapiens (human)
ATP bindingLIM domain kinase 2Homo sapiens (human)
metal ion bindingLIM domain kinase 2Homo sapiens (human)
protein serine kinase activityLIM domain kinase 2Homo sapiens (human)
magnesium ion bindingMitogen-activated protein kinase 12Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 12Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 12Homo sapiens (human)
protein bindingMitogen-activated protein kinase 12Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 12Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 12Homo sapiens (human)
JUN kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
protein bindingMitogen-activated protein kinase 10Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 10Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
tRNA bindingTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
RNA bindingTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
tyrosine-tRNA ligase activityTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
interleukin-8 receptor bindingTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
protein bindingTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
ATP bindingTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
small molecule bindingTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
protein kinase activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cAMP-dependent protein kinase activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
protein binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
ATP binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cAMP-dependent protein kinase regulator activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
AMP binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
protein kinase regulator activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
protein kinase binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
ADP binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
chromatin binding5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein serine/threonine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
AMP-activated protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein binding5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
ATP binding5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
metal ion binding5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein serine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
histone H2BS36 kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
ephrin receptor activityEphrin type-B receptor 3Homo sapiens (human)
protein bindingEphrin type-B receptor 3Homo sapiens (human)
ATP bindingEphrin type-B receptor 3Homo sapiens (human)
axon guidance receptor activityEphrin type-B receptor 3Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-B receptor 3Homo sapiens (human)
ephrin receptor activityEphrin type-A receptor 5Homo sapiens (human)
GPI-linked ephrin receptor activityEphrin type-A receptor 5Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 5Homo sapiens (human)
protein bindingEphrin type-A receptor 5Homo sapiens (human)
ATP bindingEphrin type-A receptor 5Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEphrin type-B receptor 4Homo sapiens (human)
ephrin receptor activityEphrin type-B receptor 4Homo sapiens (human)
protein bindingEphrin type-B receptor 4Homo sapiens (human)
ATP bindingEphrin type-B receptor 4Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-B receptor 1Homo sapiens (human)
protein bindingEphrin type-B receptor 1Homo sapiens (human)
ATP bindingEphrin type-B receptor 1Homo sapiens (human)
axon guidance receptor activityEphrin type-B receptor 1Homo sapiens (human)
protein-containing complex bindingEphrin type-B receptor 1Homo sapiens (human)
amyloid-beta bindingEphrin type-A receptor 4Homo sapiens (human)
protein kinase activityEphrin type-A receptor 4Homo sapiens (human)
protein tyrosine kinase activityEphrin type-A receptor 4Homo sapiens (human)
GPI-linked ephrin receptor activityEphrin type-A receptor 4Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 4Homo sapiens (human)
protein bindingEphrin type-A receptor 4Homo sapiens (human)
ATP bindingEphrin type-A receptor 4Homo sapiens (human)
kinase activityEphrin type-A receptor 4Homo sapiens (human)
PH domain bindingEphrin type-A receptor 4Homo sapiens (human)
identical protein bindingEphrin type-A receptor 4Homo sapiens (human)
ephrin receptor bindingEphrin type-A receptor 4Homo sapiens (human)
DH domain bindingEphrin type-A receptor 4Homo sapiens (human)
protein tyrosine kinase bindingEphrin type-A receptor 4Homo sapiens (human)
adenylate kinase activityAdenylate kinase 2, mitochondrialHomo sapiens (human)
protein bindingAdenylate kinase 2, mitochondrialHomo sapiens (human)
ATP bindingAdenylate kinase 2, mitochondrialHomo sapiens (human)
RNA bindingAdenosine kinaseHomo sapiens (human)
deoxyadenosine kinase activityAdenosine kinaseHomo sapiens (human)
ATP bindingAdenosine kinaseHomo sapiens (human)
metal ion bindingAdenosine kinaseHomo sapiens (human)
adenosine kinase activityAdenosine kinaseHomo sapiens (human)
amyloid-beta bindingBeta-secretase 1Homo sapiens (human)
endopeptidase activityBeta-secretase 1Homo sapiens (human)
aspartic-type endopeptidase activityBeta-secretase 1Homo sapiens (human)
protein bindingBeta-secretase 1Homo sapiens (human)
peptidase activityBeta-secretase 1Homo sapiens (human)
beta-aspartyl-peptidase activityBeta-secretase 1Homo sapiens (human)
enzyme bindingBeta-secretase 1Homo sapiens (human)
protein serine/threonine kinase bindingBeta-secretase 1Homo sapiens (human)
protein bindingHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
ATP bindingHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
protein serine kinase activityHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
protein serine/threonine kinase activityHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase SIK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
cAMP response element binding protein bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
histone deacetylase bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
14-3-3 protein bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase SIK1Homo sapiens (human)
protein serine/threonine kinase activityReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
protein bindingReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
ATP bindingReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
protein serine kinase activityReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
G protein activityRas-related protein Rab-10Homo sapiens (human)
protein bindingRas-related protein Rab-10Homo sapiens (human)
GTP bindingRas-related protein Rab-10Homo sapiens (human)
GDP bindingRas-related protein Rab-10Homo sapiens (human)
myosin V bindingRas-related protein Rab-10Homo sapiens (human)
cadherin binding involved in cell-cell adhesionRas-related protein Rab-10Homo sapiens (human)
actin filament bindingActin-related protein 3Homo sapiens (human)
structural constituent of cytoskeletonActin-related protein 3Homo sapiens (human)
protein bindingActin-related protein 3Homo sapiens (human)
ATP bindingActin-related protein 3Homo sapiens (human)
actin filament bindingActin-related protein 2Homo sapiens (human)
structural constituent of cytoskeletonActin-related protein 2Homo sapiens (human)
protein bindingActin-related protein 2Homo sapiens (human)
ATP bindingActin-related protein 2Homo sapiens (human)
nuclear export signal receptor activityGTP-binding nuclear protein RanHomo sapiens (human)
pre-miRNA bindingGTP-binding nuclear protein RanHomo sapiens (human)
magnesium ion bindingGTP-binding nuclear protein RanHomo sapiens (human)
chromatin bindingGTP-binding nuclear protein RanHomo sapiens (human)
RNA bindingGTP-binding nuclear protein RanHomo sapiens (human)
GTPase activityGTP-binding nuclear protein RanHomo sapiens (human)
G protein activityGTP-binding nuclear protein RanHomo sapiens (human)
protein bindingGTP-binding nuclear protein RanHomo sapiens (human)
GTP bindingGTP-binding nuclear protein RanHomo sapiens (human)
GDP bindingGTP-binding nuclear protein RanHomo sapiens (human)
protein domain specific bindingGTP-binding nuclear protein RanHomo sapiens (human)
cadherin bindingGTP-binding nuclear protein RanHomo sapiens (human)
dynein intermediate chain bindingGTP-binding nuclear protein RanHomo sapiens (human)
protein heterodimerization activityGTP-binding nuclear protein RanHomo sapiens (human)
importin-alpha family protein bindingGTP-binding nuclear protein RanHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit alphaHomo sapiens (human)
protein bindingCasein kinase II subunit alphaHomo sapiens (human)
ATP bindingCasein kinase II subunit alphaHomo sapiens (human)
kinase activityCasein kinase II subunit alphaHomo sapiens (human)
identical protein bindingCasein kinase II subunit alphaHomo sapiens (human)
Hsp90 protein bindingCasein kinase II subunit alphaHomo sapiens (human)
protein serine kinase activityCasein kinase II subunit alphaHomo sapiens (human)
protein bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
ATP bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
GTP bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 5-kinase activityPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
protein homodimerization activityPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
1-phosphatidylinositol-5-phosphate 4-kinase activityPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
magnesium ion bindingSRSF protein kinase 2Homo sapiens (human)
RNA bindingSRSF protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activitySRSF protein kinase 2Homo sapiens (human)
protein bindingSRSF protein kinase 2Homo sapiens (human)
ATP bindingSRSF protein kinase 2Homo sapiens (human)
14-3-3 protein bindingSRSF protein kinase 2Homo sapiens (human)
protein serine kinase activitySRSF protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform gamma-2Homo sapiens (human)
protein bindingCasein kinase I isoform gamma-2Homo sapiens (human)
ATP bindingCasein kinase I isoform gamma-2Homo sapiens (human)
protein serine kinase activityCasein kinase I isoform gamma-2Homo sapiens (human)
double-stranded DNA bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
RNA bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein serine/threonine kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA-dependent protein kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
ATP bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
enzyme bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein domain specific bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
U3 snoRNA bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
histone H2AXS139 kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein serine kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
molecular function activator activityMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
protein bindingCyclin-dependent kinase 3Homo sapiens (human)
ATP bindingCyclin-dependent kinase 3Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 3Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 3Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 3Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase-like 1Homo sapiens (human)
ATP bindingCyclin-dependent kinase-like 1Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase-like 1Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase-like 1Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 6Homo sapiens (human)
protein bindingCyclin-dependent kinase 6Homo sapiens (human)
ATP bindingCyclin-dependent kinase 6Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 6Homo sapiens (human)
FBXO family protein bindingCyclin-dependent kinase 6Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 6Homo sapiens (human)
microtubule bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
p53 bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
protein kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
ErbB-2 class receptor bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
protein bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
ATP bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
acetylcholine receptor activator activityCyclin-dependent-like kinase 5 Homo sapiens (human)
ErbB-3 class receptor bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
tau protein bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
tau-protein kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
Hsp90 protein bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
protein serine kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 16Homo sapiens (human)
protein bindingCyclin-dependent kinase 16Homo sapiens (human)
ATP bindingCyclin-dependent kinase 16Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 16Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 16Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 17Homo sapiens (human)
protein bindingCyclin-dependent kinase 17Homo sapiens (human)
ATP bindingCyclin-dependent kinase 17Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 17Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 17Homo sapiens (human)
6-phosphofructokinase activityATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
protein bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
protein-containing complex bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
cadherin bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
metal ion bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
ATP bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
monosaccharide bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
AMP bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
identical protein bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
fructose-6-phosphate bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
actin monomer bindingProtein kinase C epsilon typeHomo sapiens (human)
protein kinase activityProtein kinase C epsilon typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C epsilon typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C epsilon typeHomo sapiens (human)
diacylglycerol-dependent, calcium-independent serine/threonine kinase activityProtein kinase C epsilon typeHomo sapiens (human)
protein bindingProtein kinase C epsilon typeHomo sapiens (human)
ATP bindingProtein kinase C epsilon typeHomo sapiens (human)
enzyme activator activityProtein kinase C epsilon typeHomo sapiens (human)
enzyme bindingProtein kinase C epsilon typeHomo sapiens (human)
signaling receptor activator activityProtein kinase C epsilon typeHomo sapiens (human)
ethanol bindingProtein kinase C epsilon typeHomo sapiens (human)
metal ion bindingProtein kinase C epsilon typeHomo sapiens (human)
14-3-3 protein bindingProtein kinase C epsilon typeHomo sapiens (human)
protein serine kinase activityProtein kinase C epsilon typeHomo sapiens (human)
protein kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
MAP-kinase scaffold activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein kinase activator activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein serine/threonine kinase activator activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
scaffold protein bindingDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein kinase activityAngiopoietin-1 receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityAngiopoietin-1 receptorHomo sapiens (human)
protein bindingAngiopoietin-1 receptorHomo sapiens (human)
ATP bindingAngiopoietin-1 receptorHomo sapiens (human)
growth factor bindingAngiopoietin-1 receptorHomo sapiens (human)
signaling receptor activityAngiopoietin-1 receptorHomo sapiens (human)
identical protein bindingAngiopoietin-1 receptorHomo sapiens (human)
transcription corepressor activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
bHLH transcription factor bindingMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
DNA bindingDNA topoisomerase 2-betaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-betaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-betaHomo sapiens (human)
protein bindingDNA topoisomerase 2-betaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-betaHomo sapiens (human)
ribonucleoprotein complex bindingDNA topoisomerase 2-betaHomo sapiens (human)
metal ion bindingDNA topoisomerase 2-betaHomo sapiens (human)
transcription cis-regulatory region bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
transcription coactivator bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA bindingTranscription factor p65Homo sapiens (human)
chromatin bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activityTranscription factor p65Homo sapiens (human)
protein bindingTranscription factor p65Homo sapiens (human)
enzyme bindingTranscription factor p65Homo sapiens (human)
protein kinase bindingTranscription factor p65Homo sapiens (human)
chromatin DNA bindingTranscription factor p65Homo sapiens (human)
ubiquitin protein ligase bindingTranscription factor p65Homo sapiens (human)
peptide bindingTranscription factor p65Homo sapiens (human)
phosphate ion bindingTranscription factor p65Homo sapiens (human)
identical protein bindingTranscription factor p65Homo sapiens (human)
protein homodimerization activityTranscription factor p65Homo sapiens (human)
actinin bindingTranscription factor p65Homo sapiens (human)
histone deacetylase bindingTranscription factor p65Homo sapiens (human)
NF-kappaB bindingTranscription factor p65Homo sapiens (human)
ankyrin repeat bindingTranscription factor p65Homo sapiens (human)
general transcription initiation factor bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor bindingTranscription factor p65Homo sapiens (human)
protein kinase activityProtein kinase C theta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C theta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C theta typeHomo sapiens (human)
protein bindingProtein kinase C theta typeHomo sapiens (human)
ATP bindingProtein kinase C theta typeHomo sapiens (human)
metal ion bindingProtein kinase C theta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C theta typeHomo sapiens (human)
activin receptor activity, type IActivin receptor type-1Homo sapiens (human)
protein kinase activityActivin receptor type-1Homo sapiens (human)
protein serine/threonine kinase activityActivin receptor type-1Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityActivin receptor type-1Homo sapiens (human)
protein bindingActivin receptor type-1Homo sapiens (human)
ATP bindingActivin receptor type-1Homo sapiens (human)
peptide hormone bindingActivin receptor type-1Homo sapiens (human)
protein homodimerization activityActivin receptor type-1Homo sapiens (human)
cadherin bindingActivin receptor type-1Homo sapiens (human)
SMAD bindingActivin receptor type-1Homo sapiens (human)
metal ion bindingActivin receptor type-1Homo sapiens (human)
activin bindingActivin receptor type-1Homo sapiens (human)
transforming growth factor beta bindingActivin receptor type-1Homo sapiens (human)
BMP receptor activityActivin receptor type-1Homo sapiens (human)
protein tyrosine kinase bindingActivin receptor type-1Homo sapiens (human)
transforming growth factor beta receptor activity, type IActivin receptor type-1Homo sapiens (human)
macrophage colony-stimulating factor receptor activityMacrophage-stimulating protein receptorHomo sapiens (human)
protein bindingMacrophage-stimulating protein receptorHomo sapiens (human)
ATP bindingMacrophage-stimulating protein receptorHomo sapiens (human)
enzyme bindingMacrophage-stimulating protein receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityMacrophage-stimulating protein receptorHomo sapiens (human)
actin bindingFocal adhesion kinase 1Homo sapiens (human)
protein tyrosine kinase activityFocal adhesion kinase 1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityFocal adhesion kinase 1Homo sapiens (human)
protein tyrosine phosphatase activityFocal adhesion kinase 1Homo sapiens (human)
integrin bindingFocal adhesion kinase 1Homo sapiens (human)
protein bindingFocal adhesion kinase 1Homo sapiens (human)
ATP bindingFocal adhesion kinase 1Homo sapiens (human)
JUN kinase bindingFocal adhesion kinase 1Homo sapiens (human)
protein kinase bindingFocal adhesion kinase 1Homo sapiens (human)
protein phosphatase bindingFocal adhesion kinase 1Homo sapiens (human)
SH2 domain bindingFocal adhesion kinase 1Homo sapiens (human)
molecular function activator activityFocal adhesion kinase 1Homo sapiens (human)
protein kinase activityProtein kinase C zeta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C zeta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C zeta typeHomo sapiens (human)
protein bindingProtein kinase C zeta typeHomo sapiens (human)
ATP bindingProtein kinase C zeta typeHomo sapiens (human)
potassium channel regulator activityProtein kinase C zeta typeHomo sapiens (human)
protein kinase bindingProtein kinase C zeta typeHomo sapiens (human)
phospholipase bindingProtein kinase C zeta typeHomo sapiens (human)
insulin receptor substrate bindingProtein kinase C zeta typeHomo sapiens (human)
protein-containing complex bindingProtein kinase C zeta typeHomo sapiens (human)
metal ion bindingProtein kinase C zeta typeHomo sapiens (human)
14-3-3 protein bindingProtein kinase C zeta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C zeta typeHomo sapiens (human)
protein kinase activityProtein kinase C delta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
diacylglycerol-dependent, calcium-independent serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProtein kinase C delta typeHomo sapiens (human)
protein bindingProtein kinase C delta typeHomo sapiens (human)
ATP bindingProtein kinase C delta typeHomo sapiens (human)
enzyme activator activityProtein kinase C delta typeHomo sapiens (human)
enzyme bindingProtein kinase C delta typeHomo sapiens (human)
protein kinase bindingProtein kinase C delta typeHomo sapiens (human)
insulin receptor substrate bindingProtein kinase C delta typeHomo sapiens (human)
metal ion bindingProtein kinase C delta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C delta typeHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase BTKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase BTKHomo sapiens (human)
protein bindingTyrosine-protein kinase BTKHomo sapiens (human)
ATP bindingTyrosine-protein kinase BTKHomo sapiens (human)
phosphatidylinositol-3,4,5-trisphosphate bindingTyrosine-protein kinase BTKHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase BTKHomo sapiens (human)
identical protein bindingTyrosine-protein kinase BTKHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase BTKHomo sapiens (human)
metal ion bindingTyrosine-protein kinase BTKHomo sapiens (human)
virus receptor activityTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
protein bindingTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
ATP bindingTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
phosphatidylinositol 3-kinase bindingTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
protein bindingCyclin-dependent kinase 18Homo sapiens (human)
ATP bindingCyclin-dependent kinase 18Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 18Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 18Homo sapiens (human)
protein serine/threonine kinase activityActivated CDC42 kinase 1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityActivated CDC42 kinase 1Homo sapiens (human)
protein tyrosine kinase activityActivated CDC42 kinase 1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityActivated CDC42 kinase 1Homo sapiens (human)
GTPase inhibitor activityActivated CDC42 kinase 1Homo sapiens (human)
epidermal growth factor receptor bindingActivated CDC42 kinase 1Homo sapiens (human)
protein bindingActivated CDC42 kinase 1Homo sapiens (human)
ATP bindingActivated CDC42 kinase 1Homo sapiens (human)
ubiquitin protein ligase bindingActivated CDC42 kinase 1Homo sapiens (human)
identical protein bindingActivated CDC42 kinase 1Homo sapiens (human)
metal ion bindingActivated CDC42 kinase 1Homo sapiens (human)
WW domain bindingActivated CDC42 kinase 1Homo sapiens (human)
protein serine kinase activityActivated CDC42 kinase 1Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
protein bindingEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
collagen bindingEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
ATP bindingEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
protein tyrosine kinase collagen receptor activityEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
metal ion bindingEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase ITK/TSKHomo sapiens (human)
protein bindingTyrosine-protein kinase ITK/TSKHomo sapiens (human)
ATP bindingTyrosine-protein kinase ITK/TSKHomo sapiens (human)
metal ion bindingTyrosine-protein kinase ITK/TSKHomo sapiens (human)
protein serine/threonine kinase activityMyotonin-protein kinaseHomo sapiens (human)
protein bindingMyotonin-protein kinaseHomo sapiens (human)
ATP bindingMyotonin-protein kinaseHomo sapiens (human)
myosin phosphatase regulator activityMyotonin-protein kinaseHomo sapiens (human)
metal ion bindingMyotonin-protein kinaseHomo sapiens (human)
protein serine kinase activityMyotonin-protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
MAP kinase kinase kinase kinase activityMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein serine/threonine kinase activator activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein bindingTyrosine-protein kinase MerHomo sapiens (human)
ATP bindingTyrosine-protein kinase MerHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityTyrosine-protein kinase MerHomo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase 4Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase 4Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 4Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 4Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 4Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase 4Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase 4Homo sapiens (human)
protein serine/threonine kinase activator activitySerine/threonine-protein kinase 4Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingSerine/threonine-protein kinase 4Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 4Homo sapiens (human)
chromatin binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein serine/threonine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
AMP-activated protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cAMP-dependent protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
ATP binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
metal ion binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
tau protein binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
tau-protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein serine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
histone H2BS36 kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
collagen bindingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
gamma-tubulin bindingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein kinase activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
metal ion bindingDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 7Homo sapiens (human)
enzyme inhibitor activityMitogen-activated protein kinase 7Homo sapiens (human)
protein bindingMitogen-activated protein kinase 7Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 7Homo sapiens (human)
mitogen-activated protein kinase bindingMitogen-activated protein kinase 7Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 7Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 7Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein tyrosine kinase activator activitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cadherin bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase 3Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase 3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 3Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase 3Homo sapiens (human)
protein serine/threonine kinase activator activitySerine/threonine-protein kinase 3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 3Homo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
zinc ion bindingMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein kinase activitycGMP-dependent protein kinase 2Homo sapiens (human)
cGMP-dependent protein kinase activitycGMP-dependent protein kinase 2Homo sapiens (human)
ATP bindingcGMP-dependent protein kinase 2Homo sapiens (human)
cGMP bindingcGMP-dependent protein kinase 2Homo sapiens (human)
identical protein bindingcGMP-dependent protein kinase 2Homo sapiens (human)
mitogen-activated protein kinase bindingcGMP-dependent protein kinase 2Homo sapiens (human)
protein serine kinase activitycGMP-dependent protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityIntegrin-linked protein kinaseHomo sapiens (human)
protein bindingIntegrin-linked protein kinaseHomo sapiens (human)
ATP bindingIntegrin-linked protein kinaseHomo sapiens (human)
protein kinase bindingIntegrin-linked protein kinaseHomo sapiens (human)
protein serine kinase activityIntegrin-linked protein kinaseHomo sapiens (human)
protein kinase activityRho-associated protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityRho-associated protein kinase 1Homo sapiens (human)
protein bindingRho-associated protein kinase 1Homo sapiens (human)
ATP bindingRho-associated protein kinase 1Homo sapiens (human)
small GTPase bindingRho-associated protein kinase 1Homo sapiens (human)
metal ion bindingRho-associated protein kinase 1Homo sapiens (human)
tau protein bindingRho-associated protein kinase 1Homo sapiens (human)
tau-protein kinase activityRho-associated protein kinase 1Homo sapiens (human)
Rho-dependent protein serine/threonine kinase activityRho-associated protein kinase 1Homo sapiens (human)
protein serine kinase activityRho-associated protein kinase 1Homo sapiens (human)
protein tyrosine kinase activityNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
protein bindingNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
ATP bindingNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
RNA bindingSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
protein bindingSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
protein kinase activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
death receptor bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
ATP bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
ubiquitin protein ligase bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
signaling adaptor activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
identical protein bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein homodimerization activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein-containing complex bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
death domain bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein serine kinase activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
JUN kinase kinase kinase activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
actin bindingCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
calcium-dependent protein serine/threonine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
identical protein bindingCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
protein homodimerization activityCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
calcium-dependent protein serine/threonine phosphatase activityCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
identical protein bindingCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
protein homodimerization activityCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
protein serine/threonine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
sodium channel inhibitor activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
titin bindingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
identical protein bindingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
protein homodimerization activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
transmembrane transporter bindingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
protein kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein serine/threonine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein bindingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
ATP bindingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
identical protein bindingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
tau protein bindingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
tau-protein kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein serine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
histone H3T45 kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
transcription coactivator activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
activin receptor activity, type IIActivin receptor type-2BHomo sapiens (human)
protein serine/threonine kinase activityActivin receptor type-2BHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityActivin receptor type-2BHomo sapiens (human)
protein bindingActivin receptor type-2BHomo sapiens (human)
ATP bindingActivin receptor type-2BHomo sapiens (human)
activin receptor activity, type IIActivin receptor type-2BHomo sapiens (human)
kinase activator activityActivin receptor type-2BHomo sapiens (human)
growth factor bindingActivin receptor type-2BHomo sapiens (human)
metal ion bindingActivin receptor type-2BHomo sapiens (human)
activin bindingActivin receptor type-2BHomo sapiens (human)
activin receptor activityActivin receptor type-2BHomo sapiens (human)
protein bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
ATP bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
activin receptor activity, type IIBone morphogenetic protein receptor type-2Homo sapiens (human)
growth factor bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
BMP bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
cadherin bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
metal ion bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
BMP receptor activityBone morphogenetic protein receptor type-2Homo sapiens (human)
protein tyrosine kinase bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
transforming growth factor beta receptor activityBone morphogenetic protein receptor type-2Homo sapiens (human)
protein tyrosine kinase activityProtein-tyrosine kinase 6Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProtein-tyrosine kinase 6Homo sapiens (human)
protein bindingProtein-tyrosine kinase 6Homo sapiens (human)
ATP bindingProtein-tyrosine kinase 6Homo sapiens (human)
identical protein bindingProtein-tyrosine kinase 6Homo sapiens (human)
signaling receptor bindingProtein-tyrosine kinase 6Homo sapiens (human)
protein kinase activitycGMP-dependent protein kinase 1 Homo sapiens (human)
cGMP-dependent protein kinase activitycGMP-dependent protein kinase 1 Homo sapiens (human)
calcium channel regulator activitycGMP-dependent protein kinase 1 Homo sapiens (human)
protein bindingcGMP-dependent protein kinase 1 Homo sapiens (human)
ATP bindingcGMP-dependent protein kinase 1 Homo sapiens (human)
cGMP bindingcGMP-dependent protein kinase 1 Homo sapiens (human)
identical protein bindingcGMP-dependent protein kinase 1 Homo sapiens (human)
mitogen-activated protein kinase p38 bindingcGMP-dependent protein kinase 1 Homo sapiens (human)
protein serine kinase activitycGMP-dependent protein kinase 1 Homo sapiens (human)
RNA bindingCyclin-dependent kinase 13Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 13Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 13Homo sapiens (human)
protein bindingCyclin-dependent kinase 13Homo sapiens (human)
ATP bindingCyclin-dependent kinase 13Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityCyclin-dependent kinase 13Homo sapiens (human)
protein kinase bindingCyclin-dependent kinase 13Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 13Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 13Homo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
K63-linked polyubiquitin modification-dependent protein bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
protein serine/threonine kinase activityInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
protein bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
ATP bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
IkappaB kinase activityInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
protein phosphatase bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
ubiquitin protein ligase bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
K48-linked polyubiquitin modification-dependent protein bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
identical protein bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
calmodulin-dependent protein kinase activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein tyrosine kinase activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
ATP bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
ubiquitin protein ligase bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
glutamate receptor bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
3-phosphoinositide-dependent protein kinase bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein-containing complex bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
neurotransmitter receptor regulator activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein serine/threonine kinase activityMaternal embryonic leucine zipper kinaseHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityMaternal embryonic leucine zipper kinaseHomo sapiens (human)
calcium ion bindingMaternal embryonic leucine zipper kinaseHomo sapiens (human)
protein bindingMaternal embryonic leucine zipper kinaseHomo sapiens (human)
ATP bindingMaternal embryonic leucine zipper kinaseHomo sapiens (human)
lipid bindingMaternal embryonic leucine zipper kinaseHomo sapiens (human)
protein serine kinase activityMaternal embryonic leucine zipper kinaseHomo sapiens (human)
chromatin bindingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
RNA bindingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
protein bindingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
ATP bindingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
ATP hydrolysis activityStructural maintenance of chromosomes protein 1AHomo sapiens (human)
mediator complex bindingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
protein heterodimerization activityStructural maintenance of chromosomes protein 1AHomo sapiens (human)
DNA bindingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
nucleosomal DNA bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
transcription coregulator bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
transcription corepressor activityChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
helicase activityChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
protein bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
ATP bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
zinc ion bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
ATP hydrolysis activityChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
histone deacetylase bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
ATP-dependent chromatin remodeler activityChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
chromatin bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
DNA bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
histone bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
acyl-CoA oxidase activityPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
protein bindingPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
PDZ domain bindingPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
protein homodimerization activityPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
FAD bindingPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
fatty acid bindingPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
flavin adenine dinucleotide bindingPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
palmitoyl-CoA oxidase activityPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase D1Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activitySerine/threonine-protein kinase D1Homo sapiens (human)
protein kinase C bindingSerine/threonine-protein kinase D1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase D1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase D1Homo sapiens (human)
kinase activitySerine/threonine-protein kinase D1Homo sapiens (human)
heat shock protein bindingSerine/threonine-protein kinase D1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase D1Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase D1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase D1Homo sapiens (human)
phosphatidylinositol 3-kinase activator activitySerine/threonine-protein kinase D1Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase 38Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 38Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 38Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 38Homo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingSerine/threonine-protein kinase 38Homo sapiens (human)
cadherin bindingSerine/threonine-protein kinase 38Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 38Homo sapiens (human)
histone reader activitySerine/threonine-protein kinase 38Homo sapiens (human)
UFM1-modified protein reader activitySerine/threonine-protein kinase 38Homo sapiens (human)
transcription cis-regulatory region bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
epidermal growth factor receptor activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
epidermal growth factor receptor bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ATP bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neuregulin receptor activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein homodimerization activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
GABA receptor bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-2Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase alpha-2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityRibosomal protein S6 kinase alpha-2Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-2Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-2Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-2Homo sapiens (human)
ribosomal protein S6 kinase activityRibosomal protein S6 kinase alpha-2Homo sapiens (human)
protein tyrosine kinase activityEphrin type-A receptor 7Homo sapiens (human)
GPI-linked ephrin receptor activityEphrin type-A receptor 7Homo sapiens (human)
protein bindingEphrin type-A receptor 7Homo sapiens (human)
ATP bindingEphrin type-A receptor 7Homo sapiens (human)
axon guidance receptor activityEphrin type-A receptor 7Homo sapiens (human)
growth factor bindingEphrin type-A receptor 7Homo sapiens (human)
chemorepellent activityEphrin type-A receptor 7Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 7Homo sapiens (human)
delta24(24-1) sterol reductase activityDelta(24)-sterol reductaseHomo sapiens (human)
protein bindingDelta(24)-sterol reductaseHomo sapiens (human)
oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptorDelta(24)-sterol reductaseHomo sapiens (human)
enzyme bindingDelta(24)-sterol reductaseHomo sapiens (human)
peptide antigen bindingDelta(24)-sterol reductaseHomo sapiens (human)
delta24-sterol reductase activityDelta(24)-sterol reductaseHomo sapiens (human)
FAD bindingDelta(24)-sterol reductaseHomo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-1Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase alpha-1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityRibosomal protein S6 kinase alpha-1Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-1Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-1Homo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processRibosomal protein S6 kinase alpha-1Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-1Homo sapiens (human)
ribosomal protein S6 kinase activityRibosomal protein S6 kinase alpha-1Homo sapiens (human)
protein kinase activityDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein tyrosine kinase activityDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein bindingDual specificity testis-specific protein kinase 1Homo sapiens (human)
ATP bindingDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein kinase bindingDual specificity testis-specific protein kinase 1Homo sapiens (human)
metal ion bindingDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein serine kinase activityDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityDual specificity testis-specific protein kinase 1Homo sapiens (human)
actin bindingMyosin light chain kinase, smooth muscleHomo sapiens (human)
myosin light chain kinase activityMyosin light chain kinase, smooth muscleHomo sapiens (human)
protein bindingMyosin light chain kinase, smooth muscleHomo sapiens (human)
calmodulin bindingMyosin light chain kinase, smooth muscleHomo sapiens (human)
ATP bindingMyosin light chain kinase, smooth muscleHomo sapiens (human)
metal ion bindingMyosin light chain kinase, smooth muscleHomo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 11Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 11Homo sapiens (human)
protein bindingMitogen-activated protein kinase 11Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 11Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 11Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase STK11Homo sapiens (human)
p53 bindingSerine/threonine-protein kinase STK11Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase STK11Homo sapiens (human)
protein bindingSerine/threonine-protein kinase STK11Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase STK11Homo sapiens (human)
LRR domain bindingSerine/threonine-protein kinase STK11Homo sapiens (human)
protein kinase activator activitySerine/threonine-protein kinase STK11Homo sapiens (human)
protein-containing complex bindingSerine/threonine-protein kinase STK11Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase STK11Homo sapiens (human)
protein kinase activityRhodopsin kinase GRK1Homo sapiens (human)
ATP bindingRhodopsin kinase GRK1Homo sapiens (human)
rhodopsin kinase activityRhodopsin kinase GRK1Homo sapiens (human)
p53 bindingNT-3 growth factor receptorHomo sapiens (human)
neurotrophin receptor activityNT-3 growth factor receptorHomo sapiens (human)
protein bindingNT-3 growth factor receptorHomo sapiens (human)
ATP bindingNT-3 growth factor receptorHomo sapiens (human)
neurotrophin bindingNT-3 growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityNT-3 growth factor receptorHomo sapiens (human)
chromatin bindingSerine/threonine-protein kinase N1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase N1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase N1Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activitySerine/threonine-protein kinase N1Homo sapiens (human)
protein kinase C bindingSerine/threonine-protein kinase N1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase N1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase N1Homo sapiens (human)
nuclear receptor coactivator activitySerine/threonine-protein kinase N1Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase N1Homo sapiens (human)
histone H3T11 kinase activitySerine/threonine-protein kinase N1Homo sapiens (human)
histone bindingSerine/threonine-protein kinase N1Homo sapiens (human)
histone deacetylase bindingSerine/threonine-protein kinase N1Homo sapiens (human)
nuclear androgen receptor bindingSerine/threonine-protein kinase N1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase N1Homo sapiens (human)
RNA bindingSerine/threonine-protein kinase N2Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase N2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase N2Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activitySerine/threonine-protein kinase N2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase N2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase N2Homo sapiens (human)
kinase activitySerine/threonine-protein kinase N2Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase N2Homo sapiens (human)
histone deacetylase bindingSerine/threonine-protein kinase N2Homo sapiens (human)
cadherin bindingSerine/threonine-protein kinase N2Homo sapiens (human)
RNA polymerase bindingSerine/threonine-protein kinase N2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase N2Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 14Homo sapiens (human)
enzyme bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein phosphatase bindingMitogen-activated protein kinase 14Homo sapiens (human)
mitogen-activated protein kinase p38 bindingMitogen-activated protein kinase 14Homo sapiens (human)
NFAT protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
calcium-dependent protein serine/threonine kinase activityCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
small GTPase bindingMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
mitogen-activated protein kinase kinase bindingMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protease bindingBDNF/NT-3 growth factors receptorHomo sapiens (human)
protein bindingBDNF/NT-3 growth factors receptorHomo sapiens (human)
ATP bindingBDNF/NT-3 growth factors receptorHomo sapiens (human)
protein homodimerization activityBDNF/NT-3 growth factors receptorHomo sapiens (human)
neurotrophin bindingBDNF/NT-3 growth factors receptorHomo sapiens (human)
brain-derived neurotrophic factor bindingBDNF/NT-3 growth factors receptorHomo sapiens (human)
brain-derived neurotrophic factor receptor activityBDNF/NT-3 growth factors receptorHomo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 6Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 6Homo sapiens (human)
protein bindingMitogen-activated protein kinase 6Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 6Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase 6Homo sapiens (human)
protein heterodimerization activityMitogen-activated protein kinase 6Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 6Homo sapiens (human)
phosphorylase kinase activityPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
calmodulin bindingPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
ATP bindingPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
enzyme bindingPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
tau-protein kinase activityPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
protein serine kinase activityPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityDiscoidin domain-containing receptor 2Homo sapiens (human)
protein bindingDiscoidin domain-containing receptor 2Homo sapiens (human)
collagen bindingDiscoidin domain-containing receptor 2Homo sapiens (human)
ATP bindingDiscoidin domain-containing receptor 2Homo sapiens (human)
protein tyrosine kinase collagen receptor activityDiscoidin domain-containing receptor 2Homo sapiens (human)
protein serine/threonine kinase activityAP2-associated protein kinase 1Homo sapiens (human)
Notch bindingAP2-associated protein kinase 1Homo sapiens (human)
protein bindingAP2-associated protein kinase 1Homo sapiens (human)
ATP bindingAP2-associated protein kinase 1Homo sapiens (human)
AP-2 adaptor complex bindingAP2-associated protein kinase 1Homo sapiens (human)
protein serine kinase activityAP2-associated protein kinase 1Homo sapiens (human)
calmodulin-dependent protein kinase activityMyosin light chain kinase 3Homo sapiens (human)
myosin light chain kinase activityMyosin light chain kinase 3Homo sapiens (human)
protein bindingMyosin light chain kinase 3Homo sapiens (human)
ATP bindingMyosin light chain kinase 3Homo sapiens (human)
protein serine/threonine kinase activityUncharacterized aarF domain-containing protein kinase 5Homo sapiens (human)
protein bindingUncharacterized aarF domain-containing protein kinase 5Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase SBK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase SBK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase SBK1Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 19Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 19Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 19Homo sapiens (human)
molecular_functionPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
ATP hydrolysis activityPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
ATP-dependent protein folding chaperonePutative heat shock protein HSP 90-beta 2Homo sapiens (human)
disordered domain specific bindingPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
ATP bindingPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
unfolded protein bindingPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase TNNI3KHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase TNNI3KHomo sapiens (human)
protein bindingSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
metal ion bindingSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase TNNI3KHomo sapiens (human)
SNARE bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
magnesium ion bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
actin bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
GTPase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
JUN kinase kinase kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
MAP kinase kinase kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
GTPase activator activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
ATP bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
GTP bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
microtubule bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
tubulin bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
syntaxin-1 bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
signaling receptor complex adaptor activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
clathrin bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
small GTPase bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
GTP-dependent protein kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
peroxidase inhibitor activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
co-receptor bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
identical protein bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein homodimerization activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
transmembrane transporter bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein kinase A bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein serine kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
beta-catenin destruction complex bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
protein bindingSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
identical protein bindingSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
protein bindingSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
acyl-CoA dehydrogenase activityAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
flavin adenine dinucleotide bindingAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek5Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek5Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek5Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek5Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase Nek5Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase N3Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activitySerine/threonine-protein kinase N3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase N3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase N3Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase N3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase N3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase N3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase ULK3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase ULK3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase ULK3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase ULK3Homo sapiens (human)
protein serine/threonine kinase activityDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
protein tyrosine kinase activityDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
protein bindingDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
ATP bindingDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
protein serine kinase activityDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 15Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 15Homo sapiens (human)
metal ion bindingMitogen-activated protein kinase kinase kinase 15Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 15Homo sapiens (human)
acyl-CoA dehydrogenase activityAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
long-chain fatty acyl-CoA dehydrogenase activityAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
protein bindingAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
very-long-chain fatty acyl-CoA dehydrogenase activityAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
flavin adenine dinucleotide bindingAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
medium-chain fatty acyl-CoA dehydrogenase activityAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
endonuclease activitySerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
RNA endonuclease activitySerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
unfolded protein bindingSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
RNA bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase MARK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
lipid bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
protein kinase activator activitySerine/threonine-protein kinase MARK2Homo sapiens (human)
cadherin bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase MARK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase MARK2Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase TAO1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase TAO1Homo sapiens (human)
kinase activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
transferase activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
alpha-tubulin bindingSerine/threonine-protein kinase TAO1Homo sapiens (human)
protein serine/threonine kinase activator activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase TAO1Homo sapiens (human)
beta-tubulin bindingSerine/threonine-protein kinase TAO1Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
protein kinase activitySTE20-related kinase adapter protein alphaHomo sapiens (human)
protein bindingSTE20-related kinase adapter protein alphaHomo sapiens (human)
ATP bindingSTE20-related kinase adapter protein alphaHomo sapiens (human)
kinase bindingSTE20-related kinase adapter protein alphaHomo sapiens (human)
protein kinase activator activitySTE20-related kinase adapter protein alphaHomo sapiens (human)
protein serine/threonine kinase activator activitySTE20-related kinase adapter protein alphaHomo sapiens (human)
microfilament motor activityMyosin-14Homo sapiens (human)
actin filament bindingMyosin-14Homo sapiens (human)
calmodulin bindingMyosin-14Homo sapiens (human)
ATP bindingMyosin-14Homo sapiens (human)
protein serine/threonine kinase activityAarF domain-containing protein kinase 1Homo sapiens (human)
ATP bindingAarF domain-containing protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 32CHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase 32CHomo sapiens (human)
metal ion bindingSerine/threonine-protein kinase 32CHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 32CHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 32CHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase pim-3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase pim-3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase pim-3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase pim-3Homo sapiens (human)
RNA bindingATP-dependent RNA helicase DDX42Homo sapiens (human)
RNA helicase activityATP-dependent RNA helicase DDX42Homo sapiens (human)
protein bindingATP-dependent RNA helicase DDX42Homo sapiens (human)
ATP bindingATP-dependent RNA helicase DDX42Homo sapiens (human)
ATP hydrolysis activityATP-dependent RNA helicase DDX42Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase VRK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase VRK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase VRK2Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase VRK2Homo sapiens (human)
protein domain specific bindingSerine/threonine-protein kinase VRK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase VRK2Homo sapiens (human)
protein bindingMyosin light chain kinase family member 4Homo sapiens (human)
ATP bindingMyosin light chain kinase family member 4Homo sapiens (human)
protein serine kinase activityMyosin light chain kinase family member 4Homo sapiens (human)
myosin light chain kinase activityMyosin light chain kinase family member 4Homo sapiens (human)
protein bindingHomeodomain-interacting protein kinase 1Homo sapiens (human)
ATP bindingHomeodomain-interacting protein kinase 1Homo sapiens (human)
protein serine kinase activityHomeodomain-interacting protein kinase 1Homo sapiens (human)
protein tyrosine kinase activityHomeodomain-interacting protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityHomeodomain-interacting protein kinase 1Homo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
MAP kinase kinase kinase kinase activityMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
protein kinase activityCyclin-dependent kinase-like 3Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase-like 3Homo sapiens (human)
protein bindingCyclin-dependent kinase-like 3Homo sapiens (human)
ATP bindingCyclin-dependent kinase-like 3Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase-like 3Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase-like 3Homo sapiens (human)
p53 bindingMAP kinase-activated protein kinase 5Homo sapiens (human)
protein serine/threonine kinase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
MAP kinase kinase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
protein bindingMAP kinase-activated protein kinase 5Homo sapiens (human)
ATP bindingMAP kinase-activated protein kinase 5Homo sapiens (human)
protein serine kinase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
calmodulin-dependent protein kinase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
mitogen-activated protein kinase bindingMAP kinase-activated protein kinase 5Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
calmodulin bindingMAP kinase-activated protein kinase 5Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
ATPase bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
ATPase regulator activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase NIM1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase NIM1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase NIM1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase NIM1Homo sapiens (human)
RNA bindingEukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)
translation release factor activityEukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)
GTPase activityEukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)
protein bindingEukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)
GTP bindingEukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase ULK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase ULK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase ULK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase ULK2Homo sapiens (human)
protein kinase activityMisshapen-like kinase 1Homo sapiens (human)
protein serine/threonine kinase activityMisshapen-like kinase 1Homo sapiens (human)
protein bindingMisshapen-like kinase 1Homo sapiens (human)
ATP bindingMisshapen-like kinase 1Homo sapiens (human)
protein serine kinase activityMisshapen-like kinase 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase DCLK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase DCLK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase DCLK2Homo sapiens (human)
microtubule bindingSerine/threonine-protein kinase DCLK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase DCLK2Homo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
ATP bindingCasein kinase I isoform alpha-likeHomo sapiens (human)
protein serine kinase activityCasein kinase I isoform alpha-likeHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform alpha-likeHomo sapiens (human)
protein bindingHomeodomain-interacting protein kinase 4Homo sapiens (human)
ATP bindingHomeodomain-interacting protein kinase 4Homo sapiens (human)
histone kinase activityHomeodomain-interacting protein kinase 4Homo sapiens (human)
protein serine kinase activityHomeodomain-interacting protein kinase 4Homo sapiens (human)
protein tyrosine kinase activityHomeodomain-interacting protein kinase 4Homo sapiens (human)
protein serine/threonine kinase activityHomeodomain-interacting protein kinase 4Homo sapiens (human)
microfilament motor activityMyosin-IIIaHomo sapiens (human)
actin bindingMyosin-IIIaHomo sapiens (human)
protein kinase activityMyosin-IIIaHomo sapiens (human)
protein bindingMyosin-IIIaHomo sapiens (human)
calmodulin bindingMyosin-IIIaHomo sapiens (human)
ATP bindingMyosin-IIIaHomo sapiens (human)
ADP bindingMyosin-IIIaHomo sapiens (human)
plus-end directed microfilament motor activityMyosin-IIIaHomo sapiens (human)
protein serine kinase activityMyosin-IIIaHomo sapiens (human)
protein serine/threonine kinase activityMyosin-IIIaHomo sapiens (human)
protein serine/threonine kinase activityAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
protein bindingAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
ATP bindingAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
protein serine kinase activityAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek11Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek11Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek11Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek11Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek11Homo sapiens (human)
protein kinase activityAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
protein bindingAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
ATP bindingAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
kinase activityAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
ADP bindingAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
protein bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
ATP bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 5-kinase activityPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
identical protein bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
1-phosphatidylinositol-5-phosphate 4-kinase activityPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
chromatin bindingMitogen-activated protein kinase 15Homo sapiens (human)
protein kinase activityMitogen-activated protein kinase 15Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 15Homo sapiens (human)
protein bindingMitogen-activated protein kinase 15Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 15Homo sapiens (human)
kinase activityMitogen-activated protein kinase 15Homo sapiens (human)
SH3 domain bindingMitogen-activated protein kinase 15Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 15Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 15Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek9Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek9Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek9Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase Nek9Homo sapiens (human)
protein kinase activator activitySerine/threonine-protein kinase Nek9Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek9Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek9Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase BRSK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase BRSK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase BRSK1Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase BRSK1Homo sapiens (human)
gamma-tubulin bindingSerine/threonine-protein kinase BRSK1Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase BRSK1Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase BRSK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase BRSK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 35Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 35Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 35Homo sapiens (human)
eukaryotic translation initiation factor 2alpha kinase activitySerine/threonine-protein kinase 35Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek7Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek7Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek7Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek7Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek7Homo sapiens (human)
molecular function activator activitySerine/threonine-protein kinase Nek7Homo sapiens (human)
protein bindingRhodopsin kinase GRK7Homo sapiens (human)
ATP bindingRhodopsin kinase GRK7Homo sapiens (human)
rhodopsin kinase activityRhodopsin kinase GRK7Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 32AHomo sapiens (human)
metal ion bindingSerine/threonine-protein kinase 32AHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 32AHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 32AHomo sapiens (human)
actin bindingMyosin-IIIbHomo sapiens (human)
protein bindingMyosin-IIIbHomo sapiens (human)
ATP bindingMyosin-IIIbHomo sapiens (human)
protein serine kinase activityMyosin-IIIbHomo sapiens (human)
protein serine/threonine kinase activityMyosin-IIIbHomo sapiens (human)
microfilament motor activityMyosin-IIIbHomo sapiens (human)
DNA bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
chromatin bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
transcription coregulator activityATP-dependent RNA helicase DDX1Homo sapiens (human)
RNA bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
RNA helicase activityATP-dependent RNA helicase DDX1Homo sapiens (human)
double-stranded RNA bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
nuclease activityATP-dependent RNA helicase DDX1Homo sapiens (human)
exonuclease activityATP-dependent RNA helicase DDX1Homo sapiens (human)
protein bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
ATP bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
poly(A) bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
ATP hydrolysis activityATP-dependent RNA helicase DDX1Homo sapiens (human)
DNA/RNA helicase activityATP-dependent RNA helicase DDX1Homo sapiens (human)
magnesium ion bindingDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein serine/threonine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein bindingDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
ATP bindingDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
manganese ion bindingDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein serine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein kinase activityCyclin-dependent kinase-like 2Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase-like 2Homo sapiens (human)
ATP bindingCyclin-dependent kinase-like 2Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase-like 2Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase-like 2Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
MAP kinase kinase kinase kinase activityMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
calcium channel regulator activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Sgk3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Sgk3Homo sapiens (human)
potassium channel regulator activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
sodium channel regulator activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
chloride channel regulator activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
phosphatidylinositol bindingSerine/threonine-protein kinase Sgk3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
protein kinase activityAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
ATP bindingAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
lipid bindingAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
ATP hydrolysis activityAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase BHomo sapiens (human)
protein bindingAurora kinase BHomo sapiens (human)
ATP bindingAurora kinase BHomo sapiens (human)
kinase bindingAurora kinase BHomo sapiens (human)
protein serine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine kinase activityMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
protein bindingMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
ATP bindingMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
microtubule bindingMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
cytoskeletal anchor activityMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
gamma-tubulin bindingMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
ubiquitin bindingMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
tau protein bindingMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
tau-protein kinase activityMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
protein serine kinase activityMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase Nek1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek1Homo sapiens (human)
protein tyrosine kinase activitySerine/threonine-protein kinase Nek1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek1Homo sapiens (human)
kinase activitySerine/threonine-protein kinase Nek1Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek1Homo sapiens (human)
14-3-3 protein bindingSerine/threonine-protein kinase Nek1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek1Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 15Homo sapiens (human)
protein bindingCyclin-dependent kinase 15Homo sapiens (human)
ATP bindingCyclin-dependent kinase 15Homo sapiens (human)
metal ion bindingCyclin-dependent kinase 15Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 15Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 15Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 15Homo sapiens (human)
protein serine/threonine kinase activityPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
protein bindingPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
phosphatidylinositol bindingPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
protein serine kinase activityPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein tyrosine kinase activityCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
calcium ion bindingCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein serine/threonine kinase activityCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
p53 bindingEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
protein serine/threonine kinase activityEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
protein bindingEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
ATP bindingEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
hydrolase activityEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
protein serine kinase activityEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
magnesium ion bindingSRSF protein kinase 1Homo sapiens (human)
RNA bindingSRSF protein kinase 1Homo sapiens (human)
protein kinase activitySRSF protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activitySRSF protein kinase 1Homo sapiens (human)
protein bindingSRSF protein kinase 1Homo sapiens (human)
ATP bindingSRSF protein kinase 1Homo sapiens (human)
protein serine kinase activitySRSF protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
protein bindingMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
ATP bindingMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
kinase activityMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
metal ion bindingMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
protein serine kinase activityMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
protein kinase activityMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
magnesium ion bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein phosphatase bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein domain specific bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
1-phosphatidylinositol-3-phosphate 5-kinase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
protein bindingPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
ATP bindingPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 5-kinase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
kinase bindingPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
phosphatidylinositol kinase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
1-phosphatidylinositol-5-kinase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
metal ion bindingMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
eukaryotic translation initiation factor 2alpha kinase activityEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
protein bindingEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
ATP bindingEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
heme bindingEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
protein homodimerization activityEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
protein serine kinase activityEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase RIO1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase RIO1Homo sapiens (human)
hydrolase activitySerine/threonine-protein kinase RIO1Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase RIO1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase RIO1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase RIO1Homo sapiens (human)
protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein bindingMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
ATP bindingMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
metal ion bindingMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein serine kinase activityMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
calmodulin-dependent protein kinase activityMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
calmodulin bindingMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase RIO2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase RIO2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase RIO2Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase RIO2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase RIO2Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase RIO2Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 19Homo sapiens (human)
ATP bindingCyclin-dependent kinase 19Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 19Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 19Homo sapiens (human)
protein serine/threonine kinase activityTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
protein bindingTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
ATP bindingTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
metal ion bindingTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
protein serine kinase activityTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
monoatomic cation channel activityTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
magnesium ion bindingTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
protein bindingTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
ATP bindingTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
protein-containing complex bindingTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
protein serine kinase activityTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 33Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 33Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 33Homo sapiens (human)
RNA bindingNucleolar GTP-binding protein 1Homo sapiens (human)
GTPase activityNucleolar GTP-binding protein 1Homo sapiens (human)
protein bindingNucleolar GTP-binding protein 1Homo sapiens (human)
GTP bindingNucleolar GTP-binding protein 1Homo sapiens (human)
preribosome bindingNucleolar GTP-binding protein 1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase D2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase D2Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activitySerine/threonine-protein kinase D2Homo sapiens (human)
protein kinase C bindingSerine/threonine-protein kinase D2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase D2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase D2Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase D2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase D2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase DCLK3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase DCLK3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase DCLK3Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase DCLK3Homo sapiens (human)
magnesium ion bindingNUAK family SNF1-like kinase 2Homo sapiens (human)
protein serine/threonine kinase activityNUAK family SNF1-like kinase 2Homo sapiens (human)
protein bindingNUAK family SNF1-like kinase 2Homo sapiens (human)
ATP bindingNUAK family SNF1-like kinase 2Homo sapiens (human)
protein serine kinase activityNUAK family SNF1-like kinase 2Homo sapiens (human)
RNA bindingRNA cytidine acetyltransferaseHomo sapiens (human)
protein bindingRNA cytidine acetyltransferaseHomo sapiens (human)
ATP bindingRNA cytidine acetyltransferaseHomo sapiens (human)
N-acetyltransferase activityRNA cytidine acetyltransferaseHomo sapiens (human)
tRNA N-acetyltransferase activityRNA cytidine acetyltransferaseHomo sapiens (human)
DNA polymerase bindingRNA cytidine acetyltransferaseHomo sapiens (human)
mRNA N-acetyltransferase activityRNA cytidine acetyltransferaseHomo sapiens (human)
tRNA bindingRNA cytidine acetyltransferaseHomo sapiens (human)
rRNA cytidine N-acetyltransferase activityRNA cytidine acetyltransferaseHomo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase SIK2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase SIK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase SIK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase SIK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase SIK2Homo sapiens (human)
calmodulin-dependent protein kinase activityMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
myosin light chain kinase activityMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
protein bindingMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
calmodulin bindingMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
ATP bindingMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
myosin light chain bindingMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
protein serine/threonine kinase activitySTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein bindingSTE20-like serine/threonine-protein kinase Homo sapiens (human)
ATP bindingSTE20-like serine/threonine-protein kinase Homo sapiens (human)
identical protein bindingSTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein homodimerization activitySTE20-like serine/threonine-protein kinase Homo sapiens (human)
cadherin bindingSTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein serine kinase activitySTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase TAO3Homo sapiens (human)
protein kinase inhibitor activitySerine/threonine-protein kinase TAO3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase TAO3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase TAO3Homo sapiens (human)
transferase activitySerine/threonine-protein kinase TAO3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase TAO3Homo sapiens (human)
transcription coactivator activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
transcription corepressor activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein kinase activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein bindingHomeodomain-interacting protein kinase 2Homo sapiens (human)
ATP bindingHomeodomain-interacting protein kinase 2Homo sapiens (human)
SMAD bindingHomeodomain-interacting protein kinase 2Homo sapiens (human)
virion bindingHomeodomain-interacting protein kinase 2Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein serine kinase activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein tyrosine kinase activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase SrmsHomo sapiens (human)
protein bindingTyrosine-protein kinase SrmsHomo sapiens (human)
ATP bindingTyrosine-protein kinase SrmsHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase SrmsHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase SrmsHomo sapiens (human)
protein kinase activityHomeodomain-interacting protein kinase 3Homo sapiens (human)
protein serine/threonine kinase activityHomeodomain-interacting protein kinase 3Homo sapiens (human)
ATP bindingHomeodomain-interacting protein kinase 3Homo sapiens (human)
protein serine kinase activityHomeodomain-interacting protein kinase 3Homo sapiens (human)
protein tyrosine kinase activityHomeodomain-interacting protein kinase 3Homo sapiens (human)
p53 bindingSerine/threonine-protein kinase PLK3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PLK3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PLK3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PLK3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PLK3Homo sapiens (human)
magnesium ion bindingdCTP pyrophosphatase 1Homo sapiens (human)
protein bindingdCTP pyrophosphatase 1Homo sapiens (human)
pyrimidine deoxyribonucleotide bindingdCTP pyrophosphatase 1Homo sapiens (human)
identical protein bindingdCTP pyrophosphatase 1Homo sapiens (human)
nucleoside triphosphate diphosphatase activitydCTP pyrophosphatase 1Homo sapiens (human)
dCTP diphosphatase activitydCTP pyrophosphatase 1Homo sapiens (human)
protein serine/threonine kinase activityDual specificity protein kinase CLK4Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity protein kinase CLK4Homo sapiens (human)
protein bindingDual specificity protein kinase CLK4Homo sapiens (human)
ATP bindingDual specificity protein kinase CLK4Homo sapiens (human)
protein serine kinase activityDual specificity protein kinase CLK4Homo sapiens (human)
protein tyrosine kinase activityDual specificity protein kinase CLK4Homo sapiens (human)
protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
ATP bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
metal ion bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein serine kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
calmodulin-dependent protein kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
calmodulin bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
transcription corepressor bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek6Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
kinesin bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
ubiquitin protein ligase bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek6Homo sapiens (human)
DNA-binding transcription factor bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform gamma-1Homo sapiens (human)
protein bindingCasein kinase I isoform gamma-1Homo sapiens (human)
ATP bindingCasein kinase I isoform gamma-1Homo sapiens (human)
protein serine kinase activityCasein kinase I isoform gamma-1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PAK 6Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PAK 6Homo sapiens (human)
cadherin bindingSerine/threonine-protein kinase PAK 6Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PAK 6Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PAK 6Homo sapiens (human)
magnesium ion bindingSNF-related serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase activitySNF-related serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingSNF-related serine/threonine-protein kinaseHomo sapiens (human)
protein serine kinase activitySNF-related serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase LATS2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase LATS2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase LATS2Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase LATS2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase LATS2Homo sapiens (human)
transcription corepressor bindingSerine/threonine-protein kinase 36Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 36Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 36Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 36Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase 36Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 36Homo sapiens (human)
magnesium ion bindingPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
RNA bindingPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
phenylalanine-tRNA ligase activityPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
protein bindingPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
ATP bindingPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
tRNA bindingIsoleucine--tRNA ligase, mitochondrialHomo sapiens (human)
aminoacyl-tRNA editing activityIsoleucine--tRNA ligase, mitochondrialHomo sapiens (human)
isoleucine-tRNA ligase activityIsoleucine--tRNA ligase, mitochondrialHomo sapiens (human)
ATP bindingIsoleucine--tRNA ligase, mitochondrialHomo sapiens (human)
protein bindingBMP-2-inducible protein kinaseHomo sapiens (human)
ATP bindingBMP-2-inducible protein kinaseHomo sapiens (human)
protein serine kinase activityBMP-2-inducible protein kinaseHomo sapiens (human)
phosphatase regulator activityBMP-2-inducible protein kinaseHomo sapiens (human)
AP-2 adaptor complex bindingBMP-2-inducible protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityBMP-2-inducible protein kinaseHomo sapiens (human)
protein bindingObg-like ATPase 1Homo sapiens (human)
ATP bindingObg-like ATPase 1Homo sapiens (human)
GTP bindingObg-like ATPase 1Homo sapiens (human)
ATP hydrolysis activityObg-like ATPase 1Homo sapiens (human)
ribosomal large subunit bindingObg-like ATPase 1Homo sapiens (human)
cadherin bindingObg-like ATPase 1Homo sapiens (human)
metal ion bindingObg-like ATPase 1Homo sapiens (human)
protein bindingMidasinHomo sapiens (human)
ATP bindingMidasinHomo sapiens (human)
ATP hydrolysis activityMidasinHomo sapiens (human)
magnesium ion bindingInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
protein serine/threonine kinase activityInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
interleukin-1 receptor bindingInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
protein bindingInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
ATP bindingInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
kinase activityInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
protein kinase bindingInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
protein serine kinase activityInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 32BHomo sapiens (human)
metal ion bindingSerine/threonine-protein kinase 32BHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 32BHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 32BHomo sapiens (human)
magnesium ion bindingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
RNA bindingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein kinase activator activityMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
ribosome bindingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
small ribosomal subunit rRNA bindingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 12Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 12Homo sapiens (human)
protein bindingCyclin-dependent kinase 12Homo sapiens (human)
ATP bindingCyclin-dependent kinase 12Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityCyclin-dependent kinase 12Homo sapiens (human)
protein kinase bindingCyclin-dependent kinase 12Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 12Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 12Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PLK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PLK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PLK2Homo sapiens (human)
ATP-dependent protein bindingSerine/threonine-protein kinase PLK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PLK2Homo sapiens (human)
protein bindingNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
ATP bindingNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
endopeptidase activator activityNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
phosphatidylserine bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase MARK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase MARK1Homo sapiens (human)
phosphatidic acid bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase MARK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase pim-2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase pim-2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase pim-2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PAK 5Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PAK 5Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PAK 5Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PAK 5Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase 26Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase 26Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 26Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 26Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase 26Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase 26Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 26Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 26Homo sapiens (human)
tRNA bindingeIF-2-alpha kinase GCN2Homo sapiens (human)
protein serine/threonine kinase activityeIF-2-alpha kinase GCN2Homo sapiens (human)
eukaryotic translation initiation factor 2alpha kinase activityeIF-2-alpha kinase GCN2Homo sapiens (human)
ATP bindingeIF-2-alpha kinase GCN2Homo sapiens (human)
protein serine kinase activityeIF-2-alpha kinase GCN2Homo sapiens (human)
magnesium ion bindingSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
succinate-CoA ligase (ADP-forming) activitySuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
protein bindingSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
ATP bindingSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase NLKHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase NLKHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase NLKHomo sapiens (human)
MAP kinase activitySerine/threonine-protein kinase NLKHomo sapiens (human)
protein bindingSerine/threonine-protein kinase NLKHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase NLKHomo sapiens (human)
ubiquitin protein ligase bindingSerine/threonine-protein kinase NLKHomo sapiens (human)
SH2 domain bindingSerine/threonine-protein kinase NLKHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase NLKHomo sapiens (human)
DNA-binding transcription factor bindingSerine/threonine-protein kinase NLKHomo sapiens (human)
1-phosphatidylinositol 4-kinase activityPhosphatidylinositol 4-kinase betaHomo sapiens (human)
protein bindingPhosphatidylinositol 4-kinase betaHomo sapiens (human)
ATP bindingPhosphatidylinositol 4-kinase betaHomo sapiens (human)
14-3-3 protein bindingPhosphatidylinositol 4-kinase betaHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 17AHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase 17AHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 17AHomo sapiens (human)
protein serine/threonine kinase activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
protein bindingSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
ATP bindingSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
kinase activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
protein kinase bindingSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
protein serine kinase activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
molecular_functionEphrin type-A receptor 6Homo sapiens (human)
protein bindingEphrin type-A receptor 6Homo sapiens (human)
ATP bindingEphrin type-A receptor 6Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 6Homo sapiens (human)
AMP-activated protein kinase activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cAMP-dependent protein kinase inhibitor activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
protein binding5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
ATP binding5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cAMP-dependent protein kinase regulator activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
phosphorylase kinase regulator activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
protein kinase regulator activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
protein kinase binding5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
protein kinase activator activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
ADP binding5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
AMP binding5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
nucleic acid bindingSerine/threonine-protein kinase TBK1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase TBK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase TBK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase TBK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase TBK1Homo sapiens (human)
protein phosphatase bindingSerine/threonine-protein kinase TBK1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase TBK1Homo sapiens (human)
phosphoprotein bindingSerine/threonine-protein kinase TBK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase TBK1Homo sapiens (human)
protein bindingSeptin-9Homo sapiens (human)
GTP bindingSeptin-9Homo sapiens (human)
cadherin bindingSeptin-9Homo sapiens (human)
GTPase activitySeptin-9Homo sapiens (human)
molecular adaptor activitySeptin-9Homo sapiens (human)
protein serine/threonine kinase activityDeath-associated protein kinase 2Homo sapiens (human)
protein bindingDeath-associated protein kinase 2Homo sapiens (human)
calmodulin bindingDeath-associated protein kinase 2Homo sapiens (human)
ATP bindingDeath-associated protein kinase 2Homo sapiens (human)
identical protein bindingDeath-associated protein kinase 2Homo sapiens (human)
protein serine kinase activityDeath-associated protein kinase 2Homo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-6Homo sapiens (human)
protein kinase activityRibosomal protein S6 kinase alpha-6Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-6Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-6Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-6Homo sapiens (human)
ribosomal protein S6 kinase activityRibosomal protein S6 kinase alpha-6Homo sapiens (human)
protein kinase activityTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein bindingTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
ATP bindingTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein serine kinase activityTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase TAO2Homo sapiens (human)
MAP kinase kinase kinase activitySerine/threonine-protein kinase TAO2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase TAO2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase TAO2Homo sapiens (human)
mitogen-activated protein kinase kinase bindingSerine/threonine-protein kinase TAO2Homo sapiens (human)
neuropilin bindingSerine/threonine-protein kinase TAO2Homo sapiens (human)
protein serine/threonine kinase activator activitySerine/threonine-protein kinase TAO2Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase TAO2Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase TAO2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase TAO2Homo sapiens (human)
long-chain fatty acid-CoA ligase activityLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
protein bindingLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
ATP bindingLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
arachidonate-CoA ligase activityLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
oleoyl-CoA ligase activityLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
protein tyrosine kinase activityALK tyrosine kinase receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityALK tyrosine kinase receptorHomo sapiens (human)
protein bindingALK tyrosine kinase receptorHomo sapiens (human)
ATP bindingALK tyrosine kinase receptorHomo sapiens (human)
heparin bindingALK tyrosine kinase receptorHomo sapiens (human)
receptor signaling protein tyrosine kinase activator activityALK tyrosine kinase receptorHomo sapiens (human)
identical protein bindingALK tyrosine kinase receptorHomo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein bindingSRSF protein kinase 3Homo sapiens (human)
ATP bindingSRSF protein kinase 3Homo sapiens (human)
protein serine kinase activitySRSF protein kinase 3Homo sapiens (human)
protein serine/threonine kinase activitySRSF protein kinase 3Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase ICKHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase ICKHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase ICKHomo sapiens (human)
protein bindingSerine/threonine-protein kinase ICKHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase ICKHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase ICKHomo sapiens (human)
protein kinase activityCyclin-dependent kinase 11AHomo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 11AHomo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 11AHomo sapiens (human)
ATP bindingCyclin-dependent kinase 11AHomo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 11AHomo sapiens (human)
protein kinase activityAurora kinase CHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase CHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase CHomo sapiens (human)
protein bindingAurora kinase CHomo sapiens (human)
ATP bindingAurora kinase CHomo sapiens (human)
protein serine kinase activityAurora kinase CHomo sapiens (human)
protein serine/threonine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
kinase activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
glutamate receptor bindingCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
identical protein bindingCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
protein homodimerization activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
metal ion bindingCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
protein kinase activityRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
protein bindingRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
protein serine kinase activityRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase 38-likeHomo sapiens (human)
actin bindingSerine/threonine-protein kinase 38-likeHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 38-likeHomo sapiens (human)
protein bindingSerine/threonine-protein kinase 38-likeHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase 38-likeHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 38-likeHomo sapiens (human)
magnesium ion bindingMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
protein bindingMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
ATP bindingMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
microtubule bindingMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
protein serine kinase activityMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase SIK3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase SIK3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase SIK3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase SIK3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase SIK3Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase SIK3Homo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
metal ion bindingMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
transcription coregulator activityThyroid hormone receptor-associated protein 3Homo sapiens (human)
transcription coactivator activityThyroid hormone receptor-associated protein 3Homo sapiens (human)
RNA bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
protein bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
ATP bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
nuclear receptor coactivator activityThyroid hormone receptor-associated protein 3Homo sapiens (human)
nuclear vitamin D receptor bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
nuclear thyroid hormone receptor bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
phosphoprotein bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
DNA bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
transcription coactivator activityDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein bindingDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
ATP bindingDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein serine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein serine/threonine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
MAP kinase kinase kinase kinase activityMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
transcription coactivator activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein kinase activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein serine/threonine kinase activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein bindingReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
ATP bindingReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
identical protein bindingReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein-containing complex bindingReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein serine kinase activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase MRCK betaHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase MRCK betaHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
protein-containing complex bindingSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase MRCK betaHomo sapiens (human)
magnesium ion bindingInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein serine/threonine kinase activityInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein bindingInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
ATP bindingInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein kinase bindingInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein homodimerization activityInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein heterodimerization activityInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase 24Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 24Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 24Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 24Homo sapiens (human)
cadherin bindingSerine/threonine-protein kinase 24Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase 24Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 24Homo sapiens (human)
protein kinase activityCasein kinase I isoform gamma-3Homo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform gamma-3Homo sapiens (human)
ATP bindingCasein kinase I isoform gamma-3Homo sapiens (human)
protein serine kinase activityCasein kinase I isoform gamma-3Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
metal ion bindingMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (472)

Processvia Protein(s)Taxonomy
plasma membraneBone morphogenetic protein receptor type-1BHomo sapiens (human)
dendriteBone morphogenetic protein receptor type-1BHomo sapiens (human)
neuronal cell bodyBone morphogenetic protein receptor type-1BHomo sapiens (human)
receptor complexBone morphogenetic protein receptor type-1BHomo sapiens (human)
HFE-transferrin receptor complexBone morphogenetic protein receptor type-1BHomo sapiens (human)
plasma membraneBone morphogenetic protein receptor type-1BHomo sapiens (human)
nucleusCell division cycle 7-related protein kinaseHomo sapiens (human)
nucleoplasmCell division cycle 7-related protein kinaseHomo sapiens (human)
cytoplasmCell division cycle 7-related protein kinaseHomo sapiens (human)
intercellular bridgeCell division cycle 7-related protein kinaseHomo sapiens (human)
mitotic spindleCell division cycle 7-related protein kinaseHomo sapiens (human)
nucleusCell division cycle 7-related protein kinaseHomo sapiens (human)
cytoplasmCell division cycle 7-related protein kinaseHomo sapiens (human)
cytosolPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
plasma membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complex, class IAPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complexPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
cytoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
plasma membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
XY bodySerine/threonine-protein kinase PLK4Homo sapiens (human)
nucleolusSerine/threonine-protein kinase PLK4Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK4Homo sapiens (human)
centrioleSerine/threonine-protein kinase PLK4Homo sapiens (human)
cytosolSerine/threonine-protein kinase PLK4Homo sapiens (human)
cleavage furrowSerine/threonine-protein kinase PLK4Homo sapiens (human)
deuterosomeSerine/threonine-protein kinase PLK4Homo sapiens (human)
procentrioleSerine/threonine-protein kinase PLK4Homo sapiens (human)
procentriole replication complexSerine/threonine-protein kinase PLK4Homo sapiens (human)
nucleusSerine/threonine-protein kinase PLK4Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase 25Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 25Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase 25Homo sapiens (human)
FAR/SIN/STRIPAK complexSerine/threonine-protein kinase 25Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 25Homo sapiens (human)
eukaryotic translation initiation factor 3 complexATP-dependent RNA helicase DDX3XHomo sapiens (human)
cytosolic small ribosomal subunitATP-dependent RNA helicase DDX3XHomo sapiens (human)
cytoplasmATP-dependent RNA helicase DDX3XHomo sapiens (human)
extracellular regionATP-dependent RNA helicase DDX3XHomo sapiens (human)
nucleusATP-dependent RNA helicase DDX3XHomo sapiens (human)
nucleoplasmATP-dependent RNA helicase DDX3XHomo sapiens (human)
cytoplasmATP-dependent RNA helicase DDX3XHomo sapiens (human)
centrosomeATP-dependent RNA helicase DDX3XHomo sapiens (human)
cytosolATP-dependent RNA helicase DDX3XHomo sapiens (human)
plasma membraneATP-dependent RNA helicase DDX3XHomo sapiens (human)
cytoplasmic stress granuleATP-dependent RNA helicase DDX3XHomo sapiens (human)
lamellipodiumATP-dependent RNA helicase DDX3XHomo sapiens (human)
cell leading edgeATP-dependent RNA helicase DDX3XHomo sapiens (human)
secretory granule lumenATP-dependent RNA helicase DDX3XHomo sapiens (human)
extracellular exosomeATP-dependent RNA helicase DDX3XHomo sapiens (human)
ficolin-1-rich granule lumenATP-dependent RNA helicase DDX3XHomo sapiens (human)
NLRP3 inflammasome complexATP-dependent RNA helicase DDX3XHomo sapiens (human)
nucleusATP-dependent RNA helicase DDX3XHomo sapiens (human)
P granuleATP-dependent RNA helicase DDX3XHomo sapiens (human)
nucleoplasmPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
endoplasmic reticulumPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
cytosolPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
endocytic vesiclePhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
intracellular membrane-bounded organellePhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
cytoplasmPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
phosphatidylinositol 3-kinase complexPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
extracellular regionPyridoxal kinaseHomo sapiens (human)
nucleusPyridoxal kinaseHomo sapiens (human)
nucleoplasmPyridoxal kinaseHomo sapiens (human)
cytosolPyridoxal kinaseHomo sapiens (human)
secretory granule lumenPyridoxal kinaseHomo sapiens (human)
specific granule lumenPyridoxal kinaseHomo sapiens (human)
extracellular exosomePyridoxal kinaseHomo sapiens (human)
cytosolPyridoxal kinaseHomo sapiens (human)
cytosolCitron Rho-interacting kinaseHomo sapiens (human)
membraneCitron Rho-interacting kinaseHomo sapiens (human)
cytosolSerine/threonine-protein kinase RIO3Homo sapiens (human)
preribosome, small subunit precursorSerine/threonine-protein kinase RIO3Homo sapiens (human)
cytosolSerine/threonine-protein kinase RIO3Homo sapiens (human)
nucleusDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
cytoplasmDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
chromosome, telomeric regionSerine/threonine-protein kinase Chk1Homo sapiens (human)
condensed nuclear chromosomeSerine/threonine-protein kinase Chk1Homo sapiens (human)
extracellular spaceSerine/threonine-protein kinase Chk1Homo sapiens (human)
nucleusSerine/threonine-protein kinase Chk1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Chk1Homo sapiens (human)
replication forkSerine/threonine-protein kinase Chk1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Chk1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Chk1Homo sapiens (human)
cytosolSerine/threonine-protein kinase Chk1Homo sapiens (human)
intracellular membrane-bounded organelleSerine/threonine-protein kinase Chk1Homo sapiens (human)
chromatinSerine/threonine-protein kinase Chk1Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase Chk1Homo sapiens (human)
nucleusSerine/threonine-protein kinase Chk1Homo sapiens (human)
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
nucleusInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cytosolInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
IkappaB kinase complexInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cytoplasmic side of plasma membraneInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
membrane raftInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
CD40 receptor complexInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
basement membranePeripheral plasma membrane protein CASKHomo sapiens (human)
nuclear laminaPeripheral plasma membrane protein CASKHomo sapiens (human)
nucleolusPeripheral plasma membrane protein CASKHomo sapiens (human)
cytoplasmPeripheral plasma membrane protein CASKHomo sapiens (human)
cytosolPeripheral plasma membrane protein CASKHomo sapiens (human)
cell-cell junctionPeripheral plasma membrane protein CASKHomo sapiens (human)
focal adhesionPeripheral plasma membrane protein CASKHomo sapiens (human)
actin cytoskeletonPeripheral plasma membrane protein CASKHomo sapiens (human)
nuclear matrixPeripheral plasma membrane protein CASKHomo sapiens (human)
vesiclePeripheral plasma membrane protein CASKHomo sapiens (human)
presynaptic membranePeripheral plasma membrane protein CASKHomo sapiens (human)
ciliary membranePeripheral plasma membrane protein CASKHomo sapiens (human)
Schaffer collateral - CA1 synapsePeripheral plasma membrane protein CASKHomo sapiens (human)
basement membranePeripheral plasma membrane protein CASKHomo sapiens (human)
cell-cell junctionPeripheral plasma membrane protein CASKHomo sapiens (human)
basolateral plasma membranePeripheral plasma membrane protein CASKHomo sapiens (human)
plasma membranePeripheral plasma membrane protein CASKHomo sapiens (human)
spindle microtubuleAurora kinase AHomo sapiens (human)
nucleusAurora kinase AHomo sapiens (human)
nucleoplasmAurora kinase AHomo sapiens (human)
centrosomeAurora kinase AHomo sapiens (human)
centrioleAurora kinase AHomo sapiens (human)
spindleAurora kinase AHomo sapiens (human)
cytosolAurora kinase AHomo sapiens (human)
postsynaptic densityAurora kinase AHomo sapiens (human)
microtubule cytoskeletonAurora kinase AHomo sapiens (human)
basolateral plasma membraneAurora kinase AHomo sapiens (human)
midbodyAurora kinase AHomo sapiens (human)
spindle pole centrosomeAurora kinase AHomo sapiens (human)
ciliary basal bodyAurora kinase AHomo sapiens (human)
germinal vesicleAurora kinase AHomo sapiens (human)
axon hillockAurora kinase AHomo sapiens (human)
pronucleusAurora kinase AHomo sapiens (human)
perinuclear region of cytoplasmAurora kinase AHomo sapiens (human)
mitotic spindleAurora kinase AHomo sapiens (human)
meiotic spindleAurora kinase AHomo sapiens (human)
mitotic spindle poleAurora kinase AHomo sapiens (human)
glutamatergic synapseAurora kinase AHomo sapiens (human)
spindle pole centrosomeAurora kinase AHomo sapiens (human)
chromosome passenger complexAurora kinase AHomo sapiens (human)
spindle midzoneAurora kinase AHomo sapiens (human)
kinetochoreAurora kinase AHomo sapiens (human)
Golgi apparatusCyclin-G-associated kinaseHomo sapiens (human)
cytosolCyclin-G-associated kinaseHomo sapiens (human)
focal adhesionCyclin-G-associated kinaseHomo sapiens (human)
membraneCyclin-G-associated kinaseHomo sapiens (human)
clathrin-coated vesicleCyclin-G-associated kinaseHomo sapiens (human)
vesicleCyclin-G-associated kinaseHomo sapiens (human)
intracellular membrane-bounded organelleCyclin-G-associated kinaseHomo sapiens (human)
perinuclear region of cytoplasmCyclin-G-associated kinaseHomo sapiens (human)
presynapseCyclin-G-associated kinaseHomo sapiens (human)
vesicleCyclin-G-associated kinaseHomo sapiens (human)
cytoplasmCyclin-G-associated kinaseHomo sapiens (human)
intracellular membrane-bounded organelleCyclin-G-associated kinaseHomo sapiens (human)
plasma membraneSerine/threonine-protein kinase DCLK1Homo sapiens (human)
postsynaptic densitySerine/threonine-protein kinase DCLK1Homo sapiens (human)
nucleoplasmInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cytosolInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
IkappaB kinase complexInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cytoplasmic side of plasma membraneInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
CD40 receptor complexInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
plasma membraneMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
neuromuscular junctionMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
postsynaptic membraneMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
receptor complexMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
plasma membraneMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
extracellular regionEphrin type-B receptor 6Homo sapiens (human)
cytosolEphrin type-B receptor 6Homo sapiens (human)
plasma membraneEphrin type-B receptor 6Homo sapiens (human)
plasma membraneEphrin type-B receptor 6Homo sapiens (human)
dendriteEphrin type-B receptor 6Homo sapiens (human)
peroxisomePeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
peroxisomal matrixPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
cytosolPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
membranePeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
peroxisomePeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
cytosolMitogen-activated protein kinase 13Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 13Homo sapiens (human)
nucleusMitogen-activated protein kinase 13Homo sapiens (human)
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
nucleus3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytoplasm3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytosol3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
plasma membrane3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
focal adhesion3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
postsynaptic density3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytoplasmic vesicle3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cell projection3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
membraneMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
nucleusDeath-associated protein kinase 3Homo sapiens (human)
nucleoplasmDeath-associated protein kinase 3Homo sapiens (human)
cytosolDeath-associated protein kinase 3Homo sapiens (human)
PML bodyDeath-associated protein kinase 3Homo sapiens (human)
nucleusDeath-associated protein kinase 3Homo sapiens (human)
cytoplasmDeath-associated protein kinase 3Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
nucleusMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
plasma membraneMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
endosome membraneMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
ATAC complexMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
plasma membraneReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cytoplasmReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
endoplasmic reticulumReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cytosolReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cytoskeletonReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
vesicleReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein-containing complexReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
kinetochoreMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
nucleoplasmMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
cytosolMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
membraneMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
intracellular membrane-bounded organelleMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
outer kinetochoreMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
kinetochoreMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
nucleusMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
fibrillar centerNUAK family SNF1-like kinase 1Homo sapiens (human)
nucleusNUAK family SNF1-like kinase 1Homo sapiens (human)
nucleoplasmNUAK family SNF1-like kinase 1Homo sapiens (human)
cytoplasmNUAK family SNF1-like kinase 1Homo sapiens (human)
microtubule cytoskeletonNUAK family SNF1-like kinase 1Homo sapiens (human)
nucleoplasmDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial outer membraneDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial inner membraneDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial intermembrane spaceDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
cytosolDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
membraneDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial cristaDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
dendriteDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
axon cytoplasmDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial intermembrane spaceDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
cytoplasmDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
microtubuleDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial membraneDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
phagocytic cupPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
uropodPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
nucleoplasmPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
cytosolPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
adherens junctionPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
focal adhesionPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
endosome membranePhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
ruffle membranePhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
presynapsePhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
extrinsic component of plasma membraneTyrosine-protein kinase JAK2Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneTyrosine-protein kinase JAK2Homo sapiens (human)
nucleusTyrosine-protein kinase JAK2Homo sapiens (human)
nucleoplasmTyrosine-protein kinase JAK2Homo sapiens (human)
cytoplasmTyrosine-protein kinase JAK2Homo sapiens (human)
cytosolTyrosine-protein kinase JAK2Homo sapiens (human)
cytoskeletonTyrosine-protein kinase JAK2Homo sapiens (human)
plasma membraneTyrosine-protein kinase JAK2Homo sapiens (human)
caveolaTyrosine-protein kinase JAK2Homo sapiens (human)
focal adhesionTyrosine-protein kinase JAK2Homo sapiens (human)
granulocyte macrophage colony-stimulating factor receptor complexTyrosine-protein kinase JAK2Homo sapiens (human)
endosome lumenTyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-12 receptor complexTyrosine-protein kinase JAK2Homo sapiens (human)
membrane raftTyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-23 receptor complexTyrosine-protein kinase JAK2Homo sapiens (human)
postsynapseTyrosine-protein kinase JAK2Homo sapiens (human)
glutamatergic synapseTyrosine-protein kinase JAK2Homo sapiens (human)
euchromatinTyrosine-protein kinase JAK2Homo sapiens (human)
cytosolTyrosine-protein kinase JAK2Homo sapiens (human)
nucleusRho-associated protein kinase 2Homo sapiens (human)
centrosomeRho-associated protein kinase 2Homo sapiens (human)
cytosolRho-associated protein kinase 2Homo sapiens (human)
plasma membraneRho-associated protein kinase 2Homo sapiens (human)
cytoplasmic ribonucleoprotein granuleRho-associated protein kinase 2Homo sapiens (human)
centrosomeRho-associated protein kinase 2Homo sapiens (human)
cytoskeletonRho-associated protein kinase 2Homo sapiens (human)
cytoplasmRho-associated protein kinase 2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase ULK1Homo sapiens (human)
phagophore assembly siteSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagosome membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase ULK1Homo sapiens (human)
mitochondrial outer membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagosomeSerine/threonine-protein kinase ULK1Homo sapiens (human)
endoplasmic reticulum membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
cytosolSerine/threonine-protein kinase ULK1Homo sapiens (human)
axonSerine/threonine-protein kinase ULK1Homo sapiens (human)
phagophore assembly site membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
recycling endosomeSerine/threonine-protein kinase ULK1Homo sapiens (human)
omegasome membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
Atg1/ULK1 kinase complexSerine/threonine-protein kinase ULK1Homo sapiens (human)
cytosolSerine/threonine-protein kinase ULK1Homo sapiens (human)
phagophore assembly siteSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagosomeSerine/threonine-protein kinase ULK1Homo sapiens (human)
phagophore assembly site membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
nuclear inner membraneSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
mitochondrionSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
endoplasmic reticulumSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
endoplasmic reticulum membraneSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
Ire1 complexSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
AIP1-IRE1 complexSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
IRE1-TRAF2-ASK1 complexSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
IRE1-RACK1-PP2A complexSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
nucleusRibosomal protein S6 kinase alpha-5Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-5Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-5Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-5Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-5Homo sapiens (human)
nucleusU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
nucleoplasmU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
membraneU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
U4/U6 x U5 tri-snRNP complexU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
spliceosomal complexU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
U5 snRNPU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
U2-type precatalytic spliceosomeU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
U2-type catalytic step 1 spliceosomeU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
catalytic step 2 spliceosomeU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
nucleusRibosomal protein S6 kinase alpha-4Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-4Homo sapiens (human)
cytosolRibosomal protein S6 kinase alpha-4Homo sapiens (human)
synapseRibosomal protein S6 kinase alpha-4Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-4Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-4Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase 16Homo sapiens (human)
Golgi-associated vesicleSerine/threonine-protein kinase 16Homo sapiens (human)
cytosolSerine/threonine-protein kinase 16Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase 16Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase 16Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase 16Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 16Homo sapiens (human)
cytosolPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
membranePhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
phosphatidylinositol 3-kinase complexPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
cytoplasmPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
cytosolSerine/threonine-protein kinase PAK 3Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase PAK 3Homo sapiens (human)
postsynaptic densitySerine/threonine-protein kinase PAK 3Homo sapiens (human)
glutamatergic synapseSerine/threonine-protein kinase PAK 3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 3Homo sapiens (human)
ruffle membraneCyclin-dependent kinase-like 5Homo sapiens (human)
glutamatergic synapseCyclin-dependent kinase-like 5Homo sapiens (human)
nucleusCyclin-dependent kinase-like 5Homo sapiens (human)
nucleoplasmCyclin-dependent kinase-like 5Homo sapiens (human)
centrosomeCyclin-dependent kinase-like 5Homo sapiens (human)
dendrite cytoplasmCyclin-dependent kinase-like 5Homo sapiens (human)
ciliary basal bodyCyclin-dependent kinase-like 5Homo sapiens (human)
dendritic growth coneCyclin-dependent kinase-like 5Homo sapiens (human)
perinuclear region of cytoplasmCyclin-dependent kinase-like 5Homo sapiens (human)
ciliary tipCyclin-dependent kinase-like 5Homo sapiens (human)
postsynaptic density, intracellular componentCyclin-dependent kinase-like 5Homo sapiens (human)
nucleusCyclin-dependent kinase-like 5Homo sapiens (human)
dendrite cytoplasmCyclin-dependent kinase-like 5Homo sapiens (human)
nucleusSerine/threonine-protein kinase 17BHomo sapiens (human)
nucleoplasmSerine/threonine-protein kinase 17BHomo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentSerine/threonine-protein kinase 17BHomo sapiens (human)
plasma membraneSerine/threonine-protein kinase 17BHomo sapiens (human)
actin cytoskeletonSerine/threonine-protein kinase 17BHomo sapiens (human)
Flemming bodySerine/threonine-protein kinase 17BHomo sapiens (human)
nucleusSerine/threonine-protein kinase 17BHomo sapiens (human)
cytosolSerine/threonine-protein kinase 10Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase 10Homo sapiens (human)
specific granule membraneSerine/threonine-protein kinase 10Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase 10Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 10Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase D3Homo sapiens (human)
cytosolSerine/threonine-protein kinase D3Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase D3Homo sapiens (human)
cytosolSerine/threonine-protein kinase D3Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 14Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 14Homo sapiens (human)
cytosolCyclin-dependent kinase 14Homo sapiens (human)
plasma membraneCyclin-dependent kinase 14Homo sapiens (human)
cytoplasmic cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 14Homo sapiens (human)
cytoplasmCyclin-dependent kinase 14Homo sapiens (human)
cytosolCyclin-dependent kinase 14Homo sapiens (human)
nucleusCyclin-dependent kinase 14Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nuclear chromosomeStructural maintenance of chromosomes protein 2Homo sapiens (human)
condensed chromosomeStructural maintenance of chromosomes protein 2Homo sapiens (human)
condensed nuclear chromosomeStructural maintenance of chromosomes protein 2Homo sapiens (human)
condensin complexStructural maintenance of chromosomes protein 2Homo sapiens (human)
nucleusStructural maintenance of chromosomes protein 2Homo sapiens (human)
nucleoplasmStructural maintenance of chromosomes protein 2Homo sapiens (human)
nucleolusStructural maintenance of chromosomes protein 2Homo sapiens (human)
cytoplasmStructural maintenance of chromosomes protein 2Homo sapiens (human)
cytosolStructural maintenance of chromosomes protein 2Homo sapiens (human)
extracellular exosomeStructural maintenance of chromosomes protein 2Homo sapiens (human)
condensed chromosomeStructural maintenance of chromosomes protein 2Homo sapiens (human)
chromatinStructural maintenance of chromosomes protein 2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase OSR1Homo sapiens (human)
cytosolSerine/threonine-protein kinase OSR1Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase OSR1Homo sapiens (human)
cytosolSerine/threonine-protein kinase OSR1Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
focal adhesionMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase LATS1Homo sapiens (human)
spindle poleSerine/threonine-protein kinase LATS1Homo sapiens (human)
nucleusSerine/threonine-protein kinase LATS1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase LATS1Homo sapiens (human)
cytosolSerine/threonine-protein kinase LATS1Homo sapiens (human)
midbodySerine/threonine-protein kinase LATS1Homo sapiens (human)
spindle poleSerine/threonine-protein kinase LATS1Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cytosolSerine/threonine-protein kinase PAK 4Homo sapiens (human)
adherens junctionSerine/threonine-protein kinase PAK 4Homo sapiens (human)
focal adhesionSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 4Homo sapiens (human)
chromosome, telomeric regionSerine/threonine-protein kinase Chk2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Chk2Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase Chk2Homo sapiens (human)
PML bodySerine/threonine-protein kinase Chk2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Chk2Homo sapiens (human)
nucleusSerine/threonine-protein kinase Chk2Homo sapiens (human)
ruffleTyrosine-protein kinase ABL1Homo sapiens (human)
nucleusTyrosine-protein kinase ABL1Homo sapiens (human)
nucleoplasmTyrosine-protein kinase ABL1Homo sapiens (human)
nucleolusTyrosine-protein kinase ABL1Homo sapiens (human)
cytoplasmTyrosine-protein kinase ABL1Homo sapiens (human)
mitochondrionTyrosine-protein kinase ABL1Homo sapiens (human)
cytosolTyrosine-protein kinase ABL1Homo sapiens (human)
actin cytoskeletonTyrosine-protein kinase ABL1Homo sapiens (human)
nuclear bodyTyrosine-protein kinase ABL1Homo sapiens (human)
dendriteTyrosine-protein kinase ABL1Homo sapiens (human)
growth coneTyrosine-protein kinase ABL1Homo sapiens (human)
nuclear membraneTyrosine-protein kinase ABL1Homo sapiens (human)
neuronal cell bodyTyrosine-protein kinase ABL1Homo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase ABL1Homo sapiens (human)
postsynapseTyrosine-protein kinase ABL1Homo sapiens (human)
protein-containing complexTyrosine-protein kinase ABL1Homo sapiens (human)
plasma membraneTyrosine-protein kinase ABL1Homo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
ruffle membraneEpidermal growth factor receptorHomo sapiens (human)
Golgi membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceEpidermal growth factor receptorHomo sapiens (human)
nucleusEpidermal growth factor receptorHomo sapiens (human)
cytoplasmEpidermal growth factor receptorHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
endoplasmic reticulum membraneEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
focal adhesionEpidermal growth factor receptorHomo sapiens (human)
cell surfaceEpidermal growth factor receptorHomo sapiens (human)
endosome membraneEpidermal growth factor receptorHomo sapiens (human)
membraneEpidermal growth factor receptorHomo sapiens (human)
basolateral plasma membraneEpidermal growth factor receptorHomo sapiens (human)
apical plasma membraneEpidermal growth factor receptorHomo sapiens (human)
cell junctionEpidermal growth factor receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneEpidermal growth factor receptorHomo sapiens (human)
early endosome membraneEpidermal growth factor receptorHomo sapiens (human)
nuclear membraneEpidermal growth factor receptorHomo sapiens (human)
membrane raftEpidermal growth factor receptorHomo sapiens (human)
perinuclear region of cytoplasmEpidermal growth factor receptorHomo sapiens (human)
multivesicular body, internal vesicle lumenEpidermal growth factor receptorHomo sapiens (human)
intracellular vesicleEpidermal growth factor receptorHomo sapiens (human)
protein-containing complexEpidermal growth factor receptorHomo sapiens (human)
receptor complexEpidermal growth factor receptorHomo sapiens (human)
Shc-EGFR complexEpidermal growth factor receptorHomo sapiens (human)
basal plasma membraneEpidermal growth factor receptorHomo sapiens (human)
plasma membraneRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
nucleusRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
mitochondrial outer membraneRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
Golgi apparatusRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
cytosolRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
plasma membraneRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
pseudopodiumRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
cytosolRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
mitochondrionRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
semaphorin receptor complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
nucleusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
nucleoplasmReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
early endosomeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cytosolReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
endosome membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
basolateral plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
apical plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuromuscular junctionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ruffle membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
presynaptic membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
myelin sheathReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
perinuclear region of cytoplasmReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB3:ERBB2 complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
receptor complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
basal plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
early endosomeHigh affinity nerve growth factor receptorHomo sapiens (human)
late endosomeHigh affinity nerve growth factor receptorHomo sapiens (human)
plasma membraneHigh affinity nerve growth factor receptorHomo sapiens (human)
cell surfaceHigh affinity nerve growth factor receptorHomo sapiens (human)
endosome membraneHigh affinity nerve growth factor receptorHomo sapiens (human)
dendriteHigh affinity nerve growth factor receptorHomo sapiens (human)
early endosome membraneHigh affinity nerve growth factor receptorHomo sapiens (human)
late endosome membraneHigh affinity nerve growth factor receptorHomo sapiens (human)
neuronal cell bodyHigh affinity nerve growth factor receptorHomo sapiens (human)
recycling endosome membraneHigh affinity nerve growth factor receptorHomo sapiens (human)
protein-containing complexHigh affinity nerve growth factor receptorHomo sapiens (human)
receptor complexHigh affinity nerve growth factor receptorHomo sapiens (human)
axonHigh affinity nerve growth factor receptorHomo sapiens (human)
plasma membraneHigh affinity nerve growth factor receptorHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
nucleoplasmGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
cytoplasmGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
centrosomeGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
cytosolGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
membraneGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
dendriteGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
midbodyGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
cell bodyGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
synapseGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
extracellular exosomeGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
neuronal dense core vesicleGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
extracellular vesicleGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
heterotrimeric G-protein complexGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
cytoplasmGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
nucleusADP/ATP translocase 2Homo sapiens (human)
mitochondrionADP/ATP translocase 2Homo sapiens (human)
mitochondrial inner membraneADP/ATP translocase 2Homo sapiens (human)
plasma membraneADP/ATP translocase 2Homo sapiens (human)
membraneADP/ATP translocase 2Homo sapiens (human)
mitochondrial nucleoidADP/ATP translocase 2Homo sapiens (human)
mitochondrial permeability transition pore complexADP/ATP translocase 2Homo sapiens (human)
MMXD complexADP/ATP translocase 2Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
mitochondrial inner membraneCytochrome P450 2E1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2E1Homo sapiens (human)
cytoplasmCytochrome P450 2E1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2E1Homo sapiens (human)
nucleusProtein kinase C beta typeHomo sapiens (human)
nucleoplasmProtein kinase C beta typeHomo sapiens (human)
cytoplasmProtein kinase C beta typeHomo sapiens (human)
centrosomeProtein kinase C beta typeHomo sapiens (human)
cytosolProtein kinase C beta typeHomo sapiens (human)
plasma membraneProtein kinase C beta typeHomo sapiens (human)
brush border membraneProtein kinase C beta typeHomo sapiens (human)
calyx of HeldProtein kinase C beta typeHomo sapiens (human)
extracellular exosomeProtein kinase C beta typeHomo sapiens (human)
presynaptic cytosolProtein kinase C beta typeHomo sapiens (human)
spectrinProtein kinase C beta typeHomo sapiens (human)
nuclear envelopeInsulin receptorHomo sapiens (human)
nuclear lumenInsulin receptorHomo sapiens (human)
lysosomeInsulin receptorHomo sapiens (human)
late endosomeInsulin receptorHomo sapiens (human)
plasma membraneInsulin receptorHomo sapiens (human)
caveolaInsulin receptorHomo sapiens (human)
external side of plasma membraneInsulin receptorHomo sapiens (human)
endosome membraneInsulin receptorHomo sapiens (human)
membraneInsulin receptorHomo sapiens (human)
dendrite membraneInsulin receptorHomo sapiens (human)
neuronal cell body membraneInsulin receptorHomo sapiens (human)
extracellular exosomeInsulin receptorHomo sapiens (human)
insulin receptor complexInsulin receptorHomo sapiens (human)
receptor complexInsulin receptorHomo sapiens (human)
plasma membraneInsulin receptorHomo sapiens (human)
axonInsulin receptorHomo sapiens (human)
pericentriolar materialTyrosine-protein kinase LckHomo sapiens (human)
immunological synapseTyrosine-protein kinase LckHomo sapiens (human)
cytosolTyrosine-protein kinase LckHomo sapiens (human)
plasma membraneTyrosine-protein kinase LckHomo sapiens (human)
membrane raftTyrosine-protein kinase LckHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase LckHomo sapiens (human)
plasma membraneTyrosine-protein kinase LckHomo sapiens (human)
membrane raftTyrosine-protein kinase FynHomo sapiens (human)
dendriteTyrosine-protein kinase FynHomo sapiens (human)
nucleusTyrosine-protein kinase FynHomo sapiens (human)
mitochondrionTyrosine-protein kinase FynHomo sapiens (human)
endosomeTyrosine-protein kinase FynHomo sapiens (human)
cytosolTyrosine-protein kinase FynHomo sapiens (human)
actin filamentTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
postsynaptic densityTyrosine-protein kinase FynHomo sapiens (human)
dendriteTyrosine-protein kinase FynHomo sapiens (human)
perikaryonTyrosine-protein kinase FynHomo sapiens (human)
cell bodyTyrosine-protein kinase FynHomo sapiens (human)
membrane raftTyrosine-protein kinase FynHomo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase FynHomo sapiens (human)
perinuclear endoplasmic reticulumTyrosine-protein kinase FynHomo sapiens (human)
glial cell projectionTyrosine-protein kinase FynHomo sapiens (human)
Schaffer collateral - CA1 synapseTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
mitochondrial matrixCyclin-dependent kinase 1Homo sapiens (human)
chromosome, telomeric regionCyclin-dependent kinase 1Homo sapiens (human)
nucleusCyclin-dependent kinase 1Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 1Homo sapiens (human)
mitochondrionCyclin-dependent kinase 1Homo sapiens (human)
endoplasmic reticulum membraneCyclin-dependent kinase 1Homo sapiens (human)
centrosomeCyclin-dependent kinase 1Homo sapiens (human)
cytosolCyclin-dependent kinase 1Homo sapiens (human)
spindle microtubuleCyclin-dependent kinase 1Homo sapiens (human)
membraneCyclin-dependent kinase 1Homo sapiens (human)
midbodyCyclin-dependent kinase 1Homo sapiens (human)
extracellular exosomeCyclin-dependent kinase 1Homo sapiens (human)
mitotic spindleCyclin-dependent kinase 1Homo sapiens (human)
cyclin A1-CDK1 complexCyclin-dependent kinase 1Homo sapiens (human)
cyclin A2-CDK1 complexCyclin-dependent kinase 1Homo sapiens (human)
cyclin B1-CDK1 complexCyclin-dependent kinase 1Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 1Homo sapiens (human)
cytoplasmCyclin-dependent kinase 1Homo sapiens (human)
nucleusCyclin-dependent kinase 1Homo sapiens (human)
extracellular regionGlycogen phosphorylase, liver formHomo sapiens (human)
cytosolGlycogen phosphorylase, liver formHomo sapiens (human)
secretory granule lumenGlycogen phosphorylase, liver formHomo sapiens (human)
extracellular exosomeGlycogen phosphorylase, liver formHomo sapiens (human)
ficolin-1-rich granule lumenGlycogen phosphorylase, liver formHomo sapiens (human)
cytoplasmGlycogen phosphorylase, liver formHomo sapiens (human)
cytoplasmic vesicleTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cytoplasmTyrosine-protein kinase Fes/FpsHomo sapiens (human)
Golgi apparatusTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cytosolTyrosine-protein kinase Fes/FpsHomo sapiens (human)
focal adhesionTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein kinase Fes/FpsHomo sapiens (human)
microtubule cytoskeletonTyrosine-protein kinase Fes/FpsHomo sapiens (human)
plasma membraneTyrosine-protein kinase Fes/FpsHomo sapiens (human)
nucleoplasmMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
plasma membraneMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cell surfaceMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
intracellular membrane-bounded organelleMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
CSF1-CSF1R complexMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
receptor complexMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
plasma membraneMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
extracellular regionAdenine phosphoribosyltransferaseHomo sapiens (human)
nucleoplasmAdenine phosphoribosyltransferaseHomo sapiens (human)
cytoplasmAdenine phosphoribosyltransferaseHomo sapiens (human)
cytosolAdenine phosphoribosyltransferaseHomo sapiens (human)
secretory granule lumenAdenine phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeAdenine phosphoribosyltransferaseHomo sapiens (human)
cytoplasmAdenine phosphoribosyltransferaseHomo sapiens (human)
Golgi apparatusTyrosine-protein kinase YesHomo sapiens (human)
centrosomeTyrosine-protein kinase YesHomo sapiens (human)
cytosolTyrosine-protein kinase YesHomo sapiens (human)
actin filamentTyrosine-protein kinase YesHomo sapiens (human)
plasma membraneTyrosine-protein kinase YesHomo sapiens (human)
focal adhesionTyrosine-protein kinase YesHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase YesHomo sapiens (human)
plasma membraneTyrosine-protein kinase YesHomo sapiens (human)
plasma membraneTyrosine-protein kinase LynHomo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein kinase LynHomo sapiens (human)
nucleusTyrosine-protein kinase LynHomo sapiens (human)
cytoplasmTyrosine-protein kinase LynHomo sapiens (human)
lysosomal membraneTyrosine-protein kinase LynHomo sapiens (human)
Golgi apparatusTyrosine-protein kinase LynHomo sapiens (human)
cytosolTyrosine-protein kinase LynHomo sapiens (human)
plasma membraneTyrosine-protein kinase LynHomo sapiens (human)
adherens junctionTyrosine-protein kinase LynHomo sapiens (human)
mitochondrial cristaTyrosine-protein kinase LynHomo sapiens (human)
endocytic vesicle membraneTyrosine-protein kinase LynHomo sapiens (human)
intracellular membrane-bounded organelleTyrosine-protein kinase LynHomo sapiens (human)
membrane raftTyrosine-protein kinase LynHomo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase LynHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase LynHomo sapiens (human)
glutamatergic synapseTyrosine-protein kinase LynHomo sapiens (human)
postsynaptic specialization, intracellular componentTyrosine-protein kinase LynHomo sapiens (human)
integrin alpha2-beta1 complexTyrosine-protein kinase LynHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
early endosomeProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
endosome membraneProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
dendriteProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
neuronal cell bodyProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
receptor complexProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
plasma membrane protein complexProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
axonProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
plasma membraneInsulin-like growth factor 1 receptorHomo sapiens (human)
caveolaInsulin-like growth factor 1 receptorHomo sapiens (human)
membraneInsulin-like growth factor 1 receptorHomo sapiens (human)
T-tubuleInsulin-like growth factor 1 receptorHomo sapiens (human)
neuronal cell bodyInsulin-like growth factor 1 receptorHomo sapiens (human)
intracellular membrane-bounded organelleInsulin-like growth factor 1 receptorHomo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexInsulin-like growth factor 1 receptorHomo sapiens (human)
receptor complexInsulin-like growth factor 1 receptorHomo sapiens (human)
protein kinase complexInsulin-like growth factor 1 receptorHomo sapiens (human)
axonInsulin-like growth factor 1 receptorHomo sapiens (human)
plasma membraneInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor complexInsulin-like growth factor 1 receptorHomo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
signal recognition particle receptor complexSignal recognition particle receptor subunit alphaHomo sapiens (human)
endoplasmic reticulum membraneSignal recognition particle receptor subunit alphaHomo sapiens (human)
membraneSignal recognition particle receptor subunit alphaHomo sapiens (human)
extracellular exosomeSignal recognition particle receptor subunit alphaHomo sapiens (human)
endoplasmic reticulum membraneSignal recognition particle receptor subunit alphaHomo sapiens (human)
nucleusCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
mitochondrionCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
mitochondrial respiratory chain complex IIICytochrome c1, heme protein, mitochondrialHomo sapiens (human)
membraneCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
extracellular regionHepatocyte growth factor receptorHomo sapiens (human)
plasma membraneHepatocyte growth factor receptorHomo sapiens (human)
basal plasma membraneHepatocyte growth factor receptorHomo sapiens (human)
cell surfaceHepatocyte growth factor receptorHomo sapiens (human)
membraneHepatocyte growth factor receptorHomo sapiens (human)
postsynapseHepatocyte growth factor receptorHomo sapiens (human)
basal plasma membraneHepatocyte growth factor receptorHomo sapiens (human)
plasma membraneHepatocyte growth factor receptorHomo sapiens (human)
receptor complexHepatocyte growth factor receptorHomo sapiens (human)
actin filamentTyrosine-protein kinase HCKHomo sapiens (human)
nucleusTyrosine-protein kinase HCKHomo sapiens (human)
lysosomeTyrosine-protein kinase HCKHomo sapiens (human)
Golgi apparatusTyrosine-protein kinase HCKHomo sapiens (human)
cytosolTyrosine-protein kinase HCKHomo sapiens (human)
plasma membraneTyrosine-protein kinase HCKHomo sapiens (human)
caveolaTyrosine-protein kinase HCKHomo sapiens (human)
focal adhesionTyrosine-protein kinase HCKHomo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein kinase HCKHomo sapiens (human)
transport vesicleTyrosine-protein kinase HCKHomo sapiens (human)
cell projectionTyrosine-protein kinase HCKHomo sapiens (human)
intracellular membrane-bounded organelleTyrosine-protein kinase HCKHomo sapiens (human)
plasma membraneTyrosine-protein kinase HCKHomo sapiens (human)
membraneProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
receptor complexProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
nucleusPlatelet-derived growth factor receptor betaHomo sapiens (human)
cytoplasmPlatelet-derived growth factor receptor betaHomo sapiens (human)
Golgi apparatusPlatelet-derived growth factor receptor betaHomo sapiens (human)
plasma membranePlatelet-derived growth factor receptor betaHomo sapiens (human)
focal adhesionPlatelet-derived growth factor receptor betaHomo sapiens (human)
membranePlatelet-derived growth factor receptor betaHomo sapiens (human)
apical plasma membranePlatelet-derived growth factor receptor betaHomo sapiens (human)
cytoplasmic vesiclePlatelet-derived growth factor receptor betaHomo sapiens (human)
lysosomal lumenPlatelet-derived growth factor receptor betaHomo sapiens (human)
intracellular membrane-bounded organellePlatelet-derived growth factor receptor betaHomo sapiens (human)
plasma membranePlatelet-derived growth factor receptor betaHomo sapiens (human)
receptor complexPlatelet-derived growth factor receptor betaHomo sapiens (human)
cytoskeletonTyrosine-protein kinase FgrHomo sapiens (human)
actin cytoskeletonTyrosine-protein kinase FgrHomo sapiens (human)
ruffle membraneTyrosine-protein kinase FgrHomo sapiens (human)
extracellular regionTyrosine-protein kinase FgrHomo sapiens (human)
mitochondrial inner membraneTyrosine-protein kinase FgrHomo sapiens (human)
mitochondrial intermembrane spaceTyrosine-protein kinase FgrHomo sapiens (human)
cytosolTyrosine-protein kinase FgrHomo sapiens (human)
plasma membraneTyrosine-protein kinase FgrHomo sapiens (human)
aggresomeTyrosine-protein kinase FgrHomo sapiens (human)
secretory granule lumenTyrosine-protein kinase FgrHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase FgrHomo sapiens (human)
plasma membraneTyrosine-protein kinase FgrHomo sapiens (human)
nucleoplasmWee1-like protein kinase 2Homo sapiens (human)
cytosolWee1-like protein kinase 2Homo sapiens (human)
plasma membraneWee1-like protein kinase 2Homo sapiens (human)
cytoplasmWee1-like protein kinase 2Homo sapiens (human)
nucleusWee1-like protein kinase 2Homo sapiens (human)
cellular_componentSerine/threonine-protein kinase A-RafHomo sapiens (human)
cytosolSerine/threonine-protein kinase A-RafHomo sapiens (human)
cytosolSerine/threonine-protein kinase A-RafHomo sapiens (human)
mitochondrionSerine/threonine-protein kinase A-RafHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C8Homo sapiens (human)
plasma membraneCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
cytoplasmCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
fibrillar centerMast/stem cell growth factor receptor KitHomo sapiens (human)
acrosomal vesicleMast/stem cell growth factor receptor KitHomo sapiens (human)
extracellular spaceMast/stem cell growth factor receptor KitHomo sapiens (human)
plasma membraneMast/stem cell growth factor receptor KitHomo sapiens (human)
cell-cell junctionMast/stem cell growth factor receptor KitHomo sapiens (human)
external side of plasma membraneMast/stem cell growth factor receptor KitHomo sapiens (human)
cytoplasmic side of plasma membraneMast/stem cell growth factor receptor KitHomo sapiens (human)
plasma membraneMast/stem cell growth factor receptor KitHomo sapiens (human)
receptor complexMast/stem cell growth factor receptor KitHomo sapiens (human)
extracellular regionGlycogen phosphorylase, brain formHomo sapiens (human)
cytoplasmGlycogen phosphorylase, brain formHomo sapiens (human)
membraneGlycogen phosphorylase, brain formHomo sapiens (human)
azurophil granule lumenGlycogen phosphorylase, brain formHomo sapiens (human)
extracellular exosomeGlycogen phosphorylase, brain formHomo sapiens (human)
cytoplasmGlycogen phosphorylase, brain formHomo sapiens (human)
cytosolBreakpoint cluster region proteinHomo sapiens (human)
plasma membraneBreakpoint cluster region proteinHomo sapiens (human)
postsynaptic densityBreakpoint cluster region proteinHomo sapiens (human)
membraneBreakpoint cluster region proteinHomo sapiens (human)
axonBreakpoint cluster region proteinHomo sapiens (human)
dendritic spineBreakpoint cluster region proteinHomo sapiens (human)
extracellular exosomeBreakpoint cluster region proteinHomo sapiens (human)
protein-containing complexBreakpoint cluster region proteinHomo sapiens (human)
Schaffer collateral - CA1 synapseBreakpoint cluster region proteinHomo sapiens (human)
glutamatergic synapseBreakpoint cluster region proteinHomo sapiens (human)
membraneBreakpoint cluster region proteinHomo sapiens (human)
nucleusSerine/threonine-protein kinase pim-1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
nucleolusSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytosolSerine/threonine-protein kinase pim-1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
extracellular regionFibroblast growth factor receptor 1Homo sapiens (human)
nucleusFibroblast growth factor receptor 1Homo sapiens (human)
cytosolFibroblast growth factor receptor 1Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 1Homo sapiens (human)
membraneFibroblast growth factor receptor 1Homo sapiens (human)
cytoplasmic vesicleFibroblast growth factor receptor 1Homo sapiens (human)
receptor complexFibroblast growth factor receptor 1Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 1Homo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
nuclear chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
centrioleDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome, centromeric regionDNA topoisomerase 2-alphaHomo sapiens (human)
condensed chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
male germ cell nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
cytoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA topoisomerase 2-alphaHomo sapiens (human)
protein-containing complexDNA topoisomerase 2-alphaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
cytosolMyosin light chain kinase, smooth muscleGallus gallus (chicken)
stress fiberMyosin light chain kinase, smooth muscleGallus gallus (chicken)
cleavage furrowMyosin light chain kinase, smooth muscleGallus gallus (chicken)
lamellipodiumMyosin light chain kinase, smooth muscleGallus gallus (chicken)
cytoplasmMyosin light chain kinase, smooth muscleGallus gallus (chicken)
nucleusCyclin-dependent kinase 4Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 4Homo sapiens (human)
nucleolusCyclin-dependent kinase 4Homo sapiens (human)
cytosolCyclin-dependent kinase 4Homo sapiens (human)
bicellular tight junctionCyclin-dependent kinase 4Homo sapiens (human)
nuclear membraneCyclin-dependent kinase 4Homo sapiens (human)
cyclin D1-CDK4 complexCyclin-dependent kinase 4Homo sapiens (human)
cyclin D2-CDK4 complexCyclin-dependent kinase 4Homo sapiens (human)
cyclin D3-CDK4 complexCyclin-dependent kinase 4Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 4Homo sapiens (human)
chromatinCyclin-dependent kinase 4Homo sapiens (human)
transcription regulator complexCyclin-dependent kinase 4Homo sapiens (human)
nucleusCyclin-dependent kinase 4Homo sapiens (human)
cytoplasmCyclin-dependent kinase 4Homo sapiens (human)
nucleusADP/ATP translocase 3Homo sapiens (human)
mitochondrionADP/ATP translocase 3Homo sapiens (human)
mitochondrial inner membraneADP/ATP translocase 3Homo sapiens (human)
membraneADP/ATP translocase 3Homo sapiens (human)
TIM23 mitochondrial import inner membrane translocase complexADP/ATP translocase 3Homo sapiens (human)
extracellular regionInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
nucleusInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
peroxisomal membraneInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytosolInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
membraneInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
secretory granule lumenInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
extracellular exosomeInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
ficolin-1-rich granule lumenInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
podosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
nucleoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cytoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
mitochondrionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
mitochondrial inner membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
lysosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
late endosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cytosolProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
actin filamentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
caveolaProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
focal adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell junctionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ruffle membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
neuronal cell bodyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
dendritic growth coneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
membrane raftProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
perinuclear region of cytoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
extracellular exosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
synaptic membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
glutamatergic synapseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
postsynaptic specialization, intracellular componentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
dendritic filopodiumProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
axonemecAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cytoplasmcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
centrosomecAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cytosolcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
plasma membranecAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
focal adhesioncAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
membranecAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
plasma membrane raftcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
extracellular exosomecAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
ciliary basecAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cAMP-dependent protein kinase complexcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
nucleotide-activated protein kinase complexcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
protein-containing complexcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cytosolcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
plasma membraneInsulin receptor-related proteinHomo sapiens (human)
receptor complexInsulin receptor-related proteinHomo sapiens (human)
insulin receptor complexInsulin receptor-related proteinHomo sapiens (human)
plasma membraneInsulin receptor-related proteinHomo sapiens (human)
axonInsulin receptor-related proteinHomo sapiens (human)
nucleusSerine/threonine-protein kinase B-rafHomo sapiens (human)
cytosolSerine/threonine-protein kinase B-rafHomo sapiens (human)
plasma membraneSerine/threonine-protein kinase B-rafHomo sapiens (human)
neuron projectionSerine/threonine-protein kinase B-rafHomo sapiens (human)
intracellular membrane-bounded organelleSerine/threonine-protein kinase B-rafHomo sapiens (human)
cell bodySerine/threonine-protein kinase B-rafHomo sapiens (human)
presynapseSerine/threonine-protein kinase B-rafHomo sapiens (human)
cytosolSerine/threonine-protein kinase B-rafHomo sapiens (human)
mitochondrionSerine/threonine-protein kinase B-rafHomo sapiens (human)
plasma membraneSerine/threonine-protein kinase B-rafHomo sapiens (human)
cytosolPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
phosphorylase kinase complexPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
nucleoplasmRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cytosolRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
extracellular exosomeRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cytosolRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
nucleusPlatelet-derived growth factor receptor alphaHomo sapiens (human)
nucleoplasmPlatelet-derived growth factor receptor alphaHomo sapiens (human)
cytoplasmPlatelet-derived growth factor receptor alphaHomo sapiens (human)
endoplasmic reticulum membranePlatelet-derived growth factor receptor alphaHomo sapiens (human)
Golgi apparatusPlatelet-derived growth factor receptor alphaHomo sapiens (human)
plasma membranePlatelet-derived growth factor receptor alphaHomo sapiens (human)
microvillusPlatelet-derived growth factor receptor alphaHomo sapiens (human)
ciliumPlatelet-derived growth factor receptor alphaHomo sapiens (human)
external side of plasma membranePlatelet-derived growth factor receptor alphaHomo sapiens (human)
membranePlatelet-derived growth factor receptor alphaHomo sapiens (human)
cell junctionPlatelet-derived growth factor receptor alphaHomo sapiens (human)
protein-containing complexPlatelet-derived growth factor receptor alphaHomo sapiens (human)
receptor complexPlatelet-derived growth factor receptor alphaHomo sapiens (human)
plasma membranePlatelet-derived growth factor receptor alphaHomo sapiens (human)
actin cytoskeletonTyrosine-protein kinase FerHomo sapiens (human)
microtubule cytoskeletonTyrosine-protein kinase FerHomo sapiens (human)
lamellipodiumTyrosine-protein kinase FerHomo sapiens (human)
cell junctionTyrosine-protein kinase FerHomo sapiens (human)
nucleusTyrosine-protein kinase FerHomo sapiens (human)
cytoplasmTyrosine-protein kinase FerHomo sapiens (human)
cytosolTyrosine-protein kinase FerHomo sapiens (human)
adherens junctionTyrosine-protein kinase FerHomo sapiens (human)
cell cortexTyrosine-protein kinase FerHomo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein kinase FerHomo sapiens (human)
chromatinTyrosine-protein kinase FerHomo sapiens (human)
plasma membraneTyrosine-protein kinase FerHomo sapiens (human)
ciliary basal bodyProtein kinase C alpha typeHomo sapiens (human)
nucleoplasmProtein kinase C alpha typeHomo sapiens (human)
cytoplasmProtein kinase C alpha typeHomo sapiens (human)
mitochondrionProtein kinase C alpha typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C alpha typeHomo sapiens (human)
cytosolProtein kinase C alpha typeHomo sapiens (human)
plasma membraneProtein kinase C alpha typeHomo sapiens (human)
mitochondrial membraneProtein kinase C alpha typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C alpha typeHomo sapiens (human)
extracellular exosomeProtein kinase C alpha typeHomo sapiens (human)
alphav-beta3 integrin-PKCalpha complexProtein kinase C alpha typeHomo sapiens (human)
axonemecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cytoplasmcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
acrosomal vesiclecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
nucleuscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
nucleoplasmcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cytoplasmcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
mitochondrial matrixcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
centrosomecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cytosolcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
plasma membranecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
nuclear speckcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
neuromuscular junctioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
sperm flagellumcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
dendritic spinecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
plasma membrane raftcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
perinuclear region of cytoplasmcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
extracellular exosomecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
ciliary basecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
glutamatergic synapsecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cAMP-dependent protein kinase complexcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
calcium channel complexcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cytosolcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
nucleuscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
extracellular spaceVascular endothelial growth factor receptor 1 Homo sapiens (human)
endosomeVascular endothelial growth factor receptor 1 Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 1 Homo sapiens (human)
focal adhesionVascular endothelial growth factor receptor 1 Homo sapiens (human)
actin cytoskeletonVascular endothelial growth factor receptor 1 Homo sapiens (human)
receptor complexVascular endothelial growth factor receptor 1 Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 1 Homo sapiens (human)
nucleusGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
nucleoplasmGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
cytoplasmGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
spindleGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
cytosolGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription factor TFIIH core complexGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription factor TFIID complexGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription factor TFIIH holo complexGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
CAK-ERCC2 complexGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
MMXD complexGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
nucleusGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
cytoplasmInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
nucleoplasmInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
cytoplasmInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
cytosolInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
ribosomeInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
membraneInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
perinuclear region of cytoplasmInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
nucleusInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
PcG protein complexCasein kinase II subunit alpha'Homo sapiens (human)
acrosomal vesicleCasein kinase II subunit alpha'Homo sapiens (human)
nucleusCasein kinase II subunit alpha'Homo sapiens (human)
nucleoplasmCasein kinase II subunit alpha'Homo sapiens (human)
cytosolCasein kinase II subunit alpha'Homo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit alpha'Homo sapiens (human)
chromatinCasein kinase II subunit alpha'Homo sapiens (human)
cytosolCasein kinase II subunit alpha'Homo sapiens (human)
nucleusCasein kinase II subunit alpha'Homo sapiens (human)
Golgi membraneRas-related protein Rab-6AHomo sapiens (human)
acrosomal membraneRas-related protein Rab-6AHomo sapiens (human)
endoplasmic reticulum membraneRas-related protein Rab-6AHomo sapiens (human)
Golgi apparatusRas-related protein Rab-6AHomo sapiens (human)
trans-Golgi networkRas-related protein Rab-6AHomo sapiens (human)
cytosolRas-related protein Rab-6AHomo sapiens (human)
plasma membraneRas-related protein Rab-6AHomo sapiens (human)
membraneRas-related protein Rab-6AHomo sapiens (human)
secretory granule membraneRas-related protein Rab-6AHomo sapiens (human)
cytoplasmic vesicleRas-related protein Rab-6AHomo sapiens (human)
trans-Golgi network membraneRas-related protein Rab-6AHomo sapiens (human)
extracellular exosomeRas-related protein Rab-6AHomo sapiens (human)
endosome to plasma membrane transport vesicleRas-related protein Rab-6AHomo sapiens (human)
Golgi apparatusRas-related protein Rab-6AHomo sapiens (human)
endomembrane systemRas-related protein Rab-6AHomo sapiens (human)
photoreceptor outer segmentSerine/threonine-protein kinase MAKHomo sapiens (human)
photoreceptor inner segmentSerine/threonine-protein kinase MAKHomo sapiens (human)
nucleusSerine/threonine-protein kinase MAKHomo sapiens (human)
centrosomeSerine/threonine-protein kinase MAKHomo sapiens (human)
axonemeSerine/threonine-protein kinase MAKHomo sapiens (human)
midbodySerine/threonine-protein kinase MAKHomo sapiens (human)
motile ciliumSerine/threonine-protein kinase MAKHomo sapiens (human)
photoreceptor connecting ciliumSerine/threonine-protein kinase MAKHomo sapiens (human)
mitotic spindleSerine/threonine-protein kinase MAKHomo sapiens (human)
ciliumSerine/threonine-protein kinase MAKHomo sapiens (human)
nucleusSerine/threonine-protein kinase MAKHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase MAKHomo sapiens (human)
nucleusCyclin-dependent kinase 11BHomo sapiens (human)
cytoplasmCyclin-dependent kinase 11BHomo sapiens (human)
nucleusCyclin-dependent kinase 11BHomo sapiens (human)
plasma membraneEphrin type-A receptor 1Homo sapiens (human)
receptor complexEphrin type-A receptor 1Homo sapiens (human)
plasma membraneEphrin type-A receptor 1Homo sapiens (human)
collagen-containing extracellular matrixFibroblast growth factor receptor 2Homo sapiens (human)
extracellular regionFibroblast growth factor receptor 2Homo sapiens (human)
nucleusFibroblast growth factor receptor 2Homo sapiens (human)
cytoplasmFibroblast growth factor receptor 2Homo sapiens (human)
Golgi apparatusFibroblast growth factor receptor 2Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 2Homo sapiens (human)
cell cortexFibroblast growth factor receptor 2Homo sapiens (human)
cell surfaceFibroblast growth factor receptor 2Homo sapiens (human)
membraneFibroblast growth factor receptor 2Homo sapiens (human)
cytoplasmic vesicleFibroblast growth factor receptor 2Homo sapiens (human)
excitatory synapseFibroblast growth factor receptor 2Homo sapiens (human)
receptor complexFibroblast growth factor receptor 2Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 2Homo sapiens (human)
extracellular spaceReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
basolateral plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
apical plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
lateral plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
ERBB3:ERBB2 complexReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
receptor complexReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
basal plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
cytoplasmMultifunctional protein ADE2Homo sapiens (human)
cytosolMultifunctional protein ADE2Homo sapiens (human)
membraneMultifunctional protein ADE2Homo sapiens (human)
extracellular exosomeMultifunctional protein ADE2Homo sapiens (human)
cell-cell junctionFibroblast growth factor receptor 4Homo sapiens (human)
extracellular regionFibroblast growth factor receptor 4Homo sapiens (human)
endosomeFibroblast growth factor receptor 4Homo sapiens (human)
endoplasmic reticulumFibroblast growth factor receptor 4Homo sapiens (human)
Golgi apparatusFibroblast growth factor receptor 4Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 4Homo sapiens (human)
transport vesicleFibroblast growth factor receptor 4Homo sapiens (human)
receptor complexFibroblast growth factor receptor 4Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 4Homo sapiens (human)
focal adhesionFibroblast growth factor receptor 3Homo sapiens (human)
extracellular regionFibroblast growth factor receptor 3Homo sapiens (human)
endoplasmic reticulumFibroblast growth factor receptor 3Homo sapiens (human)
Golgi apparatusFibroblast growth factor receptor 3Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 3Homo sapiens (human)
cell surfaceFibroblast growth factor receptor 3Homo sapiens (human)
transport vesicleFibroblast growth factor receptor 3Homo sapiens (human)
receptor complexFibroblast growth factor receptor 3Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 3Homo sapiens (human)
nucleoplasmcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
cytosolcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
ciliary basecAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
cytosolcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
nucleuscAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
cAMP-dependent protein kinase complexcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
nucleoplasmcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
centrosomecAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
cytosolcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
plasma membranecAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
extracellular exosomecAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
ciliary basecAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
cAMP-dependent protein kinase complexcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
cytosolcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
nucleuscAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
mitochondrial inner membraneFerrochelatase, mitochondrialHomo sapiens (human)
mitochondrial matrixFerrochelatase, mitochondrialHomo sapiens (human)
mitochondrionFerrochelatase, mitochondrialHomo sapiens (human)
nucleoplasmRibosomal protein S6 kinase beta-1Homo sapiens (human)
mitochondrionRibosomal protein S6 kinase beta-1Homo sapiens (human)
mitochondrial outer membraneRibosomal protein S6 kinase beta-1Homo sapiens (human)
cytosolRibosomal protein S6 kinase beta-1Homo sapiens (human)
cell surfaceRibosomal protein S6 kinase beta-1Homo sapiens (human)
neuron projectionRibosomal protein S6 kinase beta-1Homo sapiens (human)
perinuclear region of cytoplasmRibosomal protein S6 kinase beta-1Homo sapiens (human)
postsynapseRibosomal protein S6 kinase beta-1Homo sapiens (human)
glutamatergic synapseRibosomal protein S6 kinase beta-1Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase beta-1Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase beta-1Homo sapiens (human)
cytoplasmTyrosine-protein kinase JAK1Homo sapiens (human)
plasma membraneTyrosine-protein kinase JAK1Homo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein kinase JAK1Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneTyrosine-protein kinase JAK1Homo sapiens (human)
nucleusTyrosine-protein kinase JAK1Homo sapiens (human)
cytoplasmTyrosine-protein kinase JAK1Homo sapiens (human)
endosomeTyrosine-protein kinase JAK1Homo sapiens (human)
cytosolTyrosine-protein kinase JAK1Homo sapiens (human)
cytoskeletonTyrosine-protein kinase JAK1Homo sapiens (human)
focal adhesionTyrosine-protein kinase JAK1Homo sapiens (human)
cytosolTyrosine-protein kinase JAK1Homo sapiens (human)
cytoplasmProtein kinase C eta typeHomo sapiens (human)
cytosolProtein kinase C eta typeHomo sapiens (human)
plasma membraneProtein kinase C eta typeHomo sapiens (human)
cell-cell junctionProtein kinase C eta typeHomo sapiens (human)
extracellular exosomeProtein kinase C eta typeHomo sapiens (human)
chromosome, telomeric regionCyclin-dependent kinase 2Homo sapiens (human)
condensed chromosomeCyclin-dependent kinase 2Homo sapiens (human)
X chromosomeCyclin-dependent kinase 2Homo sapiens (human)
Y chromosomeCyclin-dependent kinase 2Homo sapiens (human)
male germ cell nucleusCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
nuclear envelopeCyclin-dependent kinase 2Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
endosomeCyclin-dependent kinase 2Homo sapiens (human)
centrosomeCyclin-dependent kinase 2Homo sapiens (human)
cytosolCyclin-dependent kinase 2Homo sapiens (human)
Cajal bodyCyclin-dependent kinase 2Homo sapiens (human)
cyclin A1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin A2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 2Homo sapiens (human)
transcription regulator complexCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmBeta-adrenergic receptor kinase 1Homo sapiens (human)
cytosolBeta-adrenergic receptor kinase 1Homo sapiens (human)
plasma membraneBeta-adrenergic receptor kinase 1Homo sapiens (human)
ciliumBeta-adrenergic receptor kinase 1Homo sapiens (human)
membraneBeta-adrenergic receptor kinase 1Homo sapiens (human)
presynapseBeta-adrenergic receptor kinase 1Homo sapiens (human)
postsynapseBeta-adrenergic receptor kinase 1Homo sapiens (human)
P-bodyProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
nucleusProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cytoplasmProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cytosolProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cytoplasmic stress granuleProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
membraneProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cytoplasmic ribonucleoprotein granuleProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
RISC complexProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cytoplasmic stress granuleProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
P-bodyProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cytoplasmActivin receptor type-2AHomo sapiens (human)
plasma membraneActivin receptor type-2AHomo sapiens (human)
cell surfaceActivin receptor type-2AHomo sapiens (human)
inhibin-betaglycan-ActRII complexActivin receptor type-2AHomo sapiens (human)
receptor complexActivin receptor type-2AHomo sapiens (human)
plasma membraneActivin receptor type-2AHomo sapiens (human)
activin receptor complexActivin receptor type-2AHomo sapiens (human)
nucleusMitogen-activated protein kinase 3 Homo sapiens (human)
nuclear envelopeMitogen-activated protein kinase 3 Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 3 Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 3 Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 3 Homo sapiens (human)
early endosomeMitogen-activated protein kinase 3 Homo sapiens (human)
late endosomeMitogen-activated protein kinase 3 Homo sapiens (human)
endoplasmic reticulum lumenMitogen-activated protein kinase 3 Homo sapiens (human)
Golgi apparatusMitogen-activated protein kinase 3 Homo sapiens (human)
cytosolMitogen-activated protein kinase 3 Homo sapiens (human)
cytoskeletonMitogen-activated protein kinase 3 Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 3 Homo sapiens (human)
caveolaMitogen-activated protein kinase 3 Homo sapiens (human)
focal adhesionMitogen-activated protein kinase 3 Homo sapiens (human)
pseudopodiumMitogen-activated protein kinase 3 Homo sapiens (human)
glutamatergic synapseMitogen-activated protein kinase 3 Homo sapiens (human)
nucleusMitogen-activated protein kinase 3 Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 3 Homo sapiens (human)
cytoplasmMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
cytosolMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
plasma membraneMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
dendriteMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
extracellular exosomeMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
plasma membraneMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
cytoplasmMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
nucleoplasmDeoxycytidine kinaseHomo sapiens (human)
cytosolDeoxycytidine kinaseHomo sapiens (human)
mitochondrionDeoxycytidine kinaseHomo sapiens (human)
cytoplasmDeoxycytidine kinaseHomo sapiens (human)
extracellular regionMitogen-activated protein kinase 1Homo sapiens (human)
nucleusMitogen-activated protein kinase 1Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 1Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 1Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 1Homo sapiens (human)
early endosomeMitogen-activated protein kinase 1Homo sapiens (human)
late endosomeMitogen-activated protein kinase 1Homo sapiens (human)
endoplasmic reticulum lumenMitogen-activated protein kinase 1Homo sapiens (human)
Golgi apparatusMitogen-activated protein kinase 1Homo sapiens (human)
centrosomeMitogen-activated protein kinase 1Homo sapiens (human)
cytosolMitogen-activated protein kinase 1Homo sapiens (human)
cytoskeletonMitogen-activated protein kinase 1Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 1Homo sapiens (human)
caveolaMitogen-activated protein kinase 1Homo sapiens (human)
focal adhesionMitogen-activated protein kinase 1Homo sapiens (human)
pseudopodiumMitogen-activated protein kinase 1Homo sapiens (human)
azurophil granule lumenMitogen-activated protein kinase 1Homo sapiens (human)
synapseMitogen-activated protein kinase 1Homo sapiens (human)
mitotic spindleMitogen-activated protein kinase 1Homo sapiens (human)
ficolin-1-rich granule lumenMitogen-activated protein kinase 1Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 1Homo sapiens (human)
nucleusMitogen-activated protein kinase 1Homo sapiens (human)
plasma membraneEphrin type-A receptor 2Homo sapiens (human)
focal adhesionEphrin type-A receptor 2Homo sapiens (human)
cell surfaceEphrin type-A receptor 2Homo sapiens (human)
lamellipodiumEphrin type-A receptor 2Homo sapiens (human)
leading edge membraneEphrin type-A receptor 2Homo sapiens (human)
lamellipodium membraneEphrin type-A receptor 2Homo sapiens (human)
ruffle membraneEphrin type-A receptor 2Homo sapiens (human)
tight junctionEphrin type-A receptor 2Homo sapiens (human)
receptor complexEphrin type-A receptor 2Homo sapiens (human)
plasma membraneEphrin type-A receptor 2Homo sapiens (human)
extracellular regionEphrin type-A receptor 3Homo sapiens (human)
nucleoplasmEphrin type-A receptor 3Homo sapiens (human)
early endosomeEphrin type-A receptor 3Homo sapiens (human)
cytosolEphrin type-A receptor 3Homo sapiens (human)
plasma membraneEphrin type-A receptor 3Homo sapiens (human)
actin cytoskeletonEphrin type-A receptor 3Homo sapiens (human)
nuclear membraneEphrin type-A receptor 3Homo sapiens (human)
dendriteEphrin type-A receptor 3Homo sapiens (human)
plasma membraneEphrin type-A receptor 3Homo sapiens (human)
plasma membraneEphrin type-A receptor 8Homo sapiens (human)
early endosome membraneEphrin type-A receptor 8Homo sapiens (human)
neuron projectionEphrin type-A receptor 8Homo sapiens (human)
dendriteEphrin type-A receptor 8Homo sapiens (human)
plasma membraneEphrin type-A receptor 8Homo sapiens (human)
extracellular regionEphrin type-B receptor 2Homo sapiens (human)
nucleoplasmEphrin type-B receptor 2Homo sapiens (human)
cytosolEphrin type-B receptor 2Homo sapiens (human)
plasma membraneEphrin type-B receptor 2Homo sapiens (human)
cell surfaceEphrin type-B receptor 2Homo sapiens (human)
axonEphrin type-B receptor 2Homo sapiens (human)
dendriteEphrin type-B receptor 2Homo sapiens (human)
presynaptic membraneEphrin type-B receptor 2Homo sapiens (human)
neuronal cell bodyEphrin type-B receptor 2Homo sapiens (human)
dendritic spineEphrin type-B receptor 2Homo sapiens (human)
postsynaptic membraneEphrin type-B receptor 2Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseEphrin type-B receptor 2Homo sapiens (human)
postsynapseEphrin type-B receptor 2Homo sapiens (human)
glutamatergic synapseEphrin type-B receptor 2Homo sapiens (human)
plasma membraneEphrin type-B receptor 2Homo sapiens (human)
dendriteEphrin type-B receptor 2Homo sapiens (human)
plasma membraneLeukocyte tyrosine kinase receptorHomo sapiens (human)
membraneLeukocyte tyrosine kinase receptorHomo sapiens (human)
receptor complexLeukocyte tyrosine kinase receptorHomo sapiens (human)
plasma membraneLeukocyte tyrosine kinase receptorHomo sapiens (human)
plasma membraneNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytoplasmic side of plasma membraneNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
extrinsic component of plasma membraneNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
nucleusNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytoplasmNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytosolNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytoskeletonNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
plasma membraneNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
interleukin-12 receptor complexNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
extracellular exosomeNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
interleukin-23 receptor complexNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytosolNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
nucleoplasmUMP-CMP kinase Homo sapiens (human)
nucleolusUMP-CMP kinase Homo sapiens (human)
cytosolUMP-CMP kinase Homo sapiens (human)
extracellular exosomeUMP-CMP kinase Homo sapiens (human)
cytoplasmUMP-CMP kinase Homo sapiens (human)
nucleusUMP-CMP kinase Homo sapiens (human)
nucleusPhosphatidylethanolamine-binding protein 1Homo sapiens (human)
cytosolPhosphatidylethanolamine-binding protein 1Homo sapiens (human)
extracellular exosomePhosphatidylethanolamine-binding protein 1Homo sapiens (human)
nucleusWee1-like protein kinaseHomo sapiens (human)
nucleoplasmWee1-like protein kinaseHomo sapiens (human)
nucleolusWee1-like protein kinaseHomo sapiens (human)
cytoplasmWee1-like protein kinaseHomo sapiens (human)
endoplasmic reticulum membraneHeme oxygenase 2Homo sapiens (human)
plasma membraneHeme oxygenase 2Homo sapiens (human)
membraneHeme oxygenase 2Homo sapiens (human)
specific granule membraneHeme oxygenase 2Homo sapiens (human)
extracellular spaceTyrosine-protein kinase receptor UFOHomo sapiens (human)
plasma membraneTyrosine-protein kinase receptor UFOHomo sapiens (human)
cell surfaceTyrosine-protein kinase receptor UFOHomo sapiens (human)
actin cytoskeletonTyrosine-protein kinase receptor UFOHomo sapiens (human)
intracellular membrane-bounded organelleTyrosine-protein kinase receptor UFOHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase receptor UFOHomo sapiens (human)
plasma membraneTyrosine-protein kinase receptor UFOHomo sapiens (human)
receptor complexTyrosine-protein kinase receptor UFOHomo sapiens (human)
nucleusMitogen-activated protein kinase 4Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 4Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 4Homo sapiens (human)
cytosolMitogen-activated protein kinase 4Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 4Homo sapiens (human)
nucleusMitogen-activated protein kinase 4Homo sapiens (human)
cytosolS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
methionine adenosyltransferase complexS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
cytosolS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
nucleusDnaJ homolog subfamily A member 1Homo sapiens (human)
mitochondrionDnaJ homolog subfamily A member 1Homo sapiens (human)
cytosolDnaJ homolog subfamily A member 1Homo sapiens (human)
microtubule cytoskeletonDnaJ homolog subfamily A member 1Homo sapiens (human)
membraneDnaJ homolog subfamily A member 1Homo sapiens (human)
perinuclear region of cytoplasmDnaJ homolog subfamily A member 1Homo sapiens (human)
extracellular exosomeDnaJ homolog subfamily A member 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneDnaJ homolog subfamily A member 1Homo sapiens (human)
cytoplasmDnaJ homolog subfamily A member 1Homo sapiens (human)
cytosolDnaJ homolog subfamily A member 1Homo sapiens (human)
cytoplasmRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
mitochondrial intermembrane spaceRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
membraneRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
nucleusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
nucleoplasmRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
spindleRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cytosolRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
plasma membraneRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cell-cell junctionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cell cortexRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
microtubule cytoskeletonRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
lamellipodiumRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
vesicleRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
ciliary basal bodyRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
postsynapseRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
glutamatergic synapseRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein-containing complexRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
nucleusRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
nucleoplasmRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
early endosomeRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
cytosolRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
plasma membraneRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
cell cortexRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
ruffle membraneRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
intracellular membrane-bounded organelleRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
cytosolG protein-coupled receptor kinase 4Homo sapiens (human)
plasma membraneG protein-coupled receptor kinase 4Homo sapiens (human)
cell cortexG protein-coupled receptor kinase 4Homo sapiens (human)
photoreceptor disc membraneG protein-coupled receptor kinase 4Homo sapiens (human)
cytoplasmG protein-coupled receptor kinase 4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
cytoplasmDual specificity protein kinase TTKHomo sapiens (human)
spindleDual specificity protein kinase TTKHomo sapiens (human)
membraneDual specificity protein kinase TTKHomo sapiens (human)
kinetochoreDual specificity protein kinase TTKHomo sapiens (human)
nucleusDual specificity protein kinase TTKHomo sapiens (human)
chromosome, telomeric regionDNA replication licensing factor MCM4Homo sapiens (human)
nucleusDNA replication licensing factor MCM4Homo sapiens (human)
nucleoplasmDNA replication licensing factor MCM4Homo sapiens (human)
membraneDNA replication licensing factor MCM4Homo sapiens (human)
MCM complexDNA replication licensing factor MCM4Homo sapiens (human)
CMG complexDNA replication licensing factor MCM4Homo sapiens (human)
nucleusDNA replication licensing factor MCM4Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
plasma membraneTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
receptor complexTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
extracellular regionVascular endothelial growth factor receptor 3Homo sapiens (human)
nucleoplasmVascular endothelial growth factor receptor 3Homo sapiens (human)
cytosolVascular endothelial growth factor receptor 3Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 3Homo sapiens (human)
receptor complexVascular endothelial growth factor receptor 3Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 3Homo sapiens (human)
extracellular regionVascular endothelial growth factor receptor 2Homo sapiens (human)
nucleusVascular endothelial growth factor receptor 2Homo sapiens (human)
endosomeVascular endothelial growth factor receptor 2Homo sapiens (human)
early endosomeVascular endothelial growth factor receptor 2Homo sapiens (human)
endoplasmic reticulumVascular endothelial growth factor receptor 2Homo sapiens (human)
Golgi apparatusVascular endothelial growth factor receptor 2Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 2Homo sapiens (human)
external side of plasma membraneVascular endothelial growth factor receptor 2Homo sapiens (human)
cell junctionVascular endothelial growth factor receptor 2Homo sapiens (human)
membrane raftVascular endothelial growth factor receptor 2Homo sapiens (human)
anchoring junctionVascular endothelial growth factor receptor 2Homo sapiens (human)
sorting endosomeVascular endothelial growth factor receptor 2Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 2Homo sapiens (human)
receptor complexVascular endothelial growth factor receptor 2Homo sapiens (human)
extracellular regionDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
nucleusDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
mitochondrionDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
early endosomeDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
late endosomeDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
peroxisomal membraneDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
endoplasmic reticulumDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
Golgi apparatusDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
microtubuleDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
cell-cell junctionDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
focal adhesionDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
cytoplasmic side of plasma membraneDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
perinuclear region of cytoplasmDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
endoplasmic reticulumReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
endoplasmic reticulum lumenReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
plasma membraneReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
endosome membraneReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
receptor complexReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
plasma membraneReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
caveolaBone morphogenetic protein receptor type-1AHomo sapiens (human)
plasma membraneBone morphogenetic protein receptor type-1AHomo sapiens (human)
external side of plasma membraneBone morphogenetic protein receptor type-1AHomo sapiens (human)
membraneBone morphogenetic protein receptor type-1AHomo sapiens (human)
dendriteBone morphogenetic protein receptor type-1AHomo sapiens (human)
neuronal cell bodyBone morphogenetic protein receptor type-1AHomo sapiens (human)
HFE-transferrin receptor complexBone morphogenetic protein receptor type-1AHomo sapiens (human)
plasma membraneBone morphogenetic protein receptor type-1AHomo sapiens (human)
receptor complexBone morphogenetic protein receptor type-1AHomo sapiens (human)
cytosolActivin receptor type-1BHomo sapiens (human)
plasma membraneActivin receptor type-1BHomo sapiens (human)
cell surfaceActivin receptor type-1BHomo sapiens (human)
receptor complexActivin receptor type-1BHomo sapiens (human)
activin receptor complexActivin receptor type-1BHomo sapiens (human)
plasma membraneActivin receptor type-1BHomo sapiens (human)
nucleusTGF-beta receptor type-1Homo sapiens (human)
endosomeTGF-beta receptor type-1Homo sapiens (human)
plasma membraneTGF-beta receptor type-1Homo sapiens (human)
bicellular tight junctionTGF-beta receptor type-1Homo sapiens (human)
cell surfaceTGF-beta receptor type-1Homo sapiens (human)
membrane raftTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta ligand-receptor complexTGF-beta receptor type-1Homo sapiens (human)
receptor complexTGF-beta receptor type-1Homo sapiens (human)
plasma membraneTGF-beta receptor type-1Homo sapiens (human)
activin receptor complexTGF-beta receptor type-1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase receptor R3Homo sapiens (human)
cell surfaceSerine/threonine-protein kinase receptor R3Homo sapiens (human)
dendriteSerine/threonine-protein kinase receptor R3Homo sapiens (human)
neuronal cell bodySerine/threonine-protein kinase receptor R3Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase receptor R3Homo sapiens (human)
BMP receptor complexSerine/threonine-protein kinase receptor R3Homo sapiens (human)
extracellular regionTGF-beta receptor type-2Homo sapiens (human)
cytosolTGF-beta receptor type-2Homo sapiens (human)
plasma membraneTGF-beta receptor type-2Homo sapiens (human)
caveolaTGF-beta receptor type-2Homo sapiens (human)
external side of plasma membraneTGF-beta receptor type-2Homo sapiens (human)
membraneTGF-beta receptor type-2Homo sapiens (human)
membrane raftTGF-beta receptor type-2Homo sapiens (human)
transforming growth factor beta ligand-receptor complexTGF-beta receptor type-2Homo sapiens (human)
receptor complexTGF-beta receptor type-2Homo sapiens (human)
plasma membraneTGF-beta receptor type-2Homo sapiens (human)
mitochondrionElectron transfer flavoprotein subunit betaHomo sapiens (human)
mitochondrial matrixElectron transfer flavoprotein subunit betaHomo sapiens (human)
electron transfer flavoprotein complexElectron transfer flavoprotein subunit betaHomo sapiens (human)
mitochondrionElectron transfer flavoprotein subunit betaHomo sapiens (human)
cytoplasmTyrosine-protein kinase CSKHomo sapiens (human)
cytosolTyrosine-protein kinase CSKHomo sapiens (human)
plasma membraneTyrosine-protein kinase CSKHomo sapiens (human)
cell-cell junctionTyrosine-protein kinase CSKHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase CSKHomo sapiens (human)
plasma membraneTyrosine-protein kinase CSKHomo sapiens (human)
mitochondrial matrixGlycine--tRNA ligaseHomo sapiens (human)
cytosolGlycine--tRNA ligaseHomo sapiens (human)
secretory granuleGlycine--tRNA ligaseHomo sapiens (human)
axonGlycine--tRNA ligaseHomo sapiens (human)
extracellular exosomeGlycine--tRNA ligaseHomo sapiens (human)
cytoplasmGlycine--tRNA ligaseHomo sapiens (human)
mitochondrionGlycine--tRNA ligaseHomo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 8Homo sapiens (human)
Golgi membraneProtein kinase C iota typeHomo sapiens (human)
nucleusProtein kinase C iota typeHomo sapiens (human)
nucleoplasmProtein kinase C iota typeHomo sapiens (human)
endosomeProtein kinase C iota typeHomo sapiens (human)
cytosolProtein kinase C iota typeHomo sapiens (human)
plasma membraneProtein kinase C iota typeHomo sapiens (human)
brush borderProtein kinase C iota typeHomo sapiens (human)
bicellular tight junctionProtein kinase C iota typeHomo sapiens (human)
microtubule cytoskeletonProtein kinase C iota typeHomo sapiens (human)
apical plasma membraneProtein kinase C iota typeHomo sapiens (human)
cell leading edgeProtein kinase C iota typeHomo sapiens (human)
Schmidt-Lanterman incisureProtein kinase C iota typeHomo sapiens (human)
intercellular bridgeProtein kinase C iota typeHomo sapiens (human)
extracellular exosomeProtein kinase C iota typeHomo sapiens (human)
tight junctionProtein kinase C iota typeHomo sapiens (human)
Schaffer collateral - CA1 synapseProtein kinase C iota typeHomo sapiens (human)
glutamatergic synapseProtein kinase C iota typeHomo sapiens (human)
PAR polarity complexProtein kinase C iota typeHomo sapiens (human)
nuclear exosome (RNase complex)Exosome RNA helicase MTR4Homo sapiens (human)
exosome (RNase complex)Exosome RNA helicase MTR4Homo sapiens (human)
nucleusExosome RNA helicase MTR4Homo sapiens (human)
nucleoplasmExosome RNA helicase MTR4Homo sapiens (human)
nucleolusExosome RNA helicase MTR4Homo sapiens (human)
nuclear speckExosome RNA helicase MTR4Homo sapiens (human)
TRAMP complexExosome RNA helicase MTR4Homo sapiens (human)
catalytic step 2 spliceosomeExosome RNA helicase MTR4Homo sapiens (human)
nucleusExosome RNA helicase MTR4Homo sapiens (human)
cytosolPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complex, class IAPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
intercalated discPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
lamellipodiumPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
perinuclear region of cytoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complexPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complex, class IBPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
plasma membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cytoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
nucleusPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
nucleoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
nucleolusPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
cytosolPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complex, class IAPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
midbodyPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
intracellular membrane-bounded organellePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
plasma membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
cytoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complexPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
PML bodySerine/threonine-protein kinase mTORHomo sapiens (human)
lysosomal membraneSerine/threonine-protein kinase mTORHomo sapiens (human)
cytosolSerine/threonine-protein kinase mTORHomo sapiens (human)
Golgi membraneSerine/threonine-protein kinase mTORHomo sapiens (human)
nucleoplasmSerine/threonine-protein kinase mTORHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase mTORHomo sapiens (human)
mitochondrial outer membraneSerine/threonine-protein kinase mTORHomo sapiens (human)
lysosomeSerine/threonine-protein kinase mTORHomo sapiens (human)
lysosomal membraneSerine/threonine-protein kinase mTORHomo sapiens (human)
endoplasmic reticulum membraneSerine/threonine-protein kinase mTORHomo sapiens (human)
cytosolSerine/threonine-protein kinase mTORHomo sapiens (human)
endomembrane systemSerine/threonine-protein kinase mTORHomo sapiens (human)
membraneSerine/threonine-protein kinase mTORHomo sapiens (human)
dendriteSerine/threonine-protein kinase mTORHomo sapiens (human)
TORC1 complexSerine/threonine-protein kinase mTORHomo sapiens (human)
TORC2 complexSerine/threonine-protein kinase mTORHomo sapiens (human)
phagocytic vesicleSerine/threonine-protein kinase mTORHomo sapiens (human)
nuclear envelopeSerine/threonine-protein kinase mTORHomo sapiens (human)
nucleusSerine/threonine-protein kinase mTORHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase mTORHomo sapiens (human)
cytosolMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
plasma membraneMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
cytosolTyrosine-protein kinase TecHomo sapiens (human)
cytoskeletonTyrosine-protein kinase TecHomo sapiens (human)
plasma membraneTyrosine-protein kinase TecHomo sapiens (human)
plasma membraneTyrosine-protein kinase TecHomo sapiens (human)
nucleusTyrosine-protein kinase TXKHomo sapiens (human)
nucleoplasmTyrosine-protein kinase TXKHomo sapiens (human)
nucleolusTyrosine-protein kinase TXKHomo sapiens (human)
cytoplasmTyrosine-protein kinase TXKHomo sapiens (human)
cytosolTyrosine-protein kinase TXKHomo sapiens (human)
plasma membraneTyrosine-protein kinase TXKHomo sapiens (human)
plasma membraneTyrosine-protein kinase TXKHomo sapiens (human)
cytosolTyrosine-protein kinase ABL2Homo sapiens (human)
actin cytoskeletonTyrosine-protein kinase ABL2Homo sapiens (human)
plasma membraneTyrosine-protein kinase ABL2Homo sapiens (human)
extracellular regionTyrosine-protein kinase FRKHomo sapiens (human)
nucleusTyrosine-protein kinase FRKHomo sapiens (human)
nucleoplasmTyrosine-protein kinase FRKHomo sapiens (human)
cytosolTyrosine-protein kinase FRKHomo sapiens (human)
azurophil granule lumenTyrosine-protein kinase FRKHomo sapiens (human)
specific granule lumenTyrosine-protein kinase FRKHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase FRKHomo sapiens (human)
plasma membraneTyrosine-protein kinase FRKHomo sapiens (human)
plasma membraneG protein-coupled receptor kinase 6Homo sapiens (human)
membraneG protein-coupled receptor kinase 6Homo sapiens (human)
cytoplasmG protein-coupled receptor kinase 6Homo sapiens (human)
membrane raftTyrosine-protein kinase ZAP-70Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneTyrosine-protein kinase ZAP-70Homo sapiens (human)
immunological synapseTyrosine-protein kinase ZAP-70Homo sapiens (human)
cytoplasmTyrosine-protein kinase ZAP-70Homo sapiens (human)
cytosolTyrosine-protein kinase ZAP-70Homo sapiens (human)
plasma membraneTyrosine-protein kinase ZAP-70Homo sapiens (human)
cell-cell junctionTyrosine-protein kinase ZAP-70Homo sapiens (human)
T cell receptor complexTyrosine-protein kinase ZAP-70Homo sapiens (human)
plasma membraneTyrosine-protein kinase ZAP-70Homo sapiens (human)
cytoplasmTyrosine-protein kinase SYKHomo sapiens (human)
nucleusTyrosine-protein kinase SYKHomo sapiens (human)
cytoplasmTyrosine-protein kinase SYKHomo sapiens (human)
cytosolTyrosine-protein kinase SYKHomo sapiens (human)
plasma membraneTyrosine-protein kinase SYKHomo sapiens (human)
early phagosomeTyrosine-protein kinase SYKHomo sapiens (human)
B cell receptor complexTyrosine-protein kinase SYKHomo sapiens (human)
protein-containing complexTyrosine-protein kinase SYKHomo sapiens (human)
T cell receptor complexTyrosine-protein kinase SYKHomo sapiens (human)
plasma membraneTyrosine-protein kinase SYKHomo sapiens (human)
proteasome complex26S proteasome regulatory subunit 6BHomo sapiens (human)
nucleus26S proteasome regulatory subunit 6BHomo sapiens (human)
nucleoplasm26S proteasome regulatory subunit 6BHomo sapiens (human)
cytosol26S proteasome regulatory subunit 6BHomo sapiens (human)
membrane26S proteasome regulatory subunit 6BHomo sapiens (human)
inclusion body26S proteasome regulatory subunit 6BHomo sapiens (human)
synapse26S proteasome regulatory subunit 6BHomo sapiens (human)
proteasome accessory complex26S proteasome regulatory subunit 6BHomo sapiens (human)
cytosolic proteasome complex26S proteasome regulatory subunit 6BHomo sapiens (human)
proteasome regulatory particle, base subcomplex26S proteasome regulatory subunit 6BHomo sapiens (human)
cytoplasmMitogen-activated protein kinase 8Homo sapiens (human)
nucleusMitogen-activated protein kinase 8Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 8Homo sapiens (human)
cytosolMitogen-activated protein kinase 8Homo sapiens (human)
axonMitogen-activated protein kinase 8Homo sapiens (human)
synapseMitogen-activated protein kinase 8Homo sapiens (human)
basal dendriteMitogen-activated protein kinase 8Homo sapiens (human)
nucleusMitogen-activated protein kinase 8Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 9Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 9Homo sapiens (human)
cytosolMitogen-activated protein kinase 9Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 9Homo sapiens (human)
nuclear speckMitogen-activated protein kinase 9Homo sapiens (human)
Schaffer collateral - CA1 synapseMitogen-activated protein kinase 9Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 9Homo sapiens (human)
nucleusMitogen-activated protein kinase 9Homo sapiens (human)
nucleusDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
axonDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
dendrite cytoplasmDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
perikaryonDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
cytoplasmDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
nucleoplasmDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
membraneDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
photoreceptor outer segmentPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
photoreceptor inner segmentPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
nucleoplasmPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
lysosomePhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
autophagosomePhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
cytosolPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
plasma membranePhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
plasma membranePhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
mRNA cleavage and polyadenylation specificity factor complexCasein kinase I isoform alphaHomo sapiens (human)
keratin filamentCasein kinase I isoform alphaHomo sapiens (human)
kinetochoreCasein kinase I isoform alphaHomo sapiens (human)
centrosomeCasein kinase I isoform alphaHomo sapiens (human)
spindleCasein kinase I isoform alphaHomo sapiens (human)
cytosolCasein kinase I isoform alphaHomo sapiens (human)
ciliumCasein kinase I isoform alphaHomo sapiens (human)
membraneCasein kinase I isoform alphaHomo sapiens (human)
nuclear speckCasein kinase I isoform alphaHomo sapiens (human)
beta-catenin destruction complexCasein kinase I isoform alphaHomo sapiens (human)
ciliary basal bodyCasein kinase I isoform alphaHomo sapiens (human)
cytoplasmCasein kinase I isoform alphaHomo sapiens (human)
nucleusCasein kinase I isoform alphaHomo sapiens (human)
nucleusCasein kinase I isoform deltaHomo sapiens (human)
nucleoplasmCasein kinase I isoform deltaHomo sapiens (human)
Golgi apparatusCasein kinase I isoform deltaHomo sapiens (human)
centrosomeCasein kinase I isoform deltaHomo sapiens (human)
spindleCasein kinase I isoform deltaHomo sapiens (human)
cytosolCasein kinase I isoform deltaHomo sapiens (human)
spindle microtubuleCasein kinase I isoform deltaHomo sapiens (human)
plasma membraneCasein kinase I isoform deltaHomo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membraneCasein kinase I isoform deltaHomo sapiens (human)
ciliary basal bodyCasein kinase I isoform deltaHomo sapiens (human)
perinuclear region of cytoplasmCasein kinase I isoform deltaHomo sapiens (human)
nucleusCasein kinase I isoform deltaHomo sapiens (human)
cytoplasmCasein kinase I isoform deltaHomo sapiens (human)
spindle microtubuleCasein kinase I isoform deltaHomo sapiens (human)
cytoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
cytosolPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
plasma membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IAPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IBPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
plasma membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
cytoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
nucleusMAP kinase-activated protein kinase 2Homo sapiens (human)
nucleoplasmMAP kinase-activated protein kinase 2Homo sapiens (human)
cytoplasmMAP kinase-activated protein kinase 2Homo sapiens (human)
centrosomeMAP kinase-activated protein kinase 2Homo sapiens (human)
cytosolMAP kinase-activated protein kinase 2Homo sapiens (human)
extracellular exosomeMAP kinase-activated protein kinase 2Homo sapiens (human)
nucleusMAP kinase-activated protein kinase 2Homo sapiens (human)
cytoplasmMAP kinase-activated protein kinase 2Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 8Homo sapiens (human)
nucleusCyclin-dependent kinase 8Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 8Homo sapiens (human)
nucleolusCyclin-dependent kinase 8Homo sapiens (human)
CKM complexCyclin-dependent kinase 8Homo sapiens (human)
ubiquitin ligase complexCyclin-dependent kinase 8Homo sapiens (human)
mediator complexCyclin-dependent kinase 8Homo sapiens (human)
protein-containing complexCyclin-dependent kinase 8Homo sapiens (human)
nucleusCyclin-dependent kinase 8Homo sapiens (human)
mitochondrionElongation factor Tu, mitochondrialHomo sapiens (human)
mitochondrial outer membraneElongation factor Tu, mitochondrialHomo sapiens (human)
membraneElongation factor Tu, mitochondrialHomo sapiens (human)
mitochondrial nucleoidElongation factor Tu, mitochondrialHomo sapiens (human)
synapseElongation factor Tu, mitochondrialHomo sapiens (human)
extracellular exosomeElongation factor Tu, mitochondrialHomo sapiens (human)
mitochondrionElongation factor Tu, mitochondrialHomo sapiens (human)
cytoplasmCysteine--tRNA ligase, cytoplasmicHomo sapiens (human)
cytosolCysteine--tRNA ligase, cytoplasmicHomo sapiens (human)
cytoplasmCysteine--tRNA ligase, cytoplasmicHomo sapiens (human)
nucleusCasein kinase I isoform epsilonHomo sapiens (human)
nucleoplasmCasein kinase I isoform epsilonHomo sapiens (human)
cytoplasmCasein kinase I isoform epsilonHomo sapiens (human)
cytosolCasein kinase I isoform epsilonHomo sapiens (human)
growth coneCasein kinase I isoform epsilonHomo sapiens (human)
neuronal cell bodyCasein kinase I isoform epsilonHomo sapiens (human)
ribonucleoprotein complexCasein kinase I isoform epsilonHomo sapiens (human)
cytoplasmCasein kinase I isoform epsilonHomo sapiens (human)
nucleusCasein kinase I isoform epsilonHomo sapiens (human)
nucleoplasmVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
nucleolusVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrionVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrial inner membraneVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrial matrixVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrial membraneVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrial nucleoidVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
nucleusDual specificity protein kinase CLK1Homo sapiens (human)
nucleusDual specificity protein kinase CLK2Homo sapiens (human)
nucleoplasmDual specificity protein kinase CLK2Homo sapiens (human)
nuclear bodyDual specificity protein kinase CLK2Homo sapiens (human)
nuclear speckDual specificity protein kinase CLK2Homo sapiens (human)
nucleusDual specificity protein kinase CLK2Homo sapiens (human)
acrosomal vesicleDual specificity protein kinase CLK3Homo sapiens (human)
nucleusDual specificity protein kinase CLK3Homo sapiens (human)
nucleoplasmDual specificity protein kinase CLK3Homo sapiens (human)
membraneDual specificity protein kinase CLK3Homo sapiens (human)
nuclear speckDual specificity protein kinase CLK3Homo sapiens (human)
intermediate filament cytoskeletonDual specificity protein kinase CLK3Homo sapiens (human)
mitochondrionGlycogen synthase kinase-3 alphaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 alphaHomo sapiens (human)
beta-catenin destruction complexGlycogen synthase kinase-3 alphaHomo sapiens (human)
neuronal cell bodyGlycogen synthase kinase-3 alphaHomo sapiens (human)
apical dendriteGlycogen synthase kinase-3 alphaHomo sapiens (human)
postsynapseGlycogen synthase kinase-3 alphaHomo sapiens (human)
proximal dendriteGlycogen synthase kinase-3 alphaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 alphaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 alphaHomo sapiens (human)
axonGlycogen synthase kinase-3 alphaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 alphaHomo sapiens (human)
glutamatergic synapseGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
mitochondrionGlycogen synthase kinase-3 betaHomo sapiens (human)
centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 betaHomo sapiens (human)
plasma membraneGlycogen synthase kinase-3 betaHomo sapiens (human)
axonGlycogen synthase kinase-3 betaHomo sapiens (human)
dendriteGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin destruction complexGlycogen synthase kinase-3 betaHomo sapiens (human)
presynapseGlycogen synthase kinase-3 betaHomo sapiens (human)
postsynapseGlycogen synthase kinase-3 betaHomo sapiens (human)
Wnt signalosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 betaHomo sapiens (human)
axonGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 7Homo sapiens (human)
fibrillar centerCyclin-dependent kinase 7Homo sapiens (human)
male germ cell nucleusCyclin-dependent kinase 7Homo sapiens (human)
nucleusCyclin-dependent kinase 7Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 7Homo sapiens (human)
cytosolCyclin-dependent kinase 7Homo sapiens (human)
plasma membraneCyclin-dependent kinase 7Homo sapiens (human)
perinuclear region of cytoplasmCyclin-dependent kinase 7Homo sapiens (human)
transcription factor TFIIH core complexCyclin-dependent kinase 7Homo sapiens (human)
transcription factor TFIIH holo complexCyclin-dependent kinase 7Homo sapiens (human)
CAK-ERCC2 complexCyclin-dependent kinase 7Homo sapiens (human)
transcription factor TFIIK complexCyclin-dependent kinase 7Homo sapiens (human)
cytoplasmCyclin-dependent kinase 7Homo sapiens (human)
nucleusCyclin-dependent kinase 7Homo sapiens (human)
nucleusCyclin-dependent kinase 9Homo sapiens (human)
nucleusCyclin-dependent kinase 9Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 9Homo sapiens (human)
cyclin/CDK positive transcription elongation factor complexCyclin-dependent kinase 9Homo sapiens (human)
membraneCyclin-dependent kinase 9Homo sapiens (human)
PML bodyCyclin-dependent kinase 9Homo sapiens (human)
cytoplasmic ribonucleoprotein granuleCyclin-dependent kinase 9Homo sapiens (human)
transcription elongation factor complexCyclin-dependent kinase 9Homo sapiens (human)
P-TEFb complexCyclin-dependent kinase 9Homo sapiens (human)
photoreceptor outer segmentRas-related protein Rab-27AHomo sapiens (human)
extracellular regionRas-related protein Rab-27AHomo sapiens (human)
lysosomeRas-related protein Rab-27AHomo sapiens (human)
late endosomeRas-related protein Rab-27AHomo sapiens (human)
cytosolRas-related protein Rab-27AHomo sapiens (human)
dendriteRas-related protein Rab-27AHomo sapiens (human)
multivesicular body membraneRas-related protein Rab-27AHomo sapiens (human)
Weibel-Palade bodyRas-related protein Rab-27AHomo sapiens (human)
melanosome membraneRas-related protein Rab-27AHomo sapiens (human)
specific granule lumenRas-related protein Rab-27AHomo sapiens (human)
melanosomeRas-related protein Rab-27AHomo sapiens (human)
extracellular exosomeRas-related protein Rab-27AHomo sapiens (human)
exocytic vesicleRas-related protein Rab-27AHomo sapiens (human)
exocytic vesicleRas-related protein Rab-27AHomo sapiens (human)
apical plasma membraneRas-related protein Rab-27AHomo sapiens (human)
Golgi apparatusRas-related protein Rab-27AHomo sapiens (human)
secretory granuleRas-related protein Rab-27AHomo sapiens (human)
melanosomeRas-related protein Rab-27AHomo sapiens (human)
cytosolTyrosine-protein kinase BlkHomo sapiens (human)
plasma membraneTyrosine-protein kinase BlkHomo sapiens (human)
cytoplasmInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
cell surfaceInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
nucleoplasmInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
lipid dropletInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
cytosolInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
plasma membraneInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
endosome membraneInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein-containing complexInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
nucleusInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
plasma membraneInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-3Homo sapiens (human)
nucleolusRibosomal protein S6 kinase alpha-3Homo sapiens (human)
cytosolRibosomal protein S6 kinase alpha-3Homo sapiens (human)
synapseRibosomal protein S6 kinase alpha-3Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-3Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-3Homo sapiens (human)
nucleoplasmCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
cytosolCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
plasma membraneCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
ruffle membraneCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
plasma membraneCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
nucleuscAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
nucleoplasmcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
cytoplasmcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
kinetochoreSerine/threonine-protein kinase Nek2Homo sapiens (human)
kinetochoreSerine/threonine-protein kinase Nek2Homo sapiens (human)
condensed nuclear chromosomeSerine/threonine-protein kinase Nek2Homo sapiens (human)
spindle poleSerine/threonine-protein kinase Nek2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Nek2Homo sapiens (human)
nucleolusSerine/threonine-protein kinase Nek2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Nek2Homo sapiens (human)
cytosolSerine/threonine-protein kinase Nek2Homo sapiens (human)
microtubuleSerine/threonine-protein kinase Nek2Homo sapiens (human)
midbodySerine/threonine-protein kinase Nek2Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase Nek2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Nek2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek2Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek2Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek3Homo sapiens (human)
axonSerine/threonine-protein kinase Nek3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek4Homo sapiens (human)
cytosolSerine/threonine-protein kinase Nek4Homo sapiens (human)
ciliary rootletSerine/threonine-protein kinase Nek4Homo sapiens (human)
ciliary transition zoneSerine/threonine-protein kinase Nek4Homo sapiens (human)
ciliary basal bodySerine/threonine-protein kinase Nek4Homo sapiens (human)
ciliary plasmSerine/threonine-protein kinase Nek4Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek4Homo sapiens (human)
extrinsic component of plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
endosomeTyrosine-protein kinase JAK3Homo sapiens (human)
cytosolTyrosine-protein kinase JAK3Homo sapiens (human)
cytoskeletonTyrosine-protein kinase JAK3Homo sapiens (human)
plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
cytosolTyrosine-protein kinase JAK3Homo sapiens (human)
cytoplasmDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
nucleoplasmDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cytoskeletonDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
spindle microtubuleSerine/threonine-protein kinase PLK1Homo sapiens (human)
kinetochoreSerine/threonine-protein kinase PLK1Homo sapiens (human)
synaptonemal complexSerine/threonine-protein kinase PLK1Homo sapiens (human)
spindle poleSerine/threonine-protein kinase PLK1Homo sapiens (human)
nucleusSerine/threonine-protein kinase PLK1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase PLK1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK1Homo sapiens (human)
centrioleSerine/threonine-protein kinase PLK1Homo sapiens (human)
spindleSerine/threonine-protein kinase PLK1Homo sapiens (human)
cytosolSerine/threonine-protein kinase PLK1Homo sapiens (human)
microtubule cytoskeletonSerine/threonine-protein kinase PLK1Homo sapiens (human)
midbodySerine/threonine-protein kinase PLK1Homo sapiens (human)
centriolar satelliteSerine/threonine-protein kinase PLK1Homo sapiens (human)
spindle midzoneSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic spindle poleSerine/threonine-protein kinase PLK1Homo sapiens (human)
chromatinSerine/threonine-protein kinase PLK1Homo sapiens (human)
outer kinetochoreSerine/threonine-protein kinase PLK1Homo sapiens (human)
nucleusSerine/threonine-protein kinase PLK1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PLK1Homo sapiens (human)
spindle poleSerine/threonine-protein kinase PLK1Homo sapiens (human)
kinetochoreSerine/threonine-protein kinase PLK1Homo sapiens (human)
cytoplasmDeath-associated protein kinase 1Homo sapiens (human)
plasma membraneDeath-associated protein kinase 1Homo sapiens (human)
postsynaptic densityDeath-associated protein kinase 1Homo sapiens (human)
actin cytoskeletonDeath-associated protein kinase 1Homo sapiens (human)
glutamatergic synapseDeath-associated protein kinase 1Homo sapiens (human)
DAPK1-calmodulin complexDeath-associated protein kinase 1Homo sapiens (human)
cytoplasmDeath-associated protein kinase 1Homo sapiens (human)
nucleusDeath-associated protein kinase 1Homo sapiens (human)
postsynapseLIM domain kinase 1Homo sapiens (human)
glutamatergic synapseLIM domain kinase 1Homo sapiens (human)
male germ cell nucleusLIM domain kinase 1Homo sapiens (human)
cytoplasmLIM domain kinase 1Homo sapiens (human)
cytosolLIM domain kinase 1Homo sapiens (human)
cytoskeletonLIM domain kinase 1Homo sapiens (human)
focal adhesionLIM domain kinase 1Homo sapiens (human)
membraneLIM domain kinase 1Homo sapiens (human)
nuclear speckLIM domain kinase 1Homo sapiens (human)
lamellipodiumLIM domain kinase 1Homo sapiens (human)
neuron projectionLIM domain kinase 1Homo sapiens (human)
nucleusLIM domain kinase 1Homo sapiens (human)
neuron projectionLIM domain kinase 1Homo sapiens (human)
cytoplasmLIM domain kinase 1Homo sapiens (human)
nucleusLIM domain kinase 2Homo sapiens (human)
cytoplasmLIM domain kinase 2Homo sapiens (human)
cis-Golgi networkLIM domain kinase 2Homo sapiens (human)
centrosomeLIM domain kinase 2Homo sapiens (human)
perinuclear region of cytoplasmLIM domain kinase 2Homo sapiens (human)
mitotic spindleLIM domain kinase 2Homo sapiens (human)
nucleusLIM domain kinase 2Homo sapiens (human)
cytoplasmLIM domain kinase 2Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 12Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 12Homo sapiens (human)
cytosolMitogen-activated protein kinase 12Homo sapiens (human)
nucleusMitogen-activated protein kinase 12Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 12Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 10Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 10Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 10Homo sapiens (human)
cytosolMitogen-activated protein kinase 10Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 10Homo sapiens (human)
nucleusMitogen-activated protein kinase 10Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 10Homo sapiens (human)
nucleusTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
cytoplasmTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
cytosolTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
extracellular spaceTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
cytosolTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
nuclear bodyTyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)
nucleus5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cytosol5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
membrane5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
Golgi apparatus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cytosol5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cytoplasmic stress granule5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nuclear speck5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
axon5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
dendrite5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
neuronal cell body5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nucleus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
extracellular regionEphrin type-B receptor 3Homo sapiens (human)
cytosolEphrin type-B receptor 3Homo sapiens (human)
plasma membraneEphrin type-B receptor 3Homo sapiens (human)
dendriteEphrin type-B receptor 3Homo sapiens (human)
plasma membraneEphrin type-B receptor 3Homo sapiens (human)
rough endoplasmic reticulumEphrin type-A receptor 5Homo sapiens (human)
plasma membraneEphrin type-A receptor 5Homo sapiens (human)
external side of plasma membraneEphrin type-A receptor 5Homo sapiens (human)
axonEphrin type-A receptor 5Homo sapiens (human)
dendriteEphrin type-A receptor 5Homo sapiens (human)
neuronal cell bodyEphrin type-A receptor 5Homo sapiens (human)
perinuclear region of cytoplasmEphrin type-A receptor 5Homo sapiens (human)
plasma membraneEphrin type-A receptor 5Homo sapiens (human)
dendriteEphrin type-A receptor 5Homo sapiens (human)
extracellular regionEphrin type-B receptor 4Homo sapiens (human)
cytosolEphrin type-B receptor 4Homo sapiens (human)
plasma membraneEphrin type-B receptor 4Homo sapiens (human)
extracellular exosomeEphrin type-B receptor 4Homo sapiens (human)
receptor complexEphrin type-B receptor 4Homo sapiens (human)
plasma membraneEphrin type-B receptor 4Homo sapiens (human)
extracellular regionEphrin type-B receptor 1Homo sapiens (human)
endoplasmic reticulumEphrin type-B receptor 1Homo sapiens (human)
cytosolEphrin type-B receptor 1Homo sapiens (human)
plasma membraneEphrin type-B receptor 1Homo sapiens (human)
axonEphrin type-B receptor 1Homo sapiens (human)
early endosome membraneEphrin type-B receptor 1Homo sapiens (human)
filopodium tipEphrin type-B receptor 1Homo sapiens (human)
membrane raftEphrin type-B receptor 1Homo sapiens (human)
extracellular exosomeEphrin type-B receptor 1Homo sapiens (human)
glutamatergic synapseEphrin type-B receptor 1Homo sapiens (human)
plasma membraneEphrin type-B receptor 1Homo sapiens (human)
dendriteEphrin type-B receptor 1Homo sapiens (human)
cytoplasmEphrin type-A receptor 4Homo sapiens (human)
mitochondrial outer membraneEphrin type-A receptor 4Homo sapiens (human)
plasma membraneEphrin type-A receptor 4Homo sapiens (human)
adherens junctionEphrin type-A receptor 4Homo sapiens (human)
cell surfaceEphrin type-A receptor 4Homo sapiens (human)
filopodiumEphrin type-A receptor 4Homo sapiens (human)
axonEphrin type-A receptor 4Homo sapiens (human)
dendriteEphrin type-A receptor 4Homo sapiens (human)
neuromuscular junctionEphrin type-A receptor 4Homo sapiens (human)
early endosome membraneEphrin type-A receptor 4Homo sapiens (human)
presynaptic membraneEphrin type-A receptor 4Homo sapiens (human)
dendritic spineEphrin type-A receptor 4Homo sapiens (human)
dendritic shaftEphrin type-A receptor 4Homo sapiens (human)
perikaryonEphrin type-A receptor 4Homo sapiens (human)
axon terminusEphrin type-A receptor 4Homo sapiens (human)
axonal growth coneEphrin type-A receptor 4Homo sapiens (human)
Schaffer collateral - CA1 synapseEphrin type-A receptor 4Homo sapiens (human)
postsynaptic density membraneEphrin type-A receptor 4Homo sapiens (human)
glutamatergic synapseEphrin type-A receptor 4Homo sapiens (human)
plasma membraneEphrin type-A receptor 4Homo sapiens (human)
dendriteEphrin type-A receptor 4Homo sapiens (human)
mitochondrial intermembrane spaceAdenylate kinase 2, mitochondrialHomo sapiens (human)
extracellular exosomeAdenylate kinase 2, mitochondrialHomo sapiens (human)
sperm mitochondrial sheathAdenylate kinase 2, mitochondrialHomo sapiens (human)
cytoplasmAdenylate kinase 2, mitochondrialHomo sapiens (human)
mitochondrionAdenylate kinase 2, mitochondrialHomo sapiens (human)
nucleoplasmAdenosine kinaseHomo sapiens (human)
cytosolAdenosine kinaseHomo sapiens (human)
plasma membraneAdenosine kinaseHomo sapiens (human)
nucleusAdenosine kinaseHomo sapiens (human)
cytosolAdenosine kinaseHomo sapiens (human)
lysosomeBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
early endosomeBeta-secretase 1Homo sapiens (human)
late endosomeBeta-secretase 1Homo sapiens (human)
multivesicular bodyBeta-secretase 1Homo sapiens (human)
endoplasmic reticulum lumenBeta-secretase 1Homo sapiens (human)
Golgi apparatusBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
synaptic vesicleBeta-secretase 1Homo sapiens (human)
cell surfaceBeta-secretase 1Homo sapiens (human)
endosome membraneBeta-secretase 1Homo sapiens (human)
membraneBeta-secretase 1Homo sapiens (human)
axonBeta-secretase 1Homo sapiens (human)
dendriteBeta-secretase 1Homo sapiens (human)
neuronal cell bodyBeta-secretase 1Homo sapiens (human)
membrane raftBeta-secretase 1Homo sapiens (human)
recycling endosomeBeta-secretase 1Homo sapiens (human)
Golgi-associated vesicle lumenBeta-secretase 1Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
cytoplasmHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
nucleusSerine/threonine-protein kinase SIK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase SIK1Homo sapiens (human)
nucleusSerine/threonine-protein kinase SIK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase SIK1Homo sapiens (human)
cytoplasmReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
membraneReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
cytoplasmReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
exocystRas-related protein Rab-10Homo sapiens (human)
plasma membraneRas-related protein Rab-10Homo sapiens (human)
Golgi membraneRas-related protein Rab-10Homo sapiens (human)
endosomeRas-related protein Rab-10Homo sapiens (human)
endoplasmic reticulum membraneRas-related protein Rab-10Homo sapiens (human)
Golgi apparatusRas-related protein Rab-10Homo sapiens (human)
trans-Golgi networkRas-related protein Rab-10Homo sapiens (human)
cytosolRas-related protein Rab-10Homo sapiens (human)
cytoskeletonRas-related protein Rab-10Homo sapiens (human)
plasma membraneRas-related protein Rab-10Homo sapiens (human)
adherens junctionRas-related protein Rab-10Homo sapiens (human)
focal adhesionRas-related protein Rab-10Homo sapiens (human)
ciliumRas-related protein Rab-10Homo sapiens (human)
endosome membraneRas-related protein Rab-10Homo sapiens (human)
cytoplasmic vesicle membraneRas-related protein Rab-10Homo sapiens (human)
secretory granule membraneRas-related protein Rab-10Homo sapiens (human)
phagocytic vesicle membraneRas-related protein Rab-10Homo sapiens (human)
insulin-responsive compartmentRas-related protein Rab-10Homo sapiens (human)
perinuclear region of cytoplasmRas-related protein Rab-10Homo sapiens (human)
recycling endosomeRas-related protein Rab-10Homo sapiens (human)
recycling endosome membraneRas-related protein Rab-10Homo sapiens (human)
extracellular exosomeRas-related protein Rab-10Homo sapiens (human)
exocytic vesicleRas-related protein Rab-10Homo sapiens (human)
endoplasmic reticulum tubular networkRas-related protein Rab-10Homo sapiens (human)
recycling endosomeRas-related protein Rab-10Homo sapiens (human)
secretory vesicleRas-related protein Rab-10Homo sapiens (human)
membraneRas-related protein Rab-10Homo sapiens (human)
Golgi apparatusRas-related protein Rab-10Homo sapiens (human)
nucleusActin-related protein 3Homo sapiens (human)
cytoplasmActin-related protein 3Homo sapiens (human)
cytosolActin-related protein 3Homo sapiens (human)
brush borderActin-related protein 3Homo sapiens (human)
cell-cell junctionActin-related protein 3Homo sapiens (human)
focal adhesionActin-related protein 3Homo sapiens (human)
actin cytoskeletonActin-related protein 3Homo sapiens (human)
membraneActin-related protein 3Homo sapiens (human)
lamellipodiumActin-related protein 3Homo sapiens (human)
site of double-strand breakActin-related protein 3Homo sapiens (human)
extracellular exosomeActin-related protein 3Homo sapiens (human)
Arp2/3 protein complexActin-related protein 3Homo sapiens (human)
extracellular regionActin-related protein 2Homo sapiens (human)
nucleusActin-related protein 2Homo sapiens (human)
cytoplasmActin-related protein 2Homo sapiens (human)
cytosolActin-related protein 2Homo sapiens (human)
focal adhesionActin-related protein 2Homo sapiens (human)
actin cytoskeletonActin-related protein 2Homo sapiens (human)
membraneActin-related protein 2Homo sapiens (human)
actin capActin-related protein 2Homo sapiens (human)
azurophil granule lumenActin-related protein 2Homo sapiens (human)
site of double-strand breakActin-related protein 2Homo sapiens (human)
cell projectionActin-related protein 2Homo sapiens (human)
extracellular exosomeActin-related protein 2Homo sapiens (human)
ficolin-1-rich granule lumenActin-related protein 2Homo sapiens (human)
Arp2/3 protein complexActin-related protein 2Homo sapiens (human)
cell cortexActin-related protein 2Homo sapiens (human)
Flemming bodyGTP-binding nuclear protein RanHomo sapiens (human)
male germ cell nucleusGTP-binding nuclear protein RanHomo sapiens (human)
manchetteGTP-binding nuclear protein RanHomo sapiens (human)
nucleusGTP-binding nuclear protein RanHomo sapiens (human)
nuclear envelopeGTP-binding nuclear protein RanHomo sapiens (human)
nucleoplasmGTP-binding nuclear protein RanHomo sapiens (human)
nucleolusGTP-binding nuclear protein RanHomo sapiens (human)
cytoplasmGTP-binding nuclear protein RanHomo sapiens (human)
centrioleGTP-binding nuclear protein RanHomo sapiens (human)
cytosolGTP-binding nuclear protein RanHomo sapiens (human)
membraneGTP-binding nuclear protein RanHomo sapiens (human)
midbodyGTP-binding nuclear protein RanHomo sapiens (human)
sperm flagellumGTP-binding nuclear protein RanHomo sapiens (human)
melanosomeGTP-binding nuclear protein RanHomo sapiens (human)
recycling endosomeGTP-binding nuclear protein RanHomo sapiens (human)
extracellular exosomeGTP-binding nuclear protein RanHomo sapiens (human)
chromatinGTP-binding nuclear protein RanHomo sapiens (human)
nuclear poreGTP-binding nuclear protein RanHomo sapiens (human)
protein-containing complexGTP-binding nuclear protein RanHomo sapiens (human)
RNA nuclear export complexGTP-binding nuclear protein RanHomo sapiens (human)
nucleusGTP-binding nuclear protein RanHomo sapiens (human)
cytoplasmGTP-binding nuclear protein RanHomo sapiens (human)
PcG protein complexCasein kinase II subunit alphaHomo sapiens (human)
PML bodyCasein kinase II subunit alphaHomo sapiens (human)
nucleusCasein kinase II subunit alphaHomo sapiens (human)
nucleoplasmCasein kinase II subunit alphaHomo sapiens (human)
cytosolCasein kinase II subunit alphaHomo sapiens (human)
plasma membraneCasein kinase II subunit alphaHomo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit alphaHomo sapiens (human)
Sin3-type complexCasein kinase II subunit alphaHomo sapiens (human)
cytosolCasein kinase II subunit alphaHomo sapiens (human)
nucleusCasein kinase II subunit alphaHomo sapiens (human)
nucleusPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
nucleoplasmPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
autophagosomePhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
endoplasmic reticulum membranePhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
cytosolPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
plasma membranePhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
plasma membranePhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
nucleusSRSF protein kinase 2Homo sapiens (human)
nucleoplasmSRSF protein kinase 2Homo sapiens (human)
nucleolusSRSF protein kinase 2Homo sapiens (human)
cytoplasmSRSF protein kinase 2Homo sapiens (human)
cytosolSRSF protein kinase 2Homo sapiens (human)
nuclear speckSRSF protein kinase 2Homo sapiens (human)
chromatinSRSF protein kinase 2Homo sapiens (human)
nucleusSRSF protein kinase 2Homo sapiens (human)
cytoplasmSRSF protein kinase 2Homo sapiens (human)
cytosolCasein kinase I isoform gamma-2Homo sapiens (human)
cell cortexCasein kinase I isoform gamma-2Homo sapiens (human)
membraneCasein kinase I isoform gamma-2Homo sapiens (human)
cytoplasmCasein kinase I isoform gamma-2Homo sapiens (human)
plasma membraneCasein kinase I isoform gamma-2Homo sapiens (human)
nucleusCasein kinase I isoform gamma-2Homo sapiens (human)
chromosome, telomeric regionDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleoplasmDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleolusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
cytosolDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
membraneDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA-dependent protein kinase complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
chromatinDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
transcription regulator complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA-dependent protein kinase-DNA ligase 4 complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
small-subunit processomeDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein-containing complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein-DNA complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nonhomologous end joining complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
cellular_componentMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 3Homo sapiens (human)
nucleusCyclin-dependent kinase 3Homo sapiens (human)
cytoplasmCyclin-dependent kinase 3Homo sapiens (human)
nucleoplasmCyclin-dependent kinase-like 1Homo sapiens (human)
cytoplasmCyclin-dependent kinase-like 1Homo sapiens (human)
ciliary transition zoneCyclin-dependent kinase-like 1Homo sapiens (human)
intracellular membrane-bounded organelleCyclin-dependent kinase-like 1Homo sapiens (human)
extracellular exosomeCyclin-dependent kinase-like 1Homo sapiens (human)
nucleusCyclin-dependent kinase-like 1Homo sapiens (human)
ruffleCyclin-dependent kinase 6Homo sapiens (human)
nucleusCyclin-dependent kinase 6Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 6Homo sapiens (human)
cytoplasmCyclin-dependent kinase 6Homo sapiens (human)
centrosomeCyclin-dependent kinase 6Homo sapiens (human)
cytosolCyclin-dependent kinase 6Homo sapiens (human)
cyclin D1-CDK6 complexCyclin-dependent kinase 6Homo sapiens (human)
cyclin D3-CDK6 complexCyclin-dependent kinase 6Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 6Homo sapiens (human)
cyclin D2-CDK6 complexCyclin-dependent kinase 6Homo sapiens (human)
cytoplasmCyclin-dependent kinase 6Homo sapiens (human)
nucleusCyclin-dependent kinase 6Homo sapiens (human)
microtubuleCyclin-dependent-like kinase 5 Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent-like kinase 5 Homo sapiens (human)
nucleusCyclin-dependent-like kinase 5 Homo sapiens (human)
nucleoplasmCyclin-dependent-like kinase 5 Homo sapiens (human)
cytoplasmCyclin-dependent-like kinase 5 Homo sapiens (human)
cytosolCyclin-dependent-like kinase 5 Homo sapiens (human)
plasma membraneCyclin-dependent-like kinase 5 Homo sapiens (human)
postsynaptic densityCyclin-dependent-like kinase 5 Homo sapiens (human)
membraneCyclin-dependent-like kinase 5 Homo sapiens (human)
protein kinase 5 complexCyclin-dependent-like kinase 5 Homo sapiens (human)
lamellipodiumCyclin-dependent-like kinase 5 Homo sapiens (human)
cell junctionCyclin-dependent-like kinase 5 Homo sapiens (human)
filopodiumCyclin-dependent-like kinase 5 Homo sapiens (human)
axonCyclin-dependent-like kinase 5 Homo sapiens (human)
dendriteCyclin-dependent-like kinase 5 Homo sapiens (human)
growth coneCyclin-dependent-like kinase 5 Homo sapiens (human)
neuromuscular junctionCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron projectionCyclin-dependent-like kinase 5 Homo sapiens (human)
neuronal cell bodyCyclin-dependent-like kinase 5 Homo sapiens (human)
perikaryonCyclin-dependent-like kinase 5 Homo sapiens (human)
presynapseCyclin-dependent-like kinase 5 Homo sapiens (human)
nucleusCyclin-dependent-like kinase 5 Homo sapiens (human)
cytoplasmCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic vesicleCyclin-dependent kinase 16Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 16Homo sapiens (human)
cytoplasmCyclin-dependent kinase 16Homo sapiens (human)
cytosolCyclin-dependent kinase 16Homo sapiens (human)
plasma membraneCyclin-dependent kinase 16Homo sapiens (human)
cytoplasmic side of plasma membraneCyclin-dependent kinase 16Homo sapiens (human)
microtubule cytoskeletonCyclin-dependent kinase 16Homo sapiens (human)
neuron projectionCyclin-dependent kinase 16Homo sapiens (human)
cytoplasmCyclin-dependent kinase 16Homo sapiens (human)
nucleusCyclin-dependent kinase 16Homo sapiens (human)
cytoplasmCyclin-dependent kinase 17Homo sapiens (human)
nucleusCyclin-dependent kinase 17Homo sapiens (human)
nucleusATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
cytoplasmATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
cytosolATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
membraneATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
extracellular exosomeATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
membraneATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
6-phosphofructokinase complexATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
Golgi apparatusProtein kinase C epsilon typeHomo sapiens (human)
nucleusProtein kinase C epsilon typeHomo sapiens (human)
cytoplasmProtein kinase C epsilon typeHomo sapiens (human)
mitochondrionProtein kinase C epsilon typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C epsilon typeHomo sapiens (human)
cytosolProtein kinase C epsilon typeHomo sapiens (human)
plasma membraneProtein kinase C epsilon typeHomo sapiens (human)
intracellular membrane-bounded organelleProtein kinase C epsilon typeHomo sapiens (human)
intermediate filament cytoskeletonProtein kinase C epsilon typeHomo sapiens (human)
synapseProtein kinase C epsilon typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C epsilon typeHomo sapiens (human)
cell peripheryProtein kinase C epsilon typeHomo sapiens (human)
nucleusDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
mitochondrionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
early endosomeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
late endosomeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
endoplasmic reticulumDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
Golgi apparatusDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
centrosomeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
plasma membraneDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
focal adhesionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
stress fiberAngiopoietin-1 receptorHomo sapiens (human)
actin filamentAngiopoietin-1 receptorHomo sapiens (human)
extracellular regionAngiopoietin-1 receptorHomo sapiens (human)
cytoplasmAngiopoietin-1 receptorHomo sapiens (human)
plasma membraneAngiopoietin-1 receptorHomo sapiens (human)
microvillusAngiopoietin-1 receptorHomo sapiens (human)
cell-cell junctionAngiopoietin-1 receptorHomo sapiens (human)
focal adhesionAngiopoietin-1 receptorHomo sapiens (human)
basal plasma membraneAngiopoietin-1 receptorHomo sapiens (human)
cell surfaceAngiopoietin-1 receptorHomo sapiens (human)
basolateral plasma membraneAngiopoietin-1 receptorHomo sapiens (human)
apical plasma membraneAngiopoietin-1 receptorHomo sapiens (human)
centriolar satelliteAngiopoietin-1 receptorHomo sapiens (human)
membrane raftAngiopoietin-1 receptorHomo sapiens (human)
plasma membraneAngiopoietin-1 receptorHomo sapiens (human)
receptor complexAngiopoietin-1 receptorHomo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
nucleolusDNA topoisomerase 2-betaHomo sapiens (human)
heterochromatinDNA topoisomerase 2-betaHomo sapiens (human)
nucleusDNA topoisomerase 2-betaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-betaHomo sapiens (human)
nucleolusDNA topoisomerase 2-betaHomo sapiens (human)
cytosolDNA topoisomerase 2-betaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-betaHomo sapiens (human)
nucleusDNA topoisomerase 2-betaHomo sapiens (human)
nucleolusTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
glutamatergic synapseTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
nucleoplasmTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
cytosolTranscription factor p65Homo sapiens (human)
NF-kappaB p50/p65 complexTranscription factor p65Homo sapiens (human)
NF-kappaB complexTranscription factor p65Homo sapiens (human)
chromatinTranscription factor p65Homo sapiens (human)
transcription regulator complexTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
immunological synapseProtein kinase C theta typeHomo sapiens (human)
cytosolProtein kinase C theta typeHomo sapiens (human)
plasma membraneProtein kinase C theta typeHomo sapiens (human)
aggresomeProtein kinase C theta typeHomo sapiens (human)
centriolar satelliteProtein kinase C theta typeHomo sapiens (human)
plasma membraneActivin receptor type-1Homo sapiens (human)
apical part of cellActivin receptor type-1Homo sapiens (human)
activin receptor complexActivin receptor type-1Homo sapiens (human)
BMP receptor complexActivin receptor type-1Homo sapiens (human)
plasma membraneActivin receptor type-1Homo sapiens (human)
stress fiberMacrophage-stimulating protein receptorHomo sapiens (human)
vacuoleMacrophage-stimulating protein receptorHomo sapiens (human)
plasma membraneMacrophage-stimulating protein receptorHomo sapiens (human)
cell surfaceMacrophage-stimulating protein receptorHomo sapiens (human)
receptor complexMacrophage-stimulating protein receptorHomo sapiens (human)
plasma membraneMacrophage-stimulating protein receptorHomo sapiens (human)
stress fiberFocal adhesion kinase 1Homo sapiens (human)
nucleusFocal adhesion kinase 1Homo sapiens (human)
cytoplasmFocal adhesion kinase 1Homo sapiens (human)
centrosomeFocal adhesion kinase 1Homo sapiens (human)
cytosolFocal adhesion kinase 1Homo sapiens (human)
cytoskeletonFocal adhesion kinase 1Homo sapiens (human)
plasma membraneFocal adhesion kinase 1Homo sapiens (human)
focal adhesionFocal adhesion kinase 1Homo sapiens (human)
cell cortexFocal adhesion kinase 1Homo sapiens (human)
ciliary basal bodyFocal adhesion kinase 1Homo sapiens (human)
intracellular membrane-bounded organelleFocal adhesion kinase 1Homo sapiens (human)
perinuclear region of cytoplasmFocal adhesion kinase 1Homo sapiens (human)
plasma membraneFocal adhesion kinase 1Homo sapiens (human)
focal adhesionFocal adhesion kinase 1Homo sapiens (human)
dendritic spineFocal adhesion kinase 1Homo sapiens (human)
stress fiberProtein kinase C zeta typeHomo sapiens (human)
nuclear envelopeProtein kinase C zeta typeHomo sapiens (human)
cytoplasmProtein kinase C zeta typeHomo sapiens (human)
endosomeProtein kinase C zeta typeHomo sapiens (human)
microtubule organizing centerProtein kinase C zeta typeHomo sapiens (human)
cytosolProtein kinase C zeta typeHomo sapiens (human)
plasma membraneProtein kinase C zeta typeHomo sapiens (human)
cell-cell junctionProtein kinase C zeta typeHomo sapiens (human)
bicellular tight junctionProtein kinase C zeta typeHomo sapiens (human)
postsynaptic densityProtein kinase C zeta typeHomo sapiens (human)
membraneProtein kinase C zeta typeHomo sapiens (human)
apical plasma membraneProtein kinase C zeta typeHomo sapiens (human)
nuclear matrixProtein kinase C zeta typeHomo sapiens (human)
cell junctionProtein kinase C zeta typeHomo sapiens (human)
cell leading edgeProtein kinase C zeta typeHomo sapiens (human)
vesicleProtein kinase C zeta typeHomo sapiens (human)
myelin sheath abaxonal regionProtein kinase C zeta typeHomo sapiens (human)
axon hillockProtein kinase C zeta typeHomo sapiens (human)
apical cortexProtein kinase C zeta typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C zeta typeHomo sapiens (human)
extracellular exosomeProtein kinase C zeta typeHomo sapiens (human)
tight junctionProtein kinase C zeta typeHomo sapiens (human)
Schaffer collateral - CA1 synapseProtein kinase C zeta typeHomo sapiens (human)
glutamatergic synapseProtein kinase C zeta typeHomo sapiens (human)
PAR polarity complexProtein kinase C zeta typeHomo sapiens (human)
extracellular regionProtein kinase C delta typeHomo sapiens (human)
nucleusProtein kinase C delta typeHomo sapiens (human)
nucleoplasmProtein kinase C delta typeHomo sapiens (human)
cytoplasmProtein kinase C delta typeHomo sapiens (human)
mitochondrionProtein kinase C delta typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C delta typeHomo sapiens (human)
cytosolProtein kinase C delta typeHomo sapiens (human)
plasma membraneProtein kinase C delta typeHomo sapiens (human)
cell-cell junctionProtein kinase C delta typeHomo sapiens (human)
nuclear matrixProtein kinase C delta typeHomo sapiens (human)
azurophil granule lumenProtein kinase C delta typeHomo sapiens (human)
endolysosomeProtein kinase C delta typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C delta typeHomo sapiens (human)
extracellular exosomeProtein kinase C delta typeHomo sapiens (human)
nucleusTyrosine-protein kinase BTKHomo sapiens (human)
cytoplasmTyrosine-protein kinase BTKHomo sapiens (human)
cytosolTyrosine-protein kinase BTKHomo sapiens (human)
plasma membraneTyrosine-protein kinase BTKHomo sapiens (human)
cytoplasmic vesicleTyrosine-protein kinase BTKHomo sapiens (human)
membrane raftTyrosine-protein kinase BTKHomo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase BTKHomo sapiens (human)
plasma membraneTyrosine-protein kinase BTKHomo sapiens (human)
nucleusTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
nuclear envelopeTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
endoplasmic reticulum membraneTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
plasma membraneTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
cell surfaceTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
plasma membraneTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
receptor complexTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
cellular_componentCyclin-dependent kinase 18Homo sapiens (human)
nucleusCyclin-dependent kinase 18Homo sapiens (human)
cytoplasmCyclin-dependent kinase 18Homo sapiens (human)
nucleusActivated CDC42 kinase 1Homo sapiens (human)
cytoplasmActivated CDC42 kinase 1Homo sapiens (human)
endosomeActivated CDC42 kinase 1Homo sapiens (human)
cytosolActivated CDC42 kinase 1Homo sapiens (human)
plasma membraneActivated CDC42 kinase 1Homo sapiens (human)
clathrin-coated pitActivated CDC42 kinase 1Homo sapiens (human)
adherens junctionActivated CDC42 kinase 1Homo sapiens (human)
membraneActivated CDC42 kinase 1Homo sapiens (human)
clathrin-coated vesicleActivated CDC42 kinase 1Homo sapiens (human)
cytoplasmic vesicle membraneActivated CDC42 kinase 1Homo sapiens (human)
intracellular membrane-bounded organelleActivated CDC42 kinase 1Homo sapiens (human)
perinuclear region of cytoplasmActivated CDC42 kinase 1Homo sapiens (human)
cytoophidiumActivated CDC42 kinase 1Homo sapiens (human)
Grb2-EGFR complexActivated CDC42 kinase 1Homo sapiens (human)
plasma membraneActivated CDC42 kinase 1Homo sapiens (human)
extracellular spaceEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
plasma membraneEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
extracellular exosomeEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
receptor complexEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
plasma membraneEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
nucleusTyrosine-protein kinase ITK/TSKHomo sapiens (human)
cytosolTyrosine-protein kinase ITK/TSKHomo sapiens (human)
cell-cell junctionTyrosine-protein kinase ITK/TSKHomo sapiens (human)
plasma membraneTyrosine-protein kinase ITK/TSKHomo sapiens (human)
nuclear outer membraneMyotonin-protein kinaseHomo sapiens (human)
mitochondrial outer membraneMyotonin-protein kinaseHomo sapiens (human)
endoplasmic reticulum membraneMyotonin-protein kinaseHomo sapiens (human)
cytosolMyotonin-protein kinaseHomo sapiens (human)
plasma membraneMyotonin-protein kinaseHomo sapiens (human)
nuclear membraneMyotonin-protein kinaseHomo sapiens (human)
sarcoplasmic reticulum membraneMyotonin-protein kinaseHomo sapiens (human)
Golgi membraneMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
basolateral plasma membraneMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
plasma membraneMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
membraneMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
growth coneMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
photoreceptor outer segmentTyrosine-protein kinase MerHomo sapiens (human)
extracellular spaceTyrosine-protein kinase MerHomo sapiens (human)
cytoplasmTyrosine-protein kinase MerHomo sapiens (human)
plasma membraneTyrosine-protein kinase MerHomo sapiens (human)
plasma membraneTyrosine-protein kinase MerHomo sapiens (human)
receptor complexTyrosine-protein kinase MerHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase 4Homo sapiens (human)
nucleusSerine/threonine-protein kinase 4Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase 4Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 4Homo sapiens (human)
cytosolSerine/threonine-protein kinase 4Homo sapiens (human)
nuclear bodySerine/threonine-protein kinase 4Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase 4Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cytosol5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
apical plasma membrane5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nuclear speck5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
axon5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
dendrite5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
neuronal cell body5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
chromatin5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
ruffleSerine/threonine-protein kinase PAK 1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase PAK 1Homo sapiens (human)
chromosomeSerine/threonine-protein kinase PAK 1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PAK 1Homo sapiens (human)
cytosolSerine/threonine-protein kinase PAK 1Homo sapiens (human)
actin filamentSerine/threonine-protein kinase PAK 1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase PAK 1Homo sapiens (human)
cell-cell junctionSerine/threonine-protein kinase PAK 1Homo sapiens (human)
focal adhesionSerine/threonine-protein kinase PAK 1Homo sapiens (human)
intercalated discSerine/threonine-protein kinase PAK 1Homo sapiens (human)
Z discSerine/threonine-protein kinase PAK 1Homo sapiens (human)
lamellipodiumSerine/threonine-protein kinase PAK 1Homo sapiens (human)
axonSerine/threonine-protein kinase PAK 1Homo sapiens (human)
dendriteSerine/threonine-protein kinase PAK 1Homo sapiens (human)
nuclear membraneSerine/threonine-protein kinase PAK 1Homo sapiens (human)
ruffle membraneSerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase PAK 1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 1Homo sapiens (human)
spindleDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
nucleusMitogen-activated protein kinase 7Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 7Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 7Homo sapiens (human)
cytosolMitogen-activated protein kinase 7Homo sapiens (human)
PML bodyMitogen-activated protein kinase 7Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 7Homo sapiens (human)
nucleusMitogen-activated protein kinase 7Homo sapiens (human)
nucleusSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cytosolSerine/threonine-protein kinase PAK 2Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cell-cell junctionSerine/threonine-protein kinase PAK 2Homo sapiens (human)
postsynaptic densitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
secretory granuleSerine/threonine-protein kinase PAK 2Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase PAK 2Homo sapiens (human)
glutamatergic synapseSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 3Homo sapiens (human)
centrosomeSerine/threonine-protein kinase 3Homo sapiens (human)
nucleusSerine/threonine-protein kinase 3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 3Homo sapiens (human)
cytosolSerine/threonine-protein kinase 3Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase 3Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
cytosolcGMP-dependent protein kinase 2Homo sapiens (human)
apical plasma membranecGMP-dependent protein kinase 2Homo sapiens (human)
nuclear membranecGMP-dependent protein kinase 2Homo sapiens (human)
cytosolIntegrin-linked protein kinaseHomo sapiens (human)
plasma membraneIntegrin-linked protein kinaseHomo sapiens (human)
focal adhesionIntegrin-linked protein kinaseHomo sapiens (human)
membraneIntegrin-linked protein kinaseHomo sapiens (human)
sarcomereIntegrin-linked protein kinaseHomo sapiens (human)
lamellipodiumIntegrin-linked protein kinaseHomo sapiens (human)
focal adhesionIntegrin-linked protein kinaseHomo sapiens (human)
stress fiberIntegrin-linked protein kinaseHomo sapiens (human)
Golgi membraneRho-associated protein kinase 1Homo sapiens (human)
ruffleRho-associated protein kinase 1Homo sapiens (human)
extracellular regionRho-associated protein kinase 1Homo sapiens (human)
centrioleRho-associated protein kinase 1Homo sapiens (human)
cytosolRho-associated protein kinase 1Homo sapiens (human)
cytoskeletonRho-associated protein kinase 1Homo sapiens (human)
plasma membraneRho-associated protein kinase 1Homo sapiens (human)
cytoplasmic stress granuleRho-associated protein kinase 1Homo sapiens (human)
lamellipodiumRho-associated protein kinase 1Homo sapiens (human)
blebRho-associated protein kinase 1Homo sapiens (human)
secretory granule lumenRho-associated protein kinase 1Homo sapiens (human)
Schaffer collateral - CA1 synapseRho-associated protein kinase 1Homo sapiens (human)
cytoskeletonRho-associated protein kinase 1Homo sapiens (human)
cytoplasmRho-associated protein kinase 1Homo sapiens (human)
cytoplasmic stress granuleRho-associated protein kinase 1Homo sapiens (human)
cytoplasmNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
membraneNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
plasma membraneNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
nucleusSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
kinetochoreSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
nucleusSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
nucleoplasmSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
nuclear speckSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
catalytic step 2 spliceosomeSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
mitochondrionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cytosolReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
plasma membraneReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
endosome membraneReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
death-inducing signaling complexReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein-containing complexReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
receptor complexReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
ripoptosomeReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
centrosomeCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
endocytic vesicle membraneCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
sarcoplasmic reticulum membraneCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
synapseCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
calcium- and calmodulin-dependent protein kinase complexCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
neuron projectionCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
membraneCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
endocytic vesicle membraneCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
sarcoplasmic reticulum membraneCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
calcium- and calmodulin-dependent protein kinase complexCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
neuron projectionCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
nucleusCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
membraneCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
endocytic vesicle membraneCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
sarcoplasmic reticulum membraneCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
sarcolemmaCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
calcium- and calmodulin-dependent protein kinase complexCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
neuron projectionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
cytoskeletonDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nucleoplasmDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
cytoplasmDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nuclear speckDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
axonDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
dendriteDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
ribonucleoprotein complexDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
cytoplasmActivin receptor type-2BHomo sapiens (human)
plasma membraneActivin receptor type-2BHomo sapiens (human)
protein-containing complexActivin receptor type-2BHomo sapiens (human)
receptor complexActivin receptor type-2BHomo sapiens (human)
activin receptor complexActivin receptor type-2BHomo sapiens (human)
plasma membraneActivin receptor type-2BHomo sapiens (human)
caveolaBone morphogenetic protein receptor type-2Homo sapiens (human)
extracellular spaceBone morphogenetic protein receptor type-2Homo sapiens (human)
nucleoplasmBone morphogenetic protein receptor type-2Homo sapiens (human)
plasma membraneBone morphogenetic protein receptor type-2Homo sapiens (human)
clathrin-coated pitBone morphogenetic protein receptor type-2Homo sapiens (human)
adherens junctionBone morphogenetic protein receptor type-2Homo sapiens (human)
basal plasma membraneBone morphogenetic protein receptor type-2Homo sapiens (human)
cell surfaceBone morphogenetic protein receptor type-2Homo sapiens (human)
postsynaptic densityBone morphogenetic protein receptor type-2Homo sapiens (human)
apical plasma membraneBone morphogenetic protein receptor type-2Homo sapiens (human)
axonBone morphogenetic protein receptor type-2Homo sapiens (human)
dendriteBone morphogenetic protein receptor type-2Homo sapiens (human)
neuronal cell bodyBone morphogenetic protein receptor type-2Homo sapiens (human)
plasma membraneBone morphogenetic protein receptor type-2Homo sapiens (human)
receptor complexBone morphogenetic protein receptor type-2Homo sapiens (human)
ruffleProtein-tyrosine kinase 6Homo sapiens (human)
nucleusProtein-tyrosine kinase 6Homo sapiens (human)
nucleoplasmProtein-tyrosine kinase 6Homo sapiens (human)
cytoplasmProtein-tyrosine kinase 6Homo sapiens (human)
cytosolProtein-tyrosine kinase 6Homo sapiens (human)
plasma membraneProtein-tyrosine kinase 6Homo sapiens (human)
nuclear bodyProtein-tyrosine kinase 6Homo sapiens (human)
plasma membraneProtein-tyrosine kinase 6Homo sapiens (human)
acrosomal vesiclecGMP-dependent protein kinase 1 Homo sapiens (human)
nucleoplasmcGMP-dependent protein kinase 1 Homo sapiens (human)
cytoplasmcGMP-dependent protein kinase 1 Homo sapiens (human)
Golgi apparatuscGMP-dependent protein kinase 1 Homo sapiens (human)
cytosolcGMP-dependent protein kinase 1 Homo sapiens (human)
plasma membranecGMP-dependent protein kinase 1 Homo sapiens (human)
sarcolemmacGMP-dependent protein kinase 1 Homo sapiens (human)
cyclin K-CDK13 complexCyclin-dependent kinase 13Homo sapiens (human)
extracellular regionCyclin-dependent kinase 13Homo sapiens (human)
extracellular spaceCyclin-dependent kinase 13Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 13Homo sapiens (human)
Golgi apparatusCyclin-dependent kinase 13Homo sapiens (human)
cytosolCyclin-dependent kinase 13Homo sapiens (human)
nuclear speckCyclin-dependent kinase 13Homo sapiens (human)
ficolin-1-rich granule lumenCyclin-dependent kinase 13Homo sapiens (human)
nuclear cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 13Homo sapiens (human)
nucleusCyclin-dependent kinase 13Homo sapiens (human)
cyclin/CDK positive transcription elongation factor complexCyclin-dependent kinase 13Homo sapiens (human)
nucleusCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
intracellular anatomical structureCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
nucleusInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
nucleoplasmInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
cytosolInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
PML bodyInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
mitochondrial membraneInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
serine/threonine protein kinase complexInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
NMDA selective glutamate receptor complexProtein-tyrosine kinase 2-betaHomo sapiens (human)
nucleusProtein-tyrosine kinase 2-betaHomo sapiens (human)
cytoplasmProtein-tyrosine kinase 2-betaHomo sapiens (human)
cytosolProtein-tyrosine kinase 2-betaHomo sapiens (human)
cytoskeletonProtein-tyrosine kinase 2-betaHomo sapiens (human)
focal adhesionProtein-tyrosine kinase 2-betaHomo sapiens (human)
cell cortexProtein-tyrosine kinase 2-betaHomo sapiens (human)
postsynaptic densityProtein-tyrosine kinase 2-betaHomo sapiens (human)
lamellipodiumProtein-tyrosine kinase 2-betaHomo sapiens (human)
dendriteProtein-tyrosine kinase 2-betaHomo sapiens (human)
growth coneProtein-tyrosine kinase 2-betaHomo sapiens (human)
neuronal cell bodyProtein-tyrosine kinase 2-betaHomo sapiens (human)
cell bodyProtein-tyrosine kinase 2-betaHomo sapiens (human)
perinuclear region of cytoplasmProtein-tyrosine kinase 2-betaHomo sapiens (human)
apical dendriteProtein-tyrosine kinase 2-betaHomo sapiens (human)
Schaffer collateral - CA1 synapseProtein-tyrosine kinase 2-betaHomo sapiens (human)
presynapseProtein-tyrosine kinase 2-betaHomo sapiens (human)
glutamatergic synapseProtein-tyrosine kinase 2-betaHomo sapiens (human)
postsynaptic density, intracellular componentProtein-tyrosine kinase 2-betaHomo sapiens (human)
dendritic spineProtein-tyrosine kinase 2-betaHomo sapiens (human)
focal adhesionProtein-tyrosine kinase 2-betaHomo sapiens (human)
plasma membraneProtein-tyrosine kinase 2-betaHomo sapiens (human)
plasma membraneMaternal embryonic leucine zipper kinaseHomo sapiens (human)
cell cortexMaternal embryonic leucine zipper kinaseHomo sapiens (human)
membraneMaternal embryonic leucine zipper kinaseHomo sapiens (human)
cytoplasmMaternal embryonic leucine zipper kinaseHomo sapiens (human)
chromosome, centromeric regionStructural maintenance of chromosomes protein 1AHomo sapiens (human)
kinetochoreStructural maintenance of chromosomes protein 1AHomo sapiens (human)
condensed nuclear chromosomeStructural maintenance of chromosomes protein 1AHomo sapiens (human)
nucleusStructural maintenance of chromosomes protein 1AHomo sapiens (human)
nucleoplasmStructural maintenance of chromosomes protein 1AHomo sapiens (human)
chromosomeStructural maintenance of chromosomes protein 1AHomo sapiens (human)
cytosolStructural maintenance of chromosomes protein 1AHomo sapiens (human)
nuclear matrixStructural maintenance of chromosomes protein 1AHomo sapiens (human)
mitotic cohesin complexStructural maintenance of chromosomes protein 1AHomo sapiens (human)
meiotic cohesin complexStructural maintenance of chromosomes protein 1AHomo sapiens (human)
mitotic spindle poleStructural maintenance of chromosomes protein 1AHomo sapiens (human)
cohesin complexStructural maintenance of chromosomes protein 1AHomo sapiens (human)
nucleusStructural maintenance of chromosomes protein 1AHomo sapiens (human)
chromosome, telomeric regionChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
nucleusChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
nucleoplasmChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
cytoplasmChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
centrosomeChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
membraneChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
NuRD complexChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
site of DNA damageChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
cerebellar granule cell to Purkinje cell synapseChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
chromatinChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
protein-containing complexChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
RNA polymerase II transcription regulator complexChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
nucleusChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
peroxisomePeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
peroxisomePeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
peroxisomal membranePeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
peroxisomal matrixPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
cytosolPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
membranePeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
autophagosome membraneSerine/threonine-protein kinase D1Homo sapiens (human)
nucleusSerine/threonine-protein kinase D1Homo sapiens (human)
trans-Golgi networkSerine/threonine-protein kinase D1Homo sapiens (human)
cytosolSerine/threonine-protein kinase D1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase D1Homo sapiens (human)
cell-cell junctionSerine/threonine-protein kinase D1Homo sapiens (human)
cell cortexSerine/threonine-protein kinase D1Homo sapiens (human)
Z discSerine/threonine-protein kinase D1Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase D1Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase D1Homo sapiens (human)
cytosolSerine/threonine-protein kinase D1Homo sapiens (human)
site of double-strand breakSerine/threonine-protein kinase 38Homo sapiens (human)
nucleusSerine/threonine-protein kinase 38Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 38Homo sapiens (human)
cytosolSerine/threonine-protein kinase 38Homo sapiens (human)
glutamatergic synapseSerine/threonine-protein kinase 38Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
extracellular regionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nucleusReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nucleoplasmReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mitochondrionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mitochondrial matrixReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cytosolReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
basolateral plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neuromuscular junctionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
presynaptic membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
postsynaptic membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
postsynaptic density membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
glutamatergic synapseReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
GABA-ergic synapseReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
receptor complexReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
basal plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nucleusRibosomal protein S6 kinase alpha-2Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-2Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-2Homo sapiens (human)
cytosolRibosomal protein S6 kinase alpha-2Homo sapiens (human)
synapseRibosomal protein S6 kinase alpha-2Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-2Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-2Homo sapiens (human)
plasma membraneEphrin type-A receptor 7Homo sapiens (human)
glutamatergic synapseEphrin type-A receptor 7Homo sapiens (human)
plasma membraneEphrin type-A receptor 7Homo sapiens (human)
dendriteEphrin type-A receptor 7Homo sapiens (human)
Golgi membraneDelta(24)-sterol reductaseHomo sapiens (human)
nucleusDelta(24)-sterol reductaseHomo sapiens (human)
endoplasmic reticulumDelta(24)-sterol reductaseHomo sapiens (human)
endoplasmic reticulum membraneDelta(24)-sterol reductaseHomo sapiens (human)
membraneDelta(24)-sterol reductaseHomo sapiens (human)
cytoplasmDelta(24)-sterol reductaseHomo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-1Homo sapiens (human)
cytosolRibosomal protein S6 kinase alpha-1Homo sapiens (human)
synapseRibosomal protein S6 kinase alpha-1Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-1Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-1Homo sapiens (human)
cytoplasmic vesicleDual specificity testis-specific protein kinase 1Homo sapiens (human)
cytoplasmDual specificity testis-specific protein kinase 1Homo sapiens (human)
centrosomeDual specificity testis-specific protein kinase 1Homo sapiens (human)
cytosolDual specificity testis-specific protein kinase 1Homo sapiens (human)
lamellipodiumDual specificity testis-specific protein kinase 1Homo sapiens (human)
perinuclear region of cytoplasmDual specificity testis-specific protein kinase 1Homo sapiens (human)
cytoplasmDual specificity testis-specific protein kinase 1Homo sapiens (human)
nucleusDual specificity testis-specific protein kinase 1Homo sapiens (human)
stress fiberMyosin light chain kinase, smooth muscleHomo sapiens (human)
cytoplasmMyosin light chain kinase, smooth muscleHomo sapiens (human)
cytosolMyosin light chain kinase, smooth muscleHomo sapiens (human)
plasma membraneMyosin light chain kinase, smooth muscleHomo sapiens (human)
actin cytoskeletonMyosin light chain kinase, smooth muscleHomo sapiens (human)
lamellipodiumMyosin light chain kinase, smooth muscleHomo sapiens (human)
cleavage furrowMyosin light chain kinase, smooth muscleHomo sapiens (human)
cleavage furrowMyosin light chain kinase, smooth muscleHomo sapiens (human)
stress fiberMyosin light chain kinase, smooth muscleHomo sapiens (human)
lamellipodiumMyosin light chain kinase, smooth muscleHomo sapiens (human)
cytoplasmMyosin light chain kinase, smooth muscleHomo sapiens (human)
nucleoplasmMitogen-activated protein kinase 11Homo sapiens (human)
cytosolMitogen-activated protein kinase 11Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 11Homo sapiens (human)
nucleusMitogen-activated protein kinase 11Homo sapiens (human)
nucleusSerine/threonine-protein kinase STK11Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase STK11Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase STK11Homo sapiens (human)
mitochondrionSerine/threonine-protein kinase STK11Homo sapiens (human)
cytosolSerine/threonine-protein kinase STK11Homo sapiens (human)
membraneSerine/threonine-protein kinase STK11Homo sapiens (human)
Z discSerine/threonine-protein kinase STK11Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase STK11Homo sapiens (human)
serine/threonine protein kinase complexSerine/threonine-protein kinase STK11Homo sapiens (human)
intracellular protein-containing complexSerine/threonine-protein kinase STK11Homo sapiens (human)
nucleusSerine/threonine-protein kinase STK11Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase STK11Homo sapiens (human)
photoreceptor disc membraneRhodopsin kinase GRK1Homo sapiens (human)
cytoplasmRhodopsin kinase GRK1Homo sapiens (human)
plasma membraneNT-3 growth factor receptorHomo sapiens (human)
receptor complexNT-3 growth factor receptorHomo sapiens (human)
plasma membraneNT-3 growth factor receptorHomo sapiens (human)
axonNT-3 growth factor receptorHomo sapiens (human)
nucleusSerine/threonine-protein kinase N1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase N1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase N1Homo sapiens (human)
endosomeSerine/threonine-protein kinase N1Homo sapiens (human)
cytosolSerine/threonine-protein kinase N1Homo sapiens (human)
midbodySerine/threonine-protein kinase N1Homo sapiens (human)
cleavage furrowSerine/threonine-protein kinase N1Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase N1Homo sapiens (human)
nucleusSerine/threonine-protein kinase N2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase N2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase N2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase N2Homo sapiens (human)
cytosolSerine/threonine-protein kinase N2Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase N2Homo sapiens (human)
nuclear bodySerine/threonine-protein kinase N2Homo sapiens (human)
lamellipodiumSerine/threonine-protein kinase N2Homo sapiens (human)
midbodySerine/threonine-protein kinase N2Homo sapiens (human)
cleavage furrowSerine/threonine-protein kinase N2Homo sapiens (human)
apical junction complexSerine/threonine-protein kinase N2Homo sapiens (human)
intermediate filament cytoskeletonSerine/threonine-protein kinase N2Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase N2Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase N2Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
spindle poleMitogen-activated protein kinase 14Homo sapiens (human)
extracellular regionMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 14Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
nuclear speckMitogen-activated protein kinase 14Homo sapiens (human)
secretory granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
glutamatergic synapseMitogen-activated protein kinase 14Homo sapiens (human)
ficolin-1-rich granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
fibrillar centerCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
extracellular exosomeCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
nucleusCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
centrosomeMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
microtubuleMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
membraneMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
centrosomeMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
early endosomeBDNF/NT-3 growth factors receptorHomo sapiens (human)
cytosolBDNF/NT-3 growth factors receptorHomo sapiens (human)
plasma membraneBDNF/NT-3 growth factors receptorHomo sapiens (human)
postsynaptic densityBDNF/NT-3 growth factors receptorHomo sapiens (human)
axonBDNF/NT-3 growth factors receptorHomo sapiens (human)
dendriteBDNF/NT-3 growth factors receptorHomo sapiens (human)
early endosome membraneBDNF/NT-3 growth factors receptorHomo sapiens (human)
terminal boutonBDNF/NT-3 growth factors receptorHomo sapiens (human)
perinuclear region of cytoplasmBDNF/NT-3 growth factors receptorHomo sapiens (human)
receptor complexBDNF/NT-3 growth factors receptorHomo sapiens (human)
axon terminusBDNF/NT-3 growth factors receptorHomo sapiens (human)
plasma membraneBDNF/NT-3 growth factors receptorHomo sapiens (human)
postsynaptic densityBDNF/NT-3 growth factors receptorHomo sapiens (human)
axonBDNF/NT-3 growth factors receptorHomo sapiens (human)
dendritic spineBDNF/NT-3 growth factors receptorHomo sapiens (human)
nucleusMitogen-activated protein kinase 6Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 6Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 6Homo sapiens (human)
cytosolMitogen-activated protein kinase 6Homo sapiens (human)
septin cytoskeletonMitogen-activated protein kinase 6Homo sapiens (human)
protein-containing complexMitogen-activated protein kinase 6Homo sapiens (human)
nucleusMitogen-activated protein kinase 6Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 6Homo sapiens (human)
cytosolPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
phosphorylase kinase complexPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
plasma membraneDiscoidin domain-containing receptor 2Homo sapiens (human)
focal adhesionDiscoidin domain-containing receptor 2Homo sapiens (human)
actin cytoskeletonDiscoidin domain-containing receptor 2Homo sapiens (human)
apical plasma membraneDiscoidin domain-containing receptor 2Homo sapiens (human)
receptor complexDiscoidin domain-containing receptor 2Homo sapiens (human)
plasma membraneDiscoidin domain-containing receptor 2Homo sapiens (human)
cytosolAP2-associated protein kinase 1Homo sapiens (human)
plasma membraneAP2-associated protein kinase 1Homo sapiens (human)
clathrin-coated pitAP2-associated protein kinase 1Homo sapiens (human)
clathrin-coated vesicleAP2-associated protein kinase 1Homo sapiens (human)
cell leading edgeAP2-associated protein kinase 1Homo sapiens (human)
terminal boutonAP2-associated protein kinase 1Homo sapiens (human)
intracellular membrane-bounded organelleAP2-associated protein kinase 1Homo sapiens (human)
presynapseAP2-associated protein kinase 1Homo sapiens (human)
cytoplasmMyosin light chain kinase 3Homo sapiens (human)
cytosolMyosin light chain kinase 3Homo sapiens (human)
cytoplasmMyosin light chain kinase 3Homo sapiens (human)
actin cytoskeletonMyosin light chain kinase 3Homo sapiens (human)
membraneUncharacterized aarF domain-containing protein kinase 5Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase SBK1Homo sapiens (human)
extracellular exosomePutative heat shock protein HSP 90-beta 2Homo sapiens (human)
perinuclear region of cytoplasmPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
protein-containing complexPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
plasma membranePutative heat shock protein HSP 90-beta 2Homo sapiens (human)
cytosolPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
nucleusSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
Golgi membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
extracellular spaceLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cytoplasmLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrial outer membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrial inner membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrial matrixLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
lysosomeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
endosomeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
endoplasmic reticulumLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
endoplasmic reticulum membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
Golgi apparatusLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
Golgi-associated vesicleLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
trans-Golgi networkLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cytosolLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cytoskeletonLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
plasma membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
microvillusLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
axonLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
dendriteLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
growth coneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
synaptic vesicle membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cytoplasmic vesicleLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrial membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cytoplasmic side of mitochondrial outer membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
dendrite cytoplasmLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
neuron projectionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
neuronal cell bodyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
terminal boutonLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
perikaryonLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
intracellular membrane-bounded organelleLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
amphisomeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
autolysosomeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
extracellular exosomeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
endoplasmic reticulum exit siteLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
multivesicular body, internal vesicleLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
postsynapseLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
glutamatergic synapseLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
caveola neckLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
presynaptic cytosolLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
ribonucleoprotein complexLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
Wnt signalosomeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cytosolSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
cell-cell junctionSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
lamellipodiumSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
cell leading edgeSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
actomyosinSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
actomyosinSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
cytoskeletonSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
cytosolSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
cell leading edgeSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
centriolar satelliteSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
cytoskeletonSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
mitochondrionAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
mitochondrial matrixAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
cytoplasmAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
nucleusSerine/threonine-protein kinase N3Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase N3Homo sapiens (human)
cytosolSerine/threonine-protein kinase N3Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase N3Homo sapiens (human)
phagophore assembly siteSerine/threonine-protein kinase ULK3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase ULK3Homo sapiens (human)
ciliary tipSerine/threonine-protein kinase ULK3Homo sapiens (human)
phagophore assembly site membraneSerine/threonine-protein kinase ULK3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase ULK3Homo sapiens (human)
cytosolSerine/threonine-protein kinase ULK3Homo sapiens (human)
autophagosomeSerine/threonine-protein kinase ULK3Homo sapiens (human)
phagophore assembly siteSerine/threonine-protein kinase ULK3Homo sapiens (human)
cytoplasmDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
basolateral plasma membraneDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
apical plasma membraneDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
anchoring junctionDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
cytoplasmDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
nucleusAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
mitochondrial inner membraneAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
peroxisomeAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
mitochondrial membraneAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
mitochondrionAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
cytoplasmAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
endoplasmic reticulumSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
cytosolSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
endoplasmic reticulum quality control compartmentSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
IRE1-TRAF2-ASK1 complexSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase MARK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase MARK2Homo sapiens (human)
mitochondrionSerine/threonine-protein kinase MARK2Homo sapiens (human)
actin filamentSerine/threonine-protein kinase MARK2Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase MARK2Homo sapiens (human)
membraneSerine/threonine-protein kinase MARK2Homo sapiens (human)
lateral plasma membraneSerine/threonine-protein kinase MARK2Homo sapiens (human)
dendriteSerine/threonine-protein kinase MARK2Homo sapiens (human)
microtubule bundleSerine/threonine-protein kinase MARK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase MARK2Homo sapiens (human)
cytosolSerine/threonine-protein kinase TAO1Homo sapiens (human)
microtubule cytoskeletonSerine/threonine-protein kinase TAO1Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase TAO1Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase TAO1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase TAO1Homo sapiens (human)
nucleusSTE20-related kinase adapter protein alphaHomo sapiens (human)
nucleoplasmSTE20-related kinase adapter protein alphaHomo sapiens (human)
cytoplasmSTE20-related kinase adapter protein alphaHomo sapiens (human)
cytosolSTE20-related kinase adapter protein alphaHomo sapiens (human)
serine/threonine protein kinase complexSTE20-related kinase adapter protein alphaHomo sapiens (human)
intracellular protein-containing complexSTE20-related kinase adapter protein alphaHomo sapiens (human)
stress fiberMyosin-14Homo sapiens (human)
cytosolMyosin-14Homo sapiens (human)
brush borderMyosin-14Homo sapiens (human)
membraneMyosin-14Homo sapiens (human)
growth coneMyosin-14Homo sapiens (human)
actomyosinMyosin-14Homo sapiens (human)
extracellular exosomeMyosin-14Homo sapiens (human)
myosin II filamentMyosin-14Homo sapiens (human)
myosin II complexMyosin-14Homo sapiens (human)
cytoplasmMyosin-14Homo sapiens (human)
myosin filamentMyosin-14Homo sapiens (human)
mitochondrionAarF domain-containing protein kinase 1Homo sapiens (human)
mitochondrial inner membraneAarF domain-containing protein kinase 1Homo sapiens (human)
nucleusSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
intermediate filamentSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
nucleusSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
cytosolSerine/threonine-protein kinase pim-3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-3Homo sapiens (human)
nucleusATP-dependent RNA helicase DDX42Homo sapiens (human)
nucleoplasmATP-dependent RNA helicase DDX42Homo sapiens (human)
cytoplasmATP-dependent RNA helicase DDX42Homo sapiens (human)
cytosolATP-dependent RNA helicase DDX42Homo sapiens (human)
Cajal bodyATP-dependent RNA helicase DDX42Homo sapiens (human)
membraneATP-dependent RNA helicase DDX42Homo sapiens (human)
nuclear speckATP-dependent RNA helicase DDX42Homo sapiens (human)
U2-type prespliceosomeATP-dependent RNA helicase DDX42Homo sapiens (human)
nucleusATP-dependent RNA helicase DDX42Homo sapiens (human)
nucleusSerine/threonine-protein kinase VRK2Homo sapiens (human)
nuclear envelopeSerine/threonine-protein kinase VRK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase VRK2Homo sapiens (human)
endoplasmic reticulumSerine/threonine-protein kinase VRK2Homo sapiens (human)
endoplasmic reticulum membraneSerine/threonine-protein kinase VRK2Homo sapiens (human)
mitochondrial membraneSerine/threonine-protein kinase VRK2Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase VRK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase VRK2Homo sapiens (human)
nucleusSerine/threonine-protein kinase VRK2Homo sapiens (human)
nucleusHomeodomain-interacting protein kinase 1Homo sapiens (human)
nucleoplasmHomeodomain-interacting protein kinase 1Homo sapiens (human)
cytoplasmHomeodomain-interacting protein kinase 1Homo sapiens (human)
centrosomeHomeodomain-interacting protein kinase 1Homo sapiens (human)
cytosolHomeodomain-interacting protein kinase 1Homo sapiens (human)
nuclear speckHomeodomain-interacting protein kinase 1Homo sapiens (human)
cytoplasmHomeodomain-interacting protein kinase 1Homo sapiens (human)
PML bodyHomeodomain-interacting protein kinase 1Homo sapiens (human)
nucleusHomeodomain-interacting protein kinase 1Homo sapiens (human)
nucleusCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
intracellular anatomical structureCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
cytoplasmCyclin-dependent kinase-like 3Homo sapiens (human)
nucleusCyclin-dependent kinase-like 3Homo sapiens (human)
nucleoplasmMAP kinase-activated protein kinase 5Homo sapiens (human)
cytosolMAP kinase-activated protein kinase 5Homo sapiens (human)
septin cytoskeletonMAP kinase-activated protein kinase 5Homo sapiens (human)
protein-containing complexMAP kinase-activated protein kinase 5Homo sapiens (human)
cytoplasmMAP kinase-activated protein kinase 5Homo sapiens (human)
nucleusMAP kinase-activated protein kinase 5Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase BRSK2Homo sapiens (human)
endoplasmic reticulumSerine/threonine-protein kinase BRSK2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase BRSK2Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase BRSK2Homo sapiens (human)
distal axonSerine/threonine-protein kinase BRSK2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase BRSK2Homo sapiens (human)
cytosolEukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)
translation release factor complexEukaryotic peptide chain release factor GTP-binding subunit ERF3BHomo sapiens (human)
cytoplasmic vesicle membraneSerine/threonine-protein kinase ULK2Homo sapiens (human)
phagophore assembly site membraneSerine/threonine-protein kinase ULK2Homo sapiens (human)
phagophore assembly site membraneSerine/threonine-protein kinase ULK2Homo sapiens (human)
cytosolSerine/threonine-protein kinase ULK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase ULK2Homo sapiens (human)
phagophore assembly siteSerine/threonine-protein kinase ULK2Homo sapiens (human)
autophagosomeSerine/threonine-protein kinase ULK2Homo sapiens (human)
cytoplasmMisshapen-like kinase 1Homo sapiens (human)
Golgi apparatusMisshapen-like kinase 1Homo sapiens (human)
cytosolMisshapen-like kinase 1Homo sapiens (human)
postsynaptic densityMisshapen-like kinase 1Homo sapiens (human)
axonMisshapen-like kinase 1Homo sapiens (human)
dendriteMisshapen-like kinase 1Homo sapiens (human)
extracellular exosomeMisshapen-like kinase 1Homo sapiens (human)
cytoplasmMisshapen-like kinase 1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase DCLK2Homo sapiens (human)
cytoskeletonSerine/threonine-protein kinase DCLK2Homo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
cytosolCasein kinase I isoform alpha-likeHomo sapiens (human)
nucleusCasein kinase I isoform alpha-likeHomo sapiens (human)
cytoplasmCasein kinase I isoform alpha-likeHomo sapiens (human)
nucleusHomeodomain-interacting protein kinase 4Homo sapiens (human)
cytoplasmHomeodomain-interacting protein kinase 4Homo sapiens (human)
cytoplasmMyosin-IIIaHomo sapiens (human)
filopodiumMyosin-IIIaHomo sapiens (human)
stereocilium tipMyosin-IIIaHomo sapiens (human)
filopodium tipMyosin-IIIaHomo sapiens (human)
myosin complexMyosin-IIIaHomo sapiens (human)
filamentous actinMyosin-IIIaHomo sapiens (human)
photoreceptor inner segmentMyosin-IIIaHomo sapiens (human)
stereocilium tipMyosin-IIIaHomo sapiens (human)
filopodium tipMyosin-IIIaHomo sapiens (human)
nucleusAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
cell projectionAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
cytoplasmAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Nek11Homo sapiens (human)
nucleolusSerine/threonine-protein kinase Nek11Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Nek11Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek11Homo sapiens (human)
mitochondrionAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
membraneAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
nucleoplasmPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
autophagosomePhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
endoplasmic reticulumPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
cytosolPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
plasma membranePhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
intracellular organellePhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
extracellular exosomePhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
plasma membranePhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
axonemeMitogen-activated protein kinase 15Homo sapiens (human)
extracellular regionMitogen-activated protein kinase 15Homo sapiens (human)
nucleusMitogen-activated protein kinase 15Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 15Homo sapiens (human)
autophagosomeMitogen-activated protein kinase 15Homo sapiens (human)
Golgi apparatusMitogen-activated protein kinase 15Homo sapiens (human)
centrioleMitogen-activated protein kinase 15Homo sapiens (human)
cell-cell junctionMitogen-activated protein kinase 15Homo sapiens (human)
bicellular tight junctionMitogen-activated protein kinase 15Homo sapiens (human)
cytoplasmic vesicleMitogen-activated protein kinase 15Homo sapiens (human)
ciliary basal bodyMitogen-activated protein kinase 15Homo sapiens (human)
meiotic spindleMitogen-activated protein kinase 15Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 15Homo sapiens (human)
nucleusMitogen-activated protein kinase 15Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Nek9Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek9Homo sapiens (human)
cytosolSerine/threonine-protein kinase Nek9Homo sapiens (human)
nucleusSerine/threonine-protein kinase BRSK1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase BRSK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase BRSK1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase BRSK1Homo sapiens (human)
synaptic vesicleSerine/threonine-protein kinase BRSK1Homo sapiens (human)
cell junctionSerine/threonine-protein kinase BRSK1Homo sapiens (human)
presynaptic active zoneSerine/threonine-protein kinase BRSK1Homo sapiens (human)
distal axonSerine/threonine-protein kinase BRSK1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase BRSK1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase 35Homo sapiens (human)
nucleolusSerine/threonine-protein kinase 35Homo sapiens (human)
nuclear bodySerine/threonine-protein kinase 35Homo sapiens (human)
nucleusSerine/threonine-protein kinase 35Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 35Homo sapiens (human)
microtubule organizing centerSerine/threonine-protein kinase Nek7Homo sapiens (human)
spindle poleSerine/threonine-protein kinase Nek7Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Nek7Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek7Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Nek7Homo sapiens (human)
microtubuleSerine/threonine-protein kinase Nek7Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek7Homo sapiens (human)
photoreceptor disc membraneRhodopsin kinase GRK7Homo sapiens (human)
cytoplasmRhodopsin kinase GRK7Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase 32AHomo sapiens (human)
cytoplasmMyosin-IIIbHomo sapiens (human)
stereocilium tipMyosin-IIIbHomo sapiens (human)
myosin complexMyosin-IIIbHomo sapiens (human)
stereocilium tipMyosin-IIIbHomo sapiens (human)
filopodium tipMyosin-IIIbHomo sapiens (human)
photoreceptor inner segmentMyosin-IIIbHomo sapiens (human)
nucleusATP-dependent RNA helicase DDX1Homo sapiens (human)
nucleoplasmATP-dependent RNA helicase DDX1Homo sapiens (human)
cytoplasmATP-dependent RNA helicase DDX1Homo sapiens (human)
mitochondrionATP-dependent RNA helicase DDX1Homo sapiens (human)
cytosolATP-dependent RNA helicase DDX1Homo sapiens (human)
cytoplasmic stress granuleATP-dependent RNA helicase DDX1Homo sapiens (human)
membraneATP-dependent RNA helicase DDX1Homo sapiens (human)
cleavage bodyATP-dependent RNA helicase DDX1Homo sapiens (human)
tRNA-splicing ligase complexATP-dependent RNA helicase DDX1Homo sapiens (human)
ribonucleoprotein complexATP-dependent RNA helicase DDX1Homo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
nucleoplasmDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
cytoplasmDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
cytosolDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
ubiquitin ligase complexDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
ribonucleoprotein complexDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
cytoplasmDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
cytoskeletonDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
nucleoplasmCyclin-dependent kinase-like 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase-like 2Homo sapiens (human)
centrosomeCyclin-dependent kinase-like 2Homo sapiens (human)
nucleusCyclin-dependent kinase-like 2Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
membraneMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
early endosomeSerine/threonine-protein kinase Sgk3Homo sapiens (human)
cytosolSerine/threonine-protein kinase Sgk3Homo sapiens (human)
recycling endosomeSerine/threonine-protein kinase Sgk3Homo sapiens (human)
mitochondrionAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
cytosolAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
plasma membraneAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
mitochondrial membraneAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
condensed chromosome, centromeric regionAurora kinase BHomo sapiens (human)
nucleusAurora kinase BHomo sapiens (human)
nucleoplasmAurora kinase BHomo sapiens (human)
spindleAurora kinase BHomo sapiens (human)
cytosolAurora kinase BHomo sapiens (human)
chromocenterAurora kinase BHomo sapiens (human)
microtubule cytoskeletonAurora kinase BHomo sapiens (human)
midbodyAurora kinase BHomo sapiens (human)
chromosome passenger complexAurora kinase BHomo sapiens (human)
mitotic spindle poleAurora kinase BHomo sapiens (human)
mitotic spindle midzoneAurora kinase BHomo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
spindle pole centrosomeAurora kinase BHomo sapiens (human)
spindle microtubuleAurora kinase BHomo sapiens (human)
spindle midzoneAurora kinase BHomo sapiens (human)
microtubule organizing centerMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
cytoplasmMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
centrosomeMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
microtubule organizing centerMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
cytosolMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
microtubule cytoskeletonMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
dendriteMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
midbodyMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
neuron projectionMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
gamma-tubulin complexMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
ciliary basal bodyMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
cytoplasmMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
Golgi membraneCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
plasma membraneCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
calcium- and calmodulin-dependent protein kinase complexCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
intracellular anatomical structureCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
pericentriolar materialSerine/threonine-protein kinase Nek1Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Nek1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Nek1Homo sapiens (human)
cytosolSerine/threonine-protein kinase Nek1Homo sapiens (human)
centriolar satelliteSerine/threonine-protein kinase Nek1Homo sapiens (human)
cytoplasmCyclin-dependent kinase 15Homo sapiens (human)
nucleusCyclin-dependent kinase 15Homo sapiens (human)
cytosolCyclin-dependent kinase 15Homo sapiens (human)
nucleusPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
cytosolPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
cytosolPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
nucleusPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
neuron projectionCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
nucleusEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
nucleoplasmEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
cytoplasmEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
EKC/KEOPS complexEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
cytosolEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
nucleusEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
nucleusSRSF protein kinase 1Homo sapiens (human)
nucleoplasmSRSF protein kinase 1Homo sapiens (human)
cytoplasmSRSF protein kinase 1Homo sapiens (human)
endoplasmic reticulumSRSF protein kinase 1Homo sapiens (human)
cytosolSRSF protein kinase 1Homo sapiens (human)
plasma membraneSRSF protein kinase 1Homo sapiens (human)
nuclear matrixSRSF protein kinase 1Homo sapiens (human)
nuclear speckSRSF protein kinase 1Homo sapiens (human)
chromatinSRSF protein kinase 1Homo sapiens (human)
nucleusSRSF protein kinase 1Homo sapiens (human)
cytoplasmSRSF protein kinase 1Homo sapiens (human)
Golgi membraneMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
nucleoplasmMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
nucleolusMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
endoplasmic reticulumMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
endoplasmic reticulum membraneMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
Golgi apparatusMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
cytosolMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
membraneMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
cytoplasmMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
nucleusMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
external side of plasma membraneMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein-containing complexMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein kinase complexMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
IRE1-TRAF2-ASK1 complexMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
mRNA cleavage and polyadenylation specificity factor complexPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
nucleusPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
nucleoplasmPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
cytosolPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
focal adhesionPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
nuclear speckPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
lamellipodiumPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
ruffle membranePhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
cytosolEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
cytosolEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
nucleusEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
cytoplasmEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase RIO1Homo sapiens (human)
cytosolSerine/threonine-protein kinase RIO1Homo sapiens (human)
preribosome, small subunit precursorSerine/threonine-protein kinase RIO1Homo sapiens (human)
methyltransferase complexSerine/threonine-protein kinase RIO1Homo sapiens (human)
cytosolSerine/threonine-protein kinase RIO1Homo sapiens (human)
nucleoplasmMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cytosolMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cytoplasmMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
nucleusMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase RIO2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase RIO2Homo sapiens (human)
cytosolSerine/threonine-protein kinase RIO2Homo sapiens (human)
preribosome, small subunit precursorSerine/threonine-protein kinase RIO2Homo sapiens (human)
cytosolSerine/threonine-protein kinase RIO2Homo sapiens (human)
nucleusSerine/threonine-protein kinase RIO2Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 19Homo sapiens (human)
cytosolCyclin-dependent kinase 19Homo sapiens (human)
perinuclear region of cytoplasmCyclin-dependent kinase 19Homo sapiens (human)
CKM complexCyclin-dependent kinase 19Homo sapiens (human)
nucleusCyclin-dependent kinase 19Homo sapiens (human)
cytosolCyclin-dependent kinase 19Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
brush border membraneTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
apical plasma membraneTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
acrosomal vesicleTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
motile ciliumTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase 33Homo sapiens (human)
nucleusSerine/threonine-protein kinase 33Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 33Homo sapiens (human)
nucleusNucleolar GTP-binding protein 1Homo sapiens (human)
nucleoplasmNucleolar GTP-binding protein 1Homo sapiens (human)
nucleolusNucleolar GTP-binding protein 1Homo sapiens (human)
cytoplasmNucleolar GTP-binding protein 1Homo sapiens (human)
cytosolNucleolar GTP-binding protein 1Homo sapiens (human)
membraneNucleolar GTP-binding protein 1Homo sapiens (human)
nuclear membraneNucleolar GTP-binding protein 1Homo sapiens (human)
perinuclear region of cytoplasmNucleolar GTP-binding protein 1Homo sapiens (human)
nucleolusNucleolar GTP-binding protein 1Homo sapiens (human)
nucleusSerine/threonine-protein kinase D2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase D2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase D2Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase D2Homo sapiens (human)
cytosolSerine/threonine-protein kinase D2Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase D2Homo sapiens (human)
cytosolSerine/threonine-protein kinase D2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase DCLK3Homo sapiens (human)
nucleusSerine/threonine-protein kinase DCLK3Homo sapiens (human)
chromosome, telomeric regionRNA cytidine acetyltransferaseHomo sapiens (human)
nucleusRNA cytidine acetyltransferaseHomo sapiens (human)
nucleoplasmRNA cytidine acetyltransferaseHomo sapiens (human)
nucleolusRNA cytidine acetyltransferaseHomo sapiens (human)
membraneRNA cytidine acetyltransferaseHomo sapiens (human)
midbodyRNA cytidine acetyltransferaseHomo sapiens (human)
telomerase holoenzyme complexRNA cytidine acetyltransferaseHomo sapiens (human)
small-subunit processomeRNA cytidine acetyltransferaseHomo sapiens (human)
nucleolusRNA cytidine acetyltransferaseHomo sapiens (human)
endoplasmic reticulum membraneSerine/threonine-protein kinase SIK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase SIK2Homo sapiens (human)
nucleusSerine/threonine-protein kinase SIK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase SIK2Homo sapiens (human)
nucleusMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
cytoplasmMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
sarcomereMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
synapseMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
cytoplasmMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
cytoplasmSTE20-like serine/threonine-protein kinase Homo sapiens (human)
cytosolSTE20-like serine/threonine-protein kinase Homo sapiens (human)
cell leading edgeSTE20-like serine/threonine-protein kinase Homo sapiens (human)
perinuclear region of cytoplasmSTE20-like serine/threonine-protein kinase Homo sapiens (human)
extracellular exosomeSTE20-like serine/threonine-protein kinase Homo sapiens (human)
cytoplasmSTE20-like serine/threonine-protein kinase Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase TAO3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase TAO3Homo sapiens (human)
PML bodyHomeodomain-interacting protein kinase 2Homo sapiens (human)
nucleusHomeodomain-interacting protein kinase 2Homo sapiens (human)
nucleoplasmHomeodomain-interacting protein kinase 2Homo sapiens (human)
cytoplasmHomeodomain-interacting protein kinase 2Homo sapiens (human)
cytoplasmic stress granuleHomeodomain-interacting protein kinase 2Homo sapiens (human)
nuclear bodyHomeodomain-interacting protein kinase 2Homo sapiens (human)
RNA polymerase II transcription regulator complexHomeodomain-interacting protein kinase 2Homo sapiens (human)
nucleusHomeodomain-interacting protein kinase 2Homo sapiens (human)
cytoplasmHomeodomain-interacting protein kinase 2Homo sapiens (human)
cytoplasmTyrosine-protein kinase SrmsHomo sapiens (human)
cytosolTyrosine-protein kinase SrmsHomo sapiens (human)
plasma membraneTyrosine-protein kinase SrmsHomo sapiens (human)
cytosolHomeodomain-interacting protein kinase 3Homo sapiens (human)
plasma membraneHomeodomain-interacting protein kinase 3Homo sapiens (human)
nuclear bodyHomeodomain-interacting protein kinase 3Homo sapiens (human)
cytoplasmHomeodomain-interacting protein kinase 3Homo sapiens (human)
nucleusHomeodomain-interacting protein kinase 3Homo sapiens (human)
PML bodyHomeodomain-interacting protein kinase 3Homo sapiens (human)
nucleusSerine/threonine-protein kinase PLK3Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase PLK3Homo sapiens (human)
nucleolusSerine/threonine-protein kinase PLK3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PLK3Homo sapiens (human)
Golgi stackSerine/threonine-protein kinase PLK3Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK3Homo sapiens (human)
dendriteSerine/threonine-protein kinase PLK3Homo sapiens (human)
neuronal cell bodySerine/threonine-protein kinase PLK3Homo sapiens (human)
kinetochoreSerine/threonine-protein kinase PLK3Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK3Homo sapiens (human)
nucleusSerine/threonine-protein kinase PLK3Homo sapiens (human)
spindle poleSerine/threonine-protein kinase PLK3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PLK3Homo sapiens (human)
nucleusdCTP pyrophosphatase 1Homo sapiens (human)
nucleoplasmdCTP pyrophosphatase 1Homo sapiens (human)
mitochondriondCTP pyrophosphatase 1Homo sapiens (human)
cytosoldCTP pyrophosphatase 1Homo sapiens (human)
cytosoldCTP pyrophosphatase 1Homo sapiens (human)
nucleusDual specificity protein kinase CLK4Homo sapiens (human)
nucleoplasmMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
nuclear bodyMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
PML bodyMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
nucleusMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cytoplasmMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Nek6Homo sapiens (human)
spindle poleSerine/threonine-protein kinase Nek6Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek6Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Nek6Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek6Homo sapiens (human)
cytosolSerine/threonine-protein kinase Nek6Homo sapiens (human)
microtubuleSerine/threonine-protein kinase Nek6Homo sapiens (human)
nuclear speckSerine/threonine-protein kinase Nek6Homo sapiens (human)
centriolar satelliteSerine/threonine-protein kinase Nek6Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase Nek6Homo sapiens (human)
cytosolSerine/threonine-protein kinase Nek6Homo sapiens (human)
cytosolCasein kinase I isoform gamma-1Homo sapiens (human)
nucleusCasein kinase I isoform gamma-1Homo sapiens (human)
plasma membraneCasein kinase I isoform gamma-1Homo sapiens (human)
cytoplasmCasein kinase I isoform gamma-1Homo sapiens (human)
fibrillar centerSerine/threonine-protein kinase PAK 6Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase PAK 6Homo sapiens (human)
cytosolSerine/threonine-protein kinase PAK 6Homo sapiens (human)
postsynaptic densitySerine/threonine-protein kinase PAK 6Homo sapiens (human)
cell junctionSerine/threonine-protein kinase PAK 6Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 6Homo sapiens (human)
nucleusSNF-related serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase LATS2Homo sapiens (human)
spindle poleSerine/threonine-protein kinase LATS2Homo sapiens (human)
nucleusSerine/threonine-protein kinase LATS2Homo sapiens (human)
cytosolSerine/threonine-protein kinase LATS2Homo sapiens (human)
centriolar satelliteSerine/threonine-protein kinase LATS2Homo sapiens (human)
nucleusSerine/threonine-protein kinase LATS2Homo sapiens (human)
spindle poleSerine/threonine-protein kinase LATS2Homo sapiens (human)
extracellular regionSerine/threonine-protein kinase 36Homo sapiens (human)
nucleusSerine/threonine-protein kinase 36Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 36Homo sapiens (human)
cytosolSerine/threonine-protein kinase 36Homo sapiens (human)
cytoskeletonSerine/threonine-protein kinase 36Homo sapiens (human)
cell projectionSerine/threonine-protein kinase 36Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 36Homo sapiens (human)
cytoplasmPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
cytosolPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
phenylalanine-tRNA ligase complexPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
membranePhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
mitochondrial matrixIsoleucine--tRNA ligase, mitochondrialHomo sapiens (human)
mitochondrionIsoleucine--tRNA ligase, mitochondrialHomo sapiens (human)
nuclear speckBMP-2-inducible protein kinaseHomo sapiens (human)
cytoplasmBMP-2-inducible protein kinaseHomo sapiens (human)
nucleusBMP-2-inducible protein kinaseHomo sapiens (human)
extracellular regionObg-like ATPase 1Homo sapiens (human)
nucleolusObg-like ATPase 1Homo sapiens (human)
cytoplasmObg-like ATPase 1Homo sapiens (human)
centrosomeObg-like ATPase 1Homo sapiens (human)
cytosolObg-like ATPase 1Homo sapiens (human)
membraneObg-like ATPase 1Homo sapiens (human)
platelet alpha granule lumenObg-like ATPase 1Homo sapiens (human)
extracellular exosomeObg-like ATPase 1Homo sapiens (human)
cytoplasmObg-like ATPase 1Homo sapiens (human)
nucleusMidasinHomo sapiens (human)
nucleoplasmMidasinHomo sapiens (human)
nucleolusMidasinHomo sapiens (human)
cytosolMidasinHomo sapiens (human)
membraneMidasinHomo sapiens (human)
intermediate filament cytoskeletonMidasinHomo sapiens (human)
nucleusMidasinHomo sapiens (human)
preribosome, large subunit precursorMidasinHomo sapiens (human)
cytoplasmInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
cell surfaceInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
extrinsic component of plasma membraneInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
extracellular spaceInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
cytosolInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
plasma membraneInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
endosome membraneInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
nucleusInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
plasma membraneInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
nucleusMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cyclin K-CDK12 complexCyclin-dependent kinase 12Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 12Homo sapiens (human)
nuclear speckCyclin-dependent kinase 12Homo sapiens (human)
nuclear cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 12Homo sapiens (human)
nucleusCyclin-dependent kinase 12Homo sapiens (human)
cyclin/CDK positive transcription elongation factor complexCyclin-dependent kinase 12Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PLK2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK2Homo sapiens (human)
centrioleSerine/threonine-protein kinase PLK2Homo sapiens (human)
cytosolSerine/threonine-protein kinase PLK2Homo sapiens (human)
dendriteSerine/threonine-protein kinase PLK2Homo sapiens (human)
chromatinSerine/threonine-protein kinase PLK2Homo sapiens (human)
spindle poleSerine/threonine-protein kinase PLK2Homo sapiens (human)
centrioleSerine/threonine-protein kinase PLK2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PLK2Homo sapiens (human)
kinetochoreSerine/threonine-protein kinase PLK2Homo sapiens (human)
nucleusSerine/threonine-protein kinase PLK2Homo sapiens (human)
nucleoplasmNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
cytoplasmNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
mitochondrionNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
mitochondrial inner membraneNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
mitochondrial respirasomeNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
mitochondrial respiratory chain complex INADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
mitochondrial membraneNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase MARK1Homo sapiens (human)
cytoskeletonSerine/threonine-protein kinase MARK1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase MARK1Homo sapiens (human)
microtubule cytoskeletonSerine/threonine-protein kinase MARK1Homo sapiens (human)
dendriteSerine/threonine-protein kinase MARK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase MARK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase PAK 5Homo sapiens (human)
mitochondrionSerine/threonine-protein kinase PAK 5Homo sapiens (human)
cytosolSerine/threonine-protein kinase PAK 5Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase PAK 5Homo sapiens (human)
nuclear membraneSerine/threonine-protein kinase PAK 5Homo sapiens (human)
synapseSerine/threonine-protein kinase PAK 5Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 5Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 26Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase 26Homo sapiens (human)
Golgi-associated vesicleSerine/threonine-protein kinase 26Homo sapiens (human)
cytosolSerine/threonine-protein kinase 26Homo sapiens (human)
vesicle membraneSerine/threonine-protein kinase 26Homo sapiens (human)
membraneSerine/threonine-protein kinase 26Homo sapiens (human)
apical plasma membraneSerine/threonine-protein kinase 26Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase 26Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase 26Homo sapiens (human)
cell peripherySerine/threonine-protein kinase 26Homo sapiens (human)
FAR/SIN/STRIPAK complexSerine/threonine-protein kinase 26Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase 26Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 26Homo sapiens (human)
cytoplasmeIF-2-alpha kinase GCN2Homo sapiens (human)
cytosolic ribosomeeIF-2-alpha kinase GCN2Homo sapiens (human)
cytosoleIF-2-alpha kinase GCN2Homo sapiens (human)
cytoplasmeIF-2-alpha kinase GCN2Homo sapiens (human)
nucleuseIF-2-alpha kinase GCN2Homo sapiens (human)
mitochondrionSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
mitochondrial matrixSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
succinate-CoA ligase complex (ADP-forming)Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
extracellular exosomeSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
mitochondrionSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
succinate-CoA ligase complexSuccinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)
nucleusSerine/threonine-protein kinase NLKHomo sapiens (human)
nucleoplasmSerine/threonine-protein kinase NLKHomo sapiens (human)
cytosolSerine/threonine-protein kinase NLKHomo sapiens (human)
nucleusSerine/threonine-protein kinase NLKHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase NLKHomo sapiens (human)
Golgi membranePhosphatidylinositol 4-kinase betaHomo sapiens (human)
mitochondrial outer membranePhosphatidylinositol 4-kinase betaHomo sapiens (human)
endosomePhosphatidylinositol 4-kinase betaHomo sapiens (human)
Golgi apparatusPhosphatidylinositol 4-kinase betaHomo sapiens (human)
cytosolPhosphatidylinositol 4-kinase betaHomo sapiens (human)
rough endoplasmic reticulum membranePhosphatidylinositol 4-kinase betaHomo sapiens (human)
perinuclear region of cytoplasmPhosphatidylinositol 4-kinase betaHomo sapiens (human)
membranePhosphatidylinositol 4-kinase betaHomo sapiens (human)
cytoplasmPhosphatidylinositol 4-kinase betaHomo sapiens (human)
nucleusSerine/threonine-protein kinase 17AHomo sapiens (human)
plasma membraneSerine/threonine-protein kinase 17AHomo sapiens (human)
nuclear speckSerine/threonine-protein kinase 17AHomo sapiens (human)
nucleusSerine/threonine-protein kinase 17AHomo sapiens (human)
nucleoplasmSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cytosolSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cell cortexSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
basolateral plasma membraneSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
apical plasma membraneSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
intracellular membrane-bounded organelleSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cell bodySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cytoplasmSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cytosolSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
nucleoplasmEphrin type-A receptor 6Homo sapiens (human)
plasma membraneEphrin type-A receptor 6Homo sapiens (human)
dendriteEphrin type-A receptor 6Homo sapiens (human)
plasma membraneEphrin type-A receptor 6Homo sapiens (human)
extracellular space5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cytosol5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
nucleus5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase TBK1Homo sapiens (human)
cytosolSerine/threonine-protein kinase TBK1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase TBK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase TBK1Homo sapiens (human)
cytosolSerine/threonine-protein kinase TBK1Homo sapiens (human)
intracellular membrane-bounded organelleSerine/threonine-protein kinase TBK1Homo sapiens (human)
serine/threonine protein kinase complexSerine/threonine-protein kinase TBK1Homo sapiens (human)
stress fiberSeptin-9Homo sapiens (human)
cytoplasmSeptin-9Homo sapiens (human)
microtubuleSeptin-9Homo sapiens (human)
axonemeSeptin-9Homo sapiens (human)
actin cytoskeletonSeptin-9Homo sapiens (human)
perinuclear region of cytoplasmSeptin-9Homo sapiens (human)
non-motile ciliumSeptin-9Homo sapiens (human)
septin complexSeptin-9Homo sapiens (human)
septin ringSeptin-9Homo sapiens (human)
microtubule cytoskeletonSeptin-9Homo sapiens (human)
cell division siteSeptin-9Homo sapiens (human)
cytoplasmDeath-associated protein kinase 2Homo sapiens (human)
Golgi apparatusDeath-associated protein kinase 2Homo sapiens (human)
cytoplasmic vesicleDeath-associated protein kinase 2Homo sapiens (human)
autophagosome lumenDeath-associated protein kinase 2Homo sapiens (human)
intracellular membrane-bounded organelleDeath-associated protein kinase 2Homo sapiens (human)
cytoplasmDeath-associated protein kinase 2Homo sapiens (human)
nucleusDeath-associated protein kinase 2Homo sapiens (human)
fibrillar centerRibosomal protein S6 kinase alpha-6Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-6Homo sapiens (human)
nucleolusRibosomal protein S6 kinase alpha-6Homo sapiens (human)
mitochondrionRibosomal protein S6 kinase alpha-6Homo sapiens (human)
cytosolRibosomal protein S6 kinase alpha-6Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-6Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-6Homo sapiens (human)
nucleusTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
nucleoplasmTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
cytoplasmTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
cytosolTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
cytoskeletonTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
apical plasma membraneTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
recycling endosomeTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
extracellular exosomeTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
presynapseTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
glutamatergic synapseTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
postsynaptic density, intracellular componentTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
cytoplasmTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
nucleusSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
nucleusSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
actin cytoskeletonSerine/threonine-protein kinase TAO2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase TAO2Homo sapiens (human)
nucleolusSerine/threonine-protein kinase TAO2Homo sapiens (human)
cytosolSerine/threonine-protein kinase TAO2Homo sapiens (human)
axonSerine/threonine-protein kinase TAO2Homo sapiens (human)
cytoplasmic vesicle membraneSerine/threonine-protein kinase TAO2Homo sapiens (human)
cytoplasmic vesicleSerine/threonine-protein kinase TAO2Homo sapiens (human)
neuron projectionSerine/threonine-protein kinase TAO2Homo sapiens (human)
dendritic growth coneSerine/threonine-protein kinase TAO2Homo sapiens (human)
axonal growth coneSerine/threonine-protein kinase TAO2Homo sapiens (human)
receptor complexSerine/threonine-protein kinase TAO2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase TAO2Homo sapiens (human)
nucleoplasmLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
nucleolusLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
mitochondrionLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
mitochondrial outer membraneLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
endoplasmic reticulumLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
endoplasmic reticulum membraneLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
plasma membraneLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
membraneLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
endoplasmic reticulumLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
membraneLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
mitochondrionLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
plasma membraneALK tyrosine kinase receptorHomo sapiens (human)
plasma membraneALK tyrosine kinase receptorHomo sapiens (human)
extracellular exosomeALK tyrosine kinase receptorHomo sapiens (human)
protein-containing complexALK tyrosine kinase receptorHomo sapiens (human)
receptor complexALK tyrosine kinase receptorHomo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular_componentSRSF protein kinase 3Homo sapiens (human)
nucleusSRSF protein kinase 3Homo sapiens (human)
cytoplasmSRSF protein kinase 3Homo sapiens (human)
fibrillar centerSerine/threonine-protein kinase ICKHomo sapiens (human)
nucleusSerine/threonine-protein kinase ICKHomo sapiens (human)
cytosolSerine/threonine-protein kinase ICKHomo sapiens (human)
ciliumSerine/threonine-protein kinase ICKHomo sapiens (human)
ciliary basal bodySerine/threonine-protein kinase ICKHomo sapiens (human)
ciliary tipSerine/threonine-protein kinase ICKHomo sapiens (human)
ciliary baseSerine/threonine-protein kinase ICKHomo sapiens (human)
nucleusSerine/threonine-protein kinase ICKHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase ICKHomo sapiens (human)
ciliumSerine/threonine-protein kinase ICKHomo sapiens (human)
nucleusCyclin-dependent kinase 11AHomo sapiens (human)
cytoplasmCyclin-dependent kinase 11AHomo sapiens (human)
nucleusCyclin-dependent kinase 11AHomo sapiens (human)
condensed chromosomeAurora kinase CHomo sapiens (human)
nucleusAurora kinase CHomo sapiens (human)
cytoplasmAurora kinase CHomo sapiens (human)
spindleAurora kinase CHomo sapiens (human)
midbodyAurora kinase CHomo sapiens (human)
spindle midzoneAurora kinase CHomo sapiens (human)
chromosome passenger complexAurora kinase CHomo sapiens (human)
kinetochoreAurora kinase CHomo sapiens (human)
spindle midzoneAurora kinase CHomo sapiens (human)
spindle pole centrosomeAurora kinase CHomo sapiens (human)
spindle microtubuleAurora kinase CHomo sapiens (human)
nucleusCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
mitochondrionCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
postsynaptic densityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
endocytic vesicle membraneCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
dendritic spineCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
calcium- and calmodulin-dependent protein kinase complexCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
neuron projectionCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
nucleusRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
membraneRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
nucleoplasmRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase 38-likeHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase 38-likeHomo sapiens (human)
cytosolSerine/threonine-protein kinase 38-likeHomo sapiens (human)
actin cytoskeletonSerine/threonine-protein kinase 38-likeHomo sapiens (human)
membraneSerine/threonine-protein kinase 38-likeHomo sapiens (human)
glutamatergic synapseSerine/threonine-protein kinase 38-likeHomo sapiens (human)
cytoplasmMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
cytoskeletonMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
plasma membraneMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
axonMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
dendriteMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
neuron projectionMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
neuronal cell bodyMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase SIK3Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
exon-exon junction complexThyroid hormone receptor-associated protein 3Homo sapiens (human)
nucleusThyroid hormone receptor-associated protein 3Homo sapiens (human)
nucleoplasmThyroid hormone receptor-associated protein 3Homo sapiens (human)
nuclear speckThyroid hormone receptor-associated protein 3Homo sapiens (human)
extracellular exosomeThyroid hormone receptor-associated protein 3Homo sapiens (human)
mediator complexThyroid hormone receptor-associated protein 3Homo sapiens (human)
nucleoplasmDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
chromosomeDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
nucleolusDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
plasma membraneMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
nucleusReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
nucleusReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
cytosolReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein-containing complexReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
cytoplasmReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
cytosolSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
plasma membraneSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
cell-cell junctionSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
lamellipodiumSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
cell leading edgeSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
actomyosinSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
cytoskeletonSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
actomyosinSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
nucleusInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
cytoplasmInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
nucleusInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
plasma membraneInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
cytoplasmInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
Golgi membraneSerine/threonine-protein kinase 24Homo sapiens (human)
nucleusSerine/threonine-protein kinase 24Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase 24Homo sapiens (human)
nucleolusSerine/threonine-protein kinase 24Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 24Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase 24Homo sapiens (human)
cytosolSerine/threonine-protein kinase 24Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase 24Homo sapiens (human)
FAR/SIN/STRIPAK complexSerine/threonine-protein kinase 24Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase 24Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 24Homo sapiens (human)
cytoplasmCasein kinase I isoform gamma-3Homo sapiens (human)
plasma membraneCasein kinase I isoform gamma-3Homo sapiens (human)
cytoplasmCasein kinase I isoform gamma-3Homo sapiens (human)
nucleusCasein kinase I isoform gamma-3Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
perinuclear region of cytoplasmMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2596)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1798634Fluorescence Binding Assay from Article 10.1073/pnas.0709662105: \\The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.\\2008Proceedings of the National Academy of Sciences of the United States of America, Feb-12, Volume: 105, Issue:6
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.
AID1801713Competition Binding Assays from Article 10.1021/acschembio.5b01063: \\Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors.\\2016ACS chemical biology, 05-20, Volume: 11, Issue:5
Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors.
AID1798633Fluorescence Binding Assay from Article 10.1016/j.ccr.2006.12.017: \\Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.\\2007Cancer cell, Mar, Volume: 11, Issue:3
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.
AID1802936EGFR Tyrosine Kinase Activity Assay from Article 10.3109/14756360903169485: \\Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.\\2010Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 25, Issue:2
Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
AID1801080In vitro EGFR TK Inhibition Assays from Article 10.1111/cbdd.12383: \\Synthesis and evaluation of salicylanilide derivatives as potential epidermal growth factor receptor inhibitors.\\2015Chemical biology & drug design, Mar, Volume: 85, Issue:3
Synthesis and evaluation of salicylanilide derivatives as potential epidermal growth factor receptor inhibitors.
AID1795774Kinase Inhibition Assay from Article 10.1016/j.bmcl.2003.10.010: \\Synthesis and SAR of potent EGFR/erbB2 dual inhibitors.\\2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Synthesis and SAR of potent EGFR/erbB2 dual inhibitors.
AID1802937VEGFR-2 Tyrosine Kinase Activity Assay from Article 10.3109/14756360903169485: \\Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.\\2010Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 25, Issue:2
Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
AID625075Binding constant for INSRR kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424942Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624804Binding constant for ERBB2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624914Binding constant for WEE1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1441914Inhibition of EGFR L858R/T790M double mutant in human NCI-H1975 cells assessed as reduction in cell viability after 96 hrs by CellTiterGlo assay2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.
AID624794Binding constant for MET kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID256639Average Binding Constant for PHkg1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1712166Growth inhibition of human Non-small cell lung cancer cell line incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID748061Antitumor activity against gefitinib-resistant human NCI-H1975 cells harboring EGFR L858R/T90M double mutant xenografted in athymic BALB/c nude mouse assessed as tumor growth inhibition at 16 mg/kg, ip qd administered for 14 days measured every other day 2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID1443511Growth inhibition of human MDA-MB-231 cells2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID1305368Antitumor activity against human PC9 cells harboring EGFR exon19 deletion activating mutant xenografted in mouse at 6.25 mg/kg/day, po qd for 7 days2016ACS medicinal chemistry letters, May-12, Volume: 7, Issue:5
Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation.
AID624997Binding constant for EGFR(E746-A750del) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425212Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435157Binding constant for EGFR(G719C) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624829Binding constant for CDK8 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID256605Average Binding Constant for STK17B; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1585920Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
AID1712105Growth inhibition of human Hs-578T cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1378277Inhibition of EGFR in human A549 cells assessed as reduction in EGF-induced Akt phosphorylation at S473 residue at 25 uM preincubated for 2 hrs followed by EGF stimulation for 10 mins by Western blot analysis
AID624935Binding constant for FLT3(D835H) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1762240Inhibition of EGFR (unknown origin)2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines.
AID1870649Growth inhibition of human NCI-H3255 cells harbouring EGFR L858R mutant incubated for 72 hrs by CCK8 assay2022Journal of medicinal chemistry, 08-11, Volume: 65, Issue:15
Ynamide Electrophile for the Profiling of Ligandable Carboxyl Residues in Live Cells and the Development of New Covalent Inhibitors.
AID1442477MRT (0 to infinity) in Sprague-Dawley rat plasma at 10 mg/kg, po measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID624780Binding constant for CDK4-cyclinD1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624979Binding constant for ABL1(F317I)-non phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224766Delta TM value showing the stabilisation of CK1G3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID489609Inhibition of human EGFR autophosphorylation expressed in Sf9 cells DELFIA assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and antiproliferative activity of indolizine derivatives incorporating a cyclopropylcarbonyl group against Hep-G2 cancer cell line.
AID1353466Inhibition of EGF-induced EGFR activation in human A549 cells assessed as reduction in Akt phosphorylation at S473 residue at 5 uM preincubated for 2 hrs followed by EGF stimulation measured after 10 mins by Western blot analysis2018European journal of medicinal chemistry, Mar-10, Volume: 1476,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
AID1712104Growth inhibition of human MDA-MB-231/ATCC cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID451988Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).
AID256629Average Binding Constant for HCK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1742796Cytotoxicity against human HCV-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis and in vitro anti-bladder cancer activity evaluation of quinazolinyl-arylurea derivatives.
AID1224777Delta TM value showing the stabilisation of MST4(1) produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1250371Fraction unbound in Han Wistar rat brain at 5 uM by equilibrium dialysis method2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
AID624930Binding constant for TNK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1442463AUMC (0 to infinity) in Sprague-Dawley rat plasma at 1 mg/kg, iv measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID1499600Inhibition of recombinant human His-tagged EGFR (1 to 645 residues) expressed in HEK293 cells at 0.0001 uM using Tyr66-biotinylated PTP1B peptide as substrate preincubated for 5 mins followed by substrate addition measured after 1 hr by ELISA relative to 2017European journal of medicinal chemistry, Sep-29, Volume: 138Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
AID624845Binding constant for CDK7 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1586912Cytotoxicity against human A549 cells after 72 hrs by MTT assay2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Acrylamide Functional Group Incorporation Improves Drug-like Properties: An Example with EGFR Inhibitors.
AID1585933Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant assessed as cell viability at 1 uM after 48 hrs by MTT assay (Rvb = 98.3%)2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
AID1283992Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay2016Bioorganic & medicinal chemistry letters, Mar-15, Volume: 26, Issue:6
Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
AID1381744Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr by mobility shift assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
AID1877685Cytotoxicity against human L02 cells by CCK8 assay2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID256625Average Binding Constant for PAK3; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435563Binding constant for TNIK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424966Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1637536Antiproliferative activity against human A549 cells after 48 hrs in presence of 10% FBS by MTT method2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Discovery of N-(benzyloxy)-1,3-diphenyl-1H-pyrazole-4-carboxamide derivatives as potential antiproliferative agents by inhibiting MEK.
AID1463975Inhibition of wild type recombinant EGFR (unknown origin) at 50 nM by ELISA relative to control2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Quinazoline-1-deoxynojirimycin hybrids as high active dual inhibitors of EGFR and α-glucosidase.
AID1810183Cytotoxicity against human HCC827 cells assessed as reduction in cell viability at 20 nM after 72 hrs in presence of pro-HGF by crystal violet staining based assay2021Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24
Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression.
AID1876266Binding affinity to GAK (unknown origin) assessed as dissociation constant2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID666831Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel 2-(2-arylmethylene)hydrazinyl-4-aminoquinazoline derivatives as potent antitumor agents.
AID1532910Toxicity in human A549 cells xenografted BALB/c nude mouse assessed as effect on body weight at 30 mg/kg, ig administered every 2 days for 19 days2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold.
AID624926Binding constant for RIOK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1562603Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay
AID1585929Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant assessed as cell viability at 0.1 uM after 24 hrs by MTT assay (Rvb = 98.3%)2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
AID1424939Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1715114Inhibition of EPHA6 (unknown origin) at 1 uM relative to control2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1742795Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis and in vitro anti-bladder cancer activity evaluation of quinazolinyl-arylurea derivatives.
AID1424937Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1702618Antiproliferative activity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant assessed as inhibition of cell growth by MTT assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Design, synthesis and biological evaluation of 2-amino-4-(1,2,4-triazol)pyridine derivatives as potent EGFR inhibitors to overcome TKI-resistance.
AID624797Binding constant for PHKG2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435525Binding constant for EGFR(L858R) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID748092Cytotoxicity against gefitinib-sensitive human HCC827 cells harboring EGFR E746_A740 deletion mutant assessed as growth inhibition after 72 hrs by MTT assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID1425088Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID488724Cytotoxicity against human MIAPaCa2 cells assessed as suppression of colony formation at 1 uM after 9 to 10 days by crystal violet staining2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.
AID624812Binding constant for SBK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435807Binding constant for MARK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID410945Antiproliferative activity against human HN5 cells overexpressing EGFR after 3 days by methylene blue staining2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors.
AID695419Induction of apoptosis in human HCT116 cells expressing KRAS mutant assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Synthesis and evaluation of apoptosis induction of thienopyrimidine compounds on KRAS and BRAF mutated colorectal cancer cell lines.
AID457038Inhibition of EGFR autophosphorylation in human NCI-H1975 cells up to 10 uM by Western blot2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion.
AID256601Average Binding Constant for EPHA3; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1168676Cytotoxicity against human A549 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay (Rvb = 100%)2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Optimization of gefitinib analogues with potent anticancer activity.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID256594Average Binding Constant for BMX; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1309512Inhibition of wild type human EGFR preincubated for 5 mins followed by ATP addition for 30 mins by HTRF assay2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
6-Oxooxazolidine-quinazolines as noncovalent inhibitors with the potential to target mutant forms of EGFR.
AID1855769Inhibition of recombinant human EGFR incubated for 40 to 45 mins and measured after 15 mins by Kinase-Glo Max assay2022European journal of medicinal chemistry, Nov-05, Volume: 241New thiazole-based derivatives as EGFR/HER2 and DHFR inhibitors: Synthesis, molecular modeling simulations and anticancer activity.
AID435555Binding constant for PRKR kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624999Binding constant for EGFR(G719S) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1768070Antiproliferative activity against human WI-26 AV4 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Investigation of 3-sulfamoyl coumarins against cancer-related IX and XII isoforms of human carbonic anhydrase as well as cancer cells leads to the discovery of 2-oxo-2H-benzo[h]chromene-3-sulfonamide - A new caspase-activating proapoptotic agent.
AID1425188Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1690748Induction of DNA damage in human A549 cells at 0.1 to 10 uM after 2 hrs by comet assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Comparative analysis of the dual EGFR-DNA targeting and growth inhibitory properties of 6-mono-alkylamino- and 6,6-dialkylaminoquinazoline-based type II combi-molecules.
AID1224805Delta TM value showing the stabilisation of VRK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1425071Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1582385Inhibition of EGFR L858R in human H3255 cells assessed as reduction in EGFR autophosphorylation at 1 uM treated 8 hrs post serum starvation measured after 16 hrs by Western blot analysis2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
AID624821Binding constant for YANK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425027Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID269265Inhibition of EGFR-mediated polyGAT phosphorylation at 0.001 uM2006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
5-benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity.
AID1424994Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1712171Growth inhibition of human Panel renal (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1586913Thermodynamic solubility of the compound in pH 7.4 phosphate buffered saline measured after 24 hrs by UV-HPLC analysis2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Acrylamide Functional Group Incorporation Improves Drug-like Properties: An Example with EGFR Inhibitors.
AID435310Binding constant for FLT3(ITD) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624785Binding constant for JAK3(JH1domain-catalytic) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1760621Antitumor activity against human NCI-H1975 cells xenografted in BALB/c nude mouse assessed as reduction in tumor growth at 60 mg/kg, ig administered once daily for 3 weeks2021European journal of medicinal chemistry, Feb-05, Volume: 211Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
AID69565Inhibition of EGF-stimulated epidermal growth factor receptor phosphorylation at 0.1 ug/mL2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Synthesis and biological evaluation of benzamides and benzamidines: structural requirement of a pyrimidine ring for inhibition of EGFR tyrosine kinase.
AID1424965Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1617468Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki2019Journal of natural products, 11-22, Volume: 82, Issue:11
Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
AID624986Binding constant for ABL1(Q252H)-non phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435660Binding constant for full-length MELK2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1532892Inhibition of wild type human N-terminal His-tagged HER2 cytoplasmic domain (676 to 1255 residues) expressed in baculovirus expression system after 1 hr in presence of ULight-labeled peptide substrate and ATP by LANCE ultra kinase assay2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1403041Induction of apoptosis in human A549 cells assessed as late apoptotic cells after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.11%)2018European journal of medicinal chemistry, Jan-20, Volume: 144Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
AID1768129Antifibrotic activity in C57BL mouse model of BLM-induced lung fibrosis assessed as HYP level at 60 mg/kg (Rvb = 5.31 +/- 0.79 ug/mg)2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Synthesis and biological evaluation of selenogefitinib for reducing bleomycin-induced pulmonary fibrosis.
AID1443499Inhibition of NF-kappaB in human MDA-MB-231 cells assessed as decrease in CBP/p300 level in NF-kappaB transcriptional complex in cell nuclear extracts at 2.5 to 15 uM incubated for 12 hrs by ELISA2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID435661Binding constant for full-length MKNK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1676529Inhibition of HER2-G776delinsVC mutant (unknown origin) expressed in human H1781 cells assessed as reduction in HER2 induced cell viability after 96 hrs by CellTiter-Glo assay2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.
AID1637535Antiproliferative activity against human MCF7 cells after 48 hrs in presence of 10% FBS by MTT method2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Discovery of N-(benzyloxy)-1,3-diphenyl-1H-pyrazole-4-carboxamide derivatives as potential antiproliferative agents by inhibiting MEK.
AID1224774Delta TM value showing the stabilisation of p38beta produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1443520Solubility in water2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID1499601Inhibition of recombinant human His-tagged EGFR (1 to 645 residues) expressed in HEK293 cells at 0.001 uM using Tyr66-biotinylated PTP1B peptide as substrate preincubated for 5 mins followed by substrate addition measured after 1 hr by ELISA relative to c2017European journal of medicinal chemistry, Sep-29, Volume: 138Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
AID435822Binding constant for MEK4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625010Binding constant for FER kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1473928AUC in human at 250 to 500 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1712093Growth inhibition of human UACC-62 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID489615Antiproliferative activity against human A375 cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and preliminary biological evaluation of novel taspine derivatives as anticancer agents.
AID1424977Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID410944Inhibition of ERBb2 by HTRF assay2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors.
AID589577Inhibition of human EGFR-mediated poly(Glu4Tyr) phosphorylation after 1 hr2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.
AID488728Induction of apoptosis in human MIAPaCa2 cells at 5 to 10 uM after 48 hrs by propidium iodide staining-based FACS analysis2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.
AID1224798Delta TM value showing the stabilisation of DRAK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1425191Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1896793Antiproliferative activity against mouse BaF3 cells expressing EGFR WT assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay2022Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23
Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.
AID256611Average Binding Constant for RIPK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624855Binding constant for FRK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID271143Inhibition of tumor volume in human LoVo cell xenografted in nude mouse at 50 mg/kg, po2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID1896772Inhibition of wild type EGFR (unknown origin) preincubated with compound 30 mins followed ATP addition incubated for 30 mins by HTRF KinEASE TK assay2022Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23
Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.
AID1702617Antiproliferative activity against human A-431 cells harboring wild type EGFR assessed as inhibition of cell growth by MTT assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Design, synthesis and biological evaluation of 2-amino-4-(1,2,4-triazol)pyridine derivatives as potent EGFR inhibitors to overcome TKI-resistance.
AID295769Inhibition of human VEGFR2 in presence of 1 uM ATP2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
AID1443456Inhibition of TNFalpha-stimulated NF-kappaB (unknown origin) expressed in human U937 cells incubated for 3 hrs followed by TNFalpha stimulation measured after 2.5 hrs by luciferase reporter gene assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID625050Binding constant for PKN2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624837Binding constant for IRAK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425129Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID436047Binding constant for full-length PRKX2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1460601Growth inhibition of Staphylococcus aureus SAK2378 up to 100 ug/ml by broth microdilution assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID1574931Inhibition of human C-terminal His6-tagged ERBB2 (676 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
AID435284Binding constant for DCAMKL1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1168675Cytotoxicity against human BFTC905 cells assessed as reduction in cell viability at 20 to 80 uM after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Optimization of gefitinib analogues with potent anticancer activity.
AID1425196Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625131Binding constant for FGFR2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1712072Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID624784Binding constant for INSR kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624936Binding constant for FLT3(D835Y) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1175522Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
AID1425107Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID775614Antiproliferative activity against gefitinib-sensitive human HCC827 cells harboring EGFR E746 to A750 deletion after 72 hrs by MTS assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
AID1129571Antiproliferative activity against gefitinib-sensitive human HCC827 cells bearing EGFR del E746_A750 mutant after 72 hrs by MTT assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID624948Binding constant for CSK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1365576Inhibition of EGFR E746_A750 deletion mutant in human PC9 cells assessed as reduction in cell viability after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID708784Antitumor activity against human NCI-H1975 cells xenografted in BALB/c mouse assessed as inhibition of tumor growth at 100 mg/kg, po qd2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.
AID1585931Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant assessed as cell viability at 0.1 uM after 72 hrs by MTT assay (Rvb = 98.3%)2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
AID624978Binding constant for ABL1(E255K)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435902Binding constant for BRAF(V600E) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID611842Inhibition of EGFR after 1 hrs by luminescence assay2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
AID1407099Inhibition of EGFR in human HepG2 cells2018European journal of medicinal chemistry, Aug-05, Volume: 156Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity.
AID435656Binding constant for FGFR4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1595621Inhibition of tracer 5 binding to human N-terminal nano luciferase-fused GAK expressed in HEK293 cells measured after 2 hrs by nanoBRET assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID1499604Inhibition of recombinant human His-tagged EGFR (1 to 645 residues) expressed in HEK293 cells at 1 uM using Tyr66-biotinylated PTP1B peptide as substrate preincubated for 5 mins followed by substrate addition measured after 1 hr by ELISA relative to contr2017European journal of medicinal chemistry, Sep-29, Volume: 138Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
AID1168674Cytotoxicity against human RKO cells assessed as reduction in cell viability at 20 to 80 uM after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Optimization of gefitinib analogues with potent anticancer activity.
AID1224754Delta TM value showing the stabilisation of CAMK2G produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1585935Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant assessed as cell viability at 10 uM after 24 hrs by MTT assay (Rvb = 98.3%)2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
AID624790Binding constant for KIT(L576P) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID674793Antiproliferative activity against human KB cells expressing EGFR and SRC by MTT assay2012European journal of medicinal chemistry, Sep, Volume: 55Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases.
AID256671Average Binding Constant for ABL1(Y253F); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624872Binding constant for PAK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435924Binding constant for MARK4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1896795Antiproliferative activity against mouse BaF3 cells expressing L858R/C797S assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay2022Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23
Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.
AID256593Average Binding Constant for NEK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624813Binding constant for MINK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624944Binding constant for ALK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624975Binding constant for PLK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID256665Average Binding Constant for ABL1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435783Binding constant for full-length BRSK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID489616Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and preliminary biological evaluation of novel taspine derivatives as anticancer agents.
AID1574934Antiproliferative activity against human A549 cells harboring wild-type EGFR after 72 hrs by EZ-Cytox assay2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
AID1715111Inhibition of PDGFRA (unknown origin) at 1 uM relative to control2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435653Binding constant for EGFR(L747-S752del, P753S) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID436033Binding constant for PIK3CA kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID662617Inhibition of EGFR del E746-A750 mutant Y1068 autophosphorylation in human HCC827 cells up to 125 nM after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1425102Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435937Binding constant for TESK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1391277Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors.
AID394732Cytotoxicity against human MDA-MB-231 cells after 96 hrs by MTT assay2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
2,3-Disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazolines: a novel class of antitumor agents.
AID1756974Induction of apoptosis in human NCI-H1975 cells assessed as early apoptotic cells at 2 uM incubated for 24 hrs by annexin V-FITC and propidium iodide based flow cytometry analysis (Rvb = 1.34 %)2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
AID435199Binding constant for TLK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435532Binding constant for MST3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1212341Cytotoxicity against human Fa2N-4 cells by lactate dehydrogenase assay2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID599959Binding affinity to human KIT D816V mutant incubated for 1 hr by kinase binding assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
AID435790Binding constant for DRAK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624991Binding constant for ABL1-non phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625133Binding constant for CDC2L2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID488713Cytotoxicity against human NCI-H661 cells after 4 to 5 days by MTT assay2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.
AID1712101Growth inhibition of human UO-31 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID271135Free drug level in mouse plasma at 50 mg/kg, po at 6 hrs2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID1896798Antiproliferative activity against mouse BaF3 cells expressing Del19 assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay2022Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23
Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.
AID1312556Inhibition of ErbB2 (unknown origin)2016European journal of medicinal chemistry, Aug-08, Volume: 118Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
AID435657Binding constant for full-length IKK-epsilon2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1689696Inhibition of NFkappaB p65 in human RPMI-8226 cells incubated for 2 hrs by ELISA2020European journal of medicinal chemistry, Mar-01, Volume: 1891,2,3-Triazole-Chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226.
AID1582386Inhibition of EGFR exon 19 deletion mutant in human HCC827 cells assessed as reduction in AKT phosphorylation at 1 uM treated 8 hrs post serum starvation measured after 16 hrs by Western blot analysis2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
AID1424194Selectivity index, ratio of IC50 for inhibition of wild type N-terminal GST tagged human recombinant EGFR (695 to end amino acids) expressed in baculovirus infected Sf9 insect cells to IC50 for inhibition of N-terminal GST tagged human recombinant EGFR L82017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
AID624775Binding constant for STK16 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435401Binding constant for full-length DRAK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1163060Antiproliferative activity against human ER-negative MCF7 cells after 24 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID435432Binding constant for MLK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624939Binding constant for FLT3(N841I) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624814Binding constant for DCAMKL2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625012Binding constant for GAK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624834Binding constant for DAPK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1321927Antiproliferative activity against human NCI-H1975 cells harboring L858R/T790M double mutant after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of azole-diphenylpyrimidine derivatives (AzDPPYs) as potent T790M mutant form of epidermal growth factor receptor inhibitors.
AID1425057Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1240083Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
The discovery of oxazolones-grafted spirooxindoles via three-component diversity oriented synthesis and their preliminary biological evaluation.
AID1365578Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID761596Antiproliferative activity against human 16HBE cells expressing wild type EGFR after 72 hrs by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID1224765Delta TM value showing the stabilisation of CK1G2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID627045Antiproliferative activity against gefitinib resistant human NCI-H292 cells after 3 days by SRB assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Growth inhibition of human lung cancer cells via down-regulation of epidermal growth factor receptor signaling by yuanhuadine, a daphnane diterpene from Daphne genkwa.
AID1756975Induction of apoptosis in human NCI-H1975 cells assessed as late apoptotic cells at 2 uM incubated for 24 hrs by annexin V-FITC and propidium iodide based flow cytometry analysis (Rvb = 4.98 %)2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
AID1305354Antitumor activity against human A431 cells harboring wild-type EGFR xenografted in mouse at 6.25 mg/kg/day, po qd for 7 days2016ACS medicinal chemistry letters, May-12, Volume: 7, Issue:5
Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation.
AID256626Average Binding Constant for NTRK1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1824045Antiproliferative activity against human A549 cells expressing wild type EGFR assessed as inhibition in cell viability after 72 hrs by CCK8 assay
AID435329Binding constant for YSK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256661Average Binding Constant for PDGFRB; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1464635Cytotoxicity against human A549 cells after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20
Synthesis and evaluation of the NSCLC anti-cancer activity and physical properties of 4-aryl-N-phenylpyrimidin-2-amines.
AID1424195Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
AID1425119Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624744Binding constant for ZAP70 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425018Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1817355Protac activity at VHL/EGFR in human NCI-H1299 cells assessed as induction of EGFR degradation at up to 15 uM incubated for 36 hrs by Western blot analysis2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP.
AID662596Antiproliferative activity against human HCC827 cells harboring EGFR del E746-A750 mutant after 72 hrs by MTS assay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID68106Inhibitory activity against ERBB2 receptor kinase2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Synthesis and SAR of potent EGFR/erbB2 dual inhibitors.
AID625142Binding constant for TSSK1B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1904133Reversal of BCRP-mediated multidrug resistance in dog MDCK-II-BCRP cells assessed as fold reduction in mitoxantrone IC50 at 5 uM measured after 48 hrs by MTT assay relative to mitoxantrone IC50 alone2022European journal of medicinal chemistry, Apr-05, Volume: 233Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID624818Binding constant for ULK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1365577Inhibition of EGFR E746_A750 deletion/T790M mutant in human growth-resistant PC9 cells assessed as reduction in cell viability after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID1163064Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID624800Binding constant for IGF1R kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435279Binding constant for full-length CDK92008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625101Binding constant for TAOK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1312563Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay2016European journal of medicinal chemistry, Aug-08, Volume: 118Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
AID1236610Resistance ratio, ratio of IC50 for human gefitinib-resistant NCI-H1975 cells to IC50 for human HCC827 cells2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity.
AID435833Binding constant for full-length TNK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625028Binding constant for ASK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID256570Average Binding Constant for PIM2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1442468Tmax in Sprague-Dawley rat plasma at 10 mg/kg, po measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID1896773Inhibition of EGFR (unknown origin) Del19 mutant preincubated with compound 30 mins followed ATP addition incubated for 30 mins by HTRF KinEASE TK assay2022Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23
Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.
AID625137Binding constant for MEK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1236608Antiproliferative activity against human HCC827 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity.
AID625115Binding constant for PAK6 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID666828Cytotoxicity against human H460 cells after 72 hrs by MTT assay2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel 2-(2-arylmethylene)hydrazinyl-4-aminoquinazoline derivatives as potent antitumor agents.
AID435399Binding constant for DCAMKL3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1460603Growth inhibition of Staphylococcus aureus SA1199B up to 100 ug/ml by broth microdilution assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID1877682Antiproliferative activity against human MDA-MB-231 cells by CCK8 assay2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID625117Binding constant for PAK7 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625033Binding constant for PCTK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID256624Average Binding Constant for FGFR3; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1574930Inhibition of human N-terminal GST-tagged EGFR T790M/L858R double mutant (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
AID625060Binding constant for CAMKK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1396811Inhibition of EGFR isolated from human A431 cells2018Bioorganic & medicinal chemistry letters, 08-15, Volume: 28, Issue:15
ROCK inhibitors 2. Improving potency, selectivity and solubility through the application of rationally designed solubilizing groups.
AID436024Binding constant for MRCKA kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1381739Cytotoxicity against human BT549 cells after 72 hrs by SRB assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
AID1525110Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay2019Journal of natural products, 05-24, Volume: 82, Issue:5
Strepantibins A-C: Hexokinase II Inhibitors from a Mud Dauber Wasp Associated Streptomyces sp.
AID435564Binding constant for TRKB kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1442454Terminal half life in Sprague-Dawley rat plasma at 1 mg/kg, iv measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID435806Binding constant for MAPKAPK5 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1458982Antiproliferative activity against human NCI-H1975 cells harboring EGFR-L858R/T790M double mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1712081Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1403036Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase after 24 hrs by propidium iodide staining based flow cytometry relative to control2018European journal of medicinal chemistry, Jan-20, Volume: 144Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
AID507084Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID435411Binding constant for KIT(D816V) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1053599Inhibition of EGFR L858R/T790M double mutant phosphorylation in human NCI-H1975 cells at 330 nM after 2 hrs by Western blotting analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties.
AID1425131Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID778804Cytotoxicity against gefitinib-resistant human HCC827 cells assessed as growth inhibition at 0.5 uM after 72 hrs2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.
AID1129572Antiproliferative activity against human A431 cells overexpressing WT EGFR after 72 hrs by MTT assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID1425193Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435290Binding constant for FGFR2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1756976Induction of apoptosis in human NCI-H1975 cells assessed as necrotic cells at 2 uM incubated for 24 hrs by annexin V-FITC and propidium iodide based flow cytometry analysis (Rvb = 0.455 %)2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
AID1595620Inhibition of EGFR in human A431 cells assessed as reduction in EGF-stimulated EGFR autophosphorylation preincuabted for 90 mins followed by EGF-stimulation by sandwich-ELISA2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID624890Binding constant for p38-beta kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1712085Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1654045Antifibrotic activity against bleomycin-induced pulmonary fibrosis C57BL/6J mouse model assessed as reduction in IL17A expression in plasma at 60 mg/kg, po administered via gavage qd for 14 days at 3 days post bleomycin challenge by FACSCalibur flow cytom2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
AID1425181Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624963Binding constant for LATS1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435834Binding constant for YANK3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1585981Inhibition of EGFR T790M/L858R double mutant auto-phosphorylation in human NCI-H1975 cells at 1 uM by Western blot analysis relative to control2019European journal of medicinal chemistry, Jan-15, Volume: 162Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR.
AID770791Aqueous solubility of the compound at 20 degC2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors.
AID1307964Inhibition of BACE1 (unknown origin)2016Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9
Impact of Binding Site Comparisons on Medicinal Chemistry and Rational Molecular Design.
AID435666Binding constant for full-length NEK72008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1265466Induction of apoptosis in human A549 cells assessed as upregulation of caspase-3 expression at 10 uM after 48 hrs by Western blot analysis2016European journal of medicinal chemistry, Jan-01, Volume: 107Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents.
AID780348Antiproliferative activity against human A549 cells after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Discovery of 2-aryl-8-hydroxy (or methoxy)-isoquinolin-1(2H)-ones as novel EGFR inhibitor by scaffold hopping.
AID1403037Induction of apoptosis in human A549 cells assessed as increase in early apoptotic cells after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry relative to control2018European journal of medicinal chemistry, Jan-20, Volume: 144Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
AID625071Binding constant for STK39 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1186995Cytotoxicity against human HepG2 cells assessed as cell viability at 10 uM after 24 hrs by Cell-Titer Glo assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID624729Binding constant for FAK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID770052Antitumor activity against human NCI-H1975 cells harboring EGFR L858R/T970M double mutant xenografted in SCID mouse assessed as tumor growth inhibition at 100 mg/kg/day, po after 7 days relative to vehicle-treated control2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
AID1424909Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID456590Inhibition of EGF-induced EGFR phosphorylation in human A431 cells pretreated for 5 hrs followed by media washout and EGF-stimulation by immunoblot analysis2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
AID1617470Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay2019Journal of natural products, 11-22, Volume: 82, Issue:11
Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
AID1904132Reversal of P-gp-mediated multidrug resistance in human K562/A02 cells assessed as fold reduction in adriamycin IC50 at 5 uM measured after 48 hrs by MTT assay relative to adriamycin IC50 alone2022European journal of medicinal chemistry, Apr-05, Volume: 233Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID625073Binding constant for SGK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1712077Growth inhibition of human HOP-92 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID271147AUC in nude mouse xenografted with human LoVo cell at 100 mg/kg, po2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID1532901Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 8 uM after 72 hrs by FITC-annexin V/propidium iodide-double staining based flow cytometry (Rvb = 9.38%)2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold.
AID1353460Inhibition of EGFR L858R mutant (unknown origin) using ULight-poly GT as substrate preincubated for 120 mins followed by substrate addition measured after 2 hrs by spectrophotometric method2018European journal of medicinal chemistry, Mar-10, Volume: 1476,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
AID624850Binding constant for DDR1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1443473Selectivity ratio of GI50 for HUVEC to GI50 for human A549 cells2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID256610Average Binding Constant for Aurora3; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1186992Cytotoxicity against human HepG2 cells assessed as cell viability at 10 uM after 4 hrs by Cell-Titer Glo assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID436012Binding constant for full-length CSNK2A12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435517Binding constant for AKT2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624734Binding constant for YANK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1532890Antiproliferative activity against human A549 cells after 72 hrs by MTT assay2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold.
AID394728Cytotoxicity against human A549 cells after 96 hrs by MTT assay2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
2,3-Disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazolines: a novel class of antitumor agents.
AID1251002Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.
AID435443Binding constant for TXK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425172Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1712089Growth inhibition of human U-251 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1312555Inhibition of ErbB4 (unknown origin)2016European journal of medicinal chemistry, Aug-08, Volume: 118Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
AID256628Average Binding Constant for LYN; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435523Binding constant for CIT kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1676531Inhibition of C-terminal His6-tagged HER2 (703 to 1029 residues) (unknown origin) expressed in Sf9 insect cells using TK as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins in presence of XL665-labeled streptavi2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.
AID708790Inhibition of EGFR in human NCI-H1975 cells assessed as reduction in ERK phosphorylation at 10 uM incubated for 8 hrs by Western blotting method2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.
AID256559Average Binding Constant for EPHB4; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1264286Inhibition of human recombinant EGFR T790M/L858R double mutant preincubated for 10 mins followed by FAM-labeled peptide/ATP addition measured after 1 hr by mobility shift assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
AID624911Binding constant for TXK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1442461Clearance in Sprague-Dawley rat plasma at 1 mg/kg, iv measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID1443478Inhibition of MNK2 (unknown origin) at 0.5 uM2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID435530Binding constant for MAP3K4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1163814Cytotoxicity against human H460 cells after 72 hrs by SRB assay2014Journal of natural products, Sep-26, Volume: 77, Issue:9
Polyoxypregnane steroids from the stems of Marsdenia tenacissima.
AID528339Antiproliferative activity against human HCC827 cells by MTS assay2010Journal of medicinal chemistry, Oct-28, Volume: 53, Issue:20
Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency.
AID488711Cytotoxicity against human PC3 cells after 4 to 5 days by MTT assay2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.
AID1068983Inhibition of EGF-stimulated autophosphorylation of EGFR in human KB cells incubated for 1 hr prior to EGF challenge measured after 6 mins by ELISA2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 1: erlotinib analogs.
AID1499598Inhibition of recombinant human His-tagged EGFR (1 to 645 residues) expressed in HEK293 cells at 0.000001 uM using Tyr66-biotinylated PTP1B peptide as substrate preincubated for 5 mins followed by substrate addition measured after 1 hr by ELISA relative t2017European journal of medicinal chemistry, Sep-29, Volume: 138Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
AID1353456Antiproliferative activity against human HCC827 cells harboring EGFR E746-A750 del mutant after 72 hrs by MTT assay2018European journal of medicinal chemistry, Mar-10, Volume: 1476,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
AID435395Binding constant for CDC2L1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256592Average Binding Constant for LIMK1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435800Binding constant for FYN kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1896803Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion NPG mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay2022Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23
Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.
AID624728Binding constant for NIM1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624759Binding constant for PFCDPK1(P.falciparum) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624816Binding constant for HPK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID433870Antiproliferative activity against human A549 cells at 20 uM after 72 hrs by trypan blue exclusion method2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line.
AID1443470Growth inhibition of HUVEC after 48 hrs by MTT assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID1545393Antiproliferative activity against human MCF7 by MTT assay2019Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7
Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.
AID625085Binding constant for ULK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424908Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID256563Average Binding Constant for ULK3 m; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID625074Binding constant for IKK-epsilon kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1443451Inhibition of IL-1beta-stimulated nuclear translocation of GFP-tagged NF-kappaB-p65 (unknown origin) expressed in CHO cells at 15 uM preincubated with IL-1beta for 30 mins followed by compound addition by fluorescence assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID435934Binding constant for PLK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224761Delta TM value showing the stabilisation of CLK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1574933Antiproliferative activity against human PC9 cells harboring EGFR exon-19 del mutant after 72 hrs by EZ-Cytox assay2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
AID624754Binding constant for NEK7 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1609535Antitumour activity against human HCT116 cells xenografted in BALB/c nude mouse assessed as reduction in tumour growth at 10 mg/kg, ip administered daily for 18 days started from 2 days after tumor cell inoculation by digital caliper method2019European journal of medicinal chemistry, Nov-15, Volume: 182Design and synthesis of novel artemisinin derivatives with potent activities against colorectal cancer in vitro and in vivo.
AID435897Binding constant for ABL1(T315I) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1712167Growth inhibition of human Panel colon (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1445475Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as growth inhibition after 96 hrs by CellTiter-Glo assay2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
AID589578Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.
AID1425078Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624876Binding constant for PDPK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1315992Stability in rat hepatocytes assessed as length of time required to give 50% loss of parent compound at 1 uM by mass spectrometric analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID435156Binding constant for EGFR kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1589893Growth inhibition of human MOLT4 cells incubated for 48 hrs by SRB assay2019Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12
Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors.
AID1424995Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID256676Average Binding Constant for SRC; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1425199Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID770048Antitumor activity against wild type human A431 cells xenografted in SCID mouse assessed as tumor growth inhibition at 6.25 mg/kg/day, po after 7 days relative to vehicle-treated control2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
AID624853Binding constant for FLT1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625093Binding constant for TNIK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1443484Inhibition of EPHA6 (unknown origin) at 0.5 uM2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID507074Inhibition of recombinant PI3Kdelta by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID625005Binding constant for EGFR(L861Q) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625121Binding constant for RET kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1470942Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as decrease in cell viability after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10
C-2 (E)-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFR
AID624894Binding constant for MEK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1595624Antiproliferative activity against human UCH7 cells measured after 72 hrs by alamar blue assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID624861Binding constant for LIMK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1186991Cytotoxicity against human HepG2 cells assessed as cell viability at 1 uM after 4 hrs by Cell-Titer Glo assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID1171420Inhibition of wild type EGFR T790M mutant (unknown origin) incubated for 5 mins by HTRF assay2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.
AID740936Inhibition of EGFR tyrosine kinase (unknown origin) using poly (Glu,Tyr) as substrate at 10 uM after 40 mins by Kinase-Glo Plus luminescence kinase assay2013European journal of medicinal chemistry, Mar, Volume: 61Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors.
AID1425067Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1224801Delta TM value showing the stabilisation of MST1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID625126Binding constant for TAOK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1186993Cytotoxicity against human HepG2 cells assessed as cell viability at 100 uM after 4 hrs by Cell-Titer Glo assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID435646Binding constant for BLK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1582441Antiproliferative activity against human H3255 cells measured after 3 days by CCK8 assay2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
AID256585Average Binding Constant for EPHA7; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435910Binding constant for MAP4K4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256664Average Binding Constant for EGFR; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435903Binding constant for CDK8 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435791Binding constant for EGFR(E746-A750del) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID436023Binding constant for MERTK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624952Binding constant for EPHA4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID436042Binding constant for full-length PHKG12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID15869151-Octanol-buffer partition coefficient, log D of compound at pH 7.4 after 24 hrs by shake-flask method2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Acrylamide Functional Group Incorporation Improves Drug-like Properties: An Example with EGFR Inhibitors.
AID1712174Growth inhibition of human Panel NCI-60 (60 carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1212314Drug uptake in lysosomes of human Fa2N-4 cells assessed as inhibition of LysoTracker Red fluorescence after 30 mins2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1562648Inhibition of EGF-induced EGFR phosphorylation at Y1068 in human A431 cells at 5 uM preincubated for 2 hrs followed by EGF treatment and measured after 10 mins by Western blot analysis
AID435692Binding constant for STK16 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1442474AUMC (0 to t) in Sprague-Dawley rat plasma at 10 mg/kg, po measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID1649880Growth inhibition of human DU145 cells after 5 days by SRB assay2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Design and Synthesis of a Trifunctional Molecular System "Programmed" to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer Cells.
AID1667572Antiproliferative activity against human BT474 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay2020Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9
Design and synthesis of a novel class EGFR/HER2 dual inhibitors containing tricyclic oxazine fused quinazolines scaffold.
AID1545413Antiproliferative activity against human HCT116 after 18 hrs by MTT assay2019Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7
Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.
AID1717441Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay
AID435780Binding constant for BMPR2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435898Binding constant for ACVR1B kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625039Binding constant for PIK3CA(E545A) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624889Binding constant for JNK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID761592Induction of nitric oxide production in human 16HBE cells expressing wild type EGFR at 100 uM after 72 hrs by Griess assay2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID1499607Cytotoxicity against human HepG2 cells at 5 uM after 48 hrs by LDH release assay (Rvb = 100%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
AID1904126Cytotoxicity against human K562 cells after 48 hrs by MTT assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID507085Inhibition of recombinant EphB4R by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID1425056Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1445468Inhibition of human N-terminal GST-fused EGFR L858R mutant (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 15 mins by HTFR assay2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
AID624756Binding constant for MAP4K4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1565416Antiproliferative activity against wild type human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 1821,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC.
AID1240082Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
The discovery of oxazolones-grafted spirooxindoles via three-component diversity oriented synthesis and their preliminary biological evaluation.
AID1712074Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID435528Binding constant for IRAK3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID507075Inhibition of recombinant PI3Kgamma by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID625119Binding constant for CAMK1G kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224802Delta TM value showing the stabilisation of TNIK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID256603Average Binding Constant for FER; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1724873Antiproliferative activity against EGFR/C-RAF knockdown human Panc-4 cells harboring K-RAS G12D/TP53 P72R/R28W mutant xenografted in mouse tumor model assessed as inhibition of cell proliferation by MTT assay in presence of gefitinib2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Complete Regression of Carcinoma via Combined C-RAF and EGFR Targeted Therapy.
AID1425198Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID765704Cytotoxicity against human DU145 cells after 72 hrs by MTT assay2013European journal of medicinal chemistry, Sep, Volume: 67Design and synthesis of novel quinazoline nitrogen mustard derivatives as potential therapeutic agents for cancer.
AID1424975Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID748093Inhibition of EGFR L858R/T90M double mutant (unknown origin) after 1.5 hrs by FRET-based Z'Lyte assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID1442459AUC (0 to infinity) in Sprague-Dawley rat plasma at 1 mg/kg, iv measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID1353458Antiproliferative activity against human SW480 cells harboring wild type EGFR after 72 hrs by MTT assay2018European journal of medicinal chemistry, Mar-10, Volume: 1476,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
AID1470864Inhibition of human EGFR preincubated for 5 mins with substrate followed by ATP addition measured after 30 mins by HTRF method2017Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10
Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
AID1424955Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1068995Cytotoxicity against human A431 cells expressing EGFR after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 1: erlotinib analogs.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID435515Binding constant for ABL1(Q252H) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425019Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625091Binding constant for MAST1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1442476MRT (0 to t) in Sprague-Dawley rat plasma at 10 mg/kg, po measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID1442467Terminal half life in Sprague-Dawley rat plasma at 10 mg/kg, po measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID1586917Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Acrylamide Functional Group Incorporation Improves Drug-like Properties: An Example with EGFR Inhibitors.
AID435311Binding constant for HCK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1303326Antiproliferative activity against human SMMC7721 cells over expressing EGFR after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Facile and efficient synthesis and biological evaluation of 4-anilinoquinazoline derivatives as EGFR inhibitors.
AID66608In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.
AID624731Binding constant for CAMK2G kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625062Binding constant for MAP3K2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625140Binding constant for MARK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID256642Average Binding Constant for VEGFR2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID777400Toxicity in nude mouse xenografted with human A431 cells assessed as mortality at 200 mg/kg/day, po qd after 12 days2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR.
AID1460143Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Design, synthesis, and biological evaluation of novel 1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide analogs in MCF-7 and MDA-MB-468 breast cancer cell lines.
AID589580Antiproliferative activity against human HT-29 cells at 10 uM after 72 hrs by MTS assay2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.
AID1192068Inhibition of cell proliferation of human SW1990 cells at <10 nM after 72 hrs by cell counting method2015Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6
Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib.
AID435281Binding constant for full-length CSNK1A1L2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624992Binding constant for ABL1-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1443466Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID256668Average Binding Constant for ABL1(H396P); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1424919Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1168680Cytotoxicity against human A549 cells assessed as cell viability at 80 uM after 24 hrs by MTT assay (Rvb = 100%)2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Optimization of gefitinib analogues with potent anticancer activity.
AID624879Binding constant for PIK3CG kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425053Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625078Binding constant for SRPK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID679514TP_TRANSPORTER: stimulation of ATPase activity (0.1~1 u M) in BCRP-expressing Sf9 cells2004Molecular pharmacology, Jun, Volume: 65, Issue:6
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.
AID1756964Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
AID127929Blood levels in mice 6 hour post oral dose (200 mg/kg)2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.
AID624772Binding constant for AURKB kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID271155Terminal half life in cancer affected human2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID1424924Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624848Binding constant for CSNK2A1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1445469Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
AID1762239Cytotoxicity against human MCF7 cells incubated for 2 to 4 hrs by MTT assay2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines.
AID1224758Delta TM value showing the stabilisation of CDK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1582387Inhibition of EGFR L858R in human H3255 cells assessed as reduction in AKT phosphorylation at 1 uM treated 8 hrs post serum starvation measured after 16 hrs by Western blot analysis2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
AID1616564Inhibition of EGFR del19 mutant autophosphorylation at Tyr1068 residue in human HCC827 cells at 1.6 to 8 nM by Western blotting analysis2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer.
AID1163813Cytotoxicity against human NCI-H292 cells after 72 hrs by SRB assay2014Journal of natural products, Sep-26, Volume: 77, Issue:9
Polyoxypregnane steroids from the stems of Marsdenia tenacissima.
AID537734Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID1724875Antiproliferative activity against EGFR/C-RAF knockdown human H-PDAC-M-X3 cells harboring K-RAS G12D/TP53 H179Y mutant xenografted in mouse tumor model assessed as inhibition of cell proliferation by MTT assay in presence of gefitinib2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Complete Regression of Carcinoma via Combined C-RAF and EGFR Targeted Therapy.
AID708797Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTT assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID624721Binding constant for MEK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1068996Cytotoxicity against human BT474 cells expressing HER2 after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 1: erlotinib analogs.
AID1896775Inhibition of EGFR (unknown origin) L858R/T790M mutant preincubated with compound 30 mins followed ATP addition incubated for 30 mins by HTRF KinEASE TK assay2022Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23
Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.
AID624865Binding constant for MAP3K3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1378276Inhibition of EGF-induced EGFR phosphorylation at Y992-residue in human A549 cells at 25 uM preincubated for 2 hrs followed by EGF stimulation for 10 mins by Western blot analysis
AID256567Average Binding Constant for EPHA6; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435925Binding constant for PCTK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435664Binding constant for MYLK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425159Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625079Binding constant for NEK6 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624940Binding constant for FLT3(R834Q) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID695418Induction of apoptosis in human HeLa cells expressing wild type KRAS and BRAF assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Synthesis and evaluation of apoptosis induction of thienopyrimidine compounds on KRAS and BRAF mutated colorectal cancer cell lines.
AID1756983Induction of cell cycle arrest in human NCI-H1975 cells assessed as G1 phase at 2 uM incubated for 24 hrs by propidium iodide based flow cytometry analysis (Rvb = 60.76 %)2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
AID1425208Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID256616Average Binding Constant for CDK5; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624895Binding constant for MEK6 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1068998Cytotoxicity against human NCI-N87 cells expressing HER2 after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 1: erlotinib analogs.
AID1278392Inhibition of wild type recombinant human EGFR assessed as reduction in autophosphorylation of cytoplasmic domain by Z'-Lyte assay2016European journal of medicinal chemistry, Mar-03, Volume: 110Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines.
AID1873220Inhibition of ABCG2 (unknown origin) expressing human PC-6/SN2-5 cells assessed as increase in topotecan accumulation for 15 mins by flow cytometry2022European journal of medicinal chemistry, Jul-05, Volume: 237Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID1425122Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435151Binding constant for CAMK1G kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1283994Antiproliferative activity against human NCI-H358 cells assessed as viable cells after 48 hrs by CCK8 assay2016Bioorganic & medicinal chemistry letters, Mar-15, Volume: 26, Issue:6
Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
AID771345Inhibition of wild type human EGFR tyrosine kinase assessed as Ulight-CAGAGAIETDKEYYTVKD phosphorylation after 15 mins by time-resolved fluorometry2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors.
AID624923Binding constant for MAPKAPK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435183Binding constant for PLK3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1676530Inhibition of C-terminal His6-tagged HER2-A775_G776insYVMA mutant (703 to 1029 residues) (unknown origin) expressed in Sf9 insect cells using TK as substrate preincubated for 30 mins followed by substrate addition and measured after 40 mins in presence of2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.
AID761600Antiproliferative activity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant after 72 hrs by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID457035Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion.
AID1425033Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1460154Cytotoxicity against human MCF7 cells assessed as cell viability at 3 uM after 48 hrs by MTT assay relative to control2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Design, synthesis, and biological evaluation of novel 1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide analogs in MCF-7 and MDA-MB-468 breast cancer cell lines.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1712082Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID256574Average Binding Constant for STK3_m; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID761601Inhibition of EGFR L858R/T790M mutant (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET based Z'-lyte assay2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID1443992Total Cmax in human administered as single dose2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1378275Inhibition of EGF-induced EGFR phosphorylation at Y1086-residue in human A549 cells at 25 uM preincubated for 2 hrs followed by EGF stimulation for 10 mins by Western blot analysis
AID1715112Inhibition of ARG (unknown origin) at 1 uM relative to control2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID295768Ratio of IC50 for EGFR in presence of 1 mM ATP to IC50 for EGFR in presence of 1 uM ATP2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
AID1439616Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7
Synthesis and in vitro biological evaluation of novel quinazoline derivatives.
AID625043Binding constant for PIK3CA(I800L) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424973Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID748091Inhibition of wild type EGFR (unknown origin) after 1.5 hrs by FRET-based Z'Lyte assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID371183Inhibition of human EGFR2008European journal of medicinal chemistry, Jul, Volume: 43, Issue:7
Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors.
AID625080Binding constant for EIF2AK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424985Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1712090Growth inhibition of human LOX IMVI cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1585969Ratio of drug uptake in human A549 cells at 1 uM measured after 1 hr to drug uptake in human A549 cells at 1 uM incubated for 1 hr followed by compound washout and measured after 8 hrs2019European journal of medicinal chemistry, Jan-15, Volume: 162Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR.
AID624822Binding constant for CDKL3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID619792Cytotoxicity against human DLD1 cells assessed as cell viability at 10 uM after 3 days by colorimetric MTT assay2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.
AID456589Inhibition of EGF-induced EGFR phosphorylation in human A431 cells pretreated for 1 hrs followed by EGF-stimulation by immunoblot analysis2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
AID1717443Antiproliferative activity against human A-431 cells incubated for 72 hrs by MTT assay
AID1266269Inhibition of VEGFR-2 (unknown origin) assessed as ATP level by luminescence analysis2016Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2
Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents.
AID256583Average Binding Constant for CAMKK1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1439619Inhibition of wild type recombinant EGFR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA2017Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7
Synthesis and in vitro biological evaluation of novel quinazoline derivatives.
AID1768130Antifibrotic activity in C57BL mouse model of BLM-induced lung fibrosis assessed as MDA content at 60 mg/kg measured after 14 days (Rvb = 9.93 +/- 1.41 nmol/ml)2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Synthesis and biological evaluation of selenogefitinib for reducing bleomycin-induced pulmonary fibrosis.
AID271146AUC in nude mouse xenografted with human LoVo cell at 50 mg/kg, po2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID1460162Inhibition of EGFR phosphorylation in gefitinib-resistant human MDA-MB-468 cells at 10 uM after 6 hrs by Western blot method2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Design, synthesis, and biological evaluation of novel 1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide analogs in MCF-7 and MDA-MB-468 breast cancer cell lines.
AID1224773Delta TM value showing the stabilisation of ASK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1250365Inhibition of EGFR exon19 deletion mutant phosphorylation in human PC9 cells2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
AID271149Cmax in nude mouse xenografted with human LoVo cell at 50 mg/kg, po2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID1715120Inhibition of DDR1 (unknown origin) at 1 uM relative to control2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1425201Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID256636Average Binding Constant for JNK3; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1904124Inhibition of BCRP (unknown origin)2022European journal of medicinal chemistry, Apr-05, Volume: 233Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID761599Antiproliferative activity against wild type EGFR/k-Ras dependent human A549 cells after 72 hrs by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID771342Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured at 1 hr by Western blot analysis2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors.
AID435808Binding constant for full-length MEK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625045Binding constant for PIK3CA(Q546K) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1264284Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by MTT assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
AID310063Inhibition of EGFR2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
AID435534Binding constant for NEK5 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424964Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1224785Delta TM value showing the stabilisation of PDK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID449028Inhibition of EGFR-mediated poly(L-glutamic acid L-tyrosine) phosphorylation2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
Design and synthesis of new stabilized combi-triazenes for targeting solid tumors expressing the epidermal growth factor receptor (EGFR) or its closest homologue HER2.
AID1425210Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID436009Binding constant for full-length CAMK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1600796Cytotoxicity against human MCF10A cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
New amide linked dimeric 1,2,3-triazoles bearing aryloxy scaffolds as a potent antiproliferative agents and EGFR tyrosine kinase phosphorylation inhibitors.
AID1378273Inhibition of recombinant human C-terminal His-tagged EGFR (1 to 645 residues) expressed in HEK293 cells by ELISA
AID1432782Induction of ROS generation in human NCI-H1975 cells harboring EGFR L858R/T790M double mutant at 15 to 60 uM after 4 hrs by DCFH-DA staining based flow cytometry2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Novel conjugates of endoperoxide and 4-anilinoquinazoline as potential anticancer agents.
AID1896774Inhibition of EGFR (unknown origin) L858R mutant preincubated with compound 30 mins followed ATP addition incubated for 30 mins by HTRF KinEASE TK assay2022Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23
Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.
AID436055Binding constant for full-length YANK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID761598Antiproliferative activity against human HCC827 cells expressing EGFR E746_A750 deletion mutant after 72 hrs by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID435690Binding constant for RPS6KA1(Kin.Dom.1 - N-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425177Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1222793Dissociation constant, pKa of the compound2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID1473930Ratio of drug concentration at steady state in human at 250 to 500 mg, po QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID449029Growth inhibition of mouse NIH/3T3 cells expressing erB2 gene2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
Design and synthesis of new stabilized combi-triazenes for targeting solid tumors expressing the epidermal growth factor receptor (EGFR) or its closest homologue HER2.
AID1425179Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625030Binding constant for LOK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1407100Inhibition of recombinant human EGFR L858R mutant expressed in baculovirus infected insect cells preincubated for 5 mins followed by ATP addition and measured after 30 mins by HTRF assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity.
AID1712172Growth inhibition of human Panel prostate (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1425134Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625096Binding constant for STK36 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424989Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425167Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624719Binding constant for GRK7 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435149Binding constant for AMPK-alpha2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435167Binding constant for KIT(V559D) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256600Average Binding Constant for EPHA8; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1432771Antiproliferative activity against EGFR over-expressing human A431 cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Novel conjugates of endoperoxide and 4-anilinoquinazoline as potential anticancer agents.
AID624769Binding constant for AURKC kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1399721Antitumor activity against human NCI-H460 cells xenografted in nude mouse assessed as inhibition of tumor volume at 100 mg/kg, po qd for 14 consecutive days relative to control2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.
AID1425130Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID271134Free drug level in mouse plasma at 50 mg/kg, po at 4 hrs2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID91107Inhibition of human epidermal growth factor receptor-2 autophosphorylation2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents.
AID745324Cytotoxicity against human HCT116 cells after 72 hrs by WST-8 assay2013European journal of medicinal chemistry, May, Volume: 63Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
AID1425006Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424898Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1168678Cytotoxicity against human A549 cells assessed as cell viability at 40 uM after 24 hrs by MTT assay (Rvb = 100%)2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Optimization of gefitinib analogues with potent anticancer activity.
AID256643Average Binding Constant for CAMK1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435295Binding constant for MAP4K3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1824043Antiproliferative activity against human NCI-H1975 cells expressing EGFR T790M/L858R mutant assessed as inhibition in cell viability after 72 hrs by CCK-8 assay
AID1424945Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425155Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625000Binding constant for EGFR(L747-E749del, A750P) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1378293Inhibition of EGFR L858R/T790M double mutant in human NCI-H1975 cells assessed as reduction in EGF-induced STAT3 phosphorylation at 25 uM preincubated for 2 hrs followed by EGF stimulation for 10 mins by Western blot analysis
AID435438Binding constant for full-length p38-gamma2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1315991Stability in human liver microsomes assessed as length of time required to give 50% loss of parent compound at 5 uM by mass spectrometric analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.
AID624964Binding constant for DYRK1B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624965Binding constant for LZK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624768Binding constant for SRPK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID256621Average Binding Constant for CAMK2A; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624941Binding constant for CDKL1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1712073Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1768072Antiproliferative activity against human WI-26 AV4 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Investigation of 3-sulfamoyl coumarins against cancer-related IX and XII isoforms of human carbonic anhydrase as well as cancer cells leads to the discovery of 2-oxo-2H-benzo[h]chromene-3-sulfonamide - A new caspase-activating proapoptotic agent.
AID624882Binding constant for PKAC-beta kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425153Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1499609Cytotoxicity against human HepG2 cells at 10 uM after 48 hrs by LDH release assay (Rvb = 100%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
AID1441913Inhibition of wild-type EGFR in human A431 cells assessed as reduction in cell viability after 96 hrs by CellTiterGlo assay2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.
AID1595409Cytotoxicity against human HGC27 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Jun-15, Volume: 1722,4-Disubstituted quinazolines targeting breast cancer cells via EGFR-PI3K.
AID1312559Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2016European journal of medicinal chemistry, Aug-08, Volume: 118Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
AID624858Binding constant for JAK1(JH2domain-pseudokinase) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624863Binding constant for MARK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1399703Toxicity in nude mouse xenografted with human NCI-H460 cells assessed as body weight at 25 mg/kg, po qd for 14 consecutive days (Rvb = 20.6 +/- 1.5 g)2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.
AID1424952Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425106Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID492109Inhibition of GST-tagged EGFR expressed in Escherichia coli2010Journal of medicinal chemistry, Jul-08, Volume: 53, Issue:13
Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.
AID488727Induction of apoptosis in human MIAPaCa2 cells at 5 to 10 uM after 24 hrs by propidium iodide staining-based FACS analysis2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.
AID1353462Inhibition of EGFR T790M mutant (unknown origin) preincubated for 10 mins followed by TK substrate-botion addition measured after 1 hr by spectrophotometric method2018European journal of medicinal chemistry, Mar-10, Volume: 1476,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
AID1306582Antiproliferative activity against gefitinib-sensitive human PC9 cells assessed as cell viability after 72 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.
AID256588Average Binding Constant for PCTK1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435560Binding constant for SNF1LK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID507424Inhibition of recombinant PDGFR by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID435688Binding constant for full-length PCTK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625048Binding constant for PRKCD kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1443472Selectivity ratio of GI50 for CHOK1 cells to GI50 for human MDA-MB-231 cells2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID1167182Antitumor activity against human A431 cells xenografted in SCID mouse assessed as tumor growth inhibition at 100 mg/kg/day, po qd for 7 days relative to control2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.
AID1403027Antitumor activity against mouse EAC cells implanted in albino mouse assessed as tumor growth inhibition at 10 mg/kg, po once daily for 8 consecutive days relative to control2018European journal of medicinal chemistry, Jan-20, Volume: 144Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
AID1442458AUC (0 to t) in Sprague-Dawley rat plasma at 1 mg/kg, iv measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID624881Binding constant for PKAC-alpha kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625025Binding constant for MAK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1896771Inhibition of EGFR (unknown origin) d747-752/P7535 mutant assessed as percent of control activity at 1 uM by radiometric protein kinase-reaction biology assay2022Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23
Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.
AID1585934Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant assessed as cell viability at 1 uM after 72 hrs by MTT assay (Rvb = 98.3%)2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
AID457039Inhibition of ERBB2 autophosphorylation in human NCI-H1975 cells up to 10 uM by Western blot2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion.
AID1585936Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant assessed as cell viability at 10 uM after 48 hrs by MTT assay (Rvb = 98.3%)2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
AID1403038Induction of apoptosis in human A549 cells assessed as increase in late apoptotic cells after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry relative to control2018European journal of medicinal chemistry, Jan-20, Volume: 144Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
AID1460598Inhibition of NorA in Staphylococcus aureus SA1199B harboring GrlA A116E mutant assessed as inhibition of ethidium bromide efflux at 50 uM measured after 5 mins by fluorometric method relative to control2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID436022Binding constant for full-length MEK32008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1585930Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant assessed as cell viability at 0.1 uM after 48 hrs by MTT assay (Rvb = 98.3%)2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
AID488735Antitumor activity against human MIAPaCa2 cells xenografted in NCr nu/nu mouse assessed as mild inhibition of tumor growth pretreated with 2.5 uM before implantation measured after 40 days of implantation2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.
AID1403040Induction of apoptosis in human A549 cells assessed as early apoptotic cells after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.26%)2018European journal of medicinal chemistry, Jan-20, Volume: 144Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
AID256660Average Binding Constant for KIT; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID748087Cytotoxicity against human BEAS2B cells harboring wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID624819Binding constant for ACVR1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435779Binding constant for ALK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1738679Antiproliferative activity against human PC9 cells harboring EGFRdel19 mutant assessed as reduction in cell viability measured after 72 hrs by MTT assay2020European journal of medicinal chemistry, Aug-01, Volume: 199Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
AID1464637Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for human A549 cells2017Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20
Synthesis and evaluation of the NSCLC anti-cancer activity and physical properties of 4-aryl-N-phenylpyrimidin-2-amines.
AID1717440Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay
AID436051Binding constant for RPS6KA5(Kin.Dom.2 - N-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435940Binding constant for full-length TSSK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256612Average Binding Constant for GAK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624896Binding constant for PRKR kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID256577Average Binding Constant for CLK4; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1140575Antiproliferative activity against human macrophages assessed as alteration in cell morphology after 24 hrs by CCK8 assay2014Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10
Synthesis and biological evaluation of compounds which contain pyrazole, thiazole and naphthalene ring as antitumor agents.
AID436034Binding constant for PRKCH kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID770083Inhibition of EGFR L858R/T970M double mutant phosphorylation in human NCI-H1975 cells after 2 hrs by fluorescence assay2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
AID435911Binding constant for MEK6 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224751Delta TM value showing the stabilisation of CAMK2A produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID436046Binding constant for PRKD2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435202Binding constant for TRKC kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1442470AUC (0 to t) in Sprague-Dawley rat plasma at 10 mg/kg, po measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID271133Free drug level in mouse plasma at 50 mg/kg, po at 2 hrs2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID1717442Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay
AID1140572Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 24 to 48 hrs by CCK8 assay2014Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10
Synthesis and biological evaluation of compounds which contain pyrazole, thiazole and naphthalene ring as antitumor agents.
AID625098Binding constant for IRAK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1667575Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition measured after 40 mins in presence of ATP by caliper mobility shift assay2020Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9
Design and synthesis of a novel class EGFR/HER2 dual inhibitors containing tricyclic oxazine fused quinazolines scaffold.
AID1877688Antiproliferative activity against human H1650 cells by CCK8 assay2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID1702620Antiproliferative activity against human U87MG Human EGFR vIII cells overexpressing EGFRvIII mutant assessed as inhibition of cell growth by MTT assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Design, synthesis and biological evaluation of 2-amino-4-(1,2,4-triazol)pyridine derivatives as potent EGFR inhibitors to overcome TKI-resistance.
AID201868Inhibition of SW-620 cell proliferation2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents.
AID748088Cytotoxicity against human A431 cells overexpressing wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID1303327Inhibition of EGFR autophosphorylation at Tyr1068 site in human NCI-H1975 cells at 1 uM by western blotting analysis2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Facile and efficient synthesis and biological evaluation of 4-anilinoquinazoline derivatives as EGFR inhibitors.
AID1389964Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID624779Binding constant for BTK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1632290Inhibition of EGFR phosphorylation in EGF-stimulated human KB cells preincubated for 1 hr followed by EGF stimulation measured after 6 mins by ELISA2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 2: Gefitinib analogs.
AID435516Binding constant for ADCK3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID271131Volume of distribution in Wistar rat at 2 mg/kg, iv and 10 mg/kg, po2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID435276Binding constant for BMPR1A kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID745323Cytotoxicity against human K562 cells after 72 hrs by WST-8 assay2013European journal of medicinal chemistry, May, Volume: 63Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
AID1241288Inhibition of EGFR L858R/T790M mutant (unknown origin) expressed in Sf9 cells pre-incubated for 60 mins before substrate and ATP addition by homogeneous time-resolved FRET assay2015Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.
AID1425154Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624761Binding constant for CDC2L5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624955Binding constant for EPHB3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID488717Inhibition of MET at 10 uM2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.
AID1425063Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625111Binding constant for RIOK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1586914Thermodynamic solubility of the compound in 1-octanol solution measured after 24 hrs by UV-HPLC analysis2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Acrylamide Functional Group Incorporation Improves Drug-like Properties: An Example with EGFR Inhibitors.
AID435402Binding constant for EGFR(G719S) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1702615Inhibition of wild type N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus infected Sf21 cells using biotin-labeled TK substrate preincubated for 30 mins followed by substrate and ATP addition at Km concent2020European journal of medicinal chemistry, Feb-01, Volume: 187Design, synthesis and biological evaluation of 2-amino-4-(1,2,4-triazol)pyridine derivatives as potent EGFR inhibitors to overcome TKI-resistance.
AID625022Binding constant for MUSK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1876084Cytotoxicity against human HEp-2 cells2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1896799Antiproliferative activity against mouse BaF3 cells expressing De119/C797S assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay2022Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23
Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.
AID435169Binding constant for full-length MEK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID528338Inhibition of EGFR L858R/T790M double mutant2010Journal of medicinal chemistry, Oct-28, Volume: 53, Issue:20
Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency.
AID1443471Selectivity ratio of GI50 for CHOK1 cells to GI50 for human A549 cells2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID1460161Inhibition of EGFR in gefitinib-resistant human MDA-MB-468 cells assessed as reduction in Akt phosphorylation at 10 uM after 6 hrs by Western blot method2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Design, synthesis, and biological evaluation of novel 1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide analogs in MCF-7 and MDA-MB-468 breast cancer cell lines.
AID435784Binding constant for CAMK2G kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625020Binding constant for ITK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425058Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1129569Inhibition of EGFR L858R/T790M mutant (unknown origin) after 1.5 hr by FRET-based Z-lyte assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID1163073Antiproliferative activity against human ER-negative MCF7 cells after 72 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID1425165Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1532106Therapeutic index, ratio of GI50 for cytotoxicity against MDCK2 cells harboring GFP-fused human ABCG2 to IC50 for inhibition of GFP-fused human ABCG2 expressed in MDCK2 cells2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.
AID1069183Toxicity in nude mouse xenografted with human A549 cells assessed as body weight change at 20 mg/kg, ip qd for 60 days measured up to 60 days2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Synthesis and biological evaluation of novel tetrahydro-β-carboline derivatives as antitumor growth and metastasis agents through inhibiting the transforming growth factor-β signaling pathway.
AID624976Binding constant for PRKX kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1876269Inhibition of EGFR (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID1425093Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425161Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507077Inhibition of DNA-PK by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID435277Binding constant for full-length CDK32008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1595623Cytotoxicity against human WS1 cells measured after 72 hrs by alamar blue assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID1171418Antiproliferative activity against human NCI-H1975 cells after 48 hrs by Celltiter-Glo assay2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.
AID1562610Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay
AID1424917Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1712084Growth inhibition of human HCT-15 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID624868Binding constant for MST1R kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1712078Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1712173Growth inhibition of human Panel breast (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID256674Average Binding Constant for PKMYT1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1463974Inhibition of recombinant alpha-glucosidase (unknown origin) using PNP-G as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by spectrophotometric analysis2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Quinazoline-1-deoxynojirimycin hybrids as high active dual inhibitors of EGFR and α-glucosidase.
AID1525108Cytotoxicity against human LO2 cells assessed as reduction in cell viability by MTT assay2019Journal of natural products, 05-24, Volume: 82, Issue:5
Strepantibins A-C: Hexokinase II Inhibitors from a Mud Dauber Wasp Associated Streptomyces sp.
AID624745Binding constant for PKN1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID708799Cytotoxicity against human FADU cells incubated for 72 hrs by MTT assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.
AID1265422Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 10 uM by propidium iodide staining based flow cytometric analysis (Rvb = 23.41 +/- 2.19%)2016European journal of medicinal chemistry, Jan-01, Volume: 107Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents.
AID435275Binding constant for BIKE kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425051Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID256575Average Binding Constant for NEK6; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1499558Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
AID1425100Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID619789Cytotoxicity against human MV4-11 cells assessed as cell viability at 1 uM after 3 days by colorimetric MTT assay2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.
AID256658Average Binding Constant for p38-beta; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID360729Inhibition of human JAK2 V617F mutant expressed in COS7 cells2007The Journal of biological chemistry, Feb-09, Volume: 282, Issue:6
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.
AID1399713Antitumor activity against human NCI-H460 cells xenografted in nude mouse assessed as inhibition of tumor weight at 100 mg/kg, po qd for 14 consecutive days relative to control2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.
AID1616558Cytotoxicity in human NCI-H1975 cells assessed as reduction in cell viability incubated for 96 hrs by MTS method2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer.
AID624840Binding constant for AXL kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1224796Delta TM value showing the stabilisation of LOK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1425173Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425186Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1250815Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Design, synthesis, and biofunctional evaluation of novel pentacyclic triterpenes bearing O-[4-(1-piperazinyl)-4-oxo-butyryl moiety as antiproliferative agents.
AID1381738Cytotoxicity against human A549 cells after 72 hrs by SRB assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
AID1425108Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435414Binding constant for MLK3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224807Delta TM value showing the stabilisation of YSK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1471177Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Design of antitumor agents containing carbohydrate based on GLUT1, and evaluation of antiproliferative activity.
AID435153Binding constant for full-length DAPK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435320Binding constant for PRKCE kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1306583Antiproliferative activity against gefitinib-resistant human PC9/GR4 cells expressing Del19/T790M double mutant assessed as cell viability after 72 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.
AID1824046Antiproliferative activity against human NCI-H1299 cells expressing wild type EGFR assessed as inhibition in cell viability after 72 hrs by CCK8 assay
AID624792Binding constant for KIT(V559D,T670I) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1585937Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant assessed as cell viability at 10 uM after 72 hrs by MTT assay (Rvb = 98.3%)2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
AID1562643Inhibition of human recombinant His-tagged wild type EGFR expressed in HEK293 cells at 50 nM using poly[Glu:Tyr] (4:1) as substrate incubated for 60 mins by ELISA relative to control
AID625014Binding constant for PRKCE kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1442464MRT (0 to t) in Sprague-Dawley rat plasma at 1 mg/kg, iv measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID435406Binding constant for FLT3(D835H) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624931Binding constant for CLK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425061Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1175520Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
AID1224762Delta TM value showing the stabilisation of CLK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1312561Antiproliferative activity against human BT474 cells after 72 hrs by MTT assay2016European journal of medicinal chemistry, Aug-08, Volume: 118Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
AID1562621Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 20 uM incubated for 48 hrs by annexin V -FITC and PI staining based flow cytometric analysis (Rvb = 2.24%)
AID260895Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
AID1532908Antitumor activity against human A549 cells xenografted in BALB/c nude mouse assessed as tumor growth inhibition at 30 mg/kg, ig administered every 2 days for 19 days2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold.
AID625052Binding constant for PRKG1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID777417Cytotoxicity against human SW620 cells after 48 hrs by CellTiter-Glo assay2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR.
AID624799Binding constant for TIE2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1378272Antiproliferative activity against human SW480 cells harboring wild type EGFR after 72 hrs by MTT assay
AID1425080Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425146Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID394661Binding affinity to EGFR with L858R/T790M mutant2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Kinase domain mutations in cancer: implications for small molecule drug design strategies.
AID1443479Inhibition of SIK2 (unknown origin) at 0.5 uM2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID1499606Inhibition of recombinant human His-tagged EGFR (1 to 645 residues) expressed in HEK293 cells using Tyr66-biotinylated PTP1B peptide as substrate preincubated for 5 mins followed by substrate addition measured after 1 hr by ELISA2017European journal of medicinal chemistry, Sep-29, Volume: 138Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
AID625056Binding constant for TESK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1250383AUC (0 to 7 hrs) in Han Wistar rat CSF at 20 mg/kg, po measured after 0.5 to 24 hrs by LC-MS/MS analysis2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
AID1425021Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424897Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1442480Toxicity in BALB/c nude mouse xenografted with human MDA-MB-231 cells assessed as liver damage at 40 mg/kg, po qd administered for 32 days by H&E staining based light microscopy2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID1532104Growth inhibition of MDCK2 cells harboring GFP-fused human ABCG2 after 72 hrs by MTT assay2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.
AID435939Binding constant for TIE2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625097Binding constant for TNNI3K kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1704490Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Dec-01, Volume: 207Antiproliferative effect of mitochondria-targeting allobetulin 1,2,3-triazolium salt derivatives and their mechanism of inducing apoptosis of cancer cells.
AID1595626Antiproliferative activity against human CH22 cells measured after 72 hrs by alamar blue assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID1424971Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1712079Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1756963Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
AID1768071Antiproliferative activity against human WI-26 AV4 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Investigation of 3-sulfamoyl coumarins against cancer-related IX and XII isoforms of human carbonic anhydrase as well as cancer cells leads to the discovery of 2-oxo-2H-benzo[h]chromene-3-sulfonamide - A new caspase-activating proapoptotic agent.
AID624884Binding constant for PRKD1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID492110Inhibition of EGFR L858R/T790M double mutant2010Journal of medicinal chemistry, Jul-08, Volume: 53, Issue:13
Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.
AID1424940Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID271129Bioavailability in Wistar rat at 2 mg/kg, iv and 10 mg/kg, po2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID256641Average Binding Constant for ABL2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1068981Inhibition of HER2 (unknown origin) after 10 mins2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 1: erlotinib analogs.
AID435184Binding constant for PTK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435562Binding constant for STK36 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624713Binding constant for ERK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224769Delta TM value showing the stabilisation of GSK3B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1407104Inhibition of recombinant human FGFR preincubated for 5 mins followed by ATP addition and measured after 30 mind by HTRF assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity.
AID1425046Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624866Binding constant for MLK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID708990Antitumor activity against human HCC827 cells xenografted in BALB/c mouse assessed as reduction tumor volume at 100 mg/kg, po qd2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.
AID1425050Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1224784Delta TM value showing the stabilisation of PCTK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1283995Antiproliferative activity against human A549 cells assessed as viable cells after 48 hrs by CCK8 assay2016Bioorganic & medicinal chemistry letters, Mar-15, Volume: 26, Issue:6
Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
AID624846Binding constant for CSNK1A1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1068997Cytotoxicity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 1: erlotinib analogs.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1171419Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.
AID256580Average Binding Constant for CAMKK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID625042Binding constant for PIK3CA(H1047Y) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425000Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1715793Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo luminescent cell viability assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1589080Anti-tubercular activity against Mycobacterium tuberculosis H37Rv expressing LuxABCDE assessed as relative luminescence by measuring ratio of RLU (test compound)/RLU(no compound) at 20 uM by luminescence based assay2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.
AID765699Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay2013European journal of medicinal chemistry, Sep, Volume: 67Design and synthesis of novel quinazoline nitrogen mustard derivatives as potential therapeutic agents for cancer.
AID1425007Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1470860Antiproliferative activity against human A549 cells harboring wild type EGFR after 48 hrs by SRB assay2017Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10
Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
AID1460141Cytotoxicity against human MCF7 cells assessed as cell viability at 30 uM after 48 hrs by MTT assay relative to control2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Design, synthesis, and biological evaluation of novel 1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide analogs in MCF-7 and MDA-MB-468 breast cancer cell lines.
AID1676528Inhibition of HER2-A775_G776insYVMA mutant (unknown origin) expressed in mouse BaF3 cells assessed as reduction in HER2 induced cell viability after 96 hrs by CellTiter-Glo assay2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.
AID1442482Toxicity in BALB/c nude mouse xenografted with human MDA-MB-231 cells assessed as lung damage at 40 mg/kg, po qd administered for 32 days by H&E staining based light microscopy2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID1171417Antiproliferative activity against human A431 cells after 48 hrs by Celltiter-Glo assay2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.
AID435288Binding constant for EPHB2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1499610Cytotoxicity against human HepG2 cells at 20 uM after 48 hrs by LDH release assay (Rvb = 100%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
AID624998Binding constant for EGFR(G719C) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425084Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1499597Antiproliferative activity against human CCC-HPF1 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
AID435801Binding constant for full-length GSK3A2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624732Binding constant for PYK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1460153Cytotoxicity against human MCF7 cells assessed as cell viability at 1 uM after 48 hrs by MTT assay relative to control2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Design, synthesis, and biological evaluation of novel 1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide analogs in MCF-7 and MDA-MB-468 breast cancer cell lines.
AID1817371Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP.
AID1466879Growth inhibition of human Hs578T cells at 4 uM after 48 hrs by sulforhodamine assay relative to control2017Bioorganic & medicinal chemistry letters, 06-15, Volume: 27, Issue:12
Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors.
AID1529996Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
Dihydropyrazothiazole derivatives as potential MMP-2/MMP-8 inhibitors for cancer therapy.
AID435559Binding constant for SNARK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1443498Inhibition of NF-kappaB-p65 binding to NF-kappaB response element oligonucleotide in nuclear extracts of 12 hrs compound pre-treated human MDA-MB-231 cells at 2.5 to 15 uM by ELISA2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID435828Binding constant for full-length PIP5K2B2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625019Binding constant for AKT3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID256587Average Binding Constant for ACK1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1128933Antiproliferative activity against human SK-MEL-28 cells harboring BRAF V600E mutant after 68 hrs by MTS assay2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib.
AID1425003Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425052Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624871Binding constant for PAK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID477295Octanol-water partition coefficient, log P of the compound2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
AID1690729Growth inhibition of human NCI-H1975 cells incubated for 5 days by SRB assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Comparative analysis of the dual EGFR-DNA targeting and growth inhibitory properties of 6-mono-alkylamino- and 6,6-dialkylaminoquinazoline-based type II combi-molecules.
AID624961Binding constant for TGFBR1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435531Binding constant for MKNK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID507080Inhibition of recombinant HCK by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID624847Binding constant for CSNK1E kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435405Binding constant for ERK8 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624712Binding constant for DYRK1A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424976Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID745321Cytotoxicity against human U937 cells after 72 hrs by WST-8 assay2013European journal of medicinal chemistry, May, Volume: 63Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
AID256653Average Binding Constant for FGFR1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID295765Inhibition of human EGFR in presence of 1 mM ATP2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
AID1632289Cytotoxicity against human Calu cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 2: Gefitinib analogs.
AID435171Binding constant for NEK9 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625095Binding constant for SIK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435293Binding constant for JNK3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256572Average Binding Constant for STK36; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624730Binding constant for CAMK2A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424950Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1129574Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID1424904Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID256669Average Binding Constant for ABL1(M351T); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1586918Cytotoxicity against human FHS cells assessed as reduction in cell viability after 72 hrs by MTT assay2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Acrylamide Functional Group Incorporation Improves Drug-like Properties: An Example with EGFR Inhibitors.
AID624901Binding constant for RSK1(Kin.Dom.2-C-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625026Binding constant for MAP3K1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624766Binding constant for p38-gamma kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624807Binding constant for TNK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424196Antiproliferative activity against human A431 cells incubated for 72 hrs by MTT assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
AID1896804Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion GV mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay2022Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23
Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.
AID1730892Inhibition of EGFR in human NCI-H1975 cells assessed as reduction in EGFR phosphorylation at Tyr-1173 residues at 2.5 uM after 1 to 12 hrs by Western blot analysis2021European journal of medicinal chemistry, Mar-05, Volume: 213Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
AID435912Binding constant for MRCKB kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1445476Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as growth inhibition after 96 hrs by CellTiter-Glo assay2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
AID1896770Inhibition of EGFR (unknown origin) Del19 mutant assessed as percent of control activity at 1 uM by radiometric protein kinase-reaction biology assay2022Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23
Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.
AID625099Binding constant for TAOK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1632287Cytotoxicity against human A431 cells overexpressing EGFR assessed as growth inhibition after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 2: Gefitinib analogs.
AID1768131Antifibrotic activity in C57BL mouse model of BLM-induced lung fibrosis assessed as IL-4 level in blood at 60 mg/kg measured after 14 days by flow cytometry (Rvb = 2.72 +/- 0.14 pg/ml)2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Synthesis and biological evaluation of selenogefitinib for reducing bleomycin-induced pulmonary fibrosis.
AID625038Binding constant for PIK3CA(E542K) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1264283Antiproliferative activity against human A549 cells harboring wild type EGFR/k-Ras mutation after 72 hrs by MTT assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
AID1425059Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1442475AUMC (0 to infinity) in Sprague-Dawley rat plasma at 10 mg/kg, po measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID1163075Safety index, ratio of IC50 for human MCF10A cells to EC50 for human ER-negative MCF7 cells2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID1724870Antiproliferative activity against EGFR/C-RAF knockdown human PDAC003T cells harboring K-RAS G12D/TP53 Q136P mutant xenografted in mouse tumor model assessed as inhibition of cell proliferation by MTT assay in presence of gefitinib2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Complete Regression of Carcinoma via Combined C-RAF and EGFR Targeted Therapy.
AID435194Binding constant for RPS6KA6(Kin.Dom.2 - N-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256613Average Binding Constant for Aurora2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435164Binding constant for IGF1R kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424997Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID256645Average Binding Constant for JAK2 (Kin.Dom. 2); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435326Binding constant for TYRO3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624707Binding constant for DCAMKL3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1756966Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
AID1424199Antiproliferative activity against NHBE cells incubated for 72 hrs by MTT assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
AID1240079Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
The discovery of oxazolones-grafted spirooxindoles via three-component diversity oriented synthesis and their preliminary biological evaluation.
AID770794Inhibition of wild type EGFR (unknown origin) after 24 hrs by fluorescence assay2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors.
AID1562645Inhibition of EGF-induced EGFR phosphorylation at Y1068 in human A549 cells at 10 uM preincubated for 2 hrs followed by EGF treatment and measured after 10 mins by Western blot analysis
AID1470945Antiproliferative activity against human HCC827 cells harboring EGFR del E746 to A750 mutant assessed as decrease in cell viability after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10
C-2 (E)-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFR
AID1473929Drug concentration at steady state in human at 250 to 500 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1278395Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as reduction in cell viability after 72 hrs by MTT assay2016European journal of medicinal chemistry, Mar-03, Volume: 110Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines.
AID1330926Inhibition of HDAC1 (unknown origin) using acetylated peptide substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence analysis2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
AID624934Binding constant for FLT3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1265456Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 10 uM by propidium iodide staining based flow cytometric analysis (Rvb = 12.77 +/- 1.55%)2016European journal of medicinal chemistry, Jan-01, Volume: 107Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents.
AID436045Binding constant for PRKD1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1532114Non-competitive inhibition of GFP-fused human ABCG2 expressed in MDCK2 cells up to 3160 nM using varying levels of Hoechst 33342 as substrate preincubated for 30 mins followed by Hoechst 33342 addition by Lineweaver-Burk plot analysis2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.
AID1425189Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625132Binding constant for FGFR1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1470943Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant assessed as decrease in cell viability after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10
C-2 (E)-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFR
AID1589078Anti-tubercular activity against Mycobacterium tuberculosis H37Rv expressing LuxABCDE assessed as relative luminescence by measuring ratio of RLU (test compound)/RLU(no compound) at 5 uM by luminescence based assay2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.
AID1460599Inhibition of NorA in Staphylococcus aureus SA1199B harboring GrlA A116E mutant assessed as inhibition of ethidium bromide efflux after 5 mins by fluorometric method2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID1589891Growth inhibition of human NCI-H460 cells incubated for 48 hrs by SRB assay2019Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12
Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors.
AID1442462AUMC (0 to t) in Sprague-Dawley rat plasma at 1 mg/kg, iv measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID256619Average Binding Constant for RPS6KA3 (Kin.Dom. 1); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624928Binding constant for CDKL2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425133Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1224792Delta TM value showing the stabilisation of RIOK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435393Binding constant for CAMK1D kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224789Delta TM value showing the stabilisation of PLK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1250381AUC (0 to 7 hrs) in Han Wistar rat brain at 20 mg/kg, po measured after 0.5 to 24 hrs by LC-MS/MS analysis2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
AID745318Inhibition of human recombinant SRC at 10 uM relative to control2013European journal of medicinal chemistry, May, Volume: 63Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
AID624962Binding constant for ASK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1244850Inhibition of epidermal growth factor receptor kinase (unknown origin) using [33P]-ATP after 20 to 30 mins by radiometric assay2015European journal of medicinal chemistry, Sep-18, Volume: 102Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.
AID435518Binding constant for AURKA kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1880625Antiproliferative activity against human OVCAR-8 cells expressing wild type EGFR assessed as cell growth inhibition at 1 uM2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras.
AID624716Binding constant for CSNK1D kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224787Delta TM value showing the stabilisation of PIM2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID625021Binding constant for LIMK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425022Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1442437Toxicity in BALB/c nude mouse xenografted with human MDA-MB-231 cells assessed as reduction in body weight at 40 mg/kg, po administered for 32 days2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID625084Binding constant for HUNK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424914Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1673304Binding affinity to T7-tagged GAK (unknown origin) expressed in Escherichia coli BL21 incubated for 1 hr2019Bioorganic & medicinal chemistry letters, 07-15, Volume: 29, Issue:14
Utilizing comprehensive and mini-kinome panels to optimize the selectivity of quinoline inhibitors for cyclin G associated kinase (GAK).
AID507421Inhibition of recombinant CK1 by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID625135Binding constant for ADCK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425202Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID69892Inhibitory activity against epidermal growth factor receptor2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Synthesis and SAR of potent EGFR/erbB2 dual inhibitors.
AID436019Binding constant for FRK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1499562Antiproliferative activity against human SH-SY5Y cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
AID1163072Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID770050Antitumor activity against human PC9 cells harboring EGFR exon 19 deletion activating mutant xenografted in SCID mouse assessed as tumor growth inhibition at 6.25 mg/kg/day, po after 7 days relative to vehicle-treated control2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
AID1499560Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
AID1442483Toxicity in BALB/c nude mouse xenografted with human MDA-MB-231 cells assessed as kidney damage at 40 mg/kg, po qd administered for 32 days by H&E staining based light microscopy2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID625069Binding constant for TLK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1585961Cysteine reactivity in pH 10 CAPS buffer assessed as peak area for cysteine-compound adduct formation at 10 uM after 24 hrs in presence of 100 molar excess cysteine by LC-MS analysis relative to 2-chloro-N-(4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquina2019European journal of medicinal chemistry, Jan-15, Volume: 162Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR.
AID512581Selectivity ratio of Ki for EGFR to Ki for ErbB22005Chemistry & biology, Jun, Volume: 12, Issue:6
Features of selective kinase inhibitors.
AID1425140Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1712168Growth inhibition of human Panel CNS (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1424934Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID394729Cytotoxicity against human K562 cells after 96 hrs by MTT assay2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
2,3-Disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazolines: a novel class of antitumor agents.
AID1224782Delta TM value showing the stabilisation of PAK5 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID662616Inhibition of EGFR L858R/T790M mutant Y1068 autophosphorylation in human NCI-H1975 cells up to 125 nM after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1586911Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate measured after 20 mins in presence of [gamma33P]ATP by filter-binding assay2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Acrylamide Functional Group Incorporation Improves Drug-like Properties: An Example with EGFR Inhibitors.
AID1399725Toxicity in nude mouse xenografted with human NCI-H460 cells assessed as death at 25 to 100 mg/kg, po qd for 14 consecutive days2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.
AID435663Binding constant for full-length MST42008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435777Binding constant for ABL2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1760623Toxicity in BALB/c nude mouse xenografted with human NCI-H1975 cells assessed as body weight loss at 60 mg/kg, ig administered once daily for 3 weeks2021European journal of medicinal chemistry, Feb-05, Volume: 211Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
AID256649Average Binding Constant for CSK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1667576Inhibition of HER2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition measured after 40 mins in presence of ATP by caliper mobility shift assay2020Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9
Design and synthesis of a novel class EGFR/HER2 dual inhibitors containing tricyclic oxazine fused quinazolines scaffold.
AID1595619Binding affinity to wild-type human partial length GAK (G13 to Y338 residues) expressed in bacterial expression system by Kinomescan method2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID1321930Antiproliferative activity against NHBE cells after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of azole-diphenylpyrimidine derivatives (AzDPPYs) as potent T790M mutant form of epidermal growth factor receptor inhibitors.
AID624925Binding constant for RIPK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1265432Cell cycle arrest in human A549 cells assessed as accumulation at G0/G1 phase at 10 uM by propidium iodide staining based flow cytometric analysis (Rvb = 63.82 +/- 2.66%)2016European journal of medicinal chemistry, Jan-01, Volume: 107Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents.
AID1600798Inhibition of EGFR in human MCF7 cells assessed as reduction in EGFR phosphorylation at 10 uM incubated for 48 hrs by Western blot analysis2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
New amide linked dimeric 1,2,3-triazoles bearing aryloxy scaffolds as a potent antiproliferative agents and EGFR tyrosine kinase phosphorylation inhibitors.
AID619785Cytotoxicity against human A549 cells assessed as cell viability at 1 uM after 3 days by colorimetric MTT assay2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.
AID661590Reversible inhibition of EGFR autophosphorylation in human A549 cells at 1 uM for 1 hr measured 8 hrs post-washout by Western blot analysis2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides.
AID1407101Inhibition of N-terminal GST-tagged recombinant human EGFR T790M mutant expressed in baculovirus infected Sf21 insect cells preincubated for 5 mins followed by ATP addition and measured after 30 mins by HTRF assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity.
AID435561Binding constant for SRMS kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256581Average Binding Constant for CAMK1G; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1224806Delta TM value showing the stabilisation of VRK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1637534Antiproliferative activity against human HeLa cells after 48 hrs in presence of 10% FBS by MTT method2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Discovery of N-(benzyloxy)-1,3-diphenyl-1H-pyrazole-4-carboxamide derivatives as potential antiproliferative agents by inhibiting MEK.
AID624854Binding constant for FLT4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624913Binding constant for TYK2(JH2domain-pseudokinase) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID537735Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID624817Binding constant for MYO3B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1309514Inhibition of EGFR T790M mutant (unknown origin) preincubated for 5 mins followed by ATP addition for 30 mins by HTRF assay2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
6-Oxooxazolidine-quinazolines as noncovalent inhibitors with the potential to target mutant forms of EGFR.
AID435318Binding constant for PAK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425121Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624874Binding constant for PCTK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1585924Selectivity index, ratio of IC50 for human A431 cells harboring wild-type EGFR to IC50 for human NCI-H1975 cells harboring EGFR T790M/L858R double mutant2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
AID436021Binding constant for LATS2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID780347Inhibition of EGFR in shed membrane vesicles of human A431 cells using poly-Glu-Tyr as substrate after 30 mins by ELISA2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Discovery of 2-aryl-8-hydroxy (or methoxy)-isoquinolin-1(2H)-ones as novel EGFR inhibitor by scaffold hopping.
AID624757Binding constant for PKMYT1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424895Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624726Binding constant for HIPK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425072Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624824Binding constant for PIP5K1A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425164Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID256604Average Binding Constant for STK10; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1425064Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1306587Inhibition of EGFR in human PC9 cells assessed as reduction in Akt phosphorylation at 10 uM after 6 hrs by Western blot analysis2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.
AID1609531Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell viability after 48 hrs by MTS assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Design and synthesis of novel artemisinin derivatives with potent activities against colorectal cancer in vitro and in vivo.
AID1768068Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Investigation of 3-sulfamoyl coumarins against cancer-related IX and XII isoforms of human carbonic anhydrase as well as cancer cells leads to the discovery of 2-oxo-2H-benzo[h]chromene-3-sulfonamide - A new caspase-activating proapoptotic agent.
AID644745Inhibition of EGFR at 10 uM after 50 mins by HTRF assay2012European journal of medicinal chemistry, Mar, Volume: 49Synthesis and biological evaluation of quinazoline and quinoline bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors and EPR bio-probe agents.
AID1224759Delta TM value showing the stabilisation of CDKL1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1667573Antiproliferative activity against human Calu3 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay2020Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9
Design and synthesis of a novel class EGFR/HER2 dual inhibitors containing tricyclic oxazine fused quinazolines scaffold.
AID435677Binding constant for LOK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256562Average Binding Constant for PAK4; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID436011Binding constant for full-length CLK32008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID436007Binding constant for AXL kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID662599Antiproliferative activity against human A549 cells expressing wild type EGFR coexpressing k-Ras mutant after 72 hrs by MTS assay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID624733Binding constant for SIK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625103Binding constant for MST4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1589889Growth inhibition of human A549 cells incubated for 48 hrs by SRB assay2019Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12
Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors.
AID1425144Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624851Binding constant for ERBB3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1532906Cytotoxicity against mouse L929 cells assessed as cell growth inhibition at 1 uM after 72 hrs by MTT assay relative to control2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold.
AID624922Binding constant for CAMK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624767Binding constant for MERTK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625118Binding constant for CAMK1D kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1432774Antiproliferative activity against human HL7702 cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Novel conjugates of endoperoxide and 4-anilinoquinazoline as potential anticancer agents.
AID624704Binding constant for NEK9 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1712096Growth inhibition of human OVCAR-4 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1301351Antiproliferative activity against human NCI-H358 cells assessed as reduction in cell viability after 48 hrs by cck8 assay2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant.
AID625006Binding constant for EGFR(S752-I759del) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224800Delta TM value showing the stabilisation of MST4 (2) produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID256633Average Binding Constant for PRKACA; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1617467Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k2019Journal of natural products, 11-22, Volume: 82, Issue:11
Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
AID1265424Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 10 uM after 48 hrs by Annexin-V/Propidium iodide dual staining based flow cytometric analysis (Rvb = 3.53 +/- 0.89%)2016European journal of medicinal chemistry, Jan-01, Volume: 107Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents.
AID435776Binding constant for ABL1(Y253F) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256609Average Binding Constant for AAK1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID625011Binding constant for FGR kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID271154Terminal half life in human2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID1532907Cytotoxicity against mouse L929 cells assessed as cell growth inhibition after 72 hrs by MTT assay2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold.
AID1425015Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435786Binding constant for full-length CLK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1057947Cytotoxicity against MDCK cells after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
AID624749Binding constant for CASK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424930Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1595618Binding affinity to wild-type human partial length EGFR (R669 to V1011 residues) expressed in bacterial expression system by Kinomescan method2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID775613Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells expressing T790M/L858R mutation after 72 hrs by MTS assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
AID708981Cytotoxicity against human NCI-H1975 cells incubated for 72 hrs by MTT assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.
AID435328Binding constant for YES kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625072Binding constant for TBK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435904Binding constant for full-length CSK2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624873Binding constant for PAK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID256635Average Binding Constant for CAMK2D; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1236609Antiproliferative activity against human gefitinib-resistant NCI-H1975 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity.
AID765703Cytotoxicity against human A549 cells after 72 hrs by MTT assay2013European journal of medicinal chemistry, Sep, Volume: 67Design and synthesis of novel quinazoline nitrogen mustard derivatives as potential therapeutic agents for cancer.
AID625113Binding constant for MARK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1824044Antiproliferative activity against human HCC827 cells expressing EGFR del119 mutant assessed as inhibition in cell viability after 72 hrs by CCK8 assay
AID1425110Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1654027Antifibrotic activity against bleomycin-induced pulmonary fibrosis C57BL/6J mouse model assessed as reduction in alveolar septal swelling at 60 mg/kg, po administered via gavage qd for 14 days at 3 days post bleomycin challenge by hematoxylin and eosin st2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
AID624830Binding constant for CDK9 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424932Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435553Binding constant for PRKCD kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID748089Cytotoxicity against human A549 cells harboring wild type EGFR and k-RAS mutation assessed as growth inhibition after 72 hrs by MTT assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID436050Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1904170Inhibition of P-gp in human K562/A02 cells assessed as rescue of intracellular Rhodamine 123 accumulation at 5 uM incubated for 5 to 120 mins and measured by flow cytometry analysis2022European journal of medicinal chemistry, Apr-05, Volume: 233Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID256640Average Binding Constant for PTK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1894146Inhibition of EGFR in human A-431 cells membrane2021European journal of medicinal chemistry, Mar-15, Volume: 214FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
AID410946Antiproliferative activity against human BT474 cells overexpressing ERBb2 after 3 days by methylene blue staining2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors.
AID1585965Inhibition of wild type EGFR autophosphorylation in human A549 cells at 1 uM by Western blot analysis relative to control2019European journal of medicinal chemistry, Jan-15, Volume: 162Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR.
AID1499603Inhibition of recombinant human His-tagged EGFR (1 to 645 residues) expressed in HEK293 cells at 0.1 uM using Tyr66-biotinylated PTP1B peptide as substrate preincubated for 5 mins followed by substrate addition measured after 1 hr by ELISA relative to con2017European journal of medicinal chemistry, Sep-29, Volume: 138Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
AID1768125Cytotoxicity against human HBE cells assessed as inhibition of cell growth measured by CCK8 assay2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Synthesis and biological evaluation of selenogefitinib for reducing bleomycin-induced pulmonary fibrosis.
AID1738680Cytotoxicity against human L0-2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2020European journal of medicinal chemistry, Aug-01, Volume: 199Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
AID674792Inhibition of SRC at >100 uM2012European journal of medicinal chemistry, Sep, Volume: 55Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases.
AID435900Binding constant for AKT3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1264289Inhibition of wild type recombinant human EGFR preincubated for 10 mins followed by FAM-labeled peptide/ATP addition measured after 1 hr by mobility shift assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
AID1585921Selectivity index, ratio of IC50 for wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells to IC50 for human N-terminal GST-tagged EGFR T790M/L858R double mutant (695 to end residues) expressed2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
AID1330931Inhibition of EGFR in human A431 cell membranes preincubated for 30 mins prior to addition of peptide substrate and [gamma32]-ATP measured after 10 mins by scintillation counting method2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
AID1545394Antiproliferative activity against human HepG2 cells by MTT assay2019Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7
Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.
AID624989Binding constant for ABL1(T315I)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1585922Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by MTT assay2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
AID1224788Delta TM value showing the stabilisation of PIM3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435524Binding constant for full-length CSNK1D2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1403033Antitumor activity against mouse EAC cells implanted in albino mouse assessed as increase in caspase-3 expression in tumor at 10 mg/kg, po once daily for 8 consecutive days by immunohistochemical analysis relative to control2018European journal of medicinal chemistry, Jan-20, Volume: 144Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
AID1589077Anti-tubercular activity against Mycobacterium tuberculosis H37Rv expressing LuxABCDE assessed as relative luminescence by measuring ratio of RLU (test compound)/RLU(no compound) at 2.5 uM by luminescence based assay2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.
AID1876267Binding affinity to AAK1 (unknown origin) assessed as dissociation constant2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID625120Binding constant for EPHA8 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID436053Binding constant for full-length STK332008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256589Average Binding Constant for EPHA4; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256606Average Binding Constant for STK16; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1442460Apparent volume of distribution in Sprague-Dawley rat plasma at 1 mg/kg, iv measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID256650Average Binding Constant for PIM1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435291Binding constant for FGFR3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624994Binding constant for AKT1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435794Binding constant for EPHA3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624862Binding constant for LYN kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1525111Cytotoxicity against human PLC/PRF/5 cells assessed as reduction in cell viability by MTT assay2019Journal of natural products, 05-24, Volume: 82, Issue:5
Strepantibins A-C: Hexokinase II Inhibitors from a Mud Dauber Wasp Associated Streptomyces sp.
AID708800Cytotoxicity against human A431 cells incubated for 72 hrs by MTT assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.
AID1391276Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors.
AID1460602Growth inhibition of Staphylococcus aureus SA1199 up to 100 ug/ml by broth microdilution assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID1632285Cytotoxicity against human NCI-N87 cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 2: Gefitinib analogs.
AID625061Binding constant for MAP4K5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625068Binding constant for NEK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425158Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1167183Antitumor activity against human A431 cells xenografted in SCID mouse assessed as tumor growth inhibition at 6.25 mg/kg/day, po qd for 7 days relative to control2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.
AID1762238Cytotoxicity against human A549 cells incubated for 2 to 4 hrs by MTT assay2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines.
AID1442478Anticancer activity against human MDA-MB-231 cells xenografted in BALB/c nude mouse assessed as reduction in tumor volume at 40 mg/kg, po qd2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID1751265Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 08-01, Volume: 43Design, synthesis and biological evaluation of novel 2,4-disubstituted quinazoline derivatives targeting H1975 cells via EGFR-PI3K signaling pathway.
AID1595407Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Jun-15, Volume: 1722,4-Disubstituted quinazolines targeting breast cancer cells via EGFR-PI3K.
AID1129575Antiproliferative activity against human 16HBE cells after 72 hrs by MTT assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID624849Binding constant for CSNK2A2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624977Binding constant for OSR1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425169Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624796Binding constant for MET(Y1235D) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1068982Inhibition of EGFR (unknown origin) after 10 mins2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 1: erlotinib analogs.
AID624908Binding constant for TEC kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625104Binding constant for MYO3A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624782Binding constant for FGFR3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625016Binding constant for SRC kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424969Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624835Binding constant for ERN1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1616593Antitumor activity against human HCC827 cells xenografted in athymic NU-Fox1nu nude mouse assessed as inhibition of tumor growth at 20 mg/kg, po dosed via gavage for 5 days/week for 2 consecutive weeks relative to control2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer.
AID662597Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTS assay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1460600Growth inhibition of Staphylococcus aureus SA1902 up to 100 ug/ml by broth microdilution assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID1693246Inhibition of EGFR in human A431 cell line assessed as reduction in EGF-induced EGFR autophosphorylation by measuring relative pEGFR at 3 uM measured upto 24 hrs by ELISA method in relative to control2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Development of a novel acetyl glucose-modified gefitinib derivative to enhance the radiosensitizing effect.
AID435195Binding constant for SRC kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424983Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435659Binding constant for full-length MARK32008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID295770Inhibition of human VEGFR2 in presence of 1 uM ATP at <10000 nM2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
AID435409Binding constant for full-length JNK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224764Delta TM value showing the stabilisation of CK1G1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID624802Binding constant for PIM3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425017Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625057Binding constant for TYRO3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624966Binding constant for DCAMKL1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1715796Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1562644Inhibition of EGF-induced EGFR phosphorylation at Tyr-residue in human A549 cells at 10 uM preincubated for 2 hrs followed by EGF treatment and measured after 10 mins by Western blot analysis
AID1129586Induction of NO production in human NCI-H1975 cells harboring EGFR L858R/T790M mutant at 100 uM incubated for 150 mins2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID624985Binding constant for ABL1(M351T)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625058Binding constant for VRK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1654037Antifibrotic activity against bleomycin-induced pulmonary fibrosis C57BL/6J mouse model assessed as reduction in oxidative stress by measuring reduction in MDA level in plasma at 60 mg/kg, po administered via gavage qd for 14 days at 3 days post bleomycin2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
AID1321929Antiproliferative activity against human A549 cells harboring K-ras mutation after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of azole-diphenylpyrimidine derivatives (AzDPPYs) as potent T790M mutant form of epidermal growth factor receptor inhibitors.
AID624806Binding constant for RPS6KA4(Kin.Dom.1-N-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1904127Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID484275Inhibition of Trypanosoma cruzi cruzaine preincubated for 5 mins before substrate addition by fluorescence assay in presence of 0.01% Triton X-1002010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1224770Delta TM value showing the stabilisation of JAK1~B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1306588Inhibition of EGFR Del19/T790M double mutant in human PC9/GR4 cells assessed as reduction in Akt phosphorylation at 10 uM after 6 hrs by Western blot analysis2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.
AID256673Average Binding Constant for PAK1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID777423Inhibition of wild type EGFR in human A431 cells assessed as growth inhibition after 48 hrs by MTT assay2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR.
AID1278396Antiproliferative activity against human HCC827 cells harboring EGFR E746 to A750 deletion mutant assessed as reduction in cell viability after 72 hrs by MTT assay2016European journal of medicinal chemistry, Mar-03, Volume: 110Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines.
AID435908Binding constant for EPHA2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435204Binding constant for WEE1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425104Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1574929Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
AID624987Binding constant for ABL1(Q252H)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1399720Antitumor activity against human NCI-H460 cells xenografted in nude mouse assessed as inhibition of tumor volume at 50 mg/kg, po qd for 14 consecutive days relative to control2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.
AID624880Binding constant for PIK4CB kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID256564Average Binding Constant for MAP3K4; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID456588Inhibition of recombinant EGFR by ELISA2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
AID625037Binding constant for PIK3CA(C420R) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID644746Inhibition of EGFR after 50 mins by HTRF assay2012European journal of medicinal chemistry, Mar, Volume: 49Synthesis and biological evaluation of quinazoline and quinoline bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors and EPR bio-probe agents.
AID428425Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and in vitro antitumor activities of novel 4-anilinoquinazoline derivatives.
AID1424931Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435188Binding constant for PAK6 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1712092Growth inhibition of human UACC-257 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1424935Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624949Binding constant for CSNK1G3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1309511Antiproliferative activity against human NCI-H1975 cells expressing L858R/T790M mutant EGFR after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
6-Oxooxazolidine-quinazolines as noncovalent inhibitors with the potential to target mutant forms of EGFR.
AID435201Binding constant for TRKA kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425138Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625029Binding constant for BRK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1068994Cytotoxicity against human Calu3 cells expressing HER2 after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 1: erlotinib analogs.
AID394884Cell cycle arrest in human K562 cells assessed as accumulation at G2/M phase at 10 umol/L after 24 hrs by FACS relative to untreated control2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
2,3-Disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazolines: a novel class of antitumor agents.
AID1353464Inhibition of EGF-induced EGFR phosphorylation at Y1086 residue in human A549 cells at 5 uM preincubated for 2 hrs followed by EGF stimulation measured after 10 mins by Western blot analysis2018European journal of medicinal chemistry, Mar-10, Volume: 1476,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
AID435785Binding constant for full-length CDK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256627Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624904Binding constant for NEK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435413Binding constant for MLCK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624967Binding constant for RPS6KA5(Kin.Dom.2-C-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1880626Antiproliferative activity against human NCI-H1299 cells expressing wild type EGFR assessed as cell growth inhibition at 1 uM2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras.
AID1129592Inhibition of ERK phosphorylation in human H1975 cells harboring EGFR L858R/T790M mutant at 1 uM by Western blotting analysis2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID1425035Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1128932Inhibition of EGFR (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib.
AID435826Binding constant for full-length PCTK32008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424900Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624836Binding constant for IKK-beta kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624910Binding constant for TTK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624774Binding constant for QSK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625088Binding constant for ARK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1265407Antiproliferative activity against human A549 cells by MTT assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents.
AID1870650Growth inhibition of human A549 cells expressing EGFR incubated for 72 hrs by CCK8 assay2022Journal of medicinal chemistry, 08-11, Volume: 65, Issue:15
Ynamide Electrophile for the Profiling of Ligandable Carboxyl Residues in Live Cells and the Development of New Covalent Inhibitors.
AID435694Binding constant for TNK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425187Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435679Binding constant for PIM3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1715115Inhibition of MNK1 (unknown origin) at 1 uM relative to control2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1425206Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1585932Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant assessed as cell viability at 1 uM after 24 hrs by MTT assay (Rvb = 98.3%)2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
AID260898Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
AID435905Binding constant for full-length CSNK1G32008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435440Binding constant for PIM2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435529Binding constant for LATS1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1201369Inhibition of EGFR (unknown origin) using Poly(Glu:Tyr) 4:1 as substrate after 12 to 16 hrs2015European journal of medicinal chemistry, Apr-13, Volume: 94Truncated structures used in search for new lead compounds and in a retrospective analysis of thienopyrimidine-based EGFR inhibitors.
AID1845392Inhibition of EGFR (unknown origin) incubated for 40 mins by intrinsic ATPase activity luminescence assay2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Evaluation of imidazo[2,1-b]thiazole-based anticancer agents in one decade (2011-2020): Current status and future prospects.
AID670515Antiproliferative activity against human A431 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors.
AID1264288Inhibition of human recombinant EGFR T790M mutant preincubated for 10 mins followed by FAM-labeled peptide/ATP addition measured after 1 hr by mobility shift assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
AID1250813Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Design, synthesis, and biofunctional evaluation of novel pentacyclic triterpenes bearing O-[4-(1-piperazinyl)-4-oxo-butyryl moiety as antiproliferative agents.
AID1403034Antitumor activity against mouse EAC cells implanted in albino mouse assessed as increase in cytochrome-c expression in tumor at 10 mg/kg, po once daily for 8 consecutive days by immunohistochemical analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
AID1309510Antiproliferative activity against human A431 cells overexpressing wild-type EGFR after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
6-Oxooxazolidine-quinazolines as noncovalent inhibitors with the potential to target mutant forms of EGFR.
AID1470940Inhibition of recombinant human EGFR T790M/L858R double mutant (695 to end residues) using Poly (4:1 Glu, Tyr) as substrate after 1 hr by ADP-Glo assay2017Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10
C-2 (E)-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFR
AID1712083Growth inhibition of human HCT-116 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID624909Binding constant for TGFBR2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1470939Inhibition of recombinant wild type human EGFR (695 to end residues) using Poly (4:1 Glu, Tyr) as substrate after 1 hr by ADP-Glo assay2017Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10
C-2 (E)-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFR
AID436006Binding constant for full-length AURKC2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID410943Inhibition of EGFR by HTRF assay2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors.
AID625076Binding constant for PLK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624838Binding constant for ACVR2A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID264807Inhibition of EGFR in presence of 2 uM ATP2006Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10
Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors.
AID435404Binding constant for EPHB4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1163061Antiproliferative activity against human ER-positive MDA-MB-231 cells after 24 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID1425143Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435148Binding constant for AMPK-alpha1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424920Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID256663Average Binding Constant for INSR; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID435935Binding constant for RIPK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1053577Irreversible inhibition of EGFR in human HCC827 cells assessed as recovery of EGFR autophosphorylation at 110 nM incubated for 1 hr followed by compound washout measured after 24 hrs by Western blotting analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties.
AID1704491Cytotoxicity against human ECa-109 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Dec-01, Volume: 207Antiproliferative effect of mitochondria-targeting allobetulin 1,2,3-triazolium salt derivatives and their mechanism of inducing apoptosis of cancer cells.
AID1424947Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1756985Induction of cell cycle arrest in human NCI-H1975 cells assessed as G2/M phase at 2 uM incubated for 24 hrs by propidium iodide based flow cytometry analysis (Rvb = 14.74 %)2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
AID1511361Antiproliferative activity against human SH-SY5Y cells incubated for 72 hrs by MTT assay2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
AID1595627Antiproliferative activity against human UCH12 cells measured after 72 hrs by alamar blue assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID507073Inhibition of recombinant PI3Kbeta by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID624787Binding constant for KIT(A829P) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1460142Cytotoxicity against gefitinib-resistant human MDA-MB-468 cells assessed as cell viability at 30 uM after 48 hrs by MTT assay relative to control2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Design, synthesis, and biological evaluation of novel 1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide analogs in MCF-7 and MDA-MB-468 breast cancer cell lines.
AID435182Binding constant for full-length PKAC-beta2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1460164Inhibition of EGFR phosphorylation in gefitinib-resistant human MDA-MB-468 cells at 10 uM after 18 hrs by Western blot method2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Design, synthesis, and biological evaluation of novel 1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide analogs in MCF-7 and MDA-MB-468 breast cancer cell lines.
AID1768133Antifibrotic activity in C57BL mouse model of BLM-induced lung fibrosis assessed as TNF-alpha level in blood at 60 mg/kg measured after 14 days by flow cytometry (Rvb = 3.12 +/- 0.11 pg/ml)2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Synthesis and biological evaluation of selenogefitinib for reducing bleomycin-induced pulmonary fibrosis.
AID94336In vitro inhibitory activity against EGF-stimulated proliferation of KB2 cells in culture2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.
AID1312560Antiproliferative activity against human A549 cells after 72 hrs by MTT assay2016European journal of medicinal chemistry, Aug-08, Volume: 118Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
AID1425041Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425095Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1471176Antiproliferative activity against human A549 cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Design of antitumor agents containing carbohydrate based on GLUT1, and evaluation of antiproliferative activity.
AID256590Average Binding Constant for EPHB1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1443474Selectivity ratio of GI50 for HUVEC to GI50 for human MDA-MB-231 cells2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID435433Binding constant for full-length MST12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625123Binding constant for RET(V804L) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435519Binding constant for AURKB kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435526Binding constant for FGFR1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624864Binding constant for CTK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435901Binding constant for BRAF kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625065Binding constant for CIT kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID777422Inhibition of EGFR L858R/T790M mutant in human NCI-H1975 cells assessed as growth inhibition after 48 hrs by MTT assay2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR.
AID1425081Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID256648Average Binding Constant for RPS6KA5 (Kin.Dom 1); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1514364Cytotoxicity against human MCF7 cells assessed as cell viability at 10 uM after 48 hrs by MTT assay relative to control2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Discovery and SAR studies of novel 2-anilinopyrimidine-based selective inhibitors against triple-negative breast cancer cell line MDA-MB-468.
AID1768126Antifibrotic activity in C57BL mouse model of BLM-induced lung fibrosis assessed as reduction in alveolar wall thickness by measuring lung coefficient at 60 mg/kg by hematoxylin and eosin staining based assay (Rvb = 12.89 +/- 2.52 g)2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Synthesis and biological evaluation of selenogefitinib for reducing bleomycin-induced pulmonary fibrosis.
AID1266271Toxicity in nude BALB/C mouse assessed as weight loss at 50 mg/kg, po qd for 12 days2016Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2
Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents.
AID1470941Selectivity index, ratio of IC50 for recombinant wild type human EGFR (695 to end residues) to IC50 for recombinant human EGFR T790M/L858R double mutant (695 to end residues)2017Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10
C-2 (E)-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFR
AID1378269Antiproliferative activity against human A431 cells harboring wild type EGFR after 72 hrs by MTT assay
AID1425213Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1224790Delta TM value showing the stabilisation of PLK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID436044Binding constant for PLK4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624839Binding constant for AKT2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1715787Inhibition of autophosphorylation of EGFR in human A431 cells at 10 times of IC50 incubated for 1 hr and thoroughly washed with fresh medium 3 times for 8 hrs before EGF treatment and measured after 15 mins by Western blot analysis2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID435650Binding constant for full-length CSNK1E2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425011Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID394664Binding affinity to wild type EGFR2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Kinase domain mutations in cancer: implications for small molecule drug design strategies.
AID625082Binding constant for RSK4(Kin.Dom.2-C-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1715116Inhibition of HIPK4 (unknown origin) at 1 uM relative to control2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID271152Volume of distribution in rat2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID394882Cell cycle arrest in human K562 cells assessed as accumulation at G0/G1 phase at 10 umol/L after 24 hrs by FACS relative to untreated control2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
2,3-Disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazolines: a novel class of antitumor agents.
AID435941Binding constant for ZAK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1315979Irreversible inhibition of GST-tagged ERBB2 (unknown origin) (Ile-675 to Val-1256 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.
AID435397Binding constant for CSNK1G1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1403042Induction of apoptosis in human A549 cells assessed as necrotic cells after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.17%)2018European journal of medicinal chemistry, Jan-20, Volume: 144Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
AID1712170Growth inhibition of human Panel ovarian (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1742797Selectivity index, ratio of IC50 for cytotoxicity against human HCV-29 cells to IC50 for cytotoxicity against human T-24 cells2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis and in vitro anti-bladder cancer activity evaluation of quinazolinyl-arylurea derivatives.
AID463638Inhibition of EGFR2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Selectively nonselective kinase inhibition: striking the right balance.
AID624953Binding constant for EPHA7 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1312562Antiproliferative activity against human SK-BR-3 cells after 72 hrs by MTT assay2016European journal of medicinal chemistry, Aug-08, Volume: 118Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
AID1407103Inhibition of recombinant human GST-tagged HER2 (676-end) expressed in baculovirus infected Sf9 insect cells preincubated for 5 mins followed by ATP addition and measured after 30 mins by HTRF assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity.
AID1425185Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424896Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425203Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1129568Inhibition of EGFR L858R mutant (unknown origin) after 1.5 hr by FRET-based Z-lyte assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID625138Binding constant for STK33 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1306577Inhibition of EGFR L858R mutant (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.
AID256634Average Binding Constant for CSNK1G2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID507079Inhibition of recombinant c-Abl by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID256579Average Binding Constant for MAP3K5; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435154Binding constant for DDR2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1756994Inhibition of EGFR in human NCI-H1975 cells assessed as reduction in EGFR phosphorylation at 2 uM incubated for 24 hrs by Western blot analysis2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
AID436054Binding constant for TLK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435522Binding constant for CDK11 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624832Binding constant for IKK-alpha kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1904131Reversal of BCRP-mediated multidrug resistance in dog MDCK-II-BCRP cells assessed as potentiation of mitoxantrone-induced cytotoxicity at 5 uM by measuring mitoxantrone IC50 after 48 hrs by MTT assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID1532889Antiproliferative activity against human A431 cells after 72 hrs by MTT assay2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold.
AID256630Average Binding Constant for FYN; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1656985Inhibition of EGFR1 (unknown origin)2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Acetylene Group, Friend or Foe in Medicinal Chemistry.
AID1424990Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435181Binding constant for full-length p38-alpha2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435689Binding constant for full-length PFTK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624912Binding constant for TYK2(JH1domain-catalytic) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424963Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1250814Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Design, synthesis, and biofunctional evaluation of novel pentacyclic triterpenes bearing O-[4-(1-piperazinyl)-4-oxo-butyryl moiety as antiproliferative agents.
AID436017Binding constant for ERK4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435545Binding constant for NEK6 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID748094Inhibition of EGFR L858R mutant (unknown origin) after 1.5 hrs by FRET-based Z'Lyte assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID1312558Inhibition of EGFR (unknown origin) at 1 uM by z-lyte assay2016European journal of medicinal chemistry, Aug-08, Volume: 118Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
AID1425001Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1471175Antiproliferative activity against human U87 cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Design of antitumor agents containing carbohydrate based on GLUT1, and evaluation of antiproliferative activity.
AID256576Average Binding Constant for MKNK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1278397Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as reduction in cell viability after 72 hrs by MTT assay2016European journal of medicinal chemistry, Mar-03, Volume: 110Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines.
AID624718Binding constant for PFTAIRE2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435430Binding constant for INSRR kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID771336Percentage unbound in human A549 cells at 1 uM after 4 hrs by equilibrium dialysis method2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors.
AID1562604Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay
AID1381748Inhibition of PI3K p110delta (unknown origin) using PIP2 as substrate by ELISA2018European journal of medicinal chemistry, Feb-25, Volume: 146Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
AID1424998Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435832Binding constant for SLK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625054Binding constant for MST2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425043Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624743Binding constant for LTK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624970Binding constant for CDK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435155Binding constant for full-length DLK2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625063Binding constant for PLK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224771Delta TM value showing the stabilisation of MEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1667571Antiproliferative activity against human A431 cells overexpressing EGFR assessed as cell growth inhibition measured after 72 hrs by MTT assay2020Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9
Design and synthesis of a novel class EGFR/HER2 dual inhibitors containing tricyclic oxazine fused quinazolines scaffold.
AID1771703Inhibiton of wild type EGFR (unknown origin) assessed as residual enzyme activity using fluoresceine-labelled poly-GT peptide as substrate preincubated with enzyme for 3 hrs at 10XIC50 followed by 100-fold dilution and measured after 30 mins by rapid dilu
AID1425149Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1303325Antiproliferative activity against human HepG2 cells over expressing EGFR after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Facile and efficient synthesis and biological evaluation of 4-anilinoquinazoline derivatives as EGFR inhibitors.
AID761593Induction of nitric oxide production in human NCI-H1975 cells expressing EGFR L858R/T790M mutant at 100 uM after 72 hrs by Griess assay2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID1702616Inhibition of human EGFR cytoplasmic domain L858R/T790M mutant (669 to 1210 residues) expressed in baculovirus infected Sf21 cells using biotin-labeled TK substrate preincubated for 30 mins followed by substrate and ATP addition at Km concentration and fu2020European journal of medicinal chemistry, Feb-01, Volume: 187Design, synthesis and biological evaluation of 2-amino-4-(1,2,4-triazol)pyridine derivatives as potent EGFR inhibitors to overcome TKI-resistance.
AID1617466Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay2019Journal of natural products, 11-22, Volume: 82, Issue:11
Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
AID624703Binding constant for MAPKAPK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425014Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435687Binding constant for PAK7/PAK5 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1442472Apparent volume of distribution in Sprague-Dawley rat plasma at 10 mg/kg, po measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID435297Binding constant for MLK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256675Average Binding Constant for PTK6; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID771341Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured after 8 hrs by Western blot analysis2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors.
AID729551Binding affinity to human full-length His-tagged Myt1 kinase expressed in HEK293 cells at 10 uM by TR-FRET based binding assay2013European journal of medicinal chemistry, Mar, Volume: 61Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
AID1443454Inhibition of TNFalpha-stimulated NF-kappaB (unknown origin) expressed in human U937 cells at 10 uM incubated for 3 hrs followed by TNFalpha stimulation measured after 2.5 hrs by luciferase reporter gene assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID624833Binding constant for CSNK1G2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID740935Inhibition of EGFR tyrosine kinase (unknown origin) using poly (Glu,Tyr) as substrate after 30 mins by ADP-GloTM assay2013European journal of medicinal chemistry, Mar, Volume: 61Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors.
AID435554Binding constant for PRKD3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1771676Inhibition of wild type EGFR (unknown origin) using fluoresceine-labelled poly-GT peptide as substrate preincubated with enzyme for 3 hrs followed by substrate and ATP addition by TR-FRET assay
AID1585964Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis2019European journal of medicinal chemistry, Jan-15, Volume: 162Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR.
AID1616557Cytotoxicity in human HCC827 cells assessed as reduction in cell viability incubated for 96 hrs by MTS method2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer.
AID1224783Delta TM value showing the stabilisation of PAK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID624717Binding constant for JNK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425141Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID777418Cytotoxicity against human A549 cells after 48 hrs by CellTiter-Glo assay2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR.
AID1702613Inhibition of wild type N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus infected Sf21 cells at 1 uM using biotin-labeled TK substrate preincubated for 30 mins followed by substrate and ATP addition at Km2020European journal of medicinal chemistry, Feb-01, Volume: 187Design, synthesis and biological evaluation of 2-amino-4-(1,2,4-triazol)pyridine derivatives as potent EGFR inhibitors to overcome TKI-resistance.
AID777399Toxicity in nude mouse xenografted with human A431 cells assessed as weight loss at 200 mg/kg/day, po qd after 12 days2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR.
AID271153Half life in rat2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID435827Binding constant for PDGFRA kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425038Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624906Binding constant for S6K1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1250368Permeability from apical to basolateral side in BCRP transfected MDCK2 cells2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
AID1424978Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1224757Delta TM value showing the stabilisation of CDK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID256662Average Binding Constant for ERBB2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624942Binding constant for DRAK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425156Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625125Binding constant for CLK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID271127Free drug level in rat plasma at 37 degC2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID345876Inhibition of human recombinant EGFR2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship analysis, and virtual screening studies.
AID771344Inhibition of wild type EGFR autophosphorylation in human A549 cells at 1 uM incubated for 1 hr followed by compound washout measured at 1 hr by Western blot analysis2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors.
AID1278398Antiproliferative activity against human A549 cells harboring K-ras mutation assessed as reduction in cell viability after 72 hrs by MTT assay2016European journal of medicinal chemistry, Mar-03, Volume: 110Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines.
AID1473931Ratio of drug concentration at steady state in human at 250 to 500 mg, po QD after 24 hrs to IC50 for human MRP4 overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1381746Inhibition of PI3K p110beta (unknown origin) using PIP2 as substrate by ELISA2018European journal of medicinal chemistry, Feb-25, Volume: 146Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
AID256644Average Binding Constant for CSNK1E; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1425157Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1916783Cytotoxicity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay2022European journal of medicinal chemistry, Aug-05, Volume: 238Recent contribution of medicinally active 2-aminothiophenes: A privileged scaffold for drug discovery.
AID256666Average Binding Constant for ABL1(Q252H); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID256622Average Binding Constant for JNK1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID662510Inhibition of EGFR L858R/T790M mutant-mediated Akt phosphorylation in human NCI-H1975 cells up to 500 nM after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1458980Antiproliferative activity against human A431 cells expressing wild type EGFR incubated for 96 hrs measured on day 5 by CellTiterGlo assay2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1877681Antiproliferative activity against human HeLa cells by CCK8 assay2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID625035Binding constant for PHKG1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID761603Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET based Z'-lyte assay2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID1424912Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424961Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1240085Cytotoxicity against human HuH7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
The discovery of oxazolones-grafted spirooxindoles via three-component diversity oriented synthesis and their preliminary biological evaluation.
AID1424910Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425009Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624762Binding constant for DLK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID260896Inhibition of erbB2 fusion protein expressed in baculovirus by ELISA2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
AID1424918Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435327Binding constant for VEGFR2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1442481Toxicity in BALB/c nude mouse xenografted with human MDA-MB-231 cells assessed as spleen damage at 40 mg/kg, po qd administered for 32 days by H&E staining based light microscopy2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID625089Binding constant for AAK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425128Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1712106Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1309515Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
6-Oxooxazolidine-quinazolines as noncovalent inhibitors with the potential to target mutant forms of EGFR.
AID748086Cytotoxicity against human 16HBE14o- cells harboring wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID1425039Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624886Binding constant for ERK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624980Binding constant for ABL1(F317I)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425197Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425004Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1174872Cytotoxicity against human HT-29 cells after 72 hrs under normoxia conditions by SRB assay2015European journal of medicinal chemistry, Jan-07, Volume: 89Design, synthesis and biological evaluation of 6-(nitroimidazole-1H-alkyloxyl)-4-anilinoquinazolines as efficient EGFR inhibitors exerting cytotoxic effects both under normoxia and hypoxia.
AID435796Binding constant for ERBB2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1442473Clearance in Sprague-Dawley rat plasma at 10 mg/kg, po measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID394660Binding affinity to EGFR with L858R mutant2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Kinase domain mutations in cancer: implications for small molecule drug design strategies.
AID1224795Delta TM value showing the stabilisation of SLK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID619793Cytotoxicity against human A549 cells assessed as cell viability at 10 uM after 3 days by colorimetric MTT assay2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.
AID625004Binding constant for EGFR(L858R,T790M) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1439615Cytotoxicity against human SW480 cells assessed as decrease in cell viability after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7
Synthesis and in vitro biological evaluation of novel quinazoline derivatives.
AID435292Binding constant for ITK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624820Binding constant for ACVR2B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507072Inhibition of recombinant PI3Kalpha by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID435899Binding constant for AKT1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425086Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624969Binding constant for ROCK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1460145Cytotoxicity against human MCF7 cells assessed as cell viability at 10 uM after 48 hrs by MTT assay relative to control2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Design, synthesis, and biological evaluation of novel 1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide analogs in MCF-7 and MDA-MB-468 breast cancer cell lines.
AID624781Binding constant for CDK4-cyclinD3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435667Binding constant for full-length NLK2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID729550Binding affinity to human full-length His-tagged Myt1 kinase expressed in HEK293 cells by TR-FRET based binding assay2013European journal of medicinal chemistry, Mar, Volume: 61Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
AID1306576Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.
AID625049Binding constant for PRKCH kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1654044Antifibrotic activity against bleomycin-induced pulmonary fibrosis C57BL/6J mouse model assessed as reduction in IL6 expression in plasma at 60 mg/kg, po administered via gavage qd for 14 days at 3 days post bleomycin challenge by FACSCalibur flow cytomet2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
AID1443995Hepatotoxicity in human assessed as drug-induced liver injury2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID625100Binding constant for NLK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435441Binding constant for RPS6KA4(Kin.Dom.2 - N-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID271124Inhibition of EGFR2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID1378278Inhibition of EGFR in human A549 cells assessed as reduction in EGF-induced ERK1/2 phosphorylation at T202/Y204 residues at 25 uM preincubated for 2 hrs followed by EGF stimulation for 10 mins by Western blot analysis
AID1712165Growth inhibition of human Panel leukemia (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1712169Growth inhibition of human Panel melanoma (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID256598Average Binding Constant for FRK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624907Binding constant for SYK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1708302Inhibition of EGFR (unknown origin)2021European journal of medicinal chemistry, Feb-15, Volume: 212Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
AID1756995Inhibition of EGFR in human NCI-H1975 cells assessed as reduction in AKT phosphorylation at 2 uM incubated for 24 hrs by Western blot analysis2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
AID1224791Delta TM value showing the stabilisation of PRKACA produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1742794Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis and in vitro anti-bladder cancer activity evaluation of quinazolinyl-arylurea derivatives.
AID1586919Inhibition of human ERG2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Acrylamide Functional Group Incorporation Improves Drug-like Properties: An Example with EGFR Inhibitors.
AID1306585Inhibition of EGFR phosphorylation in human PC9 cells at 10 uM after 6 hrs by Western blot analysis2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.
AID624915Binding constant for PIP5K2B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1595616Antiproliferative activity against human UCH1 cells measured after 72 hrs by alamar blue assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID771339Cellular uptake in human A549 cells incubated for 1 hr followed by compound washout measured after 8 hrs by HPLC-MS/MS analysis2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors.
AID670517Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors.
AID1163062Antiproliferative activity against human prostate, androgen receptor positive DU145 cells after 24 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID1171421Inhibition of wild type HER2 (unknown origin) incubated for 5 mins by HTRF assay2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.
AID1616556Inhibition of GST-tagged human EGFR kinase domain I858R/T790M mutant (696 to 1022 residues) using EGFR L858R/T790M substrate peptide incubated for 120 mins by kinase-Glo plus luminescent kinase assay2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer.
AID1458979Selectivity ratio of IC50 for wild type N-terminal GST-fused human EGFR cytoplasmic domain to IC50 for human recombinant GST-tagged EGFR L858R/T790M double mutant2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1562609Antiproliferative activity against human A431 cells incubated for 72 hrs by MTT assay
AID624990Binding constant for ABL1(Y253F)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID770793Cytotoxicity against human A549 cells after 72 hrs by CCK-8 assay2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors.
AID1224753Delta TM value showing the stabilisation of CAMK2D produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435546Binding constant for PRKG1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID778801Inhibition of EGFR phosphorylation in gefitinib-resistant human HCC827 cells at 0.5 uM after 2 hrs by Western blotting analysis2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.
AID1532115Non-competitive inhibition of GFP-fused human ABCG2 expressed in MDCK2 cells using varying levels of Hoechst 33342 as substrate preincubated for 30 mins followed by Hoechst 33342 addition by Cornish-Bowden plot analysis2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.
AID1424925Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624917Binding constant for MST3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224768Delta TM value showing the stabilisation of DMPK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1250373Ratio of unbound AUC (0 to 24 hrs) in CSF to blood of Han Wistar rat at 20 mg/kg, po by LC-MS/MS analysis2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
AID435161Binding constant for FES kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435285Binding constant for DMPK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624897Binding constant for RAF1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224763Delta TM value showing the stabilisation of CLK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1690730Growth inhibition of human PC-9 cells incubated for 5 days by SRB assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Comparative analysis of the dual EGFR-DNA targeting and growth inhibitory properties of 6-mono-alkylamino- and 6,6-dialkylaminoquinazoline-based type II combi-molecules.
AID662600Antiproliferative activity against human HL7702 cells expressing wilt type EGFR after 72 hrs by MTS assay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1186996Cytotoxicity against human HepG2 cells assessed as cell viability at 100 uM after 24 hrs by Cell-Titer Glo assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID624983Binding constant for ABL1(H396P)-non phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435552Binding constant for PIK3CA(E545K) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424968Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424999Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID256677Average Binding Constant for STK38L; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624810Binding constant for GCN2(Kin.Dom.2,S808G) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435189Binding constant for full-length PDPK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424996Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID256623Average Binding Constant for MYLK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID489619Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and preliminary biological evaluation of novel taspine derivatives as anticancer agents.
AID624921Binding constant for MAP4K3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID271144Inhibition of tumor volume in human LoVo cell xenografted in nude mouse at 100 mg/kg, po2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID624815Binding constant for ERBB4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1756984Induction of cell cycle arrest in human NCI-H1975 cells assessed as S phase at 2 uM incubated for 24 hrs by propidium iodide based flow cytometry analysis (Rvb = 24.50 %)2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
AID625064Binding constant for PIM2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1306580Inhibition of EGFR L858R/T790M double mutant (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.
AID1168679Cytotoxicity against human A549 cells assessed as cell viability at 60 uM after 24 hrs by MTT assay (Rvb = 100%)2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Optimization of gefitinib analogues with potent anticancer activity.
AID1315980Irreversible inhibition of GST-tagged ERBB4 (unknown origin) (Gly-259 to Gly-690 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.
AID1224780Delta TM value showing the stabilisation of OSR1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1403035Cell cycle arrest in human A549 cells assessed as accumulation at pre-G1 phase after 24 hrs by propidium iodide staining based flow cytometry relative to control2018European journal of medicinal chemistry, Jan-20, Volume: 144Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
AID1425115Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1312565Inhibition of cytoplasmic GST-tagged human recombinant EGFR L858R mutant expressed in baculovirus system by z-lyte assay2016European journal of medicinal chemistry, Aug-08, Volume: 118Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
AID624776Binding constant for PCTK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1582369Binding affinity to human wild-type partial length EGFR L858R mutant (R669 to V1011 residues) expressed in bacterial expression system by kinomescan assay2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
AID435287Binding constant for EPHA8 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424921Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425010Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435434Binding constant for RET kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624742Binding constant for NEK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1175521Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
AID1252466Inhibition of EGFR (unknown origin) using omnia tyr peptide 7 substrate by fluorescence assay2015European journal of medicinal chemistry, Oct-20, Volume: 103Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
AID1425029Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1719558Inhibition of recombinant wild type EGFR (696 to C terminal end) (unknown origin) using poly (Glu-Tyr) as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by ELISA
AID1464636Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20
Synthesis and evaluation of the NSCLC anti-cancer activity and physical properties of 4-aryl-N-phenylpyrimidin-2-amines.
AID435146Binding constant for ABL1(H396P) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID436010Binding constant for full-length CDK52008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625023Binding constant for HIPK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425005Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425101Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1896794Antiproliferative activity against mouse BaF3 cells expressing L858R assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay2022Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23
Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.
AID1224760Delta TM value showing the stabilisation of CHEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID625036Binding constant for PIK3CA kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1353457Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay2018European journal of medicinal chemistry, Mar-10, Volume: 1476,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
AID1424992Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435665Binding constant for NEK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424889Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID708980Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.
AID599779Antiproliferative activity against human MDA-MB-468 cells after 48 hrs by MTT assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
AID624795Binding constant for MET(M1250T) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625051Binding constant for PRKCQ kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1471178Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Design of antitumor agents containing carbohydrate based on GLUT1, and evaluation of antiproliferative activity.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1425170Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1175523Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
AID624735Binding constant for ANKK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1715118Inhibition of ERBB4 (unknown origin) at 1 uM relative to control2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID394731Cytotoxicity against human MOLT4 cells after 96 hrs by MTT assay2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
2,3-Disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazolines: a novel class of antitumor agents.
AID624803Binding constant for CHEK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1756965Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
AID1511363Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
AID1649878Growth inhibition of human 22Rv1 cells after 5 days by SRB assay2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Design and Synthesis of a Trifunctional Molecular System "Programmed" to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer Cells.
AID435431Binding constant for MAP4K1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1768124Cytotoxicity against human L02 cells assessed as inhibition of cell growth measured by CCK8 assay2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Synthesis and biological evaluation of selenogefitinib for reducing bleomycin-induced pulmonary fibrosis.
AID599957Binding affinity to human KIT incubated for 1 hr by kinase binding assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
AID625116Binding constant for ADCK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224797Delta TM value showing the stabilisation of MPSK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID624946Binding constant for BRAF kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425174Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1432799Inhibition of EGFR L858R/T790M double mutant in human NCI-H1975 cells assessed as inhibition of Akt phosphorylation at Ser-473 residue at 10 uM after 24 hrs by Western blot method2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Novel conjugates of endoperoxide and 4-anilinoquinazoline as potential anticancer agents.
AID624715Binding constant for ERK8 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625034Binding constant for PDGFRA kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID778800Inhibition of c-Met in gefitinib-resistant human HCC827 cells assessed as inhibition of p44/42 phosphorylation at 0.5 uM after 2 hrs by Western blotting analysis2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.
AID1532894Cytotoxicity against human A549 cells assessed as effect on intracellular ATP levels at 0 to 2 uM after 24 hrs by luciferase-luciferin based assay2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold.
AID256652Average Binding Constant for CAMK2B; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID662512Inhibition of EGFR L858R/T790M mutant-mediated Erk phosphorylation in human NCI-H1975 cells up to 500 nM after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1224786Delta TM value showing the stabilisation of PIM1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID433872Induction of p53 protein expression in human A549 cells at 20 uM after 48 hrs by Western blot relative to untreated control2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line.
AID624903Binding constant for SRPK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID463639Inhibition of erbB22010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Selectively nonselective kinase inhibition: striking the right balance.
AID624752Binding constant for SNRK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1129570Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTT assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID1424984Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624993Binding constant for ABL2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1378274Inhibition of EGF-induced EGFR phosphorylation at Tyr-residue in human A549 cells at 25 uM preincubated for 2 hrs followed by EGF stimulation for 10 mins by Western blot analysis
AID1399711Antitumor activity against human NCI-H460 cells xenografted in nude mouse assessed as inhibition of tumor weight at 25 mg/kg, po qd for 14 consecutive days relative to control2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.
AID1719559Inhibition of recombinant wild type EGFR T790M/L858R mutant (696 to C terminal end) (unknown origin) using poly (Glu-Tyr) as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by ELISA
AID1265415Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 10 uM after 6 hrs by Annexin-V-FITC/Propidium iodide staining based flow cytometric analysis (Rvb = 3.83 +/- 0.49%)2016European journal of medicinal chemistry, Jan-01, Volume: 107Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents.
AID780349Antiproliferative activity against human A431 cells after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Discovery of 2-aryl-8-hydroxy (or methoxy)-isoquinolin-1(2H)-ones as novel EGFR inhibitor by scaffold hopping.
AID1712100Growth inhibition of human TK-10 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID624875Binding constant for PDGFRB kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224794Delta TM value showing the stabilisation of RSK2b produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435795Binding constant for EPHA4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1824048Selectivity index, ratio of IC50 for Antiproliferative activity against human NCI-H1299 cells expressing wild type EGFR to IC50 for antiproliferative activity against human NCI-H1975 cells expressing EGFR T790M/L858R mutant
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1432800Inhibition of EGFR L858R/T790M double mutant in human NCI-H1975 cells assessed as inhibition of ERK-1/2 phosphorylation at Thr202/Tyr204 residues at 10 uM after 24 hrs by Western blot method2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Novel conjugates of endoperoxide and 4-anilinoquinazoline as potential anticancer agents.
AID1424923Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435675Binding constant for KIT(V559D,T670I) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425062Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID552133Antiproliferative activity against growth-resistant human PC9 cells expressing EGFR E746_A750/T790M mutant2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Discovery of selective irreversible inhibitors for EGFR-T790M.
AID625139Binding constant for SNARK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID436052Binding constant for full-length SNF1LK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624738Binding constant for MLCK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425040Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425163Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID708982Cytotoxicity against human HCC827 cells incubated for 72 hrs by MTT assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.
AID1425125Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID127927In vivo concentration in blood levels in mice assay at a dose of 200 mg/kg by oral administration after 24 hours2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.
AID625017Binding constant for TIE1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424993Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1129590Inhibition of EGFR phosphorylation in human H1975 cells harboring EGFR L858R/T790M mutant at 1 uM by Western blotting analysis2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID625130Binding constant for FGFR4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID662578Inhibition of EGFR del E746-A750 mutant-mediated Akt phosphorylation in human HCC827 cells up to 125 nM after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1632288Cytotoxicity against human BT474 cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 2: Gefitinib analogs.
AID1499599Inhibition of recombinant human His-tagged EGFR (1 to 645 residues) expressed in HEK293 cells at 0.00001 uM using Tyr66-biotinylated PTP1B peptide as substrate preincubated for 5 mins followed by substrate addition measured after 1 hr by ELISA relative to2017European journal of medicinal chemistry, Sep-29, Volume: 138Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
AID770080Selectivity ratio of IC50 for wild type EGFR phosphorylation in human LoVo cells over IC50 for EGFR L858R/T970M double mutant phosphorylation in human NCI-H1975 cells2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
AID435805Binding constant for MAP4K5 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624714Binding constant for p38-alpha kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID662598Antiproliferative activity against human A431 cells overexpressing EGFR after 72 hrs by MTS assay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1174873Cytotoxicity against human HT-29 cells after 72 hrs under hypoxia conditions by SRB assay2015European journal of medicinal chemistry, Jan-07, Volume: 89Design, synthesis and biological evaluation of 6-(nitroimidazole-1H-alkyloxyl)-4-anilinoquinazolines as efficient EGFR inhibitors exerting cytotoxic effects both under normoxia and hypoxia.
AID625129Binding constant for HIPK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1499561Antiproliferative activity against human A549 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
AID507083Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID624843Binding constant for CAMK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID488715Inhibition of EGFR at 10 uM2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.
AID1425209Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1441910Inhibition of wild-type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 end amino acid residues) expressed in baculovirus expression system using TK peptide substrate preincubated with enzyme for 30 mins followed by substrate addition mea2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.
AID528340Inhibition of EGFR2010Journal of medicinal chemistry, Oct-28, Volume: 53, Issue:20
Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency.
AID634927Antiproliferative activity against human MCF7 cells overexpressing EGFR gene after 48 hrs by MTT assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Synthesis, molecular modeling and biological evaluation of 2-(benzylthio)-5-aryloxadiazole derivatives as anti-tumor agents.
AID435198Binding constant for TIE1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224775Delta TM value showing the stabilisation of ERK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435674Binding constant for JAK3(Kin.Dom.2/JH1 - catalytic) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425025Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1585925Antiproliferative activity against human A549 cells after 72 hrs by MTT assay2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
AID1442466Oral bioavailability in Sprague-Dawley rat at 10 mg/kg measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID1057942Increase of plasma membrane expression of BCRP expressing reporter gene GFP in BCRP-MDCK2 cells at 0.5 to 1.8 uM after 72 hrs by fluorescence assay2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
AID624842Binding constant for BMX kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1163063Antiproliferative activity against human ER-positive Ishikawa cells after 24 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID1424192Inhibition of N-terminal GST tagged human recombinant EGFR L858R/T790M mutant (695 to end amino acids) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) Peptide substrate by ADP-Glo assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
AID1585972Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) T790M/L858R double mutant expressed in baculovirus expression system after 1 hr by kinase tracer 199 based TR-FRET assay2019European journal of medicinal chemistry, Jan-15, Volume: 162Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR.
AID1511360Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
AID625086Binding constant for SLK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425207Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID271128Free drug level in mouse plasma at 37 degC2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID436025Binding constant for NDR2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425137Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624945Binding constant for BMPR1A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID777415Cytotoxicity against human K562 cells after 48 hrs by CellTiter-Glo assay2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR.
AID1715795Antiproliferative activity against human A431 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo luminescent cell viability assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID625077Binding constant for DAPK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID484386Colloidal aggregation in fed state simulated intestinal fluid assessed as colloid radius at 250 uM by dynamic light scattering assay in presence of 1% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1425205Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624823Binding constant for MKNK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624793Binding constant for KIT(V559D,V654A) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435792Binding constant for EGFR(S752-I759del) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID394662Cytotoxicity against mouse BA/F3 cells expressing EGFR L858R mutant2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Kinase domain mutations in cancer: implications for small molecule drug design strategies.
AID1368036Inhibition of recombinant EGFR (unknown origin) T790M/L858R double mutant preincubated for 30 mins followed by poly (Glu-Tyr) biotinylated peptide substrate addition measured after 30 mins in presence of ATP by ELISA2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Design, synthesis, and evaluation of A-ring-modified lamellarin N analogues as noncovalent inhibitors of the EGFR T790M/L858R mutant.
AID1140573Inhibition of autophosphorylation of recombinant his-tagged EGFR (amino acid 645-1186) (unknown origin) expressed in Sf-9 cells after 10 mins by time-resolved fluorometry2014Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10
Synthesis and biological evaluation of compounds which contain pyrazole, thiazole and naphthalene ring as antitumor agents.
AID1425085Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1585960Cysteine reactivity in pH 10 CAPS buffer assessed as half life for cysteine-compound adduct formation at 10 uM after 24 hrs in presence of 100 molar excess cysteine by LC-MS analysis2019European journal of medicinal chemistry, Jan-15, Volume: 162Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR.
AID1673922Growth inhibition of human LoVo cells harboring wild type EGFR2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.
AID1425068Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1389965Cytotoxicity against human SGC cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID624809Binding constant for MYLK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624857Binding constant for HCK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1315985Irreversible inhibition of ERBB1 autophosphorylation in EGF-stimulated human A431 cells incubated for 2 hrs followed by stimulation with EGF for 5 mins by sandwich ELISA2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.
AID435403Binding constant for EPHB1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224767Delta TM value showing the stabilisation of DAPK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID761597Antiproliferative activity against human A431 cells expressing wild type EGFR after 72 hrs by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID1499608Cytotoxicity against human HepG2 cells at 2.5 uM after 48 hrs by LDH release assay (Rvb = 100%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
AID1424954Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID256657Average Binding Constant for LCK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1565419Antiproliferative activity against human CL68 cells harbouring EGFR delE746-A750/T790M mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 1821,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC.
AID256656Average Binding Constant for p38-alpha; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1463973Inhibition of wild type recombinant EGFR (unknown origin) by ELISA2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Quinazoline-1-deoxynojirimycin hybrids as high active dual inhibitors of EGFR and α-glucosidase.
AID271150Cmax in nude mouse xenografted with human LoVo cell at 100 mg/kg, po2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID1425012Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1616554Inhibition of EGFR L858/T790M mutant autophosphorylation at Tyr1068 residue in human NCI-H1975 cells at 312.5 to 20000 nM by Western blotting analysis2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer.
AID1480298Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors.
AID624723Binding constant for CSNK1A1L kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624746Binding constant for WEE2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425182Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425023Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1224804Delta TM value showing the stabilisation of VRK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435324Binding constant for full-length RIOK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID295772Inhibition of human VEGFR2 in presence of 1 mM ATP at <10000 nM2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
AID456593Growth inhibition of human A431 cells after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
AID1751266Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 08-01, Volume: 43Design, synthesis and biological evaluation of novel 2,4-disubstituted quinazoline derivatives targeting H1975 cells via EGFR-PI3K signaling pathway.
AID435396Binding constant for CHEK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435407Binding constant for FLT3(D835Y) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425065Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1250367Efflux ratio of permeability from basolateral to apical side over apical to basolateral side in MDCK2-MDR1 cells2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
AID1250380Inhibition of EGFR L858R mutant phosphorylation in human H3255 cells2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
AID1458976Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1742793Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis and in vitro anti-bladder cancer activity evaluation of quinazolinyl-arylurea derivatives.
AID1353455Antiproliferative activity against human A549 cells harboring wild type EGFR/K-ras mutant after 72 hrs by MTT assay2018European journal of medicinal chemistry, Mar-10, Volume: 1476,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
AID1353461Inhibition of EGFR L858R/T790M double mutant (unknown origin) using ULight-poly GT as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by spectrophotometric method2018European journal of medicinal chemistry, Mar-10, Volume: 1476,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
AID1424911Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1460144Cytotoxicity against gefitinib-resistant human MDA-MB-468 cells assessed as reduction in cell viability after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Design, synthesis, and biological evaluation of novel 1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide analogs in MCF-7 and MDA-MB-468 breast cancer cell lines.
AID435533Binding constant for NEK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1175524Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
AID627046Antiproliferative activity against gefitinib resistant human NCI-H1993 cells after 3 days by SRB assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Growth inhibition of human lung cancer cells via down-regulation of epidermal growth factor receptor signaling by yuanhuadine, a daphnane diterpene from Daphne genkwa.
AID1266268Inhibition of EGFR tyrosine kinase L858R mutant (unknown origin) assessed as ATP level by luminescence analysis2016Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2
Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents.
AID1704494Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Dec-01, Volume: 207Antiproliferative effect of mitochondria-targeting allobetulin 1,2,3-triazolium salt derivatives and their mechanism of inducing apoptosis of cancer cells.
AID1756967Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
AID1738677Antiproliferative activity against human H1975 cells harboring EGFR L858R/T790M double mutant assessed as reduction in cell viability measured after 72 hrs by MTT assay2020European journal of medicinal chemistry, Aug-01, Volume: 199Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
AID624867Binding constant for MLK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1585967Drug uptake in human A549 cells at 1 uM after 1 hr by LC-MS analysis2019European journal of medicinal chemistry, Jan-15, Volume: 162Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR.
AID1315989Irreversible inhibition of human recombinant GST-tagged JAK3 expressed in baculovirus infected Sf9 insect cells assessed as reduction in polyglutamic acid-tyrosine phosphorylation after 30 mins by ELISA2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.
AID1712098Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1425044Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID488709Cytotoxicity against human PANC1 cells after 4 to 5 days by MTT assay2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.
AID256584Average Binding Constant for CAMK1D; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1251004Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.
AID624725Binding constant for NEK11 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425049Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435645Binding constant for ACVRL1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1353467Inhibition of EGF-induced EGFR activation in human A549 cells assessed as reduction in ERK1/2 phosphorylation at T202/Y204 residues at 5 uM preincubated for 2 hrs followed by EGF stimulation measured after 10 mins by Western blot analysis2018European journal of medicinal chemistry, Mar-10, Volume: 1476,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
AID1712097Growth inhibition of human OVCAR-8 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID435551Binding constant for full-length p38-beta2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425123Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID256573Average Binding Constant for PAK6; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID625090Binding constant for ICK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1445470Inhibition of human N-terminal GST-fused EGFR T790M/L858R double mutant (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 20 mins by HTFR assay2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
AID1056128Selectivity for human HCC827 cells over human MDA-MB-231 cells2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Synthesis of Novel 3,5-Disubstituted-2-oxindole Derivatives As Antitumor Agents against Human Nonsmall Cell Lung Cancer.
AID1738678Antiproliferative activity against human A549 cells harboring wild type EGFR assessed as reduction in cell viability measured after 72 hrs by MTT assay2020European journal of medicinal chemistry, Aug-01, Volume: 199Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
AID1198997Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, May-01, Volume: 25, Issue:9
Design, synthesis, biological evaluation and molecular modeling of dihydropyrazole sulfonamide derivatives as potential COX-1/COX-2 inhibitors.
AID739694Inhibition of human GST-tagged EGFR L834R mutant expressed in Sf9 cells by luminescence assay2013Journal of medicinal chemistry, May-23, Volume: 56, Issue:10
Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors.
AID1458983Antiproliferative activity against human A549 cells harboring KRAS-G12S mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID745325Cytotoxicity against human DLD1 cells after 72 hrs by WST-8 assay2013European journal of medicinal chemistry, May, Volume: 63Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
AID1425036Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID771338Irreversible inhibition of recombinant EGFR tyrosine kinase (unknown origin) at 1 uM after 60 mins by real-time fluorescence assay2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors.
AID1532895Cytotoxicity against human A549 cells assessed as reduction in intracellular ATP levels at 8 uM after 24 hrs by luciferase-luciferin based assay2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold.
AID625110Binding constant for TRPM6 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435283Binding constant for DAPK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID778802Inhibition of c-Met phosphorylation in gefitinib-resistant human HCC827 cells at 0.5 uM after 2 hrs by Western blotting analysis2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.
AID345874Inhibition of human recombinant EGFR at 100 uM2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship analysis, and virtual screening studies.
AID1174875Metabolic stability in mouse liver microsomes assessed as compound remaining at 5 uM after 30 mins under normoxia conditions in presence of NADPH by HPLC method2015European journal of medicinal chemistry, Jan-07, Volume: 89Design, synthesis and biological evaluation of 6-(nitroimidazole-1H-alkyloxyl)-4-anilinoquinazolines as efficient EGFR inhibitors exerting cytotoxic effects both under normoxia and hypoxia.
AID1425127Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425148Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1756996Inhibition of EGFR in human NCI-H1975 cells assessed as reduction in ERK phosphorylation at 2 uM incubated for 24 hrs by Western blot analysis2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
AID1712087Growth inhibition of human SF-295 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID739693Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay2013Journal of medicinal chemistry, May-23, Volume: 56, Issue:10
Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors.
AID1278399Antiproliferative activity against human MCF7 cells overexpressing EGFR assessed as reduction in cell viability after 72 hrs by MTT assay2016European journal of medicinal chemistry, Mar-03, Volume: 110Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines.
AID624702Binding constant for BRSK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435938Binding constant for TGFBR1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624827Binding constant for CAMK2B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624825Binding constant for BMPR1B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424892Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1532105Growth inhibition of MDCK2 cells after 72 hrs by MTT assay2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.
AID1283993Inhibition of EGFR-T790M/L858 mutant (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay2016Bioorganic & medicinal chemistry letters, Mar-15, Volume: 26, Issue:6
Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
AID1315999In vivo inhibition of full length human ERBB1 autophosphorylation transfected in NIH/3T3 cells implanted in mouse at 130 mg/kg, po qd for 2 days measured 6 hrs post last dose by Western blot analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.
AID435787Binding constant for CLK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1673305Binding affinity to T7-tagged EGFR (unknown origin) expressed in Escherichia coli BL21 incubated for 1 hr2019Bioorganic & medicinal chemistry letters, 07-15, Volume: 29, Issue:14
Utilizing comprehensive and mini-kinome panels to optimize the selectivity of quinoline inhibitors for cyclin G associated kinase (GAK).
AID624755Binding constant for ZAK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1595410Cytotoxicity against human MGC803 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Jun-15, Volume: 1722,4-Disubstituted quinazolines targeting breast cancer cells via EGFR-PI3K.
AID1432772Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Novel conjugates of endoperoxide and 4-anilinoquinazoline as potential anticancer agents.
AID1582384Inhibition of EGFR exon 19 deletion mutant in human HCC827 cells assessed as reduction in EGFR autophosphorylation at 1 uM treated 8 hrs post serum starvation measured after 16 hrs by Western blot analysis2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
AID435693Binding constant for TGFBR2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID507082Inhibition of recombinant c-Src T338I mutant by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID436032Binding constant for MYO3B kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1265425Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 10 uM after 48 hrs by Annexin-V/Propidium iodide dual staining based flow cytometric analysis (Rvb = 1.44 +/- 0.43%)2016European journal of medicinal chemistry, Jan-01, Volume: 107Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents.
AID1425117Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID489620Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and preliminary biological evaluation of novel taspine derivatives as anticancer agents.
AID1368093Cytotoxicity against human NCI-H23 cells assessed as reduction in cell viability after 46 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24
Imidazo[1,2-a]pyridines linked with thiazoles/thiophene motif through keto spacer as potential cytotoxic agents and NF-κB inhibitors.
AID624773Binding constant for AMPK-alpha1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507081Inhibition of recombinant c-Src by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID625109Binding constant for BIKE kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425031Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625009Binding constant for EPHA3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224803Delta TM value showing the stabilisation of PBK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID625001Binding constant for EGFR(L747-S752del, P753S) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID770792Cytotoxicity against human HCC827 cells after 72 hrs by CCK-8 assay2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors.
AID435896Binding constant for AAK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624786Binding constant for KIT kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624869Binding constant for NEK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1768123Inhibition of EGFR (unknown origin) by ADP-Glo kinase assay2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Synthesis and biological evaluation of selenogefitinib for reducing bleomycin-induced pulmonary fibrosis.
AID271125Antiproliferative activity against EGF-stimulated KB cells2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID1654046Antifibrotic activity against bleomycin-induced pulmonary fibrosis C57BL/6J mouse model assessed as reduction in TNF-alpha expression in plasma at 60 mg/kg, po administered via gavage qd for 14 days at 3 days post bleomycin challenge by FACSCalibur flow c2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
AID624996Binding constant for EGFR kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624783Binding constant for FGFR3(G697C) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624959Binding constant for MAP4K2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID256615Average Binding Constant for p38-gamma; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1470862Selectivity index, ratio of IC50 for human A549 cells harboring wild type EGFR to IC50 for human NCI-H1975 cells harboring EGFR L858R/T790M double mutant2017Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10
Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
AID1582368Binding affinity to human wild-type partial length EGFR (R669 to V1011 residues) expressed in bacterial expression system by kinomescan assay2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
AID435649Binding constant for CDC2L2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624740Binding constant for LRRK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1470944Antiproliferative activity against human A549 cells harboring EGFR K-ras mutant assessed as decrease in cell viability after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10
C-2 (E)-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFR
AID625122Binding constant for RET(M918T) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID537736Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID624951Binding constant for EPHA2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1589081Anti-tubercular activity against Mycobacterium tuberculosis H37Rv expressing LuxABCDE assessed as relative luminescence by measuring ratio of RLU (test compound)/RLU(no compound) at 0.625 uM by luminescence based assay2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.
AID1667570Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as cell growth inhibition measured after 72 hrs by MTT assay2020Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9
Design and synthesis of a novel class EGFR/HER2 dual inhibitors containing tricyclic oxazine fused quinazolines scaffold.
AID624995Binding constant for CSF1R kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1585980Inhibition of EGFR T790M/L858R double mutant auto-phosphorylation in human NCI-H1975 cells at 0.1 uM by Western blot analysis relative to control2019European journal of medicinal chemistry, Jan-15, Volume: 162Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR.
AID624765Binding constant for TRKC kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1562646Inhibition of EGF-induced EGFR phosphorylation at Y992 in human A549 cells at 10 uM preincubated for 2 hrs followed by EGF treatment and measured after 10 mins by Western blot analysis
AID624878Binding constant for PIM1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1712102Growth inhibition of human PC-3 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID625087Binding constant for MELK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435197Binding constant for TEC kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1359917Inhibition of EGFR (unknown origin)2018European journal of medicinal chemistry, Jun-25, Volume: 154Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors.
AID428424Cytotoxicity against EGFR overexpressing human A431 cells after 24 hrs by MTT assay2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and in vitro antitumor activities of novel 4-anilinoquinazoline derivatives.
AID507422Inhibition of recombinant Ret by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID1424198Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
AID624798Binding constant for LKB1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425076Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425145Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424936Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424991Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID488708Cytotoxicity against human MIAPaCa2 cells after 4 to 5 days by MTT assay2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.
AID1724871Antiproliferative activity against EGFR/C-RAF knockdown human PANC-1 cells harboring K-RAS G12D/TP53 P72R/K129R mutant xenografted in mouse tumor model assessed as inhibition of cell proliferation by MTT assay in presence of gefitinib2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Complete Regression of Carcinoma via Combined C-RAF and EGFR Targeted Therapy.
AID634930Inhibition of recombinant His6-tagged EGFR expressed in baculovirus infected insect Sf9 cells using ATP as substrate and cofactor MgCl2 after 2 hrs by DELFIA/Time-resolved fluorometric analysis2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Synthesis, molecular modeling and biological evaluation of 2-(benzylthio)-5-aryloxadiazole derivatives as anti-tumor agents.
AID1425192Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1595408Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Jun-15, Volume: 1722,4-Disubstituted quinazolines targeting breast cancer cells via EGFR-PI3K.
AID1876161Inhibition of EGFR (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID678801TP_TRANSPORTER: efflux of Hoechst33342 in BCRP-expressing Sf9 cells2004Molecular pharmacology, Jun, Volume: 65, Issue:6
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.
AID1057943Reduction of plasma membrane expression of BCRP expressing reporter gene GFP in BCRP-MDCK2 cells at 0.5 to 1.8 uM after 72 hrs by fluorescence assay relative to control2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
AID624947Binding constant for BRAF(V600E) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID638068Inhibition of Her-2 by time-resolved fluorescence assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery of novel 5-alkynyl-4-anilinopyrimidines as potent, orally active dual inhibitors of EGFR and Her-2 tyrosine kinases.
AID1730891Inhibition of EGFR in human NCI-H1975 cells assessed as reduction in EGFR phosphorylation at Tyr-1068 residues at 2.5 uM after 1 to 12 hrs by Western blot analysis2021European journal of medicinal chemistry, Mar-05, Volume: 213Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
AID1424907Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1389971Inhibition of EGFR T790M/L858R double mutant (unknown origin) using peptide substrate after 60 mins by HTRF assay
AID488722Growth inhibition of human MIAPaCa2 cells at 2.5 uM after 72 hrs2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.
AID1562639Induction of cell cycle arrest in human A549 cells assessed as accumulation at G0/G1 phase at 20 uM incubated for 48 hrs by PI staining based flow cytometric analysis (Rvb = 51.73%)
AID1403032Antitumor activity against mouse EAC cells implanted in albino mouse assessed as cell death in thigh muscle tumor cells at 10 mg/kg, po once daily for 8 consecutive days by hematoxylin and eosin staining based light microscopic method2018European journal of medicinal chemistry, Jan-20, Volume: 144Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
AID625013Binding constant for LCK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425194Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID256565Average Binding Constant for MAP4K5; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1265417Induction of apoptosis in human A549 cells assessed as necrotic cells at 10 uM after 6 hrs by Annexin-V-FITC/Propidium iodide staining based flow cytometric analysis (Rvb = 0.28 +/- 0.09%)2016European journal of medicinal chemistry, Jan-01, Volume: 107Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents.
AID625070Binding constant for PFTK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID256602Average Binding Constant for EPHA2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1425098Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1330927Inhibition of HDAC6 (unknown origin) using acetylated peptide substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence analysis2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
AID1574932Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by EZ-Cytox assay2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
AID777401Antitumor activity against human A431 cells xenografted in nude mouse assessed as inhibition of tumor growth at 200 mg/kg/day, po qd after 12 days2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR.
AID1425047Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1241286Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay2015Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.
AID624919Binding constant for AURKA kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1715119Inhibition of LOK (unknown origin) at 1 uM relative to control2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1425111Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425037Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1693244Cytotoxicity against human A431 cells measured after 24 hrs by WST-1 assay2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Development of a novel acetyl glucose-modified gefitinib derivative to enhance the radiosensitizing effect.
AID624920Binding constant for MRCKA kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624751Binding constant for PIP5K1C kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1595406Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Jun-15, Volume: 1722,4-Disubstituted quinazolines targeting breast cancer cells via EGFR-PI3K.
AID1424928Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435166Binding constant for full-length JNK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1230129Antiproliferative activity against human HepG2 cells assessed as cell growth by MTT assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Combination of 4-anilinoquinazoline and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors.
AID1460604Synergistic antibacterial activity against Staphylococcus aureus SAK1902 in presence of CPX by checkerboard assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID528332Antitumor activity against human HCC827 cells xenografted in mouse assessed as reduction of tumor growth at 100 mg/kg, iv for 5 days a week measured after 2 weeks2010Journal of medicinal chemistry, Oct-28, Volume: 53, Issue:20
Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency.
AID624770Binding constant for CAMK2D kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1163074Antiproliferative activity against human ER-positive MDA-MB-231 cells after 72 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID1904172Effect on P-gp expression in human K562/A02 cells at 5 uM measured by Western blot analysis2022European journal of medicinal chemistry, Apr-05, Volume: 233Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID729552Binding affinity to human full-length His-tagged Myt1 kinase expressed in HEK293 cells at 5 uM by TR-FRET based binding assay2013European journal of medicinal chemistry, Mar, Volume: 61Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
AID1425171Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624957Binding constant for EPHB6 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1529998Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
Dihydropyrazothiazole derivatives as potential MMP-2/MMP-8 inhibitors for cancer therapy.
AID264808Antiproliferative activity against EGF-stimulated human KB cell line2006Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10
Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors.
AID1381740Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
AID1425113Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID256561Average Binding Constant for BTK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624764Binding constant for CLK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435152Binding constant for CAMK4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1129573Antiproliferative activity against k-RAS dependent human A549 cells overexpressing WT EGFR after 72 hrs by MTT assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID1589079Anti-tubercular activity against Mycobacterium tuberculosis H37Rv expressing LuxABCDE assessed as relative luminescence by measuring ratio of RLU (test compound)/RLU(no compound) at 10 uM by luminescence based assay2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.
AID1565445Antitumor activity against human NCI-H1975 cells harbouring EGFR L858R/T790M double mutant xenografted in athymic Nude-Foxn1nu BALB/c mouse assessed as tumor growth inhibition at 50 mg/kg, po administered once daily via gavage for 20 days measured twice a2019European journal of medicinal chemistry, Nov-15, Volume: 1821,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC.
AID433871Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion method2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line.
AID1425083Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1824047Selectivity index, ratio of IC50 for Antiproliferative activity against human A549 cells expressing wild type EGFR to IC50 for antiproliferative activity against human NCI-H1975 cells expressing EGFR T790M/L858R mutant
AID1425097Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1585971Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) T790M/L858R double mutant expressed in baculovirus expression system preincubated for 5 hrs followed by kinase tracer 199 addition by TR-FRET assay2019European journal of medicinal chemistry, Jan-15, Volume: 162Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR.
AID435909Binding constant for full-length LKB12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425126Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1659246Inhibition of human EGFR-TK using PTK substrate after 40 mins in presence of ATP by Kinase-Glo luminescent assay2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Synthesis, biological evaluation and molecular modeling study of [1,2,4]-Triazolo[4,3-c]quinazolines: New class of EGFR-TK inhibitors.
AID1250372Ratio of unbound AUC (0 to 24 hrs) in brain to blood of Han Wistar rat at 20 mg/kg, po by LC-MS/MS analysis2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
AID1514365Cytotoxicity against EGFR over-expressing human MDA-MB-468 cells assessed as cell viability at 10 uM after 48 hrs by MTT assay relative to control2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Discovery and SAR studies of novel 2-anilinopyrimidine-based selective inhibitors against triple-negative breast cancer cell line MDA-MB-468.
AID1442479Toxicity in BALB/c nude mouse xenografted with human MDA-MB-231 cells assessed as heart damage at 40 mg/kg, po qd administered for 32 days by H&E staining based light microscopy2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID625031Binding constant for MRCKB kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435158Binding constant for EPHA5 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1654031Antifibrotic activity against bleomycin-induced pulmonary fibrosis C57BL/6J mouse model assessed as reduction in lung coefficient at 60 mg/kg, po administered via gavage qd for 14 days at 3 days post bleomycin challenge2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
AID1425024Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID624859Binding constant for JAK1(JH1domain-catalytic) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435831Binding constant for RPS6KA5(Kin.Dom.1 - C-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1278401Inhibition of EGFR L858R/T790M double mutant in human NCI-H1975 cells assessed as reduction in phosphorylated AKT level at 1 uM after 12 hrs by Western blot analysis2016European journal of medicinal chemistry, Mar-03, Volume: 110Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines.
AID1224778Delta TM value showing the stabilisation of NEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID624708Binding constant for CDC2L1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425180Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435527Binding constant for FGFR3(G697C) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID492111Antiproliferative activity against human HCC827 cells after 96 hrs by MTS assay2010Journal of medicinal chemistry, Jul-08, Volume: 53, Issue:13
Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.
AID1424960Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1167082Inhibition of EGFR (unknown origin) at 10 uM by HTScan assay2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Discovery of 4-aminoquinazoline--urea derivatives as Aurora kinase inhibitors with antiproliferative activity.
AID256632Average Binding Constant for CDK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID202680Inhibition of SKBR-3 cell proliferation2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents.
AID1562620Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 20 uM incubated for 48 hrs by annexin V -FITC and PI staining based flow cytometric analysis (Rvb = 2.93%)
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1704492Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Dec-01, Volume: 207Antiproliferative effect of mitochondria-targeting allobetulin 1,2,3-triazolium salt derivatives and their mechanism of inducing apoptosis of cancer cells.
AID1425175Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625046Binding constant for PIK3CB kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625134Binding constant for PIP5K2C kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1381743Cytotoxicity against human SNU638 cells after 72 hrs by SRB assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
AID1565418Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M double mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 1821,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC.
AID435829Binding constant for RPS6KA1(Kin.Dom.2 - C-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256596Average Binding Constant for CLK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435676Binding constant for LCK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1330925Inhibition of HER2 (unknown origin) assessed as remaining ATP level measured after 15 mins by luminescence analysis2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
AID1199000Cytotoxicity against human 293T cells after 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, May-01, Volume: 25, Issue:9
Design, synthesis, biological evaluation and molecular modeling of dihydropyrazole sulfonamide derivatives as potential COX-1/COX-2 inhibitors.
AID1224772Delta TM value showing the stabilisation of MAP2K6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID624737Binding constant for EPHA5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1687591Antiproliferative activity against human NCI-H1975 cells measured after 72 hrs by MTT assay2020European journal of medicinal chemistry, Jan-15, Volume: 186Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker.
AID1460605Synergistic antibacterial activity against Staphylococcus aureus SA1199 in presence of CPX by checkerboard assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID624887Binding constant for ERK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1443469Growth inhibition of CHOK1 cells after 48 hrs by MTT assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID625027Binding constant for MAP3K4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1129591Inhibition of Akt phosphorylation in human H1975 cells harboring EGFR L858R/T790M mutant at 1 uM by Western blotting analysis2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID1652807Antitumor activity against mouse LLC cells allografted in C57BL/6J mouse assessed as inhibition of tumor growth at 5 mg/kg, ip dosed every 3 days for 17 days starting from 2 days after inoculation relative to control2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
Evaluation of Manassantin A Tetrahydrofuran Core Region Analogues and Cooperative Therapeutic Effects with EGFR Inhibition.
AID435203Binding constant for TTK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256560Average Binding Constant for FGR; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID488716Inhibition of HER2 at 10 uM2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.
AID1424929Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1439618Cytotoxicity against human A431 cells assessed as decrease in cell viability after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7
Synthesis and in vitro biological evaluation of novel quinazoline derivatives.
AID457044Cytotoxicity against human SW620 cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion.
AID625107Binding constant for DMPK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1389969Inhibition of EGFR (unknown origin) using peptide substrate after 60 mins by HTRF assay
AID1425045Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1877687Antiproliferative activity against human H460 cells by CCK8 assay2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID1425070Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1712103Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID295773Ratio of IC50 for VEGFR2 in presence of 1 mM ATP to IC50 for VEGFR2 in presence of 1 uM ATP2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
AID435439Binding constant for PAK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID599781Antiproliferative activity against human MDA-MB-468 cells after 120 hrs by MTT assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
AID1424899Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425073Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID451987Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).
AID1916784Inhibition of EGFR (unknown origin) incubated for 1 hr in presence of ATP by Kinase-Glo Plus luminescence kinase assay2022European journal of medicinal chemistry, Aug-05, Volume: 238Recent contribution of medicinally active 2-aminothiophenes: A privileged scaffold for drug discovery.
AID435556Binding constant for RAF1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1163076Safety index, ratio of IC50 for human MCF10A cells to EC50 for human ER-positive MDA-MB-231 cells2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID1198995Antiproliferative activity against mouse B16F10 cells after 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, May-01, Volume: 25, Issue:9
Design, synthesis, biological evaluation and molecular modeling of dihydropyrazole sulfonamide derivatives as potential COX-1/COX-2 inhibitors.
AID1265418Induction of apoptosis in human A549 cells assessed as viable cells at 10 uM after 48 hrs by Annexin-V-FITC/Propidium iodide staining based flow cytometric analysis (Rvb = 92.46 +/- 4.23%)2016European journal of medicinal chemistry, Jan-01, Volume: 107Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents.
AID1315993Stability in human hepatocytes assessed as length of time required to give 50% loss of parent compound at 1 uM by mass spectrometric analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.
AID256646Average Binding Constant for JAK1 (Kin.Dom. 1); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435654Binding constant for full-length ERK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID666830Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel 2-(2-arylmethylene)hydrazinyl-4-aminoquinazoline derivatives as potent antitumor agents.
AID624778Binding constant for ACVRL1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID436004Binding constant for ACVR2A kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425013Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1389963Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID256582Average Binding Constant for NEK9; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID625102Binding constant for PRKD2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1312564Inhibition of cytoplasmic GST-tagged human recombinant EGFR expressed in baculovirus system by z-lyte assay2016European journal of medicinal chemistry, Aug-08, Volume: 118Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
AID435936Binding constant for full-length SRPK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1264287Inhibition of human recombinant EGFR T790M/delE746_A750 double mutant preincubated for 10 mins followed by FAM-labeled peptide/ATP addition measured after 1 hr by mobility shift assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
AID619791Cytotoxicity against human MV4-11 cells assessed as cell viability at 10 uM after 3 days by colorimetric MTT assay2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.
AID1904122Inhibition of EGFR (unknown origin)2022European journal of medicinal chemistry, Apr-05, Volume: 233Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID625136Binding constant for YSK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624981Binding constant for ABL1(F317L)-non phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1562622Induction of apoptosis in human A549 cells assessed as necrotic cells at 20 uM incubated for 48 hrs by annexin V -FITC and PI staining based flow cytometric analysis (Rvb = 0.27%)
AID256670Average Binding Constant for ABL1(T315I); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1443481Inhibition of STK10 (unknown origin) at 0.5 uM2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID1585928Antiproliferative activity against NHBE cells after 72 hrs by MTT assay2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
AID624933Binding constant for PLK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1224799Delta TM value showing the stabilisation of NDR1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID436043Binding constant for PKMYT1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224776Delta TM value showing the stabilisation of ERK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1877684Antiproliferative activity against human A549 cells by CCK8 assay2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID1545469Inhibition of EGFR (unknown origin)2019European journal of medicinal chemistry, May-15, Volume: 170Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
AID1771675Inhibition of wild type EGFR (unknown origin) using fluoresceine-labelled poly-GT peptide as substrate incubated for 1 hr by TR-FRET assay
AID1424906Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1250385AUC (0 to 7 hrs) in Han Wistar rat blood at 20 mg/kg, po measured after 0.5 to 24 hrs by LC-MS/MS analysis2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
AID624974Binding constant for PIK3CD kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424193Inhibition of wild type N-terminal GST tagged human recombinant EGFR (695 to end amino acids) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) Peptide substrate by ADP-Glo assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
AID1425099Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424197Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
AID1353465Inhibition of EGF-induced EGFR phosphorylation at Y992 residue in human A549 cells at 5 uM preincubated for 2 hrs followed by EGF stimulation measured after 10 mins by Western blot analysis2018European journal of medicinal chemistry, Mar-10, Volume: 1476,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
AID435150Binding constant for ARK5 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425124Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435168Binding constant for LTK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID456904Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry2010Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3
Design, synthesis and biological evaluation of chrysin long-chain derivatives as potential anticancer agents.
AID1424970Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625143Binding constant for CAMKK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1768132Antifibrotic activity in C57BL mouse model of BLM-induced lung fibrosis assessed as IL-6 level in blood at 60 mg/kg measured after 14 days by flow cytometry (Rvb = 2.36 +/- 0.16 pg/ml)2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Synthesis and biological evaluation of selenogefitinib for reducing bleomycin-induced pulmonary fibrosis.
AID435398Binding constant for DAPK3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624971Binding constant for DAPK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435445Binding constant for ZAP70 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425042Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624711Binding constant for STK35 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID435410Binding constant for KIT kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1442465MRT (0 to infinity) in Sprague-Dawley rat plasma at 1 mg/kg, iv measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID1875898Antiviral activity against vaccinia virus infected in human HepG2 cells assessed as reduction in plaque formation2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID271130Clearance in Wistar rat at 2 mg/kg, iv and 10 mg/kg, po2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID1638772Binding affinity to GAK (unknown origin)2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK).
AID1432776Inhibition of recombinant human GST-tagged EGFR L858R mutant cytoplasmic domain (695-end residues) expressed in insect cells by Z'-Lyte assay2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Novel conjugates of endoperoxide and 4-anilinoquinazoline as potential anticancer agents.
AID435163Binding constant for full-length GSK3B2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1266264Antiproliferative activity against human A431 cells after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2
Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents.
AID1432773Antiproliferative activity against human HCC827 cells harboring EGFR E746_A750 deletion mutant after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Novel conjugates of endoperoxide and 4-anilinoquinazoline as potential anticancer agents.
AID1876083Antiviral activity against VACV2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID624720Binding constant for HIPK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435781Binding constant for full-length BMX2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID394883Cell cycle arrest in human K562 cells assessed as accumulation at S phase at 10 umol/L after 24 hrs by FACS relative to untreated control2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
2,3-Disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazolines: a novel class of antitumor agents.
AID624760Binding constant for PFPK5(P.falciparum) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID708803Cytotoxicity against human PC9 cells incubated for 72 hrs by MTT assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.
AID1904130Reversal of P-gp-mediated multidrug resistance in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity at 5 uM by measuring adriamycin IC50 after 48 hrs by MTT assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID256631Average Binding Constant for FLT4; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID745322Cytotoxicity against human A549 cells after 72 hrs by WST-8 assay2013European journal of medicinal chemistry, May, Volume: 63Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
AID1424915Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425060Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1057953Inhibition of human BCRP expressed in MDCK2 cells assessed as Hoechst 33342 accumulation treated 30 mins before Hoechst 33342 addition measured up to 120 mins by fluorescence assay2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
AID1712099Growth inhibition of human RXF 393 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1877686Antiproliferative activity against human Calu-3 cells by CCK8 assay2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID260903Inhibition of ligand stimulated erbB2 autophosphorylation in T24 NIH cells2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
AID1762237Cytotoxicity against human PCS-800-011 cells2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines.
AID624937Binding constant for FLT3(ITD) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID708801Cytotoxicity against human Calu3 cells incubated for 72 hrs by MTT assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.
AID1715121Inhibition of EGFR (unknown origin) at 1 uM relative to control2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1321928Antiproliferative activity against wild type human A431 cells after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of azole-diphenylpyrimidine derivatives (AzDPPYs) as potent T790M mutant form of epidermal growth factor receptor inhibitors.
AID435802Binding constant for KIT(V559D,V654A) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1532893Inhibition of human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 residues) T790M mutant expressed in baculovirus expression system after 1 hr in presence of ULight-labeled peptide substrate and ATP by LANCE ultra kinase assay2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold.
AID1425096Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625055Binding constant for MST1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1315978Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.
AID1425089Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1514366Growth inhibition of human MCF7 cells after 48 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Discovery and SAR studies of novel 2-anilinopyrimidine-based selective inhibitors against triple-negative breast cancer cell line MDA-MB-468.
AID1399719Antitumor activity against human NCI-H460 cells xenografted in nude mouse assessed as inhibition of tumor volume at 25 mg/kg, po qd for 14 consecutive days relative to control2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.
AID1250366Permeability from apical to basolateral side in MDCK2-MDR1 cells2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
AID1442469Cmax in Sprague-Dawley rat plasma at 10 mg/kg, po measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID624898Binding constant for GRK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624788Binding constant for KIT(D816H) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID670514Inhibition of HDAC derived from human HeLa cell nuclear extract using Boc-Lys(acetyl)-AMC as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorimetry2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors.
AID1365583Inhibition of EGFR (unknown origin)2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID1381741Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
AID435278Binding constant for full-length CDK72008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID456591Prolonged inhibitory activity of EGF-induced EGFR phosphorylation in human A431 cells 10 to 100 uM by immunoblot analysis2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
AID1768128Antifibrotic activity in C57BL mouse model of BLM-induced lung fibrosis assessed as reduction in collagen deposition in the lung at 60 mg/kg by masson staining method2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Synthesis and biological evaluation of selenogefitinib for reducing bleomycin-induced pulmonary fibrosis.
AID624902Binding constant for MEK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424905Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID256654Average Binding Constant for FGFR2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1673921Growth inhibition of human NCI-H1975 cells harboring EGFR L858R/T790M double mutant2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.
AID435798Binding constant for FGR kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624724Binding constant for TAK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID627042Antiproliferative activity against human NCI-H1993 cells after 3 days by SRB assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Growth inhibition of human lung cancer cells via down-regulation of epidermal growth factor receptor signaling by yuanhuadine, a daphnane diterpene from Daphne genkwa.
AID1511364Antiproliferative activity against human DU145 cells incubated for 72 hrs by MTT assay2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
AID256586Average Binding Constant for STK4; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1689697Inhibition of EGFR in human RPMI-8226 cells incubated for 2 hrs by ELISA2020European journal of medicinal chemistry, Mar-01, Volume: 1891,2,3-Triazole-Chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226.
AID435147Binding constant for ACVR2B kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID624984Binding constant for ABL1(H396P)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425162Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624899Binding constant for ROS1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424933Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1724046Inhibition of EGFR (unknown origin)2020Bioorganic & medicinal chemistry, 09-15, Volume: 28, Issue:18
Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors.
AID1235687Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 72 hrs by CellTiter-Glo assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.
AID256655Average Binding Constant for CSNK1G1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID625032Binding constant for TRKB kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435282Binding constant for full-length CSNK1G22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID633731Cytotoxicity against serum-starved human MCF7 cells over-expressing ErbB2 cells at 10 uM after 48 hrs by Cell Titer-Glo luminescent assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling.
AID127928In vivo concentration in blood levels in mice assay at a dose of 200 mg/kg by oral administration after 2 hr2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.
AID435644Binding constant for ABL1(E255K) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1458984Selectivity ratio of EC50 for human A431 cells expressing wild type EGFR to EC50 for human NCI-H1975 cells harboring EGFR-L858R/T790M double mutant2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1424891Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1632301Inhibition of EGFR (unknown origin) using FAM-labeled peptide substrate preincubated for 10 mins followed by substrate addition measured after 40 mins by caliper motility shift assay2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 2: Gefitinib analogs.
AID1751264Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 08-01, Volume: 43Design, synthesis and biological evaluation of novel 2,4-disubstituted quinazoline derivatives targeting H1975 cells via EGFR-PI3K signaling pathway.
AID435429Binding constant for FLT1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224748Delta TM value showing the stabilisation of AMPKA2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID624710Binding constant for SRMS kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID436015Binding constant for EPHA6 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID599780Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by MTT assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
AID1425105Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435442Binding constant for SYK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1174876Metabolic stability in mouse liver microsomes assessed as compound remaining at 5 uM after 30 mins under hypoxia conditions in presence of NADPH by HPLC method2015European journal of medicinal chemistry, Jan-07, Volume: 89Design, synthesis and biological evaluation of 6-(nitroimidazole-1H-alkyloxyl)-4-anilinoquinazolines as efficient EGFR inhibitors exerting cytotoxic effects both under normoxia and hypoxia.
AID1470859Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 48 hrs by SRB assay2017Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10
Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
AID69416Inhibition of Epidermal Growth Factor Receptor (EGFR) autophosphorylation2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents.
AID1265406Antiproliferative activity against human MGC803 cells by MTT assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents.
AID1460146Cytotoxicity against gefitinib-resistant human MDA-MB-468 cells assessed as cell viability at 10 uM after 48 hrs by MTT assay relative to control2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Design, synthesis, and biological evaluation of novel 1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide analogs in MCF-7 and MDA-MB-468 breast cancer cell lines.
AID435907Binding constant for EGFR(L861Q) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID589579Antiproliferative activity against human PC3 cells at 10 uM after 72 hrs by MTS assay2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.
AID624826Binding constant for BMPR2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID662580Inhibition of EGFR del E746-A750 mutant-mediated Erk phosphorylation in human HCC827 cells up to 125 nM after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1443482Inhibition of ERBB2 (unknown origin) at 0.5 uM2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID1532116Binding affinity to ABCG2 in human PLB985 cells assessed as induction of conformational changes by measuring 5D3-labeling at 10 uM after 5 mins by immunostaining based FACS analysis relative to Ko1432019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.
AID1128934Antiproliferative activity against vemurafenib-resistant human SK-MEL-28-PR30 cells harboring BRAF V600E mutant and EGFR after 68 hrs by MTS assay2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib.
AID771346Ratio of IC50 for wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured after 8 hrs to IC50 for wild type EGFR autophosphorylation in human A549 cells at 1 uM incubated for 1 hr followed by compoun2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors.
AID1545412Antiproliferative activity against human A549 after 18 hrs by MTT assay2019Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7
Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.
AID1600795Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
New amide linked dimeric 1,2,3-triazoles bearing aryloxy scaffolds as a potent antiproliferative agents and EGFR tyrosine kinase phosphorylation inhibitors.
AID625092Binding constant for NDR2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID256595Average Binding Constant for CLK3; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1443483Inhibition of RIPK2 (unknown origin) at 0.5 uM2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID1057946Therapeutic index, ratio of GI50 for MDCK cells to IC50 for human BCRP expressed in MDCK2 cells2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
AID435558Binding constant for RPS6KA3(Kin.Dom.1 - N-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1205944Binding affinity to human GAK fused to T7 bacteriophage expressed in Escherichia coli BL21 after 1 hr by qPCR analysis2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents.
AID256568Average Binding Constant for STK17A; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435322Binding constant for PRKG2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624747Binding constant for SgK110 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1585966Irreversible inhibition of wild type EGFR autophosphorylation in human A549 cells at 1 uM incubated for 1 hr followed by compound wash out measured after 8 hrs by Western blot analysis relative to control2019European journal of medicinal chemistry, Jan-15, Volume: 162Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR.
AID1702614Inhibition of human EGFR cytoplasmic domain L858R/T790M mutant (669 to 1210 residues) expressed in baculovirus infected Sf21 cells at 1 uM using biotin-labeled TK substrate preincubated for 30 mins followed by substrate and ATP addition at Km concentratio2020European journal of medicinal chemistry, Feb-01, Volume: 187Design, synthesis and biological evaluation of 2-amino-4-(1,2,4-triazol)pyridine derivatives as potent EGFR inhibitors to overcome TKI-resistance.
AID625007Binding constant for EGFR(T790M) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1915705Inhibition of EGFR (unknown origin)2021European journal of medicinal chemistry, Feb-05, Volume: 211Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
AID1817372Binding affinity to recombinant human His/GST tagged EFGR (668 to 1220 residues) expressed in baculovirus infected cells assessed as dissociation constant incubated for 30 mins by microscale thermophoresis analysis2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP.
AID1715117Inhibition of SLK (unknown origin) at 1 uM relative to control2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID674789Inhibition of EGFR2012European journal of medicinal chemistry, Sep, Volume: 55Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases.
AID625044Binding constant for PIK3CA(M1043I) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID627040Antiproliferative activity against human NCI-H292 cells after 3 days by SRB assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Growth inhibition of human lung cancer cells via down-regulation of epidermal growth factor receptor signaling by yuanhuadine, a daphnane diterpene from Daphne genkwa.
AID1441911Inhibition of human N-terminal GST-tagged EGFR L858R mutant cytoplasmic domain (669 to 1210 end amino acid residues) expressed in baculovirus expression system using TK peptide substrate preincubated with enzyme for 30 mins followed by substrate addition 2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.
AID624727Binding constant for FYN kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425132Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID674794Antiproliferative activity against human A498 cells expressing EGFR and SRC by MTT assay2012European journal of medicinal chemistry, Sep, Volume: 55Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases.
AID1425176Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1301352Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by cck8 assay2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant.
AID624885Binding constant for ERK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625003Binding constant for EGFR(L858R) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1712076Growth inhibition of human HOP-62 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID745319Cytotoxicity against human NCI-H661 cells after 72 hrs by WST-8 assay2013European journal of medicinal chemistry, May, Volume: 63Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
AID1443455Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID1140571Antiproliferative activity against human HeLa cells assessed as growth inhibition after 24 to 48 hrs by CCK8 assay2014Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10
Synthesis and biological evaluation of compounds which contain pyrazole, thiazole and naphthalene ring as antitumor agents.
AID256591Average Binding Constant for EPHA5; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435793Binding constant for EPHA1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID765700Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay2013European journal of medicinal chemistry, Sep, Volume: 67Design and synthesis of novel quinazoline nitrogen mustard derivatives as potential therapeutic agents for cancer.
AID1224749Delta TM value showing the stabilisation of CAMK1D produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1533637Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Antitumoral activity of quinoxaline derivatives: A systematic review.
AID435797Binding constant for ERBB4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID770081Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
AID624893Binding constant for MEK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID436008Binding constant for full-length BTK2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624791Binding constant for KIT(V559D) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID770082Inhibition of EGFR exon 19 deletion activating mutant phosphorylation in human PC9 cells after 2 hrs by fluorescence assay2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
AID394730Cytotoxicity against human PC3 cells after 96 hrs by MTT assay2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
2,3-Disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazolines: a novel class of antitumor agents.
AID1667574Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA2020Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9
Design and synthesis of a novel class EGFR/HER2 dual inhibitors containing tricyclic oxazine fused quinazolines scaffold.
AID1306589Cytotoxicity against human BT474 cells expressing Her2 assessed as reduction in cell viability after 72 hrs by cell titer-glo luminescence assay2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.
AID1425147Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1904123Inhibition of P-gp (unknown origin)2022European journal of medicinal chemistry, Apr-05, Volume: 233Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID1652809Antitumor activity against mouse LLC cells allografted in C57BL/6J mouse assessed as reduction tumor weight at 5 mg/kg, ip dosed every 3 days for 17 days starting from 2 days after inoculation relative to control2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
Evaluation of Manassantin A Tetrahydrofuran Core Region Analogues and Cooperative Therapeutic Effects with EGFR Inhibition.
AID1224750Delta TM value showing the stabilisation of CAMK1G produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1425118Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624844Binding constant for CDK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1460609Inhibition of NorA in Staphylococcus aureus SA1199B harboring GrlA A116E mutant assessed as potentiation of CPX-induced antibacterial activity by measuring fold reduction in CPX MIC at 6.25 to 12.5 ug/ml by checkerboard assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID1424946Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435444Binding constant for TYK2(Kin.Dom.2/JH1 - catalytic) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435926Binding constant for PDGFRB kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID771340Cellular uptake in human A549 cells incubated for 1 hr followed by compound washout measured at 1 hr by HPLC-MS/MS analysis2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors.
AID624801Binding constant for MAP3K15 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435678Binding constant for MUSK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1266270Anticancer activity against human A549 cells xenografted in nude BALB/C mouse assessed as decrease in tumor volume at 50 mg/kg, po qd for 12 days2016Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2
Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents.
AID507423Inhibition of recombinant INSR by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID435165Binding constant for JAK1(Kin.Dom.1/JH2 - pseudokinase) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1582383Induction of EGFR L858R degradation in human H3255 cells at 1 uM treated 8 hrs post serum starvation measured after 16 hrs by Western blot analysis2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
AID1585970Inhibition of recombinant human wild type GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system after 1 hr by kinase tracer 199 based TR-FRET assay2019European journal of medicinal chemistry, Jan-15, Volume: 162Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR.
AID295771Inhibition of human VEGFR2 in presence of 1 mM ATP2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
AID435286Binding constant for EPHA7 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1224756Delta TM value showing the stabilisation of CAMKK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1424974Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435823Binding constant for full-length PAK32008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624771Binding constant for TLK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID436020Binding constant for GCN2(Kin.Dom.2,S808G) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1589076Anti-tubercular activity against Mycobacterium tuberculosis H37Rv expressing LuxABCDE assessed as relative luminescence by measuring ratio of RLU (test compound)/RLU(no compound) at 1.25 uM by luminescence based assay2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.
AID435274Binding constant for ACVR1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1545414Antiproliferative activity against human MCF7 after 18 hrs by MTT assay2019Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7
Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.
AID1265405Antiproliferative activity against human HepG2 cells by MTT assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents.
AID435400Binding constant for DDR1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424944Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435651Binding constant for DCAMKL2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435180Binding constant for MAPKAPK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624748Binding constant for EPHA6 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424363Binding affinity to human EGFR assessed as residence time2017European journal of medicinal chemistry, Dec-15, Volume: 142How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.
AID1443513Antitumor activity against human MDA-MB-231 cells xenografted in NMRI nu/nu mouse at 25 mg/kg, sc administered 5 days post tumor cell inoculation treated for 14 days followed by treatment pause for 6 days followed by treatment continuation on every second2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID1724874Antiproliferative activity against EGFR/C-RAF knockdown human Panc198 cells harboring K-RAS G12D/TP53 D208V mutant xenografted in mouse tumor model assessed as inhibition of cell proliferation by MTT assay in presence of gefitinib2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Complete Regression of Carcinoma via Combined C-RAF and EGFR Targeted Therapy.
AID1265460Induction of apoptosis in human A549 cells assessed as increase in ROS production at 10 uM after 12 hrs by DCF staining based luminescence spectrometric analysis2016European journal of medicinal chemistry, Jan-01, Volume: 107Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents.
AID1265426Induction of apoptosis in human A549 cells assessed as necrotic cells at 10 uM after 48 hrs by Annexin-V/Propidium iodide dual staining based flow cytometric analysis (Rvb = 2.57 +/- 0.39%)2016European journal of medicinal chemistry, Jan-01, Volume: 107Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents.
AID256647Average Binding Constant for SYK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID436016Binding constant for full-length ERK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256571Average Binding Constant for BIKE; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624763Binding constant for RIPK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1432770Antiproliferative activity against human A549 cells harboring wild type EGFR after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Novel conjugates of endoperoxide and 4-anilinoquinazoline as potential anticancer agents.
AID1224781Delta TM value showing the stabilisation of PAK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID256618Average Binding Constant for PHkg2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624811Binding constant for PAK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID666829Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel 2-(2-arylmethylene)hydrazinyl-4-aminoquinazoline derivatives as potent antitumor agents.
AID256672Average Binding Constant for CAMK2G; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1399705Toxicity in nude mouse xenografted with human NCI-H460 cells assessed as body weight at 100 mg/kg, po qd for 14 consecutive days (Rvb = 20.6 +/- 1.5 g)2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.
AID1425034Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1511362Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
AID435775Binding constant for ABL1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1240081Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
The discovery of oxazolones-grafted spirooxindoles via three-component diversity oriented synthesis and their preliminary biological evaluation.
AID436018Binding constant for FLT4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435778Binding constant for full-length ADCK42008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256667Average Binding Constant for ABL1(E255K); NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID624722Binding constant for MKK7 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID745317Inhibition of human recombinant ABL at 10 uM relative to control2013European journal of medicinal chemistry, May, Volume: 63Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
AID1443480Inhibition of MNK1 (unknown origin) at 0.5 uM2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID1565417Antiproliferative activity against human PC9 cells harbouring EGFR delE746-A750 mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 1821,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC.
AID625081Binding constant for RSK4(Kin.Dom.1-N-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1595628Antiproliferative activity against human UCH14 cells measured after 72 hrs by alamar blue assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID1525109Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay2019Journal of natural products, 05-24, Volume: 82, Issue:5
Strepantibins A-C: Hexokinase II Inhibitors from a Mud Dauber Wasp Associated Streptomyces sp.
AID624960Binding constant for RSK2(Kin.Dom.1-N-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1712088Growth inhibition of human SNB-75 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1595617Antiproliferative activity against human UCH2 cells measured after 72 hrs by alamar blue assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID1562608Antiproliferative activity against human SW480 cells incubated for 72 hrs by MTT assay
AID624805Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1649879Growth inhibition of human PC3 cells after 5 days by SRB assay2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Design and Synthesis of a Trifunctional Molecular System "Programmed" to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer Cells.
AID1425008Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1894147Antiproliferative activity against EGF-stimulated human KB cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay2021European journal of medicinal chemistry, Mar-15, Volume: 214FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
AID624968Binding constant for DRAK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425026Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435312Binding constant for MET kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425135Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1306586Inhibition of EGFR Del19/T790M double mutant phosphorylation in human PC9/GR4 cells at 10 uM after 6 hrs by Western blot analysis2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.
AID435821Binding constant for GAK kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1402963Inhibition of EGFR (unknown origin)2018European journal of medicinal chemistry, Jan-20, Volume: 144Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
AID1177586Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability2014Journal of natural products, Aug-22, Volume: 77, Issue:8
Brocazines A-F, Cytotoxic Bisthiodiketopiperazine Derivatives from Penicillium brocae MA-231, an Endophytic Fungus Derived from the Marine Mangrove Plant Avicennia marina.
AID1353454Antiproliferative activity against human A431 cells harboring wild type EGFR after 72 hrs by MTT assay2018European journal of medicinal chemistry, Mar-10, Volume: 1476,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
AID1689707Induction of ROS accumulation in human RPMI-8226 cells incubated for 2 hrs by ELISA (Rvb = 26.06 +/- 1.45 pg/ml)2020European journal of medicinal chemistry, Mar-01, Volume: 1891,2,3-Triazole-Chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226.
AID1391278Antiproliferative activity against human A549 cells after 72 hrs by MTT assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors.
AID1690749Inhibition of EGFR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate incubated for 8 mins in presence of ATP by colorimetric analysis2020European journal of medicinal chemistry, Apr-15, Volume: 192Comparative analysis of the dual EGFR-DNA targeting and growth inhibitory properties of 6-mono-alkylamino- and 6,6-dialkylaminoquinazoline-based type II combi-molecules.
AID1443485Inhibition of ERBB4 (unknown origin) at 0.5 uM2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID1756968Inhibition of recombinant human N-terminal GST-tagged EGFR T790M mutant (669 to 1210 residues) expressed in baculovirus expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET a2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
AID1424926Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624709Binding constant for MYLK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1353459Inhibition of recombinant human N-terminal His-tagged EGFR (1 to 645 residues) expressed in HEK293 cells by ELISA2018European journal of medicinal chemistry, Mar-10, Volume: 1476,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
AID1424901Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435835Selectivity for EGFR as proportion of 290 kinases in screen with similar potency; non-selective = 1 highly selective = 02008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256614Average Binding Constant for YES; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435191Binding constant for full-length RIOK32008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256597Average Binding Constant for CLK1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1389970Inhibition of VEGFR2 (unknown origin) using peptide substrate after 60 mins by HTRF assay
AID256608Average Binding Constant for MARK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1896769Inhibition of wild type EGFR (unknown origin) assessed as percent of control activity at 1 uM by radiometric protein kinase-reaction biology assay2022Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23
Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.
AID1224779Delta TM value showing the stabilisation of NEK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID456903Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3
Design, synthesis and biological evaluation of chrysin long-chain derivatives as potential anticancer agents.
AID1425054Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625002Binding constant for EGFR(L747-T751del,Sins) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID765701Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay2013European journal of medicinal chemistry, Sep, Volume: 67Design and synthesis of novel quinazoline nitrogen mustard derivatives as potential therapeutic agents for cancer.
AID624856Binding constant for GSK3B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID256637Average Binding Constant for JNK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435323Binding constant for RET(M918T) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID633730Cytotoxicity against serum-starved human BT474 cells at 10 uM after 48 hrs by Cell Titer-Glo luminescent assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling.
AID435929Binding constant for PAK4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1439617Cytotoxicity against human NCI-H1975 cells assessed as decrease in cell viability after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7
Synthesis and in vitro biological evaluation of novel quinazoline derivatives.
AID1470863Inhibition of recombinant human N-terminal GST-tagged EGFR T790M mutant (668 to 1210 residues) expressed in baculovirus expression system preincubated for 5 mins with substrate followed by ATP addition measued after 30 mins by HTRF method2017Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10
Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
AID1424902Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1585923Antiproliferative activity against human A431 cells harboring wild-type EGFR after 72 hrs by MTT assay2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
AID435192Binding constant for ROS1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425055Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1264285Cytotoxicity against human HT-29 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
AID1424988Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624870Binding constant for NEK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624789Binding constant for KIT(D816V) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425090Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1656984Inhibition of EGFR2 (unknown origin)2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Acetylene Group, Friend or Foe in Medicinal Chemistry.
AID1432775Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-Lyte assay2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Novel conjugates of endoperoxide and 4-anilinoquinazoline as potential anticancer agents.
AID1443519Inhibition of IL-1beta-stimulated nuclear translocation of GFP-tagged NF-kappaB-p65 (unknown origin) expressed in CHO cells at 15 uM preincubated with IL-1beta for 30 mins followed by compound addition in presence of Pluronic F127 by fluorescence assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID435933Binding constant for PKN2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1562641Induction of cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 20 uM incubated for 48 hrs by PI staining based flow cytometric analysis (Rvb = 14.36%)
AID1693247Radio-sensitinzing effect in human A431 cells assessed as reduction in surviving fraction incubated at 1 uM for 24 hrs with X-ray followed by measured after 7 days by Giemsa staining relative to control2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Development of a novel acetyl glucose-modified gefitinib derivative to enhance the radiosensitizing effect.
AID624956Binding constant for EPHB4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID256566Average Binding Constant for TNIK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624988Binding constant for ABL1(T315I)-non phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625041Binding constant for PIK3CA(H1047L) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624954Binding constant for EPHB1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1315982Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.
AID1751267Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 08-01, Volume: 43Design, synthesis and biological evaluation of novel 2,4-disubstituted quinazoline derivatives targeting H1975 cells via EGFR-PI3K signaling pathway.
AID435294Binding constant for full-length LIMK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424941Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435658Binding constant for JAK2(Kin.Dom.2/JH1 - catalytic) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256607Average Binding Constant for STK18; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1441907Inhibition of EGFR delE746_A750 mutant in human HCC827 cells assessed as reduction in cell viability after 96 hrs by CellTiterGlo assay2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.
AID484274Inhibition of Trypanosoma cruzi cruzaine preincubated for 5 mins before substrate addition by fluorescence assay in absence of Triton X-1002010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1442456Cmax in Sprague-Dawley rat plasma at 1 mg/kg, iv measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID1425069Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1756973Induction of apoptosis in human NCI-H1975 cells assessed as viable cells at 2 uM incubated for 24 hrs by annexin V-FITC and propidium iodide based flow cytometry analysis (Rvb = 93.2 %)2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
AID1053598Inhibition of EGFR L858R/T790M double mutant in human NCI-H1975 cells assessed as reduction in ERK phosphorylation at 330 nM after 2 hrs by Western blotting analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties.
AID1609530Antiproliferative activity against human HCT116 cells assessed as inhibition of cell viability after 48 hrs by MTS assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Design and synthesis of novel artemisinin derivatives with potent activities against colorectal cancer in vitro and in vivo.
AID1532904Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 8 uM after 72 hrs by FITC-annexin V/propidium iodide-double staining based flow cytometry (Rvb = 6.59%)2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold.
AID435162Binding constant for FLT3(N841I) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1251003Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.
AID1533636Antiproliferative activity against human A549 cells after 48 hrs by MTT assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Antitumoral activity of quinoxaline derivatives: A systematic review.
AID1305370Antitumor activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant xenografted in mouse at 100 mg/kg/day, po qd for 7 days2016ACS medicinal chemistry letters, May-12, Volume: 7, Issue:5
Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation.
AID1306581Inhibition of EGFR Del19/T790M double mutant (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.
AID1381747Inhibition of PI3K p110gamma (unknown origin) using PIP2 as substrate by ELISA2018European journal of medicinal chemistry, Feb-25, Volume: 146Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
AID1712091Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID256659Average Binding Constant for DAPK3; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1904125Antiproliferative activity against human A549 cells highly expressing EGFR after 48 hrs by MTT assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID625083Binding constant for LATS2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1712086Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID619787Cytotoxicity against human DLD1 cells assessed as cell viability at 1 uM after 3 days by colorimetric MTT assay2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.
AID1632286Cytotoxicity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as growth inhibition after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 2: Gefitinib analogs.
AID1230128Antiproliferative activity against human A549 cells assessed as cell growth by MTT assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Combination of 4-anilinoquinazoline and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors.
AID256651Average Binding Constant for DAPK2; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1424981Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435415Binding constant for MYLK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1053597Inhibition of EGFR L858R/T790M double mutant in human NCI-H1975 cells assessed as reduction in AKT phosphorylation at 330 nM after 2 hrs by Western blotting analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design, synthesis, and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties.
AID435296Binding constant for MARK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624924Binding constant for RIPK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435662Binding constant for MST2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625015Binding constant for ROCK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624927Binding constant for RPS6KA4(Kin.Dom.2-C-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425142Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID761602Inhibition of EGFR L858R mutant (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET based Z'-lyte assay2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID1425166Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1458978Inhibition of recombinant human GST-tagged EGFR L858R/T790M double mutant expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 20 mins by HTRF assay2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1425178Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624929Binding constant for BRSK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435799Binding constant for FLT3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1174871Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay2015European journal of medicinal chemistry, Jan-07, Volume: 89Design, synthesis and biological evaluation of 6-(nitroimidazole-1H-alkyloxyl)-4-anilinoquinazolines as efficient EGFR inhibitors exerting cytotoxic effects both under normoxia and hypoxia.
AID1460608Inhibition of Staphylococcus aureus SAK2378 norA assessed as potentiation of CPX-induced antibacterial activity by measuring fold reduction in CPX MIC at 12.5 to 25 ug/ml by checkerboard assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID1589887Inhibition of probe binding to EGFR L858R mutant (unknown origin) using rabbit reticulate lysate system after 1 hr by luminescence assay2019Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12
Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors.
AID670513Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors.
AID1600794Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
New amide linked dimeric 1,2,3-triazoles bearing aryloxy scaffolds as a potent antiproliferative agents and EGFR tyrosine kinase phosphorylation inhibitors.
AID1368035Inhibition of recombinant wild type EGFR (696 to C-terminal residues) (unknown origin) preincubated for 30 mins followed by poly (Glu-Tyr) biotinylated peptide substrate addition measured after 30 mins in presence of ATP by ELISA2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Design, synthesis, and evaluation of A-ring-modified lamellarin N analogues as noncovalent inhibitors of the EGFR T790M/L858R mutant.
AID624972Binding constant for MTOR kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1251005Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.
AID1425136Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1250369Efflux ratio of permeability from basolateral to apical side over apical to basolateral side in BCRP transfected MDCK2 cells2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
AID624973Binding constant for JAK2(JH1domain-catalytic) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425211Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1585968Drug uptake in human A549 cells at 1 uM incubated for 1 hr followed by compound washout and measured after 8 hrs by LC-MS analysis2019European journal of medicinal chemistry, Jan-15, Volume: 162Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR.
AID624888Binding constant for ERK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624753Binding constant for PKNB(M.tuberculosis) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID777419Irreversible inhibition of EGFR autophosphorylation in human A431 cells at 1 uM incubated for 1 hr followed by compound wash out measured 5 hrs post EGF addition by Western blotting analysis2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR.
AID624950Binding constant for DMPK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1265416Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 10 uM after 6 hrs by Annexin-V-FITC/Propidium iodide staining based flow cytometric analysis (Rvb = 0.41 +/- 0.19%)2016European journal of medicinal chemistry, Jan-01, Volume: 107Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents.
AID1562649Inhibition of EGF-induced EGFR phosphorylation at Y992 in human A431 cells at 5 uM preincubated for 2 hrs followed by EGF treatment and measured after 10 mins by Western blot analysis
AID537733Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID435520Binding constant for CAMK2A kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID552132Antiproliferative activity against EGFR-deficient human PC9 cells2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Discovery of selective irreversible inhibitors for EGFR-T790M.
AID1330924Inhibition of wild-type EGFR (unknown origin) assessed as remaining ATP level measured after 15 mins by luminescence analysis2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
AID624739Binding constant for GRK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625047Binding constant for AMPK-alpha2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435170Binding constant for MYO3A kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424922Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1499611Cytotoxicity against human HepG2 cells at 40 uM after 48 hrs by LDH release assay (Rvb = 100%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
AID1535423Inhibition of human A431 cell-derived EGFR2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
AID1224755Delta TM value showing the stabilisation of CAMK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1715113Inhibition of MEK5 (unknown origin) at 1 uM relative to control2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID625106Binding constant for MARK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435782Binding constant for BRSK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID1425074Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1595625Antiproliferative activity against human UMCHOR1 cells measured after 72 hrs by alamar blue assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID670516Antiproliferative activity against human A549 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors.
AID435289Binding constant for ERK3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1381742Cytotoxicity against human SKHEP1 cells after 72 hrs by SRB assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
AID435804Binding constant for LYN kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID484280Colloidal aggregation in fed state simulated intestinal fluid by dynamic light scattering assay in presence of 0.5% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1442457Initial plasma concentration in Sprague-Dawley rat at 1 mg/kg, iv measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID507076Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP2008Nature chemical biology, Nov, Volume: 4, Issue:11
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
AID488712Cytotoxicity against human A549 cells after 4 to 5 days by MTT assay2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.
AID1399704Toxicity in nude mouse xenografted with human NCI-H460 cells assessed as body weight at 50 mg/kg, po qd for 14 consecutive days (Rvb = 20.6 +/- 1.5 g)2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.
AID1186994Cytotoxicity against human HepG2 cells assessed as cell viability at 1 uM after 24 hrs by Cell-Titer Glo assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
AID1565420Antiproliferative activity against human CL97 cells harbouring EGFR G719A/T790M mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 1821,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC.
AID624706Binding constant for MLK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435408Binding constant for INSR kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435193Binding constant for RPS6KA6(Kin.Dom.1 - C-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1428363Inhibition of HRG stimulated erbB2 phosphorylation in human MCF-7 cells preincubated for 90 mins followed by HRG addition for 5 mins by ELISA method2017European journal of medicinal chemistry, Jan-27, Volume: 126Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors.
AID512582Selectivity ratio of Ki for EGFR to Ki for ErbB42005Chemistry & biology, Jun, Volume: 12, Issue:6
Features of selective kinase inhibitors.
AID1442471AUC (0 to infinity) in Sprague-Dawley rat plasma at 10 mg/kg, po measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID625114Binding constant for GSK3A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435394Binding constant for CAMK2B kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1167181Antitumor activity against human NCI-H1975 cells harboring EGFR L858R/T970M double mutant xenografted in SCID mouse assessed as tumor growth inhibition at 100 mg/kg/day, po qd for 7 days relative to control2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.
AID1425200Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424948Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435514Binding constant for ABL1(M351T) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624750Binding constant for PRP4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624918Binding constant for DYRK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624891Binding constant for JNK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435906Binding constant for EGFR(L747-T751del,Sins) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435325Binding constant for RPS6KA4(Kin.Dom.1 - C-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625024Binding constant for PRKD3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1312557Inhibition of EGFR L858R/T790M double mutant (unknown origin)2016European journal of medicinal chemistry, Aug-08, Volume: 118Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID1407102Inhibition of GST-tagged recombinant human VEGFR (789-end) expressed in baculovirus infected Sf9 insect cells preincubated for 5 mins followed by ATP addition and measured after 30 mins by HTRF assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity.
AID624932Binding constant for CLK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624758Binding constant for RIPK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1306574Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.
AID435932Binding constant for PKAC-alpha kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1589075Cytotoxicity in human WS1 cells assessed as reduction in cell viability incubated fro 48 hrs by alamar blue dye based assay2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.
AID625067Binding constant for NDR1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1768067Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Investigation of 3-sulfamoyl coumarins against cancer-related IX and XII isoforms of human carbonic anhydrase as well as cancer cells leads to the discovery of 2-oxo-2H-benzo[h]chromene-3-sulfonamide - A new caspase-activating proapoptotic agent.
AID624916Binding constant for ULK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID435319Binding constant for PKN1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1499602Inhibition of recombinant human His-tagged EGFR (1 to 645 residues) expressed in HEK293 cells at 0.01 uM using Tyr66-biotinylated PTP1B peptide as substrate preincubated for 5 mins followed by substrate addition measured after 1 hr by ELISA relative to co2017European journal of medicinal chemistry, Sep-29, Volume: 138Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
AID1278393Inhibition of recombinant human EGFR L858R/T790M double mutant assessed as reduction in autophosphorylation of cytoplasmic domain by Z'-Lyte assay2016European journal of medicinal chemistry, Mar-03, Volume: 110Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines.
AID625053Binding constant for PRKG2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624943Binding constant for ACVR1B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425030Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID271136Free drug level in mouse plasma at 50 mg/kg, po at 24 hrs2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID435655Binding constant for ERK5 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1730893Inhibition of HDAC in human NCI-H1975 cells assessed as increase in histone H3 acetylation at 2.5 uM after 1 to 12 hrs by Western blot analysis2021European journal of medicinal chemistry, Mar-05, Volume: 213Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
AID1425112Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425204Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425032Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1702619Antiproliferative activity against human U-87MG cells harboring wild type EGFR assessed as inhibition of cell growth by MTT assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Design, synthesis and biological evaluation of 2-amino-4-(1,2,4-triazol)pyridine derivatives as potent EGFR inhibitors to overcome TKI-resistance.
AID271126Aqueous solubility at pH 7.42006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID435190Binding constant for full-length PIP5K1A2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435521Binding constant for CAMKK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625124Binding constant for RET(V804M) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID489618Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and preliminary biological evaluation of novel taspine derivatives as anticancer agents.
AID435652Binding constant for EGFR(L747-E749del, A750P) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435159Binding constant for EPHB3 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID436013Binding constant for DMPK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256599Average Binding Constant for TTK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1499559Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
AID1616555Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer.
AID1424890Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1198996Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, May-01, Volume: 25, Issue:9
Design, synthesis, biological evaluation and molecular modeling of dihydropyrazole sulfonamide derivatives as potential COX-1/COX-2 inhibitors.
AID1589892Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by SRB assay2019Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12
Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors.
AID271132AUC in Wistar rat at 10 mg/kg, po normalized to 1 mg/kg2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID708798Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.
AID1425087Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID708802Cytotoxicity against human NCI-H292 cells incubated for 72 hrs by MTT assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.
AID435647Binding constant for CAMK2D kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1712095Growth inhibition of human OVCAR-3 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID625040Binding constant for PIK3CA(E545K) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID745320Inhibition of EGFR (unknown origin) at 10 uM relative to control2013European journal of medicinal chemistry, May, Volume: 63Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
AID1667569Antiproliferative activity against human NCI-N87 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay2020Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9
Design and synthesis of a novel class EGFR/HER2 dual inhibitors containing tricyclic oxazine fused quinazolines scaffold.
AID1241287Inhibition of EGFR L858R mutant (unknown origin) expressed in Sf9 cells pre-incubated for 60 mins before substrate and ATP addition by homogeneous time-resolved FRET assay2015Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.
AID624883Binding constant for PRKCI kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID748090Cytotoxicity against gefitinib-resistant human NCI-H1975 cells harboring EGFR L858R/T90M double mutant assessed as growth inhibition after 72 hrs by MTT assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID436048Binding constant for full-length PTK2B2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1250370Fraction unbound in Han Wistar rat blood at 5 uM by equilibrium dialysis method2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
AID1768069Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Investigation of 3-sulfamoyl coumarins against cancer-related IX and XII isoforms of human carbonic anhydrase as well as cancer cells leads to the discovery of 2-oxo-2H-benzo[h]chromene-3-sulfonamide - A new caspase-activating proapoptotic agent.
AID435830Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1690731Growth inhibition of human A549 cells incubated for 5 days by SRB assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Comparative analysis of the dual EGFR-DNA targeting and growth inhibitory properties of 6-mono-alkylamino- and 6,6-dialkylaminoquinazoline-based type II combi-molecules.
AID256620Average Binding Constant for FLT3; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1511366Inhibition of EGFR (unknown origin) using TK substrate incubated for 60 mins by FRET assay2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
AID1460163Inhibition of EGFR in gefitinib-resistant human MDA-MB-468 cells assessed as reduction in Akt phosphorylation at 10 uM after 18 hrs by Western blot method2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Design, synthesis, and biological evaluation of novel 1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide analogs in MCF-7 and MDA-MB-468 breast cancer cell lines.
AID1424956Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624860Binding constant for VEGFR2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425002Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425120Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624736Binding constant for RPS6KA5(Kin.Dom.1-N-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1712094Growth inhibition of human IGROV-1 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID1877683Antiproliferative activity against human MCF7 cells by CCK8 assay2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID435803Binding constant for full-length LIMK12008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424972Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435691Binding constant for SgK085 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1069185Antitumor activity against human A549 cells xenografted in nude mouse assessed as suppression of tumor volume at 20 mg/kg, ip qd for 60 days measured up to 60 days2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Synthesis and biological evaluation of novel tetrahydro-β-carboline derivatives as antitumor growth and metastasis agents through inhibiting the transforming growth factor-β signaling pathway.
AID1424962Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424894Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID271137Dissociation constant, pKa of the compound2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
AID1425016Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424953Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1353463Inhibition of EGF-induced EGFR phosphorylation at Tyrosine residue in human A549 cells at 5 uM preincubated for 2 hrs followed by EGF stimulation measured after 10 mins by Western blot analysis2018European journal of medicinal chemistry, Mar-10, Volume: 1476,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
AID435321Binding constant for PRKCQ kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1315990Stability in rat liver microsomes assessed as length of time required to give 50% loss of parent compound at 5 uM by mass spectrometric analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.
AID435200Binding constant for full-length TNNI3K2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425168Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1224752Delta TM value showing the stabilisation of CAMK2B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1458977Inhibition of human recombinant GST-tagged EGFR L858R mutant expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 15 mins by HTRF assay2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID589662Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.
AID435557Binding constant for RIPK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID436049Binding constant for PTK6 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435160Binding constant for FER kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625128Binding constant for CSNK1G1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1632302Inhibition of HER2 (unknown origin) using FAM-labeled peptide substrate preincubated for 10 mins followed by substrate addition measured after 40 mins by caliper motility shift assay2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 2: Gefitinib analogs.
AID1424980Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID457043Induction of apoptosis in human NCI-H1975 cells assessed as activation of caspase-3 at 5 uM after 2 days by Western blot2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion.
AID1424949Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1224793Delta TM value showing the stabilisation of RSK2a produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1265467Induction of apoptosis in human A549 cells assessed as upregulation of caspase-8 expression at 10 uM after 48 hrs by Western blot analysis2016European journal of medicinal chemistry, Jan-01, Volume: 107Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents.
AID624841Binding constant for BLK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625008Binding constant for EPHA1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1442455Tmax in Sprague-Dawley rat plasma at 1 mg/kg, iv measured after 24 hrs by UPLC analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
AID1562647Inhibition of EGF-induced EGFR phosphorylation at Tyr-residue in human A431 cells at 5 uM preincubated for 2 hrs followed by EGF treatment and measured after 10 mins by Western blot analysis
AID1585926Antiproliferative activity against human Aspc-1 cells after 72 hrs by MTT assay2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
AID256617Average Binding Constant for TEK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID1330932Inhibition of HER2 (unknown origin) expressed in baculovirus infected insect cells after 20 mins in presence of ATP by ELISA2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
AID1443989Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell plasma membrane vesicles assessed as reduction in ATP-dependent [3H]-taurocholate uptake in to vesicles preincubated for 10 mins followed by ATP addition measured after 10 to 2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID7892Inhibition of A431 cell proliferation2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents.
AID435930Binding constant for PHKG2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1425190Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1443991Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1712075Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID624741Binding constant for LRRK2(G2019S) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1378270Antiproliferative activity against human A549 cells harboring wild type EGFR/K-Ras mutant after 72 hrs by MTT assay
AID1301349Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant.
AID624892Binding constant for p38-delta kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1399712Antitumor activity against human NCI-H460 cells xenografted in nude mouse assessed as inhibition of tumor weight at 50 mg/kg, po qd for 14 consecutive days relative to control2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.
AID1425048Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624828Binding constant for CDK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID488710Cytotoxicity against human DU145 cells after 4 to 5 days by MTT assay2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1177590Cytotoxicity against human U251 cells assessed as reduction in cell viability2014Journal of natural products, Aug-22, Volume: 77, Issue:8
Brocazines A-F, Cytotoxic Bisthiodiketopiperazine Derivatives from Penicillium brocae MA-231, an Endophytic Fungus Derived from the Marine Mangrove Plant Avicennia marina.
AID395851Inhibition of autophosphorylation of immunoprecipitated flag-tagged Bmx expressed in human LNCaP cells assessed as incorporation of [32P]ATP at 10 uM pretreated for 2 hrs before transfection by immunoblot analysis2008Bioorganic & medicinal chemistry letters, Nov-15, Volume: 18, Issue:22
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.
AID436005Binding constant for ANKK1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID256638Average Binding Constant for PRKAA1; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624831Binding constant for CHEK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625094Binding constant for CDK11 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1301350Inhibition of EGFR T790M/L858R double mutant (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant.
AID1443465Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells at 150 nM using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID488734Antitumor activity against human MIAPaCa2 cells xenografted in NCr nu/nu mouse assessed as partial delay in tumor formation pretreated with 2.5 uM before implantation measured after 40 days of implantation2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.
AID1425020Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425160Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1425028Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624958Binding constant for PIK3C2G kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID436014Binding constant for full-length DYRK1B2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1424959Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID435412Binding constant for MAP3K5 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID435280Binding constant for CSF1R kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624852Binding constant for FES kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID580190Inhibition of EGFR by homogeneous time-resolved fluorescence assay2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Synthesis and evaluation of novel pyrimidine-based dual EGFR/Her-2 inhibitors.
AID625066Binding constant for IRAK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID778803Inhibition of c-Met in gefitinib-resistant human HCC827 cells assessed as inhibition of AKT phosphorylation at 0.5 uM after 2 hrs by Western blotting analysis2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.
AID295762Inhibition of human EGFR in presence of 1 uM ATP2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
AID435789Binding constant for full-length CSNK2A22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1617469Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay2019Journal of natural products, 11-22, Volume: 82, Issue:11
Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
AID488731Induction of apoptosis in human MIAPaCa2 cells assessed as caspase 3 activation at 20 uM after 24 hrs by fluorescence assay2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.
AID625059Binding constant for YSK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1129567Inhibition of EGFR (unknown origin) after 1.5 hr by FRET-based Z-lyte assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID1240084Cytotoxicity against human HCCC9810 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
The discovery of oxazolones-grafted spirooxindoles via three-component diversity oriented synthesis and their preliminary biological evaluation.
AID695420Induction of apoptosis in human HT-29 cells expressing BRAF mutant assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Synthesis and evaluation of apoptosis induction of thienopyrimidine compounds on KRAS and BRAF mutated colorectal cancer cell lines.
AID624777Binding constant for DDR2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624877Binding constant for PIK3C2B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1562619Induction of apoptosis in human A549 cells assessed as viable cells at 20 uM incubated for 48 hrs by annexin V -FITC and PI staining based flow cytometric analysis (Rvb = 94.56%)
AID580189Inhibition of HER2 by homogeneous time-resolved fluorescence assay2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Synthesis and evaluation of novel pyrimidine-based dual EGFR/Her-2 inhibitors.
AID1817362Protac activity at VHL/PARP-1 in human NCI-H1299 cells assessed as induction of PARP degradation at up to 15 uM incubated for 36 hrs by Western blot analysis2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP.
AID1771702Ratio of IC50 for inhibition of wild type EGFR (unknown origin) using fluoresceine-labelled poly-GT peptide as substrate incubated for 1 hr to IC50 for inhibition of wild type EGFR (unknown origin) using fluoresceine-labelled poly-GT peptide as substrate
AID1896802Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion SVD mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay2022Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23
Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.
AID624808Binding constant for TRKA kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1724872Antiproliferative activity against EGFR/C-RAF knockdown human PDAC013T cells harboring K-RAS G12D/TP53 I254T mutant xenografted in mouse tumor model assessed as inhibition of cell proliferation by MTT assay in presence of gefitinib2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Complete Regression of Carcinoma via Combined C-RAF and EGFR Targeted Therapy.
AID435788Binding constant for CLK4 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1514367Growth inhibition of EGFR over-expressing human MDA-MB-468 cells after 48 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Discovery and SAR studies of novel 2-anilinopyrimidine-based selective inhibitors against triple-negative breast cancer cell line MDA-MB-468.
AID1532891Inhibition of wild type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system after 1 hr in presence of ULight-labeled peptide substrate and ATP by LANCE ultra kinase assay2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold.
AID1424893Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1381745Inhibition of PI3K p110alpha (unknown origin) using PIP2 as substrate by ELISA2018European journal of medicinal chemistry, Feb-25, Volume: 146Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
AID1585979Growth inhibition of human NCI-H1975 cells after 72 hrs by MTT assay2019European journal of medicinal chemistry, Jan-15, Volume: 162Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR.
AID1574935Antiproliferative activity against HER2-dependant human SKBR3 cells after 72 hrs by EZ-Cytox assay2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
AID625127Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1443468Growth inhibition of human A549 cells after 48 hrs by MTT assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
AID512580Inhibition of EGFR2005Chemistry & biology, Jun, Volume: 12, Issue:6
Features of selective kinase inhibitors.
AID625141Binding constant for RIOK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624938Binding constant for FLT3(K663Q) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625108Binding constant for MKNK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1428362Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method2017European journal of medicinal chemistry, Jan-27, Volume: 126Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors.
AID1265414Induction of apoptosis in human A549 cells assessed as viable cells at 10 uM after 6 hrs by Annexin-V-FITC/Propidium iodide staining based flow cytometric analysis (Rvb = 95.48 +/- 2.03%)2016European journal of medicinal chemistry, Jan-01, Volume: 107Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents.
AID256578Average Binding Constant for SLK; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID624705Binding constant for MYLK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1403039Induction of apoptosis in human A549 cells assessed as live cells after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 97.93%)2018European journal of medicinal chemistry, Jan-20, Volume: 144Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
AID624900Binding constant for RSK1(Kin.Dom.1-N-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1303324Antiproliferative activity against human NCI-H1975 cells over expressing EGFR after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Facile and efficient synthesis and biological evaluation of 4-anilinoquinazoline derivatives as EGFR inhibitors.
AID1389962Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID489617Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and preliminary biological evaluation of novel taspine derivatives as anticancer agents.
AID1687592Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells measured after 72 hrs by MTT assay2020European journal of medicinal chemistry, Jan-15, Volume: 186Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker.
AID638084Inhibition of EGFR phosphorylation in EGF-stimulated human A431 after 2 hrs by Western blot analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Discovery of novel 5-alkynyl-4-anilinopyrimidines as potent, orally active dual inhibitors of EGFR and Her-2 tyrosine kinases.
AID395852Inhibition of autophosphorylation of immunopurified flag-tagged Bmx in human LNCaP cells assessed as incorporation of [32P]ATP at 10 uM pretreated for 4 hrs before immunopurification by immunoblot analysis2008Bioorganic & medicinal chemistry letters, Nov-15, Volume: 18, Issue:22
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.
AID1514368Selectivity index, ratio of GI50 for human MCF7 cells to GI50 for EGFR over-expressing human MDA-MB-468 cells2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Discovery and SAR studies of novel 2-anilinopyrimidine-based selective inhibitors against triple-negative breast cancer cell line MDA-MB-468.
AID1562640Induction of cell cycle arrest in human A549 cells assessed as accumulation at S phase at 20 uM incubated for 48 hrs by PI staining based flow cytometric analysis (Rvb = 33.67%)
AID1470946Antiproliferative activity against NHBE cells assessed as decrease in cell viability after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10
C-2 (E)-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFR
AID1128931Inhibition of BRAF V600E mutant (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib.
AID1589890Growth inhibition of human NCI-H322M cells incubated for 48 hrs by SRB assay2019Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12
Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors.
AID1441912Inhibition of human N-terminal GST-tagged EGFR L858R/T790M double mutant cytoplasmic domain (669 to 1210 end amino acid residues) expressed in baculovirus expression system using TK peptide substrate preincubated with enzyme for 30 mins followed by substr2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.
AID1458981Antiproliferative activity against human HCC827 cells harboring EGFR-delE746_A750 mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID435931Binding constant for PIM1 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID624982Binding constant for ABL1(F317L)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425150Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1266267Inhibition of wild-type EGFR tyrosine kinase (unknown origin) assessed as ATP level by luminescence analysis2016Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2
Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents.
AID1309516Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
6-Oxooxazolidine-quinazolines as noncovalent inhibitors with the potential to target mutant forms of EGFR.
AID1425116Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1168677Cytotoxicity against human A549 cells assessed as cell viability at 20 uM after 24 hrs by MTT assay (Rvb = 100%)2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Optimization of gefitinib analogues with potent anticancer activity.
AID1657034Antiproliferative activity against human A549 cells assessed as cell death2020Bioorganic & medicinal chemistry letters, 04-01, Volume: 30, Issue:7
Pro-apoptotic carboxamide analogues of natural fislatifolic acid targeting Mcl-1 and Bcl-2.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1712080Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening.
AID624905Binding constant for CDKL5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1266265Antiproliferative activity against human A549 cells after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2
Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents.
AID625105Binding constant for EPHB2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1582382Induction of EGFR exon 19 deletion mutant degradation in human HCC827 cells at 1 uM treated 8 hrs post serum starvation measured after 16 hrs by Western blot analysis2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
AID1585919Inhibition of human N-terminal GST-tagged EGFR T790M/L858R double mutant (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
AID435648Binding constant for CAMKK2 kinase domain2008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID589582Antiproliferative activity against human EAhy926 cells at 10 uM after 72 hrs by MTS assay2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.
AID1470861Antiproliferative activity against non-special gene type human HT-29 cells after 48 hrs by SRB assay2017Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10
Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
AID1704493Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Dec-01, Volume: 207Antiproliferative effect of mitochondria-targeting allobetulin 1,2,3-triazolium salt derivatives and their mechanism of inducing apoptosis of cancer cells.
AID1424987Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625112Binding constant for YANK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID256569Average Binding Constant for PAK7/PAK5; NA=Not Active at 10 uM2005Nature biotechnology, Mar, Volume: 23, Issue:3
A small molecule-kinase interaction map for clinical kinase inhibitors.
AID435196Binding constant for full-length SRPK22008Nature biotechnology, Jan, Volume: 26, Issue:1
A quantitative analysis of kinase inhibitor selectivity.
AID1378271Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTT assay
AID1499605Inhibition of recombinant human His-tagged EGFR (1 to 645 residues) expressed in HEK293 cells at 10 uM using Tyr66-biotinylated PTP1B peptide as substrate preincubated for 5 mins followed by substrate addition measured after 1 hr by ELISA relative to cont2017European journal of medicinal chemistry, Sep-29, Volume: 138Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
AID625018Binding constant for YES kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID634928Antiproliferative activity against human A549 cells overexpressing EGFR gene after 48 hrs by MTT assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Synthesis, molecular modeling and biological evaluation of 2-(benzylthio)-5-aryloxadiazole derivatives as anti-tumor agents.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID493040Navigating the Kinome2011Nature chemical biology, Apr, Volume: 7, Issue:4
Navigating the kinome.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1345502Human epidermal growth factor receptor (Type I RTKs: ErbB (epidermal growth factor) receptor family)2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
AID1345502Human epidermal growth factor receptor (Type I RTKs: ErbB (epidermal growth factor) receptor family)2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,096)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1905 (37.38)29.6817
2010's2559 (50.22)24.3611
2020's632 (12.40)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 66.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index66.95 (24.57)
Research Supply Index8.67 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index115.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (66.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials566 (10.82%)5.53%
Reviews688 (13.15%)6.00%
Case Studies461 (8.81%)4.05%
Observational19 (0.36%)0.25%
Other3,497 (66.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (338)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Controlled Phase III Trial to Evaluate the Efficacy of Elortinib vs Gefitinib in Advanced Non-small-cell Lung Cancer With EGFR Exon 19 or 21 Mutations [NCT01024413]Phase 3256 participants (Actual)Interventional2009-07-31Completed
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Gefitinib in Combination With MEDI4736 (Anti PD-L1) in Subjects With Non-Small Cell Lung Cancer(NSCLC) [NCT02088112]Phase 156 participants (Actual)Interventional2014-03-24Completed
A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Effective on Erlotinib or Gefitinib(RT1001) [NCT01158170]Phase 3200 participants (Anticipated)Interventional2010-06-30Recruiting
Paclitaxel/Carboplatin (PC) Followed by Gefitinib or Paclitaxel/Carboplatin (PC) in Advanced Non-small Cell Lung Cancer (NSCLC): Randomized Phase II Study [NCT01196234]Phase 284 participants (Actual)Interventional2009-12-31Completed
A Randomized, Open-label, Controlled, Multi-Center Phase II/III Study to Assess the Efficacy and Safety of AZD3759 vs. a Standard of Care EGFR TKI, as First Line Treatment to EGFR Mutation Positive Advanced NSCLC With CNS Metastases [NCT03653546]Phase 2/Phase 3492 participants (Actual)Interventional2018-10-29Completed
A Prospective, Single-arm, Multicenter Study of Anlotinib Hydrochloride Combined With First-generation EGFR TKIs as Second-line Treatment in Acquired (Non-T790M Mutation) Resistance Advanced Non-small Cell Lung Cancer [NCT03766490]66 participants (Anticipated)Interventional2019-03-30Not yet recruiting
A Single-arm, Phase II Study of Preoperative Gefitinib for Stage II-IIIa NSCLC With Activating EGFR Mutation [NCT01833572]Phase 236 participants (Actual)Interventional2013-05-31Completed
A Randomized, Double-blind, Positive-controlled, Multi-center Phase III Clinical Study of Evaluating Alflutinib Mesylate Versus Gefitinib as First-line Therapy in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) With EGFR-se [NCT03787992]Phase 3358 participants (Actual)Interventional2019-05-30Active, not recruiting
A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare Tepotinib (MSC2156119J) Combined With Gefitinib Versus Chemotherapy as Second-Line Treatment in Subjects With MET Positive, Locally Advanced or Metastatic NSCLC Harboring EGFR Mutation and [NCT01982955]Phase 1/Phase 288 participants (Actual)Interventional2013-12-23Completed
Oral Navelbine Carboplatin Versus Gefitinib Neoadjuvant Therapy for Resectable EGFR Mutation Positive Stage Ⅱ-ⅢA NSCLC, Prospective, Randomized, Multicenter, Phase Ⅲ Clinical Trial [NCT03203590]Phase 3590 participants (Anticipated)Interventional2017-09-30Not yet recruiting
Randomized to Assess the Efficacy of Whole Brain Radiation Therapy (WBRT) With Concomitant Gefitinib Followed by Maintenance Gefitinib, and Gefitinib Alone, in Lung Cancer Patients With Brain Metastasis [NCT01363557]1 participants (Actual)Interventional2012-03-31Terminated(stopped due to Decision of Sponsor)
A Phase III, Multi Center, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination Gefitinib With Thalidomide in Patients With Locally Advanced and Metastatic Non-Small-Cell-Lung-Cancer With EGFR Mutation [NCT02387086]Phase 2/Phase 3380 participants (Anticipated)Interventional2015-05-31Not yet recruiting
A Phase III Randomized, Controlled, Double-Blind, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of HS-10296 Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic NSCLC With EGFR Sensitizing Mutations [NCT03849768]Phase 3429 participants (Actual)Interventional2019-02-01Active, not recruiting
A Phase II Trial of Gefitinib Monotherapy in Pretreated Patients With Advanced Non-small Cell Lung Cancer Not Harboring Active EGFR Mutations [NCT01312337]Phase 292 participants (Anticipated)Interventional2010-09-30Recruiting
A Phase I/II Study of MK-3475 (SCH900475) in Combination With Chemotherapy or Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma [NCT02039674]Phase 1/Phase 2267 participants (Actual)Interventional2014-02-21Completed
Combination of Chemotherapy and Gefitinib as First-line Treatment of Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomised Controlled Trial [NCT02148380]121 participants (Actual)Interventional2014-05-31Completed
Pilot Neoadjuvant Study of ZD1839 (IRESSA®) as Single Agent Preoperative Therapy for Clinical Stage 1A and 1B (T1-2N0), II (T1-2N1, T3N0) and Selected IIIA (T3N1) Non-Small Cell Lung Cancer (NSCLC) With Molecular Correlates [NCT00104728]42 participants (Actual)Interventional2004-10-31Terminated(stopped due to Early Stopping Rule: Would not meet interim analysis goal to proceed with enrollment)
A Phase I/II Trial of Fixed Doses of Daily Gefitinib With Escalating Doses of Daily RAD001 in Advanced Non-Small Cell Lung Cancer [NCT00096486]Phase 1/Phase 274 participants (Actual)Interventional2004-05-31Completed
A Phase III, Double-blind, Randomised Study to Assess the Safety and Efficacy of AZD9291 Versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First Line Treatment in Patients With Epidermal Growth Factor Receptor Mutatio [NCT02296125]Phase 3674 participants (Actual)Interventional2014-12-03Active, not recruiting
Evaluation of the Efficacy of Domestic Gefitinib Tablets in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Using a Multicenter, Randomized, Positive Drug Gefitinib Pharmacodynamics and Pharmacodynamics [NCT03264794]Phase 4100 participants (Anticipated)Interventional2017-08-31Not yet recruiting
ARCHER 1050: A RANDOMIZED, OPEN-LABEL, PHASE 3, EFFICACY AND SAFETY STUDY OF DACOMITINIB (PF-00299804) VERSUS GEFITINIB FOR THE FIRST LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN SUBJECTS WITH EPIDERMAL GROWTH FACTOR RECE [NCT01774721]Phase 3452 participants (Actual)Interventional2013-05-09Completed
Observational Clinical Trial of Adjuvant Chemotherapy for Non-squamous Cell Carcinoma of Non-small Cell Lung Cancer [NCT03656393]Phase 348 participants (Anticipated)Interventional2018-08-31Recruiting
The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation: A Phase II Single Arm Prospective Study [NCT03399669]Phase 2100 participants (Anticipated)Interventional2015-02-17Active, not recruiting
Dose Climbing Trial of Anlotinib Plus Gefitinib in the First-line Treatment of Advanced Gene Positive Non-squamous Non-small Cell Lung Cancer [NCT03602027]9 participants (Anticipated)Interventional2018-08-01Not yet recruiting
An Open-label, Multi-centre Study to Evaluate Efficacy and Safety of Gefitinib as the First-line Treatment for Locally Advanced (IIIB), Metastatic (IV) or Recurrent Pulmonary Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation. [NCT00344773]Phase 246 participants (Actual)Interventional2006-03-31Completed
N-of-1 Trial of Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy [NCT02142036]Phase 250 participants (Actual)Interventional2014-05-31Completed
Single-dose, Open-label, Randomized, 2-way Crossover Bioequivalence Study of Gefitinib Tablets Under Fasting Conditions in Chinese Healthy Male Subjects [NCT03050164]Phase 138 participants (Actual)Interventional2016-09-08Completed
A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy. [NCT03944772]Phase 2250 participants (Anticipated)Interventional2019-06-25Active, not recruiting
A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma [NCT01185158]Phase 246 participants (Actual)Interventional2002-05-31Completed
Pemetrexed Disodium and Cisplatin Chemotherapy Combined With Synchronous Gefitinib vs Chemotherapy Alone as Adjuvent Therapy in Patient With Stage II-IIIA, Epidermal Growth Factor Receptor Mutant Expressing Lung Adenocarcinoma [NCT02518802]Phase 3220 participants (Anticipated)Interventional2015-01-31Recruiting
A Phase 1/2 Safety And Pharmacokinetic Study Of SU011248 In Combination With Gefitinib (Iressa) In Patients With Metastatic Renal Cell Carcinoma [NCT00113529]Phase 1/Phase 242 participants (Actual)Interventional2004-10-31Completed
A Randomized Phase II Trial of Combination Anastrozole (NSC #719344) Plus ZD1839 (Iressa, NSC #715055, IND #61187) and of Combination Fulvestrant (NSC #719276) Plus ZD1839 in the Treatment of Postmenopausal Women With Hormone Receptor-Positive Metastatic [NCT00057941]Phase 2148 participants (Actual)Interventional2003-09-30Completed
A Randomized, Open-label, Phase III Study of Single Agent Nazartinib Versus Investigator's Choice (Erlotinib or Gefitinib) as First-Line Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutatio [NCT03529084]Phase 30 participants (Actual)Interventional2018-07-24Withdrawn(stopped due to Decision by Sponsor not to continue with the trial.)
A Phase Ib Trial of Gefitinib (EGFR Tyrosine Kinase Inhibitor, Iressa™) in Combination With BKM120, an Oral Pan-class I PI3K Inhibitor in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alter [NCT01570296]Phase 138 participants (Actual)Interventional2011-10-03Completed
An Open-label Phase II Trial of Gefitinib and Berberine in Patients With Advanced Non-small Cell Lung Cancer and Activating EGFR Mutations [NCT03486496]Phase 250 participants (Anticipated)Interventional2018-06-05Not yet recruiting
An Multicenter,Phase II Trial of EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC [NCT03720873]Phase 290 participants (Anticipated)Interventional2018-10-31Recruiting
Phase 2 Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small [NCT01192243]Phase 268 participants (Anticipated)Interventional2009-12-31Recruiting
Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer [NCT03170180]Phase 266 participants (Actual)Interventional2017-03-01Completed
A Open-label, One-arm Trial of Gefitinib Combined With Radiotherapy as Adjuvant Therapy in Completely Resected Patients With Pathological Stage IIIA-N2 Non-small Cell Lung Cancer Harbouring Sensitive Mutations of EGFR [NCT03381430]50 participants (Anticipated)Interventional2018-06-30Not yet recruiting
β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer [NCT03123484]Phase 280 participants (Anticipated)Interventional2017-04-30Not yet recruiting
A Phase II Study of Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal [NCT01291823]Phase 270 participants (Anticipated)Interventional2010-12-31Recruiting
A Randomized Controlled, Double-blind, Multicenter, Phase III Clinical Study to Compare Efficacy and Safety of Abivertinib Maleate Versus First-line Standard Therapy EGFR-TKI in Patients With Advanced NSCLC With Sensitive EGFR Mutation [NCT03856697]Phase 3406 participants (Anticipated)Interventional2019-03-31Not yet recruiting
A Randomized Ph 3 Study Comparing First-Line Pemetrexed/Cisplatin Followed by Gefitinib With Gefitinib Alone in East Asian Never Smoker or Light Ex-Smoker Patients With Locally Advanced or Metastatic Nonsquamous NSCLC [NCT01017874]Phase 3236 participants (Actual)Interventional2009-11-30Completed
Phase 1 Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of the Combination of Cetuximab (C-225), a Chimeric Monoclonal Antibody Against the Epidermal Growth Factor Receptor (EGFR), and Gefitinib (ZD1839), a Selective EGFR Tyrosine Kinase Inhibitor, in [NCT00820417]Phase 163 participants (Actual)Interventional2004-06-30Completed
A Multicenter, Randomized,Double-Blind Study of Gefitinib in Combination With Apatinib or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Advanced Non-squamous Non-Small-Cell Lung Cancer [NCT02824458]Phase 3246 participants (Anticipated)Interventional2016-06-30Recruiting
A Phase III Study of IRESSA in Combination With Intravesical BCG Versus Intravesical BCG Alone in High Risk Superficial Transitional Cell Carcinoma of the Bladder [NCT00352079]Phase 341 participants (Actual)Interventional2007-01-04Terminated(stopped due to terminated due to poor accrual)
EGFR-TKI With Chemotherapy as First Line Treatment in Stage IIIB/IV NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism [NCT02859077]Phase 3100 participants (Anticipated)Interventional2016-08-31Not yet recruiting
Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer [NCT02151721]Phase 112 participants (Actual)Interventional2014-06-01Active, not recruiting
Phase I Study of Cisplatin And ZD1839 (IRESSA®) in Combination With Concomitant Re-Irradiation in Patients With Loco-Regional Recurrent Squamous Cell Cancer of the Head and Neck [NCT00185835]Phase 110 participants (Actual)Interventional2002-06-30Completed
A Phase 1/2 Study of Osimertinib in Combination With Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer [NCT03122717]Phase 1/Phase 248 participants (Actual)Interventional2017-05-09Active, not recruiting
Phase II Trial of Adding UFUR to Non-small-cell Lung Cancer Patients Treated With Iressa [NCT01037998]Phase 2115 participants (Actual)Interventional2005-11-30Completed
A Phase 1b/2 Study of AV-299 (Formerly SCH 900105) in Combination With Gefitinib in Asian Subjects With Non-Small Cell Lung Cancer (P06162) [NCT01039948]Phase 1/Phase 2203 participants (Actual)Interventional2009-12-31Completed
"A Phase 2 Trial of Pemetrexed and Cisplatin Followed Sequentially by Gefitinib Versus Pemetrexed and Cisplatin in Asian Never Smoker Patients With Advanced Non-Small Cell Lung Cancer" [NCT00409006]Phase 270 participants (Actual)Interventional2007-02-28Completed
A Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin [NCT00054691]Phase 240 participants (Actual)Interventional2004-05-31Completed
A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer [NCT00049543]Phase 3503 participants (Actual)Interventional2002-09-30Completed
A Phase II With a Lead in Phase I Study to Examine the Tolerability, Safety Profile and Efficacy of Hydroxychloroquine and Gefitinib in Advanced Non-Small Cell Lung Cancer [NCT00809237]Phase 1/Phase 271 participants (Anticipated)Interventional2008-11-30Recruiting
Phase I/II Trial of Gefitinib and Radiation in Pediatric Patients Newly Diagnosed With Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas With Phase II Limited to Brain Stem Tumors [NCT00042991]Phase 1/Phase 269 participants (Actual)Interventional2002-07-31Completed
A Phase II Study of ZD1839 and Radiation in Patients With Squamous Cell Carcinoma of the Skin [NCT00126555]Phase 223 participants (Actual)Interventional2005-03-31Completed
Phase II, Open-Label Trial to Assess the Activity of ZD1839 (IRESSA TM) in Patients With Recurrent Prostate Cancer Who Have Rising Serum PSA Levels Despite Serum Testosterone < 50mg/dl [NCT00635856]Phase 2100 participants (Anticipated)Interventional2001-05-31Completed
A Phase II Trial of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy [NCT02788058]Phase 276 participants (Anticipated)Interventional2016-05-31Not yet recruiting
Whole Brain Radiotherapy Concurrent With EGFR-TKI Versus EGFR-TKI Alone in the Treatment of Non-small Cell Lung Cancer Patients With Brain Metastasis [NCT02714010]Phase 3601 participants (Anticipated)Interventional2015-08-31Recruiting
A PreSurgical Study to Evaluate Molecular Alterations That Occur in Human Breast Cancer Tissue and Normal Skin After Short Term Exposure to ZD1839 (IRESSA) and to Correlate These Alterations With Pharmacokinetic Parameters. [NCT00637026]Phase 265 participants (Anticipated)Interventional2003-07-31Completed
A Phase II Trial to Assess the Efficacy of IRESSA™ (Gefitinib) 500 mg/Day in Patients With Breast Cancer Who Have Failed Tamoxifen or Have an Oestrogen Receptor Negative Tumour and Would be Considered for Systemic Therapy [NCT00632723]Phase 254 participants (Actual)Interventional2001-04-30Completed
A Multicentre, Open-label, Randomised, Controlled Study of Molecularly Precision Target Therapy Based on Tumor Molecular Profiling With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma [NCT02836847]Phase 2152 participants (Anticipated)Interventional2016-07-31Recruiting
A Phase III, Double-blind, Randomised Study of SH-1028 Tablets Versus Gefiitinib as First Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer [NCT04239833]Phase 3240 participants (Anticipated)Interventional2020-01-31Not yet recruiting
An International Phase 4 Field Study for Analyzing the Psychometric Properties of the Updated Module on Assessing Quality of Life of Patients With Lung Cancer (EORTC QLQ-LC29) [NCT02745691]523 participants (Actual)Observational2016-04-01Completed
A Phase 2 Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer [NCT03292133]Phase 211 participants (Actual)Interventional2017-10-31Active, not recruiting
A Phase II Stdy of ZD 1839 in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck [NCT00015964]Phase 251 participants (Actual)Interventional2001-03-31Completed
Multicentre, Open Label, Extension Study of Treatment With Gefitinib(IRESSA™) for Patients Completing Other Gefitinib Clinical Studies Who May Benefit From Gefitinib Treatment [NCT00683306]0 participants Expanded AccessApproved for marketing
Phase II Multi-centre Randomized Controlled Study of Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg [NCT01017679]Phase 296 participants (Actual)Interventional2009-05-31Completed
A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-line Treatment in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Sm [NCT04248829]Phase 3393 participants (Actual)Interventional2020-02-13Active, not recruiting
A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Ch [NCT00770588]Phase 4296 participants (Actual)Interventional2008-09-30Completed
Evaluation of ZD1839 (NSC #715055) for Advanced Transitional Cell Carcinoma of the Urothelium, Phase II [NCT00014144]Phase 231 participants (Actual)Interventional2001-02-28Completed
A Phase II Trial of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy [NCT01485809]Phase 236 participants (Actual)Interventional2011-10-31Completed
Conventional Postoperative Radiotherapy (Standard Fractionation) Plus Iressa or Hyperfractionated Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer: A Phase I Pilot Trial [NCT00681967]Phase 130 participants (Actual)Interventional2004-02-29Completed
PROGRESS: PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery [NCT02804776]Phase 215 participants (Actual)Interventional2015-01-27Completed
An International Expanded Access Clinical Programme With ZD1839 (IRESSA) for Patients With Advanced Non-small Cell Lung Cancer(NSCLC) and Patients With Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck ( [NCT00684385]0 participants Expanded AccessApproved for marketing
Can Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis of the Thoracic and Lumbar Spine?- A Retrospective Comparison With Platinum-based Chem [NCT02740894]100 participants (Actual)Observational2016-02-29Completed
A Randomized, Open-label Trial of Gefitinib Versus Combination of Vinorelbine Plus Platinum as Adjuvant Treatment in Pathological Stage II-IIIA(N1-N2) Non-small Cell Lung Cancer With EGFR Mutation [NCT01405079]Phase 3222 participants (Actual)Interventional2011-09-19Active, not recruiting
Tyrosine Kinase Inhibitors in DyplAsia of Lung Epithelium [NCT01405846]Phase 232 participants (Actual)Interventional2011-12-31Terminated(stopped due to Futility)
Phase 2 Randomized, Controlled, Open-label Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without EGFR Mutations [NCT00891579]Phase 2161 participants (Actual)Interventional2009-02-28Completed
Phase II Study of EGFR Status Based Gefitinib Neoadjuvant Therapy in NSCLC Patients [NCT00986284]Phase 2102 participants (Actual)Interventional2009-09-30Suspended(stopped due to Lack of patients and some progressed disease soon after surgery)
A Randomized Phase II Study Of ZD1839 (IRESSA) In Patients With Hormone Refractory Prostate Cancer [NCT00025116]Phase 240 participants (Actual)Interventional2001-04-24Completed
An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma [NCT00787410]Phase 223 participants (Actual)Interventional2003-09-30Completed
A Phase II Trial of Hypofractionated Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy [NCT02787447]Phase 246 participants (Anticipated)Interventional2016-05-31Recruiting
Multi-Centre, Open-Label Extension Trial of Treatment With ZD1839 (Iressa) in Patients Who Have Been Treated in Other ZD1839 Clinical Trials and May Benefit From Continued Monotherapy ZD 1839. [NCT00635973]Phase 3100 participants (Anticipated)Interventional2000-02-29Completed
Multicentric Randomized Phase III Study Comparing Gefitinib Versus Platinum-Based Chemotherapy In EGFR Fish Positive NSCLC Patients (Range) [NCT00807066]Phase 31 participants (Actual)Interventional2008-11-30Completed
A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer [NCT00162318]Phase 130 participants Interventional2005-03-31Completed
A Phase III, Multi-center, Randomized Trial of Pemetrexed and Gefitinib in Never-smoker and Adenocarcinoma Patients With Non-small Cell Lung Cancer Previously Treated With Platinum-based Chemotherapy [NCT01066195]Phase 3129 participants (Anticipated)Interventional2008-05-31Enrolling by invitation
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study [NCT04115410]4,724 participants (Anticipated)Observational2020-07-01Not yet recruiting
Third-line Treatment of Gefitinib in NSCLC Patients Who Had Received First-line Gefitinib With EGFR 19del/L858R Mutation and Tumor Progression After the Second-line Chemotherapy: a Single-arm, Prospective and Multi-center Study [NCT01933347]Phase 246 participants (Actual)Interventional2014-04-07Completed
A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Nonprogressive on Gefitinib or Erlotinib [NCT00955695]Phase 3242 participants (Anticipated)Interventional2009-05-31Not yet recruiting
Phase I, Open-label, Safety, Tolerability and Preliminary Efficacy Study of Tremelimumab in Combination With Gefitinib in EGFR Mutant NSCLC Patients [NCT02040064]Phase 127 participants (Actual)Interventional2014-01-31Completed
A Randomized, Double Blind, Phase III Comparative Trial of 2 Doses of ZD1839 (IRESSA) in Combination With Gemcitabine and Cisplatin Versus Placebo in Combination With Gemcitabine and Cisplatin in Chemotherapy Naive Patients With Advanced (Stage III or IV) [NCT00006048]Phase 30 participants Interventional2000-05-31Active, not recruiting
A Trial of ZD1839 (Iressa) in Patients With Advanced Renal Cell Carcinoma [NCT00012337]Phase 20 participants Interventional2001-01-31Completed
Phase II Study Of ZD1839 (NSC 715055) In Newly Diagnosed Patients With Glioblastoma (Grade 4 Astrocytoma) [NCT00014170]Phase 292 participants (Actual)Interventional2001-03-31Completed
Safety and Efficacy of Anlotinib Hydrochloride Combined With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) in Treating Advanced Non-small-cell Lung Cancer (NSCLC) Patients With Acquired Resistance to EGFR TKIs [NCT04007835]120 participants (Anticipated)Interventional2019-07-31Not yet recruiting
CARISSA Trial - Multicenter Randomized Phase II Trial Comparing Post-operative Radiotherapy and Cisplatin Alone or in Combination With the EGFR Inhibitor ZD 1839 (Iressa) in Upper Aerodigestive Tract Carcinomas [NCT00169221]Phase 254 participants (Actual)Interventional2005-09-30Terminated(stopped due to Toxicity in an independent study IMEX. The trial was subsequently terminated (54 pts instead of 140) despite safety analyses showing no excess of toxicity)
Clinical Study of Yiqi-yangyin-jiedu Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma Patients With Activating EGFR Mutation [NCT02929693]Phase 3198 participants (Anticipated)Interventional2016-10-31Enrolling by invitation
A Phase 2 Randomised, Double-Blind, Placebo-Controlled, Multicentre Comparative Study of Gefitinib 250 mg or 500 mg (IRESSA™) Given Either Continuously or Concomitantly With Cisplatin Plus Radiotherapy for the Treatment of Patients With Previously Untreat [NCT00229723]Phase 2224 participants (Actual)Interventional2004-11-30Completed
Paclitaxel/Carboplatin Combined With Intermittent Gefitinib in Patients With Untreated Advanced Non-small Cell Lung Cancer: A Phase Ⅱa Trial [NCT01024712]Phase 226 participants (Anticipated)Interventional2009-05-31Recruiting
Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) as Monotherapy in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck [NCT00519077]Phase 244 participants (Actual)Interventional2005-03-31Completed
Phase II Study of Taxotere® (Docetaxel) + ZD1839 (IRESSA®) in Previously Untreated Elderly Patients (≥70 Years Old) With Stage III-b (With Malignant Pleural Effusion [MPE+]) or Stage IV Non-Small Cell Lung Cancer (NSCLC) [NCT00231465]Phase 244 participants (Actual)Interventional2003-07-31Completed
Open Label, Randomised, Parallel Group, Multicentre, Ph III Study To Assess Efficacy, Safety & Tolerability Of Gefitinib (IRESSA™) Versus Carboplatin/Paclitaxel DC As 1st-Line Treatment In Selected Patients With Stage IIIB / IV NSCLC In Asia [NCT00322452]Phase 31,329 participants (Actual)Interventional2006-03-31Completed
A Phase II Study of ZD 1839 (IRESSA®) in Patients With Advanced Thyroid Cancer [NCT00095836]Phase 227 participants (Actual)Interventional2003-03-31Completed
Phase II Study in Operable Adenocarcinoma of the Esophagus to Measure Response Rate and Toxicity of Preoperative Combined Modality Paclitaxel (Taxol®, Bristol-Myers Squibb), Cisplatin (Platinol®, Abbott Laboratories), ZD1839 (IRESSA®) and Radiotherapy Fol [NCT00493025]Phase 219 participants (Actual)Interventional2005-04-30Terminated(stopped due to Closed due to early stopping rule-Low accrual)
A Phase I/II Study of Weekly Topotecan and Gefitinib (Iressa) in Patients With Platinum-Resistant Ovarian, Peritoneal, of Fallopian Tube Cancer [NCT00317772]Phase 1/Phase 219 participants (Actual)Interventional2004-09-02Completed
A Phase I Study of ZD1839 (Iressa) and Hypofractionated Thoracic Radiotherapy With Stereotactic Body Frame Immobilization for Patients With Advanced Non-Small Cell Lung Cancer [NCT00328562]Phase 113 participants (Actual)Interventional2003-12-31Completed
A Randomized, Open-Label Phase II Study Of ZD1839 (IRESSA™) Versus Gemcitabine And Carboplatin In Chemotherapy-Naive Patients With Advanced (Stage IIIB OR IV) Non-Small Cell Lung Cancer And ECOG Performance Status 2 [NCT00264498]Phase 238 participants (Actual)Interventional2004-10-31Completed
A Phase II Trial of ZD1839 (IRESSA®) for Patients With Recurrent or Metastatic Cancer of the Esophagus or Gastroesophageal Junction [NCT00268346]Phase 258 participants (Actual)Interventional2005-10-31Completed
Ph II Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Local [NCT01185171]Phase 270 participants (Actual)Interventional2003-01-27Completed
A Phase I/Phase II Study of Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients [NCT06071013]Phase 1/Phase 220 participants (Anticipated)Interventional2023-09-28Not yet recruiting
Phase II of Gefitinib (IRESSA) Administered as First-line Treatment in Patients With Non-resectable Pneumonic-type Adenocarcinoma (P-ADC) [NCT00198380]Phase 290 participants (Actual)Interventional2005-04-30Completed
A Phase III Randomised, Stratified, Parallel-Group, Multi-Centre, Comparative Study of ZD1839 (Iressa®) 250 Mg and 500 Mg Versus Methotrexate for Previously Treated Patients With Squamous Cell Carcinoma of the Head and Neck [NCT00206219]Phase 3477 participants Interventional2003-11-30Completed
A Phase II, Open Label Study of Gefitinib (IRESSA) in Treatment-Naïve Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer and Somatic Activating Mutations in the Epidermal Growth Factor Receptor [NCT00411047]Phase 234 participants (Actual)Interventional2005-09-30Completed
Arimidex/Faslodex/Iressa Study: A Phase II Trial of Primary Systemic Therapy Using a Combination of Arimidex, Faslodex and Iressa (Gefitinib) in Postmenopausal Women With Hormone Receptor Positive Breast Cancer [NCT00206414]Phase 215 participants (Actual)Interventional2003-01-31Terminated(stopped due to Difficulty accruing subjects the study accrual was closed)
A Randomized, Placebo-Controlled, Double-Blind Phase 2b Study of Raltitrexed (Tomudex) and ZD1839 (Iressa) Versus Raltitrexed Alone as Second Line Chemotherapy in Subjects With Colorectal Carcinoma [NCT00234429]Phase 2/Phase 374 participants Interventional2003-11-30Completed
A Phase III, Double-Blind, Randomised Study Comparing ZD1839 (IressaTM) Versus Placebo As Maintenance Therapy In Subjects With Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) After Combined Modality Therapy [NCT00234468]Phase 3490 participants (Anticipated)Interventional2004-01-31Terminated(stopped due to Closed due to insufficient recruitment)
Whole Brain Radiotherapy in Combination With Gefitinib (Iressa) or Temozolomide (Temodal) for Brain Metastases From Non-Small Lung Cancer (NSCLC) A Randomized Phase II Trial [NCT00238251]Phase 259 participants (Actual)Interventional2005-05-31Completed
A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839 [NCT00212108]Phase 1/Phase 222 participants (Actual)Interventional2003-11-30Completed
UpSwinG: Real World Study on TKI Activity in Uncommon Mutations and Sequencing Giotrif® [NCT04179890]462 participants (Actual)Observational2019-12-17Completed
A Randomized, Open-label Phase II Trial of Erlotinib 100mg Daily Versus Gefitinib 250mg Daily in Patients With Advanced Non-small Cell Lung Cancer Who Harbor EGFR Mutations. [NCT01955421]Phase 2224 participants (Anticipated)Interventional2013-07-31Recruiting
An Open,Multi Center Trial to Evaluate the Efficacy and Safety of High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced Non-Small Cell Lung Cancer Patients After Failure of Standard Dose EGFR-TKIs [NCT01965275]Phase 220 participants (Anticipated)Interventional2013-10-31Recruiting
A Prospective Clinical Study of Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma [NCT04642547]30 participants (Actual)Interventional2020-12-02Completed
A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers [NCT02013089]50 participants (Anticipated)Interventional2013-12-31Recruiting
Iressa Re-challenge in Advanced NSCLC EGFR Mutated Patients Who Responded to an EGFR-TKI Used as First-line or Previous Treatment (NVALT 16) [NCT02025218]Phase 221 participants (Actual)Interventional2014-01-31Terminated
A Phase I Study of Intravenous (IV) Calcitriol in Combination With ZD1839 (IRESSA®) in Refractory Solid Tumors [NCT00084708]Phase 153 participants (Actual)Interventional2002-11-30Completed
A Phase I/II Pilot Study of Bioimmunotherapy With IRESSA (Gefitinib) and Pegylated Interferon Alpha-2a for Patients With Unresectable/Metastatic Squamous Cell Carcinoma of the Skin [NCT00423397]Phase 1/Phase 216 participants (Anticipated)Interventional2006-09-30Active, not recruiting
A Randomized, Double-Blind, Phase III Comparative Trial of 2 Doses of ZD1839 (IRESSA) in Combination With Paclitaxel and Carboplatin Versus Placebo in Combination With Paclitaxel and Carboplatin in Chemotherapy-Naive Patients With Advanced (Stage III or I [NCT00006049]Phase 30 participants Interventional2000-05-31Active, not recruiting
Tyrosine-kinase Inhibitor （TKI） With or Without SBRT in Newly Diagnosed EGFRm Advanced Staged Lung Adenocarcinoma [NCT02893332]Phase 3200 participants (Anticipated)Interventional2016-01-15Terminated(stopped due to After interim analysis, IRB recommend termination.)
Real World Study to Evaluate the Efficacy and Resistant Mechanism of Erlotinib/Gefitinib Combined With Bevacizumab in First Line EGFR Mutation Positive Advanced Non-aquamous Non-small Cell Lung Cancer [NCT03647592]30 participants (Anticipated)Observational2018-06-01Recruiting
A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA®) as a Second-line Therapy in NSCLC Patients [NCT00608868]Phase 4156 participants (Actual)Interventional2007-01-31Completed
A Randomized/Open Label/Parallel Group/Multicenter/Phase IV Study to Assess Safety/Tolerability/Efficacy of Oral Gefitinib 250 mg Versus IV Docetaxel 60 mg/m2 in Patients With Locally Advanced or Metastatic NSCL Cancer of Adenocarcinoma Histology Previous [NCT00536107]Phase 414 participants (Actual)Interventional2007-10-31Terminated
ZD-1839 (Iressa®) With Concurrent Docetaxel and Conformal Three Dimensional Thoracic Radiation Followed by Consolidative Docetaxel and ZD-1839 for Patients With Stage III Non Small Cell Lung Cancer: A Phase I Study [NCT00310154]Phase 145 participants (Anticipated)Interventional2003-11-30Completed
A Phase II Trial of Neoadjuvant Gefitinib Therapy Based on Mutation Study in Biopsy- Proven Stage IIIA N2 Non-Squamous Non-Small Cell Lung Cancer [NCT00616499]Phase 235 participants (Anticipated)Interventional2006-11-30Recruiting
A Phase II Study of Gefitinib in Benefited Patients With Asymptomatic Brain Metastasis Advanced Non-Small Cell Lung Cancer by Chemotherapy [NCT00614809]Phase 245 participants (Anticipated)Interventional2007-12-31Active, not recruiting
An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First Line Treatment in Caucasian Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Adva [NCT01203917]Phase 41,060 participants (Actual)Interventional2010-09-30Completed
Comparing Whole Brain Radiation With Hypofractionated Stereotactic RadioSurgery (HFSRS) in Patients With NSCL Brain Metastases [NCT02882984]Phase 3325 participants (Anticipated)Interventional2015-03-31Recruiting
A Phase II Trial of Radiation Therapy Combined With Iressa in Patients With Locally Advanced Non-small Cell Lung Cancer With Harboring Active EGFR Mutations [NCT01391260]Phase 230 participants (Anticipated)Interventional2011-07-31Recruiting
Multicenter Phase III Study of Gefitinib Mono-therapy or Gefitinib Combined With Chemotherapy in Patients With Brain Metastases From Non-small Cell Lung Cancer Harboring EGFR Mutation [NCT01951469]Phase 3160 participants (Anticipated)Interventional2016-01-31Recruiting
Randomized Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Patients With Advanced Non-small Cell Lung Cancer: Dual-agent Molecular Targeting of EGFR (DATE) [NCT01498562]Phase 2160 participants (Actual)Interventional2011-12-31Completed
A Phase I/II Trial of Induction Chemotherapy Plus Gefitinib (Iressa) Followed by Concurrent Chemotherapy, Radiation Therapy, and Gefitinib (Iressa) For Patients With Locally Advanced Squamous Carcinoma of the Head and Neck [NCT00193284]Phase 250 participants Interventional2003-10-31Completed
A Phase I/II Study of Capecitabine (XELODA®, Roche) Plus Oxaliplatin (Eloxatin®, Sanofi) Plus ZD 1893 (IRESSA®) in the Treatment of Metastatic Colorectal Cancer [NCT00087334]Phase 1/Phase 210 participants (Actual)Interventional2004-01-31Terminated(stopped due to Withdrawn due to poor/low accrual)
A Randomized Phase III Study of Follow Up With or Without Adjuvant Gefitinib (Iressa™) Following Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer [NCT00091156]Phase 3598 participants (Anticipated)Interventional2004-05-31Terminated(stopped due to low accrual)
ZD1839 (IRESSA®) With Oxaliplatin and Radiotherapy for Esophageal Carcinoma. A Phase I/II Study With Biologic Correlates [NCT00093652]Phase 1/Phase 20 participants Interventional2003-05-31Terminated
A Phase II Study of ZD1839 (Iressa)in Chemotherapy Refractory Germ Cell Tumors Expressing Epidermal Growth Factor Receptor (EGFR) [NCT00198159]Phase 221 participants Interventional2002-09-30Terminated
Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV [NCT00198393]Phase 2126 participants (Actual)Interventional2004-11-30Completed
Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene in Patients With NSCLC [NCT00588445]Phase 265 participants (Actual)Interventional2004-06-30Completed
A Randomized,Double-blind,Multicenter Phase III Trial to Evaluate the Safety and Efficacy of Icotinib and Gefitinib in Advanced NSCLC Patients Previously Treated With Chemotherapy [NCT01040780]Phase 3399 participants (Actual)Interventional2009-02-28Completed
Phase II Trial of Chronic Oral ZD1839 (Iressa®) (NSC-715055) in Both Previously-Untreated and Previously-Treated Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) [NCT00029003]Phase 290 participants (Actual)Interventional2001-12-31Completed
A Phase II Study of ZD1839 (Iressa) Plus Anastrozole (Arimidex) in Patients With Relapsed Ovarian Cancer [NCT00181688]Phase 235 participants Interventional2003-10-31Completed
Bevacizumab Plus EGFR Tyrosine Kinase Inhibitors in Chinese Patients With Stage IIIB-IV EGFR-mutant Non-small Cell Lung Cancer: a Prospective,Multicenter, Non-interventional,Real-world Study [NCT04575415]272 participants (Anticipated)Observational2020-10-07Recruiting
Multicenter Phase II Trial of Gefitinib (Iressa™) First Line Therapy Followed by Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC) [NCT00217698]Phase 263 participants (Actual)Interventional2003-11-30Completed
A Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) [NCT00215202]Phase 216 participants (Actual)Interventional2004-08-31Completed
A Phase II, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination of Gefitinib and Metformin in Patients With Locally Advanced and Metastatic Non-Small-Cell-Lung-Cancer [NCT01864681]Phase 2224 participants (Actual)Interventional2013-05-31Completed
An Open-label, Randomized, Controlled Study of Gefitinib Plus Autologous Cytokine-Induced Killer Cell Immunotherapy（CIK）Versus Gefitinib Alone As Second Or Third-Line Treatment in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer [NCT01871480]Phase 250 participants (Anticipated)Interventional2013-05-31Terminated
A Randomized, Double-blind, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of BPI-7711 Capsule in Locally Advanced or Recurrent/Metastatic Treatment-naïve Non-small Cell Lung Cancer Patients With EGFR Mutation [NCT03866499]Phase 3369 participants (Actual)Interventional2021-04-30Active, not recruiting
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy [NCT02906163]Phase 1/Phase 2188 participants (Anticipated)Interventional2016-10-31Not yet recruiting
Phase II Trial of ZD1839 (IRESSA®) and Pegylated Interferon Alfa 2b (PEG-Intron™) in Unresectable or Metastatic Renal Cell Carcinoma [NCT00467077]Phase 221 participants (Actual)Interventional2004-09-30Terminated(stopped due to Protocol was closed due to slow accrual.)
Randomized Phase II Trail Comparing Gefitinib Plus Simvastatin and Gefitinib Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) [NCT00452244]Phase 2110 participants (Actual)Interventional2006-05-31Completed
A Randomized Phase III Study of Gefitinib (IRESSATM) Versus Standard Chemotherapy (Gemcitabine Plus Cisplatin) as First-line Treatment for in Never Smokers Advance or Metastatic Adenocarcinoma of Lung [NCT00455936]Phase 3315 participants (Actual)Interventional2005-10-31Completed
Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy [NCT00497250]Phase 132 participants (Anticipated)Interventional2007-07-31Recruiting
A Randomized, Open Label, Parallel Group, Regional, Multicenter, Phase III Study of Oral Gefitinib (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non Small Cell Lung Cancer Who Have Previously [NCT00478049]Phase 3163 participants (Actual)Interventional2005-09-30Completed
Chemotherapy Plus Gefitinib Versus Gefitinib Alone as First-line Treatment for Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial [NCT02951637]Phase 2300 participants (Anticipated)Interventional2016-12-31Not yet recruiting
A Dose Finding Study (Phase I) of the Combination of ZD1839 (Iressa®) and an Oral Formulation of Irinotecan (Camptosar™) in Children With Refractory Solid Tumors [NCT00132158]Phase 119 participants (Actual)Interventional2005-09-30Completed
Combination of Gefitinib With Chemotherapy or Anti-angiogenesis as 1st Line Treatment in Advanced NSCLC Patients Detected With Bim Deletion or Low EGFR Activating Mutation Abundance [NCT02930954]Phase 2180 participants (Anticipated)Interventional2016-11-30Not yet recruiting
A Randomized, Controlled, Open-label, Prospective Trial of S-1 Plus Gefitinib Versus Gefitinib Monotherapy for First-line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With EGFR-sensitive Mutation [NCT03457337]Phase 2200 participants (Anticipated)Interventional2018-03-28Recruiting
A Phase IB/II, Open Label, Multicenter Study of INC280 Administered Orally in Combination With Gefitinib in Adult Patients With EGFR Mutated, c-MET-amplified Non-small Cell Lung Cancer Who Have Progressed After EGFR Inhibitor Treatment [NCT01610336]Phase 2161 participants (Actual)Interventional2012-04-05Completed
A Multi-center, Open-label, Fixed-sequence Study of Effect of Gefitinib on the Pharmacokinetics of Apatinib Mesylate in Non-squamous, Non-small-cell Lung Cancer Patients [NCT04390984]Phase 122 participants (Anticipated)Interventional2020-05-26Recruiting
An Open-Label, Phase II Trial Of 250 mg ZD1839 (IRESSA™) In Prostate Cancer Patients With Early Biochemical Failure Post Prostatectomy [NCT00265070]Phase 280 participants (Actual)Interventional2003-01-31Completed
An Open-label, Multi-center, Global, Rollover Study for Patients Who Have Previously Been Treated With Capmatinib (INC280) as Monotherapy or in Combination in a Novartis Sponsored Trial. [NCT03040973]Phase 240 participants (Anticipated)Interventional2017-07-04Recruiting
Phase II Study of Iressa in Relapsed and Refractory Small Cell Lung Cancer [NCT00298688]Phase 256 participants Interventional2004-09-30Completed
A Randomised, Non-Comparative, Multicentre, Phase II, Parallel-Group Trial Of ZD1839 (Iressa™) In Combination With 5 Fluorouracil, Leucovorin And Cpt-11 (Irinotecan) In Patients With Metastatic Colorectal Cancer [NCT00233623]Phase 2190 participants Interventional2004-07-31Withdrawn
A Phase II Trial to Evaluate the Combination of ZD1839 (Iressa) and Fulvestrant (Faslodex®) in Patients With Advanced or Metastatic Breast Cancer [NCT00234403]Phase 260 participants Interventional2004-05-31Completed
A Phase II, Multicentre, Non-Comparative, Open-Label Study To Evaluate The Efficacy And Tolerability Of ZD1839 (Iressa™) In Asymptomatic Radio-Naive Patients With Brain Metastases From Non-Small Cell Lung Carcinoma (NSCLC) Who Have Relapsed Following Prio [NCT00234442]Phase 247 participants Interventional2004-07-31Terminated(stopped due to Closed due to insufficient recruitment.)
Phase II Multicenter, Double-Blind, Randomized Trial Comparing Anastrozole (ZD1033, Arimidex™)-Placebo to the Combination Anastrozole-ZD1839 (Gefitinib, IRESSA™) in Postmenopausal Patients With Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Met [NCT00077025]Phase 2174 participants (Anticipated)Interventional2004-01-31Completed
A Phase 2 Trial to Evaluate ZD1839 (IRESSA) in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma (Unresectable &Inoperable) [NCT00242749]Phase 247 participants Interventional2002-12-31Completed
A Phase I/II, Multicentre Clinical Study Of ZD1839 (Iressa™) In Combination With Capecitabine (Xeloda™) In Subjects With Advanced Colorectal Carcinoma After Failure Of First-Line Chemotherapy [NCT00242788]Phase 1/Phase 240 participants Interventional2004-02-29Completed
A Phase II, Randomised, Double-Blind, Placebocontrolled Study To Investigate The Effects Of ZD1839 (IRESSA™) On Cell Proliferation In Oestrogen And Progesterone Receptor Negative Breast Cancer Prior To Surgery [NCT00252811]Phase 260 participants Interventional2004-02-29Withdrawn
Phase II, Placebo Controlled, Parallel Group, Double Blind, Randomised, Multicentre Trial Comparing the Anastrozole (Arimidex®) Placebo Combination to the Anastrozole - ZD1839 (Iressa™) Combination as Neoadjuvant Treatment in Postmenopausal Women With Sta [NCT00255463]Phase 2185 participants Interventional2004-01-31Completed
A Randomised, Open Label, Parallel Group, Multi-Centre, Phase II Study of Progression Free Survival Comparing ZD1839 (IRESSA™) (250 MG Tablet) Versus Vinorelbine (30 MG/M2 Infusion) in Chemonaive, Elderly Patients With Locally Advanced (Stage IIIB) or Met [NCT00256711]Phase 2192 participants Interventional2004-07-31Completed
Phase I/II Study of Induction Gefitinib and Concurrent Radiotherapy in Patients With Previously Untreated, Medically Inoperable Stage I or II Non-Small Cell Lung Cancer [NCT00268255]Phase 1/Phase 20 participants (Actual)InterventionalWithdrawn(stopped due to Study never moved forward with accrual.)
A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer Who Have Previousl [NCT00076388]Phase 31,440 participants Interventional2004-02-29Completed
A Pilot Study of Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma [NCT00282100]Phase 240 participants (Anticipated)Interventional2005-12-31Active, not recruiting
A Phase I/II Study to Evaluate Safety and Efficacy in Patients Who Have Resectable Esophageal Cancer and Are Treated With Neoadjuvant Cisplatin, Irinotecan (CPT-11) ZD1839 (IRESSA), and Radiotherapy Followed by Surgical Resection [NCT00290719]Phase 16 participants (Actual)Interventional2005-11-30Terminated(stopped due to low enrollment)
EGFR Pathway Modulation In Patients With Ductal Carcinoma In Situ Of The Breast [NCT00082667]Phase 21 participants (Actual)Interventional2002-10-31Terminated(stopped due to PI left VICC)
A Pilot Phase I Dose Escalation Study Of The EGFR Tyrosine Kinase Inhibitor Gefitinib (Iressa) Combined With Paclitaxel (Taxol) And External Beam Radiation Therapy In Patients With Advanced Squamous Cell Carcinoma Of The Head And Neck (SCCHN) [NCT00083057]Phase 130 participants (Anticipated)Interventional2004-05-31Completed
A Phase IIIb Randomized, Double-Blind Study Comparing Maintenance ZD1839 (IRESSA®) or Placebo Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer [NCT00090675]Phase 30 participants (Actual)Interventional2006-01-31Withdrawn(stopped due to No patients randomised)
A Randomised Phase II Study: Treatment With Daily p.o. Iressa™ (ZD1839) or Placebo in Combination With Weekly IV Infusion of Docetaxel in Patients With Metastatic Breast Cancer [NCT00319618]Phase 266 participants Interventional2003-06-30Completed
A Pilot Feasibility Study to Evaluate the Efficacy of ZD1839 (IRESSA) in Eliminating Chemo- and Hormone- Resistant Cytokeratin-Positive Tumour Cells Circulating in the Blood of Women With Breast Cancer [NCT00428896]Phase 224 participants (Actual)Interventional2005-04-30Completed
A Phase I/II Trial of ZD1839 (Iressa®) and Rapamycin (Rapamune) in Patients With Advanced Non Small Cell Lung Cancer [NCT00098462]Phase 1/Phase 20 participants (Actual)Interventional2004-10-31Withdrawn(stopped due to Withdrawn as study never opened)
Neuroblastoma Protocol 2005: Therapy for Children With Advanced Stage High-Risk Neuroblastoma [NCT00135135]Phase 223 participants (Actual)Interventional2005-08-31Completed
A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer [NCT00144066]Phase 3600 participants Interventional2003-01-31Completed
A Phase I, Open-Label, Dose Escalation Study Evaluating High-Dose Gefitinib (IRESSA®) on Weekly and Twice Weekly Schedules in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic [NCT00127829]Phase 166 participants (Anticipated)Interventional2005-07-31Completed
Phase I Study of High Dose Gefitinib (Iressa) for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations [NCT00372515]Phase 17 participants (Actual)Interventional2006-06-30Completed
A Phase I Open-Label Study to Assess the Safety, Tolerability and PK of Ascending Multiple Oral Doses of AZD2171 When co-Administered With Fixed Multiple Oral Doses of ZD1839 (250mg or 500mg Once Daily) in Patients With Advanced Cancer [NCT00502060]Phase 165 participants (Anticipated)Interventional2004-08-31Completed
Synergistic Real-World Study and Evidence-based Medicine Evaluation of Elemene Combined With Tyrosine Kinase Inhibitors（TKIs）in the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC): Prospective Study [NCT04401059]Phase 4744 participants (Anticipated)Interventional2020-11-09Recruiting
A Randomized Phase II Trial of Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib [NCT04358562]Phase 2240 participants (Anticipated)Interventional2020-05-01Not yet recruiting
EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism [NCT03002844]Phase 250 participants (Anticipated)Interventional2016-12-31Not yet recruiting
Phase I-II Study of ZD1839 (IRESSA®), Cisplatin, and External-Beam Radiation Therapy in Patients With Locally Advanced, Non-Metastatic, Squamous Cell Carcinoma of the Head and Neck [NCT00195078]Phase 1/Phase 229 participants (Anticipated)Interventional2004-04-30Terminated
A Phase Ib, Multi-center, Open Label Study of Ningetinib (CT053PTSA) in Combination With Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative Who Have Progressed After EGFR TKI Therapy [NCT03758287]Phase 1/Phase 2158 participants (Anticipated)Interventional2016-11-30Active, not recruiting
Phase II Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma [NCT00177242]Phase 245 participants Interventional2004-09-30Completed
An Open, Single.Centre, Phase I/II Study of ZD1839 (Iressa) in Combination With 5-Fluorouracil, Leucovorin and Radiotherapy in Subjects With Resectable Gastric Cancer [NCT00237900]Phase 1/Phase 234 participants Interventional2003-07-31Terminated
A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa™) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme [NCT00238797]Phase 236 participants Interventional2003-02-28Completed
A Phase I/II Trial of ZD1839 (Iressa) Given Concurrently With Cisplatin and Radiotherapy in Patients With Locally Advanced Head and Neck Cancer [NCT00239304]Phase 1/Phase 240 participants Interventional2003-06-30Completed
Randomised Placebo-controlled Phase II Trial of Preoperative Therapy With Gefitinib (Iressa®/ZD1839) and Epirubicin-Cyclophosphamide in Patients With Primary Operable (T2-T3) Oestrogen Receptor Negative Breast Cancer [NCT00239343]Phase 2160 participants (Anticipated)Interventional2004-10-31Completed
A Phase I Trial to Evaluate ZD1839(Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer [NCT00252798]Phase 144 participants Interventional2002-07-31Completed
Study of Chinese Medicine Plus Targeted Therapy Maintenance Versus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma: A Randomized Double-blind Controlled Clinical Trial [NCT02889692]Phase 323 participants (Actual)Interventional2013-03-31Completed
Multicenter, Randomized, Phase Ib/IIb Study to Evaluate the Efficacy and Tolerability of Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone, in Patients With EGFR Mutation Positive Advanced Non-small-cell Lung Cancer [NCT01513174]Phase 1/Phase 2186 participants (Actual)Interventional2011-08-31Completed
A Randomized, Controlled Phase II Clinical Trial of Apatinib in Combination With EGFR-TKI Versus EGFR-TKI for Non-squamous, Non-small Cell Lung Cancer(NSCLC) With T790M-negative After the Failure of EGFR-TKI Therapy [NCT03389256]Phase 2144 participants (Anticipated)Interventional2018-12-30Not yet recruiting
Phase II Randomised Clinical Trial Evaluating an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI) Versus an EGFR-TKI Combined With an Anti-oestrogen Treatment (Fulvestrant) in Women With Advanced Stage Non-squamous Lung Cancer [NCT01556191]Phase 2379 participants (Actual)Interventional2012-05-15Completed
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent [NCT00100945]Phase 270 participants (Actual)Interventional2005-07-31Completed
Phase II Study With Gefitinib (Sequentially) Following Gemcitabine/Cisplatin as Induction Regimen for Patients With Stage IIIA N2 NSCLC [NCT00103051]Phase 20 participants Interventional2004-12-31Completed
A Phase I/II Trial of Herceptin and ZD1839 (Iressa, NSC #715055, IND#61187) in Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu (erbB-2) [NCT00024154]Phase 2132 participants (Actual)Interventional2002-02-28Completed
A Phase II Study Of ZD 1839 (NSC 715055, IND 61187) In Patients With Malignant Mesothelioma [NCT00025207]Phase 240 participants (Actual)Interventional2001-09-30Completed
ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs [NCT00025675]Phase 2105 participants (Actual)Interventional2001-10-09Completed
A Phase I/ Randomized Phase II Trial Of Oxaliplatin (NSC #266046) With Or Without ZD 1839 (NSC # 715055) In Patients With Advanced Colorectal Carcinoma [NCT00026299]Phase 1/Phase 214 participants (Actual)Interventional2001-09-30Completed
A Phase I Study Of ZD 1839 And Temozolomide For The Treatment Of Gliomas [NCT00027625]Phase 10 participants Interventional2002-01-28Completed
An Expanded Access Clinical Program With ZD1839 (IRESSA®) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) [NCT00034879]Phase 30 participants Interventional2000-08-31Completed
A Phase II Trial Of IRESSA (NSC 715055, IND 61187) In Combination With 5-FU/LV/ CPT-11 In Patients With Advanced Or Recurrent Colorectal Cancer [NCT00052585]Phase 250 participants (Actual)Interventional2002-10-31Terminated(stopped due to Administratively complete.)
A Phase II, Randomized Double-blind, 2-part, Multicenter Study to Compare the Efficacy of ZD6474 With the Efficacy of ZD1839 (Iressa™) in Subjects With Locally Advanced or Metastatic (IIIB/IV) Non-small Cell Lung Cancer After Failure of First-line Platinu [NCT00059722]Phase 2160 participants Interventional2003-05-31Completed
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age [NCT00062062]Phase 265 participants (Actual)Interventional2004-10-31Completed
Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger) [NCT00068497]40 participants (Anticipated)Interventional2003-08-31Completed
Phase II Study of the Combination of ZD1839 (Iressa) and Celecoxib in Patients With Platinum Refractory Non-Small Cell Lung Cance [NCT00068653]Phase 227 participants (Actual)Interventional2003-06-30Completed
A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors [NCT00075439]Phase 290 participants (Anticipated)Interventional2003-12-31Completed
ZD1839 (IRESSA) In Tamoxifen-Resistant Metastatic Breast Cancer [NCT00080743]Phase 22 participants (Actual)Interventional2004-01-31Completed
A Phase II Study of Docetaxel in Combination With ZD 1839 (IRESSA) in Previously Treated Patients With Metastatic Pancreatic Cancer [NCT00137761]Phase 232 participants (Actual)Interventional2004-10-31Completed
A Phase II Study Of ZD1839 (NSC #715055) In Renal Cell Carcinoma Stage IV And Renal Cell Carcinoma Recurrent [NCT00014183]Phase 20 participants Interventional2001-01-31Completed
A Phase II Study of ZD 1839 (NSC 715055) for Patients With First Relapse Glioblastoma Multiforme [NCT00016991]Phase 20 participants Interventional2001-06-30Completed
A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy With ZD1839 (NSC-715055) or Placebo in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer [NCT00020709]Phase 3840 participants (Actual)Interventional2001-06-30Completed
A Randomized Phase II Trial of Two Dose Levels of ZD1839 (Iressa) (NSC 715055, IND 61187) in Patients With Recurrent Colorectal Adenocarcinoma [NCT00025350]Phase 20 participants Interventional2001-10-31Completed
A Phase I Study Of ZD1839 (Iressa) In Combination With Irinotecan, Leucovorin, And 5-Fluorouracil In Previously Untreated, Stage IV Colorectal Cancer [NCT00026364]Phase 122 participants (Actual)Interventional2001-11-30Completed
A Phase II Trial of ZD 1839 (IRESSA) (NSC #715055) in the Treatment of Persistent or Recurrent Endometrial Carcinoma [NCT00027690]Phase 256 participants (Actual)Interventional2002-06-30Completed
A Phase I Trial of ZD1839 With Capecitabine in Patients With Advanced Solid Tumors (Formerly a Phase I Trial of ZD1839 With Capecitabine and Celecoxib) [NCT00039390]Phase 141 participants (Actual)Interventional2002-04-30Completed
ZD1839 (NSC #715055, IND #61187) With Induction Paclitaxel And Carboplatin Followed By Either Radiation Or Concomitant Radiation With Weekly Paclitaxel And Carboplatin In Stage III Non-Small Cell Lung Cancer, A Phase II Study [NCT00040794]Phase 2144 participants (Actual)Interventional2002-05-31Completed
Phase II Study Of Cisplatin, Gemcitabine, And ZD 1839 (IRESSA) (IND #61187; NSC 715055) For The Treatment Of Advanced Urothelial Tract Carcinoma [NCT00041106]Phase 250 participants (Actual)Interventional2002-05-31Completed
A Phase II And Biologic Correlative Study Investigating ARIMIDEX In Combination With IRESSA (ZD1839) In Post-Menopausal Patients With Estrogen Receptor-Positive Metastatic Breast Carcinoma Who Have Previously Failed Hormonal Therapy [NCT00049062]Phase 20 participants Interventional2002-09-30Completed
A Phase II Trial of ZD1839 (Iressa) (NSC# 715055) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma [NCT00023699]Phase 20 participants Interventional2001-08-31Completed
A Phase II Study of ZD 1839 (Iressa) in Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck [NCT00024089]Phase 260 participants (Actual)Interventional2001-07-31Completed
A Study of ZD1839 (Iressa) in Combination With Oxaliplatin, 5-Fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Malignancies (Phase I) and Advanced Colorectal Cancers (Phase II) [NCT00025142]Phase 20 participants Interventional2001-07-31Completed
A Phase II Clinical, Biological and Pharmacological Study of ZD1839 in Patients With Advanced Colorectal Carcinoma Refractory to 5-Fluorouracil (5-FU) and Irinotecan Chemotherapy [NCT00030524]Phase 20 participants Interventional2002-01-31Completed
A Phase I Study Of ZD 1839 In Combination With Radiation And Chemotherapy In Locally Advanced Squamous Cell Carcinoma Of The Head And Neck [NCT00033449]Phase 130 participants (Actual)Interventional2002-02-28Terminated(stopped due to Administratively complete.)
An IDBBC Single Arm Phase II Trial Evaluating The Activity Of Iressa (ZD1839) In Metastatic Breast Cancer Patients Pretreated With An Antiestrogen And A Non-Steroidal Aromatase Inhibitor (Anastrozole Or Letrozole) [NCT00066339]Phase 244 participants (Actual)Interventional2003-05-31Completed
An EORTC Randomized, Double Blind, Placebo-Controlled, Phase II Multi-Center Trial Of Anastrozole (Arimidex) In Combination With ZD 1839 (Iressa) Or Placebo In Patients With Advanced Breast Cancer [NCT00066378]Phase 271 participants (Actual)Interventional2003-05-31Completed
A Phase II Study of ZD1839 (Iressa, Gefitinib, NSC 715055) in Advanced Unresectable Hepatocellular Carcinoma [NCT00071994]Phase 259 participants (Actual)Interventional2004-02-29Completed
A Phase I Study Of ZD1839 (Iressa TM), An Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, In Children With Refractory Solid Tumors [NCT00040781]Phase 145 participants (Actual)Interventional2002-06-30Completed
A Pilot Trial of Daily Oral ZD1839 (Iressa) With Standard Doses of Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer [NCT00005806]Phase 10 participants Interventional1999-09-30Completed
A Phase II Study of Cisplatin and Irinotecan Induction Chemotherapy, Followed by ZD 1839 (IRESSA) in Adult Patients With Surgically Unresectable and/or Metastatic Esophageal or Gastric Carcinomas [NCT00215995]Phase 221 participants (Actual)Interventional2003-07-31Completed
A Phase II Study of Iressa (Gefitinib), in Patients With Relapsed or Refractory Acute Myelogenous Leukemia and in Older Patients With Newly Diagnosed Acute Myelogenous Leukemia [NCT00130702]Phase 218 participants (Actual)Interventional2005-08-31Completed
Phase 3 Randomized Study of TLK286 (Telcyta) Versus Gefitinib (Iressa) as Third-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer [NCT00080340]Phase 3520 participants InterventionalCompleted
Phase II Pilot Study of Clinical Activity and Proteomic Pathway Profiling of the EGFR Inhibitor, ZD1839 (Iressa; Gefitinib), in Patients With Epithelial Ovarian Cancer or Cervical Cancer [NCT00049556]Phase 20 participants Interventional2002-10-31Completed
A Phase 2, Multi-Center Trial of ZD1839 (IRESSA) in Combination With Docetaxel as First-Line Treatment in Patients With Advanced Breast Cancer [NCT00052169]Phase 233 participants (Actual)Interventional2003-01-31Completed
A Phase I/II Study of an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), ZD 1839 (Iressa), [NSC #715055] With Radiation Therapy in Glioblastoma Multiforme [NCT00052208]Phase 1/Phase 2158 participants (Actual)Interventional2002-03-31Completed
Phase II Study Of Iressa (ZD 1839) In Locally Advanced And/Or Metastatic Synovial Sarcoma Expressing HER1/EGFR1 [NCT00052754]Phase 248 participants (Actual)Interventional2002-10-31Completed
A Phase II Study to Evaluate the Efficacy and Safety of Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer (NSCLC) [NCT00173875]Phase 2108 participants (Actual)Interventional2005-03-31Completed
A Phase I Study of ZD1839 (Iressa) in Combination With Irinotecan (Camptosar or CPT-11) and Vincristine in Pediatric Patients With Refractory Solid Tumors [NCT00186979]Phase 134 participants (Actual)Interventional2003-05-31Completed
Phase II Study Of Single Agent Gefitinib (Iressa) In Patients With Clinical Stage I Non-Small Cell Lung Cancer (NSCLC) Proceeding To Mediastinoscopy And Surgery [NCT00188617]Phase 235 participants (Actual)Interventional2005-01-31Completed
A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy [NCT00189358]Phase 20 participants InterventionalCompleted
Phase II Trial of Single Agent ZD1839 (Iressa) in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer [NCT00193336]Phase 260 participants Interventional2003-03-31Completed
A Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in Combination With Docetaxel in Patients With Recurrent or Metastatic Advanced Non-Small Cell Lung Cancer [NCT00048087]Phase 20 participants (Actual)Interventional2002-08-31Withdrawn(stopped due to Slow accrual.)
A Phase I Dose Escalation of ZD1839 (Iressa®) (Days 1 and 2) and Docetaxel (Day 3) Every 3 Weeks in Patients With an Advanced Solid Tumor [NCT00084786]Phase 10 participants Interventional2004-03-31Completed
Neoadjuvant Chemoradiotherapy (Gemcitabine/Cisplatin and Taxotere) With or Without Co-Administration of ZD 1839 (Iressa) for Stage IIIA (N2) and Selective Stage IIIB Non-Small Cell Lung Cancer: Phase I-II Study [NCT00062270]Phase 1/Phase 20 participants Interventional2003-05-31Completed
Efficacy and Safety of Precision Therapy in Refractory Tumor (Long March Pathway) [NCT03239015]Phase 2300 participants (Anticipated)Interventional2017-01-01Recruiting
Phase II Trial of Weekly Docetaxel (Taxotere) Vs. Weekly Docetaxel in Combination With ZD1839 (Iressa®) As Consolidation Therapy For Metastatic Urothelial Cancer Following Maximal Response To Multi-Agent Chemotherapy [NCT00479089]Phase 250 participants (Actual)Interventional2004-02-29Terminated(stopped due to Study halted due to drug sponsor decision to not continue.)
Bone Metastasis on the Survival of Gefitinib Effective Patients With Non-small Cell Lung Cancer [NCT03157310]265 participants (Actual)Interventional2009-05-01Completed
A Phase I Study of ZD1839 (Iressa) and Palliative Thoracic Radiotherapy in Patients With Non-small Cell Lung Cancer [NCT00255489]Phase 136 participants Interventional2004-05-31Completed
Phase II Study of Iressa With/Without Concurrent Chemoradiotherapy in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma and to Study the Effect of Iressa™ (ZD1839) on Tumour Gene Expression Profiles ® [NCT00228488]Phase 260 participants Interventional2004-06-30Completed
A Phase II Randomised, Double-Blind, Stratified, Multi-Centre Trial Comparing the Nolvadex 20 Mg And Placebo Combination To The Nolvadex 20 Mg and ZD1839 (IRESSA™) 250 MG Combination In Patients With Metastatic Breast Cancer And Estrogen Receptor (ER) and [NCT00229697]Phase 2317 participants (Actual)Interventional2003-10-31Completed
A Phase II Safety, Efficacy, and Feasibility Study of Neoadjuvant ZD1839 (IRESSA) in Resectable Esophageal Cancer [NCT00258297]Phase 230 participants (Anticipated)Interventional2004-04-30Terminated(stopped due to Withdrawn for lack of funding and accrual)
A 2 Part Phase 2 Trial to Evaluate ZD1839 (Iressa™) & Radiotherapy in Patients w/Locally Advanced Inoperable Squamous Cell Carcinoma of the Head & Neck [NCT00233636]Phase 228 participants Interventional2003-07-31Withdrawn
A Trial to Evaluate ZD1839 (IRESSA) in Combination With Radiotherapy & Gemcitabine as First-Line Treatment in Patients With Locally Advanced Pancreatic Cancer [NCT00234416]Phase 1/Phase 245 participants Interventional2002-08-31Completed
A Phase I/II Study of ZD1839 (Iressa) Given Concurrently With Radiotherapy in Patients With Non-Metastatic Prostate Cancer [NCT00239291]Phase 1/Phase 242 participants (Actual)Interventional2003-01-31Completed
An Open Label, Non-Comparative, Phase II Study of ZD1839 (Iressa) as First-Line Treatment in Subjects With Relapsed Prostate Cancer Following Radical Prostatectomy or Radiotherapy [NCT00241475]Phase 230 participants Interventional2003-12-31Completed
A Phase II Study to Evaluate the Safety and Efficacy of the Combination of ZD1839 (IRESSA™), Docetaxel and Cisplatin in Subjects With Recurrent and/or Metastatic Head and Neck Cancer [NCT00242762]Phase 236 participants Interventional2003-07-31Completed
A Double Blind,Placebo Controlled,Parallel Group,Multicentre,Randomised,Phase Iii Survival Study Comparing ZD1839 (IRESSA™)(250mg Tablet) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients With Advanced NSCLC Who Have Received [NCT00242801]Phase 31,692 participants Interventional2003-07-31Completed
Phase II Trial of Neoadjuvant Docetaxel and ZD 1839 (Iressa) Followed by Radical Prostatectomy in Patients With High Risk, Locally Advanced Prostate Cancer [NCT00242918]Phase 229 participants Interventional2003-05-31Completed
An Open Randomised Phase II Study Of Gemcitabine Plus Cisplatin +/- Concomitant or Sequential ZD1839 in Patients With Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium [NCT00246974]Phase 2125 participants (Anticipated)Interventional2003-05-31Completed
A Multicentre, Randomised, Double-Blind, Non-Comparative Phase II Trial Of ZD1839 (Iressa™) And Placebo In Combination With Chemotherapy With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer [NCT00247481]Phase 277 participants Interventional2002-09-30Completed
A Multicentre, Randomised, Open-Label, Parallel-Group, Phase III Post-Marketing Clinical Study to Compare the Overall Survival Between Gefitinib and Docetaxel in Patients With Advanced or Metastatic (Stage IIIB/IV), or Recurrent Non-Small Cell Lung Cancer [NCT00252707]Phase 3484 participants (Anticipated)Interventional2003-09-30Completed
A Randomised Phase II Study to Investigate the Feasibility and Benefits of Combining ZD1839 and Cisplatin/5FU, as Induction Therapy, in Patients With Locally and Advanced Squamous Cell Carcinoma of the Head and Neck [NCT00255476]Phase 264 participants Interventional2004-02-29Completed
A Phase 1 Study of LY2875358 in Japanese Patients With Advanced Malignancies [NCT01602289]Phase 117 participants (Actual)Interventional2012-06-30Completed
A Phase II Multicentre Randomised, Parallel Group, Double-Blind, Placebo-Controlled Study of ZD1839 (IRESSATM) (250MG Tablet) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Chemotherapy-Naive Patients With Advanced (Stage IIIB or IV) Non-Small [NCT00259064]Phase 2/Phase 3216 participants (Actual)Interventional2004-09-30Completed
A Phase II Study of Second-Line Therapy With Irinotecan or Gefitinib in Docetaxel Pretreated Patients With Non-Small Cell Lung Cancer: a New Treatment Strategy According to Clinical Predictors for Response [NCT00319800]Phase 250 participants Interventional2006-02-28Active, not recruiting
A Phase II Open-Label Multicentre Study Of The Efficacy Of ZD1839 (IRESSA™) In Combination With Irradiation Followed By Chemotherapy In Patients With Inoperable Stage III Non Small Cell Lung Cancer [NCT00333294]Phase 250 participants Interventional2004-09-30Completed
A Randomized Placebo-controlled Phase II Study of Intercalated Administration of Pemetrexed/Cisplatin With Iressa® (Gefitinib) or Placebo as First-line Treatment of Stage IIIB/IV Lung Adenocarcinoma in Never-smokers [NCT01502202]Phase 2162 participants (Anticipated)Interventional2012-03-31Recruiting
First Line Gefitinib Treatment for Advanced Non-small Cell Lung Cancer (NSCLC) by the FDG-PET Metabolic Response [NCT01510990]Phase 260 participants (Anticipated)Interventional2012-04-30Recruiting
Phase Ⅱ Study of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer [NCT01732276]Phase 250 participants (Anticipated)Interventional2013-01-31Not yet recruiting
Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary Adenocarcinoma: a Randomized Double-blind Controlled Clinical Trial [NCT01745302]470 participants (Anticipated)Observational2011-11-30Enrolling by invitation
A Phase Ⅱ Randomized Controlled Trial to Compare Chemotherapy Sequenced by EGFR-TKIs and Chemotherapy Combined With EGFR-TKIs for Advanced or Metastatic NSCLC Patients Failed to EGFR-TKIs Therapy [NCT01746277]Phase 260 participants (Anticipated)Interventional2012-10-31Recruiting
A Phase Ⅱ Randomized Clinical Trial Comparing Vinorelbine-ifosfamide With Gefitinib as Third-line Treatment in Advanced EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients [NCT01749072]Phase 2120 participants (Anticipated)Interventional2012-12-31Recruiting
A Phase Ⅱ Randomized Controlled Trial to Compare Gefitinib With Docetaxel as Second-line Therapy for Advanced or Metastatic Non-squamous NSCLC Patients With Wild-type EGFR [NCT01755923]Phase 260 participants (Anticipated)Interventional2012-12-31Recruiting
Random Open Exploratory Clinical Research of Sequential Gefitinib With Pemetrexed/Platinum Compare With Pemetrexed/Platinum Treatment for Advanced Non-small Cell Lung Cancer Exploratory Clinical Research [NCT01769066]Phase 2/Phase 3117 participants (Actual)Interventional2009-12-31Completed
Detection of Resistance Genes From Serially Collected Plasma DNA in Non-small Cell Lung Cancer Patients Harboring EGFR Activating Mutation Who Are Being Treated With EGFR TKIs [NCT01776684]200 participants (Anticipated)Interventional2012-06-30Recruiting
Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients With Advanced Non-small Cell Lung Cancer [NCT01783834]Phase 295 participants (Actual)Interventional2008-02-29Completed
A Multi-center Phase II Randomized Study of Customized Neoadjuvant Therapy Versus Standard Chemotherapy in Non-small Cell Lung Cancer (NSLC) Patients With Resectable Stage IIIA (N2) Disease (CONTEST-TRIAL) [NCT01784549]Phase 2168 participants (Anticipated)Interventional2012-07-31Recruiting
Intercalating and Maintenance Use of Iressa vs. Chemotherapy in Selected Advanced NSCLC: a Randomised Study [NCT01404260]Phase 3219 participants (Actual)Interventional2011-06-30Completed
A Multicenter, Randomized, Double-Blind Study of Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer [NCT04028778]Phase 3310 participants (Anticipated)Interventional2019-04-10Recruiting
A Phase Ib, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumour Activity of Volitinib in Combination With Gefitinib in Patients With Epidermal Growth Factor Receptor-mutated Non-small Cell Lung [NCT02374645]Phase 164 participants (Actual)Interventional2015-04-30Completed
A Randomized, Open-label, Multiple-centre Study of Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced NSCLC With EGFR Mutation Positive [NCT02299765]Phase 461 participants (Actual)Interventional2014-12-31Terminated(stopped due to the research data is not statistically significant)
Gefitinib Alone or With Concomitant Whole Brain Radiotherapy for Patients Harboring an EGFR Mutation With Multiple Brain Metastases From Non-Small-cell Lung Cancer: a Phase II/III Randomized Controlled Trial [NCT02338011]Phase 2/Phase 3210 participants (Anticipated)Interventional2014-11-30Recruiting
[NCT02447419]Phase 216 participants (Actual)Interventional2014-12-03Completed
A Phase IIa, Open-Label, Multi-Center, Multi-Cohort, Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) [NCT02179671]Phase 232 participants (Actual)Interventional2014-07-25Completed
Phase III Randomized, Placebo Controlled, Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib) in Performance Status 2 or Previously Treated Patients With Recurrent or Metastatic Head and Neck Cancer [NCT00088907]Phase 3270 participants (Actual)Interventional2004-08-31Terminated(stopped due to It was unlikely that the primary endpoint would be reached based on the fifth interim analysis results.)
APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR Mutant NSCLC Patients [NCT02856893]Phase 2156 participants (Anticipated)Interventional2017-10-10Active, not recruiting
Retreatment of Gefitinib in the Patients With Non-small Cell Lung Cancer (NSCLC) Previously Responded to Gefitinib A Single Arm, Open Label, Phase II Study [NCT00824746]Phase 223 participants (Actual)Interventional2009-01-31Completed
A Randomised Phase 2 Trial of Pemetrexed and Gefitinib Versus Gefitinib as First Line Treatment for Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations [NCT01469000]Phase 2195 participants (Actual)Interventional2012-02-29Completed
LUX-Lung 7: A Randomised, Open-label Phase IIb Trial of Afatinib Versus Gefitinib as First-line Treatment of Patients With EGFR Mutation Positive Advanced Adenocarcinoma of the Lung [NCT01466660]Phase 2319 participants (Actual)Interventional2011-12-13Completed
Phase I/II Trial of ZD1839 (Iressa®), Trastuzumab (Herceptin®), and Docetaxel (Taxotere®) in Patients With erbB-2 (HER-2) Overexpressing, Stage IV Breast Carcinoma [NCT00086957]Phase 1/Phase 231 participants (Actual)Interventional2004-01-31Completed
An Open Label, Randomized, Multicenter, Phase II Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Advanced (Stage IV) EGFR Mutation Negative or T790M Single Mutation Nonsquamous NS [NCT01579630]Phase 2/Phase 352 participants (Actual)Interventional2011-03-31Active, not recruiting
A Randomized Placebo Controlled Study to Assess the Rate of PSA Decrease, Anatomical & Metabolic Changes in the Prostate Determined by MRI/3D-MRS & Histological Changes by Biopsy in Subjects With Locally Advanced Prostate Carcinoma Treated With Either Cas [NCT00319787]Phase 2102 participants Interventional2003-12-31Completed
A Phase II Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA) as 3rd Line Treatment Re-challenge in Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Loca [NCT01530334]Phase 261 participants (Actual)Interventional2012-07-31Completed
Fruquintinib in Combination With Gefitinib as First-line Therapy in Patients With Advanced Non-squamous Non-small-cell Lung Cancer Harboring Activating EGFR Mutations : a Single-arm, Multicenter, Phase II Study [NCT02976116]Phase 250 participants (Actual)Interventional2016-12-31Completed
A Phase III,Double-Blind, Randomised Study to Assess the Efficacy and Safety of ASK120067 Versus Gefitinib as First-Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Canc [NCT04143607]Phase 3334 participants (Anticipated)Interventional2019-07-23Recruiting
A Phase Ib, Open Label, Multi-center Study to Characterize the Safety, Tolerability and Preliminary Efficacy of EGF816 in Combination With Selected Targeted Agents in EGFR Mutant NSCLC [NCT03333343]Phase 1105 participants (Actual)Interventional2018-01-29Active, not recruiting
Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC Clinical Study of L858R Positive Mutation Patients [NCT04425187]Phase 2120 participants (Anticipated)Interventional2020-06-08Recruiting
A Phase III Randomised, Double Blind, Placebo Controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of Continuing IRESSA 250 mg in Addition to Chemotherapy Versus Chemotherapy Alone in Patients Who Have Epidermal Growth Factor Receptor [NCT01544179]Phase 3265 participants (Actual)Interventional2012-03-15Completed
Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease [NCT02484755]Phase 26 participants (Anticipated)Interventional2015-06-30Recruiting
Induction Therapy With Gefitinib Followed by Taxane Platinum Chemotherapy and Intercalated Gefitinib in NSCLC Stages II-IIIB With Activating EGFR Mutation - A Single Arm Phase II Trial. [NCT02326285]Phase 2/Phase 31 participants (Actual)Interventional2015-11-30Terminated(stopped due to Due to low patient enrollment was stopped. Only one patient could be enrolled. 37 patients were pre-screened, but not into the inclusion criteria (wt-EGFR))
Effect of Metformin in Combination With Tyrosine Kinase Inhibitors (TKI) on Clinical, Biochemical and Nutritional in Patients With Non-Small Cell Lung Carcinoma (NSCLC): Randomized Clinical Trial [NCT03071705]120 participants (Anticipated)Interventional2016-03-31Recruiting
Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer [NCT02031601]Phase 4250 participants (Anticipated)Interventional2014-01-31Recruiting
Multicenter Open-label, Long-term Safety Trial of Treatment Extension With ZD1839 in Patients Who Have Been Treated in Other ZD1839 Clinical Trials. [NCT00357734]Phase 314 participants (Actual)Interventional2005-01-31Completed
Phase II Study of ZD1839 (Iressa®), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor in Patients With Advanced, Recurrent or Metastatic Salivary Gland Cancer (IRUSIRES0198) [NCT00509002]Phase 237 participants (Actual)Interventional2004-05-31Completed
A Phase II Study Evaluating the Efficacy of Iressa Plus Etoposide in Patients With Advanced Hormone Refractory Prostate Cancer [NCT00483561]Phase 226 participants (Actual)Interventional2004-01-31Terminated(stopped due to PI left UNMC)
A Phase I/II Trial to Assess the Tolerability of RAD 001 With Gefitinib in Patients With Glioblastoma Multiforme and Prostate Cancer and Efficacy in Patients With Castrate Metastatic Prostate Cancer [NCT00085566]Phase 1/Phase 261 participants (Actual)Interventional2004-03-31Completed
Single-dose, Open-label, Randomized, 2-way Crossover Bioequivalence Study of Gefitinib Tablets Under Fed Conditions in Chinese Healthy Male Subjects [NCT03050177]Phase 138 participants (Actual)Interventional2016-09-01Completed
A Study of Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer [NCT03050411]Phase 130 participants (Anticipated)Interventional2016-05-31Recruiting
An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations [NCT02588261]Phase 3530 participants (Actual)Interventional2016-02-11Terminated(stopped due to Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies)
Multi-Center, Randomized, Double-Blind Phase II Study Comparing Cediranib (AZD2171) Plus Gefitinib (Iressa, ZD1839) With Cediranib Plus Placebo in Subjects With Recurrent/Progressive Glioblastoma (DORIC Trial) [NCT01310855]Phase 238 participants (Actual)Interventional2011-05-31Terminated(stopped due to closed to recruitment early due to AstraZeneca not developing cediranib further)
A Multicenter Phase II Trial of Neoadjuvant Gefitinib Followed by Surgery, Followed by Adjuvant Gefitinib in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations. [NCT02347839]Phase 237 participants (Anticipated)Interventional2016-01-31Recruiting
The Phase Three Trials of Pemetrexed/Cisplatin Intercalating Gefitinib vs Pemetrexed/Cisplatin Treating EGFR Wild NSCLC(Non Squamous Cell Carcinoma) [NCT03374280]Phase 2178 participants (Anticipated)Interventional2016-12-01Recruiting
A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations. [NCT03381066]Phase 3225 participants (Anticipated)Interventional2018-04-10Recruiting
Gefitinib Versus Combination of Gefitinib With Chemotherapy or Anti-angiogenesis as 1st Line Treatment in Advanced NSCLC Patients Detected With Bim Deletion or Low EGFR Activating Mutation Abundance：A Randomized, Multicentre, Phase II Study [NCT03267654]Phase 2100 participants (Anticipated)Interventional2017-10-12Recruiting
Randomized, Phase II Study With Gefitinib Plus Vinorelbine Versus Gefitinib Alone in Patients Affected by Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of EGFR [NCT02319577]Phase 280 participants (Anticipated)Interventional2012-03-31Recruiting
A Phase 1 Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors for Epidermal Growth Factor Receptor (EGFR)-Mutant Advanced Non-small Cell Lung Cancer [NCT02321293]Phase 120 participants (Anticipated)Interventional2015-08-31Recruiting
Blood Detection of EGFR Mutation For Iressa Treatment [NCT02282267]188 participants (Actual)Interventional2014-10-31Active, not recruiting
A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer [NCT02411448]Phase 3545 participants (Actual)Interventional2015-05-06Active, not recruiting
Drug Treatment Patterns and Effects for Metastatic Non-small Cell Lung Cancer Patients In NORway (DELINOR) [NCT05834348]20,605 participants (Anticipated)Observational2023-06-26Recruiting
A Multicenter, Open-Label Phase 1 Study of DS-1205c in Combination With Gefitinib in Subjects With Metastatic or Unresectable EGFR-Mutant Non-Small Cell Lung Cancer [NCT03599518]Phase 120 participants (Actual)Interventional2018-09-21Terminated(stopped due to This study was terminated based on a business decision by the Sponsor.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00042991 (15) [back to overview]Median Survival in Newly Diagnosed Brain Stem Gliomas
NCT00042991 (15) [back to overview]Change From Baseline in Diffusion Ratio at Two Weeks After Completion of Radiation
NCT00042991 (15) [back to overview]Change From Baseline in Perfusion Ratio at Two Weeks After Completion of Radiation
NCT00042991 (15) [back to overview]Change From Baseline in Volume Enhancing at Two Weeks After Completion of Radiation
NCT00042991 (15) [back to overview]Change in Tumor Volume Measured on Fluid Attenuated Inversion Recovery (FLAIR) Imaging at Before the Protocol Therapy Started and at Two Weeks After Completion of Radiation
NCT00042991 (15) [back to overview]Clearance of Gefitinib (Cl)
NCT00042991 (15) [back to overview]Elimination Half Life of Gefitinib (t1/2)
NCT00042991 (15) [back to overview]Gefitinib Area Under the Concentration Curve From 0-24 Hours (AUC)
NCT00042991 (15) [back to overview]Mean Tumor to Gray Matter Ratio Measured at Baseline
NCT00042991 (15) [back to overview]Mean Tumor to White Matter Ratio Measured at Baseline
NCT00042991 (15) [back to overview]Median Progression-free Survival in Newly Diagnosed Brain Stem Gliomas
NCT00042991 (15) [back to overview]Number of Participants in Phase I Stratum 1A With Dose-limiting Toxicities (DLT) Observed During the First 8 Weeks of Gefitinib Therapy
NCT00042991 (15) [back to overview]Number of Patients With Epidermal Growth Factor Receptor (EGFR) Amplification
NCT00042991 (15) [back to overview]Peak Serum Concentration of Gefitinib (Cmax)
NCT00042991 (15) [back to overview]Time of Maximum Clearance of Gefitinib (Tmax)
NCT00049543 (3) [back to overview]Disease Free Survival
NCT00049543 (3) [back to overview]Incidence of Toxicities Graded Using the NCI Common Terminology Criteria for Adverse Events Version 3.0
NCT00049543 (3) [back to overview]Overall Survival
NCT00054691 (2) [back to overview]Duration of Response
NCT00054691 (2) [back to overview]Number of Participants With Objective Response (Partial Response, Stable Disease and Progressive Disease)
NCT00057941 (1) [back to overview]Clinical Benefit Rate
NCT00085566 (1) [back to overview]Overall Objective Response
NCT00086957 (5) [back to overview]Number of Participants With at Least One Dose Limiting Toxicity in Phase I
NCT00086957 (5) [back to overview]Objective Response Rate
NCT00086957 (5) [back to overview]Overall Survival
NCT00086957 (5) [back to overview]Progression-free Survival
NCT00086957 (5) [back to overview]Recommended Phase II Dose
NCT00088907 (3) [back to overview]Overall Response Rate
NCT00088907 (3) [back to overview]Overall Survival
NCT00088907 (3) [back to overview]Time to Progression
NCT00095836 (4) [back to overview]Median Progression-free Survival
NCT00095836 (4) [back to overview]Overall Survival
NCT00095836 (4) [back to overview]Objective Tumor Response Rate at 3, 6, and 12 Months
NCT00095836 (4) [back to overview]Toxicity
NCT00096486 (1) [back to overview]Overall Objective Response
NCT00113529 (30) [back to overview]Change From Baseline in VEGFR3 by Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] Versus PD)
NCT00113529 (30) [back to overview]Time to Tumor Response (TTR)
NCT00113529 (30) [back to overview]VEGF Ratio to Baseline at Each Time Point
NCT00113529 (30) [back to overview]VEGF-C Ratio to Baseline at Each Time Point
NCT00113529 (30) [back to overview]Change From Baseline in VEGF by Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] Versus PD)
NCT00113529 (30) [back to overview]Change From Baseline in VEGF by Time Point Stratified by TTP >= Median and TTP < Median
NCT00113529 (30) [back to overview]Change From Baseline in VEGF by Time Point Stratified by PFS >= Median and PFS < Median
NCT00113529 (30) [back to overview]VEGF-C Concentration at Baseline
NCT00113529 (30) [back to overview]VEGF (Vascular Endothelial Growth Factor) Concentration at Baseline
NCT00113529 (30) [back to overview]Time to Tumor Progression (TTP)
NCT00113529 (30) [back to overview]Soluble VEGF Receptor 3 (sVEGFR3) Concentration at Baseline
NCT00113529 (30) [back to overview]Soluble VEGF Receptor 2 (sVEGFR2) Concentration at Baseline
NCT00113529 (30) [back to overview]Progression-Free Survival (PFS)
NCT00113529 (30) [back to overview]Probability of Survival at One Year
NCT00113529 (30) [back to overview]Overall Survival (OS)
NCT00113529 (30) [back to overview]Duration of Response (DR)
NCT00113529 (30) [back to overview]Change From Baseline in VEGFC by Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] Versus PD)
NCT00113529 (30) [back to overview]Ctrough of Gefitinib
NCT00113529 (30) [back to overview]Ctrough of SU-012662 (Sunitinib's Metabolite)
NCT00113529 (30) [back to overview]sVEGFR2 Ratio to Baseline at Each Time Point
NCT00113529 (30) [back to overview]sVEGFR3 Ratio to Baseline at Each Time Point
NCT00113529 (30) [back to overview]Change From Baseline in VEGFR2 by Time Point Stratified by PFS >= Median and PFS < Median
NCT00113529 (30) [back to overview]Trough Plasma Concentrations (Ctrough) of Sunitinib
NCT00113529 (30) [back to overview]Change From Baseline in VEGFR2 by Time Point Stratified by TTP >= Median and TTP < Median
NCT00113529 (30) [back to overview]Change From Baseline in VEGFC by Time Point Stratified by TTP >= Median and TTP < Median
NCT00113529 (30) [back to overview]Change From Baseline in VEGFR2 by Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] Versus PD)
NCT00113529 (30) [back to overview]Change From Baseline in VEGFR3 by Time Point Stratified by PFS >= Median and PFS < Median
NCT00113529 (30) [back to overview]Change From Baseline in VEGFR3 by Time Point Stratified by TTP >= Median and TTP < Median
NCT00113529 (30) [back to overview]Change From Baseline in VEGFC by Time Point Stratified by PFS >= Median and PFS < Median
NCT00113529 (30) [back to overview]Number of Subjects With Overall Confirmed Objective Disease Response According to the Response Evaluation Criteria in Solid Tumors (RECIST)
NCT00126555 (7) [back to overview]Toxicity as Assessed by the National Cancer Institute (NCI) Common Toxicity Criteria Associated With Gefitinib Therapy: Expected Toxicities (Grade 1 - 3)
NCT00126555 (7) [back to overview]Participant Treatment Following Induction Therapy
NCT00126555 (7) [back to overview]Number of Participants With Response Rate During Induction, Dose Escalation, and Concomitant With Radiation.
NCT00126555 (7) [back to overview]Frequency and Timing of Local and Distant Failures
NCT00126555 (7) [back to overview]Clinical Response According to Response Evaluation Criteria In Solid Tumors (RECIST)
NCT00126555 (7) [back to overview]Early Progression Rate
NCT00126555 (7) [back to overview]Toxicity as Assessed by the National Cancer Institute (NCI) Common Toxicity Criteria Associated With Gefitinib Therapy: UnExpected Toxicities (Grade 1 - 3)
NCT00229723 (6) [back to overview]Progression Free Survival
NCT00229723 (6) [back to overview]Tumour Response (Complete Response + Partial Response)
NCT00229723 (6) [back to overview]Complete Response
NCT00229723 (6) [back to overview]Local Disease Control Rate at 1 Year
NCT00229723 (6) [back to overview]Local Disease Control Rate at 2 Years
NCT00229723 (6) [back to overview]Overall Survival
NCT00231465 (3) [back to overview]Overall Response Rate (ORR)
NCT00231465 (3) [back to overview]Overall Survival (OS) Rate
NCT00231465 (3) [back to overview]Progression Free Survival (PFS) Rate
NCT00264498 (1) [back to overview]Progression Free Survival (PFS)
NCT00268346 (1) [back to overview]The Number of Patients With Complete or Partial Response Rate of Single Agent ZD1839 in a Patient Population With Recurrent or Metastatic Cancer of the Esophagus or Gastroesophageal Junction, Using the RECIST 1.0 Criteria.
NCT00317772 (3) [back to overview]Dose Limiting Toxicity (DLT)
NCT00317772 (3) [back to overview]Maximum Tolerated Dose (MTD) of Topotecan
NCT00317772 (3) [back to overview]Response Rate
NCT00322452 (16) [back to overview]Neurotoxicity
NCT00322452 (16) [back to overview]Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Thrombocytopenia
NCT00322452 (16) [back to overview]Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Neutropenia
NCT00322452 (16) [back to overview]Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Anaemia
NCT00322452 (16) [back to overview]Quality of Life (QoL) as Measured by the Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy - Lung Cancer (FACT-L) Questionnaire
NCT00322452 (16) [back to overview]Diarrhoea
NCT00322452 (16) [back to overview]Median Overall Survival (OS) in Months at OS Data Cut Off (14th June 2010)
NCT00322452 (16) [back to overview]Median Progression Free Survival (PFS) in Months
NCT00322452 (16) [back to overview]Nausea
NCT00322452 (16) [back to overview]Objective Tumour Response Rate According to RECIST
NCT00322452 (16) [back to overview]Quality of Life (QoL) as Measured by the Total Score of the Functional Assessment of Cancer Therapy - Lung Cancer (FACT-L) Questionnaire
NCT00322452 (16) [back to overview]Rashes/Acnes
NCT00322452 (16) [back to overview]Symptom Improvement as Measured by the Lung Cancer Subscale (LCS) of the FACT-L Questionnaire
NCT00322452 (16) [back to overview]Vomiting
NCT00322452 (16) [back to overview]Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Liver Transaminases
NCT00322452 (16) [back to overview]Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Leukopenia
NCT00328562 (4) [back to overview]Tumor Response
NCT00328562 (4) [back to overview]Survival From Starting Gefitinib
NCT00328562 (4) [back to overview]Patients Affected by Treatment-related Morbidities
NCT00328562 (4) [back to overview]Progression-free Survival
NCT00344773 (3) [back to overview]Overall Survival (OS)
NCT00344773 (3) [back to overview]Percentage of Participants Who Had an Objective Response Rate(ORR) Based on Response Evaluation Criteria In Solid Tumors (RECIST) Criteria.
NCT00344773 (3) [back to overview]Progression Free Survival (PFS)
NCT00357734 (6) [back to overview]Number of Other Adverse Events (AEs)
NCT00357734 (6) [back to overview]Number of Other Adverse Events (AEs) Related to ZD1839
NCT00357734 (6) [back to overview]Number of Serious Adverse Events (SAEs)
NCT00357734 (6) [back to overview]Number of Serious Adverse Events (SAEs) Related to ZD1839
NCT00357734 (6) [back to overview]Overall Survival (OS)
NCT00357734 (6) [back to overview]Progression-free Survival (PFS)
NCT00409006 (4) [back to overview]Progression-Free Survival (PFS)
NCT00409006 (4) [back to overview]Percentage of Participants Who Died During the Study
NCT00409006 (4) [back to overview]Number of Participants With Tumor Response
NCT00409006 (4) [back to overview]Duration of Response for Responders
NCT00467077 (4) [back to overview]Six-month Progression-free Survival
NCT00467077 (4) [back to overview]Progression-Free Survival
NCT00467077 (4) [back to overview]Overall Survival
NCT00467077 (4) [back to overview]Number of Participants With Overall Response as Measured by RECIST Criteria
NCT00479089 (2) [back to overview]Median Overall Survival
NCT00479089 (2) [back to overview]Median Progression Free Survival From Trial Enrollment for Overall Study
NCT00483561 (1) [back to overview]Overall Response Rate as Measured by RECIST Criteria and PSA Criteria
NCT00519077 (2) [back to overview]Response (CR or PR), Stable Disease (SD), and Progressive Disease (PD) Rates
NCT00519077 (2) [back to overview]Median Progression-free Survival Time
NCT00536107 (2) [back to overview]Number of Patients With Adverse Event (AE)
NCT00536107 (2) [back to overview]Number of Patients With Serious Adverse Events (SAEs)
NCT00588445 (2) [back to overview]Microarray Analysis to Identify Gene(s) or Gene Clusters That Exhibit Changes in Gene Expression; Time to Relapse and Overall Survival Data
NCT00588445 (2) [back to overview]The Radiographic Response to Gefitinib
NCT00608868 (4) [back to overview]Objective Response Rate(ORR)
NCT00608868 (4) [back to overview]Period of Progression-Free Survival
NCT00608868 (4) [back to overview]Quality of Life and Symptom Improvement Based on Functional Assessment of Cancer Therapy-Lung (FACT-L)
NCT00608868 (4) [back to overview]Adverse Event
NCT00770588 (5) [back to overview]Symptom Improvement
NCT00770588 (5) [back to overview]Objective Tumour Response (ORR)
NCT00770588 (5) [back to overview]Adverse Event
NCT00770588 (5) [back to overview]Overall Survival (OS)
NCT00770588 (5) [back to overview]Progression Free Survival (PFS)
NCT00824746 (3) [back to overview]Progression - Free Survival of Patients Retreated With Gefitinib
NCT00824746 (3) [back to overview]Disease Control(DC) Rate of Gefitinib Retreatment Per RECIST Criteria (V1.1) and Assessed by CT
NCT00824746 (3) [back to overview]Overall Survival
NCT01017874 (7) [back to overview]Progression Free Survival (PFS)
NCT01017874 (7) [back to overview]Time to Progressive Disease (TtPD)
NCT01017874 (7) [back to overview]Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [Disease Control Rate (DCR)]
NCT01017874 (7) [back to overview]Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]
NCT01017874 (7) [back to overview]Time to Worsening of Health-Related Quality of Life (TWQ) Using the Participant-Rated Lung Cancer Symptom Scale (LCSS)
NCT01017874 (7) [back to overview]Duration of Tumor Response
NCT01017874 (7) [back to overview]Overall Survival (OS)
NCT01040780 (5) [back to overview]Best Tumor Response
NCT01040780 (5) [back to overview]Safety and Tolerability
NCT01040780 (5) [back to overview]Overall Survival
NCT01040780 (5) [back to overview]Progression Free Survival
NCT01040780 (5) [back to overview]Time To Progression
NCT01185171 (4) [back to overview]4 Year Disease Specific Survival
NCT01185171 (4) [back to overview]4 Year Overall Survival
NCT01185171 (4) [back to overview]4 Year Progression Free Survival
NCT01185171 (4) [back to overview]Complete Response Rate Achieved 1 Month After Concurrent Chemotherapy and Radiation Treatment
NCT01203917 (7) [back to overview]Overall Survival (OS)
NCT01203917 (7) [back to overview]Progression - Free Survival (PFS) (Independent Central Review)
NCT01203917 (7) [back to overview]Progression - Free Survival (PFS) (Investigator)
NCT01203917 (7) [back to overview]Disease Control Rate (DCR) (Independent Central Review)
NCT01203917 (7) [back to overview]Disease Control Rate (DCR) (Investigator)
NCT01203917 (7) [back to overview]Objective Response Rate (ORR) (Independent Central Review))
NCT01203917 (7) [back to overview]Objective Response Rate (ORR) (Investigator)
NCT01310855 (1) [back to overview]Progression-free Survival
NCT01404260 (1) [back to overview]Progression Free Survival
NCT01466660 (10) [back to overview]Time to Treatment Failure (TTF) (Main Overall Survival Analysis Cut-off Date, 08 April 2016)
NCT01466660 (10) [back to overview]Progression-free Survival
NCT01466660 (10) [back to overview]Overall Survival
NCT01466660 (10) [back to overview]Objective Response Rate
NCT01466660 (10) [back to overview]Duration of Objective Response
NCT01466660 (10) [back to overview]Disease Control
NCT01466660 (10) [back to overview]Duration of Disease Control
NCT01466660 (10) [back to overview]Tumour Shrinkage (Main Overall Survival Analysis Cut-off Date, 08 April 2016)
NCT01466660 (10) [back to overview]Time to Objective Response
NCT01466660 (10) [back to overview]Health-related Quality of Life (Primary Analysis Cut-off Date, 21 August 2015)
NCT01469000 (7) [back to overview]Time To Progressive Disease (TTPD)
NCT01469000 (7) [back to overview]Progression Free Survival (PFS)
NCT01469000 (7) [back to overview]Percentage of Participants With CR, PR, and Stable Disease (SD) (Disease Control Rate [DCR])
NCT01469000 (7) [back to overview]Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])
NCT01469000 (7) [back to overview]Time to Worsening of Symptom (TWS) as Per Lung Cancer Symptom Scale (LCSS)
NCT01469000 (7) [back to overview]Duration of Response (DoR)
NCT01469000 (7) [back to overview]Overall Survival (OS)
NCT01530334 (6) [back to overview]Time to Worsening of Disease Related Symptoms
NCT01530334 (6) [back to overview]Objective Response Rate
NCT01530334 (6) [back to overview]Treatment Duration With Gefitinib
NCT01530334 (6) [back to overview]Overall Survival (OS)
NCT01530334 (6) [back to overview]Progression Free Survival
NCT01530334 (6) [back to overview]Clinical Benefit Rate
NCT01544179 (12) [back to overview]Progression-Free Survival (Site Read, Investigator Assessment)
NCT01544179 (12) [back to overview]Disease Control Rate (DCR)
NCT01544179 (12) [back to overview]Improvement in FACT-L Total Score
NCT01544179 (12) [back to overview]Improvement in Lung Cancer Subscale
NCT01544179 (12) [back to overview]Improvement in Trial Outcome Index
NCT01544179 (12) [back to overview]Median Overall Survival (OS) at Time of PFS Analysis
NCT01544179 (12) [back to overview]Median Progression-Free Survival (Site Read, Investigator Assessment)
NCT01544179 (12) [back to overview]Objective Response Rate (ORR) (Site Read Data)
NCT01544179 (12) [back to overview]Time to Worsening in FACT-L Total Score
NCT01544179 (12) [back to overview]Time to Worsening in Lung Cancer Subscale
NCT01544179 (12) [back to overview]Time to Worsening in Trial Outcome Index
NCT01544179 (12) [back to overview]Overall Survival (OS)
NCT01610336 (15) [back to overview]Phase I: PK Parameters Tmax of INC280 and Gefitinib
NCT01610336 (15) [back to overview]Phase I: PK Parameters Apparent Systemic Plasma Clearance Rate of INC280 and Gefitinib
NCT01610336 (15) [back to overview]Phase II: Progression Free Survival (PFS)
NCT01610336 (15) [back to overview]Phase II: Overall Survival (OS)
NCT01610336 (15) [back to overview]Phase II: Duration of Response (DoR)
NCT01610336 (15) [back to overview]Phase II : Overall Response Rate (ORR)
NCT01610336 (15) [back to overview]Phase Ib and II: Number of Participants With Serious Adverse Events (SAEs)
NCT01610336 (15) [back to overview]Phase I: Percentage of Change From Baseline in C-MET H Score at Cycle 1 Day 15
NCT01610336 (15) [back to overview]Phase Ib: Frequency of Dose Limiting Toxicities (DLTs)
NCT01610336 (15) [back to overview]Phase Ib and II: Number of Participants With Adverse Events (AEs)
NCT01610336 (15) [back to overview]Phase I: PK Parameters AUCtau of INC280 and Gefitinib
NCT01610336 (15) [back to overview]Phase I: PK Parameters Half-life of INC280 and Gefitinib
NCT01610336 (15) [back to overview]Phase I: PK Parameters Cmax of INC280 and Gefitinib
NCT01610336 (15) [back to overview]Phase I: PK Parameters AUCtau of INC280 and Gefitinib
NCT01610336 (15) [back to overview]Phase I: PK Parameters Apparent Systemic Plasma Clearance Rate of INC280 and Gefitinib
NCT01774721 (25) [back to overview]Objective Response Rate (ORR) Based on Investigator Assessment
NCT01774721 (25) [back to overview]Objective Response Rate (ORR) Based on IRC Review
NCT01774721 (25) [back to overview]OS at 30 Months (OS30m)
NCT01774721 (25) [back to overview]Overall Mean Scores of Euro Quality of Life-5 Dimension Visual Analog Scale (EQ-5D VAS)
NCT01774721 (25) [back to overview]Overall Survival (OS)
NCT01774721 (25) [back to overview]Number of Participants With Clinically Significant Abnormalities in Vital Signs
NCT01774721 (25) [back to overview]Number of Participants With Laboratory Test Abnormalities: Urinalysis
NCT01774721 (25) [back to overview]Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01774721 (25) [back to overview]Pre-dose Plasma Concentrations (Ctrough) of Dacomitinib and Its Metabolite PF-05199265
NCT01774721 (25) [back to overview]Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI CTCAE Version 4.03: Biochemistry and Haematology
NCT01774721 (25) [back to overview]Apparent Clearance (CL) of Dacomitinib
NCT01774721 (25) [back to overview]Time to Reach Maximum Observed Plasma Concentration (Tmax) of Dacomitinib and Its Metabolite PF-05199265
NCT01774721 (25) [back to overview]Number of Participants With Best Overall Response (BOR) Based on IRC Review
NCT01774721 (25) [back to overview]Number of Participants With Best Overall Response (BOR) Based on Investigator Assessment
NCT01774721 (25) [back to overview]Health Related Quality of Life (HRQOL): Time to Deterioration (TTD) in Pain, Dyspnea, Fatigue or Cough
NCT01774721 (25) [back to overview]Number of Participants With Maximum Relative Decrease From Baseline >20% in Left Ventricular Ejection Fraction (LVEF)
NCT01774721 (25) [back to overview]Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review
NCT01774721 (25) [back to overview]Progression Free Survival (PFS) Based on Investigator Assessment
NCT01774721 (25) [back to overview]Area Under the Plasma Concentration-Time Curve From Time Zero (0) to End of Dosing Interval (AUCtau) of Dacomitinib and Its Metabolite PF-05199265
NCT01774721 (25) [back to overview]Averaged Plasma Concentration at Steady State (Cavg) of Dacomitinib and Its Metabolite PF-05199265
NCT01774721 (25) [back to overview]Duration of Response (DoR)
NCT01774721 (25) [back to overview]Minimum Observed Plasma Concentration (Cmin) of Dacomitinib and Its Metabolite PF-05199265
NCT01774721 (25) [back to overview]Maximum Observed Plasma Concentration (Cmax) of Dacomitinib and Its Metabolite PF-05199265
NCT01774721 (25) [back to overview]Fluctuation Coefficient Between Trough and Peak Plasma Concentration (DF) of Dacomitinib and Its Metabolite PF-05199265
NCT01774721 (25) [back to overview]Number of Participants With Clinically Significant Abnormality in Electrocardiogram (ECG)
NCT01982955 (44) [back to overview]Phase 2: Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status Scale Score at End of Treatment (EOT)
NCT01982955 (44) [back to overview]Phase 2: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiograms (ECG) Findings
NCT01982955 (44) [back to overview]Phase 2: Number of Participants With Clinically Significant Abnormalities in Vital Signs
NCT01982955 (44) [back to overview]Phase 2: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 2 or Higher Than 2
NCT01982955 (44) [back to overview]Phase 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Permanent Treatment Discontinuation
NCT01982955 (44) [back to overview]Phase 2: Time-to-Symptom Progression (TTSP)
NCT01982955 (44) [back to overview]Phase 1b: Apparent Terminal Elimination Rate Constant Lambda(z) of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]Phase 1b: Apparent Terminal Half-Life (t1/2) of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]Phase 1b: Apparent Total Body Clearance From Plasma (CL/F) of Tepotinib and Gefitinib
NCT01982955 (44) [back to overview]Phase 1b: Apparent Volume of Distribution (Vz/F) During the Terminal Phase of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]Phase 1b: Apparent Volume of Distribution During the Steady State (Vss/F) of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]Phase 1b: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time AUC (0-t) of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]Phase 1b: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC 0-infinity) of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]Phase 1b: Area Under the Plasma Concentration-Time Curve Within 1 Dosing Interval (AUC 0-tau) of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]Phase 1b: Average Observed Plasma Concentration (Cavg) of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]Phase 1b: Maximum Observed Plasma Concentration (Cmax) of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]Phase 1b: Minimum Observed Plasma Concentration (Cmin) of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]Phase 1b: Number of Participants With Death and Reasons
NCT01982955 (44) [back to overview]Phase 1b: Number of Participants With Grade 3/4 Treatment-Emergent Adverse Events (TEAEs) and Grade 3/4 Treatment-Related TEAEs According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version 4.03
NCT01982955 (44) [back to overview]Phase 1b: Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI-CTCAE Version 4.03 Reported as Treatment-Emergent Adverse Events (TEAEs)
NCT01982955 (44) [back to overview]Phase 1b: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
NCT01982955 (44) [back to overview]Phase 1b: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Permanent Treatment Discontinuation
NCT01982955 (44) [back to overview]Phase 1b: Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Serious TEAEs According to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.03
NCT01982955 (44) [back to overview]Phase 1b: Time to Reach Maximum Plasma Concentration (Tmax) of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]Phase 2: Number of Participants With Death and Reasons
NCT01982955 (44) [back to overview]Phase 2: Number of Participants With Greater Than or Equal to (>=) Grade 3 Treatment-Emergent Adverse Events (TEAEs) and >= Grade 3 Treatment-Related TEAEs According to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.03
NCT01982955 (44) [back to overview]Phase 2: Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI-CTCAE Version 4.03 Reported as Treatment-Emergent Adverse Events (TEAEs)
NCT01982955 (44) [back to overview]Phase 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment-Related TEAEs and Treatment-Related Serious TEAEs According to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.03
NCT01982955 (44) [back to overview]Phase 1b: Number of Participants Experiencing at Least One Dose Limiting Toxicity (DLT)
NCT01982955 (44) [back to overview]Phase 1b: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiograms (ECG) Findings
NCT01982955 (44) [back to overview]Phase 1b: Number of Participants With Clinically Significant Abnormalities in Vital Signs
NCT01982955 (44) [back to overview]Phase 1b: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 2 or Higher Than 2
NCT01982955 (44) [back to overview]Phase 1b: Percentage of Participants With Disease Control Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria
NCT01982955 (44) [back to overview]Phase 1b: Percentage of Participants With Objective Response Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria
NCT01982955 (44) [back to overview]Phase 2 (Non-Randomized Part Only): Percentage of Participants With Disease Control Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria
NCT01982955 (44) [back to overview]Phase 2 (Non-Randomized Part Only): Percentage of Participants With Objective Response Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria
NCT01982955 (44) [back to overview]Phase 2 (Non-Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by Independent Review Committee (IRC)
NCT01982955 (44) [back to overview]Phase 2 (Non-Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by Investigator
NCT01982955 (44) [back to overview]Phase 2 (Randomized Part Only): Percentage of Participants With Disease Control Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria
NCT01982955 (44) [back to overview]Phase 2 (Randomized Part Only): Percentage of Participants With Objective Response Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria
NCT01982955 (44) [back to overview]Phase 2 (Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by Independent Review Committee (IRC)
NCT01982955 (44) [back to overview]Phase 2 (Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by the Investigator
NCT01982955 (44) [back to overview]Phase 2: (Non-Randomized Part Only): Overall Survival (OS) Time
NCT01982955 (44) [back to overview]Phase 2: (Randomized Part Only): Overall Survival (OS) Time
NCT02039674 (6) [back to overview]Part 2 Cohorts G+ and G-: Progression-Free Survival (PFS)
NCT02039674 (6) [back to overview]Part 2 Cohorts G+ and G-: Overall Survival (OS)
NCT02039674 (6) [back to overview]Part 2 Cohorts G+ and G-: Objective Response Rate (ORR)
NCT02039674 (6) [back to overview]Part 2 Cohorts G+ and G-: Duration of Response (DOR)
NCT02039674 (6) [back to overview]Part 2 Cohorts D4 and H: Objective Response Rate (ORR)
NCT02039674 (6) [back to overview]All Cohorts: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)
NCT02179671 (5) [back to overview]Overall Survival
NCT02179671 (5) [back to overview]Progression-free Survival
NCT02179671 (5) [back to overview]Duration of Response
NCT02179671 (5) [back to overview]Objective Response Rate (ORR)
NCT02179671 (5) [back to overview]Confirmed Complete Response (CR) Rate
NCT02296125 (13) [back to overview]Depth of Response
NCT02296125 (13) [back to overview]Overall Survival (OS)- Number of Participants With an Event
NCT02296125 (13) [back to overview]Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ) Questionnaires Lung Cancer 13 (QLQ-LC13)
NCT02296125 (13) [back to overview]Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Items (EORTC QLQ-C30)
NCT02296125 (13) [back to overview]Plasma Concentrations of Metabolites AZ5104
NCT02296125 (13) [back to overview]Plasma Concentrations of Metabolite AZ7550
NCT02296125 (13) [back to overview]Plasma Concentrations of AZD9291
NCT02296125 (13) [back to overview]Percentage of Participants in Progression Free Survival at 6, 12, and 18 Months
NCT02296125 (13) [back to overview]Participants Reported Outcome by Cancer Therapy Satisfaction Questionnaire 16 Items (CTSQ-16 Questionnaire)
NCT02296125 (13) [back to overview]Disease Control Rate (DCR)
NCT02296125 (13) [back to overview]Duration of Response (DoR)
NCT02296125 (13) [back to overview]Median Progression Free Survival (PFS) (Months)
NCT02296125 (13) [back to overview]Objective Response Rate (ORR)
NCT02411448 (12) [back to overview]Part B: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab
NCT02411448 (12) [back to overview]Part B: Best Change From Baseline on the Lung Cancer Symptom Scale (LCSS)
NCT02411448 (12) [back to overview]Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score
NCT02411448 (12) [back to overview]Number of Participants With Treatment-Emergent Adverse Events
NCT02411448 (12) [back to overview]Part B: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
NCT02411448 (12) [back to overview]Part B: Overall Survival (OS)
NCT02411448 (12) [back to overview]Part B: Percentage of Participants With CR, PR, or Stable Disease (SD) (Disease Control Rate [DCR])
NCT02411448 (12) [back to overview]Part B: Number of Participants With Anti-Ramucirumab Antibodies
NCT02411448 (12) [back to overview]Part B: Duration of Response (DoR)
NCT02411448 (12) [back to overview]Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score
NCT02411448 (12) [back to overview]Part B: Progression Free Survival (PFS)
NCT02411448 (12) [back to overview]Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score
NCT02588261 (11) [back to overview]PFS as Assessed by the Investigator
NCT02588261 (11) [back to overview]Progression Free Survival (PFS) as Assessed by Independent Radiologic Review (IRR)
NCT02588261 (11) [back to overview]EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L)
NCT02588261 (11) [back to overview]Number of Participants With Adverse Events (AEs)
NCT02588261 (11) [back to overview]Functional Assessment of Cancer Therapy - EGFR Inhibitors Subscale (FACT-EGFRI-18) Questionnaire
NCT02588261 (11) [back to overview]Duration of Response (DOR)
NCT02588261 (11) [back to overview]European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30)
NCT02588261 (11) [back to overview]European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 (EORTC-QLQ-LC13)
NCT02588261 (11) [back to overview]Percentage of Deaths
NCT02588261 (11) [back to overview]Percentage of Participants With Disease Control
NCT02588261 (11) [back to overview]Percentage of Participants With Objective Response (OR)
NCT03599518 (10) [back to overview]Pharmacokinetic Parameter Trough Plasma Concentration (Ctrough) of DS-1205a Following Administration of DS-1205c in Combination With Gefitinib
NCT03599518 (10) [back to overview]Pharmacokinetic Parameter Area Under the Plasma Concentration Curve of DS-1205a Following Administration of DS-1205c in Combination With Gefitinib
NCT03599518 (10) [back to overview]Number of Participants With Treatment-emergent Adverse Events Occurring in Participants Following Administration With DS-1205c in Combination With Gefitinib
NCT03599518 (10) [back to overview]Number of Participants With Best Overall Response With Confirmation as Assessed by Investigator Following Administration of DS-1205c in Combination With Gefitinib
NCT03599518 (10) [back to overview]Progression-free Survival Assessed by Investigator Following Administration of DS-1205c in Combination With Gefitinib
NCT03599518 (10) [back to overview]Overall Survival in Participants Following Administration of DS-1205c in Combination With Gefitinib
NCT03599518 (10) [back to overview]Number of Participants With Dose-limiting Toxicities (DLTs) Following Administration With DS-1205c in Combination With Gefitinib
NCT03599518 (10) [back to overview]Disease Control Rate Assessed by Investigator Following Administration of DS-1205c in Combination With Gefitinib
NCT03599518 (10) [back to overview]Pharmacokinetic Parameter Time to Maximum Concentration (Tmax) of DS-1205a Following Administration of DS-1205c in Combination With Gefitinib
NCT03599518 (10) [back to overview]Pharmacokinetic Parameter of Maximum Concentration (Cmax) of DS-1205a Following Administration of DS-1205c in Combination With Gefitinib
NCT03849768 (8) [back to overview]Percentage of Participants With Objective Response Rate (ORR)
NCT03849768 (8) [back to overview]Number of Participants With Dose Reductions
NCT03849768 (8) [back to overview]Number of Participants With Adverse Events (AEs)/Serious Adverse Events (SAEs)
NCT03849768 (8) [back to overview]Assess the Anti-tumor Activity: Duration of Response (DoR)
NCT03849768 (8) [back to overview]Assess the Anti-tumor Activity: Depth of Response (DepOR)
NCT03849768 (8) [back to overview]Assess the Anti-tumor Activity: Disease Control Rate (DCR)
NCT03849768 (8) [back to overview]Number of Participants With Dose Interruptions
NCT03849768 (8) [back to overview]Progression Free Survival (PFS)
NCT04179890 (16) [back to overview]Uncommon Cohort: Number of Participants for Each Type of Biological Samples Used for Mutation Detection at Index Therapy Start
NCT04179890 (16) [back to overview]Number of Participants for Each Type of Methodology Used for Mutational Testing at Second-line Treatment Stop/End of Observation
NCT04179890 (16) [back to overview]Number of Participants for Each Type of Biological Samples Used for Mutation Detection at Second Line Treatment Stop/End of Observation
NCT04179890 (16) [back to overview]Uncommon Mutation Cohort: Number of Participants for Each Type of Methodology Used for Mutation Detection at Start of First-line Chemotherapy Before Index Line
NCT04179890 (16) [back to overview]Sequencing Cohort: Overall Response Rate to First Line Afatinib
NCT04179890 (16) [back to overview]Overall Survival
NCT04179890 (16) [back to overview]Time on Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)
NCT04179890 (16) [back to overview]Uncommon Epidermal Growth Factor Receptor (EGFR) Mutation Cohort: Overall Response Rate to Index Line Treatment
NCT04179890 (16) [back to overview]Uncommon Mutation Cohort: Time on Treatment Until Failure of Second-line (TTF2)
NCT04179890 (16) [back to overview]Number of Participants for Each Category of Methodology Used for Mutational Testing at First Line Treatment Start
NCT04179890 (16) [back to overview]Number of Participants for Each Type of Biological Samples Used for Mutation Detection at First Line Treatment Start
NCT04179890 (16) [back to overview]Number of Participants for Each Type of Biological Samples Used for Mutation Detection at Second Line Treatment Start
NCT04179890 (16) [back to overview]Number of Participants for Each Type of Methodology Used for Mutational Testing at Second-line Treatment Start
NCT04179890 (16) [back to overview]Uncommon Mutation Cohort: Number of Participants for Each Type of Biological Samples Used for Mutation Detection at Start of First-line Chemotherapy Before Index Line
NCT04179890 (16) [back to overview]Uncommon Mutation Cohort: Number of Participants for Each Type of Methodology Used for Mutation Detection at Index Therapy Start
NCT04179890 (16) [back to overview]Sequencing Cohort: Overall Response Rate to Second-line Treatment Osimertinib

Median Survival in Newly Diagnosed Brain Stem Gliomas

Overall survival is defined as the interval from initiation of treatment to death or date of last contact for surviving patients (NCT00042991)
Timeframe: Assessed from the start of therapy until three years after initiation of gefitinib therapy

InterventionMonths (Median)
Stratum 1A-Dose 250 mg/m^2 of Gefitinib+Radiation12.12

[back to top]

Change From Baseline in Diffusion Ratio at Two Weeks After Completion of Radiation

This study attempted to investigate in an exploratory manner the effect of treatment on changes in various neuroimaging variables. Neuroimaging changes may have some association with outcome (response,survival, etc.). Diffusion ratio is one parameter obtained from standard magnetic resonance imaging (MRI) studies of the brain. (NCT00042991)
Timeframe: Baseline and two weeks post completion of radiation

InterventionRatio (Median)
Stratum 1A-Dose 250 mg/m^2 of Gefitinib+Radiation-0.41

[back to top]

Change From Baseline in Perfusion Ratio at Two Weeks After Completion of Radiation

This study attempted to investigate in an exploratory manner the effect of treatment on changes in various neuroimaging variables. Neuroimaging changes may have some association with outcome (response,survival, etc.). Perfusion ratio is one parameter obtained from standard magnetic resonance imaging (MRI) studies of the brain. (NCT00042991)
Timeframe: Baseline and two weeks post completion of radiation

InterventionRatio (Median)
Stratum 1A-Dose 250 mg/m^2 of Gefitinib+Radiation0.72

[back to top]

Change From Baseline in Volume Enhancing at Two Weeks After Completion of Radiation

This study attempted to investigate in an exploratory manner the effect of treatment on changes in various neuroimaging variables. Neuroimaging changes may have some association with outcome (response,survival, etc.). Volume enhancing is one parameter obtained from standard magnetic resonance imaging (MRI) studies of the brain. (NCT00042991)
Timeframe: Baseline and two weeks post completion of radiation

Interventioncc (Median)
Stratum 1A-Dose 250 mg/m^2 of Gefitinib+Radiation0.35

[back to top]

Change in Tumor Volume Measured on Fluid Attenuated Inversion Recovery (FLAIR) Imaging at Before the Protocol Therapy Started and at Two Weeks After Completion of Radiation

This study attempted to investigate in an exploratory manner the effect of treatment on changes in various neuroimaging variables. In this particular objective, the study aimed to investigate how radiation+gefitinib affect the tumor volume. Tumor volume is measured using Fluid Attenuated Inversion Recovery (FLAIR) before and after the radiation therapy. (NCT00042991)
Timeframe: Baseline and two weeks post completion of radiation

Interventioncc (Median)
Stratum 1A-Dose 250 mg/m^2 of Gefitinib+Radiation-14.03

[back to top]

Clearance of Gefitinib (Cl)

(NCT00042991)
Timeframe: Week 2 of course 1

InterventionL/hr/m2 (Median)
Dose 250 mg/m^2 of Gefitinib (Phase II, Brain Stem Gliomas)15.2
Dose 250 mg/m^2 of Gefitinib (Phase I)20.9
Dose 100 mg/m^2 of Gefitinib12.8
Dose 375 mg/m^2 of Gefitinib15.0

[back to top]

Elimination Half Life of Gefitinib (t1/2)

(NCT00042991)
Timeframe: Week 2 of course 1

Interventionhour (Median)
Dose 250 mg/m^2 of Gefitinib (Phase II, Brain Stem Gliomas)15.2
Dose 250 mg/m^2 of Gefitinib (Phase I)17.6
Dose 100 mg/m^2 of Gefitinib9.9
Dose 375 mg/m^2 of Gefitinib10.4

[back to top]

Gefitinib Area Under the Concentration Curve From 0-24 Hours (AUC)

(NCT00042991)
Timeframe: Week 2 of course 1

Interventionmcg/L*hr (Median)
Dose 250 mg/m^2 of Gefitinib (Phase II, Brain Stem Gliomas)16.4
Dose 250 mg/m^2 of Gefitinib (Phase I)11.8
Dose 100 mg/m^2 of Gefitinib5.3
Dose 375 mg/m^2 of Gefitinib25.3

[back to top]

Mean Tumor to Gray Matter Ratio Measured at Baseline

This study attempts to characterize neuroimaging parameters from positron emission tomography. For each patient, the axial image through the tumor containing the maximum activity per pixel corresponding to the highest FluoroDeoxyGlucose (FDG) uptake was identified and a region of interest (ROI) was drawn based on the FDG definition of the tumor. The mean pixel values within the tumor ROI were normalized by those for normal gray matter to provide ratios of tumor/gray matter. Each patient has a mean tumor to gray matter ratio value and the median of these values across patients is reported. (NCT00042991)
Timeframe: Baseline

InterventionRatio (Median)
Stratum 1A-Dose 250 mg/m^2 of Gefitinib+Radiation0.55

[back to top]

Mean Tumor to White Matter Ratio Measured at Baseline

This study attempts to characterize neuroimaging parameters from positron emission tomography. For each patient, the axial image through the tumor containing the maximum activity per pixel corresponding to the highest FluoroDeoxyGlucose (FDG) uptake was identified and a region of interest (ROI) was drawn based on the FDG definition of the tumor. The mean pixel values within the tumor ROI were normalized by those for normal white matter to provide ratios of tumor/gray matter. Each patient has a mean tumor to white matter ratio value and the median of these values across patients is reported. (NCT00042991)
Timeframe: Baseline

InterventionRatio (Median)
Stratum 1A-Dose 250 mg/m^2 of Gefitinib+Radiation1.16

[back to top]

Median Progression-free Survival in Newly Diagnosed Brain Stem Gliomas

Progression-free survival is defined as the interval from intiation of treatment to the earliest of disease progression (tumor increase of 25% over baseline tumor measurement; appearance of new lesion(s); or progressive/worsening neurlogical status) or death for patients who failed or to the last date of follow-up for patients without failure (NCT00042991)
Timeframe: Assessed pre-radiation, every 8 weeks for 13 courses of therapy, and then every 12 weeks

InterventionMonths (Median)
Stratum 1A-Dose 250 mg/m^2 of Gefitinib+Radiation7.43

[back to top]

Number of Participants in Phase I Stratum 1A With Dose-limiting Toxicities (DLT) Observed During the First 8 Weeks of Gefitinib Therapy

The dose limiting toxicity (DLT) analysis population consists of stratum 1A phase I participants who developed DLT during the maximum tolerated dose (MTD) estimation period (course 1 and 2) or who completed the MTD estimation period without DLTs. DLTs observed during courses 1 and 2 were used to estimate the MTD based on the tradional 3+3 design, where a dose is considered a safe dose only when 0 out of 3, or at most 1 out of 6 patients has DLTs. When two or more patients in a group of 2 to 6 patients had DLTs, then that dose level was considered to be too toxic. (NCT00042991)
Timeframe: Day 1 of gefitinib therapy to end of week 8

InterventionParticipants (Number)
Stratum 1A-100 mg/m^2 of Gefitinib + Radiation2
Stratum 1A-250 mg/m^2 of Gefitinib + Radiation0
Stratum 1A-375 mg/m^2 of Gefitinib + Radiation1

[back to top]

Number of Patients With Epidermal Growth Factor Receptor (EGFR) Amplification

Epidermal growth factor receptor (EFGR) is a protein found on the surface of cells to which epidermal growth factor (EGF) binds. When EGF attaches to EGFR, it activates the enzyme tyrosine kinase, triggering reactions that cause the cells to grow and multiply. (NCT00042991)
Timeframe: Pre-treatment

InterventionParticipants (Number)
Stratum IB and Stratum II5

[back to top]

Peak Serum Concentration of Gefitinib (Cmax)

(NCT00042991)
Timeframe: Week 2 of course 1

Interventionmcg/ml (Median)
Dose 250 mg/m^2 of Gefitinib (Phase II, Brain Stem Gliomas)1.10
Dose 250 mg/m^2 of Gefitinib (Phase I)0.83
Dose 100 mg/m^2 of Gefitinib0.44
Dose 375 mg/m^2 of Gefitinib1.89

[back to top]

Time of Maximum Clearance of Gefitinib (Tmax)

(NCT00042991)
Timeframe: Week 2 of course 1

InterventionHour (Median)
Dose 250 mg/m^2 of Gefitinib (Phase II, Brain Stem Gliomas)3.2
Dose 250 mg/m^2 of Gefitinib (Phase I)4.2
Dose 100 mg/m^2 of Gefitinib4.9
Dose 375 mg/m^2 of Gefitinib4.2

[back to top]

Disease Free Survival

The survival experience of patients in both treatment groups will be described by the Kaplan-Meier method. A stratified log-rank test will be used as the primary method to compare the disease free survival between two arms adjusting for the stratification factors. Five years disease free survival rate will be reported. (NCT00049543)
Timeframe: From randomization to the time of documented recurrence of the primary cancer, assessed up to 5 years

Interventionpercentage of 5-year disease free rate (Number)
Arm I (Gefitinib)0.49
Arm II (Placebo)0.56

[back to top]

Incidence of Toxicities Graded Using the NCI Common Terminology Criteria for Adverse Events Version 3.0

The incidence of toxicities will be summarized by type of adverse event and severity. A Fisher's exact test will be used to compare toxicities between the two arms. (NCT00049543)
Timeframe: Up to 5 years

Interventionparticipants (Number)
Arm I (Gefitinib)229
Arm II (Placebo)153

[back to top]

Overall Survival

The survival experience of patients in both treatment groups will be described by the Kaplan-Meier method. A stratified log-rank test will be used as the primary method to compare the overall survival between two arms adjusting for the stratification factors. An unadjusted analysis will also be performed. Five years survival rate will be reported. (NCT00049543)
Timeframe: From randomization to the time of death from any cause, assessed up to 5 years

Interventionpercentage of 5 years survival rate (Number)
Arm I (Gefitinib)0.52
Arm II (Placebo)0.57

[back to top]

Duration of Response

Response duration was defined as the time from initial response during therapy to progression of disease. (NCT00054691)
Timeframe: Every 8 weeks till disease progression.

Interventionmonths (Median)
Iressa (ZD1839)24.8

[back to top]

Number of Participants With Objective Response (Partial Response, Stable Disease and Progressive Disease)

Responses were assessed according to the Union Internationale Contre le Cancer (UICC) / World Health Organization (WHO) criteria. Objective response (measurable response) defined as: Partial response (PR): Applies only to participants with at least 1 measurable lesion; >/=50% decrease under baseline in sum of products of perpendicular diameters of all measurable lesions. Stable Disease (SD): No progression of evaluable disease and/or no new lesions. Progressive Disease (PD): 50% increase or an increase of 10 cm2 (whichever is smaller) in the sum of products of all measurable lesions overall smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease. (NCT00054691)
Timeframe: Every 8 weeks till disease progression.

Interventionparticipants (Number)
Stable DiseasePartial ResponseProgressive Disease
Iressa (ZD1839)14419

[back to top]

Clinical Benefit Rate

Clinical benefit = complete response (CR), partial response (PR), or stable disease (SD) lasting for at least 6 months, assessed per Response Evaluation Criteria of Solid Tumor (RECIST).CR=disappearance of all target and non-target lesions. PR= disappearance of or at least 30% decrease in the sum of the longest diameters of target lesions, with non-progressive disease in non-target lesions. SD= sum of the longest diameters of target lesions decrease <30% or increase <20%, with non-progressive disease in non-target lesions. 141 eligible, treated patients were included. (NCT00057941)
Timeframe: assessed every 3 cycles while on treatment, assessed every 3 months when follow up <2 years, every 6 months between 2-3 years,no specific requirements after 3 years

Interventionpercentage of participants (Number)
Anastrozole and ZD183944
Fulvestrant and ZD183941

[back to top]

Overall Objective Response

Response will be evaluated in this study using the new international criteria Response Evaluation Criteria in Solid Tumors (RECIST) (NCT00085566)
Timeframe: 2 years

,,
Interventionparticipants (Number)
Partial Response (PR)Stable Disease (SD)Progression of Disease (POD)
RAD 001 30 mg003
RAD 001 50 mg012
RAD 001 70 mg21526

[back to top]

Number of Participants With at Least One Dose Limiting Toxicity in Phase I

Dose Limiting Toxicity (DLT) defined as any treatment-related grade 3 or greater except for hematological toxicities which must be grade 4. Interstitial Lung Disease (ILD) related to treatment should be considered as a DLT regardless of the grade. (NCT00086957)
Timeframe: 4 weeks from start of treatment, up to 2 years

Interventionparticipants with DLTs (Number)
Phase I: Dose Level 1 - Docetaxel 75 mg/m^22
Phase I: Dose Level 2 - Docetaxel 60 mg/m^20

[back to top]

Objective Response Rate

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective Response Rate defined as percentage of patients achieving a Best Response of either CR or PR. (NCT00086957)
Timeframe: After 3 cycles of treatment, up to 2 years.

Interventionpercentage of participants (Number)
Dose Level 2 - Docetaxel 60 mg/m^264

[back to top]

Overall Survival

Estimated using the product-limit method of Kaplan and Meier. (NCT00086957)
Timeframe: Until death from any cause, up to 5 years.

InterventionMonths (Median)
Dose Level 2 - Docetaxel 60 mg/m^243.2

[back to top]

Progression-free Survival

Estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 20% increase in the sum of the longest diameter of target lesions, or the appearance of new lesions. (NCT00086957)
Timeframe: Until disease progression, up to 5 years.

InterventionMonths (Median)
Dose Level 2 - Docetaxel 60 mg/m^212.7

[back to top] [back to top]

Overall Response Rate

"Tumor response was assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. Complete response (CR) was defined disappearance of all tumor lesions. Partial response (PR) was defined as as at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum longest diameter. Overall response rate= CR+PR.~Tumor measurements may be made using physical examination, CT scans or MRI scans. While on protocol treatment, tumor measurement by physical examination to be done every 4 weeks, and tumor measurement by CT/MRI scans to be done every 8 weeks (every 2 treatment cycles).~All eligible and treated patients were included in the analysis." (NCT00088907)
Timeframe: assessed every 3 months if patient is < 2 years from study entry then every 6 months if patient is 2-5 years from study entry. No specific requirements if patient is more than 5 years from study entry.

Interventionpercentage of participants (Number)
Arm I (Docetaxel and Placebo)4.3
Arm II (Docetaxel and Gefitinib)9.8

[back to top]

Overall Survival

Overall survival is defined as time from registration to death from any cause. All eligible and treated patients were included in the analysis. (NCT00088907)
Timeframe: assessed every 3 months if patient is < 2 years from study entry then every 6 months if patient is 2-5 years from study entry. No specific requirements if patient is more than 5 years from study entry.

Interventionmonths (Median)
Arm I (Docetaxel and Placebo)5.98
Arm II (Docetaxel and Gefitinib)7.33

[back to top]

Time to Progression

"Time to progression is defined as time from registration to disease progression. Disease progression was assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, and defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, and/or the appearance of one or more new lesion(s), and/or unequivocal progression of existing nontarget lesions .~Tumor measurements may be made using physical examination, CT scans or MRI scans. While on protocol treatment, tumor measurement by physical examination to be done every 4 weeks, and tumor measurement by CT/MRI scans to be done every 8 weeks (every 2 treatment cycles).~All eligible and treated patients were included in the analysis." (NCT00088907)
Timeframe: assessed every 3 months if patient is < 2 years from study entry then every 6 months if patient is 2-5 years from study entry. No specific requirements if patient is more than 5 years from study entry.

Interventionmonths (Median)
Arm I (Docetaxel and Placebo)2.14
Arm II (Docetaxel and Gefitinib)3.55

[back to top]

Median Progression-free Survival

"The median progression-free survival as assessed by RECIST criteria (Response Evaluation Criteria In Solid Tumors) measured from the time of enrollment until disease progression or death.~Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or the appearance of new lesions." (NCT00095836)
Timeframe: From the time of enrollment until disease progression or death, whichever came first

InterventionMonths (Median)
Gefitinib 250mg3.7

[back to top]

Overall Survival

The median overall survival time, measured from the time of enrollment until death. (NCT00095836)
Timeframe: 5 years

InterventionMonths (Median)
Gefitinib 250mg17.5

[back to top]

Objective Tumor Response Rate at 3, 6, and 12 Months

"Response rate as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Tumor assessment is performed within 4 weeks of initiation of treatment and then every 8 weeks. If a patient has stable disease for four tumor assessments (6 months), then tumor assessment may occur every 4 months. If the patient continues to experience stable disease after 2 years, tumor assessments may occur every 6 months. If the patient continues to experience stable disease after 5 years, tumor assessments may occur once a year.~Complete Response (CR): Disappearance of all target lesions~Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions~Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions~Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD" (NCT00095836)
Timeframe: 3 Months, 6 Months, 1 Year

Interventionparticipants (Number)
Complete Response : 3 MonthsPartial Response : 3 MonthsStable Disease : 3 MonthsProgressive Disease : 3 MonthsComplete Response : 6 MonthsPartial Response : 6 MonthsStable Disease : 6 MonthsProgressive Disease : 6 MonthsComplete Response : 12 MonthsPartial Response : 12 MonthsStable Disease : 12 MonthsProgressive Disease : 12 Months
Gefitinib 250mg0012130061900322

[back to top]

Toxicity

Drug related toxicity as assessed by NCI CTCAE that occurred in more than 10% of patients (NCT00095836)
Timeframe: Through study completion, on average 12 months

Interventionparticipants (Number)
Rash: Grade 0Rash: Grade 1Rash: Grade 2Rash: Grade 3Diarrhea: Grade 0Diarrhea: Grade 1Diarrhea: Grade 2Diarrhea: Grade 3Nausea: Grade 0Nausea: Grade 1Anorexia: Grade 0Anorexia: Grade 1
Gefitinib 250mg1393216821225243

[back to top]

Overall Objective Response

Determine efficacy of the combination oral daily gefitinib and oral daily RAD001 in patients with advanced NSCLC. Response and progression will be evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST). (NCT00096486)
Timeframe: 2 years

,,,
Interventionparticipants (Number)
Partial Response (PR)Stable Disease (SD)Progression of Disease (POD)Not Evaluable/ Evaluable for Toxicity Only
Phase I: RAD001 10 mg, Gefitinib 250 mg1111
Phase I: RAD001 5 mg, Gefitinib 250 mg1140
Phase II: Cohort I no Prior Conventional Chemotherapy39111
Phase II: Cohort II One or More Prior Chemotherapy215181

[back to top]

Change From Baseline in VEGFR3 by Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] Versus PD)

Change = median VEGFR3 level at each specified time point for subjects with tumor response (CR or PR or [SD > = 6 weeks] versus PD) minus median VEGFR3 level at Baseline. A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality). (NCT00113529)
Timeframe: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive

Interventionpg/mL (Number)
Cycle 1, Day 1 (CR or PR or SD, n=22)Cycle 1, Day 1 (PD, n=5)Cycle 1, Day 28 (CR or PR or SD, n=22)Cycle 1, Day 28 (PD, n=4)Cycle 2, Day 1 (CR or PR or SD, n=22)Cycle 2, Day 1 (PD, n=3)Cycle 2, Day 28 (CR or PR or SD, n=21)Cycle 2, Day 28 (PD, n=2)Cycle 3, Day 1 (CR or PR or SD, n=20)Cycle 3, Day 1(PD, n=2)Cycle 3, Day 28 (CR or PR or SD, n=20)
Sunitinib + Gefitinib43325.0057300.000.410.340.870.710.411.320.851.840.37

[back to top]

Time to Tumor Response (TTR)

TTR was defined as the time from date of the first dose of study medication to first documentation of objective tumor response (CR or PR). For subjects proceeding from PR to CR, the onset of PR was taken as the onset of response. If lesion assessment data included more than 1 date, the first date was used. TTR was calculated as (first event date minus first dose date +1)/7. TTR was calculated based on the subgroup of subjects with a baseline disease assessment, who had the correct histological cancer type, and had a confirmed objective tumor response. Kaplan-Meier method was used. (NCT00113529)
Timeframe: From start of treatment until Day 28 of Cycles 1 to 4, Day 28 of even cycles thereafter

Interventionweeks (Median)
Sunitinib + Gefitinib16.0

[back to top]

VEGF Ratio to Baseline at Each Time Point

VEGF concentration at each time point divided by VEGF concentration at baseline (ratio to baseline). (NCT00113529)
Timeframe: Baseline to Cycle 3, Day 28 inclusive

Interventionratio (Mean)
Cycle 1, Day 28 (n=29)Cycle 2, Day 1 (n=26)Cycle 2, Day 28 (n=23)Cycle 3, Day 1 (n=22)Cycle 3, Day 28 (n=20)
Sunitinib + Gefitinib2.291.652.651.932.26

[back to top]

VEGF-C Ratio to Baseline at Each Time Point

VEGF-C concentration at each time point divided by VEGF-C concentration at baseline (ratio to baseline). (NCT00113529)
Timeframe: Baseline to Cycle 3, Day 28 inclusive

Interventionratio (Mean)
Cycle 1, Day 28 (n=29)Cycle 2, Day 1 (n=26)Cycle 2, Day 28 (n=23)Cycle 3, Day 1 (n=22)Cycle 3, Day 28 (n=20)
Sunitinib + Gefitinib0.930.861.011.090.93

[back to top]

Change From Baseline in VEGF by Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] Versus PD)

Change = median VEGF level at each specified time point for subjects with tumor response (CR or PR or [SD > = 6 weeks] versus PD) minus median VEGF level at Baseline. A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality). (NCT00113529)
Timeframe: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive

Interventionpg/mL (Number)
Cycle 1, Day 1 (CR or PR or SD, n=22)Cycle 1, Day 1 (PD, n=5)Cycle 1, Day 28 (CR or PR or SD, n=22)Cycle 1, Day 28 (PD, n=4)Cycle 2, Day 1 (CR or PR or SD, n=22)Cycle 2, Day 1 (PD, n=3)Cycle 2, Day 28 (CR or PR or SD, n=21)Cycle 2, Day 28 (PD, n=2)Cycle 3, Day 1 (CR or PR or SD, n=20)Cycle 3, Day 1(PD, n=2)Cycle 3, Day 28 (CR or PR or SD, n=20)
Sunitinib + Gefitinib40.7094.502.311.941.051.012.262.301.330.911.87

[back to top]

Change From Baseline in VEGF by Time Point Stratified by TTP >= Median and TTP < Median

Change = median VEGF level at each specified time point for subjects with tumor response TTP >= Median and TTP < Median minus median VEGF level at Baseline. A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality). (NCT00113529)
Timeframe: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive

Interventionpg/mL (Number)
Cycle 1, Day 1 (TTP >= Median, n=5)Cycle 1, Day 1 (TTP < Median, n=11)Cycle 1, Day 28 (TTP >= Median, n=5)Cycle 1, Day 28 (TTP < Median, n=10)Cycle 2, Day 1 (TTP >= Median, n=5)Cycle 2, Day 1 (TTP < Median, n=9)Cycle 2, Day 28 (TTP >= Median, n=5)Cycle 2, Day 28 (TTP < Median, n=8)Cycle 3, Day 1 (TTP >= Median, n=5)Cycle 3, Day 1 (TTP < Median, n=8)Cycle 3, Day 28 (TTP >= Median, n=5)Cycle 3, Day 28 (TTP < Median, n=6)
Sunitinib + Gefitinib59.3044.702.322.280.751.061.912.661.041.601.792.31

[back to top]

Change From Baseline in VEGF by Time Point Stratified by PFS >= Median and PFS < Median

Change = median VEGF level at each specified time point for subjects with tumor response PFS >= Median or PFS < Median minus median VEGF level at Baseline. A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality). (NCT00113529)
Timeframe: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive

Interventionpg/mL (Number)
Cycle 1, Day 1 (PFS >= Median, n=5)Cycle 1, Day 1 (PFS < Median, n=11)Cycle 1, Day 28 (PFS >= Median, n=5)Cycle 1, Day 28 (PFS < Median, n=10)Cycle 2, Day 1 (PFS >= Median, n=5)Cycle 2, Day 1 (PFS < Median, n=9)Cycle 2, Day 28 (PFS >= Median, n=5)Cycle 2, Day 28 (PFS < Median, n=8)Cycle 3, Day 1 (PFS >= Median, n=5)Cycle 3, Day 1 (PFS < Median, n=8)Cycle 3, Day 28 (PFS >= Median, n=5)Cycle 3, Day 28 (PFS < Median, n=6)
Sunitinib + Gefitinib59.3044.702.322.280.751.061.912.661.041.601.792.31

[back to top]

VEGF-C Concentration at Baseline

Concentration of VEGF-C at baseline. (NCT00113529)
Timeframe: Baseline (Cycle 1, Day 1)

Interventionpg/mL (Mean)
Sunitinib + Gefitinib725.82

[back to top]

VEGF (Vascular Endothelial Growth Factor) Concentration at Baseline

Concentration of VEGF at baseline. (NCT00113529)
Timeframe: Baseline (Cycle 1, Day 1)

Interventionpg/mL (Mean)
Sunitinib + Gefitinib63.79

[back to top]

Time to Tumor Progression (TTP)

TTP was defined as the time from the date of first dose of study medication to first documentation of objective tumor progression. If tumor progression data included more than 1 date, the first date was used. TTP (in weeks) was calculated as (first event date minus first dose date +1)/7. Kaplan-Meier method was used. (NCT00113529)
Timeframe: From start of treatment until Day 28 of Cycles 1 to 4, Day 28 of even cycles thereafter

Interventionweeks (Median)
Sunitinib + Gefitinib48.4

[back to top]

Soluble VEGF Receptor 3 (sVEGFR3) Concentration at Baseline

Concentration of sVEGFR3 at baseline. (NCT00113529)
Timeframe: Baseline (Cycle 1, Day 1)

Interventionpg/mL (Mean)
Sunitinib + Gefitinib48355.48

[back to top]

Soluble VEGF Receptor 2 (sVEGFR2) Concentration at Baseline

Concentration of sVEGFR2 at baseline. (NCT00113529)
Timeframe: Baseline (Cycle 1, Day 1)

Interventionpg/mL (Mean)
Sunitinib + Gefitinib10525.0

[back to top]

Progression-Free Survival (PFS)

PFS was defined as the time from the date of first dose of study medication to the date of first documentation of tumor progression or death due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used. PFS (in weeks) was calculated as (first event date minus first dose date +1)/7. Kaplan-Meier method was used. (NCT00113529)
Timeframe: From start of treatment until Day 28 of Cycles 1 to 4, Day 28 of even cycles thereafter or death

Interventionweeks (Median)
Sunitinib + Gefitinib48.4

[back to top]

Probability of Survival at One Year

Survival rate was defined as the percentage of subjects alive at 1 year after the date of first administration of study medication. Survival rate was estimated using the Kaplan-Meier method. (NCT00113529)
Timeframe: From start of treatment until Day 28 of Cycles 1 to 4, Day 28 of even cycles thereafter up until 1 year

Interventionprobability (Number)
Sunitinib + Gefitinib82.4

[back to top]

Overall Survival (OS)

OS was defined as the time from date of the first dose of study medication to date of death due to any cause. OS (in weeks) is calculated as (date of death minus first dose date +1)/7. For subjects not expiring, their survival times were censored at the last date of known contact they were known to be alive. Subjects lacking data beyond the day of first dose had their survival times censored at 1 day. Kaplan-Meier method was used. (NCT00113529)
Timeframe: From start of study treatment until death

Interventionweeks (Median)
Sunitinib + Gefitinib49.5

[back to top]

Duration of Response (DR)

DR was defined as the time from start of the first documentation of objective tumor response to the first documentation of objective tumor progression or death due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used. DR was calculated as (the end date for DR minus first CR or PR that was subsequently confirmed +1)/7. DR was calculated for the subgroup of subjects with an objective tumor response (CR or PR). (NCT00113529)
Timeframe: From start of treatment until Day 28 of Cycles 1 to 4, Day 28 of even cycles thereafter or death due to cancer

Interventionweeks (Median)
Sunitinib + Gefitinib52.2

[back to top]

Change From Baseline in VEGFC by Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] Versus PD)

Change = median VEGFC level at each specified time point for subjects with tumor response (CR or PR or [SD > = 6 weeks] versus PD) minus median VEGFC level at Baseline. A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality). (NCT00113529)
Timeframe: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive

Interventionpg/mL (Number)
Cycle 1, Day 1 (CR or PR or SD, n=22)Cycle 1, Day 1 (PD, n=5)Cycle 1, Day 28 (CR or PR or SD, n=22)Cycle 1, Day 28 (PD, n=4)Cycle 2, Day 1 (CR or PR or SD, n=22)Cycle 2, Day 1 (PD, n=3)Cycle 2, Day 28 (CR or PR or SD, n=21)Cycle 2, Day 28 (PD, n=2)Cycle 3, Day 1 (CR or PR or SD, n=20)Cycle 3, Day 1(PD, n=2)Cycle 3, Day 28 (CR or PR or SD, n=20)
Sunitinib + Gefitinib561.20751.300.950.710.900.800.841.191.040.690.93

[back to top]

Ctrough of Gefitinib

(NCT00113529)
Timeframe: prior to dosing on Cycle 1 (Days 1, 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28)

Interventionng/mL (Mean)
Cycle 1, Day 1 (n=35)Cycle 1, Day 28 (n=33)Cycle 2, Day 1 (n=24)Cycle 2, Day 28 (n=27)Cycle 3, Day 1 (n=26)Cycle 3, Day 28 (n=24)
Sunitinib + Gefitinib0.00254.74328.91263.23293.14211.43

[back to top]

Ctrough of SU-012662 (Sunitinib's Metabolite)

(NCT00113529)
Timeframe: prior to dosing on Cycle 1 (Days 1, 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28)

Interventionng/mL (Mean)
Cycle 1, Day 1 (n=35)Cycle 1, Day 28 (n=33)Cycle 2, Day 1 (n=28)Cycle 2, Day 28 (n=27)Cycle 3, Day 1 (n=25)Cycle 3, Day 28 (n=24)
Sunitinib + Gefitinib1.1616.213.0315.253.1814.56

[back to top]

sVEGFR2 Ratio to Baseline at Each Time Point

sVEGFR2 concentration at each time point divided by sVEGFR2 concentration at baseline (ratio to baseline). (NCT00113529)
Timeframe: Baseline to Cycle 3, Day 28 inclusive

Interventionratio (Mean)
Cycle 1, Day 28 (n=29)Cycle 2, Day 1 (n=26)Cycle 2, Day 28 (n=23)Cycle 3, Day 1 (n=22)Cycle 3, Day 28 (n=20)
Sunitinib + Gefitinib0.640.820.630.750.64

[back to top]

sVEGFR3 Ratio to Baseline at Each Time Point

sVEGFR3 concentration at each time point divided by sVEGFR3 concentration at baseline (ratio to baseline). (NCT00113529)
Timeframe: Baseline to Cycle 3, Day 28 inclusive

Interventionratio (Mean)
Cycle 1, Day 28 (n=29)Cycle 2, Day 1 (n=26)Cycle 2, Day 28 (n=23)Cycle 3, Day 1 (n=22)Cycle 3, Day 28 (n=20)
Sunitinib + Gefitinib0.410.960.520.890.38

[back to top]

Change From Baseline in VEGFR2 by Time Point Stratified by PFS >= Median and PFS < Median

Change = median VEGFR2 level at each specified time point for subjects with tumor response PFS >= Median or PFS < Median minus median VEGFR2 level at Baseline. A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality). (NCT00113529)
Timeframe: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive

Interventionpg/mL (Number)
Cycle 1, Day 1 (PFS >= Median, n=5)Cycle 1, Day 1 (PFS < Median, n=11)Cycle 1, Day 28 (PFS >= Median, n=5)Cycle 1, Day 28 (PFS < Median, n=10)Cycle 2, Day 1 (PFS >= Median, n=5)Cycle 2, Day 1 (PFS < Median, n=9)Cycle 2, Day 28 (PFS >= Median, n=5)Cycle 2, Day 28 (PFS < Median, n=8)Cycle 3, Day 1 (PFS >= Median, n=5)Cycle 3, Day 1 (PFS < Median, n=8)Cycle 3, Day 28 (PFS >= Median, n=5)Cycle 3, Day 28 (PFS < Median, n=6)
Sunitinib + Gefitinib9100.0010145.000.560.690.790.780.560.640.740.750.520.62

[back to top]

Trough Plasma Concentrations (Ctrough) of Sunitinib

(NCT00113529)
Timeframe: prior to dosing on Cycle 1 (Days 1, 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28)

Interventionng/mL (Mean)
Cycle 1, Day 1 (n=35)Cycle 1, Day 28 (n=33)Cycle 2, Day 1 (n=28)Cycle 2, Day 28 (n=27)Cycle 3, Day 1 (n=25)Cycle 3, Day 28 (n=24)
Sunitinib + Gefitinib1.5733.163.2535.503.7135.97

[back to top]

Change From Baseline in VEGFR2 by Time Point Stratified by TTP >= Median and TTP < Median

Change = median VEGFR2 level at each specified time point for subjects with tumor response TTP >= Median and TTP < Median minus median VEGFR2 level at Baseline. A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality). (NCT00113529)
Timeframe: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive

Interventionpg/mL (Number)
Cycle 1, Day 1 (TTP >= Median, n=5)Cycle 1, Day 1 (TTP < Median, n=11)Cycle 1, Day 28 (TTP >= Median, n=5)Cycle 1, Day 28 (TTP < Median, n=10)Cycle 2, Day 1 (TTP >= Median, n=5)Cycle 2, Day 1 (TTP < Median, n=9)Cycle 2, Day 28 (TTP >= Median, n=5)Cycle 2, Day 28 (TTP < Median, n=8)Cycle 3, Day 1 (TTP >= Median, n=5)Cycle 3, Day 1 (TTP < Median, n=8)Cycle 3, Day 28 (TTP >= Median, n=5)Cycle 3, Day 28 (TTP < Median, n=6)
Sunitinib + Gefitinib9100.0010145.000.560.690.790.780.560.640.740.750.520.62

[back to top]

Change From Baseline in VEGFC by Time Point Stratified by TTP >= Median and TTP < Median

Change = median VEGFC level at each specified time point for subjects with tumor response TTP >= Median and TTP < Median minus median VEGFC level at Baseline. A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality). (NCT00113529)
Timeframe: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive

Interventionpg/mL (Number)
Cycle 1, Day 1 (TTP >= Median, n=5)Cycle 1, Day 1 (TTP < Median, n=11)Cycle 1, Day 28 (TTP >= Median, n=5)Cycle 1, Day 28 (TTP < Median, n=10)Cycle 2, Day 1 (TTP >= Median, n=5)Cycle 2, Day 1 (TTP < Median, n=9)Cycle 2, Day 28 (TTP >= Median, n=5)Cycle 2, Day 28 (TTP < Median, n=8)Cycle 3, Day 1 (TTP >= Median, n=5)Cycle 3, Day 1 (TTP < Median, n=8)Cycle 3, Day 28 (TTP >= Median, n=5)Cycle 3, Day 28 (TTP < Median, n=6)
Sunitinib + Gefitinib650.80532.700.760.990.801.000.841.170.701.050.901.22

[back to top]

Change From Baseline in VEGFR2 by Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] Versus PD)

Change = median VEGFR2 level at each specified time point for subjects with tumor response (CR or PR or [SD > = 6 weeks] versus PD) minus median VEGFR2 level at Baseline. A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality). (NCT00113529)
Timeframe: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive

Interventionpg/mL (Number)
Cycle 1, Day 1 (CR or PR or SD, n=22)Cycle 1, Day 1 (PD, n=5)Cycle 1, Day 28 (CR or PR or SD, n=22)Cycle 1, Day 28 (PD, n=4)Cycle 2, Day 1 (CR or PR or SD, n=22)Cycle 2, Day 1 (PD, n=3)Cycle 2, Day 28 (CR or PR or SD, n=21)Cycle 2, Day 28 (PD, n=2)Cycle 3, Day 1 (CR or PR or SD, n=20)Cycle 3, Day 1(PD, n=2)Cycle 3, Day 28 (CR or PR or SD, n=20)
Sunitinib + Gefitinib10041.509760.000.590.680.790.690.620.620.740.730.59

[back to top]

Change From Baseline in VEGFR3 by Time Point Stratified by PFS >= Median and PFS < Median

Change = median VEGFR3 level at each specified time point for subjects with tumor response PFS >= Median or PFS < Median minus median VEGFR3 level at Baseline. A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality). (NCT00113529)
Timeframe: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive

Interventionpg/mL (Number)
Cycle 1, Day 1 (PFS >= Median, n=5)Cycle 1, Day 1 (PFS < Median, n=11)Cycle 1, Day 28 (PFS >= Median, n=5)Cycle 1, Day 28 (PFS < Median, n=10)Cycle 2, Day 1 (PFS >= Median, n=5)Cycle 2, Day 1 (PFS < Median, n=9)Cycle 2, Day 28 (PFS >= Median, n=5)Cycle 2, Day 28 (PFS < Median, n=8)Cycle 3, Day 1 (PFS >= Median, n=5)Cycle 3, Day 1 (PFS < Median, n=8)Cycle 3, Day 28 (PFS >= Median, n=5)Cycle 3, Day 28 (PFS < Median, n=6)
Sunitinib + Gefitinib55100.0047500.000.290.440.860.730.300.470.650.910.320.49

[back to top]

Change From Baseline in VEGFR3 by Time Point Stratified by TTP >= Median and TTP < Median

Change = median VEGFR3 level at each specified time point for subjects with tumor response TTP >= Median and TTP < Median minus median VEGFR3 level at Baseline. A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality). (NCT00113529)
Timeframe: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive

Interventionpg/mL (Number)
Cycle 1, Day 1 (TTP >= Median, n=5)Cycle 1, Day 1 (TTP < Median, n=11)Cycle 1, Day 28 (TTP >= Median, n=5)Cycle 1, Day 28 (TTP < Median, n=10)Cycle 2, Day 1 (TTP >= Median, n=5)Cycle 2, Day 1 (TTP < Median, n=9)Cycle 2, Day 28 (TTP >= Median, n=5)Cycle 2, Day 28 (TTP < Median, n=8)Cycle 3, Day 1 (TTP >= Median, n=5)Cycle 3, Day 1 (TTP < Median, n=8)Cycle 3, Day 28 (TTP >= Median, n=5)Cycle 3, Day 28 (TTP < Median, n=6)
Sunitinib + Gefitinib55100.0047500.000.290.440.860.730.300.470.650.910.320.49

[back to top]

Change From Baseline in VEGFC by Time Point Stratified by PFS >= Median and PFS < Median

Change = median VEGFC level at each specified time point for subjects with tumor response PFS >= Median or PFS < Median minus median VEGFC level at Baseline. A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality). (NCT00113529)
Timeframe: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive

Interventionpg/mL (Number)
Cycle 1, Day 1 (PFS >= Median, n=5)Cycle 1, Day 1 (PFS < Median, n=11)Cycle 1, Day 28 (PFS >= Median, n=5)Cycle 1, Day 28 (PFS < Median, n=10)Cycle 2, Day 1 (PFS >= Median, n=5)Cycle 2, Day 1 (PFS < Median, n=9)Cycle 2, Day 28 (PFS >= Median, n=5)Cycle 2, Day 28 (PFS < Median, n=8)Cycle 3, Day 1 (PFS >= Median, n=5)Cycle 3, Day 1 (PFS < Median, n=8)Cycle 3, Day 28 (PFS >= Median, n=5)Cycle 3, Day 28 (PFS < Median, n=6)
Sunitinib + Gefitinib650.80532.700.760.990.801.000.841.170.701.050.901.22

[back to top]

Number of Subjects With Overall Confirmed Objective Disease Response According to the Response Evaluation Criteria in Solid Tumors (RECIST)

Objective disease response = subjects with confirmed complete response (CR) or partial response (PR) according to RECIST. A CR was defined as the disappearance of all target lesions. A PR was defined as a ≥ 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. (NCT00113529)
Timeframe: From start of treatment until Day 28 of Cycles 1 to 4, Day 28 of even cycles thereafter

Interventionparticipants (Number)
Sunitinib + Gefitinib13

[back to top]

Toxicity as Assessed by the National Cancer Institute (NCI) Common Toxicity Criteria Associated With Gefitinib Therapy: Expected Toxicities (Grade 1 - 3)

Severity and timing of toxicities evaluated according to NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 3. Occurrences of late (post-radiation) toxicities that are radiation-related monitored and included. (NCT00126555)
Timeframe: Up to 5 years

,,,
Interventionparticipants (Number)
FatigueDry skinPruitisRash/desquamationRash/acneiformAnorexiaDiarrheaNauseaVomitingElevation of alanine transferase (ALT)Elevation of asparagine transferase (AST)Elevation of CreatinineAbdominal painDry eyesOcular/visual, other
Induction Phase11244711063342210
Induction With Dose Escalation522242010220001
Maintenance231143600010100
Radiation With Gefitinib310123031010010

[back to top]

Participant Treatment Following Induction Therapy

Treatment received following two 30-day cycles (60 days) of 250 mg gefitinib given by mouth daily. Participant treatment reported as percentage of total treated participants out of total treated. (NCT00126555)
Timeframe: Following 60 days of Gefitinib induction treatment

Interventionpercentage of participants (Number)
Surgery AloneDefinitive RadiationRadiation and Concurrent GefitinibSurgery, Post-Op Radiation & Concurrent Gefitinib
Gefitinib, Radiotherapy, Surgery11.817.611.847

[back to top]

Number of Participants With Response Rate During Induction, Dose Escalation, and Concomitant With Radiation.

Completion Induction phase, participants are evaluated for clinical response and resectability. Resectable participants who had achieved at least stable disease and received surgery followed by radiation. Unresectable participants who had achieved at least stable disease received concomitant radiation/Gefitinib. (NCT00126555)
Timeframe: Up to 100 days

,,
InterventionParticipants (Count of Participants)
Complete Response (CR)Partial Response (PR)Stable Disease (SD)Progressive Disease (PD)
Patients Completed Induction Gefitinib4553
Patients Received the Escalated Gefitinib Dose1032
Patients Treated Radiation and Concurrent Gefitinib0210

[back to top]

Frequency and Timing of Local and Distant Failures

(NCT00126555)
Timeframe: From study entry to first documented local recurrence or last patient contact, assessed up to 5 years

,
Interventionparticipants (Number)
Local recurrenceunknownDermal metastasesNo Evidence of Disease (NED)Living with diseaseDied of their disease (DOD)Died from other causes
Recurrence Status21012000
Survival Status0505023

[back to top]

Clinical Response According to Response Evaluation Criteria In Solid Tumors (RECIST)

Number participants with response defined by RECIST: Complete Response (CR): Disappearance all disease; No new lesions/non-evaluable disease; Responders on none/only maintenance doses of corticosteroids. Partial Response (PR): >/= 50% decrease under baseline in sum products perpendicular diameters of measurable lesions; No progression evaluable disease/new lesions; Responders on same/decreasing doses dexamethasone & stable/improved neurological exams. Stable/No Response (SD): Not qualify for CR, PR, or progression; requires minimum 12 weeks duration; Responders on same/decreasing doses dexamethasone & stable/improved neurological exams. Progression (PD): 25% increase in sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease), OR clear worsening any evaluable disease, OR appearance any new lesion/site, OR failure to return due to death/deteriorating condition. All measurable/evaluable sites assessed using same baseline techniques. (NCT00126555)
Timeframe: Up to 5 years

Interventionparticipants (Number)
Complete Response (CR)Partial Response (PR)Stable Disease (SD)Progressive Disease (PD)
Gefitinib, Radiotherapy, Surgery4657

[back to top]

Early Progression Rate

Number of participants out of total participants with progression following two 30 day courses of Gefitinib. Tumor response evaluated by Response Evaluation Criteria in Solid Tumors by physical exam, computed tomography (CT) or Magnetic Resonance Imaging (MRI). Progressive disease defined as determined as response to Gefitinib induction therapy: Progression: 25% increase in sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). Participants restaged on days 15 and 60 of treatment. (NCT00126555)
Timeframe: Baseline to 60 days, up to 2 courses of induction therapy

Interventionpercentage of participants (Number)
Gefitinib, Radiotherapy, Surgery31.8

[back to top]

Toxicity as Assessed by the National Cancer Institute (NCI) Common Toxicity Criteria Associated With Gefitinib Therapy: UnExpected Toxicities (Grade 1 - 3)

Severity and timing of toxicities evaluated according to NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 3. Occurrences of late (post-radiation) toxicities that are radiation-related monitored and included. (NCT00126555)
Timeframe: Up to 5 years

,,,
Interventionparticipants (Number)
Allergic reactionAnemiaWeight LossAlopeciaTaste alterationEpistaxisInfectionElevated BUNElevated White Blood Cell Count (CBC)Blurred visionInsomniaDepressionTooth pain
Induction Phase1310110111001
Induction Phase With Dose Escalation0100001000000
Maintenance Phase1311000101110
Radiation With Gefitinib0211000001000

[back to top]

Progression Free Survival

Percentage of participants who are progression free at 2 years (calculated using the Kaplan-Meier method, which allows for censored observations for example those lost to follow-up). A patient is said to have progressed if they have progression of target or non-target lesions or evidence of any new lesions (as defined by RECIST). (NCT00229723)
Timeframe: Clinical tumour assessments and tumour assessment by CT/MRI were carried out during screening and regularly throughout the study until disease progression (as defined by RECIST)

InterventionPercentage of participants (Number)
Placebo/Placebo41.9
250mg/Placebo43.1
500mg/Placebo58.1
250mg/250mg31.2
500mg/500mg43.1
Placebo/250mg30.0
Placebo/500mg42.9

[back to top]

Tumour Response (Complete Response + Partial Response)

A patient was deemed to be have a tumour response if the RECIST criteria for complete response or partial response were satisfied at any time during the study. (NCT00229723)
Timeframe: Assessed at 2 years. Clinical tumour assessments and tumour assessment by CT/MRI were carried out during screening and regularly throughout the study until disease progression

InterventionParticipants (Number)
Placebo/Placebo34
250mg/Placebo11
500mg/Placebo17
250mg/250mg18
500mg/500mg11
Placebo/250mg22
Placebo/500mg14

[back to top]

Complete Response

A patient was deemed to be a complete responder if the RECIST criteria for complete response were satisfied at any time during the study. (NCT00229723)
Timeframe: Assessed at 2 years. Clinical tumour assessments and tumour assessment by CT/MRI were carried out during screening and regularly throughout the study until disease progression.

InterventionParticipants (Number)
Placebo/Placebo28
250mg/Placebo7
500mg/Placebo11
250mg/250mg13
500mg/500mg6
Placebo/250mg14
Placebo/500mg11

[back to top]

Local Disease Control Rate at 1 Year

A patient demonstrated local disease control at 1 year if there was no evidence of failure of treatment. Failure was defined as the patient having objective disease progression (as per RECIST) inside the original irradiated area, at an isodose level (between 20% and 95%), or death. (NCT00229723)
Timeframe: Assessed after 1 year. Tumour assessments (clinical and by CT/MRI) were carried out during screening & regularly throughout the study until disease progression (as defined by RECIST).

InterventionParticipants (Number)
Placebo/Placebo27
250mg/Placebo8
500mg/Placebo16
250mg/250mg13
500mg/500mg10
Placebo/250mg14
Placebo/500mg10

[back to top]

Local Disease Control Rate at 2 Years

A patient demonstrated local disease control at 2 years if there was no evidence of failure of treatment. Failure was defined as the patient having objective disease progression (as per RECIST) inside the original irradiated area, at an isodose level (between 20% and 95%), or death. (NCT00229723)
Timeframe: Assessed at 2 yrs. Tumour assessments (clinical & by CT/MRI) were carried out during screening & regularly throughout the study until disease progression (as defined by Response evaluation criteria in solid tumours (RECIST)).

InterventionParticipants (Number)
Placebo/Placebo21
250mg/Placebo7
500mg/Placebo15
250mg/250mg7
500mg/500mg7
Placebo/250mg9
Placebo/500mg9

[back to top]

Overall Survival

Percentage of participants who are alive at 2 years (calculated using the Kaplan-Meier method, which allows for patients who do not have complete follow-up (censored observations)). (NCT00229723)
Timeframe: Overall survival assessed at 2 years

InterventionPercentage of participants (Number)
Placebo/Placebo64.6
250mg/Placebo60.0
500mg/Placebo74.8
250mg/250mg43.2
500mg/500mg49.4
Placebo/250mg48.2
Placebo/500mg61.1

[back to top]

Overall Response Rate (ORR)

ORR: Complete Response (CR) + Partial Response (PR). Response rate for Elderly (> 70 years) previously untreated patients with Stage IIIb (With Malignant Pleural Effusion (MPE)) or IV non-small cell lung cancer (NSCLC) receiving Taxotere + ZD1839. Best clinical response to treatment with combination was determined using Response Evaluation Criteria in Solid Tumors (RECIST V1.0): * Complete Response (CR)- Disappearance of all target lesions; * Partial Response (PR)- At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD; * Progressive Disease (PD)- At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; * Stable Disease (SD)- Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. (NCT00231465)
Timeframe: Duration of time on study, an average of 19 months

Interventionpercentage of participants (Mean)
Taxotere® (Docetaxel) + ZD1839 (IRESSA®)40

[back to top]

Overall Survival (OS) Rate

OS was calculated from the date of enrollment to the date of death. All 44 treated were assessed for OS, with a minimum follow-up of 19 months. (NCT00231465)
Timeframe: Duration of time on study, an average of 19 months

InterventionMonths (Median)
Taxotere® (Docetaxel) + ZD1839 (IRESSA®)9.59

[back to top]

Progression Free Survival (PFS) Rate

PFS was calculated from the date of enrollment to the date of progression. All 44 treated were assessed for PFS, with a minimum follow-up of 19 months. Progression (PD): At least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00231465)
Timeframe: Duration of time on study, an average of 19 months

InterventionMonths (Median)
Taxotere® (Docetaxel) + ZD1839 (IRESSA®)6.9

[back to top]

Progression Free Survival (PFS)

Interval between date of randomization and earliest date of objective disease progression per RECIST criteria or death due to any cause in the absence of progression (NCT00264498)
Timeframe: Date of randomization to earliest date of objective disease progression

InterventionDays (Mean)
Active Comparator131.0
Experimental42.0

[back to top]

The Number of Patients With Complete or Partial Response Rate of Single Agent ZD1839 in a Patient Population With Recurrent or Metastatic Cancer of the Esophagus or Gastroesophageal Junction, Using the RECIST 1.0 Criteria.

The overall response is the number of patients with the best response recorded in measurable disease (target lesions) from start to disease progression.Complete response is the number of patients with the disappearance of all target lesions. Partial response is the number of patients with larger than or equal to 30% decrease in sum of the longest diameters from baseline. Progressive disease is larger than or equal to 20% increase in sum of the longest diameters over the smallest sum observed or appearance of new lesions. Stable disease is neither PR nor PD criteria met. (NCT00268346)
Timeframe: at 8 weeks after initiation of treatment

Interventionparticipants (Number)
No Prior Therapy1
Prior Chemotherapy3

[back to top]

Dose Limiting Toxicity (DLT)

Dose-limiting toxicity defined as any Grade 4 hematological toxicity and any > Grade 3 non-hematologic toxicity. The DLT (dose-limiting toxicity) is defined as any Grade 4 hematological toxicity and any > Grade 3 non-hematologic toxicity. (NCT00317772)
Timeframe: Continual reassessment method, prior to each 28 day cycle, an average of 60 days

InterventionDose Limiting Toxicities (Number)
Phase 1 Dose Level 12
Phase 1 Dose Level 23
Phase 1 Dose Level 34

[back to top]

Maximum Tolerated Dose (MTD) of Topotecan

Maximum tolerated dose is highest dose level in which 6 patients treated with at most 1 experiencing DLT. (NCT00317772)
Timeframe: At end of first course, prior to each new course (28 day cycle). Continual reassessment method (CRM) during each course for toxicity, an average of 60 days

Interventionmg/m^2 (Number)
All Phase 1 Participants4

[back to top]

Response Rate

Measurable disease defined as at least one lesion that can be accurately measured in at least one dimension. Complete Response (CR): disappearance of all target and non-target lesions and no evidence of new lesions. Partial Response (PR): At least 30% decrease in sum of longest dimensions (LD) of all target measurable lesions. Increasing Disease: At least a 20% increase in sum of LD of target lesions taking as reference smallest sum LD or appearance of new lesions within 8 weeks of study entry. Progression on existing non-target lesions, other than pleural effusions without cytological proof of neoplastic origin. Death due to disease without prior objective documentation of progression. Global deterioration in health status attributable to disease requiring a change in therapy without objective evidence of progression. (NCT00317772)
Timeframe: 61 weeks

,,,
InterventionParticipants (Count of Participants)
Complete responsePartial responseStable diseaseProgressive diseaseNot evaluable
Expansion Phase00172
Phase 1 Dose Level 101020
Phase 1 Dose Level 200120
Phase 1 Dose Level 301110

[back to top]

Neurotoxicity

Number of patients with a neurotoxicity event. Based on the evaluable-for-safety population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel) (NCT00322452)
Timeframe: Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel

InterventionParticipants (Number)
Gefitinib30
Carboplatin/Paclitaxel411

[back to top]

Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Thrombocytopenia

Number of patients with a thromboctyopenia event, identified from the lab data as a worsening in platelet count from baseline to a CTC grade 3 or above. Based on the evaluable-for-safety population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel). (NCT00322452)
Timeframe: Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel

InterventionParticipants (Number)
Gefitinib5
Carboplatin/Paclitaxel29

[back to top]

Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Neutropenia

Number of patients with a neutropenia event, identified from the lab data as a worsening in absolute neutrophil count from baseline to a CTC grade 3 or above which Based on the evaluable-for-safety population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel). (NCT00322452)
Timeframe: Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel

InterventionParticipants (Number)
Gefitinib4
Carboplatin/Paclitaxel385

[back to top]

Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Anaemia

Number of patients with an anaemia event, identified from the lab data as a worsening in haemoglobin from baseline to a CTC grade 3 or above. Based on the evaluable-for-safety population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel). (NCT00322452)
Timeframe: Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel

InterventionParticipants (Number)
Gefitinib11
Carboplatin/Paclitaxel56

[back to top]

Quality of Life (QoL) as Measured by the Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy - Lung Cancer (FACT-L) Questionnaire

Number of patients improving: a patient was described as improved if they had 2 visits (at least 21 days apart) where there was an increase in TOI score (from baseline) of 6 or more, and there were no intervening visits showing a decrease from baseline of 6 or more. Includes all patients with QoL data at baseline & at least 1 post-baseline visit (NCT00322452)
Timeframe: FACT-L data were collected at baseline, week 1, every 3 weeks (from baseline) until day 127, then every 42 days until the patient was confirmed as having objectively progressed (via RECIST), and at treatment discontinuation.

InterventionParticipants (Number)
Gefitinib274
Carboplatin/Paclitaxel184

[back to top]

Diarrhoea

Number of patients with a diarrhoea event. Based on the evaluable-for-safety population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel) (NCT00322452)
Timeframe: Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel

InterventionParticipants (Number)
Gefitinib274
Carboplatin/Paclitaxel128

[back to top]

Median Overall Survival (OS) in Months at OS Data Cut Off (14th June 2010)

Overall Survival was assessed via calculation of the time to death due to any cause. If a participant was known to have died, the time to death was defined as the time from the date of randomization to the date of death. Otherwise, a participant was censored at the last date they were known to be alive. Median Overall Survival in months is presented here. (NCT00322452)
Timeframe: Following the PFS DCO on 14th April 2008 information on survival status was collected every 8 weeks.

InterventionMonths (Median)
Gefitinib18.8
Carboplatin/Paclitaxel17.4

[back to top]

Median Progression Free Survival (PFS) in Months

PFS was defined as the interval from the date of randomization to the date of objective disease progression (as per RECIST) or the date of death (from any cause) in the absence of objective disease progression. The median PFS in months is presented here. (NCT00322452)
Timeframe: Tumour assessments as per RECIST were performed at baseline and then every 42 days ± 7 days from randomization until data cut off (14th April 2008).

InterventionMonths (Median)
Gefitinib5.7
Carboplatin/Paclitaxel5.8

[back to top]

Nausea

Number of patients with a nausea event. Based on the evaluable for-safety-population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel) (NCT00322452)
Timeframe: Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel

InterventionParticipants (Number)
Gefitinib74
Carboplatin/Paclitaxel260

[back to top]

Objective Tumour Response Rate According to RECIST

Number of participants with an objective response. An objective response (OR) was defined as a patient having a best overall response of either complete response (CR) or partial response (PR) according to RECIST, confirmed at least 28 days following the date of the initial response. (NCT00322452)
Timeframe: Tumour assessments as per RECIST were performed at baseline and then every 42 days ± 7 days from randomization until data cut off (14th April 2008).

InterventionParticipants (Number)
Gefitinib262
Carboplatin/Paclitaxel196

[back to top]

Quality of Life (QoL) as Measured by the Total Score of the Functional Assessment of Cancer Therapy - Lung Cancer (FACT-L) Questionnaire

Number of patients improving: a patient was described as improved if they had 2 visits (at least 21 days apart) where there was an increase in FACT-L score (from baseline) of 6 or more, and there were no intervening visits showing a decrease from baseline of 6 or more. Includes all patients with QoL data at baseline & at least 1 post-baseline visit (NCT00322452)
Timeframe: FACT-L data were collected at baseline, week 1, every 3 weeks (from baseline) until day 127, then every 42 days until the patient was confirmed as having objectively progressed (via RECIST), and at treatment discontinuation.

InterventionParticipants (Number)
Gefitinib283
Carboplatin/Paclitaxel229

[back to top]

Rashes/Acnes

Number of patients with a rashes/acnes event. Based on the evaluable-for-safety population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel) (NCT00322452)
Timeframe: Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel

InterventionParticipants (Number)
Gefitinib398
Carboplatin/Paclitaxel132

[back to top]

Symptom Improvement as Measured by the Lung Cancer Subscale (LCS) of the FACT-L Questionnaire

Number of patients improving: a patient was described as improved if they had 2 visits (at least 21 days apart) where there was an increase in LCS score (from baseline) of 2 or more, and there were no intervening visits showing a decrease from baseline of 2 or more. Includes all patients with QoL data at baseline & at least 1 post-baseline visit (NCT00322452)
Timeframe: FACT-L data were collected at baseline, week 1, every 3 weeks (from baseline) until day 127, then every 42 days until the patient was confirmed as having objectively progressed (via RECIST), and at treatment discontinuation.

InterventionParticipants (Number)
Gefitinib304
Carboplatin/Paclitaxel272

[back to top]

Vomiting

Number of patients with a vomiting event. Based on the evaluable-for-safety population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel) (NCT00322452)
Timeframe: Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel

InterventionParticipants (Number)
Gefitinib59
Carboplatin/Paclitaxel193

[back to top]

Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Liver Transaminases

Number of patients with an elevated liver transaminase event, identified from the lab data as a worsening in ALT or AST from baseline to a CTC grade 3 or above. Based on the evaluable-for-safety population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel). (NCT00322452)
Timeframe: Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel

InterventionParticipants (Number)
Gefitinib57
Carboplatin/Paclitaxel6

[back to top]

Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Leukopenia

Number of patients with a leukopenia event, identified from the lab data as a worsening in white blood cell count from baseline to a CTC grade 3 or above. Based on the evaluable for-safety-population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel). (NCT00322452)
Timeframe: Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel

InterventionParticipants (Number)
Gefitinib1
Carboplatin/Paclitaxel202

[back to top]

Tumor Response

"Definitions of objective tumor response~Complete response - disappearance of all target lesions~Partial response - at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter~Progressive disease - at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions~Stable disease - neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started" (NCT00328562)
Timeframe: Baseline, 1, 3, and 5 months post-treatment

Interventionparticipants (Number)
Complete responsePartial responseMinor responseStable diseaseProgressive diseaseNot evaluable
Iressa and RT313113

[back to top]

Survival From Starting Gefitinib

(NCT00328562)
Timeframe: Baseline to date of expiration

Interventionmonths (Median)
Iressa and RT10

[back to top] [back to top]

Progression-free Survival

(NCT00328562)
Timeframe: Baseline to date of progression

Interventionmonths (Median)
Iressa and RT5

[back to top]

Overall Survival (OS)

Median Overal survival was not able to be calculated because the rate of OS was below 50% at the end of follow-up period. Therefore, OS percentage at 12 months is provided. (NCT00344773)
Timeframe: baseline to 12 months

InterventionPercent of Participants (Number)
Gefitinib82.26

[back to top]

Percentage of Participants Who Had an Objective Response Rate(ORR) Based on Response Evaluation Criteria In Solid Tumors (RECIST) Criteria.

"Objective Response Rate (ORR) is defined as participants who had complete response (CR) or partial response(PR) divided by the total number of patients.~RECIST criteria:~CR = disappearance of all target lesions PR = 30% decrease in the sum of the longest diameter of target lesions PD = 20% increase in the sum of the longest diameter of target lesions SD (stable disease) = small changes that do not meet above criteria" (NCT00344773)
Timeframe: baseline to 12 months

InterventionPercent of Participants (Number)
Gefitinib0

[back to top]

Progression Free Survival (PFS)

Progression free survival calculated using Kaplan-Meier Product Limit. Median PFS was not able to be calculated because the rate of PFS was below 50% at the end of follow-up period. Therefore, PFS percentage at 4 months is provided. (NCT00344773)
Timeframe: baseline to 4 months

InterventionPercent of Participants (Number)
Gefitinib86.25

[back to top]

Number of Other Adverse Events (AEs)

Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator's opinion, the condition is unlikely to resolve because of the patient's underlying disease. (NCT00357734)
Timeframe: Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until 30 days after the last dose of study treatment or 30 days after last visit (up to approximately 120 months)

Interventionnumber of other AEs (Number)
Gefitinib (ZD1839)40

[back to top] [back to top]

Number of Serious Adverse Events (SAEs)

Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator's opinion, the condition is unlikely to resolve because of the patient's underlying disease (NCT00357734)
Timeframe: Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until 30 days after the last dose of study treatment or 30 days after last visit (up to approximately 120 months)

Interventionnumber of SAEs (Number)
Gefitinib (ZD1839)13

[back to top] [back to top]

Overall Survival (OS)

(NCT00357734)
Timeframe: From randomization until death (up to 120 months)

InterventionMonths (Median)
Gefitinib (ZD1839)23.5

[back to top]

Progression-free Survival (PFS)

Objective disease progressing was assessed using the previous cancer response criteria in the parent ZD1839 trial: ie Southwest Oncology Group (SWOG) tumor response criteria, as a 50% increase or an increase of 10 cm2 (whichever is smaller) in the sum of products of all measurable lesions from the overall smallest sum observed (over baseline if no decrease) using the same techniques as baseline; Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase In the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00357734)
Timeframe: From randomization until progression or death (up to 120 months)

InterventionMonths (Median)
Gefitinib (ZD1839)26.5

[back to top]

Progression-Free Survival (PFS)

Defined as the time from randomization to the first observation of disease progression, or death due to any cause. (NCT00409006)
Timeframe: Baseline to first observation of disease progression or death, 12 weeks up to 31 months

InterventionMonths (Median)
Pemetrexed/Cisplatin/Gefitinib9.95
Pemetrexed/Cisplatin6.83

[back to top]

Percentage of Participants Who Died During the Study

This outcome measure takes the place of the outcome measure for Overall Survival, which could not be reported since the median value could not be calculated. (NCT00409006)
Timeframe: Baseline up to 31 months

InterventionPercentage of Participants (Number)
Pemetrexed/Cisplatin/Gefitinib35.9
Pemetrexed/Cisplatin19.4

[back to top]

Number of Participants With Tumor Response

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes not meeting above criteria. Responder is a participant exhibiting a best overall study response of CR or PR. (NCT00409006)
Timeframe: Baseline to measured response or death, 12 weeks up to 31 months

InterventionParticipants (Number)
Pemetrexed/Cisplatin/Gefitinib18
Pemetrexed/Cisplatin11

[back to top]

Duration of Response for Responders

The duration of a complete response (CR; the disappearance of all target lesions) or partial response (PR; at least a 30% decrease in the sum of the longest diameter of target lesions) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. A responder is a patient exhibiting a best overall study response of CR or PR. (NCT00409006)
Timeframe: Time of response to progressive disease or death, 12 weeks up to 31 months

InterventionMonths (Median)
Pemetrexed/Cisplatin/Gefitinib12.29
Pemetrexed/Cisplatin4.14

[back to top]

Six-month Progression-free Survival

Estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions or unequivocal progression of existing non-target lesions (NCT00467077)
Timeframe: From the date treatment started until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months

Interventionpercentage of participants (Number)
Gefitinib and PEG-IFNa Treatment29

[back to top]

Progression-Free Survival

Estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00467077)
Timeframe: Until disease progression, up to 5 years.

InterventionMonths (Median)
Gefitinib and PEG-IFNa Treatment5.2

[back to top]

Overall Survival

Estimated using the product-limit method of Kaplan and Meier. (NCT00467077)
Timeframe: Up to 5 years.

InterventionMonths (Median)
Gefitinib and PEG-IFNa Treatment13.6

[back to top]

Number of Participants With Overall Response as Measured by RECIST Criteria

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response = CR + PR (NCT00467077)
Timeframe: After 2 cycles of treatment, up to 2 years.

Interventionparticipants (Number)
Gefitinib and PEG-IFNa Treatment2

[back to top]

Median Overall Survival

Overall survival was summarized using the Kaplan-Meier estimation. (NCT00479089)
Timeframe: Baseline till participant death or end of follow-up period, assessed every 4 weeks, up to 5 years.

InterventionMonths (Median)
Weekly Docetaxel18.0
Weekly Docetaxel + ZD183916.6

[back to top]

Median Progression Free Survival From Trial Enrollment for Overall Study

Progressive disease was defined as at least a 25% increase from baseline, of the sum of the products of the two greatest dimensions of representative measurable lesions. Increasing severity in symptoms due to progressive tumor was also counted as progression even if they were not accompanied by an objective indicator on radiographic imaging. The development of any new measurable lesions was considered evidence of progressive cancer as well. (NCT00479089)
Timeframe: From trial enrollment to disease progression or death, up to five years

InterventionMonths (Median)
Weekly Docetaxel3.7
Weekly Docetaxel + ZD18394.4

[back to top]

Overall Response Rate as Measured by RECIST Criteria and PSA Criteria

If there is at least 1 response, then 7 additional patients will be enrolled. If there are 4 or more responders overall, then the combination will be considered active and warrant further study. Overall response rate (ORR) is defined as the proportion of patients who have a partial or complete response to therapy. (NCT00483561)
Timeframe: Approximately 3 years

InterventionParticipants (Count of Participants)
Stable Disease (by RECIST criteria)Partial Responder (by PSA criteria)
Gefitinib Plus Etoposide51

[back to top]

Response (CR or PR), Stable Disease (SD), and Progressive Disease (PD) Rates

"The proportion of subjects that responded [complete (CR) or partial response (PR)], had stable disease (SD), or progressive disease (PD) as defined by the Response Evaluation Criteria In Solid Tumors (RECIST)~Complete Response (CR): Disappearance of all target lesions~Partial Response (PR): At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter~Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter (LD) since the treatment started~Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions" (NCT00519077)
Timeframe: 8 weeks

Interventionpercentage of participants (Number)
Response (CR or PR)Stable disease (SD)Progressive disease (PD)
Gefitinib6.8118.1875.00

[back to top]

Median Progression-free Survival Time

Progression-free survival (PFS) is the number of months during and after Gefitinib treatment during which the cancer did not get worse (progress) as defined by Response Evaluation Criteria In Solid Tumors (RECIST). Progressive disease is associated with at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. All patients developed progressive disease or died during the 9-month observation period. (NCT00519077)
Timeframe: 9 months

Interventionmonths (Median)
Gefitinib1.9

[back to top]

Number of Patients With Adverse Event (AE)

(NCT00536107)
Timeframe: From time consent was given to 28 days after last dose of study drug.

InterventionParticipants (Number)
Gefitinib8
Docetaxel6

[back to top]

Number of Patients With Serious Adverse Events (SAEs)

(NCT00536107)
Timeframe: From time consent was given to 28 days after last dose

Interventionparticipants (Number)
Gefitinib2
Docetaxel1

[back to top]

Microarray Analysis to Identify Gene(s) or Gene Clusters That Exhibit Changes in Gene Expression; Time to Relapse and Overall Survival Data

Each patient provides two binary variables: presence/absence of mutation and responder/non responder. The association between the two will be tested using the Fisher's exact test for the resulting 2x2 table.Changes in expression levels within a patient will be assessed using a paired t-test. Similarly differences in expression levels between responders and non-responders will be assessed using a two-sample t-test. Appropriate adjustment will be made for the multiple comparisons problem that arises because there are over 21,000 probe sets on the U133A array. (NCT00588445)
Timeframe: 2 years

,
Interventionpercentage of participants (Number)
Disease Free SurvivalOverall Survival
EGFR Mutation Negative7692
EGFR Mutation Positive8598

[back to top]

The Radiographic Response to Gefitinib

Radiographic response is defined as a minor response ( > 25% decrease in the sum of the products of measured lesions) (NCT00588445)
Timeframe: 21 days

Interventionparticipants (Number)
Treatment21

[back to top]

Objective Response Rate(ORR)

"Primary efficacy endpoint is a change in the proportion of subjects showing overall objective response rate(ORR) from baseline to final tumor assessment point after treatment. As per RECIST, the percentage of subjects indicating PR (partial response) or CR (complete response) will be calculated.~According RECIST criteria, CR(complete response) - the disappearance of all target lesions and 'PR(partial response) - at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter." (NCT00608868)
Timeframe: Every 8 weeks until progression disease or death or Data Cut off date (2 January 2009)

InterventionPercent of participants (Number)
Gefitinib31.2

[back to top]

Period of Progression-Free Survival

The median months without event of progression disease according to RECIST criteria is analysed. (NCT00608868)
Timeframe: Every 8 weeks until progression disease or death or Data Cut off date (2 January 2009)

Interventionmonths (Median)
Gefitinib5.7

[back to top]

Quality of Life and Symptom Improvement Based on Functional Assessment of Cancer Therapy-Lung (FACT-L)

"Patients recorded the presence and severity of 7 symptoms by using the lung cancer subscale(LCS) at FACT-L; shortness of breath, weight loss, clarity of thinking, cough, appetite, chest tightness, and difficulty breathing. Severity was assessed by using 0~4 scale (0=not at all to 4=very much). A possible score was 0~28.~The improvement rate defined as change of ≥6 points in overall FACT-L from baseline and the rate of patients who reported the change of points ≥2 in LCS of FACT-L.~The percentage of patients who showed improvement is reported." (NCT00608868)
Timeframe: Every 8 weeks until progression disease or death or Data Cut off date (2 January 2009)

Interventionpercentage of participants (Number)
Gefitinib41

[back to top]

Adverse Event

An adverse event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. (NCT00608868)
Timeframe: Every 8 weeks until progression disease or death or Data Cut off date (2 January 2009)

Interventionparticipants (Number)
Gefitinib141

[back to top]

Symptom Improvement

Symptom improvement will be assessed from the 7-question Lung Cancer Subscale domain score derived from the FACT-L questionnaire. It is defined as an increase of two or more points on the LCS from randomization, maintained for 21 or more days. It will be calculated as the number of patients analysed with improvement. (NCT00770588)
Timeframe: at randomization, every 6 weeks until disease progression, and at discontinuation.

InterventionParticipants (Number)
Gefitinib34
Placebo12

[back to top]

Objective Tumour Response (ORR)

The objective tumour response will be calculated as the number of patients with CR or PR per RECIST Criteria. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00770588)
Timeframe: TTumour assessment using RECIST will be performed at baseline then every 42 days (6 weeks) ± 7 days (1 week) from randomisation until objective progression or death from any cause.

InterventionParticipants (Number)
Gefitinib35
Placebo1

[back to top]

Adverse Event

Appropriate description of AEs and laboratory data/vital signs will be produced. Number of patients who had at least one adverse events will be calculated. (NCT00770588)
Timeframe: AEs and SAEs must be collected from the time that the main study informed consent is obtained to 28 days after discontinuation of study drug. Any ongoing AE or SAE at discontinuation of study treatment and during 28 day follow-up period must be monitored

InterventionParticipants (Number)
Gefitinib118
Placebo79

[back to top]

Overall Survival (OS)

The OS will be assessed from the time of randomisation to death from any cause. For patients not known to have died(which may include those who have been lost to follow up or who have withdrawn from the study for whatever reason), OS will be censored for the analysis at the last date at which the patients were known to be alive. (NCT00770588)
Timeframe: The OS will be assessed from the time of randomization to death from any cause.For patients not known to have died or who have withdrawn from the study for whatever reason,OS will be censored at the last date at which patients were known to be alive.

Interventionmonth (Median)
Gefitinib18.7
Placebo16.9

[back to top]

Progression Free Survival (PFS)

PFS will be calculated from the tumour measurements collected at each tumour assessment per the RECIST criteria and/or the date of patient death. Progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline. (NCT00770588)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first.The primary analysis of PFS will be performed when at least 265 events have occurred, which is expected to occur approximately.

Interventionmonth (Median)
Gefitinib4.8
Placebo2.6

[back to top]

Progression - Free Survival of Patients Retreated With Gefitinib

Progression is defined, using RECIST (V1.1), as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline using CT scan every 8 weeks. (NCT00824746)
Timeframe: two year

Interventiondays (Median)
Gefitinib Retreatment Arm103

[back to top]

Disease Control(DC) Rate of Gefitinib Retreatment Per RECIST Criteria (V1.1) and Assessed by CT

Evaluation of treatment response by computed tomography (CT) was performed after the first 4 weeks according to version 1.1 of the guidelines set out by Response Evaluation Criteria in Solid Tumors (RECIST) Committee. Disease control rate (DCR) was defined as the percentage sum of best tumor response of complete response (CR), partial response (PR), and stable disease (SD). (NCT00824746)
Timeframe: 8 weeks

Interventionpercentage of participant with DC (Number)
Gefitinib Retreatment Group65.2

[back to top]

Overall Survival

(NCT00824746)
Timeframe: 2 years

Interventiondays (Median)
Single Arm343

[back to top]

Progression Free Survival (PFS)

PFS was defined as the time from date of randomization to the objective disease progression or death due to any cause. Response was defined using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. Progressive disease (PD) was defined as at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions. Participants who did not have a complete baseline disease assessment were censored at the date of randomization, regardless if PD was objectively determined or if participant died or if a participant was not known to have died or have objective PD at the data inclusion cutoff date. PFS was censored at the last complete objective progression-free disease assessment date. (NCT01017874)
Timeframe: Randomization to the first date of measured PD or death up to 37.32 months

Interventionmonths (Median)
Pemetrexed + Cisplatin + Gefitinib8.38
Gefitinib9.63

[back to top]

Time to Progressive Disease (TtPD)

TtPD was defined as the time from randomization to the first date of objectively determined progressive disease (PD). For participants who were not known to have had objective progression of disease as of the data-inclusion cut-off date for a particular analysis, or who had died without objective progression of disease, TtPD was censored at the date of the participant's last objective progression-free disease assessment prior to cut-off date. (NCT01017874)
Timeframe: Randomization to the first date of measured PD up to 37.32 months

Interventionmonths (Median)
Pemetrexed + Cisplatin + Gefitinib8.61
Gefitinib9.69

[back to top]

Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [Disease Control Rate (DCR)]

DCR was defined as the percentage of randomized participants with overall response of CR, PR or SD using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. CR was defined as the disappearance of all tumor lesions; PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and no new lesions having appeared; SD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD. PD defined as at least 20% increase in the sum of LD of target, lesions taking as reference, the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions or progression of nontarget lesions. (NCT01017874)
Timeframe: Randomization up to 37.52 months

Interventionpercentage of participants (Number)
Pemetrexed + Cisplatin + Gefitinib71.2
Gefitinib64.4

[back to top]

Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]

TRR was defined as the percentage of randomized participants having a best overall study response of CR or PR using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. CR was defined as the disappearance of all target lesions; PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and the appearance of no new lesions. (NCT01017874)
Timeframe: Randomization up to 37.52 months

Interventionpercentage of participants (Number)
Pemetrexed + Cisplatin + Gefitinib41.5
Gefitinib47.5

[back to top] [back to top]

Duration of Tumor Response

The duration of a complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria was defined as the time from first objective status assessment of CR or PR to the first time of objective disease progression or death as a result of any cause. CR was defined as the disappearance of all tumor lesions. PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum of LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and no new lesions having appeared. Participants who were not known to have died or had objective progression of disease as of the data-inclusion cut-off date were censored at the date of the participant's last complete objective progression-free disease assessment prior to that cut-off date. (NCT01017874)
Timeframe: Date of initial response to the date of measured PD or death up to 34.43 months

Interventionmonths (Median)
Pemetrexed + Cisplatin + Gefitinib12.09
Gefitinib11.93

[back to top]

Overall Survival (OS)

OS was the duration from randomization to the date of death from any cause. For participants who were not known to have died as of the data-inclusion cut-off date for a particular analysis, OS was censored at the date of last contact prior to the data inclusion cutoff date (contacts considered in the determination of last contact date included adverse event date, lesion assessment date, visit date, and last known alive date). (NCT01017874)
Timeframe: Randomization up to date of death from any cause up to 57.13 months

Interventionmonths (Median)
Pemetrexed + Cisplatin + Gefitinib26.87
Gefitinib27.86

[back to top]

Best Tumor Response

Change in size of tumor: Complete Response (CR) = no measurable tumor; Partial Response (PR) = 30% decrease in size of measurable tumor; Stable Disease (SD) = measurable tumor size has not changed; Progressive Disease (PD) = measurable tumor larger than at baseline (NCT01040780)
Timeframe: While receiving study treatment; assessed every 21 days until progression

,
Interventionpercentage of patients (Number)
Complete Response (CR)Partial Response (PR)Stable Disease (SD)Progressive Disease (PD)Disease Control (CR+PR+SD)
Gefitinib027.247.720.574.9
Icotinib0.527.147.721.175.4

[back to top]

Safety and Tolerability

"Adverse Events (AEs) and Serious AEs (SAEs) are presented regardless of causality for patients who received at least one dose of Icotinib or Gefitinib. Events were graded by the investigator using the NCI CTCAE Scale (version 3.0) which provides a grading scale for each AE term.~Grade 3 = Severe Grade 4 = Life-threatening or disabling" (NCT01040780)
Timeframe: Assessed over two years

,
Interventionparticipants (Number)
At least one AEAt least one ADRAt least one SAEGrade 3 and 4 AEs
Gefitinib1651401510
Icotinib166121139

[back to top]

Overall Survival

Median number of months from first study treatment until time of death (NCT01040780)
Timeframe: From first study treatment until time of death

Interventionmonths (Median)
Icotinib13.3
Gefitinib13.9

[back to top]

Progression Free Survival

Progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline. (NCT01040780)
Timeframe: 2-7 months

Interventionmonths (Median)
Icotinib4.6
Gefitinib3.4

[back to top]

Time To Progression

Median time until disease progression. Disease progression defined as radiological and/or symptomatic disease progression. (NCT01040780)
Timeframe: 2-7 months

Interventionmonths (Median)
Icotinib5.2
Gefitinib3.7

[back to top]

4 Year Disease Specific Survival

Percentage of patients who did not die by the disease within 4 years (NCT01185171)
Timeframe: 0.3 to 4.7 years

Interventionpercentage of patients (Number)
ZD1839 500mg by Mouth (po) Daily89

[back to top]

4 Year Overall Survival

Percentage of patients who survived 4 years or more (NCT01185171)
Timeframe: 0.3 to 4.7 years

Interventionpercentage of patients (Number)
ZD1839 500mg by Mouth (po) Daily74

[back to top]

4 Year Progression Free Survival

Percentage of patients who survived without progressive disease 4 years or more (NCT01185171)
Timeframe: 0.3 to 4.7 years

Interventionpercentage of patients (Number)
ZD1839 500mg by Mouth (po) Daily72

[back to top]

Complete Response Rate Achieved 1 Month After Concurrent Chemotherapy and Radiation Treatment

To explore the activity of ZD1839 added to concurrent chemoradiotherapy and as adjuvant monotherapy in patients with locally advanced head and neck cancer. Activity is described in terms of response rate (complete responses only). (NCT01185171)
Timeframe: 1 month

InterventionParticipants (Count of Participants)
ZD1839 500mg by Mouth (po) Daily52

[back to top]

Overall Survival (OS)

OS was defined as the time from first dose of gefitinib study treatment until death by any cause. Patients who had not died at the time of analysis were censored at the last date the patient was known to be alive. (NCT01203917)
Timeframe: Survival follow up from first dose of gefitinib till death of the patient or till end of study in absence of death.

InterventionMonths (Median)
Gefitinib19.22

[back to top]

Progression - Free Survival (PFS) (Independent Central Review)

PFS was defined as the time from the first dose of gefitinib study treatment until objective disease progression as defined by RECIST 1.1 (≥20% increase in the sum of the diameters of target lesions from minimum, clinically significant progression in non-target lesions or the presence of a new lesion) or death (by any cause in the absence of progression). Progression is based on measurements of scans by central review. (NCT01203917)
Timeframe: Scans taken at baseline and then follow up assessments taken every 6 weeks until progression, or last evaluable assessment in the absence of progression, assessed up to 23 months

InterventionMonths (Median)
Gefitinib6.97

[back to top]

Progression - Free Survival (PFS) (Investigator)

PFS was defined as the time from the first dose of gefitinib study treatment until objective disease progression as defined by RECIST 1.1 (≥20% increase in the sum of the diameters of target lesions from minimum, clinically significant progression in non-target lesions or the presence of a new lesion) or death (by any cause in the absence of progression). Progression is based on measurements made at site by investigator. (NCT01203917)
Timeframe: Scans taken at baseline and then follow up assessments taken every 6 weeks until progression, or last evaluable assessment in the absence of progression, assessed up to 23 months

InterventionMonths (Median)
Gefitinib9.72

[back to top]

Disease Control Rate (DCR) (Independent Central Review)

DCR is calculated as the % of the FAS patient population with a best visit response of CR, PR (a visit response of CR or PR which is confirmed at least 4 weeks later) or stable disease (SD). SD is defined as no evidence of CR, PR or progression and must have occurred at a minimum of 6 weeks after first dose of study treatment. (progression is defined as ≥20% increase in the sum of the diameters of target lesions from minimum; clinically significant progression in non-target lesions; the presence of a new lesion or death). Outcome is based on measurements of scans by central review. (NCT01203917)
Timeframe: Scans taken at baseline and then follow up assessments taken every 6 weeks until progression, or last evaluable assessment in the absence of progression, assessed up to 23 months

InterventionPercentage of Participants (Number)
% Controlled% Uncontrolled
Gefitinib88.711.3

[back to top]

Disease Control Rate (DCR) (Investigator)

DCR is calculated as the % of the FAS patient population with a best visit response of CR, PR (a visit response of CR or PR which is confirmed at least 4 weeks later) or stable disease (SD). SD is defined as no evidence of CR, PR or progression and must have occurred at a minimum of 6 weeks after first dose of study treatment. (progression is defined as ≥20% increase in the sum of the diameters of target lesions from minimum; clinically significant progression in non-target lesions; the presence of a new lesion or death). Outcome is based on measurements made at site by investigator. (NCT01203917)
Timeframe: Scans taken at baseline and then follow up assessments taken every 6 weeks until progression, or last evaluable assessment in the absence of progression, assessed up to 23 months

InterventionPercentage of Participants (Number)
% Controlled% Uncontrolled
Gefitinib90.69.4

[back to top]

Objective Response Rate (ORR) (Independent Central Review))

% of patients in the Full analysis set who have a complete response [CR] or partial response [PR] confirmed by repeat imaging at least 4 weeks later with no evidence of progression between confirmation visits (as defined by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1)). CR: disappearance of all target lesions (TLs) & non-target lesions (NTLs). PR: >= 30% decrease in the sum of diameters compared to baseline (with no evidence of progression) and the NTLs are at least stable with no evidence of new lesions. Outcome is based on measurements of scans by central review. (NCT01203917)
Timeframe: Scans taken at baseline and then follow up assessments taken every 6 weeks until progression, or last evaluable assessment in the absence of progression, assessed up to 23 months

InterventionPercentage of Participants (Number)
% Responders% Non-responders
Gefitinib50.050.0

[back to top]

Objective Response Rate (ORR) (Investigator)

% of patients in the Full analysis set who have a complete response [CR] or partial response [PR] confirmed by repeat imaging at least 4 weeks later with no evidence of progression between confirmation visits (as defined by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1)). CR: disappearance of all target lesions (TLs) & non-target lesions (NTLs). PR: >= 30% decrease in the sum of diameters compared to baseline (with no evidence of progression) and the NTLs are at least stable with no evidence of new lesions. Outcome is based on measurements made at site by investigator. (NCT01203917)
Timeframe: Scans taken at baseline and then follow up assessments taken every 6 weeks until progression, or last evaluable assessment in the absence of progression, assessed up to 23 months

InterventionPercentage of Participants (Number)
% Responders% Non-responders
Gefitinib69.830.2

[back to top]

Progression-free Survival

"Progression free survival (PFS) defined as the time from the date of randomisation to the date of first progression or death due to any cause, whichever one comes first.~The progression definition will be based on modified RANO criteria (Wen 2010), such that progression will be defined as the earliest time that at least one of the following occurs:~Clinical deterioration~Failure to return for evaluation as a result of death or deteriorating condition~Or, by retrospective radiographic central review:~Any new lesion~Increase in ≥25% of sum of the products of perpendicular diameters of enhancing lesions compared with baseline scan, on stable or increasing doses of steroids (dexamethasone) compared to baseline (T1 post-contrast scan)~Clear progression of non-measureable disease~Significant increase in T2/FLAIR non-enhancing lesion - on stable or increasing steroids (dexamethasone) compared with baseline or best response not caused by co-morbid events." (NCT01310855)
Timeframe: from the date of randomisation to the date of first progression or death due to any cause, until 6 months from the date the last patient finished trial treatment (the day after the date that the last trial drug was taken)

Interventionmonths (Median)
Cediranib & Gefitinib3.6
Cediranbib & Placebo2.8

[back to top]

Progression Free Survival

Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter ever recorded since study treatment started, or progression in existing non-target lesions,or the appearance of one or more new lesions . (NCT01404260)
Timeframe: The evaluation of disease is demanded every two months for the patients receiving maintenance use of Gefitinib or patients in observation after chemotherapy,until disease progression occured

Interventionmonths (Median)
Arm A: Gefitinib+Gemcitabine +Carboplatin9.7
Arm B: Gemcitabine +Carboplatin4.2

[back to top]

Time to Treatment Failure (TTF) (Main Overall Survival Analysis Cut-off Date, 08 April 2016)

Time to Treatment Failure (TTF) which was the time from the date of randomisation to the date of i.e. permanent treatment discontinuation for any reason. (NCT01466660)
Timeframe: From first drug administration until last drug administration, up to 1482 days

InterventionMonths (Median)
Afatinib13.67
Gefitinib11.53

[back to top]

Progression-free Survival

Progression-free survival (PFS) defined as the time from date of randomisation to date of disease progression, or date of death if a patient died earlier. Participants with no event (Disease progression (PD) or death) were censored. PD was primarily evaluated for the primary analysis by an independent central imaging review according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. Per RECIST version 1.1. for target lesions and assessed by Computed Tomography (CT)-scan or Magnetic Resonance Imaging (MRI): PD, At least a 20% increase in the sum of the longest diameter (SoD) of target lesions taking as reference the smallest SoD of target lesions recorded since the treatment started, together with an absolute increase in the SoD of target lesions of at least 5 millimetre (mm) or the appearance of one or more new lesions. For the final analysis (analysis cut-off date 12 April 2019) status and date of PD were determined by investigator assessment. (NCT01466660)
Timeframe: From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on disease progression or death, up to 2465 days.

InterventionMonths (Median)
Afatinib12.78
Gefitinib11.17

[back to top]

Overall Survival

Overall survival (OS) which was defined as the time from the date of randomisation to the date of death. Participants for whom there is no evidence of death at the time of the analysis will be censored at the date that they were last known to be alive. (NCT01466660)
Timeframe: From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on death, up to 2465 days.

InterventionMonths (Median)
Afatinib27.86
Gefitinib24.54

[back to top]

Objective Response Rate

Objective response rate (ORR) which was defined as the number of participants with best overall response of complete response (CR) or partial response (PR) as assessed by central independent review according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. divided by the total number of participants who received treatment. Per RECIST version 1.1. for target lesions and assessed by Computed Tomography (CT)-scan or Magnetic Resonance Imaging (MRI): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions from baseline. For the final analysis (analysis cut-off date 12 April 2019) objective response was determined by investigator assessment. (NCT01466660)
Timeframe: From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on disease progression, further anti-cancer treatment and death, up to 2465 days.

InterventionPercentage of participants (Number)
Afatinib79.4
Gefitinib74.8

[back to top]

Duration of Objective Response

Duration of objective response defined as the time of first objective response (best overall response of complete response or partial response) to the time of progression or death, whichever occurred first (or date of censoring for progression free survival). For the final analysis (analysis cut-off date 12 April 2019) objective response was determined by investigator assessment. (NCT01466660)
Timeframe: From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on disease progression, further anti-cancer treatment and death, up to 2465 days.

InterventionMonths (Median)
Afatinib11.86
Gefitinib11.07

[back to top]

Disease Control

Percentage of participants with disease control which was defined as the number of participants with best overall response of complete response (CR) or partial response (PR) or stable disease (SD) as assessed by central independent review according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. divided by the total number of participants who received treatment. Per RECIST version 1.1. for target lesions and assessed by Computed Tomography (CT)-scan or Magnetic Resonance Imaging (MRI): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions from baseline; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Responses of SD were only considered if they occur ≥42 days from date of randomisation. For the final analysis (analysis cut-off date 12 April 2019) disease control was determined by investigator assessment. (NCT01466660)
Timeframe: From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on disease progression or death, up to 2465 days.

InterventionPercentage of participants (Number)
Afatinib94.4
Gefitinib93.7

[back to top]

Duration of Disease Control

Duration of disease control defined as the time from randomisation to the time of progression or death, whichever occurred first (or date of censoring for progression free survival). For the final analysis (analysis cut-off date 12 April 2019) the status and date of disease progression were determined by investigator assessment. (NCT01466660)
Timeframe: From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on disease progression or death, up to 2465 days.

InterventionMonths (Median)
Afatinib12.88
Gefitinib11.73

[back to top]

Tumour Shrinkage (Main Overall Survival Analysis Cut-off Date, 08 April 2016)

Tumour shrinkage assessed by minimum sum of post-baseline target lesion diameters recorded after randomisation. A positive value shows a decrease in tumour size. (NCT01466660)
Timeframe: From first drug administration until last drug administration, up to 1482 days

Interventionmillimetre (mm) (Least Squares Mean)
Afatinib34.79
Gefitinib38.25

[back to top]

Time to Objective Response

Number of participants with objective response (best overall response of complete response or partial response) to study treatment over time, cumulative number of participants is displayed. Time to objective response was defined as the time from randomisation to the first recorded objective response. For the final analysis (analysis cut-off date 12 April 2019) objective response was determined by investigator assessment. (NCT01466660)
Timeframe: From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on disease progression, further anti-cancer treatment and death, up to 2465 days.

,
InterventionParticipants (Number)
Week 4Week 8Week 16Week 24Week 32Week 40Week 48
Afatinib81112119122125126127
Gefitinib74107117118118118119

[back to top] [back to top]

Time To Progressive Disease (TTPD)

TTPD is defined as time from the date of randomization to the first date of disease progression. For each participant who is not known to have had a progression of disease as of the data-inclusion cut-off date for a particular analysis, or who has died without progression of disease, TTPD will be censored for that analysis at the date of the participant's last tumor assessment prior to that cut-off date. TTPD was analyzed twice: (1) excluding clinical progressions of disease (that is,those not defined according to the RECIST version 1.1 criteria ), and (2) including clinical progressions. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. Also, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions is also considered progression. (NCT01469000)
Timeframe: Randomization to Progressive Disease (Up To 58.78 Months)

Interventionmonths (Median)
250 mg Gefitinib/500 mg Pemetrexed16.23
250 mg Gefitinib10.94

[back to top]

Progression Free Survival (PFS)

PFS is defined as the time from randomization to the first date of objectively determined progressive disease or death from any cause,whichever is earlier.The censoring is taken in the following order: If a participant didn't have a complete baseline disease assessment,then the PFS time was censored at the enrollment date, regardless of whether or not objectively determined disease progression or death has been observed for the participant;otherwise,if a participant is not known to have died or have objective progression as of the data inclusion cutoff date for the analysis,the PFS time will be censored at the last complete objective progression-free disease assessment date.Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions,taking as reference the smallest sum on study. Also,the sum must also demonstrate an absolute increase of at least 5 millimeter (mm).The appearance of one or more new lesions is also considered progression. (NCT01469000)
Timeframe: Randomization to Progressive Disease or Death Due to Any Cause (Up to 58.78 Months)

InterventionMonths (Median)
250 mg Gefitinib/500 mg Pemetrexed16.23
250 mg Gefitinib11.07

[back to top]

Percentage of Participants With CR, PR, and Stable Disease (SD) (Disease Control Rate [DCR])

Disease control rate is the percentage of participants with a confirmed CR, PR or SD as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST version 1.1) criteria. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Tumor marker results must have normalized. PR is defined at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. (NCT01469000)
Timeframe: Randomization to Progressive Disease (Up To 57.36 Months)

Interventionpercentage of participants (Number)
250 mg Gefitinib/500 mg Pemetrexed92.9
250 mg Gefitinib93.8

[back to top]

Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])

ORR is the best response of complete response (CR) or partial response (PR) as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Tumor marker results must have normalized. Partial Response (PR) is defined at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. (NCT01469000)
Timeframe: Randomization to Progressive Disease (Up to 57.36 Months)

Interventionpercentage of participants (Number)
250 mg Gefitinib/500 mg Pemetrexed80.2
250 mg Gefitinib73.8

[back to top]

Time to Worsening of Symptom (TWS) as Per Lung Cancer Symptom Scale (LCSS)

TWS was the elapsed time from the date of randomization to the first date of worsening in any one of the 6 LCSS symptoms. The LCSS (patient and observer) were administered at baseline and at the end of each 21-day cycle, until disease progression, and at short-term follow-up. Content for the patient version -collected using a visual analog scale (VAS) anchored at 0 and 100, respectively representing the best and worst outcome- included 6 disease-specific measures: (appetite, fatigue, cough, dyspnea, hemoptysis and pain) and 3 summary consequences of lung cancer (overall symptom burden, diminished normal activities, and lowered quality-of-life).The observer version included only the 6 disease-specific measures and the responses were collected using a 5-point ordinal scale that was reverse coded with 0 and 100 respectively representing the worst and best outcome.TWS was censored at the date of the last LCSS assessment for participants who were not known to have LCSS worsening. (NCT01469000)
Timeframe: Baseline to Progressive Disease (Up To 50 Months )

,
Interventionmonths (Median)
a. Loss of Appetite (Patient-rated)b. Fatigue (Patient-rated)c. Cough (Patient-rated)d. Dyspnea (Patient-rated)e. Hemoptysis (Patient-rated)f. Pain (Patient-rated)g. Overall Symptoms (Patient-rated)h. Interference (Patient-rated)i. Quality of Life (Patient-rated)j. Loss of Appetite (Observer-rated)k. Fatigue (Observer-rated)l. Cough (Observer-rated)m. Dyspnea (Observer-rated)n. Hemoptysis (Observer-rated)o. Pain (Observer-rated)
250 mg Gefitinib7.667.66NA24.87NANA30.4624.7110.6134.1012.98NANANA10.51
250 mg Gefitinib/500 mg Pemetrexed5.398.5118.7618.76NA34.8310.125.7213.408.617.5241.92NANA34.83

[back to top]

Duration of Response (DoR)

DoR was defined as the time from the date of the first CR or PR to the first date of Progressive Disease (PD) ( RECIST 1.1 Criteria) or death from any cause.CR is the disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to <10 mm.Tumor marker results must have normalized. PR is defined as at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. Also,the sum must also demonstrate an absolute increase of at least 5 mm.The appearance of one or more new lesions is also considered progression. Participants not known to have died or to have had progression of disease as of the data-inclusion cut-off date for a particular analysis,duration of tumor response was censored at the date of the participants last tumor assessment prior to that cut-off date. (NCT01469000)
Timeframe: First Observation of CR or PR to Progressive Disease or Death Due to Any Cause (Up To 57.36 Months)

InterventionMonths (Median)
250 mg Gefitinib/500 mg Pemetrexed15.44
250 mg Gefitinib11.30

[back to top]

Overall Survival (OS)

OS is defined as the time from randomization to the date of death from any cause. Survival time is censored at the date of last contact for participants who are still alive or lost to follow up. (NCT01469000)
Timeframe: Randomization to Date of Death Due to Any Cause (Up To 67.12 Months)

InterventionMonths (Median)
250 mg Gefitinib/500 mg Pemetrexed43.43
250 mg Gefitinib36.76

[back to top] [back to top]

Objective Response Rate

"Objective Response Rate is the sum of Complete response (CR) and Partial Response (PR) response.~Evaluated by recist criteria v 1.1., for target lesions and assesed by CT or MRI: Complete Response (CR), Disapperance of all target lesions; Partial Response (PR),>=30% decrease in the sum of longest diamteter of target lesions; Objective response rate (RR)=CR+PR" (NCT01530334)
Timeframe: every 6 weeks after the Start of Study Treatment until objective disease progression or time of data cut off (6 months after the last patient has started study treatment)

InterventionPatients (Number)
Gefitinib3

[back to top]

Treatment Duration With Gefitinib

Treatment duration was calculated from the date of the first to the date of the last intake. (NCT01530334)
Timeframe: every 6 weeks after the Start of Study Treatment until discontinuation of drug or time of data cut off (6 months after the last patient has started study treatment)

Interventiondays (Median)
Gefitinib108

[back to top]

Overall Survival (OS)

OS was calculated as the time from the first dose until the day of death from any cause. Any patient not known to have died at the time of data analysis was censored at the time of the last follow-up date. (NCT01530334)
Timeframe: every 6 weeks after the Start of Study Treatment until death or time of data cut off (6 months after the last patient has started study treatment)

Interventiondays (Median)
Gefitinib311

[back to top]

Progression Free Survival

Progression free Survival was calculated as the time from the first dose of gefitinib study treatment until the date of (i) progression or (ii) death from any cause in the absence of progression. (NCT01530334)
Timeframe: every 6 weeks after the Start of Study Treatment until objective disease progression or time of data cut off (6 months after the last patient has started study treatment)

InterventionDays (Median)
Gefitinib84

[back to top]

Clinical Benefit Rate

"Clinical benefit rate is the sum of patients with a best visit response of Complete Response, Partial Response or Stable Desease Objective Response Rate is the sum of Complete response (CR) and Partial Response (PR) response.~Evaluated by recist criteria v 1.1., for target lesions and assesed by CT or MRI: Complete Response (CR), Disapperance of all target lesions; Partial Response (PR),>=30% decrease in the sum of longest diamteter of target lesions, Stable Desease (SD) defined as no progression for>= 6 weeks. Objective response rate (RR)=CR+PR" (NCT01530334)
Timeframe: every 6 weeks after the Start of Study Treatment until objective disease progression or time of data cut off (6 months after the last patient has started study treatment)

InterventionPatients (Number)
Gefitinib32

[back to top]

Progression-Free Survival (Site Read, Investigator Assessment)

PFS is the time from randomisation until the date of objective disease progression as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) or death (by any cause in the absence of progression). Progression is defined using RECIST (v1.1), as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (NCT01544179)
Timeframe: Radiologic evaluations were carried out every 6 weeks from randomization until documented progression, withdrawal of consent, loss to follow up, death or the primary data cut off (DCO) for the analysis, assessed up to 50 weeks

InterventionPatients with a progression event (Number)
Gefitinib98
Placebo107

[back to top]

Disease Control Rate (DCR)

DCR is the percentage of patients who achieve disease control at 6 weeks following randomisation. DCR is defined as a Best Objective Response (BOR) of Complete Response, Partial Response or Stable Disease, as defined by Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions and assessed by CT or MRI. CR, Disappearance of all target lesions; PR, ≥30% decrease in the sum of the longest diameter of target lesions; SD, neither sufficient shrinkage to qualify for PR not sufficient increase to qualify for Progressive Disease (PD); PD, ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, and the sum must have shown an absolute increase of ≥5mm (NCT01544179)
Timeframe: Radiologic evaluations were carried out every 6 weeks from randomization until documented progression, withdrawal of consent, loss to follow up, death or the primary data cut off (DCO) for the analysis.

InterventionPercentage of Participants (Number)
Gefitinib84.2
Placebo78.8

[back to top]

Improvement in FACT-L Total Score

An improvement is defined as a change from baseline of ≥ +6 (0-136 score range). Measured by the Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) questionnaire (NCT01544179)
Timeframe: At visits 2-8, then every 6 weeks until progression, at progression or treatment discontinuation, and every 8 weeks after progression until PFS analysis data cut off.

InterventionNumber of patients improving (Number)
Gefitinib44
Placebo49

[back to top]

Improvement in Lung Cancer Subscale

An improvement is defined as a change from baseline of ≥ +2 (0-28 score range). Measured by the Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) questionnaire (NCT01544179)
Timeframe: At visits 2-8, then every 6 weeks until progression, at progression or treatment discontinuation, and every 8 weeks after progression until PFS analysis data cut off.

InterventionNumber of participants improving (Number)
Gefitinib54
Placebo55

[back to top]

Improvement in Trial Outcome Index

An improvement is defined as a change from baseline of ≥ +6 (0-84 score range). Measured by the Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) questionnaire. (NCT01544179)
Timeframe: At visits 2-8, then every 6 weeks until progression, at progression or treatment discontinuation, and every 8 weeks after progression until PFS analysis data cut off.

InterventionNumber of participants improving (Number)
Gefitinib36
Placebo39

[back to top]

Median Overall Survival (OS) at Time of PFS Analysis

(NCT01544179)
Timeframe: Baseline and then every 6 weeks after randomization until objective disease progression. OS is then assessed 8 weekly following PFS progression up to PFS analysis data cut off.

InterventionMonths (Median)
Gefitinib14.8
Placebo17.2

[back to top]

Median Progression-Free Survival (Site Read, Investigator Assessment)

PFS is the time from randomisation until the date of objective disease progression as defined by Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) or death (by any cause in the absence of progression). Progression is defined using RECIST (v1.1), as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (NCT01544179)
Timeframe: Radiologic evaluations were carried out every 6 weeks from randomization until documented progression, withdrawal of consent, loss to follow up, death or the primary data cut off (DCO) for the analysis, assessed up to 50 weeks

InterventionMonths (Median)
Gefitinib5.4
Placebo5.4

[back to top]

Objective Response Rate (ORR) (Site Read Data)

ORR rate is defined as the number (%) of subjects with at least one visit response of Complete Response (CR) or Partial Response (PR) , as defined by Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions and assessed by CT or MRI. CR, Disappearance of all target lesions; PR, ≥30% decrease in the sum of the longest diameter of target lesions. Data obtained up until progression, or last evaluable assessment in the absence of progression, was included in the assessment of ORR. (NCT01544179)
Timeframe: Radiologic evaluations were carried out every 6 weeks from randomization until documented progression, withdrawal of consent, loss to follow up, death or the primary data cut off (DCO) for the analysis.

InterventionPercentage of Participants (Number)
Gefitinib31.6
Placebo34.1

[back to top]

Time to Worsening in FACT-L Total Score

A worsening is defined as a change from baseline of ≤ -6 (0-136 score range). Measured by the Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) questionnaire (NCT01544179)
Timeframe: At visits 2-8, then every 6 weeks until progression, at progression or treatment discontinuation, and every 8 weeks after progression until PFS analysis data cut off.

InterventionWeeks (Median)
Gefitinib12.0
Placebo8.9

[back to top]

Time to Worsening in Lung Cancer Subscale

A worsening is defined as a change from baseline of ≤ -2 (0-28 score range). Measured by the Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) questionnaire (NCT01544179)
Timeframe: At visits 2-8, then every 6 weeks until progression, at progression or treatment discontinuation, and every 8 weeks after progression until PFS analysis data cut off.

InterventionWeeks (Median)
Gefitinib14.6
Placebo9.1

[back to top]

Time to Worsening in Trial Outcome Index

A worsening is defined as a change from baseline of ≤ -6 (0-84 score range). Measured by the Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) questionnaire (NCT01544179)
Timeframe: At visits 2-8, then every 6 weeks until progression, at progression or treatment discontinuation, and every 8 weeks after progression until PFS analysis data cut off.

InterventionWeeks (Median)
Gefitinib12.1
Placebo9.4

[back to top]

Overall Survival (OS)

OS is the time from the date of randomisation until death due to any cause. Any subject not known to have died at the time of analysis will be censored based on the last recorded date on which the subject was known to be alive. (NCT01544179)
Timeframe: Following progression survival data was collected every 8 weeks until documentation of death, withdrawal of consent, loss to follow-up or the final data cut-off, whichever occurs first.

InterventionNumber of patients with an OS event (Number)
Gefitinib50
Placebo37

[back to top]

Phase I: PK Parameters Tmax of INC280 and Gefitinib

"PK parameters were estimated from each individual plasma concentration-time profile using non-compartmental analysis.~Tmax is the time to reach maximum plasma concentration of INC280 and gefitinib" (NCT01610336)
Timeframe: Cycle 1 day 15 (pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose) (Cycle=28 days)

,,,,,,,,
InterventionHours (Median)
INC280Gefitinib
INC280 100 mg Cap QD Phase Ib1.963.92
INC280 200 mg Cap BID Phase Ib1.505.00
INC280 200 mg Cap QD Phase Ib2.006.00
INC280 200 mg Tab BID Phase Ib2.006.00
INC280 400 mg Cap BID Phase Ib2.006.00
INC280 400 mg Cap QD Phase Ib2.006.02
INC280 400 mg Tab BID Phase Ib1.086.00
INC280 600 mg Cap BID Phase Ib5.0011.3
INC280 800 mg Cap QD Phase Ib2.055.94

[back to top]

Phase I: PK Parameters Apparent Systemic Plasma Clearance Rate of INC280 and Gefitinib

"PK parameters were estimated from each individual plasma concentration-time profile using non-compartmental analysis.~Apparent systemic plasma clearance rate of INC280 and gefitinib" (NCT01610336)
Timeframe: Cycle 1 day 15 (pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose) (Cycle=28 days)

InterventionL/hr (Mean)
INC 280
INC280 600 mg Cap BID Phase Ib18.4

[back to top]

Phase II: Progression Free Survival (PFS)

Progression-free survivalis the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. (NCT01610336)
Timeframe: Up to 60.8 months

InterventionMonths (Median)
INC280 400 mg Cap BID Phase II5.1
INC280 400 mg Tab BID Phase II5.5

[back to top]

Phase II: Overall Survival (OS)

Overall survival is defined as the time from the start of treatment date to the date of death, due to any cause (NCT01610336)
Timeframe: From date of treatment until death due to any cause, up to 70.2 months

InterventionMonths (Median)
INC280 400 mg Cap BID Phase II12.3
INC280 400 mg Tab BID Phase II15.2

[back to top]

Phase II: Duration of Response (DoR)

Duration of overall response (DOR) is defined as the time between the date of first documented response (CR or PR) and the date of first documented disease progression or death due to underlying cancer. (NCT01610336)
Timeframe: Up to 23.2 months

InterventionMonths (Median)
INC280 400 mg Cap BID Phase II5.6
INC280 400 mg Tab BID Phase II5.6

[back to top]

Phase II : Overall Response Rate (ORR)

"Overall response rate is defined as the proportion of patients with best overall response (BOR) of complete response (CR) or partial response (PR), as per RECIST 1.1 (Overall Response (OR) = CR + PR).~Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters." (NCT01610336)
Timeframe: Until disease progression, up to 60.8 weeks

InterventionParticipants (Count of Participants)
INC280 400 mg Cap BID Phase II12
INC280 400 mg Tab BID Phase II17

[back to top]

Phase Ib and II: Number of Participants With Serious Adverse Events (SAEs)

Serious adverse events were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (NCT01610336)
Timeframe: Up to 421 weeks

InterventionParticipants (Count of Participants)
INC280 100 mg Cap QD Phase Ib1
INC280 200 mg Cap QD Phase Ib2
INC280 400 mg Cap QD Phase Ib2
INC280 800 mg Cap QD Phase Ib3
INC280 200 mg Cap BID Phase Ib0
INC280 400 mg Cap BID Phase Ib4
INC280 600 mg Cap BID Phase Ib3
INC280 200 mg Tab BID Phase Ib5
INC280 400 mg Tab BID Phase Ib3
INC280 400 mg Cap BID Phase II12
INC280 400 mg Tab BID Phase II19

[back to top]

Phase I: Percentage of Change From Baseline in C-MET H Score at Cycle 1 Day 15

Inhibition of c-MET signaling by pre- and post- treatment immunohistochemistry of p-c-MET (NCT01610336)
Timeframe: Baseline, Day 15 of cycle 1 (Cycle=28days)

InterventionPercentage (Median)
INC280 100 mg Cap QD Phase Ib-100
INC280 400 mg Cap BID Phase Ib-100
INC280 400 mg Cap BID Phase II-31

[back to top]

Phase Ib: Frequency of Dose Limiting Toxicities (DLTs)

A dose-limiting toxicity (DLT) was defined as an adverse event or abnormal laboratory value assessed as unrelated to disease progression, inter-current illness, or concomitant medications that met certain criteria as defined in the protocol. (NCT01610336)
Timeframe: Up to 215 weeks

,,,,,,,,
InterventionParticipants (Count of Participants)
CoughDizzinessDyspnoea
INC280 100 mg Cap QD Phase Ib000
INC280 200 mg Cap BID Phase Ib000
INC280 200 mg Cap QD Phase Ib000
INC280 200 mg Tab BID Phase Ib000
INC280 400 mg Cap BID Phase Ib000
INC280 400 mg Cap QD Phase Ib000
INC280 400 mg Tab BID Phase Ib000
INC280 600 mg Cap BID Phase Ib101
INC280 800 mg Cap QD Phase Ib010

[back to top]

Phase Ib and II: Number of Participants With Adverse Events (AEs)

Adverse events were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (NCT01610336)
Timeframe: Up to 421 weeks

,,,,,,,,,,
InterventionParticipants (Count of Participants)
AEsGrade 3/4 AEs
INC280 100 mg Cap QD Phase Ib53
INC280 200 mg Cap BID Phase Ib42
INC280 200 mg Cap QD Phase Ib74
INC280 200 mg Tab BID Phase Ib76
INC280 400 mg Cap BID Phase Ib126
INC280 400 mg Cap BID Phase II5124
INC280 400 mg Cap QD Phase Ib62
INC280 400 mg Tab BID Phase Ib84
INC280 400 mg Tab BID Phase II4735
INC280 600 mg Cap BID Phase Ib54
INC280 800 mg Cap QD Phase Ib74

[back to top]

Phase I: PK Parameters AUCtau of INC280 and Gefitinib

"PK parameters were estimated from each individual plasma concentration-time profile using non-compartmental analysis.~Area under the plasma concentration-time curve (AUC) from time zero to the end of dosing interval at steady state (tau), where tau=24 hours for once daily dosing and tau=12 hours for twice daily dosing" (NCT01610336)
Timeframe: Cycle 1 day 15 (pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose) (Cycle=28 days)

,,,,,,,
Interventionhr∙ng/mL (Mean)
INC280Gefitinib
INC280 200 mg Cap BID Phase Ib96608440
INC280 200 mg Cap QD Phase Ib91408070
INC280 200 mg Tab BID Phase Ib139007160
INC280 400 mg Cap BID Phase Ib214008500
INC280 400 mg Cap QD Phase Ib292007140
INC280 400 mg Tab BID Phase Ib287007820
INC280 100 mg Cap QD Phase Ib45107690
INC280 800 mg Cap QD Phase Ib3030012800

[back to top]

Phase I: PK Parameters Half-life of INC280 and Gefitinib

"PK parameters were estimated from each individual plasma concentration-time profile using non-compartmental analysis.~The elimination half-life of INC280 and gefitinib associated with the terminal slope (Lamda_z) of a semi-logarithmic plasma concentration-time curve" (NCT01610336)
Timeframe: Cycle 1 day 15 (pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose)(Cycle=28 days)

,,,,,,,
Interventionhours (Mean)
INC280Gefitinib
INC280 100 mg Cap QD Phase Ib3.8618.8
INC280 200 mg Cap BID Phase Ib3.1916.3
INC280 200 mg Cap QD Phase Ib5.1026.9
INC280 200 mg Tab BID Phase Ib3.7517.8
INC280 400 mg Cap BID Phase Ib3.0118.7
INC280 400 mg Cap QD Phase Ib3.1636.3
INC280 400 mg Tab BID Phase Ib3.1723.9
INC280 800 mg Cap QD Phase Ib3.6737.8

[back to top]

Phase I: PK Parameters Cmax of INC280 and Gefitinib

"PK parameters were estimated from each individual plasma concentration-time profile using non-compartmental analysis.~Cmax is the maximum observed plasma concentration of INC280 and gefitinib" (NCT01610336)
Timeframe: Cycle 1 day 15 (pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose) (Cycle=28 days)

,,,,,,,,
Interventionng/mL (Mean)
INC280Gefitinib
INC280 100 mg Cap QD Phase Ib826417
INC280 200 mg Cap BID Phase Ib1950480
INC280 200 mg Cap QD Phase Ib1490378
INC280 200 mg Tab BID Phase Ib2550479
INC280 400 mg Cap BID Phase Ib4220464
INC280 400 mg Cap QD Phase Ib4620405
INC280 400 mg Tab BID Phase Ib6760355
INC280 600 mg Cap BID Phase Ib4840255
INC280 800 mg Cap QD Phase Ib6570357

[back to top]

Phase I: PK Parameters AUCtau of INC280 and Gefitinib

"PK parameters were estimated from each individual plasma concentration-time profile using non-compartmental analysis.~Area under the plasma concentration-time curve (AUC) from time zero to the end of dosing interval at steady state (tau), where tau=24 hours for once daily dosing and tau=12 hours for twice daily dosing" (NCT01610336)
Timeframe: Cycle 1 day 15 (pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose) (Cycle=28 days)

Interventionhr∙ng/mL (Mean)
INC280
INC280 600 mg Cap BID Phase Ib37300

[back to top]

Phase I: PK Parameters Apparent Systemic Plasma Clearance Rate of INC280 and Gefitinib

"PK parameters were estimated from each individual plasma concentration-time profile using non-compartmental analysis.~Apparent systemic plasma clearance rate of INC280 and gefitinib" (NCT01610336)
Timeframe: Cycle 1 day 15 (pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose) (Cycle=28 days)

,,,,,,,
InterventionL/hr (Mean)
INC 280Gefitinib
INC280 100 mg Cap QD Phase Ib26.933.3
INC280 200 mg Cap BID Phase Ib27.030.8
INC280 200 mg Cap QD Phase Ib29.432.9
INC280 200 mg Tab BID Phase Ib15.436.9
INC280 400 mg Cap BID Phase Ib24.241.0
INC280 400 mg Cap QD Phase Ib16.336.5
INC280 400 mg Tab BID Phase Ib14.432.5
INC280 800 mg Cap QD Phase Ib47.719.5

[back to top]

Objective Response Rate (ORR) Based on Investigator Assessment

Percentage of participants with a BOR of either CR or PR based on investigator assessment recorded from the start of treatment until disease progression based on RECIST v1.1. CR: disappearance of all target lesions (TLs), non TLs; any pathological lymph nodes (LN) must reduce in short axis to <10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (<10 mm short axis); PR:>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. PD:>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of >=5 mm, appearance of >=1 new lesions; unequivocal progression of existing non TLs. (NCT01774721)
Timeframe: Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression (up to 48 months)

Interventionpercentage of participants (Number)
Dacomitinib75.3
Gefitinib70.2

[back to top]

Objective Response Rate (ORR) Based on IRC Review

Percentage of participants with a BOR of either CR or PR based on IRC review recorded from the start of treatment until disease progression based on RECIST v1.1. CR: disappearance of all target lesions (TLs), non TLs; any pathological lymph nodes (LN) must reduce in short axis to <10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (<10 mm short axis); PR:>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. PD:>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of >=5 mm, appearance of >=1 new lesions; unequivocal progression of existing non TLs. (NCT01774721)
Timeframe: Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression (up to 48 months)

Interventionpercentage of participants (Number)
Dacomitinib74.9
Gefitinib71.6

[back to top]

OS at 30 Months (OS30m)

OS30m was defined as the probability of a participant being alive at 30 months from date of randomization. (NCT01774721)
Timeframe: Up to 30 months from date of randomization

Interventionprobability of survival (Number)
Dacomitinib56.4
Gefitinib45.7

[back to top]

Overall Mean Scores of Euro Quality of Life-5 Dimension Visual Analog Scale (EQ-5D VAS)

The Euro Quality of Life-5 dimension (EQ-5D) is a brief self-administered, validated reliable generic health status instrument. EQ-5D general health status can also be measured by a visual analog scale (EQ-5D VAS). EQ-5D VAS measures the participant's self-rated health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state). (NCT01774721)
Timeframe: From Cycle 1 Day 1 up to 48 months

Interventionunits on a scale (Mean)
Dacomitinib73.3869
Gefitinib77.6923

[back to top]

Overall Survival (OS)

OS was defined as the time from randomization to the date of death for any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. OS (month)=[death date or last known alive date - randomization date + 1]/30.4375. (NCT01774721)
Timeframe: From randomization until death or last date known as alive, up to 45 months

Interventionmonths (Median)
Dacomitinib34.1
Gefitinib27.0

[back to top]

Number of Participants With Clinically Significant Abnormalities in Vital Signs

Criteria for vital signs abnormalities: postbaseline pulse rate less than (<) 50 beats per minute (bpm) or greater than (>)130 bpm and maximum increase from baseline in pulse rate >=30 bpm and maximum decrease from baseline in pulse rate <=30 bpm. Systolic blood pressure (BP) of maximum increase from baseline (MIB) >=40 millimeters of mercury (mmHg), maximum decrease from baseline (MDB) in systolic blood pressure =<60 mmHg. Diastolic blood pressure of MIB >=20 mmHg and MDB in diastolic blood pressure >-40 and =<-20 mm Hg. And MDB in diastolic BP<=-40 mmHg. Only categories with at least 1 participant with abnormality are reported in this outcome measure. (NCT01774721)
Timeframe: From randomization until death or last date known as alive, up to 61 months

,
InterventionParticipants (Count of Participants)
MIB in systolic BP >=40 mmHgMDB in systolic BP <=-60 mmHgMIB in diastolic BP >=20 mmHgMDB in diastolic BP >-40 and <=-20mmHgMDB in diastolic BP <=-40 mmHgMaximum post baseline pulse rate >130 bpmMinimum post baseline pulse rate <50 bpmMIB in pulse rate >=30 bpmMDB in pulse rate <=-30 bpmMIB in body weight >=10%MDB in body weight <=-10%
Dacomitinib160425102316172846
Gefitinib221445312012154232

[back to top]

Number of Participants With Laboratory Test Abnormalities: Urinalysis

Urinalysis parameter included urine protein, urine blood/haemoglobin, urine glucose and urine sediment. Test abnormalities was defined as deviation from normal range (higher or lower). Normal range of 24-hour urine protein test: less than 150 mg of protein per day, urine glucose: 0 to 0.8 mmol/L (millimole per liter), urine protein: 0 to 20 mg/dL (milligrams per deciliter). Urine blood/haemoglobin abnormality was defined as presence and absence of blood/haemoglobin in urine of participants. Urine sediment abnormality was defined as the presence of any bacteria, casts, crystals, and epithelial cells. Only categories with at least 1 participant with abnormality are reported in this outcome measure. (NCT01774721)
Timeframe: From randomization until death or last date known as alive, up to 61 months

,
InterventionParticipants (Count of Participants)
High Urine ProteinLow Urine GlucoseHigh Urine Blood/Haemoglobin
Dacomitinib114
Gefitinib104

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.AEs included both serious and non- serious adverse events. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events between first dose of study drug and up to 28-35 days after last dose that were absent before treatment or that worsened relative to pretreatment state. (NCT01774721)
Timeframe: From randomization until death or last date known as alive, up to 91 months

,,
InterventionParticipants (Count of Participants)
TEAEsSAEs
Dacomitinib22669
Dacomitinib (Ongoing at DCO)114
Gefitinib22053

[back to top]

Pre-dose Plasma Concentrations (Ctrough) of Dacomitinib and Its Metabolite PF-05199265

Trough plasma concentration was defined as the measured concentration at the end of a dosing interval at steady state (taken directly before next administration). (NCT01774721)
Timeframe: Pre-dose on Day 1 of Cycle 2, 3, 4, 5 and 6

Interventionng/mL (Mean)
Cycle 2 Day 1: DacomitinibCycle 3 Day 1: DacomitinibCycle 4 Day 1: DacomitinibCycle 5 Day 1: DacomitinibCycle 6 Day 1: DacomitinibCycle 2 Day 1: PF-05199265Cycle 3 Day 1: PF-05199265Cycle 4 Day 1: PF-05199265Cycle 5 Day 1: PF-05199265Cycle 6 Day 1: PF-05199265
Dacomitinib70.2468.3468.1664.5061.6813.2014.4213.7012.4813.05

[back to top]

Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI CTCAE Version 4.03: Biochemistry and Haematology

Parameters included anaemia, activated partial thromboplastin time, haemoglobin, international normalized ratio, lymphocyte count, lymphopenia, neutrophils (absolute), platelets, prothrombin time and white blood cells. Biochemistry parameters included alanine aminotransferase (increased), alkaline phosphatase (increased), aspartate aminotransferase (increased), bilirubin (total), creatinine (increased), hypercalcaemia, hyperglycaemia, hyperkalaemia, hypermagnesaemia, hypernatraemia, hypoalbuminaemia, hypocalcaemia, hypoglycaemia, hypokalaemia, hypomagnesaemia, hyponatraemia. Test abnormalities were graded by AEs according to the Common Terminology Criteria for Adverse Events(NCI CTCAE) version 4.03 as Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening; Grade 5=death related to AE. Only categories with at least 1 participant with abnormality are reported in this outcome measure. (NCT01774721)
Timeframe: From randomization until death or last date known as alive, up to 61 months

,
InterventionParticipants (Count of Participants)
Anaemia (Grade 3)Haemoglobin increased(Grade 3)Lymphopenia (Grade 3)Neutrophil count (absolute) (Grade 3)WBC count (Grade 3)Alanine aminotransferase increased (Grade 3)Alanine aminotransferase increased (Grade 4)Aspartate aminotransferase increased (Grade 3)Aspartate aminotransferase increased (Grade 4)Alkaline phosphatase increased (Grade 3)Bilirubin increased (total) (Grade 3)Creatinine increased (Grade 3)Hypercalcemia (Grade 3)Hyperglycemia (Grade 3)Hyperkalemia (Grade 3)Hyperkalemia (Grade 4)Hypermagnesemia (Grade 3)Hypocalcemia (Grade 3)Hypoglycemia (Grade 3)Hypoglycemia (Grade 4)Hypokalemia (Grade 3)Hypokalemia (Grade 4)Hypomagnesemia (Grade 3)Hyponatremia (Grade 3)Hyponatremia (Grade 4)
Dacomitinib501301502021112009301132251
Gefitinib616212631535110512742050041

[back to top]

Apparent Clearance (CL) of Dacomitinib

Drug clearance was a quantitative measure of the rate at which a drug substance was removed from the blood (rate at which a drug is metabolized or eliminated by normal biological processes). (NCT01774721)
Timeframe: Pre-dose and 2, 4, 6, 8, and 24 hours post-dose on Cycle 2 Day 1 (Day 29)

InterventionLiter/hour (Mean)
Dacomitinib27.61

[back to top]

Time to Reach Maximum Observed Plasma Concentration (Tmax) of Dacomitinib and Its Metabolite PF-05199265

Tmax was defined as time to first occurrence of Cmax and can be observed directly from data as time of first occurrence. (NCT01774721)
Timeframe: Pre-dose and 2, 4, 6, 8, and 24 hours post-dose (sample collection time points had window of +/- 10% of nominal time) on Cycle 2 Day 1 (Day 29)

Interventionhour (Median)
DacomitinibPF-05199265
Dacomitinib4.036.0

[back to top]

Number of Participants With Best Overall Response (BOR) Based on IRC Review

BOR for CR/PR:>=1 objective status (OBS) of CR/PR documented before PD; SD:>=1 OBS of stable documented >=8 weeks (wks) post treatment & before PD, not qualifying as CR/PR; PD:OBS of PD within 12 wks treatment, not qualifying as CR/PR/SD; indeterminate:PD not documented within 12 wks post treatment & no other response category applies. RECIST v1.1, CR:disappearance of all target lesions (TLs), non TLs;any pathological lymph nodes (LN) must reduce in short axis to <10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (<10 mm short axis); PR:>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. SD:neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referring smallest sum diameters on study. PD:>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of >=5 mm, appearance of >=1 new lesions;unequivocal progression of existing non TLs. (NCT01774721)
Timeframe: Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression (up to 48 months)

,
InterventionParticipants (Count of Participants)
Complete responsePartial responseStable diseaseProgressive diseaseIndeterminate
Dacomitinib12158301215
Gefitinib4157271522

[back to top]

Number of Participants With Best Overall Response (BOR) Based on Investigator Assessment

BOR for CR/PR:>=1 objective status (OBS) of CR/PR documented before PD; SD:>=1 OBS of stable documented >=8 weeks (wks) post treatment & before PD, not qualifying as CR/PR; PD:OBS of PD within 12 wks treatment, not qualifying as CR/PR/SD; indeterminate:PD not documented within 12 wks post treatment & no other response category applies. RECIST v1.1, CR:disappearance of all target lesions (TLs), non TLs;any pathological lymph nodes (LN) must reduce in short axis to <10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (<10 mm short axis); PR:>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. SD:neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referring smallest sum diameters on study. PD:>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of >=5 mm, appearance of >=1 new lesions;unequivocal progression of existing non TLs. (NCT01774721)
Timeframe: Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression (up to 48 months)

,
InterventionParticipants (Count of Participants)
Complete responsePartial responseStable diseaseProgressive diseaseIndeterminate
Dacomitinib21693899
Gefitinib115749117

[back to top] [back to top]

Number of Participants With Maximum Relative Decrease From Baseline >20% in Left Ventricular Ejection Fraction (LVEF)

An ejection fraction (EF) was the volumetric fraction of blood ejected from a ventricle of the heart with each heartbeat; it was a measure of the pumping efficiency of the heart. The EF of the left heart, known as the left ventricular ejection fraction, was a measure of the efficiency of pumping into the body's systemic circulation. (NCT01774721)
Timeframe: From baseline up to 7 days of Cycle 4 (up to 91 days)

InterventionParticipants (Count of Participants)
Dacomitinib5
Gefitinib5

[back to top]

Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review

PFS: time from randomization to date of progression of disease (PD) as determined by IRC review as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria or death due to any cause, whichever occurred first. PD: >=20% increase in sum of diameters of target lesions (TLs), referring smallest sum on study, sum must be an absolute increase of >=5 mm, appearance of >=1 new lesions; unequivocal progression of existing non TLs. Overall tumor burden increased sufficiently to merit discontinuation of therapy. In presence of stable disease (did not achieve partial response, complete response or PD) or partial response (>=30% decrease under baseline of sum of diameters of all target measurable lesions, short diameter used in the sum for target nodes, longest diameter used in sum for all other target lesions) in target disease; for new lesions: appearance of any new unequivocal malignant lesion indicated PD. (NCT01774721)
Timeframe: Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)

Interventionmonths (Median)
Dacomitinib14.7
Gefitinib9.2

[back to top]

Progression Free Survival (PFS) Based on Investigator Assessment

PFS: time from randomization to date of PD as determined by investigator assessment as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria or death due to any cause, whichever occurred first. PD for target lesions: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, with minimum absolute increase of 5 mm; for non-target lesions: unequivocal progression of pre-existing lesions. Overall tumor burden increased sufficiently to merit discontinuation of therapy. In presence of stable disease (did not achieve partial response, complete response or PD) or partial response (>=30% decrease under baseline of sum of diameters of all target measurable lesions, short diameter used in the sum for target nodes, longest diameter used in sum for all other target lesions) in target disease; for new lesions: appearance of any new unequivocal malignant lesion indicated PD. (NCT01774721)
Timeframe: Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)

Interventionmonths (Median)
Dacomitinib16.6
Gefitinib11.0

[back to top]

Area Under the Plasma Concentration-Time Curve From Time Zero (0) to End of Dosing Interval (AUCtau) of Dacomitinib and Its Metabolite PF-05199265

AUCtau was defined as area under the plasma concentration-time curve over dosing interval tau and was determined by Linear/Log trapezoidal method. (NCT01774721)
Timeframe: Pre-dose and 2, 4, 6, 8, and 24 hours post-dose on Cycle 2 Day 1 (Day 29)

Interventionnanogram*hour/milliliter (ng*hr/mL) (Mean)
DacomitinibPF-05199265
Dacomitinib1712.08278.47

[back to top]

Averaged Plasma Concentration at Steady State (Cavg) of Dacomitinib and Its Metabolite PF-05199265

Cavg was defined as averaged plasma concentration at steady state, and was calculated as AUCtau/tau. (NCT01774721)
Timeframe: Pre-dose and 2, 4, 6, 8, and 24 hours post-dose on Cycle 2 Day 1 (Day 29)

Interventionng/mL (Mean)
DacomitinibPF-05199265
Dacomitinib71.3311.60

[back to top]

Duration of Response (DoR)

DoR was defined as time from first documentation of objective response(CR or PR, whichever occurred first)to date of PD/death from any cause, whichever occurred first. CR: disappearance of all target lesions (TLs), non TLs; any pathological lymph nodes (LN) must reduce in short axis to <10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (<10 mm short axis); PR:>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. PD:>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of >=5 mm, appearance of >=1 new lesions; unequivocal progression of existing non TLs. DoR was recorded based on IRC review and investigator's assessment and summarized for subgroup of participants with objective disease response. (NCT01774721)
Timeframe: Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)

,
Interventionmonths (Median)
DoR: IRC reviewDoR: Investigator assessment
Dacomitinib14.815.9
Gefitinib8.39.2

[back to top]

Minimum Observed Plasma Concentration (Cmin) of Dacomitinib and Its Metabolite PF-05199265

Cmin was defined as minimum observed plasma concentration and can be observed directly from data. (NCT01774721)
Timeframe: Pre-dose and 2, 4, 6, 8, and 24 hours post-dose on Cycle 2 Day 1 (Day 29)

Interventionng/mL (Mean)
DacomitinibPF-05199265
Dacomitinib60.6410.49

[back to top]

Maximum Observed Plasma Concentration (Cmax) of Dacomitinib and Its Metabolite PF-05199265

Cmax was defined as maximum observed plasma concentration and can be observed directly from data. (NCT01774721)
Timeframe: Pre-dose and 2, 4, 6, 8, and 24 hours post-dose on Cycle 2 Day 1 (Day 29)

Interventionnanogram per milliliter (ng/mL) (Mean)
DacomitinibPF-05199265
Dacomitinib84.1912.77

[back to top]

Fluctuation Coefficient Between Trough and Peak Plasma Concentration (DF) of Dacomitinib and Its Metabolite PF-05199265

Fluctuation coefficient between trough and peak plasma concentration was determined as Cmax-Ctrough divided by Cavg, where Cmax was the maximum observed concentration within the dosing interval, Ctrough was the observed concentration prior to dose administration and Cavg was averaged plasma concentration at steady state. (NCT01774721)
Timeframe: Pre-dose and 2, 4, 6, 8, and 24 hours post-dose on Cycle 2 Day 1 (Day 29)

InterventionFluctuation coefficient (Mean)
DacomitinibPF-05199265
Dacomitinib0.28830.1105

[back to top]

Number of Participants With Clinically Significant Abnormality in Electrocardiogram (ECG)

ECG parameters included corrected QT interval using Bazett's formula (QTcB) and corrected QT interval using Fridericia's formula (QTcF). ECG criteria for abnormality: absolute value 450 - <480 msec, 480 - <500 msec, >=500msec. The number of participants with potentially clinically significant ECG findings at any visit were reported. (NCT01774721)
Timeframe: From randomization until death or last date known as alive, up to 61 months

,
InterventionParticipants (Count of Participants)
QTcF Criteria: 450-<480QTcB Criteria: 450-<480QTcB Criteria: 480-<500
Dacomitinib5223
Gefitinib000

[back to top]

Phase 2: Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status Scale Score at End of Treatment (EOT)

EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnoea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact. The EORTC QLQ-C30 GHS/QoL score ranges from 0 to 100; High score indicates better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL. (NCT01982955)
Timeframe: Baseline and EOT (up to 110 weeks)

InterventionUnits on a Scale (Mean)
Phase 2: Tepotinib 500 mg + Gefitinib 250 mg (MET + T790 Negative)-16.29
Phase 2: Pemetrexed and Cisplatin/Carboplatin (MET + T790 Negative)-2.78
Phase 2: Single-arm Cohort (MET+ T790M Positive)-24.19

[back to top]

Phase 2: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiograms (ECG) Findings

ECG parameters included heart rhythm, pulse rate intervals, QRS, QT intervals, RR intervals and corrected QT(QTc) intervals. Clinical significance was determined by the investigator. Number of participants with clinically significant abnormalities in 12-lead ECG were reported. (NCT01982955)
Timeframe: Up to 328 weeks

InterventionParticipants (Count of Participants)
Phase 2: Tepotinib 500 mg + Gefitinib 250 mg (MET + T790 Negative)2
Phase 2: Pemetrexed and Cisplatin/Carboplatin (MET + T790 Negative)1
Phase 2: Single-arm Cohort (MET+ T790M Positive)0

[back to top]

Phase 2: Number of Participants With Clinically Significant Abnormalities in Vital Signs

Vital signs assessment included blood pressure, heart rate, respiratory rate and body temperature. Number of Participants with any clinically significant abnormalities in vital signs were reported. Clinical significance was determined by the investigator. (NCT01982955)
Timeframe: Up to 328 weeks

InterventionParticipants (Count of Participants)
Phase 2: Tepotinib 500 mg + Gefitinib 250 mg (MET + T790 Negative)0
Phase 2: Pemetrexed and Cisplatin/Carboplatin (MET + T790 Negative)0
Phase 2: Single-arm Cohort (MET+ T790M Positive)0

[back to top]

Phase 2: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 2 or Higher Than 2

ECOG PS score is widely used by doctors and researchers to assess how a participants' disease is progressing, and is used to assess how the disease affects the daily living abilities of the participant, and determine appropriate treatment and prognosis. The score ranges from Grade 0 to Grade 5, where Grade 0 = Fully active, able to carry on all pre-disease performance without restriction, Grade 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (like light house work, office work), Grade 2 = Ambulatory and capable of all self-care but unable to carry out any work activities, Grade 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours and Grade 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair, Grade 5 = Death. Number of participants with ECOG performance status score of 2 or higher than 2 were reported. (NCT01982955)
Timeframe: Up to 328 weeks

InterventionParticipants (Count of Participants)
Phase 2: Tepotinib 500 mg + Gefitinib 250 mg (MET + T790 Negative)6
Phase 2: Pemetrexed and Cisplatin/Carboplatin (MET + T790 Negative)1
Phase 2: Single-arm Cohort (MET+ T790M Positive)1

[back to top]

Phase 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Permanent Treatment Discontinuation

An adverse event (AE) was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs. Number of participants with TEAEs leading to permanent treatment discontinuation were reported. (NCT01982955)
Timeframe: Up to 328 weeks

InterventionParticipants (Count of Participants)
Phase 2: Tepotinib 500 mg + Gefitinib 250 mg (MET + T790 Negative)3
Phase 2: Pemetrexed and Cisplatin/Carboplatin (MET + T790 Negative)1
Phase 2: Single-arm Cohort (MET+ T790M Positive)2

[back to top]

Phase 2: Time-to-Symptom Progression (TTSP)

TTSP was measured from randomization to symptomatic progression by lung cancer symptom scale (LCSS) used to measure symptom changes relevant to quality of life (QoL).It consisted of 9 items focused on cancer symptoms (loss of appetite, fatigue, cough, shortness of breath, blood in sputum, pain, symptoms of cancer, illness affecting normal activity, QoL).For each symptom score distance from left boundary to point where participant has marked line was measured in millimeters (mm).Total scale length was 100 mm. Symptomatic progression was defined as increase/worsening of average symptomatic burden index (ASBI) (mean of 6 major lung cancer specific symptom scores);Worsening defined as 10% increase of scale breadth from baseline. Score 0 indicate no/minimum symptoms;100 indicates maximum level of symptoms. (NCT01982955)
Timeframe: Up to 328 weeks

InterventionMonths (Median)
Phase 2: Tepotinib 500 mg + Gefitinib 250 mg (MET + T790 Negative)5.75
Phase 2: Pemetrexed and Cisplatin/Carboplatin (MET + T790 Negative)7.95
Phase 2: Single-arm Cohort (MET+ T790M Positive)2.63

[back to top]

Phase 1b: Apparent Terminal Elimination Rate Constant Lambda(z) of Tepotinib, Its Metabolites and Gefitinib

Lambda(z) was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method. (NCT01982955)
Timeframe: Pre dose, 0.25, 0.5, 1, 2, 4, 8, 10 and 24 hours post dose on Day 1 and 15 of Cycle 1 (each Cycle is 21 days)

,
Intervention1 per hour (Geometric Mean)
Tepotinib: Day 1 of Cycle 1Tepotinib: Day 15 of Cycle 1MSC2571109A: Day 1 of Cycle 1MSC2571109A: Day 15 of Cycle 1MSC2571107A: Day 1 of Cycle 1MSC2571107A: Day 15 of Cycle 1Gefitinib: Day 1 of Cycle 1Gefitinib: Day 15 of Cycle 1
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mgNANANANANANANANA
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mgNANANANANANANANA

[back to top]

Phase 1b: Apparent Terminal Half-Life (t1/2) of Tepotinib, Its Metabolites and Gefitinib

Apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50 percent in the final stage of its elimination. (NCT01982955)
Timeframe: Pre dose, 0.25, 0.5, 1, 2, 4, 8, 10 and 24 hours post dose on Day 1 and 15 of Cycle 1 (each Cycle is 21 days)

,
InterventionHours (Median)
Tepotinib: Day 1 of Cycle 1Tepotinib: Day 15 of Cycle 1MSC2571109A: Day 1 of Cycle 1MSC2571109A: Day 15 of Cycle 1MSC2571107A: Day 1 of Cycle 1MSC2571107A: Day 15 of Cycle 1Gefitinib: Day 1 of Cycle 1Gefitinib: Day 15 of Cycle 1
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mgNANANANANANANANA
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mgNANANANANANANANA

[back to top]

Phase 1b: Apparent Total Body Clearance From Plasma (CL/F) of Tepotinib and Gefitinib

The CL/f is a measure of the rate at which it was metabolized or eliminated by normal biological processes. Clearance obtained after oral dose was influenced by the fraction of the dose absorbed. The CL/F from plasma was calculated using the formula: Dose divided by area under the concentration time curve from time zero to infinity (AUC0-inf). (NCT01982955)
Timeframe: Pre dose, 0.25, 0.5, 1, 2, 4, 8, 10 and 24 hours post dose on Day 15 of Cycle 1 (each Cycle is 21 days)

,
Interventionliter per hour (L/h) (Geometric Mean)
TepotinibGefitinib
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mg17.332.5
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mg20.335.3

[back to top]

Phase 1b: Apparent Volume of Distribution (Vz/F) During the Terminal Phase of Tepotinib, Its Metabolites and Gefitinib

The Vz/f was defined as the theoretical volume in which the total amount of required to uniformly distribute to produce the desired plasma concentration. Apparent volume of distribution after oral dose (Vz/F) was influenced by the fraction absorbed. The Vz/f was calculated by dividing the dose with area under the concentration time curve from time zero to infinity multiplied with terminal elimination rate constant Lambda(z). Vz/f=Dose/AUC(0-inf) multiply Lambda(z). (NCT01982955)
Timeframe: Pre dose, 0.25, 0.5, 1, 2, 4, 8, 10 and 24 hours post dose on Day 1 and 15 of Cycle 1 (each Cycle is 21 days)

,
InterventionLiter (Geometric Mean)
Tepotinib: Day 1 of Cycle 1Tepotinib: Day 15 of Cycle 1MSC2571109A: Day 1 of Cycle 1MSC2571109A: Day 15 of Cycle 1MSC2571107A: Day 1 of Cycle 1MSC2571107A: Day 15 of Cycle 1Gefitinib: Day 1 of Cycle 1Gefitinib: Day 15 of Cycle 1
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mgNANANANANANANANA
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mgNANANANANANANANA

[back to top]

Phase 1b: Apparent Volume of Distribution During the Steady State (Vss/F) of Tepotinib, Its Metabolites and Gefitinib

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vss/f after oral dose was influenced by the fraction absorbed. (NCT01982955)
Timeframe: Pre dose, 0.25, 0.5, 1, 2, 4, 8, 10 and 24 hours post dose on Day 1 and 15 of Cycle 1 (each Cycle is 21 days)

,
InterventionLiter (Geometric Mean)
Tepotinib: Day 1 of Cycle 1Tepotinib: Day 15 of Cycle 1MSC2571109A: Day 1 of Cycle 1MSC2571109A: Day 15 of cycle 1MSC2571107A: Day 1 of Cycle 1MSC2571107A: Day 15 of Cycle 1Gefitinib: Day 1 of Cycle 1Gefitinib: Day 15 of Cycle 1
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mgNANANANANANANANA
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mgNANANANANANANANA

[back to top]

Phase 1b: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time AUC (0-t) of Tepotinib, Its Metabolites and Gefitinib

Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration is at or above the lower limit of quantification (LLLQ). AUC(0-t) was calculated according to the mixed log-linear trapezoidal rule. (NCT01982955)
Timeframe: Pre dose, 0.25, 0.5, 1, 2, 4, 8, 10 and 24 hours post dose on Day 1 and 15 of Cycle 1 (each Cycle is 21 days)

,
Interventionnanogram*hour per milliliter (ng*h/mL) (Geometric Mean)
Tepotinib: Day 1 of Cycle 1Tepotinib: Day 15 of Cycle 1MSC2571109A: Day 1 of Cycle 1MSC2571109A Day15 of Cycle 1MSC2571107A Day 1 of Cycle 1MSC2571107A Day 15 of Cycle 1Gefitinib: Day 1 of Cycle 1Gefitinib: Day 15 of Cycle 1
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mg62801560016804420248872NA7690
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mg92102220017707530324188029307080

[back to top]

Phase 1b: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC 0-infinity) of Tepotinib, Its Metabolites and Gefitinib

The AUC(0-inf) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. (NCT01982955)
Timeframe: Pre dose, 0.25, 0.5, 1, 2, 4, 8, 10 and 24 hours post dose on Day 1 and 15 of Cycle 1 (each Cycle is 21 days)

,
Interventionng*h/mL (Geometric Mean)
Tepotinib: Day 1 of Cycle 1Tepotinib: Day 15 of Cycle 1MSC2571109A: Day 1 of Cycle 1MSC2571109A: Day 15 of Cycle 1MSC2571107A: Day 1 of Cycle 1MSC2571107A: Day 15 of Cycle 1Gefitinib: Day 1 of Cycle 1Gefitinib: Day 15 of Cycle 1
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mgNANANANANANANANA
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mgNANANANANANANANA

[back to top]

Phase 1b: Area Under the Plasma Concentration-Time Curve Within 1 Dosing Interval (AUC 0-tau) of Tepotinib, Its Metabolites and Gefitinib

AUC (0-tau) is the area under the plasma concentration time curve within 1 dosing interval. (NCT01982955)
Timeframe: Pre dose, 0.25, 0.5, 1, 2, 4, 8, 10 and 24 hours post dose on Day 1 and 15 of Cycle 1 (each Cycle is 21 days)

,
Interventionng*h/mL (Geometric Mean)
Tepotinib: Day 1 of Cycle 1Tepotinib: Day 15 of Cycle 1MSC2571109A: Day 1 of Cycle 1MSC2571109A: Day 15 of Cycle 1MSC2571107A: Day 1 of Cycle 1MSC2571107A: Day 15 of Cycle 1Gefitinib: Day 1 of Cycle 1Gefitinib: Day 15 of Cycle 1
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mg62801560016804420248872NA7690
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mg92102220017707530324188029307080

[back to top]

Phase 1b: Average Observed Plasma Concentration (Cavg) of Tepotinib, Its Metabolites and Gefitinib

Cavg is the average plasma concentration within 1 dosing interval obtained directly from the concentration versus time curve. (NCT01982955)
Timeframe: Pre dose, 0.25, 0.5, 1, 2, 4, 8, 10 and 24 hours post dose on Day 15 of Cycle 1 (each Cycle is 21 days)

,
Interventionng/mL (Geometric Mean)
TepotinibMSC2571109AMSC2571107AGefitinib
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mg65418536.4321
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mg92431478.3295

[back to top]

Phase 1b: Maximum Observed Plasma Concentration (Cmax) of Tepotinib, Its Metabolites and Gefitinib

Cmax is the maximum observed plasma concentration obtained directly from the concentration versus time curve. (NCT01982955)
Timeframe: Pre dose, 0.25, 0.5, 1, 2, 4, 8, 10 and 24 hours post dose on Day 1 and 15 of Cycle 1 (each Cycle is 21 days)

,
InterventionNanogram per Milliliter (ng/mL) (Geometric Mean)
Tepotinib: Day 1 of Cycle 1Tepotinib: Day 15 of Cycle 1MSC2571109A: Day 1 of Cycle 1MSC2571109A: Day 15 of Cycle 1MSC2571107A: Day 1 of Cycle 1MSC2571107A: Day 15 of Cycle 1Gefitinib: Day 1 of Cycle 1Gefitinib: Day 15 of Cycle 1
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mg37576313228016.844.9NA432
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mg575105014944424.394.9215366

[back to top]

Phase 1b: Minimum Observed Plasma Concentration (Cmin) of Tepotinib, Its Metabolites and Gefitinib

Cmin is minimum observed plasma concentration obtained directly from the concentration versus time curve. (NCT01982955)
Timeframe: Pre dose, 0.25, 0.5, 1, 2, 4, 8, 10 and 24 hours post dose on Day 15 of Cycle 1 (each Cycle is 21 days)

,
Interventionng/mL (Geometric Mean)
TepotinibMSC2571109AMSC2571107AGeftinib
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mg53415632.8231
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mg73527068.7190

[back to top]

Phase 1b: Number of Participants With Death and Reasons

Number of participants with death due to progressive disease (PD), adverse event (AE) related to study treatment, AE not related to study treatment were reported. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. PD defined as an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 mm. Number of participants with deaths due to PD, AE related to study treatment, AE not related to study treatment were reported. (NCT01982955)
Timeframe: Up to 175 weeks

,
InterventionParticipants (Count of Participants)
Death due to PDDeath due to AE related to study treatmentDeath due to AE not related to study treatment
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mg001
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mg300

[back to top] [back to top]

Phase 1b: Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI-CTCAE Version 4.03 Reported as Treatment-Emergent Adverse Events (TEAEs)

The laboratory measurements included hematology and coagulation, biochemistry and urinalysis. (NCT01982955)
Timeframe: Up to 175 weeks

,
InterventionParticipants (Count of Participants)
Amylase increasedLipase increasedNeutrophil count decreasedHyperglycemiaHypocalcemiaHyponatremiaHypoproteinemia
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mg2100101
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mg2212020

[back to top]

Phase 1b: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. Number of Participants with TEAEs and serious TEAEs were reported. (NCT01982955)
Timeframe: Up to 175 weeks

,
InterventionParticipants (Count of Participants)
Any TEAEsAny Serious TEAEs
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mg64
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mg127

[back to top]

Phase 1b: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Permanent Treatment Discontinuation

An adverse event (AE) was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs. Number of participants with TEAEs leading to permanent treatment discontinuation were reported. (NCT01982955)
Timeframe: Up to 175 weeks

,
InterventionParticipants (Count of Participants)
TEAE Leading Permanent Tepotinib DiscontinuationTEAE Leading Permanent Gefitinib Discontinuation
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mg00
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mg21

[back to top] [back to top]

Phase 1b: Time to Reach Maximum Plasma Concentration (Tmax) of Tepotinib, Its Metabolites and Gefitinib

Tmax is time to reach maximum observed plasma concentration obtained directly from the concentration versus time curve. (NCT01982955)
Timeframe: Pre dose, 0.25, 0.5, 1, 2, 4, 8, 10 and 24 hours post dose on Day 1 and 15 of Cycle 1 (each Cycle is 21 days)

,
InterventionHours (Median)
Tepotinib: Day 1 of Cycle 1Tepotinib: Day 15 of Cycle 1MSC2571109A: Day 1 of Cycle 1MSC2571109A: Day 15 of Cycle 1MSC2571107A: Day 1 of Cycle 1MSC2571107A: Day 15 of Cycle 1Gefitinib: Day 1 of Cycle 1Gefitinib: Day 15 of Cycle 1
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mg8.006.0024.000.0024.000.13NA4.00
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mg9.019.0024.000.0024.000.258.008.00

[back to top]

Phase 2: Number of Participants With Death and Reasons

An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. PD defined as an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 mm. Number of participants with deaths due to progression disease (PD), AE related to study treatment, unknown reason was reported. (NCT01982955)
Timeframe: Up to 328 weeks

,,
InterventionParticipants (Count of Participants)
Death due to disease progressionDeath due to AE related to study treatmentDeath due to unknown reason
Phase 2: Pemetrexed and Cisplatin/Carboplatin (MET + T790 Negative)1505
Phase 2: Single-arm Cohort (MET+ T790M Positive)802
Phase 2: Tepotinib 500 mg + Gefitinib 250 mg (MET + T790 Negative)2102

[back to top] [back to top]

Phase 2: Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI-CTCAE Version 4.03 Reported as Treatment-Emergent Adverse Events (TEAEs)

The laboratory measurements included hematology and coagulation, biochemistry and urinalysis. (NCT01982955)
Timeframe: Up to 328 weeks

,,
InterventionParticipants (Count of Participants)
AnaemiaNeutropeniaAlanine aminotransferase increasedAmylase increasedGamma-glutamyltransferase increasedLipase increasedNeutrophil count decreasedWhite blood cell count decreasedHyponatremiaHypokalemiahypophosphatemiaHypoalbuminemia
Phase 2: Pemetrexed and Cisplatin/Carboplatin (MET + T790 Negative)710212323210
Phase 2: Single-arm Cohort (MET+ T790M Positive)000201000000
Phase 2: Tepotinib 500 mg + Gefitinib 250 mg (MET + T790 Negative)001705211001

[back to top] [back to top]

Phase 1b: Number of Participants Experiencing at Least One Dose Limiting Toxicity (DLT)

Dose limiting toxicity (DLT) using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.0 was defined as toxicities at any dose level and judged to be related to the study treatment by investigator and/or the sponsor. DLTs included Grade 4 neutropenia for more than 7 days; Grade greater than or equal to (>=) 3 febrile neutropenia for more than 1 day; Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with non-traumatic bleeding; Grade >= 3 uncontrolled nausea/vomiting and/or diarrhea despite adequate and optimal treatment and Grade >= 3 any non-hematological adverse event (AE), except the aforementioned gastrointestinal events and alopecia. Number of participants who experienced DLT during Phase 1b were reported. (NCT01982955)
Timeframe: Day 1 to Day 21 of Cycle 1 (each cycle is 21 days)

InterventionParticipants (Count of Participants)
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mg0
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mg0

[back to top]

Phase 1b: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiograms (ECG) Findings

ECG parameters included heart rhythm, pulse rate intervals, QRS, QT intervals, RR intervals and corrected QT(QTc) intervals. Clinical significance was determined by the investigator. Number of participants with clinically significant abnormalities in 12-lead ECG were reported. (NCT01982955)
Timeframe: Up to 175 weeks

InterventionParticipants (Count of Participants)
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mg0
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mg0

[back to top]

Phase 1b: Number of Participants With Clinically Significant Abnormalities in Vital Signs

Vital signs assessment included blood pressure, heart rate, respiratory rate and body temperature. Number of Participants with any clinically significant abnormalities in vital signs were reported. Clinical significance was determined by the investigator. (NCT01982955)
Timeframe: Up to 175 weeks

InterventionParticipants (Count of Participants)
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mg0
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mg0

[back to top]

Phase 1b: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 2 or Higher Than 2

ECOG PS score is widely used by doctors and researchers to assess how a participants' disease is progressing, and is used to assess how the disease affects the daily living abilities of the participant, and determine appropriate treatment and prognosis. The score ranges from Grade 0 to Grade 5, where Grade 0 = Fully active, able to carry on all pre-disease performance without restriction, Grade 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (like light house work, office work), Grade 2 = Ambulatory and capable of all self-care but unable to carry out any work activities, Grade 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours and Grade 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair, Grade 5 = Death. Number of participants with ECOG performance status score of 2 or higher than 2 were reported. (NCT01982955)
Timeframe: Up to 175 weeks

InterventionParticipants (Count of Participants)
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mg1
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mg9

[back to top]

Phase 1b: Percentage of Participants With Disease Control Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria

Disease control defined as CR, PR, or stable disease(SD) as the best overall response according to local radiological assessments from the date of randomization/the first administration of the study treatment to the first observation of PD. CR:disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR:at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. PD:an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5mm. SD:as any cases that do not qualify for either PR or PD at minimum interval of 42 days after randomization/start of study treatment (NCT01982955)
Timeframe: Up to 328 weeks

InterventionPercentage of Participants (Number)
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mg50.0
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mg58.3

[back to top]

Phase 1b: Percentage of Participants With Objective Response Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria

Objective response (OR) was defined as the percentage of participants who had achieved complete response (CR) or partial response (PR) as the best overall response according to local radiological assessments from randomization/the first administration of the study treatment to the first observation of disease progression (PD). CR: defined as disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. PD defined as an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 mm. (NCT01982955)
Timeframe: Up to 328 weeks

InterventionPercentage of Participants (Number)
Phase 1b: Tepotinib 300 mg + Gefitinib 250 mg33.3
Phase 1b: Tepotinib 500 mg + Gefitinib 250 mg33.3

[back to top]

Phase 2 (Non-Randomized Part Only): Percentage of Participants With Disease Control Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria

Disease control defined as CR, PR, or stable disease(SD) as the best overall response according to local radiological assessments from the date of randomization/the first administration of the study treatment to the first observation of PD. CR:disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR:at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. PD:an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5mm. SD:as any cases that do not qualify for either PR/PD at minimum interval of 42 days after randomization/start of study treatment. (NCT01982955)
Timeframe: Up to 328 weeks

InterventionPercentage of Participants (Number)
Phase 2: Single-arm Cohort (MET+ T790M Positive)40

[back to top]

Phase 2 (Non-Randomized Part Only): Percentage of Participants With Objective Response Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria

Objective response (OR) was defined as the percentage of participants who had achieved complete response (CR) or partial response (PR) as the best overall response according to local radiological assessments from randomization/the first administration of the study treatment to the first observation of disease progression (PD). CR: defined as disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. PD defined as an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 mm. (NCT01982955)
Timeframe: Up to 328 weeks

InterventionPercentage of Participants (Number)
Phase 2: Single-arm Cohort (MET+ T790M Positive)0

[back to top]

Phase 2 (Non-Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by Independent Review Committee (IRC)

Progression-free survival (assessed by Independent Review Committee) time was defined as the time in months from randomization to either first observation of radiologically confirmed progression disease by the IRC or occurrence of death due to any cause within 84 days of either randomization or the last tumor assessment. PD is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study; and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 mm. PFS was measured using Kaplan-Meier (KM) estimates. (NCT01982955)
Timeframe: Up to 328 weeks

InterventionMonths (Median)
Phase 2: Single-arm Cohort (MET+ T790M Positive)2.63

[back to top]

Phase 2 (Non-Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by Investigator

Progression-free survival (assessed by Investigator) time was defined as the time in months from randomization to either first observation of radiologically confirmed progression disease by the Investigator or occurrence of death due to any cause within 84 days of either randomization or the last tumor assessment. PD is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study; and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 mm. PFS was measured using Kaplan-Meier (KM) estimates. (NCT01982955)
Timeframe: Up to 328 weeks

InterventionMonths (Median)
Phase 2: Single-arm Cohort (MET+ T790M Positive)1.41

[back to top]

Phase 2 (Randomized Part Only): Percentage of Participants With Disease Control Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria

Disease control defined as CR, PR, or stable disease(SD) as the best overall response according to local radiological assessments from the date of randomization/the first administration of the study treatment to the first observation of PD. CR:disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR:at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. PD:an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5mm. SD:as any cases that do not qualify for either PR/PD at minimum interval of 42 days after randomization/start of study treatment. (NCT01982955)
Timeframe: Up to 328 weeks

InterventionPercentage of Participants (Number)
Phase 2: Tepotinib 500 mg + Gefitinib 250 mg (MET + T790 Negative)83.9
Phase 2: Pemetrexed and Cisplatin/Carboplatin (MET + T790 Negative)70.8

[back to top]

Phase 2 (Randomized Part Only): Percentage of Participants With Objective Response Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria

Objective response (OR) was defined as the percentage of participants who had achieved complete response (CR) or partial response (PR) as the best overall response according to local radiological assessments from randomization/the first administration of the study treatment to the first observation of disease progression (PD). CR: defined as disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. PD defined as an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 mm. (NCT01982955)
Timeframe: Up to 328 weeks

InterventionPercentage of Participants (Number)
Phase 2: Tepotinib 500 mg + Gefitinib 250 mg (MET + T790 Negative)45.2
Phase 2: Pemetrexed and Cisplatin/Carboplatin (MET + T790 Negative)33.3

[back to top]

Phase 2 (Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by Independent Review Committee (IRC)

Progression-free survival (assessed by Independent Review Committee) time was defined as the time in months from randomization to either first observation of radiologically confirmed progression disease (PD) by the IRC or occurrence of death due to any cause within 84 days of either randomization or the last tumor assessment. PD is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study; and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 mm. PFS was measured using Kaplan-Meier (KM) estimates. (NCT01982955)
Timeframe: Up to 328 weeks

InterventionMonths (Median)
Phase 2: Tepotinib 500 mg + Gefitinib 250 mg (MET + T790 Negative)10.15
Phase 2: Pemetrexed and Cisplatin/Carboplatin (MET + T790 Negative)4.34

[back to top]

Phase 2 (Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by the Investigator

Progression-free survival (assessed by the Investigator) time was defined as the time in months from randomization to either first observation of radiologically confirmed progression disease (PD) by the investigator or occurrence of death due to any cause within 84 days of either randomization or the last tumor assessment. PD is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study; and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 millimeter (mm). PFS was measured using Kaplan-Meier (KM) estimates. (NCT01982955)
Timeframe: Up to 328 weeks

InterventionMonths (Median)
Phase 2: Tepotinib 500 mg + Gefitinib 250 mg (MET + T790 Negative)4.86
Phase 2: Pemetrexed and Cisplatin/Carboplatin (MET + T790 Negative)4.37

[back to top]

Phase 2: (Non-Randomized Part Only): Overall Survival (OS) Time

Overall survival time was measured as time in months between the date of randomization and the date of death. (NCT01982955)
Timeframe: Up to 328 weeks

InterventionMonths (Median)
Phase 2: Single-arm Cohort (MET+ T790M Positive)25.86

[back to top]

Phase 2: (Randomized Part Only): Overall Survival (OS) Time

Overall survival time was measured as time in months between the date of randomization and the date of death. (NCT01982955)
Timeframe: Up to 328 weeks

InterventionMonths (Median)
Phase 2: Tepotinib 500 mg + Gefitinib 250 mg (MET + T790 Negative)17.25
Phase 2: Pemetrexed and Cisplatin/Carboplatin (MET + T790 Negative)19.48

[back to top]

Part 2 Cohorts G+ and G-: Progression-Free Survival (PFS)

PFS was defined as the time from randomization to the first documented disease progression, or death due to any cause, whichever occurred first. Per RECIST 1.1, progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression. PFS was assessed by BICR. (NCT02039674)
Timeframe: Up to approximately 2 years

InterventionMonths (Median)
Part 2 Cohort G+ (Pembro 200 mg+Pe+C)24.5
Part 2 Cohort G- (Placebo+Pe+C)9.9

[back to top]

Part 2 Cohorts G+ and G-: Overall Survival (OS)

OS was defined as the time from randomization to death due to any cause. (NCT02039674)
Timeframe: Up to approximately 2 years

InterventionMonths (Median)
Part 2 Cohort G+ (Pembro 200 mg+Pe+C)34.5
Part 2 Cohort G- (Placebo+Pe+C)21.1

[back to top]

Part 2 Cohorts G+ and G-: Objective Response Rate (ORR)

ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR). (NCT02039674)
Timeframe: Up to approximately 2 years

InterventionPercentage of Participants (Number)
Part 2 Cohort G+ (Pembro 200 mg+Pe+C)55.0
Part 2 Cohort G- (Placebo+Pe+C)28.6

[back to top]

Part 2 Cohorts G+ and G-: Duration of Response (DOR)

For participants who demonstrated a confirmed response (Complete Response [CR]: Disappearance of all target lesions or Partial Response [PR]: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. Per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until disease progression or death. DOR was assessed by BICR. (NCT02039674)
Timeframe: Up to approximately 2 years

InterventionMonths (Median)
Part 2 Cohort G+ (Pembro 200 mg+Pe+C)NA
Part 2 Cohort G- (Placebo+Pe+C)NA

[back to top]

Part 2 Cohorts D4 and H: Objective Response Rate (ORR)

For participants who demonstrated a confirmed response (Complete Response [CR]: Disappearance of all target lesions or Partial Response [PR]: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. Per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until disease progression or death. DOR was assessed by BICR. (NCT02039674)
Timeframe: Up to approximately 2 years

InterventionPercentage of Participants (Number)
Part 2 Cohorts D4 & H (Pembro 2mg/kg+I)29.5

[back to top]

All Cohorts: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)

DLTs were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4. A DLT was defined as any of the following events: Grade 4 non-hematologic toxicity (not laboratory); Grade 4 hematologic toxicity lasting ≥7 days; Grade 3 non-hematologic toxicity (not laboratory, specifically nausea, vomiting and diarrhea) lasting >3 days despite optimal supportive care; Any Grade 3 or Grade 4 non-hematologic laboratory value requiring treatment or hospitalization, or persisting for >1 week; Febrile neutropenia Grade 3 or Grade 4; Qualifying thrombocytopenia <25,000/mm^3; Prolonged delay (>2 weeks) in initiating Cycle 2 due to treatment-related toxicity; Missing >10% of erlotinib or gefitinib doses as a result of adverse events (AEs) during the DLT window of observation; or Grade 5 toxicity. (NCT02039674)
Timeframe: Cycle 1 (Up to 21 days)

InterventionParticipants (Count of Participants)
Part1 Cohort A2 (Pembro 2 mg/kg+Paclitaxel [Pa]+Carboplatin [C])0
Part1 Cohort A10 (Pembro10mg/kg+Pa+C)0
Part 1 Cohort B2 (Pembro 2mg/kg+Pa+C+Bevacizumab [B])0
Part 1 Cohort B10 (Pembro 10 mg/kg+Pa+C+B)0
Part 1 Cohort C2 (Pembro 2 mg/kg+Pemetrexed [Pe]+C)0
Part 1 Cohort C10 (Pembro 10 mg/kg+Pe+C)0
Part 1 Cohort D1 (Pembro 10mg/kg+Ipilimumab [I])0
Part 1 Cohort D2 (Pembro 10 mg/kg+I)0
Part 1 Cohort D4 (Pembro 2 mg/kg+I)0
Part 1 Cohort E (Pembro 2 mg/kg+Erlotinib)0
Part 1 Cohort F (Pembro 2 mg/kg+Gefitinib)0
Part 2 Cohort G+ (Pembro 200 mg+Pe+C)0
Part 2 Cohort G- (Placebo+Pe+C)0
Part 2 Cohort H (Pembro 2 mg/kg+I)0

[back to top]

Overall Survival

To assess the efficacy of various sequences. In survival follow up at data cut off. (NCT02179671)
Timeframe: Up to 2 years

Interventionpatients (Number)
Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI47360
Tremelimumab (2 Cycles) With a Seq. Switch to MEDI47360

[back to top]

Progression-free Survival

Progression-free survival (per RECIST 1.1 as assessed by Investigator) is defined as the date of 1st dose of MEDI4736 until the date of objective disease progression or death. Progression of disease (PD) At least a 20% increase in the sum of diameters of TLs, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT02179671)
Timeframe: Up to 2 years

Interventionpatients (Number)
Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI47361
Tremelimumab (2 Cycles) With a Seq. Switch to MEDI47360

[back to top]

Duration of Response

Duration of response (DoR; per RECIST 1.1 as assessed by the site Investigator) will be defined as the time from the date of 1st documented response (which is subsequently confirmed) until the 1st date of documented progression or death in the absence of disease progression. (NCT02179671)
Timeframe: Within 12 months

InterventionMonths (Median)
Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736NA

[back to top]

Objective Response Rate (ORR)

To further assess the efficacy of various sequences. Objective response rate (ORR; per RECIST 1.1 as assessed by the site Investigator) is defined as the number (%) of patients with a confirmed overall response of CR or PR and was based on the evaluable analysis set. Per RECIST v1.0 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT02179671)
Timeframe: Up to 2 years

Interventionpatients (%) (Number)
Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI473611.1
Tremelimumab (2 Cycles) With a Seq. Switch to MEDI47360

[back to top]

Confirmed Complete Response (CR) Rate

To assess the efficacy of various sequences. CR (per RECIST 1.1 as assessed by the local/site Investigator) is defined as the disappearance of all target and non-target lesions. Confirmed complete response rate (CR rate) is defined as the number (%) of patients with a confirmed overall response of CR and was based on the evaluable analysis set. (NCT02179671)
Timeframe: Up to 2 years

Interventionpatients (%) (Number)
Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI47360
Tremelimumab (2 Cycles) With a Seq. Switch to MEDI47360

[back to top]

Depth of Response

The Depth of response was defined as the relative change in the sum of the longest diameters of Response Evaluation Criteria in Solid Tumors (RECIST) Target lesions (TLs) at the nadir, in the absence of new lesions (NLs) or progression of Non-target lesions (NTLs), compared to baseline and was used to further assess the efficacy of osimertinib compared with SoC EGFR-TKI therapy (NCT02296125)
Timeframe: At baseline and every 6 weeks for the first 18 months and then every 12 weeks until objective disease progression

Interventionpercentage of change (Mean)
Osimertinib 80 mg (Global Cohort)-52.36
SoC EGFR-TKI (Global Cohort)-45.66
Osimertinib 80 mg (China Cohort)-49.17
SoC EGFR-TKI (China Cohort)-42.92

[back to top]

Overall Survival (OS)- Number of Participants With an Event

Overall survival was defined as the time from the date of randomisation until death from any cause and was used to further assess the efficacy of osimertinib compared with SoC EGFR-TKI therapy (NCT02296125)
Timeframe: From first dose to end of study or date of death from any cause, whichever comes first, assessed every 6 weeks (approximately 29 months)

,,,
InterventionParticipants (Count of Participants)
DeathStill in survival follow-upTerminated prior to death
Osimertinib 80 mg (China Cohort)45251
Osimertinib 80 mg (Global Cohort)15510420
SoC EGFR-TKI (China Cohort)44174
SoC EGFR-TKI (Global Cohort)1668625

[back to top]

Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ) Questionnaires Lung Cancer 13 (QLQ-LC13)

The EORTC QLQ-LC13 was a lung-cancer-specific module comprising 13 questions to assess lung cancer symptoms (cough, haemoptysis, dyspnoea, and site-specific pain); treatment related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia); and pain medication. An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items. Higher scores on the global health status/QoL and functioning scales indicated better health status/QoL and function. Higher scores on the symptoms scales indicated greater symptom burden. The analysis was performed using a Mixed-effects model for repeated measures analysis on the change from baseline in PRO symptom score at each visit up to 9 months (281 days), including participants, treatment, visit and treatment by visit interaction as explanatory variables, the baseline PRO score as a covariate along with the baseline PRO score by visit interaction, using an unstructured covariance structure. (NCT02296125)
Timeframe: Questionnaires completed at baseline, first 9 months, and at week 1, 2, 3, 4, 5, 6, 12, 18, 24, 30 and 36

,,,
InterventionUnit on scale (Least Squares Mean)
Dyspnoea, First 9 monthsDyspnoea, week 1Dyspnoea, week 2Dyspnoea, week 3Dyspnoea, week 4Dyspnoea, week 5Dyspnoea, week 6Dyspnoea, week 12Dyspnoea, week 18Dyspnoea, week 24Dyspnoea, week 30Dyspnoea, week 36Cough, First 9 monthsCough, week 1Cough, week 2Cough, week 3Cough, week 4Cough, week 5Cough, week 6Cough, week 12Cough, week 18Cough, week 24Cough, week 30Cough, week 36Pain in Chest, First 9 monthsPain in Chest, week 1Pain in Chest, week 2Pain in Chest, week 3Pain in Chest, week 4Pain in Chest, week 5Pain in Chest, week 6Pain in Chest, week 12Pain in Chest, week 18Pain in Chest, week 24Pain in Chest, week 30Pain in Chest, week 36
Osimertinib 80 mg (China Cohort)-4.87-1.61-2.27-3.09-5.35-5.72-4.83-5.38-7.67-7.59-5.81-4.21-13.75-4.60-12.26-11.95-12.78-17.74-16.92-15.51-11.79-17.61-15.45-14.62-2.79-1.79-4.76-0.76-2.13-0.620.94-3.71-4.40-5.66-4.25-3.56
Osimertinib 80 mg (Global Cohort)-4.04-3.46-3.94-3.99-4.81-3.51-4.51-3.83-4.97-4.65-3.89-2.88-10.97-6.90-9.04-9.78-11.25-12.98-11.88-13.36-12.31-11.34-10.34-11.49-6.62-1.93-5.94-7.17-7.45-7.33-4.99-7.28-6.79-7.72-8.33-7.94
SoC EGFR-TKI (China Cohort)-4.820.68-5.03-5.55-5.55-5.76-6.37-6.67-7.48-5.67-3.46-2.18-8.49-3.69-3.73-5.56-10.32-9.20-10.58-8.04-9.44-14.92-9.35-8.55-4.74-4.16-3.00-4.77-4.22-6.82-6.26-5.13-7.24-3.15-4.02-3.40
SoC EGFR-TKI (Global Cohort)-4.14-3.60-3.64-3.27-4.11-5.19-4.45-5.75-5.21-4.56-3.68-2.04-11.65-4.83-9.52-10.24-13.36-13.55-11.92-13.57-11.00-13.16-12.43-14.62-6.41-4.26-6.32-5.36-6.40-6.98-7.08-6.70-7.90-7.34-6.60-5.58

[back to top]

Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Items (EORTC QLQ-C30)

The EORTC QLQ-C30 cancer-specific questionnaire consisted of 30 questions, combined to produce 5 functional scales, 3 symptom scales, 6 individual items, and a global measure of health status/QoL. An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items, the functional scales, and the global health status/QoL scale in the EORTC QLQ-C30. Higher scores on the global health status and functioning scales indicated better health status/function. Higher scores on the symptoms scales indicated greater symptom burden. The analysis was performed using a Mixed-effects model for repeated measures analysis on the change from baseline in PRO symptom score at each visit up to 9 months (281 days), including participants, treatment, visit and treatment by visit interaction as explanatory variables, the baseline PRO score as a covariate along with the baseline PRO score by visit interaction, using an unstructured covariance structure. (NCT02296125)
Timeframe: Questionnaires completed at baseline, first 9 months, and at week 6, 12, 18, 24, 30, and 36.

,,,
InterventionUnit on scale (Least Squares Mean)
Fatigue, First 9 monthsFatigue, week 6Fatigue, week 12Fatigue, week 18Fatigue, week 24Fatigue, week 30Fatigue, week 36Appetite Loss, First 9 monthsAppetite Loss, week 6Appetite Loss, week 12Appetite Loss, week 18Appetite Loss, week 24Appetite Loss, week 30Appetite Loss, week 36
Osimertinib 80 mg (China Cohort)-5.65-1.73-5.40-6.64-8.92-4.43-6.781.183.201.581.42-2.262.190.98
Osimertinib 80 mg (Global Cohort)-5.48-4.13-5.11-6.83-6.18-5.19-5.47-6.15-4.54-6.52-7.27-7.14-4.50-6.90
SoC EGFR-TKI (China Cohort)-5.79-6.81-6.36-7.90-3.87-6.31-3.46-1.73-6.27-1.44-4.430.24-1.833.36
SoC EGFR-TKI (Global Cohort)-4.72-5.78-6.52-5.77-4.96-3.26-2.00-5.64-5.67-6.95-6.84-5.08-4.17-5.15

[back to top]

Plasma Concentrations of Metabolites AZ5104

To characterise the pharmacokinetics (PK) of osimertinib metabolite AZ5104. (NCT02296125)
Timeframe: Blood samples collected from each participant at pre-dose, 0.5 to 2 hours, and 3 to 5 hours post-dose on Day 1 Cycle 1, and every other cycle thereafter up to and including Cycle 13 (approximately 9 months)

,
InterventionNano moles (Geometric Mean)
Cycle 1 Day 1 PredoseCycle 1 Day 1-0.5 - 2 hoursCycle 1 Day 1-3 - 5 hoursCycle 3 Day 1-PredoseCycle 3 Day 1, 0.5 - 2 hoursCycle 3 Day 1, 3 - 5 hoursCycle 5 Day 1, PredoseCycle 5 Day 1, 0.5 - 2 hoursCycle 5 Day 1, 3-5 hoursCycle 7 Day 1- PredoseCycle 7 Day 1, 0.5-2 hoursCycle 7 Day 1, 3-5 hoursCycle 9 Day 1, PredoseCycle 9 Day 1, 0.5-2 hoursCycle 9 Day 1, 3-5 hoursCycle 11 Day 1, PredoseCycle 11 Day 1, 0.5-2 hoursCycle 11 Day 1, 3-5 hoursCycle 13 Day 1, PredoseCycle 13 Day 1, 0.5- 2 hoursCycle 13 Day 1, 3-5 hours
Osimertinib 80 mg (China Cohort)NANA6.305356.831955.994764.062156.033055.376763.921652.578652.763860.620154.434954.715860.464956.478257.409565.194355.116254.385861.7426
Osimertinib 80 mg (Global Cohort)NA0.15423.939942.912342.743448.354739.371839.414545.684238.384738.530144.467040.123040.498746.031038.385938.762043.913540.435640.111645.9083

[back to top]

Plasma Concentrations of Metabolite AZ7550

To characterise the pharmacokinetics (PK) of osimertinib metabolite AZ7550. (NCT02296125)
Timeframe: Blood samples collected from each participant at pre-dose, 0.5 to 2 hours, and 3 to 5 hours post-dose on Day 1 Cycle 1, and every other cycle thereafter up to and including Cycle 13 (approximately 9 months)

,
InterventionNano moles (Geometric Mean)
Cycle 1 Day 1, PredoseCycle 1 Day 1, 0.5 - 2 hoursCycle 1 Day 1, 3 - 5 hoursCycle 3 Day 1, PredoseCycle 3 Day 1, 0.5 - 2 hoursCycle 3 Day 1, 3 - 5 hoursCycle 5 Day 1, PredoseCycle 5 Day 1, 0.5 - 2 hoursCycle 5 Day 1, 3-5 hoursCycle 7 Day 1, PredoseCycle 7 Day 1, 0.5-2 hoursCycle 7 Day 1,3-5 hoursCycle 9 Day 1, PredoseCycle 9 Day 1, 0.5-2 hoursCycle 9 Day 1, 3-5 hoursCycle 11 Day 1, PredoseCycle 11 Day 1, 0.5- 2 hoursCycle 11 Day 1, 3- 5 hoursCycle 13 Day 1, PredoseCycle 13 Day 1, 0.5-2 hoursCycle 13 Day 1, 3-5 hours
Osimertinib 80 mg (China Cohort)NANA2.187655.995855.675462.349353.043453.190162.521853.416754.394261.900454.820755.243760.893356.464357.477865.305356.066656.875063.3365
Osimertinib 80 mg (Global Cohort)NA0.14371.861046.128646.004551.718244.453745.218651.401846.291246.354052.353349.605849.938156.535450.971051.977357.698654.523854.122461.6053

[back to top]

Plasma Concentrations of AZD9291

To characterise the pharmacokinetics (PK) of osimertinib (NCT02296125)
Timeframe: Blood samples collected from each participant at pre-dose, 0.5 to 2 hours, and 3 to 5 hours post-dose on Day 1 Cycle 1, and every other cycle thereafter up to and including Cycle 13 (approximately 9 months)

,
InterventionNano moles (Geometric Mean)
Cycle 1 Day 1-PredoseCycle 1 Day 1-0.5 - 2 hoursCycle 1 Day 1-3 - 5 hoursCycle 3 Day 1- PredoseCycle 3 Day 1, 0.5 - 2 hoursCycle 3 Day 1, 3 - 5 hoursCycle 5 Day 1, PredoseCycle 5 Day 1, 0.5 - 2 hoursCycle 5 Day 1, 3-5 hoursCycle 7 Day 1-PredoseCycle 7 Day 1-0.5 - 2 hoursCycle 7 Day 1-3-5 hoursCycle 9 Day 1-PredoseCycle 9 Day 1-0.5-2 hoursCycle 9 Day 1-3-5 hoursCycle 11 Day 1-PredoseCycle 11 Day 1-0.5 -2 hoursCycle 11 Day 1-3-5 hoursCycle 13 Day 1-PredoseCycle 13 Day 1-0.5 -2 hoursCycle 13 Day 1-3-5 hours
Osimertinib 80 mg (China Cohort)NA5.0249131.5669441.5606441.7343553.8090419.5893426.8197570.7729397.5857411.6170530.7212383.2238395.2179490.5964410.4023415.2427528.8081404.2678393.1688499.0220
Osimertinib 80 mg (Global Cohort)NA4.9487129.3340394.3489397.7406512.4012358.5487369.0696485.8142347.6176357.8529475.6587359.5284363.0106485.6006354.5330367.7450476.4472369.9834371.4157496.6866

[back to top]

Percentage of Participants in Progression Free Survival at 6, 12, and 18 Months

Progression-free survival was defined as the time from randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression and was used to assess the efficacy of single agent osimertinib compared with SoC EGFR-TKI therapy as measured by PFS. (NCT02296125)
Timeframe: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomisation until progression

,,,
InterventionPercentage of Participants (Number)
Progression free at 6 months (%)Progression free at 12 months (%)Progression free at 18 months (%)
Osimertinib 80 mg (China Cohort)78.867.346.9
Osimertinib 80 mg (Global Cohort)88.468.250.9
SoC EGFR-TKI (China Cohort)72.344.625.8
SoC EGFR-TKI (Global Cohort)75.242.324.4

[back to top]

Participants Reported Outcome by Cancer Therapy Satisfaction Questionnaire 16 Items (CTSQ-16 Questionnaire)

The CTSQ-16 was a 16-item questionnaire measuring 3 domains related to participant's satisfaction with cancer therapy: Expectations of therapy, Feelings about side effects, and Satisfaction with therapy. Scores ranged from 0 to 100 for each domain, with a higher score associated with the best outcome on each domain. The three domains of interest were separately analysed using an ANCOVA stratified by race (Asian versus Non-Asian) and mutation type (Ex19del versus L858R). The results of the analyses were presented in terms of mean together with standard deviation. (NCT02296125)
Timeframe: Questionnaire completed in cycle 2 and 3, prior to Week 6 scan (approximately 2 months)

,,,
InterventionUnit on scale (Mean)
Expectations with Therapy, Week 3Expectations with Therapy, Week 6Feelings about Side-Effects, Week 3Feelings about Side-Effects, Week 6Satisfaction with Therapy, Week 3Satisfaction with Therapy, Week 6
Osimertinib 80 mg (China Cohort)77.182.273.369.087.287.4
Osimertinib 80 mg (Global Cohort)74.176.374.574.684.484.2
SoC EGFR-TKI (China Cohort)79.282.672.569.786.687.2
SoC EGFR-TKI (Global Cohort)70.374.069.169.982.684.6

[back to top]

Disease Control Rate (DCR)

The DCR was defined as the percentage of participants who had a best overall response (BOR) of Complete response (CR), Partial response (PR) or Stable disease (SD) ≥6 weeks prior to any Progressive disease (PD) event and was used to further assess the efficacy of osimertinib compared with SoC EGFR-TKI therapy. (NCT02296125)
Timeframe: At baseline and every 6 weeks for the first 18 months and then every 12 weeks until objective disease progression

InterventionPercentage of participants (Number)
Osimertinib 80 mg (Global Cohort)97.1
SoC EGFR-TKI (Global Cohort)92.4
Osimertinib 80 mg (China Cohort)97.2
SoC EGFR-TKI (China Cohort)95.4

[back to top]

Duration of Response (DoR)

Duration of response was defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression and was used to further assess the efficacy of osimertinib compared with SoC EGFR-TKI therapy. (NCT02296125)
Timeframe: At baseline and every 6 weeks for the first 18 months and then every 12 weeks until objective disease progression

InterventionMonths (Median)
Osimertinib 80 mg (Global Cohort)17.2
SoC EGFR-TKI (Global Cohort)8.5
Osimertinib 80 mg (China Cohort)16.4
SoC EGFR-TKI (China Cohort)10.9

[back to top]

Median Progression Free Survival (PFS) (Months)

Progression-free survival was defined as the time from randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression and was used to assess the efficacy of single agent osimertinib compared with SoC EGFR-TKI therapy as measured by PFS. The primary endpoint of PFS was based on Investigator assessment. (NCT02296125)
Timeframe: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomisation until progression

InterventionMonths (Median)
Osimertinib 80 mg (Global Cohort)18.9
SoC EGFR-TKI (Global Cohort)10.2
Osimertinib 80 mg (China Cohort)17.8
SoC EGFR-TKI (China Cohort)9.8

[back to top]

Objective Response Rate (ORR)

ORR was defined as the number (%) of participants with measurable disease with at least 1 visit response of Complete response (CR) or Partial response (PR) and it was used to further assess the efficacy of osimertinib compared with SoC EGFR-TKI therapy. ORR was based on Investigator assessment. (NCT02296125)
Timeframe: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomisation until progression

InterventionPercentage of participants (Number)
Osimertinib 80 mg (Global Cohort)76.7
SoC EGFR-TKI (Global Cohort)69.0
Osimertinib 80 mg (China Cohort)76.1
SoC EGFR-TKI (China Cohort)70.8

[back to top]

Part B: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab

Part B: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab (NCT02411448)
Timeframe: Cycle 2 Day 1: Predose; Cycle 4 Day 1: Predose; Cycle 7 Day 1: Predose; Cycle 14 Day 1

Interventionmicrogram per milliliter (µg/mL) (Geometric Mean)
Cycle 2Cycle 4Cycle 7Cycle 14
Part B: Ramucirumab+ Erlotinib39.668.585.799.4

[back to top]

Part B: Best Change From Baseline on the Lung Cancer Symptom Scale (LCSS)

The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms [loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain] and 3 global items (symptom distress, interference with activity level, and global quality of life). Participant responses to each item were measured using visual analogue scales (VAS) with 100-millimeter (mm) lines. A higher score for any item represented a higher level of symptoms/problems. The LCSS total score was defined as the mean of all 9 items. Average symptom burden index (ASBI) was calculated as the mean of the six symptom-specific questions from the LCSS. Potential scores range from 0 (for best outcome) to 100 (for worst outcome). (NCT02411448)
Timeframe: Baseline, End of Study (Up To 37 Months)

,
Interventionmillimeter (Least Squares Mean)
Loss of AppetiteFatigueCoughShortness of BreathBlood in SputumPainSymptom distressInterference with Activity LevelGlobal Quality of LifeAverage Symptom Burden IndexTotal LCSS
Part B: Placebo+ Erlotinib-18.16-19.45-22.09-15.93-1.94-14.69-16.15-15.60-18.12-13.05-12.71
Part B: Ramucirumab+ Erlotinib-17.07-19.35-21.22-14.46-1.58-13.57-15.91-14.43-16.21-12.17-12.00

[back to top]

Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score

The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death. (NCT02411448)
Timeframe: Baseline, Cycle 10 (each cycle is 2 weeks)

Interventionscore on a scale (Mean)
Part B: Ramucirumab+ Erlotinib0.02
Part B: Placebo+ Erlotinib0.02

[back to top]

Number of Participants With Treatment-Emergent Adverse Events

A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section. (NCT02411448)
Timeframe: Cycle 1 Day 1 through End of Study (Up To 3 Years)

InterventionParticipants (Count of Participants)
Part A: Ramucirumab + Erlotinib14
Part B: Ramucirumab + Erlotinib221
Part B: Placebo + Erlotinib225

[back to top]

Part B: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])

ORR was defined as the percentage of randomized participants achieving a best overall response of partial response (PR) or complete response (CR) assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to <10 mm, and normalization of tumor marker levels of non-target lesions. PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression. (NCT02411448)
Timeframe: Randomization to Progressive Disease (Up To 37 Months)

Interventionpercentage of participants (Number)
Part B: Ramucirumab+ Erlotinib76.3
Part B: Placebo+ Erlotinib74.7

[back to top]

Part B: Overall Survival (OS)

OS was defined as the time from the date of randomization to the date of death from any cause. For each participant who was not known to have died as of the data-inclusion cutoff date for a particular analysis,OS was censored for that analysis at the date of last contact prior to the data-inclusion cutoff date (contacts considered in the determination of last contact date include adverse event (AE) date, lesion assessment date, visit date, and last known alive date). (NCT02411448)
Timeframe: Randomization to Date of Death from Any Cause (Up To 37 Months)

Interventionmonths (Median)
Part B: Ramucirumab+ ErlotinibNA
Part B: Placebo+ ErlotinibNA

[back to top]

Part B: Percentage of Participants With CR, PR, or Stable Disease (SD) (Disease Control Rate [DCR])

DCR was defined as the percentage of randomized participants achieving a best overall response of CR,PR, or stable disease(SD) assessed via Response Evaluation Criteria in Solid Tumors(RECIST) version 1.1. CR was defined as the disappearance of all lesions,pathological lymph node reduction in short axis to <10 mm, and normalization of tumor marker levels of non-target lesions.PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters.SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease(PD) was at least a 20% increase in the sum of the diameters of target lesions,taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.The appearance of 1 or more new lesions is also considered progression. (NCT02411448)
Timeframe: Randomization to Progressive Disease (Up To 37 Months)

Interventionpercentage of participants (Number)
Part B: Ramucirumab+ Erlotinib95.1
Part B: Placebo+ Erlotinib95.6

[back to top]

Part B: Number of Participants With Anti-Ramucirumab Antibodies

Part B: Number of Participants With Anti-Ramucirumab Antibodies. (NCT02411448)
Timeframe: Cycle 1 Predose through Follow-up (Up To 37 Months)

InterventionParticipants (Count of Participants)
Part B: Ramucirumab+ Erlotinib14
Part B: Placebo+ Erlotinib18

[back to top]

Part B: Duration of Response (DoR)

DoR was defined as the date of first documented CR or PR (responder) to the date of progressive disease or the date of death due to any cause, whichever was earlier. If a responder was not known to have died or have progressive disease, then the participant was censored at the date of last evaluable tumor assessment.CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to <10 mm, and normalization of tumor marker levels of non-target lesions. PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression. (NCT02411448)
Timeframe: Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Up To 37 Months)

Interventionmonths (Median)
Part B: Ramucirumab+ Erlotinib18.0
Part B: Placebo+ Erlotinib11.1

[back to top]

Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score

The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death. (NCT02411448)
Timeframe: Baseline, Cycle 40 (each cycle is 2 weeks)

Interventionscore on a scale (Mean)
Part B: Ramucirumab+ Erlotinib0.01
Part B: Placebo+ Erlotinib-0.01

[back to top]

Part B: Progression Free Survival (PFS)

PFS is defined as the time from the date of randomization to the date of radiographically documented progressive disease (PD) based on investigator assessment, or the date of death due to any cause, whichever is first assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression. (NCT02411448)
Timeframe: Randomization to Measured Progressive Disease or Death from Any Cause (Up To 37 Months)

InterventionMonths (Median)
Part B: Ramucirumab+ Erlotinib19.4
Part B: Placebo+ Erlotinib12.4

[back to top]

Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score

The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death. (NCT02411448)
Timeframe: Baseline, Cycle 28 (each cycle is 2 weeks)

Interventionscore on a scale (Mean)
Part B: Ramucirumab+ Erlotinib0.02
Part B: Placebo+ Erlotinib0.01

[back to top]

PFS as Assessed by the Investigator

PFS was defined as the time from the date of randomization until the date of radiological disease progression or until death due to any cause, based on RECIST V1.1, as assessed by local investigator. Results are based Kaplan-Meier estimate. If a participant had neither progressed nor died, who received any further anticancer therapy for the disease before radiological progression, the participant was censored at the date of last radiological assessment. If progression or death occurred after missing 2 scheduled radiological assessments, the participant was censored at the date of last radiological assessment or at the date of randomization if no post-baseline radiological assessment was available. (NCT02588261)
Timeframe: From date of randomization up to data cut-off date 09 May 2017 (approximately 15 months)

Interventionmonths (Median)
ASP82737.43
Erlotinib or Gefitinib10.12

[back to top]

Progression Free Survival (PFS) as Assessed by Independent Radiologic Review (IRR)

PFS was defined as the time from the date of randomization until the date of radiological disease progression or until death due to any cause, based on the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, as assessed by IRR. Results are based Kaplan-Meier estimate. If a participant had neither progressed nor died, who received any further anticancer therapy for the disease before radiological progression, the participant was censored at the date of last radiological assessment. If progression or death occurred after missing 2 scheduled radiological assessments, the participant was censored at the date of last radiological assessment or at the date of randomization if no post-baseline radiological assessment was available. (NCT02588261)
Timeframe: From date of randomization up to data cut-off date 09 May 2017 (approximately 15 months)

Interventionmonths (Median)
ASP82739.26
Erlotinib or Gefitinib9.59

[back to top]

EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L)

The EQ-5D is a generic preference-based measure that indirectly measures the utility for health that generates an index-based summary score based upon societal preference weights. The EQ-5D-5L consists of 6 items that cover 5 main domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a general visual analog scale (VAS) for health status. Each item has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity). The VAS ranges from 0 (worst health status) and 100 (best health status). (NCT02588261)
Timeframe: Day 1 of each cycle up to data cut off 09 May 2017 (approximately 15 months)

,
InterventionUnits on a scale (Mean)
MobilitySelf-careUsual ActivitiesPain/DiscomfortAnxiety/DepressionVAS
ASP82731.781.281.711.791.6169.44
Erlotinib or Gefitinib1.481.191.541.711.5472.36

[back to top]

Number of Participants With Adverse Events (AEs)

Safety was assessed by AEs, which included abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A treatment-emergent AE (TEAE) was defined as an AE observed after starting administration of the study drug. AEs were considered serious (SAEs) if the AE resulted in death, was life threatening, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, resulted in congenital anomaly, or birth defect or required inpatient hospitalization or led to prolongation of hospitalization. (NCT02588261)
Timeframe: From first dose of study drug up to 30 days after last dose of study drug taken up to data cut-off 09 May 2017

,
Interventionparticipants (Number)
TEAEDrug-Related TEAESerious TEAEDrug-Related Serious TEAETEAE Leading to DeathDrug-Related TEAE Leading to DeathTEAE Leading to Treatment WithdrawalDrug-Related TEAE Leading to Treatment WithdrawalTEAE Leading to Dose ReductionDrug-Related TEAE Leading to Dose ReductionTEAE Leading to Dose InterruptionDrug-Related TEAE Leading to Dose InterruptionDeath
ASP8273251235844614139275151958339
Erlotinib or Gefitinib261246671817128175150745535

[back to top]

Functional Assessment of Cancer Therapy - EGFR Inhibitors Subscale (FACT-EGFRI-18) Questionnaire

"ACT-EGFRI-18 is an 18-item Likert-scaled questionnaire, used to assess the effect of EGFR inhibitors on quality of life (QoL). The questionnaire is arranged in three HRQL dimensions: physical (seven items), social/emotional (six items), and functional well-being (five items). The response scores ranged from 0 to 4, and the response categories include not at all, a little bit, somewhat, quite a bit, and very much. Negatively worded items (e.g., My skin bleeds easily or My skin condition affects my mood) are reverse-scored, so that participants who experience a higher impact of symptom burden on HRQL receive a lower score (range 0-72)." (NCT02588261)
Timeframe: Day 1 of each cycle up to data cut off 09 May 2017 (approximately 15 months)

Interventionunits on a scale (Mean)
ASP82732.79
Erlotinib or Gefitinib9.34

[back to top]

Duration of Response (DOR)

DOR was defined as the time from the date of the first response CR/PR (whichever was first recorded) as assessed by IRR to the date of radiographical progression or date of censoring. If a participant had not progressed, the participant was censored at the date of last radiological assessment or at the date of first CR/PR if no post-baseline radiological assessment was available. Results are based Kaplan-Meier estimate. (NCT02588261)
Timeframe: From date of first response up to data cut-off date 09 May 2017 (approximately 15 months)

Interventionmonths (Median)
ASP82739.17
Erlotinib or Gefitinib9.03

[back to top]

European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30)

EORTC-QLQ-LC30 is a 30-item cancer-specific questionnaire with multitrait scaling was used to create five functional domain scales: Physical, Role, Emotional, Social and Cognitive; two items evaluate global QoL; in addition, three symptom scales assess Fatigue, Pain and Emesis; and six single items assess other symptoms. The total score ranges from 0 to 100, with a high score for a functional scale representing a high/healthy level of functioning and a high score for a symptom scale or item representing a high level of symptomatology or problems. (NCT02588261)
Timeframe: Day 1 of each cycle up to data cut off 09 May 2017 (approximately 15 months)

Interventionunits on a scale (Mean)
ASP827353.77
Erlotinib or Gefitinib52.01

[back to top]

European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 (EORTC-QLQ-LC13)

The EORTC-QLQ-LC13 is a validated module of the EORTC-QLQ-Core 30, which includes module items that evaluate symptoms such as cough, hemoptysis, shortness of breath, sore mouth or tongue, dysphagia, tingling hands or feet, hair loss and pain. The total score for the questionnaire ranges from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems. (NCT02588261)
Timeframe: Day 1 of each cycle up to data cut off 09 May 2017 (approximately 15 months)

Interventionunits on a scale (Mean)
ASP827318.93
Erlotinib or Gefitinib18.78

[back to top]

Percentage of Deaths

All events of death after the first study drug administration were included. (NCT02588261)
Timeframe: From date of randomization up to data cut-off date 21 Dec 2017 (approximately 22 months)

Interventionpercentage of participants (Number)
ASP827314.7
Erlotinib or Gefitinib13.4

[back to top]

Percentage of Participants With Disease Control

Percentage of participants with disease control was defined as the proportion of participants whose best overall response was rated as CR, PR or stable disease (SD) among all analyzed participants based on RECIST V1.1. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to < 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters. SD was defined as neither sufficient decrease to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference the smallest sum of diameters while on study drug. (NCT02588261)
Timeframe: From date of first dose of study drug up to data cut-off date 09 May 2017 (approximately 15 months)

Interventionpercentage of participants (Number)
ASP827362.2
Erlotinib or Gefitinib66.2

[back to top]

Percentage of Participants With Objective Response (OR)

Percentage of participants with OR was defined as the proportion of participants with best overall response as complete response (CR) or partial response (PR) without confirmation based on the RECIST v1.1 as assessed by the blinded IRR. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to < 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters. (NCT02588261)
Timeframe: From date of first dose of study drug up to data cut-off date 09 May 2017 (approximately 15 months)

Interventionpercentage of participants (Number)
ASP827333.0
Erlotinib or Gefitinib47.9

[back to top]

Pharmacokinetic Parameter Trough Plasma Concentration (Ctrough) of DS-1205a Following Administration of DS-1205c in Combination With Gefitinib

Blood samples for pharmacokinetic (PK) analyses of DS-1205a were obtained at specified time points. Plasma concentrations of DS-1205a were measured using validated assays and non-compartmental analysis. (NCT03599518)
Timeframe: Predose, 1, 2, 4, 6, 8, and 10 hours of Cycle 0 (7-day cycle; DS-1205c alone), Days 1 and 7; Predose of Cycle 1 (21-day cycle), Day 1 (DS-1205c + gefitinib); Predose, 1, 2, 4, 6, 8, and 10 hours of Cycle 2 (21-day cycle; DS-1205c + gefitinib), Day 1

,,,,
Interventionng/mL (Mean)
Cycle 0, Day 7Cycle 1, Day 1Cycle 2, Day 1
DS-1205c 1000 mg + Gefitinib437486496
DS-1205c 1200 mg + Gefitinib104011301090
DS-1205c 200 mg + Gefitinib335315408
DS-1205c 400 mg + Gefitinib497551503
DS-1205c 800 mg + Gefitinib691768643

[back to top]

Pharmacokinetic Parameter Area Under the Plasma Concentration Curve of DS-1205a Following Administration of DS-1205c in Combination With Gefitinib

Blood samples for pharmacokinetic (PK) analyses of DS-1205a were obtained at specified time points. Plasma concentrations of DS-1205a were measured using validated assays and non-compartmental analysis. Area under the plasma concentration curve from time 0 to 8 hours (AUC8h), area under the plasma concentration-time curve from time 0 to 10 hours (AUC10h), and area under the plasma concentration-time curve during a dosing interval (AUCtau) were assessed. (NCT03599518)
Timeframe: Predose, 1, 2, 4, 6, 8, and 10 hours of Cycle 0 (7-day cycle; DS-1205c alone), Days 1 and 7; Predose of Cycle 1 (21-day cycle), Day 1 (DS-1205c + gefitinib); Predose, 1, 2, 4, 6, 8, and 10 hours of Cycle 2 (21-day cycle; DS-1205c + gefitinib), Day 1

,,,,
Interventionng*h/mL (Mean)
Cycle 0, Day 1: AUC10hCycle 0, Day 7: AUC10hCycle 0, Day 7: AUCtauCycle 1, Day 1: AUC8hCycle 1, Day 1: AUCtauCycle 2, Day 1: AUC10hCycle 2, Day 1: AUCtau
DS-1205c 1000 mg + Gefitinib2440456054904520677050306060
DS-1205c 1200 mg + Gefitinib428082501030083901280076509800
DS-1205c 200 mg + Gefitinib1710376044302980429037804520
DS-1205c 400 mg + Gefitinib2800599070005670793052906300
DS-1205c 800 mg + Gefitinib3860812094906820982073508530

[back to top]

Number of Participants With Treatment-emergent Adverse Events Occurring in Participants Following Administration With DS-1205c in Combination With Gefitinib

An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A treatment-emergent adverse event (TEAE) was defined as an AE that occurs, having been absent before the first dose of study drug, or has worsened in severity after the initiating the study drug until 37 days after last dose of the study drug. (NCT03599518)
Timeframe: Screening, Cycle 0 (7-day cycle), Days -1, 1, 2, 4, 6, and 7; Cycle 1 (21-day cycle), Days 1, 4, 8, and 15; Cycle 2 (21-day cycle), Days 1, 2, and 8; Cycle 3 and beyond (21-day cycles), Day 1; and end-of-treatment, 30 days after last dose, up to 1 year

,,,,
InterventionParticipants (Count of Participants)
Any TEAEInfections and InfestationsUpper respiratory tract infectionNasopharyngitisParonychiaNeoplasms Benign, Malignant, and Unspecified (including Cysts and Polyps)Tumour painBlood and Lymphatic System DisordersAnaemiaNeutropeniaMetabolism and Nutrition DisordersDecreased appetiteHypertriglyceridaemiaHyperuricaemiaNervous System DisordersHypoaesthesiaVagus nerve disorderEye DisordersConjunctival haemorrhageDry eyeEye disorderEar and Labyrinth DisordersVertigoRespiratory, Thoracic and Mediastinal DisordersCoughGastrointestinal DisordersDiarrhoeaNauseaVomitingConstipationDyspepsiaStomatitisAbdominal pain lowerAbdominal pain upperHepatobiliary DisordersHepatic function abnormalSkin and Subcutaneous Tissue DisordersRash maculo-papularDermatitis acneiformPruritusRashDry skinSkin hyperpigmentationMusculoskeletal and Connective Tissue DisordersNeck painGeneral Disorders and Administration Site ConditionsPyrexiaMalaisePainInvestigationsAspartate aminotransferase increasedAlanine aminotransferase increasedWhite blood cell count decreasedElectrocardiogram QT prolongedNeutrophil count decreasedAmylase increasedBlood alkaline phosphatase increasedBlood creatinine phosphokinase increasedLipase increasedWeight decreasedInjury, Poisoning and Procedural ComplicationsFall
DS-1205c 1000 mg + Gefitinib00000000000000000000000000000000000000000000000000000000000000
DS-1205c 1200 mg + Gefitinib41100001100000000000000003120010011132001000011002221010000000
DS-1205c 200 mg + Gefitinib52101110003111211000011004012211000031010010011003210001000100
DS-1205c 400 mg + Gefitinib41010110000000000211000113300001000030300101100002110000010000
DS-1205c 800 mg + Gefitinib60000111010000000100100003101000100053011000021114223210101011

[back to top]

Number of Participants With Best Overall Response With Confirmation as Assessed by Investigator Following Administration of DS-1205c in Combination With Gefitinib

Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Objective response rate was calculated as the number of participants with best objective response (CR + PR) determined by Investigator assessment based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1]. (NCT03599518)
Timeframe: Screening; Cycle 0 (7-day cycle); Cycle 1 and beyond (21-day cycles), Every 6 weeks (± 7 days) in the first 24 weeks after Day 1 of Cycle 1, and every 12 weeks (± 7 days) thereafter; and end-of-treatment, 30 days after last dose, up to 1 year

,,,,
InterventionParticipants (Count of Participants)
Complete response (CR)Partial response (PR)Stable disease (SD)Progressive disease (PD)Non-Evaluable (NE)Objective response rate (CR+PR)
DS-1205c 1000 mg + Gefitinib000100
DS-1205c 1200 mg + Gefitinib001210
DS-1205c 200 mg + Gefitinib002300
DS-1205c 400 mg + Gefitinib001300
DS-1205c 800 mg + Gefitinib001500

[back to top]

Progression-free Survival Assessed by Investigator Following Administration of DS-1205c in Combination With Gefitinib

Progression-free survival (PFS) was defined as the time from the date of the first dose to the earlier of the dates of the first objective documentation of radiographic PD or death due to any cause. As per the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions. (NCT03599518)
Timeframe: Screening; Cycle 0 (7-day cycle); Cycle 1 and beyond (21-day cycles), Every 6 weeks (± 7 days) in the first 24 weeks after Day 1 of Cycle 1, and every 12 weeks (± 7 days) thereafter; and end-of-treatment, 30 days after last dose, up to 1 year

Interventionweeks (Median)
DS-1205c 200 mg + Gefitinib6.7
DS-1205c 400 mg + Gefitinib7.1
DS-1205c 800 mg + Gefitinib6.9
DS-1205c 1000 mg + Gefitinib6.7
DS-1205c 1200 mg + Gefitinib6.9

[back to top]

Overall Survival in Participants Following Administration of DS-1205c in Combination With Gefitinib

Overall Survival (OS) was defined as the time from the date of first dose to the date of death from any cause. (NCT03599518)
Timeframe: Screening; Cycle 0 (7-day cycle); Cycle 1 and beyond (21-day cycles), Every 6 weeks (± 7 days) in the first 24 weeks after Day 1 of Cycle 1, and every 12 weeks (± 7 days) thereafter; and end-of-treatment, 30 days after last dose, up to 1 year

Interventionweeks (Median)
DS-1205c 200 mg + Gefitinib27.4
DS-1205c 400 mg + GefitinibNA
DS-1205c 800 mg + GefitinibNA
DS-1205c 1000 mg + Gefitinib35.4
DS-1205c 1200 mg + GefitinibNA

[back to top]

Number of Participants With Dose-limiting Toxicities (DLTs) Following Administration With DS-1205c in Combination With Gefitinib

A dose-limiting toxicity (DLT) was defined as any treatment-emergent adverse event (TEAE) not attributable to disease or disease-related processes that occurs during the DLT-evaluation period (Cycle 0 Day 1 to Cycle 1 Day 21 of Dose Escalation) and is Grade 3 or above, according to NCI-CTCAE version 5.0. (NCT03599518)
Timeframe: Cycle 0 Day 1 (7-day cycle) to Cycle 1 Day 21 (each cycle is 21 days)

InterventionParticipants (Count of Participants)
DS-1205c 200 mg + Gefitinib0
DS-1205c 400 mg + Gefitinib0
DS-1205c 800 mg + Gefitinib1
DS-1205c 1000 mg + Gefitinib0
DS-1205c 1200 mg + Gefitinib1

[back to top]

Disease Control Rate Assessed by Investigator Following Administration of DS-1205c in Combination With Gefitinib

Disease control rate (DCR) was defined number of participants with CR+PR+SD objective response. As per the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. (NCT03599518)
Timeframe: Screening; Cycle 0 (7-day cycle); Cycle 1 and beyond (21-day cycles), Every 6 weeks (± 7 days) in the first 24 weeks after Day 1 of Cycle 1, and every 12 weeks (± 7 days) thereafter; and end-of-treatment, 30 days after last dose, up to 1 year

InterventionParticipants (Count of Participants)
DS-1205c 200 mg + Gefitinib2
DS-1205c 400 mg + Gefitinib1
DS-1205c 800 mg + Gefitinib1
DS-1205c 1000 mg + Gefitinib0
DS-1205c 1200 mg + Gefitinib1

[back to top]

Pharmacokinetic Parameter Time to Maximum Concentration (Tmax) of DS-1205a Following Administration of DS-1205c in Combination With Gefitinib

Blood samples for pharmacokinetic (PK) analyses of DS-1205a were obtained at specified time points. Plasma concentrations of DS-1205a were measured using validated assays and non-compartmental analysis. (NCT03599518)
Timeframe: Predose, 1, 2, 4, 6, 8, and 10 hours of Cycle 0 (7-day cycle; DS-1205c alone), Days 1 and 7; Predose of Cycle 1 (21-day cycle), Day 1 (DS-1205c + gefitinib); Predose, 1, 2, 4, 6, 8, and 10 hours of Cycle 2 (21-day cycle; DS-1205c + gefitinib), Day 1

,,,,
Interventionhours (Median)
Cycle 0, Day 1Cycle 0, Day 7Cycle 1, Day 1Cycle 2, Day 1
DS-1205c 1000 mg + Gefitinib4.154.026.034.02
DS-1205c 1200 mg + Gefitinib5.081.973.080
DS-1205c 200 mg + Gefitinib3.993.973.901.93
DS-1205c 400 mg + Gefitinib4.994.024.004.99
DS-1205c 800 mg + Gefitinib3.995.084.014.13

[back to top]

Pharmacokinetic Parameter of Maximum Concentration (Cmax) of DS-1205a Following Administration of DS-1205c in Combination With Gefitinib

Blood samples for pharmacokinetic (PK) analyses of DS-1205a were obtained at specified time points. Plasma concentrations of DS-1205a were measured using validated assays and non-compartmental analysis. (NCT03599518)
Timeframe: Predose, 1, 2, 4, 6, 8, and 10 hours of Cycle 0 (7-day cycle; DS-1205c alone), Days 1 and 7; Predose of Cycle 1 (21-day cycle), Day 1 (DS-1205c + gefitinib); Predose, 1, 2, 4, 6, 8, and 10 hours of Cycle 2 (21-day cycle; DS-1205c + gefitinib), Day 1

,,,,
Interventionng/mL (Mean)
Cycle 0, Day 1Cycle 0, Day 7Cycle 1, Day 1Cycle 2, Day 1
DS-1205c 1000 mg + Gefitinib521580677632
DS-1205c 1200 mg + Gefitinib779108012701090
DS-1205c 200 mg + Gefitinib316521462490
DS-1205c 400 mg + Gefitinib500838907688
DS-1205c 800 mg + Gefitinib62311209951030

[back to top]

Percentage of Participants With Objective Response Rate (ORR)

ORR is defined as the percentage of patients who have at least 1 response of CR or PR prior to any evidence of progression. Target lesions and assessed by CT per RECIST v1.1 (Complete Response(CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.). (NCT03849768)
Timeframe: From baseline, then every 6 weeks, until disease progression or discontinuation from study.（up to 24 months）

Interventionpercentage of participants (Number)
HS-1029673.8
Gefitinib72.1

[back to top]

Number of Participants With Dose Reductions

"Participants had at least one reduction in planned treatment dosage due to treatment emergent adverse events. Every participant took 2 pills of HS~-10296 + 1 pill of placebo(experimental arm) or 2pills of placebo + 1pill of Gefitinib (control arm). When a dose reduction was decided by INV, the set of 2 pills of placebo was decreased resulting in no reduction of active compound in control arm, compliance with dose modification for AEs in Gefitinib's label which includes interruption, discontinuation but reduction." (NCT03849768)
Timeframe: From baseline, then every 6 weeks, until disease progression or discontinuation from study. (up to 24 months)

InterventionParticipants (Count of Participants)
HS-102969
Gefitinib10

[back to top]

Number of Participants With Adverse Events (AEs)/Serious Adverse Events (SAEs)

Safety was assessed by AEs, which included abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A treatment-emergent AE (TEAE) was defined as an AE observed after starting administration of the study drug. AEs were considered serious (SAEs) if the AE resulted in death, was life threatening, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, resulted in congenital anomaly, or birth defect or required inpatient hospitalization or led to prolongation of hospitalization. (NCT03849768)
Timeframe: Continuously throughout the study until 28 days after HS-10296 discontinuation.From first dose of study drug up to 28 days after last dose of study drug taken (up to data cut-off (15 Jan 2021)),approximately 2 years.

InterventionParticipants (Count of Participants)
HS-10296211
Gefitinib213

[back to top]

Assess the Anti-tumor Activity: Duration of Response (DoR)

DoR is defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression assessed up to 24 months. (NCT03849768)
Timeframe: From baseline, then every 6 weeks, until disease progression or discontinuation from study. (up to 24 months)

Interventionmonths (Median)
HS-1029618.1
Gefitinib8.3

[back to top]

Assess the Anti-tumor Activity: Depth of Response (DepOR)

DepOR is defined as the percentage change in tumor shrinkage, based on longest diameter or reconstructed volume, observed at the lowest point (nadir) compared with baseline. (NCT03849768)
Timeframe: From baseline, then every 6 weeks, until disease progression or discontinuation from study.（up to 24 months）

Interventionpercentage of change from baseline (Mean)
HS-10296-44.95
Gefitinib-41.95

[back to top]

Assess the Anti-tumor Activity: Disease Control Rate (DCR)

The DCR is defined as the proportion of patients with a best overall response of CR, PR, or SD assessed up to 24 months. (NCT03849768)
Timeframe: From baseline, then every 6 weeks, until disease progression or discontinuation from study.

Interventionpercentage (Number)
HS-1029693.0
Gefitinib96.7

[back to top]

Number of Participants With Dose Interruptions

Participants had at least one delay in planned treatment due to treatment emergent adverse events. (NCT03849768)
Timeframe: From baseline, then every 6 weeks, until disease progression or discontinuation from study. (up to 24 months)

InterventionParticipants (Count of Participants)
HS-1029636
Gefitinib53

[back to top]

Progression Free Survival (PFS)

PFS was defined as the time from the date of first dose until the date of radiological disease progression or until death due to any cause, based on the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, as assessed by investigators. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT03849768)
Timeframe: From baseline, then every 6 weeks, until disease progression or discontinuation from study. From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, approximately 2 years.

Interventionmonths (Median)
HS-1029619.3
Gefitinib9.9

[back to top]

Uncommon Cohort: Number of Participants for Each Type of Biological Samples Used for Mutation Detection at Index Therapy Start

"Number of participants for each type of biological samples used for mutation detection at index therapy start (index therapy refers to therapy switch from first-line chemotherapy to second-line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) therapy (index line)) is reported.~The reported categories of biological samples are:~Tissue, Histological sample (solid biopsy);~Cytological sample;~Blood (liquid biopsy);~Other and~Unknown." (NCT04179890)
Timeframe: Up to 13 years.

InterventionParticipants (Count of Participants)
Tissue, Histological sample (solid biopsy)Cytological sampleBlood (liquid biopsy)OtherUnknown
Uncommon EGFR Mutation Cohort19929223

[back to top]

Number of Participants for Each Type of Methodology Used for Mutational Testing at Second-line Treatment Stop/End of Observation

"Number of participants for each type of methodology used for mutational testing is reported.~The reported types of methodologies are:~Polymerase Chain Reaction (PCR)-based techniques;~Next-Generation Sequencing (NGS);~Unknown." (NCT04179890)
Timeframe: At second-line treatment stop/end of observation (i.e. between 2007 and 16-Jul-2020 for Uncommon Epidermal Growth Factor Receptor (EGFR) mutation cohort and between 2014 and 23-Oct-2020 for the Sequencing Cohort).

,
InterventionParticipants (Count of Participants)
PCR-based techniquesNext-Generation Sequencing (NGS)Unknown
Sequencing Cohort1123
Uncommon EGFR Mutation Cohort721

[back to top]

Number of Participants for Each Type of Biological Samples Used for Mutation Detection at Second Line Treatment Stop/End of Observation

"Number of participants for each type of biological samples used for mutation detection at second line treatment stop/end of observation is reported.~The reported categories of biological samples are:~Tissue, Histological sample (solid biopsy);~Cytological sample;~Blood (liquid biopsy);~Other." (NCT04179890)
Timeframe: At second-line treatment start (i.e. between 2007 and 16-Jul-2020 for Uncommon Epidermal Growth Factor Receptor (EGFR) mutation cohort and between 2014 and 23-Oct-2020 for the Sequencing Cohort).

,
InterventionParticipants (Count of Participants)
Tissue, Histological sample (solid biopsy)Blood (liquid biopsy)OtherCytological sample
Sequencing Cohort9901
Uncommon EGFR Mutation Cohort5410

[back to top]

Uncommon Mutation Cohort: Number of Participants for Each Type of Methodology Used for Mutation Detection at Start of First-line Chemotherapy Before Index Line

"Number of participants for each type of methodology used for mutation detection at start of first-line chemotherapy before index line is reported.~The reported types of methodologies are:~PCR-based techniques;~Sequencing;~Next-Generation Sequencing (NGS);~Unknown.~Index therapy refers to therapy switch from first-line chemotherapy to second-line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) therapy (index line)." (NCT04179890)
Timeframe: At start of first-line chemotherapy before index line (i.e. between 2007 and 2019).

InterventionParticipants (Count of Participants)
PCR-based techniquesSequencingNext-Generation Sequencing (NGS)Unknown
Uncommon EGFR Mutation Cohort9521

[back to top]

Sequencing Cohort: Overall Response Rate to First Line Afatinib

"Overall response rate (ORR) using RECIST criteria as assessed by investigator. Overall response rate to first line afatinib treatment for the Common Epidermal Growth Factor Receptor (EGFR) mutation cohort is reported. (ORR is defined as number of patients with complete or partial response evaluated by Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1)).~(Per RECIST 1.1: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR)." (NCT04179890)
Timeframe: Up to 6 years.

InterventionParticipants (Count of Participants)
Sequencing Cohort131

[back to top]

Overall Survival

Uncommon Mutation Cohort: Overall survival since index line treatment start of Tyrosine Kinase Inhibitor (TKI) medication administered per generation until death date by any cause or the end of index line is reported. Sequencing cohort: Overall survival for since first-line afatinib treatment start until death date by any cause or the end of index line. Kaplan-Meier estimates of quartiles of time to death were computed (with their 95% Confidence Intervals, using Greenwood's variance estimate. (NCT04179890)
Timeframe: Up to 13 years for Uncommon EGFR mutation cohort and up to 6 years for the Sequencing Cohort.

InterventionMonths (Median)
Uncommon EGFR Mutation Cohort24.44
Sequencing Cohort36.50

[back to top]

Time on Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)

"Uncommon Mutation Cohort: Time on treatment with EGFR-TKI assessed as the time from start of EGFR-TKI treatment until the end of treatment or death by any cause is reported.~Common mutation cohort: Time on treatment with EGFR-TKI assessed as the time from start of afatinib (Gi(l)otrif®) as first-line treatment until the end of the second line treatment (the last dose of osimertinib) or death date by any cause.~Time on treatment was analysed using Kaplan-Meier method, and the median was tabulated along with two-sided 95% confidence interval using the Greenwood's variance estimate." (NCT04179890)
Timeframe: Up to 13 years for Uncommon EGFR mutation cohort and up to 6 years for the Sequencing Cohort.

InterventionMonths (Median)
Uncommon EGFR Mutation Cohort9.89
Sequencing Cohort27.7

[back to top]

Uncommon Epidermal Growth Factor Receptor (EGFR) Mutation Cohort: Overall Response Rate to Index Line Treatment

"Overall response rate (ORR) using RECIST criteria as assessed by investigator. ORR to index line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) treatment is reported (ORR is defined as number of patients with complete or partial response evaluated by Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1)).~(Per RECIST 1.1: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR)." (NCT04179890)
Timeframe: Up to 13 years.

InterventionParticipants (Count of Participants)
Uncommon EGFR Mutation Cohort96

[back to top]

Uncommon Mutation Cohort: Time on Treatment Until Failure of Second-line (TTF2)

Time on treatment until failure of second-line (TTF2), defined as time elapsed from start of first-line treatment (regardless the type of treatment) to stop of second-line (regardless of the type of treatment) or death by any cause is reported. Kaplan-Meier estimates of quartiles of time to second-line treatment failure were computed (with their 95% Confidence Intervals, using Greenwood's variance estimate). (NCT04179890)
Timeframe: From start of first-line treatment to stop of second-line or death by any cause, up to 13 years.

InterventionMonths (Median)
Uncommon EGFR Mutation Cohort14.46

[back to top]

Number of Participants for Each Category of Methodology Used for Mutational Testing at First Line Treatment Start

"Number of participants for each type of methodologies used for mutational testing is reported.~The reported types of methodology are:~Amplification Refractory Mutation System (ARMS);~Polymerase Chain reactions (PCR)-based techniques;~Sequencing;~Next-Generation Sequencing (NGS);~Other;~Unknown." (NCT04179890)
Timeframe: At first-line treatment start (i.e. between 2007 and 2019 for the Uncommon Epidermal Growth Factor Receptor (EGFR) mutation cohort and between 2014 and 2018 for the Sequencing Cohort).

,
InterventionParticipants (Count of Participants)
Amplification Refractory Mutation System (ARMS)PCR-based techniquesSequencingNext-Generation Sequencing (NGS)UnknownOther
Sequencing Cohort4122158411
Uncommon EGFR Mutation Cohort41553920420

[back to top]

Number of Participants for Each Type of Biological Samples Used for Mutation Detection at First Line Treatment Start

"Number of participants for each type of biological samples used for mutation detection at first line treatment start is reported.~The reported types of biological samples are:~Tissue, histological sample (solid biopsy);~Cytological sample;~Blood (liquid biopsy);~Other and~Unknown." (NCT04179890)
Timeframe: At first-line treatment start (i.e. between 2007 and 2019 for the Uncommon Epidermal Growth Factor Receptor (EGFR) mutation cohort and between 2014 and 2018 for Sequencing Cohort).

,
InterventionParticipants (Count of Participants)
Tissue, Histological sample (solid biopsy)Cytological sampleBlood (liquid biopsy)OtherUnknown
Sequencing Cohort16019626
Uncommon EGFR Mutation Cohort21232323

[back to top]

Number of Participants for Each Type of Biological Samples Used for Mutation Detection at Second Line Treatment Start

"Number of participants for each type of biological samples used for mutation detection at second line treatment start is reported.~The reported types of biological samples are:~Tissue, Histological sample (solid biopsy);~Cytological sample;~Blood (liquid biopsy);~Not applicable-Clinical evaluation;~Other;~Unknown. Not applicable - Clinical evaluation: The uncommon Epidermal Growth Factor Receptor (EGFR) mutational status had become available after Progression on conventional second-line therapy. Erlotinib was given as state of the art second-line therapy in 2014, and an EGFR mutation was clinically suspected due to the Long-Lasting response. However, due to the unavailability of tumor tissue, this could be proven only after liquid biopsy had subsequently become available at the center in 2016.~For the Sequencing cohort second-line treatment start is initiated by the beginning of the therapy with Osimertinib." (NCT04179890)
Timeframe: "At second-line treatment start (i.e. between 2007 and 16-Jul-2020 for Uncommon EGFR mutation cohort and between 2014 and 23-Oct-2020 for the Sequencing Cohort"

,
InterventionParticipants (Count of Participants)
Tissue, Histological sample (solid biopsy)Cytological sampleBlood (liquid biopsy)Not applicable - Clinical evaluationOtherUnknown
Sequencing Cohort9318570719
Uncommon EGFR Mutation Cohort2238100

[back to top]

Number of Participants for Each Type of Methodology Used for Mutational Testing at Second-line Treatment Start

"Number of participants for each type of methodology used for mutational testing at second-line treatment start is reported.~The reported types of methodologies are:~Amplification Refractory Mutation System (ARMS);~Polymerase Chain Reaction (PCR)-based techniques;~Sequencing;~Next-Generation Sequencing (NGS);~Other;~Unknown/Not applicable- Clinical evaluation." (NCT04179890)
Timeframe: At second-line treatment start (i.e. between 2007 and 16-Jul-2020 for Uncommon Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR) mutation cohort and between 2014 and 23-Oct-2020 for the Sequencing Cohort).

,
InterventionParticipants (Count of Participants)
PCR-based techniquesSequencingNext-Generation Sequencing (NGS)Unknown/Not applicable- Clinical evaluationAmplification Refractory Mutation System (ARMS)Other
Sequencing Cohort1212135131
Uncommon EGFR Mutation Cohort2323600

[back to top]

Uncommon Mutation Cohort: Number of Participants for Each Type of Biological Samples Used for Mutation Detection at Start of First-line Chemotherapy Before Index Line

"Number of participants for each type of biological samples used for mutation detection at start of first-line chemotherapy before index line is reported. Index therapy refers to therapy switch from first-line chemotherapy to second-line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) therapy (index line).~The reported types of biological samples are:~Tissue, Histological sample (solid biopsy);~Cytological sample, Blood (liquid biopsy)." (NCT04179890)
Timeframe: At start of first-line chemotherapy before index line (i.e. between 2007 and 2019).

InterventionParticipants (Count of Participants)
Tissue, Histological sample (solid biopsy)Cytological sampleBlood (liquid biopsy)
Uncommon EGFR Mutation Cohort1331

[back to top]

Uncommon Mutation Cohort: Number of Participants for Each Type of Methodology Used for Mutation Detection at Index Therapy Start

"Number of participants for each type of methodology used for mutation detection at index therapy start is reported. Index therapy refers to therapy switch from first-line chemotherapy to second-line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) therapy (index line).~The reported categories of methodology are:~Amplification Refractory Mutation System (ARMS),~Polymerase chain reaction based techniques (PCR-based techniques),~Sequencing,~Next-Generation Sequencing (NGS),~Unknown." (NCT04179890)
Timeframe: Up to 13 years.

InterventionParticipants (Count of Participants)
Amplification Refractory Mutation System (ARMS)PCR-based techniquesSequencingNext-Generation Sequencing (NGS)Unknown
Uncommon EGFR Mutation Cohort4146341841

[back to top]

Sequencing Cohort: Overall Response Rate to Second-line Treatment Osimertinib

"Overall response rate (ORR) using RECIST criteria as assessed by investigator. Overall response rate to second-line treatment (Osimertinib) is reported. (ORR is defined as number of patients with complete or partial response evaluated by Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1)).~(Per RECIST 1.1: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR)." (NCT04179890)
Timeframe: Up to 6 years.

InterventionParticipants (Count of Participants)
Sequencing Cohort75

[back to top]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ethylene dichloride
ethylene dichloride: RN given refers to 1,2-isomer; structure given in first source. 1,2-dichloroethane : A member of the class of chloroethanes substituted by two chloro groups at positions 1 and 2.		2.0510chloroethaneshepatotoxic agent;
mutagen;
non-polar solvent
gamma-aminobutyric acid
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.		4.7721amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
aminolevulinic acid
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.. 5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.		4.46604-oxo monocarboxylic acid;
amino acid zwitterion;
delta-amino acid		antineoplastic agent;
dermatologic drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
ethylene glycol
Ethylene Glycol: A colorless, odorless, viscous dihydroxy alcohol. It has a sweet taste, but is poisonous if ingested. Ethylene glycol is the most important glycol commercially available and is manufactured on a large scale in the United States. It is used as an antifreeze and coolant, in hydraulic fluids, and in the manufacture of low-freezing dynamites and resins.. ethanediol : Any diol that is ethane or substituted ethane carrying two hydroxy groups.. ethylene glycol : A 1,2-glycol compound produced via reaction of ethylene oxide with water.		2.0510ethanediol;
glycol		metabolite;
mouse metabolite;
solvent;
toxin
acetic acid
Acetic Acid: Product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed). acetic acid : A simple monocarboxylic acid containing two carbons.		2.0510monocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent
acetamide
acetimidic acid : A carboximidic acid that is acetic acid in which the carbonyl oxygen is replaced by an imino group.		2.8230acetamides;
carboximidic acid;
monocarboxylic acid amide;
N-acylammonia
adenine
[no description available]		6.09816-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
allantoin
[no description available]		2.0510imidazolidine-2,4-dione;
ureas		Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite;
vulnerary
ammonium hydroxide
azane : Saturated acyclic nitrogen hydrides having the general formula NnHn+2.		4.6111azane;
gas molecular entity;
mononuclear parent hydride		EC 3.5.1.4 (amidase) inhibitor;
metabolite;
mouse metabolite;
neurotoxin;
NMR chemical shift reference compound;
nucleophilic reagent;
refrigerant
quinacrine
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.		2.4520acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
betaine
glycine betaine : The amino acid betaine derived from glycine.		3.8830amino-acid betaine;
glycine derivative		fundamental metabolite
butyric acid
Butyric Acid: A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.. butyrate : A short-chain fatty acid anion that is the conjugate base of butyric acid, obtained by deprotonation of the carboxy group.. butyric acid : A straight-chain saturated fatty acid that is butane in which one of the terminal methyl groups has been oxidised to a carboxy group.		2.110fatty acid 4:0;
straight-chain saturated fatty acid		human urinary metabolite;
Mycoplasma genitalium metabolite
cadaverine
[no description available]		2.0810alkane-alpha,omega-diamineDaphnia magna metabolite;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite
carbamates
[no description available]		2.1310amino-acid anion
formic acid
formic acid: RN given refers to parent cpd. formic acid : The simplest carboxylic acid, containing a single carbon. Occurs naturally in various sources including the venom of bee and ant stings, and is a useful organic synthetic reagent. Principally used as a preservative and antibacterial agent in livestock feed. Induces severe metabolic acidosis and ocular injury in human subjects.		2.2110monocarboxylic acidantibacterial agent;
astringent;
metabolite;
protic solvent;
solvent
carnitine
[no description available]		2.4520amino-acid betainehuman metabolite;
mouse metabolite
methane
Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed). methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).		4.6111alkane;
gas molecular entity;
mononuclear parent hydride;
one-carbon compound		bacterial metabolite;
fossil fuel;
greenhouse gas
choline
[no description available]		7.0410cholinesallergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite
citric acid, anhydrous
Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.. citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.		4.9721tricarboxylic acidantimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite
salicylic acid
Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).		2.7830monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
gallic acid
gallate : A trihydroxybenzoate that is the conjugate base of gallic acid.		2.1310trihydroxybenzoic acidantineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite
4-aminophenol
4-aminophenol: RN given refers to parent cpd. 4-aminophenol : An amino phenol (one of the three possible isomers) which has the single amino substituent located para to the phenolic -OH group.		2.0510aminophenolallergen;
metabolite
bupropion
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.. bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.		4.0840aromatic ketone;
monochlorobenzenes;
secondary amino compound		antidepressant;
environmental contaminant;
xenobiotic
aminocaproic acid
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.		4.0840amino acid zwitterion;
epsilon-amino acid;
omega-amino fatty acid		antifibrinolytic drug;
hematologic agent;
metabolite
creatine
[no description available]		2.0510glycine derivative;
guanidines;
zwitterion		geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical
lactic acid
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.		3.66802-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
dimethyl sulfoxide
Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.		2.8130sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
formaldehyde
paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy		2.7430aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
hexachlorocyclohexane
Lindane: An organochlorine insecticide made up of greater than 99% gamma-Hexachlorocyclohexane. It has been used as a pediculicide and scabicide, and shown to cause cancer.. beta-hexachlorocyclohexane : The beta-isomer of hexachlorocyclohexane.		2.0510chlorocyclohexane
glycine
[no description available]		2.7630alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
glycerol
Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.		5.3131alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
dalteparin
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)		2.1110
histamine
[no description available]		4.6111aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
hydrogen
Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.. dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.		4.6111elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite
hydroquinone
[no description available]		2.0510benzenediol;
hydroquinones		antioxidant;
carcinogenic agent;
cofactor;
Escherichia coli metabolite;
human xenobiotic metabolite;
mouse metabolite;
skin lightening agent
imidazole
imidazole: RN given refers to parent cpd. 1H-imidazole : An imidazole tautomer which has the migrating hydrogen at position 1.		2.0510imidazole
indole
[no description available]		2.1710indole;
polycyclic heteroarene		Escherichia coli metabolite
thioctic acid
Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.		2.0810dithiolanes;
heterocyclic fatty acid;
thia fatty acid		fundamental metabolite;
geroprotector
inositol
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.		2.4620cyclitol;
hexol
melatonin
[no description available]		7.7730acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
naphthalene
[no description available]		7.520naphthalenes;
ortho-fused bicyclic arene		apoptosis inhibitor;
carcinogenic agent;
environmental contaminant;
mouse metabolite;
plant metabolite;
volatile oil component
niacinamide
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.		11.16351pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
niacin
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.		3.8630pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3		antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
nitrates
Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.		4.6111monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species
nitrites
Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)		4.6111monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		human metabolite
orotic acid
Orotic Acid: An intermediate product in PYRIMIDINE synthesis which plays a role in chemical conversions between DIHYDROFOLATE and TETRAHYDROFOLATE.. orotic acid : A pyrimidinemonocarboxylic acid that is uracil bearing a carboxy substituent at position C-6.		2.0510pyrimidinemonocarboxylic acidEscherichia coli metabolite;
metabolite;
mouse metabolite
4-aminobenzoic acid
4-Aminobenzoic Acid: An aminobenzoic acid isomer that combines with pteridine and GLUTAMIC ACID to form FOLIC ACID. The fact that 4-aminobenzoic acid absorbs light throughout the UVB range has also resulted in its use as an ingredient in SUNSCREENS.. 4-ammoniobenzoate : A zwitterion obtained by transfer of a proton from the carboxy to the amino group of 4-aminobenzoic acid.. 4-aminobenzoic acid : An aminobenzoic acid in which the amino group is para to the carboxy group.		2.0510aminobenzoic acid;
aromatic amino-acid zwitterion		allergen;
Escherichia coli metabolite;
plant metabolite
triphosphoric acid
triphosphoric acid: used as water softener, peptizing agent, emulsifier & dispersing agent; ingredient of cleansers; meat preservative; RN given refers to parent cpd; structure		2.1510acyclic phosphorus acid anhydride;
phosphorus oxoacid
phenol
[no description available]		7.4620phenolsantiseptic drug;
disinfectant;
human xenobiotic metabolite;
mouse metabolite
phenylacetic acid
phenylacetic acid : A monocarboxylic acid that is toluene in which one of the hydrogens of the methyl group has been replaced by a carboxy group.		2.0510benzenes;
monocarboxylic acid;
phenylacetic acids		allergen;
Aspergillus metabolite;
auxin;
EC 6.4.1.1 (pyruvate carboxylase) inhibitor;
Escherichia coli metabolite;
human metabolite;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite;
toxin
phosphorylcholine
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.		3.8830phosphocholinesallergen;
epitope;
hapten;
human metabolite;
mouse metabolite
propylene glycol
Propylene Glycol: A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.. propane-1,2-diol : The simplest member of the class of propane-1,2-diols, consisting of propane in which a hydrogen at position 1 and a hydrogen at position 2 are substituted by hydroxy groups. A colourless, viscous, hygroscopic, low-melting (-59degreeC) and high-boiling (188degreeC) liquid with low toxicity, it is used as a solvent, emulsifying agent, and antifreeze.		4.6111glycol;
propane-1,2-diols		allergen;
human xenobiotic metabolite;
mouse metabolite;
protic solvent
pteridines
[no description available]		2.4920azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
pteridines
purine
1H-purine : The 1H-tautomer of purine.. 3H-purine : The 3H-tautomer of purine.. 9H-purine : The 9H-tautomer of purine.. 7H-purine : The 7H-tautomer of purine.		7.2110purine
pyrazinamide
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.		4.0940monocarboxylic acid amide;
N-acylammonia;
pyrazines		antitubercular agent;
prodrug
pyrazole
1H-pyrazole : The 1H-tautomer of pyrazole.		2.1710pyrazole
pyridoxal phosphate
Pyridoxal Phosphate: This is the active form of VITAMIN B 6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (PYRIDOXAMINE).. pyridoxal 5'-phosphate : The monophosphate ester obtained by condensation of phosphoric acid with the primary hydroxy group of pyridoxal.		2.0510methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6 phosphate		coenzyme;
cofactor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pyridoxine
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source. vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).		3.8630hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine;
vitamin B6		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
thiosulfates
Thiosulfates: Inorganic salts of thiosulfuric acid possessing the general formula R2S2O3.. thiosulfate(2-) : A divalent inorganic anion obtained by removal of both protons from thiosulfuric acid.		2.2110divalent inorganic anion;
sulfur oxide;
sulfur oxoanion		human metabolite
sulfur dioxide
Sulfur Dioxide: A highly toxic, colorless, nonflammable gas. It is used as a pharmaceutical aid and antioxidant. It is also an environmental air pollutant.		4.6111sulfur oxideEscherichia coli metabolite;
food bleaching agent;
refrigerant
thiamine
thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.		3.8630primary alcohol;
vitamin B1		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
trimethylamine
[no description available]		2.2510methylamines;
tertiary amine		Escherichia coli metabolite;
human xenobiotic metabolite
uracil
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder		9.5251pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
uric acid
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.. uric acid : An oxopurine that is the final oxidation product of purine metabolism.. 6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.. 7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.		2.1110uric acidEscherichia coli metabolite;
human metabolite;
mouse metabolite
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		2.0510isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
catechin
[no description available]		2.0510hydroxyflavan
b 844-39
[no description available]		3.5110diarylmethane
vanilmandelic acid
Vanilmandelic Acid: A 3-O-methyl ether of 3,4-dihydroxymandelic acid. It is an end-stage metabolite of CATECHOLAMINES; EPINEPHRINE; and NOREPINEPHRINE.. vanillylmandelic acid : An aromatic ether that is the 3-O-methyl ether of 3,4-dihydroxymandelic acid.		3.46112-hydroxy monocarboxylic acid;
aromatic ether;
phenols		human metabolite
menthol
Menthol: A monoterpene cyclohexanol produced from mint oils.		2.0510p-menthane monoterpenoid;
secondary alcohol		volatile oil component
pk 11195
PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine		2.0810aromatic amide;
isoquinolines;
monocarboxylic acid amide;
monochlorobenzenes		antineoplastic agent
1-(3-chlorophenyl)piperazine
1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure. 1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.		2.4620monochlorobenzenes;
N-arylpiperazine		drug metabolite;
environmental contaminant;
serotonergic agonist;
xenobiotic
pd 173074
[no description available]		2.9840aromatic amine;
biaryl;
dimethoxybenzene;
pyridopyrimidine;
tertiary amino compound;
ureas		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist
hoe 33342
BXI-72: structure in first source		2.4920bibenzimidazole;
N-methylpiperazine		fluorochrome
2,2'-dipyridyl
2,2'-Dipyridyl: A reagent used for the determination of iron.. 2,2'-bipyridine : A bipyridine in which the two pyridine moieties are linked by a bond between positions C-2 and C-2'.		2.1310bipyridinechelator;
ferroptosis inhibitor
2,4-dinitrophenol
2,4-Dinitrophenol: A toxic dye, chemically related to trinitrophenol (picric acid), used in biochemical studies of oxidative processes where it uncouples oxidative phosphorylation. It is also used as a metabolic stimulant. (Stedman, 26th ed). dinitrophenol : Members of the class of nitrophenol carrying two nitro substituents.. 2,4-dinitrophenol : A dinitrophenol having the nitro groups at the 2- and 4-positions.		2.0510dinitrophenolallergen;
antiseptic drug;
bacterial xenobiotic metabolite;
geroprotector;
oxidative phosphorylation inhibitor
aminopropionitrile
Aminopropionitrile: Reagent used as an intermediate in the manufacture of beta-alanine and pantothenic acid.		2.2510aminopropionitrileantineoplastic agent;
antirheumatic drug;
collagen cross-linking inhibitor;
plant metabolite
enprofylline
enprofylline : Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.		2.0410oxopurineanti-arrhythmia drug;
anti-asthmatic drug;
bronchodilator agent;
non-steroidal anti-inflammatory drug
4,5,6,7-tetrabromo-2-azabenzimidazole
4,5,6,7-tetrabromobenzotriazole: a CK2 kinase inhibitor		2.0310
cgp 52411
4,5-dianilinophthalimide: structure given in first source. 4,5-dianilinophthalimide : Phthalimide substituted at the 4- and 5-positions by anilino groups.		210phthalimidesgeroprotector;
tyrosine kinase inhibitor
homovanillic acid
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.. homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.. homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.		3.4611guaiacols;
monocarboxylic acid		human metabolite;
mouse metabolite
phenytoin
[no description available]		10.7961imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
oxyquinoline
Oxyquinoline: An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics.. quinolin-8-ol : A monohydroxyquinoline that is quinoline substituted by a hydroxy group at position 8. Its fungicidal properties are used for the control of grey mould on vines and tomatoes.		2.0510monohydroxyquinolineantibacterial agent;
antifungal agrochemical;
antiseptic drug;
iron chelator
tacrine
Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.		2.9740acridines;
aromatic amine		EC 3.1.1.7 (acetylcholinesterase) inhibitor
N-(2-aminoethyl)-5-chloro-1-naphthalenesulfonamide
[no description available]		2.0310naphthalenes;
sulfonic acid derivative
abt 702
[no description available]		2.0810bipyridines
acebutolol
Acebutolol: A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.. acebutolol : An ether that is the 2-acetyl-4-(butanoylamino)phenyl ether of the primary hydroxy group of 3-(propan-2-ylamino)propane-1,2-diol.		3.8630aromatic amide;
ethanolamines;
ether;
monocarboxylic acid amide;
propanolamine;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympathomimetic agent
acetaminophen
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.		4.87100acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
acetazolamide
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)		4.6980monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
acetohexamide
Acetohexamide: A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide.. acetohexamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is replaced by a p-acetylphenylsulfonyl group, while a hydrogen attached to the other nitrogen is replaced by a cyclohexyl group.		2.4620acetophenones;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue
acetohydroxamic acid
acetohydroxamic acid: urease inhibitor. oxime : Compounds of structure R2C=NOH derived from condensation of aldehydes or ketones with hydroxylamine. Oximes from aldehydes may be called aldoximes; those from ketones may be called ketoximes.. N-hydroxyacetimidic acid : A carbohydroximic acid consisting of acetimidic acid having a hydroxy group attached to the imide nitrogen.. acetohydroxamic acid : A member of the class of acetohydroxamic acids that is acetamide in which one of the amino hydrogens has been replaced by a hydroxy group.		3.5920acetohydroxamic acids;
carbohydroximic acid		algal metabolite;
EC 3.5.1.5 (urease) inhibitor
tyrphostin ag 1024
tyrphostin AG 1024: modulates radiosensitivity in human breast cancer cells; also an IGF1 receptor inhibitor		2.4420alkylbenzene
ag 1295
[no description available]		2.0310quinoxaline derivativegeroprotector
rtki cpd
[no description available]		3.8730aromatic ether;
monochlorobenzenes;
quinazolines		antineoplastic agent;
antiviral agent;
epidermal growth factor receptor antagonist;
geroprotector
tyrphostin a23
tyrphostin A23: inhibits EGF-stimulated thymidine incorporation as well as EGF-stimulated receptor autophosphorylation & tyrosine phosphorylation & cell proliferation; structure given in first source		2.0310catechols
alaproclate
alaproclate: specific 5-hydroxytryptamine uptake inhibitors; RN given refers to (DL)-isomer		3.2310alpha-amino acid ester
albendazole
[no description available]		4.2850aryl sulfide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		anthelminthic drug;
microtubule-destabilising agent;
tubulin modulator
albuterol
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).		4.2750phenols;
phenylethanolamines;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic
alendronate
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.		3.23101,1-bis(phosphonic acid);
primary amino compound		bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
alfuzosin
alfuzosin: structure given in first source		4.6240monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
alosetron
alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.		3.8530imidazoles;
pyridoindole		antiemetic;
gastrointestinal drug;
serotonergic antagonist
alprazolam
Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.		3.5820organochlorine compound;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic
alprenolol
Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.. alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.		2.7530secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
altretamine
Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.		3.5920triamino-1,3,5-triazine
amantadine
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source		4.7850adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
ambenonium
ambenonium : A symmetrical oxalamide-based bis-quaternary ammonium ion having ethyl and 2-chlorobenzyl groups attached to the nitrogens.		3.2310quaternary ammonium ionEC 3.1.1.8 (cholinesterase) inhibitor
ambroxol
Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.		2.0510aromatic amine
diatrizoic acid
Diatrizoate: A commonly used x-ray contrast medium. As DIATRIZOATE MEGLUMINE and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.. amidotrizoic acid : A member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography.		3.8730acetamides;
benzoic acids;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
amifostine anhydrous
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.. amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.		3.2310diamine;
organic thiophosphate		antioxidant;
prodrug;
radiation protective agent
aminoglutethimide
Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.. aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.		2.7630dicarboximide;
piperidones;
substituted aniline		adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
pimagedine
pimagedine: diamine oxidase & nitric oxide synthase inhibitor; an advanced glycosylation end product inhibitor; used in the treatment of diabetic complications; structure. aminoguanidine : A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide.		2.0510guanidines;
one-carbon compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 1.4.3.4 (monoamine oxidase) inhibitor
p-aminohippuric acid
p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.. p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.. p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.		3.5820N-acylglycineDaphnia magna metabolite
theophylline
[no description available]		4.5470dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
amiodarone
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.		5.791101-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug
dan 2163
[no description available]		2.0810aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone		environmental contaminant;
second generation antipsychotic;
xenobiotic
amitriptyline
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.		4.4160carbotricyclic compound;
tertiary amine		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic
amlexanox
amlexanox: SRA-A antagonist;structure given in first source. amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.		2.0810monocarboxylic acid;
pyridochromene		anti-allergic agent;
anti-ulcer drug;
non-steroidal anti-inflammatory drug
amlodipine
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.		4.0840dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound		antihypertensive agent;
calcium channel blocker;
vasodilator agent
amobarbital
Amobarbital: A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565). amobarbital : A member of the class of barbiturates that is pyrimidine-2,4,6(1H,3H,5H)-trione substituted by a 3-methylbutyl and an ethyl group at position 5. Amobarbital has been shown to exhibit sedative and hypnotic properties.		2.0510barbiturates
amodiaquine
Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.. amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.		2.0810aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug
amoxapine
Amoxapine: The N-demethylated derivative of the antipsychotic agent LOXAPINE that works by blocking the reuptake of norepinephrine, serotonin, or both; it also blocks dopamine receptors. Amoxapine is used for the treatment of depression.. amoxapine : A dibenzooxazepine compound having a chloro substituent at the 2-position and a piperazin-1-yl group at the 11-position.		4.140dibenzooxazepineadrenergic uptake inhibitor;
antidepressant;
dopaminergic antagonist;
geroprotector;
serotonin uptake inhibitor
amsacrine
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.		3.1650acridines;
aromatic ether;
sulfonamide		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
anastrozole
[no description available]		11.85207nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
anethole trithione
Anethole Trithione: Choleretic used to allay dry mouth and constipation due to tranquilizers.		2.0510methoxybenzenes
anthralin
Anthralin: An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.. anthralin : An anthracene compound derived by the substitution of -OH groups for hydrogen at C-1 and C-8, and with an oxo group at C-9.		2.4720anthracenesantipsoriatic
antipyrine
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29). antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.		2.9740pyrazoloneantipyretic;
cyclooxygenase 3 inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
aprindine
Aprindine: A class Ib anti-arrhythmia agent used to manage ventricular and supraventricular arrhythmias.		2.1710indanes
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		12.26121benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
astemizole
Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.		8.3360benzimidazoles;
piperidines		anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist
atenolol
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.		4.2650ethanolamines;
monocarboxylic acid amide;
propanolamine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic
azathioprine
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed). azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.		4.9260aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine		antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug
azelastine
azelastine: azeptin is azelastine hydrochloride; structure; eye drop formulation effective in relieving symptoms of allergic conjunctivitis; do not confuse with 5-loxin which is an extract of Boswellia. azelastine : A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position.		2.0410monochlorobenzenes;
phthalazines;
tertiary amino compound		anti-allergic agent;
anti-asthmatic drug;
bronchodilator agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
H1-receptor antagonist;
platelet aggregation inhibitor
baclofen
[no description available]		3.8730amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant
barbital
5,5-diethylbarbituric acid : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by two ethyl groups. Formerly used as a hypnotic (sleeping aid).		2.0510barbituratesdrug allergen
bendazac
bendazac : A monocarboxylic acid that is glycolic acid in which the hydrogen attached to the 2-hydroxy group is replaced by a 1-benzyl-1H-indazol-3-yl group. Although it has anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties and has been used for the treatment of various inflammatory skin disorders, its principal effect is to inhibit the denaturation of proteins. Its lysine salt is used in the management of cataracts.		3.5920indazoles;
monocarboxylic acid		non-steroidal anti-inflammatory drug;
radical scavenger
bendroflumethiazide
Bendroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810). bendroflumethiazide : A sulfonamide consisting of 7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by a trifluoromethyl group and that at position 3 is substituted by a benzyl group.		3.2310benzothiadiazine;
sulfonamide		antihypertensive agent;
diuretic
benserazide
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.. benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.		2.2110carbohydrazide;
catechols;
primary alcohol;
primary amino compound		antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
benzbromarone
Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.		5.2801-benzofurans;
aromatic ketone		uricosuric drug
benzo(a)pyrene
Benzo(a)pyrene: A potent mutagen and carcinogen. It is a public health concern because of its possible effects on industrial workers, as an environmental pollutant, an as a component of tobacco smoke.. benzo[a]pyrene : An ortho- and peri-fused polycyclic arene consisting of five fused benzene rings.		2.4520ortho- and peri-fused polycyclic arenecarcinogenic agent;
mouse metabolite
benzocaine
Benzocaine: A surface anesthetic that acts by preventing transmission of impulses along NERVE FIBERS and at NERVE ENDINGS.. dextran sulfate sodium : An organic sodium salt of dextran sulfate. It induces colitis in mice.. benzocaine : A benzoate ester having 4-aminobenzoic acid as the acid component and ethanol as the alcohol component. A surface anaesthetic, it is used to suppress the gag reflex, and as a lubricant and topical anaesthetic on the larynx, mouth, nasal cavity, respiratory tract, oesophagus, rectum, urinary tract, and vagina.		2.0810benzoate ester;
substituted aniline		allergen;
antipruritic drug;
sensitiser;
topical anaesthetic
benzothiazide
benzothiazide: structure. benzthiazide : 7-Sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by chlorine and that at position 3 is substituted by a benzylsulfanylmethyl group. A diuretic, it is used to treat hypertension and edema.		4.6111benzothiadiazine;
sulfonamide		antihypertensive agent;
diuretic
cogentin
[no description available]		2.1710diarylmethane
benzyl isothiocyanate
benzyl isothiocyanate: inhibits carcinogen-induced neoplasia; structure in Negwer, 5th ed, #715; also promotes urinary bladder carcinoma		2.5220benzenes;
isothiocyanate		antibacterial drug
berberine
[no description available]		8.7530alkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound		antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker
betaxolol
[no description available]		3.5820propanolamineantihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
bethanechol
Bethanechol: A slowly hydrolyzing muscarinic agonist with no nicotinic effects. Bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, HEART RATE changes, and BRONCHIAL SPASM.. bethanechol : The carbamic acid ester of 2-methylcholine. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used as its chloride salt to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention.		3.2310carbamate ester;
quaternary ammonium ion		muscarinic agonist
bevantolol
bevantolol: structure given in first source. bevantolol : A propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by 3-methylphenyl and one of the hydrogens attached to the nitrogen is substituted by 2-(3,4-dimethoxyphenyl)ethyl. A beta1 adrenoceptor antagonist, it has been shown to be as effective as other beta-blockers for the treatment of angina pectoris and hypertension.		2.0410propanolamineanti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
calcium channel blocker
bicalutamide
bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.		4.7690(trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol
bay h 4502
bifonazole : A racemate comprising equimolar amounts of R- and S-bifonazole. It is a broad spectrum antifungal drug used for the treatment of fungal skin and nail infections.. 1-[biphenyl-4-yl(phenyl)methyl]imidazole : A member of the class of imidazoles carrying an alpha-(biphenyl-4-yl)benzyl substituent at position 1.		2.4720biphenyls;
imidazoles
biperiden
Biperiden: A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.. biperiden : A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease.		3.5820piperidines;
tertiary alcohol;
tertiary amino compound		antidote to sarin poisoning;
antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist;
parasympatholytic
2-cyano-3-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-2-propenamide
[no description available]		2.0610hydroxycinnamic acid
bisacodyl
Bisacodyl: A diphenylmethane stimulant laxative used for the treatment of CONSTIPATION and for bowel evacuation. (From Martindale, The Extra Pharmacopoeia, 30th ed, p871)		3.6120diarylmethane
bisbenzimidazole
Bisbenzimidazole: A benzimidazole antifilarial agent; it is fluorescent when it binds to certain nucleotides in DNA, thus providing a tool for the study of DNA replication; it also interferes with mitosis.		2.0410bibenzimidazole;
N-methylpiperazine		anthelminthic drug;
fluorochrome
bisindolylmaleimide i
bisindolylmaleimide I: a bis(indolyl)maleimide		2.4620
bisindolylmaleimide iv
[no description available]		2.5120indoles;
maleimides
bisoprolol
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.		3.8630secondary alcohol;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
bithionol
Bithionol: Halogenated anti-infective agent that is used against trematode and cestode infestations.. bithionol : An aryl sulfide that is diphenyl sulfide in which each phenyl group is substituted at position 2 by hydroxy and at positions 3 and 5 by chlorine. A fungicide and anthelmintic, it was used in various topical drug products for the treatment of liver flukes, but withdrawn after being shown to be a potent photosensitizer with the potential to cause serious skin disorders.		2.0510aryl sulfide;
bridged diphenyl antifungal drug;
bridged diphenyl fungicide;
dichlorobenzene;
organochlorine pesticide;
polyphenol		antifungal agrochemical;
antiplatyhelmintic drug
bohemine
bohemine : Purine substituted on C-2, C-6 and N-9 with (3-hydroxypropyl)amino, benzylamino and isopropyl groups respectively; a synthetic, cell-permeable, cyclin-dependent kinase (CDK) inhibitor that is structurally similar to olomoucine and roscovitine.		2.0310purinesEC 2.7.11.22 (cyclin-dependent kinase) inhibitor
bromazepam
Bromazepam: One of the BENZODIAZEPINES that is used in the treatment of ANXIETY DISORDERS.		2.0410organic molecular entity
bromhexine
Bromhexine: A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744). bromhexine : A substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum).		2.0810organobromine compound;
substituted aniline;
tertiary amino compound		mucolytic
bromopride
bromopride: RN given refers to parent cpd; structure		2.4620benzamides
bromisovalum
Bromisovalum: A sedative and mild hypnotic with potentially toxic effects.. bromisoval : A racemate comprising equimolar amounts of (R)- and (S)-bromisoval. It was previously used for its hypnotic and sedative properties but the use of bromides is now deprecated due to the possibility of the toxic accumulation of bromine in the body.. 2-bromo-N-carbamoyl-3-methylbutanamide : An N-acylurea that is urea in which one of the hydrogens is replaced by a 2-bromo-3-methybutanoyl group.		2.0510N-acylurea;
organobromine compound
bronopol
[no description available]		2.0810nitro compound
brotizolam
brotizolam: structure		2.4520organic molecular entity
buflomedil
buflomedil: RN given refers to parent cpd; synonym LL 1656 refers to HCl; structure		2.0410aromatic ketone
bumetanide
[no description available]		4.5470amino acid;
benzoic acids;
sulfonamide		diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
bunazosin
bunazosin: structure		3.6120quinazolines
bupivacaine
Bupivacaine: A widely used local anesthetic agent.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.. bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.		2.7430aromatic amide;
piperidinecarboxamide;
tertiary amino compound
buspirone
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.. buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.		4.2850azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines		anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist
busulfan
[no description available]		4.86100methanesulfonate esteralkylating agent;
antineoplastic agent;
carcinogenic agent;
insect sterilant;
teratogenic agent
secbutabarbital
secbutabarbital: Butabarbital (a synonym for Secbutabarbital) should be distinguished from Butobarbital		3.2310barbiturates
butalbital
butalbital: management of butalbital withdrawal can be simplified by using a phenobarbital-loading protocol; RN given refers to parent cpd. butalbital : A member of the class of barbiturates that is barbituric acid in which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. Frequently combined with other medicines, such as aspirin, paracetamol and codeine, it is used for treatment of pain and headache.		2.0510barbituratesanalgesic;
sedative
cacodylic acid
dimethylarsinic acid : The organoarsenic compound that is arsenic acid substituted on the central arsenic atom with two methyl groups.		2.0510organoarsenic compoundxenobiotic metabolite
caffeine
[no description available]		5.1980purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		5.05120aromatic ether;
nitrile;
polyether;
tertiary amino compound
metrizoate
Metrizoic Acid: A diagnostic radiopaque that usually occurs as the sodium salt.		2.0410monocarboxylic acidradioopaque medium
candesartan cilexetil
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects		3.8930biphenyls
candesartan
candesartan: a nonpeptide angiotensin II receptor antagonist. candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.		3.8530benzimidazolecarboxylic acid;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
carbamazepine
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.		4.4160dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
carbinoxamine
carbinoxamine: Note: tradenames that start with Histex refer to more than one drug. carbinoxamine : An organochlorine compound that is 2-(4-chlorobenzyl)pyridine in which one of the benzylic hydrogens is substituted by 2-(dimethylamino)ethoxy group. It is an ethanolamine-type antihistamine, used as its maleate salt for treating hay fever, as well as mild cases of Parkinson's disease.		3.2310monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist
carisoprodol
Carisoprodol: A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202). carisoprodol : A carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm.		3.5920carbamate estermuscle relaxant
carmustine
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.		3.1550N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
carprofen
carprofen: RN given refers to cpd without isomeric designation. carprofen : Propanoic acid in which one of the methylene hydrogens is substituted by a 6-chloro-9H-carbazol-2-yl group. A non-steroidal anti-inflammatory drug, it is no longer used in human medicine but is still used for treatment of arthritis in elderly dogs.		2.4720carbazoles;
organochlorine compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug;
photosensitizing agent
carvedilol
[no description available]		4.0840carbazoles;
secondary alcohol;
secondary amino compound		alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent
carbonyl cyanide m-chlorophenyl hydrazone
Carbonyl Cyanide m-Chlorophenyl Hydrazone: A proton ionophore. It is commonly used as an uncoupling agent and inhibitor of photosynthesis because of its effects on mitochondrial and chloroplast membranes.. CCCP : A member of the class of monochlorobenzenes that is benzene substituted by 2-(1,3-dinitrilopropan-2-ylidene)hydrazinyl and chloro groups at positions 1 and 3, respectively. It is a mitochondrial depolarizing agent that induces reactive oxygen species mediated cell death.		2.0510hydrazone;
monochlorobenzenes;
nitrile		antibacterial agent;
geroprotector;
ionophore
celecoxib
[no description available]		8.49314organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
cetirizine
Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.. cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.		3.8730ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines		anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic
chelerythrine
chelerythrine : A benzophenanthridine alkaloid isolated from the root of Zanthoxylum simulans, Chelidonium majus L., and other Papaveraceae.		2.4620benzophenanthridine alkaloid;
organic cation		antibacterial agent;
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
chloral hydrate
[no description available]		2.0510aldehyde hydrate;
ethanediol;
organochlorine compound		general anaesthetic;
mouse metabolite;
sedative;
xenobiotic
chlorambucil
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.		4.6780aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
chlorcyclizine
chlorcyclizine: was heading 1964-94 (Prov 1964-73); CHLOROCYCLIZINE & HISTACHLORAZINE were see CHLORCYCLIZINE 1977-94; use PIPERAZINES to search CHLORCYCLIZINE 1966-94; histamine H1-blocker used both orally and topically in allergies and also for the prevention of motion sickness		3.2310diarylmethane
chlordiazepoxide
Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.. chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.		4.2650benzodiazepine
chlormezanone
Chlormezanone: A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.. chlormezanone : A 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions.		3.59201,3-thiazine;
lactam;
monochlorobenzenes;
sulfone		antipsychotic agent;
anxiolytic drug;
muscle relaxant
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		5.85160aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
chlorothiazide
Chlorothiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812). thiazide : Heterocyclic compound with sulfur and nitrogen in the ring.. chlorothiazide : 4H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position is substituted by chlorine and that at position 7 is substituted by a sulfonamide group. A diuretic, it is used for treatment of oedema and hypertension.		3.2310benzothiadiazineantihypertensive agent;
diuretic
chloroxylenol
chloroxylenol: topical antiseptic; RN given refers to parent cpd; structure. 4-chloro-3,5-dimethylphenol : A member of the class of phenols that is 3,5-xylenol which is substituted at position 4 by chlorine. It is bactericidal against most Gram-positive bacteria but less effective against Staphylococci and Gram-negative bacteria, and often inactive against Pseudomonas species. It is ineffective against bacterial spores.		2.0510monochlorobenzenes;
phenols		antiseptic drug;
disinfectant;
molluscicide
chlorpheniramine
Chlorpheniramine: A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.. chlorphenamine : A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma.		4.4260monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor
chlorpromazine
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.		9.87100organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
chlorpropamide
Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277). chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification.		4.4260monochlorobenzenes;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue
chlorthalidone
Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.		3.8730isoindoles;
monochlorobenzenes;
sulfonamide
chlorzoxazone
Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202). chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.		4.26501,3-benzoxazoles;
heteroaryl hydroxy compound;
organochlorine compound		muscle relaxant;
sedative
cifenline
[no description available]		2.4620diarylmethane
ciclopirox
[no description available]		2.4720cyclic hydroxamic acid;
hydroxypyridone antifungal drug;
pyridone		antibacterial agent;
antiseborrheic
ciglitazone
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes. ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.		2.7630aromatic ether;
thiazolidinone		antineoplastic agent;
insulin-sensitizing drug
cilostazol
[no description available]		3.6120lactam;
tetrazoles		anticoagulant;
bronchodilator agent;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
fibrin modulating drug;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
cimetidine
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.		4.7690aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
cinoxacin
Cinoxacin: Synthetic antimicrobial related to OXOLINIC ACID and NALIDIXIC ACID and used in URINARY TRACT INFECTIONS.. cinoxacin : A member of the class of cinnolines that is 6,7-methylenedioxycinnolin-4(1H)-one bearing an ethyl group at position 1 and a carboxylic acid group at position 3. An analogue of oxolinic acid, it has similar antibacterial actions. It was formerly used for the treatment of urinary tract infections.		2.0510cinnolines;
oxacycle;
oxo carboxylic acid		antibacterial drug;
antiinfective agent
ciprofibrate
[no description available]		2.9840cyclopropanes;
monocarboxylic acid;
organochlorine compound		antilipemic drug
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		4.5570aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
cisapride
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed). cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.		2.7630benzamides
citalopram
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.		4.26502-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound
cl 387785
CL 387785: structure in first source. N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide : A member of the class of quinazolines that is 4,6-diaminoquinazoine in which the one of the hydrogens attached to the amino group at position 4 has been replaced by a m-bromophenyl group while one of the hydrogens attached to the amino group at position 6 has been replaced by a but-2-ynoyl group.		3.83110bromobenzenes;
quinazolines;
secondary carboxamide;
ynamide		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist
clioquinol
Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.. 5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.		2.4720monohydroxyquinoline;
organochlorine compound;
organoiodine compound		antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator
clobazam
Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.. clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.		2.47201,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator
clofazimine
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619). clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.		4.4460monochlorobenzenes;
phenazines		dye;
leprostatic drug;
non-steroidal anti-inflammatory drug
clofibrate
angiokapsul: contains clofibrate & insoitolnicotinate		4.4160aromatic ether;
ethyl ester;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist
clofibric acid
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.. clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.		2.1310aromatic ether;
monocarboxylic acid;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
antineoplastic agent;
herbicide;
marine xenobiotic metabolite;
PPARalpha agonist
clomiphene
[no description available]		4.0940tertiary amineestrogen antagonist;
estrogen receptor modulator
clomipramine
Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.		4.2650dibenzoazepineanticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor
clonazepam
Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.. clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.		3.85301,4-benzodiazepinone;
monochlorobenzenes		anticonvulsant;
anxiolytic drug;
GABA modulator
clonidine
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.		4.0740clonidine;
imidazoline
4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide
[no description available]		2.4720sulfonamide
chlorazepate
clorazepic acid : A 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively.		3.58201,4-benzodiazepinoneanticonvulsant;
anxiolytic drug;
GABA modulator;
prodrug
clotiazepam
clotiazepam: was heading 1975-94 (see under AZEPINES 1978-90; was Y 6047 see under AZEPINES 1975-77); Y 6047 was see CLOTIAZEPAM 1978-94; use AZEPINES to search CLOTIAZEPAM 1975-94; thienodiazepine derivative with actions similar to those of benzodiazepines		2.0510organic molecular entity
clotrimazole
[no description available]		4.4260conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes		antiinfective agent;
environmental contaminant;
xenobiotic
cromolyn
cromoglycic acid : A dicarboxylic acid that is the bis-chromone derivative of glycerol. It is effective as a mast cell stabilizer.		2.0510chromones;
dicarboxylic acid		anti-asthmatic drug;
calcium channel blocker
cyclandelate
Cyclandelate: A direct-acting SMOOTH MUSCLE relaxant used to dilate BLOOD VESSELS.. cyclandelate : The ester obtained by formal condensation of mandelic acid and 3,3,5-tricyclohexanol. It is a direct-acting smooth muscle relaxant used to dilate blood vessels.		2.0510carboxylic ester;
secondary alcohol		vasodilator agent
cyclobenzaprine
cyclobenzaprine: RN given refers to parent cpd; Lisseril is synonymous for HCl; structure. cyclobenzaprine : 5-Methylidene-5H-dibenzo[a,d]cycloheptene in which one of the hydrogens of the methylidene group is substituted by a 2-(dimethylamino)ethyl group. A centrally acting skeletal muscle relaxant, it is used as its hydrochloride salt in the symptomatic treatment of painful muscle spasm.		3.2310carbotricyclic compoundantidepressant;
muscle relaxant;
tranquilizing drug
cyclofenil
Cyclofenil: A gonadal stimulant and inducer of ovulation. It is used in the treatment of infertility and amenorrhea, but is thought to be less effective than CLOMIPHENE.		3.2310organic molecular entity
cyproheptadine
Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.. cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.		3.5920piperidines;
tertiary amine		anti-allergic agent;
antipruritic drug;
gastrointestinal drug;
H1-receptor antagonist;
serotonergic antagonist
damnacanthal
damnacanthal: structure given in first source; isolated from the stem bark and roots of Morinda lucida; a selective inhibitor of p56(lck) tyrosine kinase activity		2.0310aldehyde;
monohydroxyanthraquinone
danthron
danthron: structure. chrysazin : A dihydroxyanthraquinone that is anthracene-9,10-dione substituted by hydroxy groups at positions 1 and 8.		2.0510dihydroxyanthraquinoneapoptosis inducer;
plant metabolite
dapsone
[no description available]		4.5470substituted aniline;
sulfone		anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug
deferoxamine
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.		3.9130acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore
desipramine
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.		4.6780dibenzoazepine;
secondary amino compound		adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor
nordazepam
Nordazepam: An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.. nordazepam : A 1,4-benzodiazepinone having phenyl and chloro substituents at positions 5 and 7 respectively; it has anticonvulsant, anxiolytic, muscle relaxant and sedative properties but is used primarily in the treatment of anxiety.		2.04101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator;
human metabolite;
sedative
amphetamine
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.		3.8630primary amine
eflornithine
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.		2.4720alpha-amino acid;
fluoroamino acid		trypanocidal drug
r 59022
R 59022: diacylglycerol kinase inhibitor; structure given in first source; platelet activator factor antagonist		2.0310diarylmethane
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		4.55701,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
diazoxide
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.		4.2650benzothiadiazine;
organochlorine compound;
sulfone		antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent
diclofenac
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.		4.5570amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
ddt
1,1-bis(p-chlorophenyl)-2,2,2-trichloroethane: structure in first source		2.0510benzenoid aromatic compound;
chlorophenylethane;
monochlorobenzenes;
organochlorine insecticide		bridged diphenyl acaricide;
carcinogenic agent;
endocrine disruptor;
persistent organic pollutant
dichlorphenamide
Dichlorphenamide: A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.. diclofenamide : A sulfonamide that is benzene-1,3-disulfonamide in which the hydrogens at positions 4 and 5 are substituted by chlorine. An oral carbonic anhydrase inhibitor, it partially suppresses the secretion (inflow) of aqueous humor in the eye and so reduces intraocular pressure. It is used for the treatment of glaucoma.		3.2310dichlorobenzene;
sulfonamide		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
ophthalmology drug
dicyclomine
Dicyclomine: A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms.. dicyclomine : The ester resulting from the formal condensation of 1-cyclohexylcyclohexanecarboxylic acid with 2-(diethylamino)ethanol. An anticholinergic, it is used as the hydrochloride to treat or prevent spasm in the muscles of the gastrointestinal tract, particularly that associated with irritable bowel syndrome.		3.2310carboxylic ester;
tertiary amine		antispasmodic drug;
muscarinic antagonist;
parasympatholytic
diethylcarbamazine
Diethylcarbamazine: An anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.		2.0510N-carbamoylpiperazine;
N-methylpiperazine
pentetic acid
Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.		3.5720pentacarboxylic acidcopper chelator
diflunisal
Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.. diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.		4.2550monohydroxybenzoic acid;
organofluorine compound		non-narcotic analgesic;
non-steroidal anti-inflammatory drug
dimercaprol
Dimercaprol: An anti-gas warfare agent that is effective against Lewisite (dichloro(2-chlorovinyl)arsine) and formerly known as British Anti-Lewisite or BAL. It acts as a chelating agent and is used in the treatment of arsenic, gold, and other heavy metal poisoning.. dimercaprol : A dithiol that is propane-1,2-dithiol in which one of the methyl hydrogens is replaced by a hydroxy group. a chelating agent originally developed during World War II as an experimental antidote against the arsenic-based poison gas Lewisite, it has been used clinically since 1949 for the treatment of poisoning by arsenic, mercury and gold. It can also be used for treatment of poisoning by antimony, bismuth and possibly thallium, and (with sodium calcium edetate) in cases of acute leaad poisoning. Administration is by (painful) intramuscular injection of a suspension of dimercaprol in peanut oil, typically every 4 hours for 2-10 days depending on the toxicity. In the past, dimercaprol was also used for the treatment of Wilson's disease, a severely debilitating genetic disorder in which the body tends to retain copper, with resultant liver and brain injury.		3.5920dithiol;
primary alcohol		chelator
diphenhydramine
Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.. diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.. antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.		4.4260ether;
tertiary amino compound		anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative
dipyridamole
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.		5.0870piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol		adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
disopyramide
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.		4.2650monocarboxylic acid amide;
pyridines;
tertiary amino compound		anti-arrhythmia drug
disulfiram
[no description available]		4.4360organic disulfide;
organosulfur acaricide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor
diuron
Diuron: A pre-emergent herbicide.. diuron : A member of the class of 3-(3,4-substituted-phenyl)-1,1-dimethylureas that is urea in which both of the hydrogens attached to one nitrogen are substituted by methyl groups, and one of the hydrogens attached to the other nitrogen is substituted by a 3,4-dichlorophenyl group.		2.05103-(3,4-substituted-phenyl)-1,1-dimethylurea;
dichlorobenzene		environmental contaminant;
mitochondrial respiratory-chain inhibitor;
photosystem-II inhibitor;
urea herbicide;
xenobiotic
valproic acid
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.		10.1780branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
n(6),n(6)-dimethyladenine
N(6),N(6)-dimethyladenine : A tertiary amine that is adenine substituted at N-6 by geminal methyl groups.		2.4520tertiary amine
domperidone
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.		2.7430benzimidazoles;
heteroarylpiperidine		antiemetic;
dopaminergic antagonist
donepezil
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.		3.8730aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent
doxapram
Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225). doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.		3.5820morpholines;
pyrrolidin-2-ones		central nervous system stimulant
doxazosin
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.. doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.		3.8530aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines		alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent
doxepin
Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.. doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.		4.2650dibenzooxepine;
tertiary amino compound		antidepressant
doxylamine
Doxylamine: Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in PARKINSONISM.		3.2310pyridines;
tertiary amine		anti-allergic agent;
antiemetic;
antitussive;
cholinergic antagonist;
H1-receptor antagonist;
histamine antagonist;
sedative
droperidol
Droperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in conjunction with an opioid analgesic such as FENTANYL to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593). droperidol : An organofluorine compound that is haloperidol in which the hydroxy group has been eliminated with the introduction of a double bond in the piperidine ring, and the 4-chlorophenyl group has been replaced by a benzimidazol-2-on-1-yl group. It is used in the management of chemotherapy-induced nausea and vomiting, and in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon.		3.5920aromatic ketone;
benzimidazoles;
organofluorine compound		anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
dyphylline
Dyphylline: A THEOPHYLLINE derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis.. dyphylline : An oxopurine that is theophylline bearing a 2,3-dihydroxypropyl group at the 7 position. It has broncho- and vasodilator properties, and is used in the treatment of asthma, cardiac dyspnea, and bronchitis. It is also an ingredient in preparations that have been promoted for coughs.		3.5820oxopurine;
propane-1,2-diols		bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
muscle relaxant;
vasodilator agent
ebastine
[no description available]		2.5220organic molecular entity
econazole
Econazole: An imidazole derivative that is commonly used as a topical antifungal agent.. econazole : A racemate composed of equimolar amounts of (R)- and (S)-econazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections.. 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 4-chlorobenzyl group.		2.4820dichlorobenzene;
ether;
imidazoles;
monochlorobenzenes
edrophonium
Edrophonium: A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.. edrophonium : A quaternary ammonium ion that is N-ethyl-N,N-dimethylanilinium in which one of the meta positions is substituted by a hydroxy group. It is a reversible inhibitor of cholinesterase, with a rapid onset (30-60 seconds after injection) but a short duration of action (5-15 minutes). The chloride salt is used in myasthenia gravis both diagnostically and to distinguish between under- or over-treatment with other anticholinesterases. It has also been used for the reversal of neuromuscular blockade in anaesthesia, and for the management of poisoning due to tetrodotoxin, a neuromuscular blocking toxin found in puffer fish and other marine animals.		3.2310phenols;
quaternary ammonium ion		antidote;
diagnostic agent;
EC 3.1.1.8 (cholinesterase) inhibitor
ellipticine
ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11.		2.7630indole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound;
polycyclic heteroarene		antineoplastic agent;
plant metabolite
emodin
Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.. emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.		7.4420trihydroxyanthraquinoneantineoplastic agent;
laxative;
plant metabolite;
tyrosine kinase inhibitor
enflurane
Enflurane: An extremely stable inhalation anesthetic that allows rapid adjustments of anesthesia depth with little change in pulse or respiratory rate.. enflurane : An ether in which the oxygen atom is connected to 2-chloro-1,1,2-trifluoroethyl and difluoromethyl groups.		2.0510ether;
organochlorine compound;
organofluorine compound		anaesthetic
enoxacin
Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.. enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.		2.75301,8-naphthyridine derivative;
amino acid;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-arylpiperazine;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor
estazolam
Estazolam: A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than DIAZEPAM or NITRAZEPAM.. estazolam : A triazolo[4,3-a][1,4]benzodiazepine having a phenyl group at position 6 and a chloro substituent at position 8. A short-acting benzodiazepine with general properties similar to diazepam, it is given by mouth as a hypnotic in the short-term management of insomnia.		3.5920triazoles;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA modulator
ethacrynic acid
Ethacrynic Acid: A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.. etacrynic acid : An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor.		4.0840aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid		EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic
ethosuximide
Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.. ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.		3.8730dicarboximide;
pyrrolidinone		anticonvulsant;
geroprotector;
T-type calcium channel blocker
ethotoin
ethotoin: was heading 1966-94 (see under HYDANTOINS 1966-90); use HYDANTOINS to search ETHOTOIN 1966-94. ethotoin : An imidazolidine-2,4-dione that is hydantoin substituted by ethyl and phenyl at positions 3 and 5, respectively. An antiepileptic, it is less toxic than phenytoin but also less effective.		3.2310imidazolidine-2,4-dioneanticonvulsant
ethoxzolamide
Ethoxzolamide: A carbonic anhydrase inhibitor used as diuretic and in glaucoma. It may cause hypokalemia.. ethoxzolamide : A sulfonamide that is 1,3-benzothiazole-2-sulfonamide which is substituted by an ethoxy group at position 6. A carbonic anhydrase inhibitor, it has been used in the treatment of glaucoma, and as a diuretic.		2.0510aromatic ether;
benzothiazoles;
sulfonamide		antiglaucoma drug;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
etidronate
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.. etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.		3.23101,1-bis(phosphonic acid)antineoplastic agent;
bone density conservation agent;
chelator
etilefrine
Etilefrine: A phenylephrine-related beta-1 adrenergic and alpha adrenergic agonist used as a cardiotonic and antihypotensive agent.		2.0410phenols
etodolac
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).. etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.		3.5920monocarboxylic acid;
organic heterotricyclic compound		antipyretic;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
brl 42810
[no description available]		4.08402-aminopurines;
acetate ester		antiviral drug;
prodrug
carbonyl cyanide p-trifluoromethoxyphenylhydrazone
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone: A proton ionophore that is commonly used as an uncoupling agent in biochemical studies.. carbonyl cyanide p-trifluoromethoxyphenylhydrazone : A hydrazone that is hydrazonomalononitrile in which one of the hydrazine hydrogens is substituted by a p-trifluoromethoxyphenyl group.		2.0510aromatic ether;
hydrazone;
nitrile;
organofluorine compound		ATP synthase inhibitor;
geroprotector;
ionophore
felbamate
Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.. felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.		3.8630carbamate esteranticonvulsant;
neuroprotective agent
4-biphenylylacetic acid
biphenyl-4-ylacetic acid : A monocarboxylic acid in which one of the alpha-hydrogens is substituted by a biphenyl-4-yl group. An active metabolite of fenbufen, it is used as a topical medicine to treat muscle inflammation and arthritis.		2.0810biphenyls;
monocarboxylic acid		non-steroidal anti-inflammatory drug
felodipine
Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.. felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.		4.2650dichlorobenzene;
dihydropyridine;
ethyl ester;
methyl ester		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
fendiline
Fendiline: Coronary vasodilator; inhibits calcium function in muscle cells in excitation-contraction coupling; proposed as antiarrhythmic and antianginal agents.		2.0410diarylmethane
fenofibrate
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE		10.4100aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
fenoldopam
Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.		3.2310benzazepinealpha-adrenergic agonist;
antihypertensive agent;
dopamine agonist;
dopaminergic antagonist;
vasodilator agent
fenoprofen
Fenoprofen: A propionic acid derivative that is used as a non-steroidal anti-inflammatory agent.. fenoprofen : A monocarboxylic acid that is propanoic acid in which one of the hydrogens at position 2 is substituted by a 3-phenoxyphenyl group. A non-steroidal anti-inflammatory drug, the dihydrate form of the calcium salt is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.		3.2310monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
berotek
Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.		2.0410resorcinols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent
fenspiride
fenspiride: was heading 1975-94 (see under SPIRO COMPOUNDS 1975-90); use SPIRO COMPOUNDS to search FENSPIRIDE 1975-94; bronchodilator agent used in asthma		2.0410azaspiro compound
fentanyl
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.		2.4520anilide;
monocarboxylic acid amide;
piperidines		adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
fexofenadine
fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl. fexofenadine : A piperidine-based anti-histamine compound.		3.8630piperidines;
tertiary amine		anti-allergic agent;
H1-receptor antagonist
fipexide
fipexide: regulates dopaminergic systems at macromolecular level		3.5920benzodioxoles
flavoxate
Flavoxate: A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist.. flavoxate : A carboxylic ester resulting from the formal condensation of 3-methylflavone-8-carboxylic acid with 2-(1-piperidinyl)ethanol.		3.2310carboxylic ester;
flavones;
piperidines;
tertiary amino compound		antispasmodic drug;
muscarinic antagonist;
parasympatholytic
flecainide
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.. flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).		4.0840aromatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines		anti-arrhythmia drug
fleroxacin
Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.. fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.		2.4620difluorobenzene;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
quinolines		antibacterial drug;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
fluconazole
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.		4.5570conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
flucytosine
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.		4.6580aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone		prodrug
flufenamic acid
Flufenamic Acid: An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16). flufenamic acid : An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders.		2.4620aromatic amino acid;
organofluorine compound		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
fluphenazine
[no description available]		3.8530N-alkylpiperazine;
organofluorine compound;
phenothiazines		anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug
flumazenil
Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.. flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.		4.5570ethyl ester;
imidazobenzodiazepine;
organofluorine compound		antidote to benzodiazepine poisoning;
GABA antagonist
flunitrazepam
Flunitrazepam: A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.. flunitrazepam : A 1,4-benzodiazepinone that is nitrazepam substituted by a methyl group at position 1 and by a fluoro group at position 2'. It is a potent hypnotic, sedative, and amnestic drug used to treat chronic insomnia.		2.45201,4-benzodiazepinone;
C-nitro compound;
monofluorobenzenes		anxiolytic drug;
GABAA receptor agonist;
sedative
fluorescite
fluorescein (acid form) : A xanthene dye that is highly fluorescent and commonly used as a fluorescent tracer.		4.2650benzoic acids;
cyclic ketone;
hydroxy monocarboxylic acid;
organic heterotricyclic compound;
phenols;
xanthene dye		fluorescent dye;
radioopaque medium
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		15.457227nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
fluoxetine
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.		4.4260(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound
flurazepam
Flurazepam: A benzodiazepine derivative used mainly as a hypnotic.. flurazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a 2-(diethylamino)ethyl group, 2-fluorophenyl group and chloro group at positions 1, 5 and 7, respectively. It is a partial agonist of GABAA receptors and used for the treatment of insomnia.		3.23101,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
tertiary amino compound		anticonvulsant;
anxiolytic drug;
GABAA receptor agonist;
sedative
flurbiprofen
Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.		4.0840fluorobiphenyl;
monocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
fluspirilene
Fluspirilene: A long-acting injectable antipsychotic agent used for chronic schizophrenia.		2.0510diarylmethane
flutamide
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.		4.7790(trifluoromethyl)benzenes;
monocarboxylic acid amide		androgen antagonist;
antineoplastic agent
fomepizole
Fomepizole: A pyrazole and competitive inhibitor of ALCOHOL DEHYDROGENASE that is used for the treatment of poisoning by ETHYLENE GLYCOL or METHANOL.. fomepizole : A member of the class of pyrazoles that is 1H-pyrazole substituted by a methyl group at position 4.		3.5920pyrazolesantidote;
EC 1.1.1.1 (alcohol dehydrogenase) inhibitor;
protective agent
foscarnet
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.		3.8630carboxylic acid;
one-carbon compound;
phosphonic acids		antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor
furosemide
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.		10.48110chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
gabapentin
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.. gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.		6.5551gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic
gemfibrozil
[no description available]		4.4360aromatic etherantilipemic drug
glafenine
Glafenine: An anthranilic acid derivative with analgesic properties used for the relief of all types of pain.. glafenine : A carboxylic ester that is 2,3-dihydroxypropyl anthranilate in which the amino group is substituted by a 7-chloroquinolin-4-yl group. A non-steroidal anti-inflammatory drug, glafenine and its hydrochloride salt were used for the relief of all types of pain, but high incidence of anaphylactic reactions resulted in their withdrawal from the market.		3.8630aminoquinoline;
carboxylic ester;
glycol;
organochlorine compound;
secondary amino compound		inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
gliclazide
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.		2.9740N-sulfonylureahypoglycemic agent;
insulin secretagogue;
radical scavenger
glimepiride
glimepiride: structure given in first source		4.6680sulfonamide
glipizide
Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.. glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.		4.4160aromatic amide;
monocarboxylic acid amide;
N-sulfonylurea;
pyrazines		EC 2.7.1.33 (pantothenate kinase) inhibitor;
hypoglycemic agent;
insulin secretagogue
glutethimide
Glutethimide: A hypnotic and sedative. Its use has been largely superseded by other drugs.		2.4620piperidines
glyburide
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.		5.2990monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester
[no description available]		3.2310benzenes
go 6976
[no description available]		2.4520indolocarbazole;
organic heterohexacyclic compound		EC 2.7.11.13 (protein kinase C) inhibitor
gossypol
Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.		2.7830
granisetron
[no description available]		4.0840aromatic amide;
indazoles
guaiazulene
guaiazulene: structure		2.0510sesquiterpene
guaifenesin
Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.		3.5820methoxybenzenes
guanethidine
Guanethidine: An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.. guanethidine : A member of the class of guanidines in which one of the hydrogens of the amino group has been replaced by a 2-azocan-1-ylethyl group.. guanethidine sulfate : A organic sulfate salt composed of two molecules of guanethidine and one of sulfuric acid.		3.2310azocanes;
guanidines		adrenergic antagonist;
antihypertensive agent;
sympatholytic agent
guanfacine
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.		4.0840acetamides
guanidine
Guanidine: A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.. guanidine : An aminocarboxamidine, the parent compound of the guanidines.		3.2310carboxamidine;
guanidines;
one-carbon compound
gw8510
GW8510: 3' substituted indolone as a scaffold for the development of neuroprotective drug; structure in first source		2.0610
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
[no description available]		2.0610bromobenzenes;
isoquinolines;
olefinic compound;
secondary amino compound;
sulfonamide		EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor
1-(5-isoquinolinesulfonyl)-2-methylpiperazine
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.. 1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.		2.0610isoquinolines;
N-sulfonylpiperazine		EC 2.7.11.13 (protein kinase C) inhibitor
ha 1004
N-(2-guanidinoethyl)-5-isoquinolinesulfonamide: structure given in first source		2.0310isoquinolines
fasudil
fasudil: intracellular calcium antagonist; structure in first source. fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.		3.4670isoquinolines;
N-sulfonyldiazepane		antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent
haloperidol
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.		4.6680aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
halothane
[no description available]		2.0510haloalkane;
organobromine compound;
organochlorine compound;
organofluorine compound		inhalation anaesthetic
hexachlorophene
Hexachlorophene: A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797). hexachlorophene : An organochlorine compound that is diphenylmethane in which each of the phenyl groups is substituted by chlorines at positions 2, 3, and 5, and by a hydroxy group at position 6. An antiseptic that is effective against Gram-positive organisms, it is used in soaps and creams for the treatment of various skin disorders. It is also used in agriculture as an acaricide and fungicide, but is not approved for such use within the European Union.		2.4620bridged diphenyl fungicide;
polyphenol;
trichlorobenzene		acaricide;
antibacterial agent;
antifungal agrochemical;
antiseptic drug
miltefosine
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.		2.0510phosphocholines;
phospholipid		anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor
hexestrol
[no description available]		2.0510stilbenoid
hexetidine
Hexetidine: A bactericidal and fungicidal antiseptic. It is used as a 0.1% mouthwash for local infections and oral hygiene. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797)		2.0510organic heteromonocyclic compound;
organonitrogen heterocyclic compound
hexobarbital
Hexobarbital: A barbiturate that is effective as a hypnotic and sedative.. hexobarbital : A member of the class of barbiturates taht is barbituric acid substituted at N-1 by methyl and at C-5 by methyl and cyclohex-1-enyl groups.		2.4520barbiturates
beta-thujaplicin
beta-thujaplicin: structure. beta-thujaplicin : A monoterpenoid that is cyclohepta-2,4,6-trien-1-one substituted by a hydroxy group at position 2 and an isopropyl group at position 4. Isolated from Thuja plicata and Chamaecyparis obtusa, it exhibits antimicrobial activities.		2.110cyclic ketone;
enol;
monoterpenoid		antibacterial agent;
antifungal agent;
antineoplastic agent;
antiplasmodial drug;
plant metabolite
hycanthone
Hycanthone: Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE.. hycanthone : A thioxanthen-9-one compound having a hydroxymethyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. It was formerly used (particularly as the monomethanesulfonic acid salt) as a schistosomicide for individual or mass treatement of infection with Schistosoma haematobium and S. mansoni, but due to its toxicity and concern about possible carcinogenicity, it has been replaced by other drugs such as praziquantel.		2.0510thioxanthenesmutagen;
schistosomicide drug
hydralazine
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.		4.960azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines		antihypertensive agent;
vasodilator agent
hydrochlorothiazide
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.		4.4160benzothiadiazine;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
hydroflumethiazide
Hydroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822). hydroflumethiazide : A benzothiadiazine consisting of a 3,4-dihydro-HH-1,2,4-benzothiadiazine bicyclic system dioxygenated on sulfur and carrying trifluoromethyl and aminosulfonyl groups at positions 6 and 7 respectively. A diuretic with actions and uses similar to those of hydrochlorothiazide.		3.8730benzothiadiazine;
thiazide		antihypertensive agent;
diuretic
hydroxychloroquine
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.		4.140aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug
hydroxyurea
[no description available]		4.2650one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
hydroxyzine
Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.		3.5920hydroxyether;
monochlorobenzenes;
N-alkylpiperazine		anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist
hypericin
[no description available]		2.0410
ibuprofen
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine		5.1880monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
phenelzine
Phenelzine: One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC.		3.8630primary amine
lidocaine
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.		4.4260benzenes;
monocarboxylic acid amide;
tertiary amino compound		anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic
alverine
alverine : A tertiary amine having one ethyl and two 3-phenylprop-1-yl groups attached to the nitrogen. An antispasmodic that acts directly on intestinal and uterine smooth muscle, it is used (particularly as the citrate salt) in the treatment of irritable bowel syndrome.		2.0510tertiary amineantispasmodic drug
idebenone
[no description available]		2.05101,4-benzoquinones;
primary alcohol		antioxidant;
ferroptosis inhibitor
ifosfamide
[no description available]		4.5470ifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic
imipramine
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.		4.7790dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
amrinone
Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.. amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.		4.4260bipyridinesEC 3.1.4.* (phosphoric diester hydrolase) inhibitor
indapamide
Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine.		4.0940indoles;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic
indirubin-3'-monoxime
indirubin-3'-monoxime: has antiangiogenic activity. indirubin-3'-monoxime : A member of the class of biindoles that is indirubin in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.		2.4620
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		5.2990aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
iohexol
Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.. iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.		2.7530benzenedicarboxamide;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
iopromide
iopromide: structure given in first source. iopromide : A dicarboxylic acid diamide that consists of N-methylisophthalamide bearing three iodo substituents at positions 2, 4 and 6, a methoxyacetyl substituent at position 5 and two 2,3-dihydroxypropyl groups attached to the amide nitrogens. A water soluble x-ray contrast agent for intravascular administration.		2.0410dicarboxylic acid diamide;
organoiodine compound		environmental contaminant;
nephrotoxic agent;
radioopaque medium;
xenobiotic
iothalamic acid
Iothalamic Acid: A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.		2.0410organic molecular entity
iodipamide
Iodipamide: A water-soluble radiographic contrast media for cholecystography and intravenous cholangiography.. adipiodone : An organoiodine compound that is 3-amino-2,4,6-triiodobenzoic acid in which one of the amino hydrogens is substituted by a 6-(3-carboxy-2,4,6-triiodoanilino)-6-oxohexanoyl group. It is a water-soluble radiographic contrast media for cholecystography and intravenous cholangiography.		2.0510benzoic acids;
organoiodine compound;
secondary carboxamide		radioopaque medium
ioversol
[no description available]		3.2310amidobenzoic acid
iproniazid
[no description available]		4.2750carbohydrazide;
pyridines
avapro
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.		4.5570azaspiro compound;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
isocarboxazid
Isocarboxazid: An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)		3.5920benzenes
isoflurane
Isoflurane: A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.		4.9721organofluorine compoundinhalation anaesthetic
isoguvacine
isoguvacine: A GABA agonist; RN given refers to parent cpd; structure		2.110tetrahydropyridine
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		4.5470carbohydrazideantitubercular agent;
drug allergen
2-propanol
2-Propanol: An isomer of 1-PROPANOL. It is a colorless liquid having disinfectant properties. It is used in the manufacture of acetone and its derivatives and as a solvent. Topically, it is used as an antiseptic.. propan-2-ol : A secondary alcohol that is propane in which one of the hydrogens attached to the central carbon is substituted by a hydroxy group.		2.0510secondary alcohol;
secondary fatty alcohol		protic solvent
isoproterenol
Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.		4.2850catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
isoxsuprine
Isoxsuprine: A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.		3.5920alkylbenzene
isradipine
Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.		4.2650benzoxadiazole;
dihydropyridine;
isopropyl ester;
methyl ester
itraconazole
[no description available]		5.39100piperazines
4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline
WHI P131: a quinazoline derivative, inhibitor of glioblastoma cell adhesion and migration		2.1510
nsc 664704
kenpaullone: inhibits CDK1/cyclin B; structure in first source. kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta).		2.4520indolobenzazepine;
lactam;
organobromine compound		cardioprotective agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
geroprotector
ketamine
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.		6.3261cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
ketanserin
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.		4.4360aromatic ketone;
organofluorine compound;
piperidines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
ketoconazole
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.		4.87100dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
ketoprofen
Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.		4.4160benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
ketorolac
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed). ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.. 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.		3.8730amino acid;
aromatic ketone;
monocarboxylic acid;
pyrrolizines;
racemate		analgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
ketotifen
Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.. ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.		2.0510cyclic ketone;
olefinic compound;
organic heterotricyclic compound;
organosulfur heterocyclic compound;
piperidines;
tertiary amino compound		anti-asthmatic drug;
H1-receptor antagonist
khellin
Khellin: A vasodilator that also has bronchodilatory action. It has been employed in the treatment of angina pectoris, in the treatment of asthma, and in conjunction with ultraviolet light A, has been tried in the treatment of vitiligo. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1024). khellin : A furanochrome in which the basic tricyclic skeleton is substituted at positions 4 and 9 with methoxy groups and at position 7 with a methyl group. A major constituent of the plant Ammi visnaga it is a herbal folk medicine used for various illnesses, its main effect being as a vasodilator.		2.0510furanochromone;
organic heterotricyclic compound;
oxacycle		anti-asthmatic agent;
bronchodilator agent;
cardiovascular drug;
vasodilator agent
labetalol
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.. labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.. 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.		4.2650benzamides;
benzenes;
phenols;
primary carboxamide;
salicylamides;
secondary alcohol;
secondary amino compound
lamotrigine
[no description available]		3.87301,2,4-triazines;
dichlorobenzene;
primary arylamine		anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic
lansoprazole
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.		5.2990benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
beta-lapachone
beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase. beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.		2.0510benzochromenone;
orthoquinones		anti-inflammatory agent;
antineoplastic agent;
plant metabolite
lavendustin a
lavendustin A: from Streptomyces griseolavendus; structure given in first source		2.0310aromatic amine
2-hydroxy-5-(2,5-dihydrobenzyl)aminobenzoic acid
[no description available]		2.0310aromatic amine
leflunomide
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.		5.2890(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide		antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
letrozole
[no description available]		5.6390nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
lg 100268
LG 100268: a retinoid X receptor (RXR) selective compound; structure given in first source		2.0810
lofepramine
Lofepramine: A psychotropic IMIPRAMINE derivative that acts as a tricyclic antidepressant and possesses few anticholinergic properties. It is metabolized to DESIPRAMINE.		2.4720aromatic ketone;
dibenzoazepine;
monochlorobenzenes;
tertiary amino compound		antidepressant
lomefloxacin
lomefloxacin: structure given in first source. lomefloxacin : A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.		3.2310fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antimicrobial agent;
antitubercular agent;
photosensitizing agent
lomustine
[no description available]		4.0940N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
loperamide
Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.. loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.		9.2950monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol		anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist
loratadine
Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.. loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.		3.8730benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide		anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist
lorazepam
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.		3.5820benzodiazepine
losartan
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position		5.0770biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist
loxapine
Loxapine: An antipsychotic agent used in SCHIZOPHRENIA.		3.6120dibenzooxazepineantipsychotic agent;
dopaminergic antagonist
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source		8.88251chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
malathion
Malathion: A wide spectrum aliphatic organophosphate insecticide widely used for both domestic and commercial agricultural purposes.. malathion : A racemate comprising equimolar amounts of (R) and (S)-malathion. It is a broad spectrum organophosphate proinsecticide used to control a wide range of pests including Coleoptera, Diptera, fruit flies, mosquitos and spider mites.. diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate : A diester that is diethyl succinate in which position 2 is substituted by a (dimethoxyphosphorothioyl)thio group.		2.0510diester;
ethyl ester;
organic thiophosphate
diisopropyl 1,3-dithiol-2-ylidenemalonate
diisopropyl 1,3-dithiol-2-ylidenemalonate: structure in first source		2.0510isopropyl ester
manidipine
[no description available]		2.0510diarylmethane
maprotiline
Maprotiline: A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.		4.4160anthracenes
mazindol
Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.		2.0510organic molecular entity
mebendazole
Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.		4.2650aromatic ketone;
benzimidazoles;
carbamate ester		antinematodal drug;
microtubule-destabilising agent;
tubulin modulator
mecamylamine
Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.		3.2310primary aliphatic amine
mechlorethamine
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.		3.2310nitrogen mustard;
organochlorine compound		alkylating agent
meclizine
Meclizine: A histamine H1 antagonist used in the treatment of motion sickness, vertigo, and nausea during pregnancy and radiation sickness.		3.5920diarylmethane
meclofenamic acid
Meclofenamic Acid: A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.. meclofenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis.		3.2310aminobenzoic acid;
organochlorine compound;
secondary amino compound		analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
meclofenamate sodium anhydrous
[no description available]		2.0510organic sodium salt
meclofenoxate
Meclofenoxate: An ester of DIMETHYLAMINOETHANOL and para-chlorophenoxyacetic acid.		2.0510monocarboxylic acid
mefenamic acid
Mefenamic Acid: A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.. mefenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis.		4.2850aminobenzoic acid;
secondary amino compound		analgesic;
antipyretic;
antirheumatic drug;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
memantine
[no description available]		641adamantanes;
primary aliphatic amine		antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist
vitamin k 3
Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.		2.46201,4-naphthoquinones;
vitamin K		angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical
mepenzolate
mepenzolic acid: anticholinergic, antispasmodic agent; RN given refers to parent cpd; structure		3.2310diarylmethane
meperidine
Meperidine: A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.. pethidine : A piperidinecarboxylate ester that is piperidine which is substituted by a methyl group at position 1 and by phenyl and ethoxycarbonyl groups at position 4. It is an analgesic which is used for the treatment of moderate to severe pain, including postoperative pain and labour pain.		3.8630ethyl ester;
piperidinecarboxylate ester;
tertiary amino compound		antispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
mephenytoin
Mephenytoin: An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.. mephenytoin : An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.		3.5920imidazolidine-2,4-dioneanticonvulsant
mepivacaine
Mepivacaine: A local anesthetic that is chemically related to BUPIVACAINE but pharmacologically related to LIDOCAINE. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168). mepivacaine : A piperidinecarboxamide in which N-methylpipecolic acid and 2,6-dimethylaniline have combined to form the amide bond. It is used as a local amide-type anaesthetic.		3.8630piperidinecarboxamidedrug allergen;
local anaesthetic
meprobamate
Meprobamate: A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of ANXIETY DISORDERS, and also for the short-term management of INSOMNIA but has largely been superseded by the BENZODIAZEPINES. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603)		4.0840organic molecular entity
mesalamine
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed). mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.		4.0740amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols		non-steroidal anti-inflammatory drug
mesoridazine
Mesoridazine: A phenothiazine antipsychotic with effects similar to CHLORPROMAZINE.. mesoridazine : A phenothiazine substituted at position 2 (para to the S atom) by a methylsulfinyl group, and on the nitrogen by a 2-(1-methylpiperidin-2-yl)ethyl group.		3.2310phenothiazines;
sulfoxide;
tertiary amino compound		dopaminergic antagonist;
first generation antipsychotic
metaproterenol
Metaproterenol: A beta-2 adrenergic agonist used in the treatment of ASTHMA and BRONCHIAL SPASM.. orciprenaline : A racemate composed of equimolar amounts of (R)- and (S)-orciprenaline. Used (as its sulfate salt) to relax the airway muscles and improve breathing for patients suffering from asthma or bronchitis.. 5-[1-hydroxy-2-(isopropanylamino)ethyl]benzene-1,3-diol : A member of the class of resorcinols bearing an additional 1-hydroxy-2-(isopropanylamino)ethyl substituent at position 5 of resorcinol itself.		3.2310aralkylamino compound;
phenylethanolamines;
resorcinols;
secondary alcohol;
secondary amino compound
metformin
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.		10.44272guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
methadone
Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3). methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.. 6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.		5.9941benzenes;
diarylmethane;
ketone;
tertiary amino compound
methapyrilene
Methapyrilene: Histamine H1 antagonist with sedative action used as a hypnotic and in allergies.. methapyrilene : A member of the class of ethylenediamine derivatives that is ethylenediamine in which one of the nitrogens is substituted by two methyl groups, and the other nitrogen is substituted by a 2-pyridyl group and a (2-thienyl)methyl group.		2.4520ethylenediamine derivativeanti-allergic agent;
carcinogenic agent;
H1-receptor antagonist;
sedative
methazolamide
Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.		3.2310sulfonamide;
thiadiazoles
methocarbamol
Methocarbamol: A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206). methocarbamol : A racemate comprising equimolar amounts of (R)- and (S)-methocarbamol. A centrally acting skeletal muscle relaxant, it is used as an adjunct in the short-term symptomatic treatment of painful muscle spasm. The (R)-enantiomer is more active than the (S)-enantiomer.. 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate : A carbamate ester that is glycerol in which one of the primary alcohol groups has been converted to its 2-methoxyphenyl ether while the other has been converted to the corresponding carbamate ester.		3.2310aromatic ether;
carbamate ester;
secondary alcohol
methoxsalen
Methoxsalen: A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.. methoxsalen : A member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis.		3.5920aromatic ether;
psoralens		antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite
methoxyflurane
Methoxyflurane: An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with NITROUS OXIDE to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180). methoxyflurane : An ether in which the two groups attached to the central oxygen atom are methyl and 2,2-dichloro-1,1-difluoroethyl.		2.0510ether;
organochlorine compound;
organofluorine compound		hepatotoxic agent;
inhalation anaesthetic;
nephrotoxic agent;
non-narcotic analgesic
methyclothiazide
Methyclothiazide: A thiazide diuretic with properties similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)		3.2310benzothiadiazine
nocodazole
[no description available]		3.6220aromatic ketone;
benzimidazoles;
carbamate ester;
thiophenes		antimitotic;
antineoplastic agent;
microtubule-destabilising agent;
tubulin modulator
methyl salicylate
methyl salicylate: used in over-the-counter liniments, ointments, lotions for relief of musculoskeletal aches and pains; has hemolytic effect on human & sheep erythrocytes; RN given refers to parent cpd; structure in Merck Index, 9th ed, #5990. methyl salicylate : A benzoate ester that is the methyl ester of salicylic acid.		4.9721benzoate ester;
methyl ester;
salicylates		flavouring agent;
insect attractant;
metabolite
methylphenidate
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.. methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.. methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.		4.0840beta-amino acid ester;
methyl ester;
piperidines
methyprylon
methyprylon: was heading 1973-94 (see under HYPNOTICS AND SEDATIVES 1963-72); use PIPERIDONES to search METHYPRYLON 1973-94		2.0510organic molecular entity
metoclopramide
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.		4.4160benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound		antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic
metolazone
Metolazone: A quinazoline-sulfonamide derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. metolazone : A quinazoline that consists of 1,2,3,4-tetrahydroquinazolin-4-one bearing additional methyl, 2-tolyl, sulfamyl and chloro substituents at positions 2, 3, 6 and 7 respectively. A quinazoline diuretic, with properties similar to thiazide diuretics.		3.8630organochlorine compound;
quinazolines;
sulfonamide		antihypertensive agent;
diuretic;
ion transport inhibitor
metoprolol
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.. metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.		11.7292aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound		antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic
metronidazole
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.		4.9460C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
metyrapone
Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.. metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.		3.5920aromatic ketoneantimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
mexiletine
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.. mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.		3.8730aromatic ether;
primary amino compound		anti-arrhythmia drug
mianserin
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.. mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.		2.4620dibenzoazepineadrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist
miconazole
Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion.. 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group.. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.		2.7530dichlorobenzene;
ether;
imidazoles
midazolam
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.		6.41121imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
midodrine
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.. midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.		3.2310amino acid amide;
aromatic ether;
secondary alcohol		alpha-adrenergic agonist;
prodrug;
sympathomimetic agent;
vasoconstrictor agent
milrinone
[no description available]		3.8530bipyridines;
nitrile;
pyridone		cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
minoxidil
Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371). minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.		4.0940dialkylarylamine;
tertiary amino compound
mirtazapine
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.		4.0840benzazepine;
tetracyclic antidepressant		alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
oneirogen;
serotonergic antagonist
mitotane
Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.		3.8630diarylmethane
mitoxantrone
Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.		5.24150dihydroxyanthraquinoneanalgesic;
antineoplastic agent
ml 9
[no description available]		2.0310naphthalenes;
sulfonic acid derivative
moclobemide
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.. moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.		2.7530benzamides;
monochlorobenzenes;
morpholines		antidepressant;
environmental contaminant;
xenobiotic
modafinil
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.. modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.. 2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.		3.5920monocarboxylic acid amide;
sulfoxide
monodansylcadaverine
monodansylcadaverine: inhibits cross linkage of fibrin. monodansylcadaverine : A sulfonamide obtained by formal condensation of the sulfo group of 5-(dimethylamino)naphthalene-1-sulfonic acid with one of the amino groups of cadaverine.		2.0810aminonaphthalene;
primary amino compound;
sulfonamide;
tertiary amino compound		EC 2.3.2.13 (protein-glutamine gamma-glutamyltransferase) inhibitor;
fluorochrome;
protective agent
moxisylyte
Moxisylyte: An alpha-adrenergic blocking agent that is used in Raynaud's disease. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312)		3.5920monoterpenoid
entinostat
[no description available]		2.0810benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
deet
N,N-diethyl-m-toluamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of m-toluic acid with the nitrogen of diethylamine. First developed by the U.S. Army in 1946 for use by military personnel in insect-infested areas, it is the most widely used insect repellent worldwide.		2.0510benzamides;
monocarboxylic acid amide		environmental contaminant;
insect repellent;
xenobiotic
n-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide
N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide: calmodulin antagonist; structure given in first source. N-(4-aminobutyl)-5-chloronaphthalene-2-sulfonamide : A sulfonamide that is 5-chloronaphthalene-2-sulfonamide in which one of the hydrogens of the nitrogen atom is substituted by a 4-aminobutyl group.		2.2110naphthalenes;
organochlorine compound;
primary amino compound;
sulfonamide
acecainide
Acecainide: A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure.. N-acetylprocainamide : A benzamide obtained via formal condensation of 4-acetamidobenzoic acid and 2-(diethylamino)ethylamine.		2.7530acetamides;
benzamides		anti-arrhythmia drug
nabumetone
Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.. nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.		3.5920methoxynaphthalene;
methyl ketone		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
nadolol
[no description available]		3.8730tetralins
nafamostat
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic		2.3110benzoic acids;
guanidines
nalidixic acid
[no description available]		4.27501,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor
naratriptan
naratriptan: structure given in first source		3.8530heteroarylpiperidine;
sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
nefazodone
nefazodone: may be useful as an opiate adjunct		4.6780aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles		alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor
nefopam
Nefopam: Non-narcotic analgesic chemically similar to ORPHENADRINE. Its mechanism of action is unclear. It is used for the relief of acute and chronic pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p26). nefopam : A racemate comprising equal amounts of (R)- and (S)-nefopam. The hydrochloride is a centrally acting non-opiate analgesic commonly used for the treatment of moderate to severe pain.. 5-methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine : A member of the class of benzoxazocines that is 3,4,5,6-tetrahydro-1H-2,5-benzoxazocine substituted by phenyl and methyl groups at positions 1 and 5 respectively.		2.7530benzoxazocine;
tertiary amino compound
neostigmine
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.. neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.		2.4720quaternary ammonium ionantidote to curare poisoning;
EC 3.1.1.7 (acetylcholinesterase) inhibitor
nevirapine
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.		4.6780cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
nialamide
Nialamide: An MAO inhibitor that is used as an antidepressive agent.		3.5920organonitrogen compound;
organooxygen compound
nicardipine
Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.. nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.. 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.		5.280benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound
niceritrol
Niceritrol: An ester of nicotinic acid that lowers cholesterol and triglycerides in total plasma and in the VLD- and LD-lipoprotein fractions.		2.0510organic molecular entity
niclosamide
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48). niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.		2.2110benzamides;
C-nitro compound;
monochlorobenzenes;
salicylanilides;
secondary carboxamide		anthelminthic drug;
anticoronaviral agent;
antiparasitic agent;
apoptosis inducer;
molluscicide;
piscicide;
STAT3 inhibitor
nifedipine
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.		5.48110C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
niflumic acid
Niflumic Acid: An analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.		2.0510aromatic carboxylic acid;
pyridines
nilutamide
[no description available]		3.5920(trifluoromethyl)benzenes;
C-nitro compound;
imidazolidinone		androgen antagonist;
antineoplastic agent
nimesulide
nimesulide: structure. nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.		4.0940aromatic ether;
C-nitro compound;
sulfonamide		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
nimodipine
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.		5.391002-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester		antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
nisoldipine
Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.. nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.. methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.		4.4260C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
methyl ester
nitrazepam
Nitrazepam: A benzodiazepine derivative used as an anticonvulsant and hypnotic.. nitrazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome).		3.15501,4-benzodiazepinone;
C-nitro compound		anticonvulsant;
antispasmodic drug;
drug metabolite;
GABA modulator;
sedative
nitrendipine
Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.. nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.		4.4260C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester		antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent
nitroglycerin
Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.		3.5920nitroglycerolexplosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic
nizatidine
[no description available]		4.25501,3-thiazoles;
C-nitro compound;
carboxamidine;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
cholinergic drug;
H2-receptor antagonist
nomifensine
Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266). nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.		3.8630isoquinolinesdopamine uptake inhibitor
masoprocol
nordihydroguaretic acid: antioxidant compound found in the creosote bush (Larrea tridentata)		2.4620catechols;
lignan;
tetrol		antioxidant;
ferroptosis inhibitor;
geroprotector;
plant metabolite
norfloxacin
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.		3.8730fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
nortriptyline
Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.. nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.		4.4260organic tricyclic compound;
secondary amine		adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source. NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.		2.4420aromatic ether;
C-nitro compound;
sulfonamide		antineoplastic agent;
cyclooxygenase 2 inhibitor
nu6102
NU6102: structure in first source		2.0310
ofloxacin
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.		4.08403-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
olomoucine
olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.		2.78302,6-diaminopurines;
ethanolamines		EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
olprinone
olprinone: RN refers to HCl; structure given in first source		2.0810bipyridines
omeprazole
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.		5.39100aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
ondansetron
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.		4.2650carbazoles
orphenadrine
Orphenadrine: A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.. orphenadrine : A tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol.		3.5920ether;
tertiary amino compound		antidyskinesia agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic
oxonic acid
Oxonic Acid: Antagonist of urate oxidase.		9.451531,3,5-triazines;
monocarboxylic acid
oxamniquine
Oxamniquine: An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs. (From Martindale, The Extra Pharmacopoeia, 31st ed, p121). oxamniquine : A racemate comprising equimolar amounts of (R)- and (S)-oxamniquine. An anthelmintic, it is administered orally for the treatment of schistomiasis caused by Schistosoma mansoni (but not by other Schistosoma species); intramuscular administration is no longer used as it causes severe pain at the injection site.. {2-[(isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl}methanol : A member of the class of quinolines that is 1,2,3,4-tetrahydroquinoline which is substituted at positions 2, 6, and 7 by (isopropylamino)methyl, hydroxymethyl, and nitro groups, respectively.		2.0510aromatic primary alcohol;
C-nitro compound;
quinolines;
secondary amino compound
oxaprozin
Oxaprozin: An oxazole-propionic acid derivative, cyclooxygenase inhibitor, and non-steroidal anti-inflammatory drug that is used in the treatment of pain and inflammation associated with of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; and ARTHRITIS, JUVENILE.. oxaprozin : A monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis.		4.09401,3-oxazoles;
monocarboxylic acid		analgesic;
non-steroidal anti-inflammatory drug
oxazepam
Oxazepam: A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia.. oxazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5.		4.07401,4-benzodiazepinone;
organochlorine compound		anxiolytic drug;
environmental contaminant;
xenobiotic
oxethazaine
[no description available]		2.0510amino acid amide
oxibendazole
oxibendazole: structure		2.0510benzimidazoles;
carbamate ester
oxiracetam
oxiracetam: structure in first source		2.0410organonitrogen compound;
organooxygen compound
oxprenolol
Oxprenolol: A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.		2.0510aromatic ether
oxybenzone
oxybenzone : A hydroxybenzophenone that is benzophenone which is substituted at the 2- and 4-positions of one of the benzene rings by hydroxy and methoxy groups respectively.		2.0510hydroxybenzophenone;
monomethoxybenzene		dermatologic drug;
environmental contaminant;
protective agent;
ultraviolet filter;
xenobiotic
oxybutynin
oxybutynin: RN given refers to parent cpd. oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.		4.2750acetylenic compound;
carboxylic ester;
racemate;
tertiary alcohol;
tertiary amino compound		antispasmodic drug;
calcium channel blocker;
local anaesthetic;
muscarinic antagonist;
muscle relaxant;
parasympatholytic
oxyphenbutazone
Oxyphenbutazone: A non-steroidal anti-inflammatory drug. Oxyphenbutazone eyedrops have been used abroad in the management of postoperative ocular inflammation, superficial eye injuries, and episcleritis. (From AMA, Drug Evaluations Annual, 1994, p2000) It had been used by mouth in rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis but such use is no longer considered justified owing to the risk of severe hematological adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p27). oxyphenbutazone : A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome.		2.0510phenols;
pyrazolidines		antimicrobial agent;
antineoplastic agent;
antipyretic;
drug metabolite;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite
aminosalicylic acid
Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.		3.8630aminobenzoic acid;
phenols		antitubercular agent
pamidronate
[no description available]		4.0940phosphonoacetic acid
pantoprazole
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.. pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.		5.0970aromatic ether;
benzimidazoles;
organofluorine compound;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
environmental contaminant;
xenobiotic
papaverine
Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.		4.850benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent
4-dichlorobenzene
dichlorobenzene : Any member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.. 1,4-dichlorobenzene : A dichlorobenzene carrying chloro groups at positions 1 and 4.		2.0510dichlorobenzeneinsecticide
pargyline
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.		2.0510aromatic amine
pd 153035
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline: structure given in first source. PD-153035 : A member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7.		6.16230aromatic amine;
aromatic ether;
bromobenzenes;
quinazolines;
secondary amino compound		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist
pd168393
PD 168393 : A member of the class of quinazolines carrying bromoanilino and acrylamido substituents at positions 4 and 6 respectively.		3.6790acrylamides;
bromobenzenes;
quinazolines;
secondary carboxamide;
substituted aniline		epidermal growth factor receptor antagonist
pd 169316
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole: p38 MAP kinase inhibitor		2.0310imidazoles
pd 98059
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.		3.84110aromatic amine;
monomethoxyflavone		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
pemoline
Pemoline: A central nervous system stimulant used in fatigue and depressive states and to treat hyperkinetic disorders in children.. pemoline : A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted by an amino group at position 2 and by a phenyl group at position 5. A central nervous system stimulant, it was used to treat hyperactivity disorders in children, but withdrawn from use following reports of serious hepatotoxicity.		4.09401,3-oxazolescentral nervous system stimulant
pentamidine
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.		4.0840aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
pentobarbital
Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.		3.8630barbituratesGABAA receptor agonist
pentoxifylline
[no description available]		4.2650oxopurine
perazine
Perazine: A phenothiazine antipsychotic with actions and uses similar to those of CHLORPROMAZINE. Extrapyramidal symptoms may be more common than other side effects.. perazine : A phenothiazine derivative in which 10H-phenothiazinecarries a 3-(4-methylpiperazin-1-yl)propyl substituent at the N-10 position.		2.0510N-alkylpiperazine;
N-methylpiperazine;
phenothiazines		dopaminergic antagonist;
phenothiazine antipsychotic drug
perhexiline
Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.		3.5920piperidinescardiovascular drug
perphenazine
Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.		4.2650N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines		antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug
phenacetin
Saridon: contains phenacetin, caffeine, propyphenazone & pyrithyldione		3.3160acetamides;
aromatic ether		cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug
phenobarbital
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.		4.460barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
phenolphthalein
Phenolphthalein: An acid-base indicator which is colorless in acid solution, but turns pink to red as the solution becomes alkaline. It is used medicinally as a cathartic.		2.0510phenols
phenoxybenzamine
Phenoxybenzamine: An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.		3.8830aromatic amine
phentermine
Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.		3.2310primary amineadrenergic agent;
appetite depressant;
central nervous system drug;
central nervous system stimulant;
dopaminergic agent;
sympathomimetic agent
4-phenylbutyric acid
4-phenylbutyric acid: RN refers to the parent cpd. 4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.		3.8730monocarboxylic acidantineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug
phenylbutazone
Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.		2.4620pyrazolidinesantirheumatic drug;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
phloretin
[no description available]		2.1510dihydrochalconesantineoplastic agent;
plant metabolite
moxonidine
moxonidine: structure given in first source		2.4520organohalogen compound;
pyrimidines
3,3',4,5'-tetrahydroxystilbene
[no description available]		2.0610stilbenoid
pimobendan
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source		2.0410benzimidazoles;
pyridazinone		cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
pinacidil
Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed)		2.4620pyridines
pindolol
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638). pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.		4.2650indoles;
secondary amine		antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
serotonergic antagonist;
vasodilator agent
pioglitazone
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.		4.6780aromatic ether;
pyridines;
thiazolidinediones		antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic
pipemidic acid
Pipemidic Acid: Antimicrobial against Gram negative and some Gram positive bacteria. It is protein bound and concentrated in bile and urine and used for gastrointestinal, biliary, and urinary infections.. pipemidic acid : A pyridopyrimidine that is 5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid substituted at position 2 by a piperazin-1-yl group and at position 8 by an ethyl group. A synthetic broad-spectrum antibacterial, it is used for treatment of gastrointestinal, biliary, and urinary infections.		2.0510amino acid;
monocarboxylic acid;
N-arylpiperazine;
pyridopyrimidine;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor
piperazine
[no description available]		2.0510azacycloalkane;
piperazines;
saturated organic heteromonocyclic parent		anthelminthic drug
pipobroman
Pipobroman: An antineoplastic agent that acts by alkylation.. pipobroman : An N-acylpiperazine that is piperazine in which each of the nitrogens has been acylated by a 3-bromopropionoyl group. An anti-cancer drug.		2.0510N-acylpiperazine;
organobromine compound;
tertiary carboxamide		alkylating agent;
antineoplastic agent
piracetam
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.		2.0810organonitrogen compound;
organooxygen compound
piretanide
piretanide: potent inhibitor of chloride transport; structure		2.0410aromatic ether
piribedil
Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist.		2.0810N-arylpiperazine
polythiazide
[no description available]		3.2310benzothiadiazine
1-NA-PP1
[no description available]		2.0310pyrazolopyrimidinetyrosine kinase inhibitor
ag 1879
3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor		3.1650aromatic amine;
monochlorobenzenes;
pyrazolopyrimidine		beta-adrenergic antagonist;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
duodote
duodote: consists of atropine and pralidoxime chloride; for treating those exposed to organophosphorus-containing nerve agents		3.2310pyridinium ionantidote to organophosphate poisoning;
antidote to sarin poisoning;
cholinergic drug;
cholinesterase reactivator
pramoxine
pramoxine: RN given refers to parent cpd; structure. pramocaine : A member of the class of morpholines that is morpholine substituted at the nitrogen atom by a 3-(4-butoxyphenoxy)propyl group.		2.0410aromatic ether;
morpholines		local anaesthetic
ono 1078
pranlukast: SRS-A antagonist; leukotriene D4 receptor antagonist		2.4720chromones
pyranoprofen
pyranoprofen: RN given refers to unlabled parent cpd; structure given in first source		2.0810pyridochromene
praziquantel
azinox: Russian drug		4.2750isoquinolines
prazosin
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.		5.1880aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
prilocaine
Prilocaine: A local anesthetic that is similar pharmacologically to LIDOCAINE. Currently, it is used most often for infiltration anesthesia in dentistry.. prilocaine : An amino acid amide in which N-propyl-DL-alanine and 2-methylaniline have combined to form the amide bond; used as a local anaesthetic.		2.0410amino acid amide;
monocarboxylic acid amide		anticonvulsant;
local anaesthetic
primaquine
Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.		4.2650aminoquinoline;
aromatic ether;
N-substituted diamine		antimalarial
primidone
Primidone: A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite.. primidone : A pyrimidone that is dihydropyrimidine-4,6(1H,5H)-dione substituted by an ethyl and a phenyl group at position 5. It is used as an anticonvulsant for treatment of various types of seizures.		4.2650pyrimidoneanticonvulsant;
environmental contaminant;
xenobiotic
probenecid
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.		4.4160benzoic acids;
sulfonamide		uricosuric drug
probucol
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).. probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.		2.4620dithioketal;
polyphenol		anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug
procainamide
Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.		4.4160benzamidesanti-arrhythmia drug;
platelet aggregation inhibitor;
sodium channel blocker
procarbazine
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.. procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.		3.8630benzamides;
hydrazines		antineoplastic agent
prochlorperazine
Prochlorperazine: A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612). prochlorperazine : A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position.		4.2650N-alkylpiperazine;
N-methylpiperazine;
organochlorine compound;
phenothiazines		alpha-adrenergic antagonist;
antiemetic;
cholinergic antagonist;
dopamine receptor D2 antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic
procyclidine
Procyclidine: A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.. procyclidine : A tertiary alcohol that consists of propan-1-ol substituted by a cyclohexyl and a phenyl group at position 1 and a pyrrolidin-1-yl group at position 3.		4.0840pyrrolidines;
tertiary alcohol		antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist
promazine
Promazine: A phenothiazine with actions similar to CHLORPROMAZINE but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic.. promazine : A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position.		2.0410phenothiazines;
tertiary amine		antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist
promethazine
Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.		4.2650phenothiazines;
tertiary amine		anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative
propafenone
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.		4.2750aromatic ketone;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug
propanil
Propanil: A chlorinated anilide that is used as an herbicide.. propanil : An anilide resulting from the formal condensation of the carboxy group of propanoic acid with the amino group of 3,4-dichloroaniline. It is a herbicide used for the treatment of numerous grasses and broad-leaved weeds in rice, potatoes, and wheat.		2.0510anilide;
dichlorobenzene		herbicide
propantheline
Propantheline: A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.		3.2310xanthenes
propofol
Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.. propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.		4.0840phenolsanticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative
propranolol
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.		4.88100naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
protoporphyrin ix
protoporphyrin IX: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7685. protoporphyrin : A cyclic tetrapyrrole that consists of porphyrin bearing four methyl substituents at positions 3, 8, 13 and 17, two vinyl substituents at positions 7 and 12 and two 2-carboxyethyl substituents at positions 2 and 18. The parent of the class of protoporphyrins.		3.2110
protriptyline
Protriptyline: Tricyclic antidepressant similar in action and side effects to IMIPRAMINE. It may produce excitation.		3.5720carbotricyclic compoundantidepressant
pyridinolcarbamate
Pyridinolcarbamate: A drug that has been given by mouth in the treatment of atherosclerosis and other vascular disorders, hyperlipidemias, and thrombo-embolic disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1408)		2.0510pyridines
pyridostigmine
[no description available]		3.5820pyridinium ion
pyrimethamine
Maloprim: contains above 2 cpds		4.0840aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
pyroxamide
[no description available]		3.110aromatic amide
sch 16134
quazepam: structure given in first source		3.2310benzodiazepine
quetiapine
[no description available]		3.6120dibenzothiazepine;
N-alkylpiperazine;
N-arylpiperazine		adrenergic antagonist;
dopaminergic antagonist;
histamine antagonist;
second generation antipsychotic;
serotonergic antagonist
rabeprazole
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.		4.4230benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one
[no description available]		2.0810indoles
raloxifene
raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.		4.26501-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols		bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
ranitidine
[no description available]		3.1550aralkylamine
opc 12759
rebamipide: structure in first source; RN refers to (+-)-isomer; inhibits gastric xanthine oxidase		2.0510secondary carboxamide
riluzole
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.		4.4360benzothiazoles
rimantadine
Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.		3.2310alkylamine
risperidone
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.. risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.		4.66801,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist
ritanserin
Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.. ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.		2.0410organofluorine compound;
piperidines;
thiazolopyrimidine		antidepressant;
antipsychotic agent;
anxiolytic drug;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
rizatriptan
rizatriptan: structure given in first source; RN given refers to benzoate		3.8530tryptaminesanti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
rofecoxib
[no description available]		4.8271butenolide;
sulfone		analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
ropinirole
[no description available]		3.5720indolones;
tertiary amine		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist
saccharin
Saccharin: Flavoring agent and non-nutritive sweetener.. saccharin : A 1,2-benzisothiazole having a keto-group at the 3-position and two oxo substituents at the 1-position. It is used as an artificial sweetening agent.		2.03101,2-benzisothiazole;
N-sulfonylcarboxamide		environmental contaminant;
sweetening agent;
xenobiotic
salicylamide
salamide: a major impurity of hydrochlorothiazide; structure in first source		2.0510phenols;
salicylamides		antirheumatic drug;
non-narcotic analgesic
sanguinarine
benzophenanthridine alkaloid : A specific group of isoquinoline alkaloids that occur only in higher plants and are constituents mainly of the Papaveraceae family.		2.1310alkaloid antibiotic;
benzophenanthridine alkaloid;
botanical anti-fungal agent
salicylsalicylic acid
salicylsalicylic acid: structure. salsalate : A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes.		3.2310benzoate ester;
benzoic acids;
phenols;
salicylates		antineoplastic agent;
antirheumatic drug;
EC 3.5.2.6 (beta-lactamase) inhibitor;
hypoglycemic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
sb 206553
SB 206553: a high-affinity 5-HT(2C/2B) antagonist; structure given in first source		2.0810pyrroloindole
sb 220025
SB 220025: inhibits p38 mitogen-activated protein kinase; structure in first source. SB220025 : Am member of the class of imidazoles carrying piperidin-4-yl, 4-fluophenyl and 2-aminopyrimidin-4-yl substituents at posiitons 1, 4 and 5 respectively.		2.7530aminopyrimidine;
imidazoles;
organofluorine compound;
piperidines		angiogenesis inhibitor;
anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sb 239063
SB 239063: structure in first source. SB-239063 : A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.		2.4520imidazoles
sb 202190
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase		5.0590imidazoles;
organofluorine compound;
phenols;
pyridines		apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
secobarbital
Secobarbital: A barbiturate that is used as a sedative. Secobarbital is reported to have no anti-anxiety activity.. secobarbital : A member of the class of barbiturates that is barbituric acid in which the hydrogens at position 5 are substituted by prop-2-en-1-yl and pentan-2-yl groups.		3.2310barbituratesanaesthesia adjuvant;
GABA modulator;
sedative
sevoflurane
Sevoflurane: A non-explosive inhalation anesthetic used in the induction and maintenance of general anesthesia. It does not cause respiratory irritation and may also prevent PLATELET AGGREGATION.. sevoflurane : An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups.		2.0510ether;
organofluorine compound		central nervous system depressant;
inhalation anaesthetic;
platelet aggregation inhibitor
sibutramine
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride		3.5920organochlorine compound;
tertiary amino compound		anti-obesity agent;
serotonin uptake inhibitor
sulfadiazine
Sulfadiazine: One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.. sulfadiazine : A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.. diazine : The parent structure of the diazines.		4.2650pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
antimicrobial agent;
antiprotozoal drug;
coccidiostat;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
sk&f 86002
6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole: inhibits p38 MAP kinase		2.0810imidazoles
sodium fluoride
[no description available]		2.0510fluoride saltmutagen
risedronic acid
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.		3.5820pyridines
sotalol
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.. sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.		4.4160ethanolamines;
secondary alcohol;
secondary amino compound;
sulfonamide		anti-arrhythmia drug;
beta-adrenergic antagonist;
environmental contaminant;
xenobiotic
4-phenylbutyric acid, sodium salt
sodium phenylbutyrate : The organic sodium salt of 4-phenylbutyric acid. A prodrug for phenylacetate, it is used to treat urea cycle disorders.		2.0510organic sodium saltEC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector;
neuroprotective agent;
orphan drug;
prodrug
stearic acid
octadecanoic acid : A C18 straight-chain saturated fatty acid component of many animal and vegetable lipids. As well as in the diet, it is used in hardening soaps, softening plastics and in making cosmetics, candles and plastics.		2.0710long-chain fatty acid;
saturated fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
human metabolite;
plant metabolite
imatinib
[no description available]		8.88290aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines		antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		9.38223dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
succinylcholine
Succinylcholine: A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for.. succinylcholine : A quaternary ammonium ion that is the bis-choline ester of succinic acid.		3.2310quaternary ammonium ion;
succinate ester		drug allergen;
muscle relaxant;
neuromuscular agent
sulfabenzamide
sulfabenzamide : A sulfonamide containing a benzamido substituent on nitrogen. An antibacterial/antimicrobial, it is often used in conjunction with sulfathiazole and sulfacetamide as a topical, intravaginal antibacterial preparation.		2.0510benzenes;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
antimicrobial drug
sulfacetamide
Sulfacetamide: An anti-bacterial agent that is used topically to treat skin infections and orally for urinary tract infections.. sulfacetamide : A sulfonamide that is sulfanilamide acylated on the sulfonamide nitrogen.		2.0310N-sulfonylcarboxamide;
substituted aniline		antibacterial drug;
antiinfective agent;
antimicrobial agent;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfadimethoxine
Sulfadimethoxine: A sulfanilamide that is used as an anti-infective agent.. sulfadimethoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 2- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position.		2.0510aromatic ether;
pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
antimicrobial agent;
drug allergen;
environmental contaminant;
xenobiotic
sulfamerazine
[no description available]		2.0510pyrimidines;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen
sulfameter
Sulfameter: Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections.. sulfamethoxydiazine : A sulfonamide consisting of pyrimidine having a methoxy substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 2-position.		2.0510pyrimidines;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
leprostatic drug;
renal agent
sulfamethazine
Sulfamethazine: A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.. sulfamethazine : A sulfonamide consisting of pyrimidine with methyl substituents at the 4- and 6-positions and a 4-aminobenzenesulfonamido group at the 2-position.		2.0510pyrimidines;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
antiinfective agent;
antimicrobial agent;
carcinogenic agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
ligand;
xenobiotic
sulfamethizole
Sulfamethizole: A sulfathiazole antibacterial agent.. sulfamethizole : A sulfonamide consisting of a 1,3,4-thiadiazole nucleus with a methyl substituent at C-5 and a 4-aminobenzenesulfonamido group at C-2.		3.8630sulfonamide antibiotic;
sulfonamide;
thiadiazoles		antiinfective agent;
antimicrobial agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfamethoxazole
Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.		2.9740isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic
sulfanilamide
[no description available]		2.4620substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
drug allergen;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
sulfanitran
[no description available]		2.4620sulfonamide
sulfaphenazole
Sulfaphenazole: A sulfonilamide anti-infective agent.. sulfaphenazole : A sulfonamide that is sulfanilamide in which the sulfonamide nitrogen is substituted by a 1-phenyl-1H-pyrazol-5-yl group. It is a selective inhibitor of cytochrome P450 (CYP) 2C9 isozyme, and antibacterial agent.		2.0510primary amino compound;
pyrazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor;
P450 inhibitor
sulfapyridine
Sulfapyridine: Antibacterial, potentially toxic, used to treat certain skin diseases.. sulfapyridine : A sulfonamide consisting of pyridine with a 4-aminobenzenesulfonamido group at the 2-position.		2.0510pyridines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
dermatologic drug;
drug allergen;
environmental contaminant;
xenobiotic
sulfasalazine
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.		5.2990
sulfathiazole
Sulfathiazole: A sulfathiazole compound that is used as a short-acting anti-infective agent. It is no longer commonly used systemically due to its toxicity, but may still be applied topically in combination with other drugs for the treatment of vaginal and skin infections, and is still used in veterinary medicine.. sulfathiazole : A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position.		3.23101,3-thiazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
sulfinpyrazone
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.		3.1550pyrazolidines;
sulfoxide		uricosuric drug
sulfisoxazole
Sulfisoxazole: A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.. sulfisoxazole : A sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.		2.7530isoxazoles;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
drug allergen
sulfobromophthalein
Sulfobromophthalein: A phenolphthalein that is used as a diagnostic aid in hepatic function determination.		2.05102-benzofurans;
organobromine compound;
organosulfonic acid;
phenols		dye
sulforaphane
sulforaphane: from Cardaria draba L.. sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.		7.3110isothiocyanate;
sulfoxide		antineoplastic agent;
antioxidant;
EC 3.5.1.98 (histone deacetylase) inhibitor;
plant metabolite
2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol
[no description available]		3.5920alkylbenzene
sulpiride
Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.		2.0510benzamides;
N-alkylpyrrolidine;
sulfonamide		antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
sumatriptan
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.. sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.		4.2650sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
suprofen
Suprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic.. suprofen : An aromatic ketone that is thiophene substituted at C-2 by a 4-(1-carboxyethyl)benzoyl group.		2.4520aromatic ketone;
monocarboxylic acid;
thiophenes		antirheumatic drug;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
suramin
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.		2.4520naphthalenesulfonic acid;
phenylureas;
secondary carboxamide		angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine
[no description available]		2.0810stilbenoid
gatifloxacin
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.		3.1650N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
tazarotene
tazarotene: a topical acetylenic retinoid; a topical kerytolytic. tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.		2.0810acetylenic compound;
ethyl ester;
pyridines;
retinoid;
thiochromane		keratolytic drug;
prodrug;
teratogenic agent
tegafur
[no description available]		15.18205organohalogen compound;
pyrimidines
telenzepine
telenzepine: structure given in first source		2.4520benzodiazepine
temazepam
Temazepam: A benzodiazepine that acts as a GAMMA-AMINOBUTYRIC ACID modulator and anti-anxiety agent.		3.5920benzodiazepine
temozolomide
[no description available]		11.06203imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
terazosin
Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia		4.7950furans;
piperazines;
primary amino compound;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
terbutaline
Terbutaline: A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.. terbutaline : A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group.		4.2650phenylethanolamines;
resorcinols		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
sympathomimetic agent;
tocolytic agent
terfenadine
Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.		3.1650diarylmethane
tetracaine
Tetracaine: A potent local anesthetic of the ester type used for surface and spinal anesthesia.. tetracaine : A benzoate ester in which 4-N-butylbenzoic acid and 2-(dimethylamino)ethanol have combined to form the ester bond; a local ester anaesthetic (ester caine) used for surface and spinal anaesthesia.		2.0510benzoate ester;
tertiary amino compound		local anaesthetic
thalidomide
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.		11.25110phthalimides;
piperidones
thiabendazole
Tresaderm: dermatologic soln containing dexamethasone, thiabendazole & neomycin sulfate		3.59201,3-thiazoles;
benzimidazole fungicide;
benzimidazoles		antifungal agrochemical;
antinematodal drug
thioridazine
Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.. thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.		4.6240phenothiazines;
piperidines		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
thiotepa
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).		4.0840aziridines
tiapride
[no description available]		2.0810benzamides
tiaprofenic acid
tiaprofenic acid: RN given refers to parent cpd; structure. tiaprofenic acid : An aromatic ketone that is thiophene substituted at C-2 by benzoyl and at C-4 by a 1-carboxyethyl group.		2.0510aromatic ketone;
monocarboxylic acid;
thiophenes		drug allergen;
non-steroidal anti-inflammatory drug
ticlopidine
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.. ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.		3.8630monochlorobenzenes;
thienopyridine		anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
tilorone
Tilorone: An antiviral agent used as its hydrochloride. It is the first recognized synthetic, low-molecular-weight compound that is an orally active interferon inducer, and is also reported to have antineoplastic and anti-inflammatory actions.. tilorone : A member of the class of fluoren-9-ones that is 9H-fluoren-9-one which is substituted by a 2-(diethylamino)ethoxy group at positions 2 and 7. It is an interferon inducer and a selective alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonist. Its hydrochloride salt is used as an antiviral drug.		2.4720aromatic ether;
diether;
fluoren-9-ones;
tertiary amino compound		anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
interferon inducer;
nicotinic acetylcholine receptor agonist
tinidazole
Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.. tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.		4.0840imidazolesantiamoebic agent;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
tiopronin
Tiopronin: Sulfhydryl acylated derivative of GLYCINE.		3.5920N-acyl-amino acid
tizanidine
tizanidine: RN given refers to parent cpd; structure. tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.		4.2650benzothiadiazole;
imidazoles		alpha-adrenergic agonist;
muscle relaxant
nikethamide
Nikethamide: A central nervous system stimulant. It was formerly used in the treatment of barbiturate overdose but is now considered to be of no value for such purposes and may be dangerous. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1229)		2.0810pyridinecarboxamide
tolazamide
Tolazamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.. tolazamide : An N-sulfonylurea that is 1-tosylurea in which a hydrogen attached to the nitrogen at position 3 is replaced by an azepan-1-yl group. A hypoglycemic agent, it is used for the treatment of type 2 diabetes mellitus.		3.8630N-sulfonylureahypoglycemic agent;
potassium channel blocker
tolbutamide
Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.		4.5470N-sulfonylureahuman metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker
tolmetin
Tolmetin: A non-steroidal anti-inflammatory agent (ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL) similar in mode of action to INDOMETHACIN.. tolmetin : A monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug.		3.5920aromatic ketone;
monocarboxylic acid;
pyrroles		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
tolnaftate
[no description available]		2.0810monothiocarbamic esterantifungal drug
tolperisone
Tolperisone: A centrally acting muscle relaxant that has been used for the symptomatic treatment of spasticity and muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1211)		2.0510aromatic ketone
ultram
2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol : A tertiary alcohol that is cyclohexanol substituted at positions 1 and 2 by 3-methoxyphenyl and dimethylaminomethyl groups respectively.		4.4160aromatic ether;
tertiary alcohol;
tertiary amino compound
tranexamic acid
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.		3.8630amino acid
trazodone
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309). trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.		4.4260monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine		adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
triamterene
Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.. triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.		4.2650pteridinesdiuretic;
sodium channel blocker
triazolam
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.		4.0740triazolobenzodiazepinesedative
triclosan
[no description available]		2.0510aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols		antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic
trifluoperazine
[no description available]		4.140N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines		antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug
triflupromazine
Triflupromazine: A phenothiazine used as an antipsychotic agent and as an antiemetic.. triflupromazine : A member of the class of phenothiazines that is 10H-phenothiazine having a trifluoromethyl subsitituent at the 2-position and a 3-(dimethylamino)propyl group at the N-10 position.		2.0510organofluorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
trihexyphenidyl
Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.		3.2310amine
trimethadione
Trimethadione: An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378). trimethadione : An oxazolidinone that is 1,3-oxazolidine-2,4-dione substituted by methyl groups at positions 3, 5 and 5. It is an antiepileptic agent.		3.8630oxazolidinoneanticonvulsant;
geroprotector
trimethobenzamide
trimethobenzamide: major descriptor (64-84); on-line search BENZAMIDES (64-84); Index Medicus search TRIMETHOBENZAMIDE (64-84); RN given refers to parent cpd. trimethobenzamide : The amide obtained by formal condensation of 3,4,5-trihydroxybenzoic acid with 4-[2-(N,N-dimethylamino)ethoxy]benzylamine. It is used to prevent nausea and vomitting in humans.		3.2310benzamides;
tertiary amino compound		antiemetic
trimethoprim
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.		4.6680aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
trimetrexate
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.		4.4130
trimipramine
Trimipramine: Tricyclic antidepressant similar to IMIPRAMINE, but with more antihistaminic and sedative properties.. trimipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant.		3.5820dibenzoazepine;
tertiary amino compound		antidepressant;
environmental contaminant;
xenobiotic
troglitazone
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.		4.5670chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent
thenoyltrifluoroacetone
Thenoyltrifluoroacetone: Chelating agent and inhibitor of cellular respiration.		2.0810
tyramine
[no description available]		3.2310monoamine molecular messenger;
primary amino compound;
tyramines		EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter
tyrphostin a9
[no description available]		3.9220alkylbenzenegeroprotector
delavirdine
Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.		4.4130aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide		antiviral drug;
HIV-1 reverse transcriptase inhibitor
undecylenic acid
undecylenic acid: a fatty acid with a terminal double bond. 10-undecenoic acid : An undecenoic acid having its double bond in the 10-position. It is derived from castor oil and is used for the treatment of skin problems.. undecenoic acid : A C11, straight-chain fatty acid carrying a C=C double bond at any position.		2.0810undecenoic acidantifungal drug;
plant metabolite
urapidil
[no description available]		2.7530piperazines
urethane
[no description available]		7.5920carbamate esterfungal metabolite;
mutagen
venlafaxine
venlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group.		4.4260cyclohexanols;
monomethoxybenzene;
tertiary alcohol;
tertiary amino compound		adrenergic uptake inhibitor;
analgesic;
antidepressant;
dopamine uptake inhibitor;
environmental contaminant;
serotonin uptake inhibitor;
xenobiotic
vesnarinone
[no description available]		2.0510organic molecular entity
vigabatrin
[no description available]		3.8730gamma-amino acidanticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
viloxazine
Viloxazine: A morpholine derivative used as an antidepressant. It is similar in action to IMIPRAMINE.		2.0410aromatic ether
whi p180
[no description available]		2.0310
pirinixic acid
pirinixic acid: structure		2.4720aryl sulfide;
organochlorine compound;
pyrimidines
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source. lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.		2.6920aromatic primary alcohol;
furans;
indazoles		antineoplastic agent;
apoptosis inducer;
platelet aggregation inhibitor;
soluble guanylate cyclase activator;
vasodilator agent
ici 204,219
zafirlukast: a leukotriene D4 receptor antagonist		4.2850carbamate ester;
indoles;
N-sulfonylcarboxamide		anti-asthmatic agent;
leukotriene antagonist
zaleplon
zaleplon: an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam. zaleplon : A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.		9.2850nitrile;
pyrazolopyrimidine		anticonvulsant;
anxiolytic drug;
central nervous system depressant;
sedative
zm 336372
N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide: an inhibitor of c-Raf; activates Raf-1; structure in first source		2.0310benzamides
zolpidem
Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.. zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.		4.2550imidazopyridinecentral nervous system depressant;
GABA agonist;
sedative
zomepirac
zomepirac: RN given refers to parent cpd; structure		2.0510aromatic ketone;
monocarboxylic acid;
monochlorobenzenes;
pyrroles		cardiovascular drug;
non-steroidal anti-inflammatory drug
zonisamide
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.. zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.		3.87301,2-benzoxazoles;
sulfonamide		anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker
zopiclone
zopiclone: S(+)-enantiomer of racemic zopiclone; azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; was term of zopiclone 2004-2007. zopiclone : A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position.		2.4620monochloropyridine;
pyrrolopyrazine		central nervous system depressant;
sedative
guanidine hydrochloride
[no description available]		2.0510one-carbon compound;
organic chloride salt		protein denaturant
hydrocortisone acetate
hydrocortisone acetate: RN given refers to cpd without isomeric designation		2.0510cortisol ester;
tertiary alpha-hydroxy ketone
cortisone acetate
Cortisone Acetate: The acetate ester of cortisone that is used mainly for replacement therapy in adrenocortical insufficiency and in the treatment of many allergic and inflammatory disorders.		3.5920corticosteroid hormone
mitomycin
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.		4.9160mitomycinalkylating agent;
antineoplastic agent
oxyphenonium
Oxyphenonium: A quaternary ammonium anticholinergic agent with peripheral side effects similar to those of ATROPINE. It is used as an adjunct in the treatment of gastric and duodenal ulcer, and to relieve visceral spasms. The drug has also been used in the form of eye drops for mydriatic effect.		2.0510acylcholine
corticosterone
[no description available]		2.061011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
prednisolone
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.		6.4212111beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
estriol
hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone. chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.		2.051016alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid		estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite
reserpine
Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.		5.0970alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
cephaloridine
Cephaloridine: A cephalosporin antibiotic.. cefaloridine : A cephalosporin compound having pyridinium-1-ylmethyl and 2-thienylacetamido side-groups. A first-generation semisynthetic derivative of cephalosporin C.		2.7430beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
phentolamine
Phentolamine: A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.. phentolamine : A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension.		3.8830imidazoles;
phenols;
substituted aniline;
tertiary amino compound		alpha-adrenergic antagonist;
vasodilator agent
sorbitol
D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).		3.8630glucitolcathartic;
Escherichia coli metabolite;
food humectant;
human metabolite;
laxative;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite;
sweetening agent
thymidine
[no description available]		3.6630pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
floxuridine
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.		2.9640nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
piperonyl butoxide
[no description available]		2.0510benzodioxolespesticide synergist
bromouracil
Bromouracil: 5-Bromo-2,4(1H,3H)-pyrimidinedione. Brominated derivative of uracil that acts as an antimetabolite, substituting for thymine in DNA. It is used mainly as an experimental mutagen, but its deoxyriboside (BROMODEOXYURIDINE) is used to treat neoplasms.. 5-bromouracil : A pyrimidine having keto groups at the 2- and 4-positions and a bromo group at the 5-position. Used mainly as an experimental mutagen.		2.5220nucleobase analogue;
pyrimidines		mutagen
3,3',5-triiodothyroacetic acid
tiratricol : A monocarboxylic acid that is (4-hydroxy-3,5-diiodophenyl)acetic acid in which the phenolic hydroxy group has been replaced by a 4-hydroxy-3-iodophenoxy group. It is a thyroid hormone analogue that has been used in the treatment of thyroid hormone resistance syndrome.		2.0510
isoproterenol hydrochloride
[no description available]		2.0510catechols
histamine dihydrochloride
Ceplene: Tradename for histamine dihydrochloride.		2.0510
thyroxine
Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.. thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.		4.14402-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine		antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone
dextroamphetamine
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.. (S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.		3.59201-phenylpropan-2-amineadrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent
carbachol
Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.		2.0510ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic
norethindrone acetate
norethisterone acetate : A 3-oxo Delta(4)-steroid that is norethisterone in which the hydroxy group has been converted to its acetate ester.		2.05103-oxo-Delta(4) steroid;
acetate ester;
terminal acetylenic compound		progestin;
synthetic oral contraceptive
spironolactone
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827). spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.		4.25503-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester		aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
cyclobarbital
cyclobarbital: was heading 1977-94 (see under BARBITURATES 1977-90); CYCLOBARBITONE, HEXEMAL, & TETRAHYDROPHENOBARBITAL were see CYCLOBARBITAL 1977-94; use BARBITURATES to search CYCLOBARBITAL 1977-94; short to intermediate duration barbiturate used as hypnotic and sedative		2.0510barbiturates
allobarbital
allobarbital: was heading 1976-94 (see under BARBITURATES 1976-90); ALLOBARBITONE, DIALLYLBARBITAL, DIALLYLBARBITURIC ACID, & DIALLYLMAL were see ALLOBARBITAL 1976-94; use BARBITURATES to search ALLOBARBITAL 1976-94; a barbiturate derivative with effects of intermediate duration; at lower doses, it is used as a sedative; at higher doses, it displays hypnotic effects		2.0510barbiturates
penicillamine
Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.. penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.		3.8730non-proteinogenic alpha-amino acid;
penicillamine		antirheumatic drug;
chelator;
copper chelator;
drug allergen
trichlorfon
Trichlorfon: An organochlorophosphate cholinesterase inhibitor that is used as an insecticide for the control of flies and roaches. It is also used in anthelmintic compositions for animals. (From Merck, 11th ed). trichlorfon : A phosphonic ester that is dimethyl phosphonate in which the hydrogen atom attched to the phosphorous is substituted by a 2,2,2-trichloro-1-hydroxyethyl group.		2.0510organic phosphonate;
organochlorine compound;
phosphonic ester		agrochemical;
anthelminthic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
insecticide
cysteine
[no description available]		3.2310cysteine zwitterion;
cysteine;
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid		EC 4.3.1.3 (histidine ammonia-lyase) inhibitor;
flour treatment agent;
human metabolite
prednisone
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.		10.927111-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug
estrone
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.		4.074017-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
oxandrolone
Oxandrolone: A synthetic hormone with anabolic and androgenic properties.		3.592017beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid;
oxa-steroid		anabolic agent;
androgen
dehydroepiandrosterone
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.. dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.		3.832117-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
androstanoid		androgen;
human metabolite;
mouse metabolite
promazine hydrochloride
[no description available]		2.0510hydrochloride
nad
[no description available]		2.0510NADgeroprotector
dichlororibofuranosylbenzimidazole
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.		2.0310
trifluoromethyluracil
[no description available]		2.2510
penicillin g
Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.		4.2550penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
idoxuridine
[no description available]		2.0510organoiodine compound;
pyrimidine 2'-deoxyribonucleoside		antiviral drug;
DNA synthesis inhibitor
pilocarpine
Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.. (+)-pilocarpine : The (+)-enantiomer of pilocarpine.		3.8630pilocarpineantiglaucoma drug
triiodothyronine
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.. 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.		4.09402-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine		human metabolite;
mouse metabolite;
thyroid hormone
diethylnitrosamine
Diethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties.. N-nitrosodiethylamine : A nitrosamine that is N-ethylethanamine substituted by a nitroso group at the N-atom.		2.0210nitrosaminecarcinogenic agent;
hepatotoxic agent;
mutagen
carbon tetrachloride
Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.		2.7630chlorocarbon;
chloromethanes		hepatotoxic agent;
refrigerant
alanine
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.		3.8421alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
serine
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.		2.4520L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
4-nitroquinoline-1-oxide
4-nitroquinoline N-oxide : A quinoline N-oxide carrying a nitro substituent at position 4.		2.0510C-nitro compound;
quinoline N-oxide		carcinogenic agent
chloramphenicol
Amphenicol: Chloramphenicol and its derivatives.		5.1980C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
glutamine
Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.		4.1340amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
cetrimonium bromide
cetyltrimethylammonium bromide : The organic bromide salt that is the bromide salt of cetyltrimethylammonium; one of the components of the topical antiseptic cetrimide.		2.0510organic bromide salt;
quaternary ammonium salt		detergent;
surfactant
vincristine
[no description available]		4.4260acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
physostigmine
Physostigmine: A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.		4.0840carbamate ester;
indole alkaloid		antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic
sucrose
Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.		2.0510glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent
ethinyl estradiol
Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.		3.36017-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
testosterone propionate
Testosterone Propionate: An ester of TESTOSTERONE with a propionate substitution at the 17-beta position.. androgen : A sex hormone that stimulates or controls the development and maintenance of masculine characteristics in vertebrates by binding to androgen receptors.		2.0510steroid ester
tubocurarine
Tubocurarine: A neuromuscular blocker and active ingredient in CURARE; plant based alkaloid of Menispermaceae.. tubocurarine : A benzylisoquinoline alkaloid muscle relaxant which constitutes the active component of curare.. isoquinoline alkaloid : Any alkaloid that has a structure based on an isoquinoline nucleus. They are derived from the amino acids like tyrosine and phenylalanine.		2.4720bisbenzylisoquinoline alkaloiddrug allergen;
muscle relaxant;
nicotinic antagonist
apomorphine
Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.		4.2650aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
aminopyrine
Aminopyrine: A pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of AGRANULOCYTOSIS. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of CYTOCHROME P-450 metabolic activity in LIVER FUNCTION TESTS.. aminophenazone : A pyrazolone that is 1,2-dihydro-3H-pyrazol-3-one substituted by a dimethylamino group at position 4, methyl groups at positions 1 and 5 and a phenyl group at position 2. It exhibits analgesic, anti-inflammatory, and antipyretic properties.		2.0510pyrazolone;
tertiary amino compound		antipyretic;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
methyltestosterone
Methyltestosterone: A synthetic hormone used for androgen replacement therapy and as an hormonal antineoplastic agent (ANTINEOPLASTIC AGENTS, HORMONAL).. methyltestosterone : A 17beta-hydroxy steroid that is testosterone bearing a methyl group at the 17alpha position.		3.592017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
enone		anabolic agent;
androgen;
antineoplastic agent
promethazine hydrochloride
[no description available]		2.0510hydrochlorideanti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
geroprotector;
H1-receptor antagonist;
local anaesthetic;
sedative
tetrabenazine
9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one : A benzoquinolizine that is 1,2,3,4,4a,9,10,10a-octahydrophenanthrene in which the carbon at position 10a is replaced by a nitrogen and which is substituted by an isobutyl group at position 2, an oxo group at position 3, and methoxy groups at positions 6 and 7.		3.5920benzoquinolizine;
cyclic ketone;
tertiary amino compound
cephalothin
Cephalothin: A cephalosporin antibiotic.. cefalotin : A semisynthetic, first-generation cephalosporin antibiotic with acetoxymethyl and (2-thienylacetyl)nitrilo moieties at positions 3 and 7, respectively, of the core structure. Administered parenterally during surgery and to treat a wide spectrum of blood infections.		2.4520azabicycloalkene;
beta-lactam antibiotic allergen;
carboxylic acid;
cephalosporin;
semisynthetic derivative;
thiophenes		antibacterial drug;
antimicrobial agent
uridine
[no description available]		2.4820uridinesdrug metabolite;
fundamental metabolite;
human metabolite
uridine diphosphate
Uridine Diphosphate: A uracil nucleotide containing a pyrophosphate group esterified to C5 of the sugar moiety.		2.4110pyrimidine ribonucleoside 5'-diphosphate;
uridine 5'-phosphate		Escherichia coli metabolite;
mouse metabolite
kanamycin a
Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.		4.4260kanamycinsbacterial metabolite
bromodeoxyuridine
Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.		2.4110pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		6.5370monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
phenylephrine
Phenylephrine: An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.. phenylephrine : A member of the class of the class of phenylethanolamines that is (1R)-2-(methylamino)-1-phenylethan-1-ol carrying an additional hydroxy substituent at position 3 on the phenyl ring.		2.0510phenols;
phenylethanolamines;
secondary amino compound		alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent
n-nitrosomorpholine
N-nitrosomorpholine : A nitrosamine that is morpholine in which the hydrogen attached to the nitrogen is replaced by a nitroso group. A carcinogen and mutagen, it is found in snuff tobacco.		2.1310nitrosaminecarcinogenic agent;
mutagen
levodopa
Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease		2.9740amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug
edetic acid
Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.		3.6120ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector
tyrosine
Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.		9.79304amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
cysteamine
Cysteamine: A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS.. cysteamine : An amine that consists of an ethane skeleton substituted with a thiol group at C-1 and an amino group at C-2.		3.2310amine;
thiol		geroprotector;
human metabolite;
mouse metabolite;
radiation protective agent
acetylcholine chloride
acetylcholine chloride : The chloride salt of acetylcholine, and a parasympatomimetic drug.		3.5920quaternary ammonium salt
mepazine
mepazine: major descriptor (66-85); on-line search PHENOTHIAZINES (66-85); Index Medicus search MEPAZINE (66-85); RN given refers to parent cpd. pacatal : A phenothiazine derivative in which 10H-phenothiazine has an N-methylpiperidin-4-ylmethyl substituent at the N-10 position.		3.2310phenothiazines
methoxamine hydrochloride
[no description available]		2.0510dimethoxybenzene
adenosine monophosphate
Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.		2.0710adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
methicillin
Methicillin: One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.. methicillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.		2.0410penicillin allergen;
penicillin		antibacterial drug
niridazole
Niridazole: An antischistosomal agent that has become obsolete.		2.05101,3-thiazoles;
C-nitro compound
cloxacillin
Cloxacillin: A semi-synthetic antibiotic that is a chlorinated derivative of OXACILLIN.. cloxacillin : A semisynthetic penicillin antibiotic carrying a 3-(2-chlorophenyl)-5-methylisoxazole-4-carboxamido group at position 6.		3.5720penicillin allergen;
penicillin;
semisynthetic derivative		antibacterial agent;
antibacterial drug
methylene blue
Methylene Blue: A compound consisting of dark green crystals or crystalline powder, having a bronze-like luster. Solutions in water or alcohol have a deep blue color. Methylene blue is used as a bacteriologic stain and as an indicator. It inhibits GUANYLATE CYCLASE, and has been used to treat cyanide poisoning and to lower levels of METHEMOGLOBIN.. methylene blue : An organic chloride salt having 3,7-bis(dimethylamino)phenothiazin-5-ium as the counterion. A commonly used dye that also exhibits antioxidant, antimalarial, antidepressant and cardioprotective properties.		2.0510organic chloride saltacid-base indicator;
antidepressant;
antimalarial;
antimicrobial agent;
antioxidant;
cardioprotective agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 4.6.1.2 (guanylate cyclase) inhibitor;
fluorochrome;
histological dye;
neuroprotective agent;
physical tracer
leucine
Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.		4.761amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
aniline
[no description available]		2.4720anilines;
primary arylamine
calcium acetate
calcium acetate: a principal compound used as phosphate binders in patients with chronic renal failure; used like sevelamer. calcium acetate : The calcium salt of acetic acid. It is used, commonly as a hydrate, to treat hyperphosphataemia (excess phosphate in the blood) in patients with kidney disease: the calcium ion combines with dietary phosphate to form (insoluble) calcium phosphate, which is excreted in the faeces.		3.2310calcium saltchelator
dimethylnitrosamine
Dimethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties. It causes serious liver damage and is a hepatocarcinogen in rodents.		2.0510nitrosaminegeroprotector;
mutagen
carbaryl
Carbaryl: A carbamate insecticide and parasiticide. It is a potent anticholinesterase agent belonging to the carbamate group of reversible cholinesterase inhibitors. It has a particularly low toxicity from dermal absorption and is used for control of head lice in some countries.. carbaryl : A carbamate ester obtained by the formal condensation of 1-naphthol with methylcarbamic acid.		2.0510carbamate ester;
naphthalenes		acaricide;
agrochemical;
carbamate insecticide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant growth retardant
lactose
Lactose: A disaccharide of GLUCOSE and GALACTOSE in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.. lactose : A glycosylglucose disaccharide, found most notably in milk, that consists of D-galactose and D-glucose fragments bonded through a beta-1->4 glycosidic linkage. The glucose fragment can be in either the alpha- or beta-pyranose form, whereas the galactose fragment can only have the beta-pyranose form.. beta-lactose : The beta-anomer of lactose.		2.4620lactose
primaquine phosphate
[no description available]		2.0510
methionine
Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.		5.9870aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
Mebutamate
[no description available]		2.0510organic molecular entity
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		4.96110alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
yohimbine hydrochloride
[no description available]		2.0510
gallamine triethiodide
Gallamine Triethiodide: A synthetic nondepolarizing blocking drug. The actions of gallamine triethiodide are similar to those of TUBOCURARINE, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac output. It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198)		2.0510
mebanazine
mebanazine: RN given refers to parent cpd without isomeric designation; structure		3.2310benzenes
uracil mustard
Uracil Mustard: Nitrogen mustard derivative of URACIL. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage.		2.0510aminouracil;
nitrogen mustard
oxacillin
Oxacillin: An antibiotic similar to FLUCLOXACILLIN used in resistant staphylococci infections.. oxacillin : A penicillin antibiotic carrying a 5-methyl-3-phenylisoxazole-4-carboxamide group at position 6beta.		3.5820penicillinantibacterial agent;
antibacterial drug
cycloheximide
Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.		2.0510antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
chloroform
Chloroform: A commonly used laboratory solvent. It was previously used as an anesthetic, but was banned from use in the U.S. due to its suspected carcinogenicity.. chloroform : A one-carbon compound that is methane in which three of the hydrogens are replaced by chlorines.		2.4720chloromethanes;
one-carbon compound		carcinogenic agent;
central nervous system drug;
inhalation anaesthetic;
non-polar solvent;
refrigerant
triamcinolone diacetate
triamcinolone diacetate: lysyl oxidase antagonist; Polcortolon may also refers to triamcinolone		2.0810corticosteroid hormone
norethindrone
Norethindrone: A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION.. norethisterone : A 17beta-hydroxy steroid that is testosterone in which the hydrogen at position 17 is replaced by an ethynyl group and in which the methyl group attached to position 10 is replaced by hydrogen.		2.964017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol		progestin;
synthetic oral contraceptive
norethynodrel
Norethynodrel: A synthetic progestational hormone with actions and uses similar to those of PROGESTERONE. It has been used in the treatment of functional uterine bleeding and ENDOMETRIOSIS. As a contraceptive (CONTRACEPTIVE AGENTS), it has usually been administered in combination with MESTRANOL.		2.0510oxo steroid
cycloserine
Cycloserine: Antibiotic substance produced by Streptomyces garyphalus.. D-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis).		3.23104-amino-1,2-oxazolidin-3-one;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic;
zwitterion		antiinfective agent;
antimetabolite;
antitubercular agent;
metabolite;
NMDA receptor agonist
benziodarone
benziodarone: minor descriptor (75-89); on-line & INDEX MEDICUS search BENZOFURANS (68-89) & IODOBENZOATES (74)		3.5920aromatic ketone
chlorpromazine hydrochloride
[no description available]		2.0510hydrochloride;
phenothiazines		anticoronaviral agent;
phenothiazine antipsychotic drug
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		5.1550beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
mannitol
[no description available]		3.8930mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent
cytarabine
[no description available]		4.2750beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
asparagine
Asparagine: A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed). asparagine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 2-amino-2-oxoethyl group.		7.610amino acid zwitterion;
asparagine;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
histidine
Histidine: An essential amino acid that is required for the production of HISTAMINE.. L-histidine : The L-enantiomer of the amino acid histidine.. histidine : An alpha-amino acid that is propanoic acid bearing an amino substituent at position 2 and a 1H-imidazol-4-yl group at position 3.		4.6111amino acid zwitterion;
histidine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
medroxyprogesterone acetate
[no description available]		2.984020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester		adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive
sulfobromophthalein sodium
bromosulfophthalein sodium : An organic sodium salt that is the disodium salt of bromosulfophthalein.. bromosulfophthalein : An organosulfonic acid that consists of phthalide bearing four bromo substituents at positions 4, 5, 6 and 7 as well as two 4-hydroxy-3-sulfophenyl groups both located at position 1.		2.0410organic sodium saltdye
valine
Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.		2.0310L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
threonine
Threonine: An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.. threonine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 1-hydroxyethyl group.		4.9840amino acid zwitterion;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
threonine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
mestranol
[no description available]		2.462017beta-hydroxy steroid;
aromatic ether;
terminal acetylenic compound		prodrug;
xenoestrogen
methaqualone
Methaqualone: A quinazoline derivative with hypnotic and sedative properties. It has been withdrawn from the market in many countries because of problems with abuse. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604). methaqualone : A member of the class of quinazolines that is quinazolin-4-one substituted at positions 2 and 3 by methyl and o-tolyl groups respectively. A depressant that increases the activity of the GABA receptors in the brain and nervous system, it is used as a sedative and hypnotic medication. It became popular as a recreational drug and club drug in the late 1960s and 1970s.		3.6220quinazolinesGABA agonist;
sedative
trypan blue
VisionBlue: A trypan blue ophthalmic solution.		2.0510
cordycepin
[no description available]		2.53203'-deoxyribonucleoside;
adenosines		antimetabolite;
nucleoside antibiotic
tryptophan
Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.		2.4520erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
isoleucine
Isoleucine: An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of LEUCINE. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels.. isoleucine : A 2-amino-3-methylpentanoic acid having either (2R,3R)- or (2S,3S)-configuration.. L-isoleucine : The L-enantiomer of isoleucine.		2.0310aspartate family amino acid;
isoleucine;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		10.9371arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
ethylene
Plastipore: high density polyethylene sponge biocompatible material; used as posts in dental bridges		4.6111alkene;
gas molecular entity		plant hormone;
refrigerant
acetonitrile
acetonitrile: RN given refers to unlabeled cpd. acetonitrile : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by a methyl group.		2.5420aliphatic nitrile;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
NMR chemical shift reference compound;
polar aprotic solvent
methylene chloride
Methylene Chloride: A chlorinated hydrocarbon that has been used as an inhalation anesthetic and acts as a narcotic in high concentrations. Its primary use is as a solvent in manufacturing and food technology.. dichloromethane : A member of the class of chloromethanes that is methane in which two of the hydrogens have been replaced by chlorine. A dense, non-flammible colourless liquid at room temperature (b.p. 40degreeC, d = 1.33) which is immiscible with water, it is widely used as a solvent, a paint stripper, and for the removal of caffeine from coffee and tea.		2.0710chloromethanes;
volatile organic compound		carcinogenic agent;
polar aprotic solvent;
refrigerant
trichloroacetic acid
Trichloroacetic Acid: A strong acid used as a protein precipitant in clinical chemistry and also as a caustic for removing warts.. trichloroacetic acid : A monocarboxylic acid that is acetic acid in which all three methyl hydrogens are substituted by chlorine.		2.0510monocarboxylic acid;
organochlorine compound		carcinogenic agent;
metabolite;
mouse metabolite
perflutren
Definity: a fluorocarbon-filled ultrasonic contrast agent; Definity is tradename. octafluoropropane : A fluorocarbon that is propane in which all of the hydrogens have been replaced by fluorines.		3.2310fluoroalkane;
fluorocarbon
triamcinolone acetonide
Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.		2.753011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
fluoxymesterone
Fluoxymesterone: An anabolic steroid that has been used in the treatment of male HYPOGONADISM, delayed puberty in males, and in the treatment of breast neoplasms in women.		3.231011beta-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid;
fluorinated steroid		anabolic agent;
antineoplastic agent
allylpropymal
allylpropymal: RN given refers to parent cpd. aprobarbital : A member of the class of barbiturates that is pyrimidine-2,4,6(1H,3H,5H)-trione substituted by an isopropyl and a prop-1-en-3-yl group at position 5.		2.0510barbiturates
phencyclidine
Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.		2.4420benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug
butobarbital
butobarbital: Butobarbital should be distinguished from Butabarbital (a synonym for Secbutabarbital)		2.0510barbiturates
methsuximide
methsuximide: anticonvulsant effective in petit mal & psychomotor epilepsy; has a number of unpleasant & toxic side effects; minor descriptor (75-86); on-line & INDEX MEDICUS search SUCCINIMIDES (75-86); RN given refers to parent cpd without isomeric designation		3.2310organic molecular entity
tromethamine
Tromethamine: An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)		3.5920primary amino compound;
triol		buffer
trichloroethylene
Trichloroethylene: A highly volatile inhalation anesthetic used mainly in short surgical procedures where light anesthesia with good analgesia is required. It is also used as an industrial solvent. Prolonged exposure to high concentrations of the vapor can lead to cardiotoxicity and neurological impairment.. triol : A chemical compound containing three hydroxy groups.		2.4620chloroethenesinhalation anaesthetic;
mouse metabolite
acrylic acid
acrylic acid: RN given refers to parent cpd. acrylic acid : A alpha,beta-unsaturated monocarboxylic acid that is ethene substituted by a carboxy group.		2.2110alpha,beta-unsaturated monocarboxylic acidmetabolite
dichloroacetic acid
[no description available]		2.4820monocarboxylic acid;
organochlorine compound		astringent;
marine metabolite
dehydrocholic acid
Dehydrocholic Acid: A semisynthetic bile acid made from cholic acid. It is used as a cholagogue, hydrocholeretic, diuretic, and as a diagnostic aid.. 3,7,12-trioxo-5beta-cholanic acid : An oxo-5beta-cholanic acid in which three oxo substituents are located at positions 3, 7 and 12 on the cholanic acid skeleton.		2.051012-oxo steroid;
3-oxo-5beta-steroid;
7-oxo steroid;
oxo-5beta-cholanic acid		gastrointestinal drug
taurocholic acid
Taurocholic Acid: The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.. taurocholate : An organosulfonate oxoanion that is the conjugate base of taurocholic acid.. taurocholic acid : A bile acid taurine conjugate of cholic acid that usually occurs as the sodium salt of bile in mammals.		2.0410amino sulfonic acid;
bile acid taurine conjugate		human metabolite
cyclizine
Cyclizine: A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935). cyclizine : An N-alkylpiperazine in which one nitrogen of the piperazine ring is substituted by a methyl group, while the other is substituted by a diphenylmethyl group.		2.0510N-alkylpiperazineantiemetic;
central nervous system depressant;
cholinergic antagonist;
H1-receptor antagonist;
local anaesthetic
methylprednisolone
Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.		4.851006-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
rotenone
Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.		2.7530organic heteropentacyclic compound;
rotenones		antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin
diquat
Diquat: A contact herbicide used also to produce desiccation and defoliation. (From Merck Index, 11th ed). diquat : The organic cation formed formally by addition of an ethylene bridge between the nitrogen atoms of 2,2'-bipyridine. Most often available as the dibromide.		2.0510organic cationdefoliant;
herbicide
brompheniramine
Brompheniramine: Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.. brompheniramine : Pheniramine in which the hydrogen at position 4 of the phenyl substituent is substituted by bromine. A histamine H1 receptor antagonist, brompheniramine is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.		3.6120organobromine compound;
pyridines		anti-allergic agent;
H1-receptor antagonist
penicillin v
Penicillin V: A broad-spectrum penicillin antibiotic used orally in the treatment of mild to moderate infections by susceptible gram-positive organisms.. phenoxymethylpenicillin : A penicillin compound having a 6beta-(phenoxyacetyl)amino side-chain.		3.5820penicillin allergen;
penicillin
acetopyrrothine
acetopyrrothine: structure. thiolutin : A dithiolopyrrolone antibiotic that is 4,5-dihydro[1,2]dithiolo[4,3-b]pyrrole in which the hydrogens at positions 4,5 and 6 have been replaced by methyl, oxo and acetamido groups, respectively. It is a potent inhibitor of RNA polymerases, inhibits the angiogenesis of human umbilical vein endothelial cells, and also inhibits JAMM metalloproteases.		2.0510acetamides;
dithiolopyrrolone antibiotic		angiogenesis inhibitor;
antibacterial agent;
antifungal agent;
antineoplastic agent;
bacterial metabolite;
chelator;
EC 2.7.7.6 (RNA polymerase) inhibitor;
marine metabolite;
protein synthesis inhibitor;
toxin
salicylanilide
salicylanilide: RN given refers to parent cpd. salicylanilide : An amide of salicylic acid and of aniline; it is therefore both a salicylamide and an anilide.		2.1110benzanilide fungicide;
salicylamides;
salicylanilides
isosorbide dinitrate
Isosorbide Dinitrate: A vasodilator used in the treatment of ANGINA PECTORIS. Its actions are similar to NITROGLYCERIN but with a slower onset of action.		4.9160glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent
n-vinyl-2-pyrrolidinone
N-vinyl-2-pyrrolidinone: monomer of POVIDONE; structure given in first source		2.2110pyrrolidin-2-ones
pseudoephedrine
Pseudoephedrine: A phenethylamine that is an isomer of EPHEDRINE which has less central nervous system effects and usage is mainly for respiratory tract decongestion.. pseudoephedrine : A member of the class of the class of phenylethanolamines that is (1S)-2-(methylamino)-1-phenylethan-1-ol in which the pro-S hydrogen at position 2 is replaced by a methyl group.		3.2310phenylethanolamines;
secondary alcohol;
secondary amino compound		anti-asthmatic drug;
bronchodilator agent;
central nervous system drug;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
diethylpropion
Diethylpropion: A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290). diethylpropion : An aromatic ketone that is propiophenone in which one of the hydrogens alpha- to the carbonyl is substituted by a diethylamino group. A central stimulant and indirect-acting sympathomimetic, it is an appetite depressant and is used as the hydrochloride as an anoretic in the short term management of obesity.		3.2310aromatic ketone;
tertiary amine		appetite depressant
quinoxalines
quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.		6.4441mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
tolonium chloride
Tolonium Chloride: A phenothiazine that has been used as a hemostatic, a biological stain, and a dye for wool and silk. Tolonium chloride has also been used as a diagnostic aid for oral and gastric neoplasms and in the identification of the parathyroid gland in thyroid surgery.. tolonium chloride : An organic chloride salt having 3-amino-7-(dimethylamino)-2-methylphenothiazin-5-ium (tolonium) as the counterion. It is a blue nuclear counterstain that can be used to demonstrate Nissl substance and is also useful for staining mast cell granules, both in metachromatic and orthochromatic techniques.		2.0210
xanthenes
Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.		2.4820xanthene
phenothiazine
10H-phenothiazine : The 10H-tautomer of phenothiazine.		2.0510phenothiazineferroptosis inhibitor;
plant metabolite;
radical scavenger
synephrine
[no description available]		2.0510ethanolamines;
phenethylamine alkaloid;
phenols		alpha-adrenergic agonist;
plant metabolite
benzoyl peroxide
Benzoyl Peroxide: A peroxide derivative that has been used topically for BURNS and as a dermatologic agent in the treatment of ACNE and POISON IVY DERMATITIS. It is used also as a bleach in the food industry.		2.0510carbonyl compound
2-bromophenol
bromophenol : A halophenol that is any phenol containing one or more covalently bonded bromine atoms.		2.0510bromophenolmarine metabolite
pyridostigmine bromide
Pyridostigmine Bromide: A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.		2.0510pyridinium salt
4,4'-diaminodiphenylmethane
4,4'-diaminodiphenylmethane: RN given refers to parent cpd; structure. 4,4'-diaminodiphenylmethane : An aromatic amine that is diphenylmethane substituted at the 4-position of each benzene ring by an amino group.		2.0510aromatic amineallergen;
carcinogenic agent
1,3-diphenylurea
1,3-diphenylurea : A member of the class of phenylureas that is urea in which one of the hydrogens of each amino group is replaced by a phenyl group. It is present in coconut milk (Cocos nucifera).		2.0610phenylureascytokinin;
plant metabolite
phenylisothiocyanate
phenylisothiocyanate: structure. phenyl isothiocyanate : An isothiocyanate having a phenyl group attached to the nitrogen; used for amino acid sequencing in the Edman degradation.		2.0510isothiocyanateallergen;
reagent
benzonatate
benzonatate: structure in Merck Index, 9th ed, #1107. benzonatate : The ester obtained by formal condensation of 4-butylaminobenzoic acid with nonaethylene glycol monomethyl ether. Structurally related to procaine and benzocaine, it has an anaesthetic effect on the stretch sensors in the lungs, and is used as a non-narcotic cough suppressant.		3.2310benzoate ester;
secondary amino compound;
substituted aniline		anaesthetic;
antitussive
caprolactam
Caprolactam: Cyclic amide of caproic acid used in manufacture of synthetic fibers of the polyamide type. Can cause local irritation.. epsilon-caprolactam : A member of the class of caprolactams that is azepane substituted by an oxo group at position 2.		4.6111caprolactamshuman blood serum metabolite
4-bromophenol
4-bromophenol : A bromophenol containing only hydroxy and bromo substituents that are para to one another.		2.0510bromophenolhuman urinary metabolite;
human xenobiotic metabolite;
marine metabolite;
mouse metabolite;
persistent organic pollutant;
rat metabolite
epichlorohydrin
Epichlorohydrin: A chlorinated epoxy compound used as an industrial solvent. It is a strong skin irritant and carcinogen.. epichlorohydrin : An epoxide that is 1,2-epoxypropene in which one of the methyl hydrogens is substituted by chlorine.		7.1710epoxide;
organochlorine compound
acrolein
[no description available]		2.0410enalherbicide;
human xenobiotic metabolite;
toxin
2-bromoethylamine
[no description available]		2.0510
allyl alcohol
allyl alcohol: structure. allylic alcohol : An alcohol where the hydroxy group is attached to a saturated carbon atom adjacent to a double bond (R groups may be H, organyl, etc.).. allyl alcohol : A propenol in which the C=C bond connects C-2 and C-3. It is has been found in garlic (Allium sativum). Formerly used as a herbicide for the control of various grass and weed seeds.		2.0510primary allylic alcohol;
propenol		antibacterial agent;
fungicide;
herbicide;
insecticide;
plant metabolite
maleic anhydride
Maleic Anhydrides: Used in copolymerization reactions, in the Diels-Alder(diene)synthesis, in the preparation of resins, pharmaceuticals and agricultural chemicals. It is a powerful irritant and causes burns.. maleic anhydride : A cyclic dicarboxylic anhydride that is the cyclic anhydride of maleic acid.		7.4110cyclic dicarboxylic anhydride;
furans		allergen
bromobenzene
[no description available]		2.0510bromoarene;
bromobenzenes;
volatile organic compound		hepatotoxic agent;
mouse metabolite;
non-polar solvent
n-pentanoic acid
n-pentanoic acid: RN given refers to unlabeled parent cpd. valeric acid : A straight-chain saturated fatty acid containing five carbon atoms.		2.0510short-chain fatty acid;
straight-chain saturated fatty acid		plant metabolite
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		12.16401pyrrole;
secondary amine
furan
furan : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing four carbons and one oxygen, with formula C4H4O. It is a toxic, flammable, low-boiling (31degreeC) colourless liquid.		2.0510furans;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		carcinogenic agent;
hepatotoxic agent;
Maillard reaction product
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		6.7252mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
isopropyl myristate
isopropyl myristate: used for microemulsions; structure		4.6111fatty acid ester
morpholine
[no description available]		7.1510morpholines;
saturated organic heteromonocyclic parent		NMR chemical shift reference compound
octylamine
octylamine: RN given refers to 1-octylamine. octan-1-amine : An 8-carbon primary aliphatic amine.		2.2510primary aliphatic aminemetabolite
1-octadecene
octadec-1-ene : An octadecene with unsaturation at C-1.. octadecene : An alkene that is octadecane containing one double bond at unspecified position.		7.4110octadecene
ergotamine
Ergotamine: A vasoconstrictor found in ergot of Central Europe. It is a serotonin agonist that has been used as an oxytocic agent and in the treatment of MIGRAINE DISORDERS.. ergotamine : A peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10.		2.4520peptide ergot alkaloidalpha-adrenergic agonist;
mycotoxin;
non-narcotic analgesic;
oxytocic;
serotonergic agonist;
vasoconstrictor agent
methylergonovine
Methylergonovine: A homolog of ERGONOVINE containing one more CH2 group. (Merck Index, 11th ed)		3.2310ergoline alkaloid
imipramine hydrochloride
[no description available]		2.0510hydrochlorideantidepressant
neostigmine bromide
neostigmine bromide : The bromide salt of neostigmine.		2.4520bromide salt
phenformin
Phenformin: A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). phenformin : A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a 2-phenylethyl group. It was used as an anti-diabetic drug but was later withdrawn from the market due to potential risk of lactic acidosis.		8.3460biguanidesantineoplastic agent;
geroprotector;
hypoglycemic agent
mephobarbital
Mephobarbital: A barbiturate that is metabolized to PHENOBARBITAL. It has been used for similar purposes, especially in EPILEPSY, but there is no evidence mephobarbital offers any advantage over PHENOBARBITAL.. mephobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by ethyl and phenyl groups.		2.4620barbituratesanticonvulsant
edrophonium chloride
edrophonium chloride : The chloride salt of edrophonium. A reversible inhibitor of cholinesterase with a rapid onset (30-60 seconds after injection) but a short duration of action (5-15 minutes), it is used in myasthenia gravis both diagnostically and to distinguish between under- or over-treatment with other anticholinesterases. It has also been used for the reversal of neuromuscular blockade in anaesthesia, and for the management of poisoning due to tetrodotoxin, a neuromuscular blocking toxin found in puffer fish and other marine animals.		2.0510chloride salt;
quaternary ammonium salt		antidote;
diagnostic agent;
EC 3.1.1.8 (cholinesterase) inhibitor
hexachlorobenzene
Hexachlorobenzene: An agricultural fungicide and seed treatment agent.. hexachlorobenzene : A member of the class of chlorobenzenes that is benzene in which all of the hydrogens are replaced by chlorines. An agricultural fungicide introduced in the mid-1940s and formerly used as a seed treatment, its use has been banned since 1984 under the Stockholm Convention on Persistent Organic Pollutants.		2.0510aromatic fungicide;
chlorobenzenes		antifungal agrochemical;
carcinogenic agent;
persistent organic pollutant
trinitrotoluene
Trinitrotoluene: A 2,4,6-trinitrotoluene, which is an explosive chemical that can cause skin irritation and other toxic consequences.. 2,4,6-trinitrotoluene : A trinitrotoluene having the nitro groups at positions 2, 4 and 6.		2.0510trinitrotolueneexplosive
framycetin
Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.		2.4620aminoglycosideallergen;
antibacterial drug;
Escherichia coli metabolite
pyrazolanthrone
pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.		4.4160anthrapyrazole;
aromatic ketone;
cyclic ketone		antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector
1,4-naphthoquinone
naphthoquinone : A polycyclic aromatic ketone metabolite of naphthalene.. 1,4-naphthoquinone : The parent structure of the family of 1,4-naphthoquinones, in which the oxo groups of the quinone moiety are at positions 1 and 4 of the naphthalene ring. Derivatives have pharmacological properties.		2.03101,4-naphthoquinones
di-n-pentyl phthalate
dipentyl phthalate : A phthalate ester that is the dipentyl ester of benzene-1,2-dicarboxylic acid.		2.0510diester;
phthalate ester		plasticiser
meglumine
Meglumine: 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.. N-methylglucamine : A hexosamine that is D-glucitol in which the hydroxy group at position 1 is substituted by the nitrogen of a methylamino group. A crystalline base, it is used in preparing salts of certain acids for use as diagnostic radiopaque media, while its antimonate is used as an antiprotozoal in the treatment of leishmaniasis.		2.7730hexosamine;
secondary amino compound
cinchophen
cinchophen: was heading 1963-94; ACIPHENOCHINOLIUM was see CHINOPHEN 1978-94; use QUINOLINES to search CINCHOPHEN 1966-94		3.8630quinolines
phenazopyridine hydrochloride
phenazopyridine hydrochloride : A hydrochloride obtained by combining phenazopyridine with one equivalent of hydrochloric acid. A local anesthetic that has topical analgesic effect on mucosa lining of the urinary tract. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.		2.0510hydrochloridecarcinogenic agent;
local anaesthetic;
non-narcotic analgesic
tetrracaine hydrochloride
leocaine: a crystal beta-modification of the beta-dimethylaminoethyl ether of n-butylaminobenzoic acid hydrochloride		2.0510benzoate ester
ethyl acetate
ethyl acetate : The acetate ester formed between acetic acid and ethanol.		2.0710acetate ester;
ethyl ester;
volatile organic compound		EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor;
metabolite;
polar aprotic solvent;
Saccharomyces cerevisiae metabolite
yohimbine
Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.. yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.		2.0510methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist
diphenhydramine hydrochloride
Antitussive Agents: Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally.. diphenhydramine hydrochloride : The hydrochloride salt of diphenhydramine.		2.0510hydrochloride;
organoammonium salt		anti-allergic agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
sedative
nafcillin
Nafcillin: A semi-synthetic antibiotic related to penicillin.. nafcillin : A penicillin in which the substituent at position 6 of the penam ring is a (2-ethoxy-1-naphthoyl)amino group.		3.5820penicillin allergen;
penicillin		antibacterial drug
1,2-dihydroxybenzene-3,5-disulfonic acid disodium salt
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt: A colorimetric reagent for iron, manganese, titanium, molybdenum, and complexes of zirconium. (From Merck Index, 11th ed)		2.1110organic molecular entity
mequinol
mequinol: depigmenting agent; RN given refers to parent cpd		2.4420methoxybenzenes;
phenols		metabolite
methohexital
Methohexital: An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.. methohexital : A barbiturate, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by allyl and 1-methylpent-2-ynyl groups.		3.5820acetylenic compound;
barbiturates		drug allergen;
intravenous anaesthetic
quinestrol
Quinestrol: The 3-cyclopentyl ether of ETHINYL ESTRADIOL. After gastrointestinal absorption, it is stored in ADIPOSE TISSUE, slowly released, and metabolized principally to the parent compound. It has been used in ESTROGEN REPLACEMENT THERAPY. (From AMA Drug Evaluations Annual, 1992, p1011)		2.051017-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
dydrogesterone
[no description available]		2.051020-oxo steroid;
3-oxo-Delta(4) steroid		progestin
fluocortolone
Fluocortolone: A glucocorticoid with anti-inflammatory activity used topically for various skin disorders.		2.031021-hydroxy steroid
catechin
Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.		3.0440catechinantioxidant;
plant metabolite
tripelennamine hydrochloride
[no description available]		2.0510
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		35.684,189583azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
acridines
Acridines: Compounds that include the structure of acridine.. acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom.		2.7630acridines;
mancude organic heterotricyclic parent;
polycyclic heteroarene		genotoxin
indazoles
Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.		6.49130indazole
benzoxazoles
1,3-benzoxazole : A benzoxazole in which the benzene ring is fused to a 1,3-oxazole ring across positions 4 and 5.. benzoxazole : Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.		4.61111,3-benzoxazoles;
mancude organic heterobicyclic parent
1,3-benzodioxole
1,3-benzodioxole : A benzodioxole consisting of a benzene ring substituted by a the methylenedioxy group.		3.5110benzodioxole
adamantane
Adamantane: A tricyclo bridged hydrocarbon.		2.0210adamantanes;
polycyclic alkane
isoxazoles
Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.		4.5470isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
oxazoles
Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.		2.13101,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
thiazoles
[no description available]		9.822321,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
pyrimidine
pyrimidine : The parent compound of the pyrimidines; a diazine having the two nitrogens at the 1- and 3-positions.		3.6120diazine;
pyrimidines		Daphnia magna metabolite
pyrazines
Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.		11.13262diazine;
pyrazines		Daphnia magna metabolite
ethynodiol diacetate
Ethynodiol Diacetate: A synthetic progestational hormone used alone or in combination with estrogens as an oral contraceptive (CONTRACEPTIVES, ORAL).		2.4820steroid ester;
terminal acetylenic compound		contraceptive drug;
estrogen receptor modulator;
synthetic oral contraceptive
ephedrine
Ephedrine: A phenethylamine found in EPHEDRA SINICA. PSEUDOEPHEDRINE is an isomer. It is an alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used for asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.. (-)-ephedrine : A phenethylamine alkaloid that is 2-phenylethanamine substituted by a methyl group at the amino nitrogen and a methyl and a hydroxy group at position 2 and 1 respectively.		3.5920phenethylamine alkaloid;
phenylethanolamines		bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
hydrazine
diamine : Any polyamine that contains two amino groups.		2.0510azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
chlormadinone acetate
Chlormadinone Acetate: An orally active synthetic progestational hormone used often in combinations as an oral contraceptive (CONTRACEPTIVES, ORAL).		2.0510corticosteroid hormone
pirinitramide
Pirinitramide: A diphenylpropylamine with intense narcotic analgesic activity of long duration. It is a derivative of MEPERIDINE with similar activity and usage.		2.0410nitrile
edrophonium bromide
[no description available]		2.0410
2,3-dimercaptosuccinic acid
[no description available]		2.0510
evans blue
Evans Blue: An azo dye used in blood volume and cardiac output measurement by the dye dilution method. It is very soluble, strongly bound to plasma albumin, and disappears very slowly.. Evans blue : An organic sodium salt that is the tetrasodium salt of 6,6'-{(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis[diazene-2,1-diyl]}bis(4-amino-5-hydroxynaphthalene-1,3-disulfonate). It is sometimes used as a counterstain, especially in fluorescent methods to suppress background autofluorescence.		2.0510organic sodium saltfluorochrome;
histological dye;
sodium channel blocker;
teratogenic agent
monocrotaline
Monocrotaline: A pyrrolizidine alkaloid and a toxic plant constituent that poisons livestock and humans through the ingestion of contaminated grains and other foods. The alkaloid causes pulmonary artery hypertension, right ventricular hypertrophy, and pathological changes in the pulmonary vasculature. Significant attenuation of the cardiopulmonary changes are noted after oral magnesium treatment.		2.4720pyrrolizidine alkaloid
testosterone enanthate
[no description available]		2.0510heptanoate ester;
sterol ester		androgen
thioproperazine
thioproperazine: was heading 1963-94; use PHENOTHIAZINES to search THIOPROPERAZINE 1966-94. thioproperazine : A phenothiazine derivative in which the phenothiazine tricycle has a dimethylaminosulfonyl substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at N-10.		2.1710N-alkylpiperazine;
N-methylpiperazine;
phenothiazines;
sulfonamide		phenothiazine antipsychotic drug
aminophylline
Aminophylline: A drug combination that contains THEOPHYLLINE and ethylenediamine. It is more soluble in water than theophylline but has similar pharmacologic actions. It's most common use is in bronchial asthma, but it has been investigated for several other applications.. aminophylline : A mixture comprising of theophylline and ethylenediamine in a 2:1 ratio.		3.8730mixturebronchodilator agent;
cardiotonic drug
azacitidine
Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.		4.96110N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent
phenyramidol
phenyramidol: considered as a drug that possibly causes hepatotoxicity		2.0510aminopyridine
6-aminonicotinamide
6-Aminonicotinamide: A vitamin antagonist which has teratogenic effects.. 6-aminonicotinamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 6-aminonicotinic acid with ammonia. An inhibitor of the NADP(+)-dependent enzyme, 6-phosphogluconate dehydrogenase, it interferes with glycolysis, resulting in ATP depletion and synergizes with DNA-crosslinking chemotherapy drugs, such as cisplatin, in killing cancer cells.		2.1110aminopyridine;
monocarboxylic acid amide;
primary amino compound		antimetabolite;
EC 1.1.1.44 (NADP(+)-dependent decarboxylating phosphogluconate dehydrogenase) inhibitor;
teratogenic agent
linuron
Linuron: A selective pre- and post-emergence herbicide. (From Merck Index, 11th ed). linuron : A member of the class of phenylureas that is N-methyl urea substituted by a methoxy group at position 1 and a 3,4-dichlorophenyl group at position 3.		2.0510dichlorobenzene;
phenylureas		agrochemical;
environmental contaminant;
herbicide;
xenobiotic
carbutamide
Carbutamide: A sulfonylurea antidiabetic agent with similar actions and uses to CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277)		2.0510benzenes;
sulfonamide
pseudoephedrine hydrochloride
pseudoephedrine hydrochloride : A hydrochloride that is the monohydrochloride salt of pseudoephedrine.		2.0510hydrochlorideplant metabolite
galantamine
Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils.		4.0840benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound		antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite
nandrolone decanoate
Nandrolone Decanoate: Decanoic acid ester of nandrolone that is used as an anabolic agent to prevent or treat WASTING SYNDROME associated with severe chronic illness or HIV infection (HIV WASTING SYNDROME). It may also be used in the treatment of POSTMENOPAUSAL OSTEOPOROSIS.		3.5920steroid ester
aminoimidazole carboxamide
Aminoimidazole Carboxamide: An imidazole derivative which is a metabolite of the antineoplastic agents BIC and DIC. By itself, or as the ribonucleotide, it is used as a condensation agent in the preparation of nucleosides and nucleotides. Compounded with orotic acid, it is used to treat liver diseases.. 5-aminoimidazole-4-carboxamide : An aminoimidazole in which the amino group is at C-5 with a carboxamido group at C-4.		2.5420aminoimidazole;
monocarboxylic acid amide		mouse metabolite
bucladesine
[no description available]		2.05103',5'-cyclic purine nucleotide;
butanamides;
butyrate ester		agonist;
cardiotonic drug;
vasodilator agent
procarbazine hydrochloride
procarbazine hydrochloride : A hydrochloride obtained by combining procarbazine with one equivalent of hydrochloric acid. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.		2.4720hydrochlorideantineoplastic agent
betamethasone
Betamethasone: A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)		3.155011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic agent;
anti-inflammatory drug;
immunosuppressive agent
perflubron
perflubron: potential anti-obesity compound; reduces food adsorption; 8-carbon perfluorocarbon radiopaque compound; an oral contrast agent for use with MRI to enhance delineation of the bowel distinguishing it from adjacent organs. perflubron : A haloalkane that is perfluorooctane in which a fluorine attached to one of the terminal carbons has been replaced by a bromine.		2.0510haloalkane;
organobromine compound;
perfluorinated compound		blood substitute;
radioopaque medium
cyproterone acetate
[no description available]		2.462020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
chlorinated steroid;
steroid ester		androgen antagonist;
geroprotector;
progestin
lithocholic acid
Lithocholic Acid: A bile acid formed from chenodeoxycholate by bacterial action, usually conjugated with glycine or taurine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as cholagogue and choleretic.. lithocholic acid : A monohydroxy-5beta-cholanic acid with a alpha-hydroxy substituent at position 3. It is a bile acid obtained from chenodeoxycholic acid by bacterial action.. lithocholate : A bile acid anion that is the conjugate base of lithocholic acid.		2.0510bile acid;
C24-steroid;
monohydroxy-5beta-cholanic acid		geroprotector;
human metabolite;
mouse metabolite
nandrolone
Nandrolone: C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of ESTRADIOL to resemble TESTOSTERONE but less one carbon at the 19 position.. nandrolone : A 3-oxo Delta(4)-steroid that is estr-4-en-3-one substituted by a beta-hydroxy group at position 17.		2.041017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid		human metabolite
hydantoins
Hydantoins: Compounds based on imidazolidine dione. Some derivatives are ANTICONVULSANTS.. imidazolidine-2,4-dione : An imidazolidinone with oxo groups at position 2 and 4.		2.0410imidazolidine-2,4-dione
dextropropoxyphene
Dextropropoxyphene: A narcotic analgesic structurally related to METHADONE. Only the dextro-isomer has an analgesic effect; the levo-isomer appears to exert an antitussive effect.. propoxyphene : A racemate of the (1R,2R)- and (1S,2R)- diastereoisomers.. dextropropoxyphene : The (1S,2R)-(+)-diastereoisomer of propoxyphene.		3.86301-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoatemu-opioid receptor agonist;
opioid analgesic
ketobemidone
ketobemidone: structure		2.0410piperidines
glycyrrhetinic acid
[no description available]		2.4820cyclic terpene ketone;
hydroxy monocarboxylic acid;
pentacyclic triterpenoid		immunomodulator;
plant metabolite
chenodeoxycholic acid
Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.		4.2750bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
funiculosin (anthraquinone)
funiculosin (anthraquinone): see also a pyridone cpd called funiculosin; structure		2.1110trihydroxyanthraquinone
cepharanthine
cepharanthine: isoquinoline alkaloid from tubers of STEPHANIA; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation. cepharanthine : A bisbenzylisoquinoline alkaloid from tubers of Stephania; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation.		2.1710bisbenzylisoquinoline alkaloid;
isoquinolines
emetine
Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.		2.4720isoquinoline alkaloid;
pyridoisoquinoline		antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor
dihydralazine
Dihydralazine: 1,4-Dihydrazinophthalazine. An antihypertensive agent with actions and uses similar to those of HYDRALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p354)		2.0510phthalazines
phenylpropanolamine
Phenylpropanolamine: A sympathomimetic that acts mainly by causing release of NOREPINEPHRINE but also has direct agonist activity at some adrenergic receptors. It is most commonly used as a nasal vasoconstrictor and an appetite depressant.. phenylpropanolamine : An amphetamine in which the parent 1-phenylpropan-2-amine skeleton is substituted at position 1 with an hydroxy group. A decongestant and appetite suppressant, it is commonly used in prescription and over-the-counter cough and cold preparations.. (-)-norephedrine : An amphetamine that is propylbenzene substituted by a hydroxy group at position 1 and by an amino group at position 2 (the 1R,2S-stereoisomer). It is a plant alkaloid.		2.0510amphetamines;
phenethylamine alkaloid		plant metabolite
4-hydroxybutyric acid
4-hydroxybutyric acid: was an entry term to Sodium Oxybate (74-98). 4-hydroxybutyric acid : A 4-hydroxy monocarboxylic acid that is butyric acid in which one of the hydrogens at position 4 is replaced by a hydroxy group.		3.23104-hydroxy monocarboxylic acid;
hydroxybutyric acid		general anaesthetic;
GHB receptor agonist;
neurotoxin;
sedative
azetidine
[no description available]		2.0810azacycloalkane;
azetidines;
saturated organic heteromonocyclic parent
alpha-aminopyridine
alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.		4.7890
margaric acid
margaric acid: RN given refers to unlabeled parent cpd. heptadecanoic acid : A C17 saturated fatty acid and trace component of fats in ruminants.		2.2110long-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
mammalian metabolite
oleanolic acid
[no description available]		2.8430hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite
dihydroergotamine
Dihydroergotamine: A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.. dihydroergotamine : Ergotamine in which a single bond replaces the double bond between positions 9 and 10. A semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine, it is used (as the methanesulfonic or tartaric acid salts) for the treatment of migraine and orthostatic hypotension.		3.5920ergot alkaloid;
semisynthetic derivative		dopamine agonist;
non-narcotic analgesic;
serotonergic agonist;
sympatholytic agent;
vasoconstrictor agent
podophyllotoxin
Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.		4.3350furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
hesperidin
Hesperidin: A flavanone glycoside found in CITRUS fruit peels.. hesperidin : A disaccharide derivative that consists of hesperetin substituted by a 6-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.		2.05103'-hydroxyflavanones;
4'-methoxyflavanones;
dihydroxyflavanone;
disaccharide derivative;
flavanone glycoside;
monomethoxyflavanone;
rutinoside		mutagen
medroxyprogesterone
[no description available]		3.582017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		contraceptive drug;
progestin;
synthetic oral contraceptive
dihydrotestosterone
Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.		2.432017beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
dimenhydrinate
gravinol: has antioxidant and ant-inflammatory activities; structure in first source		3.6120diarylmethane
copper gluconate
Gluconates: Derivatives of gluconic acid (the structural formula HOCH2(CHOH)4COOH), including its salts and esters.		2.1110organic molecular entity
azomycin
azomycin: RN given refers to parent cpd with specified locant; structure		2.4920C-nitro compound;
imidazoles		antitubercular agent
chlormethiazole
Chlormethiazole: A sedative and anticonvulsant often used in the treatment of alcohol withdrawal. Chlormethiazole has also been proposed as a neuroprotective agent. The mechanism of its therapeutic activity is not entirely clear, but it does potentiate GAMMA-AMINOBUTYRIC ACID receptors response and it may also affect glycine receptors.		2.4520thiazoles
tropolone
Tropolone: A seven-membered aromatic ring compound. It is structurally related to a number of naturally occurring antifungal compounds (ANTIFUNGAL AGENTS).. tropolone : A cyclic ketone that is cyclohepta-2,4,6-trien-1-one substituted by a hydroxy group at position 2. It is a toxin produced by the agricultural pathogen Burkholderia plantarii.		2.110alpha-hydroxy ketone;
cyclic ketone;
enol		bacterial metabolite;
fungicide;
toxin
methamphetamine
Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.		3.8630amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
levocarnitine
(R)-carnitine : The (R)-enantiomer of carnitine.		3.2310carnitineantilipemic drug;
nootropic agent;
nutraceutical;
Saccharomyces cerevisiae metabolite;
water-soluble vitamin (role)
muscone
muscone: structure in first source		4.6111
sulfanilylurea
sulfanilylurea: antimicrobial agent; structure		3.2310benzenes;
sulfonamide
gentian violet
Gentian Violet: A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.. crystal violet : An organic chloride salt that is the monochloride salt of crystal violet cation. It has been used in creams for the topical treatment of bacterial and fungal infections, being effective against some Gram-positive bacteria (notably Staphylococcus species) and some pathogenic fungi (including Candida species) but use declined following reports of animal carcinogenicity. It has also been used for dying wood, silk, and paper, as well as a histological stain.		2.0510organic chloride saltanthelminthic drug;
antibacterial agent;
antifungal agent;
antiseptic drug;
histological dye
amitriptyline hydrochloride
[no description available]		2.0510organic tricyclic compound
resazurin
resazurin: used as indicator in detection of hyposulfite (sulfoxylate); in food research (reductase test); structure		2.0610phenoxazine
1-naphthylisothiocyanate
1-Naphthylisothiocyanate: A tool for the study of liver damage which causes bile stasis and hyperbilirubinemia acutely and bile duct hyperplasia and biliary cirrhosis chronically, with changes in hepatocyte function. It may cause skin and kidney damage.		2.7630isothiocyanateinsecticide
hematoporphyrin
Hematoporphyrins: Iron-free derivatives of heme with 4 methyl groups, 2 hydroxyethyl groups and 2 propionic acid groups attached to the pyrrole rings. Some of these PHOTOSENSITIZING AGENTS are used in the PHOTOTHERAPY of malignant NEOPLASMS.. hematoporphyrin : A dicarboxylic acid that is protoporphyrin in which the vinyl groups at positions 7 and 12 are replaced by 1-hydroxyethyl groups.		7.5220
lithium carbonate
Lithium Carbonate: A lithium salt, classified as a mood-stabilizing agent. Lithium ion alters the metabolism of BIOGENIC MONOAMINES in the CENTRAL NERVOUS SYSTEM, and affects multiple neurotransmission systems.		2.0410carbonate salt;
lithium salt		antimanic drug
formestane
[no description available]		2.081017-oxo steroid;
3-oxo-Delta(4) steroid;
enol;
hydroxy steroid		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
lactulose
[no description available]		3.5920glycosylfructosegastrointestinal drug;
laxative
isoxsuprine hydrochloride
[no description available]		2.0510alkylbenzene
diphenylamine
Diphenylamine: In humans it may be irritating to mucous membranes. Methemoglobinemia has been produced experimentally. In veterinary use, it is one of active ingredients in topical agents for prevention and treatment of screwworm infestation. An indicator in tests for nitrate poisoning.. diphenylamine : An aromatic amine containing two phenyl substituents. It has been used as a fungicide for the treatment of superficial scald in apples and pears, but is no longer approved for this purpose within the European Union.		2.0810aromatic amine;
bridged diphenyl fungicide;
secondary amino compound		antifungal agrochemical;
antioxidant;
carotogenesis inhibitor;
EC 1.3.99.29 [phytoene desaturase (zeta-carotene-forming)] inhibitor;
ferroptosis inhibitor;
radical scavenger
betaine hydrochloride
[no description available]		2.0510
megestrol acetate
[no description available]		2.472020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
pamabrom
[no description available]		3.2310
acetylcysteine
N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.		10.680acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
3-hydroxyacetanilide
metacetamol : A derivative of phenol which has an acetamido substituent located meta to the phenolic -OH group. It is a non-toxic regioisomer of paracetamol with analgesic properties, but has never been marketed as a drug.		2.0510acetamides;
phenols		non-narcotic analgesic
methoxyacetic acid
methoxyacetic acid: RN given refers to parent cpd. methoxyacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a methoxy group.		2.0510ether;
monocarboxylic acid		antineoplastic agent;
apoptosis inducer;
human xenobiotic metabolite;
mutagen
Berberine chloride (TN)
[no description available]		2.0510organic molecular entity
erythromycin stearate
[no description available]		2.0510aminoglycoside
erythromycin
Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.		4.6780cyclic ketone;
erythromycin
dehydroepiandrosterone sulfate
Dehydroepiandrosterone Sulfate: The circulating form of a major C19 steroid produced primarily by the ADRENAL CORTEX. DHEA sulfate serves as a precursor for TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE.. dehydroepiandrosterone sulfate : A steroid sulfate that is the 3-sulfooxy derivative of dehydroepiandrosterone.		3.822117-oxo steroid;
steroid sulfate		EC 2.7.1.33 (pantothenate kinase) inhibitor;
human metabolite;
mouse metabolite
isosorbide
Isosorbide: 1,4:3,6-Dianhydro D-glucitol. Chemically inert osmotic diuretic used mainly to treat hydrocephalus; also used in glaucoma.		2.0210organic molecular entity
2-piperidone
2-piperidone: structure given in first source. piperidin-2-one : A delta-lactam that is piperidine which is substituted by an oxo group at position 2.		2.1510delta-lactam;
piperidones		EC 1.2.1.88 (L-glutamate gamma-semialdehyde dehydrogenase) inhibitor
methylnitrosourea
Methylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-methyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by methyl and nitroso groups.		2.0410N-nitrosoureasalkylating agent;
carcinogenic agent;
mutagen;
teratogenic agent
hydroxychloroquine sulfate
[no description available]		2.4920
ethylnitrosourea
Ethylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-ethyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by ethyl and nitroso groups.		2.2110N-nitrosoureasalkylating agent;
carcinogenic agent;
genotoxin;
mutagen
levonorgestrel
Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.		4.084017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin;
synthetic oral contraceptive
lormetazepam
lormetazepam: RN given refers to cpd with specified locant for methyl group; structure given in first source. lormetazepam : A 1,4-benzodiazepinone compound having a methyl substituent at the 1-position, a hydroxy substituent at the 3-position, a 2-chlorophenyl group at the 5-position and a chloro substituent at the 7-position.		2.04101,4-benzodiazepinone;
organochlorine compound		sedative
vinblastine
[no description available]		3.1550
diphenoxylate
Diphenoxylate: A MEPERIDINE congener used as an antidiarrheal, usually in combination with ATROPINE. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity.. diphenoxylate : A piperidinecarboxylate ester that is the ethyl ester of difenoxin.		3.2310ethyl ester;
nitrile;
piperidinecarboxylate ester;
tertiary amine		antidiarrhoeal drug
deoxycytidine
[no description available]		16.998730pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
cyproheptadine hydrochloride (anhydrous)
cyproheptadine hydrochloride (anhydrous) : The hydrochloride salt of cyproheptadine. Note that the drug named cyproheptadine hydrochloride generally refers to cyproheptadine hydrochloride sesquihydrate.		2.0510hydrochloride
estradiol valerate
[no description available]		2.4520steroid ester
ethambutol hydrochloride
ethambutol dihydrochloride : The dihydrchloride salt of ethambutol. A bacteriostatic antimycobacterial drug, it is effective against Mycobacterium tuberculosis and some other mycobacteria. It is used in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol dihydrochloride is used alone.		2.0810hydrochlorideantitubercular agent
ethambutol
Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.		3.8530ethanolamines;
ethylenediamine derivative		antitubercular agent;
environmental contaminant;
xenobiotic
tetramethylpyrazine
tetramethylpyrazine: found in Ligusticum chuanxiong. tetramethylpyrazine : A member of the class of pyrazines that is pyrazine in which all four hydrogens have been replaced by methyl groups. An alkaloid extracted from Chuanxiong (Ligusticum wallichii).		2.2510alkaloid;
pyrazines		antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
durapatite
Durapatite: The mineral component of bones and teeth; it has been used therapeutically as a prosthetic aid and in the prevention and treatment of osteoporosis.. hydroxylapatite : A phosphate mineral with the formula Ca5(PO4)3(OH).		2.2110
manganese dioxide
[no description available]		2.4110manganese molecular entity;
metal oxide
zinc oxide
Zinc Oxide: A mild astringent and topical protectant with some antiseptic action. It is also used in bandages, pastes, ointments, dental cements, and as a sunblock.		2.2510zinc molecular entity
arsenic trioxide
Arsenic Trioxide: An inorganic compound with the chemical formula As2O3 that is used for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA in patients who have relapsed from, or are resistant to, conventional drug therapy.		8.5420
antimycin a
[no description available]		2.7930benzamides;
formamides;
macrodiolide;
phenols		antifungal agent;
mitochondrial respiratory-chain inhibitor;
piscicide
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		4.0840glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
glycyrrhizic acid
glycyrrhizinic acid : A triterpenoid saponin that is the glucosiduronide derivative of 3beta-hydroxy-11-oxoolean-12-en-30-oic acid.		2.0410enone;
glucosiduronic acid;
pentacyclic triterpenoid;
tricarboxylic acid;
triterpenoid saponin		EC 3.4.21.5 (thrombin) inhibitor;
plant metabolite
d-alpha tocopherol
Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.		4.5770alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite
pregnenolone carbonitrile
Pregnenolone Carbonitrile: A catatoxic steroid and microsomal enzyme inducer having significant effects on the induction of cytochrome P450. It has also demonstrated the potential for protective capability against acetaminophen-induced liver damage.		2.0810aliphatic nitrile
1,2-epoxyhexane
[no description available]		4.6111
ibufenac
ibufenac: used in the treatment of rheumatism; also possesses antipyretic properties; minor descriptor (75-84); on-line & Index Medicus search PHENYLACETATES (75-84); RN given refers to parent cpd. ibufenac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 4-isobutylphenyl group. Although it was shown to be effective in treatment of rheumatoid arthritis, the clinical use of ibufenac was discontinued due to hepatotoxic side-effects.		3.5920monocarboxylic acidEC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
metylperon
metylperon: RN given refers to parent cpd		2.4620aromatic ketone
metaxalone
[no description available]		3.2310aromatic ether
spectinomycin
Spectinomycin: An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of GONORRHEA.. spectinomycin dihydrochloride : A hydrochloride obtained by combining spectinomycin with two molar equivalents of hydrochloric acid. An antibiotic that is active against gram-negative bacteria and used (as its pentahydrate) to treat gonorrhea.. spectinomycin : A pyranobenzodioxin and antibiotic that is active against gram-negative bacteria and used (as its dihydrochloride pentahydrate) to treat gonorrhea. It is produced by the bacterium Streptomyces spectabilis.		3.5820cyclic acetal;
cyclic hemiketal;
cyclic ketone;
pyranobenzodioxin;
secondary alcohol;
secondary amino compound		antibacterial drug;
antimicrobial agent;
bacterial metabolite
paraquat
Paraquat: A poisonous dipyridilium compound used as contact herbicide. Contact with concentrated solutions causes irritation of the skin, cracking and shedding of the nails, and delayed healing of cuts and wounds.. paraquat : An organic cation that consists of 4,4'-bipyridine bearing two N-methyl substituents loctated at the 1- and 1'-positions.		2.0510organic cationgeroprotector;
herbicide
dronabinol
Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.		4.0740benzochromene;
diterpenoid;
phytocannabinoid;
polyketide		cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic
amiloride hydrochloride, anhydrous
amiloride hydrochloride : A hydrochloride obtained by combining amiloride with one molar equivalent of hydrochloric acid.		2.0810hydrochloridediuretic;
sodium channel blocker
amiloride
Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.		3.8630aromatic amine;
guanidines;
organochlorine compound;
pyrazines		diuretic;
sodium channel blocker
pimozide
Pimozide: A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403). pimozide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group.		4.0840benzimidazoles;
heteroarylpiperidine;
organofluorine compound		antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
benperidol
Benperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It has been used in the treatment of aberrant sexual behavior. (From Martindale, The Extra Pharmacopoeia, 30th ed, p567)		2.0410aromatic ketone
7-hydroxychlorpromazine
7-hydroxychlorpromazine: RN given refers to parent cpd		2.0810phenothiazines
phenethyl isothiocyanate
phenethyl isothiocyanate: a dietary liver aldehyde dehydrogenase inhibitor; promotes urinary bladder carcinoma. phenethyl isothiocyanate : An isothiocyanate having a phenethyl group attached to the nitrogen. It is a naturally occurring compound found in some cruciferous vegetables (e.g. watercress) and is known to possess anticancer properties.		2.8130isothiocyanateantineoplastic agent;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
metabolite
dexbrompheniramine
dexbrompheniramine : The (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.		3.2310brompheniramineanti-allergic agent;
H1-receptor antagonist
sulfadoxine
Sulfadoxine: A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.. sulfadoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 5- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. In combination with the antiprotozoal pyrimethamine (CHEBI:8673) it is used as an antimalarial.		2.0510pyrimidines;
sulfonamide		antibacterial drug;
antimalarial
acadesine
[no description available]		2.47201-ribosylimidazolecarboxamide;
aminoimidazole;
nucleoside analogue		antineoplastic agent;
platelet aggregation inhibitor
chlordesmethyldiazepam
[no description available]		2.0410benzodiazepine
stavudine
Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase		4.5670dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
doxifluridine
doxifluridine : A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase.		2.9640organofluorine compound;
pyrimidine 5'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
prodrug
dicloxacillin
Dicloxacillin: One of the PENICILLINS which is resistant to PENICILLINASE.. dicloxacillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]formyl group.		4.0840dichlorobenzene;
penicillin		antibacterial drug
fluorescein-5-isothiocyanate
Fluorescein-5-isothiocyanate: Fluorescent probe capable of being conjugated to tissue and proteins. It is used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.. fluorescein 5-isothiocyanate : The 5-isomer of fluorescein isothiocyanate. Acts as a fluorescent probe capable of being conjugated to tissue and proteins; used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.		2.7330fluorescein isothiocyanate
iproclozide
iproclozide: structure		2.0510aromatic ether
megestrol
Megestrol: A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.. megestrol : A 3-oxo Delta(4)-steroid that is pregna-4,6-diene-3,20-dione substituted by a methyl group at position 6 and a hydroxy group at position 17.		3.231017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
streptomycin
[no description available]		4.9460antibiotic antifungal drug;
antibiotic fungicide;
streptomycins		antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor
butylhydroxybutylnitrosamine
Butylhydroxybutylnitrosamine: A substituted carcinogenic nitrosamine.. N-butyl-N-(4-hydroxybutyl)nitrosamine : A nitrosamine that has butyl and 4-hydroxybutyl substituents. In mice, it causes high-grade, invasive cancers in the urinary bladder, but not in any other tissues.		2.4520nitrosamine;
primary alcohol		carcinogenic agent
clonidine hydrochloride
[no description available]		2.0510dichlorobenzene
cladribine
[no description available]		4.6880organochlorine compound;
purine 2'-deoxyribonucleoside		antineoplastic agent;
immunosuppressive agent
beclomethasone
[no description available]		2.11011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
corticosteroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic drug;
anti-inflammatory drug
ethylene dimethanesulfonate
ethylene dimethanesulfonate: antispermatogenic agent; structure		2.0510
carbenicillin
Carbenicillin: Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.. carbenicillin : A penicillin antibiotic having a 6beta-2-carboxy-2-phenylacetamido side-chain.		3.5820penicillin allergen;
penicillin		antibacterial drug
carbenicillin disodium
[no description available]		2.0510organic sodium salt
dehydroemetine
dehydroemetine: was MH 1991-94 (see under EMETINE 1976-90); use EMETINE to search DEHYDROEMETINE 1976-94; amebicide, derivative of emetine. dehydroemetine : A pyridoisoquinoline which was developed in response to the cardiovascular toxicity associated with emetine and results from the dehydrogenation of the heterotricylic ring of emetine. It is an antiprotozoal agent and displays antimalarial, antiamoebic, and antileishmanial properties.		2.0510aromatic ether;
isoquinolines;
pyridoisoquinoline		antileishmanial agent;
antimalarial;
antiprotozoal drug
benorilate
benorilate: was heading 1980-94 (see under SALICYLATES 1980-90); was BENORYLATE see under SALICYLATES 1975-79; BENORYLATE was see BENORILATE 1980-94; use SALICYLATES to search BENORILATE 1980-90 & BENORYLATE 1975-79; an ester of aspirin and paracetamol with analgesic, antipyretic, and anti-inflammatory activity used in the treatment of rheumatoid diseases; it has less severe side effects than aspirin		2.0510carbonyl compound
trimetazidine
Trimetazidine: A vasodilator used in angina of effort or ischemic heart disease.		2.0510aromatic amine
buthionine sulfoximine
Buthionine Sulfoximine: A synthetic amino acid that depletes glutathione by irreversibly inhibiting gamma-glutamylcysteine synthetase. Inhibition of this enzyme is a critical step in glutathione biosynthesis. It has been shown to inhibit the proliferative response in human T-lymphocytes and inhibit macrophage activation. (J Biol Chem 1995;270(33):1945-7). 2-amino-4-(S-butylsulfonimidoyl)butanoic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group carries an oxo, imino and butyl groups.. S-butyl-DL-homocysteine (S,R)-sulfoximine : A sulfoximide that is the sulfoximine derivative of an analogue of DL-methionine in which the S-methyl group is replaced by S-butyl.		2.2510diastereoisomeric mixture;
homocysteines;
non-proteinogenic alpha-amino acid;
sulfoximide		EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor;
ferroptosis inducer
metocurine
metocurine: from Chinese herb Cyclea hainanensis Mrr		2.4720isoquinolines
floxacillin
Floxacillin: Antibiotic analog of CLOXACILLIN.. flucloxacillin : A penicillin compound having a 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido] side-chain.		2.9640penicillin allergen;
penicillin		antibacterial drug
clomacran
clomacran: RN given refers to parent cpd; structure		3.2310acridines
mexiletine hydrochloride
mexiletine hydrochloride : A hydrochloride composed of equimolar amounts of mexiletine and hydrogen chloride.		2.0510hydrochlorideanti-arrhythmia drug
beclomethasone dipropionate
beclomethasone dipropionate : A steroid ester comprising beclomethasone having propionyl groups at the 17- and 21-positions.		2.452011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
corticosteroid;
enone;
glucocorticoid;
propanoate ester;
steroid ester		anti-arrhythmia drug;
anti-asthmatic drug;
anti-inflammatory drug;
prodrug
vidarabine
adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.		2.4620beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
iodinated glycerol
iodinated glycerol: secretolytic agent; RN given refers to cpd without iodine locant		2.6320dioxolane
methenamine hippurate
methenamine hippurate: both parts of molecule contribute to its antibacterial action		3.2310N-acylglycine
levomethadone
levomethadone : A 6-(dimethylamino)-4,4-diphenylheptan-3-one that has (R)-configuration. It is the active enantiomer of methadone and its hydrochloride salt is used to treat adults who are addicted to drugs such as heroin and morphine.		2.03106-(dimethylamino)-4,4-diphenylheptan-3-oneantitussive;
mu-opioid receptor agonist;
NMDA receptor antagonist;
opioid analgesic
olsalazine
olsalazine: cpd with 2 salicylate molecules linked together by an azo bond. olsalazine : An azobenzene that consists of two molecules of 4-aminosalicylic acid joined by an azo linkage. A prodrug for mesalazine, an anti-inflammatory drug, it is used (as the disodium salt) in the treatment of inflammatory bowel disease.		3.5820azobenzenes;
dicarboxylic acid		non-steroidal anti-inflammatory drug;
prodrug
tiadenol
tiadenol: structure		2.0510aliphatic sulfide
terodiline
[no description available]		2.0410diarylmethane
1-(4-carboxyphenyl)-3,3-dimethyltriazene
1-(4-carboxyphenyl)-3,3-dimethyltriazene: RN given refers to parent cpd		2.0410
phenylethylmalonamide
Phenylethylmalonamide: A metabolite of primidone.		2.0310amine
metoclopramide hydrochloride
metoclopramide hydrochloride : A hydrate that is the monohydrate form of metoclopramide monohydrochloride.		2.0510
etidronate disodium
etidronate disodium : An organic sodium salt resulting from the replacement of two protons from etidronic acid (one from from each of the phosphonic acid groups) by sodium ions.		2.0810organic sodium saltantineoplastic agent;
bone density conservation agent;
chelator
palladium
Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.. palladium : Chemical element (nickel group element atom) with atomic number 46.		2.1310metal allergen;
nickel group element atom;
platinum group metal atom
platinum
Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.		9.99145elemental platinum;
nickel group element atom;
platinum group metal atom
ruthenium
Ruthenium: A hard, brittle, grayish-white rare earth metal with an atomic symbol Ru, atomic number 44, and atomic weight 101.07. It is used as a catalyst and hardener for PLATINUM and PALLADIUM.		2.5220iron group element atom;
platinum group metal atom
silver
Silver: An element with the atomic symbol Ag, atomic number 47, and atomic weight 107.87. It is a soft metal that is used medically in surgical instruments, dental prostheses, and alloys. Long-continued use of silver salts can lead to a form of poisoning known as ARGYRIA.		5.121copper group element atom;
elemental silver		Escherichia coli metabolite
technetium
Technetium: The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, and atomic number 43. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years.		2.4820manganese group element atom
thulium
Thulium: An element of the rare earth family of metals. It has the atomic symbol Tm, atomic number 69, and atomic weight 168.93.		4.6111f-block element atom;
lanthanoid atom
titanium
Titanium: A dark-gray, metallic element of widespread distribution but occurring in small amounts with atomic number, 22, atomic weight, 47.867 and symbol, Ti; specific gravity, 4.5; used for fixation of fractures.		4.6111titanium group element atom
gadolinium
Gadolinium: An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.		2.2110f-block element atom;
lanthanoid atom
gold
Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.		2.5420copper group element atom;
elemental gold
uranium
Uranium: A radioactive element of the actinide series of metals. It has an atomic symbol U, atomic number 92, and atomic weight 238.03. U-235 is used as the fissionable fuel in nuclear weapons and as fuel in nuclear power reactors.		4.6111actinoid atom;
f-block element atom;
monoatomic uranium
zalcitabine
Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.		2.9740pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
metocurine iodide
[no description available]		2.0410aromatic ether
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		14.376616delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
sodium thiosulfate
sodium thiosulfate: do not confuse synonym sodium hyposulfite with sodium hyposulfite, synonym for di-Na salt of dithionous acid. sodium thiosulfate : An inorganic sodium salt composed of sodium and thiosulfate ions in a 2:1 ratio.		3.6620inorganic sodium saltantidote to cyanide poisoning;
antifungal drug;
nephroprotective agent
fluorine
Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.		2.0310diatomic fluorine;
gas molecular entity		NMR chemical shift reference compound
galactose
aldohexose : A hexose with a (potential) aldehyde group at one end.		4.6111
ozone
Ozone: The unstable triatomic form of oxygen, O3. It is a powerful oxidant that is produced for various chemical and industrial uses. Its production is also catalyzed in the ATMOSPHERE by ULTRAVIOLET RAY irradiation of oxygen or other ozone precursors such as VOLATILE ORGANIC COMPOUNDS and NITROGEN OXIDES. About 90% of the ozone in the atmosphere exists in the stratosphere (STRATOSPHERIC OZONE).. ozone : An elemental molecule with formula O3. An explosive, pale blue gas (b.p. -112degreeC) that has a characteristic, pungent odour, it is continuously produced in the upper atmosphere by the action of solar ultraviolet radiation on atmospheric oxygen. It is an antimicrobial agent used in the production of bottled water, as well as in the treatment of meat, poultry and other foodstuffs.		4.6111elemental molecule;
gas molecular entity;
reactive oxygen species;
triatomic oxygen		antiseptic drug;
disinfectant;
electrophilic reagent;
greenhouse gas;
mutagen;
oxidising agent;
tracer
cadmium chloride
Cadmium Chloride: A cadmium halide in the form of colorless crystals, soluble in water, methanol, and ethanol. It is used in photography, in dyeing, and calico printing, and as a solution to precipitate sulfides. (McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed). cadmium dichloride : A cadmium coordination entity in which cadmium(2+) and Cl(-) ions are present in the ratio 2:1. Although considered to be ionic, it has considerable covalent character to its bonding.		2.0610cadmium coordination entity
stanozolol
Stanozolol: A synthetic steroid that has anabolic and androgenic properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1194). stanozolol : An organic heteropentacyclic compound resulting from the formal condensation of the 3-keto-aldehyde moiety of oxymetholone with hydrazine. Like oxymetholone, it is a synthetic anabolic steroid. It has both anabolic and androgenic properties, and has been used to treat hereditary angioedema and various vascular disorders. It has also been widely abused by professional athletes.		2.051017beta-hydroxy steroid;
anabolic androgenic steroid;
organic heteropentacyclic compound;
tertiary alcohol		anabolic agent;
androgen
clodronic acid
Clodronic Acid: A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification.. clodronic acid : An organochlorine compound that is methylene chloride in which both hydrogens are replaced by phosphonic acid groups. It inhibits bone resorption and soft tissue calcification, and is used (often as the disodium salt tetrahydrate) as an adjunct in the treatment of severe hypercalcaemia associated with malignancy, and in the management of osteolytic lesions and bone pain associated with skeletal metastases.		2.05101,1-bis(phosphonic acid);
one-carbon compound;
organochlorine compound		antineoplastic agent;
bone density conservation agent
carbendazim
carbendazim: carcinogen when combined with sodium nitrite; principle metabolite of thiophanate methyl & benomyl; structure. carbendazim : A member of the class of benzimidazoles that is 2-aminobenzimidazole in which the primary amino group is substituted by a methoxycarbonyl group. A fungicide, carbendazim controls Ascomycetes, Fungi Imperfecti, and Basidiomycetes on a wide variety of crops, including bananas, cereals, cotton, fruits, grapes, mushrooms, ornamentals, peanuts, sugarbeet, soybeans, tobacco, and vegetables.		2.0510benzimidazole fungicide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		antifungal agrochemical;
antinematodal drug;
metabolite;
microtubule-destabilising agent
mafenide acetate
[no description available]		2.0810carboxylic acid
ethionine
L-ethionine : An S-ethylhomocysteine that has S-configuration at the chiral centre.		2.0510S-ethylhomocysteineantimetabolite;
carcinogenic agent
chlorbromuron
chlorbromuron: structure		2.0510ureas
apazone
Apazone: An anti-inflammatory agent used in the treatment of rheumatoid arthritis. It also has uricosuric properties and has been used to treat gout.. apazone : A member of the class of benzotriazines that is 1,2-dihydro-1,2,4-benzotriazine bearing a dimethylamino substitutent at position 3 and a methyl substituent at position 7 and in which the nitrogens at positions 1 and 2 are both acylated by a carboxy group of propylmalonic acid.		2.0410benzotriazinesnon-steroidal anti-inflammatory drug;
uricosuric drug
diacerein
diacerein: chelates with bivalent metals; a quinone which possesses redox properties; metabolized to active rhein; proposed mechanisms include inhibiting IL1 and metalloproteinases; called a slow acting symptomatic drug in osteoarthritis; no effect of cyclooxygenase;		2.0810anthraquinone
metopimazine
metopimazine: RN given refers to parent cpd; structure		2.0310phenothiazines
xipamide
Xipamide: A sulfamoylbenzamide analog of CLOPAMIDE. It is diuretic and saluretic with antihypertensive activity. It is bound to PLASMA PROTEINS, thus has a delayed onset and prolonged action.		2.0510benzamides
selegiline
Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.		4.140selegiline;
terminal acetylenic compound		geroprotector
selegiline hydrochloride, (r)-isomer
[no description available]		2.4720hydrochloride;
terminal acetylenic compound		antiparkinson drug;
dopaminergic agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor
levamisole
Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.		2.05106-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazoleantinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator
clemastine
Clemastine: A histamine H1 antagonist used as the hydrogen fumarate in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.. clemastine : 2-[(2R)-1-Methylpyrrolidin-2-yl]ethanol in which the hydrogen of the hydroxy group is substituted by a 1-(4-chlorophenyl)-1-phenylethyl group (R configuration). An antihistamine with antimuscarinic and moderate sedative properties, it is used as its fumarate salt for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions.		3.6520monochlorobenzenes;
N-alkylpyrrolidine		anti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist
thiamphenicol
[no description available]		2.4720monocarboxylic acid amide;
sulfone		antimicrobial agent;
immunosuppressive agent
pancuronium bromide
pancuronium bromide : A bromide salt consisting of two bromide ions and one pancuronium dication.		2.0810bromide saltcholinergic antagonist;
muscle relaxant;
nicotinic antagonist
pizotyline
Pizotyline: Serotonin antagonist used against MIGRAINE DISORDERS and vascular headaches.. pizotifen : A benzocycloheptathiophene that is 9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thiophene 4-ylidene)-1-methylpiperidine which is joined from the 4 position to the 4 position of an N-methylpiperidine moiety by a double bond. It is a sedating antihistamine, with strong serotonin antagonist and weak antimuscarinic activity. It is generally used as the malate salt for the treatment of migraine and the prevention of headache attacks during cluster periods.		2.0510benzocycloheptathiophenehistamine antagonist;
muscarinic antagonist;
serotonergic antagonist
cephalexin
Cephalexin: A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.. cephalexin : A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.		4.6140beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
isosorbide-5-mononitrate
isosorbide-5-mononitrate: for prevention of angina pectoris; structure given in first source; a Russian drug		2.4520glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent
tetradecanoylphorbol acetate
Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.		2.0110acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
tocopheryl nicotinate
alpha-tocopheryl nicotinate: RN given refers to (2R-(2R*(2R*(4R*,8R*))-isomer		2.0510tocol
ornidazole
Ornidazole: A nitroimidazole antiprotozoal agent used in ameba and trichomonas infections. It is partially plasma-bound and also has radiation-sensitizing action.. ornidazole : A C-nitro compound that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by 3-chloro-2-hydroxypropyl and methyl groups, respectively. It is used in the treatment of susceptible protozoal infections and for the treatment of anaerobic bacterial infections.		2.0810C-nitro compound;
imidazoles;
organochlorine compound;
secondary alcohol		antiamoebic agent;
antibacterial drug;
antiinfective agent;
antiprotozoal drug;
antitrichomonal drug;
epitope
danazol
Danazol: A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.		4.285017beta-hydroxy steroid;
terminal acetylenic compound		anti-estrogen;
estrogen antagonist;
geroprotector
metergoline
Metergoline: A dopamine agonist and serotonin antagonist. It has been used similarly to BROMOCRIPTINE as a dopamine agonist and also for MIGRAINE DISORDERS therapy.. metergoline : An ergoline alkaloid that is the N-benzyloxycarbonyl derivative of lysergamine. A 5-HT2 antagonist. Also 5-HT1 antagonist and 5-HT1D ligand. Has moderate affinity for 5-HT6 and high affinity for 5-HT7.		2.0310carbamate ester;
ergoline alkaloid		dopamine agonist;
geroprotector;
serotonergic antagonist
benomyl
[no description available]		2.0510aromatic amide;
benzimidazole fungicide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		acaricide;
anthelminthic drug;
antifungal agrochemical;
microtubule-destabilising agent;
tubulin modulator
fenclozic acid
fenclozic acid: an analgesic & antipyretic with anti-inflammatory properties; minor descriptor (75-86); on-line & INDEX MEDICUS search THIAZOLES (75-86); RN given refers to parent cpd		3.2310
laxagetten 4,4'-diacetoxydiphenylpyridylemethane
[no description available]		3.2310
daunorubicin
Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.		4.0840aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
cephapirin
Cephapirin: Cephalosporin antibiotic, partly plasma-bound, that is effective against gram-negative and gram-positive organisms.. cephapirin : A cephalosporin with acetoxymethyl and 2(pyridin-4-ylsulfanyl)acetamido substituents at positions 3 and 7, respectively, of the cephem skeleton. It is used (as its sodium salt) as an antibiotic, being effective against gram-negative and gram-positive organisms.		2.0410cephalosporinantibacterial drug
fludarabine phosphate
fludarabine phosphate: structure given in first source. fludarabine phosphate : A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas.		4.3730nucleoside analogue;
organofluorine compound;
purine arabinonucleoside monophosphate		antimetabolite;
antineoplastic agent;
antiviral agent;
DNA synthesis inhibitor;
immunosuppressive agent;
prodrug
phosphotyrosine
Phosphotyrosine: An amino acid that occurs in endogenous proteins. Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly in cell growth control and carcinogenesis.. O(4)-phospho-L-tyrosine : A non-proteinogenic L-alpha-amino acid that is L-tyrosine phosphorylated at the phenolic hydroxy group.		3.1450L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid;
O(4)-phosphotyrosine		Escherichia coli metabolite;
immunogen
disopyramide phosphate
[no description available]		2.0510organoammonium phosphate
alclofenac
alclofenac: was heading 1975-94 (was see under PHENYLACETATES 1975-90); use PHENYLACETATES to search ALCLOFENAC 1975-94; an anti-inflammatory agent used in the treatment of rheumatoid arthritis; acts also as an analgesic and an antipyretic. alclofenac : An aromatic ether in which the ether oxygen links an allyl group to the 4-position of (3-chlorophenyl)acetic acid.A non-steroidal anti-inflammatory drug, it was withdrawn from the UK market in 1979 due to concerns with its association with vasculitis and rash.		3.2310aromatic ether;
monocarboxylic acid;
monochlorobenzenes		drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
carbimazole
Carbimazole: An imidazole antithyroid agent. Carbimazole is metabolized to METHIMAZOLE, which is responsible for the antithyroid activity.. carbimazole : A member of the class of imidazoles that is methimazole in which the nitrogen bearing a hydrogen is converted into its ethoxycarbonyl derivative. A prodrug for methimazol, carbimazole is used for the treatment of hyperthyroidism.		2.05101,3-dihydroimidazole-2-thiones;
carbamate ester		antithyroid drug;
prodrug
bromocriptine
Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.		3.8530indole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist
ergocristine
ergocristine: an ergot alkaloid; one of the three components of ergotoxine; has alpha blocking action, stimulates smooth muscles & antagonizes serotonin; used as oxytocic & in peripheral disorders; minor descriptor (77-86); on-line & INDEX MEDICUS search EROLINES (77-86); RN given refers to ((5'alpha)-isomer). ergocristine : Ergotaman bearing benzyl, hydroxy, and isopropyl groups at the 5', 12' and 2' positions, respectively, and oxo groups at positions 3', 6', and 18. It is a natural ergot alkaloid.		2.0410ergot alkaloid
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		2.5320benzenes;
phenyl acetates
triamcinolone
Triamcinolone: A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739). triamcinolone : A C21-steroid hormone that is 1,4-pregnadiene-3,20-dione carrying four hydroxy substituents at positions 11beta, 16alpha, 17alpha and 21 as well as a fluoro substituent at position 9. Used in the form of its 16,17-acetonide to treat various skin infections.		2.442011beta-hydroxy steroid;
16alpha-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
oxyphenisatin
[no description available]		3.5920indoles
tetrachloroethylene
Tetrachloroethylene: A chlorinated hydrocarbon used as an industrial solvent and cooling liquid in electrical transformers. It is a potential carcinogen.		2.0510chlorocarbon;
chloroethenes		nephrotoxic agent
fludrocortisone
Fludrocortisone: A synthetic mineralocorticoid with anti-inflammatory activity.		3.231011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
fluorinated steroid;
mineralocorticoid		adrenergic agent;
anti-inflammatory drug
ursodeoxycholic acid
Ursodeoxycholic Acid: An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.. ursodeoxycholic acid : A bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones.. ursodeoxycholate : A bile acid anion that is the conjugate base of ursodeoxycholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.		3.8630bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
pregnanolone
Pregnanolone: A pregnane found in the urine of pregnant women and sows. It has anesthetic, hypnotic, and sedative properties.. 3alpha-hydroxy-5beta-pregnan-20-one : The 3alpha-stereoisomer of 3-hydroxy-5beta-pregnan-20-one.		2.04103-hydroxy-5beta-pregnan-20-one;
3alpha-hydroxy steroid		human metabolite;
intravenous anaesthetic;
sedative
butylated hydroxytoluene
2,6-di-tert-butyl-4-methylphenol : A member of the class of phenols that is 4-methylphenol substituted by tert-butyl groups at positions 2 and 6.		2.0510phenolsantioxidant;
ferroptosis inhibitor;
food additive;
geroprotector
proquazone
proquazone: nonsteroid anti-inflammatory agent; structure		3.4110pyrimidines
benzonidazole
benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.		2.0810C-nitro compound;
imidazoles;
monocarboxylic acid amide		antiprotozoal drug
butachlor
butachlor : An aromatic amide that is 2-choro-N-(2,6-diethylphenyl)acetamide in which the amide nitrogen has been replaced by a butoxymethyl group.		2.0510aromatic amide;
organochlorine compound;
tertiary carboxamide		environmental contaminant;
herbicide;
xenobiotic
du-21220
Ritodrine: An adrenergic beta-2 agonist used to control PREMATURE LABOR.. 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol : A secondary amino compound that is 4-(2-amino-1-hydroxypropyl)phenol in which one of the hydrogens attached to the nitrogen is replaced by a 2-(4-hydroxyphenyl)ethyl group.		2.4420benzyl alcohols;
polyphenol;
secondary alcohol;
secondary amino compound
bisbenzimidazole trihydrochloride
[no description available]		2.2510
transferrin
Transferrin: An iron-binding beta1-globulin that is synthesized in the LIVER and secreted into the blood. It plays a central role in the transport of IRON throughout the circulation. A variety of transferrin isoforms exist in humans, including some that are considered markers for specific disease states.		2.0310
rose bengal b disodium salt
[no description available]		2.0510
tridemorph
tridemorph: RN given refers to cpd with unspecified isomeric designation; structure. tridemorph : A mixture of 4-alkyl-2,6-dimethylmorpholines, where 'alkyl' is a mixture of C11 to C14 homologues of which 60-70% is tridecyl. A systemic fungicide, it is no longer approved for use within the European Union.. 2,6-dimethyl-4-tridecylmorpholine : A member of the class of morpholines that is 2,6-dimethylmorpholine in which the hydrogen attached to the nitrogen is replaced by a tridecyl group. The configuration at positions 2 and 6 is unknown or unspecified.		2.0210morpholines;
tertiary amino compound		antifungal agrochemical
clobetasol propionate
Clobetasol Propionate: This is the form in trademark preparations.. clobetasol propionate : The 17-O-propionate ester of clobetasol. A potent corticosteroid, it is used to treat various skin disorders, including exzema and psoriasis.		2.11011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
fluorinated steroid;
glucocorticoid		anti-inflammatory drug
alkenes
[no description available]		2.6920
glutamic acid
Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.		4.1331glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
dexchlorpheniramine
dexchlorpheniramine: RN given refers to parent cpd(S)-isomer		3.2310chlorphenamine
ribostamycin
Ribostamycin: A broad-spectrum antimicrobial isolated from Streptomyces ribosifidicus.. ribostamycin : An amino cyclitol glycoside that is 4,6-diaminocyclohexane-1,2,3-triol having a 2,6-diamino-2,6-dideoxy-alpha-D-glucosyl residue attached at position 1 and a beta-D-ribosyl residue attached at position 2. It is an antibiotic produced by Streptomyces ribosidificus (formerly S. thermoflavus).		2.0410amino cyclitol glycoside;
aminoglycoside antibiotic		antibacterial drug;
antimicrobial agent;
metabolite
clometacin
clometacin: structure		3.2310N-acylindole
azoxymethane
Azoxymethane: A potent carcinogen and neurotoxic compound. It is particularly effective in inducing colon carcinomas.		2.7330
cefazolin
Cefazolin: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.. cefazolin : A first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively.		4.0740beta-lactam antibiotic allergen;
cephalosporin;
tetrazoles;
thiadiazoles		antibacterial drug
amoxicillin
Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.		5.4370penicillin allergen;
penicillin		antibacterial drug
timolol
(S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.		4.4160timololanti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist
indoramin
Indoramin: An alpha-1 adrenergic antagonist that is commonly used as an antihypertensive agent.		2.7530tryptamines
nicergoline
Nicergoline: An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It may ameliorate cognitive deficits in CEREBROVASCULAR DISORDERS.		2.0510organic heterotetracyclic compound;
organonitrogen heterocyclic compound
oxcarbazepine
Oxcarbazepine: A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.. oxcarbazepine : A dibenzoazepine derivative, having a carbamoyl group at the ring nitrogen, substituted with an oxo group at C-4 of the azepeine ring which is also hydrogenated at C-4 and C-5. It is a anticholinergic anticonvulsant and mood stabilizing drug, used primarily in the treatment of epilepsy.		3.8730cyclic ketone;
dibenzoazepine		anticonvulsant;
drug allergen
carbidopa
carbidopa (anhydrous) : 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa.		3.6120catechols;
hydrazines;
monocarboxylic acid		antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
toloxatone
toloxatone: oxazolidinone derivative; psychotropic drug; structure. toloxatone : A racemate consisting of equimolar amounts of (R)- and (S)-toloxatone. It is a reversible monoamine oxidase A inhibitor and antidepressant.. 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one : A member of the class of oxazolidinones that is 5-(hydroxymethyl)-1,3-oxazolidin-2-one substituted by a 3-methylphenyl group at position 3.		2.0410oxazolidinone;
primary alcohol;
toluenes
moricizine hydrochloride
moricizine hydrochloride : A hydrochloride salt obtained from equimola amounts of moricizine and hydrogen chloride.		2.0510hydrochlorideanti-arrhythmia drug
moricizine
Moricizine: An antiarrhythmia agent used primarily for ventricular rhythm disturbances.. moricizine : A phenothiazine substituted on the nitrogen by a 3-(morpholin-4-yl)propanoyl group, and at position 2 by an (ethoxycarbonyl)amino group.		3.6420carbamate ester;
morpholines;
phenothiazines		anti-arrhythmia drug
vidarabine phosphate
Vidarabine Phosphate: An adenosine monophosphate analog in which ribose is replaced by an arabinose moiety. It is the monophosphate ester of VIDARABINE with antiviral and possibly antineoplastic properties.		3.1210
amineptin
amineptin: used in treatment of neuroses with psychoasthenic, anxio-phobic & depressive manifestations; synonym S 1694 refers to HCl; structure. amineptine : A carbocyclic fatty acid that is 5-aminoheptanoic acid in which one of the hydrogens attached to the nitrogen is replaced by a 10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl group. A tricyclic antidepressant, it was never approved in the US and was withdrawn from the French market in 1999 due to concerns over abuse, dependence and severe acne.		3.5920amino acid;
carbocyclic fatty acid;
carbotricyclic compound;
secondary amino compound		antidepressant;
dopamine uptake inhibitor
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		4.7790azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
feprazone
Feprazone: A pyrazole that has analgesic, anti-inflammatory, and antipyretic properties. It has been used in mild to moderate pain, fever, and inflammation associated with musculoskeletal and joint disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p15)		2.0810organic molecular entity
pirprofen
pirprofen: anti-inflammatory agent used in therapy of rheumatoid arthritis; prostaglandin synthetase inhibitor; more potent than indomethacin; structure		3.8630pyrroline
sisomicin
Sisomicin: Antibiotic produced by Micromonospora inyoensis. It is closely related to gentamicin C1A, one of the components of the gentamicin complex (GENTAMICINS).		2.0410amino cyclitol glycoside;
aminoglycoside antibiotic;
beta-L-arabinoside;
monosaccharide derivative
serentil
mesoridazine besylate : The benzenesulfonate salt of mesoridazine prepared using equimolar amounts of mesoridazine and benzenesulfonic acid.		2.0510organosulfonate saltdopaminergic antagonist;
first generation antipsychotic
amdinocillin
Amdinocillin: An amidinopenicillanic acid derivative with broad spectrum antibacterial action.. mecillinam : A penicillin in which the 6beta substituent is [(azepan-1-yl)methylidene]amino; an extended-spectrum penicillin antibiotic that binds specifically to penicillin binding protein 2 (PBP2), and is only considered to be active against Gram-negative bacteria.		2.0410penicillinantibacterial drug;
antiinfective agent
tobramycin
Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.		2.9740amino cyclitol glycosideantibacterial agent;
antimicrobial agent;
toxin
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		20.1216971taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
etoposide
[no description available]		14.5301beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
propafenone hydrochloride
propafenone hydrochloride : A hydrochloride that is the monohydrochloride salt of propafenone. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used in the management of supraventricular and ventricular arrhythmias.		2.0510hydrochlorideanti-arrhythmia drug
dobutamine
Dobutamine: A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.. dobutamine : A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.		3.8830catecholamine;
secondary amine		beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent
ticarcillin
Ticarcillin: An antibiotic derived from penicillin similar to CARBENICILLIN in action.. ticarcillin : A penicillin compound having a 6beta-[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino side-group.		2.0410penicillin allergen;
penicillin		antibacterial drug
trimazosin
trimazosin: RN given refers to parent cpd; structure		2.0410N-arylpiperazine
penbutolol
Penbutolol: A nonselective beta-blocker used as an antihypertensive and an antianginal agent.		3.2310ethanolamines
ribavirin
Rebetron: Rebetron is tradename		4.41601-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
adinazolam
adinazolam: structure in first source. adinazolam : A triazolo[4,3-a][1,4]benzodiazepine having a dimethylaminomethyl group at the 1-position, a phenyl group at the 6-position and a chloro substituent at the 8-position.		2.0410triazolobenzodiazepineanticonvulsant;
antidepressant;
anxiolytic drug;
sedative
amikacin
Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.		4.2650alpha-D-glucoside;
amino cyclitol glycoside;
aminoglycoside;
carboxamide		antibacterial drug;
antimicrobial agent;
nephrotoxin
tolamolol
[no description available]		2.0410
carbidopa
[no description available]		2.0510catechols;
hydrate;
hydrazines;
monocarboxylic acid		antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
cephradine
Cephradine: A semi-synthetic cephalosporin antibiotic.. cephradine : A first-generation cephalosporin antibiotic with a methyl substituent at position 3, and a (2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetamido substituent at position 7, of the cephem skeleton.		3.8630beta-lactam antibiotic allergen;
cephalosporin		antibacterial drug
ticrynafen
Ticrynafen: A novel diuretic with uricosuric action. It has been proposed as an antihypertensive agent.. tienilic acid : An aromatic ketone that is 2,3-dichlorophenoxyacetic acid in which the hydrogen at position 4 on the benzene ring is replaced by a thiophenecarbonyl group. A loop diuretic used to treat hypertension, it was withdrawn from the market in 1982 due to links with hepatitis.		3.8630aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid;
thiophenes		antihypertensive agent;
hepatotoxic agent;
loop diuretic
methyldopa
Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.. alpha-methyl-L-dopa : A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.		4.0840L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		alpha-adrenergic agonist;
antihypertensive agent;
hapten;
peripheral nervous system drug;
sympatholytic agent
tocainide
Tocainide: An antiarrhythmic agent which exerts a potential- and frequency-dependent block of SODIUM CHANNELS.. tocainide : A monocarboxylic acid amide in which 2,6-dimethylphenylaniline and isobutyric acid have combined to form the amide bond; used as a local anaesthetic.		2.0410monocarboxylic acid amideanti-arrhythmia drug;
local anaesthetic;
sodium channel blocker
sulbenicillin
Sulbenicillin: Semisynthetic penicillin-type antibiotic.. sulbenicillin : A penicillin antibiotic having a 6beta-[phenyl(sulfo)acetamido] side-chain.		2.0410penicillin
bezafibrate
[no description available]		2.4620aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
sq-11725
Nadolol: A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.. nadolol : Nadolol is a diastereoisomeric mixture consisting of equimolar amounts of the four possible 2,3-cis-isomers of 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol.		2.7430
diltiazem
Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.		4.66805-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetateantihypertensive agent;
calcium channel blocker;
vasodilator agent
nimustine
Nimustine: Antineoplastic agent especially effective against malignant brain tumors. The resistance which brain tumor cells acquire to the initial effectiveness of this drug can be partially overcome by the simultaneous use of membrane-modifying agents such as reserpine, calcium antagonists such as nicardipine or verapamil, or the calmodulin inhibitor, trifluoperazine. The drug has also been used in combination with other antineoplastic agents or with radiotherapy for the treatment of various neoplasms.. nimustine : An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-amino-2-methylpyrimidin-5-ylmethyl] group. An antineoplastic agent especially effective against malignant brain tumors.		2.0710aminopyrimidine;
N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
1-methyl-4-phenylpyridinium
1-Methyl-4-phenylpyridinium: An active neurotoxic metabolite of 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE. The compound reduces dopamine levels, inhibits the biosynthesis of catecholamines, depletes cardiac norepinephrine and inactivates tyrosine hydroxylase. These and other toxic effects lead to cessation of oxidative phosphorylation, ATP depletion, and cell death. The compound, which is related to PARAQUAT, has also been used as an herbicide.. N-methyl-4-phenylpyridinium : A pyridinium ion that is N-methylpyridinium having a phenyl substituent at the 4-position.		2.0410pyridinium ionapoptosis inducer;
herbicide;
human xenobiotic metabolite;
neurotoxin
lonidamine
lonidamine: structure. lonidamine : A member of the class of indazoles that is 1H-indazole that is substituted at positions 1 and 3 by 2,4-dichlorobenzyl and carboxy groups, respectively.		2.0810dichlorobenzene;
indazoles;
monocarboxylic acid		antineoplastic agent;
antispermatogenic agent;
EC 2.7.1.1 (hexokinase) inhibitor;
geroprotector
vecuronium bromide
Vecuronium Bromide: Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.. vecuronium bromide : The organic bromide salt of a 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidinino- and 16beta-N-methylpiperidinium substituents.		2.4620organic bromide salt;
quaternary ammonium salt		muscle relaxant;
neuromuscular agent;
nicotinic antagonist
vecuronium
vecuronium : A 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidino- and 16beta-N-methylpiperidinium substituents.		3.2310acetate ester;
androstane;
quaternary ammonium ion		drug allergen;
muscle relaxant;
neuromuscular agent;
nicotinic antagonist
ng-nitroarginine methyl ester
NG-Nitroarginine Methyl Ester: A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.		2.4420alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor
dexibuprofen
dexibuprofen: structure in first source		2.0310ibuprofennon-narcotic analgesic;
non-steroidal anti-inflammatory drug
benoxaprofen
benoxaprofen: RN given refers to parent cpd; structure. benoxaprofen : A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group. It was used as a non-steroidal anti-inflammatory drug until 1982 when it was withdrawn from the market due to adverse side-effects including liver necrosis, photosensitivity, and carcinogenicity in animals.		3.86301,3-benzoxazoles;
monocarboxylic acid;
monochlorobenzenes		antipsoriatic;
antipyretic;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
hepatotoxic agent;
nephrotoxin;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
protein kinase C agonist
permethrin
hemoglobin Atlanta-Coventry: Leu replaced by Pro at beta75 and Leu deleted at beta141		2.4620cyclopropanecarboxylate ester;
cyclopropanes		agrochemical;
ectoparasiticide;
pyrethroid ester acaricide;
pyrethroid ester insecticide;
scabicide
exifone
[no description available]		3.2310benzophenones
pirfenidone
pirfenidone : A pyridone that is 2-pyridone substituted at positions 1 and 5 by phenyl and methyl groups respectively. An anti-inflammatory drug used for the treatment of idiopathic pulmonary fibrosis.		2.5220pyridoneantipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
mefloquine
(-)-(11S,2'R)-erythro-mefloquine : An optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (-)-(11S,2'R)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown.		4.2220[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanolantimalarial
vindesine
Vindesine: Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).		3.511methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
primary carboxamide;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent
desogestrel
Desogestrel: A synthetic progestational hormone used often as the progestogenic component of combined oral contraceptive agents (ORAL CONTRACEPTIVES, COMBINED).		2.051017beta-hydroxy steroid;
terminal acetylenic compound		contraceptive drug;
progestin;
synthetic oral contraceptive
flecainide acetate
flecainide acetate : An acetate salt obtained by combining flecainide with one molar equivalent of acetic acid. An antiarrhythmic agent used to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).		2.0510acetate saltanti-arrhythmia drug
meptazinol
Meptazinol: A narcotic antagonist with analgesic properties. It is used for the control of moderate to severe pain.		2.0410azepanes
nicardipine hydrochloride
[no description available]		2.0510dihydropyridinegeroprotector
muzolimine
Muzolimine: A pyrazole diuretic with long duration and high capacity of action. It was proposed for kidney failure and hypertension but was withdrawn worldwide because of severe neurological effects.		2.0510dichlorobenzene
nitazoxanide
nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug		3.8530benzamides;
carboxylic ester
sufentanil
Sufentanil: An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.. sufentanil : An anilide resulting from the formal condensation of the aryl amino group of 4-(methoxymethyl)-N-phenyl-1-[2-(2-thienyl)ethyl]piperidin-4-amine with propanoic acid.		3.5820anilide;
ether;
piperidines;
thiophenes		anaesthesia adjuvant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
acarbose
[no description available]		3.6120tetrasaccharide derivativeEC 3.2.1.1 (alpha-amylase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
geroprotector;
hypoglycemic agent
torsemide
Torsemide: A pyridine and sulfonamide derivative that acts as a sodium-potassium chloride symporter inhibitor (loop diuretic). It is used for the treatment of EDEMA associated with CONGESTIVE HEART FAILURE; CHRONIC RENAL INSUFFICIENCY; and LIVER DISEASES. It is also used for the management of HYPERTENSION.. torasemide : An N-sulfonylurea obtained by formal condensation of [(3-methylphenyl)amino]pyridine-3-sulfonic acid with the free amino group of N-isopropylurea. It is a potent loop diuretic used for the treatment of hypertension and edema in patients with congestive heart failure.		3.8530aminopyridine;
N-sulfonylurea;
secondary amino compound		antihypertensive agent;
loop diuretic
medroxalol
medroxalol: RN given refers to parent cpd without isomeric designation		2.0410salicylamides
epirubicin
Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.		6.9683aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
cefmetazole
Cefmetazole: A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.. cefmetazole : A second-generation cephalosporin antibiotic having N(1)-methyltetrazol-5-ylthiomethyl, {[(cyanomethyl)sulfanyl]acetyl}amino and methoxy side-groups at positions 3, 7beta and 7alpha respectively of the parent cephem bicyclic structure.		2.0410cephalosporinantibacterial drug
desflurane
Desflurane: A fluorinated ether that is used as a volatile anesthetic for maintenance of general anesthesia.		2.0510organofluorine compoundinhalation anaesthetic
indacrinone
indacrinone: polyvalent saluretic; RN given refers to parent cpd without isomeric designation; structure		2.0510
lorcainide
[no description available]		2.7530acetamides
idarubicin
Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.		4.0740anthracycline antibiotic;
deoxy hexoside;
monosaccharide derivative
eniluracil
eniluracil: structure in first source; inactivates dihydropyrimidine dehydrogenase		2.2510pyrimidone
ceforanide
ceforanide: RN given refers to (6R-(trans))-isomer. ceforanide : A second-generation cephalosporin antibiotic with {[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and 2-(aminomethyl)phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is effective against many coliforms, including Escherichia coli, Klebsiella, Enterobacter and Proteus, and most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.		2.0410cephalosporinantibacterial drug
piperacillin
Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.		3.8630penicillin allergen;
penicillin		antibacterial drug
paroxetine
Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.		4.4260aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines		antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
triciribine phosphate
[no description available]		2.1510
captopril
Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.		4.4160alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cefoperazone
Cefoperazone: Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections.. cefoperazone : A semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance.		3.8630cephalosporinantibacterial drug
staurosporine
[no description available]		5.66170indolocarbazole alkaloid;
organic heterooctacyclic compound		apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector
foscarnet sodium
trisodium phosphonoformate : The trisodium salt of phosphonoformic acid. It is used as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.		2.4720one-carbon compound;
organic sodium salt		antiviral drug
4-(n-methyl-n-nitrosamino)-1-(3-pyridyl)-1-butanone
4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone: structure; from tobacco smoke		2.4720nitrosamine;
pyridines
atracurium
Atracurium: A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.. atracurium : A diester compound consisting of pentane-1,5-diol with both hydroxyls bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups.		3.5820diester;
quaternary ammonium ion		muscle relaxant;
nicotinic antagonist
atracurium besylate
atracurium besylate : The bisbenzenesulfonate salt of atracurium.		2.0810organosulfonate salt;
quaternary ammonium salt		muscle relaxant;
nicotinic antagonist
butoconazole nitrate
butoconazole nitrate : An organic nitrate salt obtained by reaction of equimolar amounts of butaconazole and nitric acid. An antifungal agent, it is used in gynaecology for treatment of vulvovaginal infections caused by Candida species, particularly Candida albicans.		2.0510aryl sulfide;
conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
organic nitrate salt
moxalactam
Moxalactam: Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.. moxalactam : A broad-spectrum oxacephem antibiotic in which the oxazine ring is substituted with a tetrazolylthiomethyl group and the azetidinone ring carries methoxy and 2-carboxy-2-(4-hydroxyphenyl)acetamido substituents.		2.4520cephalosporin;
oxacephem		antibacterial drug
nicorandil
Nicorandil: A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase.. nicorandil : A pyrimidinecarboxamide that is nicotinamide in which one of the hydrogens attached to the carboxamide nitrogen is replaced by a 2-(nitrooxy)ethyl group. It has both nitrate-like and ATP-sensitive potassium channel activator properties, and is used for the prevention and treatment of angina pectoris.		2.4720nitrate ester;
pyridinecarboxamide		potassium channel opener;
vasodilator agent
endralazine
BQ 22-708: RN given refers to parent cpd		2.4420benzamides
pergolide
Pergolide: A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.. pergolide : A diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.		3.2310diamine;
methyl sulfide;
organic heterotetracyclic compound		antiparkinson drug;
dopamine agonist
pergolide mesylate
pergolide mesylate : A methanesulfonate salt obtained from pergolide by mixing eqimolar amount of pergolide and methanesulfonic acid. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.		2.0810methanesulfonate saltantiparkinson drug;
dopamine agonist;
geroprotector
cefadroxil anhydrous
Cefadroxil: Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.. cefadroxil : A cephalosporin bearing methyl and (2R)-2-amino-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		4.4160cephalosporinantibacterial drug
encainide
Encainide: One of the ANTI-ARRHYTHMIA AGENTS, it blocks VOLTAGE-GATED SODIUM CHANNELS and slows conduction within the His-Purkinje system and MYOCARDIUM.. encainide : 4-Methoxy-N-phenylbenzamide in which the hydrogen at the 2 position of the phenyl group is substituted by a 2-(1-methylpiperidin-2-yl)ethyl group. A class Ic antiarrhythmic, the hydrochloride was used for the treatment of severe or life-threatening ventricular arrhythmias, but it was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack and was withdrawn from the market.		2.7530benzamides;
piperidines		anti-arrhythmia drug;
sodium channel blocker
talniflumate
talniflumate: an anti-inflammatory molecule for the treatment of cystic fibrosis, chronic obstructive pulmonary disease and asthma		2.0810benzofurans
fenoldopam mesylate
[no description available]		2.0810benzazepine
triclabendazole
[no description available]		2.0510aromatic ether
fialuridine
[no description available]		3.5920
cefaclor anhydrous
Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.. cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		4.0840cephalosporinantibacterial drug;
drug allergen
pefloxacin
Pefloxacin: A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.. pefloxacin : A quinolone that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6 and 7 by ethyl, carboxy, fluorine, and 4-methylpiperazin-1-yl groups, respectively.		2.7530fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
N-arylpiperazine;
quinolone antibiotic;
quinolone		antibacterial drug;
antiinfective agent;
DNA synthesis inhibitor
mitoxantrone hydrochloride
[no description available]		2.0510hydrochlorideantineoplastic agent
pirazolac
[no description available]		2.0310
alfentanil
Alfentanil: A short-acting opioid anesthetic and analgesic derivative of FENTANYL. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.. alfentanil : A member of the class of piperidines that is piperidine having a 2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl group at the 1-position as well as N-phenylpropanamido- and methoxymethyl groups at the 4-position.		3.8630monocarboxylic acid amide;
piperidines		central nervous system depressant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
peripheral nervous system drug
miglustat
miglustat: a glucosylceramide synthase inhibitor. miglustat : A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group.		3.5920piperidines;
tertiary amino compound		anti-HIV agent;
EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
haloperidol decanoate
[no description available]		3.2310organic molecular entity
cefotetan
Cefotetan: A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.. cefotetan : A semi-synthetic second-generation cephamycin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl, methoxy and {[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino groups at the 3, 7alpha, and 7beta positions, respectively, of the cephem skeleton. It is resistant to a wide range of beta-lactamases and is active against a broad spectrum of aerobic and anaerobic Gram-positive and Gram-negative microorganisms.		4.4260
recainam
recainam: structure given in first source		2.0410
lovastatin
Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).		5.17140delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
flupirtine
flupirtine: RN given refers to parent cpd without isomeric designation		2.7530aminopyridine
tolrestat
tolrestat: RN & structure given in first source		3.5920naphthalenesEC 1.1.1.21 (aldehyde reductase) inhibitor
rimcazole
rimcazole: RN given refers to (cis)-isomer; structure given in first source		2.0810carbazoles
enoximone
Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.		2.9740aromatic ketone
stepronin
[no description available]		2.0810N-acyl-amino acid
piritrexim
piritrexim: RN given refers to parent cpd; structure given in first source		2.0510
simvastatin
Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.		7.63161delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug
idazoxan
Idazoxan: A benzodioxane-linked imidazole that has alpha-2 adrenoceptor antagonist activity.. idazoxan : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group.		2.7530benzodioxine;
imidazolines		alpha-adrenergic antagonist
remoxipride
Remoxipride: An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.		2.7530dimethoxybenzene
balsalazide
balsalazide: a mesalamine 5-aminosalicylate prodrug; 99% of ingested drug remains intact through the stomach and is delivered to and activated in the colon; used for inflammatory bowel disease, ulcerative colitis and radiation-induced proctosigmoiditis but avoided in patients with known hypersensitivity reaction to salicylates or mesalamine; structure in first source. balsalazide : A monohydroxybenzoic acid consisting of 5-aminosalicylic acid (mesalazine) linked to 4-aminobenzoyl-beta-alanine via an azo bond.		3.2310
pravastatin
Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.		4.41603-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic)		anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic
cabergoline
Cabergoline: An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.. cabergoline : An N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia.		5.3530N-acylureaantineoplastic agent;
antiparkinson drug;
dopamine agonist
bambuterol
bambuterol: selective inhibitor of butyrylcholinesterase & acetylcholinesterase. bambuterol : A carbamate ester that is terbutaline in which both of the phenolic hydroxy groups have been protected as the corresponding N,N-dimethylcarbamates. A long acting beta-adrenoceptor agonist used in the treatment of asthma, it is a prodrug for terbutaline.		2.4520carbamate ester;
phenylethanolamines		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
prodrug;
sympathomimetic agent;
tocolytic agent
atomoxetine hydrochloride
Atomoxetine Hydrochloride: A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.. atomoxetine hydrochloride : The hydrochloride salt of atomoxetine.		2.7430hydrochlorideadrenergic uptake inhibitor;
antidepressant
atomoxetine
atomoxetine : A secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.		4.4160aromatic ether;
secondary amino compound;
toluenes		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
xenobiotic
quinapril
Quinapril: A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE.. quinapril : A member of the class of isoquinolines that is (3S)-2-L-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in which the alpha-amino group of the alanyl residue has been substituted by a 1-ethoxycarbonyl-4-phenylbutan-2-yl group (the all-S isomer). A prodrug for quinaprilat (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) used (generally as the hydrochloride salt) for the treatment of hypertension and congestive heart failure.		4.0940dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
alpidem
[no description available]		3.8830imidazoles
raloxifene hydrochloride
Raloxifene Hydrochloride: A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.. raloxifene hydrochloride : A hydrochloride salt resulting from the reaction of equimolar amounts of raloxifene and hydrogen chloride.		2.520hydrochloridebone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
eproxindine
eproxindine: structure given in first source		2.0310
gepirone
gepirone: RN given refers to parent cpd; structure given in first source		2.0510N-arylpiperazine
mifepristone
Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.		4.29503-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound		abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive
itraconazole
Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.. itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.		9.7132aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles		EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor
trospectomycin
trospectomycin: active against Neisseria gonorrhoeae; RN refers to 2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9beta,9alpha,9aalpha,10abeta)-(9CI)-isomer		2.0410dioxanes
(S)-nomifensine
(S)-nomifensine : The S enantiomer of nomifensine.		2.0310nomifensine
fosphenytoin
fosphenytoin: structure given in first & second source		3.2310imidazolidine-2,4-dione
pravadoline
[no description available]		2.0810
salmeterol xinafoate
Salmeterol Xinafoate: A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.		2.0810naphthoic acid
ranolazine
Ranolazine: An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS.. N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide : An aromatic amide obtained by formal condensation of the carboxy group of 2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetic acid with the amino group of 2,6-dimethylaniline.. ranolazine : A racemate comprising equal amounts of (R)- and (S)-ranolazine. Used for treatment of chronic angina.		3.6120aromatic amide;
monocarboxylic acid amide;
monomethoxybenzene;
N-alkylpiperazine;
secondary alcohol
finasteride
Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.		4.27503-oxo steroid;
aza-steroid;
delta-lactam		androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
imiquimod
Imiquimod: A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.. imiquimod : An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.		3.5520imidazoquinolineantineoplastic agent;
interferon inducer
sematilide
sematilide: RN refers to HCl; structure given in first source		2.0410
esmolol
methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate : A methyl ester that is methyl 3-(4-hydroxyphenyl)propanoate in which the hydrogen attached to the phenolic hydroxy group is substituted by a 2-hydroxy-3-(isopropylamino)propyl group.. esmolol : A racemate comprising equimolar amounts of (R)- and (S)-esmolol. A cardioselective and short-acting beta1 receptor blocker with rapid onset but lacking intrinsic sympathomimetic and membrane-stabilising properties, it is used as the hydrochloride salt in the management of supraventricular arrhythmias, and for the control of hypertension and tachycardia during surgery. While the S enantiomer possesses all of the heart rate control, both enantiomers contribute to lowering blood pressure.		3.5820aromatic ether;
ethanolamines;
methyl ester;
secondary alcohol;
secondary amino compound
temafloxacin
temafloxacin: structure given in first source. temafloxacin : A racemate comprising equimolar amounts of (R)- and (S)-temafloxacin. Both enantiomers both exhibit similar pharmacological profiles. Temafloxacin was briefly used (either as the free base or as the hydrochloride salt) as an antibacterial drug but was withdrawn worldwide in 1992 following reports of serious side effects, including severe hypoglycaemia, haemolytic anaemia, liver and kidney dysfunction, anaphylaxis, and death.. 1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid : A quinolone that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted at positions 1, 6, and 7 by 2,4-difluorophenyl, fluorine, and 3-methylpiperazin-1-yl groups, respectively.		2.0510amino acid;
monocarboxylic acid;
N-arylpiperazine;
organofluorine compound;
quinolone antibiotic;
quinolone;
secondary amino compound;
tertiary amino compound
(2S)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid
[no description available]		2.0310phenylalanine derivative
clinafloxacin
clinafloxacin: structure given in first source; RN given is for monoHCl		2.4520quinolines
sertindole
sertindole : A phenylindole that is 1H-indole which is substituted on the nitrogen by a p-chlorophenyl group, at position 5 by chlorine, and at position 3 by a piperidin-4-yl group, which is itself substituted on the nitrogen by a 2-(2-oxoimidazolidin-1-yl)ethyl group.		2.0810heteroarylpiperidine;
imidazolidinone;
organochlorine compound;
organofluorine compound;
phenylindole		alpha-adrenergic antagonist;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic antagonist
adapalene
Adapalene: A naphthalene derivative that has specificity for RETINOIC ACID RECEPTORS. It is used as a DERMATOLOGIC AGENT for the treatment of ACNE.. adapalene : A naphthoic acid that is CD437 in which the phenolic hydroxy group has been converted to its methyl ether.		2.0810adamantanes;
monocarboxylic acid;
naphthoic acid		dermatologic drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
non-steroidal anti-inflammatory drug
adefovir
adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.		3.85306-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent
loxiglumide
loxiglumide: cholecystokinin receptor antagonist; RN refers to (+-)-isomer; structure in first source		2.0410organic molecular entity
aromasil
[no description available]		5.526017-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor;
environmental contaminant;
xenobiotic
sparfloxacin
[no description available]		2.9740fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone
zileuton
[no description available]		4.44601-benzothiophenes;
ureas		anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug
niguldipine
[no description available]		2.4720diarylmethane
clopidogrel
Clopidogrel: A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.. clopidogrel : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks.		3.5920methyl ester;
monochlorobenzenes;
thienopyridine		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
cidofovir anhydrous
Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.		4.0840phosphonic acids;
pyrimidone		anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent
tiagabine
Tiagabine: A nipecotic acid derivative that acts as a GABA uptake inhibitor and anticonvulsant agent. It is used in the treatment of EPILEPSY, for refractory PARTIAL SEIZURES.. tiagabine : A piperidinemonocarboxylic acid that is (R)-nipecotic acid in which the hydrogen attached to the nitrogen has been replaced by a 1,1-bis(3-methyl-2-thienyl)but-1-en-4-yl group. A GABA reuptake inhibitor, it is used (generally as the hydrochloride salt) for the treatment of epilepsy.		3.8530beta-amino acid;
piperidinemonocarboxylic acid;
tertiary amino compound;
thiophenes		anticonvulsant;
GABA reuptake inhibitor
mibefradil
Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.		2.9840tetralinsT-type calcium channel blocker
topotecan
Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.		5.95190pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
eliprodil
1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol : A member of the class of piperidines that is piperidine substituted by a 2-(4-chlorophenyl)-2-hydroxyethyl group at position 1 and by a 4-fluorobenzyl group at position 4.		2.0810monochlorobenzenes;
monofluorobenzenes;
piperidines;
secondary alcohol;
tertiary amino compound
bromfenac
bromfenac: bromfenac sodium is the active cpd; structure in first source. bromfenac : Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure.		4.2650aromatic amino acid;
benzophenones;
organobromine compound;
substituted aniline		non-narcotic analgesic;
non-steroidal anti-inflammatory drug
gemcitabine hydrochloride
[no description available]		2.0810hydrochloride;
organofluorine compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral drug;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
immunosuppressive agent;
radiosensitizing agent
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		16.337724organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
ibutilide
ibutilide: RN & structure in first source; RN refers to the fumarate salt		3.5820benzenes;
organic amino compound
aripiprazole
Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.		3.8730aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone		drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist
remifentanil
Remifentanil: A piperidine-propionate derivative and opioid analgesic structurally related to FENTANYL. It functions as a short-acting MU OPIOID RECEPTOR agonist, and is used as an analgesic during induction or maintenance of general anesthesia, following surgery, during childbirth, and in mechanically ventilated patients under intensive care.. remifentanil : A piperidinecarboxylate ester that is methyl piperidine-4-carboxylate in which the hydrogen attached to the nitrogen is substituted by a 3-methoxy-3-oxopropyl group and the hydrogen at position 4 is substituted the nitrogen of N-propanoylaniline.		3.5820alpha-amino acid ester;
anilide;
monocarboxylic acid amide;
piperidinecarboxylate ester		intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
sedative
atorvastatin calcium anhydrous
[no description available]		2.0810organic calcium salt
atorvastatin
[no description available]		10.390aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic)		environmental contaminant;
xenobiotic
lamivudine
[no description available]		4.4160monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
duloxetine hydrochloride
Duloxetine Hydrochloride: A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.. (S)-duloxetine hydrochloride : A duloxetine hydrochloride in which the duloxetine moiety has S configuration.		2.0810duloxetine hydrochlorideantidepressant
duloxetine
[no description available]		3.8730duloxetine
irinotecan
[no description available]		13.366013carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
valsartan
Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.		4.2650biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
ibandronic acid
Ibandronic Acid: Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.		3.5820
ziprasidone
ziprasidone: a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone. ziprasidone : A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.		3.85301,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines		antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist
zanamivir
Zanamivir: A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.		2.0410guanidinesantiviral agent;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
zolmitriptan
zolmitriptan: an antimigraine compound; a serotonin (5HT)-1D receptor agonist. zolmitriptan : A member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine.		4.0840oxazolidinone;
tryptamines		anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
adefovir dipivoxil
bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine: structure given in first source. adefovir pivoxil : An organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection.		2.47206-aminopurines;
carbonate ester;
ether;
organic phosphonate		antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug
emtricitabine
Emtricitabine: A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.. emtricitabine : An organofluorine compound that is 5-fluorocytosine substituted at the 1 position by a 2-(hydroxymethyl)-1,3-oxathiolan-5-yl group (2R,5S configuration). It is used in combination therapy for the treatment of HIV-1 infection.		3.8630monothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
tasosartan
tasosartan: angiotensin II antagonist; structure given in first source		3.5920biphenyls
saquinavir monomethanesulfonate
[no description available]		2.0510organic molecular entity
tiludronic acid
tiludronic acid: a bone resorption inhibitor; an antihypercalcemic agent; used in the tratment of Paget's disease; used in the treatment and prevention of osteoporosis; structure given in first source		3.2310organochlorine compound
tirofiban
Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME.. tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group.		3.5820L-tyrosine derivative;
piperidines;
sulfonamide		anticoagulant;
fibrin modulating drug;
platelet glycoprotein-IIb/IIIa receptor antagonist
capecitabine
Capecitabine: A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.. capecitabine : A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers.		11.22236carbamate ester;
cytidines;
organofluorine compound		antimetabolite;
antineoplastic agent;
prodrug
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		4.2950adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
allyl formate
[no description available]		2.0510
acridine orange
Acridine Orange: A cationic cytochemical stain specific for cell nuclei, especially DNA. It is used as a supravital stain and in fluorescence cytochemistry. It may cause mutations in microorganisms.. acridine orange : Fluorescent dye useful for cell cycle determination. It is cell-permeable, and interacts with DNA and RNA by intercalation or electrostatic attractions respectively.. acridine orange free base : A member of the class of aminoacridines that is acridine carrying two dimethylamino substituents at positions 3 and 6. The hydrochloride salt is the fluorescent dye 'acridine orange', used for cell cycle determination.		2.110aminoacridines;
aromatic amine;
tertiary amino compound		fluorochrome;
histological dye
benzylaminopurine
benzylaminopurine: a plant growth regulator. N-benzyladenine : A member of the class of 6-aminopurines that is adenine in which one of the hydrogens of the amino group is replaced by a benzyl group.		2.05106-aminopurinescytokinin;
plant metabolite
caloreen
caloreen: glucose polymer with average length of five glucose units for dietary energy supplement. dextrin : Glucans produced by the hydrolysis of starch or glycogen. They are mixtures of polymers of D-glucose units linked by alpha(1->4) or alpha(1->6) glycosidic bonds.		2.0510
pipothiazine
pipothiazine: was heading 1975-94 (see under PHENOTHIAZINE TRANQUILIZERS 1975-90); use PHENOTHIAZINES to search PIPOTHIAZINE 1975-94; a member of the family of phenothiazine tranquilizers		2.0310
paroxetine hydrochloride
paroxetine hydrochloride : The hydrochloride salt of paroxetine. It is an antidepressant drug.		2.0810hydrochlorideantidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
desferrioxamine b mesylate
desferrioxamine B mesylate : A methanesulfonate salt obtained by reaction of desferrioxamine B with one molar equivalent of methanesulfonic acid. It is an iron-chelating medicine used to remove excess iron from the body. It binds to iron in the blood, which is then passed out in the urine.		2.0510methanesulfonate saltantidote;
ferroptosis inhibitor;
iron chelator
bupropion hydrochloride
[no description available]		2.4720aromatic ketone
cisatracurium
cisatracurium: RN refers to (1R-(1alpha,2alpha(1'R*,2'R*)))-isomer. cisatracurium : A diester that is the (1R,1'R,2R,2'R)-diastereoisomer of atracurium, a quaternary ammonium ion consisting of pentane-1,5-diol with both hydroxy functions bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups. The active species in the skeletal muscle relaxant cisatracurium besylate.		2.0410diester;
quaternary ammonium ion		muscle relaxant;
nicotinic antagonist
halofuginone
[no description available]		2.0510quinazolines
diltiazem hydrochloride
Carex: fluoride (1.8%) containing varnish; no further information available 8/91. diltiazem hydrochloride : A hydrochloride salt resulting from the reaction of equimolar amounts of diltiazem and hydrogen chloride. A calcium-channel blocker and vasodilator, it is used in the management of angina pectoris and hypertension.		2.0510hydrochlorideantihypertensive agent;
calcium channel blocker;
vasodilator agent
trazodone hydrochloride
Triticum: A plant genus of the family POACEAE that is the source of EDIBLE GRAIN. A hybrid with rye (SECALE CEREALE) is called TRITICALE. The seed is ground into FLOUR and used to make BREAD, and is the source of WHEAT GERM AGGLUTININS.. trazodone hydrochloride : A hydrochloride salt prepared from equimolar amounts of trazodone and hydrogen chloride.		2.4720hydrochlorideadrenergic antagonist;
antidepressant;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
fosinoprilat
fosinoprilat: active phosphinic acid metabolite of prodrug fosenopril, which is activated by esterases in vivo; structure given in first source; binds zinc with phosphinic acid group. fosinoprilat : A phosphinic acid-containing N-acyl derivative of (4S)-cyclohexyl-L-proline. An inhibitor of angiotensin converting enzyme (ACE), it is used as the phosphinate ester pro-drug fosinopril for treatment of hypertension and chronic heart failure.		2.0410L-proline derivative;
phosphinic acids		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
ortho-cept
ethinyl estradiol-desogestrel combination: Ethinyl Estradiol and Desogestrell given in fixed proportions; has proved to be an effective & well-tolerated oral contraceptive, which improves cycle control & has a beneficial effect on acne		2.0510
trovafloxacin
trovafloxacin: a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity. trovafloxacin : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.		3.8630
verapamil hydrochloride
verapamil hydrochloride : A racemate comprising equimolar amounts of dexverapamil hydrochloride and (S)-verapamil hydrochloride.		2.4720
cefprozil
[no description available]		3.8630cephalosporin;
semisynthetic derivative		antibacterial drug
doxazosin mesylate
Cardura: Trade name in United States.		2.0810methanesulfonate saltgeroprotector
ciprofloxacin hydrochloride anhydrous
[no description available]		2.0510hydrochlorideantibacterial drug;
antiinfective agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
[no description available]		2.520stilbenoid
efavirenz
efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.		4.9660acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
nelfinavir
Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.		5.280aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound		antineoplastic agent;
HIV protease inhibitor
amantadine hydrochloride
[no description available]		2.0510hydrochlorideantiviral agent;
dopamine agonist;
NMDA receptor antagonist
doxapram hydrochloride
[no description available]		2.0510hydrochloridecentral nervous system stimulant
mevastatin
mevastatin: antifungal metabolite from Penicillium brevicopactum; potent inhibitory activity to sterol synthesis; structure. mevastatin : A carboxylic ester that is pravastatin that is lacking the allylic hydroxy group. A hydroxymethylglutaryl-CoA reductase inhibitor (statin) isolated from Penicillium citrinum and from Penicillium brevicompactum, its clinical use as a lipid-regulating drug ceased following reports of toxicity in animals.		2.08102-pyranones;
carboxylic ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		antifungal agent;
apoptosis inducer;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
fungal metabolite;
Penicillium metabolite
bupivacaine hydrochloride
bupivacaine hydrochloride (anhydrous) : A racemate composed of equimolar amounts of dextrobupivacaine hydrochloride and levobupivacaine hydrochloride. The monohydrate form is commonly used as a local anaesthetic.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrochloride : A hydrochloride obtained by combining 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide with one molar equivalent of hydrochloric acid.		2.0810hydrochloride;
racemate		adrenergic antagonist;
amphiphile;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
local anaesthetic
fenofibric acid
fenofibric acid: RN given refers to parent cpd without isomeric designation; structure. fenofibric acid : A monocarboxylic acid that is 2-methylpropanoic acid substituted by a 4-(4-chlorobenzoyl)phenoxy group at position 2. It is a metabolite of the drug fenofibrate.		3.6320aromatic ketone;
chlorobenzophenone;
monocarboxylic acid		drug metabolite;
marine xenobiotic metabolite
ursolic acid
[no description available]		2.1110hydroxy monocarboxylic acid;
pentacyclic triterpenoid		geroprotector;
plant metabolite
n-methylnicotinamide
N-methylnicotinamide: structure. N-methylnicotinamide : A pyridinecarboxamide that is nicotinamide in which one of the amide hydrogens is substituted by a methyl group.		2.0410pyridinecarboxamidemetabolite
1,5-anhydroglucitol
1,5-anhydroglucitol: structure. 1,5-anhydro-D-glucitol : An anhydro sugar of D-glucitol.		2.0510anhydro sugarhuman metabolite
norharman
norharman: RN given refers to parent cpd. beta-carboline : The parent compound of the beta-carbolines, a tricyclic structure comprising an indole ring system ortho- fused to C-3 and C-4 of a pyridine ring.		2.0610beta-carbolines;
mancude organic heterotricyclic parent		fungal metabolite;
marine metabolite
thiazolyl blue
thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.		2.9440organic bromide saltcolorimetric reagent;
dye
betulinic acid
[no description available]		2.0510hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
arctigenin
arctigenin: precursor to catechols; in many plants		2.0310lignan
baicalin
[no description available]		4.9621dihydroxyflavone;
glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative		antiatherosclerotic agent;
antibacterial agent;
anticoronaviral agent;
antineoplastic agent;
antioxidant;
cardioprotective agent;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
ferroptosis inhibitor;
neuroprotective agent;
non-steroidal anti-inflammatory drug;
plant metabolite;
prodrug
plerixafor
plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.		4.1340azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound		anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant
amprenavir
[no description available]		4.9660carbamate ester;
sulfonamide;
tetrahydrofuryl ester		antiviral drug;
HIV protease inhibitor
oseltamivir
Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.		3.8930acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic
epigallocatechin gallate
epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.		2.8530flavans;
gallate ester;
polyphenol		antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite
25-hydroxycholesterol
[no description available]		2.131025-hydroxy steroid;
oxysterol		human metabolite
aica ribonucleotide
AICA ribonucleotide: purine precursor that has antineoplastic activity. AICA ribonucleotide : A 1-(phosphoribosyl)imidazolecarboxamide that is acadesine in which the hydroxy group at the 5' position has been converted to its monophosphate derivative.		2.54201-(phosphoribosyl)imidazolecarboxamide;
aminoimidazole		cardiovascular drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
dobutamine hydrochloride
dobutamine hydrochloride : The hydrochloride salt of dobutamine. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used to increase the contractility of the heart in the management of acute heart failure.		2.0510hydrochloridebeta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent
ticlopidine hydrochloride
[no description available]		2.0810hydrochloride
epirubicin hydrochloride
[no description available]		2.0810
pyrrolidine dithiocarbamate
pyrrolidine dithiocarbamic acid: spelled pyrolidine in J Nutr 1979 reference; RN given refers to parent cpd. pyrrolidine dithiocarbamate : A member of the class of dithiocarbamic acids that is the N-dithiocarboxy derivative of pyrrolidine.		7.1510dithiocarbamic acids;
pyrrolidines		anticonvulsant;
antineoplastic agent;
geroprotector;
neuroprotective agent;
NF-kappaB inhibitor;
radical scavenger
glutathione disulfide
Glutathione Disulfide: A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.		2.4520glutathione derivative;
organic disulfide		Escherichia coli metabolite;
mouse metabolite
iopamidol
Iopamidol: A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures.. iopamidol : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a (2S)-2-hydroxypropanamido group at the 5-position.		2.4520benzenedicarboxamide;
organoiodine compound;
pentol		environmental contaminant;
radioopaque medium;
xenobiotic
sulconazole, mononitrate, (+-)-isomer
[no description available]		2.0510conazole antifungal drug;
imidazole antifungal drug;
organic nitrate salt
histamine phosphate
histamine phosphate : A phosphate salt that is the diphosphate salt of histamine.		3.2310phosphate salthistamine agonist
imipramine n-oxide
imipramine N-oxide: RN given refers to parent cpd; structure		2.0410dibenzooxazepine
tilbroquinol
[no description available]		3.2310organohalogen compound;
quinolines
bendamustine
[no description available]		4.1240benzimidazoles
erdosteine
[no description available]		2.0510N-acyl-amino acid
droxicam
droxicam: structure given in first source. droxicam : An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respectively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.		3.2310organic heterotricyclic compound;
pyridines		cyclooxygenase 1 inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor;
prodrug
caroverine
caroverine: structure		2.0810quinoxaline derivative
ebrotidine
ebrotidine: an H2-receptor antagonist and gastric mucosa protector		3.2310sulfonamide
mizolastine
[no description available]		2.0510benzimidazoles
cgs 9343b
[no description available]		2.0810benzimidazoles
dexloxiglumide
dexloxiglumide: a CCK receptor antagonist; structure given in first source		2.0410glutamic acid derivative
intoplicine
intoplicine: structure in first source		2.4520pyridoindole
pazufloxacin
[no description available]		2.0810quinolines
repaglinide
[no description available]		4.2650piperidines
telmisartan
Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.		5.390benzimidazoles;
biphenyls;
carboxybiphenyl		angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic
dexfenfluramine
Dexfenfluramine: The S-isomer of FENFLURAMINE. It is a serotonin agonist and is used as an anorectic. Unlike fenfluramine, it does not possess any catecholamine agonist activity.. (S)-fenfluramine : The S-enantiomer of fenfluramine. It stimulates the release of serotonin and selectively inhibits its reuptake, but unlike fenfluramine it does not possess catecholamine agonist activity. It was formerly given by mouth as the hydrochloride in the treatment of obesity, but, like fenfluramine, was withdrawn wolrdwide following reports of valvular heart defects.		2.7330fenfluramineappetite depressant;
serotonergic agonist;
serotonin uptake inhibitor
2-methoxyestradiol
2-methoxy-17beta-estradiol : A 17beta-hydroxy steroid, being 17beta-estradiol methoxylated at C-2.		2.472017beta-hydroxy steroid;
3-hydroxy steroid		angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite
ethinyl estradiol-17-sulfate
ethinyl estradiol-17-sulfate: RN given refers to the (17alpha)-isomer		2.0410
1,7-phenanthroline
[no description available]		2.1310phenanthroline
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		11.652071,2,3-triazole
trimethobenzamide monohydrochloride
[no description available]		2.0510
amiloride hydrochloride
amiloride hydrochloride dihydrate : A hydrate that is the dihydrate of amiloride hydrochloride.		2.0510hydratediuretic;
sodium channel blocker
miconazole nitrate
miconazole nitrate : A racemate composed of equimolar amounts of (R)- and (S)-miconazole nitrate. An antifungal used for the treatment of athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.		2.0810
ethinylestradiol-3-sulfate
ethinylestradiol-3-sulfate: binds to albumin at 2 sites		2.041017beta-hydroxy steroid;
steroid sulfate		antineoplastic agent;
estrogen
econazole nitrate
econazole nitrate : A racemate composed of equimolar amounts of (R)- and (S)-econazole nitrate. Used to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections.		2.0510
medetomidine
Medetomidine: An agonist of RECEPTORS, ADRENERGIC ALPHA-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of DEXMEDETOMIDINE.		2.0510imidazoles
fluorodeoxyglucose f18
Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)		8.651622-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose
sertraline
Sertraline: A selective serotonin uptake inhibitor that is used in the treatment of depression.. sertraline : A member of the class of tetralins that is tetralin which is substituted at positions 1 and 4 by a methylamino and a 3,4-dichlorophenyl group, respectively (the S,S diastereoisomer). A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as the hydrochloride salt as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder.		4.0940dichlorobenzene;
secondary amino compound;
tetralins		antidepressant;
serotonin uptake inhibitor
lomefloxacin hydrochloride
lomefloxacin hydrochloride : The hydrochloride salt of lomefloxacin. It is administered by mouth to treat bacterial infections including bronchitis and urinary tract infections. It is also used topically as eye drops for the treatment of bacterial conjunctivitis, and as ear drops for the treatment of otitis externa and otitis media.		2.0510hydrochlorideantimicrobial agent;
antitubercular agent;
photosensitizing agent
sanguinarine chloride
[no description available]		2.0410
picosulfate sodium
picosulfate sodium: contains two active ingredients, sodium picosulfate and magnesium citrate, which are both laxatives; structure		2.0510aryl sulfate;
pyridines
cefcanel
cefcanel: RN given refers to (6R-(6 alpha,7 beta(R*)))-isomer; structure		2.0410
zoledronic acid
Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.		4.981101,1-bis(phosphonic acid);
imidazoles		bone density conservation agent
epristeride
epristeride: structure given in first source		2.0410steroid acid
talinolol
[no description available]		2.0410ureas
artemisinin
(+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		2.4920organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite
brinzolamide
brinzolamide: an antiglaucoma agent		2.0810sulfonamide;
thienothiazine		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
dienogest
[no description available]		2.051017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
aliphatic nitrile;
steroid hormone		progesterone receptor agonist;
progestin;
synthetic oral contraceptive
flunoxaprofen
flunoxaprofen: structure given in first source. flunoxaprofen : A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group (the S-enantiomer). Although it was shown to be effective in treatment of rheumatoid arthritis and osteoarthritis, the clinical use of flunoxaprofen was discontinued due to possible hepatotoxic side-effects.		2.05101,3-benzoxazoles;
monocarboxylic acid;
organofluorine compound		antirheumatic drug;
hepatotoxic agent;
non-steroidal anti-inflammatory drug;
protein kinase C agonist
tianeptine
tianeptine: structure given in first source. tianeptine : A racemate comprising of equimolar amounts of (R)- and (S)-tianeptine. It is an atypical antidepressant used in Europe to treat patients who respond poorly to selective serotonin reuptake inhibitors (SSRIs).. 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid : A member of the class of dibenzothiazepines that is 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide substituted by a (6-carboxyhexyl)amino group at position 11.. (S)-tianeptine : The S-enantiomer of tianeptine.		2.0510dibenzothiazepine;
monocarboxylic acid;
organochlorine compound
drospirenone
drospirenone: a progestational compound with antimineralocorticoid and antiandrogenic activity; structure given in first source		2.46203-oxo-Delta(4) steroid;
steroid lactone		aldosterone antagonist;
contraceptive drug;
progestin
artemether
Artemether: An artemisinin derivative that is used in the treatment of MALARIA.. artemether : An artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		2.0810artemisinin derivative;
cyclic acetal;
organic peroxide;
semisynthetic derivative;
sesquiterpenoid		antimalarial
fenflumizole
fenflumizole: structure in first source		2.0310
5-fluoropyrimidine
[no description available]		3.8221
morphazinamide
morphazinamide: RN given refers to parent cpd; RN in Chemline for mono-HCL: 1473-73-0; structure in Merck Index		2.0510morpholines;
pyrazines;
secondary carboxamide
denaverine
denaverine: RN given refers to parent cpd; structure		2.0410diarylmethane
acamprosate
Acamprosate: Structural analog of taurine that is used for the prevention of relapse in individuals with ALCOHOLISM.. acamprosate : An organosulfonic acid that is propane-1-sulfonic acid substituted by an acetylamino group at position 3.		3.2310acetamides;
organosulfonic acid		environmental contaminant;
neurotransmitter agent;
xenobiotic
isaxonine
isaxonine: promotes nerve growth		3.2310aminopyrimidine
diprafenone
diprafenone: structure given in first source		2.0410aromatic compound
nebivolol
2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol] : A member of the class of chromanes that is 2,2'-iminodiethanol in which one hydrogen attached to each hydroxy-bearing carbon is replaced by a 6-fluorochroman-2-yl group.		3.5820chromanes;
diol;
organofluorine compound;
secondary alcohol;
secondary amino compound
uk 68798
[no description available]		3.8730aromatic ether;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
potassium channel blocker
ljc 10627
biapenem: structure given in first source. biapenem : A carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively.		2.0410carbapenems;
organic sulfide;
pyrazolotriazole		antibacterial drug
dapoxetine
[no description available]		4.6111naphthalenes
hp 873
iloperidone: an atypical, negative symptom antipsychotic agent. iloperidone : A member of the class of piperidines that is the 4-acetyl-2-methoxyphenyl ether of 3-(piperidin-1-yl)propan-1-ol which is substituted at position 4 of the piperidine ring by a 6-fluoro-1,2-benzoxazol-3-yl group. A member of the group of second generation antipsychotics (also known as an atypical antipsychotics), it is used for the treatment of schizophrenia.		3.61201,2-benzoxazoles;
aromatic ether;
aromatic ketone;
methyl ketone;
monoamine;
organofluorine compound;
piperidines;
tertiary amino compound		dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist
dexrazoxane
Dexrazoxane: The (+)-enantiomorph of razoxane.		3.8630razoxaneantineoplastic agent;
cardiovascular drug;
chelator;
immunosuppressive agent
masoprocol
Masoprocol: A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils.. masoprocol : The meso-form of nordihydroguaiaretic acid. An antioxidant found in the creosote bush, Larrea divaricata, it is a potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. It also inhibits (though to a lesser extent) formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase.		2.0410nordihydroguaiaretic acidantineoplastic agent;
hypoglycemic agent;
lipoxygenase inhibitor;
metabolite
loxapine succinate
[no description available]		2.0810succinate saltgeroprotector
tocophersolan
tocophersolan: RN given refers to parent cpd		2.610tocol
loperamide hydrochloride
loperamide hydrochloride : A hydrochloride obtained by combining loperamide with one equivalent of hydrochloric acid. Used for treatment of diarrhoea resulting from gastroenteritis or inflammatory bowel disease.		2.0510hydrochlorideanticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist
fenoxypropazine
[no description available]		3.2310aromatic ether
voriconazole
Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.		6.3261conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug		P450 inhibitor
betamipron
[no description available]		2.7530organonitrogen compound;
organooxygen compound
bufuralol
bufuralol: RN given refers to cpd without isomeric designation; structure		2.4620benzofurans
uroxatral
[no description available]		2.0810hydrochloride
aceclofenac
[no description available]		3.6120amino acid;
carboxylic ester;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
nitrefazole
[no description available]		3.2310imidazoles
alacepril
[no description available]		2.0810dipeptide;
thioacetate ester		EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
panipenem
panipenem: synthetic cpd; structure given in first source		2.0410organic molecular entity
perindoprilat
perindoprilat : A dipeptide obtained by formal condensation of one of the carboxy groups of N-[(1S)-1-carboxyethyl]-L-norvaline with the amino group of (2S,3aS,7aS)-octahydroindole-2-carboxylic acid. The major active metabolite of perindopril.		2.0410dicarboxylic acid;
dipeptide;
L-alanine derivative;
organic heterobicyclic compound		antihypertensive agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
a-76745
fenleuton: LoFrin is tradename		2.2510
cyclobutyrol
cyclobutyrol: RN given refers to parent cpd; structure. cyclobutyrol : A hydroxy monocarboxylic acid in which the hydroxy group is geminal to a 1-carboxypropyl group on a cyclohexane ring.		2.0510hydroxy monocarboxylic acidbile therapy drug
thiocolchicoside
[no description available]		2.0810glycoside
prednisolone phosphate
prednisolone phosphate: RN given refers to (11 beta)-isomer. prednisolone phosphate : A synthetic glucocorticoid resulting from the formal condensation of the 21-hydroxy group of prednisolone with one of the hydroxy groups of phosphoric acid. It is a prodrug for prednisolone that is activated in vivo by phosphatases.		2.031011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
glucocorticoid;
steroid phosphate;
tertiary alpha-hydroxy ketone		anti-inflammatory agent;
antineoplastic agent;
glucocorticoid receptor agonist;
prodrug
terlipressin
terlivaz: first FDA approved injection to improve kidney function in adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function.		2.0510polypeptide
(S)-flurbiprofen
[no description available]		2.0310flurbiprofen
ubenimex
ubenimex: growth inhibitor		2.0810
7-hydroxystaurosporine
[no description available]		2.0410
methotrimeprazine
Methotrimeprazine: A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604). methotrimeprazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively.		2.0410phenothiazines;
tertiary amine		anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist
isoflavone
[no description available]		2.0510isoflavones
chelerythrine chloride
[no description available]		2.4420
betulin
betulin: isolated from various white birch bark (BETULA). betulin : A pentacyclic triterpenoid that is lupane having a double bond at position 20(29) as well as 3beta-hydroxy and 28-hydroxymethyl substituents.		7.6120diol;
pentacyclic triterpenoid		analgesic;
anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
metabolite
clevudine
[no description available]		2.0510
9-aminocamptothecin
[no description available]		2.0410pyranoindolizinoquinoline
picropodophyllin
picropodophyllin: isolated from American May apple (Podophyllum); inhibits IGF-I autophosphorylation without interfering with tyrosine kinase activity. picropodophyllotoxin : An organic heterotetracyclic compound that has a furonaphthodioxole skeleton bearing 3,4,5-trimethoxyphenyl and hydroxy substituents.		3.6420furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antineoplastic agent;
insulin-like growth factor receptor 1 antagonist;
plant metabolite;
tyrosine kinase inhibitor
sch 34343
Sch 34343: structure given in first source; RN given refers to (5R-(5alpha,6alpha))-isomer		2.0410
grepafloxacin
grepafloxacin: structure in first source		2.0510fluoroquinolone antibiotic;
quinolines;
quinolone antibiotic
squalamine
squalamine: from dogfish shark Squalus acanthias; structure given in first source		2.0410bile acid
tetrandrine
tetrandrine: a bisbenzylisoquinoline that exhibits antifibrogenic activity		7.8130bisbenzylisoquinoline alkaloid;
isoquinolines
3-deazaneplanocin
3-deazaneplanocin: S-adenosylhomocysteine hydrolase antagonist		2.2510
5-diazouracil
5-diazouracil: RN given refers to parent cpd; structure		2.2510
fascaplysine
fascaplysine: from tropic sea sponges		2.0310
hederagenin
[no description available]		2.2110dihydroxy monocarboxylic acid;
pentacyclic triterpenoid;
sapogenin		plant metabolite
doripenem
Doripenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.		3.6120carbapenems
5-benzylhydantoin
5-benzylhydantoin: structure given in first source		2.0410
2-naphthylisothiocyanate
[no description available]		2.0510
1,2,3,4,5,6-hexabromocyclohexane
[no description available]		2.0310bromoalkane;
bromohydrocarbon		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
atovaquone
Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.		4.6140hydroxy-1,2-naphthoquinone
rivastigmine
[no description available]		3.5820carbamate ester;
tertiary amino compound		cholinergic drug;
EC 3.1.1.8 (cholinesterase) inhibitor;
neuroprotective agent
frovatriptan
[no description available]		3.5820carbazoles
eletriptan
eletriptan: 5-HT(1B/1D) receptor agonist; structure in first source. eletriptan : An N-alkylpyrrolidine, that is N-methylpyrrolidine in which the pro-R hydrogen at position 2 is replaced by a {5-[2-(phenylsulfonyl)ethyl]-1H-indol-3-yl}methyl group.		4.0640indoles;
N-alkylpyrrolidine;
sulfone		non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
rosiglitazone
[no description available]		4.87100aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
tamiflu
[no description available]		2.0810phosphate salt
5-cyanouracil
[no description available]		2.2510
bexarotene
[no description available]		6.0581benzoic acids;
naphthalenes;
retinoid		antineoplastic agent
s20098
[no description available]		2.0810acetamides
flunisolide
flunisolide: flunisolide HFA is a formulation of flunisolide using hydrofluoroalkane (HFA) as propellant in place of chlorofluorocarbon (CFC) ones		2.462011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic ketal;
fluorinated steroid;
primary alpha-hydroxy ketone		anti-asthmatic drug;
anti-inflammatory drug;
immunosuppressive agent
4-nitrophenylglucuronide
4-nitrophenyl beta-D-glucuronide : A beta-D-glucosiduronic acid having a 4-nitrophenyl substituent at the anomeric position.		2.0410beta-D-glucosiduronic acid;
C-nitro compound		chromogenic compound
chloroquine diphosphate
[no description available]		2.0510
orphenadrine citrate
orphenadrine citrate : A citrate salt which comprises equimolar amounts of orphenadrine and citric acid.		2.0510citrate saltH1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic
acetaminophen glucuronide
acetaminophen glucuronide: acetaminophen metabolite in rats. acetaminophen O-beta-D-glucosiduronic acid : A beta-D-glucosiduronic acid that is the O-glucuronide of paracetamol (acetaminophen).		2.0410beta-D-glucosiduronic aciddrug metabolite
ketorolac tromethamine
Ketorolac Tromethamine: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.. ketorolac tromethamine : An organoammonium salt resulting from the mixture of equimolar amounts of ketorolac and tromethamine (tris). It has potent non-sedating analgesic and moderate anti-inflammatory effects. It is used in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis.		2.4720organoammonium saltanalgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor
clarithromycin
Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.		9.7890macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
zwittergent 3-12
zwittergent 3-12: zwitterionic detergent. lauryl sulfobetaine : An ammonium betaine in which the ammonium nitrogen is substituted by dodecyl, 3-sulfatopropyl and two methyl groups.		2.0510ammonium betainedetergent
nicotine
(S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.		5.94713-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
n-(3,5-dichlorophenyl)succinimide
N-(3,5-dichlorophenyl)succinimide: nephrotoxic; post-treatment enhanced induction of renal cell tumors in rats by dimethylnitrosamine, pre-treatment inhibited induction of tumors, & alone caused interstitial nephritis but no tumors		2.0510pyrrolidines
fibrinogen
Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.. D-iditol : The D-enantiomer of iditol.		2.5520iditolfungal metabolite
moexipril
[no description available]		3.5720peptide
phentolamine mesylate
[no description available]		2.0510
matrine
[no description available]		2.4110alkaloid
oxybutynin hydrochloride
[no description available]		2.0510hydrochloride
4-hydroxypropranolol
4-hydroxypropranolol: metabolite of propanolol; RN given refers to parent cpd without isomeric designation		2.0810naphthols
gliquidone
gliquidone: structure; RN given refers to parent cpd		2.0810isoquinolines
cordium
bepridil hydrochloride monohydrate : The hydrochloride monohydrate of bepridril.		2.0510hydrate;
hydrochloride
meclizine hydrochloride
[no description available]		2.0510
lekoptin
(S)-verapamil : A 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile that has S configuration.		2.03102-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
tarenflurbil
tarenflurbil: R-enantiomer of flurbiprofen but not a COX inhibitor; modulates NF-kB, gamma-secretase, amyloid beta-protein;		2.0310flurbiprofen
mci 9038
[no description available]		3.5820peptide
lopinavir
[no description available]		6.3361amphetamines;
dicarboxylic acid diamide		anticoronaviral agent;
antiviral drug;
HIV protease inhibitor
firefly luciferin
Firefly Luciferin: A benzothaizole which is oxidized by LUCIFERASES, FIREFLY to cause emission of light (LUMINESCENCE).. Photinus luciferin : A 1,3-thiazolemonocarboxylic acid consisting of 3,5-dihydrothiophene-4-carboxylic acid having a 6-hydroxybenzothiazol-2-yl group at the 2-position.		2.51201,3-thiazolemonocarboxylic acid;
benzothiazoles;
imidothioate		luciferin
norcantharidin
norcantharidin: structure given in first source; RN given refers to cpds without isomeric designation		7.830furofuran
glucuronic acid
Glucuronic Acid: A sugar acid formed by the oxidation of the C-6 carbon of GLUCOSE. In addition to being a key intermediate metabolite of the uronic acid pathway, glucuronic acid also plays a role in the detoxification of certain drugs and toxins by conjugating with them to form GLUCURONIDES.. D-glucuronic acid : The D-enantiomer of glucuronic acid.. D-glucopyranuronic acid : A D-glucuronic acid in cyclic pyranose form.		2.0510D-glucuronic acidalgal metabolite
eupatorin
eupatorin: a flavonoid from the East Asian medicinal plant Orthosiphon spicatus; prevents oxidative inactivation of 15-lipoxygenase; structure given in first source. eupatorin : A trimethoxyflavone that is 6-hydroxyluteolin in which the phenolic hydogens at positions 4', 6 and 7 have been replaced by methyl groups.		2.0610dihydroxyflavone;
polyphenol;
trimethoxyflavone		anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
Brassica napus metabolite;
calcium channel blocker;
P450 inhibitor;
vasodilator agent
5-iodotubercidin
7-iodotubercidin: inhibits Toxoplasma gondii adenosine kinase		2.0310organoiodine compound
diosgenin
[no description available]		2.55203beta-sterol;
hexacyclic triterpenoid;
sapogenin;
spiroketal		antineoplastic agent;
antiviral agent;
apoptosis inducer;
metabolite
combretastatin
combretastatin: cytotoxic principle from South African tree COMBRETUM caffrum; structure given in first source; acts at COLCHICINE site of TUBULIN		3.5420
moxifloxacin hydrochloride
moxifloxacin hydrochloride : A hydrochloride comprising equimolar amounts of moxifloxacin and hydrogen chloride.		2.0810hydrochlorideantibacterial drug
fulvestrant
Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.		10.8325217beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide		antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
mizoribine
[no description available]		2.0810imidazolesanticoronaviral agent
u 73122
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione: structure given in first source. U-73122 : An aza-steroid that is 3-O-methyl-17beta-estradiol in which the 17beta-hydroxy group is replaced by a 6-(maleimid-1-yl)hexylamino group. An inibitor of phospholipase C.		2.6620aromatic ether;
aza-steroid;
maleimides		EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
imipenem, anhydrous
Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.		2.0410beta-lactam antibiotic allergen;
carbapenems;
zwitterion		antibacterial drug
sr141716
[no description available]		2.4720amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles		anti-obesity agent;
appetite depressant;
CB1 receptor antagonist
bosentan anhydrous
Bosentan: A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.		4.7790primary alcohol;
pyrimidines;
sulfonamide		antihypertensive agent;
endothelin receptor antagonist
diacetyldichlorofluorescein
diacetyldichlorofluorescein: stable storage form of dichlorofluorescein		2.610
fluo-3
Fluo-3: fluorescent Ca(2+) indicator; permits continuous monitoring of Ca without interference with use of UV-sensitive caged compounds		2.0410xanthene dyefluorochrome
1,n(6)-ethenoadenine
1,N(6)-ethenoadenine: biologically active fluorescent derivatives of this cpd potentially valuable in studies concerning interactions between adenine cpds & various enzymes for which they serve as substrates or co-factors; structure		4.6111imidazo[2,1-i]purinemutagen
paxilline
paxilline: structure given in first source; RN given refers to (2R-(2alpha,4bbeta,6aalpha,12bbeta,12calpha,14abeta))-isomer. paxilline : An indole diterpene alkaloid with formula C27H33NO4 isolated from Penicillium paxilli. It is a potent inhibitor of large conductance Ca2(+)- and voltage-activated K(+) (BK)-type channels.		2.0310diterpene alkaloid;
enone;
organic heterohexacyclic compound;
terpenoid indole alkaloid;
tertiary alcohol		anticonvulsant;
Aspergillus metabolite;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
genotoxin;
geroprotector;
mycotoxin;
Penicillium metabolite;
potassium channel blocker
prolinedithiocarbamate
prolinedithiocarbamate: do not confuse with pyrrolidine dithiocarbamate which is also abbreviated PDTC		2.1710
selenomethionine
[no description available]		2.0510amino acid zwitterion;
selenomethionine		plant metabolite
artesunic acid
[no description available]		2.4110
vinpocetine
[no description available]		2.0810
thiamethoxam
Thiamethoxam: A nitro-oxazine and thiazole derivative that is used as a broad spectrum neonicotinoid insecticide.. thiamethoxam : An oxadiazane that is tetrahydro-N-nitro-4H-1,3,5-oxadiazin-4-imine bearing (2-chloro-1,3-thiazol-5-yl)methyl and methyl substituents at positions 3 and 5 respectively.		4.61111,3-thiazoles;
2-nitroguanidine derivative;
organochlorine compound;
oxadiazane		antifeedant;
carcinogenic agent;
environmental contaminant;
neonicotinoid insectide;
xenobiotic
sivelestat
sivelestat: inhibitor of neutrophil elastase; structure given in first source		2.4820N-acylglycine;
pivalate ester
racecadotril
racecadotril: parenterally active enkephalinase inhibitor		2.0810N-acyl-amino acid
perindopril
Perindopril: An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure.. perindopril : An alpha-amino acid ester that is the ethyl ester of N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvaline		3.5920alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
n-monodemethyldiltiazem
N-monodemethyldiltiazem: RN given refers to (cis)-isomer; structure given in first source		2.0810benzothiazepine
asulacrine
asulacrine: derivative of amsacrine; structure given in first source		2.0410acridines
deguelin
deguelin: a natural product from Mundulea sericea; RN refers to (7aS-cis)-isomer; structure given in first source. deguelin : A rotenone that is 13,13a-dihydro-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(7aH)-one substituted by methoxy groups at positions 9 and 10, and by two methyl groups at position 3 (the 7aS,13aS-stereoisomer). It exists in abundant quantities in the bark, roots, and leaves of the Leguminosae family of plants and reported to exert anti-tumour effects in various cancers.		2.0810aromatic ether;
diether;
organic heteropentacyclic compound;
rotenones		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
mitochondrial NADH:ubiquinone reductase inhibitor;
plant metabolite
hydroxycotinine
hydroxycotinine: metabolite of nicotine; RN given refers to (S)-isomer; structure. trans-3-hydroxycotinine : An N-alkylpyrrolidine that is cotinine substituted at position C-3 by a hydroxy group (the 3R,5S-diastereomer).		2.0410N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid
fingolimod hydrochloride
Fingolimod Hydrochloride: A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.. fingolimod hydrochloride : The hydrochloride salt of 2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol (fingolimod).		2.1510hydrochlorideimmunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
fingolimod
fingolimod : An aminodiol that consists of propane-1,3-diol having amino and 2-(4-octylphenyl)ethyl substituents at the 2-position. It is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis. A prodrug, fingolimod is phosphorylated by sphingosine kinase to active metabolite fingolimod-phosphate, a structural analogue of sphingosine 1-phosphate.		2.0510aminodiol;
primary amino compound		antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
triptolide
[no description available]		2.8230diterpenoid;
epoxide;
gamma-lactam;
organic heteroheptacyclic compound		antispermatogenic agent;
plant metabolite
quinaprilat
quinaprilat: metabolite of quinapril. quinaprilat : A dicarboxylic acid resulting from the hydrolysis of the ethyl ester group of quinapril to give the corresponding dicarboxylic acid. The active angiotensin-converting enzyme inhibitor (ACE inhibitor) of the prodrug quinapril.		2.0410dicarboxylic acid;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
vasodilator agent
2-hydroxyimipramine
2-hydroxyimipramine: RN given refers to parent cpd		2.0410dibenzoazepine
tryptoquivaline
tryptoquivaline: tremor-producing metabolite from Aspergillus clavatus; tetrapeptide derived from tryptophan, anthranilic acid, valine, & methylalanine; structure & N1 names previously assigned to tryptoquivaline C & tryptoquivaline D found to be incorrect & are revised in third source; see also record for tryptoquivalone; structure in third source		2.1110
ecteinascidin 743
[no description available]		2.4520acetate ester;
azaspiro compound;
bridged compound;
hemiaminal;
isoquinoline alkaloid;
lactone;
organic heteropolycyclic compound;
organic sulfide;
oxaspiro compound;
polyphenol;
tertiary amino compound		alkylating agent;
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
marine metabolite
ci 988
PD 134308: selective cholecystokinin type B receptor antagonist; inhibits growth of LoVo, a human colon cancer cell line; structure given in first source		2.1110
deoxyglucose
Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.		2.2510
tadalafil
[no description available]		3.8930benzodioxoles;
pyrazinopyridoindole		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
ibuprofen, (r)-isomer
[no description available]		2.0310ibuprofen
tanshinone
tanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agent		2.2110abietane diterpenoidanticoronaviral agent
paliperidone
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one : A member of the class of pyridopyrimidines that is 9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.. paliperidone : A racemate comprising equimolar amounts of (R)- and (S)-paliperidone. Paliperidone is the primary active metabolite of the older antipsychotic risperidone and is used for treatment of schizophrenia.		3.23101,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine;
secondary alcohol
2-aminobicyclo(2,2,1)heptane-2-carboxylic acid
2-aminobicyclo(2,2,1)heptane-2-carboxylic acid: amino acid analog; releases insulin; RN given refers to unlabeled cpd without isomeric designation		2.0510monoterpenoid
nitisinone
[no description available]		3.5920(trifluoromethyl)benzenes;
C-nitro compound;
cyclohexanones;
mesotrione		EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
plavix
[no description available]		2.4720azaheterocycle sulfate salt;
organoammonium sulfate salt		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
marimastat
marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary. marimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide.		4.5640hydroxamic acid;
secondary carboxamide		antineoplastic agent;
matrix metalloproteinase inhibitor
asiatic acid
[no description available]		2.1110monocarboxylic acid;
pentacyclic triterpenoid;
triol		angiogenesis modulating agent;
metabolite
clofarabine
[no description available]		4.850adenosines;
organofluorine compound		antimetabolite;
antineoplastic agent
sr 48692
SR 48692: structure in first source; a neurotensin receptor-1 antagonist		2.4920N-acyl-amino acid
elacridar
Elacridar: inhibitor of MDR1 PROTEIN; structure given in first source		3.3160
pramipexole
Pramipexole: A benzothiazole derivative and dopamine agonist with antioxidant properties that is used in the treatment of PARKINSON DISEASE and RESTLESS LEGS SYNDROME.. pramipexole : A member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively.		3.8630benzothiazoles;
diamine		antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
radical scavenger
valdecoxib
[no description available]		3.8930isoxazoles;
sulfonamide		antipyretic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid: structure given in first source. DOTA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 7 and 10 of a twelve-membered ring are each substituted with a carboxymethyl group.		2.0210azamacrocyclechelator;
copper chelator
mitiglinide
mitiglinide: a rapid and short-acting hypoglycemic agent; acts on sulfonylurea receptor closing KATP channels; considered one of the glinides-an imprecise grouping; structure given in first source		2.0510benzenes;
monocarboxylic acid
astragaloside a
[no description available]		2.1510
celastrol
[no description available]		2.8330monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory drug;
antineoplastic agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Hsp90 inhibitor;
metabolite
peroxynitrous acid
Peroxynitrous Acid: A potent oxidant synthesized by the cell during its normal metabolism. Peroxynitrite is formed from the reaction of two free radicals, NITRIC OXIDE and the superoxide anion (SUPEROXIDES).		4.6111nitrogen oxoacid
imatinib mesylate
imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.		12.95802methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
almotriptan
almotriptan : An indole compound having a 2-(dimethylamino)ethyl group at the 3-position and a (pyrrolidin-1-ylsulfonyl)methyl group at the 5-position.		3.8530indoles;
sulfonamide;
tertiary amine		non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
mk 0663
[no description available]		2.7530bipyridines;
organochlorine compound;
sulfone		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine: structure given in first source; a selective A(3) adenosine receptor agonist. 3-iodobenzyl-5'-N-methylcarboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by N-ethylcarboxamido and one of the hydrogens of the exocyclic amino function is substituted by a 3-iodobenzyl group.		2.0510adenosines;
monocarboxylic acid amide;
organoiodine compound		adenosine A3 receptor agonist
bay x 1005
2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid: inhibits synthesis of leukotriene B4 and 5-hydroxyeicosatetraenoic acid; inhibits five-lipoxygenase activating protein(FLAP)and leukotriene A4 hydrolase(LTA4H); structure given in first source;		2.0810
desloratadine
desloratadine: major metabolite of loratadine. desloratadine : Loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness.		3.8930benzocycloheptapyridineanti-allergic agent;
cholinergic antagonist;
drug metabolite;
H1-receptor antagonist
desvenlafaxine
O-desmethylvenlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-hydroxyphenyl group. It is a metabolite of the drug venlafaxine.		3.2310cyclohexanols;
phenols;
tertiary amino compound		antidepressant;
drug metabolite;
marine xenobiotic metabolite
1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene
1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene: inhibits tubulin polymerization; RN & structure given in first source		2.1110
lestaurtinib
[no description available]		2.8330indolocarbazole
gyki 53655
GYKI 53655: an AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate) receptor antagonist		2.0810
methotrexate
[no description available]		10316dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
idph-791
[no description available]		2.0510
4-(3-chloroanilino)quinazoline
4-(3-chloroanilino)quinazoline: structure given in first source		2.1310
tamsulosin
[no description available]		3.58205-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamidealpha-adrenergic antagonist;
antineoplastic agent
rufinamide
rufinamide: for treatment of Lennox-Gastaut syndrome; structure in first source		3.2310aromatic amide;
heteroarene
antiprimod
azaspirane: structure given in first source		2.0510
sulbactam
[no description available]		2.7530penicillanic acids
olmesartan medoxomil
Olmesartan Medoxomil: An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION.		3.8730biphenyls
dexpanthenol
dexpanthenol: The alcohol of pantothenic acid		3.2310amino alcohol;
monocarboxylic acid amide		cholinergic drug;
provitamin
fosamprenavir
fosamprenavir: a prodrug of the protease inhibitor amprenavir. fosamprenavir : A sulfonamide with a structure based on that of sulfanilamide substituted on the sulfonamide nitrogen by a (2R,3S)-4-phenyl-2-(phosphonooxy)-3-({[(3S)-tetrahydrofuran-3-yloxy]carbonyl}amino)butyl group. It is a pro-drug of the HIV protease inhibitor and antiretroviral drug amprenavir.		3.2310sulfonamideprodrug
pagoclone
RP 59037: a partial benzodiazepine receptor agonist; a cyclopyrrolone that induces hypothermia		2.0810
ilomastat
CS 610: matrix metalloproteinase inhibitor; structure in first source. ilomastat : An N-acyl-amino acid obtained by formal condensation of the carboxy group of (2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the amino group of N-methyl-L-tryptophanamide. A cell permeable broad-spectrum matrix metalloproteinase (MMP) inhibitor		2.0510hydroxamic acid;
L-tryptophan derivative;
N-acyl-amino acid		anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
EC 3.4.24.24 (gelatinase A) inhibitor;
neuroprotective agent
abiraterone
[no description available]		2.08103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
pyridines		antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
ml-3000
[no description available]		2.7830
ns 1608
NS 1608: a BK(Ca) channel opener		2.0610ureas
5-carboxyfluorescein diacetate
[no description available]		2.0410
febuxostat
Febuxostat: A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment of HYPERURICEMIA in patients with chronic GOUT.. febuxostat : A 1,3-thiazolemonocarboxylic acid that is 4-methyl-1,3-thiazole-5-carboxylic acid which is substituted by a 3-cyano-4-(2-methylpropoxy)phenyl group at position 2. It is an orally-active, potent, and selective xanthine oxidase inhibitor used for the treatment of chronic hyperuricaemia in patients with gout.		4.45301,3-thiazolemonocarboxylic acid;
aromatic ether;
nitrile		EC 1.17.3.2 (xanthine oxidase) inhibitor
dilevalol
(R,R)-labetalol : A 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide that has 1R,2R-configuration.		2.04102-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide
calcium borate
calcium borate: RN given refers to cpd with MF CaB4O7		4.6111
cd 437
CD 437: selective for retinoic acid receptors gamma. CD437 : A naphthoic acid that is 6-phenylnaphthylene-2-carboxyic acid in which the phenyl substituent has been substituted at positions 3 and 4 by adamant-1-yl and hydroxy groups, respectively. It acts as a selective agonist of retinoic acid receptor (RAR)gamma and induces cell cycle arrest and apoptosis in various cancer cells.		2.0810adamantanes;
monocarboxylic acid;
naphthoic acid;
phenols		apoptosis inducer;
retinoic acid receptor gamma agonist
proline
Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2.		2.6620amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid		algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
escitalopram
Escitalopram: S-enantiomer of CITALOPRAM. Belongs to a class of drugs known as SELECTIVE SEROTONIN REUPTAKE INHIBITORS, used to treat depression and generalized anxiety disorder.. escitalopram : A 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has S-configuration at the chiral centre. It is the active enantiomer of citalopram.		3.57201-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrileantidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
lexapro
Lexapro: Trade name of escitalopram, the active S-enantiomer of the racemic citalopram.		2.0810
10-propargyl-10-deazaaminopterin
10-propargyl-10-deazaaminopterin: structure in first source. pralatrexate : A pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma.		4.220N-acyl-L-glutamic acid;
pteridines;
terminal acetylenic compound		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
docetaxel
[no description available]		2.7430hydrate;
secondary alpha-hydroxy ketone		antineoplastic agent
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		18.9713343secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
perifosine
[no description available]		9.2850ammonium betaine;
phospholipid		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
irofulven
irofulven: structure in first source		2.0410cyclohexenones
atazanavir
atazanavir : A heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV).		4.4330carbohydrazideantiviral drug;
HIV protease inhibitor
lonafarnib
lonafarnib: inhibitor of farnesyl protein transferase. lonafarnib : A 4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide that has R configuration. It is used as oral farnesyltransferase inhibitor.		4.04204-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamideantineoplastic agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
ym 872
YM 872: structure in first source		2.0410
tariquidar
[no description available]		2.830benzamides
nsc-141549
[no description available]		2.0510
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		4.41609-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
ezetimibe
Ezetimibe: An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.. ezetimibe : A beta-lactam that is azetidin-2-one which is substituted at 1, 3, and 4 by p-fluorophenyl, 3-(p-fluorophenyl)-3-hydroxypropyl, and 4-hydroxyphenyl groups, respectively (the 3R,3'S,4S enantiomer).		3.8730azetidines;
beta-lactam;
organofluorine compound		anticholesteremic drug;
antilipemic drug;
antimetabolite
ertapenem
Ertapenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.. ertapenem : Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.		3.5820carbapenemcarboxylic acid;
pyrrolidinecarboxamide		antibacterial drug
dx 8951
[no description available]		2.0410pyranoindolizinoquinoline
cox 189
lumiracoxib: a COX-2 inhibitor. lumiracoxib : An amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity.		3.8730amino acid;
monocarboxylic acid;
organochlorine compound;
organofluorine compound;
secondary amino compound		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
cilomilast
[no description available]		2.0410methoxybenzenes
conivaptan
conivaptan : The amide resulting from the formal condensation of 4-[(biphenyl-2-ylcarbonyl)amino]benzoic acid with the benzazepine nitrogen of 2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine. It is an antagonist for two of the three types of arginine vasopressin (AVP) receptors, V1a and V2. It is used as its hydrochloride salt for the treatment of hyponatraemia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).		3.5820benzazepineaquaretic;
vasopressin receptor antagonist
cariporide
cariporide: a selective sodium-hydrogen exchange subtype 1 inhibitor; structure in first source		2.0510
tezosentan
tezosentan: structure in first source		2.4520
mk 767
5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide: an antihyperlipidemic agent that also functions as an insulin sensitizer, PPARalpha agonist, and PPARgamma agonist; structure in first source		2.0810
vatalanib
[no description available]		8.07180monochlorobenzenes;
phthalazines;
pyridines;
secondary amino compound		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
oleanolic acid 3-acetate
oleanolic acid 3-acetate: from Gardenia jasminoides; RN given for (3beta)-isomer		2.2110
sabarubicin
sabarubicin: structure given in first source		2.0410
moxifloxacin
Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.		4.0740aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
pralnacasan
pralnacasan: NSAID, ICE inhibitor & metastasis inhibitor; RN & structure in first source		3.2310
clevidipine
clevidipine: a calcium channel blocker and antihypertensive agent; structure in first source		3.5820dihydropyridine
ruboxistaurin
ruboxistaurin: inhibits protein kinase C beta; structure in first source		4.8270
jtt 501
JTT 501: an insulin sensitizer; structure in first source		2.0510
solifenacin
[no description available]		3.5820isoquinolines
dexmethylphenidate
dexmethylphenidate : A methyl phenyl(piperidin-2-yl)acetate in which both stereocentres have R configuration. It is the active enantiomer in the racemic drug methylphenidate.		3.2310methyl phenyl(piperidin-2-yl)acetateadrenergic agent
bazedoxifene acetate
[no description available]		2.0810
bazedoxifene
[no description available]		2.1710phenylindole
schizandrin a
schizandrin A: the major lignan, 2-9%, of Schisandra plant; has hepatoprotective, antioxidant, and antineoplastic activities		7.2110
xamoterol
Xamoterol: A phenoxypropanolamine derivative that is a selective beta-1-adrenergic agonist.		2.4620morpholines
disopyramide, (s)-isomer
[no description available]		2.4420
naproxen
Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.		9.5570methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
canertinib dihydrochloride
[no description available]		2.7630
canertinib
[no description available]		9.91370monochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
cinacalcet
cinacalcet : A secondary amino compound that is (1R)-1-(naphthalen-1-yl)ethanamine in which one of the hydrogens attached to the nitrogen is substituted by a 3-[3-(trifluoromethyl)phenyl]propyl group.		3.2310(trifluoromethyl)benzenes;
naphthalenes;
secondary amino compound		calcimimetic;
P450 inhibitor
birb 796
[no description available]		6.1590aromatic ether;
morpholines;
naphthalenes;
pyrazoles;
ureas		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
immunomodulator
lubiprostone
[no description available]		3.2310
methyl 5-aminolevulinate
methyl 5-aminolevulinate: esterified form of aminolevulinic acid used as PHOTOCHEMOTHERAPY. methyl 5-aminolevulinate : The methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumulation of protoporphyrin IX in the skin lesions to which the cream has been applied. Subsequent illumination with red light results in the generation of toxic singlet oxygen that destroys cell membranes and thereby kills the tumour cells.		2.0510delta-amino acid esterantineoplastic agent;
dermatologic drug;
photosensitizing agent;
prodrug
isradipine, (s)-isomer
[no description available]		2.0310
olmesartan
olmesartan: an active metabolite of CS 866		2.4520biphenylyltetrazoleangiotensin receptor antagonist;
antihypertensive agent
telbivudine
[no description available]		3.6120pyrimidine 2'-deoxyribonucleosideantiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
tipifarnib
[no description available]		6.5370imidazoles;
monochlorobenzenes;
primary amino compound;
quinolone		antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
atrasentan
Atrasentan: A pyrrolidine and benzodioxole derivative that acts a RECEPTOR, ENDOTHELIN A antagonist. It has therapeutic potential as an antineoplastic agent and for the treatment of DIABETIC NEPHROPATHIES.		2.0310pyrrolidines
singlet oxygen
Singlet Oxygen: An excited state of molecular oxygen generated photochemically or chemically. Singlet oxygen reacts with a variety of biological molecules such as NUCLEIC ACIDS; PROTEINS; and LIPIDS; causing oxidative damages.		7.6320chalcogen;
monoatomic oxygen;
nonmetal atom		macronutrient
cryptotanshinone
cryptotanshinone: from Salvia miltiorrhiza		7.6620abietane diterpenoidanticoronaviral agent
cyc 202
seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.		7.271202,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
methylselenic acid
methylseleninic acid : An organoselenium compound that is seleninic acid in which the hydrogen attached to selenium is replaced by a methyl group.		2.610one-carbon compound;
organoselenium compound		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
human xenobiotic metabolite
abanoquil
[no description available]		2.0410
paromomycin
Paromomycin: An aminoglycoside antibacterial and antiprotozoal agent produced by species of STREPTOMYCES.. paromomycin : An amino cyclitol glycoside that is the 1-O-(2-amino-2-deoxy-alpha-D-glucopyranoside) and the 3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranoside of 4,6-diamino-2,3-dihydroxycyclohexane (the 1R,2R,3S,4R,6S diastereoisomer). It is obtained from various Streptomyces species. A broad-spectrum antibiotic, it is used (generally as the sulfate salt) for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.		3.5920amino cyclitol glycoside;
aminoglycoside antibiotic		anthelminthic drug;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
anidulafungin
Anidulafungin: Echinocandin antifungal agent that is used in the treatment of CANDIDEMIA and CANDIDIASIS.. anidulafungin : A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis.		3.5820antibiotic antifungal drug;
azamacrocycle;
echinocandin;
heterodetic cyclic peptide;
semisynthetic derivative
avasimibe
[no description available]		2.0510monoterpenoid
mahanimbine
mahanimbine: from Murraya koenigii leaves; structure in first source		2.4110carbazoles
beta-solamarine
beta-solamarine: RN given refers to (3beta,22beta,25S)-isomer; structure given in first source		2.610steroid saponin
aminopterin
Aminopterin: A folic acid derivative used as a rodenticide that has been shown to be teratogenic.		2.9210dicarboxylic acidEC 1.5.1.3 (dihydrofolate reductase) inhibitor;
mutagen
17 alpha-hydroxyprogesterone caproate
17 alpha-Hydroxyprogesterone Caproate: Hydroxyprogesterone derivative that acts as a PROGESTIN and is used to reduce the risk of recurrent MISCARRIAGE and of PREMATURE BIRTH. It is also used in combination with ESTROGEN in the management of MENSTRUATION DISORDERS.		3.2310corticosteroid hormone
varenicline
Varenicline: A benzazepine derivative that functions as an ALPHA4-BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION.. varenicline : An organic heterotetracyclic compound that acts as a partial agonist for nicotinic cholinergic receptors and is used (in the form of its tartate salt) as an aid to giving up smoking.		3.2310
biotin
vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.		9.1431biotins;
vitamin B7		coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite
angiotensin ii
Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).		2.5220amino acid zwitterion;
angiotensin II		human metabolite
fiduxosin
fiduxosin: fiduxosin (ABT-980) is the (3aR,9bR)-isomer; structure in first source		3.2310
atropine
tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.		4.4160
ropivacaine
Ropivacaine: An anilide used as a long-acting local anesthetic. It has a differential blocking effect on sensory and motor neurons.. ropivacaine : The piperidinecarboxamide obtained by the formal condensation of N-propylpipecolic acid and 2,6-dimethylaniline.. (S)-ropivacaine : A piperidinecarboxamide-based amide-type local anaesthetic (amide caine) in which (S)-N-propylpipecolic acid and 2,6-dimethylaniline are combined to form the amide bond.		2.0410piperidinecarboxamide;
ropivacaine		local anaesthetic
sb 203580
[no description available]		6.8180imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
enzastaurin
[no description available]		3.1650indoles;
maleimides
paris saponin vii
Paris saponin VII: has antineoplastic activity; isolated from Trillium tschonoskii; structure in first source		2.1310
erlotinib
[no description available]		15.14730aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
erlotinib hydrochloride
[no description available]		25.511,07479hydrochloride;
terminal acetylenic compound		antineoplastic agent;
protein kinase inhibitor
cilengitide
Cilengitide: an alphaVbeta3 integrin antagonist that paralyzes cancer cells		3.1910oligopeptide
piboserod
Serotonin 5-HT4 Receptor Antagonists: Drugs that bind to but do not activate SEROTONIN 5-HT4 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN RECEPTOR AGONISTS.		2.0810
organophosphonates
hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.		2.0510divalent inorganic anion;
phosphite ion
l 163191
[no description available]		2.0810
ketoprofen
[no description available]		2.0310
melagatran
[no description available]		2.0410azetidines;
carboxamidine;
dicarboxylic acid monoamide;
non-proteinogenic alpha-amino acid;
secondary amino compound		anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
serine protease inhibitor
dimethylarsinous acid
dimethylarsinous acid: a reactive organic intermediate of dimethylarsinic acid involved in toxicity		2.0510methylarsinous acid
aflatoxin b1
Aflatoxin B1: A potent hepatotoxic and hepatocarcinogenic mycotoxin produced by the Aspergillus flavus group of fungi. It is also mutagenic, teratogenic, and causes immunosuppression in animals. It is found as a contaminant in peanuts, cottonseed meal, corn, and other grains. The mycotoxin requires epoxidation to aflatoxin B1 2,3-oxide for activation. Microsomal monooxygenases biotransform the toxin to the less toxic metabolites aflatoxin M1 and Q1.. aflatoxin B1 : An aflatoxin having a tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene skeleton with oxygen functionality at positions 1, 4 and 11.		2.0510aflatoxin;
aromatic ether;
aromatic ketone		carcinogenic agent;
human metabolite
bd 1047
N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin: sigma receptor ligand; putative sigma receptor antagonist with antidystonic activity		2.0810primary amine
etravirine
[no description available]		3.5920aminopyrimidine;
aromatic ether;
dinitrile;
organobromine compound		antiviral agent;
HIV-1 reverse transcriptase inhibitor
2-anilino-5-thiazolinone
[no description available]		2.0310
chelidonine
chelidonine: benzophenanthridine derived from scoulerine from Chelidonium majus; RN given refers to parent cpd (chelidonine, (5bR-(5balpha,6beta,12alpha))-isomer)		7.2510alkaloid antibiotic;
alkaloid fundamental parent;
benzophenanthridine alkaloid
troleandomycin
Troleandomycin: A macrolide antibiotic that is similar to ERYTHROMYCIN.. troleandomycin : A semi-synthetic macrolide antibiotic obtained by acetylation of the three free hydroxy groups of oleandomycin. Troleandomycin is only found in individuals that have taken the drug.		2.4620acetate ester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyketide;
semisynthetic derivative		EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor;
xenobiotic
dibenzheptropine
dibenzheptropine: minor descriptor (65-85); on-line & Index Medicus search TROPANES (66-85); RN given refers to parent cpd. deptropine : An azabicycloalkane that is the 10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl ether of tropine.		2.1710organic tricyclic compound
orantinib
[no description available]		2.0610monocarboxylic acid;
oxindoles;
pyrroles		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
dronedarone
Dronedarone: A non-iodinated derivative of amiodarone that is used for the treatment of ARRHYTHMIA.. dronedarone : A member of the class of 1-benzofurans used for the treatment of cardiac arrhythmias.		3.65201-benzofurans;
aromatic ether;
aromatic ketone;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
environmental contaminant;
xenobiotic
tesaglitazar
tesaglitazar: structure in first source		2.0410
ramelteon
ramelteon: melatonin MT1/MT2 receptor agonist		3.6120indanes
tv3326
[no description available]		2.2510indanes
lapatinib
[no description available]		14.311311furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
albaconazole
albaconazole: UR-9825 is the (1R,2R)-isomer; structure in first source		3.4110
darunavir
Darunavir: An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.. darunavir : An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors.		3.2310carbamate ester;
furofuran;
sulfonamide		antiviral drug;
HIV protease inhibitor
deferasirox
Deferasirox: A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA.. deferasirox : A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions.		3.8730benzoic acids;
monocarboxylic acid;
phenols;
triazoles		iron chelator
bms204352
BMS204352: a calcium-sensitive opener of maxi-K potassium channels; structure in first source		2.7530
fosfluconazole
fosfluconazole: prodrug of fluconazole		2.0410conazole antifungal drug;
triazole antifungal drug;
triazoles		prodrug
taspine
taspine: RN given refers to parent cpd; structure		2.0510
tbc-11251
sitaxsentan: endothelin A receptor antagonist; structure in first source		3.8730benzodioxoles
tolvaptan
[no description available]		3.6120benzazepine;
benzenedicarboxamide		aquaretic;
vasopressin receptor antagonist
sorafenib
[no description available]		12.81681(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
lenalidomide
[no description available]		5.2660aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide
[no description available]		2.0810aminoquinoline
regadenoson
[no description available]		3.2310purine nucleoside
sr 142806
[no description available]		2.5220
lacosamide
Lacosamide: An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.		3.6120N-acyl-amino acid
cp 101,606
traxoprodil mesylate: a selective NMDA antagonist; structure given in first source		2.0410
cholic acid
Cholic Acid: A major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.. cholic acid : A bile acid that is 5beta-cholan-24-oic acid bearing three alpha-hydroxy substituents at position 3, 7 and 12.		2.041012alpha-hydroxy steroid;
3alpha-hydroxy steroid;
7alpha-hydroxy steroid;
bile acid;
C24-steroid;
trihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
n-phenylacrylamide
N-phenylacrylamide: structure in first source		2.0810
sitosterol, (3beta)-isomer
Sobatum: tradename; active fraction of Solanum trilobatum; reduces side-effects of radiation-induced toxicity. sitosterol : A member of the class of phytosterols that is stigmast-5-ene substituted by a beta-hydroxy group at position 3.		2.05103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
C29-steroid;
phytosterols;
stigmastane sterol		anticholesteremic drug;
antioxidant;
mouse metabolite;
plant metabolite;
sterol methyltransferase inhibitor
fludrocortisone acetate
fludrocortisone acetate : An acetate ester resulting from the formal condensation of the primary hydroxy group of fludrocortisone with acetic acid. A synthetic corticosteroid, it has glucocorticoid actions about 10 times as potent as hydrocortisone, while its mineralocorticoid actions are over 100 times as potent. It is used in partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenal hyperplasia.		2.051011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
fluorinated steroid;
mineralocorticoid;
tertiary alpha-hydroxy ketone
gossypol acetic acid
[no description available]		2.1310
vincaleukoblastine
[no description available]		4.1140acetate ester;
indole alkaloid fundamental parent;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
immunosuppressive agent;
microtubule-destabilising agent;
plant metabolite
vincristine sulfate
[no description available]		2.4720organic sulfate saltantineoplastic agent;
geroprotector
nsc 74859
NSC 74859: inhibits Stat3 binding activity; structure in first source. S3I-201 : An amidobenzoic acid obtained by formal condensation of the carboxy group of [(4-methylbenzene-1-sulfonyl)oxy]acetic acid with the amino group of 4-amino-2-hydroxybenzoic acid.		2.5420amidobenzoic acid;
monohydroxybenzoic acid;
tosylate ester		STAT3 inhibitor
anisomycin
Anisomycin: An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.. (-)-anisomycin : An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.		2.0510monohydroxypyrrolidine;
organonitrogen heterocyclic antibiotic		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
antiparasitic agent;
bacterial metabolite;
DNA synthesis inhibitor;
protein synthesis inhibitor
benzofurans
Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.		2.3110
benzarone
benzarone: antihemorrhagic agent; structure		3.59201-benzofurans
nsc-89199
estramustine phosphate : A steroid phosphate which is the 17-O-phospho derivative of estramustine.		2.0410carbamate ester;
organochlorine compound;
steroid phosphate
estramustine
Estramustine: A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.. estramustine : A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid.		10.464117beta-hydroxy steroid;
carbamate ester;
organochlorine compound		alkylating agent;
antineoplastic agent;
radiation protective agent
withaferin a
withaferin A: an antiestrogen and phytogenic antineoplastic agent isolated from leaves of Withania somnifera Dun.; structure. withaferin A : A withanolide that is 5,6:22,26-diepoxyergosta-2,24-diene-1,26-dione substituted by hydroxy groups at positions 4 and 27 (the 4beta,5beta,6beta,22R stereoisomer). Isolated from Physalis longifolia, it exhibits cytotoxic activity.		2.151027-hydroxy steroid;
4-hydroxy steroid;
delta-lactone;
enone;
epoxy steroid;
ergostanoid;
primary alcohol;
secondary alcohol;
withanolide		antineoplastic agent;
apoptosis inducer
phenethicillin
phenethicillin: minor descriptor (85); major descriptor (63-84); on-line search PENICILLIN, PHENOXYMETHYL/AA (66-85); Index Medicus search PHENETHICILLIN (63-84); RN given refers to (2S-(2alpha,5alpha,6beta))-isomer. phenethicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-phenoxypropanamido group.		2.0410penicillin allergen;
penicillin
noscapine
Noscapine: A naturally occurring opium alkaloid that is a centrally acting antitussive agent.. (-)-noscapine : A benzylisoquinoline alkaloid that is 1,2,3,4-tetrahydroisoquinoline which is substituted by a 4,5-dimethoxy-3-oxo-1,3-dihydro-2-benzofuran-1-yl group at position 1, a methylenedioxy group at positions 6-7 and a methoxy group at position 8. Obtained from plants of the Papaveraceae family, it lacks significant painkilling properties and is primarily used for its antitussive (cough-suppressing) effects.		2.4520aromatic ether;
benzylisoquinoline alkaloid;
cyclic acetal;
isobenzofuranone;
organic heterobicyclic compound;
organic heterotricyclic compound;
tertiary amino compound		antineoplastic agent;
antitussive;
apoptosis inducer;
plant metabolite
homoharringtonine
Homoharringtonine: Semisynthetic derivative of harringtonine that acts as a protein synthesis inhibitor and induces APOPTOSIS in tumor cells. It is used in the treatment of MYELOID LEUKEMIA, CHRONIC.. omacetaxine mepesuccinate : A cephalotaxine-derived alkaloid ester obtained from Cephalotaxus harringtonia; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia.		7.4820alkaloid ester;
enol ether;
organic heteropentacyclic compound;
tertiary alcohol		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
protein synthesis inhibitor
acivicin
[no description available]		2.4520isoxazoles;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		antileishmanial agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor;
glutamine antagonist;
metabolite
elesclomol
[no description available]		2.0810carbohydrazide;
thiocarbonyl compound		antineoplastic agent;
apoptosis inducer
wortmannin
[no description available]		2.7430acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
withanolides
Withanolides: Ergostane derivatives of 28 carbons with oxygens at C1, C22, and C26 positions and the side chain cyclized. They are found in WITHANIA plant genus and have cytotoxic and other effects.		2.1510
anthricin
anthricin: antitumor constituent from Anthriscus sylvestris (L.) Hoffm; structure in first source. deoxypodophyllotoxin : A member of the class of furonaphthodioxoles that is (5R,5aR,8aR)-5,8,8a,9-tetrahydro-2H-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one substituted at position 5 by a 3,4,5-trimethoxyphenyl group.		2.3110furonaphthodioxole;
gamma-lactone;
lignan;
methoxybenzenes		antineoplastic agent;
apoptosis inducer;
plant metabolite
trimethoprim, sulfamethoxazole drug combination
Trimethoprim, Sulfamethoxazole Drug Combination: A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.. co-trimoxazole : A two-component mixture comprising trimethoprim and sulfamethoxazole.		2.3110
o-(chloroacetylcarbamoyl)fumagillol
O-(Chloroacetylcarbamoyl)fumagillol: Semisynthetic analog of fumagillin (a cyclohexane-sesquiterpene antibiotic isolated from ASPERGILLUS FUMIGATUS) that inhibits angiogenesis.. O-(chloroacetylcarbamoyl)fumagillol : A carbamate ester that is fumagillol in which the hydroxy group has been converted to the corresponding N-(chloroacetyl)carbamate derivative.		2.0510carbamate ester;
organochlorine compound;
semisynthetic derivative;
sesquiterpenoid;
spiro-epoxide		angiogenesis inhibitor;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
methionine aminopeptidase 2 inhibitor;
retinoic acid receptor alpha antagonist
nsc 663284
NSC 663284: structure in first source		2.0810quinolone
taurochenodeoxycholic acid
Taurochenodeoxycholic Acid: A bile salt formed in the liver by conjugation of chenodeoxycholate with taurine, usually as the sodium salt. It acts as detergent to solubilize fats in the small intestine and is itself absorbed. It is used as a cholagogue and choleretic.. taurochenodeoxycholate : An organosulfonate oxoanion that is the conjugate base of taurochenodeoxycholic acid arising from deprotonation of the sulfonate OH group; major species at pH 7.3.. taurochenodeoxycholic acid : A bile acid taurine conjugate of chenodeoxycholic acid.		2.1110bile acid taurine conjugatehuman metabolite;
mouse metabolite
bortezomib
[no description available]		7.94280amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
ritonavir
Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.		6.57811,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
bardoxolone methyl
methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate: structure in first source		2.0810cyclohexenones
5-iodoindirubin-3'-monoxime
5-iodoindirubin-3'-monoxime: inhibits GSK-3beta		2.0310
tryptoquivaline
fumitremorgin C : An organic heteropentacyclic compound that is a mycotoxic indole alkaloid produced by several fungi. A potent and specific inhibitor of the breast cancer resistance protein multidrug transporter.		3.6320aromatic ether;
indole alkaloid;
organic heteropentacyclic compound		breast cancer resistance protein inhibitor;
mycotoxin
nexavar
[no description available]		2.0510organosulfonate salt
nsc 23766
[no description available]		2.0810aminopyrimidine;
aminoquinoline;
primary amino compound;
secondary amino compound;
tertiary amino compound		antiviral agent;
apoptosis inducer;
EC 3.6.5.2 (small monomeric GTPase) inhibitor;
muscarinic antagonist
gant 61
GANT 61: a sonic hedgehog pathway inhibitor and Gli inhibitor; structure in first source. GANT61 : An aminal that is hexahydropyrimidine which is substituted on each nitrogen by a 2-(dimethylamino)benzyl group, and at the aminal carbon by a pyridin-4-yl group. A Hedgehog signaling pathway and Gli protein inhibitor.		2.1710aminal;
dialkylarylamine;
pyridines;
substituted aniline;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
glioma-associated oncogene inhibitor;
Hedgehog signaling pathway inhibitor
permanganate
[no description available]		4.6111manganese oxoacid
leupeptins
Leupeptins: A group of acylated oligopeptides produced by Actinomycetes that function as protease inhibitors. They have been known to inhibit to varying degrees trypsin, plasmin, KALLIKREINS, papain and the cathepsins.		2.2510
carboplatin
[no description available]		19.1813577
leptomycin b
[no description available]		7.1510
2H-pyrazolo[4,3-b]quinoxalin-3-amine
[no description available]		2.0310quinoxaline derivative
bradykinin
[no description available]		2.0110oligopeptidehuman blood serum metabolite;
vasodilator agent
glucosamine
D-glucosamine : An amino sugar whose structure comprises D-glucose having an amino substituent at position 2.. 2-amino-2-deoxy-D-glucopyranose : A D-glucosamine whose structure comprises D-glucopyranose having an amino substituent at position 2.		7.7830D-glucosamineEscherichia coli metabolite;
geroprotector;
mouse metabolite
mevalonic acid
Mevalonic Acid: A dihydroxy monocarboxylic acid and precursor in the biosynthetic pathway known as the mevalonate pathway, which produces terpenes and steroids that are vital for diverse cellular functions.. mevalonic acid : A racemate composed of equimolar amounts of (R)- and (S)-mevalonic acid.. (R)-mevalonic acid : The (R)-enantiomer of mevalonic acid.		2.02103,5-dihydroxy-3-methylpentanoic acid
naringenin
(S)-naringenin : The (S)-enantiomer of naringenin.		7.4920(2S)-flavan-4-one;
naringenin		expectorant;
plant metabolite
oxytocin
Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.		3.2310heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
ouabain
Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.		2.532011alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite
puromycin
[no description available]		2.0510puromycinsantiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor
taxifolin
(+)-taxifolin : A taxifolin that has (2R,3R)-configuration.		2.0410taxifolinmetabolite
pentostatin
Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.. pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia.		3.8730coformycinsantimetabolite;
antineoplastic agent;
Aspergillus metabolite;
bacterial metabolite;
EC 3.5.4.4 (adenosine deaminase) inhibitor
taurolithocholic acid
Taurolithocholic Acid: A bile salt formed in the liver from lithocholic acid conjugation with taurine, usually as the sodium salt. It solubilizes fats for absorption and is itself absorbed. It is a cholagogue and choleretic.. taurolithocholic acid : The bile acid taurine conjugate of lithocholic acid.		2.4520bile acid taurine conjugate;
monocarboxylic acid amide		human metabolite
(+)-limonene
(4R)-limonene : An optically active form of limonene having (4R)-configuration.		2.0510limoneneplant metabolite
quinidine
Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.		4.96110cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
meropenem
Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.		4.0840alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen
griseofulvin
Griseofulvin: An antifungal agent used in the treatment of TINEA infections.. griseofulvin : An oxaspiro compound produced by Penicillium griseofulvum. It is used by mouth as an antifungal drug for infections involving the scalp, hair, nails and skin that do not respond to topical treatment.		3.86301-benzofurans;
antibiotic antifungal drug;
benzofuran antifungal drug;
organochlorine compound;
oxaspiro compound		antibacterial agent;
Penicillium metabolite
monensin
Monensin: An antiprotozoal agent produced by Streptomyces cinnamonensis. It exerts its effect during the development of first-generation trophozoites into first-generation schizonts within the intestinal epithelial cells. It does not interfere with hosts' development of acquired immunity to the majority of coccidial species. Monensin is a sodium and proton selective ionophore and is widely used as such in biochemical studies.. monensin A : A spiroketal, monensin A is the major component of monensin, a mixture of antibiotic substances produced by Streptomyces cinnamonensis. An antiprotozoal, it is used as the sodium salt as a feed additive for the prevention of coccidiosis in poultry and as a growth promoter in cattle.		2.1110cyclic hemiketal;
monocarboxylic acid;
polyether antibiotic;
spiroketal		antifungal agent;
coccidiostat;
ionophore
cefoxitin
Cefoxitin: A semisynthetic cephamycin antibiotic resistant to beta-lactamase.. cefoxitin : A semisynthetic cephamycin antibiotic which, in addition to the methoxy group at the 7alpha position, has 2-thienylacetamido and carbamoyloxymethyl side-groups. It is resistant to beta-lactamase.		3.8630beta-lactam antibiotic allergen;
cephalosporin;
cephamycin;
semisynthetic derivative		antibacterial drug
digitoxin
Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.		8.1650cardenolide glycosideEC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
moxalactam disodium
[no description available]		2.0510
saquinavir
Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.		5.2990L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor
pancuronium
Pancuronium: A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than CURARE but has less effect on the circulatory system and on histamine release.. pancuronium : A steroid ester in which a 5alpha-androstane skeleton is C-3alpha- and C-17beta-disubstituted with acetoxy groups and 2beta- and 16beta-disubstituted with 1-methylpiperidinium-1-yl groups. It is a non-depolarizing curare-mimetic muscle relaxant.		3.5820acetate ester;
steroid ester		cholinergic antagonist;
muscle relaxant;
nicotinic antagonist
rocuronium
Rocuronium: An androstanol non-depolarizing neuromuscular blocking agent. It has a mono-quaternary structure and is a weaker nicotinic antagonist than PANCURONIUM.. rocuronium : A 5alpha-androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents.		2.04103alpha-hydroxy steroid;
acetate ester;
androstane;
morpholines;
quaternary ammonium ion;
tertiary amino compound		drug allergen;
muscle relaxant;
neuromuscular agent
abacavir
abacavir: a carbocyclic nucleoside with potent selective anti-HIV activity. abacavir : A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.		4.79502,6-diaminopurinesantiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor
netilmicin
Netilmicin: Semisynthetic 1-N-ethyl derivative of SISOMYCIN, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity.		2.4520
trimethaphan camsylate
trimethaphan camsylate : The (S)-camphorsulfonate salt of trimethaphan.		2.0510
perindopril erbumine
[no description available]		2.0810addition compoundantihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
miglitol
[no description available]		4.140piperidines
amiodarone hydrochloride
[no description available]		2.0510aromatic ketone
mometasone furoate
Mometasone Furoate: A pregnadienediol derivative ANTI-ALLERGIC AGENT and ANTI-INFLAMMATORY AGENT that is used in the management of ASTHMA and ALLERGIC RHINITIS. It is also used as a topical treatment for skin disorders.		4.694011beta-hydroxy steroid;
2-furoate ester;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
organochlorine compound;
steroid ester		anti-allergic agent;
anti-inflammatory drug
metyrosine
alpha-methyl-L-tyrosine : An L-tyrosine derivative that consists of L-tyrosine bearing an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma.		3.2310L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		antihypertensive agent;
EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor
rocuronium bromide
rocuronium bromide : The organic bromide salt of a 5alpha androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents.		2.0810organic bromide salt;
quaternary ammonium salt		muscle relaxant;
neuromuscular agent
nortriptyline hydrochloride
[no description available]		2.0510organic tricyclic compoundgeroprotector
erythromycin estolate
Erythromycin Estolate: A macrolide antibiotic, produced by Streptomyces erythreus. It is the lauryl sulfate salt of the propionic ester of erythromycin. This erythromycin salt acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.		2.9840aminoglycoside sulfate salt;
erythromycin derivative		enzyme inhibitor
kanamycin sulfate
[no description available]		2.0510aminoglycoside sulfate saltantibacterial drug;
geroprotector
paromomycin sulfate
paromomycin sulfate : An aminoglycoside sulfate salt resulting from the treatment of paromomycin with sulfuric acid. A broad-spectrum antibiotic, it is used for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.		2.0510
delavirdine mesylate
delavirdine mesylate : The monomethanesulfonic acid salt of delavirdine, a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.		2.0510methanesulfonate saltantiviral drug;
HIV-1 reverse transcriptase inhibitor
linezolid
[no description available]		4.0840acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
cyclopamine
[no description available]		3.6590piperidinesglioma-associated oncogene inhibitor
lignans
Lignans: A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)		2.5820
6-prenylchrysin
6-prenylchrysin: structure in first source. 6-(3,3-dimethylallyl)chrysin : A dihydroxyflavone that is chrysin substituted by a prenyl group at position 6.		3.51107-hydroxyflavonol;
dihydroxyflavone
bq 123
cyclo(Trp-Asp-Pro-Val-Leu): derived from the modification of a natural lead of BE-18257B, an endothelin A receptor antagonist; has neuroprotective activity; amino acid sequence given in first source		2.1510cyclic peptide
devazepide
Devazepide: A derivative of benzodiazepine that acts on the cholecystokinin A (CCKA) receptor to antagonize CCK-8's (SINCALIDE) physiological and behavioral effects, such as pancreatic stimulation and inhibition of feeding.. devazepide : An indolecarboxamide obtained by formal condensation of the carboxy group of indole-2-carboxylic acid with the exocyclic amino group of (3S)-3-amino-1-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one. A cholecystokinin antagonist used for treatment of gastrointestinal disorders.		2.05101,4-benzodiazepinone;
indolecarboxamide		antineoplastic agent;
apoptosis inducer;
cholecystokinin antagonist;
gastrointestinal drug
chloramphenicol palmitate
chloramphenicol palmitate: RN given refers to ((R-(R*,R*))-isomer)		2.4520hexadecanoate ester
clindamycin phosphate
[no description available]		3.2310
calcium pantothenate
[no description available]		2.0510polymer
pemirolast potassium salt
[no description available]		2.0810
eplerenone
Eplerenone: A spironolactone derivative and selective ALDOSTERONE RECEPTOR antagonist that is used in the management of HYPERTENSION and CONGESTIVE HEART FAILURE, post-MYOCARDIAL INFARCTION.		3.61203-oxo-Delta(4) steroid;
epoxy steroid;
gamma-lactone;
methyl ester;
organic heteropentacyclic compound;
oxaspiro compound;
steroid acid ester		aldosterone antagonist;
antihypertensive agent
tolterodine
[no description available]		4.0840tertiary amineantispasmodic drug;
muscarinic antagonist;
muscle relaxant
doxorubicin hydrochloride
[no description available]		3.0340anthracycline
erythromycin ethylsuccinate
Erythromycin Ethylsuccinate: A macrolide antibiotic, produced by Streptomyces erythreus. This compound is an ester of erythromycin base and succinic acid. It acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin ethylsuccinate : A erythromycin derivative that is erythromycin A in which the hydroxy group at position 3R is substituted by a (4-ethoxy-4-oxobutanoyl)oxy group. It is used for the treatment of a wide variety of bacterial infections.		2.0510cyclic ketone;
erythromycin derivative;
ethyl ester;
succinate ester
tibolone
tibolone: used in prevention of postmenopausal osteoporosis. tibolone : Estran-3-one with a double bond between positions 5 and 10, and bearing both an ethynyl group and a hydroxy group at position 17 (R-configuration). A synthetic steroid hormone drug which acts as an agonist at all five type I steroid hormone receptors, it is used in the prevention of postmenopausal osteoporosis and for treatment of endometriosis.		2.081017beta-hydroxy steroid;
terminal acetylenic compound		bone density conservation agent;
hormone agonist
ao 128
AO 128: alpha-glucosidase inhibitor; structure given in first source		2.4720organic molecular entity
loteprednol etabonate
Loteprednol Etabonate: An androstadiene derivative corticosteroid that is used as an ANTI-ALLERGIC AGENT for the treatment of inflammatory and allergic eye conditions.		2.081011beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
etabonate ester;
organochlorine compound;
steroid acid ester;
steroid ester		anti-inflammatory drug
darifenacin
darifenacin : 2-[(3S)-1-Ethylpyrrolidin-3-yl]-2,2-diphenylacetamide in which one of the hydrogens at the 2-position of the ethyl group is substituted by a 2,3-dihydro-1-benzofuran-5-yl group. It is a selective antagonist for the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions, and is used as the hydrobromide salt in the management of urinary incontinence.		3.87301-benzofurans;
monocarboxylic acid amide;
pyrrolidines		antispasmodic drug;
muscarinic antagonist
fluticasone propionate
fluticasone propionate : A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity.		2.462011beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
corticosteroid;
fluorinated steroid;
propanoate ester;
steroid ester;
thioester		adrenergic agent;
anti-allergic agent;
anti-asthmatic drug;
anti-inflammatory drug;
bronchodilator agent;
dermatologic drug
betadex
beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.		3.250cyclodextrin
acarbose
[no description available]		2.4520amino cyclitol;
glycoside
maleic acid
maleic acid: RN given refers to parent cpd(Z)-isomer which is maleic acid; all RR's given refer to (Z)-isomer; (E)-isomer is fumaric acid. maleic acid : A butenedioic acid in which the double bond has cis- (Z)-configuration.		2.0510butenedioic acidalgal metabolite;
mouse metabolite;
plant metabolite
trichostatin a
trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES		2.0310antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
tretinoin
Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.		8.1891retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
resveratrol
trans-resveratrol : A resveratrol in which the double bond has E configuration.		3.7590resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
retinol
Vitamin A: Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of CAROTENOIDS found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products.. vitamin A : Any member of a group of fat-soluble retinoids produced via metabolism of provitamin A carotenoids that exhibit biological activity against vitamin A deficiency. Vitamin A is involved in immune function, vision, reproduction, and cellular communication.. all-trans-retinol : A retinol in which all four exocyclic double bonds have E- (trans-) geometry.. retinol : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraen-1-ol substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).		3.8630retinol;
vitamin A		human metabolite;
mouse metabolite;
plant metabolite
cyanoginosin lr
cyanoginosin LR: cyclic heptapeptide from cyanobacterium Microcystis aeruginosa. microcystin-LR : A microcystin consisting of D-alanyl, L-leucyl, (3S)-3-methyl-D-beta-aspartyl,L-arginyl, 2S,3S,4E,6E,8S,9S)-3-amino-4,5,6,7-tetradehydro-9-methoxy-2,6,8-trimethyl-10-phenyldecanoyl, D-gamma-glutamyl, and 2,3-didehydro-N-methylalanyl residues joined into a 25-membered macrocycle. Produced by the cyanobacterium Microcystis aeruginosa, it is the most studied of the microcystins.		2.0510microcystinbacterial metabolite;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
environmental contaminant;
xenobiotic
alpha-D-fructofuranose 1,6-bisphosphate
alpha-D-fructofuranose 1,6-bisphosphate : A D-fructofuranose 1,6-bisphosphate with an alpha-configuration at the anomeric position.		2.0510D-fructofuranose 1,6-bisphosphate
docosahexaenoate
efalex: a mixture of fish oil and primrose oil; used as a high-docosahexaenoic acid fatty acid supplement. docosahexaenoic acid : Any C22 polyunsaturated fatty acid containing six double bonds.. docosahexaenoate : A polyunsaturated fatty acid anion that is the conjugate base of docosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.. all-cis-docosa-4,7,10,13,16,19-hexaenoic acid : A docosahexaenoic acid having six cis-double bonds at positions 4, 7, 10, 13, 16 and 19.		2.0510docosahexaenoic acid;
omega-3 fatty acid		algal metabolite;
antineoplastic agent;
Daphnia tenebrosa metabolite;
human metabolite;
mouse metabolite;
nutraceutical
oleic acid
Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed). oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.		2.0510octadec-9-enoic acidantioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent
tacrolimus
Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.		4.9460macrolide lactambacterial metabolite;
immunosuppressive agent
farnesyl pyrophosphate
farnesyl pyrophosphate: a sesquiterpene that dimerizes to SQUALENE; RN given refers to cpd without isomeric designation. 2-trans,6-trans-farnesyl diphosphate : The trans,trans-stereoisomer of farnesyl diphosphate.		3.1110farnesyl diphosphateEscherichia coli metabolite;
mouse metabolite
cerivastatin
cerivastatin: cerivastatin is the ((E)-(+))-isomer; structure given in first source. cerivastatin : (3R,5S)-3,5-dihydroxyhept-6-enoic acid in which the (7E)-hydrogen is substituted by a 4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl group. Formerly used (as its sodium salt) to lower cholesterol and prevent cardiovascular disease, it was withdrawn from the market worldwide in 2001 following reports of a severe form of muscle toxicity.		2.9740dihydroxy monocarboxylic acid;
pyridines;
statin (synthetic)
rosuvastatin
rosuvastatin : A dihydroxy monocarboxylic acid that is (6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl} hept-6-enoic acid carrying two hydroxy substituents at positions 3 and 5 (the 3R,5S-diastereomer).		4.0840dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrimidines;
statin (synthetic);
sulfonamide		anti-inflammatory agent;
antilipemic drug;
cardioprotective agent;
CETP inhibitor;
environmental contaminant;
xenobiotic
cocaine
Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.		2.4520benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
eicosapentaenoic acid
icosapentaenoic acid : Any straight-chain, C20 polyunsaturated fatty acid having five C=C double bonds.. all-cis-5,8,11,14,17-icosapentaenoic acid : An icosapentaenoic acid having five cis-double bonds at positions 5, 8, 11, 14 and 17.		2.0510icosapentaenoic acid;
omega-3 fatty acid		anticholesteremic drug;
antidepressant;
antineoplastic agent;
Daphnia galeata metabolite;
fungal metabolite;
micronutrient;
mouse metabolite;
nutraceutical
thapsigargin
Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES.. thapsigargin : An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.		2.2110butyrate ester;
organic heterotricyclic compound;
sesquiterpene lactone		calcium channel blocker;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
mycophenolic acid
Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.		4.08402-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic
mupirocin
Mupirocin: A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.. mupirocin : An alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections.		2.0810alpha,beta-unsaturated carboxylic ester;
epoxide;
monocarboxylic acid;
oxanes;
secondary alcohol;
triol		antibacterial drug;
bacterial metabolite;
protein synthesis inhibitor
clindamycin
Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.		4.0740
fosfomycin
Fosfomycin: An antibiotic produced by Streptomyces fradiae.. fosfomycin : A phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus.		3.8630epoxide;
phosphonic acids		antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
zithromax
Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.		4.5670macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
pd 173955
PD 173955: inhibits src family-selective tyrosine kinase; structure in first source		2.0610aryl sulfide;
dichlorobenzene;
methyl sulfide;
pyridopyrimidine		tyrosine kinase inhibitor
geranylgeranyl pyrophosphate
geranylgeranyl pyrophosphate: RN given refers to (E,E,E)-isomer. geranylgeranyl diphosphate : A polyprenol diphosphate having geranylgeranyl as the polyprenyl component.. 2-trans,6-trans,10-trans-geranylgeranyl diphosphate : The all-trans-isomer of geranylgeranyl diphosphate.		2.1710geranylgeranyl diphosphatemouse metabolite
drf 2725
ragaglitazar: a phenoxazine analogue of phenyl propanoic acid; Ragaglitazar is a coligand of PPARalpha and PPARgamma		2.4620
pd 166326
PD 166326: a pyrido(2,3-d)pyrimidine src tyrosine kinase inhibitor		2.4110
gw 3965
GW 3965: a liver X receptor ligand		2.5220diarylmethane
t0901317
T0901317: an LXRalpha and LXRbeta agonist		7.8430
epothilone b
[no description available]		2.0210epothilone;
epoxide		antineoplastic agent;
apoptosis inducer;
microtubule-stabilising agent
n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea
N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea: structure in first source		2.4520
y 27632
Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source. Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme.		2.4620aromatic amide
h 1152
(S)-2-methyl-1-(4-methylisoquinoline-5-sulfonyl)-1,4-diazepane : A member of the class of isoquinolines that is the sulfonamide formed by the formal condensation of the sulfo group of 4-methylisoquinoline-5-sulfonic acid with the 1-amino group of (S)-2-methyl-1,4-diazepane.		2.0310isoquinolines;
N-sulfonyldiazepane		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
diethylstilbestrol
Diethylstilbestrol: A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed). diethylstilbestrol : An olefinic compound that is trans-hex-3-ene in which the hydrogens at positions 3 and 4 have been replaced by p-hydroxyphenyl groups.		2.4520olefinic compound;
polyphenol		antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen
bms 214662
7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine: a farnesyltransferase inhibitor; structure in first source. BMS-214662 : A member of the class of benzodiazepines that is 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine substituted by (1H-imidazol-5-yl)methyl, benzyl, (thiophen-2-yl)sulfonyl, and cyano groups at positions 1, 3R, 4 and 7, respectively. It is a potent inhibitor of farnesyltransferase (IC50 = 1.35nM) which was under clinical development for the treatment of solid tumors.		3.5320benzenes;
benzodiazepine;
imidazoles;
nitrile;
sulfonamide;
thiophenes		antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
octreotide
[no description available]		3.2310
epothilone a
Epothilones: A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES).		3.8230epothilone;
epoxide		antineoplastic agent;
metabolite;
microtubule-stabilising agent;
tubulin modulator
eptifibatide
[no description available]		3.5820homodetic cyclic peptide;
macrocycle;
organic disulfide		anticoagulant;
platelet aggregation inhibitor
7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine
[no description available]		2.0310
6-bromoindirubin-3'-oxime
6-bromoindirubin-3'-oxime: structure in first source. 6-bromoindirubin-3'-oxime : A member of the class of biindoles that is indirubin substituted at position 6 by a bromo group and in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.		2.4620
purvalanol b
purvalanol B: protein kinase inhibitor; structure in first source		2.0810purvalanolprotein kinase inhibitor
y-700
[no description available]		2.0810
repsox
RepSox: inhibits TGF-beta signaling; structure in first source appears to be incorrect		2.0810pyrazolopyridine
alitretinoin
Alitretinoin: A retinoid that is used for the treatment of chronic hand ECZEMA unresponsive to topical CORTICOSTEROIDS. It is also used to treat cutaneous lesions associated with AIDS-related KAPOSI SARCOMA.		2.0510retinoic acidantineoplastic agent;
keratolytic drug;
metabolite;
retinoid X receptor agonist
h 89
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide: structure given in first source. N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N(1)-[3-(4-bromophenyl)prop-2-en-1-yl]ethane-1,2-diamine. It is a protein kinase A inhibitor.. (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide in which the double bond adopts a trans-configuration.		2.0310N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
gs 4071
GS 4071: The acid form.. oseltamivir acid : A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid which is substituted at positions 3, 4, and 5 by pentan-3-yloxy, acetamido, and amino groups, respectively (the 3R,4R,5S enantiomer). An antiviral drug, it is used as the corresponding ethyl ester prodrug, oseltamivir, to slow the spread of influenza.		2.0410acetate ester;
amino acid;
cyclohexenecarboxylic acid;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
marine xenobiotic metabolite
afimoxifene
afimoxifene : A tertiary amino compound that is tamoxifen in which the phenyl group which is in a Z- relationship to the ethyl substituent is hydroxylated at the para- position. It is the active metabolite of tamoxifen.		3.1550phenols;
tertiary amino compound		antineoplastic agent;
estrogen receptor antagonist;
metabolite
decitabine
[no description available]		9.67802'-deoxyribonucleoside
sm 8668
Sch 39304: Sch 42427 is the active entantiomer of the antifungal agent Sch 39304 which consists of Sch 42426 & Sch 42427; Sch 42426, the (S,S)-isomer, is inactive		2.0410
teniposide
[no description available]		4.2650aromatic ether;
beta-D-glucoside;
cyclic acetal;
furonaphthodioxole;
gamma-lactone;
monosaccharide derivative;
phenols;
thiophenes		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
troxacitabine
troxacitabine: shows good anti-HIV activity without cytotoxicity		2.0410carbohydrate derivative;
nucleobase-containing molecular entity
valrubicin
[no description available]		2.4720anthracycline;
trifluoroacetamide
ketoconazole
(2R,4S)-ketoconazole : A cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2R,4S)-configuration.		3.7820cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
purvalanol a
6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine: purvalanol A is the (1R)-isomer;		2.5120purvalanol
cefamandole
Cefamandole: Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate.. cefamandole : A cephalosporin compound having (R)-mandelamido and N-methylthiotetrazole side-groups.		2.4420cephalosporin;
semisynthetic derivative		antibacterial drug
artenimol
[no description available]		3.3110
dactinomycin
Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)		4.0840actinomycinmutagen
tiazofurin
tiazofurin: RN given refers to (beta-D)-isomer; structure given in first source. tiazofurine : A C-glycosyl compound that is 1,3-thiazole-4-carboxamide in which the hydrogen at position 2 has been replaced by a beta-D-ribofuranosyl group. It is metabolised to thiazole-4-carboxamide adenine dinucleotide (TAD), a selective inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase).		2.45201,3-thiazoles;
C-glycosyl compound;
monocarboxylic acid amide		antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
prodrug
azaserine
Azaserine: Antibiotic substance produced by various Streptomyces species. It is an inhibitor of enzymatic activities that involve glutamine and is used as an antineoplastic and immunosuppressive agent.. azaserine : A carboxylic ester resulting from the formal condensation of the carboxy group of diazoacetic acid with the alcoholic hydroxy group of L-serine. An antibiotic produced by a Streptomyces species.		2.0510carboxylic ester;
diazo compound;
L-serine derivative;
non-proteinogenic L-alpha-amino acid		antifungal agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
glutamine antagonist;
immunosuppressive agent;
metabolite
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		6.0581L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
sitafloxacin
[no description available]		2.0410fluoroquinolone antibiotic;
quinolines;
quinolone antibiotic
benzyloxycarbonylleucyl-leucyl-leucine aldehyde
benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.		2.2510amino aldehyde;
carbamate ester;
tripeptide		proteasome inhibitor
tenofovir
tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.		4.140nucleoside analogue;
phosphonic acids		antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor
posaconazole
[no description available]		4.4530aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles		trypanocidal drug
dibekacin
Dibekacin: Analog of KANAMYCIN with antitubercular as well as broad-spectrum antimicrobial properties.. dibekacin : A kanamycin that is kanamycin B lacking the 3- and 4-hydroxy groups on the 2,6-diaminosugar ring.		2.0410kanamycinsantibacterial agent;
protein synthesis inhibitor
rubitecan
rubitecan: RN refers to (+-)-isomer; anti-HIV agent; DNA Topoisomerases, Type I inhibitor. rubitecan : A pyranoindolizinoquinoline that is camptothecin in which the hydrogen at position 9 has been replaced by a nitro group. It is a prodrug for 9-aminocamptothecin.		2.4720C-nitro compound;
delta-lactone;
pyranoindolizinoquinoline;
semisynthetic derivative;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
micafungin
Micafungin: A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.. micafungin : A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.		4.6240antibiotic antifungal drug;
echinocandin		antiinfective agent
shikonin
shikonin: a naphthazarin; has antineoplastic and angiogenesis inhibiting activities		3.3350hydroxy-1,4-naphthoquinone
2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione
[no description available]		2.0310aminotoluene
4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide
[no description available]		2.0810tropane alkaloid
riboflavin
vitamin B2 : Any member of a group of vitamers that belong to the chemical structural class called flavins that exhibit biological activity against vitamin B2 deficiency. Symptoms associated with vitamin B2 deficiency include glossitis, seborrhea, angular stomaitis, cheilosis and photophobia. The vitamers include riboflavin and its phosphate derivatives (and includes their salt, ionised and hydrate forms).		3.5920flavin;
vitamin B2		anti-inflammatory agent;
antioxidant;
cofactor;
Escherichia coli metabolite;
food colouring;
fundamental metabolite;
human urinary metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite
2,3-bis(bromomethyl)quinoxaline-1,4-dioxide
conoidin A: inhibits the peroxiredoxin TgPrx11; structure in first source		4.6111
sodium bicarbonate
Sodium Bicarbonate: A white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.		3.5920one-carbon compound;
organic sodium salt		antacid;
food anticaking agent
sodium acetate, anhydrous
Sodium Acetate: The trihydrate sodium salt of acetic acid, which is used as a source of sodium ions in solutions for dialysis and as a systemic and urinary alkalizer, diuretic, and expectorant.		2.0510organic sodium saltNMR chemical shift reference compound
sodium benzoate
Sodium Benzoate: The sodium salt of BENZOIC ACID. It is used as an antifungal preservative in pharmaceutical preparations and foods. It may also be used as a test for liver function.. sodium benzoate : An organic sodium salt resulting from the replacement of the proton from the carboxy group of benzoic acid by a sodium ion.		2.0510organic sodium saltalgal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite
arsenic trioxide
Tetraarsenic Oxide: A form of As2O3 that exists as As4O6 in the solid state. It dissociates to As2O3 upon heating to the vapor phase above 800 degrees Celsius.		3.5920arsenic oxideantineoplastic agent;
insecticide
dipyrone
Dipyrone: A drug that has analgesic, anti-inflammatory, and antipyretic properties. It is the sodium sulfonate of AMINOPYRINE.. metamizole sodium : An organic sodium salt of antipyrine substituted at C-4 by a methyl(sulfonatomethyl)amino group, commonly used as a powerful analgesic and antipyretic.		2.0510organic sodium saltanti-inflammatory agent;
antipyretic;
antirheumatic drug;
cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug;
prodrug
ditiocarb sodium
[no description available]		2.0510organic molecular entity
bromochloroacetic acid
Keratins: A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.. bromochloroacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by bromine while a second is replaced by chlorine. A low-melting (27.5-31.5degreeC), hygroscopic crystalline solid, it can be formed during the disinfection (by chlorination) of water that contains bromide ions and organic matter, so can occur in drinking water as a byproduct of the disinfection process.		2.02102-bromocarboxylic acid;
monocarboxylic acid;
organochlorine compound
idarubicin hydrochloride
[no description available]		2.0510anthracycline
sr 90107
fondaparinux sodium : An organic sodium salt, being the decasodium salt of fondaparinux.		3.2310
carbenoxolone sodium
Carbenoxolone: An agent derived from licorice root. It is used for the treatment of digestive tract ulcers, especially in the stomach. Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity.		2.0510triterpenoid
carbenoxolone
[no description available]		2.0510
meglumine iodipamide
[no description available]		3.2310organoammonium saltradioopaque medium
methyl ursolate
methyl ursolate: structure in first source		2.1110
glycosides
[no description available]		2.110
chalcone
trans-chalcone : The trans-isomer of chalcone.		7.1510chalconeEC 3.2.1.1 (alpha-amylase) inhibitor
isomethyleugenol
Methylation: Addition of methyl groups. In histo-chemistry methylation is used to esterify carboxyl groups and remove sulfate groups by treating tissue sections with hot methanol in the presence of hydrochloric acid. (From Stedman, 25th ed)		2.8230isomethyleugenol
stilbenes
Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.		3.790stilbene
thyrotropin-releasing hormone
PR 546: no other info available 9/89. protirelin : A tripeptide composed of L-pyroglutamyl, L-histidyl and L-prolinamide residues joined in sequence.		3.2310peptide hormone;
tripeptide		human metabolite
chloroquine diphosphate
[no description available]		2.0310chloroquine
discodermolide
[no description available]		2.0510diterpenoid
dextromethadone
D-methadone: an NMDA receptor antagonist analgesic that lacks opioid activity. dextromethadone : A 6-(dimethylamino)-4,4-diphenylheptan-3-one that has (S)-configuration. It is the less active enantiomer of methadone and has very little activity on opioid receptors and mainly responsible for the inhibition of hERG K+ channels and thus for cardiac toxicity. The drug is currently under clinical development for the treatment of major depressive disorder.		2.03106-(dimethylamino)-4,4-diphenylheptan-3-oneNMDA receptor antagonist;
opioid analgesic
cannabidiol
Cannabidiol: Compound isolated from Cannabis sativa extract.. cannabidiol : An cannabinoid that is cyclohexene which is substituted by a methyl group at position 1, a 2,6-dihydroxy-4-pentylphenyl group at position 3, and a prop-1-en-2-yl group at position 4.		2.0510olefinic compound;
phytocannabinoid;
resorcinols		antimicrobial agent;
plant metabolite
arginine vasopressin
Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.		3.6120vasopressincardiovascular drug;
hematologic agent;
mitogen
s 1033
[no description available]		7.94170(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
N-[3-(trifluoromethyl)phenyl]-4-quinazolinamine
[no description available]		2.0810quinazolines
mezlocillin
Mezlocillin: Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.. mezlocillin : A penicillin in which the substituent at position 6 of the penam ring is a (2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido group.		2.0410penicillin allergen;
penicillin		antibacterial drug
trilostane
trilostane: inhibits conversion of pregnenolone to progesterone; adrenal blocking agent used in treatment of Cushing's syndrome. trilostane : An epoxy steroid that is 3,17beta-dihydroxy-5alpha-androst-2-ene-2-carbonitrile in which the oxygen of the epoxy group is joined to the 4alpha and 5 alpha positions.		2.081017beta-hydroxy steroid;
3-hydroxy steroid;
androstanoid;
epoxy steroid;
nitrile		abortifacient;
antineoplastic agent;
EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor
tropisetron
Tropisetron: An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting.. tropisetron : An indolyl carboxylate ester obtained by formal condensation of the carboxy group of indole-3-carboxylic acid with the hydroxy group of tropine.		2.0410indolyl carboxylic acid
leuprolide acetate
leuprolide acetate : An acetate salt obtained by combining the nonapeptide leuprolide with acetic acid. A long lasting GnRH analog, LH-Rh agonist. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.		2.0810acetate saltantineoplastic agent;
gonadotropin releasing hormone agonist
leuprolide
Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.		3.5320oligopeptideanti-estrogen;
antineoplastic agent;
gonadotropin releasing hormone agonist
fludarabine
[no description available]		2.4520purine nucleoside
propylthiouracil
Propylthiouracil: A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534). 6-propyl-2-thiouracil : A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group.		4.2650pyrimidinethioneantidote to paracetamol poisoning;
antimetabolite;
antioxidant;
antithyroid drug;
carcinogenic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
hormone antagonist
r 59949
R 59949: diacylglycerol kinase inhibitor		2.0310diarylmethane
prothionamide
Prothionamide: Antitubercular agent similar in action and side effects to ETHIONAMIDE. It is used mostly in combination with other agents.		2.0510pyridines
sesquiterpenes
[no description available]		4.5940
chlorprothixene
Chlorprothixene: A thioxanthine with effects similar to the phenothiazine antipsychotics.. (Z)-chlorprothixene : A chlorprothixene in which the double bond adopts a (Z)-configuration.		3.6120chlorprothixene
etomidate
Etomidate: Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.. etomidate : The ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity.		3.8630ethyl ester;
imidazoles		intravenous anaesthetic;
sedative
mercaptopurine
Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.		4.5570aryl thiol;
purines;
thiocarbonyl compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent
dexketoprofen
dexketoprofen : A monocarboxylic acid that is (S)-hydratropic acid substituted at position 3 on the phenyl ring by a benzoyl group. A cyclooxygenase inhibitor, it is used to relieve short-term pain, such as muscular pain, dental pain and dysmenorrhoea.		2.0310benzophenones;
monocarboxylic acid		cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
ag-213
tyrphostin 47: inhibits protein-tyrosine kinase activity of EGF-R both in vitro and in living cells;		2.0410
3,3',4,5'-tetrahydroxystilbene
3,3',4,5'-tetrahydroxystilbene: demethyl derivative of isorhapontigenin; structure in first source; a Syk kinase inhibitor; found in heartwood of FABACEAE; inhibitor of photosynthesis in spinach chloroplasts; may be inhibitor of plant growth; RN given refers to (E)-isomer. piceatannol : A stilbenol that is trans-stilbene in which one of the phenyl groups is substituted by hydroxy groups at positions 3 and 4, while the other phenyl group is substituted by hydroxy groups at positions 3 and 5.		2.0310catechols;
polyphenol;
resorcinols;
stilbenol		antineoplastic agent;
apoptosis inducer;
geroprotector;
hypoglycemic agent;
plant metabolite;
protein kinase inhibitor;
tyrosine kinase inhibitor
levosulpiride
(S)-(-)-sulpiride : An optically active form of sulpiride having (S)-configuration. The active enantiomer of the racemic drug sulpiride. Selective D2-like dopamine antagonist (Ki values are ~ 0.015. ~ 0.013, 1, ~ 45 and ~ 77 muM at D2, D3, D4, D1 and D5 receptors respectively).		2.0810sulpirideantidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
5-(2-bromovinyl)uracil
5-(2-bromovinyl)uracil: RN given refers to (E)-isomer		2.2510
ondansetron, (s)-isomer
[no description available]		2.0310
rg108
RG108: DNA methyltransferase inhibitor; structure in first source		2.0810indolyl carboxylic acid
pyrantel
Pyrantel: A depolarizing neuromuscular-blocking agent, that causes persistent nicotinic activation resulting in spastic paralysis of susceptible nematodes. It is a drug of second-choice after benzimidazoles for treatment of ascariasis, hookworm, and pinworm infections, being effective after a single dose. (From Smith and Reynard, Textbook of Pharmacology, 1992, p920). pyrantel : A carboxamidine that is 1,4,5,6-tetrahydropyrimidine that is substituted at position 1 by a methyl group and at position 2 by an (E)-2-(2-thienyl)vinyl group. It is used, particularly as the embonate [4,4'-methylenebis(3-hydroxy-2-naphthoate)] salt, as an anthelmintic that is effective against intestinal nematodes including threadworms, roundworms and hookworms, and is included in the WHO 'Model List of Essential Medicines'.		3.23101,4,5,6-tetrahydropyrimidines;
carboxamidine;
thiophenes		antinematodal drug
stf 083010
[no description available]		2.0810
4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol
[no description available]		2.5420substituted aniline
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide
[no description available]		2.0810naphthalenecarboxamide
cotinine
Cotinine: The N-glucuronide conjugate of cotinine is a major urinary metabolite of NICOTINE. It thus serves as a biomarker of exposure to tobacco SMOKING. It has CNS stimulating properties.. (-)-cotinine : An N-alkylpyrrolidine that consists of N-methylpyrrolidinone bearing a pyridin-3-yl substituent at position C-5 (the 5S-enantiomer). It is an alkaloid commonly found in Nicotiana tabacum.		2.0410N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid		antidepressant;
biomarker;
human xenobiotic metabolite;
plant metabolite
3-amino-n-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide
3-amino-N-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide: structure in first source		2.0610
thiothixene
[no description available]		3.5920N-methylpiperazineanticoronaviral agent
eszopiclone
Eszopiclone: A pyridine, pyrazine, and piperazine derivative that is used as a HYPNOTIC AND SEDATIVE in the treatment of INSOMNIA.. eszopiclone : The (5S)- (active) enantiomer of zopiclone. Unlike almost all other hypnotic sedatives, which are approved only for the relief of short-term (6-8 weeks) insomnia, eszopiclone is approved by the U.S. Food and Drug Administration for long-term use.		3.8630zopiclonecentral nervous system depressant;
sedative
tetrahydropalmatine
[no description available]		2.0710
curcumin
Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.		4.3850aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
cct018159
CCT018159: structure in first source. CCT-018159 : A member of the class of pyrazoles that is 1H-pyrazole carrying 1,4-benzodioxane-6-yl and 5-ethyl-2,4-dihydroxyphenyl substituents at positions 4 and 5 respectively.		2.4820benzodioxine;
pyrazoles;
resorcinols		antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor
secinh3
SecinH3: a small molecule antagonist of cytohesins; structure in first source		2.4820triazoles
jk184
JK184: structure in first source		2.0810
benztropine
Benztropine: A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.. benzatropine : Tropane in which a hydrogen at position 3 is substituted by a diphenylmethoxy group (endo-isomer). An acetylcholine receptor antagonist, it is used (particularly as its methanesulphonate salt) in the treatment of Parkinson's disease, and to reduce parkinsonism and akathisia side effects of antipsychotic treatments.		3.2310diarylmethane
methimazole
Methimazole: A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.. methimazole : A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen.		4.41601,3-dihydroimidazole-2-thionesantithyroid drug
cinnarizine
Cinnarizine: A piperazine derivative having histamine H1-receptor and calcium-channel blocking activity with vasodilating and antiemetic properties but it induces PARKINSONIAN DISORDERS.		2.7630diarylmethane;
N-alkylpiperazine;
olefinic compound		anti-allergic agent;
antiemetic;
calcium channel blocker;
geroprotector;
H1-receptor antagonist;
histamine antagonist;
muscarinic antagonist
sulindac
Sulindac: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.. sulindac : A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.		4.4260monocarboxylic acid;
organofluorine compound;
sulfoxide		analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent
capsaicin
ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.		7.7830capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
terbinafine
[no description available]		3.8630acetylenic compound;
allylamine antifungal drug;
enyne;
naphthalenes;
tertiary amine		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor;
sterol biosynthesis inhibitor
epalrestat
epalrestat : A monocarboxylic acid that is 1,3-thiazolidine which is substituted on the nitrogen by a carboxymethyl group, at positions 2 and 4 by thioxo and oxo groups, respectively, and at position 5 by a 2-methyl-3-phenylprop-2-en-1-ylidene group. It is an inhibitor of aldose reductase (which catalyses the conversion of glucose to sorbitol) and is used for the treatment of some diabetic complications, including neuropathy.		2.0810monocarboxylic acid;
thiazolidines		EC 1.1.1.21 (aldehyde reductase) inhibitor
drotaverin
drotaverin: Hungarian drug; RN given refers to parent cpd; structure		2.7530isoquinolines
fatostatin
fatostatin: inhibits activation of SREBP; structure in first source		2.1310thiazoles
tg 003
TG 003: a Clk inhibitor; structure in first source		2.0310
xl147
[no description available]		2.1510aromatic amine;
benzothiadiazole;
quinoxaline derivative;
sulfonamide		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
thioguanine anhydrous
Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.		4.8502-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
(1R,2S)-tranylcypromine hydrochloride
(1R,2S)-tranylcypromine hydrochloride : A hydrochloride obtained by combining (1R,2S)-tranylcypromine with one equivalent of hydrochloric acid.		2.0510hydrochloride
tacrine hydrochloride
[no description available]		2.0510
thiourea
Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.		2.7530one-carbon compound;
thioureas;
ureas		antioxidant;
chromophore
sodium propionate
sodium propionate: was term of propionic acid (1986-2006). sodium propionate : An organic sodium salt comprising equal numbers of sodium and propionate ions.		2.0510organic sodium saltantifungal drug;
food preservative
thioacetamide
Thioacetamide: A crystalline compound used as a laboratory reagent in place of HYDROGEN SULFIDE. It is a potent hepatocarcinogen.. thioacetamide : A thiocarboxamide consiting of acetamide having the oxygen replaced by sulfur.		2.5120thiocarboxamidehepatotoxic agent
tempo
TEMPO: structure. TEMPO : A member of the class of aminoxyls that is piperidine that carries an oxidanediyl group at position 1 and methyl groups at positions 2, 2, 6, and 6, respectively.		2.0710aminoxyls;
piperidines		catalyst;
ferroptosis inhibitor;
radical scavenger
brij-58
Cetomacrogol: Non-ionic surfactant of the polyethylene glycol family. It is used as a solubilizer and emulsifying agent in foods, cosmetics, and pharmaceuticals, often as an ointment base, and also as a research tool.		2.0710
succimer
Succimer: A mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.. succimer : A sulfur-containing carboxylic acid that is succinic acid bearing two mercapto substituents at positions 2 and 3. A lead chelator used as an antedote to lead poisoning.		3.2310dicarboxylic acid;
dithiol;
sulfur-containing carboxylic acid		chelator
digoxin
Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.		4.460cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
streptozocin
[no description available]		4.0840
tamoxifen citrate
[no description available]		2.0810citrate saltangiogenesis inhibitor;
anticoronaviral agent
tamoxifen
[no description available]		11.77465stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
nadp
[no description available]		2.8330
hc-067047
HC-067047: a TRPA1 antagonist; structure in first source		2.0810
bi-78d3
[no description available]		2.0810aryl sulfide
ethionamide
Ethionamide: A second-line antitubercular agent that inhibits mycolic acid synthesis.. ethionamide : A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.		3.5920pyridines;
thiocarboxamide		antilipemic drug;
antitubercular agent;
fatty acid synthesis inhibitor;
leprostatic drug;
prodrug
stattic
[no description available]		2.31101-benzothiophenes;
C-nitro compound;
sulfone		antineoplastic agent;
radiosensitizing agent;
STAT3 inhibitor
gsk 3787
[no description available]		2.0810
cancidas
[no description available]		4.4230
methyl-thiohydantoin-tryptophan
methyl-thiohydantoin-tryptophan: structure in first source		2.0810organonitrogen compound;
organooxygen compound
2-[2-chloro-6-ethoxy-4-[(3-methyl-5-oxo-1-phenyl-4-pyrazolylidene)methyl]phenoxy]acetic acid methyl ester
[no description available]		2.0810monocarboxylic acid
4-(5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1h-pyrazol-1-yl)benzenesulfonamide
[no description available]		2.0810sulfonamide
lch-7749944
LCH-7749944: potent p21-activated kinase 4 inhibitor, structure in first source		3.3110
fusidic acid
Fusidic Acid: An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed). It acts by inhibiting translocation during protein synthesis.. fusidic acid : A steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum.		4.285011alpha-hydroxy steroid;
3alpha-hydroxy steroid;
alpha,beta-unsaturated monocarboxylic acid;
steroid acid;
steroid antibiotic;
sterol ester		EC 2.7.1.33 (pantothenate kinase) inhibitor;
Escherichia coli metabolite;
protein synthesis inhibitor
lincomycin
Lincomycin: An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.. lincomycin : A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis.		3.8630carbohydrate-containing antibiotic;
L-proline derivative;
monocarboxylic acid amide;
pyrrolidinecarboxamide;
S-glycosyl compound		antimicrobial agent;
bacterial metabolite
valinomycin
Valinomycin: A cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related to the enniatins. It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid linked alternately to form a 36-membered ring. (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies.. valinomycin : A twelve-membered cyclodepsipeptide composed of three repeating D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl units joined in sequence. An antibiotic found in several Streptomyces strains.		2.4720cyclodepsipeptide;
macrocycle		antimicrobial agent;
antiviral agent;
bacterial metabolite;
potassium ionophore
thiopental
Thiopental: A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration.. thiopental : A barbiturate, the structure of which is that of 2-thiobarbituric acid substituted at C-5 by ethyl and sec-pentyl groups.		2.0410barbituratesanticonvulsant;
drug allergen;
environmental contaminant;
intravenous anaesthetic;
sedative;
xenobiotic
estrone sulfate
estrone sulfate: sulfoconjugated estrone; RN given refers to parent cpd		2.964017-oxo steroid;
steroid sulfate		human metabolite;
mouse metabolite
ranitidine
Ranitidine: A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.. ranitidine : A member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease.		5.2831C-nitro compound;
furans;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic
aplaviroc
aplaviroc: a spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1; structure in first source		3.2310
hmr 3647
[no description available]		4.6780
latoconazole
latoconazole: RN refers to cpd without isomeric designation; latoconazole is (E)-isomer; structure given in first source		2.0810conazole antifungal drug;
imidazole antifungal drug
maraviroc
[no description available]		3.6120tropane alkaloid
LSM-1318
[no description available]		2.0810oxa-steroid
toremifene citrate
[no description available]		2.0810stilbenoidanticoronaviral agent
toremifene
Toremifene: A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.		3.5920aromatic ether;
organochlorine compound;
tertiary amine		antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
u 0126
U 0126: protein kinase kinase inhibitor; structure in first source		4.97110aryl sulfide;
dinitrile;
enamine;
substituted aniline		antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent
rwj 67657
RWJ 67657: inhibits p38 mitogen-activated protein kinase; structure in first source		2.0810
2',3'-didehydro-3'-deoxy-4'-ethynylthymidine
2',3'-didehydro-3'-deoxy-4'-ethynylthymidine: a highly active anti-HIV agent; structure in first source		2.2510
telaprevir
[no description available]		2.0510cyclopentapyrrole;
cyclopropanes;
oligopeptide;
pyrazines		antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic
nelarabine
nelarabine: prodrug of ara-G. nelarabine : A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G).		4.6340beta-D-arabinoside;
monosaccharide derivative;
purine nucleoside		antineoplastic agent;
DNA synthesis inhibitor;
prodrug
2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine
[no description available]		2.0410aromatic ether
6-methyl-2-(phenylethynyl)pyridine
6-methyl-2-(phenylethynyl)pyridine: an mGlu5 antagonist. 2-methyl-6-(phenylethynyl)pyridine : A methylpyridine that coinsists of 2-methylp[yridine bearing an additional phenylethynyl group at position 6. Potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors. Centrally active following systemic administration in vivo. Reverses mechanical hyperalgesia in the inflamed rat hind paw.		2.0810acetylenic compound;
methylpyridines		anxiolytic drug;
metabotropic glutamate receptor antagonist
bms 387032
N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide: a CDK2 inhibitor with antineoplastic activity; structure in first source. N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of piperidine-4-carboxylic acid with the amino group of 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine. It is an ATP-competitive inhibitor of CDK2, CDK7 and CDK9 kinases and exhibits anti-cancer properties.		4.97801,3-oxazoles;
1,3-thiazoles;
organic sulfide;
piperidinecarboxamide;
secondary carboxamide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
nitrogen dioxide
Nitrogen Dioxide: Nitrogen oxide (NO2). A highly poisonous gas. Exposure produces inflammation of lungs that may only cause slight pain or pass unnoticed, but resulting edema several days later may cause death. (From Merck, 11th ed) It is a major atmospheric pollutant that is able to absorb UV light that does not reach the earth's surface.		4.6111nitrogen oxide
dermatan sulfate
Dermatan Sulfate: A naturally occurring glycosaminoglycan found mostly in the skin and in connective tissue. It differs from CHONDROITIN SULFATE A (see CHONDROITIN SULFATES) by containing IDURONIC ACID in place of glucuronic acid, its epimer, at carbon atom 5. (from Merck, 12th ed). alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S : An oligosaccharide sulfate that is 2-acetamido-2-deoxy-4-O-sulfo-beta-D-galactopyranose in which the hydroxy group at position 3 has been converted to the corresponding alpha-L-idopyranuronoside.. dermatan sulfate : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated beta1->4-linked L-iduronyl-(alpha1->3)-N-acetyl-D-galactosamine units.		3.2310amino disaccharide;
glycosylgalactose derivative;
iduronic acids;
oligosaccharide sulfate
droloxifene
[no description available]		2.0510stilbenoid
raclopride
Raclopride: A substituted benzamide that has antipsychotic properties. It is a dopamine D2 receptor (see RECEPTORS, DOPAMINE D2) antagonist.		2.0810salicylamides
dolasetron
[no description available]		3.8730indolyl carboxylic acid
or 1259
[no description available]		2.4520hydrazone;
nitrile;
pyridazinone		anti-arrhythmia drug;
cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
vasodilator agent
gestodene
Gestodene: synthetic steroid with progestational activity; RN given refers to (17alpha)-isomer		2.7530steroidestrogen
orlistat
Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.		3.8730beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative		anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor
idoxifene
idoxifene: structure given in first source		2.0510stilbenoid
quinine
[no description available]		4.4160cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
amrubicin
amrubicin: structure in first source; a 9-amino-anthracycline antibiotic. amrubicin : A synthetic anthracycline antibiotic with molecular formula C25H25NO9. A specific inhibitor of topoisomerase II, it is used (particularly as the hydrochloride salt) in the treatment of cancer, especially lung cancer, where it is a prodrug for the active metabolite, ambrucinol.		3.5320anthracycline antibiotic;
methyl ketone;
primary amino compound;
quinone;
tetracenes		antineoplastic agent;
prodrug;
topoisomerase II inhibitor
rtki cpd
RTKI cpd: preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors		5.41220
sf 2370
SF 2370: indolocarbazole isolated from Actinomadura sp. SF-2370; structure given in first source. K-252a : A organic heterooctacyclic compound that is a potent inhibitor of protein kinase C and is isolated from Nocardiopsis sp K-252a		2.5220bridged compound;
gamma-lactam;
methyl ester;
organic heterooctacyclic compound		antimicrobial agent;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
tropomyosin-related kinase B receptor antagonist
u-50488
3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer: A non-peptide, kappa-opioid receptor agonist which has also been found to stimulate the release of adrenocorticotropin (ADRENOCORTICOTROPIC HORMONE) via the release of hypothalamic arginine vasopressin (ARGININE VASOPRESSIN) and CORTICOTROPIN-RELEASING HORMONE. (From J Pharmacol Exp Ther 1997;280(1):416-21). U50488 : A monocarboxylic acid amide obtained by formal condensation between the carboxy group of 3,4-dichlorophenylacetic acid and the secondary amino group of (1R,2R)-N-methyl-2-(pyrrolidin-1-yl)cyclohexanamine		2.0710dichlorobenzene;
monocarboxylic acid amide;
N-alkylpyrrolidine		analgesic;
antitussive;
calcium channel blocker;
diuretic;
kappa-opioid receptor agonist
ly335979
[no description available]		2.0810carbopolycyclic compound
isepamicin
[no description available]		2.0410
ifetroban
ifetroban: thromboxane receptor antagonist; structure given in first source; a 7-oxabicyclo(2.2.1)heptane derivative		2.0410benzenes;
monocarboxylic acid
lamifiban
lamifiban: a nonpeptide glycoprotein IIb/IIIa antagonist; prevents platelet loss during experimental cardiopulmonary bypass		2.0410N-acylglycine
fospropofol
[no description available]		3.2310alkylbenzene
tandutinib
[no description available]		10.0590aromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
piperidines;
quinazolines;
tertiary amino compound		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
vx-745
[no description available]		4.8270aryl sulfide;
dichlorobenzene;
difluorobenzene;
pyrimidopyridazine		anti-inflammatory drug;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
corlanor
ivabradine hydrochloride : A hydrochloride obtained by combining ivabradine with one molar equivalent of hydrochloric acid. Used to treat patients with angina who have intolerance to beta blockers and/or heart failure.		2.0810hydrochloridecardiotonic drug
azilect
[no description available]		2.0810
rasagiline
[no description available]		3.2310indanes;
secondary amine;
terminal acetylenic compound		EC 1.4.3.4 (monoamine oxidase) inhibitor;
neuroprotective agent
dasatinib
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).		11.314111,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
ha 1100
HA 1100: intracellular calcium antagonist		2.1510
7-epi-hydroxystaurosporine
[no description available]		2.1510
tocainide, (s)-isomer
[no description available]		2.0310
zd 6474
CH 331: structure in first source		12.29551aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine		antineoplastic agent;
tyrosine kinase inhibitor
telavancin
telavancin: an anti-infective agent; structure in first source. telavancin : A glycopeptide that is vancomycin substituted at position N-3'' by a 2-(decylamino)ethyl group and at position C-29 by a (phosphonomethyl)aminomethyl group. Used as its hydrochloride salt for treatment of adults with complicated skin and skin structure infections caused by bacteria.		2.0410glycopeptideantibacterial drug;
antimicrobial agent
salinomycin
salinomycin: from Streptomyces albus; RN given refers to parent cpd; structure		7.1510polyketide;
spiroketal		animal growth promotant;
potassium ionophore
silybin
[no description available]		2.0510
N-methyl-2-[[3-[2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide
[no description available]		2.0610aryl sulfide
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
[no description available]		2.0610indoles
compound 968
compound 968: a glutaminase inhibitor. 5-[3-bromo-4-(dimethylamino)phenyl]-2,2-dimethyl-2,3,5,6-tetrahydrobenzo[a]phenanthridin-4(1H)-one : A partially hydrogenated benzophenanthridine carrying an oxo group at C-4, geminal methyl groups at C-2 and a 3-bromo-4-(dimethylamino)phenyl group at C-5.		2.0810benzophenanthridineEC 3.5.1.2 (glutaminase) inhibitor
phosphothreonine
Phosphothreonine: The phosphoric acid ester of threonine. Used as an identifier in the analysis of peptides, proteins, and enzymes.. O-phospho-L-threonine : A L-threonine derivative phosphorylated at the side-chain hydroxy function.		2.2510L-threonine derivative;
non-proteinogenic L-alpha-amino acid;
O-phosphoamino acid		Escherichia coli metabolite
cambinol
cambinol: inhibitor of human silent information regulator 2 enzymes; structure in first source		2.0810
ovalbumin
Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.		2.4720
sb-224289
SB 224289 : A member of the class of benzamides obtained by formal condensation of the carboxy group of 2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxylic acid with the secondary amino group of 1'-methyl-6,7-dihydro-5H-spiro[furo[2,3-f]indole-3,4'-piperidine]. Selective 5-HT1B receptor antagonist (pKi = 8.2). Displays >60-fold selectivity over 5-HT1D, 5-HT1A, 5-HT1E, 5-HT1F, 5-HT2A and 5-HT2C receptors in radioligand binding and functional assays. Centrally active following oral administration in vivo.		2.08101,2,4-oxadiazole;
azaspiro compound;
benzamides;
organic heterotetracyclic compound		serotonergic antagonist
gtp 14564
[no description available]		2.0310pyrazoles;
ring assembly
sb 218078
[no description available]		2.0310indolocarbazole
gw 7647
GW 7647: a PPAR-alpha agonist; structure in first source. GW 7647 : A monocarboxylic acid that is 2-(phenylsulfanyl)isobutyric acid in which the phenyl group is substituted at the para- position by a 3-aza-7-cyclohexylhept-1-yl group in which the nitrogen is acylated by a (cyclohexylamino)carbonyl group.		2.0810aryl sulfide;
monocarboxylic acid;
ureas		PPARalpha agonist
mtt formazan
MTT formazan: a blue MEM-insoluble mitochondrial byproduct; used to determine viability of cells with active mitochondrial dehydrogenase enzymes		2.0210
chloramine-t
chloramine-T: RN given refers to unlabeled parent cpd. chloramine T : An organic sodium salt derivative of toluene-4-sulfonamide with a chloro substituent in place of an amino hydrogen.		2.0510organic sodium saltallergen;
antifouling biocide;
disinfectant
l 663536
MK-886: orally active leukotriene biosynthesis inhibitor. 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase.		2.0810aryl sulfide;
indoles;
monocarboxylic acid;
monochlorobenzenes		antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
leukotriene antagonist
1-[6-(4-chlorophenyl)-5-imidazo[2,1-b]thiazolyl]-N-[(3,4-dichlorophenyl)methoxy]methanimine
[no description available]		2.0810imidazoles
N4-ethyl-N6,1,2-trimethyl-N4-phenylpyrimidin-1-ium-4,6-diamine
[no description available]		2.0810aromatic amine;
tertiary amino compound
ferrostatin-1
ferrostatin-1: inhibits ferroptosis, an iron-dependent form of nonapoptotic cell death; structure in first source. ferrostatin-1 : An ethyl ester resulting from the formal condensation of the carboxy group of 3-amino-4-(cyclohexylamino)benzoic acid with ethanol. It is a potent inhibitor of ferroptosis, a distinct non-apoptotic form of cell death caused by lipid peroxidation. It is also a radical-trapping antioxidant and has the ability to reduce the accumulation of lipid peroxides and chain-carrying peroxyl radicals.		2.2510ethyl ester;
primary arylamine;
substituted aniline		antifungal agent;
antioxidant;
ferroptosis inhibitor;
neuroprotective agent;
radiation protective agent;
radical scavenger
2-[[2-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1-oxo-5-isoquinolinyl]oxy]propanoic acid ethyl ester
[no description available]		2.0810isoquinolines
naphthoquinones
Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.		3.1140
sch 79797
[no description available]		2.0810quinazolines
sitagliptin
sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.		4.0840triazolopyrazine;
trifluorobenzene		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
environmental contaminant;
hypoglycemic agent;
serine proteinase inhibitor;
xenobiotic
ver-49009
VER-49009: inhibits heat shock protein 90 molecular chaperone; structure in first source. 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-(4-methoxyphenyl)pyrazole-3-carboxamide : An aromatic amide obtained by formal condensation of the carboxy group of 5-(5-chloro-2,4-dihydroxyphenyl)-4-(4-methoxyphenyl)pyrazole-3-carboxylic acid with the amino group of ethylamine.		2.0610aromatic amide;
monochlorobenzenes;
monomethoxybenzene;
pyrazoles;
resorcinols		Hsp90 inhibitor
osteoprotegerin
Osteoprotegerin: A secreted member of the TNF receptor superfamily that negatively regulates osteoclastogenesis. It is a soluble decoy receptor of RANK LIGAND that inhibits both CELL DIFFERENTIATION and function of OSTEOCLASTS by inhibiting the interaction between RANK LIGAND and RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B.		2.0510long-chain fatty acid
flosequinan
[no description available]		2.0510quinolines
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide: a TGF-beta type I receptor kinase activity inhibitor		4.9680benzamides;
benzodioxoles;
imidazoles;
pyridines		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
rhodamine 123
Rhodamine 123: A fluorescent probe with low toxicity which is a potent substrate for ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 and the bacterial multidrug efflux transporter. It is used to assess mitochondrial bioenergetics in living cells and to measure the efflux activity of ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 in both normal and malignant cells. (Leukemia 1997;11(7):1124-30). rhodamine 123(1+) : A cationic fluorescent dye derived from 9-phenylxanthene.		2.0210organic cation;
xanthene dye		fluorochrome
tolcapone
Tolcapone: A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.. tolcapone : Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase.		4.42602-nitrophenols;
benzophenones;
catechols		antiparkinson drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
myelin basic protein
Myelin Basic Protein: An abundant cytosolic protein that plays a critical role in the structure of multilamellar myelin. Myelin basic protein binds to the cytosolic sides of myelin cell membranes and causes a tight adhesion between opposing cell membranes.		2.2110
1-(4-Fluorophenyl)-3-(3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one
[no description available]		2.0810monobactam
alsterpaullone
alsterpaullone: structure in first source. alsterpaullone : An organic heterotetracyclic compound that is 1,3-dihydro-2H-1-benzazepin-2-one which shares its 4-5 bond with the 3-2 bond of 5-nitro-1H-indole.		4.1340C-nitro compound;
caprolactams;
organic heterotetracyclic compound		anti-HIV-1 agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor
imd 0354
N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide: a cardioprotective agent that inhibits IkappaB kinase beta (IKKbeta); structure in first source		2.7830benzamides
ex 527
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide: structure in first source. 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide : A member of the class of carbazoles that is 2,3,4,9-tetrahydro-1H-carbazole which is substituted at position 1 by an aminocarbohyl group and at position 6 by a chlorine.		2.0810carbazoles;
monocarboxylic acid amide;
organochlorine compound
sq 109
N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine: has antitubercular activity		3.5110
ku 55933
2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one: specific inhibitor of the ataxia-telangiectasia mutated kinase ATM; structure in first source		3.5620
quercetin
[no description available]		8.871107-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
bilirubin
[no description available]		2.0510biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		3.6790prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
dinoprost
Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.		2.0510monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite
biochanin a
[no description available]		2.04104'-methoxyisoflavones;
7-hydroxyisoflavones		antineoplastic agent;
EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
acacetin
5,7-dihydroxy-4'-methoxyflavone : A monomethoxyflavone that is the 4'-methyl ether derivative of apigenin.		2.0610dihydroxyflavone;
monomethoxyflavone		anticonvulsant;
plant metabolite
apigenin
Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.		3.8730trihydroxyflavoneantineoplastic agent;
metabolite
luteolin
[no description available]		2.48203'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
calcitriol
dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes		6.6182D3 vitamins;
hydroxycalciol;
triol		antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical
beta carotene
beta Carotene: A carotenoid that is a precursor of VITAMIN A. Beta carotene is administered to reduce the severity of photosensitivity reactions in patients with erythropoietic protoporphyria (PORPHYRIA, ERYTHROPOIETIC).. provitamin A : A provitamin that can be converted into vitamin A by enzymes from animal tissues.		2.0510carotenoid beta-end derivative;
cyclic carotene		antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A
retinol palmitate
retinol palmitate: RN given refers to parent cpd; structure. retinyl palmitate : A palmitate ester of retinol with undefined geometry about the C=C bonds.. all-trans-retinyl palmitate : An all-trans-retinyl ester obtained by formal condensation of the carboxy group of palmitic (hexadecanoic acid) with the hydroxy group of all-trans-retinol. It is used in cosmetic products to treat various skin disorders such as acne, skin aging, wrinkles, dark spots, and also protect against psoriasis.		2.0510all-trans-retinyl ester;
retinyl palmitate		antioxidant;
Escherichia coli metabolite;
human xenobiotic metabolite
hymecromone
Hymecromone: A coumarin derivative possessing properties as a spasmolytic, choleretic and light-protective agent. It is also used in ANALYTICAL CHEMISTRY TECHNIQUES for the determination of NITRIC ACID.		2.0510hydroxycoumarinantineoplastic agent;
hyaluronic acid synthesis inhibitor
daphnetin
[no description available]		2.0310hydroxycoumarin
alprostadil
[no description available]		2.7630prostaglandins Eanticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent
vitamin d 2
Ergocalciferols: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.. vitamin D2 : A vitamin D supplement and has been isolated from alfalfa.		3.8730hydroxy seco-steroid;
seco-ergostane;
vitamin D		bone density conservation agent;
nutraceutical;
plant metabolite;
rodenticide
cholecalciferol
Cholecalciferol: Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24.. calciol : A hydroxy seco-steroid that is (5Z,7E)-9,10-secocholesta-5,7,10(19)-triene in which the pro-S hydrogen at position 3 has been replaced by a hydroxy group. It is the inactive form of vitamin D3, being hydroxylated in the liver to calcidiol (25-hydroxyvitamin D3), which is then further hydroxylated in the kidney to give calcitriol (1,25-dihydroxyvitamin D3), the active hormone.		4.9721D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone		geroprotector;
human metabolite
genistein
[no description available]		9.57707-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		4.6340antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
clavulanic acid
Clavulanic Acid: A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.. clavulanate : The conjugate base of clavulanic acid.. clavulanic acid : Antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes.		2.7330oxapenamantibacterial drug;
anxiolytic drug;
bacterial metabolite;
EC 3.5.2.6 (beta-lactamase) inhibitor
pulmicort
Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.		4.416011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic acetal;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
bronchodilator agent;
drug allergen
oxymetholone
Oxymetholone: A synthetic hormone with anabolic and androgenic properties. It is used mainly in the treatment of anemias. According to the Fourth Annual Report on Carcinogens (NTP 85-002), this compound may reasonably be anticipated to be a carcinogen. (From Merck Index, 11th ed). oxymetholone : A 3-oxo-5alpha- steroid that is 4,5alpha-dihydrotestosterone which is substituted by a hydroxymethylidene group at position 2 and by a methyl group at the 17alpha position. A synthetic androgen, it was mainly used for the treatment of anaemias until being replaced by treatments with fewer side effects.		3.8730
eprosartan
eprosartan: angiotensin II receptor antagonist. eprosartan : A member of the class of imidazoles and thiophenes that is an angiotensin II receptor antagonist used for the treatment of high blood pressure.		4.2650dicarboxylic acid;
imidazoles;
thiophenes		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
montelukast
montelukast: a leukotriene D4 receptor antagonist		4.5670aliphatic sulfide;
monocarboxylic acid;
quinolines		anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist
mivacurium
Mivacurium: An isoquinoline derivative that is used as a short-acting non-depolarizing agent.		3.5820isoquinolines
timolol maleate
(S)-timolol maleate : The maleic acid salt of the active (S)-enantiomer of timolol, comprising equimolar amounts of (S)-timolol and maleic acid.		2.0510maleate saltanti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist
brompheniramine maleate
brompheniramine maleate : The maleic acid salt of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.		2.4720maleate saltanti-allergic agent
chlorpheniramine maleate
[no description available]		2.0510organic molecular entity
clemastine fumarate
clemastine fumarate : The fumaric acid salt of clemastine. An antihistamine with antimuscarinic and moderate sedative properties, it is used for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions.		2.0510fumarate saltanti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist
dexchlorpheniramine maleate
[no description available]		2.0810organic molecular entity
methylergonovine maleate
[no description available]		2.0510ergoline alkaloidgeroprotector
hemabate
carboprost tromethamine : The tromethamine salt of carboprost. It is used as an abortifacient agent that is effective in both the first and second trimesters of pregnancy.		3.2310
mycophenolate mofetil
mycophenolate mofetil : A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.		3.8730carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound		anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug
entacapone
entacapone: structure given in first source. entacapone : A monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group.		4.43602-nitrophenols;
catechols;
monocarboxylic acid amide;
nitrile		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
paricalcitol
[no description available]		3.5820hydroxy seco-steroid;
seco-cholestane		antiparathyroid drug
butein
[no description available]		7.1110chalcones;
polyphenol		antineoplastic agent;
antioxidant;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
geroprotector;
hypoglycemic agent;
plant metabolite;
radiosensitizing agent;
tyrosine kinase inhibitor
astaxanthine
astaxanthine: a keto form of carotene; pigment in flesh of Scottish salmon (Salmo salar) crustacoa-lobster (Homarus gammarus, flamingo feathers; structure; a carotenoid without vitamin A activity, has shown anti-oxidant and anti-inflammatory activities. astaxanthin : A carotenone that consists of beta,beta-carotene-4,4'-dione bearing two hydroxy substituents at positions 3 and 3' (the 3S,3'S diastereomer). A carotenoid pigment found mainly in animals (crustaceans, echinoderms) but also occurring in plants. It can occur free (as a red pigment), as an ester, or as a blue, brown or green chromoprotein.		2.0510carotenol;
carotenone		animal metabolite;
anticoagulant;
antioxidant;
food colouring;
plant metabolite
fucoxanthin
fucoxanthin: RN given refers to (3S,3'S,5R,5'R,6S,6'R)-isomer. fucoxanthin : An epoxycarotenol that is found in brown seaweed and which exhibits anti-cancer, anti-diabetic, anti-oxidative and neuroprotective properties.		7.3110
cucurbitacin b
[no description available]		2.8930cucurbitacin;
secondary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone
7-hydroxycoumarin
7-oxycoumarin: derivatives have anti-oxidant properties. umbelliferone : A hydroxycoumarin that is coumarin substituted by a hydroxy group ay position 7.		2.2110hydroxycoumarinfluorescent probe;
food component;
plant metabolite
baicalein
[no description available]		4.6111trihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger
chrysin
chrysin : A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7.		2.04107-hydroxyflavonol;
dihydroxyflavone		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite
diosmin
[no description available]		2.0510dihydroxyflavanone;
disaccharide derivative;
glycosyloxyflavone;
monomethoxyflavone;
rutinoside		anti-inflammatory agent;
antioxidant
morin
morin: a light yellowish pigment found in the wood of old fustic (Chlorophora tinctoria). morin : A pentahydroxyflavone that is 7-hydroxyflavonol bearing three additional hydroxy substituents at positions 2' 4' and 5.		2.04107-hydroxyflavonol;
pentahydroxyflavone		angiogenesis modulating agent;
anti-inflammatory agent;
antibacterial agent;
antihypertensive agent;
antineoplastic agent;
antioxidant;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
hepatoprotective agent;
metabolite;
neuroprotective agent
quercetagetin
quercetagetin: structure given in first source; inhibits aldose reductase in rat lens. quercetagetin : A hexahydroxyflavone that is flavone substituted by hydroxy groups at positions 3, 5, 6, 7, 3' and 4' respectively.		2.1310flavonols;
hexahydroxyflavone		antioxidant;
antiviral agent;
plant metabolite
daidzein
[no description available]		7.41107-hydroxyisoflavonesantineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
phytoestrogen;
plant metabolite
pterostilbene
[no description available]		2.8230diether;
methoxybenzenes;
stilbenol		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
hypoglycemic agent;
neuroprotective agent;
neurotransmitter;
plant metabolite;
radical scavenger
cynarine
cynarine: active principle of the artichoke; functions primarily as a cholagogue and choleretic and also as antilipemic agent		2.0510alkyl caffeate ester;
quinic acid		plant metabolite
shogaol
shogaol: from ginger, ZINGIBER OFFICINALE; less mutagenic than GINGEROL; structure given in first source		7.610enone;
monomethoxybenzene;
phenols
wedelolactone
wedelolactone: antihepatotoxic coumestan from Eclipta prostrata and Wedelia calendulacea (both Asteraceae); structure given in first source. wedelolactone : A member of the class of coumestans that is coumestan with hydroxy substituents as positions 1, 8 and 9 and a methoxy substituent at position 3.		2.0310aromatic ether;
coumestans;
delta-lactone;
polyphenol		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
hepatoprotective agent;
metabolite
maytansine
Maytansine: An ansa macrolide isolated from the MAYTENUS genus of East African shrubs.. maytansine : An organic heterotetracyclic compound and 19-membered macrocyclic lactam antibiotic originally isolated from the Ethiopian shrub Maytenus serrata but also found in other Maytenus species. It exhibits cytotoxicity against many tumour cell lines.		3.6120alpha-amino acid ester;
carbamate ester;
epoxide;
maytansinoid;
organic heterotetracyclic compound;
organochlorine compound		antimicrobial agent;
antimitotic;
antineoplastic agent;
plant metabolite;
tubulin modulator
rottlerin
rottlerin: an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1);. rottlerin : A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis.		2.4110aromatic ketone;
benzenetriol;
chromenol;
enone;
methyl ketone		anti-allergic agent;
antihypertensive agent;
antineoplastic agent;
apoptosis inducer;
K-ATP channel agonist;
metabolite
flupenthixol
cis-flupenthixol : A flupenthixol in which the double bond adopts a cis-configuration.		2.4520flupenthixoldopaminergic antagonist
sdz psc 833
valspodar: nonimmunosuppressive cyclosporin analog which is a potent multidrug resistance modifier; 7-10 fold more potent than cyclosporin A; a potent P glycoprotein inhibitor; MW 1215		2.7530homodetic cyclic peptide
estradiol-17 beta-glucuronide
17beta-estradiol 17-glucosiduronic acid : A steroid glucosiduronic acid that consists of 17beta-estradiol having a beta-glucuronyl residue attached at position 17 via a glycosidic linkage.		2.05103-hydroxy steroid;
steroid glucosiduronic acid
l 660,711
[no description available]		4.140quinolines
coenzyme q10
coenzyme Q10: Ubiquinone ring with a chain of 10 isoprene units; redox equilibrium with ubiqunol serving in mitochondrial inner membrane to transfer electrons; presence during reconstitution of acetylcholine receptor into phospholipid vesicles yields vesicles active in catalyzing carbamylcholine-sensitive Na+ flux; coenzyme Q10 depletion has been noted with use of statins. coenzyme Q10 : A ubiquinone having a side chain of 10 isoprenoid units. In the naturally occurring isomer, all isoprenyl double bonds are in the E- configuration.		2.0510ubiquinonesantioxidant;
ferroptosis inhibitor;
human metabolite
tectochrysin
tectochrysin: structure in first source. tectochrysin : A monohydroxyflavone that is flavone substituted by a hydroxy group at position 4 and a methoxy group at position 7 respectively.		3.5110monohydroxyflavone;
monomethoxyflavone		antidiarrhoeal drug;
antineoplastic agent;
plant metabolite
travoprost
Travoprost: A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.. travoprost : The isopropyl ester of prostaglandin F2alpha in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2alpha, ophthalmic solutions of travoprost are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. It is a pro-drug; the isopropyl ester group is hydrolysed by esterases in the cornea to the biologically active free acid, fluprostenol.		2.0810(trifluoromethyl)benzenes;
isopropyl ester;
prostaglandins Falpha		antiglaucoma drug;
antihypertensive agent;
ophthalmology drug;
prodrug;
prostaglandin receptor agonist
tranilast
tranilast: antiallergic drug; potent inhibitor of homologous passive cutaneous anaphylaxis. tranilast : An amidobenzoic acid that is anthranilic acid in which one of the anilino hydrogens is replaced by a 3,4-dimethoxycinnamoyl group.		2.7530amidobenzoic acid;
cinnamamides;
dimethoxybenzene;
secondary carboxamide		anti-allergic agent;
anti-asthmatic drug;
antineoplastic agent;
aryl hydrocarbon receptor agonist;
calcium channel blocker;
hepatoprotective agent;
nephroprotective agent
7432 s
Ceftibuten: A cephalosporin antibacterial agent that is used in the treatment of infections, including urinary-tract and respiratory-tract infections.. ceftibuten : A third-generation cephalosporin antibiotic with a [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino substituent at the 7 position of the cephem skeleton. An orally-administered agent, ceftibuten is used as the dihydrate to treat urinary-tract and respiratory-tract infections.		3.2310cephalosporin;
dicarboxylic acid		antibacterial drug
menatetrenone
menaquinone-4 : A menaquinone whose side-chain contains 4 isoprene units in an all-trans-configuration.		2.0510menaquinoneanti-inflammatory agent;
antioxidant;
bone density conservation agent;
human metabolite;
neuroprotective agent
imipenem
[no description available]		2.0810carbapenems
etretinate
retinoid : Oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.		2.4720enoate ester;
ethyl ester;
retinoid		keratolytic drug
isotretinoin
Isotretinoin: A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.. isotretinoin : A retinoic acid that is all-trans-retinoic acid in which the double bond which is alpha,beta- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases.		4.2850retinoic acidantineoplastic agent;
keratolytic drug;
teratogenic agent
misoprostol
Misoprostol: A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties.. misoprostol : A diastereoisomeric mixture composed of approximately equal amounts of a double racemate of four of the sixteen possible diastereoisomers of methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate that is racemic prostaglandin E1 which is lacking the hydroxy group at position 15, but which has an additional hydroxy group at position 16. It is a synthetic prostaglandin E1 analogue, used in the treatment of gastric and duodenal ulcers. A weak abortifacient, it is also used for cervical ripening prior to surgical termination of pregnancy. The (11R,16S)-diastereoisomer is the pharmacologically active form.		2.0510
ketotifen fumarate
ketotifen fumarate : An organoammonium salt consisting of equimolar amounts of ketotifen(1+) and fumarate(1-) ions. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is a non-bronchodilator anti-asthmatic drug.		2.0810organoammonium saltanti-asthmatic drug;
H1-receptor antagonist
epoprostenol
[no description available]		3.2310prostaglandins Imouse metabolite
indocyanine green
[no description available]		3.85301,1-diunsubstituted alkanesulfonate;
benzoindole;
cyanine dye
dinoprost tromethamine
[no description available]		2.0810organic molecular entity
ozagrel
ozagrel: RN refers to (E)-isomer		2.0510cinnamic acids
triprolidine
Triprolidine: Histamine H1 antagonist used in allergic rhinitis; ASTHMA; and URTICARIA. It is a component of COUGH and COLD medicines. It may cause drowsiness.. triprolidine : An N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms of uticaria, rhinitis, and various pruritic skin disorders.		3.2310N-alkylpyrrolidine;
olefinic compound;
pyridines		H1-receptor antagonist
pitavastatin
pitavastatin : A dihydroxy monocarboxylic acid that is (6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]hept-6-enoic acid in which the two hydroxy groups are located at positions 3 and 5 (the 3R,5S-stereoisomer). Used as its calcium salt for treatment of hypercholesterolemia (elevated levels of cholesterol in the blood) on patients unable to sufficiently lower their cholesterol levels by diet and exercise.		3.5920cyclopropanes;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
quinolines;
statin (synthetic)		antioxidant
rosuvastatin calcium
S 4522: structure in first source		2.0810N-acyl-15-methylhexadecasphinganine-1-phosphoethanolamine;
organic calcium salt		anti-inflammatory agent;
cardioprotective agent;
CETP inhibitor
terbinafine hydrochloride
terbinafine hydrochloride : A hydrochloride obtained by reaction of terbinafine with one molar equivalent of hydrogen chloride.		2.0810allylamine antifungal drug;
hydrochloride		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor
ethamolin
monoethanolamine oleate: used for treatment of pyogenic granuloma		3.2310long-chain fatty acid
alatrofloxacin mesylate
[no description available]		3.5920
thromboxane b2
Thromboxane B2: A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin).. thromboxane B2 : A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.		3.4111thromboxanes Bhuman metabolite;
mouse metabolite
menaquinone 6
menaquinone 6: RN given refers to (all-E)-isomer		4.6111
codeine
[no description available]		4.2650morphinane alkaloid;
organic heteropentacyclic compound		antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic
cyclosporine
ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF		5.48110homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
phenoxybenzamine hydrochloride
[no description available]		2.0510organic molecular entity
phenylephrine hydrochloride
Nose: A part of the upper respiratory tract. It contains the organ of SMELL. The term includes the external nose, the nasal cavity, and the PARANASAL SINUSES.. phenylephrine hydrochloride : A hydrochloride that is the monohydrochloride salt of phenylephrine.		2.0310hydrochloride
natamycin
[no description available]		2.4720antibiotic antifungal drug;
dicarboxylic acid monoester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyene antibiotic		antifungal agrochemical;
antimicrobial food preservative;
apoptosis inducer;
bacterial metabolite;
ophthalmology drug
acitretin
Acitretin: An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.. acitretin : A retinoid that consists of 3,7-dimethylnona-2,4,6,8-tetraenoic acid having a 4-methoxy-2,3,6-trimethylphenyl group attached at position 9.		4.2850acitretin;
alpha,beta-unsaturated monocarboxylic acid;
retinoid		keratolytic drug
dothiepin
[no description available]		2.0510dothiepin
estropipate
estropipate: used therapeutically in menopausal patients		3.2310piperazinium salt;
steroid sulfate
hydromorphone
Hydromorphone: An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.. hydromorphone : A morphinane alkaloid that is a hydrogenated ketone derivative of morphine. A semi-synthetic drug, it is a centrally acting pain medication of the opioid class.		3.8530morphinane alkaloid;
organic heteropentacyclic compound		mu-opioid receptor agonist;
opioid analgesic
levetiracetam
Levetiracetam: A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.. levetiracetam : A pyrrolidinone and carboxamide that is N-methylpyrrolidin-2-one in which one of the methyl hydrogens is replaced by an aminocarbonyl group, while another is replaced by an ethyl group (the S enantiomer). An anticonvulsant, it is used for the treatment of epilepsy in both human and veterinary medicine.		3.8730pyrrolidin-2-onesanticonvulsant;
environmental contaminant;
xenobiotic
ly 163892
loracarbef: 1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; structure given in first source; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. loracarbef : A synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria.		3.5920carbacephem;
zwitterion		antibacterial drug;
antimicrobial agent
nabilone
nabilone: cannabinol deriv; RN given refers to cpd without isomeric designation; structure		3.2310
nalmefene
nalmefene: RN given refers to 5-alpha isomer		2.7530morphinane alkaloid
nalorphine
Nalorphine: A narcotic antagonist with some agonist properties. It is an antagonist at mu opioid receptors and an agonist at kappa opioid receptors. Given alone it produces a broad spectrum of unpleasant effects and it is considered to be clinically obsolete.		2.0510morphinane alkaloid
naloxone
Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.		4.4160morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
oxycodone
Oxycodone: A semisynthetic derivative of CODEINE.. oxycodone : A semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.		3.5820organic heteropentacyclic compound;
semisynthetic derivative		antitussive;
mu-opioid receptor agonist;
opioid analgesic
oxymorphone
Oxymorphone: An opioid analgesic with actions and uses similar to those of MORPHINE, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092)		3.5920morphinane alkaloid
vitamin k 1
Vitamin K 1: A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity.. phylloquinone : A member of the class of phylloquinones that consists of 1,4-naphthoquinone having methyl and phytyl groups at positions 2 and 3 respectively. The parent of the class of phylloquinones.		3.2310phylloquinones;
vitamin K		cofactor;
human metabolite;
plant metabolite
proscillaridin
Proscillaridin: A cardiotonic glycoside isolated from Scilla maritima var. alba (Squill).		2.0310organic molecular entity
sirolimus
Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.		13.8526antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
topiramate
Topiramate: A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.. topiramate : A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.		4.2650cyclic ketal;
ketohexose derivative;
sulfamate ester		anticonvulsant;
sodium channel blocker
trospium chloride
trospium chloride : An organic chloride salt of trospium. It is an antispasmodic drug used for the treatment of overactive bladder.		3.2310
menaquinone 7
menaquinone-7 : A menaquinone whose side-chain contains seven isoprene units in an all-trans-configutation.		4.6111menaquinonebone density conservation agent;
cofactor;
Escherichia coli metabolite;
human blood serum metabolite;
Mycoplasma genitalium metabolite
alvocidib
alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.		6.35110dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound		antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
seocalcitol
seocalcitol: structure given in first source		2.4820
fenretinide
Fenretinide: A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.. 4-hydroxyphenyl retinamide : A retinoid obtained by formal condensation of the carboxy group of all-trans retinoic acid and the anilino group of 4-hydroxyaniline. Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids.		2.4720monocarboxylic acid amide;
retinoid		antineoplastic agent;
antioxidant
topiroxostat
FYX-051: xanthine oxidoreductase inhibitor		3.5110
geldanamycin
[no description available]		2.45201,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound		antimicrobial agent;
antineoplastic agent;
antiviral agent;
cysteine protease inhibitor;
Hsp90 inhibitor
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: structure in first source. alvespimycin : A 19-membered macrocyle that is geldanamycin in which the methoxy group attached to the benzoquinone moiety has been replaced by a 2-(N,N-dimethylamino)ethylamino group.		2.48201,4-benzoquinones;
ansamycin;
carbamate ester;
secondary amino compound;
tertiary amino compound		Hsp90 inhibitor
morphine
Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.		4.2550morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
demycarosylturimycin h
[no description available]		2.4720
su 5402
SU 5402: structure given in first source. SU5402 : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is substituted by a 3-(2-carboxyethyl)-4-methyl-1H-pyrrol-2-yl group. It is an ATP-competitive inhibitor of the tyrosine kinase activity of fibroblast growth factor receptor 1.		2.0210
su 9516
[no description available]		2.0310
ter 199
[no description available]		2.0810
acipimox
acipimox: lipolysis inhibitor		2.0810pyrazinecarboxylic acid
arachidonylcyclopropylamide
arachidonylcyclopropylamide: a potent and selective agonist of neuronal cannabinoid receptor; structure in first source		2.0810
atosiban
[no description available]		2.0810oligopeptide
benzphetamine
Benzphetamine: A sympathomimetic agent with properties similar to DEXTROAMPHETAMINE. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222). benzphetamine : Dextroamphetamine in which the the hydrogens attached to the amino group are substituted by a methyl and a benzyl group. A sympathomimetic agent with properties similar to dextroamphetamine, it is used as its hydrochloride salt in the treatment of obesity.		3.2310amphetamines;
tertiary amine		adrenergic uptake inhibitor;
appetite depressant;
dopamine uptake inhibitor;
sympathomimetic agent
bimatoprost
Bimatoprost: A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.		2.0810monocarboxylic acid amideantiglaucoma drug;
antihypertensive agent
cicaprost
cicaprost: RN given refers to (3aS-(2E,3aalpha,4alpha(3R*,4R*),5beta,6aalpha))-isomer		2.0410monoterpenoid
clobetasol
Clobetasol: A derivative of PREDNISOLONE with high glucocorticoid activity and low mineralocorticoid activity. Absorbed through the skin faster than FLUOCINONIDE, it is used topically in treatment of PSORIASIS but may cause marked adrenocortical suppression.. clobetasol : A 3-oxo-Delta(1),Delta(4)-steroid that is 16beta-methylpregna-1,4-diene-3,20-dione bearing hydroxy groups at the 11beta and 17alpha positions, fluorine at position 9, and a chlorine substituent at position 21. It is used as its 17alpha-propionate ester to treat various skin disorders, including exzema and psoriasis.		2.211011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
fluorinated steroid;
glucocorticoid;
tertiary alpha-hydroxy ketone		anti-inflammatory drug;
SMO receptor agonist
deamino arginine vasopressin
Deamino Arginine Vasopressin: A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.		3.6920heterodetic cyclic peptidediagnostic agent;
renal agent;
vasopressin receptor agonist
dexmedetomidine
[no description available]		3.5820medetomidinealpha-adrenergic agonist;
analgesic;
non-narcotic analgesic;
sedative
fluticasone
Fluticasone: A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.. fluticasone : A trifluorinated corticosteroid used in the form of its propionate ester for treatment of allergic rhinitis.		2.031011beta-hydroxy steroid;
17alpha-hydroxy steroid;
3-oxo-Delta(4) steroid;
corticosteroid;
fluorinated steroid;
thioester		anti-allergic agent;
anti-asthmatic drug
herbimycin
herbimycin: herbicidal antibiotic produced by Streptomyces sp.; see also herbimycin B; structure for herbimycin A in second source. herbimycin : A 19-membered macrocyle incorporating a benzoquinone ring and a lactam functionality. It is an ansamycin antibiotic that induces apoptosis and displays antitumour effects.		2.03101,4-benzoquinones;
lactam;
macrocycle		antimicrobial agent;
apoptosis inducer;
herbicide;
Hsp90 inhibitor;
tyrosine kinase inhibitor
goserelin
Goserelin: A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.		3.2310organic molecular entity
iloprost
Iloprost: An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.. iloprost : A carbobicyclic compound that is prostaglandin I2 in which the endocyclic oxygen is replaced by a methylene group and in which the (1E,3S)-3-hydroxyoct-1-en-1-yl side chain is replaced by a (3R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl group. A synthetic analogue of prostacyclin, it is used as the trometamol salt (generally by intravenous infusion) for the treatment of peripheral vascular disease and pulmonary hypertension.		2.4520carbobicyclic compound;
monocarboxylic acid;
secondary alcohol		platelet aggregation inhibitor;
vasodilator agent
latanoprost
Latanoprost: A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.. latanoprost : A prostaglandin Falpha that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension.		2.0810isopropyl ester;
prostaglandins Falpha;
triol		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
prodrug
ly 320135
LY 320135: cannabinoid receptor antagonist; structure in first source		2.0810benzofurans
lysophosphatidic acid
lysophosphatidic acid: RN given refers to parent cpd. 1-oleoyl-sn-glycerol 3-phosphate : A 1-acyl-sn-glycerol 3-phosphate having oleoyl as the 1-O-acyl group.. lysophosphatidic acid : A member of the class of lysophosphatidic acids obtained by hydrolytic removal of one of the two acyl groups of any phosphatidic acid. A 'closed' class.		2.49201-acyl-sn-glycerol 3-phosphate
n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester
DAPT : A dipeptide consisting of alanylphenylglycine derivatised as a 3,5-difluorophenylacetamide at the amino terminal and a tert-butyl ester at the carboxy terminal. A gamma-secretase inhibitor.		2.4720carboxylic ester;
difluorobenzene;
dipeptide;
tert-butyl ester		EC 3.4.23.46 (memapsin 2) inhibitor
cytochalasin b
Cytochalasin B: A cytotoxic member of the CYTOCHALASINS.. cytochalasin B : An organic heterotricyclic compound, that is a mycotoxin which is cell permeable an an inhibitor of cytoplasmic division by blocking the formation of contractile microfilaments.		2.3110cytochalasin;
lactam;
lactone;
organic heterotricyclic compound		actin polymerisation inhibitor;
metabolite;
mycotoxin;
platelet aggregation inhibitor
nalbuphine
Nalbuphine: A narcotic used as a pain medication. It appears to be an agonist at KAPPA RECEPTORS and an antagonist or partial agonist at MU RECEPTORS.		3.8530organic heteropentacyclic compoundmu-opioid receptor antagonist;
opioid analgesic
nateglinide
Nateglinide: A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES.. nateglinide : An N-acyl-D-phenylalanine resulting from the formal condensation of the amino group of D-phenylalanine with the carboxy group of trans-4-isopropylcyclohexanecarboxylic acid. An orally-administered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus.		3.8730phenylalanine derivative
neurokinin b
Neurokinin B: A mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ A with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the URINARY BLADDER and UTERUS.		2.0510polypeptide
pd 166285
[no description available]		2.7730
seglitide
seglitide: more potent than somatostatin for inhibition of insulin, glucagon & growth hormone release; used experimentally in treatment of Alzheimer's disease; somatostatin receptor antagonist		2.0410
vinorelbine
[no description available]		4.2750acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
ring assembly;
vinca alkaloid		antineoplastic agent;
photosensitizing agent
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide
[no description available]		2.4110pyrimidines
kn 93
KN 93: reduces dopamine content in PC12h cells. KN-93 : A sulfonamide resulting from the formal condensation of p-methoxybenzenesulfonic acid with the anilino nitrogen of 2-(aminomethyl)-N-(2-hydroxyethyl)aniline in which the hydrogens of the primary amino group have been replaced by methyl and p-chlorocinnamyl groups. KN-93 is a selective inhibitor of Ca(2+)/calmodulin-dependent protein kinase II.		2.0310monochlorobenzenes;
monomethoxybenzene;
primary alcohol;
sulfonamide;
tertiary amino compound		EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor;
geroprotector
silodosin
silodosin: an alpha(1a)-adrenoceptor-selective antagonist; structure given in first source		3.2310indolecarboxamide
kn 62
KN 62: inhibitor of Ca/calmodulin-dependent protein kinase II		2.0810piperazines
su 6656
SU 6656: a c-Src kinase inhibitor; used to probe growth signaling; structure in first source. SU6656 : A member of the class of oxindoles that is 3-methyleneoxindole in which the hydrogeh at position 5 has been replaced by a dimethylaminosulfonyl group and in which one of the hydrogens of the methylene group has been replaced by a 4,5,6,7-tetrahydro-indol-2-yl group. It is a specific inhibitor of Src family kinase.		2.7530
andrographolide
[no description available]		2.1510carbobicyclic compound;
gamma-lactone;
labdane diterpenoid;
primary alcohol;
secondary alcohol		anti-HIV agent;
anti-inflammatory drug;
antineoplastic agent;
metabolite
licochalcone a
licochalcone A: has both anti-inflammatory and antineoplastic activities; structure given in first source; isolated from root of Glycyrrhiza inflata; RN given refers to (E)-isomer		7.4110chalcones
licochalcone b
licochalcone B: isolated from Glycyrrhiza inflata; inhibits phosphorylation of NF-kappaB p65 in LPS signaling pathway; structure in first source		2.2110chalcones
furazolidone
[no description available]		2.4620
fluvoxamine
Fluvoxamine: A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.. fluvoxamine : An oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder.		3.8630(trifluoromethyl)benzenes;
5-methoxyvalerophenone O-(2-aminoethyl)oxime		antidepressant;
anxiolytic drug;
serotonin uptake inhibitor
casein kinase ii
Casein Kinase II: A ubiquitous casein kinase that is comprised of two distinct catalytic subunits and dimeric regulatory subunit. Casein kinase II has been shown to phosphorylate a large number of substrates, many of which are proteins involved in the regulation of gene expression.		2.8430
tyrphostin ag-494
AG 494: tyrphostin that blocks Cdk2 activation; structure in first source		2.0310
ag 556
AG 556: structure given in first source		2.0110
ag-490
[no description available]		2.4420catechols;
enamide;
monocarboxylic acid amide;
nitrile;
secondary carboxamide		anti-inflammatory agent;
antioxidant;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector;
STAT3 inhibitor
bosutinib
4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile: a Src kinase inhibitor; structure in first source		5.81100aminoquinoline;
aromatic ether;
dichlorobenzene;
N-methylpiperazine;
nitrile;
tertiary amino compound		antineoplastic agent;
tyrosine kinase inhibitor
semaxinib
semaxanib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is replaced by a 3,5-dimethylpyrrol-2-yl group.		4.6480olefinic compound;
oxindoles;
pyrroles		angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
orantinib
orantinib: an antiangiogenic agent. orantinib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is substituted by a 2-(2-carboxyethyl)-3,5-dimethylpyrrol-3-yl group. It is an ATP-competitive inhibitor of the tyrosine kinase activity of fibroblast growth factor receptor 1.		4.0640
su 11248
[no description available]		12.4451monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
su 11652
SU 11652: a tyrosine kinase inhibitor; amino acid sequence in first source. SU11652 : A member of the class of pyrrolecarboxamides obtained by formal condensation of the carboxy group of 5-[(Z)-(5-chloro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethylpyrrole-3-carboxylic acid with the primary amino group of N(1),N(1)-diethylethane-1,2-diamine.		2.0310olefinic compound;
organochlorine compound;
oxindoles;
pyrrolecarboxamide;
tertiary amino compound		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor
m475271
AZM475271: a Src family kinase inhibitor		3.3110
palbociclib
[no description available]		5.2780aminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
jnj-7706621
[no description available]		4.5450sulfonamide
fosbretabulin
[no description available]		2.1110stilbenoid
romidepsin
depsipeptide : A natural or synthetic compound having a sequence of amino and hydroxy carboxylic acid residues (usually alpha-amino and alpha-hydroxy acids), commonly but not necessarily regularly alternating.		2.0410cyclodepsipeptide;
heterocyclic antibiotic;
organic disulfide		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
lead
Lead: A soft, grayish metal with poisonous salts; atomic number 82, atomic weight 207.2, symbol Pb.		4.6111carbon group element atom;
elemental lead;
metal atom		neurotoxin
bw b70c
BW B70C: arachidonic acid antagonist. BW B70C : A hydroxamic acid that is urea in which both the hydrogens attached to one of the nitrogens are replaced by a hydroxy and a (1E)-1-[3-(4-fluorophenoxy)phenyl]but-1-en-3-yl group. A selective inhibitor of arachidonate 5-lipoxygenase, it can be used for the treatment of asthma.		2.2510aromatic ether;
hydroxamic acid;
organofluorine compound;
ureas		EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid : A dihydroxy monocarboxylic acid that is N-isopropylindole which is substituted at position 3 by a p-fluorophenyl group and at position 2 by a 6-carboxy-3,5-dihydroxyhex-1-en-1-yl group. It has four possible diastereoisomers.		4.7790dihydroxy monocarboxylic acid;
indoles;
organofluorine compound
molsidomine
[no description available]		2.4720ethyl ester;
morpholines;
oxadiazole;
zwitterion		antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent
octylmethoxycinnamate
[no description available]		2.0510cinnamate ester
levorphanol
Levorphanol: A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.		3.2310morphinane alkaloid
arsenic
Arsenic: A shiny gray element with atomic symbol As, atomic number 33, and atomic weight 75. It occurs throughout the universe, mostly in the form of metallic arsenides. Most forms are toxic. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), arsenic and certain arsenic compounds have been listed as known carcinogens. (From Merck Index, 11th ed)		5.9941metalloid atom;
pnictogen		micronutrient
naltrexone
Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.		4.5570cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound		antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic
morphine-6-glucuronide
morphine-6-glucuronide: RN given refers to (5alpha,6alpha)-isomer		2.0410morphinane alkaloid
dextromethorphan
Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.		4.27506-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthreneantitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic
butorphanol
Butorphanol: A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.. butorphanol : Levorphanol in which a hydrogen at position 14 of the morphinan skeleton is substituted by hydroxy and one of the hydrogens of the N-methyl group is substituted by cyclopropyl. A semi-synthetic opioid agonist-antagonist analgesic, it is used as its (S,S)-tartaric acid salt for relief or moderate to severe pain.		4.0840morphinane alkaloidantitussive;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
cefodizime
cefodizime: RN given refers to (6R-(6alpha,7beta(Z)))-isomer. cefodizime : A cephalosporin compound having 5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.		2.04101,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
EC 1.14.18.1 (tyrosinase) inhibitor
methylnaltrexone
methylnaltrexone: RN given refers to parent cpd(5alpha)-isomer		2.0410phenanthrenes
cefixime
[no description available]		4.2650cephalosporinantibacterial drug;
drug allergen
lisinopril
Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.		4.4160dipeptideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
benazepril
benazepril: structure given in first source. benazepril : A benzazepine that is benazeprilat in which the carboxy group of the 2-amino-4-phenylbutanoic acid moiety has been converted to the corresponding ethyl ester. It is used (generally as its hydrochloride salt) as a prodrug for the angiotensin-converting enzyme inhibitor benazeprilat in the treatment of hypertension and heart failure.		3.5920benzazepine;
dicarboxylic acid monoester;
ethyl ester;
lactam		EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
ramipril
Ramipril: A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.. ramipril : A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure.. quark : Quarks comprise one of two classes of the fundamental particles. Quarks possess fractional electric charges and are not observed in free state. The word "quark" first appears in James Joyce's Finnegans Wake and has been chosen by Murray Gell-Mann as a name for fundamental building blocks of particles.		4.1140azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid monoester;
dipeptide;
ethyl ester		bradykinin receptor B2 agonist;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor;
prodrug
verteporfin
(2R,2(1)S)-8-ethenyl-2(1),2(2)-bis(methoxycarbonyl)-17-(3-methoxy-3-oxopropyl)-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13-propanoic acid : The 2(1),2(2),17-trimethyl ester of (2R,2(1)S)-2(1),2(2)-dicarboxy-8-ethenyl-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13,17-dipropanoic acid.		3.2310
indinavir sulfate
Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.		4.6780dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide		HIV protease inhibitor
geldanamycin
[no description available]		7.4520
zimeldine
Zimeldine: One of the SEROTONIN UPTAKE INHIBITORS formerly used for depression but was withdrawn worldwide in September 1983 because of the risk of GUILLAIN-BARRE SYNDROME associated with its use. (From Martindale, The Extra Pharmacopoeia, 29th ed, p385)		3.2310styrenes
3,3',4,5'-tetramethoxy-trans-stilbene
(E)-3,4,3',5'-tetramethoxystilbene: from the leaves of Eugenia rigida; structure in first source		3.5110
enalapril maleate
enalapril maleate : The maleic acid salt of enalapril. It contains one molecule of maleic acid for each molecule of enalapril. Following oral administration, the ethyl ester group of enalapril is hydrolysed to afford the corresponding carboxylic acid, enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is thus a prodrug for enalaprilat (which, unlike enalapril, is not absorbed by mouth), and its maleate is used in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients.		2.0810maleate saltantihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
enalapril
Enalapril: An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.. enalapril : A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).		3.8530dicarboxylic acid monoester;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug
vinblastine sulfate
[no description available]		2.0510
nitrofurazone
Nitrofurazone: A topical anti-infective agent effective against gram-negative and gram-positive bacteria. It is used for superficial WOUNDS AND INJURIES and skin infections. Nitrofurazone has also been administered orally in the treatment of TRYPANOSOMIASIS.. nitrofurazone : A semicarbazone resulting from the formal condensation of semicarbazide with 5-nitrofuraldehyde. A broad spectrum antibacterial drug, although with little activity against Pseudomonas species, it is used as a local application for burns, ulcers, wounds and skin infections.		2.0510
trientine hydrochloride
[no description available]		3.5920
n-methylscopolamine bromide
scopolamine methobromide : A quaternary ammonium salt resulting from the reaction of the amino group of scopolamine with methyl bromide.		3.2310
cisplatin
[no description available]		2.0810diamminedichloroplatinumantineoplastic agent;
apoptosis inducer;
cross-linking reagent;
ferroptosis inducer;
genotoxin;
mutagen;
nephrotoxin;
photosensitizing agent
astatine
Astatine: Astatine. A radioactive halogen with the atomic symbol At, and atomic number 85. Its isotopes range in mass number from 200 to 219 and all have an extremely short half-life. Astatine may be of use in the treatment of hyperthyroidism because it emits ALPHA PARTICLES.		2.4220elemental astatine
bleomycin
[no description available]		3.5920bleomycinantineoplastic agent;
metabolite
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		3.2350cysteiniumfundamental metabolite
silicon
Silicon: A trace element that constitutes about 27.6% of the earth's crust in the form of SILICON DIOXIDE. It does not occur free in nature. Silicon has the atomic symbol Si, atomic number 14, and atomic weight [28.084; 28.086].		2.0710carbon group element atom;
metalloid atom;
nonmetal atom
phosphorus
Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.		5.121monoatomic phosphorus;
nonmetal atom;
pnictogen		macronutrient
dextromethorphan hydrobromide
dextromethorphan hydrobromide : The hydrobromide and monohydrate of the antitussive drug dextromethorphan.		2.0510hydrate;
hydrobromide
indinavir sulfate
[no description available]		2.0510azaheterocycle sulfate salt
enalaprilat anhydrous
Enalaprilat: The active metabolite of ENALAPRIL and one of the potent, intravenously administered, ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.. enalaprilat dihydrate : The dihydrate form of enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor that is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is administered by intravenous injection.. enalaprilat (anhydrous) : Enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is given by intravenous injection, usually as the dihydrate.		4.0840dicarboxylic acid;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
imidapril
imidapril: structure given in first source. imidapril : A member of the class of imidazolidines that is (4S)-1-methyl-2-oxoimidazolidine-4-carboxylic acid in which the hydrogen of the imidazolidine nitrogen has been substituted by (1S)-1-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}ethyl group. It is the prodrug for imidaprilat, an ACE inhibitor used for the treatment of chronic heart failure.		2.0510dicarboxylic acid monoester;
dipeptide;
ethyl ester;
imidazolidines;
N-acylurea;
secondary amino compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
zerumbone
zerumbone: RN given for (E,E,E)-isomer; structure in first source. zerumbone : A sesquiterpenoid and cyclic ketone that is (1E,4E,8E)-alpha-humulene which is substituted by an oxo group at the carbon atom attached to two double bonds. It is obtained by steam distillation from a type of edible ginger, Zingiber zerumbet Smith, grown particularly in southeast Asia.		7.610cyclic ketone;
sesquiterpenoid		anti-inflammatory agent;
glioma-associated oncogene inhibitor;
plant metabolite
sulindac sulfone
sulindac sulfone: inhibits K-ras-dependent cyclooxygenase-2; sulfated analog of indomethacin;; CP248 is an antineoplastic agent that fosters microtubule depolymerization; structure in first source. sulindac sulfone : A sulfone metabolite of sulindac that inhibits cell growth by inducing apoptosis independently of cyclooxygenase inhibition. It inhibits the development and induces regression of premalignant adenomatous polyps. Lipoxygenase and Cox-2 inhibitor.		2.4520monocarboxylic acid;
organofluorine compound;
sulfone		apoptosis inducer;
cyclooxygenase 2 inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
ximelagatran
ximelagatran: prodrug (via hydroxylation) of melagatran & a direct thrombin inhibitor; liver toxicity concerns so AZD0837 being developed to replace this. ximelagatran : A member of the class of azetidines that is melagatran in which the carboxylic acid group has been converted to the corresponding ethyl ester and in which the amidine group has been converted into the corresponding amidoxime. A prodrug for melagatran, ximelagatran was the first orally available direct thrombin inhibitor to be brought to market as an anticoagulant, but was withdrawn in 2006 following reports of it causing liver damage.		3.8630amidoxime;
azetidines;
carboxamide;
ethyl ester;
hydroxylamines;
secondary amino compound;
secondary carboxamide;
tertiary carboxamide		anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
prodrug;
serine protease inhibitor
cefuroxime
[no description available]		3.58203-(carbamoyloxymethyl)cephalosporin;
furans;
oxime O-ether		drug allergen
ceftriaxone
[no description available]		3.86301,2,4-triazines;
1,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 3.5.2.6 (beta-lactamase) inhibitor
cefepime
Cefepime: A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.. cefepime : A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		3.5820cephalosporin;
oxime O-ether		antibacterial drug
hr 810
cefpirome: structure in first source. cefpirome : A fourth-generation cephalosporin antibiotic having 6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.		2.0410cephalosporin;
cyclopentapyridine
pafuramidine
pafuramidine: a prodrug of furamidine		3.2310
norbinaltorphimine
norbinaltorphimine: kappa opiate receptor antagonist; structure given in first source		2.0710isoquinolines
ceftazidime
[no description available]		3.8630cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
trandolapril
trandolapril : A heterobicylic compound that is (2S,3aR,7aS)-1-[(2S)-2-aminopropanoyl]octahydro-1H-indole-2-carboxylic acid in which the hydrogen of the amino group is substituted by a (2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl group. It is a angiotensin-converting enzyme inhibitor and a prodrug used for the treatment of hypertension.		4.0840dicarboxylic acid monoester;
dipeptide;
ethyl ester;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
pregabalin
Pregabalin: A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.. pregabalin : A gamma-amino acid that is gamma-aminobutyric acid (GABA) carrying an isobutyl substitutent at the beta-position (the S-enantiomer). Binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues.		3.6120gamma-amino acidanticonvulsant;
calcium channel blocker
tiotropium bromide
Tiotropium Bromide: A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.. tiotropium bromide : An organic bromide salt having (1alpha,2beta,4beta,5alpha,7beta)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0(2,4)]nonane as the counterion. Used (in the form of the hydrate) for maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.		2.0810
cefetamet
cefetamet: active against Neisseria gonorrhoeae; structure given in first source. cefetamet : A cephalosporin compound having methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side-groups; a cephalosporin antibiotic active against Neisseria gonorrhoeae.		2.0410cephalosporin
alvimopan anhydrous
alvimopan: mu opioid receptor antagonist; intended to treat constipation in patients taking opiates for pain		3.6120peptide
aliskiren
aliskiren: orally active nonpeptidic renin inhibitor. aliskiren : A monomethoxybenzene compound having a 3-methoxypropoxy group at the 2-position and a multi-substituted branched alkyl substituent at the 4-position.		3.2310monocarboxylic acid amide;
monomethoxybenzene		antihypertensive agent
2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one
2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one: a janus-activated kinase inhibitor. 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one : An organic heterotetracyclic compound that is 1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one bearing additional tert-butyl and fluoro substituents at positions 2 and 9 respectively.		2.4520organic heterotetracyclic compound;
organofluorine compound		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
vx680
[no description available]		4.9580N-arylpiperazine
arglabin
arglabin: a sesquiterpene lactone from the Chinese herb Artemisia myriantha; structure given in first source. arglabin : An organic heterotetracyclic compound and guaianolide sesquiterpene lactone that is acrylic acid which is substituted at position 2 by a 4-hydroxy-3,8-dimethyl-1,3a,4,5,6,7-hexahydroazulen-5-yl group in which the double bond in the 7-membered ring has been epoxidised and in which the hydroxy group and the carboxy group have undergone formal condensation to give the corresponding gamma-lactone. It is found in Artemisia glabella. Arglabin-DMA HCl, the hydrochloride salt of the adduct resulting from the conjugate addition of dimethylamine to the ene-lactone moiety, has been successfully used in Khazakhstan for the treatment of breast, colon, ovarian and lung cancers.		3.1210epoxide;
gamma-lactone;
organic heterotetracyclic compound;
sesquiterpene lactone		antineoplastic agent;
metabolite
guanabenz acetate
[no description available]		2.0510dichlorobenzenegeroprotector
famotidine
[no description available]		4.42601,3-thiazoles;
guanidines;
sulfonamide		anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
fenoterol
fenoterol hydrobromide : The hydrobromide salt of fenoterol. A beta2-adrenergic agonist, it is used as a bronchodilator in the management of reversible airway obstruction.		2.0510hydrobromidebeta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent
bafilomycin a
[no description available]		2.2510
cefotaxime
Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.		3.86301,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen
aztreonam
[no description available]		4.0840beta-lactam antibiotic allergen;
monobactam		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
viroxime
[no description available]		2.4110
st 638
[no description available]		2.0310
su 1498
SU 1498: structure in first source. SU1498 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2E)-2-cyano-3-[4-hydroxy-3,5-di(propan-2-yl)phenyl]prop-2-enoic acid with the amino group of 3-phenylpropylamine.		2.4420enamide;
monocarboxylic acid amide;
nitrile;
phenols;
secondary carboxamide		vascular endothelial growth factor receptor antagonist
tyrphostin ag825
tyrphostin AG825: a tyrphostin of the benzylidene malononitrile family; an erbB2 antagonist. tyrphostin AG 825 : An organic sulfide that consists of 1,3-benzothiazole-2-thiol in which the hydrogen attached to the sulfur atom is replaced by a 5-[(1E)-3-amino-2-cyano-3-oxoprop-1-en-1-yl]-2-hydroxy-3-methoxybenzyl group. It acts as an epidermal growth factor receptor antagonist.		2.0510aromatic ether;
benzothiazoles;
enamide;
nitrile;
organic sulfide;
phenols;
primary carboxamide		epidermal growth factor receptor antagonist
(R)-citalopram
(R)-citalopram : A 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has R-configuration at the chiral centre. It is the inactive enantiomer of citalopram.		2.03101-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
proguanil
Proguanil: A biguanide compound which metabolizes in the body to form cycloguanil, an anti-malaria agent.. proguanil : A biguanide compound which has isopropyl and p-chlorophenyl substituents on the terminal N atoms. A prophylactic antimalarial drug, it works by inhibiting the enzyme dihydrofolate reductase, which is involved in the reproduction of the malaria parasites Plasmodium falciparum and P. vivax within the red blood cells.		3.6320biguanides;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
cci 15641
[no description available]		2.0810cephalosporin
monorden
monorden: inhibits HSP90 Heat-Shock Proteins, DNA topoisomerase VI and human Topoisomerase II		2.0310cyclic ketone;
enone;
epoxide;
macrolide antibiotic;
monochlorobenzenes;
phenols		antifungal agent;
metabolite;
tyrosine kinase inhibitor
rifamycin sv
rifamycin SV: RN given refers to parent cpd; structure in Merck Index, 9th ed, #8009. rifamycin SV : A member of the class of rifamycins that exhibits antibiotic and antitubercular properties.		2.4820acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterotetracyclic compound;
polyphenol;
rifamycins		antimicrobial agent;
antitubercular agent;
bacterial metabolite
ginkgolide b
[no description available]		2.0410
selenium
Selenium: An element with the atomic symbol Se, atomic number 34, and atomic weight 78.97. It is an essential micronutrient for mammals and other animals but is toxic in large amounts. Selenium protects intracellular structures against oxidative damage. It is an essential component of GLUTATHIONE PEROXIDASE.		10.5441chalcogen;
nonmetal atom		micronutrient
cefpodoxime
[no description available]		3.2310carboxylic acid;
cephalosporin		antibacterial drug
palonosetron
Palonosetron: Isoquinoline and quinuclidine derivative that acts as a 5-HT3 RECEPTOR antagonist. It is used in the prevention of nausea and vomiting induced by cytotoxic chemotherapy, and for the prevention of post-operative nausea and vomiting.. palonosetron : An organic heterotricyclic compound that is an antiemetic used (as its hydrochloride salt) in combination with netupitant (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy.		3.5820azabicycloalkane;
delta-lactam;
organic heterotricyclic compound		antiemetic;
serotonergic antagonist
epoprostenol sodium
[no description available]		2.0510prostanoid
n-desmethyltamoxifen
N-desmethyltamoxifen: main metabolite of tamoxifen; RN given refers to (Z)-isomer		3.4111stilbenoid
tenofovir disoproxil fumarate
tenofovir disoproxil fumarate : A fumarate salt prepared from equimolar amounts of tenofovir disoproxil and fumaric acid. It is used in combination therapy for the treatment of HIV infection.		2.0810fumarate saltantiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug
cefatrizine
Cefatrizine: Orally active semisynthetic cephalosporin antibiotic with broad-spectrum activity.. cefatrizine : A cephalosporin compound having (1H-1,2,3-triazol-4-ylsulfanyl)methyl and [(2R)-2-amino-2-(4-hydroxyphenyl)]acetamido side-groups. An antibacterial drug first prepared in the 1970s, it has more recently been found to be an inhibitor of eukaryotic elongation factor-2 kinase (eEF2K), which is known to regulate apoptosis, autophagy and ER stress in many types of human cancers.		2.0410amino acid amide;
carboxylic acid;
cephalosporin;
phenols;
semisynthetic derivative;
triazoles		antibacterial drug;
EC 2.7.11.20 (elongation factor 2 kinase) inhibitor
ml 3403
[no description available]		2.0310
d 4476
[no description available]		2.4620imidazoles
GSK3-XIII
GSK3-XIII : A member of the class of aromatic amines that is ammonia with two of the hydrogens replaced by 5-methylpyrazol-3-yl and 2-phenylquinazolin-4-yl groups.		2.0310aromatic amine;
pyrazoles;
quinazolines;
secondary amino compound		EC 2.7.11.26 (tau-protein kinase) inhibitor
cyc 116
4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine: an aurora kinase inhibitor; structure in first source		3.0240
diphenoxylate hydrochloride
diphenoxylate hydrochloride : The hydrochloride salt of diphenoxylate.		2.0510hydrochlorideantidiarrhoeal drug
eniporide
eniporide: inhibits NHE-1 isoform; structure in first source		2.0410
bay 19-8004
BAY 19-8004: a PDE4 inhibitor; structure in first source		2.0810
dexbrompheniramine maleate
dexbrompheniramine maleate : The maleic acid salt of the (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.		2.0810brompheniramine maleateanti-allergic agent;
H1-receptor antagonist
enviradene
[no description available]		2.2510
cilastatin
[no description available]		2.0410carboxamide;
L-cysteine derivative;
non-proteinogenic L-alpha-amino acid;
organic sulfide		EC 3.4.13.19 (membrane dipeptidase) inhibitor;
environmental contaminant;
protease inhibitor;
xenobiotic
rifaximin
[no description available]		3.6120acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterohexacyclic compound;
rifamycins;
semisynthetic derivative		antimicrobial agent;
gastrointestinal drug;
orphan drug
bafilomycin a1
bafilomycin A1: from Streptomyces griseus; structure given in first source. bafilomycin A1 : The most used of the bafilomycins, a family of toxic macrolide antibiotics derived from Streptomyces griseus.		2.8230cyclic hemiketal;
macrolide antibiotic;
oxanes		apoptosis inducer;
autophagy inhibitor;
bacterial metabolite;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor;
ferroptosis inhibitor;
fungicide;
potassium ionophore;
toxin
ergonovine maleate
ergometrine maleate : A maleate salt resulting form the reaction of equimolar amounts of maleic acid and ergometrine. It is used in the active management of the third stage of labour, and to prevent or treat postpartum of postabortal haemorrhage caused by uterine atony: by maintaining uterine contraction and tone, blood vessels in the uterine wall are compressed and blood flow reduced.		2.0510maleate saltdiagnostic agent;
oxytocic
concanamycin a
concanamycin A: from Streptomyces diastatochromogenes S-45; inhibits vacuolar H+ ATPase. concanamycin A : A concanamycin in which the lactone ring contains 4 double bonds and is substituted by 4 methyl groups, 2 hydroxy groups, 2 methoxy groups and an ethyl group.		2.1110carbamate ester;
concanamycin		antifungal agent;
EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor;
metabolite
manumycin
manumycin: an NSAID; RN given for (1S-(1alpha,3(2E,4E,6S*),5alpha,5(1E,3E,5E),6alpha))-isomer; a farnesyl protein transferase inhibitor; from Streptomyces parvulus; MF C31-H38-N2-O7; structure given in first source. manumycin A : A polyketide with formula C31H38N2O7 initially isolated from Streptomyces parvulus as a result of a random screening program for farnesyl transferase (FTase) inhibitors. It is a natural product that exhibits anticancer and antibiotic properties.		2.1510enamide;
epoxide;
organic heterobicyclic compound;
polyketide;
secondary carboxamide;
tertiary alcohol		antiatherosclerotic agent;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
marine metabolite
plastochromanol 8
plastochromanol 8: has antiproliferative activity against 3T3-L1 cells and anti-adipogenic activity; structure; plastochromanol 3 is gamma-tocotrienol		2.4620
yuanhuadine
[no description available]		2.5220diterpenoidmetabolite
everolimus
[no description available]		11.4274cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol		anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
nb 598
NB 598: decreases serum total & LDL-cholesterol levels; structure given in first source; inhibits squalene epoxidase		2.0610
ixabepilone
[no description available]		4.94601,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle		antineoplastic agent;
microtubule-destabilising agent
ekb 569
EKB 569: an EGF receptor kinase inhibitor		10.11251aminoquinoline;
monocarboxylic acid amide;
monochlorobenzenes;
nitrile		protein kinase inhibitor
axitinib
[no description available]		7.2791aryl sulfide;
benzamides;
indazoles;
pyridines		antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
pai 039
tiplaxtinin: inhibitor of plasminogen activator inhibitor-1		2.0810indole-3-acetic acids
rilpivirine
[no description available]		3.5110aminopyrimidine;
nitrile		EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor
trilobatin
trilobatin: anti-inflammatory from Lithocarpus polystachyus leaves; structure in first source. trilobatin : An aryl beta-D-glucoside that is phloretin attached to a beta-D-glucopyranosyl residue at position 4' via a glycosidic linkage. It is isolated from the leaves of the Chinese sweet tea Lithocarpus polystachyus and exhibits significant anti-hyperglycemic, anti-oxidative and anti-inflammatory properties.		7.4110aryl beta-D-glucoside;
dihydrochalcones;
monosaccharide derivative		anti-inflammatory agent;
antioxidant;
plant metabolite;
sweetening agent
azlocillin
Azlocillin: A semisynthetic ampicillin-derived acylureido penicillin.. azlocillin : A semisynthetic penicillin having a 6beta-{(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl}amino side-group. It is an antibiotic used in treating infections caused by Pseudomonas aeruginosa, Escherichia coli and Haemophilus influenzae.		2.4520penicillin allergen;
penicillin;
semisynthetic derivative		antibacterial drug
epoxyfarnesyl diazoacetate
2'-deoxy-4'-C-ethynyl-2-fluoroadenosine: has anti-HIV activity; structure in first source		2.2510
tanespimycin
CP 127374: analog of herbimycin A		4.64801,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor
verlukast
verlukast: LTD4 receptor antagonist		2.0410
cefpodoxime proxetil
cefpodoxime proxetil: structure given in first source; prodrug for cefpodoxime. cefpodoxime proxetil : The 1-[(isopropoxycarbonyl)oxy]ethyl (proxetil) ester prodrug of cefpodoxime. After swallowing, hydrolysis of the ester group occurs in the intestinal epithelium, to release active cefpodoxime in the bloodstream. It is used to treat acute otitis media, pharyngitis, and sinusitis.		2.0810carboxylic acid;
carboxylic ester;
cephalosporin		antibacterial drug;
prodrug
ceftizoxime
[no description available]		3.5820cephalosporinantibacterial drug
1-azakenpaullone
1-azakenpaullone : An organic heterotetracyclic compound that is 7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indole substituted at positions 6 and 9 by oxo and bromo groups respectively.		2.0610lactam;
organic heterotetracyclic compound;
organobromine compound;
organonitrogen heterocyclic compound		EC 2.7.11.26 (tau-protein kinase) inhibitor;
Wnt signalling activator
2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole
[no description available]		2.0310aryl sulfide
a 419259
[no description available]		2.0610
gdp 366
GDP 366: an antineoplastic agent; structure in first source		2.0610
1-methyl-d-lysergic acid butanolamide
[no description available]		3.5720ergot alkaloid;
monocarboxylic acid amide		serotonergic antagonist;
sympatholytic agent;
vasoconstrictor agent
carumonam
carumonam: structure given in first source; RN given refers to (2S-(2alpha,3alpha(Z))-isomer. carumonam : An N-sulfonated monobactam antibiotic.		2.0410monobactamantibacterial drug
beta-escin
[no description available]		3.5370
fluphenazine
[no description available]		2.0810
gw2974
GW2974: quinazoline derivative, which is able to block the activation of both the EGFR and erbB2		2.4520pyridopyrimidine
dantrolene sodium
dantrolene sodium (anhydrous) : The anhydrous sodium salt of dantrolene.		2.4620
nitrofurantoin
Nitrofurantoin: A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.. nitrofurantoin : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.		4.5470imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic		antibacterial drug;
antiinfective agent;
hepatotoxic agent
aminopurvalanol a
aminopurvalanol A: casein kinase I alpha inhibitor; structure in first source		2.0310monochlorobenzenes;
purvalanol		protein kinase inhibitor
2-[[6-[(phenylmethyl)amino]-9-propan-2-yl-2-purinyl]amino]ethanol
[no description available]		2.0610thiopurine
nifurtimox
Nifurtimox: A nitrofuran thiazine that has been used against TRYPANOSOMIASIS.		2.0510nitrofuran antibiotic
ispinesib
[no description available]		2.0810benzamides
gadolinium dtpa
Gadolinium DTPA: A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see PENTETIC ACID), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)		2.0310gadolinium coordination entityMRI contrast agent
eritoran
eritoran : A lipid A derivative used for the treatment of severe sepsis.		2.0410lipid As
dantrolene
[no description available]		3.5820
fk 866
N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide: inhibits nicotinamide phosphoribosyltransferase; structure in first source		2.3110benzamides;
N-acylpiperidine
roxithromycin
(E)-roxithromycin : A major geometrical isomer of roxithromycin.		2.4720roxithromycinenvironmental contaminant;
xenobiotic
cefdinir
[no description available]		3.6120cephalosporin;
ketoxime		antibacterial drug
etonogestrel
[no description available]		3.231017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin
bisoprolol, fumarate (1:1) salt
[no description available]		2.0810
artesunate
artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether		4.1240artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid		antimalarial;
antineoplastic agent;
ferroptosis inducer
edatrexate
edatrexate: structure given in first source		2.9210glutamic acid derivative
beraprost
beraprost: stable prostacyclin analog; structure given in first source. beraprost : An organic heterotricyclic compound that is (3aS,8bS)-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan in which the hydrogens at positions 1R, 2R and 5 are replaced by (3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl, hydroxy and 3-carboxypropyl groups, respectively. It is a prostaglandin receptor agonist which is approved to treat pulmonary arterial hypertension in Asia.		2.0510enyne;
monocarboxylic acid;
organic heterotricyclic compound;
secondary alcohol;
secondary allylic alcohol		anti-inflammatory agent;
antihypertensive agent;
platelet aggregation inhibitor;
prostaglandin receptor agonist;
vasodilator agent
lanreotide
[no description available]		2.0510
etoposide phosphate
[no description available]		2.0810furonaphthodioxole
dexniguldipine
niguldipine: structure given in first source; clinical modulator of multidrug resistance		2.0410diarylmethane
ciclesonide
ciclesonide: nasal spray approved for seasonal and perennial allergic rhinitis		2.0810organic molecular entity
vorozole
vorozole: structure given in first source; vorozole/R 83842 is ((+)/dextro-isomer), RN 129731-10-8; R 83839 ((-)/levo-isomer)		8.6930benzotriazoles
napsagatran
napsagatran: structure given in first source		2.0410
temsirolimus
[no description available]		4.2950macrolide lactam
dutasteride
Dutasteride: A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.. dutasteride : An aza-steroid that is inasteride in which the tert-butyl group is replaced by a 2,5-bis(trifluoromethyl)phenyl group. A synthetic 4-azasteroid, dutasteride is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5alpha-reductase, an intracellular enzyme that converts testosterone to 5alpha-dihydrotestosterone. Dutasteride is used for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate gland.		3.8630(trifluoromethyl)benzenes;
aza-steroid;
delta-lactam		antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
soblidotin
soblidotin: a dolastatin 10 derivative; RN refers to (2S-(1(1R*(R*),2S*),2R*(1S*,2S*)))-isomer; structure given in first source. soblidotin : A tetrapeptide derivative of dolastatin 10. It is an inhibitor of tubulin polymerization which exhibits potent antitumor activity.		2.0210tetrapeptideantineoplastic agent;
apoptosis inducer;
microtubule-destabilising agent
cvt 313
CVT 313: a potent inhibitor of CDK2 that prevents neointimal proliferation; structure given in first source		2.520
beta-elemene
beta-elemene: increases tumor cell immunogenicity by inducing, at least in part, elevated expression of heat shock protein 70 on tumor cell surface. beta-elemene : A sesquiterpene that consists of cyclohexane bearing methyl and vinyl substituents at position 1 as well as two isopropenyl substituents at positions 2 and 4.. (-)-beta-elemene : The (-)-enantiomer of beta-elemene that has (1S,2S,4R)-configuration.		2.9330beta-elemeneantineoplastic agent
pki 166
[no description available]		6.7560
tekturna
[no description available]		2.0810fumarate saltantihypertensive agent
pd 184352
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide: inhibits MAP kinase kinase; structure in first source		6.39110aminobenzoic acid
laulimalide
laulimalide: isolated from Cacospongia mycofijiensis; structure in first source. laulimalide : A macrolide with formula C30H42O7 that is isolated from the marine sponges, Cacospongia mycofijiensis and Hyattella sp.		2.0210carboxylic ester;
epoxide;
macrolide;
secondary alcohol;
secondary allylic alcohol		animal metabolite;
antimitotic;
antineoplastic agent;
marine metabolite;
microtubule-stabilising agent
isavuconazole
isavuconazole : A 1,3-thiazole that is butan-2-ol which is substituted at positions 1, 2, and 3 by 1,2,4-triazol-1-yl, 2,5-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively. It is an antifungal drug used for the treatment of invasive aspergillosis and invasive mucormycosis.		3.51101,3-thiazoles;
conazole antifungal drug;
difluorobenzene;
nitrile;
tertiary alcohol;
triazole antifungal drug		EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
ergosterol biosynthesis inhibitor;
orphan drug
lu 208075
ambrisentan: an ET(A) receptor antagonist and antihypertensive agent; studied for use in pulmonary arterial hypertension		3.5920diarylmethane
bms188797
[no description available]		2.0410
bibx 1382bs
BIBX 1382BS: an ErbB receptor kinase inhibitor; no further information available 4/2001		4.1240substituted aniline
vildagliptin
[no description available]		2.0810amino acid amide
indacaterol
indacaterol: a beta2 adrenoceptor agonist; indacaterol is the (R)-isomer; structure in first source. indacaterol : A monohydroxyquinoline that consists of 5-[(1R)-2-amino-1-hydroxyethyl]-8-hydroxyquinolin-2-one having a 5,6-diethylindan-2-yl group attached to the amino function. Used as the maleate salt for treatment of chronic obstructive pulmonary disease.		2.0810indanes;
monohydroxyquinoline;
quinolone;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent
fesoterodine
fesoterodine: a muscarinic antagonist for treatment of overactive bladder		3.2310diarylmethane
belinostat
[no description available]		2.0810hydroxamic acid;
olefinic compound;
sulfonamide		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
on 01910
ON 01910: a Plk1 inhibitor with antineoplastic activity; structure in first source. N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine : A glycine derivative that is glycine in which one of the hydrogens of the amino group is substituted by a 2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl group.. rigosertib : An N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine in which the double bond has E-configuration. It is a non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM and exhibits anti-cancer properties.		2.1510N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycineantineoplastic agent;
apoptosis inducer;
EC 2.7.11.21 (polo kinase) inhibitor;
microtubule-destabilising agent
cysmethynil
cysmethynil: an Icmt inhibitor with antineoplastic activity; structure in first source		2.110
panobinostat
Panobinostat: An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.. panobinostat : A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.		7.1510cinnamamides;
hydroxamic acid;
methylindole;
secondary amino compound		angiogenesis modulating agent;
antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
hdac-42
HDAC-42: structure in first source		2.0810amidobenzoic acid
isoborneol
isoborneol: RN given refers to cpd without isomeric designation; structure		2.2510borneol
acetylcarnitine
O-acetyl-L-carnitine : An O-acyl-L-carnitine where the acyl group specified is acetyl. It facilitates movement of acetyl-CoA into the matrices of mammalian mitochondria during the oxidation of fatty acids.		2.0510O-acetylcarnitine;
saturated fatty acyl-L-carnitine		human metabolite;
Saccharomyces cerevisiae metabolite
staurosporine
staurosporinium : Conjugate acid of staurosporine.		3.8940ammonium ion derivative
bufalin
bufalin: cardiotonic; powerful anesthetic & one of the active constituents of the Chinese drug ch'an su(senso); in Japan prepared from skin of Bufo bufo garfarizans; RN given refers to (3beta,5beta)-isomer. bufalin : A 14beta-hydroxy steroid that is bufan-20,22-dienolide having hydroxy substituents at the 5beta- and 14beta-positions. It has been isolated from the skin of the toad Bufo bufo.		2.512014beta-hydroxy steroid;
3beta-hydroxy steroid		animal metabolite;
anti-inflammatory agent;
antineoplastic agent;
cardiotonic drug
taxane
taxane: produced by Taxomyces andreanae		5.2641diterpene;
terpenoid fundamental parent
a 770041
[no description available]		2.0610aromatic amide
sl 327
SL 327: a MEK inhibitor. SL-327 : A nitrile that is acrylonitrile in which the hydrogen attached to the same carbon as the cyano group has been replaced by an o-(trifluoromethyl)phenyl group, while the remaining hydrogens of the ethenyl group have been replaced by amino and (4-aminophenyl)sulfanyl groups. The configuration of the double bond is not specified. It is an inhibitor of MEK1 and MEK2.		2.0310
tws 119
[no description available]		2.0310pyrroles
krn 633
N-(2-chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N'-propylurea: a VEGF receptor-2 tyrosine kinase inhibitor; structure in first source		2.0310
((3z)-n-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1h-pyrrol-2-yl)methylene)-n-methyl-2-oxo-2,3-dihydro-1h-indole-5-sulfonamide)
[no description available]		2.4620sulfonamide
[4-[[4-(1-benzothiophen-2-yl)-2-pyrimidinyl]amino]phenyl]-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone
[no description available]		2.0810benzamides;
N-acylpiperidine
c 1368
[no description available]		2.0310
pq 401
PQ 401: an IGF receptor type I antagonist; structure in first source		2.0310quinolines
sgd 301-76
[no description available]		2.0810conazole antifungal drug;
imidazole antifungal drug;
organic nitrate salt		antiinfective agent
fluvoxamine maleate
[no description available]		2.0810(trifluoromethyl)benzenes
formazans
Formazans: Colored azo compounds formed by the reduction of tetrazolium salts. Employing this reaction, oxidoreductase activity can be determined quantitatively in tissue sections by allowing the enzymes to act on their specific substrates in the presence of tetrazolium salts.		2.0210
thioacetazone
Thioacetazone: A thiosemicarbazone that is used in association with other antimycobacterial agents in the initial and continuation phases of antituberculosis regimens. Thiacetazone containing regimens are less effective than the short-course regimen recommended by the International Union Against Tuberculosis and are used in some developing countries to reduce drug costs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p217). thiosemicarbazone : A hydrazone resulting from the formal condensation of an aldehyde or ketone with the non-thioacylated nitrogen of thiosemicarbazide or its substituted derivatives.		2.0810
s 1743
Esomeprazole: The S-isomer of omeprazole.. esomeprazole : A 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole that has S configuration at the sulfur atom. An inhibitor of gastric acid secretion, it is used (generally as its sodium or magnesium salt) for the treatment of gastro-oesophageal reflux disease, dyspepsia, peptic ulcer disease, and Zollinger-Ellison syndrome.		3.811magnesium saltanti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
azimilide
azimilide: structure given in first source; RN given refers to dihydrochloride		2.0410imidazolidine-2,4-dione
nifurtoinol
nifurtoinol : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group and at position 3 by a hydroxymethyl group.		2.0510hydrazone;
imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic		antibacterial drug;
antiinfective agent;
hepatotoxic agent
gemifloxacin
Gemifloxacin: A naphthyridine and fluoroquinolone derivative antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used for the treatment of community-acquired pneumonia and acute bacterial infections associated with chronic bronchitis.. gemifloxacin : A 1,4-dihydro-1,8-naphthyridine with a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a substituted pyrrolin-1-yl group at the 7-position.		3.57201,8-naphthyridine derivative;
fluoroquinolone antibiotic;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
topoisomerase IV inhibitor
dexlansoprazole
Dexlansoprazole: The R-isomer of lansoprazole that is used to treat severe GASTROESOPHAGEAL REFLUX DISEASE.		3.6120benzimidazoles;
sulfoxide
gemifloxacin mesylate
gemifloxacin mesylate : The mesylate salt of gemifloxacin.		2.0810methanesulfonate saltantimicrobial agent;
topoisomerase IV inhibitor
fosinopril
[no description available]		3.5920
vacuolin-1
vacuolin-1: inhibits Ca2-dependent lysosomal exocytosis		3.9220
armodafinil
armodafinil : A 2-[(diphenylmethyl)sulfinyl]acetamide that has R configuration at the sulfur atom. Like its racemate, modafinil, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. Peak concentration in the blood later occurs later following administration than with modafinil, so it is thought that armodafinil may be more effective than modafinil in treating people with excessive daytime sleepiness.		3.23102-[(diphenylmethyl)sulfinyl]acetamidecentral nervous system stimulant;
eugeroic
iniparib
[no description available]		2.0810carbonyl compound;
organohalogen compound
jnj 10198409
[no description available]		2.0310
mk 0752
[no description available]		2.0810
gw 501516
GW 501516: a selective PPARdelta agonist; structure in first source. GW 501516 : An aromatic ether that is phenoxyacetic acid in which the phenyl group is substituted at position 2 by a methyl group and at position 4 by a (1,3-thiazol-5-ylmethyl)sulfanediyl group, and in which the 1,3-thiazolyl group is substituted at positions 2 and 4 by p-trifluoromethylphenyl and methyl groups, respectively.		2.08101,3-thiazoles;
aromatic ether;
aryl sulfide;
monocarboxylic acid;
organofluorine compound		carcinogenic agent;
PPARbeta/delta agonist
eflucimibe
eflucimibe: a powerful and systemic acylcoenzyme A: cholesterol acyltransferase inhibitor		2.0510
av 412
[no description available]		3.9130
ag-041r
AG-041R: structure in first source		2.0810
telatinib
[no description available]		2.5220
tomopenem
[no description available]		2.0410
y-39983
Y-39983: SNJ-1656 is an ophthalmic solution of Y-39983; ROCK (rho kinase) inhibitor, promotes regeneration of crushed axons of retinal ganglion cells; structure in first source		2.1510pyrrolopyridine
ggti 298
GGTI 298: inhibits geranylgeranyltransferase-I; structure in first source		2.1710leucine derivative
cp 547632
3-(4-bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide: inhibits vascular endothelial growth factor receptor-2 tyrosine kinase; structure in first source		2.7830
timcodar
timcodar: a mutlidrug resistance inhibitor; structure in first source		3.5110
bms345541
4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline: structure in first source		3.8430quinoxaline derivative
norfenfluramine
Dexnorfenfluramine: D-isomer of Norfenfluramine		2.0310amphetamines
spc-839
SPC-839: an inhibitor of activator protein 1; structure in first source		3.6320
lenvatinib
lenvatinib : A member of the class of quinolines that is the carboxamide of 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxylic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine.		6.0770aromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist
andarine
[no description available]		2.0810acetamides;
anilide
adw 742
[no description available]		2.5120
gw843682x
[no description available]		2.4820(trifluoromethyl)benzenes
pd 0325901
mirdametinib: has antineoplastic activity; appears to be a MEK inhibitor. PD 0325901 : A hydroxamic acid ester that is benzhydroxamic acid (N-hydroxybenzamide) in which the hydroxamic acid group has been converted to the corresponding 2,3-dihydroxypropyl ester and in which the benzene ring has been substituted at position 2 by a (2-fluoro-4-iodophenyl)amino group and at positions 3 and 4 by fluorines (the R enantiomer).		3.0540difluorobenzene;
hydroxamic acid ester;
monofluorobenzenes;
organoiodine compound;
propane-1,2-diols;
secondary amino compound		antineoplastic agent;
EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
midostaurin
midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.		4.9780benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound		antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
efatutazone
efatutazone: a high-affinity PPARgamma agonist with antineoplastic activity		2.5720
sincalide
Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.		430oligopeptide
tapentadol
Tapentadol: An opioid analgesic, MU OPIOID RECEPTOR agonist, and noradrenaline reuptake inhibitor that is used in the treatment of moderate to severe pain, and of pain associated with DIABETIC NEUROPATHIES.		3.2310alkylbenzene
ag 14361
[no description available]		2.0810benzimidazoles
etomoxir
[no description available]		2.4820aromatic ether
sb 265610
[no description available]		2.0810
ursodoxicoltaurine
tauroursodeoxycholate : An organosulfonate oxoanion that is the conjugate base of tauroursodeoxycholic acid arising from deprotonation of the sulfonate OH group; major species at pH 7.3.. tauroursodeoxycholic acid : A bile acid taurine conjugate derived from ursoodeoxycholic acid.		2.1110bile acid taurine conjugateanti-inflammatory agent;
apoptosis inhibitor;
bone density conservation agent;
cardioprotective agent;
human metabolite;
neuroprotective agent
px-866
PX-866: inhibitor of phosphoinositide-3-kinase signaling with antitumor activity; structure in first source. PX-866 : An organic heterotetracyclic compound that is obtained from wortmanin via aminolysis of its furan ring by diallyl amine.		7.4720acetate ester;
delta-lactone;
organic heterotetracyclic compound;
tertiary amino compound		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
bb-83698
BB-83698: peptide deformylase inhibitor		2.0410
pentagastrin
Pentagastrin: A synthetic pentapeptide that has effects like gastrin when given parenterally. It stimulates the secretion of gastric acid, pepsin, and intrinsic factor, and has been used as a diagnostic aid.		3.5920organic molecular entity
nu 7026
2-(morpholin-4-yl)benzo(h)chromen-4-one: a radiosensitizing agent that inhibits DNA-dependent protein kinase; structure in first source		2.0310organic heterotricyclic compound;
organooxygen compound
sb 242235
SB 242235: p38 MAP kinase antagonist		2.0610
ripasudil
[no description available]		2.1510isoquinolines
fr 148083
5Z-7-oxozeaenol : A macrolide that is the 7-oxo derivative of zeaenol (the 5Z stereoisomer). Isolated from Fungi, it exhibits cytotoxic, antibacterial and inhibitory activity against NF-kappaB.		3.6620aromatic ether;
macrolide;
phenols;
secondary alcohol;
secondary alpha-hydroxy ketone		antibacterial agent;
antineoplastic agent;
metabolite;
NF-kappaB inhibitor
adarotene
adarotene: structure in first source		2.0210
mocetinostat
mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).		2.0810aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
sc 236
4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide: SC58236 = SC236 re email from Harris, Ray 		2.4220
osi 930
OSI 930: inhibits both receptor tyrosine kinase Kit and kinase insert domain receptor; structure in first source		2.5220aromatic amide
ki 20227
[no description available]		2.4820
cefditoren
cefditoren: structure given in first source; RN given refers to the (6R-(3(Z),6alpha,7beta(Z)))-isomer. cefditoren : A broad spectrum, third-generation cephalosporin antibiotic with (Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. Generally administered as its orally absorbed pivaloyloxymethyl ester prodrug, it is used for the treatment of mild to moderate infections caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, and uncomplicated skin and skin-structure infections.		3.2310carboxylic acid;
cephalosporin		antibacterial drug
scio-469
SCIO-469: a small-molecule p38 mitogen-activated protein (MAP) kinase inhibitor for potential oral therapy for inflammatory disorders; in phase lib clinical trials for rheumatoid arthritis 4/2004. talmapimod : An indolecarboxamide obtained by formal condensation of the carboxy group of 6-chloro-3-[(dimethylamino)(oxo)acetyl]-1-methylindole-5-carboxylic acid with the secondary amino group of (2S,5R)-1-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine. It is a potent inhibitor of MAPK and exhibits anti-cancer properties.		2.5220aromatic amide;
aromatic ketone;
chloroindole;
dicarboxylic acid diamide;
indolecarboxamide;
monofluorobenzenes;
N-acylpiperazine;
N-alkylpiperazine		antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
ticagrelor
Ticagrelor: An adenosine triphosphate analogue and reversible P2Y12 PURINORECEPTOR antagonist that inhibits ADP-mediated PLATELET AGGREGATION. It is used for the prevention of THROMBOEMBOLISM by patients with ACUTE CORONARY SYNDROME or a history of MYOCARDIAL INFARCTION.. ticagrelor : A triazolopyrimidine that is an adenosine isostere; the cyclopentane ring is similar to ribose and the nitrogen-rich [1,2,3]triazolo[4,5-d]pyrimidine moiety resembles the nucleobase adenine. A platelet aggregation inhibitor which is used for prevention of thromboembolic events in patients with acute coronary syndrome.		2.0810aryl sulfide;
hydroxyether;
organofluorine compound;
secondary amino compound;
triazolopyrimidines		P2Y12 receptor antagonist;
platelet aggregation inhibitor
ssr 69071
SSR 69071: structure in first source		2.0810pyridopyrimidine
cp 724714
2-methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide: CP-724714 is the ((2E)-isomer, 1:1.5 succinate); structure in first source		6.19902-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamideantineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
hepatotoxic agent
rivaroxaban
Rivaroxaban: A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.. rivaroxaban : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. An anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery.		2.0810aromatic amide;
lactam;
monocarboxylic acid amide;
morpholines;
organochlorine compound;
oxazolidinone;
thiophenes		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor
zotarolimus
zotarolimus: synthetic analog of rapamycin; structure in first source		2.0410lactam;
macrolide
treosulfan
treosulfan: immunosuppressant; RN given refers to (S-(R*,R*))-isomer		2.0210methanesulfonate ester
molindone hydrochloride
[no description available]		2.0510indoles
pi103
PI103: pyridofuropyrimidine antineoplastic; a potent inhibitor of class I phosphatidylinositide 3-kinases (PI3K); structure in first soruce		10.31120aromatic amine;
morpholines;
organic heterotricyclic compound;
phenols;
tertiary amino compound		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
sb 210313
[no description available]		2.0810
hmn-214
(E)-4-(2-(2-(N-acetyl-N-(4-methoxybenzenesulfonyl)amino)stilbazole)) 1-oxide: an antineoplastic agent; structure in first source		2.1510
gw 4064
[no description available]		2.0810stilbenoid
zd 6126
[no description available]		2.4320
gentamicin sulfate
[no description available]		2.4520
y 27632, dihydrochloride, (4(r)-trans)-isomer
[no description available]		2.0310
2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide
2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide: an IKK-2 kinase inhibitor; structure in first source		2.110aromatic amide;
thiophenes
tgx 221
TGX 221: a platelet aggregation inhibitor		2.0610pyridopyrimidine
sa 4503
[no description available]		2.0810
ic 87114
IC 87114: structure in first source		3.55206-aminopurines;
biaryl;
quinazolines		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
bn 52020
[no description available]		2.0410
zibotentan
ZD4054: a potent endothelin receptor A antagonist that inhibits ovarian carcinoma cell proliferation		2.9940phenylpyridine
tivozanib
N-(2-chloro-4-((6,7-dimethoxy-4-quinolyl)oxy)phenyl)-N'-(5-methyl-3-isoxazolyl)urea: KNR-951 is the HCl, monohydrate salt; an antineoplastic agent; structure in first source		4.1740aromatic ether
zm 447439
ZM447439 : A member of the class of quinazolines that is quinazoline which is substituted at positions 4, 6 and 7 by a (4-benzamidophenyl)nitrilo group, methoxy group and a 3-(morpholin-4-yl)propoxy group, respectively. It is an ATP-competitive inhibitor of Aurora A and Aurora B kinases with IC50 of 110 nM and 130 nM, respectively.		4.6640aromatic ether;
benzamides;
morpholines;
polyether;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
Aurora kinase inhibitor
hki 272
[no description available]		5.7240nitrile;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor
sorbitan monooleate
[no description available]		4.6111fatty acid ester
tofacitinib
tofacitinib : A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis.		6.1790N-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound		antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
bibr 1532
[no description available]		2.5720
n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide
[no description available]		2.4820
rhodamine 123
[no description available]		2.0510organic chloride salt;
xanthene dye		fluorochrome
rucaparib
AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source		2.7730azepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound		antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
cediranib
[no description available]		8.52124aromatic ether
tae226
TAE226: an adhesion kinase inhibitor, offers an attractive therapeutic approach in ovarian carcinoma; structure in first source		2.4920morpholines
gw0742
GW 610742: structure in first source		2.0810monocarboxylic acid
pasireotide
pasireotide : A six-membered homodetic cyclic peptide composed from L-phenylglycyl, D-tryptophyl, L-lysyl, O-benzyl-L-tyrosyl, L-phenylalanyl and modified L-hydroxyproline residues joined in sequence. A somatostatin analogue with pharmacologic properties mimicking those of the natural hormone somatostatin; used (as its diaspartate salt) for treatment of Cushing's disease.		4.2210homodetic cyclic peptide;
peptide hormone		antineoplastic agent
pf9601n
[no description available]		2.2510
pitolisant
pitolisant: functions as both inverse agonist and antagonist of histamine H3 receptors; structure in first source		4.6111organochlorine compound
ps1145
PS1145: IkappaB kinase inhibitor; structure in first source		2.0810beta-carbolines
npi 2358
NPI 2358: antineoplastic; structure in first source. plinabulin : A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione substituted by benzylidene and (5-tert-butyl-1H-imidazol-4-yl)methylidene groups at positions 3 and 6, respectively. It is a vascular disrupting agent and a microtubule destabalising agent which was in clinical trials (now discontinued) for the treatment of non-small cell lung cancer.		2.17102,5-diketopiperazines;
benzenes;
imidazoles;
olefinic compound		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
microtubule-destabilising agent
tak-715
N-(4-(2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl)-2-pyridyl)benzamide: anti-rheumatoid arthritis agent; structure in first source		2.0610benzamides
bay 41-8543
BAY 41-8543: structure in first source		2.0810pyrazolopyridine
u 18666a
3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one: inhibits cycloartenol synthase. 3beta-(2-diethylaminoethoxy)androst-5-en-17-one hydrochloride : A hydrochloride obtained by reaction of 3beta-(2-diethylaminoethoxy)androst-5-en-17-one with one equivalent of hydrochloric acid. It is a cholesterol synthesis and transport inhibitor.		2.1710hydrochlorideantiviral agent;
EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor;
Hedgehog signaling pathway inhibitor;
nicotinic antagonist;
sterol biosynthesis inhibitor
chir 99021
Chir 99021: structure in first source. CHIR 99021 : A member of the class of aminopyrimidines that is 2-aminopyrimidine substituted at positions N2, 5 and 6 by (5-cyanopyridin-2-yl)ethyl, 4-methylimidazol-2-yl and 2,4-dichlorophenyl groups respectively.		2.4820aminopyridine;
aminopyrimidine;
cyanopyridine;
diamine;
dichlorobenzene;
imidazoles;
secondary amino compound		EC 2.7.11.26 (tau-protein kinase) inhibitor
ym 201636
6-amino-N-(3-(4-(4-morpholinyl)pyrido(3',2'-4,5)furo(3,2-d)pyrimidin-2-yl)phenyl)-3-pyridinecarboxamide: an antiviral agent; structure in first source		3.5110aromatic amide
sb 525334
6-(2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline: a TGF-betaR kinase inhibitor		2.0810quinoxaline derivative
potassium oxide
potassium oxide : A metal oxide with formula K2O.		2.610metal oxide;
potassium salt
way-362450
[no description available]		2.0810indoles
osu 03012
OSU 03012: a PDK-1 inhibitor; structure in first source		2.5220antibiotic antifungal drug;
aromatic amide;
glycine derivative;
organofluorine compound;
phenanthrenes;
pyrazoles		antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
ly2090314
LY-2090314 : A member of the class of diazepinoindoles that is 1,2,3,4-tetrahydro[1,4]diazepino[6,7,1-hi]indole substituted by piperidin-1-ylcarbonyl, 4-(imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl and fluoro groups at position 2, 7 and 9, respectively. It is a potent ATP-competitive inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 values of 1.5 nM and 0.9 nM for GSK-3alpha and GSK-3beta. The drug is in clinical development for the treatment of advanced/metastatic cancer.		2.0610diazepinoindole;
imidazopyridine;
maleimides;
monofluorobenzenes;
piperidinecarboxamide;
ureas		antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
Wnt signalling activator
masitinib
[no description available]		2.78301,3-thiazoles;
benzamides;
N-alkylpiperazine;
pyridines		antineoplastic agent;
antirheumatic drug;
tyrosine kinase inhibitor
bx795
BX795: structure in first source		2.5720ureas
18f-faza
fluoroazomycin arabinoside: used for hypoxia-specific imaging; structure in first source		2.0210
ly-2157299
LY-2157299: an orally active transforming growth factor beta receptor (TGF-beraR) kinase inhibitor. LY-2157299 : A pyrrolopyrazole that is 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole which is substituted at positions 2 and 3 by 6-methylpyridin-2-yl and 6-(aminocarbonyl)quinolin-4-yl groups, respectively. A Transforming growth factor-betaRI (TGF-betaRI) kinase inhibitor, it blocks TGF-beta-mediated tumor growth in glioblastoma.		3.7320aromatic amide;
methylpyridines;
monocarboxylic acid amide;
pyrrolopyrazole;
quinolines		antineoplastic agent;
TGFbeta receptor antagonist
4-hydroxy-n-desmethyltamoxifen
4-hydroxy-N-desmethyltamoxifen: metabolite of tamoxifen in human bile		2.1710stilbenoid
linagliptin
Linagliptin: A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS.. linagliptin : A xanthine that is 7H-xanthine bearing (4-methylquinazolin-2-yl)methyl, methyl, but-2-yn-1-yl and 3-aminopiperidin-1-yl substituents at positions 1, 3, 7 and 8 respectively (the R-enantiomer). Used for treatment of type II diabetes.		3.4110aminopiperidine;
quinazolines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
pazopanib
pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.		8.01160aminopyrimidine;
indazoles;
sulfonamide		angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
sepantronium
sepantronium: a survivin suppressant with antineoplastic activity. sepantronium : An organic cation that is 1-(2-methoxyethyl)-2-methyl-1H-naphtho[2,3-d]imidazole-4,9-dione in which the nitrogen at position 3 of the napthoimidazole moiety has been alkylated by a pyrazin-2-ylmethyl group.		2.0810organic cation
azd 6244
AZD 6244: a MEK inhibitor		5.28150benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
su 14813
5-((5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-N-(2-hydroxy-3-morpholin-4-ylpropyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide: has both antineoplastic and antiangiogenic activities; structure in first source		4.5550
prasugrel hydrochloride
Prasugrel Hydrochloride: A piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.. prasugrel hydrochloride : A racemate comprising equal amounts of (R)- and (S)-prasugrel hydrochloride. Used to prevent blood clots in people with acute coronary syndrome who are undergoing a procedure after a recent heart attack or stroke, and in people with certain disorders of the heart or blood vessels.		3.2310
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea: structure in first source		2.0810
a 443654
A 443654: an Akt kinase inhibitor; structure in first source		2.4110indoles
apilimod
[no description available]		3.9220
apixaban
[no description available]		2.0810aromatic ether;
lactam;
piperidones;
pyrazolopyridine		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor
bibw 2992
[no description available]		24.6623326aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
tyrosine kinase inhibitor
bay 61-3606
[no description available]		2.0610pyrimidines
N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide : A member of the class of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)[1,1'-biphenyl]-4-carboxylic acid with the amino group of 3-cyanoaniline.		2.08101,3,4-oxadiazoles;
benzamides;
biphenyls;
nitrile		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
artenimol
artenimol: derivative of antimalarial drug artemisinin (quinghaosu)		2.6620
ar c155858
AR C155858: an MCT1 inhibitor; structure in first source		2.0810
pik 75
PIK 75: structure in first source		2.4110
edoxaban
edoxaban : A monocarboxylic acid amide that is used (as its tosylate monohydrate) for the treatment of deep vein thrombosis and pulmonary embolism.		2.3110chloropyridine;
monocarboxylic acid amide;
tertiary amino compound;
thiazolopyridine		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor;
platelet aggregation inhibitor
binimetinib
binimetinib : A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-fluorophenyl)nitrilo, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1 and MEK2 inhibitor (IC50= 12 nM). Approved by the FDA for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation in combination with encorafenib.		2.1510benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monofluorobenzenes;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sotrastaurin
sotrastaurin: a potent protein kinase C-selective inhibitor; structure in first source. sotrastaurin : A member of the class of maleimides that is maleimide which is substituted at position 3 by an indol-3-yl group and at position 4 by a quinazolin-4-yl group, which in turn is substituted at position 2 by a 4-methylpiperazin-1-yl group. It is a potent and selective inhibitor of protein kinase C and has been investigated as an immunosuppresant in renal transplant patients.		2.520indoles;
maleimides;
N-alkylpiperazine;
N-arylpiperazine;
quinazolines		anticoronaviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunosuppressive agent
aee 788
AEE 788: structure in first source		4.771106-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amineangiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist;
trypanocidal drug
saracatinib
[no description available]		5.6990aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent
sd-208
[no description available]		2.0810
ko 143
[no description available]		4.5870beta-carbolines;
tert-butyl ester
2-acetylfuranonaphthoquinone
2-acetylfuranonaphthoquinone: has antineoplastic activity; structure in first source		2.3110
demethoxyfumitremorgin c
demethoxyfumitremorgin C: isolated from the fermentation broth of Aspergillus fumigatus; a mammalian cell cycle inhibitor; structure given in first source. demethoxyfumitremorgin C : An organic heteropentacyclic compound that is a mycotoxic indole alkaloid, consisting of fumitremorgin C lacking the 9-methoxy substituent.		2.0310indole alkaloid;
organic heteropentacyclic compound		mycotoxin
vx 702
VX 702: a p38 MAP kinase inhibitor		2.7830phenylpyridine
crenolanib
[no description available]		2.5420aminopiperidine;
aromatic ether;
benzimidazoles;
oxetanes;
quinolines;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
tg100-115
3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol: for treatment of ischemia reperfusion injury; structure in first source		2.520pteridines
cc 401
CC 401: an anthrapyrazolone		2.1510pyrazoles;
ring assembly
bms 599626
[no description available]		2.1510
exel-7647
tesevatinib : A member of the class of quinazolines that is quinazoline substituted by (3,4-dichloro-2-fluorophenyl)amino, methoxy, and [(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methoxy groups at positions 4, 6 and 7, respectively. It is a multi-target tyrosine kinase inhibitor of EGFR, ErbB2, KDR, Flt4 and EphB4 and exhibits anti-cancer properties.		5.3141
volasertib
BI 6727: a polo-like kinase inhibitor with broad antitumor activity; structure in first source		2.5220
pha 665752
[no description available]		2.0610dichlorobenzene;
enamide;
indolones;
N-acylpyrrolidine;
pyrrolecarboxamide;
secondary carboxamide;
sulfone;
tertiary carboxamide		antineoplastic agent;
c-Met tyrosine kinase inhibitor
licochalcone d
licochalcone D: isolated from Glycyrrhiza inflata; inhibits phosphorylation of NF-kappaB p65 in LPS signaling pathway		7.2510
PB28
PB28 : A member of the class of tetralins that is tetralin that is substituted by 3-(4-cyclohexylpiperazin-1-yl)propyl and methoxy groups at positions 1 and 5, respectively. It is a sigma 2 (sigma2) receptor agonist (Ki = 0.68 nM) and exhibits antineoplastic and anti SARS-CoV-2 activities.		2.0810aromatic ether;
piperazines;
tetralins		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
sigma-2 receptor agonist
amg 009
AMG 009: an anti-inflammatory agent; structure in first source		2.0810
oxadiazoles
Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.		3.0640
vinflunine
vinflunine: inhibits tubulin assembly; structure in first source. vinflunine : An organic heteropentacyclic compound and an organic heterotetracyclic compound that is vinorelbine in which the tetrahydropyridine moiety of the heterotetracyclic part of the molecule has been redced to the corresponding piperidine, and in which the ethyl group attached to this ring has been replaced by a 1,1-difluoroethyl group.		2.0510acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
semisynthetic derivative;
vinca alkaloid		antineoplastic agent
cefotaxime sodium
[no description available]		2.0810organic sodium salt
ly 341495
LY 341495: structure in first source		2.0810
baci-im
[no description available]		3.8630homodetic cyclic peptide;
polypeptide;
zwitterion		antibacterial agent;
antimicrobial agent
8-oxo-2'-deoxyadenosine
8-hydroxy-2'-deoxyadenosine: structure in first source		2.0510purine 2'-deoxyribonucleoside
allobetulinol
allobetulinol : A triterpenoid that is (18alpha)-19,28-epoxyoleanane substituted by a hydroxy group at position 3.		2.2510cyclic ether;
secondary alcohol;
triterpenoid
azd 7762
[no description available]		2.5220aromatic amide;
thiophenes
krp-203
[no description available]		2.0810
mk 0354
[no description available]		2.0810
regorafenib
[no description available]		5.0660(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide		antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor
acetic acid 2-[4-methyl-8-(4-morpholinylsulfonyl)-1,3-dioxo-2-pyrrolo[3,4-c]quinolinyl]ethyl ester
[no description available]		2.0810pyrroloquinoline
wp1066
[no description available]		2.0610
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one
[no description available]		3.1950methoxybenzenes;
substituted aniline
n-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide
N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide: MK-0364 is the (1S,2S)-isomer; a cannabinoid-1 receptor inverse agonist; structure in first source		2.0810stilbenoid
abt-737
[no description available]		2.0310aromatic amine;
aryl sulfide;
biphenyls;
C-nitro compound;
monochlorobenzenes;
N-arylpiperazine;
N-sulfonylcarboxamide;
secondary amino compound;
tertiary amino compound		anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
brivanib
[no description available]		3.0140aromatic ether;
diether;
fluoroindole;
pyrrolotriazine;
secondary alcohol		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist
icg 001
[no description available]		2.0810peptide
bms 477118
[no description available]		3.2310adamantanes;
azabicycloalkane;
monocarboxylic acid amide;
nitrile;
tertiary alcohol		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
cvt-6883
3-ethyl-1-propyl-8-(1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl)-3,7-dihydropurine-2,6-dione: structure in first source		2.0610
mp470
[no description available]		2.5220N-arylpiperazine
rgb 286638
[no description available]		2.1510
nystatin a1
Nystatin: Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.. nystatin : A heterogeneous mixture of polyene compounds produced by cultures of Streptomyces noursei. It mainly consists of three biologically active components designated nystatin A1, nystatin A2, and nystatin A3. It is used to treat oral and dermal fungal infections.. nystatin A1 : A polyene macrolide antibiotic; part of the nystatin complex produced by several Streptomyces species. It is an antifungal antibiotic used for the treatment of topical fungal infections caused by a broad spectrum of fungal pathogens comprising yeast-like and filamentous species.		4.430nystatins
np 031112
tideglusib: an NSAID and neuroprotective agent. tideglusib : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a naphthalen-1-yl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta) and has neuroprotective effects. Currently under clinical investigation for the treatment of Alzheimer's disease and progressive supranuclear palsy.		2.1510benzenes;
naphthalenes;
thiadiazolidine		anti-inflammatory agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent
nu 7441
8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one: structure in first source		2.0810dibenzothiophenes
at 7519
4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide : A member of the class of pryrazoles that is 4-amino-1H-pyrazole-3-carboxylic acid in which the primary amino group has been acylated by a 2,6-dichlorobenzoyl group and in which the carboxylic acid has been converted into a carboxamide by formal condensation with the primary amino group of 4-aminopiperidine.		2.7830dichlorobenzene;
piperidines;
pyrazoles;
secondary carboxamide		antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
bms-690514
[no description available]		3.0540
artenimol
[no description available]		2.2110artemisinin derivative
bi 2536
[no description available]		3.2150
inno-406
[no description available]		2.1510biaryl
r 1487
[no description available]		2.0610
nvp-ast487
NVP-AST487: antineoplastic; a RET kinase inhibitor that blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells		4.5450
kw 2449
KW 2449: has both multikinase inhibitory activity and antineoplastic activity; structure in first source		2.520
nutlin-3a
nutlin 3: an MDM2 antagonist; structure in first source		2.110stilbenoid
danusertib
[no description available]		2.5220piperazines
N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide
[no description available]		2.0810benzamides
N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide
[no description available]		3.5520benzamides
nvp-aew541
[no description available]		2.7730
abt 869
[no description available]		4.8470aromatic amine;
indazoles;
phenylureas		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
azd 8931
sapitinib : A member of the class of quinazolines that is 4-amino-7-methoxyquinazoline in which the amino group has been substituted by a 3-chloro-2-fluorophenyl group and in which position 6 of the quinoline ring has been substituted by a {1-[2-(methylamino)-2-oxoethyl]piperidin-4-yl}oxy group. Sapitinib is a dual tyrosine kinase inhibitor (TKI) of epithelial growth factor receptors (EGFR) HER2 and HER3.		4.1940aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
tertiary amino compound		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist
fr 180204
FR 180204: structure in first source		2.0310pyrazoles;
ring assembly
arq 197
[no description available]		2.1510indoles
azd 1152
AZD-1152 : A member of the of quinazolines that is 4-aminoquinazolin-7-ol in which the amino group at position 4 has been substituted by a 5-[2-(3-fluoroanilino)-2-oxoethyl]-1H-pyrazol-3-yl group, while the hydroxy group at position 7 has been converted into the corresponding 3-[ethyl(2-hydroxyethyl)aminopropyl ether.		3.9330anilide;
monoalkyl phosphate;
monofluorobenzenes;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
Aurora kinase inhibitor;
prodrug
prx 08066
[no description available]		3.3110
pf 00299804
dacomitinib: a pan-ERBB inhibitor. dacomitinib : A member of the class of quinazolines that is 7-methoxyquinazoline-4,6-diamine in which the amino group at position 4 is substituted by a 3-chloro-4-fluorophenyl group and the amino group at position 6 is substituted by an (E)-4-(piperidin-1-yl)but-2-enoyl group.		15.474716enamide;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
ridaforolimus
[no description available]		4.3930macrolide lactam
dorsomorphin
dorsomorphin: an AMPK inhibitor. dorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling.		3.6620aromatic ether;
piperidines;
pyrazolopyrimidine;
pyridines		bone morphogenetic protein receptor antagonist;
EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
ac 261066
[no description available]		2.0810
ch 4987655
[no description available]		2.1510
6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-n-(2,2-dimethylprpyl)-3-pyridinecarboxamide
[no description available]		2.1510phenylpyridine
carfilzomib
[no description available]		2.0810epoxide;
morpholines;
tetrapeptide		antineoplastic agent;
proteasome inhibitor
lapatinib ditosylate
[no description available]		2.7530quinazolines
apremilast
[no description available]		2.0810aromatic ether;
N-acetylarylamine;
phthalimides;
sulfone		non-steroidal anti-inflammatory drug;
phosphodiesterase IV inhibitor
cytidine diphosphate choline
[no description available]		2.0510nucleotide-(amino alcohol)s;
phosphocholines		human metabolite;
mouse metabolite;
neuroprotective agent;
psychotropic drug;
Saccharomyces cerevisiae metabolite
gw9508
GW9508: structure in first source		2.0810aromatic amine
cc-930
[no description available]		2.1510
3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine
3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine : A pyrazolylpiperidine that consists of 4-(pyrazol-1-yl)piperidine carrying a 2-amino-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-5-yl group at the 4-position of the pyrazole ring.. rac-crizotinib : A racemate comprising equimolar amounts of (R)- and (S)-crizotinib. The active (R)-enantiomer acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer.		2.0610aminopyridine;
aromatic ether;
dichlorobenzene;
organofluorine compound;
pyrazolylpiperidine;
racemate		antineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
jnj 26854165
[no description available]		2.8530
resminostat
resminostat: a histone deacetylase inhibitor; structure in first source		2.2510
pf 573228
6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one: structure in first source		2.0810quinolines
gw 2580
5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine: a cFMS kinase inhibitor; structure in first source		4.8370
tak 285
N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide: also inhibits HER2; structure in first source		2.8630
milnacipran
[no description available]		3.5720acetamides
incb3619
INCB3619: ADAM inhibitor; structure in first source		2.4620
idelalisib
idelalisib: an antineoplastic agent and p110delta inhibitor; structure in first source. idelalisib : A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.		3.9430aromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
crizotinib
Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.. crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)		9.995113-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amineantineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
5-(5,6-dimethoxy-1-benzimidazolyl)-3-[(2-methylsulfonylphenyl)methoxy]-2-thiophenecarbonitrile
[no description available]		2.0810benzimidazoles
4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide
Vx-11e: ERK1-2 inhibitor		2.0810aromatic amide;
heteroarene
osi 906
[no description available]		3.0240cyclobutanes;
quinolines
vindesine
[no description available]		2.7730
zstk474
ZSTK-474 : A triamino-1,3,5-triazine that is 1,3,5-triazine in which two of the hydrogens have been replaced by morpholin-4-yl groups while the third hydrogen has been replaced by a 2-(difluoromethyl)benzimidazol-1-yl group. It is an inhibitor of phosphatidylinositol 3-kinase.		2.4920benzimidazoles;
morpholines;
organofluorine compound;
triamino-1,3,5-triazine		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
ly2109761
[no description available]		2.0810
chir-265
[no description available]		4.760aromatic ether
motesanib
[no description available]		4.760pyridinecarboxamide
fostamatinib
fostamatinib: a spleen tyrosine kinase (Syk) inhibitor, metabolized to R406		9.3250
az-628
AZ-628: a multikinase inhibitor; structure in first source		2.0810benzamides
jnj 28312141
[no description available]		2.0610
trametinib
[no description available]		9.99100acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
mln8054
[no description available]		4.760benzazepine
pf-562,271
[no description available]		2.7830indoles
pha 767491
PHA 767491: a Cdc7 inhibitor; structure in first source		2.5420pyrrolopyridine
GDC-0879
[no description available]		2.0610indanes;
ketoxime;
primary alcohol;
pyrazoles;
pyridines		antineoplastic agent;
B-Raf inhibitor
gpi 15427
[no description available]		2.0610
losartan potassium
Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.		2.0810
amrubicinol
amrubicinol: a diastereoisomeric mixture; a synthetic antracycline drug. amrubicinol : A diastereoisomeric mixture resulting from the formal reduction of the acetyl group at position 9 of amrubicin to the corresponding 1-hydroxyethyl group. The active metabolite of amrubicin in lung cancer patients.		2.0310diastereoisomeric mixture;
quinone;
secondary alcohol;
tetracenes		antineoplastic agent;
apoptosis inducer;
topoisomerase II inhibitor
jnj-26483327
JNJ-26483327: an orally active macrocyclic tyrosine kinase inhibitor for treatment of patients with advanced solid tumours; in Phase I trial, 9/2010		3.6820
ly2603618
[no description available]		2.1510ureas
wk-x-34
WK-X-34: inhibitor of P-glycoprotein and BCRP (breast cancer resistance protein); structure in first source		2.0510
veliparib
[no description available]		2.0810benzimidazolesEC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
ku-0060648
[no description available]		2.0810dibenzothiophenes
scopolamine hydrobromide
[no description available]		3.5820
cinobufagin
cinobufagin: isolated from Chinese medicinal preparation ch'an su; derived from toad venom		2.3110steroid lactone
tg100801
[no description available]		2.1510
dactolisib
dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.		3.7190imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
bgt226
BGT226 free base : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 3-trifluoromethyl-4-(piperazin-1-yl)phenyl group and at position 8 by a 6-methoxypyridin-3-yl group. A dual PI3K/mTOR inhibitor.. BGT226 : The maleate salt of 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one. A dual PI3K/mTOR inhibitor.		2.5420aromatic ether;
imidazoquinoline;
N-arylpiperazine;
organofluorine compound;
pyridines		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
palomid 529
[no description available]		2.0810
pf 03491390
[no description available]		2.0510
mefloquine
Mefloquine: A phospholipid-interacting antimalarial drug (ANTIMALARIALS). It is very effective against PLASMODIUM FALCIPARUM with very few side effects.. mefloquine : A racemate composed of (+)-(11R,2'S)- and (-)-(11S,2'R)-enantiomers of mefloquine. An antimalarial agent which acts as a blood schizonticide; its mechanism of action is unknown.		2.0810
1-deoxynojirimycin hydrochloride
[no description available]		2.1510
salvianolic acid c
salvianolic acid C: mTOR inhibitor from Salvia miltiorrhiza		2.2110benzofurans
pedunculoside
pedunculoside: from leaves of Ilex chinensis; structure given in first source		7.610
butaprost
butaprost: highly selective prostaglandin receptor agonist; structure given in first source		2.0510
rabeprazole sodium
[no description available]		2.0810organic sodium salt
a-484954
A-484954: eEF2K inhibitor; structure in first source		2.0610
tosedostat
[no description available]		2.0810carboxylic ester;
hydroxamic acid;
secondary carboxamide
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
[no description available]		3.9220organochlorine compound
mdv 3100
[no description available]		2.5420(trifluoromethyl)benzenes;
benzamides;
imidazolidinone;
monofluorobenzenes;
nitrile;
thiocarbonyl compound		androgen antagonist;
antineoplastic agent
ku 60019
[no description available]		2.0810
gsk 461364
GSK 461364: an antineoplastic agent that inhibits polo-like kinase 1		2.7830(trifluoromethyl)benzenes
n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide: a MEK inhibitor; structure in first source		2.0810
azd 1152-hqpa
AZD2811: has antineoplastic activity; structure in first source		5.9470anilide;
monofluorobenzenes;
primary alcohol;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
Aurora kinase inhibitor
nvp-tae684
[no description available]		2.9940piperidines
enmd 2076
ENMD 2076: an antiangiogenic agent with aurora kinase inhibitory and antineoplastic activities		2.1510
N-(3-ethynylphenyl)-6,7-dimethoxy-4-quinazolinamine
[no description available]		2.830quinazolines
amodiaquine hydrochloride
[no description available]		2.4520
clindamycin hydrochloride
[no description available]		2.0510S-glycosyl compound
cytochrome c-t
Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.		2.7530
gw 4869
GW 4869: inhibits neutral sphingomyelinase; structure in first source		2.1510
4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide
4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-N-(3-(trifluoromethyl)phenyl)benzamide: structure in first source		2.0810
bisaramil
[no description available]		2.0410
gsk 269962a
[no description available]		2.4820
e 7050
[no description available]		2.1510aromatic ether
2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone
[no description available]		2.1510pyrazolopyridine
tak-901
[no description available]		2.1510
cholecystokinin
Cholecystokinin: A peptide, of about 33 amino acids, secreted by the upper INTESTINAL MUCOSA and also found in the central nervous system. It causes gallbladder contraction, release of pancreatic exocrine (or digestive) enzymes, and affects other gastrointestinal functions. Cholecystokinin may be the mediator of satiety.		3.2310
bivalirudin
bivalirudin: designed to bind to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition. bivalirudin : A synthetic peptide of 20 amino acids, comprising D-Phe, Pro, Arg, Pro, Gly, Gly, Gly, Gly, Asn, Gly, Asp, Phe, Glu, Glu, Ile, Pro, Glu, Glu, Tyr, and Leu in sequence. A congener of hirudin (a naturally occurring drug found in the saliva of the medicinal leech), it a specific and reversible inhibitor of thrombin, and is used as an anticoagulant.		3.6120polypeptideanticoagulant;
EC 3.4.21.5 (thrombin) inhibitor
somatostatin
[no description available]		2.0810heterodetic cyclic peptide;
peptide hormone
teicoplanin
teicoplanin A2-1 : A teicoplanin A2 that has (4Z)-dec-4-enoyl as the variable N-acyl group.		2.0410
tannins
gallotannin : A class of hydrolysable tannins obtained by condensation of the carboxy group of gallic acid (and its polymeric derivatives) with the hydroxy groups of a monosaccharide (most commonly glucose).		2.0510tannin
enfuvirtide
Enfuvirtide: A synthetic 36-amino acid peptide that corresponds to the heptad repeat sequence of HIV-1 gp41. It blocks HIV cell fusion and viral entry and is used with other anti-retrovirals for combination therapy of HIV INFECTIONS and AIDS.. enfuvirtide : A synthetic 36-amino acid peptide consisting of N-acetyltyrosyl, threonyl, seryl, leucyl, isoleucyl, histidyl, seryl, leucyl, isoleucyl, alpha-glutamyl, alpha-glutamyl, seryl, glutaminyl, asparaginyl, glutaminyl, glutaminyl, alpha-glutamyl, lysyl, asparaginyl, alpha-glutamyl, alpha-glutamyl, alpha-glutamyl, leucyl, leucyl, alpha-glutamyl, leucyl, alpha-aspartyl, lysyl, tryptophyl, alanyl, seryl, leucyl, tryptophyl, asparaginyl, tryptophyl, and phenylalaninamide residues joined in sequence. An HIV fusion inhibitor, it was the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It interferes with entry of HIV into cells by binding to the gp41 sub-unit of the viral envelope glycoprotein, so inhibiting fusion of viral and cellular membranes.		3.2310
ganirelix
[no description available]		3.2310polypeptide
abarelix
abarelix: RN & structure in first source. abarelix : A polypeptide compound composed of ten natural and non-natural amino acid resiudes in a linear sequence.		3.1210polypeptideantineoplastic agent;
hormone antagonist
alamethicin
Alamethicin: A cyclic nonadecapeptide antibiotic that can act as an ionophore and is produced by strains of Trichoderma viride. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)		2.0710
gastrins
Gastrins: A family of gastrointestinal peptide hormones that excite the secretion of GASTRIC JUICE. They may also occur in the central nervous system where they are presumed to be neurotransmitters.		2.1110
glucagon
Glucagon: A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511). glucagon : A 29-amino acid peptide hormone consisting of His, Ser, Gln, Gly, Thr, Phe, Thr, Ser, Asp, Tyr, Ser, Lys, Tyr, Leu, Asp, Ser, Arg, Arg, Ala, Gln, Asp, Phe, Val, Gln, Trp, Leu, Met, Asn and Thr residues joined in sequence.		4.6111peptide hormone
teriparatide
[no description available]		3.2310polypeptide
salmon calcitonin
[no description available]		3.2310heterodetic cyclic peptide;
peptide hormone;
polypeptide		bone density conservation agent;
metabolite
oligonucleotides
[no description available]		5.3870
ly-146032
[no description available]		3.8730heterodetic cyclic peptide;
lipopeptide antibiotic;
lipopeptide;
macrocycle;
macrolide		antibacterial drug;
bacterial metabolite;
calcium-dependent antibiotics
dalbavancin
[no description available]		2.0410carbohydrate acid derivative;
glycopeptide;
monosaccharide derivative;
semisynthetic derivative		antibacterial drug;
antimicrobial agent
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide: FE-200486 is the acetate salt		3.2310polypeptide
exenatide
[no description available]		3.2310
gastrin 17
gastrin-17 : One of the primary forms of gastrin that is a 17-membered peptide consisting of Glp, Gly, Pro, Trp, Leu, Glu, Glu, Glu, Glu, Glu, Ala, Tyr, Gly, Trp, Met, Asp and Phe-NH2 residues joined in sequence.		2.1110gastrinantineoplastic agent
warfarin sodium
warfarin sodium : A racemate comprising equal amounts of (R)- and (S)-warfarin sodium. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.		2.0810
cellulose
DEAE-Cellulose: Cellulose derivative used in chromatography, as ion-exchange material, and for various industrial applications.		10.121glycoside
quinine sulfate
[no description available]		2.0510hydrate
endothelin-1
Endothelin-1: A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)		2.4820
phosphatidylcholines
Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.		2.04101,2-diacyl-sn-glycero-3-phosphocholine
a-83-01
A-83-01: an ALK-5 inhibitor; structure in first source		2.0810
3-[(1-methyl-3-indolyl)methylidene]-1H-pyrrolo[3,2-b]pyridin-2-one
[no description available]		2.4820indoles
vx-770
ivacaftor: a CFTR potentiator; structure in first source. ivacaftor : An aromatic amide obtained by formal condensation of the carboxy group of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid with the amino group of 5-amino-2,4-di-tert-butylphenol. Used for the treatment of cystic fibrosis.		2.0810aromatic amide;
monocarboxylic acid amide;
phenols;
quinolone		CFTR potentiator;
orphan drug
gdc-0973
cobimetinib: has antineoplastic activity; structure in first source. cobimetinib : A member of the class of N-acylazetidines obtained by selective formal condensation of the carboxy group of 3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid with the secondary amino group from the azetidine ring of 3-[(2S)-piperidin-2-yl]azetidin-3-ol. An inhibitor of mitogen-activated protein kinase that is used (as its fumarate salt) in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma.		2.1510aromatic amine;
difluorobenzene;
N-acylazetidine;
organoiodine compound;
piperidines;
secondary amino compound;
tertiary alcohol		antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
buparlisib
NVP-BKM120: a pan class I PI3 kinase inhibitor with antineoplastic activity; structure in first source		2.7930aminopyridine;
aminopyrimidine;
morpholines;
organofluorine compound		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
azd 1480
[no description available]		2.5220
azd8330
[no description available]		2.6320pyridinecarboxamide
pha 848125
N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide: a cyclin dependent kinase inhibitor		2.1510
ro5126766
RO5126766: a dual MEK/RAF kinase inhibitor. CH5126766 : A member of the class of coumarins that is 4-methyl-7-[(pyrimidin-2-yl)oxy]coumarin carrying an additional [2-[(methylaminosulfonyl)amino]-3-fluoropyridin-4-yl]methyl substituent at position 3.		2.1510aryloxypyrimidine;
coumarins;
organofluorine compound;
pyridines;
sulfamides		antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
tg101209
[no description available]		2.0610N-alkylpiperazine;
N-arylpiperazine;
pyrimidines;
secondary amino compound;
sulfonamide		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
fedratinib
fedratinib: a selective small-molecule inhibitor of JAK2		3.0440sulfonamide
gsk690693
[no description available]		3.02401,2,5-oxadiazole;
acetylenic compound;
aromatic amine;
aromatic ether;
imidazopyridine;
piperidines;
primary amino compound;
tertiary alcohol		antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
cnf 2024
[no description available]		2.08102-aminopurines;
aromatic ether;
organochlorine compound;
pyridines		antineoplastic agent;
Hsp90 inhibitor
ku 0063794
Ku 0063794: an mTOR inhibitor; structure in first source		2.0810benzyl alcohols;
monomethoxybenzene;
morpholines;
pyridopyrimidine;
tertiary amino compound		antineoplastic agent;
mTOR inhibitor
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene: has antineoplastic activity; also inhibits Fms-like tyrosine kinase-3; structure in first source		2.6320
azd 7545
AZD 7545: an anilide tertiary carbinol; a pyruvate dehydrogenase kinase 2 inhibitor. AZD7545 : A sulfone that is benzene substituted by [4-(dimethylcarbamoyl)phenyl]sulfonyl, chloro and [(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino groups at positions 1, 3 and 4, respectively. It is a potent and non-ATP-competitive inhibitor of pyruvate dehydrogenase kinase 2 (PDHK2) with IC50 of 6.4 nM and exhibits glucose-lowering activity. Also inhibits PDHK1 at higher levels (IC50 = 36.8 nM).		2.0810benzamides;
monochlorobenzenes;
organofluorine compound;
secondary carboxamide;
sulfone;
tertiary alcohol;
tertiary carboxamide		EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor;
hypoglycemic agent
azd5438
[no description available]		2.5420sulfonamide
nutlin-3b
[no description available]		2.0810Nutlin;
piperazinone		anticoronaviral agent
nsc 23766
NSC 23766 trihydrochloride : A hydrochloride resulting from the formal reaction of NSC 23766 with 3 mol eq. of hydrogen chloride. An inhibitor of the signalling G-protein known as RAC1 (Ras-related C3 botulinum toxin substrate 1).. Rac1 inhibitor : Any inhibitor of Rac1.		2.110hydrochlorideantiviral agent;
apoptosis inducer;
EC 3.6.5.2 (small monomeric GTPase) inhibitor;
muscarinic antagonist
pravastatin sodium
pravastatin sodium : An organic sodium salt that is the sodium salt of pravastatin. A reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), it is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.		2.0810organic sodium salt;
statin (semi-synthetic)		anticholesteremic drug
alendronate sodium
[no description available]		2.0810
hoe 33342
bisbenzimide ethoxide trihydrochloride: benzimidazole fluorescent dye		2.7830
sphingosine kinase
[no description available]		2.5220
pf 04217903
[no description available]		2.7830quinolines
3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-pyrazolyl]propanenitrile
[no description available]		2.0610pyrrolopyrimidine
gdc 0941
pictrelisib : A sulfonamide composed of indazole, morpholine, and methylsulfonyl-substituted piperazine rings bound to a thienopyrimidine ring.		340indazoles;
morpholines;
piperazines;
sulfonamide;
thienopyrimidine		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
sm 164
SM 164: a bivalent Smac mimetic with antineoplastic activity; structure in first source		2.0810benzenes;
organic heterobicyclic compound;
secondary carboxamide;
triazoles		antineoplastic agent;
apoptosis inducer;
radiosensitizing agent
sl 80.0750
[no description available]		2.0810
calpain
Calpain: Cysteine proteinase found in many tissues. Hydrolyzes a variety of endogenous proteins including NEUROPEPTIDES; CYTOSKELETAL PROTEINS; proteins from SMOOTH MUSCLE; CARDIAC MUSCLE; liver; platelets; and erythrocytes. Two subclasses having high and low calcium sensitivity are known. Removes Z-discs and M-lines from myofibrils. Activates phosphorylase kinase and cyclic nucleotide-independent protein kinase. This enzyme was formerly listed as EC 3.4.22.4.		7.1710
cefotiam hydrochloride
[no description available]		2.0510
chitosan
[no description available]		6.37101
icotinib
[no description available]		13.11425
ph 797804
PH 797804: an NSAID; structure in first source. PH 797804 : A member of the class of benzamides obtained by formal condensation of the carboxy group of 3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1-yl}-4-methylbenzoic acid with the amino group of methylamine.		2.7830aromatic ether;
benzamides;
organobromine compound;
organofluorine compound;
pyridone		anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
pha 408
PHA 408: an IKK-2 antagonist; structure in first source		2.0810
technetium tc 99m sestamibi
Technetium Tc 99m Sestamibi: A technetium imaging agent used to reveal blood-starved cardiac tissue during a heart attack.		2.0410
gsk 1016790a
GSK1016790A : A tertiary carboxamide that is piperazine in which one of the amino groups has undergone condensation with the carboxy group of N-[(2,4-dichlorophenyl)sulfonyl]-L-serine, while the other has undergone condensation with the carboxy group of N-(1-benzothiophen-2-ylcarbonyl)-L-leucine. It is a cell-permeable, potent and selective agonist of the TRPV4 (transient receptor potential vanilloid 4) channel.		2.08101-benzothiophenes;
aromatic primary alcohol;
dichlorobenzene;
N-acylpiperazine;
sulfonamide;
tertiary carboxamide		TRPV4 agonist
kx-01
[no description available]		2.1510
mesna
Mesna: A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.		3.8730organosulfonic acid
potassium aminobenzoate
[no description available]		2.0510
ampicillin sodium
[no description available]		2.0510organic sodium salt
cerivastatin sodium
cerivastatin sodium : The sodium salt of cerivastatin. Formerly used to lower cholesterol and prevent cardiovascular disease, it was withdrawn from the market worldwide in 2001 following reports of a severe form of muscle toxicity.		2.0510organic sodium salt;
statin (synthetic)
clavulanate potassium
potassium clavulanate : A potassium salt having clavulanate as the counterion. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes and has only weak anitbiotic activity when administered alone. However it can be used in combination with amoxicillin trihydrate (under the trade name Augmentin) for treatment of a variety of bacterial infections, where it prevents antibiotic inactivation by microbial lactamases.		2.0810potassium saltantibacterial drug;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
sodium lactate
Sodium Lactate: The sodium salt of racemic or inactive lactic acid. It is a hygroscopic agent used intravenously as a systemic and urinary alkalizer.. sodium lactate : An organic sodium salt having lactate as the counterion.		3.2310lactate salt;
organic sodium salt		food acidity regulator;
food preservative
piperacillin sodium
[no description available]		2.0810organic sodium salt
monensin
[no description available]		2.0510
sodium iothalamate
[no description available]		3.2310
methicillin sodium
[no description available]		2.0510organic sodium salt
nafcillin sodium
[no description available]		2.0510organic sodium salt
oxacillin sodium
[no description available]		2.4720organic sodium salt
penicillin g sodium
[no description available]		2.0510organic sodium salt
cefamandole nafate
cefamandole sodium : An organic sodium salt that is the sodium salt of cefamandole.		2.0510organic sodium saltantibacterial drug
sodium diatrizoate
histopaque: used for separating mononuclear & other cells. sodium amidotrizoate : The sodium salt of a benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, often as a mixture with the meglumine salt, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography.		2.0510organic sodium salt;
organoiodine compound		radioopaque medium
cephapirin sodium
cephapirin sodium : The sodium salt of cephapirin. A first-generation cephalosporin antibiotic, it is effective against gram-negative and gram-positive organisms. Being more resistant to beta-lactamases than penicillins, it is effective agains most staphylococci, though not methicillin-resistant staphylococci.		2.0510cephalosporin;
organic sodium salt		antibacterial drug
sodium cephalothin
[no description available]		2.0510organic sodium salt
cefazolin sodium
cefazolin sodium : A cephalosporin organic sodium salt having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups.		2.0810organic sodium salt
dicloxacillin sodium
[no description available]		2.0510hydrate
ro13-9904
Ceftriaxone: A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.. ceftriaxone : A third-generation cephalosporin compound having 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetylamino and [(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl side-groups.		2.2510
azlocillin sodium
[no description available]		2.4720organic sodium salt
olaparib
[no description available]		10.4141cyclopropanes;
monofluorobenzenes;
N-acylpiperazine;
phthalazines		antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
srt1720
[no description available]		2.0810
plx 4720
PLX 4720: a B-Raf(V600E) kinase inhibitor; structure in first source		2.4820aromatic ketone;
difluorobenzene;
organochlorine compound;
pyrrolopyridine;
sulfonamide		antineoplastic agent;
B-Raf inhibitor
mk 5108
[no description available]		2.1510aromatic ether
cx 4945
[no description available]		3.0340
cudc 101
7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide: a histone deacetylase inhibitor; structure in first source		4.4660
arry-614
pexmetinib: inhibits both p38 mitogen-activated protein kinase and Tie2 protein		2.1510
tak 593
TAK 593: structure in first source		2.1510
mln 8237
MLN 8237: an aurora kinase A inhibitor		2.7830benzazepine
lde225
sonidegib: specific Smoothened/Smo antagonist. sonidegib : A member of the classo of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxylic acid with the amino group of 6-(2,6-dimethylmorpholin-4-yl)pyridin-3-amine. Used (as its phosphate salt) for treatment of locally advanced basal cell carcinoma.		3.6120aminopyridine;
aromatic ether;
benzamides;
biphenyls;
morpholines;
organofluorine compound;
tertiary amino compound		antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist
gdc 0449
HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity		540benzamides;
monochlorobenzenes;
pyridines;
sulfone		antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist;
teratogenic agent
sgx 523
[no description available]		2.7830aryl sulfide;
biaryl;
pyrazoles;
quinolines;
triazolopyridazine		c-Met tyrosine kinase inhibitor;
nephrotoxic agent
bms 754807
BMS 754807: an IGR-1R kinase inhibitor; structure in first source		2.5220pyrazoles;
pyridines;
pyrrolidines;
pyrrolotriazine		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
bms 777607
N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide: a Met kinase inhibitor; structure in first source		2.7930aromatic amide
sgi 1776
SGI 1776: a Pim kinase inhibitor; structure in first source		2.7830imidazoles
picrotoxin
Picrotoxin: A noncompetitive antagonist at GABA-A receptors and thus a convulsant. Picrotoxin blocks the GAMMA-AMINOBUTYRIC ACID-activated chloride ionophore. Although it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates.. picrotoxin : A mixture consisting of equimolar amounts of picrotoxinin and picrotin found in the climbing plant Anamirta cocculus.		2.110
pci 32765
ibrutinib: a Btk protein inhibitor. ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies.		5.380acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
ponatinib
[no description available]		5.2450(trifluoromethyl)benzenes;
acetylenic compound;
benzamides;
imidazopyridazine;
N-methylpiperazine		antineoplastic agent;
tyrosine kinase inhibitor
amg 900
N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine: a pan-aurora kinase inhibitor; structure in first source		2.5220
mk-1775
adavosertib: a Wee1 kinase inhibitor; structure in first source		2.7830piperazines
oxymatrine
oxymatrine: structure in first source; has anti-apoptosis effects		2.0510
AMG-208
[no description available]		2.1510aromatic ether;
quinolines;
triazolopyridazine		antineoplastic agent;
c-Met tyrosine kinase inhibitor
sch772984
[no description available]		2.2510biaryl;
indazoles;
N-acylpiperazine;
N-alkylpyrrolidine;
N-arylpiperazine;
pyridines;
pyrimidines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary amino compound;
tertiary carboxamide		analgesic;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
bag956
BAG956: an imidazo[4,5-c]quinoline; dual PI3K/PDK-1 inhibitor, used in antileukemic therapies		2.0810
quizartinib
[no description available]		2.7830benzoimidazothiazole;
isoxazoles;
morpholines;
phenylureas		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
necroptosis inhibitor
PP121
[no description available]		3.8430aromatic amine;
cyclopentanes;
pyrazolopyrimidine;
pyrrolopyridine		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
tyrosine kinase inhibitor
at13148
[no description available]		2.1510
N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester
CAY10603: a HDAC6 inhibitor		2.0810carbamate ester
tak 733
[no description available]		2.5220
mk 2206
MK 2206: a protein kinase inhibitor and antineoplastic agent		4.8290organic heterotricyclic compoundEC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
navitoclax
[no description available]		3.7430aryl sulfide;
monochlorobenzenes;
morpholines;
N-sulfonylcarboxamide;
organofluorine compound;
piperazines;
secondary amino compound;
sulfone;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
sns 314
SNS 314: an aurora kinase inhibitor; structure in first source		2.7830ureas
jzl 184
JZL 184: inhibits monoacylglycerol lipase; structure in first source		2.0810benzodioxoles
lucitanib
E-3810: a multi-kinase inhibitor with antineoplastic activity; structure in first source. E-3810 : A hydrochloride salt obtained by reaction of 6-({7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-N-methyl-1-naphthamide with one equivalent of hydrochloric acid. E-3810 is a dual VEGFR and FGFR inhibitor. E-3810 free base : A naphthalenecarboxamide obtained from formal condensation of the carboxy group of aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-1-naphthoic acid with methylamine.		2.1510aromatic ether;
cyclopropanes;
naphthalenecarboxamide;
primary amino compound;
quinolines		antineoplastic agent;
fibroblast growth factor receptor antagonist;
vascular endothelial growth factor receptor antagonist
pf-04691502
[no description available]		2.1510
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene
[no description available]		2.0810BODIPY compound
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide: a Janus kinase 1 and Janus kinase 2 inhibitor; structure in first source. momelotinib : A benzamide obtained by formal condensation of the carboxy group of 4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzoic acid with the primary amino group of aminoacetonitrile. It is an ATP-competitive JAK1/JAK2 inhibitor with IC50 of 11 nM and 18 nM, respectively. Used for the treatment of patients with intermediate- or high-risk myelofibrosis.		3.2650aminopyrimidine;
benzamides;
morpholines;
nitrile;
secondary amino compound;
tertiary amino compound		anti-anaemic agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
dcc-2036
rebastinib: an inhibitor of Tie2 tyrosine kinase receptor and antineoplastic agent		2.5220organofluorine compound;
phenylureas;
pyrazoles;
pyridinecarboxamide;
quinolines		tyrosine kinase inhibitor
trelstar
Triptorelin Pamoate: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE with D-tryptophan substitution at residue 6.		2.0210
cetrorelix
cetrorelix: LHRH antagonist. cetrorelix : A synthetic ten-membered oligopeptide comprising N-acetyl-3-(naphthalen-2-yl)-D-alanyl, 4-chloro-D-phenylalanyl, 3-(pyridin-3-yl)-D-alanyl, L-seryl, L-tyrosyl, N(5)-carbamoyl-D-ornithyl, L-leucyl, L-arginyl, L-prolyl, and D-alaninamide residues coupled in sequence. A gonadotrophin-releasing hormone (GnRH) antagonist, it is used for treatment of infertility and of hormone-sensitive cancers of the prostate and breast.		3.5820oligopeptideantineoplastic agent;
GnRH antagonist
neurotensin
neurotensin, Tyr(11)-: RN given refers to parent cpd & (D)-isomer; RN for cpd without isomeric designation not avail 5/91		3.2310peptide hormonehuman metabolite;
mitogen;
neurotransmitter;
vulnerary
cabozantinib
cabozantinib: a multikinase inhibitor. cabozantinib : A dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer.		9.8790aromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor
defactinib
[no description available]		2.5920
ly2584702
[no description available]		2.1510
N-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonyl-1-piperazinyl)-1-piperidinyl]anilino]-4-pyrimidinyl]-2-imidazo[1,2-a]pyridinyl]-2-methoxybenzamide
[no description available]		2.0810benzamides
incb-018424
[no description available]		3.5170nitrile;
pyrazoles;
pyrrolopyrimidine		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
poziotinib
HM781-36B: antitumor irreversible Pan-HER inhibitor for treatment of gastric cancer		4.3850acrylamides;
aromatic ether;
dichlorobenzene;
diether;
monofluorobenzenes;
N-acylpiperidine;
quinazolines;
secondary amino compound;
substituted aniline		antineoplastic agent;
apoptosis inducer;
epidermal growth factor receptor antagonist
asp3026
ASP3026: an anaplastic lymphoma receptor tyrosine kinase inhibitor; structure in first source. ASP-3026 : A member of the class of diamino-1,3,5-triazines that is 1,3,5-triazine-2,4-diamine in which the amino groups at positions 2 and 4 are respectively carrying 2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl and 2-(propan-2-ylsulfonyl)phenyl substituents. It is a potent inhibitor of anaplastic lymphoma kinase (ALK), Ack and ROS1 activity (IC50 values are 3.5, 5.8 and 8.9 nM respectively) and exhibits anti-cancer properties.		2.1510aromatic amine;
diamino-1,3,5-triazine;
monomethoxybenzene;
N-methylpiperazine;
piperidines;
secondary amino compound;
sulfone		antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 6.1.1.6 (lysine--tRNA ligase) inhibitor
entrectinib
entrectinib: inhibits TRK, ROS1, and ALK receptor tyrosine kinases; structure in first source. entrectinib : A member of the class of indazoles that is 1H-indazole substituted by [4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzoyl]amino and 3,5-difluorobenzyl groups at positions 3 and 5, respectively. It is a potent inhibitor of TRKA, TRKB, TRKC, ROS1, and ALK (IC50 values of 0.1 to 1.7 nM), and used for the treatment of NTRK, ROS1 and ALK gene fusion-positive solid tumours.		2.520benzamides;
difluorobenzene;
indazoles;
N-methylpiperazine;
oxanes;
secondary amino compound;
secondary carboxamide		antibacterial agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
bix 01294
[no description available]		2.5220piperidines
pexidartinib
pexidartinib: inhibits both CSF1R and c-kit receptor tyrosine kinase; structure in first source. pexidartinib : A pyrrolopyridine that is 5-chloro-1H-pyrrolo[2,3-b]pyridine which is substituted by a [6-({[6-(trifluoromethyl)pyridin-3-yl]methyl}amino)pyridin-3-yl]methyl group at position 3. It is a potent multi-targeted receptor tyrosine kinase inhibitor of CSF-1R, KIT, and FLT3 (IC50 of 20 nM, 10 nM and 160 nM, respectively). Approved by the FDA for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT).		2.1510aminopyridine;
organochlorine compound;
organofluorine compound;
pyrrolopyridine;
secondary amino compound		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
cobicistat
[no description available]		3.51101,3-thiazoles;
carbamate ester;
monocarboxylic acid amide;
morpholines;
ureas		P450 inhibitor
pf 3845
PF 3845: inhibits fatty acid amide hydrolase		2.0810piperidines
TAK-580
MLN 2480: brain-penetrant RAF dimer antagonist. TAK-580 : A 1,3-thiazolecarboxamide that is 2-[(1R)-1-aminoethyl]-1,3-thiazole-5-carboxylic acid in which the carboxy group undergoes formal condensation with the amino group of 5-chloro-4-(trifluoromethyl)pyridin-2-amine and in which the amino group undergoes formal condensation with the carboxy group of 6-amino-5-chloropyrimidine-4-carboxylic acid. It is a pan-RAF kinase inhibitor which is currently in clinical development for the treatment of radiographically recurrent or progressive low-grade glioma in children and young adults.		2.15101,3-thiazolecarboxamide;
aminopyrimidine;
chloropyridine;
organofluorine compound;
pyrimidinecarboxamide;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor
gsk 2126458
omipalisib: inhibitor of mTOR protein. omipalisib : A member of the class of quinolines that is quinoline which is substituted by pyridazin-4-yl and 5-[(2,4-difluorobenzene-1-sulfonyl)amino]-6-methoxypyridin-3-yl groups at positions 4 and 6, respectively. It is a highly potent inhibitor of PI3K and mTOR developed by GlaxoSmithKline and was previously in human phase 1 clinical trials for the treatment of idiopathic pulmonary fibrosis and solid tumors.		2.5220aromatic ether;
difluorobenzene;
pyridazines;
pyridines;
quinolines;
sulfonamide		anticoronaviral agent;
antineoplastic agent;
autophagy inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor;
radiosensitizing agent
emd1214063
tepotinib: MET inhibitor		5.8132
gsk 1838705a
[no description available]		2.0610organonitrogen compound;
organooxygen compound
ixazomib
ixazomib: a proteasome inhibitor with antineoplastic activity; MLN2238 is the biologically active form of MLN9708; structure in first source. ixazomib : A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma.		2.0810benzamides;
boronic acids;
dichlorobenzene;
glycine derivative		antineoplastic agent;
apoptosis inducer;
drug metabolite;
orphan drug;
proteasome inhibitor
fit-039
FIT-039: CDK9 inhibitor; structure in first source		3.9220
ldn 193189
LDN 193189: inhibits bone morphogenetic protein signaling		2.4920pyrimidines
pf 3758309
PF 3758309: a PAK4 p21-activated kinase inhibitor; structure in first source		2.1510organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
gdc 0980
[no description available]		2.1510
azd2014
vistusertib: potent and selective dual mTORC1 and mTORC2 inhibitor; structure in first source		2.8830
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol
(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol: a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity; structure in first source		2.5420benzyl alcohols;
morpholines;
pyridopyrimidine;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
mTOR inhibitor
plx4032
[no description available]		5.96120aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide		antineoplastic agent;
B-Raf inhibitor
(2S)-2-[[2-(2,3-dihydro-1H-inden-5-yloxy)-9-[(4-phenylphenyl)methyl]-6-purinyl]amino]-3-phenyl-1-propanol
[no description available]		2.0810biphenyls
gsk 1363089
GSK 1363089: a multikinase inhibitor that acts on Met, RON, Axl, and VEGFR; structure in first source		4.4860aromatic ether
arry-334543
ARRY-334543: an antagonist of ATP-binding cassette subfamily G member 2 (ABCG2); structure in first source		3.9630
kin-193
[no description available]		2.5220pyridopyrimidine
mk 2461
[no description available]		2.830
osilodrostat
Osilodrostat: an orally active aldosterone-synthase inhibitor		4.2210
glycolipids
[no description available]		4.6111
bay 869766
[no description available]		2.8530
as 703026
[no description available]		2.1510pyridinecarboxamide
baricitinib
[no description available]		4.0630azetidines;
nitrile;
pyrazoles;
pyrrolopyrimidine;
sulfonamide		anti-inflammatory agent;
antirheumatic drug;
antiviral agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
immunosuppressive agent
4-[6-[4-(methoxycarbonylamino)phenyl]-4-(4-morpholinyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinecarboxylic acid methyl ester
WYE-354: an mTOR inhibitor; structure in first source		2.0810carbamate ester
piperidines
Piperidines: A family of hexahydropyridines.		13.24474
6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone
ML-265: a small molecule activator of PKM2		2.0810organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
interleukin-8
Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.		7.6392
dabrafenib
[no description available]		7.9301,3-thiazoles;
aminopyrimidine;
organofluorine compound;
sulfonamide		anticoronaviral agent;
antineoplastic agent;
B-Raf inhibitor
pki 587
gedatolisib: inhibits both phosphatidylinositol 3-kinase and mTOR; structure in first source		2.1510
3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline
[no description available]		2.0810benzenes;
sulfonamide
cp 466722
[no description available]		2.0810quinazolines
4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide
4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide: a protein kinase inhibitor; structure in first source		2.4110
CAY10626
[no description available]		2.0810ureas
n-(3-fluoro-4-((1-methyl-6-(1h-pyrazol-4-yl)-1h-indazol-5 yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide
merestinib: in phase I clinical trials (2013); structure in first source		2.1510
N-[3-[[5-chloro-2-[4-(4-methyl-1-piperazinyl)anilino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide
[no description available]		2.0610piperazines
thiopental sodium
[no description available]		5.57200organochlorine compound;
piperazines;
pyrimidines		antineoplastic agent;
tyrosine kinase inhibitor
ribociclib
ribociclib: inhibits both CDK4 and CDK6		3.7120
apatinib
apatinib: reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters; structure in first source		7.5263
mk-8033
1-(3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo(4,5)cyclohepta(1,2-b)pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide: inhibits both Ron and c-Met kinases; structure in first source		2.5420
5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine
sapanisertib: an mTOR inhibitor		4.6111benzoxazole
3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol
3-(6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenol: inhibits ALK2 protein; structure in first source		2.110
pha 793887
[no description available]		2.5220piperidinecarboxamide
abt-348
ilorasertib: an antineoplastic agent and protein kinase inhibitor; structure in first source		2.0610
ly2784544
[no description available]		2.4110pyridazines
sb 1518
[no description available]		2.6320
abemaciclib
[no description available]		3.7320
mk-8776
[no description available]		2.1510
nvp-bsk805
[no description available]		2.0810
afuresertib
[no description available]		2.1510amphetamines
xmd 8-92
XMD8-92 : A dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one carrying at C-2 on the pyrimidine ring a [2-ethoxy-4-(4-hydroxypiperidin-1-yl)phenyl]amino substituent. It is an inhibitor of the BMK1 kinase pathway.		2.0810pyrimidobenzodiazepineprotein kinase inhibitor
bms 708163
BMS 708163: structure in first source		2.1110oxadiazole;
ring assembly
gsk 1070916
GSK 1070916: an antineoplastic agent with aurora B/C kinase inhibitory activity		2.5420pyrazoles;
ring assembly
jq1 compound
[no description available]		2.0810carboxylic ester;
organochlorine compound;
tert-butyl ester;
thienotriazolodiazepine		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bromodomain-containing protein 4 inhibitor;
cardioprotective agent;
ferroptosis inducer
jnj38877605
[no description available]		2.8430quinolines
N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide
[no description available]		2.0810benzothiazoles
dinaciclib
[no description available]		4.0630pyrazolopyrimidine
gilteritinib
gilteritinib: an FLT3/AXL protein tyrosine kinase inhibitor. gilteritinib : A member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation.		2.6320aromatic amine;
monomethoxybenzene;
N-methylpiperazine;
oxanes;
piperidines;
primary carboxamide;
pyrazines;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
alectinib
[no description available]		9.2740aromatic ketone;
morpholines;
nitrile;
organic heterotetracyclic compound;
piperidines		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
glpg0634
[no description available]		2.6320
torin 1
torin 1 : A member of the class of pyridoquinolines that is 9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2-one bearing an additional 4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl substituent at position 1. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.		2.0810N-acylpiperazine;
N-arylpiperazine;
organofluorine compound;
pyridoquinoline;
quinolines		antineoplastic agent;
mTOR inhibitor
abt-199
venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.		2.3110aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
N-sulfonylcarboxamide;
oxanes;
pyrrolopyridine		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
ly2940680
[no description available]		3.6120
1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea
[no description available]		2.0810ureas
ro 4929097
[no description available]		2.0810dibenzoazepine;
dicarboxylic acid diamide;
lactam;
organofluorine compound		EC 3.4.23.46 (memapsin 2) inhibitor
gsk4112
GSK4112: a Rev-erbalpha agonist; structure in first source		2.0810
ipi-145
[no description available]		3.4110isoquinolines
delgocitinib
delgocitinib: a Janus kinase inhibitor. delgocitinib : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a (3S,4R)-1-(cyanoacetyl)-3-methyl-1,6-diazaspiro[3.4]octan-6-yl group at position 4. It is a pan-Janus kinase (JAK) inhibitor and is approved for treatment of atopic dermatitis (AD) in Japan.		2.4110azaspiro compound;
N-acylazetidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound;
tertiary carboxamide		anti-inflammatory drug;
antipsoriatic;
antiseborrheic;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
encorafenib
encorafenib: a BRAF inhibitor		7.5420
bms-911543
N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide: has antineoplastic activity; structure in first source		2.1510
azd4547
[no description available]		7.5520benzamides;
N-arylpiperazine;
pyrazoles		fibroblast growth factor receptor antagonist
gsk2141795
GSK2141795: an Akt inhibitor with antineoplastic activity; structure in first source		2.1510
torin 2
torin 2 : A member of the class of pyridoquinolines that is benzo[h][1,6]naphthyridin-2-one carrying additional 3-(trifluoromethyl)phenyl and 6-aminopyridin-3-yl substituents at positions 1 and 9 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.		2.0810aminopyridine;
organofluorine compound;
primary amino compound;
pyridoquinoline		antineoplastic agent;
mTOR inhibitor
pf-4708671
[no description available]		2.0810
azd8186
[no description available]		2.1510
eliglustat tartrate
agalsidase beta: recombinant protein for treatment of Fabry disease. eliglustat tartrate : A tartrate that is the hemitartrate salt of eliglustat. A ceramide glucosyltransferase inhibitor used (as its tartrate salt) for treatment of Gaucher's disease.		2.0210tartrate saltEC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
heme
Heme: The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.. ferroheme : Any iron(II)--porphyrin coordination complex.. ferroheme b : Heme b in which the iron has oxidation state +2.. heme : A heme is any tetrapyrrolic chelate of iron.		4.6111
incb039110
INCB039110: a JAK1 inhibitor; structure in first source		2.4110
bp-1-102
BP-1-102: a STAT3 inhibitor; structure in first source		2.1510
N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide
[no description available]		2.0810benzamides;
N-acylpiperidine
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide : A member of the class of quinazolines that is quinazoline substituted by {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino and 3-(2-methoxyacetamido)prop-1-en-1-yl groups at positions 4 and 6, respectively.		2.0810aromatic ether;
methylpyridines;
olefinic compound;
quinazolines;
secondary amino compound;
secondary carboxamide;
toluenes
belinostat
[no description available]		2.0810olefinic compound
heparitin sulfate
Heparitin Sulfate: A heteropolysaccharide that is similar in structure to HEPARIN. It accumulates in individuals with MUCOPOLYSACCHARIDOSIS.		2.0610
neuromedin b
neuromedin B: decapeptide isolated from porcine spinal cord		2.0510
ascorbic acid
Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.		4.2650ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
raltegravir
[no description available]		3.23101,2,4-oxadiazole;
dicarboxylic acid amide;
hydroxypyrimidine;
monofluorobenzenes;
pyrimidone;
secondary carboxamide		antiviral drug;
HIV-1 integrase inhibitor
novobiocin
Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.		4.2750carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols		antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent
tetracycline
Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.		8.36121
chlortetracycline
Chlortetracycline: A TETRACYCLINE with a 7-chloro substitution.. chlortetracycline : A member of the class of tetracyclines with formula C22H23ClN2O8 isolated from Streptomyces aureofaciens.		2.7330
oxytetracycline, anhydrous
Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.		4.0740
minocycline
Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.		4.7650
methacycline
Methacycline: A broad-spectrum semisynthetic antibiotic related to TETRACYCLINE but excreted more slowly and maintaining effective blood levels for a more extended period.. methacycline : A tetracycline that is the 6-methylene analogue of oxytetracycline, obtained by formal dehydration at position 6.		2.0310
dicumarol
Dicumarol: An oral anticoagulant that interferes with the metabolism of vitamin K. It is also used in biochemical experiments as an inhibitor of reductases.		2.0510hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
Hsp90 inhibitor;
vitamin K antagonist
piroxicam
[no description available]		5.0770benzothiazine;
monocarboxylic acid amide;
pyridines		analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
roquinimex
roquinimex: structure in first source		2.4620aromatic amide
acenocoumarol
Acenocoumarol: A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233). acenocoumarol : A hydroxycoumarin that is warfarin in which the hydrogen at position 4 of the phenyl substituent is replaced by a nitro group.		7.7630C-nitro compound;
hydroxycoumarin;
methyl ketone		anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
lfm a13
LFM-A13 : An enamide obtained by formal condensation of the carboxy group of (2Z)-2-cyano-3-hydroxybut-2-enoic acid with the amino group of 2,5-dibromoaniline. It is a dual-function inhibitor of Bruton's tyrosine kinase (BTK) and Polo-like kinases (PLK) that exhibits anticancer properties.		2.0310aromatic amide;
dibromobenzene;
enamide;
enol;
nitrile;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 2.7.11.21 (polo kinase) inhibitor;
geroprotector;
platelet aggregation inhibitor
mobic
Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.		4.41601,3-thiazoles;
benzothiazine;
monocarboxylic acid amide		analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
mobiflex
tenoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries.		3.1650heteroaryl hydroxy compound;
monocarboxylic acid amide;
pyridines;
thienothiazine		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
isoxicam
isoxicam : A monocarboxylic acid amide that is piroxicam in which the pyrid-2-yl group is replaced by a 5-methyl-1,2-oxazol-3-yl group. A non-steroidal anti-inflammatory drug, it was withdrawn from the market in the 1980s following its association with cases of Stevens-Johnson syndrome.		2.7530benzothiazine;
isoxazoles;
monocarboxylic acid amide		antirheumatic drug;
non-steroidal anti-inflammatory drug
ethyl 1-benzyl-3-hydroxy-2(5h)-oxopyrrole-4-carboxylate
ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate: RN & structure given in first source		2.0810carboxylic acid;
pyrroline
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		4.7690benzenes;
hydroxycoumarin;
methyl ketone
demeclocycline
Demeclocycline: A TETRACYCLINE analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.. demeclocycline : Tetracycline which lacks the methyl substituent at position 7 and in which the hydrogen para- to the phenolic hydroxy group is substituted by chlorine. Like tetracycline, it is an antibiotic, but being excreted more slowly, effective blood levels are maintained for longer. It is used (mainly as the hydrochloride) for the treatment of Lyme disease, acne and bronchitis, as well as for hyponatraemia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective.		3.5820
phenprocoumon
Phenprocoumon: Coumarin derivative that acts as a long acting oral anticoagulant.. phenprocoumon : A hydroxycoumarin that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenylpropyl group.		2.0510hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
tipranavir
tipranavir: inhibits HIV-1 protease. tipranavir : A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.		3.5820sulfonamideantiviral drug;
HIV protease inhibitor
chlortetracycline hydrochloride
Alexomycin: a thiopeptide; a cyclic peptide antibiotic produced by Streptomyces arginensis isolated from the soil		2.0510
rolitetracycline
Rolitetracycline: A pyrrolidinylmethyl TETRACYCLINE.. rolitetracycline : A derivative of tetracycline in which the amide function is substituted with a pyrrolidinomethyl group.		2.4520
sudoxicam
sudoxicam: proposed ant-inflammatory agent; minor descriptor (75-86); on-line & INDEX MEDICUS search THIAZINES (75-86)		2.0510
methacycline monohydrochloride
[no description available]		2.0510
minocycline hydrochloride
[no description available]		2.4720
demeclocycline hydrochloride
demeclocycline hydrochloride : The hydrochloride salt of demeclocycline. A tetracycline antibiotic, it is used (mainly as the hydrochloride) for the treatment of Lyme disease, acne and bronchitis, as well as for hyponatraemia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective.		2.0510
tigecycline
[no description available]		3.8730
(S)-warfarin
(S)-warfarin : A 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one that has (S)-configuration (the racemate is warfarin, an anticoagulant drug and rodenticide).		2.46204-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one
lornoxicam
lornoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 6-chloro-4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain, primarily resulting from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica and other inflammations.		2.4720heteroaryl hydroxy compound;
monocarboxylic acid amide;
organochlorine compound;
pyridines;
thienothiazine		antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
a 769662
[no description available]		2.0810biphenyls
s 1 (combination)
S 1 (combination): consists of tegafur, 5-chloro-2,4-dihydroxyuridine & potassium oxonate; an inhibitor of fluorouracil(5-FU) degradation; prolongs the blood 5-FU level as well as increases selective toxicity to tumor; used for the treatment of colon cancer		9.38143
byl719
[no description available]		7.6620proline derivative
epidermal growth factor
Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.		17.9923414
gastrin-releasing peptide
Gastrin-Releasing Peptide: Neuropeptide and gut hormone that helps regulate GASTRIC ACID secretion and motor function. Once released from nerves in the antrum of the STOMACH, the neuropeptide stimulates release of GASTRIN from the GASTRIN-SECRETING CELLS.		7.0310
transforming growth factor beta
Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.		691
cep-32496
agerafenib: inhibitor of RAF family kinases; structure in first source		2.1510
LimKi 3
LIMKi3: LIMK inhibitor. LimKi 3 : A member of the class of pyrazoles that is 1-(2,6-dichlorophenyl)-1H-pyrazole which is substituted by a difluoromethyl group at position 3 and by a 2-(isobutyrylamino)-1,3-thiazol-5-yl group at position 5. It is a a potent cell-permeable inhibitor of LIM kinase 1 and 2.		2.08101,3-thiazoles;
dichlorobenzene;
organofluorine compound;
pyrazoles;
secondary carboxamide		LIM kinase inhibitor
1-[4-amino-7-[3-(2-methoxyethylamino)propyl]-5-(4-methylphenyl)-6-pyrrolo[2,3-d]pyrimidinyl]-2-fluoroethanone
[no description available]		2.0810pyrroles
rociletinib
rociletinib: inhibits epidermal growth factor receptor tyrosine kinase activity; structure in first source		6.58130
2-[5-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-4-methoxy-2-pyrrolylidene]indole
[no description available]		2.0810dipyrrins
ceritinib
ceritinib: an anaplastic lymphoma kinase inhibitor. ceritinib : A member of the class of aminopyrimidines that is 2,6-diamino-5-chloropyrimidine in which the amino groups at positions 2 and 6 are respectively carrying 2-methoxy-4-(piperidin-4-yl)-5-methylphenyl and 2-(isopropylsulfonyl)phenyl substituents. Used for the treatment of ALK-positive metastatic non-small cell lung cancer.		9.3650aminopyrimidine;
aromatic ether;
organochlorine compound;
piperidines;
secondary amino compound;
sulfone		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-2-propenamide
[no description available]		2.0810tryptamines
3-[(5-tert-butyl-1H-imidazol-4-yl)methylidene]-6-(phenylmethylene)piperazine-2,5-dione
[no description available]		2.0810pyrazines
gsk837149a
GSK837149A: structure in first source		2.0810
N-[4-(3-chloro-4-fluoroanilino)-7-[[(3S)-3-oxolanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide
[no description available]		2.0810quinazolines
N-[4-(3-chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide
[no description available]		2.0810quinazolines
wnt-c59
2-(4-(2-methylpyridin-4-yl)phenyl)-N-(4-(pyridin-3-yl)phenyl)acetamide: a PORCN acyltransferase inhibitor; structure in first source		2.0810
5-[1-(2-hydroxyethyl)-3-pyridin-4-yl-4-pyrazolyl]-2,3-dihydroinden-1-one oxime
[no description available]		2.0810indanes
(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methyl methanesulfonate
(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methyl methanesulfonate: a GPR119 agonist		2.1710
azd1208
[no description available]		2.1510
cc-292
spebrutinib: inhibits Bruton's tyrosine kinase; structure in first source		2.2510
vx-509
[no description available]		2.1510
vx-970
berzosertib: an ATR kinase inhibitor		3.9220sulfonamide
ldn-212854
[no description available]		2.110
debio 1347
CH5183284: a fibroblast growth factor receptor antagonist; structure in first source		2.1510
sf 1126
SF 1126: an LY294002 prodrug and pan PI3K inhibitor; structure in first source		2.1110
volitinib
[no description available]		2.1510
3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester
3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester: a breast cancer resistance protein (BCRP) inhibitor; structure in first source		2.0810
ajmaline
[no description available]		2.0510
gsk343
GSK343: an EZH2 methyltransferase inhibitor. GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM).		2.2510aminopyridine;
indazoles;
N-alkylpiperazine;
N-arylpiperazine;
pyridone;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor
osimertinib
osimertinib: an EGFR tyrosine kinase inhibitor. osimertinib : A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treatment of EGFR T790M mutation positive non-small cell lung cancer.		17.0311720acrylamides;
aminopyrimidine;
biaryl;
indoles;
monomethoxybenzene;
secondary amino compound;
secondary carboxamide;
substituted aniline;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
agar
Agar: A complex sulfated polymer of galactose units, extracted from Gelidium cartilagineum, Gracilaria confervoides, and related red algae. It is used as a gel in the preparation of solid culture media for microorganisms, as a bulk laxative, in making emulsions, and as a supporting medium for immunodiffusion and immunoelectrophoresis.. agar : A complex mixture of polysaccharides extracted from species of red algae. Its two main components are agarose and agaropectin. Agarose is the component responsible for the high-strength gelling properties of agar, while agaropectin provides the viscous properties.		2.0110
pf-06463922
lorlatinib: inhibits both anaplastic lymphoma kinase and c-ros oncogene 1 (ROS1) protein. lorlatinib : A cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer.		3.7620aminopyridine;
aromatic ether;
azamacrocycle;
benzamides;
cyclic ether;
monofluorobenzenes;
nitrile;
organic heterotetracyclic compound;
pyrazoles		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
imetelstat
[no description available]		4.6930
cyclin d1
Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.		6.69191
fertinex
[no description available]		3.2310
ldc4297
LDC4297: a CDK7 inhibitor with antineoplastic activity; structure in first source. LDC4297 : A pyrazolotriazine that is pyrazolo[1,5-a][1,3,5]triazine substituted by a piperidin-3-yloxy group, [2-(1H-pyrazol-1-yl)benzyl]nitrilo group and an isopropyl group at positions 2, 4 and 8 respectively. It is a potent and selective CDK7 inhibitor and exhibits antiviral activity.		2.4110aromatic ether;
piperidines;
pyrazoles;
pyrazolotriazine;
secondary amino compound		antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
azd3759
[no description available]		2.5520
g(m3) ganglioside
G(M3) Ganglioside: A ganglioside present in abnormally large amounts in the brain and liver due to a deficient biosynthetic enzyme, G(M3):UDP-N-acetylgalactosaminyltransferase. Deficiency of this enzyme prevents the formation of G(M2) ganglioside from G(M3) ganglioside and is the cause of an anabolic sphingolipidosis.. alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer(d18:1/24:1(15Z)) : A sialotriaosylceramide consisting of beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc attached to the primary hydroxy function of ceramide(d18:1/24:1(15Z)).		2.0310alpha-N-acetylneuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-ceramide;
sialodiosylceramide;
sialotriaosylceramide		mouse metabolite
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone: an interleukin-1beta converting enzyme (ICE)-like protease inhibitor		2.0210
nitrophenols
Nitrophenols: PHENOLS carrying nitro group substituents.		2.0310
glucagon-like peptide 2
Glucagon-Like Peptide 2: A 33-amino acid peptide derived from the C-terminal of PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. It stimulates intestinal mucosal growth and decreased apoptosis of ENTEROCYTES. GLP-2 enhances gastrointestinal function and plays an important role in nutrient homeostasis.		2.0310
hyaluronoglucosaminidase
Hyaluronoglucosaminidase: An enzyme that catalyzes the random hydrolysis of 1,4-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate. (From Enzyme Nomenclature, 1992) There has been use as ANTINEOPLASTIC AGENTS to limit NEOPLASM METASTASIS.		3.2110
oridonin
[no description available]		7.1310
yuanhuacin
[no description available]		2.1110
oblimersen
oblimersen: targets the Bcl-2 oncogene good efficacy with low toxicity tumour regressions		4.6630
transforming growth factor alpha
Transforming Growth Factor alpha: An EPIDERMAL GROWTH FACTOR related protein that is found in a variety of tissues including EPITHELIUM, and maternal DECIDUA. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form which binds to the EGF RECEPTOR.		12.95361
cyclosporine
Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).		7.1310
silybin
Silybin: The major active component of silymarin flavonoids extracted from seeds of the MILK THISTLE, Silybum marianum; it is used in the treatment of HEPATITIS; LIVER CIRRHOSIS; and CHEMICAL AND DRUG INDUCED LIVER INJURY, and has antineoplastic activity; silybins A and B are diastereomers.		2.7930
catalpol
catalpol: component of dihuang; RN given refers to (1aS-(1aalpha,1bbeta,2beta,5abeta,6beta,6aalpha))-isomer; RN for cpd without isomeric designation not avail 12/92		4.6111
formosanin c
formosanin C: diosgenin saponin from Paris formosana; structure given in first source		2.1310
carboxymethyl-beta-cyclodextrin
[no description available]		7.110
nedaplatin
nedaplatin: structure given in first source		8.4311
lewis y antigen
[no description available]		2.0510
iminoquinone
iminoquinone: an electrophile; structure in first source		2.2510
exudates
Malaysia: A parliamentary democracy with a constitutional monarch in southeast Asia, consisting of 11 states (West Malaysia) on the Malay Peninsula and two states (East Malaysia) on the island of BORNEO. It is also called the Federation of Malaysia. Its capital is Kuala Lumpur. Before 1963 it was the Union of Malaya. It reorganized in 1948 as the Federation of Malaya, becoming independent from British Malaya in 1957 and becoming Malaysia in 1963 as a federation of Malaya, Sabah, Sarawak, and Singapore (which seceded in 1965). The form Malay- probably derives from the Tamil malay, mountain, with reference to its geography. (From Webster's New Geographical Dictionary, 1988, p715 & Room, Brewer's Dictionary of Names, 1992, p329)		2.0710
plicamycin
mithramycin A: structure given in first source		2.1310
protac-3
[no description available]		2.7220
at 9283
[no description available]		2.6320
otssp167
OTS167: inhibitor of maternal embryonic leucine zipper kinase (MELK) with potential antineoplastic activity		2.1510
akt-i-1,2 compound
Akt-I-1,2 compound: an aminopeptidase P inhibitor; structure in first source		4.4820
entecavir
entecavir (anhydrous) : Guanine substituted at the 9 position by a 4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl group. A synthetic analogue of 2'-deoxyguanosine, it is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. Entecavir is phosphorylated intracellularly to the active triphosphate form, which competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme's activity, although it has no activity against HIV. It is used for the treatment of chronic hepatitis B.		3.87302-aminopurines;
oxopurine;
primary alcohol;
secondary alcohol		antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
chir 258
[no description available]		6.6990
r 1530
[no description available]		2.0610
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		4.94602-aminopurines;
oxopurine		antimetabolite;
antiviral drug
osi 027
OSI 027: inhibits both mTORC1 and mTORC2; structure in first source		2.8130
levoleucovorin
Levoleucovorin: A folate analog consisting of the pharmacologically active isomer of LEUCOVORIN.. (6S)-5-formyltetrahydrofolic acid : The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid.		9.816135-formyltetrahydrofolic acidantineoplastic agent;
metabolite
guanine
[no description available]		16.0653202-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
inosine
[no description available]		2.0510inosines;
purines D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
folic acid
folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.		10110folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient
3-methyladenine
N3-methyladenine: structure in first source		3.0340
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		7.35131cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
clozapine
Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.		4.7690benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
dacarbazine
(E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.		10.44173dacarbazine
didanosine
Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.		4.2650purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
ganciclovir
[no description available]		4.94602-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
valtrex
[no description available]		2.0810organic molecular entity
valacyclovir
Valacyclovir: A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.		3.5820L-valyl esterantiviral drug
sildenafil
sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.		4.2750piperazines;
pyrazolopyrimidine;
sulfonamide		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
olanzapine
Olanzapine: A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.. olanzapine : A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4.		3.8730benzodiazepine;
N-arylpiperazine;
N-methylpiperazine		antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor
penciclovir
penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration.		2.45202-aminopurines;
propane-1,3-diols		antiviral drug
oxypurinol
Oxypurinol: A xanthine oxidase inhibitor.. alloxanthine : A pyrazolopyrimidine that is 4,5,6,7-tetrahydro-H-pyrazolo[3,4-d]pyrimidine substituted by oxo groups at positions 4 and 6.		2.0510pyrazolopyrimidinedrug metabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor
raltitrexed
[no description available]		11.3161N-acyl-amino acid
vardenafil
vardenafil : The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine.		3.8530imidazotriazine;
N-alkylpiperazine;
N-sulfonylpiperazine		EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
allopurinol
Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.		4.4260nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
hli 373
[no description available]		2.0810
citrovorum factor
[no description available]		3.8730tetrahydrofolic acid
leucovorin
5-formyltetrahydrofolic acid : A formyltetrahydrofolic acid in which the formyl group is located at position 5.		4.0740formyltetrahydrofolic acidEscherichia coli metabolite;
mouse metabolite
rifapentine
rifapentine: cyclopentyl derivative of rifampicin		3.6120N-alkylpiperazine;
N-iminopiperazine;
rifamycins		antitubercular agent;
leprostatic drug
4-hydroxyquinazoline
4-oxo-3,4-dihydroquinazoline: structure in first source		2.1510quinazolines
alanosine
[no description available]		2.0510
bl 4162a
anagrelide: imidazoquinazoline derivative which lowers platelet count probably by inhibiting thrombopoiesis and reduces platelet aggregation; used for thrombocythemia; structure in first source. anagrelide : A 1,5-dihydroimidazo[2,1-]quinazoline having an oxo substituent at the 2-position and chloro substituents at the 6- and 7-positions.		4.4230imidazoquinazolineanticoagulant;
antifibrinolytic drug;
cardiovascular drug;
platelet aggregation inhibitor
tegaserod
tegaserod: a nonbenzamide 5-hydroxytryptamine(4) agonist; used in treatment of irritable bowel syndrome; marketing suspended 2007 in US due to higher incidence of MI, stroke, and unstable angina; structure given in first source		3.5820carboxamidine;
guanidines;
hydrazines;
indoles		gastrointestinal drug;
serotonergic agonist
norclozapine
norclozapine: structure given in first source. N-desmethylclozapine : A dibenzodoazepine substituted with chloro and piperazino groups which is a major metabolite of clozapine; a potent and selective 5-HT2C serotonin receptor antagonist.		2.0810dibenzodiazepine;
organochlorine compound;
piperazines		delta-opioid receptor agonist;
metabolite;
serotonergic antagonist
pemetrexed
pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).		18.3110841N-acyl-L-glutamic acid;
pyrrolopyrimidine		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
tirapazamine
Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation.. tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4.		2.9940aromatic amine;
benzotriazines;
N-oxide		antibacterial agent;
antineoplastic agent;
apoptosis inducer
sildenafil citrate
Sildenafil Citrate: A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.. sildenafil citrate : The citrate salt of sildenafil.		2.4920citrate saltEC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
valganciclovir
Valganciclovir: A ganciclovir prodrug and antiviral agent that is used to treat CYTOMEGALOVIRUS RETINITIS in patients with AIDS, and for the prevention of CYTOMEGALOVIRUS INFECTIONS in organ transplant recipients who have received an organ from a CMV-positive donor.. valganciclovir : The L-valinyl ester of ganciclovir, into which it is rapidly converted by intestinal and hepatic esterases. It is a synthetic analogue of 2'-deoxyguanosine.		3.2310L-valyl ester;
purines		antiviral drug;
prodrug
aprepitant
Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.		4.2650(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles		antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist
fosaprepitant
fosaprepitant: a pro-drug form of aprepitant. fosaprepitant : A morpholine derivative that is the (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl ether of (3-{[(2R,3S)-3-(4-fluorophenyl)-2-hydroxymorpholin-4-yl]methyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid.		3.2310(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
phosphoramide;
triazoles		antiemetic;
neurokinin-1 receptor antagonist;
prodrug
tegaserod maleate
[no description available]		2.0810maleate saltserotonergic agonist
ceftobiprole
ceftobiprole: BAL5788 is Ceftobiprole medocaril sodium. ceftobiprole : A fifth-generation cephalosporin antibiotic having (E)-[(3'R)-2-oxo[1,3'-bipyrrolidin]-3-ylidene]methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP).		2.0410cephalosporin;
thiadiazoles		antimicrobial agent
hymenialdisine
[no description available]		2.0310
rifabutin
[no description available]		4.5570
isogranulatimide
isogranulatimide: G2 checkpoint inhibitor; structure in first source		2.0310
xav939
XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source. XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group.		2.5320(trifluoromethyl)benzenes;
thiopyranopyrimidine		tankyrase inhibitor
ag-879
AG-879: structure given in first source		3.9220
2-carboxyarabinitol 1-phosphate
[no description available]		2.0810
hesperadin
[no description available]		2.4110
nintedanib
nintedanib : A member of the class of oxindoles that is a kinase inhibitor used (in the form of its ethylsulfonate salt) for the treatment of idiopathic pulmonary fibrosis and cancer.		4.7580
bms 536924
BMS 536924: inhibits insulin-like growth factor I receptor kinase; structure in first source		2.0810
bay 65-1942
Bay 65-1942: inhibits IKK-beta protein		2.2110
amg531
[no description available]		3.5110
debromohymenialdisine
[no description available]		2.0310
cytidylyl-3'-5'-guanosine
cytidylyl-3'-5'-guanosine: also referred to as CpG		2.0310(3'->5')-dinucleotide
ver 52296
luminespib : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid with the amino group of ethylamine.		2.0810aromatic amide;
isoxazoles;
monocarboxylic acid amide;
morpholines;
resorcinols		angiogenesis inhibitor;
antineoplastic agent;
Hsp90 inhibitor
levomefolate calcium
levomefolate calcium: an ingredient in Contraceptives, Oral, Combined. levomefolate calcium : An organic calcium salt of (6S)-5-methyltetrahydrofolic acid.		3.2310organic calcium saltantidepressant
2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1h-indole-5-carbonitrile
2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1H-indole-5-carbonitrile: structure in first source. AZD1080 : A member of the class of hydroxyindoles that is 1H-indole substituted by hydroxy, 5-(morpholin-4-ylmethyl)pyridin-2-yl, and cyano groups at positions 2, 3 and 5, respectively. It is a potent, brain permeable inhibitor of human GSK3alpha and GSK3beta with Ki of 6.9 nM and 31 nM, respectively. The drug was being developed by AstraZeneca for the treatment of Alzheimer's disease (clinical trial now discontinued).		2.0610hydroxyindoles;
morpholines;
nitrile;
pyridines;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
tau aggregation inhibitor
sb-590885
N-{5-[2-{4-[2-(dimethylamino)ethoxy]phenyl}-4-(pyridin-4-yl)-1H-imidazol-5-yl]-2,3-dihydro-1H-inden-1-ylidene}hydroxylamine : A ketoxime that is the oxime of indan-1-one in which the hydrogen at position 5 has been replaced by an imidazol-5-yl group which has itself been substituted at positions 2 and 4 by p-[2-(dimethylamino)ethoxy]phenyl and pyridin-4-yl groups, respectively.		2.0810aromatic ether;
imidazoles;
ketoxime;
pyridines;
tertiary amino compound
pf-477736
PF 00477736: a Chk1 inhibitor; structure in first source. PF-00477736 : A diazepinoindole that is 8-amino-4,5-dihydro-6H-[1,2]diazepino[4,5,6-cd]indol-6-one which is substituted at position 2 by a 1-methylpyrazol-4-yl group and in which the amino group at position 8 has undergone condensation with the carboxy group of (2R)-2-cyclohexylglycine to give the corresponding carboxamide. It is an inhibitor of checkpoint kinase 1 (Chk 1).		2.0810
bay 80-6946
copanlisib: an antineoplastic agent with PI3K inhibitory activity; structure in first source. copanlisib : An imidazoquinazoline that is 2,3-dihydroimidazo[1,2-c]quinazoline substituted by (2-aminopyrimidine-5-carbonyl)amino, methoxy, and 3-(morpholin-4-yl)propoxy groups at positions 5, 7 and 8, respectively. It is a intravenous pan-class I PI3K inhibitor used for the treatment of relapsed follicular lymphoma in patients who have received at least 2 prior systemic therapies.		2.1510
pp242
torkinib : A member of the class of pyrazolopyrimidines that is 1H-pyrazolo[3,4-d]pyrimidine substituted by isopropyl, 5-hydroxyindol-2-yl and amino groups at positions 1, 3 and 4 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.		2.7630aromatic amine;
biaryl;
hydroxyindoles;
phenols;
primary amino compound;
pyrazolopyrimidine		antineoplastic agent;
mTOR inhibitor
fenobam
fenobam: in USAN fenobam refers to monohydrate		2.0810ureas
eye
[no description available]		2.7330
acetylcellulose
acetylcellulose: coating compound. cellulose acetate : A glucan derivative obtained through the esterification of cellulose by acetic anhydride or acetic acid, resulting in the substitution of some of the hydroxy groups of cellulose by acetyl groups. It is used in a variety of applications including base material for photographic film, clothing, membrane filters, coatings, food packaging, and as a frame material for eyeglasses.		5.121
pyrimidinones
Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.		8.6780
phenanthrenes
Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.		3.1140
ConditionIndicatedRelationship StrengthStudiesTrials
Carcinoma, Epidermoid
[description not available]		019.9328243
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		126.29846129
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		015.426824
Benign Neoplasms
[description not available]		020.5828626
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		125.3457252
Erythremia
[description not available]		02.0310
Polycythemia Vera
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.		02.0310
Carcinoma, Non-Small Cell Lung
[description not available]		031.943,7181,342
Cancer of Lung
[description not available]		032.294,3581,374
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		138.943,7181,342
Lung Neoplasms
Tumors or cancer of the LUNG.		138.6813,0744,122
Adverse Drug Event
[description not available]		012.492912
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.		012.492912
Adenocarcinoma, Basal Cell
[description not available]		027.671,455684
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		027.671,455684
Breast Cancer
[description not available]		019.2424535
Breast Neoplasms
Tumors or cancer of the human BREAST.		123.9849070
Acute Liver Injury, Drug-Induced
[description not available]		07.22330
Chemical and Drug Induced Liver Injury
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.		07.22330
Cancer of Liver
[description not available]		012.8788
Liver Neoplasms
Tumors or cancer of the LIVER.		012.8788
Cancer of Prostate
[description not available]		013.787713
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		115.787713
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		017.8116682
Colorectal Cancer
[description not available]		016.039125
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		118.039125
Metastase
[description not available]		017.6712342
Experimental Mammary Neoplasms
[description not available]		04.83120
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		017.6712342
Malignant Melanoma
[description not available]		06.59171
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		06.59171
Fibrodysplasia Ossificans Progressiva
[description not available]		02.110
Myositis Ossificans
A disease characterized by bony deposits or the ossification of muscle tissue.		02.110
Invasiveness, Neoplasm
[description not available]		014.4110213
Cancer of Pancreas
[description not available]		013.135117
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		115.135117
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
[description not available]		02.1110
Hepatitis C
INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.		02.1110
Cancer of Colon
[description not available]		06.85430
Colonic Neoplasms
Tumors or cancer of the COLON.		06.85430
Benign Neoplasms, Brain
[description not available]		018.3619540
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		018.3619540
Experimental Neoplasms
[description not available]		04.77290
Cardiomyopathies, Primary
[description not available]		02.5720
Cardiomyopathies
A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).		02.5720
Infections, Staphylococcal
[description not available]		02.1510
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		02.1510
Acute Myelogenous Leukemia
[description not available]		05.33121
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		17.33121
ER-Negative PR-Negative HER2-Negative Breast Cancer
[description not available]		05.91330
Triple Negative Breast Neoplasms
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.		05.91330
Innate Inflammatory Response
[description not available]		012.043016
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		012.043016
Chordoma
A malignant tumor arising from the embryonic remains of the notochord. It is also called chordocarcinoma, chordoepithelioma, and notochordoma. (Dorland, 27th ed)		03.1950
Cryptogenic Fibrosing Alveolitis
[description not available]		03.5320
Idiopathic Pulmonary Fibrosis
A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.		03.5320
Kahler Disease
[description not available]		03.0340
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		03.0340
Bladder Cancer
[description not available]		09.14331
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		111.14331
Congenital Zika Syndrome
[description not available]		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
2019 Novel Coronavirus Disease
[description not available]		09.95119
Viral Diseases
[description not available]		03.8330
Virus Diseases
A general term for diseases caused by viruses.		03.8330
Alveolitis, Fibrosing
[description not available]		04.25170
Pulmonary Fibrosis
A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.		04.25170
Disease Exacerbation
[description not available]		022.6321141
Lung Adenocarcinoma
[description not available]		018.5125949
Dermatitis Medicamentosa
[description not available]		012.59504
Hyperlipemia
[description not available]		02.4110
Blood Pressure, High
[description not available]		03.0240
Lymph Node Metastasis
[description not available]		015.32345
Adenocarcinoma of Lung
A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.		120.5125949
Hyperlipidemias
Conditions with excess LIPIDS in the blood.		02.4110
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		03.0240
Electrocardiogram QT Prolonged
[description not available]		02.8220
Long QT Syndrome
A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.		02.8220
Anoxemia
[description not available]		05.9991
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		05.9991
Hepatocellular Carcinoma
[description not available]		011.02464
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		113.02464
Carcinoma, Small Cell Lung
[description not available]		09.29221
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		010.35441
Cancer of Stomach
[description not available]		08.13302
Stomach Neoplasms
Tumors or cancer of the STOMACH.		111.99604
Small Cell Lung Carcinoma
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).		111.29221
Carcinogenesis
The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.		010.87299
Osteogenic Sarcoma
[description not available]		03.2350
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		08.2350
Rhabdomyolysis
Necrosis or disintegration of skeletal muscle often followed by myoglobinuria.		07.8220
Local Neoplasm Recurrence
[description not available]		019.0816353
Minimal Disease, Residual
[description not available]		06.62100
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		014.966328
Pemphigus Foliaceus
[description not available]		02.4110
Pemphigus
Group of chronic blistering diseases characterized histologically by ACANTHOLYSIS and blister formation within the EPIDERMIS.		07.4110
Cells, Neoplasm Circulating
[description not available]		08.03113
Carcinoma, Squamous Cell of Head and Neck
[description not available]		09.37305
Cancer of Head
[description not available]		017.3913625
Squamous Cell Carcinoma of Head and Neck
The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.		09.37305
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)		122.1127250
Silicosis
A form of pneumoconiosis resulting from inhalation of dust containing crystalline form of SILICON DIOXIDE, usually in the form of quartz. Amorphous silica is relatively nontoxic.		07.4110
Carcinoma, Oat Cell
[description not available]		08.94242
Carcinoma, Small Cell
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)		08.94242
Cancer of Cervix
[description not available]		06.3672
Uterine Cervical Neoplasms
Tumors or cancer of the UTERINE CERVIX.		18.3672
Esophageal Squamous Cell Carcinoma
A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.		06.6792
Cancer of Esophagus
[description not available]		011.86419
Esophageal Neoplasms
Tumors or cancer of the ESOPHAGUS.		113.86419
Cancer of Mouth
[description not available]		07.97240
Mouth Neoplasms
Tumors or cancer of the MOUTH.		07.97240
Exanthem
[description not available]		015.926821
Exanthema
Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.		015.926821
Acute Kidney Failure
[description not available]		03.9640
Acute Kidney Injury
Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.		03.9640
Glial Cell Tumors
[description not available]		012.86499
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		012.86499
Epithelial Ovarian Cancer
[description not available]		05.02110
Cancer of Ovary
[description not available]		012.93458
Carcinoma, Ovarian Epithelial
A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.		05.02110
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		114.93458
Carcinoma, Lewis Lung
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.		03.3960
Bone Cancer
[description not available]		010.33485
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		010.33485
Ectopic Pregnancy
[description not available]		05.9383
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		012.433620
Pregnancy, Ectopic
A potentially life-threatening condition in which EMBRYO IMPLANTATION occurs outside the cavity of the UTERUS. Most ectopic pregnancies (		05.9383
Parodontosis
[description not available]		02.610
Periodontal Diseases
Pathological processes involving the PERIODONTIUM including the gum (GINGIVA), the alveolar bone (ALVEOLAR PROCESS), the DENTAL CEMENTUM, and the PERIODONTAL LIGAMENT.		02.610
Cramp
[description not available]		02.610
Idiopathic Inflammatory Myopathies
[description not available]		02.610
Muscle Cramp
A sustained and usually painful contraction of muscle fibers. This may occur as an isolated phenomenon or as a manifestation of an underlying disease process (e.g., UREMIA; HYPOTHYROIDISM; MOTOR NEURON DISEASE; etc.). (From Adams et al., Principles of Neurology, 6th ed, p1398)		02.610
Myositis
Inflammation of a muscle or muscle tissue.		07.610
Deaf Mutism
[description not available]		03.5210
Cochlear Hearing Loss
[description not available]		03.5210
Deafness
A general term for the complete loss of the ability to hear from both ears.		03.5210
Hearing Loss, Sensorineural
Hearing loss resulting from damage to the COCHLEA and the sensorineural elements which lie internally beyond the oval and round windows. These elements include the AUDITORY NERVE and its connections in the BRAINSTEM.		03.5210
Chronic Lung Injury
[description not available]		03.5720
Experimental Lung Inflammation
Inflammation of any part, segment or lobe, of the lung parenchyma.		08.16104
Pneumonia
Infection of the lung often accompanied by inflammation.		08.16104
Colonic Polyps
Discrete tissue masses that protrude into the lumen of the COLON. These POLYPS are connected to the wall of the colon either by a stalk, pedunculus, or by a broad base.		02.2110
Injuries, Spinal Cord
[description not available]		02.2510
Spinal Cord Injuries
Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).		02.2510
Cancer of Skin
[description not available]		09.36283
Skin Neoplasms
Tumors or cancer of the SKIN.		111.36283
Cancer of Kidney
[description not available]		012.342610
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		114.342610
Capsule Opacification
Clouding or loss of transparency of the posterior lens capsule, usually following CATARACT extraction.		02.5820
Interstitial Pregnancy
[description not available]		02.2510
Astrocytoma, Grade IV
[description not available]		013.68678
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		115.68678
Anemia, Fanconi
[description not available]		02.2510
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		07.2510
Bone Fractures
[description not available]		05.5631
Disbacteriosis
[description not available]		03.1710
Bacterial Disease
[description not available]		03.1710
Cancer of Gastrointestinal Tract
[description not available]		05.2460
Bacterial Infections
Infections by bacteria, general or unspecified.		03.1710
Fractures, Bone
Breaks in bones.		05.5631
Extravascular Hemolysis
[description not available]		04.8821
Hemolysis
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.		04.8821
Eaton-Lambert Myasthenic Syndrome
[description not available]		03.1710
Lambert-Eaton Myasthenic Syndrome
An autoimmune disease characterized by weakness and fatigability of proximal muscles, particularly of the pelvic girdle, lower extremities, trunk, and shoulder girdle. There is relative sparing of extraocular and bulbar muscles. CARCINOMA, SMALL CELL of the lung is a frequently associated condition, although other malignancies and autoimmune diseases may be associated. Muscular weakness results from impaired impulse transmission at the NEUROMUSCULAR JUNCTION. Presynaptic calcium channel dysfunction leads to a reduced amount of acetylcholine being released in response to stimulation of the nerve. (From Adams et al., Principles of Neurology, 6th ed, pp 1471)		03.1710
Birth Weight
The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.		04.4311
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		06.8791
Recrudescence
[description not available]		011.13236
Diffuse Parenchymal Lung Disease
[description not available]		014.51826
Hibernation, Myocardial
[description not available]		04.4311
Tuberculosis, Drug-Resistant
[description not available]		04.4311
Infections, Coronavirus
[description not available]		09.7499
Chronic Hepatitis B
[description not available]		04.4311
Anterior Cerebral Circulation Infarction
[description not available]		04.4311
Apoplexy
[description not available]		04.821
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
[description not available]		04.4311
Airflow Obstruction, Chronic
[description not available]		05.7221
Ductal Carcinoma
[description not available]		04.4311
Gastrointestinal Stromal Neoplasm
[description not available]		05.5531
Complications of Diabetes Mellitus
[description not available]		04.4311
Overweight
A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.		09.8421
Atherogenesis
[description not available]		07.5544
Chronic Kidney Diseases
[description not available]		08.0864
Primary Graft Dysfunction
A form of ischemia-reperfusion injury occurring in the early period following transplantation. Significant pathophysiological changes in MITOCHONDRIA are the main cause of the dysfunction. It is most often seen in the transplanted lung, liver, or kidney and can lead to GRAFT REJECTION.		04.4311
Lung Injury, Acute
[description not available]		05.841
Airway Remodeling
The structural changes in the number, mass, size and/or composition of the airway tissues.		05.131
Atheroma
[description not available]		04.4311
Lower Urinary Tract Symptom
[description not available]		04.4311
Adolescent Obesity
[description not available]		04.4311
Allergic Rhinitis
[description not available]		04.4311
Thyroid Cancer, Anaplastic
[description not available]		04.4311
Encephalopathy, Traumatic
[description not available]		04.4311
Familial Nonmedullary Thyroid Cancer
[description not available]		04.821
Acute Confusional Senile Dementia
[description not available]		07.5544
Rheumatoid Arthritis
[description not available]		011.0131
Asthma, Bronchial
[description not available]		06.0231
Amaurosis
[description not available]		04.4311
Bone Loss, Osteoclastic
[description not available]		05.2521
Carcinoma, Ehrlich Tumor
A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.		04.8321
Adenocarcinoma Of Kidney
[description not available]		011.972110
Clostridioides difficile Infection
[description not available]		04.4311
Alloxan Diabetes
[description not available]		05.131
Autoimmune Diabetes
[description not available]		04.4311
Diabetes Mellitus, Adult-Onset
[description not available]		05.2941
Anasarca
[description not available]		05.2821
Cutis Elastica
[description not available]		04.4311
E coli Infections
[description not available]		04.4311
Cardiac Failure
[description not available]		011.622016
Bleeding
[description not available]		05.7441
Hepatitis B Virus Infection
[description not available]		07.5544
Fasting Hypoglycemia
HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.		04.4311
Chronic Insomnia
[description not available]		05.3322
Hypermobility, Joint
[description not available]		04.4311
Chronic Kidney Failure
[description not available]		05.2741
Cirrhosis, Liver
[description not available]		05.9151
B16 Melanoma
[description not available]		04.8521
Muscle Disorders
[description not available]		04.7921
Morbid Obesity
[description not available]		04.4311
Age-Related Osteoporosis
[description not available]		07.5544
Prediabetes
[description not available]		04.4311
Acute Respiratory Distress Syndrome
[description not available]		07.1862
Acute Hypercapnic Respiratory Failure
[description not available]		05.6161
Cancer of Salivary Gland
[description not available]		08.0272
Hemorrhagic Shock
[description not available]		04.4311
Blood Clot
[description not available]		05.0431
Cancer of the Thyroid
[description not available]		09162
Pulmonary Consumption
[description not available]		05.1531
Deficiency, Vitamin D
[description not available]		04.4311
Injuries
Used with anatomic headings, animals, and sports for wounds and injuries. Excludes cell damage, for which pathology is used.		04.4311
Injury, Ischemia-Reperfusion
[description not available]		04.4311
HIV Coinfection
[description not available]		04.8521
Bone Loss, Perimenopausal
[description not available]		04.4311
Bacterial Infections, Gram-Negative
[description not available]		07.5544
Carcinoma, Ductal, Pancreatic
[description not available]		05.8171
Hangman Fracture
[description not available]		04.7821
Idiopathic Interstitial Pneumonia
[description not available]		04.4311
Eye Infections, Fungal
Infection by a variety of fungi, usually through four possible mechanisms: superficial infection producing conjunctivitis, keratitis, or lacrimal obstruction; extension of infection from neighboring structures - skin, paranasal sinuses, nasopharynx; direct introduction during surgery or accidental penetrating trauma; or via the blood or lymphatic routes in patients with underlying mycoses.		04.4311
Cell Transformation, Viral
An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.		04.4311
Delayed Effects, Prenatal Exposure
[description not available]		04.4311
Brain Injuries, Traumatic
A form of acquired brain injury which occurs when a sudden trauma causes damage to the brain.		04.4311
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		06.872
Albuminuria
The presence of albumin in the urine, an indicator of KIDNEY DISEASES.		04.4311
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		07.5544
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		06.0131
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		06.0231
Blindness
The inability to see or the loss or absence of perception of visual stimuli. This condition may be the result of EYE DISEASES; OPTIC NERVE DISEASES; OPTIC CHIASM diseases; or BRAIN DISEASES affecting the VISUAL PATHWAYS or OCCIPITAL LOBE.		04.4311
Carcinoma, Renal Cell
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.		113.972110
Cardiovascular Diseases
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.		08.1874
Clostridium Infections
Infections with bacteria of the genus CLOSTRIDIUM and closely related CLOSTRIDIOIDES species.		04.4311
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		04.4311
Connective Tissue Diseases
A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.		04.4311
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.		04.921
Diabetes Mellitus, Type 1
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.		04.4311
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		05.2941
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		05.2821
Ehlers-Danlos Syndrome
A heterogeneous group of autosomally inherited COLLAGEN DISEASES caused by defects in the synthesis or structure of FIBRILLAR COLLAGEN. There are numerous subtypes: classical, hypermobility, vascular, and others. Common clinical features include hyperextensible skin and joints, skin fragility and reduced wound healing capability.		04.4311
Escherichia coli Infections
Infections with bacteria of the species ESCHERICHIA COLI.		04.4311
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		011.622016
Hemorrhage
Bleeding or escape of blood from a vessel.		05.7441
Hepatitis B
INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.		07.5544
Hypoglycemia
A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.		04.4311
Sleep Initiation and Maintenance Disorders
Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition.		05.3322
Kidney Failure, Chronic
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.		05.2741
Liver Cirrhosis
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.		010.9151
Muscular Diseases
Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE.		04.7921
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		05.661
Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)		18.5392
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		09.85109
Obesity, Morbid
The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.		04.4311
Osteoporosis
Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.		07.5544
Pneumonia, Viral
Inflammation of the lung parenchyma that is caused by a viral infection.		09.7499
Prediabetic State
The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2).		04.4311
Respiratory Distress Syndrome
A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.		07.1862
Respiratory Insufficiency
Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed)		05.6161
Salivary Gland Neoplasms
Tumors or cancer of the SALIVARY GLANDS.		110.0272
Thrombosis
Formation and development of a thrombus or blood clot in the blood vessel.		010.0431
Thyroid Neoplasms
Tumors or cancer of the THYROID GLAND.		09162
Tuberculosis, Pulmonary
MYCOBACTERIUM infections of the lung.		05.1531
Uveitis
Inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (sclera and cornea, and the retina). (Dorland, 27th ed)		04.4311
Vitamin D Deficiency
A nutritional condition produced by a deficiency of VITAMIN D in the diet, insufficient production of vitamin D in the skin, inadequate absorption of vitamin D from the diet, or abnormal conversion of vitamin D to its bioactive metabolites. It is manifested clinically as RICKETS in children and OSTEOMALACIA in adults. (From Cecil Textbook of Medicine, 19th ed, p1406)		04.4311
Wounds and Injuries
Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.		04.4311
Reperfusion Injury
Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.		04.4311
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		04.8521
Osteoporosis, Postmenopausal
Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.		04.4311
Spinal Fractures
Broken bones in the vertebral column.		04.7821
Gram-Negative Bacterial Infections
Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.		07.5544
Lung Diseases, Interstitial
A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.		014.51826
Tuberculosis, Multidrug-Resistant
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.		04.4311
Coronavirus Infections
Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).		09.7499
Hepatitis B, Chronic
INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.		04.4311
Brain Infarction
Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis.		04.4311
Stroke
A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)		04.821
Lymphoma, Mantle-Cell
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).		04.4311
Carcinoma, Pancreatic Ductal
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.		05.8171
Pulmonary Disease, Chronic Obstructive
A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.		05.7221
Carcinoma, Ductal
Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.		04.4311
Gastrointestinal Stromal Tumors
All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).		05.5531
Atherosclerosis
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.		07.5544
Renal Insufficiency, Chronic
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)		08.0864
Acute Lung Injury
A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).		05.841
Rhinitis, Allergic
An inflammation of the NASAL MUCOSA triggered by ALLERGENS.		04.4311
Thyroid Carcinoma, Anaplastic
An aggressive THYROID GLAND malignancy which generally occurs in IODINE-deficient areas in people with previous thyroid pathology such as GOITER. It is associated with CELL DEDIFFERENTIATION of THYROID CARCINOMA (e.g., FOLLICULAR THYROID CARCINOMA; PAPILLARY THYROID CANCER). Typical initial presentation is a rapidly growing neck mass which upon metastasis is associated with DYSPHAGIA; NECK PAIN; bone pain; DYSPNEA; and NEUROLOGIC DEFICITS.		04.4311
Cardiac Toxicity
[description not available]		02.5820
Cardiotoxicity
Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.		02.5820
Aortic Dissection
[description not available]		02.2510
Escherichia coli Meningitis
[description not available]		02.2510
Pleural Effusion, Malignant
Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.		06.57171
Insulin Sensitivity
[description not available]		07.8130
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.		02.8130
Li-Fraumeni Syndrome
Rare autosomal dominant syndrome characterized by mesenchymal and epithelial neoplasms at multiple sites. MUTATION of the p53 tumor suppressor gene, a component of the DNA DAMAGE response pathway, apparently predisposes family members who inherit it to develop certain cancers. The spectrum of cancers in the syndrome was shown to include, in addition to BREAST CANCER and soft tissue sarcomas (SARCOMA); BRAIN TUMORS; OSTEOSARCOMA; LEUKEMIA; and ADRENOCORTICAL CARCINOMA.		02.2510
HPV Infection
[description not available]		04.2860
Papillomavirus Infections
Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.		04.2860
Hyponatremia
Deficiency of sodium in the blood; salt depletion. (Dorland, 27th ed)		07.3110
Infections, Helicobacter
[description not available]		02.2510
Helicobacter Infections
Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.		02.2510
Thrombopenia
[description not available]		04.7821
Thrombocytopenia
A subnormal level of BLOOD PLATELETS.		04.7821
Acute Edematous Pancreatitis
[description not available]		02.3110
Granulocytic Leukemia, Chronic
[description not available]		05.1470
Pancreatitis
INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.		07.3110
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.		05.1470
Fibrous Histiocytoma of Tendon Sheath
[description not available]		02.3110
Chromosomal Translocation
[description not available]		05.3270
Giant Cell Tumor of Tendon Sheath
A tumor arising in the SYNOVIAL MEMBRANE; SYNOVIAL BURSA; or TENDON sheath. It is characterized by OSTEOCLAST-like GIANT CELLS; FOAM CELLS; pigmented HEMOSIDERIN-laden MACROPHAGES and inflammatory infiltrate. It is classified either as diffuse or localized tenosynovitis.		02.3110
Carcinoma, Transitional Cell
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.		07.33114
Central Diabetes Insipidus
[description not available]		07.3110
Diabetes Insipidus
A disease that is characterized by frequent urination, excretion of large amounts of dilute URINE, and excessive THIRST. Etiologies of diabetes insipidus include deficiency of antidiuretic hormone (also known as ADH or VASOPRESSIN) secreted by the NEUROHYPOPHYSIS, impaired KIDNEY response to ADH, and impaired hypothalamic regulation of thirst.		07.3110
Diabetes Insipidus, Neurogenic
A genetic or acquired polyuric disorder caused by a deficiency of VASOPRESSINS secreted by the NEUROHYPOPHYSIS. Clinical signs include the excretion of large volumes of dilute URINE; HYPERNATREMIA; THIRST; and polydipsia. Etiologies include HEAD TRAUMA; surgeries and diseases involving the HYPOTHALAMUS and the PITUITARY GLAND. This disorder may also be caused by mutations of genes such as ARVP encoding vasopressin and its corresponding neurophysin (NEUROPHYSINS).		02.3110
Response Evaluation Criteria in Solid Tumors
An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.		07.4482
Epithelial Neoplasms
[description not available]		06.6771
Thromboembolism, Venous
[description not available]		03.4620
Venous Thromboembolism
Obstruction of a vein or VEINS (embolism) by a blood clot (THROMBUS) in the blood stream.		03.4620
Dermatoses
[description not available]		07.99115
Skin Diseases
Diseases involving the DERMIS or EPIDERMIS.		07.99115
P carinii Pneumonia
[description not available]		02.3110
Pneumonia, Pneumocystis
A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.		02.3110
Bullous Dermatoses
[description not available]		03.6730
Scalp Dermatoses
Skin diseases involving the SCALP.		04.5650
Infections, Salmonella
[description not available]		02.3110
Cancer of Spleen
[description not available]		02.3110
Cachexia
General ill health, malnutrition, and weight loss, usually associated with chronic disease.		02.3110
Hypermelanosis
[description not available]		02.4820
Lichen Ruber Planus
[description not available]		02.3110
Lichen Planus
An inflammatory, pruritic disease of the skin and mucous membranes, which can be either generalized or localized. It is characterized by distinctive purplish, flat-topped papules having a predilection for the trunk and flexor surfaces. The lesions may be discrete or coalesce to form plaques. Histologically, there is a saw-tooth pattern of epidermal hyperplasia and vacuolar alteration of the basal layer of the epidermis along with an intense upper dermal inflammatory infiltrate composed predominantly of T-cells. Etiology is unknown.		07.3110
Hyperpigmentation
Excessive pigmentation of the skin, usually as a result of increased epidermal or dermal melanin pigmentation, hypermelanosis. Hyperpigmentation can be localized or generalized. The condition may arise from exposure to light, chemicals or other substances, or from a primary metabolic imbalance.		07.4820
Cancer of the Tongue
[description not available]		02.7530
Tongue Neoplasms
Tumors or cancer of the TONGUE.		02.7530
Angiogenesis, Pathologic
[description not available]		08.58510
Injury, Myocardial Reperfusion
[description not available]		02.3110
Edema-Proteinuria-Hypertension Gestosis
[description not available]		02.3110
Pre-Eclampsia
A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.		02.3110
Cystadenocarcinoma, Serous
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)		04.821
Central Nervous System Neoplasm
[description not available]		010.55175
Central Nervous System Neoplasms
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.		112.55175
Chronic Hepatitis C
[description not available]		02.4620
Hepatitis C, Chronic
INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.		02.4620
Cancer of Pituitary
[description not available]		03.7130
Adenoma, Prolactin-Secreting, Pituitary
[description not available]		03.6830
Pituitary Neoplasms
Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.		03.7130
Corneal Edema
An excessive amount of fluid in the cornea due to damage of the epithelium or endothelium causing decreased visual acuity.		02.1510
Nasopharyngeal Carcinoma
A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.		02.7830
Carcinoma, Anaplastic
[description not available]		010.26413
Cancer of Nasopharynx
[description not available]		05.71102
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.		112.26413
Nasopharyngeal Neoplasms
Tumors or cancer of the NASOPHARYNX.		17.71102
Pleural Effusion
Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.		01081
B-Cell Chronic Lymphocytic Leukemia
[description not available]		02.5220
Leukemia, Lymphocytic, Chronic, B-Cell
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.		02.5220
Cocarcinogenesis
The combination of two or more different factors in the production of cancer.		02.1510
Multiple Pulmonary Nodules
A number of small lung lesions characterized by small round masses of 2- to 3-mm in diameter. They are usually detected by chest CT scans (COMPUTED TOMOGRAPHY, X-RAY). Such nodules can be associated with metastases of malignancies inside or outside the lung, benign granulomas, or other lesions.		02.1710
Neoplasms, Bronchial
[description not available]		03.1550
Tracheal Neoplasms
New abnormal growth of tissue in the TRACHEA.		02.1710
Bronchial Neoplasms
Tumors or cancer of the BRONCHI.		03.1550
Break-Bone Fever
[description not available]		02.1510
Dengue
An acute febrile disease transmitted by the bite of AEDES mosquitoes infected with DENGUE VIRUS. It is self-limiting and characterized by fever, myalgia, headache, and rash. SEVERE DENGUE is a more virulent form of dengue.		07.1510
Genetic Predisposition
[description not available]		015.984820
Carcinoma, Ductal, Breast
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.		05.3872
Adenoma, Basal Cell
[description not available]		05.370
Adenoma
A benign epithelial tumor with a glandular organization.		05.370
Chylopericardium
[description not available]		02.4620
Pericardial Effusion
Fluid accumulation within the PERICARDIUM. Serous effusions are associated with pericardial diseases. Hemopericardium is associated with trauma. Lipid-containing effusion (chylopericardium) results from leakage of THORACIC DUCT. Severe cases can lead to CARDIAC TAMPONADE.		07.4620
Degenerative Disc Disease
[description not available]		02.1710
Intervertebral Disc Degeneration
Degenerative changes in the INTERVERTEBRAL DISC due to aging or structural damage, especially to the vertebral end-plates.		07.1710
Tetraploid
[description not available]		07.1710
Carcinoma, Colloid
[description not available]		06.8164
Adenocarcinoma, Mucinous
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)		06.8164
Constricted Pupil
[description not available]		02.1710
Miosis
Pupillary constriction. This may result from congenital absence of the dilatator pupillary muscle, defective sympathetic innervation, or irritation of the CONJUNCTIVA or CORNEA.		02.1710
Retinal Diseases
Diseases involving the RETINA.		02.1710
Kidney Failure
A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.		02.4720
Renal Insufficiency
Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.		02.4720
Epidermal Cyst
Intradermal or subcutaneous saclike structure, the wall of which is stratified epithelium containing keratohyalin granules.		02.1710
Chloracne
ACNE-like skin eruptions caused by exposure to CHLORINE-containing compounds. Exposure can be by inhalation, ingestion, or through the skin. Chloracne is often seen in people who have occupational contact with chlorinated pesticides, wood preservatives, and sealants.		02.1710
Diathesis
[description not available]		02.7530
Mandibular Neoplasms
Tumors or cancer of the MANDIBLE.		02.1710
Arthritis, Degenerative
[description not available]		02.4820
Osteoarthritis
A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.		07.4820
Paronychia
An inflammatory reaction involving the folds of the skin surrounding the fingernail. It is characterized by acute or chronic purulent, tender, and painful swellings of the tissues around the nail, caused by an abscess of the nail fold. The pathogenic yeast causing paronychia is most frequently Candida albicans. Saprophytic fungi may also be involved. The causative bacteria are usually Staphylococcus, Pseudomonas aeruginosa, or Streptococcus. (Andrews' Diseases of the Skin, 8th ed, p271)		04.67100
Cystitis
Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.		04.1431
Bronchopulmonary Dysplasia
A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.		02.1710
Adrenocorticotropic Hormone, Inappropriate Secretion
[description not available]		04.3520
Adrenal Cancer
[description not available]		04.6130
Cushing's Syndrome
[description not available]		04.3920
ACTH-Producing Pituitary Adenoma
[description not available]		04.8440
Ectopic ACTH Syndrome
[description not available]		04.0410
ACTH Syndrome, Ectopic
Symptom complex due to ACTH production by non-pituitary neoplasms.		04.0410
Cushing Syndrome
A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent.		04.3920
Pituitary ACTH Hypersecretion
A disease of the PITUITARY GLAND characterized by the excess amount of ADRENOCORTICOTROPIC HORMONE secreted. This leads to hypersecretion of cortisol (HYDROCORTISONE) by the ADRENAL GLANDS resulting in CUSHING SYNDROME.		04.3520
Cerebral Infarction, Middle Cerebral Artery
[description not available]		02.2110
Cerebral Ischemia
[description not available]		02.2110
Brain Ischemia
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.		02.2110
Infarction, Middle Cerebral Artery
NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.		02.2110
Diabetic Cardiomyopathies
Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.		02.1710
Mucorales Infection
[description not available]		02.1710
Mucormycosis
Infection in humans and animals caused by any fungus in the order MUCORALES (e.g., RHIZOPUS; MUCOR; CUNNINGHAMELLA; APOPHYSOMYCES; ABSIDIA; SAKSENAEA and RHIZOMUCOR) There are many clinical types associated with infection including central nervous system, lung, gastrointestinal tract, skin, orbit and paranasal sinuses. In humans, it usually occurs as an OPPORTUNISTIC INFECTION.		02.1710
Carcinomatous Meningitis
[description not available]		06.47150
Pneumatosis Cystoides Intestinalis
A condition characterized by the presence of multiple gas-filled cysts in the intestinal wall, the submucosa and/or subserosa of the INTESTINE. The majority of the cysts are found in the JEJUNUM and the ILEUM.		03.250
Meningeal Carcinomatosis
Primary or secondary neoplasm in the ARACHNOID or SUBARACHNOID SPACE. It appears as a diffuse fibrotic thickening of the MENINGES associated with variable degrees of inflammation.		06.47150
Carcinoma, Large Cell
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)		011.55379
Allergic Contact Dermatitis
[description not available]		02.1710
Dermatitis, Allergic Contact
A contact dermatitis due to allergic sensitization to various substances. These substances subsequently produce inflammatory reactions in the skin of those who have acquired hypersensitivity to them as a result of prior exposure.		02.1710
Iris Neoplasms
Tumors of the iris characterized by increased pigmentation of melanocytes. Iris nevi are composed of proliferated melanocytes and are associated with neurofibromatosis and malignant melanoma of the choroid and ciliary body. Malignant melanoma of the iris often originates from preexisting nevi.		02.1710
Intraocular Pressure
The pressure of the fluids in the eye.		02.1710
Neoplasms, Pleural
[description not available]		07.71104
Symptom Cluster
[description not available]		02.2110
Syndrome
A characteristic symptom complex.		02.2110
Hospital-Acquired Condition
[description not available]		02.5520
Pneumopericardium
Presence of air or gas in the space between the heart and the PERICARDIUM. The degree of respiratory distress depends on the amount of trapped air and circulation blocked in the systemic and pulmonary veins.		02.1710
Pleuropericarditis
Inflammation of both the PERICARDIUM and the PLEURA.		02.1710
Pericarditis
Inflammation of the PERICARDIUM from various origins, such as infection, neoplasm, autoimmune process, injuries, or drug-induced. Pericarditis usually leads to PERICARDIAL EFFUSION, or CONSTRICTIVE PERICARDITIS.		02.1710
Neoplasms, Skull Base
[description not available]		02.1710
Pregnancy, Tubal
The most common (		03.5611
Carcinoma, Mucoepidermoid
A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)		04.3870
Benign Meningeal Neoplasms
[description not available]		010.55254
Meningeal Neoplasms
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.		010.55254
Blood Poisoning
[description not available]		02.2110
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		02.2110
Injuries, Radiation
[description not available]		08.5183
Carotid Arteriopathies, Traumatic
[description not available]		02.2110
Vascular Injuries
[description not available]		07.2110
Hyperplasia
An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.		03.1750
Cirrhosis
[description not available]		0340
Cardiac Diseases
[description not available]		02.4820
Fibrosis
Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.		0340
Heart Diseases
Pathological conditions involving the HEART including its structural and functional abnormalities.		02.4820
Toxoplasmosis, Animal
Acquired infection of non-human animals by organisms of the genus TOXOPLASMA.		02.2110
Adrenal Gland Hypofunction
[description not available]		02.2110
Adrenal Insufficiency
Conditions in which the production of adrenal CORTICOSTEROIDS falls below the requirement of the body. Adrenal insufficiency can be caused by defects in the ADRENAL GLANDS, the PITUITARY GLAND, or the HYPOTHALAMUS.		02.2110
Allergic Alveolitis, Extrinsic
[description not available]		02.4620
Granulomas
[description not available]		02.0810
Alveolitis, Extrinsic Allergic
A common interstitial lung disease caused by hypersensitivity reactions of PULMONARY ALVEOLI after inhalation of and sensitization to environmental antigens of microbial, animal, or chemical sources. The disease is characterized by lymphocytic alveolitis and granulomatous pneumonitis.		02.4620
Granuloma
A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents.		02.0810
Behavior Disorders
[description not available]		02.0810
Cranial Nerve Diseases
Disorders of one or more of the twelve cranial nerves. With the exception of the optic and olfactory nerves, this includes disorders of the brain stem nuclei from which the cranial nerves originate or terminate.		02.0810
Bilateral Headache
[description not available]		02.0810
Emesis
[description not available]		06.0152
Mental Disorders
Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.		02.0810
Headache
The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.		02.0810
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		05.0231
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		06.0152
Cancer of Endometrium
[description not available]		04.6961
Endometrial Neoplasms
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.		04.6961
Lassitude
[description not available]		08.799
Leukocytopenia
[description not available]		06.2143
Fatigue
The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.		08.799
Leukopenia
A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).		06.2143
Neutropenia
A decrease in the number of NEUTROPHILS found in the blood.		013.06128
Dysarthosis
[description not available]		02.0810
Flaccid Quadriplegia
[description not available]		02.0810
Anterior Horn Cell Disease
[description not available]		02.0810
Autonomic Dysfunction, Paraneoplastic
[description not available]		02.0810
Motor Neuron Disease
Diseases characterized by a selective degeneration of the motor neurons of the spinal cord, brainstem, or motor cortex. Clinical subtypes are distinguished by the major site of degeneration. In AMYOTROPHIC LATERAL SCLEROSIS there is involvement of upper, lower, and brainstem motor neurons. In progressive muscular atrophy and related syndromes (see MUSCULAR ATROPHY, SPINAL) the motor neurons in the spinal cord are primarily affected. With progressive bulbar palsy (BULBAR PALSY, PROGRESSIVE), the initial degeneration occurs in the brainstem. In primary lateral sclerosis, the cortical neurons are affected in isolation. (Adams et al., Principles of Neurology, 6th ed, p1089)		02.0810
Bed Sores
[description not available]		02.110
Pressure Ulcer
An ulceration caused by prolonged pressure on the SKIN and TISSUES when one stays in one position for a long period of time, such as lying in bed. The bony areas of the body are the most frequently affected sites which become ischemic (ISCHEMIA) under sustained and constant pressure.		02.110
Acneiform Eruptions
Visible efflorescent lesions of the skin caused by acne or resembling acne. (Dorland, 28th ed, p18, 575)		07.72200
Neoplasm Metastasis, Unknown Primary
[description not available]		02.7430
Micrometastases, Neoplasm
[description not available]		02.0210
Atelectasis
[description not available]		02.0810
Carcinoma, Bronchial
[description not available]		03.8740
Coin Lesion, Pulmonary
[description not available]		02.0810
Hemothorax
Hemorrhage within the pleural cavity.		02.0810
Rupture, Spontaneous
Tear or break of an organ, vessel or other soft part of the body, occurring in the absence of external force.		02.0810
Carcinoma, Bronchogenic
Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.		03.8740
Dementia Praecox
[description not available]		02.0810
Schizophrenia
A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.		02.0810
Adenomatous Polyps
Benign neoplasms derived from glandular epithelium. (From Stedman, 25th ed)		02.0810
Liver Dysfunction
[description not available]		03.1750
Liver Diseases
Pathological processes of the LIVER.		03.1750
Alopecia Cicatrisata
[description not available]		04.0650
Cicatrization
The formation of fibrous tissue in the place of normal tissue during the process of WOUND HEALING. It includes scar tissue formation occurring in healing internal organs as well as in the skin after surface injuries.		02.4620
Alopecia
Absence of hair from areas where it is normally present.		04.0650
Cicatrix
The fibrous tissue that replaces normal tissue during the process of WOUND HEALING.		02.4620
Carcinoma, Adenosquamous
A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.		05.8781
Cholangiocellular Carcinoma
[description not available]		04.3570
Bile Duct Cancer
[description not available]		05.3980
Bile Duct Neoplasms
Tumors or cancer of the BILE DUCTS.		05.3980
Cholangiocarcinoma
A malignant tumor arising from the epithelium of the BILE DUCTS.		04.3570
Uveal Neoplasms
Tumors or cancer of the UVEA.		02.4520
Experimental Hepatoma
[description not available]		02.9940
Fibrosarcoma
A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)		07.4720
Anaplastic Oligodendroglioma
[description not available]		011.3551
Oligodendroglioma
A relatively slow-growing glioma that is derived from oligodendrocytes and tends to occur in the cerebral hemispheres, thalamus, or lateral ventricle. They may present at any age, but are most frequent in the third to fifth decades, with an earlier incidence peak in the first decade. Histologically, these tumors are encapsulated, relatively avascular, and tend to form cysts and microcalcifications. Neoplastic cells tend to have small round nuclei surrounded by unstained nuclei. The tumors may vary from well-differentiated to highly anaplastic forms. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2052; Adams et al., Principles of Neurology, 6th ed, p655)		011.3551
Infections, Yersinia
[description not available]		02.0810
Airway Obstruction
Any hindrance to the passage of air into and out of the lungs.		07.0810
Erythema
Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.		010.2741
Cancer of Parotid
[description not available]		02.4620
Parotid Neoplasms
Tumors or cancer of the PAROTID GLAND.		02.4620
Vitiligo
A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached.		07.0810
Carcinoma, Thymic
[description not available]		02.4720
Cancer of the Thymus
[description not available]		02.4820
Thymoma
A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed)		07.4720
Thymus Neoplasms
Tumors or cancer of the THYMUS GLAND.		02.4820
Empyema, Thoracic
[description not available]		02.4620
Empyema, Pleural
Suppurative inflammation of the pleural space.		02.4620
Adenocystic Carcinoma
[description not available]		05.341
Carcinoma, Adenoid Cystic
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)		05.341
Dysphagia
[description not available]		09.821
Deglutition Disorders
Difficulty in SWALLOWING which may result from neuromuscular disorder or mechanical obstruction. Dysphagia is classified into two distinct types: oropharyngeal dysphagia due to malfunction of the PHARYNX and UPPER ESOPHAGEAL SPHINCTER; and esophageal dysphagia due to malfunction of the ESOPHAGUS.		04.821
Ectopic Ossification
[description not available]		02.1110
Adenocarcinoma, Alveolar
[description not available]		012.3468
Bronchial Diseases
Diseases involving the BRONCHI.		02.110
Adenocarcinoma, Bronchiolo-Alveolar
A carcinoma derived from epithelium of terminal bronchioles, in which the neoplastic tissue extends along the alveolar walls and grows in small masses within the alveoli. Involvement may be uniformly diffuse and massive, or nodular, or lobular. The neoplastic cells are cuboidal or columnar and form papillary structures. Mucin may be demonstrated in some of the cells and in the material in the alveoli, which also includes denuded cells. Metastases in regional lymph nodes, and in even more distant sites, are known to occur, but are infrequent. (From Stedman, 25th ed)		114.3468
Neoplasms, Squamous Cell
Neoplasms of the SQUAMOUS EPITHELIAL CELLS. The concept does not refer to neoplasms located in tissue composed of squamous elements.		04.0650
Ache
[description not available]		07.353
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		012.353
Mucositis
An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).		03.3920
Cytomegalic Inclusion Disease
[description not available]		02.110
Cytomegalovirus Infections
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.		02.110
Cytomegalovirus
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.		02.110
Auricular Fibrillation
[description not available]		02.110
Atrial Fibrillation
Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.		02.110
Dermatitis, Contact, Phototoxic
[description not available]		02.110
Pulmonary Hypertension
[description not available]		02.7730
Hypertension, Pulmonary
Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.		02.7730
Drug-Induced Stevens Johnson Syndrome
[description not available]		02.4620
Stevens-Johnson Syndrome
Rare cutaneous eruption characterized by extensive KERATINOCYTE apoptosis resulting in skin detachment with mucosal involvement. It is often provoked by the use of drugs (e.g., antibiotics and anticonvulsants) or associated with PNEUMONIA, MYCOPLASMA. It is considered a continuum of Toxic Epidermal Necrolysis.		02.4620
Cardiac Remodeling, Ventricular
[description not available]		02.5220
Cardiac Hypertrophy
Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.		02.8130
Cardiomegaly
Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.		02.8130
Elevated Cholesterol
[description not available]		02.110
Hypercholesterolemia
A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.		02.110
Infectious Myelitis
[description not available]		02.1110
Spinal Neoplasms
New abnormal growth of tissue in the SPINE.		02.9640
Atrophy
Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.		07.4720
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		02.9740
Hyperuricemia
Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.		02.1110
Glomerulonephritis, Minimal Change
[description not available]		02.1110
Nephrosis, Lipoid
A kidney disease with no or minimal histological glomerular changes on light microscopy and with no immune deposits. It is characterized by lipid accumulation in the epithelial cells of KIDNEY TUBULES and in the URINE. Patients usually show NEPHROTIC SYNDROME indicating the presence of PROTEINURIA with accompanying EDEMA.		02.1110
Cancer, Second Primary
[description not available]		03.1450
Cardiac Tamponade
Compression of the heart by accumulated fluid (PERICARDIAL EFFUSION) or blood (HEMOPERICARDIUM) in the PERICARDIUM surrounding the heart. The affected cardiac functions and CARDIAC OUTPUT can range from minimal to total hemodynamic collapse.		02.1110
Carcinoma, Basal Cell, Pigmented
[description not available]		04.7140
Carcinoma, Basal Cell
A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)		04.7140
Androgen-Independent Prostatic Cancer
[description not available]		03.511
Prostatic Neoplasms, Castration-Resistant
Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.		15.511
Breathing Sounds
[description not available]		02.1110
Respiratory Sounds
Noises, normal and abnormal, heard on auscultation over any part of the RESPIRATORY TRACT.		02.1110
Pneumoperitoneum
A condition with trapped gas or air in the PERITONEAL CAVITY, usually secondary to perforation of the internal organs such as the LUNG and the GASTROINTESTINAL TRACT, or to recent surgery. Pneumoperitoneum may be purposely introduced to aid radiological examination.		02.1110
Emphysema
A pathological accumulation of air in tissues or organs.		02.1110
Intestinal Diseases
Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.		02.1110
Endotoxin Shock
[description not available]		02.1110
Shock, Septic
Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.		02.1110
Calculosis
[description not available]		02.1110
Cholangitis
Inflammation of the biliary ductal system (BILE DUCTS); intrahepatic, extrahepatic, or both.		02.1110
Nerve Pain
[description not available]		03.511
Neuralgia
Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.		03.511
Interstitial Cell Tumor
[description not available]		02.1110
Cancer, Embryonal
[description not available]		02.520
Cancer of Testis
[description not available]		02.520
Neoplasms, Germ Cell and Embryonal
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.		14.520
Testicular Neoplasms
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.		02.520
Cancer of Oropharnyx
[description not available]		05.6721
Oropharyngeal Neoplasms
Tumors or cancer of the OROPHARYNX.		05.6721
Xeroderma
[description not available]		03.420
Itching
[description not available]		05.2643
Ichthyosis
Any of several generalized skin disorders characterized by dryness, roughness, and scaliness, due to hypertrophy of the stratum corneum epidermis. Most are genetic, but some are acquired, developing in association with other systemic disease or genetic syndrome.		03.420
Pruritus
An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.		05.2643
Encapsulating Peritoneal Sclerosis
[description not available]		02.1310
Papulosquamous Disorders
[description not available]		02.1310
Orphan Diseases
Rare diseases that have not been well studied.		02.5320
Paraneoplastic Syndromes
In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products.		03.8840
Hypotrichosis
Presence of less than the normal amount of hair. (Dorland, 27th ed)		02.1310
Aortic Stenosis
[description not available]		02.1310
Prosthesis Durability
[description not available]		02.1310
Aortic Valve Stenosis
A pathological constriction that can occur above (supravalvular stenosis), below (subvalvular stenosis), or at the AORTIC VALVE. It is characterized by restricted outflow from the LEFT VENTRICLE into the AORTA.		02.1310
Choriocarcinoma
A malignant metastatic form of trophoblastic tumors. Unlike the HYDATIDIFORM MOLE, choriocarcinoma contains no CHORIONIC VILLI but rather sheets of undifferentiated cytotrophoblasts and syncytiotrophoblasts (TROPHOBLASTS). It is characterized by the large amounts of CHORIONIC GONADOTROPIN produced. Tissue origins can be determined by DNA analyses: placental (fetal) origin or non-placental origin (CHORIOCARCINOMA, NON-GESTATIONAL).		02.5120
Sarcoma, Epithelioid
[description not available]		02.7430
Sarcoma
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.		14.7430
Disease, Pulmonary
[description not available]		04.9380
Lung Diseases
Pathological processes involving any part of the LUNG.		04.9380
Complications, Neoplastic Pregnancy
[description not available]		03.6830
Abnormalities, Drug-Induced
Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.		03.0410
Pyrexia
[description not available]		03.8821
Fever
An abnormal elevation of body temperature, usually as a result of a pathologic process.		08.8821
Anemia
A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.		05.8664
Anxiety
Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.		03.0410
Depression
Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.		03.6630
Angioblastic Meningioma
[description not available]		04.7921
Meningioma
A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)		09.7921
Disease
A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.		02.1310
Necrolytic Migratory Erythema
Recurrent cutaneous manifestation of GLUCAGONOMA characterized by necrolytic polycyclic migratory lesions with scaling borders. It is associated with elevated secretion of GLUCAGON by the tumor. Other conditions with elevated serum glucagon levels such as HEPATIC CIRRHOSIS may also result in similar skin lesions, which are referred to as pseudoglucagonoma syndrome.		07.1310
Craniopharyngioma, Adamantinous
[description not available]		02.1510
Craniopharyngioma
A benign pituitary-region neoplasm that originates from Rathke's pouch. The two major histologic and clinical subtypes are adamantinous (or classical) craniopharyngioma and papillary craniopharyngioma. The adamantinous form presents in children and adolescents as an expanding cystic lesion in the pituitary region. The cystic cavity is filled with a black viscous substance and histologically the tumor is composed of adamantinomatous epithelium and areas of calcification and necrosis. Papillary craniopharyngiomas occur in adults, and histologically feature a squamous epithelium with papillations. (From Joynt, Clinical Neurology, 1998, Ch14, p50)		02.1510
Age-Related Macular Degeneration
[description not available]		03.0410
Macular Degeneration
Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms.		03.0410
Soft Tissue Neoplasms
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.		03.8521
Multiple Primary Neoplasms
[description not available]		03.4470
Angiogranuloma
[description not available]		02.7530
Allergic Bronchopulmonary Mycosis
[description not available]		02.1710
Breathlessness
[description not available]		05.7373
Dyspnea
Difficult or labored breathing.		05.7373
Choroid Neoplasms
Tumors of the choroid; most common intraocular tumors are malignant melanomas of the choroid. These usually occur after puberty and increase in incidence with advancing age. Most malignant melanomas of the uveal tract develop from benign melanomas (nevi).		04.821
Agranulocytosis
A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).		02.1510
Blast Phase
[description not available]		02.1510
Myelomonocytic Leukemia, Chronic
[description not available]		02.1510
Blast Crisis
An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.		02.1510
Leukemia, Myelomonocytic, Chronic
A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.		02.1510
Weight Reduction
[description not available]		02.4820
Acute Disease
Disease having a short and relatively severe course.		05.3780
Weight Loss
Decrease in existing BODY WEIGHT.		02.4820
Combined Immunodeficiency, X-Linked
[description not available]		02.0410
Leucocythaemia
[description not available]		02.0410
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		02.0410
X-Linked Combined Immunodeficiency Diseases
Forms of combined immunodeficiency caused by mutations in the gene for INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT. Both severe and non-severe subtypes of the disease have been identified.		02.0410
Berger Disease
[description not available]		02.0410
Interstitial Nephritis
[description not available]		07.0410
Glomerulonephritis, IGA
A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.		02.0410
Nephritis, Interstitial
Inflammation of the interstitial tissue of the kidney. This term is generally used for primary inflammation of KIDNEY TUBULES and/or surrounding interstitium. For primary inflammation of glomerular interstitium, see GLOMERULONEPHRITIS. Infiltration of the inflammatory cells into the interstitial compartment results in EDEMA, increased spaces between the tubules, and tubular renal dysfunction.		02.0410
Pneumothorax, Primary Spontaneous
[description not available]		03.3520
Pneumothorax
An accumulation of air or gas in the PLEURAL CAVITY, which may occur spontaneously or as a result of trauma or a pathological process. The gas may also be introduced deliberately during PNEUMOTHORAX, ARTIFICIAL.		03.3520
Back Ache
[description not available]		02.4520
Back Pain
Acute or chronic pain located in the posterior regions of the THORAX; LUMBOSACRAL REGION; or the adjacent regions.		02.4520
Dysmyelopoietic Syndromes
[description not available]		02.0410
Myelodysplastic Syndromes
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.		02.0410
Compression Fractures
[description not available]		02.0410
Hormone-Dependent Neoplasms
[description not available]		09176
Conus Medullaris Syndrome
[description not available]		02.4620
MEA 2a
[description not available]		02.0510
MEA 2b
[description not available]		02.0510
Carcinoma, Medullary
A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)		04.7521
Bone Marrow Diseases
Diseases involving the BONE MARROW.		03.4311
Cafe-au-Lait Spots with Pulmonic Stenosis
[description not available]		02.0410
Neoplasms, Nerve Sheath
[description not available]		02.0410
Neurofibromatosis 1
An autosomal dominant inherited disorder (with a high frequency of spontaneous mutations) that features developmental changes in the nervous system, muscles, bones, and skin, most notably in tissue derived from the embryonic NEURAL CREST. Multiple hyperpigmented skin lesions and subcutaneous tumors are the hallmark of this disease. Peripheral and central nervous system neoplasms occur frequently, especially OPTIC NERVE GLIOMA and NEUROFIBROSARCOMA. NF1 is caused by mutations which inactivate the NF1 gene (GENES, NEUROFIBROMATOSIS 1) on chromosome 17q. The incidence of learning disabilities is also elevated in this condition. (From Adams et al., Principles of Neurology, 6th ed, pp1014-18) There is overlap of clinical features with NOONAN SYNDROME in a syndrome called neurofibromatosis-Noonan syndrome. Both the PTPN11 and NF1 gene products are involved in the SIGNAL TRANSDUCTION pathway of Ras (RAS PROTEINS).		02.0410
Nerve Sheath Neoplasms
Neoplasms which arise from nerve sheaths formed by SCHWANN CELLS in the PERIPHERAL NERVOUS SYSTEM or by OLIGODENDROCYTES in the CENTRAL NERVOUS SYSTEM. Malignant peripheral nerve sheath tumors, NEUROFIBROMA, and NEURILEMMOMA are relatively common tumors in this category.		02.0410
Anaplastic Astrocytoma
[description not available]		05.7273
Astrocytoma
Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)		010.7273
Hematoma, Subdural
Accumulation of blood in the SUBDURAL SPACE between the DURA MATER and the arachnoidal layer of the MENINGES. This condition primarily occurs over the surface of a CEREBRAL HEMISPHERE, but may develop in the spinal canal (HEMATOMA, SUBDURAL, SPINAL). Subdural hematoma can be classified as the acute or the chronic form, with immediate or delayed symptom onset, respectively. Symptoms may include loss of consciousness, severe HEADACHE, and deteriorating mental status.		02.0510
Arachnoidal Cerebellar Sarcoma, Circumscribed
[description not available]		02.0510
Medulloblastoma
A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)		07.0510
Dysesthesia
[description not available]		09.3411
Mucositis, Oral
[description not available]		06.9144
Stomatitis
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.		06.9144
Cancer of the Urinary Tract
[description not available]		05.2643
Condition, Preneoplastic
[description not available]		04.6660
Precancerous Conditions
Pathological conditions that tend eventually to become malignant.		04.6660
Dermatomycoses
Superficial infections of the skin or its appendages by any of various fungi.		02.0510
Anaplastic Ependymoma
[description not available]		02.7430
Ependymoma
Glioma derived from EPENDYMOGLIAL CELLS that tend to present as malignant intracranial tumors in children and as benign intraspinal neoplasms in adults. It may arise from any level of the ventricular system or central canal of the spinal cord. Intracranial ependymomas most frequently originate in the FOURTH VENTRICLE and histologically are densely cellular tumors which may contain ependymal tubules and perivascular pseudorosettes. Spinal ependymomas are usually benign papillary or myxopapillary tumors. (From DeVita et al., Principles and Practice of Oncology, 5th ed, p2018; Escourolle et al., Manual of Basic Neuropathology, 2nd ed, pp28-9)		02.7430
Carcinoma, Papillary
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)		06.4752
Milk-Alkali Syndrome
[description not available]		03.8321
Hypercalcemia
Abnormally high level of calcium in the blood.		03.8321
Chronic Illness
[description not available]		02.0510
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		02.0510
Respiratory Tract Neoplasms
New abnormal growth of tissue in the RESPIRATORY SYSTEM.		02.0410
Brain Disorders
[description not available]		02.0510
Cyst
[description not available]		07.0510
Brain Diseases
Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.		02.0510
Anorexia
The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.		05.2843
Intradural-Extramedullary Spinal Cord Neoplasms
[description not available]		02.4420
Spinal Cord Neoplasms
Benign and malignant neoplasms which occur within the substance of the spinal cord (intramedullary neoplasms) or in the space between the dura and spinal cord (intradural extramedullary neoplasms). The majority of intramedullary spinal tumors are primary CNS neoplasms including ASTROCYTOMA; EPENDYMOMA; and LIPOMA. Intramedullary neoplasms are often associated with SYRINGOMYELIA. The most frequent histologic types of intradural-extramedullary tumors are MENINGIOMA and NEUROFIBROMA.		02.4420
Mesothelioma
A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)		18.05101
Infection
[description not available]		05.3322
Infections
Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.		05.3322
Hematuria
Presence of blood in the urine.		07.4620
Nails, Ingrown
Excessive lateral nail growth into the nail fold. Because the lateral margin of the nail acts as a foreign body, inflammation and granulation may result. It is caused by improperly fitting shoes and by improper trimming of the nail.		02.4620
Sycosis
[description not available]		07.7330
Nail Diseases
Diseases of the nail plate and tissues surrounding it. The concept is limited to primates.		03.8640
Folliculitis
Inflammation of follicles, primarily hair follicles.		07.7330
Hair Diseases
Diseases affecting the orderly growth and persistence of hair.		04.1130
Peritoneal Carcinomatosis
[description not available]		06.3553
Cancer of the Fallopian Tube
[description not available]		03.4411
Fallopian Tube Neoplasms
Benign or malignant neoplasms of the FALLOPIAN TUBES. They are uncommon. If they develop, they may be located in the wall or within the lumen as a growth attached to the wall by a stalk.		16.4122
Peritoneal Neoplasms
Tumors or cancer of the PERITONEUM.		110.06106
Cancer of Rectum
[description not available]		06.4752
Rectal Neoplasms
Tumors or cancer of the RECTUM.		06.4752
Bladder Diseases
[description not available]		02.0510
Coagulation, Disseminated Intravascular
[description not available]		02.0510
Disseminated Intravascular Coagulation
A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.		07.0510
Signet Ring Cell Carcinoma
[description not available]		02.0510
Carcinoma, Signet Ring Cell
A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.		02.0510
Animal Mammary Carcinoma
[description not available]		02.7330
Acute Promyelocytic Leukemia
[description not available]		03.1350
Leukemia, Promyelocytic, Acute
An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.		03.1350
Neoplasms, Nervous System
[description not available]		02.9710
Female Genital Neoplasms
[description not available]		05.4931
Genital Neoplasms, Female
Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).		05.4931
Chromosome Deletion
Actual loss of portion of a chromosome.		02.0510
Cancer of Gallbladder
[description not available]		02.7330
Superior Vena Cava Obstruction
[description not available]		02.0510
Gallbladder Neoplasms
Tumors or cancer of the gallbladder.		02.7330
Allergic Cutaneous Angiitis
[description not available]		02.0510
Petechiae
Pinhead size (3 mm) skin discolorization due to hemorrhage.		02.9540
Purpura
Purplish or brownish red discoloration, easily visible through the epidermis, caused by hemorrhage into the tissues. When the size of the discolorization is		07.9540
IgA Vasculitis
A systemic non-thrombocytopenic purpura caused by HYPERSENSITIVITY VASCULITIS and deposition of IGA-containing IMMUNE COMPLEXES within the blood vessels throughout the body, including those in the kidney (KIDNEY GLOMERULUS). Clinical symptoms include URTICARIA; ERYTHEMA; ARTHRITIS; GASTROINTESTINAL HEMORRHAGE; and renal involvement. Most cases are seen in children after acute upper respiratory infections.		02.0510
Brain Stem Neoplasms, Primary
[description not available]		06.6342
Benign Supratentorial Neoplasms
[description not available]		04.3611
Brain Stem Neoplasms
Benign and malignant intra-axial tumors of the MESENCEPHALON; PONS; or MEDULLA OBLONGATA of the BRAIN STEM. Primary and metastatic neoplasms may occur in this location. Clinical features include ATAXIA, cranial neuropathies (see CRANIAL NERVE DISEASES), NAUSEA, hemiparesis (see HEMIPLEGIA), and quadriparesis. Primary brain stem neoplasms are more frequent in children. Histologic subtypes include GLIOMA; HEMANGIOBLASTOMA; GANGLIOGLIOMA; and EPENDYMOMA.		06.6342
Empyema, Gall Bladder
[description not available]		02.0510
Cholecystitis
Inflammation of the GALLBLADDER; generally caused by impairment of BILE flow, GALLSTONES in the BILIARY TRACT, infections, or other diseases.		02.0510
Clubbed Fingers
[description not available]		03.3720
Carcinoma, Intraepithelial
[description not available]		02.4320
Carcinoma in Situ
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.		02.4320
Cancer of Sigmoid
[description not available]		02.0510
Angiitis
[description not available]		02.4520
Skin Diseases, Vascular
Skin diseases affecting or involving the cutaneous blood vessels and generally manifested as inflammation, swelling, erythema, or necrosis in the affected area.		02.0610
Vasculitis
Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.		02.4520
Acinar Carcinoma
[description not available]		02.7330
Carcinoma, Acinar Cell
A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)		02.7330
Argentaffinoma
[description not available]		02.7330
Cardiovascular Stroke
[description not available]		03.6630
Carcinoid Tumor
A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)		02.7330
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).		03.6630
Biliary Tract Cancer
[description not available]		08.8740
Biliary Tract Neoplasms
Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.		03.8740
Allergy, Drug
[description not available]		03.6430
Dermatitis, Radiation-Induced
[description not available]		07.37100
Drug Hypersensitivity
Immunologically mediated adverse reactions to medicinal substances used legally or illegally.		03.6430
Radiodermatitis
A cutaneous inflammatory reaction occurring as a result of exposure to ionizing radiation.		07.37100
Carcinoma, Lobular
A type of BREAST CANCER where the abnormal malignant cells form in the lobules, or milk-producing glands, of the breast.		04.9142
Cardiac Cancer
[description not available]		03.4511
Acquired Immune Deficiency Syndrome
[description not available]		02.0610
Acquired Immunodeficiency Syndrome
An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.		02.0610
Acne Rosacea
[description not available]		02.0610
Acariasis
[description not available]		02.0610
Rosacea
A cutaneous disorder primarily of convexities of the central part of the FACE, such as FOREHEAD; CHEEK; NOSE; and CHIN. It is characterized by FLUSHING; ERYTHEMA; EDEMA; RHINOPHYMA; papules; and ocular symptoms. It may occur at any age but typically after age 30. There are various subtypes of rosacea: erythematotelangiectatic, papulopustular, phymatous, and ocular (National Rosacea Society's Expert Committee on the Classification and Staging of Rosacea, J Am Acad Dermatol 2002; 46:584-7).		02.0610
Cancer of the Vulva
[description not available]		04.3240
Vulvar Neoplasms
Tumors or cancer of the VULVA.		04.3240
Cancer of the Tonsil
[description not available]		02.9810
Tonsillar Neoplasms
Tumors or cancer of the PALATINE TONSIL.		02.9810
Embolism, Pulmonary
[description not available]		02.0610
Pulmonary Embolism
Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.		02.0610
Ewing Sarcoma
[description not available]		02.0710
Sarcoma, Ewing
A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.		02.0710
Heart Disease, Ischemic
[description not available]		02.0610
Myocardial Ischemia
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).		02.0610
Primary Peritonitis
[description not available]		02.4420
Enteritis
Inflammation of any segment of the SMALL INTESTINE.		02.0610
Peritonitis
INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.		07.4420
Breast Cancer, Male
[description not available]		05.7822
Breast Neoplasms, Male
Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.		17.7822
Cancer of Intestines
[description not available]		02.0610
Intestinal Neoplasms
Tumors or cancer of the INTESTINES.		02.0610
Osteosclerosis
An abnormal hardening or increased density of bone tissue.		02.0710
Hypertrophy
General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).		02.0610
Lymphangitis
A lymphatic disease characterized by INFLAMMATION of LYMPHATIC VESSELS.		07.4520
Carcinoma, Neuroendocrine
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round blue cells, granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small (oat) cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)		02.4420
Canine Diseases
[description not available]		02.0610
Gastritis, Familial Giant Hypertrophic
[description not available]		02.0710
Arterial Obstructive Diseases
[description not available]		02.9910
Arterial Occlusive Diseases
Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.		02.9910
CACH Syndrome
[description not available]		02.0610
Cat Diseases
Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used.		02.0710
Air Embolism
[description not available]		02.0710
Fibrosis, Radiation
[description not available]		03.6430
Radiation Pneumonitis
Inflammation of the lung due to harmful effects of ionizing or non-ionizing radiation.		03.6430
Myeloproliferative Disorders
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.		02.0710
Cough
A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.		04.1431
Heritable Pulmonary Arterial Hypertension
[description not available]		02.0710
Familial Primary Pulmonary Hypertension
Familial or idiopathic hypertension in the PULMONARY CIRCULATION which is not secondary to other disease.		02.0710
Age-Related Memory Disorders
[description not available]		02.0710
Memory Disorders
Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.		02.0710
Leiomyosarcoma, Epithelioid
[description not available]		02.0710
Leiomyosarcoma
A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera. It is the most common soft tissue sarcoma of the gastrointestinal tract and uterus. The median age of patients is 60 years. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1865)		02.0710
Skin Ulcer
An ULCER of the skin and underlying tissues.		02.4520
ARPKD
[description not available]		02.0810
Polycystic Kidney, Autosomal Recessive
A genetic disorder with autosomal recessive inheritance, characterized by multiple CYSTS in both KIDNEYS and associated LIVER lesions. Serious manifestations are usually present at BIRTH with high PERINATAL MORTALITY.		02.0810
Eye Disorders
[description not available]		03.8421
Eye Diseases
Diseases affecting the eye.		03.8421
Gastric Rupture
[description not available]		02.0810
Teratocarcinoma
A malignant neoplasm consisting of elements of teratoma with those of embryonal carcinoma or choriocarcinoma, or both. It occurs most often in the testis. (Dorland, 27th ed)		02.0810
Yolk Sac Tumor
[description not available]		02.0810
Carcinoma, Embryonal
A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)		02.0810
Endodermal Sinus Tumor
An unusual and aggressive tumor of germ-cell origin that reproduces the extraembryonic structures of the early embryo. It is the most common malignant germ cell tumor found in children. It is characterized by a labyrinthine glandular pattern of flat epithelial cells and rounded papillary processes with a central capillary (Schiller-Duval body). The tumor is rarely bilateral. Before the use of combination chemotherapy, the tumor was almost invariably fatal. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1189)		02.0810
Adenocarcinoma, Clear Cell
An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)		04.7321
Cholera Infantum
[description not available]		05.544
Ascites
Accumulation or retention of free fluid within the peritoneal cavity.		02.0110
Hypoalbuminemia
A condition in which albumin level in blood (SERUM ALBUMIN) is below the normal range. Hypoalbuminemia may be due to decreased hepatic albumin synthesis, increased albumin catabolism, altered albumin distribution, or albumin loss through the urine (ALBUMINURIA).		02.0110
Colon Cancer, Familial Nonpolyposis
[description not available]		02.0110
Adenomatous Polyposis Coli, Familial
[description not available]		02.0110
Colorectal Neoplasms, Hereditary Nonpolyposis
A group of autosomal-dominant inherited diseases in which COLON CANCER arises in discrete adenomas. Unlike FAMILIAL POLYPOSIS COLI with hundreds of polyps, hereditary nonpolyposis colorectal neoplasms occur much later, in the fourth and fifth decades. HNPCC has been associated with germline mutations in mismatch repair (MMR) genes. It has been subdivided into Lynch syndrome I or site-specific colonic cancer, and LYNCH SYNDROME II which includes extracolonic cancer.		02.0110
Adenomatous Polyposis Coli
A polyposis syndrome due to an autosomal dominant mutation of the APC genes (GENES, APC) on CHROMOSOME 5. The syndrome is characterized by the development of hundreds of ADENOMATOUS POLYPS in the COLON and RECTUM of affected individuals by early adulthood.		02.0110
Gasser Syndrome
[description not available]		02.0110
Hemolytic-Uremic Syndrome
A syndrome that is associated with microvascular diseases of the KIDNEY, such as RENAL CORTICAL NECROSIS. It is characterized by hemolytic anemia (ANEMIA, HEMOLYTIC); THROMBOCYTOPENIA; and ACUTE RENAL FAILURE.		07.0110
Adenoma, beta-Cell
[description not available]		02.0110
Insulinoma
A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA.		02.0110
alpha-Galactosidase A Deficiency
[description not available]		02.0210
ADDH
[description not available]		02.0210
alpha-L-Iduronidase Deficiency
[description not available]		02.0210
Abdominal Migraine
[description not available]		02.0210
Palmoplantaris Pustulosis
[description not available]		02.4220
Lentigines
[description not available]		02.0210
Fabry Disease
An X-linked inherited metabolic disease caused by a deficiency of lysosomal ALPHA-GALACTOSIDASE A. It is characterized by intralysosomal accumulation of globotriaosylceramide and other GLYCOSPHINGOLIPIDS in blood vessels throughout the body leading to multi-system complications including renal, cardiac, cerebrovascular, and skin disorders.		02.0210
Attention Deficit Disorder with Hyperactivity
A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-V)		02.0210
Lentigo
Small circumscribed melanoses resembling, but differing histologically from, freckles. The concept includes senile lentigo ('liver spots') and nevoid lentigo (nevus spilus, lentigo simplex) and may also occur in association with multiple congenital defects or congenital syndromes (e.g., Peutz-Jeghers syndrome).		02.0210
Mucopolysaccharidosis I
Systemic lysosomal storage disease caused by a deficiency of alpha-L-iduronidase (IDURONIDASE) and characterized by progressive physical deterioration with urinary excretion of DERMATAN SULFATE and HEPARAN SULFATE. There are three recognized phenotypes representing a spectrum of clinical severity from severe to mild: Hurler syndrome, Hurler-Scheie syndrome and Scheie syndrome (formerly mucopolysaccharidosis V). Symptoms may include DWARFISM; hepatosplenomegaly; thick, coarse facial features with low nasal bridge; corneal clouding; cardiac complications; and noisy breathing.		02.0210
Migraine Disorders
A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)		02.0210
Psoriasis
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.		02.4220
B-Cell Lymphoma
[description not available]		02.0110
Lymphoma, B-Cell
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.		02.0110
Neoplasms, Otorhinolaryngologic
[description not available]		02.9310
Pain, Intractable
Persistent pain that is refractory to some or all forms of treatment.		02.4320
Focal Segmental Glomerulosclerosis
[description not available]		02.0210
Glomerulosclerosis, Focal Segmental
A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.		02.0210
Ischemia
A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.		02.0210
Proteinuria
The presence of proteins in the urine, an indicator of KIDNEY DISEASES.		02.0210
Hives
[description not available]		02.0210
Urticaria
A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress.		02.0210
Cancer of Muscle
[description not available]		02.9310
Nephrotic Syndrome
A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.		07.0210
Acne
[description not available]		03.411
Acne Vulgaris
A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors.		03.411
Rhabdoid Tumor
A rare but highly lethal childhood tumor found almost exclusively in infants. Histopathologically, it resembles RHABDOMYOSARCOMA but the tumor cells are not of myogenic origin. Although it arises primarily in the kidney, it may be found in other parts of the body. The rhabdoid cytomorphology is believed to be the expression of a very primitive malignant cell. (From Holland et al., Cancer Medicine, 3d ed, p2210)		07.0210
Cancer of Larynx
[description not available]		02.4220
Laryngeal Neoplasms
Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.		02.4220
Neuroendocrine Tumors
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.		02.4320
Congenital Epulides
[description not available]		02.9310
Papilloma, Squamous Cell
[description not available]		02.0210
Papilloma
A circumscribed benign epithelial tumor projecting from the surrounding surface; more precisely, a benign epithelial neoplasm consisting of villous or arborescent outgrowths of fibrovascular stroma covered by neoplastic cells. (Stedman, 25th ed)		07.0210
Day Blindness
[description not available]		03.4111
Ecchymosis
Extravasation of blood into the skin, resulting in a nonelevated, rounded or irregular, blue or purplish patch, larger than a petechia.		02.0210
Coronary Heart Disease
[description not available]		02.0210
Amentia
[description not available]		02.0210
Coronary Disease
An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.		02.0210
Dementia
An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.		02.0210
Peripheral Nerve Neoplasms
[description not available]		02.0210
Peripheral Nervous System Neoplasms
Neoplasms which arise from peripheral nerve tissue. This includes NEUROFIBROMAS; SCHWANNOMAS; GRANULAR CELL TUMORS; and malignant peripheral NERVE SHEATH NEOPLASMS. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1)		02.0210
Hematologic Malignancies
[description not available]		02.9410
Hematologic Neoplasms
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.		02.9410
Dehydration
The condition that results from excessive loss of water from a living organism.		03.4111
Pachymeningitis
[description not available]		02.9440
Meningitis
Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6)		02.9440
Facial Neoplasms
New abnormal growth of tissue in the FACE.		02.0210
Carditis
[description not available]		07.0210
Myocarditis
Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies.		07.0210
Synovioma
[description not available]		07.6454
Sarcoma, Synovial
A malignant neoplasm arising from tenosynovial tissue of the joints and in synovial cells of tendons and bursae. The legs are the most common site, but the tumor can occur in the abdominal wall and other trunk muscles. There are two recognized types: the monophasic (characterized by sheaths of monotonous spindle cells) and the biphasic (characterized by slit-like spaces or clefts within the tumor, lined by cuboidal or tall columnar epithelial cells). These sarcomas occur most commonly in the second and fourth decades of life. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1363)		07.6454
Dihydropyrimidine Dehydrogenase Deficiency
An autosomal recessive disorder affecting DIHYDROPYRIMIDINE DEHYDROGENASE and causing familial pyrimidinemia. It is characterized by thymine-uraciluria in homozygous deficient patients. Even a partial deficiency in the enzyme leaves individuals at risk for developing severe 5-FLUOROURACIL-associated toxicity.		02.0210
Hypopharyngeal Cancer
[description not available]		02.0210
Hypopharyngeal Neoplasms
Tumors or cancer of the HYPOPHARYNX.		02.0210
Hypertrichosis
Excessive hair growth at inappropriate locations, such as on the extremities, the head, and the back. It is caused by genetic or acquired factors, and is an androgen-independent process. This concept does not include HIRSUTISM which is an androgen-dependent excess hair growth in WOMEN and CHILDREN.		02.7230
MS (Multiple Sclerosis)
[description not available]		02.0210
Multiple Sclerosis
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)		02.0210
Angiomyolipoma
A benign tumor containing vascular, adipose, and muscle elements. It occurs most often in the kidney with smooth muscle elements (angiolipoleiomyoma) in association with tuberous sclerosis. (Dorland, 27th ed)		02.0210
Hyperglycemia, Postprandial
Abnormally high BLOOD GLUCOSE level after a meal.		02.0210
Hyperglycemia
Abnormally high BLOOD GLUCOSE level.		02.0210
Colonic Inertia
Symptom characterized by the passage of stool once a week or less.		03.4111
Constipation
Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.		03.4111
Adenocarcinoma, Scirrhous
An adenocarcinoma with a hard (Greek skirrhos, hard) structure owing to the formation of dense connective tissue in the stroma. (From Dorland, 27th ed)		02.0310
Complication, Postoperative
[description not available]		04.3211
Postoperative Complications
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.		04.3211
Facial Dermatoses
Skin diseases involving the FACE.		02.0210
Deficiency, Magnesium
[description not available]		02.0210
Magnesium Deficiency
A nutritional condition produced by a deficiency of magnesium in the diet, characterized by anorexia, nausea, vomiting, lethargy, and weakness. Symptoms are paresthesias, muscle cramps, irritability, decreased attention span, and mental confusion, possibly requiring months to appear. Deficiency of body magnesium can exist even when serum values are normal. In addition, magnesium deficiency may be organ-selective, since certain tissues become deficient before others. (Harrison's Principles of Internal Medicine, 12th ed, p1936)		02.0210
Blood Diseases
[description not available]		03.4111
Hematologic Diseases
Disorders of the blood and blood forming tissues.		03.4111
Microbial Superinvasion
[description not available]		02.0310
Infections, Staphylococcal Skin
[description not available]		02.0310
Staphylococcal Skin Infections
Infections to the skin caused by bacteria of the genus STAPHYLOCOCCUS.		02.0310
Benign Cerebellar Neoplasms
[description not available]		02.0310
Adenocarcinoma, Papillary
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)		02.4320
MODS
[description not available]		02.0310
Multiple Organ Failure
A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.		02.0310
Esophageal Diseases
Pathological processes in the ESOPHAGUS.		02.0310
Graft Occlusion, Vascular
Obstruction of flow in biological or prosthetic vascular grafts.		02.9410
Diffuse Mixed Small and Large Cell Lymphoma
[description not available]		02.9410
Lymphoma, Non-Hodgkin
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.		02.9410
Collagen Diseases
Historically, a heterogeneous group of acute and chronic diseases, including rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, dermatomyositis, etc. This classification was based on the notion that collagen was equivalent to connective tissue, but with the present recognition of the different types of collagen and the aggregates derived from them as distinct entities, the term collagen diseases now pertains exclusively to those inherited conditions in which the primary defect is at the gene level and affects collagen biosynthesis, post-translational modification, or extracellular processing directly. (From Cecil Textbook of Medicine, 19th ed, p1494)		02.9410
Pulmonary Sarcoidosis
[description not available]		02.0310
Bronchiolitis
Inflammation of the BRONCHIOLES.		02.0310
Sarcoidosis, Pulmonary
Sarcoidosis affecting predominantly the lungs, the site most frequently involved and most commonly causing morbidity and mortality in sarcoidosis. Pulmonary sarcoidosis is characterized by sharply circumscribed granulomas in the alveolar, bronchial, and vascular walls, composed of tightly packed cells derived from the mononuclear phagocyte system. The clinical symptoms when present are dyspnea upon exertion, nonproductive cough, and wheezing. (Cecil Textbook of Medicine, 19th ed, p431)		02.0310
Pyoderma Gangrenosum
An idiopathic, rapidly evolving, and severely debilitating disease occurring most commonly in association with chronic ulcerative colitis. It is characterized by the presence of boggy, purplish ulcers with undermined borders, appearing mostly on the legs. The majority of cases are in people between 40 and 60 years old. Its etiology is unknown.		07.0310
Dilatation, Pathologic
The condition of an anatomical structure's being dilated beyond normal dimensions.		02.0310
Kidney, Polycystic
[description not available]		02.0310
Polycystic Kidney Diseases
Hereditary diseases that are characterized by the progressive expansion of a large number of tightly packed CYSTS within the KIDNEYS. They include diseases with autosomal dominant and autosomal recessive inheritance.		02.0310
Cancer of Mediastinum
[description not available]		03.4211
Cancer of Pelvis
[description not available]		03.4211
Mediastinal Neoplasms
Tumors or cancer of the MEDIASTINUM.		03.4211
Adenovirus Infections
[description not available]		02.0310
Adenoviridae Infections
Virus diseases caused by the ADENOVIRIDAE.		02.0310
Barrett Epithelium
[description not available]		03.3520
Barrett Esophagus
A condition with damage to the lining of the lower ESOPHAGUS resulting from chronic acid reflux (ESOPHAGITIS, REFLUX). Through the process of metaplasia, the squamous cells are replaced by a columnar epithelium with cells resembling those of the INTESTINE or the salmon-pink mucosa of the STOMACH. Barrett's columnar epithelium is a marker for severe reflux and precursor to ADENOCARCINOMA of the esophagus.		03.3520
Adenocarcinoma, Endometrioid
[description not available]		04.3411
Carcinoma, Endometrioid
An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.		04.3411
Microsatellite Instability
The occurrence of highly polymorphic mono- and dinucleotide MICROSATELLITE REPEATS in somatic cells. It is a form of genome instability associated with defects in DNA MISMATCH REPAIR.		02.0310
Aneuploid
[description not available]		02.0310
Adenomatosis, Pulmonary
A neoplastic disease in which the alveoli and distal bronchi are filled with mucus and mucus-secreting columnar epithelial cells. It is characterized by abundant, extremely tenacious sputum, chills, fever, cough, dyspnea, and pleuritic pain. (Stedman, 25th ed)		02.0310
Airway Hyper-Responsiveness
[description not available]		02.0310
Refractory Anemia
[description not available]		02.0310
Anemia, Refractory
A severe sometimes chronic anemia, usually macrocytic in type, that does not respond to ordinary antianemic therapy.		02.0310
Blepharitis
Inflammation of the eyelids.		02.0310
Brain Swelling
[description not available]		04.3411
Brain Edema
Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)		04.3411
Adenoma, Oxyphilic
A usually benign glandular tumor composed of oxyphil cells, large cells with small irregular nuclei and dense acidophilic granules due to the presence of abundant MITOCHONDRIA. Oxyphil cells, also known as oncocytes, are found in oncocytomas of the kidney, salivary glands, and endocrine glands. In the thyroid gland, oxyphil cells are known as Hurthle cells and Askanazy cells.		04.3411
Follicular Thyroid Carcinoma
[description not available]		04.7521
Adenocarcinoma, Follicular
An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)		04.7521
Edema, Pulmonary
[description not available]		02.9510
Pulmonary Edema
Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening.		02.9510
Livedo Reticularis
A condition characterized by a reticular or fishnet pattern on the skin of lower extremities and other parts of the body. This red and blue pattern is due to deoxygenated blood in unstable dermal blood vessels. The condition is intensified by cold exposure and relieved by rewarming.		07.0310
Anaphylactic Reaction
[description not available]		02.9510
Infectious Diseases
[description not available]		02.9510
Anaphylaxis
An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death.		02.9510
Communicable Diseases
An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.		02.9510
Dermatomyositis, Adult Type
[description not available]		02.0410
Dermatomyositis
A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6)		02.0410
Cancer of ILEUM
[description not available]		02.0310
Fracture, Pathologic
[description not available]		02.9610
Bacterial Infections, Gram-Positive
[description not available]		02.0410
Gram-Positive Bacterial Infections
Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.		02.0410
Experimental Radiation Injuries
[description not available]		02.0410
Short Bowel Syndrome
A malabsorption syndrome resulting from extensive operative resection of the SMALL INTESTINE, the absorptive region of the GASTROINTESTINAL TRACT.		02.0110